PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Zheng, J; Han, W; Han, XD; Ma, XY; Zhang, P				Zheng, Jun; Han, Wen; Han, Xiao-Dong; Ma, Xiao-Yuan; Zhang, Pengbo			Effect of naloxone on intravenous fentanyl patient-controlled analgesia after laparoscopic cholecystectomy	MEDICINE			English	Article						fentanyl; naloxone; nausea; patient-controlled analgesia after surgery; tropisetron; vomiting	POSTOPERATIVE NAUSEA; TROPISETRON; ONDANSETRON; MORPHINE; PAIN	This study aims to evaluate the effect of naloxone on intravenous fentanyl patient-controlled analgesia after laparoscopic cholecystectomy under total intravenous anesthesia. A total of 90 patients, who underwent intravenous fentanyl patient-controlled analgesia after laparoscopic cholecystectomy under total intravenous anesthesia, were included into this study. All patients were randomly divided into 3 groups (each group, n=30): naloxone group (naloxone+fentanyl). tropisetron group (tropisetron+fentanyl), and fentanyl group (fentanyl). Patients in each group were given a corresponding dose of naloxone. Postoperative analgesia effect and the incidence of side effects such as nausea and vomiting were observed. Small doses of naloxone or tropisetron combined with fentanyl used for intravenous patient-controlled analgesia can significantly reduce the incidence of nausea and vomiting. Six hours after surgery. visual analogue scale (VAS) scores were significantly lower in patients that underwent intravenous patient-controlled analgesia using low-dose naloxone combined with fentanyl compared with patients who received fentanyl alone; however, the postoperative analgesic effect of tropisetron was not observed. Compared with the combination of tropisetron and fentanyl, low-dose naloxone combined with fentanyl can obviously reduce the incidence of nausea and vomiting in patients who underwent intravenous patient-controlled analgesia after laparoscopic cholecystectomy, and enhance the analgesic effect of fentanyl 6 hours after surgery. Low-dose naloxone can reduce the incidence of nausea and vomiting in patients who underwent laparoscopic cholecystectomy under total intravenous anesthesia, and exhibits a certain synergic analgesic effect.	[Zheng, Jun; Zhang, Pengbo] Xi An Jiao Tong Univ, Dept Anesthesiol, Affiliated Hosp 2, 157 West 5 Rd, Xian 710004, Shaanxi, Peoples R China; [Zheng, Jun; Han, Xiao-Dong] Yanan Univ, Dept Anesthesiol, Affiliated Hosp, Yanan, Shaanxi, Peoples R China; [Han, Wen] Yanan Univ, Digest Internal Med, Affiliated Hosp, Yanan, Shaanxi, Peoples R China; [Ma, Xiao-Yuan] Yanan Univ, Affiliated Hosp, Operat Room, Yanan, Shaanxi, Peoples R China	Zhang, P (reprint author), Xi An Jiao Tong Univ, Dept Anesthesiol, Affiliated Hosp 2, 157 West 5 Rd, Xian 710004, Shaanxi, Peoples R China.	zhpbo@mail.xjtu.edu.cn					[Anonymous], 2005, CLIN APPL GUID DRUGS, p[101, 109]; Bamigbade TA, 1998, PAIN REV, V5, P155, DOI 10.1191/096813098668122984; BASBAUM AI, 1978, ANN NEUROL, V4, P451, DOI 10.1002/ana.410040511; Bilgin H, 2006, J NEUROSURG ANESTHES, V18; Derbent A, 2005, ADV THER, V22, P307, DOI 10.1007/BF02850080; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Haj-Mirzaian A, 2016, EUR J PHARMACOL, V780, P71, DOI 10.1016/j.ejphar.2016.03.034; Herrstedt J, 2007, SUPPORT CARE CANCER, V15, P417, DOI 10.1007/s00520-006-0158-y; HODGE CW, 1995, PSYCHOPHARMACOLOGY, V119, P186, DOI 10.1007/BF02246160; Hudson S, 1998, AANA J, V66, P360; Khalifeh S, 2015, HUM EXP TOXICOL, V34, P922, DOI 10.1177/0960327114562034; Kim ES, 2004, CAN J ANAESTH, V51, P1048, DOI 10.1007/BF03018499; Mannino M J, 1999, CRNA, V10, P54; Natalini CC, 2006, CIENCIA RURAL, V36; Petrova G I, 2002, Boll Chim Farm, V141, P150; SHIPTON EA, 1984, S AFR MED J, V66, P61; Sommers DK, 1996, EUR J CLIN PHARMACOL, V50, P371, DOI 10.1007/s002280050125; Topacoglu H, 2005, ANN SAUDI MED, V25, P508, DOI 10.5144/0256-4947.2005.508; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; White LA, 2001, ANAESTHESIA, V56, P365, DOI 10.1046/j.1365-2044.2001.01708-5.x; Yokoyama T, 2006, ANESTH ANALG, V103, P1039, DOI 10.1213/01.ane.0000239034.87215.fa	21	0	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	NOV	2016	95	48							e5074	10.1097/MD.0000000000005074			4	Medicine, General & Internal	General & Internal Medicine	EE4RA	WOS:000389591500003	27902584	DOAJ Gold, Green Published			2020-06-30	J	Gupta, K; Mitra, S; Kazal, S; Saroa, R; Ahuja, V; Goel, P				Gupta, K.; Mitra, S.; Kazal, S.; Saroa, R.; Ahuja, V.; Goel, P.			IV paracetamol as an adjunct to patient-controlled epidural analgesia with levobupivacaine and fentanyl in labour: a randomized controlled study	BRITISH JOURNAL OF ANAESTHESIA			English	Article						administration; intravenous; analgesia; analgesia; epidural; obstetric labour; paracetamol; patient-controlled	POSTOPERATIVE PAIN; INTRAVENOUS-INFUSION; ACETAMINOPHEN; RELIEF	Background: Use of i. v. paracetamol for postoperative pain is well documented, but it is unclear if it can reduce the consumption of opioids during patient-controlled epidural analgesia (PCEA) in labouring parturients. Methods: In this randomized, double-blind, placebo-controlled clinical trial conducted in a tertiary care hospital, (80)parturients were randomly assigned to two groups of 40 each, to receive either 1000 mg (100 ml) i.v. paracetamol or 100 ml normal saline as placebo, 30 min before the procedure. After insertion of the epidural catheter, all patients received 10 ml of levobupivacaine 0.1% with 2 mu g ml-1 fentanyl, followed by continuous background epidural infusion of 6 ml h-1 with a provision of patient-controlled bolus 5 ml of same drug with a lock-out interval of 12 min. The primary outcome was hourly mean consumption of levobupivacaine and fentanyl mixture (ml.h-1). Secondary outcomes included pain score, sensory and motor block, haemodynamic parameters of mother, duration of second stage of labour, mode of delivery, Apgar scores, foetal heart rate and adverse effects. Results: The hourly mean drug consumption in the Paracetamol group was significantly lower as compared with the Placebo group (7.03 ml.h-1, SD 0.83 vs. 8.12 ml.h-1, SD 1.34; p < 0.001). The mean number of boluses taken were also significantly less in the paracetamol group (1.00, SD 0.93 vs. 1.43, SD 0.90; p = 0.036). Pain scores decreased in both the groups without significant inter-group differences. Conclusions: Use of 1000 mg i.v. paracetamol decreases the mean hourly drug consumption through epidural route. Thus i.v. paracetamol is a safe and effective adjunct to PCEA in labour analgesia. Clinical trial registration: Clinical Trials Registry-India (ext-link-type="uri" xlink:href="http://ctri.nic.in/Clinicaltrials/login.php">http://ctri.nic.in/Clinicaltrials/login.php), trial registration number 2013/09/003968.	[Gupta, K.; Mitra, S.; Kazal, S.; Saroa, R.; Ahuja, V.] Govt Med Coll & Hosp, Dept Anaesthesia & Intens Care, Chandigarh, India; [Goel, P.] Govt Med Coll & Hosp, Dept Obstet & Gynaecol, Chandigarh, India	Mitra, S (reprint author), Govt Med Coll & Hosp, Dept Anaesthesia & Intens Care, Chandigarh, India.	drsmitra12@yahoo.com					Abd-El-Maeboud KHI, 2014, J OBSTET GYNAECOL RE, V40, P2152, DOI 10.1111/jog.12465; Abdollahi Mohammad-Hasan, 2014, Niger Med J, V55, P54, DOI 10.4103/0300-1652.128167; Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3; Ankumah NAE, 2017, AM J PERINAT, V34, P38, DOI 10.1055/s-0036-1584143; Ankumah NAE, 2016, AM J OBSTET GYNECOL, V214, pS63, DOI 10.1016/j.ajog.2015.10.109; Ayatollahi V, 2014, ACTA CLIN CROAT, V53, P272; Brune K, 2015, EUR J PAIN, V19, P953, DOI 10.1002/ejp.621; De Oliveira GS, 2015, CLIN J PAIN, V31, P86, DOI 10.1097/AJP.0000000000000081; Elbohoty AEH, 2012, INT J GYNECOL OBSTET, V118, P7, DOI 10.1016/j.ijgo.2012.01.025; Graham GG, 2003, DRUGS, V63, P43; Hassan Hossam Ibrahim Eldesuky Ali, 2014, Anesth Essays Res, V8, P339, DOI 10.4103/0259-1162.143135; Hyllested M, 2002, BRIT J ANAESTH, V88, P199, DOI 10.1093/bja/88.2.199; Leighton BL, 2002, AM J OBSTET GYNECOL, V186, pS69, DOI 10.1067/mob.2002.121813; Lim Y, 2004, MED SCI MONITOR, V10, pPI187; Makkar JK, 2015, J CLIN ANESTH, V27, P159, DOI 10.1016/j.jclinane.2014.08.008; Malaise O, 2007, FUTUR NEUROL, V2, P673, DOI 10.2217/14796708.2.6.673; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Meenakshi L, 2015, J OBSTET GYN INDIA, V65, P17, DOI 10.1007/s13224-014-0556-x; Moore RA, 2016, EUR J HOSP PHARM-S P, V23, P187, DOI 10.1136/ejhpharm-2016-000952; Nielsen PE, 1996, ANESTH ANALG, V83, P742, DOI 10.1097/00000539-199610000-00014; Robinson AP, 2001, ANESTH ANALG, V92, P410, DOI 10.1213/00000539-200102000-00025; Ross VH, 2009, ANESTH ANALG, V109, P524, DOI 10.1213/ane.0b013e31819518e4; Silva M, 2010, LOCAL REG ANESTH, V3, P143, DOI 10.2147/LRA.S10237; Simkin P, 2000, GUIDE EFFECTIVE CARE, P313; Soltani G, 2015, ANESTH PAIN MED, V5; Wong CA, 2011, BONICAS MANAGEMENT P, P792	26	4	4	4	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	NOV	2016	117	5					617	622		10.1093/bja/aew311			6	Anesthesiology	Anesthesiology	ED0XC	WOS:000388565500014	27799176	Bronze			2020-06-30	J	Ruan, XL; Luo, JJ; Kaye, AD				Ruan, Xiulu; Luo, Jin Jun; Kaye, Alan David			Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer	EUROPEAN JOURNAL OF CANCER			English	Letter											drxruan88@gmail.com; jluo@temple.edu; alankaye44@hotmail.com					Haumann J, 2016, EUR J CANCER, V65, P121, DOI 10.1016/j.ejca.2016.06.025; Lev R, 2015, FORENSIC SCI INT, V257, P347, DOI 10.1016/j.forsciint.2015.09.021; Lev R, 2016, AM J EMERG MED, V34, P30, DOI 10.1016/j.ajem.2015.09.003; Ojanpera I, 2016, INT J LEGAL MED, P1; Paulozzi Leonard J., 2012, Morbidity and Mortality Weekly Report, V61, P493; Szalavitz M., 2012, TIME	6	0	0	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	NOV	2016	68						199	200		10.1016/j.ejca.2016.08.028			2	Oncology	Oncology	EC0SS	WOS:000387811600024	27773585				2020-06-30	J	Haumann, J; Geurts, JW; van Kuijk, SMJ; Kremer, B; Joosten, EA; van den Beuken-van Everdingen, MHJ				Haumann, J.; Geurts, J. W.; van Kuijk, S. M. J.; Kremer, B.; Joosten, E. A.; van den Beuken-van Everdingen, M. H. J.			Letter response: Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer	EUROPEAN JOURNAL OF CANCER			English	Letter											m.vanden.beuken@mumc.nl	Geurts, Jose W/O-3673-2014; Geurts, J.W./P-7822-2019	Geurts, J.W./0000-0002-7043-968X; van den Beuken-van Everdingen, Marieke/0000-0002-2446-2862			Ayonrinde OT, 2000, MED J AUSTRALIA, V173, P536, DOI 10.5694/j.1326-5377.2000.tb139323.x; Lev R, 2015, FORENSIC SCI INT, V257, P347, DOI 10.1016/j.forsciint.2015.09.021; Lev R, 2016, AM J EMERG MED, V34, P30, DOI 10.1016/j.ajem.2015.09.003; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Ojanpera I, 2016, INT J LEGAL MED, V130, P1209, DOI 10.1007/s00414-016-1358-8; Ray WA, 2015, JAMA INTERN MED, V175, P420, DOI 10.1001/jamainternmed.2014.6294; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216	7	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	NOV	2016	68						201	202		10.1016/j.ejca.2016.09.014			2	Oncology	Oncology	EC0SS	WOS:000387811600025	27771240				2020-06-30	J	Nazir, M; Salim, B; Khan, FA				Nazir, M.; Salim, B.; Khan, F. A.			Pharmacological agents for reducing the haemodynamic response to tracheal intubation in paediatric patients: a systematic review	ANAESTHESIA AND INTENSIVE CARE			English	Review						intubation; endotracheal; paediatric; haemodynamics; blood pressure; heart rate; arrhythmias	CARDIOVASCULAR-RESPONSES; REMIFENTANIL REQUIREMENTS; INTRAVENOUS LIDOCAINE; SKIN INCISION; CHILDREN; PROPOFOL; SUFENTANIL; FENTANYL; LARYNGOSCOPY; SEVOFLURANE	The primary aim of this review was to assess the effect of pharmacological agents administered to attenuate the haemodynamic response to tracheal intubation in paediatric patients up to 16 years of age undergoing elective surgery. Secondary aims were to identify adverse effects related to these agents, and the agents' roles in decreasing arrhythmias. A systematic search was conducted for articles listed in PubMed, CINAHL or the Cochrane database between January 1980 and June 2014. We included randomised controlled trials where the stated aim of the study included observing the effects of pharmacological agents on the haemodynamic response to tracheal intubation. The outcome measures were changes in mean, systolic and diastolic blood pressure and heart rate, adverse effects of drugs and arrhythmias. Sixteen publications with a total of 1408 children (ages two to 15 years) were identified. These studies varied in methodology and quality. Opioids were the commonest agents used and appeared to obtund the response in a dose-related manner. Fentanyl 2 mu g/kg, remifentanil 1 mu g/kg, sufentanil 0.1 and 0.2 mu g/kg and alfentanil 25 mu g/kg blunted the haemodynamic response. Remifentanil 3 mu g/kg and sufentanil 0.3 mu g/kg were the most effective in obliterating the response but led to hypotension in unstimulated patients. Opioid-related side-effects and arrhythmias were observed in few patients. We recommend that when required, the safe and effective doses identified in this review be used to obtund the haemodynamic response to intubation in paediatric patients, with close observation for the uncommon but recognised side-effects.	[Nazir, M.; Salim, B.] Aga Khan Univ, Anaesthesia, Karachi, Sindh, Pakistan; [Khan, F. A.] Aga Khan Univ, Dept Anaesthesia, Karachi, Sindh, Pakistan	Khan, FA (reprint author), Aga Khan Univ, Dept Anaesthesia, Karachi, Sindh, Pakistan.	fauzia.khan@aku.edu					Aouad MT, 2003, ANESTH ANALG, V96, P1325, DOI 10.1213/01.ANE.0000061586.63978.DE; Batra YK, 2004, PEDIATR ANESTH, V14, P452, DOI 10.1111/j.1460-9592.2004.01208.x; Blair JM, 2004, ANAESTHESIA, V59, P27, DOI 10.1111/j.1365-2044.2004.03524.x; Cote CJ, 2009, PRACTICE ANESTHESIA, P89; FRIESEN RH, 1987, ANESTH ANALG, V66, P874; Gerardi MJ, 1996, ANN EMERG MED, V28, P55, DOI 10.1016/S0196-0644(96)70140-3; GUAY J, 1992, CAN J ANAESTH, V39, P14, DOI 10.1007/BF03008666; Gupta A, 2006, PEDIATR ANESTH, V16, P399, DOI 10.1111/j.1460-9592.2005.01783.x; Higgins JPT, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184; Kliegman RM, 2011, NELSON TXB PAEDIAT, P1613; Liao X, 2009, EUR J ANAESTH, V26, P73, DOI 10.1097/EJA.0b013e32831a6b2f; LINDGREN L, 1991, ACTA ANAESTH SCAND, V35, P355, DOI 10.1111/j.1399-6576.1991.tb03305.x; MIKAWA K, 1995, CAN J ANAESTH, V42, P869, DOI 10.1007/BF03011033; Mireskandari SM, 2011, IRAN J PEDIATR, V21, P173; Morgan JM, 2007, ANAESTHESIA, V62, P135, DOI 10.1111/j.1365-2044.2006.04903.x; Munoz HR, 2007, ANESTH ANALG, V104, P77, DOI 10.1213/01.ane.0000251201.81210.e7; Munoz HR, 2002, ANESTHESIOLOGY, V97, P1142, DOI 10.1097/00000542-200211000-00018; Noseir RK, 2003, ANESTH ANALG, V96, P1645, DOI 10.1213/01.ANE.0000061587.13631.67; Park KS, 2009, ANAESTH INTENS CARE, V37, P577, DOI 10.1177/0310057X0903700403; Piccirillo G, 2001, CLIN SCI, V100, P267, DOI 10.1042/CS20000222; Robinson DN, 1998, PAEDIATR ANAESTH, V8, P467; Shinohara K, 2000, CAN J ANAESTH, V47, P361, DOI 10.1007/BF03020954; SHRIBMAN AJ, 1987, BRIT J ANAESTH, V59, P295, DOI 10.1093/bja/59.3.295; SINGLETON MA, 1987, CAN J ANAESTH, V34, P152, DOI 10.1007/BF03015333; SPLINTER WM, 1990, CAN J ANAESTH, V37, P440, DOI 10.1007/BF03005623; Wang S. H., 2014, BIORESOUR BIOPROCESS, V1, P1; Xue ES, 2008, EUR J ANAESTH, V25, P106, DOI 10.1017/S026502150700261X; Xue FS, 2008, BRIT J ANAESTH, V100, P717, DOI 10.1093/bja/aen032; Xue FS, 2007, ANAESTHESIA, V62, P220, DOI 10.1111/j.1365-2044.2007.04939.x; Xue FS, 2007, PEDIATR ANESTH, V17, P568, DOI 10.1111/j.1460-9592.2006.02162.x; Yang QY, 2009, CHINESE MED J-PEKING, V122, P44, DOI 10.3760/cma.j.issn.0366-6999.2009.01.009; Yoon SH, 2010, KOREAN J ANESTHESIOL, V59, P167, DOI 10.4097/kjae.2010.59.3.167	32	3	3	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	NOV	2016	44	6					681	691		10.1177/0310057X1604400605			11	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	EC3YW	WOS:000388064000005	27832553	Bronze			2020-06-30	J	Feasel, MG; Wohlfarth, A; Nilles, JM; Pang, SK; Kristovich, RL; Huestis, MA				Feasel, Michael G.; Wohlfarth, Ariane; Nilles, John M.; Pang, Shaokun; Kristovich, Robert L.; Huestis, Marilyn A.			Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry	AAPS JOURNAL			English	Article						carfentanil; metabolism; norcarfentanil; opioid	MAJOR METABOLITES; HUMAN URINE; FENTANYL; SUFENTANIL; ALFENTANIL; REMIFENTANIL; RECEPTORS; REVEALS; BINDING; PLASMA	Carfentanil is an ultra-potent synthetic opioid. No human carfentanil metabolism data are available. Reportedly, Russian police forces used carfentanil and remifentanil to resolve a hostage situation in Moscow in 2002. This alleged use prompted interest in the pharmacology and toxicology of carfentanil in humans. Our study was conducted to identify human carfentanil metabolites and to assess carfentanil's metabolic clearance, which could contribute to its acute toxicity in humans. We used Simulations Plus's ADMET Predictor (TM) and Molecular Discovery's MetaSite (TM) to predict possible metabolite formation. Both programs gave similar results that were generally good but did not capture all metabolites seen in vitro. We incubated carfentanil with human hepatocytes for up to 1 h and analyzed samples on a Sciex 3200 QTRAP mass spectrometer to measure parent compound depletion and extrapolated that to represent intrinsic clearance. Pooled primary human hepatocytes were then incubated with carfentanil up to 6 h and analyzed for metabolite identification on a Sciex 5600+ TripleTOF (QTOF) high-resolution mass spectrometer. MS and MS/MS analyses elucidated the structures of the most abundant metabolites. Twelve metabolites were identified in total. N-Dealkylation and monohydroxylation of the piperidine ring were the dominant metabolic pathways. Two N-oxide metabolites and one glucuronide metabolite were observed. Surprisingly, ester hydrolysis was not a major metabolic pathway for carfentanil. While the human liver microsomal system demonstrated rapid clearance by CYP enzymes, the hepatocyte incubations showed much slower clearance, possibly providing some insight into the long duration of carfentanil's effects.	[Feasel, Michael G.; Kristovich, Robert L.] US Army, Edgewood Chem Biol Ctr, Res Dev & Engn Command, 5183 Blackhawk Rd, Gunpowder, MD 21010 USA; [Wohlfarth, Ariane; Huestis, Marilyn A.] NIDA, Chem & Drug Metab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Wohlfarth, Ariane] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, S-58758 Linkoping, Sweden; [Wohlfarth, Ariane] Linkoping Univ, Div Drug Res, Dept Med Hlth Sci, S-58185 Linkoping, Sweden; [Nilles, John M.] Excet Inc, Springfield, VA 22150 USA; [Pang, Shaokun] SCIEX Ltd, Foster City, CA 94404 USA	Feasel, MG (reprint author), US Army, Edgewood Chem Biol Ctr, Res Dev & Engn Command, 5183 Blackhawk Rd, Gunpowder, MD 21010 USA.	michael.g.feasel.civ@mail.mil		Feasel, Michael/0000-0001-7029-2764	Defense Threat Reduction Agency (DTRA)United States Department of DefenseDefense Threat Reduction Agency [CB3281]	This work was funded by the Defense Threat Reduction Agency (DTRA) under project number CB3281.	ALLEN JL, 1989, J ZOO WILDLIFE MED, V20, P423; [Anonymous], 2015, ADMET PRED V7 2 0001; Baker P, 2002, WASH POST, pA15; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; CASHMAN JR, 1992, CHEM RES TOXICOL, V5, P639, DOI 10.1021/tx00029a008; Cole A, 2006, J ZOO WILDLIFE MED, V37, P318, DOI 10.1638/05-070.1; Dart RC, 2004, MED TOXICOL, P762; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; HANKS GW, 1987, LANCET, V2, P723; Hansch C, 1995, EXPLORING QSAR HYDRO, V2; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Krechetnkiov A, 2012, MOSCOW THEATRE SIEGE; Lave T, 1997, PHARM RES-DORDR, V14, P152, DOI 10.1023/A:1012036324237; LING GSF, 1983, EUR J PHARMACOL, V86, P487; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; McNaney CA, 2008, ASSAY DRUG DEV TECHN, V6, P121, DOI 10.1089/adt.2007.103; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; Newman A, 1988, NIDA Res Monogr, V90, P117; PIRMOHAMED M, 1995, J PHARMACOL EXP THER, V272, P984; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; Tetko IV, 2005, J COMPUT AID MOL DES, V19, P453, DOI 10.1007/s10822-005-8694-y; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; Villemagne PSR, 2002, EUR J NUCL MED MOL I, V29, P1385, DOI 10.1007/s00259-002-0897-z; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; Wohlfarth A, 2015, AAPS J, V17, P660, DOI 10.1208/s12248-015-9721-0	33	37	38	4	38	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1550-7416			AAPS J	AAPS J.	NOV	2016	18	6					1489	1499		10.1208/s12248-016-9963-5			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EB7DU	WOS:000387547000015	27495118				2020-06-30	J	Dzierba, AL; Brodie, D; Bacchetta, M; Muir, J; Wasson, L; Colabraro, M; Gannon, W; Connolly, K; Biscotti, M; Rietdijk, W; Moitra, V; Bakker, J				Dzierba, Amy L.; Brodie, Daniel; Bacchetta, Matthew; Muir, Justin; Wasson, Lauren; Colabraro, Michael; Gannon, Whitney; Connolly, Kathleen; Biscotti, Mauer; Rietdijk, Wim; Moitra, Vivek; Bakker, Jan			Ketamine use in sedation management in patients receiving extracorporeal membrane oxygenation	INTENSIVE CARE MEDICINE			English	Letter									[Dzierba, Amy L.; Muir, Justin] New York Presbyterian Hosp, Dept Pharm, New York, NY USA; [Brodie, Daniel; Colabraro, Michael; Gannon, Whitney; Connolly, Kathleen; Bakker, Jan] Columbia Univ Coll Phys & Surg, Div Pulm & Crit Care Med, New York Presbyterian Hosp, 630 W 168th St, New York, NY 10032 USA; [Bacchetta, Matthew; Biscotti, Mauer] Columbia Univ, Med Ctr, Dept Cardiothorac Surg, New York, NY USA; [Wasson, Lauren] New York Presbyterian Hosp, Div Cardiol, New York, NY USA; [Moitra, Vivek] New York Presbyterian Hosp, Dept Anesthesiol, New York, NY USA; [Rietdijk, Wim; Bakker, Jan] Univ Med Ctr Rotterdam, Erasmus MC, Rotterdam, Netherlands; [Dzierba, Amy L.] Columbia Univ, Med Ctr, New York Presbyterian Hosp, VCB, 622 West 168th St, New York, NY 10032 USA	Dzierba, AL (reprint author), Columbia Univ, Med Ctr, New York Presbyterian Hosp, VCB, 622 West 168th St, New York, NY 10032 USA.	ald9012@nyp.org	Bakker, Jan/A-4011-2009	Bakker, Jan/0000-0003-2236-7391; Muir, Justin/0000-0002-8444-5028			Dzierba AL, 2015, CRIT CARE MED S1, V43, P150; Nigoghossian CD, 2016, PHARMACOTHERAPY, V36, P607, DOI 10.1002/phar.1760; Shekar K, 2012, ANAESTH INTENS CARE, V40, P648, DOI 10.1177/0310057X1204000411; Tellor Bethany, 2015, F1000Res, V4, P16, DOI 10.12688/f1000research.6006.1; Timsit JF, 2015, INTENS CARE MED, V41, P575, DOI 10.1007/s00134-015-3755-8	5	15	15	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	NOV	2016	42	11					1822	1823		10.1007/s00134-016-4519-9			2	Critical Care Medicine	General & Internal Medicine	EA4EI	WOS:000386561900033	27620291				2020-06-30	J	Hartrick, CT; Abraham, J; Ding, L				Hartrick, Craig T.; Abraham, Jeffrey; Ding, Li			Ease-of-care from the physical therapists' perspective comparing fentanyl iontophoretic transdermal system versus morphine intravenous patient-controlled analgesia in postoperative pain management	JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH			English	Article						analgesia; analgesics; attitude of health personnel; ease-of-care; fentanyl; iontophoresis; morphine; opioid; pain; patient-controlled; physical therapists; postoperative; questionnaires; treatment outcome	SURGERY ENHANCED RECOVERY; PERIOPERATIVE CARE; INTERDISCIPLINARY APPROACH; CARDIAC-SURGERY; GUIDELINES; EFFICACY; MOBILITY; SAFETY	Aim: To compare the ease-of-care (EOC) examining time efficiency, convenience and satisfaction of fentanyl iontophoretic transdermal system ([ITS] IONSYS (R)) and morphine intravenous patient-controlled analgesia (iv. PCA) in postoperative pain management using a validated physical therapist (PT) EOC questionnaire. Materials & methods: This meta-analysis assessed EOC of fentanyl ITS versus morphine iv. PCA using data from two randomized, active-comparator studies (fentanyl ITS: n = 720 and morphine iv. PCA: n = 739) which used the PT EOC questionnaire (22 items grouped into three subscales; time efficiency, convenience and satisfaction). Each item was scored on a 6-point Likert scale. For time efficiency, PT whose average scores were = 2 on all items of the time efficiency and convenience subscales or = 4 on both satisfaction items were considered responders. Results: There were EOC questionnaires from 264 (fentanyl ITS) and 254 (morphine iv. PCA) PTs. There were significantly greater proportions of PTs classified as responders for fentanyl ITS than morphine iv. PCA for overall EOC (81.0 vs 55.7%, respectively), time efficiency (83.1 vs 59.5%, respectively), convenience (87.4 vs 72.0%, respectively) and satisfaction (51.9 vs 30.0%, respectively), all p < 0.0001. Conclusion: In this meta-analysis, fentanyl ITS is associated with a superior EOC profile (overall, time efficiency, convenience and satisfaction) from the PTs' perspective when compared with morphine iv. PCA.	[Hartrick, Craig T.] Beaumont Hlth Syst, Troy, MI USA; [Abraham, Jeffrey; Ding, Li] Medicines Co, Parsippany, NJ 07054 USA	Abraham, J (reprint author), Medicines Co, Parsippany, NJ 07054 USA.	jeffrey.abraham@themedco.com			Medicines Company	The analyses and writing of this manuscript were supported financially by The Medicines Company. C Hartrick is on the speakers bureau for The Medicines Company. J Abraham and L Ding are employees of The Medicines Company (Parsippany, NJ, USA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Bainbridge D, 2006, CAN J ANAESTH, V53, P492, DOI 10.1007/BF03022623; Batheja Priya, 2006, Expert Opin Drug Deliv, V3, P127; Bourne MH, 2010, PHYS THER, V90, P707, DOI 10.2522/ptj.20080323; Cerantola Y, 2013, CLIN NUTR, V32, P879, DOI 10.1016/j.clnu.2013.09.014; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Czaplijski Tom, 2014, Hosp Top, V92, P74, DOI 10.1080/00185868.2014.937971; Freeman R, 2013, CRIT CARE NURS Q, V36, P73, DOI 10.1097/CNQ.0b013e31827532c3; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Gustafsson UO, 2013, WORLD J SURG, V37, P259, DOI 10.1007/s00268-012-1772-0; Gustafsson UO, 2012, CLIN NUTR, V31, P783, DOI 10.1016/j.clnu.2012.08.013; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Higgins JP, COCHRANE HDB SYSTEMA; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Lassen K, 2013, WORLD J SURG, V37, P240, DOI 10.1007/s00268-012-1771-1; Lassen K, 2012, CLIN NUTR, V31, P817, DOI 10.1016/j.clnu.2012.08.011; Lindley P, 2009, J ADV NURS, V65, P1370, DOI 10.1111/j.1365-2648.2009.04991.x; Markey DW, 2002, J NURS CARE QUAL, V16, P1, DOI 10.1097/00001786-200207000-00002; Miaskowski Christine, 2005, J Perianesth Nurs, V20, P255, DOI 10.1016/j.jopan.2005.05.005; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Mortensen K, 2014, BRIT J SURG, V101, P1209, DOI 10.1002/bjs.9582; Nygren J, 2013, WORLD J SURG, V37, P285, DOI 10.1007/s00268-012-1787-6; Nygren J, 2012, CLIN NUTR, V31, P801, DOI 10.1016/j.clnu.2012.08.012; Paterno MV, 2006, PHYS THER, V86, P558, DOI 10.1093/ptj/86.4.558; Petrie A., 2009, MED STAT GLANCE; Sanguineti VA, 2014, CLIN GERIATR MED, V30, P261, DOI 10.1016/j.cger.2014.01.005; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2016, PAIN MANAG, V6, P19, DOI 10.2217/pmt.15.49; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Young Adam C, 2014, J Surg Orthop Adv, V23, P13	32	4	4	0	2	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	2042-6305	2042-6313		J COMP EFFECT RES	J. Comp. Eff. Res.	NOV	2016	5	6					529	537		10.2217/cer-2016-0038			9	Health Care Sciences & Services	Health Care Sciences & Services	EA8VJ	WOS:000386917100003	27442803	Other Gold			2020-06-30	J	Ruan, XL; Chiravuri, S; Kaye, AD				Ruan, Xiulu; Chiravuri, Srinivas; Kaye, Alan D.			Using postmortem blood and urine norfentanyl/fentanyl ratios in the investigation of fentanyl-related deaths	CLINICAL TOXICOLOGY			English	Letter									[Ruan, Xiulu; Kaye, Alan D.] Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesiol, New Orleans, LA 70112 USA; [Chiravuri, Srinivas] Univ Michigan Hlth Syst, Dept Anesthesiol, Pain Med Fellowship & Neuromodulat, Back & Pain Ctr, Ann Arbor, MI USA	Ruan, XL (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesiol, New Orleans, LA 70112 USA.	drxruan88@gmail.com					Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Hakkinen M, 2012, EUR J CLIN PHARMACOL, V68, P301, DOI 10.1007/s00228-011-1122-4; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Selden T, 2012, FORENSIC SCI INT, V220, P284, DOI 10.1016/j.forsciint.2012.03.016	5	4	4	1	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	NOV	2016	54	9					893	893		10.1080/15563650.2016.1199030			1	Toxicology	Toxicology	DZ7IK	WOS:000386038000019	27314754				2020-06-30	J	Spiller, HA; Burns, G; Casavant, MJ				Spiller, Henry A.; Burns, Glenn; Casavant, Marcel J.			Reply to "Using postmortem blood and urine norfentanyl/fentanyl ratios in the investigation of fentanyl-related deaths"	CLINICAL TOXICOLOGY			English	Letter									[Spiller, Henry A.] Ohio State Univ, Cent Ohio Poison Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Pediat, Coll Med, Columbus, OH 43210 USA	Spiller, HA (reprint author), Ohio State Univ, Cent Ohio Poison Ctr, Columbus, OH 43210 USA.	haspiller5@gmail.com					Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Juebner M, 2014, INT J LEGAL MED, V128, P949, DOI 10.1007/s00414-014-0982-4; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Van Nimmen NFJ, 2010, J CLIN PHARMACOL, V50, P667, DOI 10.1177/0091270009347872	6	0	0	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	NOV	2016	54	9					894	894		10.1080/15563650.2016.1199031			1	Toxicology	Toxicology	DZ7IK	WOS:000386038000020	27314533				2020-06-30	J	Kong, MJ; Yang, L; Li, J; Zhong, Z; Cheng, YQ; Wu, Z; Guo, R				Kong, Mingjian; Yang, Li; Li, Jing; Zhong, Zheng; Cheng, Yanqiang; Wu, Zhen; Guo, Ran			Low-dose butorphanol alleviates remifetanil-induced hyperalgesia in patients undergoing laparoscopic cholecystectomy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Remifentanil; mu-Opioid receptor; Butorphanol; kappa-Opioid receptors; laparoscopic cholecystectomy	OPIOID-INDUCED HYPERALGESIA; REMIFENTANIL; MORPHINE; RECEPTOR; TOLERANCE; PRURITUS; PHARMACOKINETICS; ANTAGONISTS; INHIBITION; ANESTHESIA	Objective: To evaluate the effects of low-dose butorphanol on hyperalgesia induced by high-dose remifetanil in patients undergoing laparoscopic cholecystectomy. Design: Randomized double-blind clinical trial. Setting: Intraoperative. Patients: Seventy-five patients scheduled for laparoscopic cholecystectomy were enrolled. Interventions: Randomly allocated into 3 groups, low dose of remifentanil (LR) group and high dose of remifentanil (HR) group received low (0.1 mu g kg(-1) min(-1)) or high (0.3 mu g kg(-1) min(-1)) doses of remifentanil, respectively, and butorphanol combined with remifentanil (BR) group received remifentanil (0.3 mu g kg(-1) min(-1)) and butorphanol (0.2 mu g/kg). Measurements: The visual analog scale scores and cumulative consumption of fentanyl were recorded. Main results: Visual analog scale scores were significantly higher in the HR group than in the LR and BR groups (P < .001). The dose of intravenously given fentanyl was significantly higher in the HR group than in the LR and BR groups (P < .001). In addition, the HR group showed a significantly higher cumulative consumption of fentanyl during 5 to 8 hours after the operation (P < .001). Conclusions: A high dose of remifenfanil induces postoperative hyperalgesia, which could be prevented by a continuous intravenous administration of a low dose of butorphanol. (C) 2016 Elsevier Inc. All rights reserved.	[Kong, Mingjian; Yang, Li; Li, Jing; Zhong, Zheng; Cheng, Yanqiang] Xuzhou Med Coll, Affiliated Hosp 2, Dept Anesthesia, Xuzhou 221000, Peoples R China; [Wu, Zhen; Guo, Ran] Southeast Univ, Coll Med, Jiangyin Hosp, Dept Anesthesia, 163 Shoushan Rd, Jiangyin 214400, Peoples R China	Kong, MJ (reprint author), Xuzhou Med Coll, Affiliated Hosp 2, Dept Anesthesia, Xuzhou 221000, Peoples R China.	mjkong@126.com					Aguado D, 2013, ANESTHESIOLOGY, V118, P1160, DOI 10.1097/ALN.0b013e3182887526; Argoff CE, 2009, MAYO CLIN PROC, V84, P602, DOI 10.1016/S0025-6196(11)60749-0; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Cabanero D, 2009, ANESTHESIOLOGY, V111, P1334, DOI 10.1097/ALN.0b013e3181bfab61; Chu LF, 2012, PAIN, V153, P974, DOI 10.1016/j.pain.2012.01.014; Gear RW, 2014, NEUROSCIENCE, V257, P139, DOI 10.1016/j.neuroscience.2013.10.061; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Gunter JB, 2000, PAEDIATR ANAESTH, V10, P167, DOI 10.1046/j.1460-9592.2000.00447.x; Hall AP, 2000, BRIT J ANAESTH, V84, P100; Hamabe W, 2008, J PHARM PHARMACOL, V60, P1183, DOI 10.1211/jpp.60.9.0010; JAW SP, 1993, PHARMACOL BIOCHEM BE, V44, P497, DOI 10.1016/0091-3057(93)90158-P; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; McNaull B, 2007, EUR J PHARMACOL, V560, P132, DOI 10.1016/j.ejphar.2006.12.013; Michelsen LG, 1996, J CLIN ANESTH, V8, P679, DOI 10.1016/S0952-8180(96)00179-1; Pan ZZ, 1998, TRENDS PHARMACOL SCI, V19, P94, DOI 10.1016/S0165-6147(98)01169-9; Rivosecchi RM, 2014, EXPERT OPIN DRUG SAF, V13, P587, DOI 10.1517/14740338.2014.902931; Sneyd JR, 2001, EUR J ANAESTH, V18, P605, DOI 10.1046/j.1365-2346.2001.00929.x; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Tuerke KJ, 2011, BEHAV PHARMACOL, V22, P558, DOI 10.1097/FBP.0b013e3283474a56; Wu Z, 2014, CELL BIOCHEM BIOPHYS, V70, P209, DOI 10.1007/s12013-014-9884-9; Wu Z, 2012, J ANESTH, V26, P752, DOI 10.1007/s00540-012-1421-7	22	5	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	NOV	2016	34						41	45		10.1016/j.jclinane.2016.03.042			5	Anesthesiology	Anesthesiology	DY2WL	WOS:000384952700008	27687343				2020-06-30	J	Komasawa, N; Nishihara, I; Nishimura, W; Minami, T				Komasawa, Nobuyasu; Nishihara, Isao; Nishimura, Wataru; Minami, Toshiaki			Cardiac arrest associated with takotsubo cardiomyopathy after tracheal intubation	JOURNAL OF CLINICAL ANESTHESIA			English	Letter							TRIAL		[Komasawa, Nobuyasu; Nishimura, Wataru; Minami, Toshiaki] Osaka Med Coll, Dept Anesthesiol, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan; [Nishihara, Isao] Hokusetsu Gen Hosp, Dept Anesthesiol, Takatsuki, Osaka, Japan	Komasawa, N (reprint author), Osaka Med Coll, Dept Anesthesiol, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan.	ane078@osaka-med.ac.jp					Kawai S, 2007, CIRC J, V71, P990, DOI 10.1253/circj.71.990; Kido H, 2015, J CLIN ANESTH, V27, P476, DOI 10.1016/j.jclinane.2015.05.011; Komasawa N, 2016, BRIT J ANAESTH, V116, P413, DOI 10.1093/bja/aev438; Liu SY, 2010, J CLIN ANESTH, V22, P64, DOI 10.1016/j.jclinane.2009.03.010	4	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	NOV	2016	34						53	54		10.1016/j.jclinane.2016.03.048			2	Anesthesiology	Anesthesiology	DY2WL	WOS:000384952700010	27687345				2020-06-30	J	Tewari, S; Bhadoria, P; Wadhawan, S; Prasad, S; Kohli, A				Tewari, Saipriya; Bhadoria, Poonam; Wadhawan, Sonia; Prasad, Sudha; Kohli, Amit			Entropy vs standard clinical monitoring using total intravenous anesthesia during transvaginal oocyte retrieval in patients for in vitro fertilization	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Entropy; Intraoperative awareness; Transvaginal oocyte retrieval	PROPOFOL-REMIFENTANIL ANESTHESIA; RANDOMIZED CONTROLLED-TRIAL; SPECTRAL ENTROPY; FASTER EMERGENCE; RECOVERY PROFILE; INDEX; AWARENESS; SYSTEM; CONSUMPTION; ALFENTANIL	Study objective: Day care surgery is an important arena for monitors of anesthetic depth where minimizing drug use is essential for rapid turnover. Underdosage, on the other hand, carries the risks of intraoperative awareness and pain. Transvaginal oocyte retrieval (TVOR), often performed under total intravenous anesthesia using propofol and fentanyl in Indian patients, is a procedure of special interest because, in addition to the above concerns, toxic effects of propofol on oocytes have been described. We have studied the role of entropy monitor, a depth of anesthesia monitor, in optomising drug titration and facilitating distinction between analgesic and hypnotic components of anesthesia. Design: Prospective randomized controlled study. Setting: Operating theater and postoperative recovery area. Patients: One hundred twenty American Society of Anesthesiologists class I and II female patients coming to the IVF centre for TVOR under total intravenous anesthesia using propofol and fentanyl. They were randomly allocated into 2 groups: Group EM (drugs titrated as per entropy values: state entropy and response entropy) and group CM (drugs titrated as per standard clinical monitoring). Intervention: None. Measurements: Total propofol consumption (TP), total fentanyl consumption (TF), on-table recovery time (T1), time to discharge (T2), intraoperative awareness (A). Main results: Patients in group EM demonstrated 6.7% lesser consumption of propofol (P=.01), 10.9% more consumption of fentanyl (P=.007) and 1 minute faster recovery on-table (P=.009) as compared to group CM. In the PACU, only 10% patients of group EM required supplemental analgesia as opposed to 28.3% in CM group (P=.01). Time to discharge was similar in both groups and no intraoperative awareness was noted. Conclusion: Entropy monitor is a useful tool allowing distinction between analgesic and hypnotic components of general anesthesia in patients undergoing TVOR and facilitating drug titration accordingly. Its impact on intraoperative awareness needs to be further evaluated. (C) 2016 Elsevier Inc. All rights reserved.	[Tewari, Saipriya] Sanjay Gandhi Post Grad Inst, Dept Anaesthesiol, Raebareli Rd, Lucknow 226014, Uttar Pradesh, India; [Bhadoria, Poonam; Wadhawan, Sonia; Kohli, Amit] Maulana Azad Med Coll, Dept Anaesthesiol, Bahadur Shah Zafar Marg, New Delhi 110002, India; [Prasad, Sudha] Maulana Azad Med Coll, Dept Obstet & Gynecol, Bahadur Shah Zafar Marg, New Delhi 110002, India	Tewari, S (reprint author), D-117, New Delhi 110018, India.	saitewari.mamc@gmail.com					Alsalili M, 1997, HUM REPROD, V12, P1271; Anderson RE, 2004, ANAESTHESIA, V59, P52, DOI 10.1111/j.1365-2044.2004.03523.x; [Anonymous], 2010, MILLERS TXB ANAESTHE; Bhardwaj N, 2010, PEDIATR ANESTH, V20, P899, DOI 10.1111/j.1460-9592.2010.03382.x; Drover DR, 2002, ANESTHESIOLOGY, V97, P82, DOI 10.1097/00000542-200207000-00012; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; Kreuer S, 2003, ANESTHESIOLOGY, V99, P34, DOI 10.1097/00000542-200307000-00009; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Palumbo P, 2013, ANN ITAL CHIR, V84, P661; Pollard RJ, 2007, ANESTHESIOLOGY, V106, P269, DOI 10.1097/00000542-200702000-00014; Sargin M, 2015, PEDIATR ANESTH, V25, P950, DOI 10.1111/pan.12692; Schmidt GN, 2004, ANESTHESIOLOGY, V101, P1283; Talawar P, 2010, PEDIATR ANESTH, V20, P1105, DOI 10.1111/j.1460-9592.2010.03441.x; Vakkuri A, 2005, ANESTHESIOLOGY, V103, P274, DOI 10.1097/00000542-200508000-00010; Vakkuri A, 2004, ACTA ANAESTH SCAND, V48, P145, DOI 10.1111/j.0001-5172.2004.00323.x	15	2	2	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	NOV	2016	34						105	112		10.1016/j.jclinane.2016.02.029			8	Anesthesiology	Anesthesiology	DY2WL	WOS:000384952700020	27687355				2020-06-30	J	Pere, P; Harju, J; Kairaluoma, P; Remes, V; Turunen, P; Rosenberg, PH				Pere, Pertti; Harju, Jukka; Kairaluoma, Pekka; Remes, Veikko; Turunen, Paivi; Rosenberg, Per H.			Randomized comparison of the feasibility of three anesthetic techniques for day-case open inguinal hernia repair	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Day-case surgery; Discharge home; Intravenous general anesthesia; Local anesthetic infiltration; Open inguinal hernia repair; Spinal anesthesia	LOW-DOSE BUPIVACAINE; GENERAL-ANESTHESIA; SPINAL-ANESTHESIA; PATIENT SATISFACTION; KNEE ARTHROSCOPY; CLINICAL-TRIAL; SUTURED MESH; HERNIORRHAPHY; SURGERY; PAIN	Study objective: Comparison of local anesthetic infiltration (LAI), spinal anesthesia (SPIN) and total intravenous anesthesia (TIVA) for open inguinal herniorrhaphy. We hypothesized that patients receiving LAI could be discharged faster than SPIN and TWA patients. Design: Randomized, prospective trial. Setting: University hospital day-surgery center. Patients: 156 adult male patients (ASA 1-3) undergoing day-case open inguinal herniorrhaphy. Interventions: Patients were randomized to either LAI (lidocaine + ropivacaine), SPIN (bupivacaine + fentanyl) or TWA (propofol + remifentanil). Perioperative Ringer infusion was 1.5 mL/h. Urinary bladder was scanned before and after surgery. Interviews were performed on postoperative days 1, 7 and 90. Measurements: Duration of surgery, duration of the patients' stay in the operating room and time until their readiness for discharge home. Patient satisfaction and adverse effects were registered. Main results: Surgery lasted longer in LAI group (median 40 min) than in SPIN group (35 min) (P = .003) and TWA group (33 min) (P < .001). Although surgery was shortest in TWA group, TWA patients stayed longer in the operating room than LAI patients (P = .001). Time until readiness for discharge was shorter in LAI group (93 min) than in TWA (147 min) and SPIN (190 min) groups (P < .001). Supplementary lidocaine infiltration was given to 32 LAI patients, and IV fentanyl to 29 LAI and 4 SPIN patients. Ephedrine was required in 34 TIVA, 5 LAI and 5 SPIN patients. One SPIN and three LAI patients had to be given TWA and another SPIN patient LAI to complete the operations. Urinary retention was absent. Discomfort in the scar (26%) three months postoperatively was not anesthesia-related. Conclusions: Logistically, LAI was superior because of the fastest recovery postoperatively. The anesthetic techniques were adequate for surgery in all but a few LAI and SPIN patients. Lack of urinary retention was probably related to the small IV infusion volumes. (C) 2016 Elsevier Inc. All rights reserved.	[Pere, Pertti; Kairaluoma, Pekka; Turunen, Paivi; Rosenberg, Per H.] Univ Helsinki, Dept Anesthesiol, Div Anesthesiol, FIN-00014 Helsinki, Finland; [Pere, Pertti; Kairaluoma, Pekka; Turunen, Paivi; Rosenberg, Per H.] Helsinki Univ Hosp, Intens Care & Pain Med, Helsinki, Finland; [Harju, Jukka; Remes, Veikko] Univ Helsinki, Dept Surg, Div Gastrointestinal Surg, FIN-00014 Helsinki, Finland; [Pere, Pertti; Harju, Jukka; Kairaluoma, Pekka; Remes, Veikko; Turunen, Paivi] Univ Helsinki, Cent Hosp, Surg Hosp, Day Surgery Ctr, POB 263, Helsinki 00029, Finland	Pere, P (reprint author), Acad Med Ctr Helsinki, Div Anesthesiol, Dept Anesthesiol Intens Care Med & Pain Med, POB 340, Helsinki 00029, Finland.	pertti.pere@hus.fi			Finska Lakaresallskapet, Finland	Our warm thanks are due to the staff of the Day Surgery Center of Helsinki University Hospital for excellent cooperation in planning and facilitating the execution of the study. The study was supported by grants from Finska Lakaresallskapet, Finland. We acknowledge the expert advice of urologist Anna-Kaisa Pere, MD, PhD, and Juho Heinonen, MD, in performing the statistical analyses.	Bachmann M, 2012, EUR J ANAESTH, V29, P22, DOI 10.1097/EJA.0b013e32834a11be; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Callesen T, 2001, ANESTH ANALG, V93, P1373, DOI 10.1097/00000539-200112000-00004; Casati A, 2007, ANESTH ANALG, V104, P959, DOI 10.1213/01.ane.0000258766.73612.d8; Chastan P, 2009, HERNIA, V13, P137, DOI 10.1007/s10029-008-0451-4; Forster JG, 2011, ACTA ANAESTH SCAND, V55, P273, DOI 10.1111/j.1399-6576.2010.02325.x; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; Jensen P, 2002, REGION ANESTH PAIN M, V27, P612, DOI 10.1053/rapm.2002.37122; Jorgensen LN, 2013, BRIT J SURG, V100, P474, DOI 10.1002/bjs.9006; Joshi GP, 2012, BRIT J SURG, V99, P168, DOI 10.1002/bjs.7660; Kehlet H, 2005, ACTA ANAESTH SCAND, V49, P143, DOI 10.1111/j.1399-6576.2004.00600.x; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; KINGSNORTH AN, 2000, HERNIA, V4, P1; Lemos P, 2009, J CLIN ANESTH, V21, P200, DOI 10.1016/j.jclinane.2008.08.016; Myles PS, 2000, BRIT J ANAESTH, V84, P6; Nordin P, 2007, BRIT J SURG, V94, P500, DOI 10.1002/bjs.5543; Nordin P, 2003, LANCET, V362, P853, DOI 10.1016/S0140-6736(03)14339-5; Nordin P, 2013, MANAGEMENT ABDOMINAL, P159; O'Dwyer PJ, 2003, ANN SURG, V237, P574, DOI 10.1097/00000658-200304000-00020; Ozgun H, 2002, EUR J SURG, V168, P455, DOI 10.1080/110241502321116442; Pierides G, 2012, BRIT J SURG, V99, P630, DOI 10.1002/bjs.8705; Rivat C, 2013, CURR OPIN ANESTHESIO, V26, P621, DOI 10.1097/01.aco.0000432511.08070.de; Saeed M, 2015, INT J SURG, V13, P76, DOI 10.1016/j.ijsu.2014.11.037; Simons MP, 2009, HERNIA, V13, P343, DOI 10.1007/s10029-009-0529-7; Song DJ, 2000, ANESTH ANALG, V91, P876, DOI 10.1097/00000539-200010000-00020; Symeonidis D, 2014, SURG TODAY, V44, P906, DOI 10.1007/s00595-013-0805-0	26	8	10	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	NOV	2016	34						166	175		10.1016/j.jclinane.2016.03.062			10	Anesthesiology	Anesthesiology	DY2WL	WOS:000384952700031	27687366	Green Published			2020-06-30	J	Ahn, JH; Ahn, HJ				Ahn, Jin Hee; Ahn, Hyun Joo			Effect of thoracic epidural analgesia on recovery of bowel function after major upper abdominal surgery	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Thoracic epidural analgesia; Intravenous patient controlled analgesia; Bowel function recovery	PATIENT-CONTROLLED ANALGESIA; COLORECTAL SURGERY; POSTOPERATIVE ANALGESIA; ENHANCED RECOVERY; OPIOID ANALGESIA; RANDOMIZED TRIAL; COLONIC SURGERY; RISK-FACTORS; ANESTHESIA; METAANALYSIS	Study Objective: We investigated whether thoracic epidural analgesia (TEA) shortens the first gas-out time compared to intravenous patient-controlled analgesia (iv-PCA) and promotes earlier discharge after major upper abdominal surgery. Design: Prospective observational study. Setting: A tertiary care university hospital. Patients: Fifty-six patients undergoing major upper abdominal surgery. Interventions: TEA (n = 28) was performed using a paramedian approach at T6-7 or T7-8. Hydromorphone (8 mu g/mL) was added to 0.15% ropivacaine (bolus/lockout time/basal: 3 mL/15 minutes/5 mL). The iv-PCA regimen (n = 28) included 20 mu g/mL fentanyl (bolus/lockout time/basal: 0.5 mL/15 minutes/0.5 mL). The 2 analgesic methods were maintained for 3 days. Measurement: The primary end point was first gas-out time, and the secondary end points were hospital discharge, pain scores, and first voiding time. Main Results: No differences in first gas-out time (TEA, 4.1 +/- 1.2 days; iv-PCA, 3.4 +/- 1.9 days; P =.15) or hospital stay (TEA, 9.8 +/- 2.2 days; iv-PCA, 11.4 +/- 5.2 days; P =.19) were observed between the 2 groups. A visual analog pain scale scores during rest and coughing were lower in the TEA than those for iv-PCA even with 40% to 46% less rescue analgesic. However, TEA delayed first voiding time (3.6 +/- 0.9 vs 2.8 +/- 1.6 days; P =.02) and required more frequent bladder catheterization (46% vs 11%; P =.008) than those of iv-PCA. Conclusion: TEA with a regimen of hydromorphone (8 mu g/mL) added to 0.15% ropivacaine did not provide earlier gas-out compared to that of iv-PCA in patients who underwent major upper abdominal surgery. (C) 2016 Elsevier Inc. All rights reserved.	[Ahn, Jin Hee; Ahn, Hyun Joo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea	Ahn, HJ (reprint author), Samsung Med Ctr, Dept Anesthesiol & Pain Med, 50 Ilwon Dong, Seoul 135710, South Korea.	hyunjooahn@skku.edu	Ahn, Jin hee/C-6122-2019	Ahn, Jin hee/0000-0002-5861-1328			Baig MK, 2004, DIS COLON RECTUM, V47, P516, DOI 10.1007/s10350-003-0067-9; Baldini G, 2009, ANESTHESIOLOGY, V110, P1139, DOI 10.1097/ALN.0b013e31819f7aea; Bauer AJ, 2004, NEUROGASTROENT MOTIL, V16, P54, DOI 10.1111/j.1743-3150.2004.00558.x; Beilin B, 2003, ANESTHESIOLOGY, V98, P151, DOI 10.1097/00000542-200301000-00024; BREDTMANN RD, 1990, BRIT J SURG, V77, P638, DOI 10.1002/bjs.1800770615; Carli F, 2001, DIS COLON RECTUM, V44, P1083, DOI 10.1007/BF02234626; CARPENTER RL, 1992, ANESTHESIOLOGY, V76, P906, DOI 10.1097/00000542-199206000-00006; Claxton AR, 1997, ANESTH ANALG, V84, P509, DOI 10.1097/00000539-199703000-00008; Freise H, 2009, CRIT CARE, V13, DOI 10.1186/cc7965; Freise H, 2009, CURR OPIN ANESTHESIO, V22, P644, DOI 10.1097/ACO.0b013e32832eb7e8; Holte K, 2002, DRUGS, V62, P2603, DOI 10.2165/00003495-200262180-00004; JORGENSEN H, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001893; Khan SA, 2013, SURG ENDOSC, V27, P2581, DOI 10.1007/s00464-013-2794-x; Kurygin A A, 2002, Vestn Khir Im I I Grek, V161, P32; Liu SS, 2007, ANESTH ANALG, V104, P689, DOI 10.1213/01.ane.0000255040.71600.41; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Mann C, 2000, ANESTHESIOLOGY, V92, P433, DOI 10.1097/00000542-200002000-00025; Marret E, 2007, BRIT J SURG, V94, P665, DOI 10.1002/bjs.5825; Mythen MG, 2005, ANESTH ANALG, V100, P196, DOI 10.1213/01.ANE.0000139376.45591.17; Park WY, 2001, ANN SURG, V234, P560; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Segal S, 2010, ANESTH ANALG, V111, P1467, DOI 10.1213/ANE.0b013e3181f713d4; Senagore AJ, 2003, BRIT J SURG, V90, P1195, DOI 10.1002/bjs.4223; Siriussawakul A, 2010, CAN J ANAESTH, V57, P415, DOI 10.1007/s12630-010-9279-3; Steinberg RB, 2002, J CLIN ANESTH, V14, P571, DOI 10.1016/S0952-8180(02)00451-8; Taqi A, 2007, SURG ENDOSC, V21, P247, DOI 10.1007/s00464-006-0069-5; Varadhan KK, 2010, CLIN NUTR, V29, P434, DOI 10.1016/j.clnu.2010.01.004; Waurick R, 2005, BEST PRACT RES-CLIN, V19, P201, DOI 10.1016/j.bpa.2004.12.001; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652; Wind J, 2006, BRIT J SURG, V93, P800, DOI 10.1002/bjs.5384; Wongyingsinn M, 2011, REGION ANESTH PAIN M, V36, P241, DOI 10.1097/AAP.0b013e31820d4362	31	7	7	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	NOV	2016	34						247	252		10.1016/j.jclinane.2016.04.042			6	Anesthesiology	Anesthesiology	DY2WL	WOS:000384952700049	27687384				2020-06-30	J	Kido, H; Komasawa, N; Ishio, J; Minami, T				Kido, Haruki; Komasawa, Nobuyasu; Ishio, Junichi; Minami, Toshiaki			Use of a modified McGRATH MAC and tracheal tube introducer for difficult nasal intubation	JOURNAL OF CLINICAL ANESTHESIA			English	Letter							TRIAL		[Kido, Haruki; Komasawa, Nobuyasu; Ishio, Junichi; Minami, Toshiaki] Osaka Med Coll, Dept Anesthesiol, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan	Komasawa, N (reprint author), Osaka Med Coll, Dept Anesthesiol, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan.	ane078@osaka-med.ac.jp					Kido H, 2015, J CLIN ANESTH, V27, P476, DOI 10.1016/j.jclinane.2015.05.011; Komasawa N, 2016, AM J EMERG MED, V34, P54, DOI 10.1016/j.ajem.2015.09.016; Komasawa N, 2014, J ANESTH, V28, P676, DOI 10.1007/s00540-014-1802-1	3	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	NOV	2016	34						255	256		10.1016/j.jclinane.2016.04.053			2	Anesthesiology	Anesthesiology	DY2WL	WOS:000384952700051	27687386				2020-06-30	J	Latimer, J; Ling, S; Flaherty, I; Jauncey, M; Salmon, AM				Latimer, Julie; Ling, Stephen; Flaherty, Ian; Jauncey, Marianne; Salmon, Allison M.			Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article							HEROIN OVERDOSE; CANADA; DRUGS		[Latimer, Julie; Flaherty, Ian; Jauncey, Marianne; Salmon, Allison M.] Sydney Med Supervised Injecting Ctr, Kings Cross, NSW, Australia; [Ling, Stephen] Hunter New England Local Hlth Dist, Tamworth, NSW, Australia; [Ling, Stephen] Univ Newcastle, Fac Hlth & Med, Sch Nursing & Midwifery, Callaghan, NSW 2308, Australia	Latimer, J (reprint author), POB 293, Kings Cross, NSW 1340, Australia.	jlatimer@uniting.org					Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Anaesthesia UK, PHARM OP; Biancofiore Giuseppe, 2006, Ther Clin Risk Manag, V2, P229, DOI 10.2147/tcrm.2006.2.3.229; Canadian Centre on Substance Abuse, 2015, DEATHS INV FENT CAN; CHODOFF P, 1965, ANESTH ANAL CURR RES, V44, P558; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Darke S, 2003, J URBAN HEALTH, V80, P189, DOI 10.1093/jurban/jtg022; [DEA U.S. Department of Justice Drug Enforcement Administration.], 2015, DEA ISS NAT AL FENT; Dietze P, 2005, ADDICTION, V100, P636, DOI 10.1111/j.1360-0443.2005.01051.x; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; THARP AM, 2004, THE AMERICAN JOURNAL, V25, P178, DOI DOI 10.1097/01.PAF.0000127398.67081.11	16	22	22	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	NOV	2016	37						111	114		10.1016/j.drugpo.2016.08.004			4	Substance Abuse	Substance Abuse	ED3YI	WOS:000388784000013	27750104				2020-06-30	J	Simon, ST; Kloke, M; Alt-Epping, B; Gartner, J; Hellmich, M; Med, R; Piel, M; Cornely, OA; Nauck, F; Voltz, R				Simon, Steffen T.; Kloke, Marianne; Alt-Epping, Bernd; Gaertner, Jan; Hellmich, Martin; Hein, Rebecca; Piel, Maren; Cornely, Oliver A.; Nauck, Friedemann; Voltz, Raymond			EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Episodic breathlessness; fentanyl; morphine; cancer	DOUBLE-BLIND; EXERCISE; DYSPNEA; INTENSITY; CITRATE; PAIN	Context. Episodic breathlessness is a frequent and burdensome symptom in cancer patients but pharmacological treatment is limited. Objectives. To determine time to onset, efficacy, feasibility, and safety of transmucosal fentanyl in comparison to immediate-release morphine for the relief of episodic breathlessness. Methods. Phase II, investigator-initiated, multicenter, open-label, randomized, morphine-controlled, crossover trial with openlabel titration of fentanyl buccal tablet (FBT) in inpatients with incurable cancer. The primary outcome was time to onset of meaningful breathlessness relief. Secondary outcomes were efficacy (breathlessness intensity difference at 10 and 30 minutes; sum of breathlessness intensity difference at 15 and 60 minutes), feasibility, and safety. Study was approved by local ethics committees. Results. Twenty-five of 1341 patients were eligible, 10 patients agreed to participate (four female, mean age 58 +/- 11, mean Karnofsky score 67 +/- 11). Two patients died before final visits and two patients dropped-out because of disease progression leaving six patients for analysis with 61 episodes of breathlessness. Mean time to onset was for FBT 12.7 +/- 10.0 and for immediate-release morphine 23.6 +/- 15.1 minutes with a mean difference of -10.9 minutes (95% CI - -24.5 to 2.7, P = 0.094). Efficacy measures were predominately in favor for FBT. Both interventions were safe. Feasibility failed because of too much study demands for a very ill patient group. Conclusion. The description of a faster and greater relief of episodic breathlessness by transmucosal fentanyl versus morphine justifies further evaluation by a full-powered trial. (C) 2016 Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine.	[Simon, Steffen T.; Piel, Maren; Voltz, Raymond] Univ Hosp Cologne, Dept Palliat Med, Kerpener St 62, D-50924 Cologne, Germany; [Simon, Steffen T.; Piel, Maren; Voltz, Raymond] Univ Hosp Cologne, Clin Trial Unit Palliat Care, Cologne, Germany; [Simon, Steffen T.; Piel, Maren; Voltz, Raymond] Univ Hosp Cologne, Ctr Integrated Oncol CIO Cologne Bonn, Cologne, Germany; [Kloke, Marianne] Kliniken Essen Mitte, Dept Palliat Med, Inst Palliat Care, Essen, Germany; [Alt-Epping, Bernd; Nauck, Friedemann] Univ Med Ctr Goettingen, Dept Palliat Med, Gottingen, Germany; [Gaertner, Jan] Univ Freiburg, Fac Med, Med Ctr, Clin Palliat Care, Freiburg, Germany; [Hellmich, Martin; Hein, Rebecca] Univ Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany; [Cornely, Oliver A.] Univ Cologne, Dept Internal Med 1, Cologne Excellence Cluster Cellular Stress Respon, ZKS Koln,Clin Trials Ctr Cologne, Cologne, Germany	Simon, ST (reprint author), Univ Hosp Cologne, Dept Palliat Med, Kerpener St 62, D-50924 Cologne, Germany.	steffen@steffensimon.de	Cornely, Oliver A/J-5095-2013	Cornely, Oliver A/0000-0001-9599-3137; Gaertner, Jan/0000-0002-1176-3164; Roth, Rebecca/0000-0002-2841-4921; Gaertner, Jan/0000-0002-8824-7117	TEVA Ltd. [3620 2461 31]; Federal Ministry of Research and Education [BMBF 01KN1106]	EffenDys was an investigator-initiated trial and was supported by an unrestricted grant (3620 2461 31) from TEVA Ltd., the pharmaceutical producer of Effentora (R) (former Cephalon Inc.). The funder had no influence on the study design and the collection of data and did not have any role in execution, analyses, interpretation of the data, decision to submit results, or writing the article. The Clinical Trial Unit in Palliative Care of the Department of Palliative Medicine in Cologne was supported by the Federal Ministry of Research and Education (BMBF 01KN1106).	Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Booth Sara, 2009, Expert Rev Respir Med, V3, P21, DOI 10.1586/17476348.3.1.21; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Currow DC, 2010, J PAIN SYMPTOM MANAG, V39, P680, DOI 10.1016/j.jpainsymman.2009.09.017; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Ekstrom M, 2015, ANN AM THORAC SOC, V12, P1079, DOI 10.1513/AnnalsATS.201501-034OC; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Freye Enno, 2007, Pain Pract, V7, P324, DOI 10.1111/j.1533-2500.2007.00157.x; Hui D, 2014, J PAIN SYMPTOM MANAG, V47, P209, DOI 10.1016/j.jpainsymman.2013.03.017; JENNINGS AL, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002066; Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007; Kotrach HG, 2015, J APPL PHYSIOL, V118, P1406, DOI 10.1152/japplphysiol.01091.2014; Maddocks M, 2012, LUNG CANCER, V76, P128, DOI 10.1016/j.lungcan.2012.01.003; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2016, J PAIN SYMPTOM MANAG, V51, P17, DOI 10.1016/j.jpainsymman.2015.07.020; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Reddy SK, 2009, J PALLIAT MED, V12, P29, DOI 10.1089/jpm.2008.0158; Simon ST, 2014, J PAIN SYMPTOM MANAG, V47, P828, DOI 10.1016/j.jpainsymman.2013.06.013; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Twycross R, 2014, PCF5 PALLIATIVE CARE; Weingartner V, 2015, PALLIATIVE MED, V29, P420, DOI 10.1177/0269216314563428; Weingartner V, 2013, J PALLIAT MED, V16, P1275, DOI 10.1089/jpm.2013.0087	23	6	6	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	NOV	2016	52	5					617	625		10.1016/j.jpainsymman.2016.05.023			9	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	EC2OE	WOS:000387961500005	27693898	Bronze			2020-06-30	J	Saccone, PA; Lindsey, AM; Koeppe, RA; Zelenock, KA; Shao, X; Sherman, P; Quesada, CA; Woods, JH; Scott, PJH				Saccone, Phillip A.; Lindsey, Angela M.; Koeppe, Robert A.; Zelenock, Kathy A.; Shao, Xia; Sherman, Phillip; Quesada, Carole A.; Woods, James H.; Scott, Peter J. H.			Intranasal Opioid Administration in Rhesus Monkeys: PET Imaging and Antinociception	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							TAIL-WITHDRAWAL PROCEDURE; CENTRAL-NERVOUS-SYSTEM; DRUG-DELIVERY; NASAL SPRAY; BREAKTHROUGH PAIN; DOUBLE-BLIND; NALOXONE; OVERDOSE; BUPRENORPHINE; FENTANYL	The goal of this study was to evaluate the effects of intranasally administered opioids in rhesus monkeys using the tail-withdrawal assay, and to correlate these effects with measures of receptor occupancy using positron emission tomography (PET) imaging. Initial experiments characterized the antinociceptive effects of intranasal (IN) fentanyl and buprenorphine relative to intramuscular (IM) injection. Fentanyl (0.010-0.032 mg/kg) and buprenorphine (0.1-1.0 mg/kg) produced dose-dependent increases in tail-withdrawal latency that did not differ between routes of delivery. The second experiment compared the ability of IN and intravenous (IV) naloxone (NLX) to block the antinociceptive effects IV fentanyl, and to measure receptor occupancy at equipotent doses of NLX using PET imaging. IN and IV NLX (0.0032-0.032 mg/kg) produced dose-dependent decreases in fentanyl-induced antinociception. Again, there was no difference observed in overall potency between routes. PET imaging showed that IV and IN NLX produced similar decreases in receptor occupancy as measured by [C-11] carfentanil blocking, although there was a trend for IV NLX to produce marginally greater occupancy changes. This study validated the first procedures to evaluate the IN effects of opioids in rhesus monkeys.	[Saccone, Phillip A.; Lindsey, Angela M.; Zelenock, Kathy A.; Woods, James H.] Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA; [Koeppe, Robert A.; Shao, Xia; Sherman, Phillip; Quesada, Carole A.; Scott, Peter J. H.] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI 48109 USA	Saccone, PA (reprint author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	acconep@umich.edu		Scott, Peter/0000-0002-6505-0450	National Institutes of Health National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F31-DA038488, T32-DA007281]; Society for Nuclear Medicine and Molecular Imaging; University of Michigan Department of Radiology	This study was supported by the National Institutes of Health National Institute on Drug Abuse [Grants F31-DA038488 and T32-DA007281], the Bradley-Alavi Student Fellowship from the Society for Nuclear Medicine and Molecular Imaging, and the University of Michigan Department of Radiology. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the National Institute on Drug Abuse, or the Society for Nuclear Medicine and Molecular Imaging. Disclosure/Conflict of Interest: None.	Barton ED, 2005, J EMERG MED, V29, P265, DOI 10.1016/j.jemermed.2005.03.007; BUTELMAN ER, 1993, J PHARMACOL EXP THER, V264, P145; Cheng TJ, 2007, J CHEM INF MODEL, V47, P2140, DOI 10.1021/ci700257y; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/j.1476-5381.1977.tb07533.x; COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/j.1476-5381.1977.tb07532.x; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Doe-Simkins M, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-297; Dowling J, 2008, THER DRUG MONIT, V30, P490, DOI 10.1097/FTD.0b013e3181816214; Dykstra L A, 1988, Psychopharmacol Ser, V4, P107; DYKSTRA LA, 1986, J PHARMACOL METHOD, V15, P263, DOI 10.1016/0160-5402(86)90056-2; Fortuna A, 2014, EUR J PHARM BIOPHARM, V88, P8, DOI 10.1016/j.ejpb.2014.03.004; Gourlay SG, 1997, CLIN PHARMACOL THER, V62, P453, DOI 10.1016/S0009-9236(97)90124-7; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; GROSS EA, 1982, J ANAT, V135, P83; Guthrie SK, 1999, EUR J CLIN PHARMACOL, V55, P639, DOI 10.1007/s002280050686; Harkema JR, 2006, TOXICOL PATHOL, V34, P252, DOI 10.1080/01926230600713475; Johnson NJ, 2010, MOL PHARMACEUT, V7, P884, DOI 10.1021/mp100029t; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Kerr D, 2009, ADDICTION, V104, P2067, DOI 10.1111/j.1360-0443.2009.02724.x; Kishioka S, 2000, EUR J PHARMACOL, V391, P289, DOI 10.1016/S0014-2999(00)00039-X; Kongsgaard UE, 2014, SUPPORT CARE CANCER, V22, P1655, DOI 10.1007/s00520-014-2128-0; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Landis MS, 2012, THER DELIV, V3, P195, DOI 10.4155/TDE.11.149; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Miyake MM, 2015, AM J RHINOL ALLERGY, V29, P124, DOI 10.2500/ajra.2015.29.4149; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Pires A, 2009, J PHARM PHARM SCI, V12, P288, DOI 10.18433/J3NC79; Rando J, 2015, AM J EMERG MED, V33, P1201, DOI 10.1016/j.ajem.2015.05.022; Sabzghabaee AM, 2014, ARCH MED SCI, V10, P309, DOI 10.5114/aoms.2014.42584; Scheibe M, 2008, ARCH OTOLARYNGOL, V134, P643, DOI 10.1001/archotol.134.6.643; Shao X, 2011, J LABELLED COMPD RAD, V54, P292, DOI 10.1002/jlcr.1865; Smith TD, 2004, ANAT REC PART A, V281A, P1173, DOI 10.1002/ar.a.20122; VANACKER B, 1986, CURR MED RES OPIN, V10, P139, DOI 10.1185/03007998609110432; WALKER EA, 1993, J PHARMACOL EXP THER, V267, P280; WALKER EA, 1995, J PHARMACOL EXP THER, V273, P1345; Wermeling DP, 2013, DRUG DELIV TRANSL RE, V3, P63, DOI 10.1007/s13346-012-0092-0; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631; Zuckerman M, 2014, PREHOSP EMERG CARE, V18, P550, DOI 10.3109/10903127.2014.896961	39	9	9	0	9	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV 1	2016	359	2					366	373		10.1124/jpet.116.235192			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EE4WE	WOS:000389605500015	27625351	Green Published, Bronze			2020-06-30	J	Cata, JP; Chavez-MacGregor, M; Valero, V; Black, W; Black, DM; Goravanchi, F; Ifeanyi, IC; Hernandez, M; Rodriguez-Restrepo, A; Gottumukkala, V				Cata, Juan P.; Chavez-MacGregor, Mariana; Valero, Vicente; Black, Walter; Black, Daliah M.; Goravanchi, Farzin; Ifeanyi, Ifey C.; Hernandez, Mike; Rodriguez-Restrepo, Andrea; Gottumukkala, Vijaya			The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							REGIONAL ANESTHESIA; PROPENSITY SCORE; RECURRENCE; MASTECTOMY; RATES	Background and Objectives: The impact of regional anesthesia on breast cancer recurrence is controversial. We tested the hypothesis that the use of paravertebral block (PVB) analgesia during breast cancer surgery prolongs the recurrence-free survival (RFS) and overall survival (OS) of women with breast cancer. Methods: Seven hundred ninety-two women with nonmetastatic breast cancer were included in this retrospective study. Patients were divided based on the administration of PVB analgesia for mastectomy surgeries. One hundred ninety-eight (25%) were given a PVB, the remainder were treated with opioid-based analgesia. Propensity score matching was developed using several variables. Univariate and multivariate analyses were used to assess the impact of PVB analgesia on RFS and OS. Results: The median follow-up times for RFS and OS were 5.8 and 6 years, respectively. In the propensity score matching model, a total of 396 women were included in each group of treatment (non-PVB group, n = 198 vs PVB group, n = 198). As expected, the fentanyl consumption was significantly lower in PVB (122.8 +/- 77.85 mu g) patients than non-PVB subjects (402.23 +/- 343.8 mu g). Other variables were not statistically significant. After adjusting for several important covariates, the analysis indicated that the use of PVB is not associated with a significant change in RFS [1.60 (0.81-3.16), P = 0.172] or OS [1.28 (0.55-3.01)] survival. Discussion: This retrospective study does not support the hypothesis that the use of regional analgesia is associated with longer survival after surgery for breast cancer.	[Cata, Juan P.; Black, Walter; Goravanchi, Farzin; Ifeanyi, Ifey C.; Rodriguez-Restrepo, Andrea; Gottumukkala, Vijaya] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Cata, Juan P.; Black, Walter; Rodriguez-Restrepo, Andrea] Univ Texas MD Anderson Canc Ctr, Anesthesiol & Surg Oncol Res Grp, Houston, TX 77030 USA; [Chavez-MacGregor, Mariana; Valero, Vicente] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Black, Daliah M.] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA; [Hernandez, Mike] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	Cata, JP (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jcata@mdanderson.org	Gregor, Mariana Chavez Mac/AAL-1455-2020	Chavez Mac Gregor, Mariana/0000-0002-7189-0763	Cancer Center Support Grant (CCSG) NCI [P30 CA016672]	This work was supported in part by the Cancer Center Support Grant (CCSG) NCI P30 CA016672.	Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Austin PC, 2013, STAT MED, V32, P2837, DOI 10.1002/sim.5705; Beecher SM, 2016, BRIT J SURG, V103, P391, DOI 10.1002/bjs.10068; Cata JP, 2015, J CLIN ANESTH, V27, P672, DOI 10.1016/j.jclinane.2015.07.012; Cata JP, 2014, CANCER MED-US, V3, P900, DOI 10.1002/cam4.236; Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Forget P, 2014, BRIT J ANAESTH, V113, P82, DOI 10.1093/bja/aet464; Goravanchi F, 2012, J CLIN ANESTH, V24, P664, DOI 10.1016/j.jclinane.2012.05.005; Habermann EB, 2010, J CLIN ONCOL, V28, P3437, DOI 10.1200/JCO.2009.27.6774; Kairaluoma P, 2016, ANTICANCER RES, V36, P415; Lee JH, 2016, KOREAN J ANESTHESIOL, V69, P126, DOI 10.4097/kjae.2016.69.2.126; Morrow M, 2009, JAMA-J AM MED ASSOC, V302, P1551, DOI 10.1001/jama.2009.1450; Retsky M, 2013, CURR MED CHEM, V20, P4163; Sessler DI, 2008, CONTEMP CLIN TRIALS, V29, P517, DOI 10.1016/j.cct.2008.01.002; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Starnes-Ott K, 2015, CRIT CARE NURS Q, V38, P200, DOI 10.1097/CNQ.0000000000000062; Tsigonis AM, 2016, REGION ANESTH PAIN M, V41, P339, DOI 10.1097/AAP.0000000000000379; Wigmore TJ, 2016, ANESTHESIOLOGY, V124, P69, DOI 10.1097/ALN.0000000000000936	19	19	21	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	NOV-DEC	2016	41	6					696	703		10.1097/AAP.0000000000000479			8	Anesthesiology	Anesthesiology	EB1BQ	WOS:000387081700008	27685344				2020-06-30	J	Al-Kazwini, H; Sandven, I; Dahl, V; Rosseland, LA				Al-Kazwini, Hadeel; Sandven, Irene; Dahl, Vegard; Rosseland, Leiv Arne			Prolonging the duration of single-shot intrathecal labour analgesia with morphine: A systematic review	SCANDINAVIAN JOURNAL OF PAIN			English	Review						Morphine; Spinal; Birth; Pain; Complications	SPINAL ANALGESIA; 0.2 MG; PAIN; BUPIVACAINE; METAANALYSIS; NARCOTICS; FENTANYL; DELIVERY; OPIOIDS; RELIEF	Background and aims: Single-shot spinal with bupivacaine plus fentanyl or sufentanil is commonly used as analgesia during labour, but the short duration limits the clinical feasibility. Different drugs have been added to prolong the analgesic duration. The additional effect of intra-thecal morphine has been studied during labour pain as well as after surgery. We assessed whether adding morphine to intra-thecal bupivacaine + fentanyl or sufentanil prolongs pain relief during labour. Methods: Meta-analysis of placebo-controlled randomized clinical trials of analgesia prolongation after single-shot intrathecal morphine <= 250 mu g during labour when given in combination with bupivacaine + fentanyl or sufentanil. After identifying 461 references, 24 eligible studies were evaluated after excluding duplicate publications, case reports, studies of analgesia after caesarean delivery, and epidural labour analgesia. Mean duration in minutes was the primary outcome measure and was included in the calculation of the standardized mean difference. Duration was defined as the time between a single shot spinal until patient request of rescue analgesia. All reported side effects were registered. Results of individual trials were combined using a random effect model. Cochrane tool was used to assess risk of bias. Results: Five randomized placebo-controlled clinical trials (286 patients) were included in the meta analysis. A dose of 50-250 mu g intrathecal morphine prolonged labour analgesia by a mean of 60.6 min (range 3-155 min). Adding morphine demonstrated a medium beneficial effect as we found a pooled effect of standardized mean difference = 0.57 (95% CI:-0.10 to 1.24) with high heterogeneity (I-2 = 88.1%). However, the beneficial effect was statistically non-significant (z = 1.66, p=0.096). The lower-bias trials showed a small statistically non-significant beneficial effect with lower heterogeneity. In influential analysis, that excluded one study at a time from the meta-analysis, the effect size appears unstable and the results indicate no robustness of effect. Omitting the study with highest effects size reduces the pooled effect markedly and that study suffers from inadequate concealment of treatment allocation and blinding. Trial quality was generally low, and there were too few trials to explore sources of heterogeneity in meta-regression and stratified analyses. In general, performing meta-analyses on a small number of trials are possible and may be helpful if one is aware of the limitations. As few as one more placebo-controlled trial would increase the reliability greatly. Conclusions: Evidence from this systematic review suggests a possible beneficial prolonging effect of adding morphine to spinal analgesia with bupivacaine + fentanyl or +sufentanil during labour. The study quality was low and heterogeneity high. No severe side effects were reported. More adequately-powered randomized trials with low bias are needed to determine the benefits and harms of adding morphine to spinal local anaesthetic analgesia during labour. Implications: Epidural analgesia is documented as the most effective method for providing pain relief during labour, but from a global perspective most women in labour have no access to epidural analgesia. Adding morphine to single shot spinal injection of low dose bupivacaine, fentanyl or sufentanil may be efficacious but needs to be investigated. (C) 2016 Scandinavian Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Al-Kazwini, Hadeel] Telemark Hosp Trust, Skien Hosp, Dept Anaesthesia, Skien, Norway; [Sandven, Irene] Oslo Univ Hosp, Oslo Ctr Biostat & Epidemiol, Res Support Serv, Oslo, Norway; [Dahl, Vegard] Akershus Univ Hosp, Dept Anaesthesia & Intens Care Med, Loerenskog, Norway; [Dahl, Vegard; Rosseland, Leiv Arne] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway; [Rosseland, Leiv Arne] Oslo Univ Hosp, Dept Res & Dev, Div Emergencies & Crit Care, Box 4950 Nydalen, N-0424 Oslo, Norway	Rosseland, LA (reprint author), Oslo Univ Hosp, Dept Res & Dev, Div Emergencies & Crit Care, Box 4950 Nydalen, N-0424 Oslo, Norway.	halkazwini@gmail.com; uxair@ous-hf.no; vegard.dahl@ahus.no; l.a.rosseland@medisin.uio.no					ABBOUD TK, 1988, ANESTH ANALG, V67, P137; ABBOUD TK, 1984, BRIT J ANAESTH, V56, P1351, DOI 10.1093/bja/56.12.1351; ABOULEISH E, 1991, ANESTHESIOLOGY, V74, P711, DOI 10.1097/00000542-199104000-00015; ABOULEISH E, 1991, REGION ANESTH, V16, P137; Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3; BARAKA A, 1981, ANESTHESIOLOGY, V54, P136, DOI 10.1097/00000542-198102000-00007; Bucklin BA, 2002, REGION ANESTH PAIN M, V27, P23, DOI 10.1053/rapm.2002.29111; CARTON EG, 1987, IRISH J MED SCI, V156, P323, DOI 10.1007/BF02951264; Carvalho B, 2008, ANESTH ANALG, V107, P956, DOI 10.1213/ane.0b013e318168b443; COHEN J, 1988, STAT ANAL BEHAV SCI; Culha HT, 2007, AGRI, V19, P16; DAILEY PA, 1985, ANESTH ANALG, V64, P658; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dyer RA, 2010, BEST PRACT RES CL OB, V24, P401, DOI 10.1016/j.bpobgyn.2009.11.005; Edwards R D, 1988, J Am Board Fam Pract, V1, P245; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 2003, Health Technol Assess, V7, P1; Eisenach JC, 2008, PAIN, V140, P87, DOI 10.1016/j.pain.2008.07.011; Fontaine P, 2002, J FAM PRACTICE, V51, P630; GJESSING J, 1981, ANAESTHESIA, V36, P268, DOI 10.1111/j.1365-2044.1981.tb10199.x; GLYNN CJ, 1979, LANCET, V2, P356; GRIECO WM, 1993, ANESTH ANALG, V77, P1149; Hein A, 2010, INT J OBSTET ANESTH, V19, P384, DOI 10.1016/j.ijoa.2010.04.003; HERPOLSHEIMER A, 1994, OBSTET GYNECOL, V84, P931; Hess PE, 2003, ANESTH ANALG, V97, P247, DOI 10.1213/01.ANE.0000066520.30763.B8; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Kuczkowski KM, 2008, J ANESTH, V22, P55, DOI 10.1007/s00540-007-0569-z; LEIGHTON BL, 1989, ANESTH ANALG, V69, P122; Minty RG, 2007, CAN FAM PHYSICIAN, V53, P437; Moher D, 2015, SYST REV-LONDON, V4, DOI 10.1186/2046-4053-4-1; MOK MS, 1981, ANESTHESIOLOGY, V55, P481; Pascual-Ramirez J, 2011, INT J GYNECOL OBSTET, V114, P246, DOI 10.1016/j.ijgo.2011.04.004; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; RAWAL N, 1987, BRIT J ANAESTH, V59, P791, DOI 10.1093/bja/59.6.791; RUST LA, 1994, AM J OBSTET GYNECOL, V170, P1643; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schwarzer G, 2007, META R PACKAGE METAA, P40; SCOTT PV, 1980, BRIT MED J, V281, P351, DOI 10.1136/bmj.281.6236.351; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Vasudevan A, 2007, BRIT J ANAESTH, V98, P241, DOI 10.1093/bja/ael346; Vasudevan A, 2002, ANESTHESIOLOGY, pU40; Wu J L, 1997, Acta Anaesthesiol Sin, V35, P209; Yeh HM, 2001, ANESTH ANALG, V92, P665, DOI 10.1097/00000539-200103000-00022; ZAPP J, 1995, MIL MED, V160, P217	45	2	2	0	4	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1877-8860	1877-8879		SCAND J PAIN	Scand. J. Pain	OCT	2016	13						36	42		10.1016/j.sjpain.2016.06.010			7	Clinical Neurology	Neurosciences & Neurology	EG7UJ	WOS:000391261500009	28850533				2020-06-30	J	Li, Z; Li, CH; Yin, PP; Wang, ZJ; Luo, F				Li, Zhen; Li, Chenhong; Yin, Pingping; Wang, Zaijie Jim; Luo, Fang			Inhibition of CaMKII alpha in the Central Nucleus of Amygdala Attenuates Fentanyl-Induced Hyperalgesia in Rats	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							OPIOID-INDUCED HYPERALGESIA; DENDRITIC PROTEIN-SYNTHESIS; LONG-LASTING HYPERALGESIA; INDUCED ABNORMAL PAIN; DEPENDENT KINASE-II; SYNAPTIC-TRANSMISSION; NEUROPATHIC PAIN; ANTINOCICEPTIVE TOLERANCE; CENTRAL SENSITIZATION; MOLECULAR-MECHANISMS	Opioid-induced hyperalgesia (OIH) is a less-studied phenomenon that has been reported in both preclinical and clinical studies. Although the underlying cause is not entirely understood, OIH is a real-life problem that affects millions of patients on a daily basis. Research has implicated the important contribution of Ca2+/calmodulin-dependent protein kinase II alpha (CaMKII alpha) to OIH at the level of spinal nociceptors. To expand our understanding of the entire brain circuitry driving OIH, in this study we investigated the role of CaMKII alpha in the laterocapcular division of the central amygdala (CeLC), the conjunctive point between the spinal cord and rostro-ventral medulla. OIH was produced by repeated fentanyl administration in the rat. Correlating with the development of mechanical allodynia and thermal hyperalgesia, CaMKII alpha activity was significantly elevated in the CeLC in OIH. In addition, the frequency and amplitude of spontaneous miniature excitatory postsynaptic currents (mEPSCs) in CeLC neurons were significantly increased in OIH. 2-[N-(2-hidroxyethyl)-N-(4-methoxybenzenesulfonyl)]-amino-N-(4-chlorocinnamyl)-N-methylbenzylamine, a CaMKII alpha inhibitor, dose dependently reversed sensory hypersensitivity, activation of CeLC CaMKII alpha, and mEPSCs in OIH. Taken together, our data for the first time implicate a critical role of CeLC CaMKII alpha in OIH.	[Li, Zhen; Yin, Pingping; Luo, Fang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Anesthesiol, Wuhan, Peoples R China; [Li, Chenhong] South Cent Univ Nat, Coll Biomed Engn, Lab Membrane Ion Channels & Med, Lab & Cognit Sci, Wuhan, Peoples R China; [Wang, Zaijie Jim] Univ Illinois, Dept Biopharmaceut Sci & Canc Ctr, Chicago, IL USA	Luo, F (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Wuhan 430030, Peoples R China.	luofang0909@hotmail.com		Luo, Fang/0000-0003-4103-5712	National Science Foundation of the People's Republic of ChinaNational Natural Science Foundation of China [81328009, 81050023, 81271234]	This work was supported by grants from the National Science Foundation of the People's Republic of China [Grants 81328009, 81050023, and 81271234].	Bruggemann I, 2000, MOL BRAIN RES, V85, P239, DOI 10.1016/S0169-328X(00)00265-5; Butler RK, 2011, PHYSIOL BEHAV, V104, P1075, DOI 10.1016/j.physbeh.2011.05.028; Carlton SM, 2002, BRAIN RES, V947, P252, DOI 10.1016/S0006-8993(02)02932-3; Carrasquillo Y, 2007, J NEUROSCI, V27, P1543, DOI 10.1523/JNEUROSCI.3536-06.2007; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chen Y, 2010, J NEUROSCI, V30, P38, DOI 10.1523/JNEUROSCI.4346-09.2010; Chen Y, 2009, J PHARMACOL EXP THER, V330, P650, DOI 10.1124/jpet.109.152165; Chu LF, 2008, CLIN J PAIN, V24, P479, DOI 10.1097/AJP.0b013e31816b2f43; Chu LF, 2011, J PAIN, V12, P108, DOI 10.1016/j.jpain.2010.05.006; DIXON WJ, 1948, J AM STAT ASSOC, V43, P109, DOI 10.2307/2280071; Dunbar SA, 2000, ANESTH ANALG, V91, P417, DOI 10.1097/00000539-200008000-00035; Fabry ME, 2003, METH MOLEC MED, V82, P213; Ferrari LF, 2013, J NEUROSCI, V33, P11002, DOI 10.1523/JNEUROSCI.1785-13.2013; Fu Y, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-26; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hamlin AS, 2007, NEUROPHARMACOLOGY, V53, P330, DOI 10.1016/j.neuropharm.2007.05.017; Han JS, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-10; Han JS, 2005, PAIN, V113, P211, DOI 10.1016/j.pain.2004.10.022; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; He Y, 2012, J PAIN, V13, P598, DOI 10.1016/j.jpain.2012.03.011; Hu XY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146393; Jordan BA, 2003, MOL PHARMACOL, V64, P1317, DOI 10.1124/mol.64.6.1317; Kaeser PS, 2014, ANNU REV PHYSIOL, V76, P333, DOI 10.1146/annurev-physiol-021113-170338; Kim SH, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00108; Kiritoshi T, 2013, NEUROPHARMACOLOGY, V66, P170, DOI 10.1016/j.neuropharm.2012.03.024; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Lee HJ, 2014, KOREAN J ANESTHESIOL, V67, P299, DOI 10.4097/kjae.2014.67.5.299; Li Z, 2011, J NEUROSCI, V31, P1114, DOI 10.1523/JNEUROSCI.5387-10.2011; Liang DY, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-7; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Luo F, 2008, J PHARMACOL EXP THER, V325, P267, DOI 10.1124/jpet.107.132167; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Martin TJ, 2008, EXP CLIN PSYCHOPHARM, V16, P357, DOI 10.1037/a0013597; Nakanishi M, 2010, MOL BIOL CELL, V21, P2568, DOI 10.1091/mbc.E10-01-0049; Neugebauer V, 2004, NEUROSCIENTIST, V10, P221, DOI 10.1177/1073858403261077; Neugebauer V, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-8; Ninan I, 2004, NEURON, V42, P129, DOI 10.1016/S0896-6273(04)00143-6; Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254; Price TJ, 2005, NEUROSCI LETT, V389, P94, DOI 10.1016/j.neulet.2005.07.029; Ramirez-Barrantes R, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/1568145; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Sah P, 2003, PHYSIOL REV, V83, P803, DOI 10.1152/physrev.00002.2003; Salling MC, 2016, BIOL PSYCHIAT, V79, P430, DOI 10.1016/j.biopsych.2014.10.020; Sandkuhler J, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-9; Sarhan M, 2005, J COMP NEUROL, V491, P418, DOI 10.1002/cne.20697; Sarhan M, 2013, INT J NEUROPSYCHOPH, V16, P1649, DOI 10.1017/S146114571200168X; Seto SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066404; Shen GF, 2009, BIOCHEM SOC T, V37, P1394, DOI 10.1042/BST0371394; Shoudai K, 2010, J NEUROSCI, V30, P14470, DOI 10.1523/JNEUROSCI.2557-10.2010; Sikand P, 2007, J PHYSIOL-LONDON, V581, P631, DOI 10.1113/jphysiol.2006.118620; Stoicea N, 2015, FRONT PHARMACOL, V6, DOI [10.3382/fphar.2015.00104, 10.3389/fphar.2015.00104]; Sutton MA, 2004, SCIENCE, V304, P1979, DOI 10.1126/science.1096202; Sutton MA, 2006, CELL, V127, P49, DOI 10.1016/j.cell.2006.09.014; Sutton MA, 2006, CELL, V125, P785, DOI 10.1016/j.cell.2006.03.040; Tang L, 2006, J PHARMACOL EXP THER, V317, P901, DOI 10.1124/jpet.105.097733; Toyoda H, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-4; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Vanderah TW, 2001, J NEUROSCI, V21, P279, DOI 10.1523/JNEUROSCI.21-01-00279.2001; Vardanyan A, 2009, J PAIN, V10, P243, DOI 10.1016/j.jpain.2008.07.004; Wang LLX, 2003, ADV DRUG DELIVER REV, V55, P949, DOI 10.1016/S0169-409X(03)00098-X; Wang XL, 2007, J PHYSIOL-LONDON, V579, P849, DOI 10.1113/jphysiol.2006.126102; Wang ZJJ, 2010, HEMATOL-AM SOC HEMAT, P403, DOI 10.1182/asheducation-2010.1.403; Wang ZW, 2008, MOL NEUROBIOL, V38, P153, DOI 10.1007/s12035-008-8039-7; Watabe AM, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-11; Wilkie DJ, 2010, J NATL MED ASSOC, V102, P18, DOI 10.1016/S0027-9684(15)30471-5; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; Xu H, 2008, J NEUROSCI, V28, P7445, DOI 10.1523/JNEUROSCI.1812-08.2008; Yang C, 2011, J PHARMACOL EXP THER, V338, P164, DOI 10.1124/jpet.110.175539; Zhang RX, 2013, NEUROSCIENCE, V252, P359, DOI 10.1016/j.neuroscience.2013.08.030; Zhao MG, 2006, J NEUROSCI, V26, P8923, DOI 10.1523/JNEUROSCI.2103-06.2006; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zissen MH, 2007, NEUROSCIENCE, V144, P247, DOI 10.1016/j.neuroscience.2006.08.078; Zschenderlein C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016116	75	4	7	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT 1	2016	359	1					82	89		10.1124/jpet.116.233817			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	ED7RR	WOS:000389067700010	27451410	Bronze			2020-06-30	J	Akhtar, S; Heng, J; Dai, F; Schonberger, RB; Burg, MM				Akhtar, Shamsuddin; Heng, Joseph; Dai, Feng; Schonberger, Robert B.; Burg, Mathew M.			A Retrospective Observational Study of Anesthetic Induction Dosing Practices in Female Elderly Surgical Patients: Are We Overdosing Older Patients?	DRUGS & AGING			English	Article							ASA CLASSIFICATION; GENERAL-ANESTHESIA; CLINICAL-OUTCOMES; RISK-FACTORS; NONCARDIAC SURGERY; SPINAL-ANESTHESIA; PHYSICAL STATUS; PROPOFOL; AGE; HYPOTENSION	Despite guidelines suggesting a 25-50 % reduction in induction doses of intravenous anesthetic agents in the elderly (aeyen65 years), we hypothesized that practitioners were not sufficiently correcting drug administration for age, contributing to an increased incidence of hypotension in older patients undergoing general anesthesia. We conducted a retrospective, observational study in a tertiary-care academic hospital. The study included 768 female patients undergoing gynecologic surgeries who received propofol-based induction of general anesthesia. Weight-adjusted anesthetic induction dosing, age-associated differences in dosing by ASA-PS (American Society of Anesthesiology-Physical Status), and hemodynamic outcomes between younger (18-64 years, n = 537) and older (aeyen65 years, n = 231) female patients were analyzed. Older patients received lower doses of propofol and midazolam than younger patients (propofol: 2.037 +/- A 0.783 vs 2.322 +/- A 0.834 mg/kg, p < 0.001; midazolam: 0.013 +/- A 0.014 vs 0.023 +/- A 0.042 mg/kg, p < 0.001). However, practitioners still consistently exceeded the FDA recommended dose (1-1.5 mg/kg) of propofol for elderly patients. There was no significant difference in the doses of fentanyl administered between the two age groups (1.343 +/- A 0.744 vs 1.363 +/- A 0.763 mu g/kg, p = 0.744), and doses of fentanyl in older patients exceeded the recommended dose (0.5-1.0 mu g/kg). Corresponding to observed overdosing of induction agents, older patients experienced larger decreases in post-induction blood pressure and were more likely to receive vasopressor therapy. Anesthetic induction doses of fentanyl and propofol were not sufficiently corrected in older patients in accordance with recommendations. Significantly greater frequency of post-induction hypotension occurred amongst older patients. Quality improvement efforts may lead to improved outcomes in this vulnerable population.	[Akhtar, Shamsuddin] Yale Sch Med, Dept Anesthesiol & Pharmacol, 333 Cedar St,TMP 3, New Haven, CT 06510 USA; [Heng, Joseph] Johns Hopkins Sch Med, Dept Internal Med, Baltimore, MD USA; [Dai, Feng] Yale Ctr Analyt Sci, New Haven, CT USA; [Schonberger, Robert B.; Burg, Mathew M.] Yale Sch Med, Dept Anesthesiol, New Haven, CT USA; [Burg, Mathew M.] Yale Sch Med, Dept Internal Med, New Haven, CT USA	Akhtar, S (reprint author), Yale Sch Med, Dept Anesthesiol & Pharmacol, 333 Cedar St,TMP 3, New Haven, CT 06510 USA.	shamsuddin.akhtar@yale.edu		Akhtar, Shamsuddin/0000-0002-1127-0538	CTSA from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000142]	Financial support and sponsorship: This publication was funded in part by CTSA Grant Number UL1 TR000142 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the views of the NIH or the United States Government.	Akhtar S, 2014, OXFORD TXB ANAESTHES; Akhtar S, 2016, J CLIN ANESTH, V33, P208, DOI 10.1016/j.jclinane.2016.02.001; Akhtar Shamsuddin, 2015, Anesthesiol Clin, V33, P457, DOI 10.1016/j.anclin.2015.05.004; American Geriatrics Society Expert Panel on Postoperative Delirium in Older A, 2015, J AM COLL SURGEONS, V220, P136; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Bekker Alex Y, 2003, Best Pract Res Clin Anaesthesiol, V17, P259, DOI 10.1016/S1521-6896(03)00005-3; Brown CH, 2014, ANESTH ANALG, V118, P977, DOI 10.1213/ANE.0000000000000157; Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165; Bushnell C, 2014, STROKE, V45, P1545, DOI 10.1161/01.str.0000442009.06663.48; Cheung C, 2014, AM J MED, V22, P030; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Credeur DP, 2014, AM J PHYSIOL-HEART C, V306, pH1417, DOI 10.1152/ajpheart.00036.2014; Cullen Karen A, 2009, Natl Health Stat Report, P1; Deiner S, 2014, J AM GERIATR SOC, V14, P12794; Diprivan, 2015, DIPR; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; Eleveld DJ, 2014, ANESTH ANALG, V118, P1221, DOI 10.1213/ANE.0000000000000165; Fillingim RB, 2000, NEUROSCI BIOBEHAV R, V24, P485, DOI 10.1016/S0149-7634(00)00017-8; Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001; Glance LG, 2015, ANESTH ANALG, V120, P526, DOI 10.1213/ANE.0000000000000522; Glen JB, 2014, ANAESTHESIA, V69, P550, DOI 10.1111/anae.12631; Ho E, 2014, HEART LUNG CIRC, V23, P242, DOI 10.1016/j.hlc.2013.08.001; JACOBS JR, 1995, ANESTH ANALG, V80, P143, DOI 10.1097/00000539-199501000-00024; Kazama T, 1999, ANESTHESIOLOGY, V90, P1517, DOI 10.1097/00000542-199906000-00004; KEATS AS, 1978, ANESTHESIOLOGY, V49, P233, DOI 10.1097/00000542-197810000-00001; Maurice-Szamburski A, 2015, JAMA-J AM MED ASSOC, V313, P916, DOI 10.1001/jama.2015.1108; Mendez GD, 2013, J CLIN MONIT COMPUT, V27, P417, DOI 10.1007/s10877-012-9426-1; MENKE H, 1993, INT SURG, V78, P266; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Oresanya LB, 2014, JAMA-J AM MED ASSOC, V311, P2110, DOI 10.1001/jama.2014.4573; PEDERSEN T, 1994, DAN MED BULL, V41, P319; Phillips AT, 2015, CLIN THER, V37, P2676, DOI 10.1016/j.clinthera.2015.10.005; Racine M, 2012, PAIN, V153, P619, DOI 10.1016/j.pain.2011.11.026; Reich DL, 2005, ANESTH ANALG, V101, P622, DOI 10.1213/01.ANE.0000175214.38450.91; Rivera R, 2009, ANESTHESIOLOGY, V110, P1176, DOI 10.1097/ALN.0b013e3181a10207; Robinson BJ, 1997, ANESTHESIOLOGY, V86, P64, DOI 10.1097/00000542-199701000-00010; Rooke GA, 2003, J CARDIOTHOR VASC AN, V17, P512, DOI 10.1016/S1053-0770(03)00161-7; Rosen SE, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-015-0523-8; Roy RC, 1997, GERIATRIC ANESTHESIO, P28; Sadean Mihai R, 2003, Best Pract Res Clin Anaesthesiol, V17, P191, DOI 10.1016/S1521-6896(03)00002-8; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; Schonberger RB, 2016, ANESTH ANALG, V122, P243, DOI 10.1213/ANE.0000000000000917; Schonberger RB, 2012, ANESTH ANALG, V115, P1286, DOI 10.1213/ANE.0b013e318259ef6b; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Shafer S L, 2000, Anesthesiol Clin North Am, V18, P1; Shafer SL, 2000, ANESTHESIOL CLIN N A, V18, pv; Sieber FE, 2010, J CLIN ANESTH, V22, P179, DOI 10.1016/j.jclinane.2009.06.005; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Turrentine FE, 2006, J AM COLL SURGEONS, V203, P865, DOI 10.1016/j.jamcollsurg.2006.08.026; Valvona J, 1985, Health Aff (Millwood), V4, P108, DOI 10.1377/hlthaff.4.3.108; Van Cleve WC, 2015, ANESTH ANALG, V121, P645, DOI 10.1213/ANE.0000000000000819; Walsh M, 2013, ANESTHESIOLOGY, V119, P507, DOI 10.1097/ALN.0b013e3182a10e26; Werner CA, 2011, US CENSUS BUREAU 201; Wickham A, 2016, PERIOPER MED, V5, DOI 10.1186/s13741-016-0036-1; Wijeysundera DN, 2015, ANESTH ANALG, V120, P502, DOI 10.1213/ANE.0000000000000600; Wolters U, 1996, BRIT J ANAESTH, V77, P217, DOI 10.1093/bja/77.2.217; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842	57	3	3	0	2	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1170-229X	1179-1969		DRUG AGING	Drugs Aging	OCT	2016	33	10					737	746		10.1007/s40266-016-0394-x			10	Geriatrics & Gerontology; Pharmacology & Pharmacy	Geriatrics & Gerontology; Pharmacology & Pharmacy	EA5YJ	WOS:000386700800005	27581549				2020-06-30	J	Lee, D; Chronister, CW; Broussard, WA; Utley-Bobak, SR; Schultz, DL; Vega, RS; Goldberger, BA				Lee, Dayong; Chronister, Chris W.; Broussard, Wilson A.; Utley-Bobak, Suzanne R.; Schultz, Daniel L.; Vega, Russell S.; Goldberger, Bruce A.			Illicit Fentanyl-Related Fatalities in Florida: Toxicological Findings	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							COOK COUNTY; DRUG; POSTMORTEM; COCAINE; DEATHS; HEROIN; EPIDEMIC; ABUSERS; MORTALITY; ILLINOIS	Fentanyl induces pharmacological effects and abuse liability comparable to other prescription opioids and heroin. A surge in fentanyl-related fatalities has been periodically reported throughout the USA. The University of Florida Forensic Toxicology Laboratory observed a significant increase in fentanyl-related deaths starting in mid-2014. The present report evaluated toxicological findings, demographics of the decedents and circumstances of death in the postmortem cases that were submitted to the laboratory for toxicological analysis from July 2014 to January 2015 and that were tested for fentanyl in biological specimens. The cases originated from 6 of the 24 Florida Medical Examiner Districts, with the majority from District 12 (Desoto, Manatee and Sarasota counties). The specimens were analyzed for fentanyl by gas chromatography-mass spectrometry; the limit of detection (LOD) was 0.62 ng/mL and the limit of quantification (LOQ) was 2.5 ng/mL. During the 7-month period, the laboratory tested 143 postmortem cases for fentanyl and 50% had quantifiable fentanyl in postmortem blood. Fentanyl concentrations ranged from 2.5 to 68 ng/mL (n = 66; median: 9.8 ng/mL); six cases were positive for fentanyl > LOD but < LOQ. The majority of the cases (85%) had indications of possible drug abuse with heroin use being the most often suspected. Concurrent detection of 6-acetylmorphine, morphine and cocaine along with other opioids and benzodiazepines was common. Of the 59 deaths from District 12, the cause of death was accidental drug intoxication with fentanyl as a sole or contributing factor for 57 cases (two non-drug intoxication deaths). The median age of the 57 decedents was 35 (range: 19-63) years. Males represented 87% of the deaths and 96% were Whites. Most of the decedents (n = 53) had no prescription for fentanyl. Considering fentanyl's high potency and abuse liability, the recent rise in fentanyl-related deaths is a serious public health concern and signifies the urgent need to establish prevention and treatment efforts.	[Lee, Dayong; Chronister, Chris W.; Goldberger, Bruce A.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Forens Toxicol Lab,Div Forens Med, Gainesville, FL 32611 USA; [Lee, Dayong] Houston Forens Sci Ctr, Houston, TX USA; [Broussard, Wilson A.; Utley-Bobak, Suzanne R.; Schultz, Daniel L.; Vega, Russell S.] Dist Twelfth Med Examiners Off, Sarasota, FL USA	Goldberger, BA (reprint author), Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Forens Toxicol Lab,Div Forens Med, Gainesville, FL 32611 USA.	bruce-goldberger@ufl.edu		Lee, Dayong/0000-0003-0725-8760			Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; Behrman AD, 2008, J EMERG NURS, V34, P80, DOI 10.1016/j.jen.2007.10.001; Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; Brunton L.L., 2011, GOODMAN GILMANS PHAR; Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P869; Comer SD, 2008, NEUROPSYCHOPHARMACOL, V33, P1179, DOI 10.1038/sj.npp.1301479; CONE EJ, 1991, J ANAL TOXICOL, V15, P1; Delcher C, 2015, DRUG ALCOHOL DEPEN, V150, P63, DOI 10.1016/j.drugalcdep.2015.02.010; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Downey KK, 2000, EXP CLIN PSYCHOPHARM, V8, P176, DOI 10.1037/1064-1297.8.2.176; Florida Department of Health, 2014, E FORC 2013 2014 PRE; Florida Department of Law Enforcement, MED EX COMM 2013 ANN; Florida Department of Law Enforcement, 2015, MED EX COMM DRUGS ID; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Greenwald MK, 2010, NEUROPSYCHOPHARMACOL, V35, P2624, DOI 10.1038/npp.2010.175; Hakkinen M, 2014, FORENSIC SCI INT, V245, P121, DOI 10.1016/j.forsciint.2014.10.028; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Henley SJ, 2014, MMWR-MORBID MORTAL W, V63, P1; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lee D, 2014, FORENSIC SCI INT, V245, P178, DOI 10.1016/j.forsciint.2014.10.024; Magura S, 1998, ADDICTION, V93, P51, DOI 10.1046/j.1360-0443.1998.931516.x; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; National Association of Medical Examiners, 2015, FOR AUT PERF STAND; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Schultz D., 2012, ACAD FORENSIC PATHOL, V2, P110; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; SHESSER R, 1991, AM J EMERG MED, V9, P336, DOI 10.1016/0735-6757(91)90053-M; Simonsen KW, 2015, FORENSIC SCI INT, V248, P172, DOI 10.1016/j.forsciint.2015.01.003; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Sofuoglu M, 2003, AM J DRUG ALCOHOL AB, V29, P713, DOI 10.1081/ADA-120026256; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Tzilos GK, 2009, EXP CLIN PSYCHOPHARM, V17, P320, DOI 10.1037/a0016835; U.S. Department of Justice D.E.A., 2007, FED REGISTER, V72, P20039; U.S. Drug Enforcement Administration, 2015, HEADQ NEWS DEA ISS N; US Food and Drug Administration, DRUGS FDA FDA APPR D	42	23	23	0	26	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2016	40	8					588	594		10.1093/jat/bkw087			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EA9IT	WOS:000386957100004	27702938	Bronze			2020-06-30	J	Cummings, OT; Enders, JR; McIntire, GL; Backer, R; Poklis, A				Cummings, Oneka T.; Enders, Jeffrey R.; McIntire, Gregory L.; Backer, R.; Poklis, A.			Fentanyl-Norfentanyl Concentrations During Transdermal Patch Application: LC-MS-MS Urine Analysis	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							PAIN PATIENTS; EXCRETION DATA; HYDROMORPHONE	Poklis and Backer published a survey of the concentrations of fentanyl and norfentanyl that could be expected in urine from patients using Duragesic(A (R)), a transdermal fentanyl patch. That study employed a relatively small number of patient data points and analysis by Gas Chromatography/Mass Spectrometry. This work examines a larger population of patient positives for fentanyl and norfentanyl to determine whether more than a decade later the original report remains accurate in predicting the range and median levels of fentanyl and norfentanyl concentrations physicians can expect to see from their patients. Additionally, these data were transformed to develop a model that results in a near Gaussian distribution of urine drug test results. This retrospective approach was developed to transform and normalize urine drug testing results to provide a historical picture of expected patient values for this important analgesic. The resulting near Gaussian distribution is dose independent and as such should be of value to physicians in quickly assessing whether their patient is consistent with this historical population in the broad terms of this model. While this comparison alone is not definitive for adherence with a treatment regimen, together with patient interviews, prescription history and other clinical criteria, it can add an idea of expected patient values from urine drug testing.	[Cummings, Oneka T.; Enders, Jeffrey R.; McIntire, Gregory L.; Backer, R.] Ameritox Ltd, 486 Gallimore Dairy Rd, Greensboro, NC 27409 USA; [Poklis, A.] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA	Cummings, OT (reprint author), Ameritox Ltd, 486 Gallimore Dairy Rd, Greensboro, NC 27409 USA.	Oneka.Cummings@ameritox.com		Enders, Jeffrey/0000-0003-1224-1664			Absalom AR, 2009, BRIT J ANAESTH, V103, P26, DOI 10.1093/bja/aep143; Barakat NH, 2012, J ANAL TOXICOL, V36, P257, DOI 10.1093/jat/bks019; Baselt R.C., 2014, DISPOSITION TOXIC DR, P846; Bush DM, 2008, FORENSIC SCI INT, V174, P111, DOI 10.1016/j.forsciint.2007.03.008; Cao Jennifer M, 2014, J Opioid Manag, V10, P177, DOI 10.5055/jom.2014.0206; Couto JE, 2011, J CLIN PHARM THER, V36, P200, DOI 10.1111/j.1365-2710.2010.01236.x; Couto Joseph E, 2009, J Opioid Manag, V5, P359; Cummings O.T., 2015, J PAIN OFFICIAL J AM, V16, pS10; Enders JR, 2015, J ANAL TOXICOL, V39, P662, DOI 10.1093/jat/bkv087; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Hughes MM, 2012, J ANAL TOXICOL, V36, P250, DOI 10.1093/jat/bks021; Leimanis E, 2012, J ANAL TOXICOL, V36, P239, DOI 10.1093/jat/bks020; PARZEN E, 1962, ANN MATH STAT, V33, P1065, DOI 10.1214/aoms/1177704472; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; R Core Team, 2014, R LANG ENV STAT COMP; Substance abuse and mental health services administration (SAMSHA), 2004, FED REG, V69, P19643; Tse SA, 2012, J ANAL TOXICOL, V36, P221, DOI 10.1093/jat/bks018; Waterlow J.C., 1976, RES OBESITY REPORT D; Webster L.R., 2013, ROLE URINE DRUG TEST, P45	19	9	9	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2016	40	8					595	600		10.1093/jat/bkw067			6	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EA9IT	WOS:000386957100005	27405369	Bronze			2020-06-30	J	Stamper, B; Gul, W; Godfrey, M; Gul, SW; ElSohly, MA				Stamper, Brandon; Gul, Waseem; Godfrey, Murrell; Gul, Shahbaz W.; ElSohly, Mahmoud A.			LC-MS-MS Method for the Analysis of Miscellaneous Drugs in Wastewater During Football Games III	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							ILLICIT DRUGS; LIQUID-CHROMATOGRAPHY; SURFACE	Continuing our previous studies analyzing drugs of abuse in municipal wastewater, a method was developed for the analysis of miscellaneous drugs of abuse in wastewater samples using liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS). Eight drugs and metabolites were analyzed including 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrolidine (EDDP), fentanyl, norfentanyl, meperidine, normeperidine, methadone, phencyclidine and tramadol. These drugs were chosen because of their widespread abuse. Wastewater samples were collected at both the Oxford Waste Water Treatment Plant in Oxford, Mississippi (MS) and the University Wastewater Treatment Plant in University, MS. These wastewater samples were collected on weekends in which the University of Mississippi football team (colloquially the "Ole Miss Rebels" football team) held home games (Vaught-Hemingway Stadium, University, MS 38677). The collected samples were analyzed using a validated method and found to contain tramadol in 25 samples at quantifiable levels. EDDP, meperidine, normeperidine and methadone were also detected but were under the limit of quantitation.	[Stamper, Brandon; Gul, Waseem; Gul, Shahbaz W.; ElSohly, Mahmoud A.] ElSohly Labs Inc, 5 Ind Pk Dr, Oxford, MS 38655 USA; [Stamper, Brandon; Godfrey, Murrell] Univ Mississippi, Dept Chem & Biochem, University, MS 38677 USA; [Gul, Waseem; ElSohly, Mahmoud A.] Univ Mississippi, Natl Ctr Nat Prod Res, University, MS 38677 USA; [ElSohly, Mahmoud A.] Univ Mississippi, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA	ElSohly, MA (reprint author), ElSohly Labs Inc, 5 Ind Pk Dr, Oxford, MS 38655 USA.; ElSohly, MA (reprint author), Univ Mississippi, Natl Ctr Nat Prod Res, University, MS 38677 USA.; ElSohly, MA (reprint author), Univ Mississippi, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA.	elsohly@elsohly.com					Berset JD, 2010, CHEMOSPHERE, V81, P859, DOI 10.1016/j.chemosphere.2010.08.011; Daughton C. G., 2001, ACS SYM SER, P348, DOI DOI 10.1021/BK-2001-0791.CH020; Gerrity D, 2011, WATER RES, V45, P5399, DOI 10.1016/j.watres.2011.07.020; Gul W, 2016, J ANAL TOXICOL, V40, P330, DOI 10.1093/jat/bkw022; Gul W, 2016, J ANAL TOXICOL, V40, P124, DOI 10.1093/jat/bkv124; Hall W, 2012, ADDICTION, V107, P1767, DOI 10.1111/j.1360-0443.2012.03887.x; Huerta-Fontela M, 2007, ANAL CHEM, V79, P3821, DOI 10.1021/ac062370x; Lai FY, 2013, DRUG ALCOHOL REV, V32, P594, DOI 10.1111/dar.12061; Pal R, 2013, SCI TOTAL ENVIRON, V463, P1079, DOI 10.1016/j.scitotenv.2012.05.086; Panawennage D, 2011, ILLICIT DRUGS ENV OC, P321; Petrie B, 2015, WATER RES, V72, P3, DOI 10.1016/j.watres.2014.08.053; Postigo C., 2010, ENVIRON INT, V37, P49; van Nuijs ALN, 2009, ANAL BIOANAL CHEM, V395, P819, DOI 10.1007/s00216-009-3017-0	13	4	5	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2016	40	8					694	699		10.1093/jat/bkw081			6	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EA9IT	WOS:000386957100018	27562966	Bronze			2020-06-30	J	Poklis, J; Poklis, A; Wolf, C; Hathaway, C; Arbefeville, E; Chrostowski, L; Devers, K; Hair, L; Mainland, M; Merves, M; Pearson, J				Poklis, Justin; Poklis, Alphonse; Wolf, Carl; Hathaway, Cindie; Arbefeville, Elise; Chrostowski, Leszek; Devers, Kelly; Hair, Laura; Mainland, Mary; Merves, Michele; Pearson, Julia			Two Fatal Intoxications Involving Butyryl Fentanyl	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							SWEDISH STRIDA PROJECT; POSTMORTEM CONCENTRATIONS; TISSUE DISTRIBUTION; ACETYL FENTANYL; TRENDS	We present the case histories, autopsy findings and toxicology findings of two fatal intoxications involving the designer drug, butyryl fentanyl. The quantitative analysis of butyryl fentanyl in postmortem fluids and tissues was performed by an ultrahigh-performance liquid chromatography tandem mass spectrometry method. In the first case, butyryl fentanyl was the only drug detected with concentrations of 99 ng/mL in peripheral blood, 220 ng/mL in heart blood, 32 ng/mL in vitreous humor, 590 ng/mL in gastric contents, 93 ng/g in brain, 41 ng/g in liver, 260 ng/mL in bile and 64 ng/mL in urine. The cause of death was ruled fatal intoxication by butyryl fentanyl. In the second case, butyryl fentanyl was detected along with acetyl fentanyl, alprazolam and ethanol. The butyryl fentanyl concentrations were 3.7 ng/mL in peripheral blood, 9.2 ng/mL in heart blood, 9.8 ng/mL in vitreous humor, 4,000 ng/mL in gastric contents, 63 ng/g in brain, 39 ng/g in liver, 49 ng/mL in bile and 2 ng/mL in urine. The acetyl fentanyl concentrations were 21 ng/mL in peripheral blood, 95 ng/mL in heart blood, 68 ng/mL in vitreous humor, 28,000 ng/mL in gastric contents, 200 ng/g in brain, 160 ng/g in liver, 330 ng/mL in bile and 8 ng/mL in urine. In addition, the alprazolam concentration was 40 ng/mL and the ethanol concentration was 0.11 g/dL, both measured in peripheral blood. The cause of death in the second case was ruled a mixed drug intoxication. In both cases, the manner of death was accident.	[Poklis, Justin; Poklis, Alphonse] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA; [Poklis, Alphonse; Wolf, Carl] Virginia Commonwealth Univ, Dept Pathol, POB 980165, Richmond, VA 23298 USA; [Poklis, Alphonse] Virginia Commonwealth Univ, Dept Forens Sci, POB 843079, Richmond, VA 23284 USA; [Hathaway, Cindie; Arbefeville, Elise; Chrostowski, Leszek; Devers, Kelly; Hair, Laura; Mainland, Mary; Merves, Michele; Pearson, Julia] Hillsborough Cty Med Examiner Dept, 11025 N 46th St, Tampa, FL 33617 USA	Pearson, J (reprint author), Hillsborough Cty Med Examiner Dept, 11025 N 46th St, Tampa, FL 33617 USA.	pearsonjm@hillsboroughcounty.org			National Institute on Health (NIH) [P30DA033934]	This project was supported in part by the National Institute on Health (NIH) grant P30DA033934.	[Anonymous], 2015, DEADCTDIR03915; Atluri S, 2014, PAIN PHYSICIAN, V17, pE119; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; EMCDDA, 2015, NEW PSYCH SUBST EUR; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), EUR DRUG REP 2014 TR; Flammia DD, 2004, J ANAL TOXICOL, V28, P533, DOI 10.1093/jat/28.6.533; Helander A, 2014, FORENSIC SCI INT, V243, P23, DOI 10.1016/j.forsciint.2014.02.022; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Pearson Julia, 2015, Acad Forensic Pathol, V5, P676, DOI 10.23907/2015.072; Poklis A., 1995, REV CLIN ANAL TOXICO, V33, P439; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Stogner JM, 2015, AM J DRUG ALCOHOL AB, V41, P519, DOI 10.3109/00952990.2014.998367	17	36	36	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2016	40	8					703	708		10.1093/jat/bkw048			6	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EA9IT	WOS:000386957100020	27339481	Green Published, Bronze			2020-06-30	J	Alberts, DS; Smith, CC; Parikh, N; Rauck, RL				Alberts, David S.; Smith, Christina Cognata; Parikh, Neha; Rauck, Richard L.			Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl	PAIN MANAGEMENT			English	Article						breakthrough cancer pain; fentanyl sublingual spray; transmucosal immediate-release fentanyl	PREVALENCE; PHARMACOKINETICS	Aim: To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP). Methods: Adults tolerating ATC opioids received open-label FSS for 26 days, followed by a 26-day double-blind phase for patients achieving an effective dose (100-1600 mu g). Results: Out of 50 patients on ATC TFP at baseline, 32 (64%) achieved an effective dose. FSS effective dose moderately correlated with mean TFP dose (r = 0.4; p = 0.03). Patient satisfaction increased during the study. Common adverse events included nausea (9%) and peripheral edema (9%). Conclusion: FSS can be safely titrated to an effective dose for BTCP in patients receiving ATC TFP as chronic cancer pain medication. ClinicalTrials.gov identifier: NCT00538850	[Alberts, David S.] Univ Arizona, Ctr Canc, Tucson, AZ 85719 USA; [Smith, Christina Cognata; Parikh, Neha] INSYS Therapeut, Chandler, AZ 85286 USA; [Rauck, Richard L.] Carolinas Pain Inst, Winston Salem, NC 27103 USA; [Rauck, Richard L.] Clin Res Ctr, Winston Salem, NC 27103 USA	Alberts, DS (reprint author), Univ Arizona, Ctr Canc, Tucson, AZ 85719 USA.	dalberts@uacc.arizona.edu			Medtronic, Inc.Medtronic; Medasys, Inc.; Alfred Mann Foundation; Archimedes; BioDelivery Sciences International, Inc.; Meda Pharmaceuticals; Jazz Pharmaceuticals; Bioness; Boston ScientificBoston Scientific; Collegium Pharmaceuticals; CNS Therapeutics; MedtronicMedtronic; Myoscience; NeurAxon, Inc.; Spinal Restoration; Spinal Modulation; St Jude MedicalSt. Jude Medical; Insys Therapeutics, Inc., Chandler, AZ, USA; Insys Therapeutics, Inc.	D Alberts has had a consulting or advisory role with Insys Therapeutics, Inc. (consultant, clinical research and drug development). CC Smith and N Parikh are employees of and hold stock in Insys Therapeutics, Inc. R Rauck has had a consulting or advisory role or received research funding from Medtronic, Inc., Medasys, Inc., the Alfred Mann Foundation, Archimedes, BioDelivery Sciences International, Inc., Meda and Jazz Pharmaceuticals, has been on speakers' bureau for Jazz Pharmaceuticals and has received research funding from Alfred Mann Foundation, Bioness, Boston Scientific, Collegium Pharmaceuticals, CNS Therapeutics, Jazz Pharmaceuticals, Medtronic, Myoscience, NeurAxon, Inc., Spinal Restoration, Spinal Modulation and St Jude Medical. Funding for this study was provided by Insys Therapeutics, Inc., Chandler, AZ, USA. Two employees of the sponsor participated as authors of this study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.; Technical editorial and medical writing assistance, under the direction of the authors, was provided by Mary Beth Moncrief, and Pratibha Hebbar, Synchrony Medical, LLC, West Chester, PA, USA. Funding for this support was provided by Insys Therapeutics, Inc.	Atkinson Mark J, 2004, Health Qual Life Outcomes, V2, P12, DOI 10.1186/1477-7525-2-12; Burton AW, 2014, J COMMUNITY SUPPORT, V12, P99, DOI 10.12788/jcso.0026; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; HARRIS D, 1992, J PHARM SCI-US, V81, P1, DOI 10.1002/jps.2600810102; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P579, DOI 10.1016/j.jpainsymman.2015.05.016; Minkowitz H, 2016, SUPPORT CARE CANCER, V24, P2669, DOI 10.1007/s00520-015-3056-3; Nalamachu Srinivas R, 2014, J Opioid Manag, V10, P247, DOI 10.5055/jom.2014.0212; Nalamachu SR, 2012, PAIN PRACT, V12, P449, DOI 10.1111/j.1533-2500.2011.00525.x; National Comprehensive Cancer Network, 2014, NCCN CLIN PRACT GUID; Parikh N, 2013, CLIN DRUG INVEST, V33, P391, DOI 10.1007/s40261-013-0079-8; Parikh N, 2013, CLIN THER, V35, P236, DOI 10.1016/j.clinthera.2013.02.017; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Rauck R, 2016, PAIN PRACT, V16, P1012, DOI 10.1111/papr.12360; Rauck R, 2015, PAIN PRACT, V15, P554, DOI 10.1111/papr.12225; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Shimoyama N, 2015, JPN J CLIN ONCOL, V45, P189, DOI 10.1093/jjco/hyu182; Stevens R A, 2000, Cancer Control, V7, P132; Taylor DR, 2013, CLIN PHARMACOL-ADV A, V5, P131, DOI 10.2147/CPAA.S26649; Rivera IV, 2014, ADV THER, V31, P107, DOI 10.1007/s12325-013-0086-4; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	32	3	3	0	3	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1758-1869	1758-1877		PAIN MANAG	Pain Manag.	OCT	2016	6	5					427	434		10.2217/pmt-2015-0009			8	Clinical Neurology	Neurosciences & Neurology	EA5WE	WOS:000386694300004	27020837	Green Accepted, Other Gold			2020-06-30	J	Yonemitsu, K; Sasao, A; Mishima, S; Ohtsu, Y; Nishitani, Y				Yonemitsu, Kosei; Sasao, Ako; Mishima, Satoko; Ohtsu, Yuki; Nishitani, Yoko			A fatal poisoning case by intravenous injection of "bath salts" containing acetyl fentanyl and 4-methoxy PV8	FORENSIC SCIENCE INTERNATIONAL			English	Article						Acetyl fentanyl; 4-Methoxy PV8; Sudden death; Bath salts; Intravenous injection	DESIGNER DRUGS; WHOLE-BLOOD; POSTMORTEM; EXTRACTION	A man in his 30's was found at home, not breathing. He was admitted to an emergency hospital and the doctor confirmed his death. He had a history of methamphetamine abuse spanning several years, and while fresh needle marks were visible on his arm, the only other autopsy findings indicated an acute death. A small plastic bag containing a pale brown white powder, and a small amount of liquid in a syringe were found at the scene. The police forensic laboratory detected acetyl fentanyl and 4-methoxy PV8 (4-methoxy PHPP) in both the powder and the liquid. Scan analysis by gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) identified acetyl fentanyl and 4-methoxy PV8 in the urine sample. Both drugs were quantitated simultaneously by liquid chromatography-tandem mass spectrometry (LC-MS/MS), using the selected reaction monitoring method. The concentration of acetyl fentanyl in the femoral vein blood, urine, and gastric contents were 153, 240, and 880 ng/mL respectively, and the concentration of 4-methoxy PV8 in the femoral vein blood, urine, and gastric contents were 389, 245, and 500 ng/mL respectively. Cause of death was attributed to acute poisoning by "bath salts" containing acetyl fentanyl and 4-methoxy PV8. Evidence indicated that self-administered intravenous injection was the most likely scenario, and that the deceased had been a habitual user of the "bath salt" drug for some time. Drugs detected in the gastric contents could be explained by the gastric secretion of basic drugs, or drug-containing bile entering the gastric contents. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Yonemitsu, Kosei; Sasao, Ako; Mishima, Satoko; Ohtsu, Yuki; Nishitani, Yoko] Kumamoto Univ, Fac Life Sci, Dept Forens Med, 1-1-1 Honjo, Kumamoto 8608556, Japan	Yonemitsu, K (reprint author), Kumamoto Univ, Fac Life Sci, Dept Forens Med, 1-1-1 Honjo, Kumamoto 8608556, Japan.	yonemie@kumamoto-u.ac.jp	Sasao, Ako/AAH-9874-2019				Anastassiades M, 2003, J AOAC INT, V86, P412; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; [Anonymous], 2013, CDC HLTH ALERT NETWO, V62, P703; BOVILL JG, 1980, BRIT J ANAESTH, V52, P795, DOI 10.1093/bja/52.8.795; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Hasegawa K, 2015, FORENSIC TOXICOL, V33, P141, DOI 10.1007/s11419-014-0262-5; Hasegawa K, 2014, FORENSIC TOXICOL, V32, P243, DOI 10.1007/s11419-014-0230-0; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Kudo K, 2015, LEGAL MED-TOKYO, V17, P421, DOI 10.1016/j.legalmed.2015.06.005; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; Moriya F., 2014, JPN J CLIN TOXICOL, V27, P161; Uchiyama N, 2014, FORENSIC TOXICOL, V32, P266, DOI 10.1007/s11419-014-0238-5; Usui K, 2012, LEGAL MED-TOKYO, V14, P286, DOI 10.1016/j.legalmed.2012.04.008; Volkow ND, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015269	15	34	34	0	15	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	OCT	2016	267						E6	E9		10.1016/j.forsciint.2016.08.025			4	Medicine, Legal	Legal Medicine	EA1EK	WOS:000386335100002	27591912				2020-06-30	J	Kim, EJ; Shim, JK; Soh, S; Song, JW; Lee, SR; Kwak, YL				Kim, Eun Jung; Shim, Jae-Kwang; Soh, Sarah; Song, Jong Wook; Lee, Se Ryeon; Kwak, Young-Lan			Patient-controlled Analgesia With Propacetamol-Fentanyl Mixture for Prevention of Postoperative Nausea and Vomiting in High-risk Patients Undergoing Spine Surgery: A Randomized Controlled Trial	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						acetaminophen; analgesia; patient-controlled; postoperative nausea and vomiting; propacetamol	INTRAVENOUS ACETAMINOPHEN; DOUBLE-BLIND; PARACETAMOL; PAIN; ANTINOCICEPTION; EFFICACY	Background: This randomized trial evaluated the effect of intravenous patient-controlled analgesia (IV-PCA) based on fentanyl mixed with either propacetamol or an equivalent volume of normal saline on postoperative nausea and vomiting (PONY) in highly susceptible patients undergoing spinal surgery. Materials and Methods: One hundred eight nonsmoking female patients were randomly and evenly allocated to receive IV-PCA with either propacetamol (4 g) or normal saline mixed to fentanyl (20 mu g/kg). Primary study outcome was PONY incidence at 24 hours postsurgery. Secondary outcomes were nausea severity, pain intensity (100-mm visual analog scale), use of rescue antiemetics and analgesics, patient satisfaction, and adverse events at 6, 12, and 24 hours postsurgery. Results: Postsurgery, the propacetamol versus normal saline group had lower PONY incidence at 24 hours (41% vs. 66%, P = 0.011); pain intensity at rest and rescue analgesic requirements at 6 to 12 hours (30 +/- 15 vs. 41 19, P = 0.008; and 25% vs. 49%, P = 0.036, respectively) and at 12 to 24 hours (25 +/- 15 vs. 35 +/- 17, P = 0.008; and 19% vs. 42%, P = 0.044, respectively); and higher patient satisfaction score (6.4 +/- 1.4 vs. 5.7 +/- 1.8, P = 0.028). Conclusions: In patients undergoing spinal surgery and at risk of developing PONY, continuous IV-PCA based on propacetamol mixed to fentanyl, relative to fentanyl alone, effectively reduced the incidence of PONY, pain intensity at rest, and additional use of rescue analgesics with higher patient satisfaction.	[Kim, Eun Jung; Shim, Jae-Kwang; Soh, Sarah; Song, Jong Wook; Kwak, Young-Lan] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 50-1 Yonsei Ro, Seoul 120752, South Korea; [Lee, Se Ryeon] Ajou Univ, Sch Med, Dept Anesthesiol & Pain Med, Suwon, South Korea	Kwak, YL (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 50-1 Yonsei Ro, Seoul 120752, South Korea.	ylkwak@yuhs.ac		Kwak, Young-Lan/0000-0002-2984-9927; Soh, Sarah/0000-0001-5022-4617; Song, Jong Wook/0000-0001-7518-2070; Kim, Eun Jung/0000-0002-5693-1336; Shim, Jae-Kwang/0000-0001-9093-9692			ANDERSEN R, 1976, CAN ANAESTH SOC J, V23, P366, DOI 10.1007/BF03005916; Anderson BJ, 2008, PEDIATR ANESTH, V18, P915, DOI 10.1111/j.1460-9592.2008.02764.x; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Apfel CC, 2013, PAIN, V154, P677, DOI 10.1016/j.pain.2012.12.025; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Berl V, 1998, CONTACT DERMATITIS, V38, P185, DOI 10.1111/j.1600-0536.1998.tb05704.x; Chandrakantan A, 2011, BRIT J ANAESTH, V107, P27, DOI 10.1093/bja/aer358; Chang WK, 2013, PAIN MED, V14, P736, DOI 10.1111/pme.12067; Chouker A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010752; Cok OY, 2011, EUR J ANAESTH, V28, P836, DOI 10.1097/EJA.0b013e32834c580b; De Oliveira GS, 2015, CLIN J PAIN, V31, P86, DOI 10.1097/AJP.0000000000000081; DEPRE M, 1992, FUNDAM CLIN PHARM, V6, P259, DOI 10.1111/j.1472-8206.1992.tb00119.x; Duggan ST, 2009, DRUGS, V69, P101, DOI 10.2165/00003495-200969010-00007; Gaitan G, 2005, LIFE SCI, V77, P85, DOI 10.1016/j.lfs.2004.12.022; Habib AS, 2012, ANESTH ANALG, V115, P493, DOI 10.1213/ANE.0b013e318254285e; Hahn TW, 2003, ACTA ANAESTH SCAND, V47, P138, DOI 10.1034/j.1399-6576.2003.00046.x; Hernandez-Palazon J, 2001, ANESTH ANALG, V92, P1473, DOI 10.1097/00000539-200106000-00024; Herring BO, 2014, PHARMACOTHERAPY, V34, p27S, DOI 10.1002/phar.1513; Hong JY, 2010, ANESTHESIOLOGY, V113, P672, DOI 10.1097/ALN.0b013e3181e2c34b; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Jahangiri Fard A, 2014, ANESTH PAIN MED, V4, P1; Kobelt P, 2014, PAIN MANAG NURS, V15, P672, DOI 10.1016/j.pmn.2013.11.002; Misra S, 2013, J NEUROSURG ANESTH, V25, P386, DOI 10.1097/ANA.0b013e31829327eb; Moon YE, 2014, KOREAN J ANESTHESIOL, V67, P164, DOI 10.4097/kjae.2014.67.3.164; Pergolizzi JV, 2012, PAIN PRACT, V12, P159, DOI 10.1111/j.1533-2500.2011.00476.x; Raffa RB, 2000, J PHARMACOL EXP THER, V295, P291; Raffa RB, 2004, EUR J PHARMACOL, V503, P209, DOI 10.1016/j.ejphar.2004.08.055; Roh GU, 2014, SPINE, V39, pE543, DOI 10.1097/BRS.0000000000000236; Shin S, 2014, YONSEI MED J, V55, P800, DOI 10.3349/ymj.2014.55.3.800; Song JW, 2013, BRIT J ANAESTH, V111, P630, DOI 10.1093/bja/aet192; Tunali Y, 2013, J NEUROSURG ANESTH, V25, P143, DOI 10.1097/ANA.0b013e31827464af; Ubaldo CD, 2014, PHARMACOTHERAPY, V34, p34S, DOI 10.1002/phar.1511; Unal SS, 2015, NIGER J CLIN PRACT, V18, P68, DOI 10.4103/1119-3077.146982; Vardy J, 2014, J CLIN ONCOL, V32, P1677, DOI 10.1200/JCO.2013.52.8356	35	3	3	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2016	28	4					316	322		10.1097/ANA.0000000000000252			7	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	DY6JI	WOS:000385211800007	26558356				2020-06-30	J	Jain, V; Prakash, PS; Dash, HH				Jain, Virendra; Prakash, Prabhakar S.; Dash, Hari H.			Anesthetic Management of a Case of Posterior Fossa Tumor With An Intracardiac Mass	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Letter									[Jain, Virendra; Prakash, Prabhakar S.; Dash, Hari H.] Fortis Mem Res Inst, Dept Anaesthesiol & Pain Med, Gurgaon, Haryana, India	Jain, V (reprint author), Fortis Mem Res Inst, Dept Anaesthesiol & Pain Med, Gurgaon, Haryana, India.						Bergman R, 2013, J CARDIOTHOR VASC AN, V27, P625, DOI 10.1053/j.jvca.2012.09.007; Korkmaz AA, 2010, ANN THORAC SURG, V89, pE33, DOI 10.1016/j.athoracsur.2010.02.039; MELLER J, 1977, AM J MED, V63, P816; Raut MS, 2015, ANN CARD ANAESTH, V18, P95, DOI 10.4103/0971-9784.148329	4	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2016	28	4					436	437		10.1097/ANA.0000000000000239			2	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	DY6JI	WOS:000385211800032	26492288				2020-06-30	J	Arikan, FGO; Turan, G; Ozgultekin, A; Sivrikaya, Z; Cosar, BC; Onder, DN				Arikan, Fatma Gulcin Ozturk; Turan, Guldem; Ozgultekin, Asu; Sivrikaya, Zubeyir; Cosar, Bekir Cem; Onder, Dondu Nisa			Rocuronium: automatic infusion versus manual administration with TOF monitorisation	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Monitoring; Neuromuscular block; Rocuronium; General anaesthesia	CLOSED-LOOP CONTROL; BISPECTRAL INDEX; NEUROMUSCULAR BLOCK; CONTROL-SYSTEM; ANESTHESIA; PROPOFOL; ISOFLURANE; MIVACURIUM; MODEL	TOF (train-of-four) monitoring provides objective data in application of neuromuscular blocking agent. Thus, applicator-based differences are eliminated and optimum muscle relaxation is maintained during operation. In the present study, we aimed to compare the effects of target-controlled infusion system and standard TOF monitoring, on use of rocuronium. ASA I-II patients, who were aged between 18 and 75 years and scheduled for elective abdominal surgery at HaydarpaAYa Numune Training and Research Hospital, were enrolled in the study. In order to evaluate neuromuscular blockade, the patients in Group 1 were connected to the acceleromyography device of the target-controlled infusion pump (Veryark-CLMRIS-I-China) while the ones in Group 2 were connected to the routinely used acceleromyography device (TOF Watch SX). There was no significant difference between groups regarding patient characteristics, the durations of anaesthesia and surgery, quality of intubation, time to extubation and time to recovery (TOF ratio of 0.9). Intubation time was significantly longer in Group 1 (Automated group) as compared to Group 2 (Control group) (p < 0.05). The total rocuronium amount used in Group 1 was found to be significantly higher than the amount used in Group 2 (p < 0.05). There was no clinical evidence of residual neuromuscular blockage or reoccurrence of neuromuscular blockage in any patient in either group. Both methods can be used for administration of neuromuscular blocker agent during moderate time anesthesia. No advantage was noted when rocuronium was administered via automatical infusion pump during anaesthesia.	[Arikan, Fatma Gulcin Ozturk; Cosar, Bekir Cem] Nigde Bor State Hosp, Dept Anaesthesiol & Intens Care, Nigde, Turkey; [Turan, Guldem] Fatih Sultan Mehmet Teaching & Res Hosp, Dept Anaesthesiol & Intens Care, Istanbul, Turkey; [Ozgultekin, Asu] Haydarpasa Numune Teaching & Res Hosp, Dept Anaesthesiol & Intens Care, Istanbul, Turkey; [Sivrikaya, Zubeyir] Trabzon Surmene State Hosp, Dept Anaesthesiol & Intens Care, Trabzon, Turkey; [Onder, Dondu Nisa] Nigde State Hosp, Dept Anaesthesiol & Intens Care, Nigde, Turkey	Arikan, FGO (reprint author), Nigde Bor State Hosp, Dept Anaesthesiol & Intens Care, Nigde, Turkey.	gulcin_ozturk@hotmail.com; gturanmd@yahoo.com; asuozgultekin@yahoo.com; drzbyrs@hotmail.com; drcemcosar@hotmail.com; drnisaonder@gmail.com					Absalom AR, 2002, ANESTHESIOLOGY, V96, P67, DOI 10.1097/00000542-200201000-00017; APFELBAUM JL, 1995, ACTA ANAESTH SCAND, V39, P55, DOI 10.1111/j.1399-6576.1995.tb04311.x; Chuang CT, 2006, BIOMED ENG-APP BAS C, V18, DOI 10.4015/S1016237206000439; Cooper RA, 1992, BRIT J ANAESTH, V69, P273; De Smet T, 2008, ANESTH ANALG, V107, P1200, DOI 10.1213/ane.0b013e31817bd1a6; Hemmerling TM, 2010, CAN J ANESTH, V57, P725, DOI 10.1007/s12630-010-9335-z; Janda M, 2011, ANAESTHESIA, V66, P1112, DOI 10.1111/j.1365-2044.2011.06875.x; Kopman AF, 1999, ANESTHESIOLOGY, V90, P425, DOI 10.1097/00000542-199902000-00016; Liu N, 2006, ANESTHESIOLOGY, V104, P686, DOI 10.1097/00000542-200604000-00012; Locher S, 2004, ANESTHESIOLOGY, V101, P591, DOI 10.1097/00000542-200409000-00007; Mahfouf M, 1994, INTELLIGENT CONTROL, P37; Miller RD, 1994, ANESTHESIA, P1345; Morgan GE, 2010, CLIN ANAESTHESIOL, P179; Murphy Glenn S, 2004, Int Anesthesiol Clin, V42, P25, DOI 10.1097/00004311-200404220-00004; ORIS B, 1993, ANESTH ANALG, V77, P570; Reid JE, 2001, CAN J ANAESTH, V48, P351, DOI 10.1007/BF03014962; Schultheis L, 2008, CLIN REV ZEMURON ROC; Schumacher PM, 2006, EUR J ANAESTH, V23, P691, DOI 10.1017/S0265021506000524; Vermeyen KM, 2003, BRIT J ANAESTH, V90, P183, DOI 10.1093/bja/aeg043; Wehbe M, 2014, J CLIN MONIT COMPUT, V28, P27, DOI 10.1007/s10877-013-9451-8	20	4	4	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	OCT	2016	30	5					545	550		10.1007/s10877-015-9751-2			6	Anesthesiology	Anesthesiology	DW4GX	WOS:000383602300007	26278704				2020-06-30	J	Silva, C; Pinheiro, F; Chieira, D; Marques, S; Orfao, MR				Silva, Carla; Pinheiro, Filipe; Chieira, Diana; Marques, Sofia; Orfao, Maria Rosario			Anesthetic Management of an Acute Bleeding Ventriculo-Cutaneous Fistula	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						ventriculo-cutaneous fistula; hemmorrhage; cardiac surgery; infection	CARDIOCUTANEOUS FISTULA; REPAIR; ANEURYSMECTOMY; INFECTION		[Silva, Carla; Pinheiro, Filipe; Chieira, Diana; Marques, Sofia; Orfao, Maria Rosario] Ctr Hosp & Univ Coimbra, Dept Anesthesiol, Ave Bissaya Barreto Praceta Mota Pinto, P-3000075 Coimbra, Portugal	Silva, C (reprint author), Ctr Hosp & Univ Coimbra, Dept Anesthesiol, Ave Bissaya Barreto Praceta Mota Pinto, P-3000075 Coimbra, Portugal.	carlitanet@gmail.com					Adams MJ, 2003, SEMIN RADIAT ONCOL, V13, P346, DOI 10.1016/S1053-4296(03)00026-2; Apostolakis E, 2008, ANN THORAC CARDIOVAS, V14, P138; CHATZIS A, 1992, BRIT HEART J, V67, P500; Conolly S, 2010, CONTIN ED ANAESTH CR, V10, P138; D'Ancona G, 2007, ANN THORAC SURG, V84, P657, DOI 10.1016/j.athoracsur.2007.03.073; Danias PG, 1999, HEART, V81, P325, DOI 10.1136/hrt.81.3.325; DEUVAERT FE, 1984, J CARDIOVASC SURG, V25, P560; Dewhurst AT, 2002, ANAESTHESIA, V57, P1016, DOI 10.1046/j.1365-2044.2002.02787.x; Formica F, 2013, EUR J CARDIO-THORAC, V44, P180, DOI 10.1093/ejcts/ezt021; Hollinger L, 2010, TEX HEART I J, V37, P230; Kaul P, 2006, J CARDIOTHORAC SURG, V1, DOI 10.1186/1749-8090-1-30; LOOSER KG, 1976, J THORAC CARDIOV SUR, V72, P280; Meloni F, 2009, J COMPUT ASSIST TOMO, V33, P215, DOI 10.1097/RCT.0b013e318173f735; Okui E, 1998, Masui, V47, P74; Pocar M, 2000, HEART RAPID RESPONSE; Rafael AE, 2014, TEX HEART I J, V41, P324, DOI 10.14503/THIJ-13-3199; Ricchi Alessandro, 2003, Eur J Cardiothorac Surg, V23, P638, DOI 10.1016/S1010-7940(03)00004-6; STANFORD W, 1980, J THORAC CARDIOV SUR, V79, P789; Svyatets M, 2010, J CARDIOTHOR VASC AN, V24, P644, DOI 10.1053/j.jvca.2010.02.010; Wellens F, 1988, J Card Surg, V3, P109, DOI 10.1111/j.1540-8191.1988.tb00231.x; Ziganshin BA, 2013, ANN CARDIOTHORAC SUR, V2, P303, DOI 10.3978/j.issn.2225-319X.2013.01.05	21	0	0	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	OCT	2016	30	5					1324	1328		10.1053/j.jvca.2015.11.020			5	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	DX1WI	WOS:000384157300026	27039109				2020-06-30	J	Wilwerth, M; Majcher, JL; Van der Linden, P				Wilwerth, M.; Majcher, J. -L.; Van der Linden, P.			Spinal fentanyl vs. sufentanil for post-operative analgesia after C-section: a double-blinded randomised trial	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							INTRATHECAL FENTANYL; LABOR ANALGESIA; BUPIVACAINE; ANESTHESIA; DELIVERY; PLACEBO	BackgroundFentanyl and sufentanil are the most commonly administered intrathecal lipophilic opioids worldwide, although their relative efficacy when given by this route is not well characterised. The primary endpoint of this prospective, randomised, double-blind study was to compare effective analgesia duration of intrathecal administered fentanyl 25 g and sufentanil 2.5 or 5 g, Second endpoints were to compare post-operative morphine consumption and incidence of side effects between these opioids dosages. MethodsAfter IRB approval, 180 full-term parturients undergoing elective Caesarean section were randomly allocated into three groups, according to the opioid added to 10 mg intrathecal hyperbaric bupivacaine: fentanyl 25 g, sufentanil 2.5 g or sufentanil 5 g. Total effective analgesia was defined as time from spinal injection (T0) to first IV morphine requirement (T1) administered with a patient controlled intravenous pump. Statistical data analysis included non-parametric tests and chi-squared. A P value < 0.05 was considered statistically significant. Data are presented as median [interquartile ranges 25-75]. ResultsDuration of analgesia was significantly longer with sufentanil 2.5 g (214 min [189-251]) and 5 g (236 min [190-372]) compared to fentanyl 25 g (187 min [151-230]) (P < 0.01). Morphine consumption at T1 + 4 h was lower in the sufentanil groups (6 mg [3-9] and 6 mg [2-10]) than in the fentanyl group (9 mg [5-13]) (P < 0.01). Incidence of adverse effects was not different between groups. ConclusionIn the conditions of our study, sufentanil 5 g was the opioid of choice, associated with the best quality of anaesthesia without increased incidence of side effects.	[Wilwerth, M.; Majcher, J. -L.; Van der Linden, P.] Univ Libre Bruxelles, Dept Anaesthesiol, Univ Hosp Brugmann, Brussels, Belgium	Wilwerth, M (reprint author), Ctr Hosp Univ Brugmann, Dept Anaesthesiol, Pl Van Gehuchten, B-1020 Brussels, Belgium.	madeleine.wilwerth@chu-brugmann.be					Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Danelli G, 2004, REGION ANESTH PAIN M, V29, P221, DOI 10.1016/j.rapm.2004.02.003; Gaiser RR, 1998, J CLIN ANESTH, V10, P488, DOI 10.1016/S0952-8180(98)00076-2; Gebhardt R, 2013, SHNIDER LEVINSONS AN, P182; Gogarten Wiebke, 2003, Best Pract Res Clin Anaesthesiol, V17, P377; Harten JM, 2005, ANAESTHESIA, V60, P348, DOI 10.1111/j.1365-2044.2005.04113.x; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Ismail S, 2009, INT J OBSTET ANESTH, V18, P352, DOI 10.1016/j.ijoa.2009.02.013; Lee JH, 2011, KOREAN J ANESTHESIOL, V60, P103, DOI 10.4097/kjae.2011.60.2.103; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; MCCULLOCH WJD, 1986, BRIT J ANAESTH, V58, P610, DOI 10.1093/bja/58.6.610; Meininger D, 2003, ANESTH ANALG, V96, P852, DOI 10.1213/01.ANE.0000049685.38809.7E; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Pitkanen Mikko, 2003, Best Pract Res Clin Anaesthesiol, V17, P305; PITKANEN MT, 1987, ANESTH ANALG, V66, P127, DOI 10.1213/00000539-198702000-00005; Reynolds L, 2004, PAIN, V110, P182, DOI 10.1016/j.pain.2004.03.024; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Tonni G, 2007, INT J GYNECOL OBSTET, V97, P143, DOI 10.1016/j.ijgo.2006.11.021; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018	20	5	7	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2016	60	9					1306	1313		10.1111/aas.12738			8	Anesthesiology	Anesthesiology	DW7YV	WOS:000383870700013	27137756				2020-06-30	J	Thompson, JP; Thompson, DF				Thompson, Joshua P.; Thompson, Dennis F.			Nebulized Fentanyl in Acute Pain: A Systematic Review	ANNALS OF PHARMACOTHERAPY			English	Review						pain management; analgesia; emergency medicine; dosage forms; pharmacokinetics	RANDOMIZED CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; INTRAVENOUS MORPHINE; INTRANASAL FENTANYL; HISTAMINE-RELEASE; INHALED FENTANYL; POSTOPERATIVE ANALGESIA; BREAKTHROUGH PAIN; ABDOMINAL-PAIN; CLINICAL-TRIAL	Objective: To provide a systematic review of the current role of nebulized fentanyl in acute pain and potentially other conditions. Data Sources: A MEDLINE literature search inclusive of the dates 1946 to May 2016 was performed using the following search terms: fentanyl and administration, inhaled. Excerpta Medica was searched from 1980 to May 2016 using the following search terms: exp fentanyl/inhalation drug administration. Additionally, Web of Science was searched using the terms fentanyl and pain inclusive of 1945 to May 2016. Study Selection and Data Extraction: We utilized the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines to select English language, human primary literature, review articles, and supporting data assessing the efficacy of nebulized fentanyl in acute pain. Data Synthesis: Seven clinical trials have demonstrated no difference in efficacy between nebulized fentanyl and intravenous (IV) opioids. Few adverse effects were reported; however, the trials were of short duration. Nebulized fentanyl appeared to be a rapid acting analgesic that does not require IV access. Conclusion: Evidence suggests that nebulized fentanyl is as effective as IV opioids in the treatment of acute pain, with relatively few adverse effects. However, questions remain about the extemporaneous preparation of fentanyl nebulized solution, the variability in nebulization devices, and ensuring consistent drug delivery to distal airways in the clinical setting. The abuse potential of nebulized fentanyl should also be considered.	[Thompson, Joshua P.; Thompson, Dennis F.] Southwestern Oklahoma State Univ, Weatherford, OK USA	Thompson, DF (reprint author), Southwestern Oklahoma State Univ, Coll Pharm, 100 Campus Dr, Weatherford, OK 73096 USA.	dennis.thompson@swosu.edu					Alexander-Williams JM, 1998, BRIT J ANAESTH, V81, P3; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1197/aemj.10.3.215; Bausewein C, 2014, CURR OPIN SUPPORT PA, V8, P208, DOI 10.1097/SPC.0000000000000071; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Boyden JY, 2015, J AEROSOL MED PULM D, V28, P1, DOI 10.1089/jamp.2014.1136; Chow AHL, 2007, PHARM RES-DORDR, V24, P411, DOI 10.1007/s11095-006-9174-3; CHRUBASIK J, 1988, BRIT J ANAESTH, V61, P228, DOI 10.1093/bja/61.2.228; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Deaton T, 2015, AM J EMERG MED, V33, P791, DOI 10.1016/j.ajem.2015.03.046; El-Hamid AM Abd, 2015, AIN SHAMS J ANESTHIO, P316; FLACKE JW, 1987, ANESTH ANALG, V66, P723; Furyk JS, 2009, EMERG MED AUSTRALAS, V21, P203, DOI 10.1111/j.1742-6723.2009.01183.x; Graff GR, 2004, RESPIRATION, V71, P646, DOI 10.1159/000081769; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; HERMENS JM, 1985, ANESTHESIOLOGY, V62, P124, DOI 10.1097/00000542-198502000-00005; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; Jamison RN, 2015, MAYO CLIN PROC, V90, P957, DOI 10.1016/j.mayocp.2015.04.010; Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007; Kuhn RJ, 2002, PHARMACOTHERAPY, V22, p80S, DOI 10.1592/phco.22.6.80S.33907; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Le J, 2010, PHARMACOTHERAPY, V30, P562, DOI 10.1592/phco.30.6.562; MacLeod DB, 2012, ANESTH ANALG, V115, P1071, DOI 10.1213/ANE.0b013e3182691898; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Masood AR, 1996, BRIT J CLIN PHARMACO, V41, P250, DOI 10.1111/j.1365-2125.1996.tb00192.x; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Miner J, 2010, ROSENS EMERGENCY MED, P2410; Miner JR, 2007, ACAD EMERG MED, V14, P895, DOI 10.1197/j.aem.2007.06.036; Patrick PA, 2015, J EMERG MED, V48, P267, DOI 10.1016/j.jemermed.2014.09.009; Richards CF, 2005, EMERG MED CLIN N AM, V23, P519, DOI 10.1016/j.emc.2004.12.014; ROERIG DL, 1987, ANESTHESIOLOGY, V67, P466, DOI 10.1097/00000542-198710000-00004; Rosenblum A, 2008, EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Sabri A, 2013, BIO-MED MATER ENG, V23, P93, DOI 10.3233/BME-120735; Shervin F, 2014, AM J EMERG MED, V32, P1011, DOI 10.1016/j.ajem.2014.05.051; Singh AP, 2013, INDIAN J ANAESTH, V57, P583, DOI 10.4103/0019-5049.123331; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Tamches E, 2007, SWISS MED WKLY, V137, P223; Tolman JA, 2010, DRUG DEV IND PHARM, V36, P1, DOI 10.3109/03639040903092319; Waters CM, 2000, ANESTHESIOLOGY, V93, P825, DOI 10.1097/00000542-200009000-00033; Wiseman R, 2013, AUST FAM PHYSICIAN, V42, P137; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Younge P, 1999, EMERGEN MED, V11, P90	49	4	4	1	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	OCT	2016	50	10					882	891		10.1177/1060028016659077			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DW6BJ	WOS:000383731100010	27413071				2020-06-30	J	Ambros, B				Ambros, Barbara			Effect of pretreatment with hydromorphone or buprenorphine on thermal antinociception induced by fentanyl in awake cats	JOURNAL OF FELINE MEDICINE AND SURGERY			English	Article							RECEPTOR-BINDING; PAIN MANAGEMENT; THRESHOLD; MORPHINE; PHARMACOKINETICS	Objectives The aim of this study was to determine the effect of pretreatment with hydromorphone or buprenorphine on thermal antinociception induced by fentanyl in cats. Methods Seven healthy cats received five different treatments consisting of two drugs. Drug 1 was administered intravenously 1 h before drug 2. Drug 2 was given as an intravenous loading dose followed by an infusion for 4 h. The drug combinations used were: buprenorphine 20 mu g/kg followed by fentanyl (BF; 7 g/kg, 7 g/kg/h), buprenorphine 20 mu g/kg followed by 0.9% saline solution (B), hydromorphone 0.07 mg/kg followed by 0.9% saline solution (H), hydromorphone 0.07 mg/kg followed by fentanyl (HF; 7 g/kg, 7 g/kg/h) and 0.9% saline solution followed by fentanyl (F; 7 g/kg, 7 g/kg/h). Thermal thresholds were obtained prior to treatment and at predetermined times up to 7 h after drug 1. Results Thermal thresholds were significantly higher than baseline in all treatment groups as follows: H from 0.25 to 2.50 h; B from 0.25 to 2.50 h; F from 1.25 to 5.50 h; HF from 0.25 to 5.50 h and BF from 0.25 to 5.25 h. Thermal thresholds were significantly higher in HF and BF than in F treatment before the fentanyl infusion was commenced (from 0.25 to 1.00 h). During the fentanyl infusion thermal thresholds in BF compared with F were lower at 1.75 h and from 2.50 to 3.50 h. After the constant rate infusion of fentanyl was started, thermal thresholds were significantly lower in HF compared with F at one time point (3 h). Conclusions and relevance Pretreatment with buprenorphine did partially inhibit the antinociceptive action of fentanyl. Hydromorphone did inhibit the antinociceptive action of fentanyl at one single time point in cats.	[Ambros, Barbara] Univ Saskatchewan, Dept Small Anim Clin Sci, Western Coll Vet Med, Saskatoon, SK, Canada	Ambros, B (reprint author), 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada.	barbara.ambros@usask.ca			WINN Feline Foundation [W13-046]	This work was supported by the WINN Feline Foundation (W13-046). All data will be stored by the principal investigator for a period of 7 years after the date of publication.	Ambros B, 2014, AM J VET RES, V75, P716, DOI 10.2460/ajvr.75.8.716; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; Davis MP, 2012, EXPERT OPIN DRUG DIS, V7, P165, DOI 10.1517/17460441.2012.648611; Dixon MJ, 2002, RES VET SCI, V72, P205, DOI 10.1053/rvsc.2001.0543; Gilmore T, 2012, AM J EMERG MED, V30, DOI 10.1016/j.ajem.2011.07.024; Harrington CJ, 2010, AM SURGEON, V76, P397; Hedges AR, 2014, J VET PHARMACOL THER, V37, P252, DOI 10.1111/jvp.12084; Hellyer PW, 2003, VET ANAESTH ANALG, V30, P172, DOI 10.1046/j.1467-2995.2003.00143.x; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Jaramillo LAG, 2006, VET ANAESTH ANALG, V33, P399, DOI 10.1111/j.1467-2995.2006.00285.x; Joubert KE, 2001, J S AFR VET ASSOC, V72, P57; Kogel B, 2005, EUR J PAIN, V9, P599, DOI 10.1016/j.ejpain.2005.02.002; Lamont LA, 2002, VET CLIN N AM-SMALL, V32, P747, DOI 10.1016/S0195-5616(02)00028-1; Lascelles BDX, 1999, VET REC, V145, P601, DOI 10.1136/vr.145.21.601; Pasternak GW, 2012, PAIN MED, V13, pS4, DOI 10.1111/j.1526-4637.2012.01335.x; Raffa RB, 2007, ACUTE PAIN, V9, P145; Riley J, 2006, SUPPORT CARE CANCER, V14, P56, DOI 10.1007/s00520-005-0843-2; Robertson SA, 2005, J VET PHARMACOL THER, V28, P453, DOI 10.1111/j.1365-2885.2005.00677.x; Robertson SA, 2003, VET REC, V153, P462, DOI 10.1136/vr.153.15.462; Robertson SA, 2009, J FELINE MED SURG, V11, P76, DOI 10.1016/j.jfms.2008.05.003; Silva-Moreno A, 2012, EUR J PHARMACOL, V674, P239, DOI 10.1016/j.ejphar.2011.10.034; Steagall PVM, 2007, VET ANAESTH ANALG, V34, P344, DOI 10.1111/j.1467-2995.2006.00331.x; Steagall PVM, 2013, VET ANAESTH ANALG, V40, P83, DOI 10.1111/j.1467-2995.2012.00779.x; Steagall PVM, 2009, VET J, V182, P203, DOI 10.1016/j.tvjl.2008.06.017; Taylor PM, 2003, VET ANAESTH ANALG, V30, P51; Traynor JR, 2004, REVS ANALGESIA, V8, P11; Troster A, 2012, CLIN J PAIN, V28, P705, DOI 10.1097/AJP.0b013e318241d948; Wegner K, 2007, VET ANAESTH ANALG, V34, P132, DOI 10.1111/j.1467-2995.2006.00311.x	28	3	3	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1098-612X	1532-2750		J FELINE MED SURG	J. Feline Med. Surg.	OCT	2016	18	10					818	825		10.1177/1098612X15595835			8	Veterinary Sciences	Veterinary Sciences	DW1WM	WOS:000383434000009	26179573				2020-06-30	J	Shibasaki, S; Kawamura, H; Homma, S; Yosida, T; Takahashi, S; Takahashi, M; Takahashi, N; Taketomi, A				Shibasaki, Susumu; Kawamura, Hideki; Homma, Shigenori; Yosida, Tadashi; Takahashi, Shusaku; Takahashi, Masahiro; Takahashi, Norihiko; Taketomi, Akinobu			A comparison between fentanyl plus celecoxib therapy and epidural anesthesia for postoperative pain management following laparoscopic gastrectomy	SURGERY TODAY			English	Article						Laparoscopic gastrectomy; Postoperative pain; Epidural anesthesia; Celecoxib; Fentanyl	ASSISTED DISTAL GASTRECTOMY; RANDOMIZED CLINICAL-TRIAL; EARLY GASTRIC-CANCER; OUTCOMES; SURGERY; SAFETY; COMPLICATIONS; DISSECTION; ANALGESIA	To clarify the efficacy of postoperative pain management following laparoscopic gastrectomy (LG), we retrospectively compared pain assessments in patients who received fentanyl plus celecoxib with those who received epidural anesthesia. From 2011 to 2012, 55 consecutive LG patients at our institution received 48 h of epidural anesthesia for postoperative pain management (group-E). Since September 2013, epidural anesthesia was replaced with 24 h of intravenous fentanyl and 4 days of oral celecoxib. Thirty-three consecutive LG patients who received this analgesic method (group-FC) were included in this analysis. The severity of postoperative pain as assessed by the FACES Pain Rating Scale and the frequency of rescue pain medication were retrospectively compared between the two groups. No significant difference in the severity of postoperative pain on postoperative day (POD) 0 or 1 was observed between the two groups. In contrast, pain was significantly lower in group-FC than group-E on PODs 2, 3, 4, and 7. The total use of rescue pain medications during the first 7 days following LG did not differ between the two groups. Pain management using 24 h of intravenous fentanyl and 4 days of oral celecoxib is comparable to epidural anesthesia following LG.	[Shibasaki, Susumu; Kawamura, Hideki; Homma, Shigenori; Yosida, Tadashi; Takahashi, Norihiko; Taketomi, Akinobu] Hokkaido Univ, Grad Sch Med, Dept Surg Gastroenterol 1, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan; [Takahashi, Shusaku; Takahashi, Masahiro] Sapporo Kosei Hosp, Dept Surg, Sapporo, Hokkaido, Japan	Kawamura, H (reprint author), Hokkaido Univ, Grad Sch Med, Dept Surg Gastroenterol 1, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	h.kawamura@med.hokudai.ac.jp		Shibasaki, Susumu/0000-0003-2454-5083			[Anonymous], 2011, GASTRIC CANC, V14, P101; De Oliveira GS, 2014, ANESTH ANALG, V118, P454, DOI 10.1213/ANE.0000000000000066; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Eom BW, 2012, SURG ENDOSC, V26, P3273, DOI 10.1007/s00464-012-2338-9; Gustafsson UO, 2012, CLIN NUTR, V31, P783, DOI 10.1016/j.clnu.2012.08.013; Huang YM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-77; Japanese Gastric Cancer Association, 2011, GASTRIC CANCER, V14, P113, DOI [10.1007/s10120-011-0042-4, DOI 10.1007/S10120-011-0042-4]]; JORGENSEN H, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001893; Katai H, 2010, GASTRIC CANCER, V13, P238, DOI 10.1007/s10120-010-0565-0; Kawamura H, 2009, WORLD J SURG, V33, P2389, DOI 10.1007/s00268-009-0208-y; Kawamura H, 2009, SURG ENDOSC, V23, P991, DOI 10.1007/s00464-008-0090-y; Kim HS, 2013, J LAPAROENDOSC ADV S, V23, P323, DOI 10.1089/lap.2012.0389; Kim JW, 2012, WORLD J SURG, V36, P2879, DOI 10.1007/s00268-012-1741-7; Kim YW, 2008, ANN SURG, V248, P721, DOI 10.1097/SLA.0b013e318185e62e; Kumar V, 2013, RECENT PATENTS INFLA, V7, P124, DOI 10.2174/1872213X11307020004; Lee JH, 2007, ANN SURG ONCOL, V14, P3148, DOI 10.1245/s10434-007-9446-0; Matsota P, 2013, ARCH MED SCI, V9, P877, DOI 10.5114/aoms.2012.31253; Matsutani N, 2014, SURG TODAY, V44, P712, DOI 10.1007/s00595-013-0743-x; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Mori T, 2010, MINIM INVASIV THER, V19, P18, DOI 10.3109/13645700903492969; Park WY, 2001, ANN SURG, V234, P560; Popping DM, 2008, BRIT J ANAESTH, V101, P832, DOI 10.1093/bja/aen300; Rawal N, 2012, REGION ANESTH PAIN M, V37, P310, DOI 10.1097/AAP.0b013e31825735c6; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Roberts GW, 2005, ANESTH ANALG, V101, P1343, DOI 10.1213/01.ANE.0000180204.64588.EC; Sakuramoto S, 2013, SURG ENDOSC, V27, P1695, DOI 10.1007/s00464-012-2658-9; Schneider V, 2006, AM J EPIDEMIOL, V164, P881, DOI 10.1093/aje/kwj331; Takiguchi S, 2013, WORLD J SURG, V37, P2379, DOI 10.1007/s00268-013-2121-7; Vigneault L, 2011, CAN J ANESTH, V58, P22, DOI 10.1007/s12630-010-9407-0; White WB, 2002, AM J CARDIOL, V89, P425, DOI 10.1016/S0002-9149(01)02265-2; Wong D L, 1988, Pediatr Nurs, V14, P9; Zhang Zhenxiang, 2014, Eur J Orthop Surg Traumatol, V24, P919, DOI 10.1007/s00590-013-1359-y	32	3	3	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	OCT	2016	46	10					1209	1216		10.1007/s00595-015-1290-4			8	Surgery	Surgery	DV3TI	WOS:000382846000013	26695406				2020-06-30	J	Green, TC; Gilbert, M				Green, Traci C.; Gilbert, Michael			Counterfeit Medications and Fentanyl	JAMA INTERNAL MEDICINE			English	Editorial Material							HEROIN		[Green, Traci C.] Boston Univ, Sch Med, Dept Emergency Med, 771 Albany St,Room 1223, Boston, MA 02118 USA; [Green, Traci C.] Boston Med Ctr Injury Prevent Ctr, Boston, MA USA; [Green, Traci C.] Brown Univ, Warren Alpert Sch Med, Dept Emergency Med, Providence, RI 02912 USA; [Gilbert, Michael] Brown Univ, Warren Alpert Sch Med, Dept Epidemiol, Providence, RI 02912 USA; [Gilbert, Michael] Epidemico Inc, Boston, MA USA	Green, TC (reprint author), Boston Univ, Sch Med, Dept Emergency Med, 771 Albany St,Room 1223, Boston, MA 02118 USA.	traci.c.green@gmail.com		Gilbert, Michael/0000-0003-4200-6104	AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R18 HS024021]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA038082]		Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Brunt TM, 2016, DRUG TEST ANAL, P17; Ciccarone D, 2009, INT J DRUG POLICY, V20, P277, DOI 10.1016/j.drugpo.2008.08.003; Connery HS, 2015, HARVARD REV PSYCHIAT, V23, P63, DOI 10.1097/HRP.0000000000000075; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174	8	41	41	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	OCT	2016	176	10					1555	1557		10.1001/jamainternmed.2016.4310			3	Medicine, General & Internal	General & Internal Medicine	DZ1ZU	WOS:000385642000028	27533891				2020-06-30	J	Poklis, JL; Mohs, AJ; Wolf, CE; Poklis, A; Peace, MR				Poklis, Justin L.; Mohs, Amanda J.; Wolf, Carl E.; Poklis, Alphonse; Peace, Michelle R.			Identification of Drugs in Parenteral Pharmaceutical Preparations from a Quality Assurance and a Diversion Program by Direct Analysis in Real-Time AccuTOF(TM)-Mass Spectrometry (DART-MS)	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							SUBSTANCE-ABUSE; ANESTHESIOLOGY; PHYSICIANS; ADDICTION	In healthcare settings drug diversion and impairment of physicians are major concerns requiring a rapid and efficient method for surveillance and detection. A Direct Analysis in Real Time ion source coupled to a JEOL AccuTOF(TM) time-of-flight mass spectrometer (DART-MS) method was developed to screen parenteral pharmaceutical formulations for potential drug diversion. Parenteral pharmaceutical formulations are also known as injectable formulations and are used with intravenous, subcutaneous, intramuscular and intra-articular administration. A library was created using the mass spectra data collected by a DART-MS operated in switching mode at 20, 60 and 90 V settings. This library contained 17 commonly encountered drugs in parenteral pharmaceutical formulations that included the surgical analgesic: fentanyl, hydromorphone and morphine; anesthetic: baclofen, bupivacaine, ketamine, midazolam, ropivacaine and succinylcholine; and a mixture of other drug classes: caffeine, clonidine, dexamethasone, ephedrine, heparin, methadone, oxytocin and phenylephrine. Randomly selected 200 de-identified parenteral pharmaceutical formulations containing one or more drugs were submitted for analysis to the FIRM Toxicology Laboratory at Virginia Commonwealth University Health and were screened using the DART-MS. The drug contents of the de-identified formulations were previously confirmed by a published high performance liquid chromatography (HPLC) method. The drugs in the formulations were rapidly and successfully identified using the generated library. The DART-MS and HPLC results were in complete agreement for all 200 parenteral pharmaceutical formulations.	[Poklis, Justin L.; Poklis, Alphonse] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Mohs, Amanda J.; Wolf, Carl E.; Poklis, Alphonse; Peace, Michelle R.] Virginia Commonwealth Univ, Dept Forens Sci, Med Coll Virginia Campus, Richmond, VA 23284 USA; [Wolf, Carl E.; Poklis, Alphonse] Virginia Commonwealth Univ, Dept Pathol, Med Coll Virginia Campus, Richmond, VA 23298 USA	Poklis, JL (reprint author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	justin.poklis@vcuhealth.org	Peace, Michelle/X-8602-2018	Peace, Michelle/0000-0002-1480-139X	National Institute on Health (NIH) Center for Drug Abuse [P30DA033934]	This project was supported in part by the National Institute on Health (NIH) Center for Drug Abuse grant P30DA033934.	Bell D M, 1999, AANA J, V67, P133; Berge KH, 2012, MAYO CLIN PROC, V87, P674, DOI 10.1016/j.mayocp.2012.03.013; Booth JV, 2002, ANESTH ANALG, V95, P1024, DOI 10.1213/01.ANE.0000026379.66419.DB; Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1; Cody R.B., 2005, JEOL NEWS, V40, P8, DOI DOI 10.1021/AC050162J; Cody RB, 2005, ANAL CHEM, V77, P2297, DOI 10.1021/ac050162j; Danhelova H, 2012, ANAL BIOANAL CHEM, V403, P2883, DOI 10.1007/s00216-012-5820-2; Devine B, 2012, AM J HEALTH-SYST PH, V69, P552, DOI 10.2146/ajhp120010; HUGHES PH, 1992, JAMA-J AM MED ASSOC, V267, P2333, DOI 10.1001/jama.267.17.2333; MCAULIFFE WE, 1987, AM J HOSP PHARM, V44, P311, DOI 10.1093/ajhp/44.2.311; McClure SR, 2011, AM J HEALTH-SYST PH, V68, P689, DOI 10.2146/ajhp100212; SILVERSTEIN JH, 1993, ANESTHESIOLOGY, V79, P354, DOI 10.1097/00000542-199308000-00022; Wolf CE, 2005, J ANAL TOXICOL, V29, P711, DOI 10.1093/jat/29.7.711	13	3	4	1	29	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2016	40	8					608	616		10.1093/jat/bkw065			9	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EA9IT	WOS:000386957100007	27474362	Bronze, Green Published			2020-06-30	J	Palermo, C; Degnan, M; Candiotti, K; Salerno, T; de Marchena, E; Rodriguez-Blanco, Y				Palermo, Christopher; Degnan, Meredith; Candiotti, Keith; Salerno, Tomas; de Marchena, Eduardo; Rodriguez-Blanco, Yiliam			Monitored Anesthesia Care Versus General Anesthesia: Experience With the Medtronic CoreValve	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						delirium; propofol; transcatheter aortic valve implantation (TAVI); CoreValve	AORTIC-VALVE-REPLACEMENT; TRANSCATHETER; IMPLANTATION; OUTCOMES; MANAGEMENT; STANDARD; REGISTRY; STENOSIS	Objective: To compare monitored anesthesia care (MAC) and general anesthesia (GA) for transcatheter aortic valve implantation (TAVI). Design: Retrospective, case-control study. Setting: A large university-affiliated hospital system. Participants: The study comprised patients who underwent TAVI with the Medtronic CoreValve (Medtronic, Minneapolis, MN) between 2011 and 2015. Interventions: None. Measurements and Main Results: MAC (n = 44) and GA (n = 21) were compared in 65 patients who underwent TAVI. Baseline characteristics/demographics, hospital stay, intraoperative conditions, and intensive care unit (ICU)/hospital stays were compared using the chi-square test, unpaired t-test, or binomial regression where appropriate. There were no significant differences between patient populations with regard to 30-day mortality, ICU/hospital stay, and complication rates. The GA group used more blood product. The rate of ICU readmission was greater in the GA group but did not reach statistical significance. Conclusions: GA provides no significant advantages over MAC during TAVI. (C) 2016 Elsevier Inc. All rights reserved.	[Palermo, Christopher; Degnan, Meredith; Candiotti, Keith; de Marchena, Eduardo; Rodriguez-Blanco, Yiliam] Univ Miami, Jackson Mem Hosp, 1111 Brickell Bay Dr,Apt 2810, Miami, FL 33131 USA; [Salerno, Tomas] Jackson Mem Hosp, Miami, FL 33136 USA	Palermo, C (reprint author), Univ Miami, Jackson Mem Hosp, 1111 Brickell Bay Dr,Apt 2810, Miami, FL 33131 USA.	Cpalermo@med.miami.edu					Adams DH, 2014, NEW ENGL J MED, V370, P1790, DOI 10.1056/NEJMoa1400590; Babaliaros V, 2014, JACC-CARDIOVASC INTE, V7, P898, DOI 10.1016/j.jcin.2014.04.005; Bartel T, 2014, CARDIOVASC DIAGN THE, V4, P277, DOI 10.3978/j.issn.2223-3652.2014.08.04; Ben-Dor I, 2012, CARDIOVASC REVASCULA, V13, P207, DOI 10.1016/j.carrev.2012.02.002; Dall'Ara G, 2014, INT J CARDIOL, V177, P448, DOI 10.1016/j.ijcard.2014.09.025; Dehedin B, 2011, J CARDIOTHOR VASC AN, V25, P1036, DOI 10.1053/j.jvca.2011.05.008; Eveborn GW, 2013, HEART, V99, P396, DOI 10.1136/heartjnl-2012-302265; Frohlich GM, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-41; Jensen HA, 2015, J THORAC CARDIOV SUR, V150, P833, DOI 10.1016/j.jtcvs.2015.07.078; Kappetein AP, 2013, J THORAC CARDIOV SUR, V145, P6, DOI 10.1016/j.jtcvs.2012.09.002; Kim WJ, 2015, J INVASIVE CARDIOL, V27, P334; Kodali SK, 2012, NEW ENGL J MED, V366, P1686, DOI 10.1056/NEJMoa1200384; Leon MB, 2010, NEW ENGL J MED, V363, P1597, DOI 10.1056/NEJMoa1008232; Maas E, 2015, CURR PHARM DES; Mack MJ, 2015, LANCET, V385, P2477, DOI 10.1016/S0140-6736(15)60308-7; Makkar RR, 2012, NEW ENGL J MED, V366, P1696, DOI 10.1056/NEJMoa1202277; Martin E, 2015, J THORAC CARDIOV SUR, V150, P1582, DOI 10.1016/j.jtcvs.2015.08.077; Mayr N, 2015, B J ANESTH, V116, P1; Motloch LJ, 2012, CLIN RES CARDIOL, V101, P45, DOI 10.1007/s00392-011-0362-8; Oguri A, 2014, CIRC-CARDIOVASC INTE, V7, P602, DOI 10.1161/CIRCINTERVENTIONS.113.000403; Patel PA, 2012, J CARDIOTHOR VASC AN, V26, P698, DOI 10.1053/j.jvca.2012.03.017; Smith CR, 2011, NEW ENGL J MED, V364, P2187, DOI 10.1056/NEJMoa1103510; Tamburino C, 2015, J AM COLL CARDIOL, V66, P804, DOI 10.1016/j.jacc.2015.06.013; Wiegerinck EMA, 2014, INT J CARDIOL, V176, P1050, DOI 10.1016/j.ijcard.2014.07.170; Yamamoto M, 2013, AM J CARDIOL, V111, P94, DOI 10.1016/j.amjcard.2012.08.053	25	6	6	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	OCT	2016	30	5					1234	1237		10.1053/j.jvca.2016.02.006			4	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	DX1WI	WOS:000384157300013	27222049				2020-06-30	J	Hui, D; Kilgore, K; Park, M; Williams, J; Liu, D; Bruera, E				Hui, David; Kilgore, Kelly; Park, Minjeong; Williams, Janet; Liu, Diane; Bruera, Eduardo			Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Dyspnea; exercise; nasal sprays; neoplasms; opioids; randomized controlled trial	OBSTRUCTIVE PULMONARY-DISEASE; TRANSMUCOSAL FENTANYL; CLINICAL-TRIALS; RUN-IN; BREAKTHROUGH PAIN; MORPHINE-SULFATE; LUNG-CANCER; MU-G; BREATHLESSNESS; PLACEBO	Context. Episodic breathlessness is common and debilitating in cancer patients. Objectives. In this pilot study, we examined the effect of prophylactic fentanyl pectin nasal spray (FPNS) on exercise-induced dyspnea, physiologic function, and adverse events. Methods. In this parallel, double-blind randomized placebo-controlled trial, opioid-tolerant patients performed three six-minute walk tests (6MWTs) to induce dyspnea. They were randomized to receive either FPNS (15%-25% of total daily opioid dose each time) or placebo 20 minutes before the second and third 6MWTs. We compared dyspnea Numeric Rating Scale (NRS, 0-10, primary outcome), walk distance, vital signs, neurocognitive function, and adverse events between the first and second 6MWTs (T2-T1) and between the first and third 6MWTs (T3-T1). Results. Twenty-four patients enrolled, with 96% completion. FPNS was associated with significant within-arm reduction in dyspnea NRS at rest (T2-T1: -0.9 [95% CI -1.7, -0.1]; T3-T1: -1.3 [95% CI -2.0, -0.5]) and at the end of a 6MWT (T2-T1: -2.0 [95% CI -3.5, -0.6]; T3-T1: -2.3 [95% CI -4.0, -0.7]), and longer walk distance (T2-T1 +23.8 m [95% CI +1.3, +46.2 m]; T3-T1: +23.3 m [95% CI -1.7, +48.2]). In the placebo arm, we observed no significant change in walk distance nor dyspnea NRS at rest, but significant reduction in dyspnea NRS at six minutes (T2-T1: -1.7 [95% CI -3.3, -0.1]; T3-T1: -2.5 [95% CI -4.2, -0.9]). Vital signs, neurocognitive function, and adverse effects did not differ significantly. Conclusion. FPNS was safe, reduced dyspnea at rest, and increased walk distance in before-after comparison. The placebo effect was substantial, which needs to be factored in future study designs. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.	[Hui, David; Kilgore, Kelly; Williams, Janet; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA; [Park, Minjeong; Liu, Diane] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	Hui, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 1414, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dhui@mdanderson.org			Depomed; American Cancer Society Mentored Research Scholar Grant in Applied and Clinical ResearchAmerican Cancer Society [MRSG-14-1418-01-CCE]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21CA186000-01A1, R01NR010162-01A1, R01CA122292-01, R01CA124481-01]	This research is supported by an investigator-initiated study grant from Depomed to Dr. Hui. Dr. Hui is supported in part by an American Cancer Society Mentored Research Scholar Grant in Applied and Clinical Research (MRSG-14-1418-01-CCE) and a National Institutes of Health grant (R21CA186000-01A1). Dr. Bruera is supported in part by National Institutes of Health grants R01NR010162-01A1, R01CA122292-01, and R01CA124481-01. The funding sources were not involved in the conduct of the study or development of the submission. The authors have no conflicts of interest.	Benitez-Rosario MA, 2014, ANN PALLIAT MED, V3, P4, DOI 10.3978/j.issn.2224-5820.2014.01.02; Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; Berger VW, 2003, CONTROL CLIN TRIALS, V24, P156, DOI 10.1016/S0197-2456(02)00316-1; BRUERA E, 1992, PAIN, V48, P163, DOI 10.1016/0304-3959(92)90053-E; BRUERA E, 1993, ANN INTERN MED, V119, P906, DOI 10.7326/0003-4819-119-9-199311010-00007; Charles MA, 2008, J PAIN SYMPTOM MANAG, V36, P29, DOI 10.1016/j.jpainsymman.2007.08.016; Chen Cuiping, 2015, J Opioid Manag, V11, P139, DOI 10.5055/jom.2015.0263; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Cook C, 2010, J MAN MANIP THER, V18, P61, DOI 10.1179/106698110X12640740712617; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; DAVIS CE, 1995, CONTROL CLIN TRIALS, V16, P41, DOI 10.1016/0197-2456(94)00027-Z; de la Cruz M, 2010, CANCER-AM CANCER SOC, V116, P766, DOI 10.1002/cncr.24751; Dorman S, 2007, PALLIATIVE MED, V21, P177, DOI 10.1177/0269216307076398; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Gift A G, 1998, Am J Crit Care, V7, P200; Granger CL, 2015, CHRON RESP DIS, V12, P146, DOI 10.1177/1479972315575715; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hui D, 2016, CANCER-AM CANCER SOC, V122, P1774, DOI 10.1002/cncr.29970; Hui D, 2015, CANCER-AM CANCER SOC, V121, P3027, DOI 10.1002/cncr.29437; Hui D, 2014, J PAIN SYMPTOM MANAG, V48, pE5, DOI 10.1016/j.jpainsymman.2014.05.001; Hui D, 2014, J PAIN SYMPTOM MANAG, V47, P209, DOI 10.1016/j.jpainsymman.2013.03.017; Hui D, 2013, J PALLIAT MED, V16, P274, DOI 10.1089/jpm.2012.0364; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007; Johnson MJ, 2016, AM J HOSP PALLIAT ME, V33, P194, DOI 10.1177/1049909114552692; Kotrach HG, 2015, J APPL PHYSIOL, V118, P1406, DOI 10.1152/japplphysiol.01091.2014; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2016, J PAIN SYMPTOM MANAG, V51, P17, DOI 10.1016/j.jpainsymman.2015.07.020; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Pablos-Mendez A, 1998, JAMA-J AM MED ASSOC, V279, P222, DOI 10.1001/jama.279.3.222; Parikh N, 2013, CLIN DRUG INVEST, V33, P391, DOI 10.1007/s40261-013-0079-8; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Reddy SK, 2009, J PALLIAT MED, V12, P29, DOI 10.1089/jpm.2008.0158; Ries Andrew L, 2005, COPD, V2, P105; Simon ST, 2014, J PAIN SYMPTOM MANAG, V47, P828, DOI 10.1016/j.jpainsymman.2013.06.013; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Simon ST, 2013, J PAIN SYMPTOM MANAG, V45, P561, DOI 10.1016/j.jpainsymman.2012.02.022; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Tanaka K, 2000, BRIT J CANCER, V82, P800, DOI 10.1054/bjoc.1999.1002; Weingartner V, 2015, PALLIATIVE MED, V29, P420, DOI 10.1177/0269216314563428; Weingartner V, 2013, J PALLIAT MED, V16, P1275, DOI 10.1089/jpm.2013.0087	47	12	12	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	OCT	2016	52	4					459	+		10.1016/j.jpainsymman.2016.05.013			11	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	EA7RZ	WOS:000386830900002	27401508	Green Accepted, Bronze			2020-06-30	J	Schrepf, A; Harper, DE; Harte, SE; Wang, H; Ichesco, E; Hampson, JP; Zubieta, JK; Clauw, DJ; Harris, RE				Schrepf, Andrew; Harper, Daniel E.; Harte, Steven E.; Wang, Heng; Ichesco, Eric; Hampson, Johnson P.; Zubieta, Jon-Kar; Clauw, Daniel J.; Harris, Richard E.			Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study	PAIN			English	Article						Opioid receptors; Fibromyalgia; Chronic pain; Positron emission tomography; Magnetic resonance imaging	CEREBROSPINAL-FLUID; RECEPTOR AVAILABILITY; INDUCED HYPERALGESIA; PRESSURE PAIN; MORPHINE; PLACEBO; BRAIN; SENSITIVITY; SYSTEM; CORTEX	Endogenous opioid system dysfunction potentially contributes to chronic pain in fibromyalgia (FM), but it is unknown if this dysfunction is related to established neurobiological markers of hyperalgesia. We previously reported that m-opioid receptor (MOR) availability was reduced in patients with FM as compared with healthy controls in several pain-processing brain regions. In the present study, we compared pain-evoked functional magnetic resonance imaging with endogenous MOR binding and clinical pain ratings in female opioid-naive patients with FM (n = 18) using whole-brain analyses and regions of interest from our previous research. Within antinociceptive brain regions, including the dorsolateral prefrontal cortex (r = 0.81, P < 0.001) and multiple regions of the anterior cingulate cortex (all r > 0.67; all P < 0.02), reduced MOR availability was associated with decreased pain-evoked neural activity. Additionally, reduced MOR availability was associated with lower brain activation in the nucleus accumbens (r = 0.47, P = 0.050). In many of these regions, pain-evoked activity and MOR binding potential were also associated with lower clinical affective pain ratings. These findings are the first to link endogenous opioid system tone to regional pain-evoked brain activity in a clinical pain population. Our data suggest that dysregulation of the endogenous opioid system in FM could lead to less excitation in antinociceptive brain regions by incoming noxious stimulation, resulting in the hyperalgesia and allodynia commonly observed in this population. We propose a conceptual model of affective pain dysregulation in FM.	[Schrepf, Andrew; Harper, Daniel E.; Harte, Steven E.; Wang, Heng; Ichesco, Eric; Hampson, Johnson P.; Clauw, Daniel J.; Harris, Richard E.] Univ Michigan, Dept Anesthesiol, Chron Pain & Fatigue Res Ctr, 24 Frank Lloyd Wright Dr,POB 385, Ann Arbor, MI 48106 USA; [Zubieta, Jon-Kar] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Schrepf, A (reprint author), Univ Michigan, Dept Anesthesiol, Chron Pain & Fatigue Res Ctr, 24 Frank Lloyd Wright Dr,POB 385, Ann Arbor, MI 48106 USA.	aschrepf@med.umich.edu	Harte, Steven/P-4840-2019		Department of Army grants DAMD [17-002-0018, W81XWH-07-2-0050]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [M01-RR000042, K01 AT01111-01, R01 AT007550-01, R01 DA 016423, K12 DE023574-03]; Cerephex; Forest Laboratories; MerckMerck & Company; PfizerPfizer; Forest	This work was funded by Department of Army grants DAMD (17-002-0018 to D.J.C. and W81XWH-07-2-0050 to R.E.H.) and National Institutes of Health (M01-RR000042, K01 AT01111-01, and R01 AT007550-01 to R.E.H.; R01 DA 016423 to J.-K.Z.; K12 DE023574-03 to D.J.C.). The authors declare no conflict of interest and no competing financial interests with this work. Steven E. Harte has received research funding from Cerephex, Forest Laboratories, and Merck, and served as a consultant for Pfizer, Analgesic Solutions, Aptinyx, and deCode Genetics. Daniel J. Clauw has received research funding from Cerephex, Forest, Merck, and Pfizer, and serves as a consultant for Tonix, Theravance, Cerephex, Pfizer, Abbott, Merck, Eli Lilly, UCB, Johnson & Johnson, Forest Laboratories, and Purdue Pharma. Richard E. Harris consults for and has received grant support from Pfizer. All other authors have no competing financial interests to disclose.	Akaishi T, 2000, NEUROSCI RES, V38, P357, DOI 10.1016/S0168-0102(00)00177-2; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; Baraniuk JN, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-22; Baraniuk JN, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-48; Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027; Bingel U, 2008, PAIN, V140, P393, DOI 10.1016/j.pain.2008.09.030; Casanova R, 2007, NEUROIMAGE, V34, P137, DOI 10.1016/j.neuroimage.2006.09.011; Chen L, 2009, PAIN, V143, P65, DOI 10.1016/j.pain.2009.01.022; Chen TC, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-41; Chiou LC, 1999, J PHYSIOL-LONDON, V518, P551, DOI 10.1111/j.1469-7793.1999.0551p.x; Chu LF, 2012, PAIN, V153, P1583, DOI 10.1016/j.pain.2012.02.028; Clauw DJ, 2014, JAMA-J AM MED ASSOC, V311, P1547, DOI 10.1001/jama.2014.3266; Cook DB, 2004, J RHEUMATOL, V31, P364; DosSantos MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102350; Dougherty DD, 2008, BEHAV BRAIN RES, V193, P63, DOI 10.1016/j.bbr.2008.04.020; Fischer HS, 2000, REGUL PEPTIDES, V96, P53, DOI 10.1016/S0167-0115(00)00200-7; Fitzcharles MA, 2013, PAIN RES TREAT, V2013, DOI 10.1155/2013/898493; Foerster BR, 2012, ARTHRITIS RHEUM-US, V64, P579, DOI 10.1002/art.33339; GABILONDO AM, 1995, BRAIN RES, V682, P245, DOI 10.1016/0006-8993(95)00333-L; Giesecke T, 2005, ARTHRITIS RHEUM-US, V52, P1577, DOI 10.1002/art.21008; Giovengo SL, 1999, J RHEUMATOL, V26, P1564; GRACELY RH, 1988, PAIN, V32, P55, DOI 10.1016/0304-3959(88)90023-1; Gracely RH, 2004, BRAIN, V127, P835, DOI 10.1093/brain/awh098; Gracely RH, 2002, ARTHRITIS RHEUM-US, V46, P1333, DOI 10.1002/art.10225; GROSSISSEROFF R, 1990, BRAIN RES, V530, P312, DOI 10.1016/0006-8993(90)91301-V; Hagelberg N, 2012, NEUROSCI LETT, V521, P11, DOI 10.1016/j.neulet.2012.05.042; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; Harris RE, 2013, ANESTHESIOLOGY, V119, P1453, DOI 10.1097/ALN.0000000000000017; Harris RE, 2012, NEUROSCI LETT, V520, P192, DOI 10.1016/j.neulet.2012.03.042; Harte SE, 2011, NEUROSCIENCE, V172, P460, DOI 10.1016/j.neuroscience.2010.10.055; Hooten WM, 2015, PAIN, V156, P1145, DOI 10.1097/j.pain.0000000000000170; Ibinson JW, 2013, J PAIN, V14, P1611, DOI 10.1016/j.jpain.2013.08.004; Jensen KB, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-32; Jensen KB, 2009, PAIN, V144, P95, DOI 10.1016/j.pain.2009.03.018; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; JONES AKP, 1994, BRIT J RHEUMATOL, V33, P909; KUPERS RC, 1991, PAIN, V47, P5, DOI 10.1016/0304-3959(91)90004-H; Le Roy C, 2011, J PAIN, V12, P1069, DOI 10.1016/j.jpain.2011.04.011; LEVINE JD, 1979, P NATL ACAD SCI USA, V76, P3528, DOI 10.1073/pnas.76.7.3528; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Manchikanti L, 2008, PAIN PHYSICIAN, V11, pS63; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MAO JR, 1995, PAIN, V61, P353, DOI 10.1016/0304-3959(95)00022-K; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; MINOSHIMA S, 1993, J NUCL MED, V34, P322; Navratilova E, 2015, J NEUROSCI, V35, P7264, DOI 10.1523/JNEUROSCI.3862-14.2015; Peng XM, 2015, CLIN J PAIN, V31, P7, DOI 10.1097/AJP.0000000000000079; Petzke F, 2005, EUR J PAIN, V9, P325, DOI 10.1016/j.ejpain.2004.09.001; Piche M, 2014, NEUROSCI RES, V81-82, P78, DOI 10.1016/j.neures.2014.02.006; Qu CL, 2015, NEUROSCI LETT, V592, P64, DOI 10.1016/j.neulet.2015.02.045; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RUSSELL IJ, 1992, ARTHRITIS RHEUM, V35, P550, DOI 10.1002/art.1780350509; Sarchielli Paola, 2007, Curr Pain Headache Rep, V11, P343, DOI 10.1007/s11916-007-0216-2; Schmidt-Wilcke T, 2011, NAT REV RHEUMATOL, V7, P518, DOI 10.1038/nrrheum.2011.98; Schweinhardt P, 2006, NMR BIOMED, V19, P702, DOI 10.1002/nbm.1076; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; UNTERWALD EM, 1995, MOL BRAIN RES, V33, P351, DOI 10.1016/0169-328X(95)00143-G; Upadhyay J, 2015, J NEUROSCI METH, V253, P38, DOI 10.1016/j.jneumeth.2015.06.001; van der Kam EL, 2008, PAIN, V136, P373, DOI 10.1016/j.pain.2007.07.027; Wasserman RA, 2015, REGION ANESTH PAIN M, V40, P687, DOI 10.1097/AAP.0000000000000315; Wey HY, 2014, NEUROIMAGE, V102, P275, DOI 10.1016/j.neuroimage.2014.07.058; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Younger J, 2013, ARTHRITIS RHEUM-US, V65, P529, DOI 10.1002/art.37734; Younger JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005180; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	68	44	44	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	OCT	2016	157	10					2217	2225		10.1097/j.pain.0000000000000633			9	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	DZ7AP	WOS:000386015500011	27420606	Green Accepted			2020-06-30	J	Sommerfield, D; Ramgolam, A; Barker, A; Bergesio, R; von Ungern-Sternberg, BS				Sommerfield, David; Ramgolam, Anoop; Barker, Andrew; Bergesio, Ric; von Ungern-Sternberg, Britta S.			Epidural insertion height for ureteric reimplant surgery; does location matter?	PEDIATRIC ANESTHESIA			English	Article						regional anesthesia; pediatric; caudal; epidural; morphine; ureteric reimplant; bladder spasm	INTRAVESICAL MORPHINE ANALGESIA; LOWER URINARY-TRACT; VESICOURETERAL REFLUX; LOCAL-ANESTHETICS; BLADDER SURGERY; PAIN MANAGEMENT; CHILDREN; CAPSAICIN; BLOCKADE; URETERONEOCYSTOSTOMY	Background: Surgical correction of vesicoureteric reflux through ureteric reimplantation is a common, highly successful treatment. Postoperative pain can be severe and may relate to somatic wound pain from the lower abdominal incision or from visceral bladder spasm pain. Aim: To conduct a prospective quality improvement audit to compare four perioperative analgesic techniques. Methods: Observational data were collected on 217 patients following open ureteroneocystostomy over 5 days. The patients were split into four groups: (i) 'morphine' infusion; (ii) 'caudal'-single-shot caudal; (iii) 'epidural'epidural catheter inserted at T10-L2 given a bolus, followed by an infusion of 0.125% bupivacaine with fentanyl 2 mu g.ml(-1); (iv) 'caudal catheter'-caudal placed epidural catheter was treated similar to the epidural catheter. Data regarding postoperative analgesic interventions were recorded. Intravesical pethidine was used for bladder spasm pain and i.v. morphine for wound pain. Results: Over the study period, the caudal catheter technique (mean interventions/patient = 1.8 +/- 2.6) and the single-shot caudal (6.1 +/- 4) needed significantly less bladder spasm interventions than morphine (9.2 +/- 4) and epidural (8.0 +/- 4.4) patients. For wound pain, the caudal catheter (8.8 +/- 3.3) and epidural groups (11.4 +/- 3.2) needed significantly less interventions than morphine (16.1 +/- 3) and caudal (15.3 +/- 3.3) patients. Overall, caudal catheter patients on average required about half the number of pain interventions and were associated with less high nursing workload. Conclusions: Despite some limitations in data collection and study design, the caudal catheter technique was superior at reducing pain interventions, particularly bladder spasm interventions. Overall epidural analgesia was not superior to a single-shot caudal followed by opioid infusion. The issue of bladder spasm may be similar to the phenomenon of sacral sparing in obstetric epidural anesthesia. Thus, regional techniques, such as caudal epidural, targeting a better balance between sacral and lumber nerves are required.	[Sommerfield, David; Ramgolam, Anoop; Bergesio, Ric; von Ungern-Sternberg, Britta S.] Princess Margaret Hosp Children, Dept Anaesthesia & Pain Management, Perth, WA, Australia; [Ramgolam, Anoop] Univ Western Australia, Telethon Kids Inst, Paediat Resp Physiol, Perth, WA, Australia; [Barker, Andrew] Princess Margaret Hosp Children, Dept Paediat Surg, Perth, WA, Australia; [von Ungern-Sternberg, Britta S.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia	von Ungern-Sternberg, BS (reprint author), Princess Margaret Hosp Children, Dept Anaesthesia & Pain Management, Roberts Rd, Subiaco, WA 6008, Australia.	Britta.regli-vonungern@health.wa.gov.au	von Ungern-Sternberg, Britta/S-5532-2019	von Ungern-Sternberg, Britta/0000-0002-8043-8541	Late Frank Callaghan; Princess Margaret Hospital Foundation; Stan Perron Charitable Trust	Britta S von Ungern-Sternberg holds the Callaghan Chair in Paediatric Anaesthesia and is partly funded by the Late Frank Callaghan, the Princess Margaret Hospital Foundation, and the Stan Perron Charitable Trust.	Arendt Katherine, 2008, Rev Obstet Gynecol, V1, P49; Berde CB, 2011, MAR DRUGS, V9, P2717, DOI 10.3390/md9122717; BIRDER LA, 1992, J NEUROSCI, V12, P4878; BRANDELL RA, 1993, UROLOGY, V42, P705, DOI 10.1016/0090-4295(93)90539-M; Brenner L, 2011, BRIT J ANAESTH, V107, P229, DOI 10.1093/bja/aer128; Burian M, 2005, PHARMACOL THERAPEUT, V107, P139, DOI 10.1016/j.pharmthera.2005.02.004; Cruz F, 1997, J UROLOGY, V157, P585, DOI 10.1016/S0022-5347(01)65211-X; DEGROAT WC, 1993, UROL CLIN N AM, V20, P383; Duckett JW, 1997, J UROLOGY, V157, P1407, DOI 10.1016/S0022-5347(01)65001-8; El-Ghoneimi A, 2002, J UROLOGY, V168, P694, DOI 10.1016/S0022-5347(05)64726-X; ELLSWORTH PI, 1995, J PEDIATR SURG, V30, P600, DOI 10.1016/0022-3468(95)90141-8; Fowler CJ, 2002, UROLOGY, V59, P37, DOI 10.1016/S0090-4295(02)01544-3; Gillies D, 2003, PEDIATR SURG INT, V19, P733, DOI 10.1007/s00383-003-1061-y; HABLER HJ, 1990, J PHYSIOL-LONDON, V425, P545; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kundra P, 1998, ANESTH ANALG, V87, P52, DOI 10.1097/00000539-199807000-00012; MAGGI CA, 1987, ACTA PHYSIOL HUNG, V69, P425; MAGGI CA, 1988, EUR J PHARMACOL, V145, P105, DOI 10.1016/0014-2999(88)90221-X; MCCOOL AC, 1995, J UROLOGY, V154, P794, DOI 10.1016/S0022-5347(01)67166-0; Merkel S I, 1997, Pediatr Nurs, V23, P293; Nolan J, 2000, ANAESTHESIA, V55, P32, DOI 10.1046/j.1365-2044.2000.01065.x; Park JM, 2000, ANESTH ANALG, V91, P11, DOI 10.1097/00000539-200007000-00003; Takagi-Matsumoto H, 2004, J PHARMACOL SCI, V95, P458, DOI 10.1254/jphs.FP0040098; Tullus K, 2015, LANCET, V385, P371, DOI 10.1016/S0140-6736(14)60383-4; Visser WA, 2008, ANESTH ANALG, V107, P708, DOI 10.1213/ane.0b013e31817e7065; Williams G, 2008, J AM SOC NEPHROL, V19, P847, DOI 10.1681/ASN.2007020245; WILTON NCT, 1995, UROL CLIN N AM, V22, P189; Yokoyama M, 2004, ANESTHESIOLOGY, V100, P1504, DOI 10.1097/00000542-200406000-00024	28	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	OCT	2016	26	10					951	959		10.1111/pan.12895			9	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	DZ5FI	WOS:000385887000002	27061337				2020-06-30	J	Blain, GM; Mangum, TS; Sidhu, SK; Weavil, JC; Hureau, TJ; Jessop, JE; Bledsoe, AD; Richardson, RS; Amann, M				Blain, Gregory M.; Mangum, Tyler S.; Sidhu, Simranjit K.; Weavil, Joshua C.; Hureau, Thomas J.; Jessop, Jacob E.; Bledsoe, Amber D.; Richardson, Russell S.; Amann, Markus			Group III/IV muscle afferents limit the intramuscular metabolic perturbation during whole body exercise in humans	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							STATIC MUSCULAR-CONTRACTION; CENTRAL MOTOR DRIVE; SKELETAL-MUSCLE; PERIPHERAL FATIGUE; RHYTHMIC EXERCISE; ALL-OUT; RESPONSES; PERFORMANCE; POWER; MOTONEURONS	Key points The purpose of this study was to determine the role of group III/IV muscle afferents in limiting the endurance exercise-induced metabolic perturbation assayed in muscle biopsy samples taken from locomotor muscle. Lumbar intrathecal fentanyl was used to attenuate the central projection of -opioid receptor-sensitive locomotor muscle afferents during a 5km cycling time trial. The findings suggest that the central projection of group III/IV muscle afferent feedback constrains voluntary neural drive' to working locomotor muscle and limits the exercise-induced intramuscular metabolic perturbation. Therefore, the CNS might regulate the degree of metabolic perturbation within locomotor muscle and thereby limit peripheral fatigue. It appears that the group III/IV muscle afferents are an important neural link in this regulatory mechanism, which probably serves to protect locomotor muscle from the potentially severe functional impairment as a consequence of severe intramuscular metabolic disturbance. AbstractTo investigate the role of metabo- and mechanosensitive group III/IV muscle afferents in limiting the intramuscular metabolic perturbation during whole body endurance exercise, eight subjects performed 5km cycling time trials under control conditions (CTRL) and with lumbar intrathecal fentanyl impairing lower limb muscle afferent feedback (FENT). Vastus lateralis muscle biopsies were obtained before and immediately after exercise. Motoneuronal output was estimated through vastus lateralis surface electromyography (EMG). Exercise-induced changes in intramuscular metabolites were determined using liquid and gas chromatography-mass spectrometry. Quadriceps fatigue was quantified by pre- to post-exercise changes in potentiated quadriceps twitch torque (QT(single)) evoked by electrical femoral nerve stimulation. Although motoneuronal output was 2112% higher during FENT compared to CTRL (P<0.05), time to complete the time trial was similar (approximate to 8.8min). Compared to CTRL, power output during FENT was 104% higher in the first half of the time trial, but 115% lower in the second half (both P<0.01). The exercise-induced increase in intramuscular inorganic phosphate, H+, adenosine diphosphate, lactate and phosphocreatine depletion was 5530, 6218, 129 +/- 63, 47 +/- 14 (P<0.001) and 27 +/- 14% (P<0.01) greater in FENT than CTRL. QT(single) was greater following FENT than CTRL (-52 +/- 2vs -31 +/- 1%, P<0.001) and this difference was positively correlated with the difference in inorganic phosphate (r(2)=0.79; P<0.01) and H+ (r(2)=0.92; P<0.01). In conclusion, during whole body exercise, group III/IV muscle afferents provide feedback to the CNS which, in turn, constrains motoneuronal output to the active skeletal muscle. This regulatory mechanism limits the exercise-induced intramuscular metabolic perturbation, preventing an abnormal homeostatic challenge and excessive peripheral fatigue. Key points The purpose of this study was to determine the role of group III/IV muscle afferents in limiting the endurance exercise-induced metabolic perturbation assayed in muscle biopsy samples taken from locomotor muscle. Lumbar intrathecal fentanyl was used to attenuate the central projection of -opioid receptor-sensitive locomotor muscle afferents during a 5km cycling time trial. The findings suggest that the central projection of group III/IV muscle afferent feedback constrains voluntary neural drive' to working locomotor muscle and limits the exercise-induced intramuscular metabolic perturbation. Therefore, the CNS might regulate the degree of metabolic perturbation within locomotor muscle and thereby limit peripheral fatigue. It appears that the group III/IV muscle afferents are an important neural link in this regulatory mechanism, which probably serves to protect locomotor muscle from the potentially severe functional impairment as a consequence of severe intramuscular metabolic disturbance.	[Blain, Gregory M.; Hureau, Thomas J.] Univ Toulon & Var, Univ Nice Sophia Antipolis, LAMHESS, EA 6312, Nice, France; [Mangum, Tyler S.; Weavil, Joshua C.; Richardson, Russell S.; Amann, Markus] Univ Utah, Dept Exercise & Sport Sci, Salt Lake City, UT USA; [Sidhu, Simranjit K.; Hureau, Thomas J.; Richardson, Russell S.; Amann, Markus] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; [Richardson, Russell S.; Amann, Markus] Salt Lake City VAMC, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA; [Jessop, Jacob E.; Bledsoe, Amber D.; Amann, Markus] Univ Utah, Dept Anesthesiol, Salt Lake City, UT USA; [Sidhu, Simranjit K.] Univ Adelaide, Sch Med, Discipline Physiol, Adelaide, SA 5005, Australia	Blain, GM (reprint author), Fac Sci Sport, 261 Blvd Mercantour, F-06205 Nice 03, France.	blain@unice.fr	Hureau, Thomas J/I-2711-2019; Sidhu, Simranjit/A-5478-2012	Sidhu, Simranjit/0000-0002-4797-8298; Amann, Markus/0000-0002-4012-8880; Weavil, Joshua/0000-0002-2032-8498	NIH Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-103786, HL-116579, HL-091830]; Veterans Affairs Rehabilitation Research and Development Merit award [E6910-R, E1697-R]; Veterans Affairs Rehabilitation Research and Development Spire award [E1572-P, E1433-P]; Veterans Affairs Rehabilitation Research and Development Senior Research Career Scientist award [E9275-L]; French Ministry of Higher Education [CIFRE 2012/0445]	This study was supported by NIH Heart, Lung, and Blood Institute grants (HL-103786, HL-116579, and HL-091830), and Veterans Affairs Rehabilitation Research and Development Merit (E6910-R, E1697-R), Spire (E1572-P, E1433-P) and Senior Research Career Scientist (E9275-L) awards, and French Ministry of Higher Education grant (CIFRE 2012/0445).	Allen DG, 2008, PHYSIOL REV, V88, P287, DOI 10.1152/physrev.00015.2007; Almeida TF, 2004, BRAIN RES, V1000, P40, DOI 10.1016/j.brainres.2003.10.073; Amann M, 2004, MED SCI SPORT EXER, V36, P1716, DOI 10.1249/01.MSS.0000142305.18543.34; Amann M, 2008, J PHYSIOL-LONDON, V586, P161, DOI 10.1113/jphysiol.2007.141838; Amann M, 2006, J PHYSIOL-LONDON, V575, P937, DOI 10.1113/jphysiol.2006.113936; Amann M, 2011, J PHYSIOL-LONDON, V589, P5299, DOI 10.1113/jphysiol.2011.213769; Amann M, 2011, MED SCI SPORT EXER, V43, P2039, DOI 10.1249/MSS.0b013e31821f59ab; Amann M, 2011, J PHYSIOL-LONDON, V589, P3855, DOI 10.1113/jphysiol.2011.209353; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2010, J APPL PHYSIOL, V108, P452, DOI 10.1152/japplphysiol.00976.2009; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; BIGLANDRITCHIE BR, 1986, J PHYSIOL-LONDON, V379, P451, DOI 10.1113/jphysiol.1986.sp016263; Borg G, 1998, BORGS PERCEIVED EXER; Burnley M, 2012, J APPL PHYSIOL, V113, P215, DOI 10.1152/japplphysiol.00022.2012; Burnley M, 2010, EXP PHYSIOL, V95, P798, DOI 10.1113/expphysiol.2010.052688; Caringi D, 1998, AM J PHYSIOL-HEART C, V274, pH139; Chidnok W, 2013, AM J PHYSIOL-REG I, V305, pR1085, DOI 10.1152/ajpregu.00406.2013; Farina D, 2010, CLIN NEUROPHYSIOL, V121, P1616, DOI 10.1016/j.clinph.2009.10.040; Forster HV, 2012, COMPR PHYSIOL, V2, P743, DOI 10.1002/cphy.c100045; Gagnon P, 2012, AM J RESP CRIT CARE, V186, P606, DOI 10.1164/rccm.201203-0404OC; Gagnon P, 2009, J APPL PHYSIOL, V107, P832, DOI 10.1152/japplphysiol.91546.2008; Hill CA, 2001, J PHYSIOL-LONDON, V531, P871, DOI 10.1111/j.1469-7793.2001.0871h.x; HILL JM, 1990, J APPL PHYSIOL, V68, P2466; Hogan MC, 1999, J APPL PHYSIOL, V86, P1367; Hureau TJ, 2016, MED SCI SPORT EXER, V48, P391, DOI 10.1249/MSS.0000000000000800; Hureau TJ, 2014, EXP PHYSIOL, V99, P951, DOI 10.1113/expphysiol.2014.077974; Jones DA, 1996, ACTA PHYSIOL SCAND, V156, P265, DOI 10.1046/j.1365-201X.1996.192000.x; KAO FF, 1963, REGULATION HUMAN RES, P461; KAUFMAN MP, 1983, J APPL PHYSIOL, V55, P105; Keenan KG, 2005, J APPL PHYSIOL, V98, P120, DOI 10.1152/japplphysiol.00894.2004; Klass M, 2008, J NEUROPHYSIOL, V99, P1096, DOI 10.1152/jn.01252.2007; KNIFFKI KD, 1978, EXP BRAIN RES, V31, P511; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Le Gal JP, 2016, J NEUROSCI, V36, P926, DOI 10.1523/JNEUROSCI.1825-15.2016; Le Gal JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089670; Light AR, 2008, J NEUROPHYSIOL, V100, P1184, DOI 10.1152/jn.01344.2007; Martin PG, 2008, J PHYSIOL-LONDON, V586, P1277, DOI 10.1113/jphysiol.2007.140426; Martin PG, 2006, J NEUROSCI, V26, P4796, DOI 10.1523/JNEUROSCI.5487-05.2006; MCCLOSKE.DI, 1972, J PHYSIOL-LONDON, V224, P173, DOI 10.1113/jphysiol.1972.sp009887; MENSE S, 1977, J PHYSIOL-LONDON, V267, P75, DOI 10.1113/jphysiol.1977.sp011802; MENSE S, 1983, J PHYSIOL-LONDON, V342, P383, DOI 10.1113/jphysiol.1983.sp014857; MERTON PA, 1954, J PHYSIOL-LONDON, V123, P553, DOI 10.1113/jphysiol.1954.sp005070; Nelson CR, 2014, AM J PHYSIOL-CELL PH, V307, pC939, DOI 10.1152/ajpcell.00206.2014; Place N, 2010, EUR J APPL PHYSIOL, V110, P1, DOI 10.1007/s00421-010-1480-0; Romer LM, 2007, AM J PHYSIOL-REG I, V292, pR598, DOI 10.1152/ajpregu.00269.2006; Rossman MJ, 2014, AM J PHYSIOL-REG I, V306, pR934, DOI 10.1152/ajpregu.00043.2014; ROTTO DM, 1988, J APPL PHYSIOL, V64, P2306; Sidhu SK, 2014, J PHYSIOL-LONDON, V592, P5011, DOI 10.1113/jphysiol.2014.275438; Stone MR, 2011, EUR J APPL PHYSIOL, V111, P1807, DOI 10.1007/s00421-010-1818-7; Taylor JL, 2006, CLIN EXP PHARMACOL P, V33, P400, DOI 10.1111/j.1440-1681.2006.04363.x; TIBES U, 1977, CIRC RES, V41, P332, DOI 10.1161/01.RES.41.3.332; Vanhatalo A, 2010, EXP PHYSIOL, V95, P528, DOI 10.1113/expphysiol.2009.050500; Zhang J, 2015, J PAIN, V16, pS56, DOI 10.1016/j.jpain.2015.01.240	53	58	58	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	SEP 15	2016	594	18					5303	5315		10.1113/JP272283			13	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	DW3VO	WOS:000383571400026	27241818	Green Published, Bronze			2020-06-30	J	Todorovic, VS; Vasovic, M; Andric, M; Todorovic, L; Kokovic, V				Todorovic, Vladimir S.; Vasovic, Miroslav; Andric, Miroslav; Todorovic, Ljubomir; Kokovic, Vladimir			Efficacy of fentanyl transdermal patch in pain control after lower third molar surgery: A preliminary study	MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL			English	Article						Analgesia; fentanyl; transdermal administration; third molar surgery; acute pain; postoperative care	CANCER PAIN; POSTOPERATIVE PAIN; ORAL MORPHINE; MANAGEMENT; SYSTEM; PHARMACOKINETICS; FORMULATIONS	Background: Surgical removal of impacted lower third molars is a common oral surgical procedure, generally followed by moderate to severe postoperative pain. Transdermal drug delivery as a concept offers interesting possibilities for postoperative pain control. The aim of this study was to evaluate the efficacy of transdermal system with fentanyl in relieving pain following impacted lower third molar surgery. Material and Methods: Seventeen patients with bilateral impacted lower third molars were included in this preliminary study. For postoperative pain control, patients randomly received a fentanyl patch plus placebo tablet after the first operation and regular (placebo) patch and an analgesic, after the second operation. Analgesia was evaluated during first 24 hours postoperatively according to patients' reports about time of first pain appearance and additional analgesic consumption. Pain severity was rated using a 10 cm long visual analogue scale (VAS). Results: Intensity of postoperative pain and postoperative analgesic consumption were significantly lower after the Fentanyl Transdermal System (FTS) was applied (p<0.05). Duration of postoperative analgesia was significantly higher with FTS when compared to control treatment (p<0.05). Conclusions: Based on the results of this preliminary study, transdermal system with fentanyl significantly reduced postoperative pain after third molar surgery.	[Todorovic, Vladimir S.; Andric, Miroslav] Univ Belgrade, Sch Dent Med, Clin Oral Surg, Belgrade 11001, Serbia; [Vasovic, Miroslav] Univ Kragujevac, Fac Med Sci, Dept Dent, Kragujevac, Serbia; [Todorovic, Ljubomir] Serbian Med Soc, Acad Med Sci, Belgrade, Serbia; [Kokovic, Vladimir] Sharjah Coll Dent Sci, Dept Dent, Adv Europe Med Ctr, Ras Al Kaimah, U Arab Emirates	Todorovic, VS (reprint author), Univ Belgrade, Sch Dent Med, Belgrade 1001, Serbia.	todent@yahoo.com		Vasovic, Miroslav/0000-0002-9415-4216; Andric, Miroslav/0000-0003-4136-7901	Ministry of Education, Science and Technological Development of the Republic of Serbia [41008]	The Grant No. 41008 of the Ministry of Education, Science and Technological Development of the Republic of Serbia supported this study.	Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Fine P G, 1997, Semin Oncol, V24, pS16; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Isiordia-Espinoza MA, 2012, J ORAL MAXIL SURG, V70, P31, DOI 10.1016/j.joms.2011.03.039; Larsen RH, 2003, PHARMACOL TOXICOL, V93, P244, DOI 10.1046/j.1600-0773.2003.pto930508.x; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Mattia Consalvo, 2007, Ther Clin Risk Manag, V3, P19, DOI 10.2147/tcrm.2007.3.1.19; MEECHAN JG, 1993, BRIT J ORAL MAX SURG, V31, P360, DOI 10.1016/0266-4356(93)90191-X; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; SEYMOUR RA, 1984, INT J ORAL MAXILLOF, V13, P457, DOI 10.1016/S0300-9785(84)80017-4; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd	17	1	1	0	1	MEDICINA ORAL S L	VALENCIA	CALLE DANIEL BALACIART N 4 PTA 17, VALENCIA, 46020, SPAIN	1698-6946			MED ORAL PATOL ORAL	Med. Oral Patol. Oral Cir. Bucal	SEP	2016	21	5					E621	E625		10.4317/medoral.21161			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	EG6ZA	WOS:000391193600013	27475691	Green Published, Bronze			2020-06-30	J	Pimentel, CB; Gurwitz, JH; Tjia, J; Hume, AL; Lapane, KL				Pimentel, Camilla B.; Gurwitz, Jerry H.; Tjia, Jennifer; Hume, Anne L.; Lapane, Kate L.			New Initiation of Long-Acting Opioids in Long-Stay Nursing Home Residents	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY			English	Article						nursing home; long-acting opioid; analgesics	MINIMUM DATA SET; PALLIATIVE CARE; GEOGRAPHIC-VARIATION; PAIN MANAGEMENT; IMPACT	OBJECTIVES: To estimate the prevalence of new initiation of long-acting opioids since introduction of national efforts to increase prescriber and public awareness on safe use of transdermal fentanyl patches. DESIGN: Cross-sectional. SETTING: U.S. nursing homes (NHs). PARTICIPANTS: Medicare-enrolled long-stay NH residents (N = 22,253). MEASUREMENTS: Minimum Data Set 3.0 was linked with Medicare enrollment, hospital claims, and prescription drug transaction data (January-December 2011) and used to determine the prevalence of new initiation of a long-acting opioid prescribed to residents in NHs. RESULTS: Of NH residents prescribed a long-acting opioid within 30 days of NH admission (n = 12,278), 9.4% (95% confidence interval = 8.9-9.9%) lacked a prescription drug claim for a short-acting opioid in the previous 60 days. The most common initial prescriptions of long-acting opioids were fentanyl patch (51.9% of opioid-naive NH residents), morphine sulfate (28.1%), and oxycodone (17.2%). CONCLUSION: New initiation of long-acting opioids-especially fentanyl patches, which have been the subject of safety communications-persists in NHs.	[Pimentel, Camilla B.; Tjia, Jennifer; Lapane, Kate L.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA; [Gurwitz, Jerry H.] Meyers Primary Care Inst, Worcester, MA USA; [Hume, Anne L.] Brown Univ, Mem Hosp Rhode Isl, Alpert Med Sch, Dept Family Med, Providence, RI 02912 USA; [Hume, Anne L.] Univ Rhode Isl, Coll Pharm, Dept Pharm Practice, Kingston, RI 02881 USA	Lapane, KL (reprint author), 368 Plantat St, Worcester, MA 01605 USA.	kate.lapane@umassmed.edu	Tjia, Jennifer/Y-2094-2019; Pimentel, Camilla B./AAI-8182-2020		National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R25CA172009, 1R21CA198172-01]	Dr. Pimentel (R25CA172009) and Dr. Lapane (1R21CA198172-01) are funded by the National Cancer Institute.	[Anonymous], 2005, SAF WARN REG US FENT; [Anonymous], 2007, FDA PUBL HLTH ADV IM; Argoff CE, 2009, MAYO CLIN PROC, V84, P602, DOI 10.1016/S0025-6196(11)60749-0; Aspinall SL, 2013, AM J MANAG CARE, V19, P748; Beech Nick, 2015, ARCHITECTURE CULTURE, V3, P3, DOI DOI 10.1097/MLR.0000000000000334; Cohen A, 2010, DIABETES CARE, V33, P823, DOI 10.2337/dc09-1834; Currow DC, 2007, J AM GERIATR SOC, V55, P590, DOI 10.1111/j.1532-5415.2007.01124.x; Dorsey ER, 2010, ARCH INTERN MED, V170, P96, DOI 10.1001/archinternmed.2009.456; Dosa DM, 2009, J PAIN SYMPTOM MANAG, V38, P515, DOI 10.1016/j.jpainsymman.2008.11.008; Edelen MO, 2010, J GERONTOL A-BIOL, V65, P778, DOI 10.1093/gerona/glp215; Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532-5415.2009.02376.x; FRIES BE, 1994, MED CARE, V32, P668, DOI 10.1097/00005650-199407000-00002; Gurwitz JH, 2005, AM J MED, V118, P251, DOI 10.1016/j.amjmed.2004.09.018; Hartung DM, 2015, CLIN THER, V37, P114, DOI 10.1016/j.clinthera.2014.10.025; Koh N. Y., 2002, SMJ Singapore Medical Journal, V43, P279; Lapane KL, 2012, DRUG AGING, V29, P385, DOI 10.2165/11599340-000000000-00000; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Mor V, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-78; Nauck F, 2004, PALLIATIVE MED, V18, P100, DOI 10.1191/0269216304pm852oa; Pimentel CB, 2015, J AM GERIATR SOC, V63, P633, DOI 10.1111/jgs.13345; Riechelmann RP, 2007, SUPPORT CARE CANCER, V15, P1407, DOI 10.1007/s00520-007-0253-8; Rigler Sally K, 2007, Am J Geriatr Pharmacother, V5, P91, DOI 10.1016/j.amjopharm.2007.05.002; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; ROGERS WH, 1993, STATA TECHNICAL B, V13, P19, DOI DOI 10.1016/J.IJFORECAST.2005.03.004; Saliba D, 2012, J AM MED DIR ASSOC, V13, P602, DOI 10.1016/j.jamda.2012.06.002; Shah ND, 2010, NEW ENGL J MED, V363, P2081, DOI 10.1056/NEJMp1011042; Stevenson DG, 2012, AM J MANAG CARE, V18, P647; U.S. Centers for Medicare and Medicaid Services, 2014, MDS 3 0 RAI MAN; U.S. Centers for Medicare and Medicaid Services, 2015, DES NURS HOM COMP 5; U.S. Department of Justice, 2006, PRACT MAN INF ONL CO; U.S. Food and Drug Administration, 2014, EXT REL ER LONG ACT; Valluri S, 2010, MED CARE, V48, P947, DOI 10.1097/MLR.0b013e3181ef9d2b; 1996, [No title captured], V84, P1243	33	8	8	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0002-8614	1532-5415		J AM GERIATR SOC	J. Am. Geriatr. Soc.	SEP	2016	64	9					1772	1778		10.1111/jgs.14306			7	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	EB0FC	WOS:000387017800034	27487158	Green Accepted			2020-06-30	J	Staeheli, SN; Baumgartner, MR; Gauthier, S; Gascho, D; Jarmer, J; Kraemer, T; Steuer, AE				Staeheli, Sandra N.; Baumgartner, Markus R.; Gauthier, Saskia; Gascho, Dominic; Jarmer, Juliane; Kraemer, Thomas; Steuer, Andrea E.			Time-dependent postmortem redistribution of butyrfentanyl and its metabolites in blood and alternative matrices in a case of butyrfentanyl intoxication	FORENSIC SCIENCE INTERNATIONAL			English	Article						Butyrfentanyl poisoning; Time-dependent postmortem redistribution; LC-MS/MS; Alternative matrices; Biopsy; Metabolite ratios	LIQUID-CHROMATOGRAPHY; DRUG REDISTRIBUTION; FENTANYL FATALITY; MASS-SPECTROMETRY; ACETYL FENTANYL; 3-METHYLFENTANYL; VARIABILITY; CALIBRATION; VALIDATION; TOXICOLOGY	A fatal case of butyrfentanyl poisoning was investigated at the Zurich Institute of Forensic Medicine. At admission at the institute approx. 9 h after death (first time point, t1), femoral and heart blood (right ventricle) was collected, as well as samples from the lung, liver, kidney, spleen, muscle and adipose tissue using computed tomography (CT)-guided biopsy sampling. At autopsy (t2), samples from the same body regions were collected manually. Additionally, urine, heart blood (left ventricle), gastric content, brain samples and hair were collected. Butyrfentanyl concentrations and relative concentrations of the metabolites carboxy-, hydroxy-, nor-, and desbutyrfentanyl were determined by LC-MS/MS and LC-QTOF. At t1, butyrfentanyl concentrations were 66 ng/mL in femoral blood, 39 ng/mL in heart blood, 110 ng/g in muscle, 57 ng/g in liver, 160 ng/g in kidney, 3100 ng/g in lung, 590 ng/g in spleen and 550 ng/g in adipose tissue. At t2, butyrfentanyl concentration in urine was 1100 ng/mL, in gastric content 2000 ng/mL, in hair 11,000 pg/mg and brain concentrations ranged between 200-340 ng/g. Carboxyand hydroxybutyrfentanyl were identified as most abundant metabolites. Comparison of t1 and t2 showed a concentration increase of butyrfentanyl in femoral blood of 120%, in heart blood of 55% and a decrease in lung of 30% within 19 h. No clear concentration changes could be observed in the other matrices. Postmortem concentration changes were also observed for the metabolites. In conclusion, butyrfentanyl seems to be prone to postmortem redistribution processes and concentrations in forensic death cases should be interpreted with caution. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Staeheli, Sandra N.; Kraemer, Thomas; Steuer, Andrea E.] Univ Zurich, Zurich Inst Forens Med, Dept Forens Pharmacol & Toxicol, Winterthurerstr 190-52, CH-8057 Zurich, Switzerland; [Baumgartner, Markus R.] Univ Zurich, Zurich Inst Forens Med, Ctr Forens Hairanalyt, CH-8006 Zurich, Switzerland; [Gauthier, Saskia; Gascho, Dominic; Jarmer, Juliane] Univ Zurich, Zurich Inst Forens Med, Dept Forens Med & Imaging, CH-8006 Zurich, Switzerland	Steuer, AE (reprint author), Univ Zurich, Zurich Inst Forens Med, Dept Forens Pharmacol & Toxicol, Winterthurerstr 190-52, CH-8057 Zurich, Switzerland.	andrea.steuer@irm.uzh.ch	Gascho, Dominic/Y-4933-2019	Gascho, Dominic/0000-0001-9004-4362; Kraemer, Thomas/0000-0002-3283-606X; Baumgartner, Markus R./0000-0002-0979-931X; Steuer, Andrea Eva/0000-0001-8983-2353			Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Baselt RC, 2008, DISPOSITION TOXIC DR; Ceelen L, 2012, AM J FOREN MED PATH, V33, P119, DOI 10.1097/PAF.0b013e3181fbbb49; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Daniel WA, 2003, PROG NEURO-PSYCHOPH, V27, P65, DOI 10.1016/S0278-5846(02)00317-2; EMCDDA, 2015, EUR DRUG REP 2015 TR; Gerostamoulos D, 2012, FORENSIC SCI MED PAT, V8, P373, DOI 10.1007/s12024-012-9341-2; Gerostamoulos J, 2000, J FORENSIC SCI, V45, P843; Han E, 2012, FORENSIC SCI INT, V219, P265, DOI 10.1016/j.forsciint.2012.01.016; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Hilberg T, 1999, J FORENSIC SCI, V44, P3; Kaufmann AM, 2007, J PHARM SCI-US, V96, P729, DOI 10.1002/jps.20792; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Madry MM, 2014, BIOANALYSIS, V6, P3183, DOI 10.4155/bio.14.207; Maurer H.H., 2014, MAURER WISSENBACH WE; Maurer H. H., 2011, MASS SPECTRAL GC DAT; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; McIntyre IM, 2014, FORENSIC SCI MED PAT, V10, P91, DOI 10.1007/s12024-013-9503-x; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Moriya F, 1999, J FORENSIC SCI, V44, P10; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Pounder DJ, 1996, J FORENSIC SCI, V41, P927; PROUTY RW, 1990, J FORENSIC SCI, V35, P243; Roemmelt AT, 2014, ANAL CHEM, V86, P11742, DOI 10.1021/ac503144p; Saar E, 2012, FORENSIC SCI INT, V222, P223, DOI 10.1016/j.forsciint.2012.05.028; Schutz Harald, 2006, Forensic Sci Med Pathol, V2, P75, DOI 10.1385/FSMP:2:2:75; Skopp G, 2010, FORENSIC SCI MED PAT, V6, P314, DOI 10.1007/s12024-010-9150-4; Staeheli SN, 2016, ANAL BIOANAL CHEM, V408, P1249, DOI 10.1007/s00216-015-9234-9; Staeheli SN, 2015, ANAL BIOANAL CHEM, V407, P8681, DOI 10.1007/s00216-015-9023-5; Steuer AE, 2014, FORENSIC SCI INT, V244, P92, DOI 10.1016/j.forsciint.2014.08.022; Yarema MC, 2005, CLIN TOXICOL, V43, P235, DOI 10.1081/CLT-200058950	36	34	34	3	20	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	SEP	2016	266						170	177		10.1016/j.forsciint.2016.05.034			8	Medicine, Legal	Legal Medicine	EA1EF	WOS:000386334600044	27289433	Green Accepted			2020-06-30	J	Minami, D; Takigawa, N; Watanabe, H; Ninomiya, T; Kubo, T; Ohashi, K; Sato, A; Hotta, K; Tabata, M; Tanimoto, M; Kiura, K				Minami, Daisuke; Takigawa, Nagio; Watanabe, Hiromi; Ninomiya, Takashi; Kubo, Toshio; Ohashi, Kadoaki; Sato, Akiko; Hotta, Katsuyuki; Tabata, Masahiro; Tanimoto, Mitsune; Kiura, Katsuyuki			Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						endoscopy-respiratory tract; clinical trials; interventional pulmonology; sedation	FLEXIBLE BRONCHOSCOPY; DOUBLE-BLIND; LUNG-CANCER; HYDROCODONE; ANALGESIA; MUTATIONS	Objective: Although sedation with fentanyl and midazolam during bronchoscopic examination is widely accepted in the USA and Europe, it is not routine practice in Japan. The objective of the present study was to evaluate sedation with fentanyl and midazolam during bronchoscopy. Methods: Thirty-seven patients were enrolled prospectively between November 2014 and July 2015 at Okayama University Hospital. Fentanyl (20 mu g) was administered to the patients just before the examination, and fentanyl (10 mu g) and midazolam (1mg) were added as needed during the procedure. A questionnaire was administered 2 hours after the examination. In the questionnaire, patient satisfaction was scored using a visual analog scale as follows: great (1 point), good (2 points), normal (3 points), uncomfortable (4 points) and very uncomfortable (5 points). An additional question ('Do you remember the bronchoscopic examination?') was also used. Predefined matters for investigation (e.g. blood pressure, heart rate, oxygen saturation and complications) were recorded. Results: The enrolled patients included 13 males and 24 females; the median age was 67 (range: 31-87) years. The patients received a median dose of fentanyl of 45.4 mu g (range: 30-100 mu g) and midazolam of 2.56 mg (range: 1-10 mg). Twenty-six patients (70.2%) agreed to undergo a second bronchoscopic examination, and the average levels of discomfort and re-examination were 2.02 points for each. Only 37.8% of the patients remembered the bronchoscopic examination. No severe complications were reported. Conclusions: Sedation with fentanyl and midazolam during bronchoscopic examination should be recommended for use in Japan.	[Minami, Daisuke; Watanabe, Hiromi; Ninomiya, Takashi; Kubo, Toshio; Ohashi, Kadoaki; Sato, Akiko; Hotta, Katsuyuki; Tabata, Masahiro; Tanimoto, Mitsune; Kiura, Katsuyuki] Okayama Univ Hosp, Dept Hematol Oncol & Resp Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan; [Takigawa, Nagio] Kawasaki Med Sch, Dept Gen Internal Med 4, Okayama, Japan	Minami, D (reprint author), Okayama Univ Hosp, Dept Hematol Oncol & Resp Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	d-minami@bj8.so-net.ne.jp	KIURA, Katsuyuki/B-1991-2011	Ohashi, Kadoaki/0000-0002-5180-3933	Ministry of Education, Culture, Sports, Science, and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [15K21185]	This work was supported by Ministry of Education, Culture, Sports, Science, and Technology, Japan (15K21185).	Asano F, 2013, RESPIROLOGY, V18, P284, DOI 10.1111/j.1440-1843.2012.02273.x; Du Rand IA, 2013, THORAX, V68, P1, DOI 10.1136/thoraxjnl-2013-203618; GREIG JH, 1995, RESP MED, V89, P53, DOI 10.1016/0954-6111(95)90071-3; Houghton CM, 2004, RESP MED, V98, P1102, DOI 10.1016/j.rmed.2004.03.023; Jose RJ, 2013, EUR RESPIR REV, V22, P106, DOI 10.1183/09059180.00006412; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maguire G P, 1998, Respirology, V3, P81, DOI 10.1111/j.1440-1843.1998.tb00101.x; Maltais F, 1996, CHEST, V109, P1195, DOI 10.1378/chest.109.5.1195; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Poi PJH, 1998, EUR RESPIR J, V11, P1147, DOI 10.1183/09031936.98.11051147; PRAKASH UBS, 1991, CHEST, V100, P1668, DOI 10.1378/chest.100.6.1668; PUE CA, 1995, CHEST, V107, P430, DOI 10.1378/chest.107.2.430; ROSOW C, 1993, ANESTHESIOLOGY, V79, P875; Schlatter L, 2011, EUR RESPIR J, V38, P529, DOI 10.1183/09031936.00121610; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Stolz D, 2004, THORAX, V59, P773, DOI 10.1136/thx.2003.019836; Takahashi R, 2011, J JPN SOC RESP ENDO, V33, P87; Vincent BD, 2007, J BRONCHOL INTERN PU, V14, P173, DOI 10.1097/LBR.0b013e3180de4984; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361	20	3	4	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	SEP	2016	46	9					871	874		10.1093/jjco/hyw083			4	Oncology	Oncology	DZ1UP	WOS:000385626700012	27380809	Bronze			2020-06-30	J	Cheng, IC; Chang, CS; Tsay, WI				Cheng, I-Chen; Chang, Chih-Shiuh; Tsay, Wen-Ing			Long-term usage of narcotic analgesics by chronic intractable noncancer pain patients in Taiwan from 2003 to 2012	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION			English	Article						chronic intractable noncancer pain (CINCP); long-term use; opioids	MANAGEMENT	Background/Purpose: Chronic pain is a common and important medical problem worldwide. Patients with chronic intractable noncancer pain (CINCP) are treated primarily with narcotics. We analyzed the characteristics of patients with CINCP and the pain prescriptions of Taiwan's physicians. Methods: We enrolled 644 patients from 66 hospitals approved by the Taiwan Food and Drug Administration to use long-term narcotics for CINCP between 2003 and 2012. Results: The majority (61.8%) of patients were 40-49-year-old men who had been treated with pethidine more often than with fentanyl in the 20-49 years age group. More than 50% of CINCP patients live in northern Taiwan, and most were treated in the department of pain; the major diagnosis (men 28.9%; women 27.7%) was neuropathy. The most frequently prescribed single analgesic was morphine (52.2%); the most frequently prescribed two-drug combination was morphine plus fentanyl (50.8%). Pethidine, however, was the most frequently prescribed analgesic in the neurology (78.0%) and plastic surgery (50.0%) departments. Conclusion: To decrease malaise and addiction in patients with CINCP, Taiwan's physicians need more education on narcotic analgesics, and greater professional cooperation to develop therapeutic guidelines that will improve pain care for patients with CINCP. Copyright (C) 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license.	[Cheng, I-Chen; Chang, Chih-Shiuh; Tsay, Wen-Ing] Food & Drug Adm, Minist Hlth & Welf, Div Controlled Drugs, 161-2 Kunyang St, Taipei 11561, Taiwan	Tsay, WI (reprint author), Food & Drug Adm, Minist Hlth & Welf, Div Controlled Drugs, 161-2 Kunyang St, Taipei 11561, Taiwan.	wening@fda.gov.tw					American Chronic Pain Association, ACPA RES GUID CHRON; Chan CW, 2011, PAIN MED, V12, P577, DOI 10.1111/j.1526-4637.2011.01089.x; Chang CJ, 2013, J FOOD DRUG ANAL, V21, P131, DOI 10.1016/j.jfda.2013.05.014; Chang SC, MED UTILIZATION CHRO; Chau Siu-Wah, 2007, Acta Anaesthesiol Taiwan, V45, P95; Cheng CL, 2000, MED TODAY, V27, P58; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Drug Addition Support, MEP AB; Fikree FF, 2004, BMJ-BRIT MED J, V328, P823, DOI 10.1136/bmj.328.7443.823; Ger LP, 2000, J PAIN SYMPTOM MANAG, V20, P335, DOI 10.1016/S0885-3924(00)00207-4; Ho ST, CHRONIC OPIOID THERA; Hsu PC, CONTROLLED DRUGS UTI; Lee YW, STUDY TREATMENT CHRO; Lin JC, 2007, TAIWAN CLIN CHIN MED, V13, P41; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Trescot Andrea M, 2006, Pain Physician, V9, P1	17	5	5	0	2	ELSEVIER TAIWAN	TAIPEI	RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN	0929-6646	1876-0821		J FORMOS MED ASSOC	J. Formos. Med. Assoc.	SEP	2016	115	9					773	778		10.1016/j.jfma.2015.08.001			6	Medicine, General & Internal	General & Internal Medicine	DZ4HH	WOS:000385818800010	26345111	DOAJ Gold			2020-06-30	J	Ding, Z; Wang, KG; Wang, BS; Zhou, NB; Li, H; Yan, B				Ding, Zhen; Wang, Kaiguo; Wang, Baosheng; Zhou, Naibao; Li, Hao; Yan, Bo			Efficacy and tolerability of oxycodone versus fentanyl for intravenous patient-controlled analgesia after gastrointestinal laparotomy: A prospective, randomized, double-blind study	MEDICINE			English	Article						fentanyl; gastric laparotomy; oxycodone; patient-controlled analgesia; postoperative pain	COLORECTAL SURGERY PATIENTS; POSTOPERATIVE PAIN; BOWEL FUNCTION; VS. FENTANYL; MORPHINE; KETOROLAC	Background:It has been suggested that oxycodone is effective in relieving acute postoperative pain. The aim of this study was to investigate the efficacy and tolerability of oxycodone (O) versus fentanyl (F), and the adequate potency ratio of oxycodone and fentanyl in patients with intravenous patient-controlled analgesia after gastric laparotomy.Methods:In this double-blinded, randomized, controlled study, 60 patients undergoing elective gastric laparotomy were allocated to receive either oxycodone or fentanyl for postoperative intravenous patient-controlled analgesia (potency ratio 60:1). The patients received ketorolac 60mg before the end of anesthesia and then continued with patient-controlled analgesia for 48hours postsurgery. Pain severity, side effects and respiration rate were recorded 30 minutes, 3, 6, 12, 24, and 48hours after the surgery. Cumulative opioid requirements and patient satisfaction were also measured.Results:The median consumption more than 48hours after operation of oxycodone was 50mg (range: 40.0-62.4mg) and fentanyl was 0.8mg (range: 0.6-1.1mg), and the percentage of patients requiring rescue medication was not statistically significant. Numeric rating scores at rest and upon movement were significantly lower in group O than in F (P<0.05). Whereas the incidences of adverse events were similar between the groups (33.3% vs 27.6%, P = 0.64), a significant higher sedation scores were found in patients given fentanyl at 30 minutes after the surgery (P = 0.04).Conclusion:Oxycodone was comparable to fentanyl in the relief of postoperative pain following gastric laparotomy. Oxycodone not only provides better postoperative pain relief and less sedation, but also there was a tendency toward more side effects with oxycodone.	[Ding, Zhen] Univ Jinan, Sch Med & Life Sci, Shandong Acad Med Sci, Jinan, Peoples R China; [Ding, Zhen; Wang, Kaiguo; Wang, Baosheng; Zhou, Naibao; Li, Hao; Yan, Bo] Shandong Univ, Shandong Canc Hosp, Dept Anesthesiol, Shandong Acad Med Sci, 440 Jiyan Rd, Jinan, Shangdong, Peoples R China	Wang, KG (reprint author), Shandong Univ, Shandong Canc Hosp, Dept Anesthesiol, Shandong Acad Med Sci, 440 Jiyan Rd, Jinan, Shangdong, Peoples R China.	wangkg8888@163.com					Chen JY, 2009, CLIN J PAIN, V25, P485, DOI 10.1097/AJP.0b013e31819a506b; Chen JY, 2005, ACTA ANAESTH SCAND, V49, P546, DOI 10.1111/j.1399-6576.2005.00674.x; Davis MP, 2012, PAIN RES TREAT, V2012, DOI 10.1155/2012/265605; Dobrogowski J, 2014, FARMAKOTERAPIA BOLU, P78; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Hwang BY, 2014, INT J MED SCI, V11, P658, DOI 10.7150/ijms.8331; Joshi Girish P, 2005, Anesthesiol Clin North Am, V23, P185, DOI 10.1016/j.atc.2004.11.010; KALSO E, 1991, ACTA ANAESTH SCAND, V35, P642, DOI 10.1111/j.1399-6576.1991.tb03364.x; Kim NS, 2015, KOREAN J ANESTHESIOL, V68, P261, DOI 10.4097/kjae.2015.68.3.261; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; Lalovic B, 2006, CLIN PHARMACOL THER, V79, P461, DOI 10.1016/j.clpt.2006.01.009; Lenz H, 2009, ANESTH ANALG, V109, P1279, DOI 10.1213/ane.0b013e3181b0f0bb; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Nielsen CK, 2007, PAIN, V132, P289, DOI 10.1016/j.pain.2007.03.022; Nozaki C, 2005, EUR J PHARMACOL, V524, P75, DOI 10.1016/j.ejphar.2005.09.051; Park JW, 2015, J NUCL MED, V56, P153, DOI 10.2967/jnumed.114.147603; Sanders JC, 2009, J CLIN ANESTH, V21, P486, DOI 10.1016/j.jclinane.2008.12.019; Silvasti M, 1998, ACTA ANAESTH SCAND, V42, P576, DOI 10.1111/j.1399-6576.1998.tb05169.x; Staahl C, 2007, SCAND J GASTROENTERO, V42, P383, DOI 10.1080/00365520601014414; Staahl C, 2006, PAIN, V123, P28, DOI 10.1016/j.pain.2006.02.006; Vadivelu Nalini, 2010, Yale Journal of Biology and Medicine, V83, P11; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6	24	5	11	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	SEP	2016	95	39							e4943	10.1097/MD.0000000000004943			5	Medicine, General & Internal	General & Internal Medicine	DZ0PE	WOS:000385541400045	27684835	DOAJ Gold, Green Published			2020-06-30	J	Lemke, J; Sardariani, E; Phipps, JB; Patel, N; Itri, LM; Caravelli, J; Viscusi, ER				Lemke, John; Sardariani, Edmond; Phipps, Joseph Bradley; Patel, Niki; Itri, Loretta M.; Caravelli, James; Viscusi, Eugene R.			Fentanyl Iontophoretic Transdermal System (IONSYSA (R)) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices	ADVANCES IN THERAPY			English	Article						CT scan; Electromagnetic immunity; Fentanyl; IONSYS; Iontophoretic transdermal system; Patient-controlled analgesia; RFID; X-ray	PATIENT-CONTROLLED ANALGESIA; PLACEBO-CONTROLLED TRIAL; POSTOPERATIVE PAIN; MORPHINE; MANAGEMENT; EFFICACY; SURGERY	Fentanyl iontophoretic transdermal system (fentanyl ITS, IONSYSA (R)) is a patient-controlled analgesia system used for the management of acute postoperative pain, designed to be utilized in a hospital setting. The objective of the two studies was to determine if fentanyl ITS could be safely used with X-rays, computerized tomography (CT) scans and radiofrequency identification (RFID) devices. The ITS system has two components: controller and drug unit; the studies utilized ITS systems without fentanyl, referred to as the ITS Placebo system. The first study evaluated the effect of X-radiation on the operation of an ITS Placebo system. Five ITS Placebo systems were exposed to X-rays (20 and 200 mSv total radiation dose-the 200 mSv radiation dose represents a tenfold higher exposure than in clinical practice) while operating in the Ready Mode and five were exposed while operating in the Dose Mode. The second study evaluated the effect of RFID (worst-case scenario of direct contact with an RFID transmitter) on the operation of an ITS Placebo system. During these tests, observations of the user interface and measurements of output voltage confirmed proper function throughout all operational modes (Ready Mode, Dose Mode, End-of-Use Mode, and End-of-Life Mode). The ITS Placebo system met all specifications and no functional anomalies were observed during and following X-ray exposure at two radiation dose levels or exposure at six different combinations of RFID frequencies and field strengths. The performance of the ITS system was unaffected by X-ray exposure levels well beyond those associated with diagnostic X-rays and CT scans, and by exposure to radiofrequency field strengths typically generated by RFID devices. These results provide added confidence to clinicians that the fentanyl ITS system does not need to be removed during diagnostic X-rays and CT scans and can also be utilized in close proximity to RFID devices. The studies and writing of this manuscript were supported financially by The Medicines Company.	[Lemke, John; Sardariani, Edmond; Phipps, Joseph Bradley] Med Co, Redwood City, CA USA; [Patel, Niki; Itri, Loretta M.] Med Co, Parsippany, NJ 07054 USA; [Caravelli, James] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Viscusi, Eugene R.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Itri, LM (reprint author), Med Co, Parsippany, NJ 07054 USA.	loretta.itri@themedco.com			Medicines Company	The studies and writing of this manuscript were supported financially by The Medicines Company.	[Anonymous], 2015, IONSYS FENT IONT TRA; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Joshi N, 2016, PAIN MANAG, V6, P137, DOI 10.2217/pmt.15.70; MET Laboratories, 2011, PROGR TEST MED DEV S; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; The Medicines Company, 2014, DAT ON FIL; U.S. Food & Drug Administration, 2016, WHAT AR RAD RISKS CT; US Food and Drug Administration, 2016, NEXT DAT SUMM; US Food and Drug Administration, 2016, MED XRAY IM; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	13	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0741-238X	1865-8652		ADV THER	Adv. Ther.	SEP	2016	33	9					1649	1659		10.1007/s12325-016-0381-y			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	DX6XX	WOS:000384530500014	27423647	Green Published, Other Gold			2020-06-30	J	Ahmed, S; Naumann, DN; Karandikar, S				Ahmed, S.; Naumann, D. N.; Karandikar, S.			Differences in screening vs non-screening colonoscopy: scope for improvement?	COLORECTAL DISEASE			English	Article						Colonoscopy; endoscopy; screening; colorectal cancer; global rating scale		AimColonoscopy performed as part of the NHS Bowel Cancer Screening Programme (BCSP) is of high standard as measured using global rating scale (GRS) criteria. Screening practitioners also provide a non-screening colonoscopy service. The current study compares colonoscopy quality indicators between screening and non-screening groups performed by a single practitioner using the GRS. MethodPatient details were obtained for all consecutive colonoscopies between 2007 and 2014 performed by a single screening practitioner. Data were collected retrospectively from electronic patient records; BCSP Exeter database and non-screening colonoscopies were compared. Data included patient demographics (age, gender), sedation, and the GRS data including caecal intubation, adenoma and neoplasia detection rates. ResultsIn all, 1961 colonoscopy procedures (1067 screening and 894 non-screening) were identified; 57% were men. Mean (SD) age for all patients was 64 (10.4) years. Non-screening patients were younger [62 (+/- 14) vs 66 (+/- 4.8) years; P<0.05] and were less likely to be men (51.5% vs 61.9%; P<0.05) than their screening counterparts. Caecal intubation was more successful in screening patients [1027/1067 (96.3%)] than non-screening patients [805/894 (90%)]; P<0.05. Adenoma detection rate was higher in the screening (46.8 +/- 4.4) than non-screening (26.3 +/- 11.8) group; P<0.05. There were no differences in neoplasia detection. Polypectomy was more likely (55.5% vs 30.2%) and polyp retrieval more successful (97.5% vs 86.7%) in the screening group. ConclusionScreening and non-screening colonoscopy differ in the GRS domains of completion and pathology detection. These differences need to be acknowledged when comparing screeners and non-screeners using GRS within units.	[Ahmed, S.; Naumann, D. N.; Karandikar, S.] Heartlands Hosp, Heart England NHS Fdn Trust, Birmingham, W Midlands, England	Karandikar, S (reprint author), Heartlands Hosp, Heart England NHS Fdn Trust, Birmingham, W Midlands, England.	sharad.karandikar@heartofengland.nhs.uk	Naumann, David/S-9917-2019	Naumann, David/0000-0003-2243-2325			Aslinia F, 2006, AM J GASTROENTEROL, V101, P721, DOI 10.1111/j.1572-0241.2006.00494.x; Beard L, 2010, ACCREDITATION SCREEN, V3; Bhangu A, 2012, BRIT J SURG, V99, P1436, DOI 10.1002/bjs.8866; Bowles CJA, 2004, GUT, V53, P277, DOI 10.1136/gut.2003.016436; British Society of Gastroenterology Association of Upper Gastrointestinal Surgeons and Association of Coloproctology of Great Britain and Ireland, 2013, GUID IND DIAGN UPP G, P3; Chilton A, 2011, QUALITY ASSURANCE GU, P7; Harewood GC, 2005, DIGEST DIS SCI, V50, P47, DOI 10.1007/s10620-005-1276-y; Hwang MJ, 2014, COLORECTAL DIS, V16, P450, DOI 10.1111/codi.12562; Komeda Y, 2013, GASTROINTEST ENDOSC, V77, P395, DOI 10.1016/j.gie.2012.10.007; Lee TJW, 2012, GUT, V61, P1050, DOI 10.1136/gutjnl-2011-300651; Levin TR, 2006, ANN INTERN MED, V145, P880, DOI 10.7326/0003-4819-145-12-200612190-00004; Sorbi D, 2000, GASTROINTEST ENDOSC, V51, P690, DOI 10.1067/mge.2000.105773; Steele RJC, 2004, BMJ-BRIT MED J, V329, P133, DOI 10.1136/bmj.38153.491887.7C; Stock C, 2013, GASTROINTEST ENDOSC, V77, P419, DOI 10.1016/j.gie.2012.10.028	14	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-8910	1463-1318		COLORECTAL DIS	Colorectal Dis.	SEP	2016	18	9					903	909		10.1111/codi.13291			7	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	DW4QP	WOS:000383628400017	26850216				2020-06-30	J	Lebon, J; Fournier, F; Begin, F; Hebert, D; Fleet, R; Foldes-Busque, G; Tanguay, A				Lebon, Johann; Fournier, Francis; Begin, Francois; Hebert, Denise; Fleet, Richard; Foldes-Busque, Guilaume; Tanguay, Alain			SUBCUTANEOUS FENTANYL ADMINISTRATION: A NOVEL APPROACH FOR PAIN MANAGEMENT IN A RURAL AND SUBURBAN PREHOSPITAL SETTING	PREHOSPITAL EMERGENCY CARE			English	Article						Basic Life Support; fentanyl; pain management; prehospital; subcutaneous administration	CLINICALLY SIGNIFICANT DIFFERENCE; EMERGENCY-DEPARTMENT; INTRANASAL FENTANYL; INTRAVENOUS FENTANYL; ADVERSE EVENTS; VENOUS ACCESS; MORPHINE; ANALGESIA; PHARMACOKINETICS; SAFETY	Objective: To determine the feasibility, safety, and effectiveness of the subcutaneous route of fentanyl administration by Basic Life Support-Emergency Medical Technicians (BLS-EMT) in a rural and suburban region, with the support of an online pain management medical control center. Methods: Retrospective study of patients who received subcutaneous fentanyl and were transported by BLS-EMT to the emergency department (ED) of an academic hospital between July 1, 2013 and January 1, 2014, inclusively. Fentanyl orders were obtained from emergency physicians via an online medical control (OLMC) center. Effectiveness was defined by changes in pain scores 15 minutes, 30 minutes, and 45+ minutes after initial fentanyl administration. Safety was evaluated by measuring vital signs, Ramsay sedation scores, and adverse events subsequent to fentanyl administration. Feasibility was defined as successful fentanyl administration by BLS-EMT. SPSS-20 was used for descriptive statistics, and independent t-tests and Mann-Whitney U tests were used to determine inter- and intra-group differences based on transport time. Results: Two hundred and eighty-eight patients (288; 14 to 93years old) with pain scores 7 were eligible for the study. Of the 284 (98.6%) who successfully received subcutaneous fentanyl, 35 had missing records or data, and 249 (86.5%) were included in analyses. Average pain score pre-fentanyl was 8.9 +/- 1.1. Patients <70years old received a higher dose of fentanyl than those 70years old (1.4 +/- 0.3vs, 0.8 +/- 0.2 mcg/kg, p < 0.05). Pain scores decreased significantly post-fentanyl administration and the proportion of patients achieving pain relief increased significantly (p < 0.05) over the course of transport to ED (15 minutes, 30 minutes, 45+ minutes). Only 1.6% of patients experienced adverse events, including hypotension (n = 2; 0.8%), nausea (n = 1; 0.4%), and Ramsay level >3 (n = 1; 0.4%). Conclusion: Prehospital subcutaneous fentanyl administration by BLS-EMT with the support of an OLMC center is a safe and feasible approach to pain relief in prehospital settings, and is not associated with major adverse events. Effectiveness, subsequent to subcutaneous fentanyl administration is characterized by a decrease in pain over the course of transport to ED. Further studies are needed to compare the effectiveness of SC administration by EMS with other routes of administration and other analgesics.	[Lebon, Johann; Hebert, Denise; Tanguay, Alain] UCCSPU, 143 Rue Wolfe, Levis, PQ G6V 3Z1, Canada; [Lebon, Johann; Begin, Francois; Fleet, Richard; Foldes-Busque, Guilaume; Tanguay, Alain] Hotel Dieu Levis, Ctr Rech, Levis, PQ, Canada; [Begin, Francois; Fleet, Richard] CISSS Chaudieres Appalaches, Hotel Dieu Levis, Dept Med Urgence, Levis, PQ, Canada; CISSS Chaudieres Appalaches, Hotel Dieu Levis, Dept Med Familiale, Levis, PQ, Canada; [Foldes-Busque, Guilaume] Univ Laval, Ecole Psychol, Quebec City, PQ, Canada; [Fournier, Francis] CISSS Bas St Laurent, Hop Reg Rimouski, Quebec City, PQ, Canada	Lebon, J (reprint author), UCCSPU, 143 Rue Wolfe, Levis, PQ G6V 3Z1, Canada.	Johann.Lebon@USherbrooke.ca			Centre de recherche de l'hopital Hotel-Dieu de Levis	The study was supported by the Centre de recherche de l'hopital Hotel-Dieu de Levis.	Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Bendall JC, 2011, PREHOSP DISASTER MED, V26, P422, DOI 10.1017/S1049023X12000180; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Bijur PE, 2010, ANN EMERG MED, V56, P517, DOI 10.1016/j.annemergmed.2010.02.007; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P77, DOI 10.1046/j.1442-2026.2002.00288.x; Bradford P, 2013, CJEM, V15, pS36; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; Brown TB, 2005, AM FAM PHYSICIAN, V71, P85; BRUERA E, 1991, J PAIN SYMPTOM MANAG, V6, P263, DOI 10.1016/0885-3924(91)90017-X; Capper SJ, 2010, EUR J ANAESTH, V27, P241, DOI 10.1097/EJA.0b013e328331a361; Cepeda MS, 2003, PAIN, V105, P151, DOI 10.1016/S0304-3959(03)00176-3; CHALLINER YC, 1994, POSTGRAD MED J, V70, P195, DOI 10.1136/pgmj.70.821.195; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Cooper IM, 1996, ANAESTH INTENS CARE, V24, P574, DOI 10.1177/0310057X9602400512; Dailey MV, 2009, ACAD EMERG MED S, V16, pS197; Daoust R, 2015, PAIN RES MANAG, V20, P23, DOI 10.1155/2015/316275; Deaton T, 2015, AM J EMERG MED, V33, P791, DOI 10.1016/j.ajem.2015.03.046; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; DONOVAN PJ, 1989, ANN EMERG MED, V18, P495, DOI 10.1016/S0196-0644(89)80831-5; Dooney NM, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-33; Fields JM, 2014, AM J EMERG MED, V32, P1179, DOI 10.1016/j.ajem.2014.07.008; Fleet J, 2014, MIDWIFERY, V30, P36, DOI 10.1016/j.midw.2013.01.014; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Fosnocht DE, 2003, AM J EMERG MED, V21, P435, DOI 10.1016/S0735-6757(03)00092-5; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; French SC, 2013, WEST J EMERG MED, V14, P96, DOI 10.5811/westjem.2012.7.6678; Garrick Jocelyn Freeman, 2011, J Opioid Manag, V7, P229; Gonzalez RP, 2008, AM SURGEON, V74, P1083; Hansen MS, 2013, DAN MED J, V60; Hennes Halim, 2005, Prehosp Emerg Care, V9, P32, DOI 10.1080/10903120590891705; Hickey R, 1999, CRIT CARE MED, V27, P2320, DOI 10.1097/00003246-199910000-00060; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Jagoda AS, 1998, ANN EMERG MED, V31, P663, DOI 10.1016/S0196-0644(98)70216-1; Jennings PA, 2009, EMERG MED J, V26, P552, DOI 10.1136/emj.2008.062539; Johnston S, 2011, EMERG MED J, V28, P57, DOI 10.1136/emj.2009.078717; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Kelly CA, 2004, ANN EMERG MED, V44, P108, DOI 10.1016/j.annemergmed.2004.03.028; Kendrick DB, 2005, AM J EMERG MED, V23, P828, DOI 10.1016/j.ajem.2005.07.009; Koshy RC, 2005, J PAIN PALLIAT CARE, V19, P27, DOI 10.1300/J354v19n01_06; Letizia M, 1999, Am J Hosp Palliat Care, V16, P585, DOI 10.1177/104990919901600407; Marinangeli F, 2009, PAIN PRACT, V9, P282, DOI 10.1111/j.1533-2500.2009.00277.x; McEachin Christine Clara, 2002, Prehosp Emerg Care, V6, P406, DOI 10.1080/10903120290938030; McLean Samuel A, 2004, Prehosp Emerg Care, V8, P155, DOI 10.1016/j.prehos.2003.12.006; McManus JG, 2005, EMERG MED CLIN N AM, V23, P415, DOI 10.1016/j.emc.2004.12.009; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Park C L, 2010, J R Army Med Corps, V156, P295; Prottengeier J, 2015, EUR J EMERG MED; Reschreiter H, 2008, CRIT CARE, V12, DOI 10.1186/cc7141; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Sebbane M, 2013, J EMERG MED, V44, P299, DOI 10.1016/j.jemermed.2012.07.051; Smith MD, 2012, J EMERG MED, V43, P69, DOI 10.1016/j.jemermed.2011.05.018; Soriya GC, 2012, J TRAUMA ACUTE CARE, V72, P755, DOI 10.1097/TA.0b013e31823c4444; Steenblik J, 2012, AM J EMERG MED, V30, P1817, DOI 10.1016/j.ajem.2012.02.019; Stephen Robert, 2012, J Opioid Manag, V8, P237, DOI 10.5055/jom.2012.0121; Tanguay A, 2015, J EMERG MED, V49, P657, DOI 10.1016/j.jemermed.2015.05.009; Tanguy-Goarin C, 2010, THERAPIE, V65, P525, DOI 10.2515/therapie/2010066; White L J, 2000, Prehosp Emerg Care, V4, P205, DOI 10.1080/10903120090941209; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616	60	3	3	2	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	SEP-OCT	2016	20	5					648	656		10.3109/10903127.2016.1162887			9	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	DW8OI	WOS:000383915000015	27058453				2020-06-30	J	Okitsu, K; Iritakenishi, T; Iwasaki, M; Imada, T; Kamibayashi, T; Fujino, Y				Okitsu, Kenta; Iritakenishi, Takeshi; Iwasaki, Mitsuo; Imada, Tatsuyuki; Kamibayashi, Takahiko; Fujino, Yuji			Paravertebral block decreases opioid administration without causing hypotension during transapical transcatheter aortic valve implantation	HEART AND VESSELS			English	Article						TAVI; Transapical; Paravertebral block; Thoracotomy; Analgesia	MEAN ARTERIAL-PRESSURE; POSTOPERATIVE ANALGESIA; EPIDURAL ANALGESIA; CLINICAL-OUTCOMES; SURGERY; REMIFENTANIL; MANAGEMENT; EFFICACY	Paravertebral block (PVB) is feasible for postoperative analgesia in patients who undergo cardiac surgery with unilateral thoracotomy. Postoperative continuous PVB is as effective as thoracic epidural anesthesia and is less likely to cause hypotension. However, the intraoperative utility and safety of PVB remains unclear. Therefore, the present study was conducted to determine the efficacy and hemodynamic influence of intraoperative paravertebral bolus injection during cardiac surgery. We retrospectively compared intraoperative medication use and blood pressure measurements between patients who underwent transapical transcatheter aortic valve implantation (TA-TAVI) with (PVB group, n = 46) or without (non-PVB group, n = 15) intraoperative PVB. Remifentanil administration was lower by more than 40 % in the PVB group compared with that in the non-PVB group (728 +/- A 319 A mu g vs. 1240 +/- A 488 A mu g, P < 0.001). The average and variability of intraoperative blood pressure showed no significant differences between groups. The duration of hypotension (blood pressure less than 80 % of baseline) was 25.1 +/- A 21.5 % and 25.4 +/- A 18.1 % of the entire anesthesia time in the non-PVB and PVB groups, respectively (P = 0.74). The use of inotropic and vasopressor agents was comparable between groups. Intraoperative paravertebral bolus injection decreased remifentanil administration without causing hypotension during TA-TAVI in hemodynamically unstable patients. This result suggests the intraoperative utility of PVB in cardiac surgery.	[Okitsu, Kenta; Iritakenishi, Takeshi; Iwasaki, Mitsuo; Imada, Tatsuyuki; Kamibayashi, Takahiko; Fujino, Yuji] Osaka Univ, Dept Anesthesiol & Intens Care Med, 2-2 Yamadaoka, Suita, Osaka, Japan	Okitsu, K (reprint author), Osaka Univ, Dept Anesthesiol & Intens Care Med, 2-2 Yamadaoka, Suita, Osaka, Japan.	kokitsu@anes.med.osaka-u.ac.jp					Amat-Santos IJ, 2012, HEART, V98, P1583, DOI 10.1136/heartjnl-2012-302185; Baidya DK, 2014, INTERACT CARDIOV TH, V18, P626, DOI 10.1093/icvts/ivt551; Bigeleisen PE, 2015, CURR OPIN ANESTHESIO, V28, P89, DOI 10.1097/ACO.0000000000000147; Bijker JB, 2012, ANESTHESIOLOGY, V116, P658, DOI 10.1097/ALN.0b013e3182472320; Bonow Robert O, 2008, Circulation, V118, pe523, DOI 10.1161/CIRCULATIONAHA.108.190748; Bottiger BA, 2014, SEMIN CARDIOTHORAC V, V18, P45, DOI 10.1177/1089253213514484; Cobey FC, 2014, J CARDIOTHOR VASC AN, V28, P1075, DOI 10.1053/j.jvca.2013.11.006; Covello RD, 2011, CURR OPIN ANESTHESIO, V24, P417, DOI 10.1097/ACO.0b013e328347f99f; Davies RG, 2006, BRIT J ANAESTH, V96, P418, DOI 10.1093/bja/ael020; Dhole S, 2001, J CARDIOTHOR VASC AN, V15, P288, DOI 10.1053/jcan.2001.23271; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Garutti I, 2006, J CARDIOTHOR VASC AN, V20, P648, DOI 10.1053/j.jvca.2006.02.033; Jakobsen CJ, 2015, SEMIN CARDIOTHORAC V, V19, P38, DOI 10.1177/1089253214548764; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff; Kim SH, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00108; Mascha EJ, 2015, ANESTHESIOLOGY, V123, P79, DOI 10.1097/ALN.0000000000000686; Mehta Y, 2008, ANN CARD ANAESTH, V11, P91, DOI 10.4103/0971-9784.41576; Nakasuji M, 2010, BRIT J ANAESTH, V105, P162, DOI 10.1093/bja/aeq121; Neuburger PJ, 2015, J CARDIOTHOR VASC AN, V29, P930, DOI 10.1053/j.jvca.2014.10.010; Pintaric TS, 2011, REGION ANESTH PAIN M, V36, P256, DOI 10.1097/AAP.0b013e3182176f42; Rodrigues ES, 2014, J CARDIOTHOR VASC AN, V28, P64, DOI 10.1053/j.jvca.2013.05.042; Tassoudis V, 2011, J ANESTH, V25, P492, DOI 10.1007/s00540-011-1152-1; Walsh M, 2013, ANESTHESIOLOGY, V119, P507, DOI 10.1097/ALN.0b013e3182a10e26; Ziyaeifard M, 2014, J CARDIOVASC THORAC, V6, P133, DOI 10.15171/jcvtr.2014.001	24	9	9	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0910-8327	1615-2573		HEART VESSELS	Heart Vessels	SEP	2016	31	9					1484	1490		10.1007/s00380-015-0750-5			7	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	DV1HK	WOS:000382671600011	26384505				2020-06-30	J	Akhtar, S; Liu, J; Heng, J; Dai, F; Schonberger, RB; Burg, MM				Akhtar, Shamsuddin; Liu, Jia; Heng, Joseph; Dai, Feng; Schonberger, Robert B.; Burg, Matthew M.			Does intravenous induction dosing among patients undergoing gastrointestinal surgical procedures follow current recommendations: a study of contemporary practice	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Elderly; Gastrointestinal surgery; Geriatric anesthesia; Hypotension; Intravenous anesthetics; Octogenarians; Propofol	HEMODYNAMIC-CHANGES; NONCARDIAC SURGERY; GENERAL-ANESTHESIA; OLDER-ADULTS; PROPOFOL; ASSOCIATION; HYPOTENSION; MULTICENTER; PREDICTORS; MIDAZOLAM	Study objective: It is recommended to correct intravenous induction doses by up to 50% for patients older than 65 years. The objectives were to determine (a) the degree to which anesthesia providers correct induction doses for age and (b) additionally adjust for American Society of Anesthesiologists physical status (ASA-PS) class (severity of illness) and (c) whether postinduction hypotension is more common among patients aged >65.. Design: Retrospective chart review. Setting: Academic medical center. Patients: A total of 1869 adult patients receiving general anesthesia for GI surgical procedures from February 2013 to January 2014. Measurements: Patients were divided into 3 age groups (age <65, 65-79, >= 80 years) and then further stratified into ASA-PS class (I/II vs III/IV). Multiple pairwise comparisons were conducted using Welch t tests for continuous variables to determine whether dosing was different for the older groups vs the younger group; separate analyses were performed within and across ASA-PS class. This approach was also used to determine differences in mean arterial pressure change in the older groups vs the younger group, whereas the rates of hypotension among different age groups were compared by Cochran-Armitage trend test. Main results: No significant decrease in dosing between age groups was observed for fentanyl and midazolam. For propofol, there was a significantly lower dosing for older patients: 17% for patients aged 65-79 and 29% for those aged >80, which was still in less than the recommendations. An inverse relationship was observed between propofol dosing and ASA-PS class, but no consistent relationship was noted for fentanyl and midazolam. There were a significantly larger drop in mean arterial pressure and a greater likelihood of hypotension following induction in patients aged 65-79 years and >80 years as compared with those aged <65 years. Conclusions: This study shows that the administered dose of anesthetic induction agents is significantly higher than that recommended for patients older than 65 years. This failure to age-adjust dose may contribute to hypotensive episodes. (C) 2016 Elsevier Inc. All rights reserved.	[Akhtar, Shamsuddin] Yale Sch Med, Dept Anesthesiol & Pharmacol, New Haven, CT USA; [Liu, Jia; Heng, Joseph; Schonberger, Robert B.; Burg, Matthew M.] Yale Sch Med, Dept Anesthesiol, New Haven, CT USA; [Dai, Feng] Yale Ctr Analyt Sci, New Haven, CT USA; [Burg, Matthew M.] Yale Sch Med, Dept Internal Med, New Haven, CT USA	Akhtar, S (reprint author), Anesthesiol & Pharmacol, POB 208051,333 Cedar St,TMP 3, New Haven, CT 06510 USA.	soorujakhtar@gmail.com		Akhtar, Shamsuddin/0000-0002-1127-0538	Clinical and Translational Science Award from the National Center for Advancing Translational Sciences at the National Institutes of Health [UL1 RR024139]	This work was supported in part by Clinical and Translational Science Award grant UL1 RR024139 from the National Center for Advancing Translational Sciences at the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the policy or views of the National Institutes of Health or the United States government.	Akhtar Shamsuddin, 2015, Anesthesiol Clin, V33, P457, DOI 10.1016/j.anclin.2015.05.004; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bowie Mark W, 2007, Am J Geriatr Pharmacother, V5, P263, DOI 10.1016/j.amjopharm.2007.10.001; Chan VWS, 1996, J CLIN ANESTH, V8, P317, DOI 10.1016/0952-8180(96)00041-4; CLAEYS MA, 1988, BRIT J ANAESTH, V60, P3, DOI 10.1093/bja/60.1.3; Cressey DM, 2001, ANAESTHESIA, V56, P108, DOI 10.1046/j.1365-2044.2001.01789.x; Cusack Barry J, 2004, Am J Geriatr Pharmacother, V2, P274, DOI 10.1016/j.amjopharm.2004.12.005; Deutsch MA, 2014, J CARDIAC SURG, V29, P14, DOI 10.1111/jocs.12233; Diprivan, 2015, DIPR; FOLKOW B, 1993, PHYSIOL REV, V73, P725; FORREST JB, 1992, ANESTHESIOLOGY, V76, P3, DOI 10.1097/00000542-199201000-00002; Fukuda Kazuhiko, 2015, MILLERS ANESTHESIA, P864; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; HE W, 2005, CURRENT POPULATION R; Jain U, 1997, ANESTHESIOLOGY, V86, P576, DOI 10.1097/00000542-199703000-00009; MCCLUNE S, 1992, BRIT J ANAESTH, V69, P240, DOI 10.1093/bja/69.3.240; MCCOLLUM JSC, 1986, ANAESTHESIA, V41, P995, DOI 10.1111/j.1365-2044.1986.tb12740.x; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Mosteller RD, 1987, NEW ENGL J MED, V22, P317; Phillips AT, 2015, CLIN THER, V37, P2676, DOI 10.1016/j.clinthera.2015.10.005; Reich DL, 2005, ANESTH ANALG, V101, P622, DOI 10.1213/01.ANE.0000175214.38450.91; Rooke GA, 2003, J CARDIOTHOR VASC AN, V17, P512, DOI 10.1016/S1053-0770(03)00161-7; Sadean Mihai R, 2003, Best Pract Res Clin Anaesthesiol, V17, P191, DOI 10.1016/S1521-6896(03)00002-8; Schonberger RB, 2014, J CARDIOTHOR VASC AN, V28, P247, DOI 10.1053/j.jvca.2013.03.014; Shafer S L, 2000, Anesthesiol Clin North Am, V18, P1; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Van Cleve WC, 2015, ANESTH ANALG, V121, P645, DOI 10.1213/ANE.0000000000000819; Veering B T, 1999, Curr Opin Anaesthesiol, V12, P333, DOI 10.1097/00001503-199906000-00014; Vuyk J, 2015, MILLERS ANESTHESIA, P821; Vuyk Jaap, 2003, Best Pract Res Clin Anaesthesiol, V17, P207; Walsh M, 2013, ANESTHESIOLOGY, V119, P507, DOI 10.1097/ALN.0b013e3182a10e26; Werner CA, 2011, CENSUS BRIEFS OLDER	32	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	SEP	2016	33						208	215		10.1016/j.jclinane.2016.02.001			8	Anesthesiology	Anesthesiology	DU7VD	WOS:000382421800043	27555166				2020-06-30	J	Copland, AP; Gaspar, JP; Wang, AY				Copland, Andrew P.; Gaspar, Jonathan P.; Wang, Andrew Y.			Colonoscopy Enables the Diagnosis of Opiate Abuse	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY			English	Editorial Material									[Copland, Andrew P.; Wang, Andrew Y.] Univ Virginia, Div Gastroenterol & Hepatol, Charlottesville, VA 22904 USA; [Gaspar, Jonathan P.] Gastroenterol Associates Fairfax, Fairfax, VA USA	Copland, AP (reprint author), Univ Virginia, Div Gastroenterol & Hepatol, Charlottesville, VA 22904 USA.						Mrvos R, 2012, J EMERG MED, V42, P549, DOI 10.1016/j.jemermed.2011.05.017; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274	2	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1542-3565	1542-7714		CLIN GASTROENTEROL H	Clin. Gastroenterol. Hepatol.	SEP	2016	14	9					XXIII	XXIII		10.1016/j.cgh.2016.05.014			1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	DT8DD	WOS:000381718400002	27211499	Bronze			2020-06-30	J	Choi, JW; Joo, JD; Kim, DW; In, JH; Kwon, SY; Seo, K; Han, D; Cheon, GY; Jung, HS				Choi, Jin Woo; Joo, Jin-Deok; Kim, Dae-Woo; In, Jang-Hyeok; Kwon, So-Young; Seo, Kwonhui; Han, Donggyu; Cheon, Ga-Young; Jung, Hong Soo			Comparison of an Intraoperative Infusion of Dexmedetomidine, Fentanyl, and Remifentanil on Perioperative Hemodynamics, Sedation Quality, and Postoperative Pain Control	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						Dexmedetomidine; Fentanyl; Remifentanil; Surgery; Pain Control; Hemodynamic Stability	MONITORED ANESTHESIA CARE; INTENSIVE-CARE; ANALGESIA; AGONISTS; SURGERY	We aimed to compare fentanyl, remifentanil and dexmedetomidine with respect to hemodynamic stability, postoperative pain control and achievement of sedation at the postanesthetic care unit (PACU). In this randomized double-blind study, 90 consecutive total laparoscopic hysterectomy patients scheduled for elective surgery were randomly assigned to receive fentanyl (1.0 mu g/kg) over 1 minute followed by a 0.4 mu g/kg/hr infusion (FK group, n = 30), or remifentanil (1.0 mu g/kg) over 1 minute followed by a 0.08 mu g/kg/min infusion (RK group, n = 30), or dexmedetomidine (1 mu g/kg) over 10 minutes followed by a 0.5 mu g/kg/hr infusion (DK group, n = 30) initiating at the end of main procedures of the operation to the time in the PACU. A single dose of intravenous ketorolac (30 mg) was given to all patients at the end of surgery. We respectively evaluated the pain VAS scores, the modified OAAS scores, the BIS, the vital signs and the perioperative side effects to compare the efficacy of fentanyl, remifentanil and dexmedetomidine. Compared with other groups, the modified OAAS scores were significantly lower in DK group at 0, 5 and 10 minutes after arrival at the PACU (P < 0.05), whereas the pain VAS and BIS were not significantly different from other groups. The blood pressure and heart rate in the DK group were significantly lower than those of other groups at the PACU (P < 0.05). DK group, at sedative doses, had the better postoperative hemodynamic stability than RK group or FK group and demonstrated a similar effect of pain control as RK group and FK group with patient awareness during sedation in the PACU.	[Choi, Jin Woo; Joo, Jin-Deok; Kim, Dae-Woo; In, Jang-Hyeok; Kwon, So-Young; Seo, Kwonhui; Han, Donggyu; Cheon, Ga-Young; Jung, Hong Soo] Catholic Univ Korea, Dept Anesthesiol & Pain Med, St Vincents Hosp, Seoul, South Korea	Jung, HS (reprint author), Catholic Univ Korea, Dept Anesthesiol & Pain Med, St Vincents Hosp, 93 Jungbu Daero, Suwon 16247, South Korea.	flood1@naver.com	Seo, Kwon Hui/G-1591-2016	Seo, Kwon Hui/0000-0003-4397-9207; Jung, Hong Soo/0000-0002-6812-1955; Joo, Jin Deok/0000-0002-4365-7091; Kwon, So Young/0000-0003-0249-4190			Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; Bekker A, 2005, NEUROSURGERY, V57, P1, DOI 10.1227/01.NEU.0000163476.42034.A1; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Busick T, 2008, AM J THER, V15, P520, DOI 10.1097/MJT.0b013e31815ae755; Cavaliere F, 2002, CAN J ANAESTH, V49, P1088, DOI 10.1007/BF03017909; Chrysostomou C, 2008, EXPERT OPIN DRUG MET, V4, P619, DOI [10.1517/17425255.4.5.619, 10.1517/17425255.4.5.619 ]; Farber NE, 1997, BRAIN RES, V774, P131, DOI 10.1016/S0006-8993(97)81696-4; Guo TZ, 1996, ANESTHESIOLOGY, V84, P873, DOI 10.1097/00000542-199604000-00015; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Joo HS, 2001, ANESTH ANALG, V92, P1342; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Lu J, 2008, J COMP NEUROL, V508, P648, DOI 10.1002/cne.21685; Mester R, 2008, AM J THER, V15, P24, DOI 10.1097/MJT.0b013e3180a72255; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Tipps LB, 2000, NEUROSURGERY, V46, P596, DOI 10.1097/00006123-200003000-00015; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; YAKSH TL, 1995, J PHARMACOL EXP THER, V272, P207	19	9	10	0	6	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	SEP	2016	31	9					1485	1490		10.3346/jkms.2016.31.9.1485			6	Medicine, General & Internal	General & Internal Medicine	DU0VT	WOS:000381923500021	27510395	DOAJ Gold, Green Published			2020-06-30	J	Holme, O; de Lange, T; Stallemo, A; Wiig, H; Hasund, A; Dvergsnes, K; Garborg, K; Ystrom, CM; Loberg, M; Hoff, G; Bretthauer, M; Kalager, M				Holme, Oyvind; de Lange, Thomas; Stallemo, Asbjorn; Wiig, Havard; Hasund, Audun; Dvergsnes, Katrine; Garborg, Kjetil; Ystrom, Carl Magnus; Loberg, Magnus; Hoff, Geir; Bretthauer, Michael; Kalager, Mette			Routine vs. on-demand analgesia in colonoscopy: a randomized clinical trial	ENDOSCOPY			English	Article							FLEXIBLE SIGMOIDOSCOPY; PATIENT SATISFACTION; PREEMPTIVE ANALGESIA; ENDOSCOPIC SEDATION; MONITORING PRACTICE; POSTOPERATIVE PAIN; NATIONWIDE SURVEY; METAANALYSIS; FENTANYL; COMPLICATIONS	Background and study aims: Colonoscopy is frequently performed with opioid analgesia, but the impact of drug delivery timing has not been studied in detail. Low-dose opioids administered before the procedure may provide better pain control than on-demand administration when the patient experiences pain. Patients and methods: A total of 119 outpatients were randomized to receive 50 mu g of fentanyl either before colonoscopy (routine group) or on demand if needed during the colonoscopy (on-demand group). Additional fentanyl or midazolam was allowed in both groups if required. The primary outcome was pain measured on both a 100-mm visual analog scale (VAS; 0= no pain, 100= worst possible pain) and a four-point Likert scale (no, slight, moderate, or severe pain) immediately after the procedure. Results: A total of 61 patients in the routine group and 58 patients in the on-demand group were included in the study. Mean VAS pain scores were 27.4mm in the routine group and 30.5mm in the on-demand group (mean difference -3.2mm; 95% confidence interval -11.9 to 5.5; P= 0.5). On the Likert scale, moderate or severe pain was experienced by 25.0% and 31.5% of patients in the routine and on-demand groups, respectively (p= 0.5). Cecal intubation rate and time to reach the cecum were similar between the groups. More patients in the on-demand group (81.0 %) than in the routine group (62.3 %) were able to leave the clinic without the need for recovery time (P= 0.03). Conclusion: Routine administration of fentanyl did not provide better analgesia during colonoscopy than on-demand fentanyl, and more patients needed time for recovery.	[Holme, Oyvind; Stallemo, Asbjorn; Wiig, Havard; Hasund, Audun; Dvergsnes, Katrine; Garborg, Kjetil; Bretthauer, Michael] Sorlandet Hosp, Dept Med, Mailbox 416, N-4604 Kristiansand, Norway; [Holme, Oyvind; Garborg, Kjetil; Loberg, Magnus; Hoff, Geir; Bretthauer, Michael; Kalager, Mette] Univ Oslo, Inst Hlth & Soc, Oslo, Norway; [de Lange, Thomas; Hoff, Geir] Canc Registry Norway, Oslo, Norway; [de Lange, Thomas] Vestre Viken Hosp, Dept Med, Baerum, Norway; [Ystrom, Carl Magnus] Innlandet Hosp, Elverum, Norway; [Loberg, Magnus; Bretthauer, Michael; Kalager, Mette] Oslo Univ Hosp, Dept Transplantat Med, Oslo, Norway; [Loberg, Magnus; Bretthauer, Michael; Kalager, Mette] Oslo Univ Hosp, KG Jebsen Ctr Colorectal Canc Res, Oslo, Norway; [Hoff, Geir] Telemark Hosp, Skien, Norway; [Kalager, Mette] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Holme, O (reprint author), Sorlandet Hosp, Dept Med, Mailbox 416, N-4604 Kristiansand, Norway.	oyvind.holme@medisin.uio.no	de Lange, Thomas/Q-9063-2016; Loberg, Magnus/F-1152-2016	de Lange, Thomas/0000-0003-3989-7487; Garborg, Kjetil/0000-0002-5484-5995; Loberg, Magnus/0000-0003-2231-1304	Sorlandet Hospital; South-Eastern Norway Regional Health Authorities	The study was supported by grants from Sorlandet Hospital and South-Eastern Norway Regional Health Authorities.	Basu S, 2004, WORLD J SURG, V28, P930, DOI 10.1007/s00268-004-7374-8; Bretthauer M, 2002, SCAND J GASTROENTERO, V37, P1103, DOI 10.1080/003655202320378329; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Cooper GS, 2013, JAMA INTERN MED, V173, P551, DOI 10.1001/jamainternmed.2013.2908; Early DS, 1999, AM J GASTROENTEROL, V94, P1862; Eberl S, 2014, TECH COLOPROCTOL, V18, P745, DOI 10.1007/s10151-014-1188-y; Eckardt VF, 1999, GASTROINTEST ENDOSC, V49, P560, DOI 10.1016/S0016-5107(99)70382-2; Fanti L, 2011, DIGEST LIVER DIS, V43, P726, DOI 10.1016/j.dld.2011.04.012; Garborg KK, 2012, ENDOSCOPY, V44, P740, DOI 10.1055/s-0032-1309755; Heuss LT, 2005, ENDOSCOPY, V37, P161, DOI 10.1055/s-2004-826143; Holme O, 2013, ENDOSCOPY, V45, P691, DOI 10.1055/s-0033-1344239; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Jones RM, 2010, AM J PREV MED, V38, P508, DOI 10.1016/j.amepre.2010.01.021; Larsen IK, 2002, SCAND J GASTROENTERO, V37, P850, DOI 10.1080/713786520; Lazaraki G, 2007, SURG ENDOSC, V21, P1631, DOI 10.1007/s00464-007-9215-y; Maslekar S, 2009, BRIT J SURG, V96, P361, DOI 10.1002/bjs.6467; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Ong CKS, 2005, ANESTH ANALG, V100, P757, DOI 10.1213/01.ANE.0000144428.98767.0E; Park DI, 2007, EUR J GASTROEN HEPAT, V19, P695, DOI 10.1097/01.meg.0000219097.32811.24; Rabenstein T, 2012, ENDOSCOPY, V44, P940, DOI 10.1055/s-0032-1310157; Rex DK, 1999, GASTROINTEST ENDOSC, V49, P554, DOI 10.1016/S0016-5107(99)70381-0; Riphaus A, 2010, Z GASTROENTEROL, V48, P392, DOI 10.1055/s-0028-1109765; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; Seip B, 2010, ENDOSCOPY, V42, P639, DOI 10.1055/s-0030-1255612; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; Speroni Karen Gabel, 2005, Gastroenterol Nurs, V28, P502, DOI 10.1097/00001610-200511000-00006; Takahashi Y, 2005, DIS COLON RECTUM, V48, P1295, DOI 10.1007/s10350-004-0940-1; Terruzzi V, 2001, GASTROINTEST ENDOSC, V54, P169, DOI 10.1067/mge.2001.113923; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Vase L, 2002, PAIN, V99, P443, DOI 10.1016/S0304-3959(02)00205-1; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; Ylinen ER, 2009, J ADV NURS, V65, P2597, DOI 10.1111/j.1365-2648.2009.05119.x	33	2	2	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	SEP	2016	48	9					823	828		10.1055/s-0042-108433			6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	EE1VM	WOS:000389371800009	27305424				2020-06-30	J	Haumann, J; Geurts, JW; van Kuijk, SMJ; Kremer, B; Joosten, EA; van den Beuken-van Everdingen, MHJ				Haumann, J.; Geurts, J. W.; van Kuijk, S. M. J.; Kremer, B.; Joosten, E. A.; van den Beuken-van Everdingen, M. H. J.			Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer	EUROPEAN JOURNAL OF CANCER			English	Article						Methadone; Fentanyl; Head-and-neck cancer; Cancer pain; NMDA receptor antagonist	CLINICAL IMPORTANCE; HOSPITAL ANXIETY; ORAL METHADONE; MORPHINE; VALIDATION; VERSION; ANTAGONISTS; ROTATION; KETAMINE; RECEPTOR	Background: Cancer pain is still inadequately treated in up to 60% of cancer patients. Based on the additional effect on the N-Methyl-D-Aspartate receptor, we expected that methadone (Met) could provide better pain relief than fentanyl (Fen) in cancer pain with a neuropathic pain component. Methods: A randomised controlled trial was performed with 52 strong opioids naive patients with head-and-neck cancer with substantial pain (pain Numerical Rating Scale [NRS] > 4) and a neuropathic pain component (Douleur Neuropathique [DN4] > 4). Twenty-six patients were treated with Met and 26 with Fen. Patients were evaluated at 1, 3 and 5 weeks. The primary outcomes were reduction in average pain, clinical success (defined as 50% average pain decrease) and reduction in pain interference. Secondary outcomes were global perceived effect (GPE) and side-effects. Findings: Reduction in NRS was higher with the use of Met at 1, 3 and 5 weeks (pain change 2.9, 3.1 and 3.1) compared to Fen (1.4, 1.7 and 2.0). This difference was significant at 1 (p = 0.011) and at 3 weeks (p = 0.03). Clinical success (> 50% improvement) was higher with Met at 1 week (15% versus 50%, p = 0.012). The change in pain interference, the GPE and side-effect profile were not significantly different between the groups. Interpretation: This is the first study to compare the effects of Met to Fen in cancer patients with a neuropathic pain component. Based on the results of this study, Met should be considered in the treatment of oncological pain with a neuropathic component. (C) 2016 Elsevier Ltd. All rights reserved.	[Haumann, J.; Geurts, J. W.; Joosten, E. A.; van den Beuken-van Everdingen, M. H. J.] Maastricht Univ, Med Ctr, Univ Pain Ctr Maastricht UPCM, Dept Anesthesiol & Pain Management, Maastricht, Netherlands; [Haumann, J.] OLVG, Dept Anaesthesiol & Pain Management, Amsterdam, Netherlands; [van Kuijk, S. M. J.] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands; [Kremer, B.] Maastricht Univ, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands; [Joosten, E. A.] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Translat Neurosci, Maastricht, Netherlands; [van den Beuken-van Everdingen, M. H. J.] Maastricht Univ, Med Ctr MUMC, Ctr Expertise Palliat Care, Maastricht, Netherlands	van den Beuken-van Everdingen, MHJ (reprint author), MUMC, RVE Patient Zorg, POB 5800, NL-6202 AZ Maastricht, Netherlands.	m.vanden.beuken@mumc.nl	Geurts, J.W./P-7822-2019; Geurts, Jose W/O-3673-2014	Geurts, J.W./0000-0002-7043-968X; van Kuijk, Sander/0000-0003-2796-729X; van den Beuken-van Everdingen, Marieke/0000-0002-2446-2862			Benitez-Rosario MA, 2009, J PAIN SYMPTOM MANAG, V37, P1061, DOI 10.1016/j.jpainsymman.2008.05.016; Boveldt NT, 2013, PAIN PHYSICIAN, V16, P379; Bredlau AL, 2013, PAIN MED, V14, P1505, DOI 10.1111/pme.12182; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; Caraceni A, 1996, PAIN, V65, P87, DOI 10.1016/0304-3959(95)00156-5; Cubero DIG, 2010, SUPPORT CARE CANCER, V18, P235, DOI 10.1007/s00520-009-0649-8; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; EBERT B, 1995, NEUROSCI LETT, V187, P165, DOI 10.1016/0304-3940(95)11364-3; Everdingen MHJVDBV, 2007, PAIN, V132, P312, DOI 10.1016/j.pain.2007.08.022; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fredheim OMS, 2008, ACTA ANAESTH SCAND, V52, P879, DOI 10.1111/j.1399-6576.2008.01597.x; Gagnon Bruno, 2003, Pain Res Manag, V8, P149; Good Phillip, 2014, J Pain Palliat Care Pharmacother, V28, P197, DOI 10.3109/15360288.2014.938883; Gorman AL, 1997, NEUROSCI LETT, V223, P5; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Haroutiunian S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008025.pub2; Ji YP, 2001, J NEUROPHYSIOL, V86, P1783; Kharasch ED, 2015, ANESTHESIOLOGY, V123, P1142, DOI 10.1097/ALN.0000000000000867; Lauretti GR, 2013, BRIT J CANCER, V108, P259, DOI 10.1038/bjc.2012.593; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; Mancini I, 2000, CURR OPIN ONCOL, V12, P308, DOI 10.1097/00001622-200007000-00006; Manfredi PL, 1997, PAIN, V70, P99, DOI 10.1016/S0304-3959(96)03313-1; Mercadante S, 1999, J CLIN ONCOL, V17, P3307, DOI 10.1200/JCO.1999.17.10.3307; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; Moksnes K, 2011, EUR J CANCER, V47, P2463, DOI 10.1016/j.ejca.2011.06.047; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Moryl Natalie, 2005, Palliat Support Care, V3, P311; Nicholson AB, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003971.pub3; QUIGLEY C, 2004, [No title captured], DOI DOI 10.1002/14651858.CD004847; Radbruch L, 1999, J PAIN SYMPTOM MANAG, V18, P180, DOI 10.1016/S0885-3924(99)00064-0; Rhondali W, 2013, J PALLIAT MED, V16, P1382, DOI 10.1089/jpm.2013.0222; Ripamonti C, 2002, HEMATOL ONCOL CLIN N, V16, P543, DOI 10.1016/S0889-8588(02)00017-5; Salas S, 2012, J PALLIAT MED, V15, P287, DOI 10.1089/jpm.2011.0353; Schmidt-Hansen M., 2015, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003870; Schmidt-Hansen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009596.pub4; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Swartjes M, 2011, ANESTHESIOLOGY, V115, P165, DOI 10.1097/ALN.0b013e31821bdb9b; van Buuren S, 2012, FLEXIBLE IMPUTATION; van den Beuken-van Everdingen MHJ, 2013, J OPIOID MANAG, V38, P263; Van Seventer R, 2010, EUR J PAIN, V14, P58, DOI 10.1016/j.ejpain.2009.01.005; Wang XS, 1996, PAIN, V67, P407, DOI 10.1016/0304-3959(96)03147-8; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Zhou Hong-Yi, 2011, Expert Rev Clin Pharmacol, V4, P379; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	46	25	25	2	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	SEP	2016	65						121	129		10.1016/j.ejca.2016.06.025			9	Oncology	Oncology	DU5BP	WOS:000382227300014	27494037				2020-06-30	J	Coopman, V; Blanckaert, P; Van Parys, G; Van Calenbergh, S; Cordonnier, J				Coopman, Vera; Blanckaert, Peter; Van Parys, Geert; Van Calenbergh, Serge; Cordonnier, Jan			A case of acute intoxication due to combined use of fentanyl and 3,4-dichloro-N-[2-( dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700)	FORENSIC SCIENCE INTERNATIONAL			English	Article						U-47700; Fentanyl; Inhalation; New psychotropic substance (NPS); Ultra performance liquid chromatography; mass spectrometry (UPLC-MS)	ABUSE	A 30-year old man was found dead in his home after inhaling fumes of a powder burned on aluminum foil. Blood and urine were taken by the medical examiner during the external body examination and submitted to the laboratory for a comprehensive systematic toxicological analysis. A toxic fentanyl level of 10.9 mu g/L was measured in the subclavian blood. Police investigation revealed that the man searched the internet for information on new psychotropic substances, among others including U-47700. A powder found in the victims' home was transferred to the laboratory for analysis, in which trace amounts of fentanyl (0.0035%, m/m) and U-47700 (0.0012%, m/m) were identified by gas chromatography mass spectrometry. U-47700 is an opioid analgesic drug, considered to have a potency of approximately 7.5 times that of morphine. A target analysis on U-47700 was performed using liquid-liquid extraction and ultra performance liquid chromatography tandem mass spectrometry operating in multiple reaction monitoring mode. The method validation was based on the Scientific Working Group of Forensic Toxicology document 'Standard Practices of Method Validation in Forensic Toxicology'. In blood and urine the U-47700 concentration was 13.8 and 71.0 mu g/L, respectively. To the author's knowledge, this is the first case report of a fatal intoxication involving U-47700 abused as a new psychotropic substance. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Coopman, Vera; Cordonnier, Jan] Eurofins Forens Belgium, Lieven Bauwensstr 6, B-8200 Brugge, Belgium; [Blanckaert, Peter] Sci Inst Publ Hlth, Belgian Early Warning Syst Drugs, Juliette Wytsmanstr 14, B-1050 Brussels, Belgium; [Van Parys, Geert] AZ Damiaan, Dept Pathol & Forens Med, Gouwelozestr 100, B-8400 Oostende, Belgium; [Van Calenbergh, Serge] Univ Ghent, Med Chem Lab, Ottergemsesteenweg 460, B-9000 Ghent, Belgium	Coopman, V; Cordonnier, J (reprint author), Eurofins Forens Belgium, Lieven Bauwensstr 6, B-8200 Brugge, Belgium.	veracoopman@eurofins.be; jancordonnier@eurofins.be	Blanckaert, Peter/AAE-1796-2019	Blanckaert, Peter/0000-0002-0020-7189			[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; BRITTAIN RT, 1973, BRIT J PHARMACOL, V49, pP158; CHENEY BV, 1985, J MED CHEM, V28, P1853, DOI 10.1021/jm00150a017; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; DESIO JM, 1993, ANESTHESIOLOGY, V79, P1139, DOI 10.1097/00000542-199311000-00036; Gibson A., 2007, 265 NAT DRUG ALC RES; Harper N., 1976, US patent, Patent No. [3,975,443, 3975443]; HAYES AG, 1983, BRIT J PHARMACOL, V79, P731, DOI 10.1111/j.1476-5381.1983.tb10011.x; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Janssen Pharmaceutica, 1998, DUR FENT TRNASD SYST; Katselou M, 2015, FORENSIC TOXICOL, V33, P195, DOI 10.1007/s11419-015-0271-z; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Purucker M, 2000, ANN EMERG MED, V35, P314, DOI 10.1016/S0196-0644(00)70091-6; Skulska A., 2004, PROBLEMS FORENSIC SC, V59, P127; Uchiyama N, 2013, FORENSIC TOXICOL, V31, P223, DOI 10.1007/s11419-013-0182-9; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	17	51	52	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	SEP	2016	266						68	72		10.1016/j.forsciint.2016.05.001			5	Medicine, Legal	Legal Medicine	EA1EF	WOS:000386334600029	27235591	Green Published			2020-06-30	J	Ruan, XL; Chiravuri, S; Kaye, AD				Ruan, Xiulu; Chiravuri, Srinivas; Kaye, Alan D.			Toxicological testing when evaluating fatal cases suspected of acute fentanyl toxicity	FORENSIC SCIENCE MEDICINE AND PATHOLOGY			English	Editorial Material							TRANSDERMAL FENTANYL; FORENSIC TOXICOLOGY; PAIN; MANAGEMENT; PATIENT; PATCHES; DEATHS; ABUSE		[Ruan, Xiulu; Kaye, Alan D.] Louisiana State Univ, Dept Anesthesiol, Hlth Sci Ctr, 1542 Tulane Ave, New Orleans, LA 70112 USA; [Chiravuri, Srinivas] Univ Michigan Hlth Syst, Dept Anesthesiol, Back & Pain Ctr, 325 E Eisenhower Pkwy,Suite 100,SPC 5721, Ann Arbor, MI 48108 USA	Ruan, XL (reprint author), Louisiana State Univ, Dept Anesthesiol, Hlth Sci Ctr, 1542 Tulane Ave, New Orleans, LA 70112 USA.	drxruan88@gmail.com; chiravun@med.umich.edu; alankaye44@hotmail.com					Anlona J, 2001, DRUGS, V61, P2289; Bleeker CP, 2001, EUR J PAIN-LONDON, V5, P325, DOI 10.1053/eujp.2000.0220; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hakkinen M, 2012, EUR J CLIN PHARMACOL, V68, P301, DOI 10.1007/s00228-011-1122-4; He P, 2005, CLIN PHARMACOL THER, V77, P373, DOI 10.1016/j.clpt.2004.11.112; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kharasch ED, 2003, CLIN PHARMACOL THER, V74, P543, DOI 10.1016/j.clpt.2003.08.011; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Moore PW, 2015, J FORENSIC SCI, V60, P243, DOI 10.1111/1556-4029.12559; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Selden T, 2012, FORENSIC SCI INT, V220, P284, DOI 10.1016/j.forsciint.2012.03.016	17	7	7	0	22	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1547-769X	1556-2891		FORENSIC SCI MED PAT	Forensic Sci. Med. Pathol.	SEP	2016	12	3					363	365		10.1007/s12024-016-9789-6			3	Medicine, Legal; Pathology	Legal Medicine; Pathology	DS3ZH	WOS:000380720700017	27383255				2020-06-30	J	Arora, S; Chhabra, A; Subramaniam, R; Arora, MK; Misra, MC; Bansal, VK				Arora, Shubhangi; Chhabra, Anjolie; Subramaniam, Rajeshwari; Arora, Mahesh K.; Misra, Mahesh C.; Bansal, Virender K.			Transversus abdominis plane block for laparoscopic inguinal hernia repair: a randomized trial	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Analgesia; Hernia repair; Laparoscopy; Anesthetics; Local; Transversus abdominis block	ANALGESIC EFFICACY; CESAREAN DELIVERY; ANESTHESIA; SPREAD; PAIN	Background: Pain after laparoscopic inguinal hernia surgery can be moderate to severe, interfering with return to normal activity. The study aimed to assess the efficacy of bilateral ultrasound-guided (USG) transversus abdominis plane (TAP) block for relieving acute pain after laparoscopic hernia repair as T10-L1 nerve endings are anesthetized with this block. Methods: Seventy-one American Society of Anesthesiologists I to II patients, aged 18 to 65 years, undergoing unilateral/bilateral laparoscopic hernia repair were randomized to port site infiltration (control, 36) and TAP block groups (35). All patients received general anesthesia (fentanyl 2 mu g/kg intravenously at induction, 0.5 mu g/kg on 20% increase in heart rate or mean blood pressure) and paracetamol 6 hourly. Postintubation, TAP group received bilateral USG TAP block (15-20 mL 0.5% ropivacaine, maximum 3 mg/kg) with 18-G Tuohy needle. Control group had 20 to 30 mL 0.5% ropivacaine infiltrated preincision, at port sites from skin to peritoneum. Postoperative patient-controlled analgesia fentanyl was provided for 6 hours; pain was assessed using 0 to 100-mm visual analog scale (VAS) at 0, 1, 2, 4, 6, and 24 hours and telephonically at 1 week and 3 months. Results: Demographic profile of the 2 groups was comparable. Significantly more number of patients required intraoperative fentanyl in the control group (24/36) than in the TAP group (13/35); VAS at rest was lower in TAP than control patients in postanesthesia care unit at 0, 2, 6, and 24 hours (median VAS TAP group: 0, 0, 0, and 0; control: 10, 20,10, and 10; P=.002, P=.001, P=.001, and P=.006, respectively); P<.01 was considered statistically significant. TAP group had significantly lower VAS on deep breathing at 6 hours and on knee bending and walking at 24 hours and lesser patient-controlled analgesia fentanyl requirement. No significant difference in pain scores was observed at 1 week and 3 months. Conclusion: TAP block reduced postoperative pain up to 24 hours after laparoscopic hernia repair. (C) 2016 Elsevier Inc. All rights reserved.	[Arora, Shubhangi; Chhabra, Anjolie; Subramaniam, Rajeshwari; Arora, Mahesh K.] All India Inst Med Sci, Dept Anesthesiol, New Delhi, India; [Misra, Mahesh C.; Bansal, Virender K.] All India Inst Med Sci, Dept Surg, New Delhi, India	Chhabra, A (reprint author), House 13,Rd 61,W Punjabi Bagh, New Delhi 110026, India.	anjolie5@hotmail.com		Chhabra, Anjolie/0000-0001-7162-6754			Aveline C, 2011, BRIT J ANAESTH, V106, P380, DOI 10.1093/bja/aeq363; Belavy D, 2009, BRIT J ANAESTH, V103, P726, DOI 10.1093/bja/aep235; Beyls F, 2011, EUR J PAIN S, V5, P507; Carney J, 2011, ANAESTHESIA, V66, P1023, DOI 10.1111/j.1365-2044.2011.06855.x; Carney J, 2008, ANESTH ANALG, V107, P2056, DOI 10.1213/ane.0b013e3181871313; Hon SF, 2009, HERNIA, V13, P53, DOI 10.1007/s10029-008-0422-9; Kanazi GE, 2010, ANESTH ANALG, V111, P475, DOI 10.1213/ANE.0b013e3181e30b9f; Kim MG, 2012, KOREAN J ANESTHESIOL, V63, P227, DOI 10.4097/kjae.2012.63.3.227; Kokulu S, 2014, MED SCI MONITOR, V20, P2783, DOI 10.12659/MSM.892055; Kozol R, 1997, ARCH SURG-CHICAGO, V132, P292; Krishna A, 2012, SURG ENDOSC, V26, P639, DOI 10.1007/s00464-011-1931-7; Kumar S, 2009, HERNIA, V13, P591, DOI 10.1007/s10029-009-0538-6; McDonnell JG, 2008, ANESTH ANALG, V106, P186, DOI 10.1213/01.ane.0000290294.64090.f3; Meyer A, 2015, J VISC SURG, V152, P155, DOI 10.1016/j.jviscsurg.2014.12.005; Mukhtar K, 2010, BRIT J ANAESTH, V104, P663, DOI 10.1093/bja/aeq077; Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016; Niraj G, 2009, BRIT J ANAESTH, V103, P601, DOI 10.1093/bja/aep175; Stebelski L, 2010, EUR J ANAESTH, V27, P139, DOI 10.1097/00003643-201006121-00446; Tolver MA, 2012, ACTA ANAESTH SCAND, V56, P549, DOI 10.1111/j.1399-6576.2011.02633.x; Tong YS, 2014, HERNIA, V18, P177, DOI 10.1007/s10029-013-1100-0; Tran TMN, 2009, BRIT J ANAESTH, V102, P123, DOI 10.1093/bja/aen344; Yarwood J, 2010, BJA EDUC, V10, P182, DOI 10.1093/bjaceaccp/mkq035	22	13	13	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	SEP	2016	33						357	364		10.1016/j.jclinane.2016.04.047			8	Anesthesiology	Anesthesiology	DU7VD	WOS:000382421800070	27555193				2020-06-30	J	Heo, BH; Lee, HJ; Lee, HG; Kim, MY; Park, KS; Choi, JI; Yoon, MH; Kim, WM				Heo, Bong Ha; Lee, Hyeon Jung; Lee, Hyung Gon; Kim, Man Young; Park, Keun Suk; Choi, Jeong Il; Yoon, Myung Ha; Kim, Woong Mo			Femoral nerve block for patient undergoing total knee arthroplasty: Prospective, randomized, double-blinded study evaluating analgesic effect of perineural fentanyl additive to local anesthetics	MEDICINE			English	Article						femoral nerve block; fentanyl; patient-controlled analgesia; total knee arthroplasty; visual analog pain scale	BRACHIAL-PLEXUS BLOCK; EPIDURAL ANALGESIA; POSTOPERATIVE ANALGESIA; IMPROVES ANALGESIA; PAIN; HIP; MANAGEMENT; SEVERITY; INFUSION; MORPHINE	Background:The existence of peripheral opioid receptors and its effectiveness in peripheral nerve block remain controversial. The aim of this prospective, randomized, double-blinded study was to examine the analgesic effects of adding fentanyl to ropivacaine for continuous femoral nerve block (CFNB) using patient-controlled analgesia after total knee arthroplasty (TKA).Methods:The patients were divided into 2 groups, each with n = 40 in ropivacaine (R) group and n = 42 in R with fentanyl (R+F) group. After operation, the patients in each group received R+F and R alone via a femoral nerve catheter, respectively. We assessed the visual analog scale (VAS) pain immediately before administration (baseline) and at 15, 30, and 60 minutes on postanesthesia care unit (PACU), and resting and ambulatory VAS score up to 24 hours.Results:Overall, the average VAS scores in the R+F group were slightly lower than those of the R group. However, the VAS score differences between groups were not statistically significant, except for 30 minutes (P = 0.009) in PACU. R group showed higher supplemental analgesics consumption in average compared with R+F group, but not significant.Conclusion:Additional fentanyl did not show prominent enhancement of analgesic effect in the field of CFNB after TKA.	[Heo, Bong Ha; Lee, Hyeon Jung; Lee, Hyung Gon; Kim, Man Young; Park, Keun Suk; Choi, Jeong Il; Yoon, Myung Ha; Kim, Woong Mo] Chonnam Natl Univ, Sch Med, Dept Anesthesiol & Pain Med, 42 Jebongro, Gwangju 501757, South Korea	Kim, WM (reprint author), Chonnam Natl Univ, Sch Med, Dept Anesthesiol & Pain Med, 42 Jebongro, Gwangju 501757, South Korea.	kimwm@jnu.ac.kr; kimwm@jnu.ac.kr		Park, Keunsuk/0000-0003-0351-6507	Chonnam National University Bitgoeul Hospital [BCRI 15 001-41]	This study was supported by a grant (BCRI 15 001-41) Chonnam National University Bitgoeul Hospital.	Ben-David B, 2003, ANESTH ANALG, V96, P1537, DOI 10.1213/01.ANE.0000063170.15467.F2; Chan EY, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009941.pub2; CHOI PT, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD003071, 10.1002/14651858.cd003071]; Fanelli G, 2001, ACTA ANAESTH SCAND, V45, P590, DOI 10.1034/j.1399-6576.2001.045005590.x; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; Fischer HBJ, 2008, ANAESTHESIA, V63, P1105, DOI 10.1111/j.1365-2044.2008.05565.x; Fowler SJ, 2008, BRIT J ANAESTH, V100, P154, DOI 10.1093/bja/aem373; Ilfeld BM, 2010, ANESTH ANALG, V111, P1552, DOI 10.1213/ANE.0b013e3181fb9507; Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205; Krych Aaron J, 2010, Instr Course Lect, V59, P99; Leffler A, 2012, ANESTHESIOLOGY, V116, P1335, DOI 10.1097/ALN.0b013e3182557917; Magistris L, 2000, EUR J ANAESTH, V17, P348, DOI 10.1046/j.1365-2346.2000.00685.x; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; Mangar D, 2014, J ANESTH, V28, P214, DOI 10.1007/s00540-013-1700-y; Moshourab R, 2012, J NEUROPHYSIOL, V108, P2827, DOI 10.1152/jn.00082.2012; Murphy DB, 2000, ANESTH ANALG, V90, P1122, DOI 10.1097/00000539-200005000-00023; Nishikawa K, 2000, ANESTH ANALG, V91, P384, DOI 10.1097/00000539-200008000-00028; Parvataneni HK, 2007, J ARTHROPLASTY, V22, P33, DOI 10.1016/j.arth.2007.03.034; Parvizi Javad, 2009, Instr Course Lect, V58, P769; Paul JE, 2010, ANESTHESIOLOGY, V113, P1144, DOI 10.1097/ALN.0b013e3181f4b18; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; RAJ PP, 1987, ANESTH ANALG, V66, P401, DOI 10.1213/00000539-198705000-00005; Richman JM, 2006, ANESTH ANALG, V102, P248, DOI 10.1213/01.ANE.0000181289.09675.7D; Seet E, 2006, ANAESTH INTENS CARE, V34, P25, DOI 10.1177/0310057X0603400110; Sinatra Raymond S, 2002, J Am Acad Orthop Surg, V10, P117; Singelyn FJ, 1998, ANESTH ANALG, V87, P88, DOI 10.1097/00000539-199807000-00019; STEIN C, 1993, ANESTH ANALG, V76, P182; Stein C, 2009, CURR OPIN PHARMACOL, V9, P3, DOI 10.1016/j.coph.2008.12.009; Toftdahl K, 2007, ACTA ORTHOP, V78, P172, DOI 10.1080/17453670710013645; WARFIELD CA, 1995, ANESTHESIOLOGY, V83, P1090, DOI 10.1097/00000542-199511000-00023; WISNER DH, 1990, J TRAUMA, V30, P799, DOI 10.1097/00005373-199007000-00006; Wisner DH, 1990, J TRAUMA, V30, P804; Yaksh T L, 1984, Eur J Anaesthesiol, V1, P201	33	7	8	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	SEP	2016	95	36							e4771	10.1097/MD.0000000000004771			5	Medicine, General & Internal	General & Internal Medicine	DX4JE	WOS:000384346200048	27603376	DOAJ Gold, Green Published			2020-06-30	J	Gladden, RM; Martinez, P; Seth, P				Gladden, R. Matthew; Martinez, Pedro; Seth, Puja			Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths-27 States, 2013-2014	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article									[Gladden, R. Matthew; Martinez, Pedro; Seth, Puja] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA	Gladden, RM (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.	mgladden@cdc.gov					[Anonymous], 2016, DEA INT REP; [Anonymous], 2016, DEA INT BRIEF; CDC, 2016, REP LAW ENF ENC TEST; CDC, 2015, CDC HLTH ADV INCR FE; Drug Enforcement Administration, 2015, DEA ISS NAT AL FENT; Hedegaard Holly, 2015, NCHS Data Brief, P1; National Center for Health Statistics, 2014, PERC DRUG POIS DEATH; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; U.S. Department of Health and Human Services, 2015, OP AB US HHS ACT ADD	10	151	150	1	23	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	AUG 26	2016	65	33					837	843		10.15585/mmwr.mm6533a2			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	DU3TO	WOS:000382135300002	27560775	Bronze	Y	N	2020-06-30	J	Peterson, AB; Gladden, RM; Delcher, C; Spies, E; Garcia-Williams, A; Wang, Y; Halpin, J; Zibbell, J; McCarty, CL; DeFiore-Hyrmer, J; DiOrio, M; Goldberger, BA				Peterson, Alexis B.; Gladden, R. Matthew; Delcher, Chris; Spies, Erica; Garcia-Williams, Amanda; Wang, Yanning; Halpin, John; Zibbell, Jon; McCarty, Carolyn Lullo; DeFiore-Hyrmer, Jolene; DiOrio, Mary; Goldberger, Bruce A.			Increases in Fentanyl-Related Overdose Deaths - Florida and Ohio, 2013-2015	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article							UNITED-STATES; PAIN		[Peterson, Alexis B.; Spies, Erica; Garcia-Williams, Amanda; McCarty, Carolyn Lullo] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA; [Peterson, Alexis B.; Gladden, R. Matthew; Halpin, John; Zibbell, Jon] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA; [Peterson, Alexis B.] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA; [Delcher, Chris; Wang, Yanning] Univ Florida, Coll Med, Dept Hlth Outcomes & Policy, Gainesville, FL USA; [Spies, Erica; Garcia-Williams, Amanda] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA; [Wang, Yanning; Goldberger, Bruce A.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; [McCarty, Carolyn Lullo] CDC, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA; [McCarty, Carolyn Lullo; DeFiore-Hyrmer, Jolene; DiOrio, Mary] Ohio Dept Hlth, Columbus, OH 43266 USA	Peterson, AB (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Peterson, AB; Gladden, RM (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.; Peterson, AB (reprint author), CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.	mgladden@cdc.gov					CDC, 2015, CDC HLTH ADV INCR FE; Drug Enforcement Administration, 2015, DEA ISS NAT AL FENT; Drug Enforcement Administration, 2016, DEA INT REP NAT HER; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Harruff RC, 2015, ACAD FORENSIC PATHOL, V5, P499; Hawk Kathryn F., 2015, Yale Journal of Biology and Medicine, V88, P235; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034	10	93	93	0	28	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	AUG 26	2016	65	33					844	849		10.15585/mmwr.mm6533a3			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	DU3TO	WOS:000382135300003	27560948	Bronze	Y	N	2020-06-30	J	Maguire, DR; France, CP				Maguire, David R.; France, Charles P.			Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Opioid; Cannabinoid; Drug-drug interactions; Drug discrimination; Monkeys	CHRONIC NONCANCER PAIN; DRUG DISCRIMINATION; POSTOPERATIVE PAIN; INTRINSIC EFFICACY; STIMULUS-INTENSITY; ANALGESIC EFFICACY; UNITED-STATES; DELTA(9)-TETRAHYDROCANNABINOL; MORPHINE; COMBINATION	Cannabinoid receptor agonists such as delta-9-tetrahydrocannabinol (Delta(9)-THC) enhance some (antinociceptive) but not other (positive reinforcing) effects of mu opioid receptor agonists, suggesting that cannabinoids might be combined with opioids to treat pain without increasing, and possibly decreasing, abuse. The degree to which cannabinoids enhance antinociceptive effects of opioids varies across drugs insofar as Delta(9)-THC and the synthetic cannabinoid receptor agonist CP55940 increase the potency of some mu opioid receptor agonists (e.g., fentanyl) more than others (e.g., nalbuphine). It is not known whether interactions between cannabinoids and opioids vary similarly for other (abuse-related) effects. This study examined whether Delta(9)-THC and CP55940 differentially impact the discriminative stimulus effects of fentanyl and nalbuphine in monkeys (n=4) discriminating 0.01 mg/kg of fentanyl (s.c.) from saline. Fentanyl (0.00178-0.0178 mg/kg) and nalbuphine (0.01-0.32 mg/kg) dose-dependently increased drug lever responding. Neither Delta(9)-THC (0.032-1.0 mg/kg) nor CP55940 (0.0032-0.032 mg/kg) enhanced the discriminative stimulus effects of fentanyl or nalbuphine; however, doses of Delta(9)-THC and CP55940 that shifted the nalbuphine dose-effect curve markedly to the right and/or down were less effective or ineffective in shifting the fentanyl dose-effect curve. The mu opioid receptor antagonist naltrexone (0.032 mg/kg) attenuated the discriminative stimulus effects of fentanyl and nalbuphine similarly. These data indicate that the discriminative stimulus effects of nalbuphine are more sensitive to attenuation by cannabinoids than those of fentanyl. That the discriminative stimulus effects of some opioids are more susceptible to modification by drugs from other classes has implications for developing maximally effective therapeutic drug mixtures with reduced abuse liability. (C) 2016 Elsevier B.V. All rights reserved.	[Maguire, David R.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA; [France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA	France, CP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA.	france@uthscsa.edu	Maguire, David/U-9058-2019	Maguire, David/0000-0002-0958-5397	National Institutes of Health National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA005018, F32DA035605, T32DA031115, K05DA17918]	The authors thank Marlisa Burton, Nicole Garcia, Hillary Halderman, and Jeff Pressley, for excellent technical assistance. This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grants R01DA005018, F32DA035605, T32DA031115, K05DA17918]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Institute on Drug Abuse. Portions of these data were presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics in 2014, and an abstract has been archived in the FASEB journal (Maguire and France, 2014, Volume 28, Issue 1 Supplement, Page 658.4).	Atluri S, 2014, PAIN PHYSICIAN, V17, pE119; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Bowen CA, 2002, J PHARMACOL EXP THER, V302, P264, DOI 10.1124/jpet.302.1.264; Bushlin I, 2010, CURR OPIN PHARMACOL, V10, P80, DOI 10.1016/j.coph.2009.09.009; Canals M, 2008, J BIOL CHEM, V283, P11424, DOI 10.1074/jbc.M710300200; Cichewicz DL, 1999, J PHARMACOL EXP THER, V289, P859; Cichewicz DL, 2004, LIFE SCI, V74, P1317, DOI 10.1016/j.lfs.2003.09.038; Cox ML, 2007, EUR J PHARMACOL, V567, P125, DOI 10.1016/j.ejphar.2007.04.010; Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009; GAUVIN DV, 1989, PSYCHOPHARMACOLOGY, V98, P212, DOI 10.1007/BF00444694; GERAK LR, 1994, J PHARMACOL EXP THER, V271, P993; Gerak LR, 1996, J PHARMACOL EXP THER, V276, P523; Gilron I, 2013, LANCET NEUROL, V12, P1084, DOI 10.1016/S1474-4422(13)70193-5; Hosking RD, 2008, BRIT J ANAESTH, V101, P59, DOI 10.1093/bja/aen119; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Kraft B, 2012, PHARMACOLOGY, V89, P237, DOI 10.1159/000337376; Li JX, 2008, PSYCHOPHARMACOLOGY, V199, P199, DOI 10.1007/s00213-008-1157-0; Li JX, 2012, BEHAV PHARMACOL, V23, P754, DOI 10.1097/FBP.0b013e32835a3907; Li JX, 2011, NEUROPSYCHOPHARMACOL, V36, P940, DOI 10.1038/npp.2010.232; Lile JA, 2009, PSYCHOPHARMACOLOGY, V203, P241, DOI 10.1007/s00213-008-1393-3; Lynch ME, 2011, BRIT J CLIN PHARMACO, V72, P735, DOI 10.1111/j.1365-2125.2011.03970.x; Maguire DR, 2016, BEHAV PHARMACOL, V27, P249, DOI 10.1097/FBP.0000000000000192; Maguire DR, 2014, J PHARMACOL EXP THER, V351, P383, DOI 10.1124/jpet.114.216648; Maguire DR, 2013, J PHARMACOL EXP THER, V345, P354, DOI 10.1124/jpet.113.204099; McMahon LR, 2006, J PHARMACOL EXP THER, V319, P1211, DOI 10.1124/jpet.106.107110; Morgan D, 1998, PSYCHOPHARMACOLOGY, V140, P20, DOI 10.1007/s002130050734; Morgan D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035; Narang S, 2008, J PAIN, V9, P254, DOI 10.1016/j.jpain.2007.10.018; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; PICKER MJ, 1993, J PHARMACOL EXP THER, V266, P756; PICKER MJ, 1989, J PHARMACOL EXP THER, V249, P557; PRESTON KL, 1991, BEHAV PHARMACOL, V2, P293; Raffa RB, 2010, DRUG TODAY, V46, P379, DOI 10.1358/dot.2010.46.6.1470106; Raffa RB, 2001, J CLIN PHARM THER, V26, P257, DOI 10.1046/j.1365-2710.2001.00355.x; Rios C, 2006, BRIT J PHARMACOL, V148, P387, DOI 10.1038/sj.bjp.0706757; SAEKI S, 1993, ANESTH ANALG, V77, P265, DOI 10.1213/00000539-199377020-00010; Sunshine A, 1997, J CLIN PHARMACOL, V37, P908, DOI 10.1002/j.1552-4604.1997.tb04265.x; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Vigano D, 2005, PHARMACOL BIOCHEM BE, V81, P360, DOI 10.1016/j.pbb.2005.01.021; WALKER EA, 1993, J PHARMACOL EXP THER, V267, P322; Welch SP, 2009, INT REV PSYCHIATR, V21, P143, DOI 10.1080/09540260902782794; Wideman GL, 1999, CLIN PHARMACOL THER, V65, P66, DOI 10.1016/S0009-9236(99)70123-2; WILEY JL, 1995, DRUG ALCOHOL DEPEN, V40, P81, DOI 10.1016/0376-8716(95)01193-5; Zhang LG, 2000, PSYCHOPHARMACOLOGY, V148, P136, DOI 10.1007/s002130050035	47	12	12	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	AUG 5	2016	784						199	206		10.1016/j.ejphar.2016.05.018			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DR1GI	WOS:000379653600022	27184925	Green Accepted			2020-06-30	J	Chun, EH; Han, MJ; Baik, HJ; Park, HS; Chung, RK; Han, JI; Lee, HJ; Kim, JH				Chun, Eun Hee; Han, Myeong Jae; Baik, Hee Jung; Park, Hahck Soo; Chung, Rack Kyung; Han, Jong In; Lee, Hun Jung; Kim, Jong Hak			Dexmedetomidine-ketamine versus Dexmedetomidine-midazolam-fentanyl for monitored anesthesia care during chemoport insertion: a Prospective Randomized Study	BMC ANESTHESIOLOGY			English	Article						Dexmedetomidine; Fentanyl; Ketamine; Midazolam; Monitored anesthesia care	INCREASING PLASMA-CONCENTRATIONS; CONSCIOUS SEDATION; PROPOFOL; HUMANS; COMBINATIONS; COLONOSCOPY	Background: Dexmedetomidine as a sole agent showed limited use for painful procedures due to its insufficient sedative/analgesic effect, pronounced hemodynamic instability and prolonged recovery. The aim of this study was to compare the effects of dexmedetomidine-ketamine (DK) versus dexmedetomidine-midazolam-fentanyl (DMF) combination on the quality of sedation/analgesia and recovery profiles for monitored anesthesia care (MAC). Methods: Fifty six patients undergoing chemoport insertion were randomly assigned to group DK or DMF. All patients received 1 mu g. kg(-1) dexmedetomidine over 10 min followed by 0.2-1.0 mu g. kg(-1)h(-1) in order to maintain 3 or 4 of modified Observer's Assessment of Analgesia and Sedation score checked every 3 min. At the start of dexmedetomidine infusion, patients in group DK or DMF received 0.5 mg. kg(-1) ketamine or 0.05 mg.kg(-1) midazolam+ 0.5 mu g. kg(-1) fentanyl intravenously, respectively. When required, rescue sedatives (0.5 mg. kg(-1) of ketamine or 0.05 mg. kg(-1) of midazolam) and analgesics (0.5 mg. kg(-1) of ketamine or 0.5 mu g. kg(-1) of fentanyl) were given to the patients in DK or DMF group, respectively. The primary outcome of this study was the recovery parameters (time to spontaneous eye opening and the length of the recovery room stay). The secondary outcomes were parameters indicating quality of sedation/analgesia, cardiorespiratory variables, and satisfaction scores. Results: There were no significant differences in the onset time, time to spontaneous eye opening, recovery room stay, the incidences of inadequate analgesia, hypotension and bradycardia between the two groups. Despite lower infusion rate of dexmedetomidine, more patients in the DMF group had bispectral index (BIS) < 60 than in the DK group and vice versa for need of rescue sedatives. The satisfaction scores of patients, surgeon, and anesthesiologist in the DMF group were significantly better than the DK group. Conclusions: The DK and DMF groups showed comparable recovery time, onset time, cardiorespiratory variables, and analgesia. However, the DMF group showed a better sedation quality and satisfaction scores despite the lower infusion rate of dexmedetomidine, and a higher incidence of BIS < 60 than the DK group.	[Chun, Eun Hee; Baik, Hee Jung; Park, Hahck Soo; Chung, Rack Kyung; Han, Jong In; Lee, Hun Jung; Kim, Jong Hak] Ewha Womans Univ, Sch Med, Dept Anesthesiol & Pain Med, 1071 Anyangcheon Ro, Seoul 07985, South Korea; [Han, Myeong Jae] CHA Univ, CHA Gumi Med Ctr, Dept Anesthesiol & Pain Med, Gumi, South Korea	Baik, HJ (reprint author), Ewha Womans Univ, Sch Med, Dept Anesthesiol & Pain Med, 1071 Anyangcheon Ro, Seoul 07985, South Korea.	baikhj@ewha.ac.kr					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Angst MS, 2004, ANESTHESIOLOGY, V101, P744, DOI 10.1097/00000542-200409000-00024; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Buck Marcia L, 2010, J Pediatr Pharmacol Ther, V15, P17; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Dere K, 2010, EUR J ANAESTH, V27, P648, DOI 10.1097/EJA.0b013e3283347bfe; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Hans P, 2005, BRIT J ANAESTH, V94, P336, DOI 10.1093/bja/aei047; Jalowiecki P, 2005, ANESTHESIOLOGY, V103, P269, DOI 10.1097/00000542-200508000-00009; Kaygusuz K, 2008, ANESTH ANALG, V106, P114, DOI 10.1213/01.ane.0000296453.75494.64; Koroglu A, 2006, ANESTH ANALG, V103, P63, DOI 10.1213/01.ane.0000219592.82598.AA; Koruk S, 2010, J ANESTH, V24, P858, DOI 10.1007/s00540-010-1023-1; Kose EA, 2012, UROLOGY, V79, P1214, DOI 10.1016/j.urology.2012.02.040; Mahmoud M, 2015, BRIT J ANAESTH, V115, P171, DOI 10.1093/bja/aev226; Miller AC, 2011, MINERVA ANESTESIOL, V77, P812; Na HS, 2011, KOREAN J ANESTHESIOL, V61, P453, DOI 10.4097/kjae.2011.61.6.453; Pal D, 2015, BRIT J ANAESTH, V114, P979, DOI 10.1093/bja/aev095; Scher CS, 2003, CAN J ANAESTH, V50, P607, DOI 10.1007/BF03018650; Tobias JD, 2012, PEDIATR CRIT CARE ME, V13, P423, DOI 10.1097/PCC.0b013e318238b81c; Tosun Z, 2006, J CARDIOTHOR VASC AN, V20, P515, DOI 10.1053/j.jvca.2005.07.018	22	5	5	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	AUG 2	2016	16								49	10.1186/s12871-016-0211-4			9	Anesthesiology	Anesthesiology	DT6DL	WOS:000381573300002	27484227	DOAJ Gold, Green Published			2020-06-30	J	Mehta, S; Meade, M; Burry, L; Mallick, R; Katsios, C; Fergusson, D; Dodek, P; Burns, K; Herridge, M; Devlin, JW; Tanios, M; Fowler, R; Jacka, M; Skrobik, Y; Olafson, K; Cook, D				Mehta, Sangeeta; Meade, Maureen; Burry, Lisa; Mallick, Ranjeeta; Katsios, Christina; Fergusson, Dean; Dodek, Peter; Burns, Karen; Herridge, Margaret; Devlin, John W.; Tanios, Maged; Fowler, Robert; Jacka, Michael; Skrobik, Yoanna; Olafson, Kendiss; Cook, Deborah		SLEAP Investigators; Canadian Critical Care Trials Grp	Variation in diurnal sedation in mechanically ventilated patients who are managed with a sedation protocol alone or a sedation protocol and daily interruption	CRITICAL CARE			English	Article						Sedation; Opioids; Mechanical ventilation; Protocols; Weaning; Diurnal rhythm; Intensive care unit	CRITICALLY-ILL PATIENTS; RANDOMIZED CONTROLLED-TRIAL; INTENSIVE-CARE-UNIT; LONG-TERM MORTALITY; DELIRIUM	Background: Mechanically ventilated patients may receive more sedation during the night than during the day, potentially delaying extubation. We compared nighttime and daytime benzodiazepine and opioid administration in adult patients enrolled in a multicenter sedation trial comparing protocolized sedation alone or protocolized sedation combined with daily sedation interruption; and we evaluated whether nighttime and daytime doses were associated with liberation from mechanical ventilation. Methods: This is a secondary analysis of a randomized trial which was conducted in 16 North American medical-surgical ICUs. In all 423 patients, nurses applied a validated sedation scale hourly to titrate benzodiazepine and opioid infusions to achieve a light level of sedation. Using fentanyl equivalents and midazolam equivalents, we compared dosages administered during night (19: 00 to 07: 00) and day (07: 00 to 19: 00) shifts. Using multivariable logistic regression we evaluated the association between nighttime and daytime opioid and sedative doses, and spontaneous breathing trial (SBT) conduct, SBT success, and extubation. Results: Nighttime benzodiazepine and opioid doses were significantly higher than daytime doses (mean difference midazolam equivalents 23.3 mg, 95 % CI 12.9, 33.8, p < 0.0001; mean difference fentanyl equivalents 356 mcg, 95 % CI 130, 582, p = 0.0021). Mean Sedation Agitation Scale score was similar between night and day, and was at target (3.2 vs 3.3, 95 % CI -0.05, 0.02, p = 0.35). Self-reported nurse workload was similar during the night and day. Patients were more often restrained during day shifts (76.3 % vs 73.7 %, p < 0.0001), and there were more unintentional device removals during the day compared with night (15.9 % vs 9.1 %, p < 0.0001). Increases in nighttime drug doses were independently associated with failure to meet SBT screening criteria, SBT failure, and the decision not to extubate the patient despite successful SBT. Conclusion: Patients received higher doses of opioids and benzodiazepines at night. Higher nighttime doses were associated with SBT failure and delayed extubation.	[Mehta, Sangeeta] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Mehta, Sangeeta] Mt Sinai Hosp, Interdepartmental Div Crit Care Med, Toronto, ON M5G 1X5, Canada; [Mehta, Sangeeta; Burry, Lisa] Univ Toronto, Toronto, ON, Canada; [Meade, Maureen] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Meade, Maureen] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Burry, Lisa] Mt Sinai Hosp, Dept Pharm & Med, Toronto, ON, Canada; [Mallick, Ranjeeta; Fergusson, Dean] Univ Ottawa, Clin Epidemiol Program, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Mallick, Ranjeeta; Fergusson, Dean] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Katsios, Christina; Burns, Karen] Univ Toronto, Interdepartmental Div Crit Care Med, Toronto, ON, Canada; [Dodek, Peter] St Pauls Hosp, Div Crit Care Med, Vancouver, BC, Canada; [Dodek, Peter] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada; [Dodek, Peter] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Burns, Karen] St Michaels Hosp, Dept Crit Care, Toronto, ON, Canada; [Burns, Karen] Li Ka Shing Inst, Toronto, ON, Canada; [Herridge, Margaret] Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Herridge, Margaret] Univ Hlth Network, Interdepartmental Div Crit Care Med, Toronto, ON, Canada; [Herridge, Margaret] Univ Toronto, Toronto, ON, Canada; [Devlin, John W.] Northeastern Univ, Sch Pharm, Boston, MA 02115 USA; [Tanios, Maged] Long Beach Mem Med Ctr, Dept Med, Long Beach, CA 90806 USA; [Fowler, Robert] Sunnybrook Hlth Sci Ctr, Dept Med & Crit Care Med, Toronto, ON, Canada; [Jacka, Michael] Univ Alberta Hosp, Dept Anesthesiol, Edmonton, AB, Canada; [Skrobik, Yoanna] Hop Royal Victoria, Dept Med, Montreal, PQ, Canada; [Olafson, Kendiss] Univ Manitoba, Dept Med, Sect Crit Care, Winnipeg, MB, Canada; [Cook, Deborah] McMaster Univ, St Josephs Healthcare, Dept Med, Hamilton, ON, Canada; [Cook, Deborah] McMaster Univ, St Josephs Healthcare, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Mehta, Sangeeta] Mt Sinai Hosp, Suite 18-216,600 Univ Ave, Toronto, ON M5G 1X5, Canada	Mehta, S (reprint author), Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada.; Mehta, S (reprint author), Mt Sinai Hosp, Interdepartmental Div Crit Care Med, Toronto, ON M5G 1X5, Canada.; Mehta, S (reprint author), Univ Toronto, Toronto, ON, Canada.	Geeta.mehta@utoronto.ca	Skrobik, Yoanna/K-8165-2014; Burry, Lisa D/C-6546-2017; Mehta, Sangeeta/C-4623-2015; Skrobik, Yoanna/J-6393-2013	Skrobik, Yoanna/0000-0002-5315-6020; Burry, Lisa D/0000-0002-6545-3890; Fergusson, Dean/0000-0002-3389-2485; Herridge, Margaret/0000-0002-2903-1631	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Mount Sinai Hospital Department of Medicine	This research was supported, in part by the Canadian Institutes of Health Research, and the Mount Sinai Hospital Department of Medicine.	Burry L, 2014, COCHRANE DB SYST REV, V7; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872; Pisani MA, 2013, AM J CRIT CARE, V22, pE62, DOI 10.4037/ajcc2013835; Rose L, 2015, J CRIT CARE, V30, P348, DOI 10.1016/j.jcrc.2014.10.021; Seymour CW, 2012, CRIT CARE MED, V40, P2788, DOI 10.1097/CCM.0b013e31825b8ade; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Trompeo AC, 2011, MINERVA ANESTESIOL, V77, P604; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D	11	4	4	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	AUG 1	2016	20								233	10.1186/s13054-016-1405-3			7	Critical Care Medicine	General & Internal Medicine	DT6RE	WOS:000381610900002	27480314	DOAJ Gold, Green Published			2020-06-30	J	Hsu, CH; Hsu, YC; Huang, GS; Lu, CC; Ho, ST; Liaw, WJ; Tsai, YT; Lin, CY; Tsai, CS; Lin, TC				Hsu, Che-Hao; Hsu, Yung-Chi; Huang, Go-Shine; Lu, Chih-Cherng; Ho, Shung-Tai; Liaw, Wen-Jinn; Tsai, Yi-Ting; Lin, Chih-Yuan; Tsai, Chien-Sung; Lin, Tso-Chou			Isoflurane compared with fentanyl-midazolam-based anesthesia in patients undergoing heart transplantation: A retrospective cohort study	MEDICINE			English	Article						fentanyl; heart transplantation; inhalation anesthetic; isoflurane	CARDIAC-SURGERY; MYOCARDIAL PROTECTION; VOLATILE ANESTHETICS; CARDIOPROTECTION; HYPERLACTATEMIA; METAANALYSIS; SURVIVAL	Inhalation anesthetics provide myocardial protection for cardiac surgery. This study was undertaken to compare the perioperative effects between isoflurane and fentanyl-midazolam-based anesthesia for heart transplantation. A retrospective cohort study was conducted by reviewing the medical records of heart transplantation in a single medical center from 1990 to 2013. Patients receiving isoflurane or fentanyl-midazolam-based anesthesia were included. Those with preoperative severe pulmonary, hepatic, or renal comorbidities were excluded. The perioperative variables and postoperative short-term outcomes were analyzed, including blood glucose levels, urine output, inotropic use, time to extubation, and length of stay in the intensive care units. After reviewing 112 heart transplantations, 18 recipients with fentanyl-midazolam-based anesthesia, and 29 receiving isoflurane anesthesia with minimal low-flow technique were analyzed. After cessation of cardiopulmonary bypass, recipients with isoflurane anesthesia had a significantly lower mean level and a less increase of blood glucose, as compared with those receiving fentanyl-based anesthesia. In addition, there was less use of dobutamine upon arriving the intensive care unit and a shorter time to extubation after isoflurane anesthesia. Compared with fentanyl-midazolam-based anesthesia, isoflurane minimal low-flow anesthesia maintained better perioperative homeostasis of blood glucose levels, less postoperative use of inotropics, and early extubation time among heart-transplant recipients without severe comorbidities.	[Hsu, Che-Hao; Liaw, Wen-Jinn] Tungs Taichung MetroHarbor Hosp, Dept Anesthesiol, Taichung, Taiwan; [Hsu, Yung-Chi; Huang, Go-Shine; Liaw, Wen-Jinn; Lin, Tso-Chou] Triserv Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Lu, Chih-Cherng; Ho, Shung-Tai] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Tsai, Yi-Ting; Lin, Chih-Yuan; Tsai, Chien-Sung] Triserv Gen Hosp, Dept Surg, Natl Def Med Ctr, Div Cardiovasc Surg, Taipei, Taiwan; [Tsai, Chien-Sung] Taoyuan Armed Forces Gen Hosp, Dept Surg, Div Cardiovasc Surg, Taoyuan, Taiwan	Lin, TC (reprint author), Triserv Gen Hosp, Dept Anesthesiol, Natl Def Med Ctr, 325 Chen Gong Rd,Sec 2, Taipei 114, Taiwan.	tclin@ndmctsgh.edu.tw			Tri-Service General Hospital [TSGH-C103-184, TSGH-C105-100]	This work was funded by grants from Tri-Service General Hospital (TSGH-C103-184 and TSGH-C105-100).	BELL J, 1994, BRIT J ANAESTH, V73, P162, DOI 10.1093/bja/73.2.162; Bignami E, 2013, J CARDIOTHOR VASC AN, V27, P50, DOI 10.1053/j.jvca.2012.06.007; BUFFINGTON CW, 1987, ANESTHESIOLOGY, V66, P280, DOI 10.1097/00000542-198703000-00004; DEMAS K, 1986, BRIT J ANAESTH, V58, P1357, DOI 10.1093/bja/58.12.1357; Glance LG, 2015, ANESTH ANALG, V120, P526, DOI 10.1213/ANE.0000000000000522; GLASS PSA, 1995, J CARDIOTHOR VASC AN, V9, P16; Handy J, 2007, CRIT CARE, V11, DOI 10.1186/cc5137; Hausenloy DJ, 2012, CARDIOVASC RES, V94, P253, DOI 10.1093/cvr/cvs131; HILGENBERG JC, 1981, ANESTHESIOLOGY, V54, P341, DOI 10.1097/00000542-198104000-00018; Hsu YC, 2015, TRANSPL P, V47, P1945, DOI 10.1016/j.transproceed.2015.02.027; Kato R, 2002, CAN J ANAESTH, V49, P777, DOI 10.1007/BF03017409; Landoni G, 2014, BRIT J ANAESTH, V113, P955, DOI 10.1093/bja/aeu290; Landoni G, 2013, BRIT J ANAESTH, V111, P886, DOI 10.1093/bja/aet231; Lu CC, 2008, PHARMACOLOGY, V81, P344, DOI 10.1159/000122960; Lu Chih-Cherng, 2003, Acta Anaesthesiol Sin, V41, P165; Pagel PS, 2013, J CARDIOTHOR VASC AN, V27, P972, DOI 10.1053/j.jvca.2012.10.011; PHILBIN DM, 1990, ANESTHESIOLOGY, V73, P5, DOI 10.1097/00000542-199007000-00002; Ramakrishna H, 2015, CURR CLIN PHARMACOL, V10, P3, DOI 10.2174/1574884709666140212104958; Tanaka K, 2004, ANESTHESIOLOGY, V100, P707, DOI 10.1097/00000542-200403000-00035; Van Allen NR, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-22	20	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	AUG	2016	95	35							e4699	10.1097/MD.0000000000004699			4	Medicine, General & Internal	General & Internal Medicine	DX0HC	WOS:000384041400060	27583900	DOAJ Gold, Green Published			2020-06-30	J	Onaka, H; Ishikawa, M; Mizuguchi, Y; Uchida, E; Sakamoto, A				Onaka, Hiroe; Ishikawa, Masashi; Mizuguchi, Yoshiaki; Uchida, Eiji; Sakamoto, Atsuhiro			Evaluation of Postoperative Pain Control and Quality of Recovery in Patients Using Intravenous Patient-Controlled Analgesia with Fentanyl: A Prospective Randomized Study	JOURNAL OF NIPPON MEDICAL SCHOOL			English	Article						40-item quality of recovery score; fentanyl; laparoscopic surgery; patient-controlled analgesia; postoperative pain	LAPAROSCOPIC CHOLECYSTECTOMY; ANESTHESIA; SURGERY	Aim: Opioids are increasingly used to control postoperative pain via intravenous patient-controlled analgesia, with several advantages. The present study evaluated the effects of intravenous patient controlled analgesia with different doses of fentanyl on postoperative pain and on the quality of physical/emotional recovery from surgery and anesthesia. Methods: We retrospectively reviewed data from 288 patients, and evaluated whether intravenous patient-controlled analgesia with fentanyl correlated with the degree of postoperative pain. We then prospectively studied 47 patients who underwent elective laparoscopic cholecystectomy. The patients were randomized into 2 groups (15 or 30 mu g/mL of fentanyl), and postoperative pain control was compared using a visual analog scale score. Furthermore, the Japanese 40-item quality of recovery (QoR-40J) score (global and dimensional) and Hospital Anxiety and Depression Scale (FADS) were used to assess the quality of recovery from surgery and anesthesia. Results: Of 288 patients, 20% complained of intolerable pain and 18% experienced postoperative nausea and vomiting. In the prospective study, the visual analog scale pain score was lower in the Fentanyl 30 group than in the Fentanyl 15 group (p<0.05) on postoperative day 1. Dimensional QoR-40J pain subscales correlated with both the emotional state subscales (postoperative day 1, p<0.05; day 2, p<0.05) and global QoR-40 scores on both postoperative days (day 1, p<0.05; day 2, p<0.05). Conclusion: The postoperative pain as well as the physical and emotional quality of recovery in the patients who underwent laparoscopic cholecystectomy could be alleviated by sufficient doses of opioids.	[Onaka, Hiroe; Ishikawa, Masashi; Sakamoto, Atsuhiro] Nippon Med Sch, Grad Sch Med, Dept Anesthesiol & Pain Med, Tokyo, Japan; [Mizuguchi, Yoshiaki; Uchida, Eiji] Nippon Med Sch, Dept Gastrointestinal & Hepatobiliary Pancreat Su, Tokyo, Japan	Onaka, H (reprint author), Nippon Med Sch, Grad Sch Med, Dept Anesthesiol & Pain Med, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	honaka@nms.ac.jp					Abdulla S, 2012, ACTA ANAESTH BELG, V63, P43; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Boddy AP, 2006, ANESTH ANALG, V103, P682, DOI 10.1213/01.ane.0000226268.06279.5a; Brandsborg B, 2012, DAN MED J, V59; Ekstein P, 2006, ANN SURG, V243, P41, DOI 10.1097/01.sla.0000193806.81428.6f; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; Hernandez-Palazon J, 2003, EUR J ANAESTH, V20, P891, DOI 10.1097/00003643-200311000-00006; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Johnson A, 1997, LANCET, V349, P631, DOI 10.1016/S0140-6736(96)10032-5; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kim WH, 2011, J ANESTH, V25, P685, DOI 10.1007/s00540-011-1208-2; Lebovits AH, 2001, PAIN MED, V2, P280, DOI 10.1046/j.1526-4637.2001.01051.x; Madsen M R, 1992, Surg Laparosc Endosc, V2, P303; Mouton WG, 1999, SURG ENDOSC, V13, P445, DOI 10.1007/s004649901011; Murphy GS, 2011, ANESTHESIOLOGY, V114, P882, DOI 10.1097/ALN.0b013e3181ec642e; Pavlin JD, 2008, CURR OPIN ANESTHESIO, V21, P729, DOI 10.1097/ACO.0b013e328316bb02; Tanaka Y, 2011, J ANESTH, V25, P509, DOI 10.1007/s00540-011-1151-2; WIESEL S, 1995, CAN J ANAESTH, V42, P37, DOI 10.1007/BF03010569; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	19	3	3	0	2	MEDICAL ASSOC NIPPON MEDICAL SCH	TOKYO	1-1-5, SENDAGI, TOKYO, 113-8602, JAPAN	1345-4676	1347-3409		J NIPPON MED SCH	J. Nippon Med. Sch.	AUG	2016	83	4					158	166		10.1272/jnms.83.158			9	Medicine, General & Internal	General & Internal Medicine	DX0EE	WOS:000384033800004	27680484	Bronze			2020-06-30	J	Park, KB; Ann, J; Lee, H				Park, Ki-Bum; Ann, Junggun; Lee, Haemi			Effects of different dosages of oxycodone and fentanyl on the hemodynamic changes during intubation	SAUDI MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; TRACHEAL INTUBATION; INTRAVENOUS MORPHINE; RESPONSES; ATTENUATION; ESMOLOL; AGONIST; PAIN	Objectives: To investigate the effectiveness of oxycodone compared with fentanyl for attenuating the hemodynamic response during endotracheal intubation. Methods: This study was conducted from June 2014 to February 2015 on healthy adults undergoing general anesthesia at the Yeungnam University Hospital, Daegu, Republic of Korea. Ninety-five patients were randomly assigned to one of 3 groups to receive the following drugs; Group F: fentanyl 2 mu g/kg; Group O/70: oxycodone 140 mu g/kg; Group O/100: oxycodone 200 mu g/kg. Five minutes after injection of the study drug, general anesthesia was induced with propofol 1.5 mg/kg and rocuronium 0.8 mg/kg. The mean blood pressure (MBP), heart rate (HR), peripheral oxygen saturation (SpO(2)), and bispectral index (BIS) were compared before administration of the study drug (T1), just before endotracheal intubation (T2), one minute after endotracheal intubation (T3), and 7.5 minutes after endotracheal intubation (T4). Complications were assessed. Results: The 2 oxycodone groups showed no significant differences in MBP, HR, SpO(2), and BIS compared to Group F at the time points assessed. The incidence of complications was comparable among the groups. Conclusions: Oxycodone could successfully be used to attenuate the sympathetic response during anesthetic induction. The hemodynamic profiles and incidence of complications were clinically similar among the groups, but Group O/70 tended to show a lower rate of complications of apnea.	[Park, Ki-Bum] Keimyung Univ, Dongsan Hosp, Sch Med, Dept Anesthesiol & Pain Med, Daegu, South Korea; [Ann, Junggun; Lee, Haemi] Yeungnam Univ, Coll Med, Dept Anesthesiol & Pain Med, Daegu, South Korea	Lee, H (reprint author), Yeungnam Univ, Coll Med, Dept Anesthesiol & Pain Med, Daegu, South Korea.	hmlee@yu.ac.kr					Cakirgoz MY, 2014, REV BRAS ANESTESIOL, V64, P425, DOI [10.1016/j.bjan.2013.09.008, 10.1016/j.bjane.2013.09.009]; Channaiah Vijayalakshmi B, 2014, Med Arch, V68, P339, DOI 10.5455/medarh.2014.68.339-344; Gogus N, 2014, REV BRAS ANESTESIOL, V64, P314, DOI [10.1016/j.bjan.2013.10.010, 10.1016/j.bjane.2013.10.012, 10.1016//j.bjane.2013.10.012]; KALSO E, 1991, ACTA ANAESTH SCAND, V35, P642, DOI 10.1111/j.1399-6576.1991.tb03364.x; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; Lee JH, 2012, KOREAN J ANESTHESIOL, V63, P124, DOI 10.4097/kjae.2012.63.2.124; Lenz H, 2009, ANESTH ANALG, V109, P1279, DOI 10.1213/ane.0b013e3181b0f0bb; Mencke T, 2003, ANESTHESIOLOGY, V98, P1049, DOI 10.1097/00000542-200305000-00005; Panda NB, 2013, J CLIN ANESTH, V25, P92, DOI 10.1016/j.jclinane.2012.06.016; Parida S, 2015, INDIAN J ANAESTH, V59, P306, DOI 10.4103/0019-5049.156885; POYHIA R, 1992, CURR THER RES CLIN E, V51, P739; Prieto-Lastra L, 2006, Allergol Immunopathol (Madr), V34, P224, DOI 10.1157/13094030; PUGSLEY MK, 1992, BRIT J PHARMACOL, V105, P521, DOI 10.1111/j.1476-5381.1992.tb09012.x; Qi DY, 2013, MINERVA ANESTESIOL, V79, P1423; Rao SP, 2003, PEPTIDES, V24, P745, DOI 10.1016/S0196-9781(03)00122-0; Ross FB, 1997, PAIN, V73, P151, DOI 10.1016/S0304-3959(97)00093-6; Ryu JH, 2012, CLIN THER, V34, P593, DOI 10.1016/j.clinthera.2012.01.017; Sameenakousar, 2013, J CLIN DIAGN RES, V7, P106, DOI 10.7860/JCDR/2012/4988.2682	19	5	5	0	7	SAUDI MED J	RIYADH	ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA	0379-5284			SAUDI MED J	Saudi Med. J.	AUG	2016	37	8					847	852		10.15537/smj.2016.8.14822			6	Medicine, General & Internal	General & Internal Medicine	DW6SR	WOS:000383782000004	27464860	DOAJ Gold, Green Published			2020-06-30	J	Peringathara, B; Robinson, S				Peringathara, B.; Robinson, S.			Fentanyl-induced cough is a risk factor for postoperative nausea and vomiting	BRITISH JOURNAL OF ANAESTHESIA			English	Letter											bijupa@yahoo.com						0	2	3	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	AUG	2016	117	2					269	269		10.1093/bja/aew207			1	Anesthesiology	Anesthesiology	DV8MQ	WOS:000383191500028	27440649	Bronze			2020-06-30	J	Bellini, L; Vadori, M; De Benedictis, GM; Busetto, R				Bellini, Luca; Vadori, Marta; De Benedictis, Giulia Maria; Busetto, Roberto			Effects of opioids on proximal renal tubular cells undergoing ATP depletion	JOURNAL OF PHARMACOLOGICAL SCIENCES			English	Article						Opioids; Tubular kidney cells; Anoxia	ISCHEMIA/REPERFUSION INJURY; APOPTOSIS; BUPRENORPHINE; PROTECTION; RECEPTOR; BINDING; RATS	This study investigated the effect of morphine, fentanyl, butorphanol and buprenorphine on viability and caspase-3 activity in renal proximal tubular cells exposed to opioids for 2 h before or 12 h after chemical anoxia. Cell viability decreased regardless the treatment although intracellular ATP content was elevated in morphine and fentanyl pre-treated cells at 12 h. Anoxia increased caspase activity but this effect was significantly reduced in cells treated before or after with morphine, fentanyl and in cell treated with butorphanol for 12 h. No influence of buprenorphine was detected. Morphine, fentanyl and butorphanol might have protective effects during kidney ischemia. (C) 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.	[Bellini, Luca; De Benedictis, Giulia Maria; Busetto, Roberto] Univ Padua, Dept Anim Med Prod & Hlth, Viale Univ 16, I-30128 Legnaro, Italy; [Vadori, Marta; De Benedictis, Giulia Maria] CORIT Consortium Res Organ Transplantat, Via Giustiniani 2, I-35128 Padua, Italy	Bellini, L (reprint author), Univ Padua, Dept Anim Med Prod & Hlth, Viale Univ 16, I-30128 Legnaro, Italy.	luca.bellini@unipd.it	Bellini, Luca/P-6957-2018; Vadori, Marta/AAN-3199-2020	Bellini, Luca/0000-0002-7145-6115; De Benedictis, Giulia Maria/0000-0002-8422-6829			Deng JP, 2000, COMPARATIVE MED, V50, P628; Fan R, 2009, ARCH MED RES, V40, P227, DOI 10.1016/j.arcmed.2009.04.009; Feldenberg LR, 1999, AM J PHYSIOL-RENAL, V276, pF837; Gharagozlou Parham, 2006, BMC Pharmacol, V6, P3, DOI 10.1186/1471-2210-6-3; Hatzoglou A, 1996, J CELL BIOCHEM, V63, P410; Huang J, 2008, J PHARMACOL SCI, V107, P370, DOI 10.1254/jphs.08044FP; Kugawa F, 2004, BIOL PHARM BULL, V27, P1340, DOI 10.1248/bpb.27.1340; Miura T, 2009, J PHARMACOL SCI, V109, P162, DOI 10.1254/jphs.08R27FM; Pazoki-Toroudi HR, 2010, FUND CLIN PHARMACOL, V24, P189, DOI 10.1111/j.1472-8206.2009.00743.x; Peng JS, 2012, DRUG ALCOHOL DEPEN, V124, P223, DOI 10.1016/j.drugalcdep.2012.01.013; Tong GA, 2011, LIFE SCI, V88, P31, DOI 10.1016/j.lfs.2010.10.018; Vianna PTG, 2009, TRANSPL P, V41, P4080, DOI 10.1016/j.transproceed.2009.09.078; Wu Y, 2014, INTERACT CARDIOV TH, V18, P308, DOI 10.1093/icvts/ivt516; Zaugg M, 2002, ANESTHESIOLOGY, V97, P15, DOI 10.1097/00000542-200207000-00004; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676	15	1	1	0	1	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN	1347-8613	1347-8648		J PHARMACOL SCI	J. Pharmacol. Sci.	AUG	2016	131	4					288	291		10.1016/j.jphs.2016.08.002			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DW3OV	WOS:000383551900010	27569459	DOAJ Gold			2020-06-30	J	Melidi, E; Papadima, A; Pandazi, A; Zografos, G				Melidi, Eleni; Papadima, Artemisia; Pandazi, Aggeliki; Zografos, George			Efficacy of Repeated Intraperitoneal Administration of Levobupivacaine in Pain and Opioid Consumption After Elective Laparoscopic Cholecystectomy: A Prospective Randomized Placebo-controlled Trial	SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES			English	Article						intraperitoneal; laparoscopic cholecystectomy; local anesthetics; levobupivacaine; pain	LOCAL-ANESTHETIC INFILTRATION; POSTOPERATIVE PAIN; PREINCISIONAL INFILTRATION; MULTIMODAL ANALGESIA; DOUBLE-BLIND; BUPIVACAINE; RELIEF; INSTILLATION; EVENTS	Purpose:To estimate the effect of intraperitoneal levobupivacaine on postoperative pain and analgesic requirements, during the first 24 hours after elective laparoscopic cholecystectomy (LC).Materials and Methods:In this prospective, randomized, placebo-controlled study, 73 consecutive patients scheduled for LC were randomized into 2 groups. In the local anesthetic group 36 patients received 10 mL of 0.5% levobupivacaine intraperitoneally at the end of the LC and at 4 hours postoperatively, whereas in the placebo group 37 patients received 10 mL of 0.9% normal saline. Visual analog scale pain scores, analgesic consumption, side-effects, and vital signs were recorded for 24 hours postoperatively.Results:In the local anesthetic group lower visual analog scale pain scores were observed postoperatively, both at rest and at movement (P-values compared with placebo, 0.012 and <0.001, respectively). Fentanyl consumption was greater in the placebo group (P-value <0.001).Conclusions:Intraperitoneal administration of 10 mL 0.5% levobupivacaine after LC is effective in reducing postoperative pain and decreasing opioid consumption.	[Melidi, Eleni; Papadima, Artemisia] Hippocrat Gen Hosp, Dept Anesthesiol, Gorgopotamou 6, Athens 15341, Greece; [Pandazi, Aggeliki] Attikon Gen Hosp, Univ Dept Anesthesiol 2, Athens, Greece; [Zografos, George] Univ Athens, Univ Dept Propaedeut Surg 1, Hippocrat Gen Hosp, Athens Med Sch, Athens, Greece	Melidi, E (reprint author), Hippocrat Gen Hosp, Dept Anesthesiol, Gorgopotamou 6, Athens 15341, Greece.	elmelidi@yahoo.gr					Alper I, 2009, AGRI, V21, P141; Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Bisgaard T, 1999, ANESTH ANALG, V89, P1017, DOI 10.1097/00000539-199910000-00036; Bisgaard T, 2001, EUR J SURG, V167, P84; Boddy AP, 2006, ANESTH ANALG, V103, P682, DOI 10.1213/01.ane.0000226268.06279.5a; CHUNDRIGAR T, 1993, ANN ROY COLL SURG, V75, P437; FREDMAN B, 1994, ANESTH ANALG, V79, P152; Hilvering B, 2011, BRIT J SURG, V98, P784, DOI 10.1002/bjs.7435; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jiranantarat V, 2002, J MED ASS THAI, V85, P897; JORIS J, 1995, ANESTH ANALG, V81, P379, DOI 10.1097/00000539-199508000-00029; Louizos AA, 2005, SURG ENDOSC, V19, P1503, DOI 10.1007/s00464-005-3002-4; Michaloliakou C, 1996, ANESTH ANALG, V82, P44, DOI 10.1097/00000539-199601000-00009; Mitra S, 2012, PAIN PRACT, V12, P485, DOI 10.1111/j.1533-2500.2011.00513.x; Moiniche S, 2000, ANESTH ANALG, V90, P899; Ng A, 2004, EUR J ANAESTH, V21, P653, DOI 10.1017/S0265021504008117; Papadima A, 2009, SURGERY, V146, P475, DOI 10.1016/j.surg.2009.04.010; Pasqualucci A, 1996, ANESTHESIOLOGY, V85, P11, DOI 10.1097/00000542-199607000-00003; Sarac AM, 1996, SURG LAPAROSC ENDOSC, V6, P362, DOI 10.1097/00019509-199610000-00005; SCHEININ B, 1995, ACTA ANAESTH SCAND, V39, P195, DOI 10.1111/j.1399-6576.1995.tb04042.x; SCHULTESTEINBERG H, 1995, ANESTHESIOLOGY, V82, P634, DOI 10.1097/00000542-199503000-00004; SOPER NJ, 1992, ARCH SURG-CHICAGO, V127, P917; URE BM, 1994, SURG ENDOSC-ULTRAS, V8, P90, DOI 10.1007/BF00316616; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652	24	3	3	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1530-4515	1534-4908		SURG LAPARO ENDO PER	Surg. Laparosc. Endosc. Pct. Tech.	AUG	2016	26	4					295	300		10.1097/SLE.0000000000000297			6	Surgery	Surgery	DV8JV	WOS:000383184200011	27380615				2020-06-30	J	Djafarzadeh, S; Vuda, M; Jeger, V; Takala, J; Jakob, SM				Djafarzadeh, Siamak; Vuda, Madhusudanarao; Jeger, Victor; Takala, Jukka; Jakob, Stephan M.			The Effects of Fentanyl on Hepatic Mitochondrial Function	ANESTHESIA AND ANALGESIA			English	Article							PROTEIN-KINASE-C; K-ATP CHANNELS; RAT-BRAIN SYNAPTOSOMES; INTENSIVE-CARE-UNIT; P-GLYCOPROTEIN; POTASSIUM CHANNELS; PLASMA-CONCENTRATIONS; OXIDATIVE-METABOLISM; LIVER MITOCHONDRIA; HEPG2 CELLS	BACKGROUND: Remifentanil interferes with hepatic mitochondrial function. The aim of the present study was to evaluate whether hepatic mitochondrial function is affected by fentanyl, a more widely used opioid than remifentanil. METHODS: Human hepatoma HepG2 cells were exposed to fentanyl or pretreated with naloxone (an opioid receptor antagonist) or 5-hydroxydecanoate (5-HD, an inhibitor of mitochondrial adenosine triphosphate (ATP)-sensitive potassium [mitoKATP] channels), followed by incubation with fentanyl. Mitochondrial function and metabolism were then analyzed. RESULTS: Fentanyl marginally reduced maximal mitochondrial complex-specific respiration rates using exogenous substrates (decrease in medians: 11%-18%; P = 0.003-0.001) but did not affect basal cellular respiration rates (P = 0.834). The effect on stimulated respiration was prevented by preincubation with naloxone or 5-HD. Fentanyl reduced cellular ATP content in a dose-dependent manner (P < 0.001), an effect that was not significantly prevented by 5-HD and not explained by increased total ATPase concentration. However, in vitro ATPase activity of recombinant human permeability glycoprotein (an ATP-dependent drug efflux transporter) was significantly stimulated by fentanyl (P = 0.004). CONCLUSIONS: Our data suggest that fentanyl reduces stimulated mitochondrial respiration of cultured human hepatocytes by a mechanism that is blocked by a mitoKATP channel antagonist. Increased energy requirements for fentanyl efflux transport may offer an explanation for the substantial decrease in cellular ATP concentration.	[Djafarzadeh, Siamak; Vuda, Madhusudanarao; Jeger, Victor; Takala, Jukka; Jakob, Stephan M.] Univ Bern, Univ Hosp Bern, Inselspital, Dept Intens Care Med, CH-3010 Bern, Switzerland; [Jeger, Victor] Univ Bern, Grad Sch Cellular & Biomed Sci, Dept Clin Res, Bern, Switzerland	Jakob, SM (reprint author), Univ Bern, Univ Hosp Bern, Inselspital, Dept Intens Care Med, CH-3010 Bern, Switzerland.	stephan.jakob@insel.ch		Jeger, Victor/0000-0002-6785-3724; Vuda, Madhusudanarao/0000-0002-6489-8927	Swiss National Science Foundation (SNSF)Swiss National Science Foundation (SNSF) [32003B_127619/1]; SNSFSwiss National Science Foundation (SNSF) [133901]	Support was provided by the Swiss National Science Foundation (SNSF) (grant no. 32003B_127619/1) and by an MD-PhD scholarship received by Dr. Jeger from the SNSF (grant no. 133901).	Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Ardehali H, 2005, J MOL CELL CARDIOL, V39, P7, DOI 10.1016/j.yjmcc.2004.12.003; Balijepalli S, 1999, NEUROPHARMACOLOGY, V38, P567, DOI 10.1016/S0028-3908(98)00215-9; BATES SE, 1993, BIOCHEMISTRY-US, V32, P9156, DOI 10.1021/bi00086a022; Berson A, 2001, J HEPATOL, V34, P346, DOI 10.1016/S0168-8278(00)00049-0; Berson A, 2001, J HEPATOL, V34, P261, DOI 10.1016/S0168-8278(00)00050-7; Bista SR, 2015, J CLIN PHARM, V2015; Bjelland TW, 2014, ACTA ANAESTH SCAND, V58, P709, DOI 10.1111/aas.12300; BLOBE GC, 1993, J BIOL CHEM, V268, P658; Borst P, 1997, TRENDS GENET, V13, P217, DOI 10.1016/S0168-9525(97)01112-8; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; Chan Katie, 2005, Expert Opin Drug Metab Toxicol, V1, P655, DOI 10.1517/17425255.1.4.655; CHILDERS SR, 1979, EUR J PHARMACOL, V55, P11, DOI 10.1016/0014-2999(79)90142-0; CHILDERS SR, 1978, LIFE SCI, V23, P759, DOI 10.1016/0024-3205(78)90077-2; Chitturi S, 2002, SEMIN LIVER DIS, V22, P169, DOI 10.1055/s-2002-30102; Costa ADT, 2006, AM J PHYSIOL-HEART C, V290, pH406, DOI 10.1152/ajpheart.00794.2005; Cunha-Oliveira T, 2007, J NEUROCHEM, V101, P543, DOI 10.1111/j.1471-4159.2006.04406.x; Cunha-Oliveira T, 2013, LIFE SCI, V92, P1157, DOI 10.1016/j.lfs.2013.04.016; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; Dagenais C, 2002, J PHARM SCI, V91, P244, DOI 10.1002/jps.1175; Das M, 2003, J PHYSIOL-LONDON, V547, P893, DOI 10.1113/jphysiol.2002.035006; Debska G, 2002, BBA-BIOENERGETICS, V1556, P97, DOI 10.1016/S0005-2728(02)00340-7; Delogu G, 2004, J TRAUMA, V57, P75, DOI 10.1097/01.TA.0000075349.66640.3E; DIXON JL, 1993, J LIPID RES, V34, P167; Djafarzadeh S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045195; Donato MT, 2008, CURR DRUG METAB, V9, P1; Dong HJ, 2000, DRUG METAB DISPOS, V28, P1397; DONG ZY, 1991, MOL PHARMACOL, V39, P563; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Ezoulin MJM, 2005, NEUROSCI LETT, V389, P61, DOI 10.1016/j.neulet.2005.07.026; Frederic S, 2008, CURRENT DIAGNOSIS TR; Fromenty B, 1997, J HEPATOL, V26, P43, DOI 10.1016/S0168-8278(97)80496-5; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Griffiths EJ, 2009, BBA-BIOENERGETICS, V1787, P1324, DOI 10.1016/j.bbabio.2009.01.019; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Grover GJ, 2000, J MOL CELL CARDIOL, V32, P677, DOI 10.1006/jmcc.2000.1111; HAMADA H, 1987, CANCER RES, V47, P2860; Hanley PJ, 2005, J MOL CELL CARDIOL, V39, P17, DOI 10.1016/j.yjmcc.2005.04.002; Hanley PJ, 2002, J PHYSIOL-LONDON, V544, P687, DOI 10.1113/jphysiol.2002.025015; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hoschele D, 2006, TOXICOL IN VITRO, V20, P535, DOI 10.1016/j.tiv.2005.11.007; Holmuhamedov EL, 1998, AM J PHYSIOL-HEART C, V275, pH1567; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Kano T, 2011, J PHARM SCI-US, V100, P5308, DOI 10.1002/jps.22718; Kato R, 2000, BRIT J ANAESTH, V84, P204; Leanza L, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00227; Letrent SP, 1999, BIOCHEM PHARMACOL, V58, P951, DOI 10.1016/S0006-2952(99)00180-X; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; LIU YG, 1994, J MOL CELL CARDIOL, V26, P661, DOI 10.1006/jmcc.1994.1078; Mansouri A, 2003, HEPATOLOGY, V38, P715, DOI 10.1053/jhep.2003.50353; Marian M, 1997, NEUROCHEM RES, V22, P287, DOI 10.1023/A:1022438805337; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MITCHELL P, 1969, EUR J BIOCHEM, V9, P149, DOI 10.1111/j.1432-1033.1969.tb00588.x; Nakagawa Y, 2012, TRANSPLANTATION, V93, P1094, DOI 10.1097/TP.0b013e31824ef1d1; Neustadt J, 2008, MOL NUTR FOOD RES, V52, P780, DOI 10.1002/mnfr.200700075; O'Rourke B, 2000, CIRC RES, V87, P845, DOI 10.1161/01.RES.87.10.845; Orlowski S, 1996, BIOCHEM J, V317, P515, DOI 10.1042/bj3170515; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Perez-Alvarez S, 2010, BBA-MOL BASIS DIS, V1802, P1036, DOI 10.1016/j.bbadis.2010.07.024; Pinti M, 2003, J BIOL REG HOMEOS AG, V17, P166; Pomerantz BJ, 2000, SURGERY, V128, P368, DOI 10.1067/msy.2000.107423; Regueira T, 2009, LIVER INT, V29, P1582, DOI 10.1111/j.1478-3231.2009.02109.x; REISINE T, 1996, [No title captured], P521; Sarah M, 1998, MOL CELL BIOCHEM, V178, P41; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; SINGLETON MA, 1987, CAN J ANAESTH, V34, P152, DOI 10.1007/BF03015333; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; SOUZA HEJ, 1994, BIOCHEM PHARMACOL, V48, P535, DOI 10.1016/0006-2952(94)90283-6; Suno M, 2015, THER CLIN RISK MANAG, V11, P751, DOI 10.2147/TCRM.S79374; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; Torlinska T, 2004, J PHYSIOL PHARMACOL, V55, P457; TSURUO T, 1988, JPN J CANCER RES, V79, P285, DOI 10.1111/j.1349-7006.1988.tb01588.x; Vasarhelyi B, 1997, CLIN CHEM, V43, P1986; Vilela SMF, 2009, MITOCHONDRION, V9, P247, DOI 10.1016/j.mito.2009.03.002; Walder B, 2004, SWISS MED WKLY, V134, P333; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Wang YG, 1999, CIRC RES, V84, P1156, DOI 10.1161/01.RES.84.10.1156; Wu GJ, 2005, ANN NY ACAD SCI, V1042, P168, DOI 10.1196/annals.1338.019; Zamparelli M, 1999, J PEDIATR SURG, V34, P260, DOI 10.1016/S0022-3468(99)90186-0; Zamparelli M, 2000, J PEDIATR SURG, V35, P736, DOI 10.1053/jpsu.2000.6047; Zaugg M, 2002, ANESTHESIOLOGY, V97, P15, DOI 10.1097/00000542-200207000-00004	87	3	3	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2016	123	2					311	325		10.1213/ANE.0000000000001280			15	Anesthesiology	Anesthesiology	DS5JX	WOS:000380819200006	27089001				2020-06-30	J	Fleischmann, T; Jirkof, P; Henke, J; Arras, M; Cesarovic, N				Fleischmann, Thea; Jirkof, Paulin; Henke, Julia; Arras, Margarete; Cesarovic, Nikola			Injection anaesthesia with fentanyl-midazolam-medetomidine in adult female mice: importance of antagonization and perioperative care	LABORATORY ANIMALS			English	Article						anaesthesia; mouse; antagonization; fentanyl; midazolam; medetomidine	KETAMINE; MIXTURE	Injection anaesthesia is commonly used in laboratory mice; however, a disadvantage is that post-anaesthesia recovery phases are long. Here, we investigated the potential for shortening the recovery phase after injection anaesthesia with fentanyl-midazolam-medetomidine by antagonization with naloxone-flumazenil-atipamezole. In order to monitor side-effects, the depth of anaesthesia, heart rate (HR), core body temperature (BT) and concentration of blood gases, as well as reflex responses, were assessed during a 50min anaesthesia. Mice were allowed to recover from the anaesthesia in their home cages either with or without antagonization, while HR, core BT and spontaneous home cage behaviours were recorded for 24h. Mice lost righting reflex at 330 +/- 47s after intraperitoneal injection of fentanyl-midazolam-medetomidine. During anaesthesia, HR averaged 225 +/- 23 beats/min, respiratory rate and core BT reached steady state at 131 +/- 15 breaths/min and 34.3 +/- 0.25?, respectively. Positive pedal withdrawal reflex, movement triggered by tail pinch and by toe pinch, still occurred in 25%, 31.2% and 100% of animals, respectively. Arterial blood gas analysis revealed acidosis, hypoxia, hypercapnia and a marked increase in glucose concentration. After anaesthesia reversal by injection with naloxone-flumazenil-atipamezole, animals regained consciousness after 110 +/- 18s and swiftly returned to physiological baseline values, yet they displayed diminished levels of locomotion and disrupted circadian rhythm. Without antagonization, mice showed marked hypothermia (22 +/- 1.9?) and bradycardia (119 +/- 69 beats/min) for several hours. Fentanyl-midazolam-medetomidine provided reliable anaesthesia in mice with reasonable intra-anaesthetic side-effects. Post-anaesthetic period and related adverse effects were both reduced substantially by antagonization with naloxone-flumazenil-atipamezole.	[Fleischmann, Thea; Jirkof, Paulin; Arras, Margarete; Cesarovic, Nikola] Univ Zurich, Univ Zurich Hosp, Div Surg Res, Zurich, Switzerland; [Jirkof, Paulin; Arras, Margarete] Univ Zurich, Neurosci Ctr Zurich, Zurich, Switzerland; [Jirkof, Paulin; Arras, Margarete] ETH, Zurich, Switzerland; [Henke, Julia] Boehringer Ingelheim Pharma GmbH & Co KG, Biol Lab Serv, Dept Nonclin Drug Safety, Biberach, Germany	Jirkof, P (reprint author), Univ Zurich Hosp, Sternwartstr 6, CH-8091 Zurich, Switzerland.	paulin.jirkof@usz.ch		Cesarovic, Nikola/0000-0001-6744-2928; Arras, Margarete/0000-0003-3864-9879			Albrecht M, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0198-3; Arras M, 2001, COMPARATIVE MED, V51, P443; Cesarovic N, 2011, JOVE-J VIS EXP, DOI 10.3791/3260; Henke J, 2004, J VET MED A, V51, P259, DOI 10.1111/j.1439-0442.2004.00632.x; Henke J, 2012, ANASTHESIE ANALGESIE, V2; Jirkof P, 2015, LAB ANIM-UK, V49, P177, DOI 10.1177/0023677214562849; Kawai S, 2011, EXP ANIM TOKYO, V60, P481, DOI 10.1538/expanim.60.481; Kirihara Y, 2015, EXP ANIM TOKYO, V64, P39, DOI 10.1538/expanim.14-0039; Kirihara Y, 2013, EXP ANIM TOKYO, V62, P173, DOI 10.1538/expanim.62.173; Mahler M, 2014, LAB ANIM-UK, V48, P178, DOI 10.1177/0023677213516312; Schernthaner A, 2011, VET ANAESTH ANALG, V38, P439, DOI 10.1111/j.1467-2995.2011.00635.x; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Worlein JM, 2011, AM J PRIMATOL, V73, P98; Zuurbier CJ, 2014, EXP BIOL MED, V239, P737, DOI 10.1177/1535370214524877	14	11	11	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	AUG	2016	50	4					264	274		10.1177/0023677216631458			11	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	DU8ED	WOS:000382445200003	26860578	Green Accepted, Bronze			2020-06-30	J	Ringer, SK; Spielmann, N; Weiss, M; Mauch, JY				Ringer, S. K.; Spielmann, N.; Weiss, M.; Mauch, J. Y.			Fentanyl bolus induces muscle tremors in sevoflurane-anaesthetized piglets	LABORATORY ANIMALS			English	Article						piglets; fentanyl; myoclonus; trembling; sevoflurane	MYOCLONUS	Intravenous fentanyl (10mcg/kg) or saline (control) was randomly administered to 10 healthy sevoflurane-mono-anaesthetized piglets. Trembling was assessed by two blinded observers using a visual analogue scale (VAS) and a simple ordinal scale at baseline and 5min (T5) after drug administration. If no trembling was observed at that time point, the opposite treatment was administered and piglets were re-evaluated after another 5min (T10). Four out of five piglets showed trembling after fentanyl (T5), while none given saline showed any trembling. With fentanyl the VAS scores were significantly higher at T5 compared either with baseline or with the control treatment. Control animals received fentanyl after the 5min evaluation and all piglets showed clear trembling afterwards. The median time after fentanyl administration until first muscle tremors was 51 (20-840) s. In summary, nine out of 10 sevoflurane-anaesthetized piglets showed muscle tremors after intravenous fentanyl. Tremors subsided over time and no specific treatment was necessary.	[Ringer, S. K.] Univ Zurich, Vetsuisse Fac, Equine Dept, Sect Anaesthesiol, Zurich, Switzerland; [Spielmann, N.; Weiss, M.] Univ Childrens Hosp Zurich, Dept Anaesthesiol, Zurich, Switzerland; [Spielmann, N.; Weiss, M.] Univ Zurich, Univ Childrens Hosp Zurich, Childrens Res Ctr, Zurich, Switzerland; [Mauch, J. Y.] Luzerner Kantonsspital, Dept Anaesthesiol, Luzern, Switzerland	Ringer, SK (reprint author), Univ Zurich, Vetsuisse Fac, Sect Anaesthesiol, Winterthurerstr 258c, CH-8057 Zurich, Switzerland.	sringer@vetclinics.uzh.ch		Ringer, Simone/0000-0002-9346-3308			Caviness JN, 1996, MAYO CLIN PROC, V71, P679; Cote CJ., 2015, MILLERS ANESTHESIA, P2757; DEARMENDI AJ, 1993, ANESTH ANALG, V77, P191; Dewhirst E, 2012, PEDIATR EMERG CARE, V28, P465, DOI 10.1097/PEC.0b013e3182535a2a; Han PKJ, 2002, J PAIN SYMPTOM MANAG, V23, P66, DOI 10.1016/S0885-3924(01)00370-0; Rajan V, 1998, BIOL NEONATE, V74, P39, DOI 10.1159/000014009; Rey-Santano C, 2014, PLOS ONE, V9	7	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	AUG	2016	50	4					312	314		10.1177/0023677215623896			3	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	DU8ED	WOS:000382445200009	26678295	Bronze			2020-06-30	J	Jung, KW; Kang, HW; Park, CH; Choi, BH; Bang, JY; Lee, SH; Lee, EK; Choi, BM; Noh, GJ				Jung, Kyeo-Woon; Kang, Hyeon-Wook; Park, Chan-Hye; Choi, Byung-Hyun; Bang, Ji-Yeon; Lee, Soo-Han; Lee, Eun-Kyung; Choi, Byung-Moon; Noh, Gyu-Jeong			Comparison of the analgesic effect of patient-controlled oxycodone and fentanyl for pain management in patients undergoing colorectal surgery	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article						fentanyl; oxycodone; pain relief	LAPAROSCOPIC CHOLECYSTECTOMY; POSTOPERATIVE PAIN; CARDIAC-SURGERY; VS. FENTANYL; MORPHINE; AGE	Oxycodone is a -opioid receptor agonist and is generally indicated for the relief of moderate to severe pain. The aim of this study was to compare the analgesic efficacy of patient-controlled oxycodone and fentanyl for postoperative pain in patients undergoing colorectal surgery. Patients scheduled to undergo elective colorectal surgery (n=82) were allocated to receive oxycodone (n=41, concentration of 1mg/mL) or fentanyl (n=41, concentration of 15g/mL) for postoperative pain management. After the operation, pain using a numerical rating scale (NRS), delivery to demand ratio, infused dose of patient-controlled analgesia (PCA), side effects, and sedation levels were evaluated. Median (25%-75%) cumulative PCA dose of oxycodone group at 48hours (66.9, 58.4-83.7mL) was significantly less than that of fentanyl group (80.0, 63.4-103.3mL, P=.037). Six hours after surgery, the mean (SD) NRS scores of the oxycodone and fentanyl groups were 6.2 (2.4) and 6.8 (1.9), respectively (P=.216). The mean equianalgesic potency ratio of oxycodone to fentanyl was 55:1. The groups did not differ in postoperative nausea, vomiting, and level of sedation. Patient-controlled oxycodone provides similar effects for pain relief compared to patient-controlled fentanyl in spite of less cumulative PCA dose. Based on these results, oxycodone can be a useful alternative to fentanyl for PCA in patients after colorectal surgery.	[Jung, Kyeo-Woon; Park, Chan-Hye; Bang, Ji-Yeon; Choi, Byung-Moon; Noh, Gyu-Jeong] Univ Ulsan, Dept Anesthesiol & Pain Med, Asan Med Ctr, Coll Med, Seoul, South Korea; [Kang, Hyeon-Wook] Univ Ulsan, Coll Med, Seoul, South Korea; [Choi, Byung-Hyun] Pusan Natl Univ, Dept Surg, Yangsan Hosp, Yangsan, South Korea; [Lee, Soo-Han] Osong Med Innovat Fdn, Div Drug Safety Evaluat, New Drug Dev Ctr, Chungju Si, Chungbuk, South Korea; [Lee, Eun-Kyung] Ewha Womans Univ, Dept Stat, Seoul, South Korea; [Noh, Gyu-Jeong] Univ Ulsan, Dept Clin Pharmacol & Therapeut, Asan Med Ctr, Coll Med, Seoul, South Korea	Choi, BM (reprint author), Univ Ulsan, Dept Anesthesiol & Pain Med, Asan Med Ctr, Coll Med, Seoul, South Korea.	byungmoonchoi7@gmail.com	Lee, Soohan/AAP-6976-2020		University of Ulsan College of Medicine, Seoul, Korea [14-15]	This work was supported by a Student Research Grant (14-15) from the University of Ulsan College of Medicine, Seoul, Korea. The authors are grateful to Do-Yang Park, M.P.H. (Research Associate, Department of Clinical Pharmacology and Therapeutics, Asan Medical Center) for preparing the data used in this study.	Bauerle K, 2004, BRIT J ANAESTH, V92, P841, DOI 10.1093/bja/aeh142; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; GINSBERG B, 1995, PAIN, V62, P95, DOI 10.1016/0304-3959(94)00255-D; Hwang BY, 2014, INT J MED SCI, V11, P658, DOI 10.7150/ijms.8331; Kalso E, 2005, J PAIN SYMPTOM MANAG, V29, pS47, DOI 10.1016/j.jpainsymman.2005.01.010; KALSO E, 1991, ACTA ANAESTH SCAND, V35, P642, DOI 10.1111/j.1399-6576.1991.tb03364.x; Kim NS, 2015, KOREAN J ANESTHESIOL, V68, P261, DOI 10.4097/kjae.2015.68.3.261; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; Kokki M, 2012, BASIC CLIN PHARMACOL, V111, P391, DOI 10.1111/j.1742-7843.2012.00916.x; Kokki M, 2012, BASIC CLIN PHARMACOL, V110, P469, DOI 10.1111/j.1742-7843.2011.00839.x; Lahtinen P, 2004, ANESTH ANALG, V99, P1295, DOI 10.1213/01.ANE.0000133913.07342.B9; Lahtinen P, 2002, ANESTH ANALG, V95, P813, DOI 10.1097/00000539-200210000-00005; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Park JH, 2015, KOREAN J ANESTHESIOL, V68, P153, DOI 10.4097/kjae.2015.68.2.153; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Rhodes V A, 1999, Oncol Nurs Forum, V26, P889; Saari TI, 2012, BRIT J ANAESTH, V108, P491, DOI 10.1093/bja/aer395; Silvasti M, 1998, ACTA ANAESTH SCAND, V42, P576, DOI 10.1111/j.1399-6576.1998.tb05169.x; Sjovall S, 2015, DRUGS, V75, P1867, DOI 10.1007/s40265-015-0482-y; Struys MMRF, 2000, ANESTHESIOLOGY, V92, P399, DOI 10.1097/00000542-200002000-00021; Wasan AD, 2005, PAIN, V117, P450, DOI 10.1016/j.pain.2005.08.006	21	2	5	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1440-1681			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	AUG	2016	43	8					745	752		10.1111/1440-1681.12586			8	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	DR5PZ	WOS:000379956200003	27128496				2020-06-30	J	Jin, HS; Kim, YC; Yoo, Y; Lee, C; Cho, CW; Kim, WJ				Jin, Hyun Seung; Kim, Yong Chul; Yoo, Yongjae; Lee, Changsoon; Cho, Chan Woo; Kim, Won-joong			Opioid sparing effect and safety of nefopam in patient controlled analgesia after laparotomy: A randomized, double blind study	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Adverse events; nefopam; fentanyl; opioid sparing; patient controlled analgesia; laparotomy	CONTINUOUS INTRAVENOUS-INJECTION; POSTOPERATIVE PAIN; ABDOMINAL-SURGERY; CARDIAC-SURGERY; MORPHINE; KETAMINE; EFFICACY; PHARMACOKINETICS	Objectives A double-blind randomised study to evaluate the opioid sparing effect and safety of nefopam when administered via intravenous patient controlled analgesia (PCA) with fentanyl. Methods Patients planned for elective open laparotomy, were randomly assigned to receive into fentanyl 25 mu g/ml (SF group) or nefopam 2.4mg/ml plus fentanyl 25 mu g/ml (NF group). Patients were assessed before surgery and for 24h postoperatively. Results Total PCA fentanyl consumption was significantly lower in the NF group (n=35) than the SF group (n=36). Pain scores were significantly lower and patients' satisfaction with treatment significantly better in the NF group than the SF group. Dry mouth and dizziness were significantly more frequent in the NF group than the SF group. There were no other statistically significant between-group differences in the incidence of adverse events. Conclusions Intravenous PCA using nefopam+fentanyl following laparotomy has an opioid sparing effect and is associated with a low incidence of some of the typical opioid related adverse events. Trial registry Clinicaltrials.gov Registration No: NCT02596269	[Jin, Hyun Seung; Kim, Yong Chul; Yoo, Yongjae; Lee, Changsoon] Seoul Natl Univ Hosp, Dept Anaesthesia & Pain Med, Seoul, South Korea; [Cho, Chan Woo] Seoul Natl Univ, Dept Anaesthesia & Pain Med, Bundang Hosp, Kyunggi Do, South Korea; [Kim, Won-joong] Ewha Womans Univ, Sch Med, Dept Anaesthesia & Pain Med, Seoul, South Korea	Kim, YC (reprint author), Seoul Natl Univ Hosp, Dept Anaesthesia & Pain Med, Coll Med, 101 Daehang Ro, Seoul 03080, South Korea.	pain@snu.ac.kr			Pharmbio Korea Co., Ltd., Korea [PBK1106ACU]	This work was supported by the Pharmbio Korea Co., Ltd., Korea [grant number PBK1106ACU].	BHATT AM, 1981, BRIT J CLIN PHARMACO, V11, P209, DOI 10.1111/j.1365-2125.1981.tb01126.x; Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103; Butterworth John f, MORGAN MIKHAILS CLIN, P297; Carstensen M, 2010, BRIT J ANAESTH, V104, P401, DOI 10.1093/bja/aeq041; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Corbonnois G, 2013, Ann Fr Anesth Reanim, V32, pe113, DOI 10.1016/j.annfar.2013.04.015; Djerada Z, 2014, BRIT J CLIN PHARMACO, V77, P1027, DOI 10.1111/bcp.12291; DORDONI PL, 1994, ANAESTHESIA, V49, P1046, DOI 10.1111/j.1365-2044.1994.tb04352.x; Du Manoir B, 2003, BRIT J ANAESTH, V91, P836, DOI 10.1093/bja/aeg264; Durrieu G, 2007, FUND CLIN PHARMACOL, V21, P555, DOI 10.1111/j.1472-8206.2007.00499.x; Eisenach JC, 2006, REGION ANESTH PAIN M, V31, P1, DOI 10.1016/j.rapm.2005.11.008; Evans MS, 2008, BRIT J ANAESTH, V101, P610, DOI 10.1093/bja/aen267; Girard P, 2001, PHARMACOL RES, V44, P541, DOI 10.1006/phrs.2001.0886; HEEL RC, 1980, DRUGS, V19, P249, DOI 10.2165/00003495-198019040-00001; Hwang Boo-Young, 2015, Int J Med Sci, V12, P644, DOI 10.7150/ijms.11828; Jeong SH, 2014, KOREAN J PAIN, V27, P23, DOI 10.3344/kjp.2014.27.1.23; Joo YC, 2014, KOREAN J PAIN, V27, P54, DOI 10.3344/kjp.2014.27.1.54; Kapfer B, 2005, ANESTH ANALG, V100, P169, DOI 10.1213/01.ANE.0000138037.19757.ED; Kim K, 2014, J INT MED RES, V42, P684, DOI 10.1177/0300060514525351; KLOHS MW, 1972, ARZNEI-FORSCHUNG, V22, P132; Lavand'homme P, 2005, ANESTHESIOLOGY, V103, P813, DOI 10.1097/00000542-200510000-00020; Martindale Sweetman SC., 2009, COMPLETE DRUG REFERE, P94; McDaid C, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14170; Mimoz O, 2001, ANAESTHESIA, V56, P520, DOI 10.1046/j.1365-2044.2001.01980.x; Mimoz O, 2010, ANESTH ANALG, V111, P1146, DOI 10.1213/ANE.0b013e3181f33488; Oh CS, 2015, CURR MED RES OPIN, V31, P1599, DOI 10.1185/03007995.2015.1058251; Ould-Ahmed M, 2007, ANN FR ANESTH, V26, P74, DOI 10.1016/j.annfar.2006.07.080; PIERCEY MF, 1981, EUR J PHARMACOL, V74, P135, DOI 10.1016/0014-2999(81)90523-9; Richebe P, 2013, J CARDIOTHOR VASC AN, V27, P427, DOI 10.1053/j.jvca.2012.08.015; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; TIGERSTEDT I, 1979, ACTA ANAESTH SCAND, V23, P555, DOI 10.1111/j.1399-6576.1979.tb01486.x; Tirault M, 2006, ANESTH ANALG, V102, P110, DOI 10.1213/01.ANE.0000181103.07170.15; Tramoni G, 2003, EUR J ANAESTH, V20, P990, DOI 10.1097/00003643-200312000-00013; Verleye M, 2004, BRAIN RES, V1013, P249, DOI 10.1016/j.brainres.2004.04.035	34	4	4	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	AUG	2016	44	4					844	854		10.1177/0300060516650783			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	DS7GG	WOS:000380950500009	27358262	DOAJ Gold, Green Published			2020-06-30	J	Karlsson, HK; Tuulari, JJ; Tuominen, L; Hirvonen, J; Honka, H; Parkkola, R; Helin, S; Salminen, P; Nuutila, P; Nummenmaa, L				Karlsson, H. K.; Tuulari, J. J.; Tuominen, L.; Hirvonen, J.; Honka, H.; Parkkola, R.; Helin, S.; Salminen, P.; Nuutila, P.; Nummenmaa, L.			Weight loss after bariatric surgery normalizes brain opioid receptors in morbid obesity	MOLECULAR PSYCHIATRY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; GASTRIC BYPASS-SURGERY; DOPAMINE-D-2 RECEPTORS; PEPTIDE-YY; BINDING; PET; AVAILABILITY; REWARD; DEPENDENCE; ADDICTION	Positron emission tomography (PET) studies suggest opioidergic system dysfunction in morbid obesity, while evidence for the role of the dopaminergic system is less consistent. Whether opioid dysfunction represents a state or trait in obesity remains unresolved, but could be assessed in obese subjects undergoing weight loss. Here we measured brain mu-opioid receptor (MOR) and dopamine D-2 receptor (D2R) availability in 16 morbidly obese women twice-before and 6 months after bariatric surgery-using PET with [C-11]carfentanil and [C-11]raclopride. Data were compared with those from 14 lean control subjects. Receptor-binding potentials (BPND) were compared between the groups and between the pre- and postoperative scans among the obese subjects. Brain MOR availability was initially lower among obese subjects, but weight loss (mean = 26.1 kg, s.d. = 7.6 kg) reversed this and resulted in similar to 23% higher MOR availability in the postoperative versus preoperative scan. Changes were observed in areas implicated in reward processing, including ventral striatum, insula, amygdala and thalamus (P's < 0.005). Weight loss did not influence D2R availability in any brain region. Taken together, the endogenous opioid system plays an important role in the pathophysiology of human obesity. Because bariatric surgery and concomitant weight loss recover downregulated MOR availability, lowered MOR availability is associated with an obese phenotype and may mediate excessive energy uptake. Our results highlight that understanding the opioidergic contribution to overeating is critical for developing new treatments for obesity.	[Karlsson, H. K.; Tuulari, J. J.; Tuominen, L.; Hirvonen, J.; Honka, H.; Parkkola, R.; Helin, S.; Nuutila, P.; Nummenmaa, L.] Univ Turku, Turku PET Ctr, Turku, Finland; [Karlsson, H. K.; Tuulari, J. J.; Tuominen, L.; Hirvonen, J.; Honka, H.; Parkkola, R.; Helin, S.; Salminen, P.; Nuutila, P.; Nummenmaa, L.] Turku Univ Hosp, Turku, Finland; [Tuominen, L.] Univ Turku, Dept Psychiat, Turku, Finland; [Hirvonen, J.] Med Imaging Ctr Southwest Finland, Turku, Finland; [Hirvonen, J.; Parkkola, R.] Univ Turku, Dept Radiol, Turku, Finland; [Salminen, P.] Univ Turku, Dept Digest Surg, Turku, Finland; [Nuutila, P.] Univ Turku, Dept Endocrinol, Turku, Finland; [Nummenmaa, L.] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, Espoo, Finland; [Nummenmaa, L.] Univ Turku, Dept Psychol, Turku, Finland	Karlsson, HK (reprint author), Univ Turku, Turku Univ Hosp, Turku PET Ctr, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.	hekrka@utu.fi	Hirvonen, Jussi/AAC-1864-2020	Karlsson, Hasse/0000-0002-4992-1893; Tuulari, Jetro/0000-0002-1797-8000	Academy of FinlandAcademy of Finland [251125, 121031]; Sigrid Juselius FoundationSigrid Juselius Foundation; University of Turku; Turku University Hospital; Abo Akademi University; Finnish Diabetes Research Foundation; The National Graduate School of Clinical Investigation	The study was conducted within the Finnish Centre of Excellence in Cardiovascular and Metabolic Diseases supported by the Academy of Finland (grants #251125 and #121031), Sigrid Juselius Foundation, University of Turku, Turku University Hospital, and Abo Akademi University. HKK was supported by personal grants from The Finnish Diabetes Research Foundation and The National Graduate School of Clinical Investigation. We thank study nurse Mia Koutu for her support in data collection. We thank Robert M Badeau, of Aura Professional English Consulting, for the language content editing and proofreading of this manuscript.	Baik JH, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00152; Billes SK, 2014, PHARMACOL RES, V84, P1, DOI 10.1016/j.phrs.2014.04.004; Caravaggio F, 2015, BIOL PSYCHIAT, V77, P196, DOI 10.1016/j.biopsych.2013.02.017; Cooper TC, 2015, OBES SURG, V25, P1474, DOI 10.1007/s11695-014-1560-z; de Weijer BA, 2014, DIABETOLOGIA, V57, P1078, DOI 10.1007/s00125-014-3178-z; de Weijer BA, 2011, EJNMMI RES, V1, DOI 10.1186/2191-219X-1-37; Dunn JP, 2010, BRAIN RES, V1350, P123, DOI 10.1016/j.brainres.2010.03.064; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Eisenstein SA, 2013, SYNAPSE, V67, P748, DOI 10.1002/syn.21680; FARDE L, 1986, SCIENCE, V231, P258, DOI 10.1126/science.2867601; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; Gloy VL, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5934; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Gosnell BA, 2009, INT J OBESITY, V33, pS54, DOI 10.1038/ijo.2009.73; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Haltia LT, 2007, SYNAPSE, V61, P748, DOI 10.1002/syn.20418; Hardman CA, 2012, PHYSIOL BEHAV, V105, P1202, DOI 10.1016/j.physbeh.2011.12.022; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Ikemoto S, 2014, NEUROPHARMACOLOGY, V76, P329, DOI 10.1016/j.neuropharm.2013.04.031; Karamanakos SN, 2008, ANN SURG, V247, P401, DOI 10.1097/SLA.0b013e318156f012; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Koch T, 2008, PHARMACOL THERAPEUT, V117, P199, DOI 10.1016/j.pharmthera.2007.10.003; Martinez D, 2012, BIOL PSYCHIAT, V71, P192, DOI 10.1016/j.biopsych.2011.08.024; Michaelides M, 2012, NEUROIMAGE, V59, P1508, DOI 10.1016/j.neuroimage.2011.08.028; Morinigo R, 2006, J CLIN ENDOCR METAB, V91, P1735, DOI 10.1210/jc.2005-0904; Small DM, 2003, NEUROIMAGE, V19, P1709, DOI 10.1016/S1053-8119(03)00253-2; Steele KE, 2010, OBES SURG, V20, P369, DOI 10.1007/s11695-009-0015-4; Tellez LA, 2013, SCIENCE, V341, P800, DOI 10.1126/science.1239275; Tuominen L, 2015, NEUROIMAGE, V122, P80, DOI 10.1016/j.neuroimage.2015.08.001; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Volkow ND, 2013, OBES REV, V14, P2, DOI 10.1111/j.1467-789X.2012.01031.x; Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452; Volkow ND, 1996, ALCOHOL CLIN EXP RES, V20, P1594, DOI 10.1111/j.1530-0277.1996.tb05936.x; Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015; Wang GJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101585; Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6; Weerts EM, 2011, ALCOHOL CLIN EXP RES, V35, P2162, DOI 10.1111/j.1530-0277.2011.01565.x; Whistler JL, 2012, DRUG ALCOHOL DEPEN, V121, P189, DOI 10.1016/j.drugalcdep.2011.10.031; Williams TM, 2007, BRIT J PSYCHIAT, V191, P63, DOI 10.1192/bjp.bp.106.031120; Yeomans MR, 2002, NEUROSCI BIOBEHAV R, V26, P713, DOI 10.1016/S0149-7634(02)00041-6; Zubieta JK, 2000, NEUROPSYCHOPHARMACOL, V23, P326, DOI 10.1016/S0893-133X(00)00110-X; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225	42	30	30	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	AUG	2016	21	8					1057	1062		10.1038/mp.2015.153			6	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	DS4GN	WOS:000380739500008	26460230				2020-06-30	J	Nuechterlein, EB; Ni, LS; Domino, EF; Zubieta, JK				Nuechterlein, Emily B.; Ni, Lisong; Domino, Edward F.; Zubieta, Jon-Kar			Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY			English	Article						Smoking; PET; [11C]-Carfentanil; OPRM1; A118G	OPRM1 A118G POLYMORPHISM; RECEPTOR-BINDING; STRIATAL DOPAMINE; TOBACCO SMOKING; MESSENGER-RNA; VARIANT A118G; HUMAN BRAIN; SMOKERS; PLACEBO; WITHDRAWAL	This study investigates differences in mu-opioid receptor mediated neurotransmission in healthy controls and overnight-abstinent smokers, and potential effects of the OPRM1 A118G genotype. It also examines the effects of smoking denicotinized (DN) and average nicotine (N) cigarettes on the mu-opioid system. Positron emission tomography with C-11-carfentanil was used to determine regional brain mu-opioid receptor (MOR) availability (non-displaceable binding potential, BPND) in a sample of 19 male smokers and 22 nonsmoking control subjects. Nonsmokers showed greater MOR BPND than overnight abstinent smokers in the basal ganglia and thalamus. BPND in the basal ganglia was negatively correlated with baseline craving levels and Fagerstrom scores. Interactions between group and genotype were seen in the nucleus accumbens bilaterally and the amygdala, with G-allele carriers demonstrating lower BPND in these regions, but only among smokers. After smoking the DN cigarette, smokers showed evidence of MOR activation in the thalamus and nucleus accumbens. No additional activation was observed after the N cigarette, with a mean effect of increases in MOR BPND (i.e., deactivation) with respect to the DN cigarette effects in the thalamus and left amygdala. Changes in MOR BPND were related to both Fagerstrom scores and changes in craving. This study showed that overnight-abstinent smokers have lower concentrations of available MORs than controls, an effect that was related to both craving and the severity of addiction. It also suggests that nicotine non-specific elements of the smoking experience have an important role in regulating MOR-mediated neurotransmission, and in turn modulating withdrawal-induced craving ratings. (C) 2016 Elsevier Inc. All rights reserved.	[Nuechterlein, Emily B.] Univ Michigan, Grad Program Neurosci, 500 S State St, Ann Arbor, MI 48109 USA; [Nuechterlein, Emily B.; Ni, Lisong; Zubieta, Jon-Kar] Univ Michigan, Mol & Behav Neurosci Inst, 500 S State St, Ann Arbor, MI 48109 USA; [Ni, Lisong; Domino, Edward F.] Univ Michigan, Dept Pharmacol, 500 S State St, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Michigan, Dept Radiol, 500 S State St, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Michigan, Dept Psychiat, 500 S State St, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Utah, Hlth Sci Ctr, 201 Presidents Cir, Salt Lake City, UT 84112 USA	Nuechterlein, EB (reprint author), Univ Michigan, Grad Program Neurosci, 500 S State St, Ann Arbor, MI 48109 USA.; Nuechterlein, EB (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, 500 S State St, Ann Arbor, MI 48109 USA.	emilybn@umich.edu			Department of Pharmacology Research and Development Fund [276157]; Psychopharmacology Fund [C361024]; Phil F. Jenkins Foundation; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA016423, R01DA027494]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32EY10787, 5T32DA007281]	This work was supported in part by the Department of Pharmacology Research and Development Fund 276157, the Psychopharmacology Fund C361024, and Phil F. Jenkins Foundation, and National Institute on Drug Abuse grants R01DA016423 (E.F.D.) and R01DA027494 (J.K.Z.). E.B.N. was supported in part by National Institutes of Health grants 5T32EY10787 and 5T32DA007281. The authors declare no conflicts of interest.	Arias A, 2006, DRUG ALCOHOL DEPEN, V83, P262, DOI 10.1016/j.drugalcdep.2005.11.024; Boyadjieva NI, 1997, LIFE SCI, V61, pPL59; Brett M., 2002, NEUROIMAGE, P497, DOI DOI 10.1016/S1053-8119(02)90010-8; Brody AL, 2004, AM J PSYCHIAT, V161, P1211, DOI 10.1176/appi.ajp.161.7.1211; BUTSCHKY MF, 1995, PHARMACOL BIOCHEM BE, V50, P91, DOI 10.1016/0091-3057(94)00269-O; Clark L. A., 1999, MANUAL POSITIVE NEGA; DAVENPORT KE, 1990, NEUROSCI LETT, V113, P40, DOI 10.1016/0304-3940(90)90491-Q; Domino EF, 2015, PROG NEURO-PSYCHOPH, V59, P100, DOI 10.1016/j.pnpbp.2015.01.007; Domino EF, 2013, NICOTINE TOB RES, V15, P11, DOI 10.1093/ntr/nts029; Domino EF, 2012, PROG NEURO-PSYCHOPH, V38, P236, DOI 10.1016/j.pnpbp.2012.04.003; Domino EF, 2002, PROG NEURO-PSYCHOPH, V26, P1071, DOI 10.1016/S0278-5846(02)00224-5; Galeote L, 2006, J NEUROCHEM, V97, P416, DOI 10.1111/j.1471-4159.2006.03751.x; Gallagher M, 1996, CURR OPIN NEUROBIOL, V6, P221, DOI 10.1016/S0959-4388(96)80076-6; Graul A.I., 2005, DRUG TODAY, P41; Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851; Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Houdi AA, 1998, BRAIN RES, V799, P257, DOI 10.1016/S0006-8993(98)00454-5; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Isola R, 2002, NEUROSCI LETT, V325, P67, DOI 10.1016/S0304-3940(02)00240-9; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; KADOYA C, 1994, CLIN PHARMACOL THER, V55, P370, DOI 10.1038/clpt.1994.44; Kroslak T, 2007, J NEUROCHEM, V103, P77, DOI 10.1111/j.1471-4159.2007.04738.x; Kuwabara H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113694; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Mague SD, 2009, P NATL ACAD SCI USA, V106, P10847, DOI 10.1073/pnas.0901800106; McNair D., 1971, MANUAL PROFILE MOOD; Pecina M, 2015, JAMA PSYCHIAT, V72, P1087, DOI 10.1001/jamapsychiatry.2015.1335; Pecina M, 2015, NEUROPSYCHOPHARMACOL, V40, P957, DOI 10.1038/npp.2014.272; Pickworth W B, 1999, Nicotine Tob Res, V1, P357, DOI 10.1080/14622299050011491; Pomerleau OF, 1998, PSYCHONEUROENDOCRINO, V23, P115, DOI 10.1016/S0306-4530(97)00074-7; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Rose JE, 2010, PSYCHOPHARMACOLOGY, V210, P1, DOI 10.1007/s00213-010-1810-2; RUSSELL MAH, 1995, ADV PHAR SC, P233; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, NEUROPSYCHOPHARMACOL, V32, P450, DOI 10.1038/sj.npp.1301238; Spielberger C., 1983, MANUAL STATE TRAIT A; Tyll Sascha, 2011, Commun Integr Biol, V4, P378, DOI 10.4161/cib.4.4.15222; Walters CL, 2005, NEURON, V46, P933, DOI 10.1016/j.neuron.2005.05.005; Wang YJ, 2012, NEUROSCIENCE, V205, P178, DOI 10.1016/j.neuroscience.2011.12.033; Weerts EM, 2013, INT J NEUROPSYCHOPH, V16, P47, DOI 10.1017/S146114571200017X; Wewers ME, 1999, BRAIN RES, V822, P107, DOI 10.1016/S0006-8993(99)01095-1; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145	47	15	15	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-5846	1878-4216		PROG NEURO-PSYCHOPH	Prog. Neuro-Psychopharmacol. Biol. Psychiatry	AUG 1	2016	69						69	77		10.1016/j.pnpbp.2016.04.006			9	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	DM2UW	WOS:000376204500008	27095017	Green Accepted			2020-06-30	J	Karjalainen, T; Tuominen, L; Manninen, S; Kalliokoski, KK; Nuutila, P; Jaaskelainen, IP; Hari, R; Sams, M; Nummenmaa, L				Karjalainen, Tomi; Tuominen, Lauri; Manninen, Sandra; Kalliokoski, Kari K.; Nuutila, Pirjo; Jaaskelainen, Iiro P.; Hari, Riitta; Sams, Mikko; Nummenmaa, Lauri			Behavioural activation system sensitivity is associated with cerebral mu-opioid receptor availability	SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE			English	Article						BAS; BIS; carfentanil; opioid; PET	OPRM1 A118G POLYMORPHISM; INDIVIDUAL-DIFFERENCES; INHIBITION SYSTEMS; MOUSE MODEL; PERSONALITY; REWARD; SEROTONIN; PAIN; PET; NEUROBIOLOGY	The reinforcement-sensitivity theory proposes that behavioural activation and inhibition systems (BAS and BIS, respectively) guide approach and avoidance behaviour in potentially rewarding and punishing situations. Their baseline activity presumably explains individual differences in behavioural dispositions when a person encounters signals of reward and harm. Yet, neurochemical bases of BAS and BIS have remained poorly understood. Here we used in vivo positron emission tomography with a m-opioid receptor (MOR) specific ligand [C-11] carfentanil to test whether individual differences in MOR availability would be associated with BAS or BIS. We scanned 49 healthy subjects and measured their BAS and BIS sensitivities using the BIS/BAS scales. BAS but not BIS sensitivity was positively associated with MOR availability in frontal cortex, amygdala, ventral striatum, brainstem, cingulate cortex and insula. Strongest associations were observed for the BAS subscale 'Fun Seeking'. Our results suggest that endogenous opioid system underlies BAS, and that differences in MOR availability could explain inter-individual differences in reward seeking behaviour.	[Karjalainen, Tomi; Tuominen, Lauri; Manninen, Sandra; Kalliokoski, Kari K.; Nuutila, Pirjo; Nummenmaa, Lauri] Univ Turku, Turku PET Ctr, FI-20520 Turku, Finland; [Karjalainen, Tomi; Tuominen, Lauri; Jaaskelainen, Iiro P.; Hari, Riitta; Sams, Mikko; Nummenmaa, Lauri] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, Espoo 00076, Finland; [Nuutila, Pirjo] Turku Univ Hosp, Dept Endocrinol, Turku 20521, Finland; [Hari, Riitta] Sch Arts Design & Architecture, Dept Art, Helsinki 00076, Finland; [Nummenmaa, Lauri] Univ Turku, Dept Psychol, Turku 20014, Finland	Karjalainen, T (reprint author), Turku Univ Hosp, Turku PET Ctr, FI-20520 Turku, Finland.	tomi.karjalainen@aalto.fi	Sams, Mikko E/G-7060-2012; Jaaskelainen, Iiro P/C-7392-2012; Hari, Riitta K/J-1880-2012	Jaaskelainen, Iiro P/0000-0001-6001-6950; Hari, Riitta K/0000-0002-3142-2703; Karjalainen, Tomi/0000-0002-8181-9493; Kalliokoski, Kari/0000-0002-8893-7126	Academy of Finland (MIND program) [265915, 138145, 218072]; ERCEuropean Research Council (ERC) [313000, 232946]	This research was supported by the Academy of Finland (MIND program grant 265915 to L.N., 138145 to I.P.J. and 218072 to R.H.), ERC Starting Grant 313000 to L.N. and ERC Advanced Grant 232946 to R.H. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alenius S, 1997, EUR J NUCL MED, V24, P258, DOI 10.1007/s002590050050; Barros-Loscertales A, 2006, EUR J NEUROSCI, V24, P2071, DOI 10.1111/j.1460-9568.2006.05084.x; Barros-Loscertales A, 2006, NEUROIMAGE, V33, P1011, DOI 10.1016/j.neuroimage.2006.07.025; Beaver JD, 2006, J NEUROSCI, V26, P5160, DOI 10.1523/JNEUROSCI.0350-06.2006; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9; Berridge KC, 2008, PSYCHOPHARMACOLOGY, V199, P457, DOI 10.1007/s00213-008-1099-6; Berridge KC, 2010, BRAIN RES, V1350, P43, DOI 10.1016/j.brainres.2010.04.003; CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319; Caseras X, 2003, PERS INDIV DIFFER, V34, P999, DOI 10.1016/S0191-8869(02)00084-3; Colasanti A, 2011, J PSYCHOPHARMACOL, V25, P1415, DOI 10.1177/0269881110367726; Coplan RJ, 2006, PERS INDIV DIFFER, V41, P917, DOI 10.1016/j.paid.2006.02.019; Costumero V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066940; Crockett MJ, 2009, J NEUROSCI, V29, P11993, DOI 10.1523/JNEUROSCI.2513-09.2009; DEAKIN J F W, 1991, Journal of Psychopharmacology, V5, P305, DOI 10.1177/026988119100500414; Depue RA, 1999, BEHAV BRAIN SCI, V22, P491; Dietrich A, 2014, FRONT PSYCHOL, V5, DOI [10.3389/fpsyg.2014.01073, 10.3389/fpsyg.2014.00079]; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Franken IHA, 2006, ADDICT BEHAV, V31, P399, DOI 10.1016/j.addbeh.2005.05.022; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Gray J, 2000, NOVART FDN SYMP, V231, P1, DOI 10.1002/0470870834.ch1; GRAY JA, 1987, J RES PERS, V21, P493, DOI 10.1016/0092-6566(87)90036-5; GRAY JA, 1970, BEHAV RES THER, V8, P249, DOI 10.1016/0005-7967(70)90069-0; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Hagelberg N, 2012, NEUROSCI LETT, V521, P11, DOI 10.1016/j.neulet.2012.05.042; Hahn T, 2009, NEUROIMAGE, V46, P1148, DOI 10.1016/j.neuroimage.2009.03.038; Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Heubeck BG, 1998, PERS INDIV DIFFER, V25, P785, DOI 10.1016/S0191-8869(98)00124-X; Hsu DT, 2013, MOL PSYCHIATR, V18, P1211, DOI [10.1038/mp.2013.96, 10.1038/mp.2013.139]; Johnson SL, 2003, J PSYCHOPATHOL BEHAV, V25, P25, DOI 10.1023/A:1022247919288; Karlsson HK, 2016, MOL PSYCHIATR, V21, P1057, DOI 10.1038/mp.2015.153; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Kasch KL, 2002, J ABNORM PSYCHOL, V111, P589, DOI 10.1037//0021-843X.111.4.589; Kimbrel NA, 2010, J ANXIETY DISORD, V24, P372, DOI 10.1016/j.janxdis.2010.02.002; Leknes S, 2008, NAT REV NEUROSCI, V9, P314, DOI 10.1038/nrn2333; Leone L, 2001, EUR J PERSONALITY, V15, P373, DOI 10.1002/per.415; Lesscher HMB, 2003, EUR J NEUROSCI, V17, P1006, DOI 10.1046/j.1460-9568.2003.02502.x; Love TM, 2009, ARCH GEN PSYCHIAT, V66, P1124, DOI 10.1001/archgenpsychiatry.2009.134; Lutz PE, 2013, TRENDS NEUROSCI, V36, P195, DOI 10.1016/j.tins.2012.11.002; Mague SD, 2009, P NATL ACAD SCI USA, V106, P10847, DOI 10.1073/pnas.0901800106; Mahler SV, 2007, NEUROPSYCHOPHARMACOL, V32, P2267, DOI 10.1038/sj.npp.1301376; Margolis E. B., 2015, TRENDS NEUROSCI, V38, P1; McConalogue K, 1999, NEUROSCIENCE, V90, P1051, DOI 10.1016/S0306-4522(98)00514-4; Mick I, 2016, NEUROPSYCHOPHARMACOL, V41, P1742, DOI 10.1038/npp.2015.340; Nummenmaa L, 2015, HUM BRAIN MAPP, V36, P3621, DOI 10.1002/hbm.22866; Papaleo F, 2007, EUR J NEUROSCI, V25, P3398, DOI 10.1111/j.1460-9568.2007.05595.x; Pecina M, 2015, NEUROPSYCHOPHARMACOL, V40, P957, DOI 10.1038/npp.2014.272; Pecina S, 2000, BRAIN RES, V863, P71, DOI 10.1016/S0006-8993(00)02102-8; Pickering A. D., 1999, HDB PERS THEORY RES, V2, P277; Rajashekara V, 2003, PHARMACOL BIOCHEM BE, V75, P909, DOI 10.1016/S0091-3057(03)00166-7; Salavert J, 2007, PERS INDIV DIFFER, V42, P1323, DOI 10.1016/j.paid.2006.10.010; Schwantes-An T., 2015, BEHAV GENET, P1; Simon JJ, 2010, NEUROIMAGE, V49, P1868, DOI 10.1016/j.neuroimage.2009.09.016; Spielberger C., 1983, MANUAL STATE TRAIT A; Tuominen L, 2015, NEUROIMAGE, V122, P80, DOI 10.1016/j.neuroimage.2015.08.001; Tuominen L, 2014, HUM BRAIN MAPP, V35, P1875, DOI 10.1002/hbm.22298; Tuominen L, 2012, NEUROIMAGE, V61, P670, DOI 10.1016/j.neuroimage.2012.03.063; Van Ree JM, 2000, EUR J PHARMACOL, V405, P89, DOI 10.1016/S0014-2999(00)00544-6; Weerts EM, 2011, ALCOHOL CLIN EXP RES, V35, P2162, DOI 10.1111/j.1530-0277.2011.01565.x; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200; Zhang Y, 2015, NEUROPSYCHOPHARMACOL, V40, P1091, DOI 10.1038/npp.2014.286; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	64	13	13	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1749-5016	1749-5024		SOC COGN AFFECT NEUR	Soc. Cogn. Affect. Neurosci.	AUG	2016	11	8					1310	1316		10.1093/scan/nsw044			7	Neurosciences; Psychology; Psychology, Experimental	Neurosciences & Neurology; Psychology	DW5ZU	WOS:000383727000014	27053768	Green Published, Other Gold			2020-06-30	J	Oppliger, M; Mauermann, E; Ruppen, W				Oppliger, Martine; Mauermann, Eckhard; Ruppen, Wilhelm			Are transdermal opioids contraindicated in patients at risk of suicide? An underappreciated problem	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							PAIN		[Oppliger, Martine; Mauermann, Eckhard; Ruppen, Wilhelm] Univ Basel Hosp, Dept Anaesthesia Surg Intens Care Prehosp Emergen, Spitalstr 21, CH-4031 Basel, Switzerland	Ruppen, W (reprint author), Univ Basel Hosp, Dept Anaesthesia Surg Intens Care Prehosp Emergen, Spitalstr 21, CH-4031 Basel, Switzerland.	wilhelm.ruppen@usb.ch					Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Hoffmann F, 2012, SCHMERZ, V26, P707, DOI 10.1007/s00482-012-1240-7; Ilgen MA, 2008, GEN HOSP PSYCHIAT, V30, P521, DOI 10.1016/j.genhosppsych.2008.09.003; Isaac M, 2012, THER ADV PSYCHOPHARM, V2, P255, DOI 10.1177/2045125312458311; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Saffier K, 2007, J SUBST ABUSE TREAT, V33, P303, DOI 10.1016/j.jsat.2006.12.011	6	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	AUG	2016	33	8					604	605		10.1097/EJA.0000000000000393			3	Anesthesiology	Anesthesiology	DQ6VX	WOS:000379344700017	26731432				2020-06-30	J	Ahiskalioglu, EO; Ahiskalioglu, A; Aydin, P; Arslan, Z; Aksoy, M; Temiz, A				Ahiskalioglu, Elif Oral; Ahiskalioglu, Ali; Aydin, Pelin; Arslan, Zakir; Aksoy, Mehmet; Temiz, Ayetullah			Effects of a single-dose preemptive pregabalin on acute and chronic pain after inguinal hernia repair with mesh under spinal anaesthesia A randomised controlled trial	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							POSTOPERATIVE PAIN		[Ahiskalioglu, Elif Oral; Aydin, Pelin; Arslan, Zakir] Erzurum Reg & Training Hosp, Dept Anaesthesiol & Reanimat, Erzurum, Turkey; [Ahiskalioglu, Ali; Aksoy, Mehmet] Ataturk Univ, Sch Med, Dept Anaesthesiol & Reanimat, Erzurum, Turkey; [Temiz, Ayetullah] Erzurum Reg & Training Hosp, Dept Gen Surg, Erzurum, Turkey	Ahiskalioglu, EO (reprint author), Reg Training & Res Hosp, Dept Anaesthesiol & Reanimat, TR-25070 Erzurum, Palandoken Erzu, Turkey.	drelforl@hotmail.com	Ahiskalioglu, Ali/B-7473-2016; Ahiskalioglu, Ali/K-5343-2019	Ahiskalioglu, Ali/0000-0002-8467-8171; Ahiskalioglu, Ali/0000-0002-8467-8171			Bafna Usha, 2014, J Anaesthesiol Clin Pharmacol, V30, P373, DOI 10.4103/0970-9185.137270; Balaban F, 2012, J CLIN ANESTH, V24, P175, DOI 10.1016/j.jclinane.2011.06.027; Buvanendran A, 2010, ANESTH ANALG, V110, P199, DOI 10.1213/ANE.0b013e3181c4273a; Fassoulaki A, 2012, EUR J ANAESTH, V29, P531, DOI 10.1097/EJA.0b013e32835800e0; Nienhuijs S, 2007, AM J SURG, V194, P394, DOI 10.1016/j.amjsurg.2007.02.012; Sagit M, 2013, J CRANIOFAC SURG, V24, P373, DOI 10.1097/SCS.0b013e31827fece5; Singla NK, 2015, J PAIN RES, V8, P9, DOI 10.2147/JPR.S67841	7	5	5	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	AUG	2016	33	8					605	607		10.1097/EJA.0000000000000395			4	Anesthesiology	Anesthesiology	DQ6VX	WOS:000379344700018	27120252				2020-06-30	J	Phillips, ML; Willis, BC; Broman, AJ; Lam, HV; Nguyen, TT; Austin, TM				Phillips, Maxie L.; Willis, Bryan C.; Broman, Aaron J.; Lam, Humphrey V.; Nguyen, Thanh T.; Austin, Thomas M.			Bimodal analgesia vs fentanyl in pediatric patients undergoing bilateral myringotomy and tympanostomy tube placement: a propensity matched cohort study	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Agitation; Analgesia; Myringotomy; Pain; Recovery; Rescue	SEVOFLURANE ANESTHESIA; INTRANASAL FENTANYL; CHILDREN; ACETAMINOPHEN; SURGERY; RELIABILITY; HALOTHANE; VALIDITY; SCALE	Study objective: Bilateral myringotomy and tympanostomy tube placement (BMT) is one of the most frequently performed pediatric outpatient procedures with 667,000 children receiving tympanostomy tubes annually. Because of this high volume, discovering the ideal analgesic regimen may lead to decreased overall postanesthesia care unit (PACU) costs while increasing patient and parent satisfaction. The purpose of this study is to determine if there is any benefit in supplementing intranasal (IN) fentanyl with intramuscular (IM) ketorolac with regard to immediate recovery characteristics. Design: Retrospective, cohort study. Setting: University-affiliated teaching hospital. Patients: One thousand one hundred forty American Society of Anesthesiologists physical status 1 and 2 pediatric patients scheduled for BMT. Interventions: No interventions were performed. Measurements: A propensity matched cohort of pediatric patients who underwent BMT at Vanderbilt Children's Hospital from 2011 to 2014 was analyzed. The authors compared PACU recovery time, rescue analgesic administration, maximal PACU pain scores, and maximal PACU agitation scores between subgroups of patients given either IN fentanyl and IM ketorolac or IN fentanyl alone intraoperatively. Main results: After adjusting for patient demographics and fentanyl dose, the fentanyl/ketorolac group received rescue analgesics 4.7% (95% confidence interval [CI], 2.0%-7.5%) less often, displayed moderate to severe pain 4.7% (95% CI, 1.5%-8.0%) less often, and experienced emergence agitation 3.6% (95% CI, 1.5%-5.8%) less often than patients in the fentanyl-only group. This corresponded to a relative risk reduction of 127%, 76%, and 200%, respectively. Conclusions: Based on our retrospective analysis, adding IM ketorolac to IN fentanyl may be beneficial to pediatric patients undergoing BMT. However, these results should be confirmed with a prospective, double blinded, randomized study. (C) 2016 Elsevier Inc. All rights reserved.	[Phillips, Maxie L.] Lincoln Mem Univ, DeBusk Coll Osteopath Med, 6965 Cumberland Gap Pkwy, Cumberland Gap, TN 37724 USA; [Willis, Bryan C.] Meharry Med Coll, 1005 Doctor DB Todd Jr Blvd, Nashville, TN 37208 USA; [Broman, Aaron J.; Lam, Humphrey V.; Nguyen, Thanh T.; Austin, Thomas M.] Vanderbilt Univ, Sch Med, Div Pediat Anesthesiol, Dept Anesthesiol, 2200 Childrens Way,Suite 3115, Nashville, TN 37232 USA	Austin, TM (reprint author), Vanderbilt Univ, Sch Med, Div Pediat Anesthesiol, Dept Anesthesiol, 2200 Childrens Way,Suite 3115, Nashville, TN 37232 USA.	thomas.austin@vanderbilt.edu			Department of Anesthesiology, Vanderbilt University School of Medicine; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32GM108554]	Financial support for the preparation of this manuscript was provided from departmental funds of the Department of Anesthesiology, Vanderbilt University School of Medicine. Dr Austin is supported by National Institutes of Health grant T32GM108554.	Austin PC, 2005, STAT MED, V24, P1563, DOI 10.1002/sim.2053; Bajwa SA, 2010, PEDIATR ANESTH, V20, P704, DOI 10.1111/j.1460-9592.2010.03328.x; Bennie RE, 1998, ANESTHESIOLOGY, V89, P385, DOI 10.1097/00000542-199808000-00015; Coca-Perraillon M, 2007, SAS GLOBAL FORUM; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Habib AS, 2006, CURR MED RES OPIN, V22, P1093, DOI 10.1185/030079906X104830; Lanehart RE, 2012, PROPENSITY SCORE ANA; Malviya S, 2006, PEDIATR ANESTH, V16, P258, DOI 10.1111/j.1460-9592.2005.01773.x; Olsson U., 2005, J STAT ED, V13, P1, DOI DOI 10.1080/10691898.2005.11910638; Pappas AL, 2003, ANESTH ANALG, V96, P1621, DOI 10.1213/01.ANE.0000064206.51296.1D; Rampersad S, 2010, PEDIATR ANESTH, V20, P1028, DOI 10.1111/j.1460-9592.2010.03427.x; Rosenfeld RM, 2013, OTOLARYNG HEAD NECK, V149, pS1, DOI 10.1177/0194599813487302; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Sarasoja I, 2013, PEDIATR INFECT DIS J, V32, P517, DOI 10.1097/INF.0b013e31827c9bcc; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Subramanyam R, 2014, PEDIATR ANESTH, V24, P467, DOI 10.1111/pan.12359; Tos M, 1984, OTOL NEUROTOL, V5, P459; Wallace IF, 2014, PEDIATRICS; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224; WILLIAMSON IG, 1994, J LARYNGOL OTOL, V108, P930, DOI 10.1017/S0022215100128567; Yang D., 2012, SAS GLOBAL FORUM	24	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	AUG	2016	32						162	168		10.1016/j.jclinane.2016.03.003			7	Anesthesiology	Anesthesiology	DP3AU	WOS:000378365600036	27290968				2020-06-30	J	Hoshijima, H; Takeuchi, R; Kuratani, N; Nishizawa, S; Denawa, Y; Shiga, T; Nagasaka, H				Hoshijima, Hiroshi; Takeuchi, Risa; Kuratani, Norifumi; Nishizawa, Shuya; Denawa, Yohei; Shiga, Toshiya; Nagasaka, Hiroshi			Incidence of postoperative shivering comparing remifentanil with other opioids: a meta-analysis	JOURNAL OF CLINICAL ANESTHESIA			English	Review						Remifentanil; Postoperative shivering	TOTAL INTRAVENOUS ANESTHESIA; SUFENTANIL-PROPOFOL; ALFENTANIL; FENTANYL; SURGERY; RECOVERY; PHARMACOKINETICS; NEUROSURGERY; ISOFLURANE; CRANIOTOMY	Study Objective: To determine whether the administration of remifentanil increases the incidence of postoperative shivering in comparison with the administration of alfentanil, fentanyl, or sufentanil. Design: Meta-analysis. Setting: Operating room and postanesthesia care unit. Measurements: We performed a computerized search of articles on PubMed, MEDLINE, and Scopus. Meta-analysis was performed using Review Manager and the DerSimonian and Laird random-effects model. The pooled effect estimates for binary variables were calculated as relative risk (RR) values with 95% confidence intervals (CIs). Main Results: Eighteen randomized controlled trials met our inclusion criteria. Remifentanil was associated with a significantly increased incidence of postoperative shivering compared with other opioids (RR = 2.17; CI, 1.76-2.68; P < .00001; I-2 = 0.00%). A subgroup analysis of remifentanil compared with alfentanil, fentanyl, or sufentanil showed that only sufentanil had a similar rate of postoperative shivering incidence (RR = 2.13; CI, 0.67-6.74; P = .20; I-2 = 0.00%). Remifentanil administration was associated with a significant increase in the incidence of postoperative shivering compared with the administration of other opioids when both propofol (RR = 2.44; CI, 1.52-3.92; P = .0002; I-2 = 0.00%) and inhalation anesthesia drugs (RR = 2.45; CI, 1.46-4.11; P = .0007; I-2 = 0.00%) were used for anesthesia maintenance. In addition, the administration of remifentanil at both low (RR = 2.06; CI, 1.63-2.60; P < .00001; I-2 = 0.00%) and high dosages (RR = 2.77; CI, 1.67-4.57; P<.0001; I-2 = 0.00%) was associated with a significant increase in the incidence of postoperative shivering compared with the administration of other opioids. Conclusions: Our meta-analysis showed that remifentanil was associated with an increased incidence of postoperative shivering compared with alfentanil or fentanyl, but no significant difference was seen when compared with sufentanil. (C) 2015 Elsevier Inc. All rights reserved.	[Hoshijima, Hiroshi; Takeuchi, Risa; Nishizawa, Shuya; Nagasaka, Hiroshi] Saitama Med Univ Hosp, Dept Anesthesiol, 38 Morohongo, Moroyama, Saitama 3500495, Japan; [Kuratani, Norifumi] Saitama Childrens Med Ctr, Dept Anesthesiol, Saitama, Japan; [Denawa, Yohei] Drexel Univ, Coll Med, Dept Internal Med, Philadelphia, PA 19104 USA; [Shiga, Toshiya] Int Univ Hlth & Welf, Kaken Hosp, Chemotherapy Res Inst, Dept Anesthesia, Chiba, Japan	Hoshijima, H (reprint author), Saitama Med Univ Hosp, Dept Anesthesiol, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	hhoshi@saitama-med.ac.jp		Shiga, Toshiya/0000-0003-0347-7181			Ahonen J, 2000, ANESTH ANALG, V90, P1269, DOI 10.1097/00000539-200006000-00003; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Apitzsch H, 1999, ANAESTHESIST, V48, P301, DOI 10.1007/s001010050705; BAY J, 1968, BRIT J ANAESTH, V40, P398, DOI 10.1093/bja/40.6.398; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bilotta F, 2007, EUR J ANAESTH, V24, P122, DOI 10.1017/S0265021506001244; Cartwright DP, 1997, ANESTH ANALG, V85, P1014, DOI 10.1097/00000539-199711000-00011; Coskun D, 2010, J ANESTH, V24, P373, DOI 10.1007/s00540-010-0898-1; Crozier TA, 2004, EUR J ANAESTH, V21, P20, DOI 10.1017/S0265021504001048; De Jongh RF, 2003, CYTOKINE, V21, P248, DOI 10.1016/S1043-4666(03)00093-0; Del Gaudio A, 2006, MINERVA ANESTESIOL, V72, P309; deWitte J, 1997, ACTA ANAESTH SCAND, V41, P506, DOI 10.1111/j.1399-6576.1997.tb04732.x; Egan TD, 1996, ANESTHESIOLOGY, V84, P821, DOI 10.1097/00000542-199604000-00009; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Erhan E, 2003, EUR J ANAESTH, V20, P37, DOI 10.1097/00003643-200301000-00007; Facco E, 1999, BRIT J ANAESTH, V82, P119; Gargiulo G, 2003, Minerva Anestesiol, V69, P119; Grottke O, 2004, ANESTH ANALG, V99, P1521, DOI 10.1213/01.ANE.0000134684.25322.26; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Gunduz M, 2004, NEUROSURG QUART, V14, P204, DOI 10.1097/00013414-200412000-00004; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184; Horn EP, 1998, ANESTHESIOLOGY, V89, P878, DOI 10.1097/00000542-199810000-00012; Horn EP, 1997, ANESTH ANALG, V84, P613, DOI 10.1097/00000539-199703000-00028; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Iannuzzi E, 2003, Minerva Anestesiol, V69, P127; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Kranke P, 2002, ANESTH ANALG, V94, P453, DOI 10.1097/00000539-200202000-00043; MACINTYRE PE, 1987, ANESTH ANALG, V66, P751; Martorano PP, 2008, MINERVA ANESTESIOL, V74, P233; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Mollhoff T, 2001, BRIT J ANAESTH, V87, P718, DOI 10.1093/bja/87.5.718; Nakasuji M, 2010, BRIT J ANAESTH, V105, P162, DOI 10.1093/bja/aeq121; Negishi C, 2001, ANESTHESIOLOGY, V94, P218, DOI 10.1097/00000542-200102000-00009; Pandazi AK, 2003, ANN OTO RHINOL LARYN, V112, P373, DOI 10.1177/000348940311200414; Rama-Maceiras P, 2005, ACTA ANAESTH SCAND, V49, P305, DOI 10.1111/j.1399-6576.2005.00650.x; Schuttler J, 1997, ANAESTHESIA, V52, P307, DOI 10.1111/j.1365-2044.1997.24-az0051.x; Sessler DI, 1994, ANESTHESIA, P1363; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Sofianou A., 2001, European Journal of Anaesthesiology, V18, P45; Wilhelm W, 2000, J CLIN ANESTH, V12, P129, DOI 10.1016/S0952-8180(00)00125-2; Wuesten R, 2001, ANESTHESIOLOGY, V94, P211, DOI 10.1097/00000542-200102000-00008	43	6	6	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	AUG	2016	32						300	312		10.1016/j.jclinane.2015.08.017			13	Anesthesiology	Anesthesiology	DP3AU	WOS:000378365600061	26432635				2020-06-30	J	Wiczling, P; Bieda, K; Przybylowski, K; Hartmann-Sobczynska, R; Borsuk, A; Matysiak, J; Kokot, ZJ; Sobczynski, P; Grzeskowiak, E; Bienert, A				Wiczling, Pawel; Bieda, Krzysztof; Przybylowski, Krzysztof; Hartmann-Sobczynska, Roma; Borsuk, Agnieszka; Matysiak, Jan; Kokot, Zenon J.; Sobczynski, Pawel; Grzeskowiak, Edmund; Bienert, Agnieszka			Pharmacokinetics and pharmacodynamics of propofol and fentanyl in patients undergoing abdominal aortic surgery - a study of pharmacodynamic drug-drug interactions	BIOPHARMACEUTICS & DRUG DISPOSITION			English	Article						propofol; fentanyl; abdominal aortic surgery; PK/PD	BISPECTRAL INDEX; FEMALE-PATIENTS; SKIN INCISION; ANESTHESIA; REMIFENTANIL; CONSCIOUSNESS; ALFENTANIL; CHILDREN; BLOOD; CHROMATOGRAPHY	Propofol is routinely combined with opioid analgesics to ensure adequate anesthesia during surgery. The aim of the study was to assess the effect of fentanyl on the hypnotic effect of propofol and the possible clinical implications of this interaction. The pharmacokinetic/pharmacodynamic (PK/PD) data were obtained from 11 patients undergoing abdominal aortic surgery, classified as ASA III. Propofol was administered by a target-controlled infusion system. Fentanyl 2-3 mu g/kg was given whenever insufficient analgesia occurred. The bispectral index (BIS) was used to monitor the depth of anesthesia. A population PK/PD analysis with a non-linear mixed-effect model (NONMEM 7.2 software) was conducted. Two-compartment models satisfactorily described the PK of propofol and fentanyl. The delay of the anesthetic effect in relation to PK was described by the effect compartment. The BIS was linked to propofol and fentanyl effect-site concentrations through an additive E-max model. Context-sensitive decrement times (CSDT) determined from the final model were used to assess the influence of fentanyl on the recovery after anesthesia. The population PK/PD model was successfully developed to describe simultaneously the time course and variability of propofol and fentanyl concentrations and BIS. Additive propofol-fentanyl interactions were observed and quantitated. The duration of the fentanyl infusion had minimal effect on CSDT when it was shorter than the duration of the propofol infusion. If the fentanyl infusion was longer than the propofol infusion, an almost two-fold increase in CSDT occurred. Additional doses of fentanyl administered after the cessation of the propofol infusion result in lower BIS values, and can prolong the time of recovery from anesthesia. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Wiczling, Pawel; Borsuk, Agnieszka] Med Univ Gdansk, Dept Biopharmaceut & Pharmacodynam, Gdansk, Poland; [Bieda, Krzysztof; Sobczynski, Pawel] Poznan Univ Med Sci, Dept Anesthesiol & Intens Therapy, Poznan, Poland; [Przybylowski, Krzysztof; Grzeskowiak, Edmund; Bienert, Agnieszka] Poznan Univ Med Sci, Dept Clin Pharm & Biopharm, Poznan, Poland; [Hartmann-Sobczynska, Roma] Poznan Univ Med Sci, Dept Expt Anesthesiol, Poznan, Poland; [Matysiak, Jan; Kokot, Zenon J.] Poznan Univ Med Sci, Dept Inorgan & Analyt Chem, Poznan, Poland	Przybylowski, K (reprint author), Poznan Univ Med Sci, Dept Clin Pharm & Biopharm, Ul Sw Marii Magdaleny 14, PL-61861 Poznan, Poland.	przybylowski@ump.edu.pl	Wiczling, Pawel/T-3987-2018; Matysiak, Jan/R-6498-2016	Wiczling, Pawel/0000-0002-2878-3161; Matysiak, Jan/0000-0002-9993-1504; Hartmann-Sobczynska, Roma/0000-0001-9530-563X; Grzeskowiak, Edmund/0000-0002-9938-6729; Sobczynski, Pawel/0000-0003-1653-0623; Kokot, Zenon/0000-0003-4950-9759; Bienert, Agnieszka/0000-0001-7272-5738; Borsuk-De Moor, Agnieszka/0000-0001-9181-0073; Bieda, Krzysztof/0000-0002-6610-684X			Agrawal D, 2004, ANN EMERG MED, V43, P247, DOI 10.1016/S0196-0644(03)00721-2; Bartkowska-Sniatkowska A, 2014, PHARMACOL REP, V66, P821, DOI 10.1016/j.pharep.2014.04.012; BENSHLOMO I, 1993, ANAESTHESIA, V48, P111; Bienert A, 2012, PHARMACOL REP, V64, P782, DOI 10.1016/S1734-1140(12)70874-5; Bienert A, 2011, ARZNEIMITTEL-FORSCH, V61, P545, DOI 10.1055/s-0031-1300552; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Dawidowicz AL, 2003, BIOMED CHROMATOGR, V17, P447, DOI 10.1002/bmc.269; Dawidowicz AL, 2000, BIOMED CHROMATOGR, V14, P249, DOI 10.1002/1099-0801(200006)14:4<249::AID-BMC981>3.0.CO;2-H; Fechner J, 2003, EUR J ANAESTH, V20, P373, DOI 10.1097/00003643-200305000-00004; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Jain U, 1996, J CLIN ANESTH, V8, pS61, DOI 10.1016/S0952-8180(96)90014-8; Jeleazcov C, 2008, BRIT J ANAESTH, V100, P509, DOI 10.1093/bja/aem408; Kazama T, 1998, ANESTHESIOLOGY, V89, P894, DOI 10.1097/00000542-199810000-00014; Koitabashi T, 2002, ANESTH ANALG, V94, P1530, DOI 10.1097/00000539-200206000-00028; Lehr T, 2010, CLIN PHARMACOKINET, V49, P53, DOI 10.2165/11317210-000000000-00000; Ludbrook GL, 2003, ANESTH ANALG, V97, P924, DOI 10.1213/01.ANE.0000077162.24188.A8; Mertens MJ, 2004, ANESTHESIOLOGY, V100, P795, DOI 10.1097/00000542-200404000-00008; Mertens MJ, 2001, ANESTHESIOLOGY, V94, P949, DOI 10.1097/00000542-200106000-00006; Mi WD, 2004, EUR J ANAESTH, V21, P807, DOI 10.1017/S0265021504000092; Mi WD, 2003, J CLIN ANESTH, V15, P103, DOI 10.1016/S0952-8180(02)00510-X; Minto CF, 2000, ANESTHESIOLOGY, V92, P1603, DOI 10.1097/00000542-200006000-00017; Parke J, 1999, COMPUT METH PROG BIO, V59, P19, DOI 10.1016/S0169-2607(98)00098-4; Peeters MMM, 2008, CLIN PHARMACOL THER, V83, P443, DOI 10.1038/sj.clpt.6100309; PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Savic RM, 2009, AAPS J, V11, P558, DOI 10.1208/s12248-009-9133-0; Schraag S, 1998, ANESTH ANALG, V86, P184, DOI 10.1097/00000539-199801000-00036; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Stanley TH, 1999, ANESTHESIA NEW MILLE; STANSKI DR, 1995, ANESTHESIOLOGY, V83, P1, DOI 10.1097/00000542-199507000-00001; Venkataraman R, 2006, CRIT CARE MED, V34, pS200, DOI 10.1097/01.CCM.0000231885.74567.4F; VUYK J, 1992, ANESTHESIOLOGY, V77, P3, DOI 10.1097/00000542-199207000-00002; Vuyk J, 2001, Acta Anaesthesiol Belg, V52, P445; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033; VUYK J, 1993, ANESTHESIOLOGY, V79, pA332; Wiczling P, 2012, PHARMACOL REP, V64, P113, DOI 10.1016/S1734-1140(12)70737-5; YOUNGS EJ, 1994, ANESTHESIOLOGY, V81, P833, DOI 10.1097/00000542-199410000-00010	38	6	6	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0142-2782	1099-081X		BIOPHARM DRUG DISPOS	Biopharm. Drug Dispos.	JUL	2016	37	5					252	263		10.1002/bdd.2009			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DW4PW	WOS:000383626500002	26990035				2020-06-30	J	de Oliveira, GL; Serralheiro, FC; Fonseca, FLA; Ribeiro, OD; Adami, F; Christofolini, DM; Bianco, B; Barbosa, CP				de Oliveira Junior, Gilvandro Lins; Serralheiro, Fernando Cesar; Affonso Fonseca, Fernando Luiz; Ribeiro Junior, Onesimo Duarte; Adami, Fernando; Christofolini, Denise Maria; Bianco, Bianca; Barbosa, Caio Parente			Randomized double-blind clinical trial comparing two anesthetic techniques for ultrasound-guided transvaginal follicular puncture	EINSTEIN-SAO PAULO			English	Article						Anesthesia; Reproductive techniques; Fentanyl; Propofol; Midazolam	OOCYTE RETRIEVAL; GENERAL-ANESTHESIA; FERTILIZATION; REMIFENTANIL; SEDATION; RATES	Objective: To compare the anesthetic techniques using propofol and fentanyl versus midazolam and remifentanil associated with a paracervical block with lidocaine in performing ultrasound-guided transvaginal oocyte aspiration. Methods: A randomized double-blind clinical trial (#RBR-8kqqxh) performed in 61 women submitted to assisted reproductive treatment. The patients were divided into two groups: anesthetic induction with 1mcg/kg of fentanyl associated with 1.5mg/kg of propofol (FP Group, n=32), in comparison with anesthetic induction using 0.075mg/kg of midazolam associated with 0.25mcg/kg/min of remifentanil, and paracervical block with 3mL of 2% lidocaine (MRPB Group, n=29). Main outcome measures: human reproduction outcomes, modified Aldrete-Kroulik index, hemodynamic parameters, and salivary cortisol. Results: The results revealed a higher number of embryos formed in the FP Group (p50=2 versus 1; p=0.025), gestation rate two times higher in the FP Group (44.4% versus 22.2%; p=0.127), less time to reach AK=10 in the MRPB Group (p50=10 versus 2; p<0.001), and lower mean of hemodynamic parameters in the MRPB Group (p<0.05). Conclusion: Anesthesia with fentanyl and propofol as well as with midazolam, remifentanil, and paracervical block offered satisfactory anesthetic conditions when performing assisted reproduction procedures, providing comfort for the patient and physician.	[de Oliveira Junior, Gilvandro Lins; Serralheiro, Fernando Cesar; Affonso Fonseca, Fernando Luiz; Ribeiro Junior, Onesimo Duarte; Adami, Fernando; Christofolini, Denise Maria; Bianco, Bianca; Barbosa, Caio Parente] ABC, Fac Med, Santo Andre, SP, Brazil	Bianco, B (reprint author), Ave Principe de Gales,821 Vila Principe Gales, BR-09060650 Santo Andre, SP, Brazil.	bianca.bianco@hotmail.com	BIANCO, BIANCA/C-2488-2012; Adami, Fernando/D-3855-2012; Christofolini, Denise Maria/H-6984-2012	Adami, Fernando/0000-0003-1918-3364; Bianco, Bianca/0000-0001-8669-3562; Barbosa, Caio/0000-0002-2922-0264			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; An Y, 2011, FERTIL STERIL, V96, P404, DOI 10.1016/j.fertnstert.2011.05.092; Azemati S, 2013, ACTA ANAESTH BELG, V64, P25; BORGEAT A, 1992, ANESTH ANALG, V74, P539; Bumen S, 2011, TURK J MED SCI, V41, P801, DOI 10.3906/sag-1009-1101; COETSIER T, 1992, HUM REPROD, V7, P1422, DOI 10.1093/oxfordjournals.humrep.a137586; Coskun D, 2011, CLINICS, V66, P811, DOI 10.1590/S1807-59322011000500017; Hammadeh ME, 1999, ARCH GYNECOL OBSTET, V263, P56, DOI 10.1007/s004040050263; Jain D, 2009, INDIAN J ANAESTH, V53, P408; Kaya K, 2005, TURK J MED SCI, V35, P99; Kwan I, 2006, HUM REPROD, V21, P1672, DOI 10.1093/humrep/del002; Liu Gao-wang, 2004, Di Yi Jun Yi Da Xue Xue Bao, V24, P1304; Peacock JE, 1999, ANESTH ANALG, V89, pS22; Roberts ADL, 2004, BRIT J PSYCHIAT, V184, P136, DOI 10.1192/bjp.184.2.136; Soares António José de Almeida, 2006, Psic., Saúde & Doenças, V7, P165	15	3	3	0	2	INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN	SAO PAULO SP	AVENIDA ALBERT EINSTEIN, 627 701, SAO PAULO SP, 05651-901, BRAZIL	1679-4508	2317-6385		EINSTEIN-SAO PAULO	Einstein	JUL-SEP	2016	14	3					305	310		10.1590/S1679-45082016AO3714			6	Medicine, General & Internal	General & Internal Medicine	DZ3CD	WOS:000385720600003	27759816	DOAJ Gold, Green Published			2020-06-30	J	Hayek, SM; Sweet, JA; Miller, JP; Sayegh, RR				Hayek, Salim M.; Sweet, Jennifer A.; Miller, Jonathan P.; Sayegh, Rony R.			Successful Management of Corneal Neuropathic Pain with Intrathecal Targeted Drug Delivery	PAIN MEDICINE			English	Article						Neuropathic Pain; Cornea; Dry Eye; Intrathecal Infusion; Intrathecal Drug Delivery System; Intrathecal Pump; Bupivacaine; Fentanyl; Trigeminal Neuropathy	CHRONIC NONMALIGNANT PAIN; SPINAL-CORD DISTRIBUTION; CEREBROSPINAL-FLUID; GASSERIAN GANGLION; BUPIVACAINE; MORPHINE; INFUSION; STIMULATION; ROPIVACAINE; PIGS	Objective. To describe the successful treatment of refractory corneal neuropathic pain with neuromodulation techniques. Design. Single case report. Setting. Academic tertiary care center in the United States of America. Subject and Methods. A 30-year-old woman presented with a 7-year history of refractory bilateral keratoneuralgia following laser-assisted in-situ keratomileusis (LASIK) procedure on both eyes. Having failed all conservative measures, the patient initially underwent trigeminal nerve stimulation and subsequently was implanted with an intrathecal drug delivery system (IDDS) with the catheter placed at the level C1. Results. Following an initial favorable response to the trigeminal nerve stimulator, the pain became refractory to neurostimulation after a few months and the system was explanted. The patient was successfully trialed with an intrathecal catheter placed at the level of C1 delivering a combination of bupivacaine and low dose fentanyl. The patient was then implanted with an IDDS equipped with a patient-activated bolus system. The patient was very satisfied with the treatment and has had greater than 50% pain relief for over a year. Conclusions. Intrathecal delivery of bupivacaine and low dose fentanyl in the upper cervical spine can be effective in controlling refractory eye pain in properly selected patients and treatment centers.	[Hayek, Salim M.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Dept Anesthesiol, Div Pain Med, Cleveland, OH 44106 USA; [Sweet, Jennifer A.; Miller, Jonathan P.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Dept Neurol Surg, Div Funct Neurosurg, Cleveland, OH 44106 USA; [Sayegh, Rony R.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Dept Ophthalmol, Univ Hosp Eye Inst, Cleveland, OH 44106 USA	Hayek, SM (reprint author), Univ Hosp Case Med Ctr, Div Pain Med, Cleveland, OH 44106 USA.	salim.hayek@uhhospitals.org	Sayegh, Rony/G-8777-2013	Sayegh, Rony/0000-0002-0119-4201			Allen JW, 2006, ANESTHESIOLOGY, V105, P581, DOI 10.1097/00000542-200609000-00024; Bartsch T, 2002, BRAIN, V125, P1496, DOI 10.1093/brain/awf166; Bernards CM, 2006, ANESTHESIOLOGY, V105, P169, DOI 10.1097/00000542-200607000-00027; BOSWELL MV, 1992, REGION ANESTH, V17, P37; Cabbell KL, 1998, NEUROSURGERY, V42, P1176, DOI 10.1097/00006123-199805000-00142; Coffey RJ, 2002, NEUROSURGERY, V50, P78, DOI 10.1097/00006123-200201000-00014; Deer Timothy R, 2004, Pain Physician, V7, P225; Deer Timothy R, 2002, Spine J, V2, P274, DOI 10.1016/S1529-9430(02)00199-7; Deer TR, 2012, NEUROMODULATION, V15, P467, DOI 10.1111/j.1525-1403.2012.00486.x; Deer TR, 2012, NEUROMODULATION, V15, P483, DOI 10.1111/j.1525-1403.2012.00449.x; Deer TR, 2012, NEUROMODULATION, V15, P436, DOI 10.1111/j.1525-1403.2012.00476.x; Flack SH, 2011, ANESTH ANALG, V112, P460, DOI 10.1213/ANE.0b013e318203b7c0; Flack SH, 2010, ANESTHESIOLOGY, V112, P165, DOI 10.1097/ALN.0b013e3181c38da5; Galor A, 2015, BRIT J OPHTHALMOL, V99, P665, DOI 10.1136/bjophthalmol-2014-306057; Grider JS, 2011, PAIN PHYSICIAN, V14, P343; Hamza M, 2012, PAIN MED, V13, P1304, DOI 10.1111/j.1526-4637.2012.01451.x; Hayek SM, 2015, NEUROMODULATION, V18, P603, DOI 10.1111/ner.12312; Hayek SM, 2013, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-013-0388-x; Hayek SM, 2011, PAIN MED, V12, P1179, DOI 10.1111/j.1526-4637.2011.01188.x; Henry-Feugeas MC, 2000, MAGN RESON IMAGING, V18, P387, DOI 10.1016/S0730-725X(99)00142-3; KERR FW, 1961, ARCH NEUROL-CHICAGO, V5, P171, DOI 10.1001/archneur.1961.00450140053005; KERR FW, 1961, EXP NEUROL, V4, P134, DOI 10.1016/0014-4886(61)90036-X; KRAMES ES, 1993, J PAIN SYMPTOM MANAG, V8, P36, DOI 10.1016/0885-3924(93)90118-F; Launay PS, 2015, EXP EYE RES, V139, P136, DOI 10.1016/j.exer.2015.06.008; LAZORTHES Y, 1987, PACE, V10, P257, DOI 10.1111/j.1540-8159.1987.tb05959.x; Levin A, 1998, ANESTH ANALG, V87, P624, DOI 10.1097/00000539-199809000-00025; Levy RM, 2013, NEUROMODULATION, V16, P495, DOI 10.1111/ner.12148; Lundborg C, 2009, ACTA ANAESTH SCAND, V53, P908, DOI 10.1111/j.1399-6576.2009.01989.x; Machado A, 2007, STEREOT FUNCT NEUROS, V85, P216, DOI 10.1159/000103260; Mammis A, 2015, ADV TECH STAND NEURO, V42, P23, DOI 10.1007/978-3-319-09066-5_2; Mironer YE, 2002, NEUROMODULATION, V5, P208, DOI 10.1046/j.1525-1403.2002.02031.x; NORTH RB, 1991, NEUROSURGERY, V29, P778, DOI 10.1227/00006123-199111000-00025; Ortner CM, 2010, ACTA ANAESTH SCAND, V54, P1000, DOI 10.1111/j.1399-6576.2010.02254.x; Parpaglioni R, 2009, ACTA ANAESTH SCAND, V53, P1214, DOI 10.1111/j.1399-6576.2009.02033.x; PENNING JP, 1992, ANESTHESIOLOGY, V77, P1186, DOI 10.1097/00000542-199212000-00021; Rosenthal P, 2016, BRIT J OPHTHALMOL, V100, P128, DOI 10.1136/bjophthalmol-2014-306280; ROZSA AJ, 1982, PAIN, V14, P105, DOI 10.1016/0304-3959(82)90092-6; TAREN JA, 1962, J NEUROSURG, V19, P116, DOI 10.3171/jns.1962.19.2.0116; TEJWANI GA, 1992, ANESTH ANALG, V74, P726; van Dongen RTM, 1999, CLIN J PAIN, V15, P166, DOI 10.1097/00002508-199909000-00002; Veizi IE, 2011, PAIN MED, V12, P1481, DOI 10.1111/j.1526-4637.2011.01232.x; YOUNG RF, 1995, J NEUROSURG, V83, P72, DOI 10.3171/jns.1995.83.1.0072	42	11	11	1	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	JUL	2016	17	7					1302	1307		10.1093/pm/pnv058			6	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	DZ1WK	WOS:000385632100013	26814286	Bronze			2020-06-30	J	Harlin, SA; Grissom, RA; LeCroy, C; Pouliot, SM; Harlin, SA				Harlin, Stuart A.; Grissom, Ruth A.; LeCroy, Christopher; Pouliot, Susan M.; Harlin, Scott A.			A Novel Anesthetic Technique for PEVAR	ANNALS OF VASCULAR SURGERY			English	Article							ABDOMINAL AORTIC-ANEURYSM; LOCAL-ANESTHESIA; OPEN REPAIR; EXPOSURE; COST	Background: Percutaneous endovascular aneurysm repair ( PEVAR) continues to evolve. Device profiles continue to decline, further reducing the physiological insult of the procedure. Anesthesia, however, has not evolved with a large proportion of patients continuing to receive general anesthesia for their increasingly less invasive procedures. We report on a novel anesthetic technique providing outstanding anesthesia in patients undergoing PEVAR in an outpatient setting. The total anesthesia used was remarkably cost effective. Methods: Six patients underwent PEVAR in an outpatient setting. The patients received moderate intravenous ( IV) access sedation using versed and fentanyl in combination with bilateral ilioinguinal nerve blocks. Patients received 25 mL bilaterally of 0.5% bupivicaine with epinephrine. All patients were American Society of Anesthesiologists class III. None received central venous access, arterial, or urinary catheters. Standard noninvasive monitoring was used. A board-certified anesthesiologist was present at all times during the procedures. Results: All patients underwent successful repair. Average cost per case for anesthetic supplies averaged around $7.00. The fentanyl dose ranged from 100 to 200 mg with an average dose of 130 mg. Versed dose ranged from 2 to 3 mg with an average dose of 2.4 mg. No patient required conversion to general anesthesia. Postoperative pain relief was excellent. Two patients required pain medication before discharge. Two patients required oral narcotic analgesic the night of discharge. No patients required narcotics after that time. Conclusions: Bilateral ilioinguinal nerve block, when combined with moderate IV sedation allows outstanding anesthesia for patients undergoing PEVAR. This novel combination has not been reported previously. The technique provides safe, effective, care for of a subset of patients not requiring general anesthesia. It offers a greatly reduced cost when compared with general anesthesia. Additional benefits include prolonged pain relief perioperatively as well as potentially decreasing the physiologic and cognitive effects seen with general anesthesia.	[Harlin, Stuart A.; Grissom, Ruth A.; LeCroy, Christopher; Pouliot, Susan M.; Harlin, Scott A.] Coastal Vasc & Intervent Ctr, Pensacola, FL USA	Harlin, SA (reprint author), 6400 Fannin St Suite,2580, Houston, TX 77030 USA.	stuart.a.harlin@uth.tmc.edu					Abdellatif Abualhassan A, 2012, Saudi J Anaesth, V6, P367, DOI 10.4103/1658-354X.105868; Demirci A, 2014, REV BRAS ANESTESIOL, V64, P350, DOI [10.1016/j.bjane.2014.01.001, 10.1016/j.bjan.2014.01.001]; Edwards ST, 2014, J VASC SURG, V59, P575, DOI 10.1016/j.jvs.2013.08.093; Henretta JP, 1999, J VASC SURG, V29, P793, DOI 10.1016/S0741-5214(99)70205-3; Hussain M, 2014, CLIN INTERV AGING, V9, P1619, DOI 10.2147/CIA.S49680; Krajcer Z, 2012, J CARDIOVASC SURG, V53, P695; Nelson PR, 2014, J VASC SURG, V59, P1181, DOI 10.1016/j.jvs.2013.10.101; Setacci F, 2013, J ENDOVASC THER, V20, P655, DOI 10.1583/13-4288MR.1; Sternbergh WC, 2000, J VASC SURG, V31, P237, DOI 10.1016/S0741-5214(00)90154-X; Stone DH, 2014, J VASC SURG, V59, P283, DOI 10.1016/j.jvs.2013.08.047; Trivascular Inc, LIFE STUD LEAST INV; Verhoeven ELG, 2005, J VASC SURG, V42, P402, DOI 10.1016/j.jvs.2005.05.047	12	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0890-5096	1615-5947		ANN VASC SURG	Ann. Vasc. Surg.	JUL	2016	34						106	110		10.1016/j.avsg.2015.12.008			5	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	DT7RY	WOS:000381685700009	27116905				2020-06-30	J	Pierik, JGJ; Berben, SA; IJzerman, MJ; Gaakeer, MI; van Eenennaam, FL; van Vugt, AB; Doggen, CJM				Pierik, Jorien G. J.; Berben, Sivera A.; IJzerman, Maarten J.; Gaakeer, Menno I.; van Eenennaam, Fred L.; van Vugt, Arie B.; Doggen, Carine J. M.			A nurse-initiated pain protocol in the ED improves pain treatment in patients with acute musculoskeletal pain	INTERNATIONAL EMERGENCY NURSING			English	Article						Nurse-initiated pain protocol; Analgesics; Acute musculoskeletal pain; Emergency department; Clinically relevant pain relief	NUMERICAL RATING-SCALE; EMERGENCY-DEPARTMENT; TRAUMA PATIENTS; MANAGEMENT; RELIEF; ANALGESIA; CONSEQUENCES; VALIDATION	While acute musculoskeletal pain is a frequent complaint, its management is often neglected. An implementation of a nurse-initiated pain protocol based on the algorithm of a Dutch pain management guideline in the emergency department might improve this. A pre-post intervention study was performed as part of the prospective PROTACT follow-up study. During the pre-( 15 months, n = 504) and post-period ( 6 months, n = 156) patients' self-reported pain intensity and pain treatment were registered. Analgesic provision in patients with moderate to severe pain ( NRS = 4) improved from 46.8% to 68.0%. Over 10% of the patients refused analgesics, resulting into an actual analgesic administration increase from 36.3% to 46.1%. Median time to analgesic decreased from 10 to 7 min ( P < 0.05), whereas time to opioids decreased from 37 to 15 min ( P < 0.01). Mean pain relief significantly increased to 1.56 NRS-points, in patients who received analgesic treatment even up to 2.02 points. The protocol appeared to lead to an increase in analgesic administration, shorter time to analgesics and a higher clinically relevant pain relief. Despite improvements, suffering moderate to severe pain at ED discharge was still common. Protocol adherence needs to be studied in order to optimize pain management. (C) 2016 Elsevier Ltd. All rights reserved.	[Pierik, Jorien G. J.; IJzerman, Maarten J.; Doggen, Carine J. M.] Univ Twente, Hlth Technol & Serv Res, MIRA Inst Biomed Technol & Tech Med, Drienerlolaan 5,POB 217, NL-7522 NB Enschede, Netherlands; [Berben, Sivera A.] Radboud Univ Nijmegen, Med Ctr, Reg Emergency Healthcare Network, Nijmegen, Netherlands; [Berben, Sivera A.] HAN Univ Appl Sci, Fac Hlth & Social Studies, Dept Emergency & Crit Care, Nijmegen, Netherlands; [Gaakeer, Menno I.] Admiraal De Ruyter Ziekenhuis, Emergency Dept, Goes, Netherlands; [van Eenennaam, Fred L.] Ambulance Oost, Hengelo, Netherlands; [van Eenennaam, Fred L.] Ziekenhuisgroep Twente, Anesthesiol, Almelo, Netherlands; [van Vugt, Arie B.] Medisch Spectrum Twente, Emergency Dept, Enschede, Netherlands	Pierik, JGJ (reprint author), Univ Twente, MB HTSR, Drienerlolaan 5,POB 217, NL-7522 NB Enschede, Netherlands.	j.g.j.pierik@utwente.nl	IJzerman, Maarten/AAB-6894-2020; Berben, Sivera AA/G-7363-2014; IJzerman, Maarten J/Q-8963-2016	IJzerman, Maarten J/0000-0001-5788-5805			Berben S, 2010, NEDERLANDS TIJDSCHRI, V155, pA3100; Berben SAA, 2008, INJURY, V39, P578, DOI 10.1016/j.injury.2007.04.013; Berben SAA, 2012, INJURY, V43, P1397, DOI 10.1016/j.injury.2011.01.029; Bhakta HC, 2014, J EMERG MED, V46, P456, DOI 10.1016/j.jemermed.2013.04.018; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Brown JC, 2003, ANN EMERG MED, V42, P197, DOI 10.1067/mem.2003.275; Cousins MJ, 2004, PAIN, V112, P1, DOI 10.1016/j.pain.2004.09.002; Curtiss C P, 2001, Orthop Nurs, V20, P27, DOI 10.1097/00006416-200103000-00008; Decosterd I, 2007, ANN EMERG MED, V50, P462, DOI 10.1016/j.annemergmed.2007.01.019; Ducharme J, 2008, AM J EMERG MED, V26, P867, DOI 10.1016/j.ajem.2007.11.020; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Finn JC, 2012, CONTEMP NURSE, V43, P29, DOI 10.5172/conu.2012.43.1.29; Fosnocht DE, 2007, AM J EMERG MED, V25, P791, DOI 10.1016/j.ajem.2006.12.020; Fry Margaret, 2002, Emerg Med (Fremantle), V14, P249, DOI 10.1046/j.1442-2026.2002.00339.x; Fry Margaret, 2004, Accid Emerg Nurs, V12, P136, DOI 10.1016/j.aaen.2004.02.006; Gaakeer MI, 2010, EUR J EMERG MED, V17, P286, DOI 10.1097/MEJ.0b013e328332114a; Hoot NR, 2008, ANN EMERG MED, V52, P126, DOI 10.1016/j.annemergmed.2008.03.014; Jackson SE, 2010, J EMERG NURS, V36, P10, DOI 10.1016/j.jen.2008.08.022; Johnston C C, 1998, J Emerg Med, V16, P377; Kelly Anne-Maree, 2005, CJEM, V7, P149; LEWIS KS, 1994, AM J HOSP PHARM, V51, P1539, DOI 10.1093/ajhp/51.12.1539; Liu S, 2008, NEURAL BLOCKADE CLIN, P144; Mohan H, 2010, EMERG MED J, V27, P372, DOI 10.1136/emj.2007.048611; Pierik JGJ, 2016, EUR J PAIN, V20, P711, DOI 10.1002/ejp.796; Sinatra R, 2010, PAIN MED, V11, P1859, DOI 10.1111/j.1526-4637.2010.00983.x; Sokoloff C, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004288; Tanabe P, 2001, J Emerg Nurs, V27, P124, DOI 10.1067/men.2001.114386; Tcherny-Lessenot S, 2003, J PAIN SYMPTOM MANAG, V25, P539, DOI 10.1016/S0885-3924(03)00147-7; Thomas SH, 2013, INT SCHOLARLY RES NO, DOI [10.1155/2013/583132, DOI 10.1155/2013/583132]; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; WILDERSMITH CH, 1992, PAIN, V50, P257, DOI 10.1016/0304-3959(92)90029-B; Williamson OD, 2009, J ORTHOP TRAUMA, V23, P139, DOI 10.1097/BOT.0b013e3181962e29; Zohar Z, 2001, J TRAUMA, V51, P767, DOI 10.1097/00005373-200110000-00024	33	14	14	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1755-599X	1878-013X		INT EMERG NURS	Int. Emerg. Nurs.	JUL	2016	27						3	10		10.1016/j.ienj.2016.02.001			8	Nursing	Nursing	DT8HA	WOS:000381729500002	26968352				2020-06-30	J	Tezcan, AH; Karakurt, O; Eryazgan, MA; Baskan, S; Ornek, DH; Baldemir, R; Kocer, B; Baydar, M				Tezcan, Aysu Hayriye; Karakurt, Ozgur; Eryazgan, Mehmet Ali; Baskan, Semih; Ornek, Dilsen Hatice; Baldemir, Ramazan; Kocer, Bulent; Baydar, Mustafa			Post-thoracotomy pain relief with subpleural analgesia or thoracic epidural analgesia: randomized clinical trial	SAO PAULO MEDICAL JOURNAL			English	Article						Pain, postoperative; Analgesia, epidural; Pleura; Thoracotomy; Analgesia, patient-controlled	INTERCOSTAL NERVE BLOCK; PARAVERTEBRAL BLOCK; INTRAVENOUS MORPHINE; THORACOTOMY; FENTANYL; ROPIVACAINE; INFUSION	CONTEXT AND OBJECTIVE: Post-thoracotomy pain is a severe and intense pain caused by trauma to ribs, muscles and peripheral nerves. The current study aimed to compare subpleural analgesia (SPA) with thoracic epidural analgesia (TEA) in patients undergoing thoracotomy. DESIGN AND SETTING: Randomized study at Ankara Numune Education and Research Hospital, in Turkey. METHODS: Thirty patients presenting American Society of Anesthesiologists physical status I-III were scheduled for elective diagnostic thoracotomy. The patients were randomized to receive either patient-controlled SPA or patient-controlled TEA for post-thoracotomy pain control over a 24-hour period. The two groups received a mixture of 3 mu g/ml fentanyl along with 0.05% bupivacaine solution through a patient-controlled analgesia pump. Rescue analgesia was administered intravenously, consisting of 100 mg tramadol in both groups. A visual analogue scale was used to assess pain at rest and during coughing over the course of 24 hours postoperatively. RESULTS: In the SPA group, all the patients required rescue analgesia, and five patients (33%) required rescue analgesia in the TEA group (P < 0.05). Patients who received subpleural analgesia exhibited higher visual analogue scores at rest and on coughing than patients who received thoracic epidural analgesia. None of the patients had any side-effects postoperatively, such as hypotension or respiratory depression. CONCLUSION: Thoracic epidural analgesia is superior to subpleural analgesia for relieving post-thoracotomy pain. We suggest that studies on effective drug dosages for providing subpleural analgesia are necessary.	[Tezcan, Aysu Hayriye; Baskan, Semih; Ornek, Dilsen Hatice; Baldemir, Ramazan] Ankara Numune Training & Res Hosp, Anesthesiol & Reanimat Dept, Talatpasa St 5, TR-06110 Ankara, Turkey; [Karakurt, Ozgur; Kocer, Bulent] Ankara Numune Training & Res Hosp, Dept Thorac Surg, Ankara, Turkey; [Eryazgan, Mehmet Ali] Ankara Numune Training & Res Hosp, Dept Thorac Surg, Ankara, Turkey; [Baydar, Mustafa] Ankara Numune Training & Res Hosp, Anesthesiol & Reanimat Dept, Dept, Ankara, Turkey	Tezcan, AH (reprint author), Ankara Numune Training & Res Hosp, Anesthesiol & Reanimat Dept, Talatpasa St 5, TR-06110 Ankara, Turkey.	aysndr@gmail.com	baskan, semih/AAC-6252-2019; Tezcan, Aysu Hayriye/Y-5478-2019	baskan, semih/0000-0003-0096-7097; Tezcan, Aysu Hayriye/0000-0001-7779-6965; Ornek, Dilsen/0000-0002-3300-4839			BACHMANNMENNENGA B, 1993, EUR J CARDIO-THORAC, V7, P12, DOI 10.1016/1010-7940(93)90141-W; Baidya DK, 2014, INTERACT CARDIOV TH, V18, P626, DOI 10.1093/icvts/ivt551; Behera BK, 2008, J POSTGRAD MED, V54, P86; Concha M, 2004, J CARDIOTHOR VASC AN, V18, P322, DOI 10.1053/j.jvca.2004.03.013; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; Gulbahara G, 2010, EUR J CARDIO-THORAC, V37, P467, DOI 10.1016/j.ejcts.2009.05.057; Helms O, 2011, EUR J CARDIO-THORAC, V40, P902, DOI 10.1016/j.ejcts.2011.01.067; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff; Kanai A, 2007, PAIN MED, V8, P546, DOI 10.1111/j.1526-4637.2006.00174.x; Kanazi GE, 2012, EUR J ANAESTH, V29, P186, DOI 10.1097/EJA.0b013e32834fcef7; Karmakar MK, 2001, ANESTHESIOLOGY, V95, P771, DOI 10.1097/00000542-200109000-00033; Macias A, 2002, ANESTH ANALG, V95, P1344, DOI 10.1097/00000539-200211000-00046; McKenzie AG, 1996, BRIT J ANAESTH, V76, P297; Richardson J, 2011, BRIT J ANAESTH, V106, P164, DOI 10.1093/bja/aeq378; Senturk M, 2002, ANESTH ANALG, V94, P11	15	0	0	0	2	ASSOCIACAO PAULISTA MEDICINA	SAO PAULO	AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL	1516-3180			SAO PAULO MED J	Sao Paulo Med. J.	JUL-AUG	2016	134	4					280	284		10.1590/1516-3180.2015.00462405			5	Medicine, General & Internal	General & Internal Medicine	DW6XE	WOS:000383793900002	26576497	DOAJ Gold			2020-06-30	J	Takase, I; Koizumi, T; Fujimoto, I; Yanai, A; Fujimiya, T				Takase, Izumi; Koizumi, Takako; Fujimoto, Ihoko; Yanai, Aya; Fujimiya, Tatsuya			An autopsy case of acetyl fentanyl intoxication caused by insufflation of 'designer drugs'	LEGAL MEDICINE			English	Article						Acetyl fentanyl; Designer drugs; Insufflation; Naloxone		We present a fatal case of intoxication due to insufflation of acetyl fentanyl. His blood concentration of acetyl fentanyl was 270 ng/mL, and the manner of death was classified as an accident. This is the first report of an autopsy case of acetyl fentanyl delivered by insufflation, rather than intravenous administration. He had been snoring loudly for at least 12 h prior to death, and transport to a hospital during this time and treatment with naloxone may have saved his life. In this sense, it can be said that his death was preventable. This case reemphasizes the risk of death associated with drug overdose and the narrow range of acetyl fentanyl between the effective dose (ED50) and lethal dose (LD50). The case should also raise awareness among medical professionals of the effectiveness of naloxone and the need to establish a comprehensive system for toxicological analysis while keeping the possibility of use of 'designer drugs' in mind. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Takase, Izumi; Fujimoto, Ihoko; Yanai, Aya; Fujimiya, Tatsuya] Yamaguchi Univ, Grad Sch Med, Dept Legal Med, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan; [Koizumi, Takako] Yamaguchi Prefectural Police Headquarters, Forens Sci Lab, Yamaguchi, Yamaguchi, Japan	Takase, I (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Legal Med, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	takase@yamaguchi-u.ac.jp					Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Drug Enforcement Administration, 2015, DRUG CHEM EV SECT AC; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Ministry of Health Labour and Welfare, 2014, WHATS NEW; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Uchiyama N, 2014, FORENSIC TOXICOL, V32, P266, DOI 10.1007/s11419-014-0238-5	9	27	27	1	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1344-6223			LEGAL MED-TOKYO	Leg. Med.	JUL	2016	21						38	44		10.1016/j.legalmed.2016.05.006			7	Medicine, Legal; Social Sciences, Biomedical	Legal Medicine; Biomedical Social Sciences	DT9SW	WOS:000381843600008	27497332				2020-06-30	J	Arslan, Z; Calik, ES; Kaplan, B; Ahiskalioglu, EO				Arslan, Zakir; Calik, Eyup Serhat; Kaplan, Bekir; Ahiskalioglu, Elif Oral			The effect of pheniramine on fentanyl-induced cough: a randomized, double blinded, placebo controlled clinical study	REVISTA BRASILEIRA DE ANESTESIOLOGIA			English	Article						Fentanyl; Cough; Pheniramine maleat; Anesthesia	INTRAVENOUS LIDOCAINE; ANESTHESIA	Background and objectives: There are many studies conducted on reducing the frequency and severity of fentayl-induced cough during anesthesia induction. We propose that pheniramine maleate, an antihistaminic, may suppress this cough. We aim to observe the effect of pheniramine on fentanyl-induced cough during anesthesia induction. Methods: This is a double-blinded, prospective, three-arm parallel, randomized clinical trial of 120 patients with ASA (American Society of Anesthesiologists) physical status III and IV who aged >= 18 and scheduled for elective open heart surgery during general anesthesia. Patients were randomly assigned to three groups of 40 patients, using computer-generated random numbers: placebo group, pheniramine group, and lidocaine group. Results: Cough incidence differed significantly between groups. In the placebo group, 37.5% of patients had cough, whereas the frequency was significantly decreased in pheniramine group (5%) and lidocaine group (15%) (Fischer exact test, p = 0.0007 and p = 0.0188, respectively). There was no significant change in cough incidence between pheniramine group (5%) and lidocaine group (15%) (Fischer exact test, p = 0.4325). Cough severity did also change between groups. Post Hoc tests with Bonferroni showed that mean cough severity in placebo differed significantly than that of pheniramine group and lidocaine group (p < 0.0001 and p = 0.009, respectively). There was no significant change in cough severity between pheniramine group and lidocaine group (p = 0.856). Conclusion: Intravenous pheniramine is as effective as lidocaine in preventing fentayl-induced cough. Our results emphasize that pheniramine is a convenient drug to decrease this cough. (C) 2015 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.	[Arslan, Zakir; Kaplan, Bekir; Ahiskalioglu, Elif Oral] Reg Training & Res Hosp, Dept Anesthesiol & Intens Care, Erzurum, Turkey; [Calik, Eyup Serhat] Reg Training & Res Hosp, Dept Cardiac Surg, Erzurum, Turkey	Arslan, Z (reprint author), Reg Training & Res Hosp, Dept Anesthesiol & Intens Care, Erzurum, Turkey.	zakir-arslan@hotmail.com		Calik, Eyupserhat/0000-0001-7682-6229			Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; AKCABOY ZN, 2012, J TURK ANAESTH INT C, V40, P33; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; Cook E. B., 2002, Current Drug Targets - Inflammation and Allergy, V1, P167, DOI 10.2174/1568010023344733; Elcock DH, 2010, ANAESTHESIA, V65, P536, DOI 10.1111/j.1365-2044.2010.06321.x; Gecaj-Gashi Agreta, 2013, Cough, V9, P20, DOI 10.1186/1745-9974-9-20; Generali Joyce A, 2014, Hosp Pharm, V49, P23, DOI 10.1310/hpj4901-23; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Kamei Junzo, 2013, Cough, V9, P3, DOI 10.1186/1745-9974-9-3; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; LOU YP, 1993, ACTA PHYSIOL SCAND, V149, P1; Lui PW, 1996, CAN J ANAESTH, V43, P1216; PAINTAL AS, 1969, J PHYSIOL-LONDON, V203, P511, DOI 10.1113/jphysiol.1969.sp008877; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; Parmar MS, 2009, BMJ CASE REP, V2009; REINHARDT D, 1982, KLIN WOCHENSCHR, V60, P983, DOI 10.1007/BF01716959; REITAN JA, 1978, ANESTH ANALG, V57, P31; Sedighinejad Abbas, 2013, Anesth Pain Med, V2, P170, DOI 10.5812/aapm.8383; STANLEY TH, 1978, ANESTH ANALG, V57, P411; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x	23	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	JUL-AUG	2016	66	4					383	387		10.1016/j.bjane.2014.11.018			5	Anesthesiology	Anesthesiology	DS5SU	WOS:000380843400009	27343788	DOAJ Gold, Green Published			2020-06-30	J	Veizi, E; Tornero-Bold, M; Hayek, SM				Veizi, Elias; Tornero-Bold, Melissa; Hayek, Salim M.			Resolution of Intrathecal Hydromorphone or Morphine-induced Peripheral Edema by Opioid Rotation to Fentanyl: A Case Series	PAIN PRACTICE			English	Article						Intrathecal therapy; intrathecal hydromorphone; fentanyl; peripheral edema; intrathecal pump	NONCANCER PAIN; DRUG-DELIVERY; SYSTEMS; CANCER	IntroductionIntrathecal therapy [IT] has become an important modality for treatment of intractable cancer and noncancer pain although adverse events limit its effectiveness. ObjectiveThe purpose of this case series was to report and discuss the lower limb edema from IT hydromorphone and morphine therapy and its resolution or nonrecurrence upon rotating the IT solution to fentanyl. MethodsCase series. ResultsFive patients, 4 women and 1 man, 55 to 67 years old implanted with IT delivery device systems [IDDS] were treated with continuous infusion of hydromorphone [4 subjects] at 95 40 mcg/24 hours and morphine [1 subject] at 0.67 mg/24 hours. They developed peripheral edema of the lower extremities at an average of 4.2 months [mean, range 1 to 8 months] after implant. In 4 subjects, peripheral edema resolved by changing the IT agent to fentanyl. The mean time for complete resolution of edema was 50 +/- 20 days while patients were treated with continuous infusion of fentanyl. It should be noted that all patients were receiving bupivacaine in addition to the IT opioid. In one subject, infusion of IT saline resulted in faster resolution of peripheral edema. ConclusionPeripheral lower extremity edema may occur in patients treated with IT infusion of hydromorphone or morphine, even at low doses. This report presents, to the best of our knowledge, the first case series describing the benefit of IT opioid rotation to fentanyl in alleviating challenging lower extremity edema from IT hydromorphone and morphine.	[Veizi, Elias] Louis Stokes Vet Adm Med Ctr, Pain Med & Spine Care, Cleveland, OH USA; [Veizi, Elias; Tornero-Bold, Melissa; Hayek, Salim M.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Tornero-Bold, Melissa; Hayek, Salim M.] Univ Hosp Case Med Ctr, Div Pain Med, Dept Anesthesiol, Cleveland, OH USA	Hayek, SM (reprint author), Case Western Reserve Univ, Univ Hosp Cleveland, Div Pain Med, Dept Anesthesiol, Cleveland, OH 44106 USA.	Salim.Hayek@uhhospitals.org					Aldrete JA, 2000, EUR J PAIN, V4, P361, DOI 10.1053/eujp.2000.0199; Anderson VC, 2001, PAIN MED, V2, P287, DOI 10.1046/j.1526-4637.2001.01052.x; Bennett G, 2000, J PAIN SYMPTOM MANAG, V20, pS12, DOI 10.1016/S0885-3924(00)00204-9; Bernards Christopher M, 2002, Best Pract Res Clin Anaesthesiol, V16, P489, DOI 10.1053/bean.2002.0255; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; Deer TR, 2012, NEUROMODULATION, V15, P467, DOI 10.1111/j.1525-1403.2012.00486.x; Deer TR, 2011, PAIN PHYSICIAN, V14, pE283; Falco Frank J E, 2013, Pain Physician, V16, pSE185; Gardner-Nix J, 2002, J PAIN SYMPTOM MANAG, V23, P453, DOI 10.1016/S0885-3924(02)00404-9; Krames Elliot, 2002, Best Pract Res Clin Anaesthesiol, V16, P619, DOI 10.1053/bean.2002.0263; Kumar K, 2002, J NEUROSURG, V97, P803, DOI 10.3171/jns.2002.97.4.0803; McNicol Ewan, 2008, J Pain Palliat Care Pharmacother, V22, P270, DOI 10.1080/15360280802537225; Raphael JH, 2002, BMC MUSCULOSKELET DI, V3, DOI 10.1186/1471-2474-3-17; Ruan Xiulu, 2007, Pain Physician, V10, P357; Ruan Xiulu, 2008, J Opioid Manag, V4, P255; Trayes KP, 2013, AM FAM PHYSICIAN, V88, P102; Veizi IE, 2011, PAIN MED, V12, P1481, DOI 10.1111/j.1526-4637.2011.01232.x; Yaksh TL, 2013, ANESTHESIOLOGY, V118, P664, DOI 10.1097/ALN.0b013e31828351aa	18	4	4	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	JUL	2016	16	6					E94	E98		10.1111/papr.12443			5	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	DR4TH	WOS:000379895100001	26990069				2020-06-30	J	Fang, XZ; Gao, J; Ge, YL; Zhou, LJ; Zhang, Y				Fang, Xiang-Zhi; Gao, Ju; Ge, Ya-Li; Zhou, Luo-Jing; Zhang, Yang			Network Meta-Analysis on the Efficacy of Dexmedetomidine, Midazolam, Ketamine, Propofol, and Fentanyl for the Prevention of Sevoflurane-Related Emergence Agitation in Children	AMERICAN JOURNAL OF THERAPEUTICS			English	Article						network meta-analysis; agitation; children; sevoflurane	POSTOPERATIVE RECOVERY; INTRANASAL FENTANYL; STRABISMUS SURGERY; PEDIATRIC-PATIENTS; REDUCES AGITATION; ANESTHESIA; DESFLURANE; END; ADENOTONSILLECTOMY; TONSILLECTOMY	Sevoflurane is associated with a relatively high incidence of emergence agitation (EA) in children. Prophylactic treatment, including midazolam, dexmedetomidine, ketamine, fentanyl and propofol, has been used to prevent EA. However, the question of which prophylactic treatment should be preferred to decrease the incidence of EA is still unclear. We conducted a network meta-analysis of randomized controlled trials to investigate the comparative efficacy of midazolam, dexmedetomidine, ketamine, fentanyl, and propofol for the prevention of sevoflurane-related EA in children. First, we used the odds ratios and 95% confidence interval as effect size. The results revealed that dexmedetomidine 0.19 (0.14-0.27), midazolam 0.22 (0.07-0.60), ketamine 0.28 (0.16-0.51), propofol 0.23 (0.10-0.53), and fentanyl 0.25 (0.17-0.36) led to a significant reduction of the incidence of EA when compared with placebo. With placebo as the standard of comparison, the degree of incoherence (a measure of how closely the entire network fits together) was small (omega = 8.66728e-08). The logor were dexmedetomidine -1.75 (-2.11 to -1.39), midazolam -1.07 (-1.54 to -0.60), ketamine -1.292 (-1.92 to -0.66), and fentanyl -1.13 (-1.56 to -0.70). When compared with dexmedetomidine, the logor were placebo 1.75 (1.39-2.11), midazolam 0.67 (0.09-1.25), ketamine 0.45 (-0.25-1.15), propofol 0.75 (0.19-1.31), and fentanyl 0.617 (0.13-1.11). When compared with ketamine, the logor were placebo 1.29 (0.66-1.92), midazolam 0.22 (-0.56 to 1.00), dexmedetomidine -0.45 (-1.15-0.25); propofol 0.29 (-0.45-1.03); and fentanyl 0.16 (-0.59-0.92). The study that showed dexmedetomidine, midazolam, ketamine, propofol, and fentanyl could significantly decrease the incidence of EA when compared with placebo. One interesting finding of this network meta-analysis is that dexmedetomidine might be the best choice to prevent EA. However, there is weak evidence that dexmedetomidine is better than ketamine for the prevention of sevoflurane-related EA in children. As a result, more studies are needed to compare dexmedetomidine with ketamine.	[Fang, Xiang-Zhi; Gao, Ju; Ge, Ya-Li; Zhang, Yang] Yangzhou Univ, Coll Clin Med, Dept Anesthesiol, 98 Nan Tong Western Rd, Yangzhou 225001, Jiangsu, Peoples R China; [Zhou, Luo-Jing] Yangzhou Univ, Coll Clin Med, Dept Sci Res, Yangzhou, Jiangsu, Peoples R China	Gao, J (reprint author), Yangzhou Univ, Coll Clin Med, Dept Anesthesiol, 98 Nan Tong Western Rd, Yangzhou 225001, Jiangsu, Peoples R China.	gaoju_003@163.com					Abdelmalak B, 2007, J CLIN ANESTH, V19, P370, DOI 10.1016/j.jclinane.2006.09.006; Abu-Shahwan I, 2008, PEDIATR ANESTH, V18, P55, DOI 10.1111/j.1460-9592.2007.02376.x; Abu-Shahwan I, 2007, PEDIATR ANESTH, V17, P846, DOI 10.1111/j.1460-9592.2007.02298.x; Ades AE, 2006, PHARMACOECONOMICS, V24, P1, DOI 10.2165/00019053-200624010-00001; Ali Monaz Abdulrahman, 2013, Saudi J Anaesth, V7, P296, DOI 10.4103/1658-354X.115363; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Asaad OM, 2011, EGYPT J ANAESTH, V27, P233, DOI [10.1016/j.egja.2011.07.006, 10.1016/j.egja.2010.12.005]; Bastola P, 2015, INDIAN J ANAESTH, V59, P287, DOI 10.4103/0019-5049.156868; Chen JY, 2013, CAN J ANESTH, V60, P385, DOI 10.1007/s12630-013-9886-x; Cohen IT, 2002, PAEDIATR ANAESTH, V12, P604, DOI 10.1046/j.1460-9592.2002.00903.x; Coursin D B, 2001, Curr Opin Crit Care, V7, P221, DOI 10.1097/00075198-200108000-00002; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Dalens BJ, 2006, ANESTH ANALG, V102, P1056, DOI 10.1213/01.ane.0000200282.38041.1f; Delgado-Herrera L, 2001, CNS DRUG REV, V7, P48; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; ECKENHOFF J, 1961, ANESTHESIOLOGY, V22, P667, DOI 10.1097/00000542-196109000-00002; Eghbal Mohammad Hossein, 2013, Middle East Journal of Anesthesiology, V22, P155; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Goa K L, 1999, Paediatr Drugs, V1, P127, DOI 10.2165/00128072-199901020-00005; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Gupta N, 2013, J NEUROSURG ANESTH, V25, P271, DOI 10.1097/ANA.0b013e31828cb6c0; He L, 2013, ANAESTH INTENS CARE, V41, P328, DOI 10.1177/0310057X1304100309; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Kain ZN, 2007, ANESTHESIOLOGY, V106, P65, DOI 10.1097/00000542-200701000-00013; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Khasawinah Tariq A, 2003, Am J Ther, V10, P303, DOI 10.1097/00045391-200307000-00012; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Kim YH, 2011, ANAESTH INTENS CARE, V39, P904, DOI 10.1177/0310057X1103900516; Ko Y P, 2001, Acta Anaesthesiol Sin, V39, P169; Kuratani N, 2008, ANESTHESIOLOGY, V109, P225, DOI 10.1097/ALN.0b013e31817f5c18; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Li J, 2011, CHINESE MED J-PEKING, V124, P3682, DOI 10.3760/cma.j.issn.0366-6999.2011.22.015; Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090313; Lin YY, 2012, CRIT CARE, V16, DOI 10.1186/cc11646; Liu JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076651; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; Meng QT, 2012, INT J PEDIATR OTORHI, V76, P1036, DOI 10.1016/j.ijporl.2012.03.028; Messieha Zakaria, 2013, Anesth Prog, V60, P67, DOI 10.2344/0003-3006-60.3.67; Mizuno Ju, 2011, Masui, V60, P425; Mountain Brian W, 2011, AANA J, V79, P219; Ozcengiz D, 2011, J ANESTH, V25, P184, DOI 10.1007/s00540-011-1099-2; Panzer Oliver, 2011, Anesthesiol Clin, V29, P587, DOI 10.1016/j.anclin.2011.09.002; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; Phan Hanna, 2008, Paediatr Drugs, V10, P49, DOI 10.2165/00148581-200810010-00006; Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643; Sato M, 2010, J ANESTH, V24, P675, DOI 10.1007/s00540-010-0976-4; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Sun L, 2014, ACTA ANAESTH SCAND, V58, P642, DOI 10.1111/aas.12292; Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6; Tobias JD, 2005, PEDIATR ANESTH, V15, P709, DOI 10.1111/j.1460-9592.2005.01661.x; Tsai PS, 2008, PEDIATR ANESTH, V18, P1114, DOI 10.1111/j.1460-9592.2008.02593.x; Uezono S, 2000, ANESTH ANALG, V91, P563, DOI 10.1213/00000539-200009000-00012; van Hoff SL, 2015, PEDIATR ANESTH, V25, P668, DOI 10.1111/pan.12669; Viitanen H, 1999, ANESTH ANALG, V89, P75, DOI 10.1097/00000539-199907000-00014; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Voepel-Lewis Terri, 2005, J Perianesth Nurs, V20, P239, DOI 10.1016/j.jopan.2005.05.006; Xu LL, 2012, J ANESTH, V26, P556, DOI 10.1007/s00540-012-1354-1; Yang ZP, 2014, INT J SURG, V12, P516, DOI 10.1016/j.ijsu.2014.02.010; Yli-Hankala A, 1999, ANESTHESIOLOGY, V91, P1596, DOI 10.1097/00000542-199912000-00009; Zhang CM, 2013, CLIN THER, V35, P1622, DOI 10.1016/j.clinthera.2013.08.016; Zhu M, 2015, PLOS ONE, V13	66	7	11	2	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1075-2765	1536-3686		AM J THER	Am. J. Ther.	JUL-AUG	2016	23	4					E1032	E1042		10.1097/MJT.0000000000000321			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DR1KG	WOS:000379663800010	26186683				2020-06-30	J	Vellucci, R; Fanelli, G; Cortesi, PA; Pannuti, R; Peruselli, C; Romualdi, P				Vellucci, R.; Fanelli, G.; Cortesi, P. A.; Pannuti, R.; Peruselli, C.; Romualdi, P.		Working Grp Nientemale DEI	Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion	DRUGS			English	Letter							MANAGEMENT; PATTERN; CARE		[Vellucci, R.] Osped Univ Careggi, SOD Cure Palliat & Terapia Dolore, Florence, Italy; [Fanelli, G.] Azienda Osped Univ Parma, SC Anestesia Rianimaz & Terapia Antalg, Parma, Italy; [Cortesi, P. A.] Univ Milano Bicocca, Res Ctr Publ Hlth CESP, Monza, Italy; [Pannuti, R.] Fdn ANT Italia Onlus, Andria, Italy; [Peruselli, C.] Osped Biella, SC Cure Palliat, Ponderano, BI, Italy; [Romualdi, P.] Univ Bologna, Alma Mater Studiorum, Dipartimento Farm & Biotecnol, Bologna, Italy	Vellucci, R (reprint author), Osped Univ Careggi, SOD Cure Palliat & Terapia Dolore, Florence, Italy.	renato.vellucci@gmail.com	Cortesi, Paolo Angelo/AAD-7926-2020	Cortesi, Paolo Angelo/0000-0001-5241-4473; Romualdi, Patrizia/0000-0002-3610-2928; vellucci, renato/0000-0002-5462-7920			Abernethy Amy P, 2008, Am J Manag Care, V14, pS129; Apolone G, 2009, BRIT J CANCER, V100, P1566, DOI 10.1038/sj.bjc.6605053; Bedard G, 2015, SUPPORT CARE CANCER, V23, P791, DOI 10.1007/s00520-014-2426-6; Cortesi Paolo A., 2015, BUDGET IMPACT ANAL F, V4; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Giusti R, 2016, DRUGS, V76, P1059, DOI 10.1007/s40265-016-0593-0; Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250; Kuo Kuan-Ling, 2013, J Pain Palliat Care Pharmacother, V27, P167, DOI 10.3109/15360288.2013.787137; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V38, P554, DOI [10.1016/j.jpainsymman.2009.04.016, 10.1016/j.jpainsymman.2008.12.008]; Vellucci R, 2016, DRUGS, V76, P315, DOI 10.1007/s40265-015-0519-2; Vellucci R, 2015, VALUE HEALTH, V18, pA665, DOI 10.1016/j.jval.2015.09.2426; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020	14	2	3	0	2	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs	JUL	2016	76	10					1063	1065		10.1007/s40265-016-0594-z			3	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	DQ8YE	WOS:000379496800009	27324270	Other Gold, Green Published			2020-06-30	J	Han, J; Saraf, SL; Gordeuk, VR; Gowhari, M				Han, Jin; Saraf, Santosh L.; Gordeuk, Victor R.; Gowhari, Michel			Safety of chronic transdermal fentanyl use in patients receiving hemodialysis	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Letter							RENAL-FAILURE; CASE-SERIES; PAIN		[Han, Jin] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60607 USA; [Han, Jin; Saraf, Santosh L.; Gordeuk, Victor R.; Gowhari, Michel] Univ Illinois, Dept Med, Ctr Comprehens Sickle Cell, Sect Hematol Oncol, Chicago, IL USA	Han, J (reprint author), Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60607 USA.; Han, J (reprint author), Univ Illinois, Dept Med, Ctr Comprehens Sickle Cell, Sect Hematol Oncol, Chicago, IL USA.	jhan35@uic.edu; mgowha1@uic.edu	Gordeuk, Victor/AAG-6577-2019	Han, Jin/0000-0003-0662-006X	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23 HL125984]		[Anonymous], 2014, DUR FENT TRANSD SYST; Joh J, 1998, ANESTH ANALG, V86, P447, DOI 10.1097/00000539-199802000-00049; Joshi R, 2009, JCR-J CLIN RHEUMATOL, V15, P81, DOI 10.1097/RHU.0b013e31819b9610; Karanikolas M, 2010, J CLIN PHARM THER, V35, P603, DOI 10.1111/j.1365-2710.2009.01114.x; King S, 2011, PALLIATIVE MED, V25, P525, DOI 10.1177/0269216311406313; Koehntop DE, 1997, PHARMACOTHERAPY, V17, P746; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mercadante S, 1997, J PAIN SYMPTOM MANAG, V13, P241, DOI 10.1016/S0885-3924(97)00076-6; OSBORNE RJ, 1986, BRIT MED J, V292, P1548, DOI 10.1136/bmj.292.6535.1548	9	3	4	0	1	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	JUL 1	2016	73	13					947	+		10.2146/ajhp150748			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DP7EH	WOS:000378661500004	27325876	Green Accepted			2020-06-30	J	Eidenbenz, D; Taffe, P; Hugli, O; Albrecht, E; Pasquier, M				Eidenbenz, D.; Taffe, P.; Hugli, O.; Albrecht, E.; Pasquier, M.			A two-year retrospective review of the determinants of pre-hospital analgesia administration by alpine helicopter emergency medical physicians to patients with isolated limb injury	ANAESTHESIA			English	Article						analgesia; emergency medical service; pain management; pre-hospital emergency care; trauma	RANDOMIZED CONTROLLED-TRIAL; TRAUMA ANALGESIA; SEVERE PAIN; MOUNTAIN RESCUE; KETAMINE; FENTANYL; MORPHINE; MODERATE; CARE; MANAGEMENT	Up to 75% of pre-hospital trauma patients experience moderate to severe pain but this is often poorly recognised and treated with insufficient analgesia. Using multi-level logistic regression analysis, we aimed to identify the determinants of pre-hospital analgesia administration and choice of analgesic agent in a single helicopter-based emergency medical service, where available analgesic drugs were fentanyl and ketamine. Of the 1156 patients rescued for isolated limb injury, 657 (57%) received analgesia. Mean (SD) initial pain scores (as measured by a numeric rating scale) were 2.8 (1.8), 3.3 (1.6) and 7.4 (2.0) for patients who did not receive, declined, and received analgesia, respectively (p < 0.001). Fentanyl as a single agent, ketamine in combination with fentanyl and ketamine as a single agent were used in 533 (84%), 94 (14%) and 10 (2%) patients, respectively. A high initial on-scene pain score and a presumptive diagnosis of fracture were the main determinants of analgesia administration. Fentanyl was preferred for paediatric patients and ketamine was preferentially administered for severe pain by physicians who had more medical experience or had trained in anaesthesia.	[Eidenbenz, D.] Univ Lausanne, Sch Med, Lausanne, Switzerland; [Taffe, P.] Inst Social & Prevent Med IUMSP, Lausanne, Switzerland; [Hugli, O.; Pasquier, M.] Univ Lausanne Hosp, Emergency Serv, Lausanne, Switzerland; [Albrecht, E.] Univ Lausanne Hosp, Anaesthesiol Serv, Reg Anaesthesia, Lausanne, Switzerland	Pasquier, M (reprint author), Univ Lausanne Hosp, Emergency Serv, Lausanne, Switzerland.	mathieu.pasquier@chuv.ch	Hugli, Olivier/AAA-7057-2020	Hugli, Olivier/0000-0003-2312-1625; Albrecht, Eric/0000-0001-6432-1311			Albrecht E, 2013, BRIT J ANAESTH, V110, P96, DOI 10.1093/bja/aes355; Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Beaudoin FL, 2014, ACAD EMERG MED, V21, P1194, DOI 10.1111/acem.12510; Begg MD, 2003, STAT MED, V22, P2591, DOI 10.1002/sim.1524; Berben SAA, 2012, INJURY, V43, P1397, DOI 10.1016/j.injury.2011.01.029; Bernhard M, 2014, ANAESTHESIST, V63, P394, DOI 10.1007/s00101-014-2313-z; Bijur PE, 2006, J PAIN, V7, P438, DOI 10.1016/j.jpain.2006.01.451; Bredmose PP, 2009, EMERG MED J, V26, P62, DOI 10.1136/emj.2007.052753; Ellerton J, 2014, HIGH ALT MED BIOL, V15, P8, DOI 10.1089/ham.2013.1135; Ellerton JA, 2013, EMERG MED J, V30, P501, DOI 10.1136/emermed-2012-202291; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; Gausche-Hill M, 2014, PREHOSP EMERG CARE, V18, P25, DOI 10.3109/10903127.2013.844873; Green SM, 2011, ANN EMERG MED, V57, P449, DOI 10.1016/j.annemergmed.2010.11.030; Jennings PA, 2012, ANN EMERG MED, V59, P497, DOI 10.1016/j.annemergmed.2011.11.012; Keene DD, 2011, TRAUMA, V13, P167, DOI 10.1177/1460408611400813; Tran KP, 2014, PREHOSP EMERG CARE, V18, P257, DOI 10.3109/10903127.2013.851307; Krauss WC, 2011, J EMERG MED, V40, P182, DOI 10.1016/j.jemermed.2009.02.009; Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017; Lord B, 2014, PREHOSP EMERG CARE, V18, P195, DOI 10.3109/10903127.2013.856502; Lord B, 2009, AM J EMERG MED, V27, P525, DOI 10.1016/j.ajem.2008.04.003; Marland S, 2013, CNS NEUROSCI THER, V19, P381, DOI 10.1111/cns.12072; McLean Samuel A, 2002, Prehosp Emerg Care, V6, P402, DOI 10.1080/10903120290938021; McManus JG, 2005, EMERG MED CLIN N AM, V23, P415, DOI 10.1016/j.emc.2004.12.009; Michael GE, 2007, AM J EMERG MED, V25, P901, DOI 10.1016/j.ajem.2007.02.001; Moore RA, 2013, ANAESTHESIA, V68, P400, DOI 10.1111/anae.12148; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; Porter K, 2004, EMERG MED J, V21, P351, DOI 10.1136/emj.2003.010843; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Russell KW, 2014, WILD ENVIRON MED, V25, pS96, DOI 10.1016/j.wem.2014.07.016; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; Thomas SH, 2008, J EMERG MED, V35, P47, DOI 10.1016/j.jemermed.2007.05.041; White L J, 2000, Prehosp Emerg Care, V4, P205, DOI 10.1080/10903120090941209; Yeaman F, 2014, EMERG MED AUSTRALAS, V26, P237, DOI 10.1111/1742-6723.12173	33	11	11	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JUL	2016	71	7					779	787		10.1111/anae.13462			9	Anesthesiology	Anesthesiology	DP8GP	WOS:000378736500008	27091515	Bronze			2020-06-30	J	Anand, JP; Boyer, BT; Mosberg, HI; Jutkiewicz, EM				Anand, Jessica P.; Boyer, Brett T.; Mosberg, Henry I.; Jutkiewicz, Emily M.			The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice	PSYCHOPHARMACOLOGY			English	Article						Mixed efficacy; mu opioid receptor; Delta opioid receptor; Tolerance; Dependence; Conditioned place preference; Reward	DELTA-OPIOID RECEPTOR; MU-AGONIST/DELTA-ANTAGONIST; DMT-TIC PHARMACOPHORE; PHYSICAL-DEPENDENCE; MORPHINE-TOLERANCE; IN-VITRO; LIGANDS; OLIGOMERIZATION; MODULATION	Rationale VRP26 displays mu opioid receptor agonist and delta opioid receptor antagonist activity in vitro, a pharmacological profile purported to produce reduced tolerance, dependence, and rewarding effects. We hypothesized that VRP26 would display reduced adverse effects after chronic administration as compared with the traditional opioid analgesic fentanyl. Objective The aim of this study is to explore the development of tolerance, dependence, and conditioned place preference of VRP26 as compared with the traditional opioid analgesic fentanyl. Methods The antinociceptive effects of VRP26 and fentanyl were assessed using the mouse warm water tail withdrawal (WWTW) assay. Measurement of antinociceptive tolerance and physical dependence occurred after 7 days of continuous administration of either fentanyl (0.3 mg/kg/day) or VRP26 (10 mg/kg/day); tolerance was measured by a shift in the antinociceptive dose response curve in the WWTW assay. Physical dependence was determined by observation of withdrawal symptoms after precipitated withdrawal. Rewarding effects were measured by the ability of VRP26 or fentanyl to produce conditioned place preference. Results Fentanyl produced significant tolerance and dependence, as well as significant conditioned place preference. VRP26 produced neither tolerance nor physical dependence, nor did it produce significant conditioned place preference. Conclusions These results suggest that chronic treatment with VRP26 may produce less tolerance or physical dependence than chronic treatment with clinically available mu opioid analgesics such as fentanyl. Additionally, VRP26 produces less rewarding effects than fentanyl. This desirable in vivo profile may be due to the mixed efficacy nature of VRP26 and could provide the framework for safer opioid analgesics.	[Anand, Jessica P.; Boyer, Brett T.; Jutkiewicz, Emily M.] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Mosberg, Henry I.] Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA	Jutkiewicz, EM (reprint author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.; Mosberg, HI (reprint author), Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA.	him@umich.ed; ejutkiew@umich.edu	Anand, Jessica/X-4064-2019	Anand, Jessica/0000-0001-6560-2211	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA003910, R01 DA039997]; National Institutes of Health under Ruth L. Kirschstein National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 DA007267]	The authors have no conflicts to disclose. This work was funded by NIH Grant DA003910 and R01 DA039997. J.P.A. was supported by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award T32 DA007267. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; Aceto MD, 2012, INT J MED CHEM, DOI 10.1155/2012/327257; Anand JP, 2012, CHEM BIOL DRUG DES, V80, P763, DOI 10.1111/cbdd.12014; Anathan S, 2004, J MED CHEM, V47, P1400; Bailey CP, 2005, CURR OPIN PHARMACOL, V5, P60, DOI 10.1016/j.coph.2004.08.012; Balboni G, 2002, J MED CHEM, V45, P713, DOI 10.1021/jm010449i; Ballantyne JC, 2007, PAIN, V129, P235, DOI 10.1016/j.pain.2007.03.028; Bender AM, 2015, ACS CHEM NEUROSCI, V6, P1428, DOI 10.1021/acschemneuro.5b00100; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Cahill CM, 2007, TRENDS PHARMACOL SCI, V28, P23, DOI 10.1016/j.tips.2006.11.003; Daniels DJ, 2005, P NATL ACAD SCI USA, V102, P19208, DOI 10.1073/pnas.0506627102; Dietis N, 2009, BRIT J ANAESTH, V103, P38, DOI 10.1093/bja/aep129; FUNDYTUS ME, 1995, EUR J PHARMACOL, V286, P105, DOI 10.1016/0014-2999(95)00554-X; Gomes I, 2011, MOL PHARMACOL, V79, P1044, DOI 10.1124/mol.110.070847; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; Healy JR, 2013, ACS CHEM NEUROSCI, V4, P1256, DOI 10.1021/cn4000428; Hepburn MJ, 1997, J PHARMACOL EXP THER, V281, P1350; Johnson L.F., 2009, NIH PUBLICATION, V1, P1; Law PY, 2005, J BIOL CHEM, V280, P11152, DOI 10.1074/jbc.M500171200; Lenard NR, 2007, EUR J PHARMACOL, V566, P75, DOI 10.1016/j.ejphar.2007.02.040; Milligan G, 2010, CURR OPIN PHARMACOL, V10, P23, DOI 10.1016/j.coph.2009.09.010; Morphy R, 2004, DRUG DISCOV TODAY, V9, P641, DOI 10.1016/S1359-6446(04)03163-0; Morphy R, 2009, CURR PHARM DESIGN, V15, P587, DOI 10.2174/138161209787315594; Mosberg HI, 2014, J MED CHEM, V57, P3148, DOI 10.1021/jm5002088; National Research Council, 2011, GUIDE CARE USE LAB A; Purington LC, 2011, ACS CHEM BIOL, V6, P1375, DOI 10.1021/cb200263q; Purington LC, 2009, J MED CHEM, V52, P7724, DOI 10.1021/jm9007483; Quock RM, 1999, PHARMACOL REV, V51, P503; RAMABADRAN K, 1982, LIFE SCI, V31, P1253, DOI 10.1016/0024-3205(82)90355-1; Ross S, 2009, CLIN NEUROPHARMACOL, V32, P269, DOI 10.1097/WNF.0b013e3181a9163c; Salvadori S, 1999, J MED CHEM, V42, P5010, DOI 10.1021/jm990165m; Schiller PW, 2010, LIFE SCI, V86, P598, DOI 10.1016/j.lfs.2009.02.025; Schiller PW, 1999, J MED CHEM, V42, P3520, DOI 10.1021/jm980724+; Schiller PW, 2009, LIFE SCI; Wisler JW, 2014, CURR OPIN CELL BIOL, V27, P18, DOI 10.1016/j.ceb.2013.10.008	35	5	5	1	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	JUL	2016	233	13					2479	2487		10.1007/s00213-016-4296-8			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	DP5ZE	WOS:000378575900007	27117141	Green Accepted			2020-06-30	J	Edry, R; Recea, V; Dikust, Y; Sessler, DI				Edry, Ruth; Recea, Vasile; Dikust, Yuri; Sessler, Daniel I.			Preliminary Intraoperative Validation of the Nociception Level Index A Noninvasive Nociception Monitor	ANESTHESIOLOGY			English	Article							PROPOFOL-REMIFENTANIL ANESTHESIA; SURGICAL STRESS INDEX; GENERAL-ANESTHESIA; NOXIOUS STIMULI; MULTIPARAMETER APPROACH; RESPONSES; SEVOFLURANE; COMPOSITE; INFUSION; SURGERY	Background: The nociception level (NoL) index is an index of nociception based on nonlinear combination of heart rate, heart rate variability, photoplethysmograph wave amplitude, skin conductance, skin conductance fluctuations, and their time derivatives. The authors evaluated the abilities of the NoL index and other measures of nociception to discriminate between noxious and nonnoxious stimuli, to progressively respond to graded stimuli, and to respond to opioid administration. Methods: Intraoperative NoL was compared to heart rate, pulse plethysmograph amplitude, noninvasive blood pressure, and the surgical pleth index around five specific stimuli: tetanic stimulation with and without fentanyl analgesia, intubation, first incision/trocar insertion, and a nonnoxious period. The response around first incision was analyzed at two target plasma concentrations of remifentanil. Results: In 58 patients, the NoL index responded progressively to increased stimulus intensity and remained unchanged in response to nonnoxious stimuli. Compared to other accepted measures of nociception, the NoL index better discriminated noxious from nonnoxious stimuli with an area under the curve of 0.93 (95% CI, 0.89 to 0.97) and a sensitivity of 87% at a specificity of 84%. The NoL index was the only measure that reliably reflected two different analgesic concentrations of remifentanil during initial skin incision or trocar insertion. Conclusions: The NoL index changes proportionately with patients' response to various clinical and experimental noxious stimuli and discriminates noxious from nonnoxious stimuli with high sensitivity and specificity. The NoL index also responds progressively to increasing stimuli intensity and is appropriately blunted by analgesic administration. The NoL index was superior to other compared measures and appears to accurately characterize nociception during general anesthesia.	[Edry, Ruth] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Anesthesiol, Haifa, Israel; [Recea, Vasile; Dikust, Yuri] Rambam Med Ctr, Dept Anesthesiol, Haifa, Israel; [Sessler, Daniel I.] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA	Edry, R (reprint author), Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Anesthesiol, 8th Aliya St, IL-20155 Yaad, Israel.	ruedry@gmail.com	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	Medasense (Ramat Yishai, Israel)	This study is supported, in part, by Medasense (Ramat Yishai, Israel).	Aho AJ, 2009, BRIT J ANAESTH, V102, P227, DOI 10.1093/bja/aen356; Ben-Israel N, 2013, J CLIN MONIT COMPUT, V27, P659, DOI 10.1007/s10877-013-9487-9; Blake DW, 1998, ANAESTH INTENS CARE, V26, P360, DOI 10.1177/0310057X9802600403; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Corsi M, 1995, INT J TISSUE REACT, V17, P211; Cowen R, 2015, ANAESTHESIA, V70, P828, DOI 10.1111/anae.13018; CROZIER TA, 1994, BRIT J ANAESTH, V72, P280, DOI 10.1093/bja/72.3.280; Do WS, 2012, KOREAN J ANESTHESIOL, V63, P327, DOI 10.4097/kjae.2012.63.4.327; Ellerkmann RK, 2013, ANESTH ANALG, V116, P580, DOI 10.1213/ANE.0b013e31827ced18; Ferreira DA, 2006, ACTA ANAESTH BELG, V57, P265; Gelb AW, 2010, MILLERS ANESTHESIA, P1234; Gruenewald M, 2009, BRIT J ANAESTH, V103, P586, DOI 10.1093/bja/aep206; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hastie T, 2009, ELEMENTS STAT LEARNI; Huiku M, 2007, BRIT J ANAESTH, V98, P447, DOI 10.1093/bja/aem004; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Korhonen I, 2009, ACTA ANAESTH SCAND, V53, P975, DOI 10.1111/j.1399-6576.2009.02026.x; KURZ A, 1995, ANESTHESIOLOGY, V83, P1212, DOI 10.1097/00000542-199512000-00012; Le Guen M, 2013, INTENS CARE MED, V39, P454, DOI 10.1007/s00134-012-2762-2; Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323; LIU H, 2003, J STAT SOFTW, V8, P1, DOI DOI 10.18637/jss.v008.i12; Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025; Martini CH, 2015, ANESTHESIOLOGY, V123, P524, DOI 10.1097/ALN.0000000000000757; Masjedi Mansoor, 2014, J Anaesthesiol Clin Pharmacol, V30, P217, DOI 10.4103/0970-9185.130024; Page G G, 1997, Semin Oncol Nurs, V13, P10, DOI 10.1016/S0749-2081(97)80044-7; Rantanen M, 2006, BRIT J ANAESTH, V96, P367, DOI 10.1093/bja/ael005; SALO M, 1992, ACTA ANAESTH SCAND, V36, P201, DOI 10.1111/j.1399-6576.1992.tb03452.x; Struys MMRF, 2007, BRIT J ANAESTH, V99, P359, DOI 10.1093/bja/aem173; Tsuchiya Y, 2003, SURGERY, V133, P547, DOI 10.1067/msy.2003.141; Vallejo Ricardo, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P139, DOI 10.1615/JEnvPathToxOncol.v22.i2.70	31	31	32	3	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUL	2016	125	1					193	203		10.1097/ALN.0000000000001130			11	Anesthesiology	Anesthesiology	DY2JO	WOS:000384919100030	27171828				2020-06-30	J	Huske, C; Sander, SE; Hamann, M; Kershaw, O; Richter, F; Richter, A				Hueske, Christin; Sander, Svenja Esther; Hamann, Melanie; Kershaw, Olivia; Richter, Franziska; Richter, Angelika			Towards optimized anesthesia protocols for stereotactic surgery in rats: Analgesic, stress and general health effects of injectable anesthetics. A comparison of a recommended complete reversal anesthesia with traditional chloral hydrate monoanesthesia	BRAIN RESEARCH			English	Article						Refinement; Injectable anesthetic; Chloral hydrate; Complete reversal anesthesia	ADULT MALE-RATS; INTRASTRIATAL INJECTIONS; INTRAPERITONEAL INJECTIONS; NONINVASIVE MEASUREMENT; KETAMINE-XYLAZINE; DT(SZ) MUTANT; WISTAR RATS; MEDETOMIDINE; FENTANYL; PAIN	Although injectable anesthetics are still widely used in laboratory rodents, scientific data concerning pain and distress during and after stereotactic surgery are rare. However, optimal anesthesia protocols have a high impact on the quality of the derived data. We therefore investigated the suitability of recommended injectable anesthesia with a traditionally used monoanesthesia for stereotactic surgery in view of optimization and refinement in rats. The influence of the recommended complete reversal anesthesia (MMF; 0.15 mg/kg medetomidine, 2 mg/kg midazolam, 0.005 mg/kg fentanyl; i.m.) with or without reversal and of chloral hydrate (430 mg/kg, 3.6%, i.p.) on various physiological, biochemical and behavioral parameters (before, during, after surgery) was analyzed. Isoflurane was also included in stress parameter analysis. In all groups, depth of anesthesia was sufficient for stereotactic surgery with no animal losses. MMF caused transient exophthalmos, myositis at the injection site and increased early postoperative pain scores. Reversal induced agitation, restlessness and hypothermia. Even the low concentrated chloral hydrate led to peritonitis and multifocal liver necrosis, corresponding to increased stress hormone levels and loss in body weight. Increased stress response was also exerted by isoflurane anesthesia. Pronounced systemic toxicity of chloral hydrate strongly questions its further use in rodent anesthesia. In view of undesired effects of MMF and isoflurane, thorough consideration of anesthesia protocols for particular research projects is indispensable. Reversal should be restricted to emergency situations. Our data support further refinement of the current protocols and the importance of sham operated controls. (C) 2016 Elsevier B.V. All rights reserved.	[Hueske, Christin; Richter, Franziska; Richter, Angelika] Univ Leipzig, Fac Vet, Inst Pharmacol Pharm & Toxicol, D-04109 Leipzig, Germany; [Sander, Svenja Esther] Free Univ Berlin, Inst Pharmacol & Toxicol, Dept Vet Med, Koserstr 20, D-14195 Berlin, Germany; [Hamann, Melanie] Univ Giessen, Inst Pharmacol & Toxicol, Dept Vet Med, Giessen, Germany; [Kershaw, Olivia] Free Univ Berlin, Inst Vet Pathol, Dept Vet Med, Koserstr 20, D-14195 Berlin, Germany	Sander, SE (reprint author), Free Univ Berlin, Inst Pharmacol & Toxicol, Dept Vet Med, Koserstr 20, D-14195 Berlin, Germany.	svenja.sander@fu-berlin.de	Richter, Franziska/N-8009-2014; Hamann, Melanie/H-9280-2016	Richter, Franziska/0000-0003-0803-4398; 			Albrecht M, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0198-3; Arras Margarete, 2007, BMC Vet Res, V3, P16, DOI 10.1186/1746-6148-3-16; Bamberg E, 2001, LAB ANIM-UK, V35, P307, DOI 10.1258/0023677011911886; Callahan LM, 2014, LAB ANIMAL, V43, P208, DOI 10.1038/laban.517; Charbonneau R, 2010, CCAC GUIDELINES EUTH; Chi OZ, 2010, PHARMACOLOGY, V85, P153, DOI 10.1159/000269811; Colussi GL, 2011, HYPERTENS RES, V34, P929, DOI 10.1038/hr.2011.62; DADA MO, 1992, LIFE SCI, V51, P29; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Diaz Marcos, 2010, Anesth Prog, V57, P25, DOI 10.2344/0003-3006-57.1.25; FIELD KJ, 1993, LAB ANIM, V27, P258, DOI 10.1258/002367793780745471; Fish RE, 2008, AM COLL LAB, P1; Flecknell P, 2007, LUMB JONES VET ANEST, P765; Flecknell P.A., 2009, LAB ANIMAL ANESTHESI, V3; FLECKNELL PA, 1994, LAB ANIM-UK, V28, P222, DOI 10.1258/002367794780681660; FLEISCHMAN RW, 1977, LAB ANIM SCI, V27, P238; Giroux M.C., 2015, EXP ANIM, V2015, P21; Hamann M, 2008, EUR J PHARMACOL, V586, P156, DOI 10.1016/j.ejphar.2008.02.052; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Jang HS, 2009, VET ANAESTH ANALG, V36, P319, DOI 10.1111/j.1467-2995.2009.00463.x; Knutson B, 2002, PSYCHOL BULL, V128, P961, DOI 10.1037//0033-2909.128.6.961; Leach MC, 2002, VET REC, V150, P808, DOI 10.1136/vr.150.26.808; Lepschy M, 2007, LAB ANIM-UK, V41, P372, DOI 10.1258/002367707781282730; Longley LA, 2008, ANESTHESIA EXOTIC PE; Mahler M, 2014, LAB ANIM-UK, V48, P178, DOI 10.1177/0023677213516312; Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; Murrell JC, 2006, J VET PHARMACOL THER, V29, P325, DOI 10.1111/j.1365-2885.2006.00758.x; Nasu I, 2006, ANESTH ANALG, V103, P413, DOI 10.1213/01.ane.0000223686.50202.38; Nishiyama Tomoki, 2005, J Anesth, V19, P213, DOI 10.1007/s00540-005-0318-0; Otovic P, 2015, ALTEX-ALTERN ANIM EX, V32, P41, DOI http://dx.doi.org/10.14573/altex.1406161; Otto KA, 2008, TIERAERZTL PRAX K H, V36, P12; Ozden S, 2004, J NEUROTRAUM, V21, P73, DOI 10.1089/089771504772695968; Palme R, 2005, ANN NY ACAD SCI, V1040, P162, DOI 10.1196/annals.1327.021; Palme R, 2005, ANN NY ACAD SCI, V1046, P75, DOI 10.1196/annals.1343.007; Pertovaara A, 2005, CNS DRUG REV, V11, P273; Plumb D.C., 2015, VET DRUG HDB; Richter F, 2008, BRAIN RES, V1188, P148, DOI 10.1016/j.brainres.2007.09.083; Rodrigues SF, 2006, LIFE SCI, V79, P1630, DOI 10.1016/j.lfs.2006.05.019; Royo F, 2004, J ENDOCRINOL, V180, P145, DOI 10.1677/joe.0.1800145; Sander SE, 2007, EUR J PHARMACOL, V563, P102, DOI 10.1016/j.ejphar.2007.01.067; Sinclair MD, 2003, CAN VET J, V44, P885; SMILER KL, 1990, LAB ANIM SCI, V40, P60; Smith JC, 2006, LAB ANIM-UK, V40, P200, DOI 10.1258/002367706776318999; Stasiak KL, 2003, CONTEMP TOP LAB ANIM, V42, P13; Stokes EL, 2009, LAB ANIM-UK, V43, P149, DOI 10.1258/la.2008.008020; Tacke S., 2007, FACHPRAX, V51, P4; Taylor DK, 2007, J AM ASSOC LAB ANIM, V46, P37; Vachon P, 2000, LAB ANIM, V34, P84, DOI 10.1258/002367700780578082; Waite A, 2010, BRIT J ANAESTH, V104, P768, DOI 10.1093/bja/aeq093; WALLENSTEIN MC, 1981, AM J PHYSIOL, V241, pR130; WIXSON SK, 1987, LAB ANIM SCI, V37, P743; Wolfensohn S., 2013, HDB LAB ANIMAL MANAG; Zambricki EA, 2004, COMPARATIVE MED, V54, P49; Zhang JF, 2015, J NEUROIMMUNE PHARM, V10, P179, DOI 10.1007/s11481-014-9580-y	55	9	9	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 1	2016	1642						364	375		10.1016/j.brainres.2016.04.019			12	Neurosciences	Neurosciences & Neurology	DP7EI	WOS:000378661600041	27067188				2020-06-30	J	Mercadante, S; Aielli, F; Adile, C; Costanzi, A; Casuccio, A				Mercadante, Sebastiano; Aielli, Federica; Adile, Claudio; Costanzi, Andrea; Casuccio, Alessandra			Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Cancer pain; breakthrough pain; fentanyl pectin nasal spray; oral morphine	PALLIATIVE CARE-UNIT; INTRAVENOUS MORPHINE; TRANSMUCOSAL FENTANYL; ONCOLOGY PATIENTS; BUCCAL TABLETS; RECOMMENDATIONS; MULTICENTER; INTENSITY; CROSSOVER; SAFETY	Context. Fentanyl products have shown superiority over oral opioids for the management of breakthrough cancer pain (BTcP). However, these studies did not use an appropriate patient selection, and drugs have been compared using a different rationale. Objectives. The aim of this randomized, crossover, controlled study was to compare the efficacy and safety of fentanyl pectin nasal spray (FPNS) and oral morphine (OM), given in doses proportional to opioid daily doses. Methods. Cancer patients with pain receiving >= 60 mg of OM equivalents/day and presenting with <= 3 episodes of BTcP/day were included. Patients received, in a randomized, crossover manner, FPNS or OM at doses proportional to the daily opioid regimen in four consecutive episodes of BTcP. Pain intensity was measured before (T0), 15 (T15), and 30 minutes (T30) after study drugs. Results. A total of 167 episodes were treated, 82 with FNPS and 85 with OM. A statistical difference in pain intensity between the two groups was observed at T15, but not at T30 (P = 0.018 and P = 0.204, respectively). In a greater number of episodes treated with FPNS, there was a pain decrease of >= 33% in comparison with OM after 15 and 30 minutes (76.5% vs. 32.8%, and 89% vs. 54.9%, respectively). Similar differences were found in the decrease in pain intensity of >= 50% after 15 and 30 minutes (52.3% vs. 11.4%, and 75% vs. 45.8%, respectively). The difference was highly significant at T15 (P < 0.0005). The mean (SD) pain difference at T15 of FPNS and OM were 3.24 (1.7) and 2.70 (1.2), respectively, whereas the mean (SD) SPIDs30 of FPNS and OM were 4.87 (1.7) and 4.54 (1.5), respectively. The difference was highly significant at T15 (P = 0.019). No severe adverse effects after study drug administration were observed. Conclusion. When used in doses proportional to the basal opioid regimen, FPNS showed a superior analgesic effect over OM for the management of BTcP. Only minor adverse effects were found with both medications. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.	[Mercadante, Sebastiano; Adile, Claudio] La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Via San Lorenzo 312, I-90145 Palermo, Italy; [Mercadante, Sebastiano; Adile, Claudio] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90145 Palermo, Italy; [Aielli, Federica] Univ LAquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy; [Costanzi, Andrea] Univ Rome, Hosp St Andrea, Dept Oncol, Rome, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Via San Lorenzo 312, I-90145 Palermo, Italy.; Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90145 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535; mercadante, sebastiano/0000-0001-9859-6487; Adile, Claudio/0000-0002-0664-3520			Bailey PL, 2003, ANESTHESIOLOGY, V99, pA967; Chistie JM, 1998, J CLIN ONCOL, V16, P3238; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2010, ANESTHESIOLOGY, V112, P1464, DOI 10.1097/ALN.0b013e3181de0e6d; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hans GH, 2013, CURR MED RES OPIN, V29, P1523, DOI 10.1185/03007995.2013.837816; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Lyseng-Williamson KA, 2011, CNS DRUGS, V25, P511, DOI 10.2165/11207470-000000000-00000; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2011, EUR J PAIN, V5, P443; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Mercadante S, 2016, SUPPORT CARE CANCER, V24, P961, DOI 10.1007/s00520-015-2951-y; Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P579, DOI 10.1016/j.jpainsymman.2015.05.016; Mercadante S, 2015, CLIN J PAIN, V31, P214, DOI 10.1097/AJP.0000000000000161; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mercadante S, 2013, CURR MED RES OPIN, V29, P1527, DOI 10.1185/03007995.2013.826640; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2013, CURR MED RES OPIN, V29, P667, DOI 10.1185/03007995.2013.792247; Mercadante S, 2013, CURR MED RES OPIN, V29, P93, DOI 10.1185/03007995.2012.755120; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; National Institute for Health and Care Excellence, NICE GUID PALL CAR A; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	41	10	11	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2016	52	1					27	34		10.1016/j.jpainsymman.2016.01.010			8	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	DT7QS	WOS:000381681900007	27208863	Bronze			2020-06-30	J	De Franceschi, L; Mura, P; Schweiger, V; Vencato, E; Quaglia, FM; Delmonte, L; Evangelista, M; Polati, E; Olivieri, O; Finco, G				De Franceschi, Lucia; Mura, Paolo; Schweiger, Vittorio; Vencato, Elisa; Quaglia, Francesca Maria; Delmonte, Letizia; Evangelista, Maurizio; Polati, Enrico; Olivieri, Oliviero; Finco, Gabriele			Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease	PAIN PRACTICE			English	Article						opioids; breakthrough pain; pain service; acute; vaso-occlusive crisis; sickle cell disease; fentanyl; buccal administration; transmuccosal	RAPID-ONSET OPIOIDS; INTRAVENOUS MORPHINE; PHARMACOKINETICS; RECOMMENDATIONS; INFUSION	BackgroundSickle cell disease (SCD) is a worldwide distributed hereditary red cell disorder. The principal clinical manifestations of SCD are the chronic hemolytic anemia and the acute vaso-occlusive crisis (VOCs), which are mainly characterized by ischemic/reperfusion tissue injury. Pain is the main symptom of VOCs, and its management is still a challenge for hematologists, requiring a multidisciplinary approach. MethodsWe carried out a crossover study on adult SCD patients, who received two different types of multimodal analgesia during two separate severe VOCs with time interval between VOCs of at least 6months. The first VOC episode was treated with ketorolac (0.86mg/kg/day) and tramadol (7.2mg/kg/day) (TK treatment). In the second VOC episode, fentanyl buccal tablet (FBT; 100g) was introduced in a single dose after three hours from the beginning of TK analgesia (TKF treatment). We focused on the first 24hours of acute pain management. The primary efficacy measure was the time-weighted-sum of pain intensity differences (SPID24). The secondary efficacy measures included the pain intensity difference (PID), the total pain relief (TOTPAR), and the time-wighted sum of anxiety (SAID24). ResultsSPID24 was significantly higher in TKF than in TK treatment. All the secondary measures were significantly ameliorated in TKF compared to TK treatment, without major opioid side effects. Patients satisfaction was higher with TKF treatment than with TK one. ConclusionsWe propose that VOCs might require breakthrough pain drug strategy as vaso-occlusive phenomena and enhanced vasoconstriction promoting acute ischemic pain component exacerbate the continuous pain of VOCs. FBT might be a powerful and feasible tool in early management of acute pain during VOCs in emergency departments.	[De Franceschi, Lucia; Vencato, Elisa; Quaglia, Francesca Maria; Delmonte, Letizia; Olivieri, Oliviero] Univ Verona AOUI Verona, Dept Med, Sect Internal Med, Verona, Italy; [Mura, Paolo; Finco, Gabriele] Univ Cagliari, Dept Med Sci M Aresu, Sect Anesthesia Intens Care & Pain Therapy, Cagliari, Italy; [Schweiger, Vittorio; Polati, Enrico] Univ Verona AOUI Verona, Dept Surg Sci, Anesthesiol Intens Care & Pain Therapy Ctr, Verona, Italy; [Evangelista, Maurizio] Univ Cattolica Sacro Cuore, Inst Anesthesia Resuscitat & Pain Med, Dept Emergency, Rome, Italy	Mura, P (reprint author), Univ Cagliari, Dept Med, Sect Anesthesia Intens Care & Pain Therapy, AOU Cagliari,Policlin Duilio Casula, SS554 Bivio Sestu, I-09042 Monserrato, CA, Italy.	mura_paolo@hotmail.com	Olivieri, Oliviero/A-9126-2008	Olivieri, Oliviero/0000-0001-8209-9056; Evangelista, Maurizio/0000-0001-8438-3480; Finco, Gabriele/0000-0002-3059-9865			Ambrosio F, 2006, MINERVA ANESTESIOL, V72, P859; Anie K. A., 2012, COCHRANE DB SYST REV, V2; Anie Kofi A, 2003, Hematol J, V4, P71, DOI 10.1038/sj.thj.6200227; Anie KA, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001274; Arthur AO, 2012, PAIN RES TREAT, V2012, DOI 10.1155/2012/768796; Ballas SK, 2012, BLOOD, V120, P3647, DOI 10.1182/blood-2012-04-383430; Ballas SK, 2001, SEMIN HEMATOL, V38, P307, DOI 10.1053/shem.2001.27567; Barrett MJ, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-74; Bartolucci P, 2009, BLOOD, V114, P3742, DOI 10.1182/blood-2009-06-227330; Benjamin Lennette, 2008, Hematology Am Soc Hematol Educ Program, P466, DOI 10.1182/asheducation-2008.1.466; Carroll CP, 2009, AM J HEMATOL, V84, P666, DOI 10.1002/ajh.21515; Dampier CD, 2011, AM J HEMATOL, V86, pE70, DOI 10.1002/ajh.22176; DAMPIER CD, 1995, J PEDIATR-US, V126, P461, DOI 10.1016/S0022-3476(95)70472-8; Darbari DS, 2011, J PAIN, V12, P531, DOI 10.1016/j.jpain.2010.10.012; Darwish M, 2010, PERSPECT MED CHEM, V4, P11; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; de Franceschi L, 2004, HAEMATOLOGICA, V89, P1389; De Franceschi L, 2004, HAEMATOLOGICA, V89, P348; De Franceschi L, 2011, SEMIN THROMB HEMOST, V37, P226, DOI 10.1055/s-0031-1273087; DesFranceschi L, 1994, J CLIN INVEST, V93, P1670; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Forni GL, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-91; Haywood C, 2009, J NATL MED ASSOC, V101, P1022, DOI 10.1016/S0027-9684(15)31069-5; Jonsson T, 2011, ACTA ANAESTH SCAND, V55, P69, DOI 10.1111/j.1399-6576.2010.02329.x; Juncos R, 2011, J CARDIOVASC PHARM, V57, P263, DOI 10.1097/FJC.0b013e318204bb34; McClish DK, 2009, PAIN, V145, P246, DOI 10.1016/j.pain.2009.06.029; Nagar S, 2004, DRUG METAB DISPOS, V32, P98, DOI 10.1124/dmd.32.1.98; Needleman JP, 2002, CHEST, V122, P43, DOI 10.1378/chest.122.1.43; Nicolazzo JA, 2005, J CONTROL RELEASE, V105, P1, DOI 10.1016/j.jconrel.2005.01.024; Osborne V, 2014, EUR J PAIN, V18, P506, DOI 10.1002/j.1532-2149.2013.00389.x; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; RAFFA RB, 1993, J PHARMACOL EXP THER, V267, P331; Sangkatumvong S, 2011, AM J RESP CRIT CARE, V184, P474, DOI 10.1164/rccm.201103-0537OC; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Smith HS, 2013, J PAIN RES, V6, P189, DOI 10.2147/JPR.S40745; van Beers EJ, 2007, AM J HEMATOL, V82, P955, DOI 10.1002/ajh.20944; Vinchi F, 2013, CIRCULATION, V127, P1317, DOI 10.1161/CIRCULATIONAHA.112.130179	37	8	8	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	JUL	2016	16	6					680	687		10.1111/papr.12313			8	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	DR4TH	WOS:000379895100004	26009799				2020-06-30	J	Jarraya, A; Elleuch, S; Zouari, J; Smaoui, M; Laabidi, S; Kolsi, K				Jarraya, Anouar; Elleuch, Sahar; Zouari, Jawhar; Smaoui, Mohamed; Laabidi, Sofiene; Kolsi, Kamel			Postoperative analgesia in children when using clonidine in addition to fentanyl with bupivacaine given caudally	PAN AFRICAN MEDICAL JOURNAL			English	Article						Caudal epidural; clonidine; fentanyl; pediatric; postoperative analgesia; bupivacaine	ROPIVACAINE; ANESTHESIA; BLOCKADE	The aim of the study was to evaluate the efficacy of clonidine in association with fentanyl as an additive to bupivacaine 0.25% given via single shot caudal epidural in pediatric patients for postoperative pain relief. In the present prospective randomized double blind study, 40 children of ASA-I-II aged 1-5 years scheduled for infraumblical surgical procedures were randomly allocated to two groups to receive either bupivacaine 0.25% (1 ml/kg) with fentanyl 1 mu g/kg and clonidine 1 mu g/kg (group I) or bupivacaine 0.25% (1 ml/kg) with fentanyl 1 mu g/kg (group II). Caudal block was performed after the induction of general anesthesia. Postoperatively patients were observed for analgesia, sedation, hemodynamic parameters, and side effects or complications. Both the groups were similar with respect to patient and various block characteristics. Heart rate and blood pressure were not different in 2 groups. Significantly prolonged duration of post-operative analgesia was observed in group I (P<0.05). Side effects such as respiratory depression, vomiting and bradycardia were similar in both groups. The adjunction of clonidine to fentanyl as additives to bupivacaine in single shot caudal epidural in children may provide better and longer analgesia after infraumblical surgical procedures.	[Jarraya, Anouar; Elleuch, Sahar; Smaoui, Mohamed; Laabidi, Sofiene; Kolsi, Kamel] Hop Hedi Chaker, Serv Anesthesie Reanimat, Sfax, Tunisia; [Zouari, Jawhar] Hop Kremlin, Serv Anesthesie Reanimat, Le Kremlin Bicetre, France	Elleuch, S (reprint author), Hop Hedi Chaker, Serv Anesthesie Reanimat, Sfax, Tunisia.			jarraya, anouar/0000-0002-4488-5491			Bajwa SJS, 2010, INDIAN J ANAESTH, V54, P226, DOI 10.4103/0019-5049.65368; BONNET F, 1990, ANESTHESIOLOGY, V72, P423, DOI 10.1097/00000542-199003000-00004; CAMPBELL FA, 1992, CAN J ANAESTH, V39, P661, DOI 10.1007/BF03008226; Cook B, 1996, PAEDIATR ANAESTH, V6, P353, DOI 10.1046/j.1460-9592.1996.d01-3.x; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; de Beer DAH, 2003, BRIT J ANAESTH, V90, P487, DOI 10.1093/bja/aeg064; De Negri P, 2001, PAEDIATR ANAESTH, V11, P679, DOI 10.1046/j.1460-9592.2001.00742.x; EISENACH J, 1993, ANESTHESIOLOGY, V78, P277, DOI 10.1097/00000542-199302000-00011; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; Ivani G, 2000, ACTA ANAESTH SCAND, V44, P446, DOI 10.1034/j.1399-6576.2000.440415.x; Koul A, 2009, INDIAN J ANAESTH, V53, P450; Laha A, 2012, SAUDI J ANAESTH, V6, P197, DOI 10.4103/1658-354X.101199; Parameswari A, 2010, INDIAN J ANAESTH, V54, P458, DOI 10.4103/0019-5049.71047; Sethna NF, 2003, PEDIAT ANESTHESIA, P267; Shukla Usha, 2011, J Anaesthesiol Clin Pharmacol, V27, P205, DOI 10.4103/0970-9185.81842; Verghese Susan T, 2005, Anesthesiol Clin North Am, V23, P163, DOI 10.1016/j.atc.2004.11.008; Vetter TR, 2007, ANESTH ANALG, V104, P1356, DOI 10.1213/01.ane.0000261521.52562.de	17	4	4	1	2	AFRICAN FIELD EPIDEMIOLOGY NETWORK-AFENET	KAMPALA	PO BOX 12874, KAMPALA, 00000, UGANDA	1937-8688			PAN AFR MED J	Pan Afr. Med. J.	JUL 1	2016	24								182	10.11604/pamj.2016.24.182.6446			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	EH4HS	WOS:000391732900001	27795779	DOAJ Gold, Green Published			2020-06-30	J	Paul, M; Bougouin, W; Geri, G; Dumas, F; Champigneulle, B; Legriel, S; Charpentier, J; Mira, JP; Sandroni, C; Cariou, A				Paul, Marine; Bougouin, Wulfran; Geri, Guillaume; Dumas, Florence; Champigneulle, Benoit; Legriel, Stephane; Charpentier, Julien; Mira, Jean-Paul; Sandroni, Claudio; Cariou, Alain			Delayed awakening after cardiac arrest: prevalence and risk factors in the Parisian registry	INTENSIVE CARE MEDICINE			English	Article						Cardiac arrest; Prognosis; Therapeutic hypothermia	ACUTE KIDNEY INJURY; EUROPEAN RESUSCITATION COUNCIL; THERAPEUTIC HYPOTHERMIA; MIDAZOLAM; PROGNOSTICATION; PHARMACOKINETICS; TIME; DISPOSITION; MANAGEMENT; SURVIVORS	Although prolonged unconsciousness after cardiac arrest (CA) is a sign of poor neurological outcome, limited evidence shows that a late recovery may occur in a minority of patients. We investigated the prevalence and the predictive factors of delayed awakening in comatose CA survivors treated with targeted temperature management (TTM). Retrospective analysis of the Parisian Region Out-of-Hospital CA Registry (2008-2013). In adult comatose CA survivors treated with TTM, sedated with midazolam and fentanyl, time to awakening was measured starting from discontinuation of sedation at the end of rewarming. Awakening was defined as delayed when it occurred after more than 48 h. A total of 326 patients (71 % male, mean age 59 +/- A 16 years) were included, among whom 194 awoke. Delayed awakening occurred in 56/194 (29 %) patients, at a median time of 93 h (IQR 70-117) from discontinuation of sedation. In 5/56 (9 %) late awakeners, pupillary reflex and motor response were both absent 48 h after sedation discontinuation. In multivariate analysis, age over 59 years (OR 2.1, 95 % CI 1.0-4.3), post-resuscitation shock (OR 2.6 [1.3-5.2]), and renal insufficiency at admission (OR 3.1 [1.4-6.8]) were associated with significantly higher rates of delayed awakening. Delayed awakening is common among patients recovering from coma after CA. Renal insufficiency, older age, and post-resuscitation shock were independent predictors of delayed awakening. Presence of unfavorable neurological signs at 48 h after rewarming from TTM and discontinuation of sedation did not rule out recovery of consciousness in late awakeners.	[Paul, Marine; Bougouin, Wulfran; Geri, Guillaume; Champigneulle, Benoit; Charpentier, Julien; Mira, Jean-Paul; Cariou, Alain] Cochin Hosp, AP HP, Med ICU, 27 Rue Faubourg St Jacques, F-75014 Paris, France; [Bougouin, Wulfran; Geri, Guillaume; Dumas, Florence; Legriel, Stephane; Cariou, Alain] Paris Cardiovasc Res Ctr, INSERM, U970, Paris, France; [Bougouin, Wulfran; Geri, Guillaume; Dumas, Florence; Champigneulle, Benoit; Charpentier, Julien; Mira, Jean-Paul; Cariou, Alain] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Bougouin, Wulfran; Geri, Guillaume; Dumas, Florence; Legriel, Stephane; Cariou, Alain] Paris Sudden Death Expertise Ctr, Paris, France; [Dumas, Florence] Cochin Hotel Dieu Hosp, AP HP, Emergency Dept, Paris, France; [Sandroni, Claudio] Catholic Univ, Sch Med, Dept Anaesthesiol & Intens Care, Rome, Italy; [Legriel, Stephane] Mignot Hosp, ICU, Le Chesnay, France	Cariou, A (reprint author), Cochin Hosp, AP HP, Med ICU, 27 Rue Faubourg St Jacques, F-75014 Paris, France.	alain.cariou@cch.aphp.fr	Sandroni, Claudio/A-7320-2019; Legriel, Stephane/J-1307-2017	Sandroni, Claudio/0000-0002-8878-2611; Legriel, Stephane/0000-0003-4782-6734			Andresen JM, 2014, CRIT CARE MED, V42, P2244, DOI 10.1097/CCM.0000000000000522; Arcangeli A, 2005, CURR DRUG TARGETS, V6, P745, DOI 10.2174/138945005774574416; Arpino PA, 2008, PHARMACOTHERAPY, V28, P102, DOI 10.1592/phco.28.1.102; Bjelland TW, 2013, DRUG METAB DISPOS, V41, P214, DOI 10.1124/dmd.112.045567; Butler JM, 2008, CLIN PHARMACOKINET, V47, P297, DOI 10.2165/00003088-200847050-00002; Chamorro C, 2010, ANESTH ANALG, V110, P1328, DOI 10.1213/ANE.0b013e3181d8cacf; Chelly J, 2012, RESUSCITATION, V83, P1444, DOI 10.1016/j.resuscitation.2012.08.321; Choi L, 2016, CRIT CARE MED, V44, P64, DOI 10.1097/CCM.0000000000001347; Chua HR, 2012, RESUSCITATION, V83, P721, DOI 10.1016/j.resuscitation.2011.11.030; Dragancea I, 2015, RESUSCITATION, V93, P164, DOI 10.1016/j.resuscitation.2015.04.013; Dragancea I, 2013, RESUSCITATION, V84, P337, DOI 10.1016/j.resuscitation.2012.09.015; Driessen J J, 1991, Acta Anaesthesiol Belg, V42, P149; Dumas F, 2014, J AM COLL CARDIOL, V64, P2360, DOI 10.1016/j.jacc.2014.09.036; Dumas F, 2011, CIRCULATION, V123, P877, DOI 10.1161/CIRCULATIONAHA.110.987347; Dumas F, 2010, CIRC-CARDIOVASC INTE, V3, P200, DOI 10.1161/CIRCINTERVENTIONS.109.913665; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Fragen RJ, 1997, CLIN THER, V19, P405, DOI 10.1016/S0149-2918(97)80126-9; Geri G, 2015, INTENS CARE MED, V41, P1273, DOI 10.1007/s00134-015-3848-4; Gold B, 2014, RESUSCITATION, V85, P211, DOI 10.1016/j.resuscitation.2013.10.030; GREENBLATT DJ, 1984, ANESTHESIOLOGY, V61, P27, DOI 10.1097/00000542-198461010-00006; Grossestreuer AV, 2013, RESUSCITATION, V84, P1741, DOI 10.1016/j.resuscitation.2013.07.009; JENNETT B, 1975, LANCET, V1, P480; Jorgensen EO, 1998, RESUSCITATION, V36, P111, DOI 10.1016/S0300-9572(97)00094-4; Kamps MJA, 2013, INTENS CARE MED, V39, P1671, DOI 10.1007/s00134-013-3004-y; Lemiale V, 2013, INTENS CARE MED, V39, P1972, DOI 10.1007/s00134-013-3043-4; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Madl Christian, 2004, Curr Opin Crit Care, V10, P213, DOI 10.1097/01.ccx.0000127542.32890.fa; Mulder M, 2014, CRIT CARE MED, V42, P2493, DOI 10.1097/CCM.0000000000000540; Nolan JP, 2015, INTENS CARE MED, V41, P2039, DOI 10.1007/s00134-015-4051-3; Perkins GD, 2015, RESUSCITATION, V96, P328, DOI 10.1016/j.resuscitation.2014.11.002; Perman SM, 2012, CRIT CARE MED, V40, P719, DOI 10.1097/CCM.0b013e3182372f93; Polasek TM, 2008, BRIT J CLIN PHARMACO, V65, P87, DOI 10.1111/j.1365-2125.2007.02964.x; Rossetti AO, 2011, LANCET NEUROL, V10, P922, DOI 10.1016/S1474-4422(11)70187-9; Sandroni C, 2016, MINERVA ANESTESIOL; Sandroni C, 2014, INTENS CARE MED, V40, P1816, DOI 10.1007/s00134-014-3470-x; Swart EL, 2005, AM J KIDNEY DIS, V45, P360, DOI 10.1053/j.ajkd.2004.09.004; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Tujjar O, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0900-2; VINIK HR, 1983, ANESTHESIOLOGY, V59, P390, DOI 10.1097/00000542-198311000-00005; Zandbergen EGJ, 2003, INTENS CARE MED, V29, P1911, DOI 10.1007/s00134-003-1951-4	40	52	54	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUL	2016	42	7					1128	1136		10.1007/s00134-016-4349-9			9	Critical Care Medicine	General & Internal Medicine	DN0VE	WOS:000376783600003	27098348				2020-06-30	J	Doi, S; Mori, T; Uzawa, N; Arima, T; Takahashi, T; Uchida, M; Yawata, A; Narita, M; Uezono, Y; Suzuki, T; Narita, M				Doi, Seira; Mori, Tomohisa; Uzawa, Naoki; Arima, Takamichi; Takahashi, Tomoyuki; Uchida, Masashi; Yawata, Ayaka; Narita, Michiko; Uezono, Yasuhito; Suzuki, Tsutomu; Narita, Minoru			Characterization of methadone as a beta-arrestin-biased mu-opioid receptor agonist	MOLECULAR PAIN			English	Article						Methadone; internalization; NMDA receptor; mu-opioid receptor	MORPHINE; PAIN; OXYCODONE; ACTIVATION; FENTANYL; ANTINOCICEPTION; DESENSITIZATION; CONSTIPATION; INVOLVEMENT; ENDOCYTOSIS	Background: Methadone is a unique mu-opioid receptor agonist. Although several researchers have insisted that the pharmacological effects of methadone are mediated through the blockade of NMDA receptor, the underlying mechanism by which methadone exerts its distinct pharmacological effects compared to those of other mu-opioid receptor agonists is still controversial. In the present study, we further investigated the pharmacological profile of methadone compared to those of fentanyl and morphine as measured mainly by the discriminative stimulus effect and in vitro assays for NMDA receptor binding, mu-opioid receptor-internalization, and mu-opioid receptor-mediated beta-arrestin recruitment. Results: We found that fentanyl substituted for the discriminative stimulus effects of methadone, whereas a relatively high dose of morphine was required to substitute for the discriminative stimulus effects of methadone in rats. Under these conditions, the non-competitive NMDA receptor antagonist MK-801 did not substitute for the discriminative stimulus effects of methadone. In association with its discriminative stimulus effect, methadone failed to displace the receptor binding of MK801 using mouse brain membrane. Methadone and fentanyl, but not morphine, induced potent mu-opioid receptor internalization accompanied by the strong recruitment of beta-arrestin-2 in mu-opioid receptor-overexpressing cells. Conclusions: These results suggest that methadone may, at least partly, produce its pharmacological effect as a beta-arrestin-biased mu-opioid receptor agonist, similar to fentanyl, and NMDA receptor blockade is not the main contributor to the pharmacological profile of methadone.	[Doi, Seira; Mori, Tomohisa; Uzawa, Naoki; Arima, Takamichi; Takahashi, Tomoyuki; Uchida, Masashi; Yawata, Ayaka; Narita, Michiko; Narita, Minoru] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pharmacol, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan; [Uezono, Yasuhito] Natl Canc Ctr, Res Inst, Div Canc Pathophysiol, Tokyo, Japan; [Suzuki, Tsutomu] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Inst Drug Addict Res, Tokyo, Japan; [Narita, Minoru] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Life Sci Tokyo Adv Res Ctr L StaR, Tokyo, Japan	Mori, T; Narita, M (reprint author), Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pharmacol, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	t-mori@hoshi.ac.jp; narita@hoshi.ac.jp			NEXT-Program for the Strategic Research Foundation at Private Universities [S1411019]; Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [24590740, 15K08686]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by grants for NEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2014-2018, S1411019 and Grants-in-Aid for Scientific Research (C) No. 24590740 and No. 15K08686 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Ackerman Stacey J, 2004, Consult Pharm, V19, P118, DOI 10.4140/TCP.n.2004.118; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; Callahan RJ, 2004, ANESTH ANALG, V98, P653, DOI 10.1213/01.ANE.0000099723.75548.DF; Carpenter KJ, 2000, EUR J PAIN, V4, P19, DOI 10.1053/eujp.1999.0147; CODD EE, 1995, J PHARMACOL EXP THER, V274, P1263; Craft RM, 2005, PHARMACOL BIOCHEM BE, V80, P639, DOI 10.1016/j.pbb.2005.02.003; Daeninck PJ, 1999, J PAIN SYMPTOM MANAG, V18, P303, DOI 10.1016/S0885-3924(99)00086-X; DeWire SM, 2013, J PHARMACOL EXP THER, V344, P708, DOI 10.1124/jpet.112.201616; EBERT B, 1995, NEUROSCI LETT, V187, P165, DOI 10.1016/0304-3940(95)11364-3; HORNG JS, 1976, RES COMMUN CHEM PATH, V14, P621; Imai Satoshi, 2008, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V28, P169; Ise Y, 2001, NEUROSCI LETT, V299, P29, DOI 10.1016/S0304-3940(00)01768-7; Kreek MJ, 2000, ANN NY ACAD SCI, V909, P186; Macey TA, 2006, J BIOL CHEM, V281, P34515, DOI 10.1074/jbc.M604278200; Mancini I, 2000, CURR OPIN ONCOL, V12, P308, DOI 10.1097/00001622-200007000-00006; Mancini I L, 2000, J Palliat Med, V3, P49, DOI 10.1089/jpm.2000.3.49; Matsui A, 2010, BRIT J PHARMACOL, V161, P1403, DOI 10.1111/j.1476-5381.2010.00967.x; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; Minami K, 2009, J PHARMACOL SCI, V111, P60, DOI 10.1254/jphs.09139FP; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; Mori T, 2004, LIFE SCI, V75, P2473, DOI 10.1016/j.lfs.2004.05.017; Mori T, 2009, J PHARMACOL EXP THER, V347, P91; Nakamura Atsushi, 2011, J Pain Palliat Care Pharmacother, V25, P318, DOI 10.3109/15360288.2011.620689; Narita M, 2005, NEUROPSYCHOPHARMACOL, V30, P111, DOI 10.1038/sj.npp.1300527; Narita M, 2013, ADDICT BIOL, V18, P614, DOI 10.1111/j.1369-1600.2011.00354.x; Radbruch L, 2006, KEIO J MED, V53, P23; Shimoyama N, 1997, J PHARMACOL EXP THER, V283, P648; Sotgiu ML, 2009, PHARMACOL RES, V60, P284, DOI 10.1016/j.phrs.2009.04.002; Swegle JM, 2006, AM FAM PHYSICIAN, V74, P1347; Torigoe K, 2012, ANESTHESIOLOGY, V116, P159, DOI 10.1097/ALN.0b013e31823c7e56; Vann RE, 2009, DRUG ALCOHOL DEPEN, V103, P124, DOI 10.1016/j.drugalcdep.2009.02.015; Weschules DJ, 2008, PAIN MED, V9, P595, DOI 10.1111/j.1526-4637.2008.00461.x; Weschules DJ, 2006, PAIN MED, V7, P320, DOI 10.1111/j.1526-4637.2006.00184.x	34	10	10	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1744-8069			MOL PAIN	Mol. Pain	JUN 17	2016	12								1744806916654146	10.1177/1744806916654146			9	Neurosciences	Neurosciences & Neurology	EA2QA	WOS:000386438200002	27317580	DOAJ Gold, Green Published			2020-06-30	J	Lucyk, S; Nelson, L				Lucyk, Scott; Nelson, Lewis			Consequences of unsafe prescribing of transdermal fentanyl	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Editorial Material							CHRONIC PAIN		[Lucyk, Scott] Univ Calgary, Emergency Med, Calgary, AB, Canada; [Lucyk, Scott] Alberta Hlth Serv, Poison & Drug Informat Serv, Calgary, AB, Canada; [Nelson, Lewis] NYU, Sch Med, Emergency Med & Med Toxicol, New York, NY USA	Lucyk, S (reprint author), Univ Calgary, Emergency Med, Calgary, AB, Canada.; Lucyk, S (reprint author), Alberta Hlth Serv, Poison & Drug Informat Serv, Calgary, AB, Canada.			Nelson, Lewis/0000-0001-9551-3922			[Anonymous], 2015, FENT TRAD NAM ACT FE; [Anonymous], 2012, FDA REM PUBL POT LIF; Friesen KJ, 2016, CMAJ; Haddox JD, 1997, CLIN J PAIN, V13, P6; McMorran M, 2008, CAN ADV REACT NEWSL, V18, P1; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Nuckols TK, 2014, ANN INTERN MED, V160, P38, DOI 10.7326/0003-4819-160-1-201401070-00732; Prosser JM, 2010, J MED TOXICOL, V6, P443, DOI 10.1007/s13181-010-0092-8; Vignali C, 2015, FORENSIC SCI INT, V257, P172, DOI 10.1016/j.forsciint.2015.08.017	10	4	4	0	5	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	JUN 14	2016	188	9					638	639		10.1503/cmaj.160291			2	Medicine, General & Internal	General & Internal Medicine	DP9DY	WOS:000378798100014	27044482	Green Published, Bronze			2020-06-30	J	Friesen, KJ; Woelk, C; Bugden, S				Friesen, Kevin J.; Woelk, Cornelius; Bugden, Shawn			Safety of fentanyl initiation according to past opioid exposure among patients newly prescribed fentanyl patches	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							TRANSDERMAL FENTANYL; CANADA; ADHERENCE; PAIN	Background: Although a convenient opioid delivery system, transdermal fentanyl patches have caused several deaths and resulted in safety warnings reminding prescribers that fentanyl patches should be prescribed only for patients who have adequate prior exposure to opioids. We conducted a longitudinal analysis of the safety of fentanyl initiation by examining past opioid exposure among patients newly prescribed fentanyl patches. Methods: We identified all patients in the province of Manitoba who were newly prescribed fentanyl patches between Apr. 1, 2001, and Mar. 31, 2013. We converted all prior opioid use to oral morphine equivalents and determined the average daily dose in the 7-30 days before initial fentanyl patch use. Fentanyl initiation was considered unsafe if the patient's pre-fentanyl opioid exposure was below the recommended level. Results: We identified 11 063 patients who began using fentanyl patches during the study period. Overall, fentanyl initiation was deemed unsafe in 74.1% of cases because the patient's prior opioid exposure was inadequate. Women and patients 65 years of age and older were more likely than men and younger patients, respectively, to have inadequate prior opioid exposure (p < 0.001 for each comparison). The proportion of patients who had unsafe prescriptions for fentanyl patches decreased significantly over the study period, from 87.0% in 2001 to 50.0% in 2012 (p < 0.001). Interpretation: The safety of fentanyl initiation improved over the study period, but still half of fentanyl patch prescriptions were written for patients with inadequate prior opioid exposure. Review of prior opioid exposure may be a simple but important way to improve the safe use of fentanyl patches.	[Friesen, Kevin J.; Bugden, Shawn] Univ Manitoba, Fac Hlth Sci, Coll Pharm, Winnipeg, MB, Canada; [Woelk, Cornelius] Univ Manitoba, Fac Hlth Sci, Coll Med, Dept Family Med, Winnipeg, MB, Canada	Bugden, S (reprint author), Univ Manitoba, Fac Hlth Sci, Coll Pharm, Winnipeg, MB, Canada.	shawn.bugden@umanitoba.ca		Bugden, Shawn/0000-0002-9842-5909; Friesen, Kevin/0000-0002-6038-550X			[Anonymous], 2009, ISMP CANADA SAFETY B, V9, P1; [Anonymous], 2007, ISMP CANADA SAFETY B, V7, P1; [Anonymous], 2006, ISMP CANADA SAFETY B, V6, P1; [Anonymous], 2005, IMP SAF INF DUR FENT; [Anonymous], 2008, ISMP CANADA SAFETY B, V8, P1; [Anonymous], 2005, DUR FENT TRANSD SYST; Breekveldt-Postma NS, 2005, PHARMACOEPIDEM DR S, V14, P129, DOI 10.1002/pds.1008; Canadian Pharmacists Association, 2014, COMP PHARM SPEC; Deaths involving fentanyl in Canada, 2009, B CCENDU; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Dosa DM, 2009, J PAIN SYMPTOM MANAG, V38, P515, DOI 10.1016/j.jpainsymman.2008.11.008; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Fischer B, 2011, PHARMACOEPIDEM DR S, V20, P1269, DOI 10.1002/pds.2190; Garbe E, 2012, PHARMACOEPIDEM DR S, V21, P191, DOI 10.1002/pds.2164; Gomes T, 2014, CAN FAM PHYSICIAN, V60, P826; Greenall J, 2008, CAN J HOSP PHARM, V61, P57; Lane ME, 2013, EUR J PHARM BIOPHARM, V84, P449, DOI 10.1016/j.ejpb.2013.01.018; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; McEvoy Theresa, 2014, Hosp Pharm, V49, P942, DOI 10.1310/hpj4910-942; McMorran M, 2008, CAN ADVERSE REACTION, V18, P1; Moon JM, 2011, J EMERG MED, V40, P37, DOI 10.1016/j.jemermed.2007.10.075; National Opioid Use Guideline Group, 2010, CAN GUID SAF EFF U B; National Prescription Drug Utilization Information System, 2014, UT PRESCR OP CAN PUB; Ripamonti C, 2006, SUPPORT CARE CANCER, V14, P400, DOI 10.1007/s00520-005-0918-0; Sattler ELP, 2013, DRUG AGING, V30, P383, DOI 10.1007/s40266-013-0074-z; Skaer TL, 2014, J PAIN RES, V7, P495, DOI 10.2147/JPR.S36446; Tassinari D, 2009, J PALLIAT CARE, V25, P172, DOI 10.1177/082585970902500304; Wichman K, 2005, CAN PHARM J, V138, P65, DOI 10.1177/171516350513800709	28	16	16	0	5	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	JUN 14	2016	188	9					648	653		10.1503/cmaj.150961			6	Medicine, General & Internal	General & Internal Medicine	DP9DY	WOS:000378798100019	27044480	Green Published, Bronze			2020-06-30	J	Ruzycki, S; Yarema, M				Ruzycki, Shannon; Yarema, Mark			Fentanyl misuse	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Editorial Material									[Ruzycki, Shannon; Yarema, Mark] Univ Calgary, Dept Med, Calgary, AB, Canada; [Yarema, Mark] Alberta Hlth Serv, Sect Clin Pharmacol & Toxicol, Calgary, AB, Canada; [Yarema, Mark] Alberta Hlth Serv, Poison & Drug Informat Serv, Calgary, AB, Canada	Ruzycki, S (reprint author), Univ Calgary, Dept Med, Calgary, AB, Canada.	sarro@ualberta.ca		Yarema, Mark/0000-0001-8714-9956			Banjo Oluwajenyo, 2014, CMAJ Open, V2, pE153, DOI 10.9778/cmajo.20140008; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Deaths involving fentanyl in Canada, 2009, B CCENDU; Lavonas EJ, 2015, CIRCULATION, V132, pS501, DOI 10.1161/CIR.0000000000000264; The availability of take-home naloxone in Canada, 2016, B CCENDU, DOI [Ottawa, Canadian Centre on Substance Abuse]; U.S. Centers for Disease Control and Prevention, 2015, INCR FENT DRUG CONF	6	0	0	0	7	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	JUN 14	2016	188	9					673	673		10.1503/cmaj.151378			1	Medicine, General & Internal	General & Internal Medicine	DP9DY	WOS:000378798100023	27091798	Bronze, Green Published			2020-06-30	J	Ray, WA; Chung, CP; Murray, KT; Hall, K; Stein, CM				Ray, Wayne A.; Chung, Cecilia P.; Murray, Katherine T.; Hall, Kathi; Stein, C. Michael			Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE RISK SCORES; PRESCRIBING PATTERNS; PROPENSITY SCORES; SLEEP; OVERDOSE; ANALGESICS; PERFORMANCE; MEDICATION; THERAPY	IMPORTANCE Long-acting opioids increase the risk of unintentional overdose deaths but also may increase mortality from cardiorespiratory and other causes. OBJECTIVE To compare all-cause mortality for patients with chronic noncancer pain who were prescribed either long-acting opioids or alternative medications for moderate to severe chronic pain. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study between 1999 and 2012 of Tennessee Medicaid patients with chronic noncancer pain and no evidence of palliative or end-of-life care. EXPOSURES Propensity score-matched new episodes of prescribed therapy for long-acting opioids or either analgesic anticonvulsants or low-dose cyclic antidepressants (control medications). MAIN OUTCOMES AND MEASURES Total and cause-specific mortality as determined from death certificates. Adjusted hazard ratios (HRs) and risk differences (difference in incidence of death) were calculated for long-acting opioid therapy vs control medication. RESULTS There were 22 912 new episodes of prescribed therapy for both long-acting opioids and control medications (mean [SD] age, 48 [11] years; 60% women). The long-acting opioid group was followed up for a mean 176 days and had 185 deaths and the control treatment group was followed up for a mean 128 days and had 87 deaths. The HR for total mortality was 1.64 (95% CI, 1.26-2.12) with a risk difference of 68.5 excess deaths (95% CI, 28.2-120.7) per 10 000 person-years. Increased risk was due to out-of-hospital deaths (154 long-acting opioid, 60 control deaths; HR, 1.90; 95% CI, 1.40-2.58; risk difference, 67.1; 95% CI, 30.1-117.3) excess deaths per 10 000 person-years. For out-of-hospital deaths other than unintentional overdose (120 long-acting opioid, 53 control deaths), the HR was 1.72 (95% CI, 1.24-2.39) with a risk difference of 47.4 excess deaths (95% CI, 15.7-91.4) per 10 000 person-years. The HR for cardiovascular deaths (79 long-acting opioid, 36 control deaths) was 1.65 (95% CI, 1.10-2.46) with a risk difference of 28.9 excess deaths (95% CI, 4.6-65.3) per 10 000 person-years. The HR during the first 30 days of therapy (53 long-acting opioid, 13 control deaths) was 4.16 (95% CI, 2.27-7.63) with a risk difference of 200 excess deaths (95% CI, 80-420) per 10 000 person-years. CONCLUSIONS AND RELEVANCE Prescription of long-acting opioids for chronic noncancer pain, compared with anticonvulsants or cyclic antidepressants, was associated with a significantly increased risk of all-cause mortality, including deaths from causes other than overdose, with a modest absolute risk difference. These findings should be considered when evaluating harms and benefits of treatment.	[Ray, Wayne A.; Hall, Kathi] Vanderbilt Univ, Dept Hlth Policy, Sch Med, Nashville, TN 37212 USA; [Chung, Cecilia P.; Murray, Katherine T.; Stein, C. Michael] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Murray, Katherine T.; Stein, C. Michael] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA	Ray, WA (reprint author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, Village Vanderbilt, 1501 21st Ave S,Ste 2600, Nashville, TN 37212 USA.	wayne.ray@vanderbilt.edu			National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5R01HL081707]; National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K23AR064768]; Rheumatology Research Foundation	This work was supported by grant 5R01HL081707 from the National Heart, Lung, and Blood Institute (Dr Ray), by grant K23AR064768 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Dr Chung), and by a grant from the Rheumatology Research Foundation (Dr Chung).	Allison P.D., 2010, SURVIVAL ANAL USING; Arbogast PG, 2008, EPIDEMIOLOGY, V19, P30, DOI 10.1097/EDE.0b013e31815be000; Arbogast PG, 2011, AM J EPIDEMIOL, V174, P613, DOI 10.1093/aje/kwr143; Arbogast PG, 2009, STAT METHODS MED RES, V18, P67, DOI 10.1177/0962280208092347; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Brack A, 2011, J NEUROIMMUNE PHARM, V6, P490, DOI 10.1007/s11481-011-9290-7; Carragee EJ, 2005, NEW ENGL J MED, V352, P1891, DOI 10.1056/NEJMcp042054; Chou R, 2007, ANN INTERN MED, V147, P505, DOI 10.7326/0003-4819-147-7-200710020-00008; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Coolen P., 2009, Morbidity and Mortality Weekly Report, V58, P1171; Correa D, 2015, ANESTH ANALG, V120, P1273, DOI 10.1213/ANE.0000000000000672; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Ghinea N, 2015, J EVAL CLIN PRACT, V21, P28, DOI 10.1111/jep.12223; Lee-Iannotti J, 2014, J CLIN SLEEP MED, V10, P645, DOI 10.5664/jcsm.3790; Mansukhani MP, 2015, AM J PHYSIOL-HEART C, V309, pH739, DOI 10.1152/ajpheart.00285.2015; McCarberg B H, 2001, Am J Ther, V8, P181, DOI 10.1097/00045391-200105000-00006; Menendez ME, 2015, CLIN ORTHOP RELAT R, V473, P2402, DOI 10.1007/s11999-015-4173-5; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Moore RA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007938.pub2; Moore R. A., 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD008242.PUB2; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Pedersen Line, 2012, Tidsskr Nor Laegeforen, V132, P2489, DOI 10.4045/tidsskr.11.1214; PIPER JM, 1990, AM J EPIDEMIOL, V132, P561, DOI 10.1093/oxfordjournals.aje.a115692; Ray WA, 2004, CLIN PHARMACOL THER, V75, P234, DOI 10.1016/j.clpt.2003.09.019; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Ray WA, 2003, NEW ENGL J MED, V349, P1592, DOI 10.1056/NEJMp038145; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Ray WA, 2015, JAMA INTERN MED, V175, P420, DOI 10.1001/jamainternmed.2014.6294; Ray WA, 2015, PHARMACOEPIDEM DR S, V24, P98, DOI 10.1002/pds.3727; Shadish WR, 2010, NEWBORN INFANT NURS, V10, P19, DOI 10.1053/j.nainr.2009.12.010; Solomon DH, 2010, ARCH INTERN MED, V170, P1968, DOI 10.1001/archinternmed.2010.391; Yue HJ, 2010, MED CLIN N AM, V94, P435, DOI 10.1016/j.mcna.2010.02.007; Zutler M, 2011, CURR PHARM DESIGN, V17, P1443, DOI 10.2174/138161211796197070	39	140	142	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	2016	315	22					2415	2423		10.1001/jama.2016.7789			9	Medicine, General & Internal	General & Internal Medicine	DO3CE	WOS:000377656900019	27299617	Green Accepted, Bronze	Y	N	2020-06-30	J	Bertrand, HGMJ; Ellen, YC; O'Keefe, S; Flecknell, PA				Bertrand, Henri G. M. J.; Ellen, Yvette C.; O'Keefe, Stevie; Flecknell, Paul A.			Comparison of the effects of ketamine and fentanyl-midazolam-medetomidine for sedation of rhesus macaques (Macaca mulatta)	BMC VETERINARY RESEARCH			English	Article						Sedation; Ketamine; Fentanyl; Midazolam; Medetomidine; Recovery macaque	VISUAL ANALOG SCALE; BLOOD-PRESSURE-MEASUREMENTS; SEIZURE ACTIVITY; ANESTHESIA; REVERSAL; COMBINATION; XYLAZINE; CHILDREN; MONKEYS; CATS	Background: This study assessed the effects of sedation using a combination of fentanyl, midazolam and medetomidine in comparison to ketamine. Rhesus Macaques (Macaca mulatta), (n = 16, 5 males and 3 females randomly allocated to each treatment group) received either ketamine (KET) (10 mg.kg-1) or fentanyl-midazolam-medetomidine (FMM) (10 mu g/kg(-1); 0.5 mg.kg(-1); 20 mu g.kg(-1)) both IM. Oxygen (100 %) was provided by mask and heart rate, blood pressure, respiratory rate, EtCO2 and depth of sedation were assessed every 5 min for 20 min. After the last time point, FMM monkeys were reversed with atipamezole-naloxone (0.2 mg.kg(-1); 10 mu g.kg(-1)). Recovery was scored using clinical scoring scheme. Differences in physiological parameters and quality of sedation were compared using Area Under the Curve (AUC) method and either Mann-Witney or t-student tests. Results: Heart rate (beats/min) (Ket = 119 +/- 18; FMM = 89 +/- 17; p = 0.0066), systolic blood pressure (mmHg) (Ket = 109 +/- 10; FMM = 97 +/- 10; p = 0.0313), and respiratory rate (breaths/min) (Ket = 39 +/- 9; FMM = 29 +/- 10; p = 0.0416) were significantly lower in the FMM group. End-tidal CO2 (mmHg) did not differ between the groups (KET = 33 +/- 8; FMM = 42 +/- 11; p = 0.0462). Although some depression of physiological parameters was seen with FMM, the variables all remained within the normal ranges in both groups. Onset of a sufficient degree of sedation for safe handling was more rapid with ketamine (KET = 2.9 +/- 1.4 min; FMM = 7.9 +/- 1.2 min; p = 0.0009), but FMM recovery was faster (KET = 21.4 +/- 13.4 min; FMM = 9.1 +/- 3.6 min; p = 0.0379) and of better quality (KET = 1.3 +/- 0.9; FMM = 7.4 +/- 1.9; p = 0.0009) most probably because of the effectiveness of the reversal agents used. Conclusion: FMM provides an easily reversible immobilization with a rapid and good recovery quality and may prove a useful alternative to ketamine.	[Bertrand, Henri G. M. J.; Ellen, Yvette C.; O'Keefe, Stevie; Flecknell, Paul A.] Newcastle Univ, Comparat Biol Ctr, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Bertrand, Henri G. M. J.] Univ Liege, Fac Vet Med, Blvd Colonster, B-4000 Liege, Belgium; [Ellen, Yvette C.] Univ Nottingham, Sch Vet Med & Sci, Sutton Bonington Campus, Loughborough LE12 5RD, Leics, England; [Flecknell, Paul A.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Bertrand, HGMJ (reprint author), Newcastle Univ, Comparat Biol Ctr, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; Bertrand, HGMJ (reprint author), Univ Liege, Fac Vet Med, Blvd Colonster, B-4000 Liege, Belgium.	henri.bertrand@newcastle.ac.uk		Flecknell, Paul/0000-0002-1075-1129			Abee CR, 2012, NONHUMAN PRIMATES BI; Abend R, 2014, J BEHAV THER EXP PSY, V45, P447, DOI 10.1016/j.jbtep.2014.06.004; Adami C, 2013, SCHWEIZ ARCH TIERH, V155, P569, DOI 10.1024/0036-7281/a000513; Agus MSD, 2006, PEDIATR DIABETES, V7, P196, DOI 10.1111/j.1399-5448.2006.00186.x; Albrecht M, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0198-3; Baker NJ, 2011, J AM ASSOC LAB ANIM, V50, P916; Bate S. T., 2014, DESIGN STAT ANAL ANI; Belenkiy S, 2013, SHOCK, V39, P495, DOI 10.1097/SHK.0b013e318292c331; Carrier CA, 2014, J MED PRIMATOL, V43, P52, DOI 10.1111/jmp.12087; CELESIA GG, 1974, ELECTROEN CLIN NEURO, V37, P345, DOI 10.1016/0013-4694(74)90110-2; Cevik E, 2013, AM J EMERG MED, V31, P108, DOI 10.1016/j.ajem.2012.06.012; Chen JY, 2010, PEDIATR ANESTH, V20, P873, DOI 10.1111/j.1460-9592.2010.03375.x; CHESTER AE, 1992, FUND APPL TOXICOL, V19, P64, DOI 10.1016/0272-0590(92)90029-H; Christe KL, 2013, COMPARATIVE MED, V63, P445; Clark JA, 2002, PEDIATRICS, V110, P920, DOI 10.1542/peds.110.5.920; Costi D, 2014, COCHRANE LIB, P1; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Fierstra J, 2013, J CLIN MONIT COMPUT, V27, P147, DOI 10.1007/s10877-012-9403-8; Flecknell P, 2015, LAB ANIMAL ANAESTHES; FLECKNELL PA, 1989, LAB ANIM, V23, P147, DOI 10.1258/002367789780863655; Freitas GC, 2012, CAN J VET RES, V76, P201; Fukuda K, 1997, ANESTH PROG, P1; Gerak LR, 1998, PSYCHOPHARMACOLOGY, V137, P164, DOI 10.1007/s002130050606; GOURIEDEVI M, 1983, INDIAN J MED RES, V77, P525; Grimm KA, 2015, VET ANESTHESIA ANALG; HASKINS SC, 1985, AM J VET RES, V46, P1855; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Janssen NJJF, 2011, INTENS CARE MED, V37, P1331, DOI 10.1007/s00134-011-2244-y; Kennedy MJ, 2015, VET ANAESTH ANALG, V42, P350, DOI 10.1111/vaa.12218; KOHN DF, 1997, ANESTHESIA ANALGESIA; LATASCH L, 1984, ANESTH ANALG, V63, P814; Lee VK, 2010, J AM ASSOC LAB ANIM, V49, P57; Liengme B., 2008, GUIDE MICROSOFT EXCE; Mamula P, 2007, GASTROINTEST ENDOSC, V65, P203, DOI 10.1016/j.gie.2006.05.002; Manifold CA, 2013, J EMERG MED, V45, P626, DOI 10.1016/j.jemermed.2013.05.012; MAXWELL C, 1978, BRIT J CLIN PHARMACO, V6, P15, DOI 10.1111/j.1365-2125.1978.tb01676.x; McQueen A, 2009, ANN EMERG MED, V54, P191, DOI 10.1016/j.annemergmed.2009.04.015; Milic M, 2010, INT J ORAL MAX SURG, V39, P5, DOI 10.1016/j.ijom.2009.09.007; MORELAND AF, 1985, LAB ANIM SCI, V35, P287; Myrvik MP, 2015, J PEDIAT HEMATOL ONC, V37, P190, DOI 10.1097/MPH.0000000000000306; NACCARATO EF, 1979, LAB ANIM, V13, P317, DOI 10.1258/002367779780943314; NOWROUZIAN I, 1981, VET REC, V108, P354, DOI 10.1136/vr.108.16.354; PLUMB DC, 2008, PLUMBS VET DRUG HDB; Rahmanian-Schwarz A, 2012, J INVEST SURG, V25, P123, DOI 10.3109/08941939.2011.611582; Rausch M, 2014, CONSCIOUS COGN, V28, P126, DOI 10.1016/j.concog.2014.06.012; Settle TL, 2010, J MED PRIMATOL, V39, P50, DOI 10.1111/j.1600-0684.2009.00393.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Sinclair MD, 2003, CAN VET J, V44, P885; Sun FJ, 2003, CONTEMP TOP LAB ANIM, V42, P32; Valverde A, 2013, VET ANAESTH ANALG, V40, P3, DOI 10.1111/j.1467-2995.2012.00782.x; Viera AJ, 2005, FAM MED, V37, P360; Votava M, 2011, VET ANAESTH ANALG, V38, P490, DOI 10.1111/j.1467-2995.2011.00637.x; Wehby GL, 2014, INT J ENV RES PUB HE, V11, P4280, DOI 10.3390/ijerph110404280; Wellington D, 2013, J AM ASSOC LAB ANIM, V52, P481; WIESTER MJ, 1976, J LAB CLIN MED, V87, P354; Winterborn AN, 2008, J MED PRIMATOL, V37, P116, DOI 10.1111/j.1600-0684.2007.00234.x; Yanagidate E, 2006, EUR J ANAESTH, V23, P257, DOI 10.1017/S0265021505002279; Yeung KR, 2014, J MED PRIMATOL, V43, P217, DOI 10.1111/jmp.12113; Young SS, 1999, LAB ANIM, V33, P162, DOI 10.1258/002367799780578363	59	11	13	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-6148			BMC VET RES	BMC Vet. Res.	JUN 8	2016	12								93	10.1186/s12917-016-0721-9			9	Veterinary Sciences	Veterinary Sciences	DN7FG	WOS:000377240100001	27277424	DOAJ Gold, Green Published			2020-06-30	J	Van Driest, SL; Marshall, MD; Hachey, B; Beck, C; Crum, K; Owen, J; Smith, AH; Kannankeril, PJ; Woodworth, A; Caprioli, RM; Choi, L				Van Driest, Sara L.; Marshall, Matthew D.; Hachey, Brian; Beck, Cole; Crum, Kim; Owen, Jill; Smith, Andrew H.; Kannankeril, Prince J.; Woodworth, Alison; Caprioli, Richard M.; Choi, Leena			Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						analgesia; opportunistic research; paediatrics; population pharmacokinetics; post-operative pain; pragmatic research	SCAVENGED SAMPLES; NEWBORN-INFANTS; PRETERM INFANTS; YOUNG INFANTS; AGE; MODEL; PAIN; FUNDAMENTALS; VALIDATION; CLEARANCE	AIMS One barrier contributing to the lack of pharmacokinetic (PK) data in paediatric populations is the need for serial sampling. Analysis of clinically obtained specimens and data may overcome this barrier. To add evidence for the feasibility of this approach, we sought to determine PK parameters for fentanyl in children after cardiac surgery using specimens and data generated in the course of clinical care, without collecting additional blood samples. METHODS We measured fentanyl concentrations in plasma from leftover clinically-obtained specimens in 130 paediatric cardiac surgery patients and successfully generated a PK dataset using drug dosing data extracted from electronic medical records. Using a population PK approach, we estimated PK parameters for this population, assessed model goodness-of-fit and internal model validation, and performed subset data analyses. Through simulation studies, we compared predicted fentanyl concentrations using model-driven weight-adjusted per kg vs. fixed per kg fentanyl dosing. RESULTS Fentanyl clearance for a 6.4 kg child, the median weight in our cohort, is 5.7 l h(-1) (2.2-9.2 l h(-1)), similar to values found in prior formal PK studies. Model assessment and subset analyses indicated the model adequately fit the data. Of the covariates studied, only weight significantly impacted fentanyl kinetics, but substantial inter-individual variability remained. In simulation studies, model-driven weight-adjusted per kg fentanyl dosing led to more consistent therapeutic fentanyl concentrations than fixed per kg dosing. CONCLUSIONS We show here that population PK modelling using sparse remnant samples and electronic medical records data provides a powerful tool for assessment of drug kinetics and generation of individualized dosing regimens. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Pharmacokinetic (PK) parameters are largely unknown for paediatric populations. A major barrier to paediatric PK research is the need for serial blood sampling. WHAT THIS STUDY ADDS We estimated fentanyl PK parameters for children using only remnant plasma specimens and electronic medical records data. Model-driven weight-adjusted per kg fentanyl dosing led tomore consistent therapeutic fentanyl concentrations than fixed per kg dosing in simulations. PK modelling using clinically-generated specimens and data is a feasible and powerful tool for personalized dosing.	[Beck, Cole; Choi, Leena] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37235 USA; [Van Driest, Sara L.; Crum, Kim; Owen, Jill; Smith, Andrew H.; Kannankeril, Prince J.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Van Driest, Sara L.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Marshall, Matthew D.] Vanderbilt Univ, Med Ctr, Dept Pharmaceut Serv, Nashville, TN USA; [Hachey, Brian; Caprioli, Richard M.] Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN USA; [Woodworth, Alison] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Choi, L (reprint author), Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37235 USA.	leena.choi@vanderbilt.edu		Beck, Cole/0000-0002-6849-6255	Pharmaceutical Research and Manufacturers of America Foundation; CTSA from the NIH National Center for Advancing Translational Sciences [KL2 TR 000446]; NIH National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG034412]; American Heart AssociationAmerican Heart Association [12CRP10560001]; NIH National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5R01 GM058008-16, 2P41 GM103391-05]; NIH National Center for Advancing Translational Sciences [UL1 TR000445]	All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare SLV had support from Pharmaceutical Research and Manufacturers of America Foundation and CTSA award KL2 TR 000446 from the NIH National Center for Advancing Translational Sciences, LC had support from NIH National Institute on Aging grant AG034412, AHS had support from the American Heart Association award 12CRP10560001, RC reports grants from NIH National Institute of General Medical Sciences 5R01 GM058008-16 and 2P41 GM103391-05, all authors were supported by NIH National Center for Advancing Translational Sciences UL1 TR000445 and there are no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.	Anderson BJ, 2011, PEDIATR ANESTH, V21, P222, DOI 10.1111/j.1460-9592.2011.03536.x; Beal SL, 2002, J PHARMACOKINET PHAR, V29, P403, DOI 10.1023/A:1020909324909; Beal SL, 2009, NONMEM USERS GUIDES; Cohen-Wolkowiez M, 2012, THER DRUG MONIT, V34, P312, DOI 10.1097/FTD.0b013e3182587665; Cohen-Wolkowiez M, 2012, ANTIMICROB AGENTS CH, V56, P1828, DOI 10.1128/AAC.06071-11; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; Efron B, 1994, INTRO BOOTSTRAP; Encinas E, 2013, PEDIATR DRUGS, V15, P247, DOI 10.1007/s40272-013-0029-1; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; Ginsberg B, 1996, ANESTHESIOLOGY, V85, P1268, DOI 10.1097/00000542-199612000-00007; Gonzalez D, 2014, CLIN PHARMACOL THER, V96, P429, DOI 10.1038/clpt.2014.134; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; HERTZKA RE, 1989, ANESTHESIOLOGY, V70, P213, DOI 10.1097/00000542-198902000-00006; Jacobs ML, 2013, J THORAC CARDIOV SUR, V145, P1046, DOI 10.1016/j.jtcvs.2012.06.029; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Kiang TKL, 2012, CLIN PHARMACOKINET, V51, P515, DOI [10.2165/11634080-000000000-00000, 10.1007/BF03261928]; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; KOREN G, 1984, ANESTH ANALG, V63, P577; Laughon Matthew M, 2011, Expert Rev Clin Pharmacol, V4, P643, DOI 10.1586/ecp.11.43; Leroux S, 2015, CLIN PHARMACOKINET, V54, P1273, DOI 10.1007/s40262-015-0291-1; Lynn A, 1998, ANESTH ANALG, V86, P958, DOI 10.1097/00000539-199805000-00008; R Core Team, 2014, R LANG ENV STAT COMP; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; Sherwin CMT, 2012, CLIN PHARMACOKINET, V51, P573, DOI 10.2165/11634200-000000000-00000; SINGLETON MA, 1987, CAN J ANAESTH, V34, P152, DOI 10.1007/BF03015333; Tremoulet A, 2014, ANTIMICROB AGENTS CH, V58, P3013, DOI 10.1128/AAC.02374-13; Wade KC, 2008, ANTIMICROB AGENTS CH, V52, P4043, DOI 10.1128/AAC.00569-08; Wheeler M, 2004, ANESTH ANALG, V99, P1347, DOI 10.1213/01.ANE.0000132777.00967.A3; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7; Zhao W, 2015, BRIT J CLIN PHARMACO, V80, P1197, DOI 10.1111/bcp.12710; Zhao W, 2014, ANTIMICROB AGENTS CH, V58, P6572, DOI 10.1128/AAC.03568-14	34	12	12	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	JUN	2016	81	6					1165	1174		10.1111/bcp.12903			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DU9AL	WOS:000382508500017	26861166	Green Published, Bronze			2020-06-30	J	Bista, SR; Haywood, A; Hardy, J; Norris, R; Hennig, S				Bista, Sudeep R.; Haywood, Alison; Hardy, Janet; Norris, Ross; Hennig, Stefanie			Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						population pharmacokinetics; fentanyl; transdermal patch; plasma; cancer pain	POPULATION PHARMACOKINETICS; NOR-FENTANYL; HUMAN PLASMA; VALIDATION; CITRATE; BIOAVAILABILITY; VARIABILITY; DISPOSITION	This study aimed to describe exposure after fentanyl transdermal patch administration in patients with advanced cancer to quantify variability around the exposure. Patients (n = 56) with advanced cancer who received transdermal fentanyl (Durogesic(R); median dose, 50 mu g/h; range, 12-200 mu g/h) provided venous blood samples (n = 163) at various times (0.5-72 hours) during several patch application intervals. Plasma fentanyl concentration was determined (median, 0.9 mu g/L; range, 0.04-9.7 mu g/L) by high-performance liquid chromatography coupled to tandem mass spectrometry. Pharmacokinetic analysis was performed using nonlinear mixed-effects modeling with NONMEM. A 1-compartment distribution model with first-order absorption and elimination described fentanyl exposure after transdermal patch administration. Fentanyl apparent clearance (between-subject variability [BSV],%) was estimated at 122 L/h/70 kg and 38.5%, respectively. The absorption rate constant was 0.013 h(-1). Between-occasion variability on apparent clearance was 22.0%, which was lower than BSV, suggesting predictable exposure within the same patient and justifying therapeutic drug monitoring. Except for weight-based dosing, no other patient characteristic could be identified to guide initial fentanyl dose selection in patients with advanced cancer.	[Bista, Sudeep R.; Haywood, Alison; Norris, Ross] Griffith Univ, Menzies Hlth Inst Queensland, Sch Pharm, Gold Coast, Australia; [Bista, Sudeep R.; Haywood, Alison; Hardy, Janet; Norris, Ross] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia; [Hardy, Janet] Mater Hlth Serv, Dept Palliat & Support Care, Brisbane, Qld, Australia; [Norris, Ross] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia; [Norris, Ross] St Vincents Hosp, SydPath, Sydney, NSW, Australia; [Hennig, Stefanie] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia	Bista, SR (reprint author), Griffith Univ, Sch Pharm, Gold Coast Campus, Gold Coast, Qld 4222, Australia.	s.bista@griffith.edu.au	Hennig, Stefanie/E-4426-2011; Hardy, Janet/F-2501-2012	Hennig, Stefanie/0000-0001-5972-3711; Haywood, Alison/0000-0002-5354-8868	School of Pharmacy, Menzies Health Institute Queensland, Griffith University; Mater Medical Research Institute	The School of Pharmacy, Menzies Health Institute Queensland, Griffith University, and Mater Medical Research Institute partially funded this study.	Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663; Beal SL, 2009, NONMEM USERS GUIDES; Bergmann TK, 2014, THER DRUG MONIT, V36, P62, DOI 10.1097/FTD.0b013e31829f1ab8; Bergstrand M, 2011, AAPS J, V13, P143, DOI 10.1208/s12248-011-9255-z; Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; Bista SR, 2015, J PAIN SYMPTOM MANAG, V49, P934, DOI 10.1016/j.jpainsymman.2014.09.017; Bista SR, 2015, XENOBIOTICA, V45, P207, DOI 10.3109/00498254.2014.971093; Charles BG, 1999, AUS J HOSP PHARM, P88; Charles B, 2014, SUPPORT CARE CANCER, V22, P325, DOI 10.1007/s00520-013-1973-6; Charles BG, 2008, THER DRUG MONIT, V30, P709, DOI 10.1097/FTD.0b013e3181898b6f; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; FDA. Food and Drug Administration, 2010, GUID FENT IN PRESS; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hennig S, 2008, BRIT J CLIN PHARMACO, V65, P502, DOI 10.1111/j.1365-2125.2007.03045.x; Hennig S, 2014, J PHARMACOKINET PHAR, V41, P109, DOI 10.1007/s10928-014-9350-8; Holford NHG, 1996, CLIN PHARMACOKINET, V30, P329, DOI 10.2165/00003088-199630050-00001; Holford NHG, 2012, THER DRUG MONIT, V34, P565, DOI 10.1097/FTD.0b013e31826aabc3; Hug CC, 1984, PHARMACOKINETICS ANA, P187; Janssen Pharmaceuticals, DUR TRANSD SYST PROD; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kokubun H, 2007, J PHARM HLTH CARE SC, V33, P200; Kokubun Hideya, 2012, J Pain Palliat Care Pharmacother, V26, P98, DOI 10.3109/15360288.2012.679725; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mould DR, 2012, CPT-PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.4; Parke J, 1999, COMPUT METH PROG BIO, V59, P19, DOI 10.1016/S0169-2607(98)00098-4; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; ROWBOTHAM DJ, 1989, BRIT J ANAESTH, V63, P56, DOI 10.1093/bja/63.1.56; Savic RM, 2009, AAPS J, V11, P558, DOI 10.1208/s12248-009-9133-0; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; Smith J, 1999, EAPC C GEN; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; Wahlby U, 2001, J PHARMACOKINET PHAR, V28, P231, DOI 10.1023/A:1011527125570	37	3	3	1	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	JUN	2016	56	6					705	713		10.1002/jcph.641			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DR6ZQ	WOS:000380050200007	26381285				2020-06-30	J	Keller, DS; Tahilramani, RN; Flores-Gonzalez, JR; Ibarra, S; Haas, EM				Keller, D. S.; Tahilramani, R. N.; Flores-Gonzalez, J. R.; Ibarra, S.; Haas, E. M.			Pilot study of a novel pain management strategy: evaluating the impact on patient outcomes	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article; Proceedings Paper	Annual Meeting of the Society-of-American-Gastrointestinal-and-Endoscopic-Surgeons (SAGES)	APR 15-18, 2015	Nashville, TN	Soc Amer Gastrointestinal & Endoscop Surg		Minimally invasive surgery; Enhanced recovery after surgery; Surgical outcomes; Pain	LAPAROSCOPIC COLORECTAL SURGERY; ENHANCED RECOVERY PATHWAYS; ABDOMINIS PLANE BLOCKS; LIPOSOME BUPIVACAINE; POSTOPERATIVE PAIN; CONTROLLED-TRIAL; DOUBLE-BLIND; PERITONEAL BUPIVACAINE; CLINICAL EFFECTIVENESS; ILEOSTOMY REVERSAL	Background Our objective was to evaluate the impact of a novel multimodal pain management strategy on intraoperative opioid requirements, postoperative pain, narcotic use, and length of stay. Methods Consecutive patients undergoing elective laparoscopic colorectal resection were managed with an experimental protocol. The protocol uses a post-induction, pre-incision bilateral TAP block and local peritoneal infiltration at port sites with long-acting liposomal bupivacaine (20 mL long-acting liposomal bupivacaine, 30 mL 0.25 % bupivacaine, 30 mL saline). Experimental patients were matched on age, body mass index, gender, comorbidity, diagnosis, and procedure to a control group that received no block or local wound infiltration. Both groups followed a standardized enhanced recovery pathway. Demographics, perioperative, and postoperative outcomes were evaluated. The main outcome measures were intraoperative opioids, postoperative pain, opioid use, and length of stay. Results Fifty patients were analyzed-25 experimental and 25 controls. Patients were well matched on all demographics. In both cohorts, the main diagnosis was colorectal cancer and primary procedure performed a segmental resection. Operative times were similar (p = 0.41). Experimental patients received significantly less intraoperative fentanyl (mean 158 mcg experimental vs. 299 mcg control; p < 0.01). The experimental group had significantly lower initial (p < 0.01) and final PACU pain scores (p = 0.04) and shorter LOS (3.0 vs. 4.1 days, p = 0.04) compared to controls. Experimental patients trended toward shorter PACU times and lower opioid use and daily pain scores throughout the hospital stay. Postoperative complication and readmission rates were similar across groups. There were no reoperations or mortality. Conclusions Our multimodal pain management strategy reduced intraoperative opioid administration. Postoperatively, improvements in PACU time, postoperative pain and narcotic use, and lengths of stay were seen in the experimental cohort. With the favorable finding from the pilot study, further investigation is warranted to fully evaluate the impact of this pain management protocol on patient satisfaction, clinical and financial outcomes.	[Keller, D. S.; Flores-Gonzalez, J. R.; Ibarra, S.] Colorectal Surg Associates LLP LTD, Houston, TX 77054 USA; [Haas, E. M.] Univ Texas Med Sch Houston, Colorectal Surg Associates LLP LTD, Minimally Invas Colon & Rectal Surg, Div Colon & Rectal Surg,Houston Methodist Hosp, 6560 Fannin,Suite 1404, Houston, TX 77030 USA; [Tahilramani, R. N.] Univ Texas Med Sch Houston, Colorectal Surg Associates LLP LTD, Minimally Invas Colon & Rectal Surg, Houston, TX 77030 USA	Keller, DS (reprint author), Colorectal Surg Associates LLP LTD, Houston, TX 77054 USA.	debby_keller@hotmail.com; ehaasmd@houstoncolon.com		mittal, sumeet/0000-0003-2760-3891			Adamina M, 2015, ANN SURG, V261, pE138, DOI 10.1097/SLA.0000000000000679; Adamina M, 2011, SURGERY, V149, P830, DOI 10.1016/j.surg.2010.11.003; Alexander DJ, 1996, BRIT J SURG, V83, P1223; Barrington John W, 2013, Am J Orthop (Belle Mead NJ), V42, pS1; Carroll James, 2009, Clin Colon Rectal Surg, V22, P47, DOI 10.1055/s-0029-1202886; Center For Medicare and Medicaid Services, PHYS QUAL REP SYST; Cohen Stephen M, 2012, J Pain Res, V5, P567, DOI 10.2147/JPR.S38621; Colbert S, 1998, CAN J ANAESTH, V45, P729, DOI 10.1007/BF03012142; Conaghan P, 2010, SURG ENDOSC, V24, P2480, DOI 10.1007/s00464-010-0989-y; Delaney CP, 2010, AM J SURG, V199, P299, DOI 10.1016/j.amjsurg.2009.08.027; Delaney CP, 2003, DIS COLON RECTUM, V46, P851, DOI 10.1007/s10350-004-6672-4; Favuzza J, 2013, SURG ENDOSC, V27, P2481, DOI 10.1007/s00464-012-2761-y; Fayezizadeh M, 2014, PLAST RECONSTR SURG, V134, p151S, DOI 10.1097/PRS.0000000000000674; Gorfine SR, 2011, DIS COLON RECTUM, V54, P1552, DOI 10.1097/DCR.0b013e318232d4c1; Gosh S, 1994, BRIT J SURG, V81, P1635; Haas E, 2012, AM SURGEON, V78, P574; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hu D, 2013, CLIN DRUG INVEST, V33, P109, DOI 10.1007/s40261-012-0043-z; Johns N, 2012, COLORECTAL DIS, V14, pE635, DOI 10.1111/j.1463-1318.2012.03104.x; Joshi GP, 2014, AM SURGEON, V80, P219; JOSHI GP, 1994, INT ANESTHESIOL CLIN, V32, P113, DOI 10.1097/00004311-199432030-00009; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Kehlet H, 2008, ANN SURG, V248, P189, DOI 10.1097/SLA.0b013e31817f2c1a; Kehlet H, 2008, LANCET, V371, P791, DOI 10.1016/S0140-6736(08)60357-8; Kehlet H, 2007, BEST PRACT RES-CLIN, V21, P149, DOI 10.1016/j.bpa.2006.12.001; Keller DS, 2014, J AM COLL SURGEONS, V219, P1143, DOI 10.1016/j.jamcollsurg.2014.08.011; Keller DS, 2014, DIS COLON RECTUM, V57, P1290, DOI 10.1097/DCR.0000000000000211; Marcet JE, 2013, J PAIN RES, V6, P549, DOI 10.2147/JPR.S46467; Recart A, 2005, J ENDOUROL, V19, P1165, DOI 10.1089/end.2005.19.1165; Ris F, 2014, ANN ROY COLL SURG, V96, P579, DOI 10.1308/003588414X13946184900921; Senagore AJ, 2007, AM J HEALTH-SYST PH, V64, pS3, DOI 10.2146/ajhp070428; Senagore AJ, 2010, CLIN EXP GASTROENTER, V3, P87; Siddiqui MRS, 2011, J CLIN ANESTH, V23, P7, DOI 10.1016/j.jclinane.2010.05.008; Stuhldreher JM, 2012, SURG ENDOSC, V26, P1617, DOI 10.1007/s00464-011-2079-1; Tong YCI, 2014, BEST PRACT RES-CLIN, V28, P15, DOI 10.1016/j.bpa.2014.02.001; Viscusi G, 2011, INT AN RES SOC ANN M; Vlug MS, 2011, ANN SURG, V254, P868, DOI 10.1097/SLA.0b013e31821fd1ce; Vogel JD, 2013, J PAIN RES, V6, P605, DOI 10.2147/JPR.S46950; Walter CJ, 2013, SURG ENDOSC, V27, P2366, DOI 10.1007/s00464-013-2791-0; Zafar N, 2010, COLORECTAL DIS, V12, P119, DOI 10.1111/j.1463-1318.2009.01768.x	40	21	23	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	JUN	2016	30	6					2192	2198		10.1007/s00464-015-4459-4			7	Surgery	Surgery	DP9AV	WOS:000378790000005	26275549				2020-06-30	J	Weigl, W; Bierylo, A; Wielgus, M; Krzemien-Wiczynska, S; Szymusik, I; Kolacz, M; Dabrowski, MJ				Weigl, Wojciech; Bierylo, Andrzej; Wielgus, Monika; Krzemien-Wiczynska, Swietlana; Szymusik, Iwona; Kolacz, Marcin; Dabrowski, Michal J.			Analgesic efficacy of intrathecal fentanyl during the period of highest analgesic demand after cesarean section A randomized controlled study	MEDICINE			English	Article						cesarean section; fentanyl; intrathecal; opioids; postoperative pain; spinal anesthesia	PATIENT-CONTROLLED ANALGESIA; SPINAL-ANESTHESIA; ENHANCED RECOVERY; PERIOPERATIVE ANALGESIA; HYPERBARIC BUPIVACAINE; RESPIRATORY ARREST; PAIN RELIEF; DELIVERY; MORPHINE; SUFENTANIL	Cesarean section (CS) is one of the most common surgical procedures in female patients. We aimed to evaluate the postoperative analgesic efficacy of intrathecal fentanyl during the period of greatest postoperative analgesic demand after CS. This period was defined by detailed analysis of patient-controlled analgesia (PCA) usage. This double-blind, placebo-controlled, parallel-group randomized trial included 60 parturients who were scheduled for elective CS. Participants received spinal anesthesia with bupivacaine supplemented with normal saline (control group) or with fentanyl 25 mg (fentanyl group). To evaluate primary endpoints, we measured total pethidine consumption over the period of greatest PCA pethidine requirement. For verification of secondary endpoints, we recorded intravenous PCA requirement in other time windows, duration of effective analgesia, pain scores assessed by visual analog scale, opioid side effects, hemodynamic changes, neonatal Apgar scores, and intraoperative pain. Detailed analysis of hour-by-hour PCA opioid requirements showed that the greatest demand for analgesics among patients in the control group occurred during the first 12 hours after surgery. Patients in the fentanyl group had significantly reduced opioid consumption compared with the controls during this period and had a prolonged duration of effective analgesia. The groups were similar in visual analog scale, incidence of analgesia-related side effects (nausea/vomiting, pruritus, oversedation, and respiratory depression), and neonatal Apgar scores. Mild respiratory depression occurred in 1 patient in each group. Fewer patients experienced intraoperative pain in the fentanyl group (3% vs 23%; relative risk 6.8, 95% confidence interval 0.9-51.6). The requirement for postoperative analgesics is greatest during the first 12hours after induction of anesthesia in patients undergoing CS. The addition of intrathecal fentanyl to spinal anesthesia is effective for intraoperative analgesia and decreases opioid consumption during the period of the highest analgesic demand after CS, without an increase in maternal or neonatal side effects. We recommend using intrathecal fentanyl for CS in medical centers not using morphine or other opioids intrathecally at present.	[Weigl, Wojciech; Bierylo, Andrzej; Wielgus, Monika; Krzemien-Wiczynska, Swietlana; Kolacz, Marcin] Med Univ Warsaw, Dept Anaesthesiol & Intens Care, Lindleya 4th St, Warsaw, Poland; [Weigl, Wojciech] Uppsala Univ, Dept Surg Sci Anaesthesiol & Intens Care, Akad Hosp, S-75185 Uppsala, Sweden; [Wielgus, Monika] Prof Gruca Teaching Hosp, Dept Anaesthesiol & Intens Care, Postgrad Med Educ Ctr, Konarskiego 13, Otwock, Poland; [Szymusik, Iwona] Med Univ Warsaw, Dept Obstet & Gynaecol 1, Warsaw, Poland; [Dabrowski, Michal J.] Polish Acad Sci, Inst Comp Sci, Jana Kazimierza 5, PL-01248 Warsaw, Poland	Weigl, W (reprint author), Uppsala Univ, Dept Surg Sci Anaesthesiol & Intens Care, Akad Hosp, S-75185 Uppsala, Sweden.; Dabrowski, MJ (reprint author), Polish Acad Sci, Inst Comp Sci, Jana Kazimierza 5, PL-01248 Warsaw, Poland.	wojciech.weigl@gmail.com; m.dabrowski@ipipan.waw.pl	Weigl, Wojciech/B-4294-2015; Dabrowski, Michal/D-4369-2014	Weigl, Wojciech/0000-0001-5184-6602; Kolacz, Marcin/0000-0002-7126-5714			ABOULEISH E, 1988, ANESTH ANALG, V67, P370; ABOULEISH E, 1991, REGION ANESTH, V16, P137; Aluri S, 2014, INT J OBSTET ANESTH, V23, P157, DOI 10.1016/j.ijoa.2013.11.006; Aubrun F, 2003, ANESTHESIOLOGY, V98, P1415, DOI 10.1097/00000542-200306000-00017; Binder P, 2011, MIDWIFERY, V27, P547, DOI 10.1016/j.midw.2010.05.002; Biswas BN, 2002, INDIAN J ANAESTH, V46, P469; Bogra J, 2005, BMC ANESTHESIOL, V5, P5, DOI DOI 10.1186/1471-2253-5-5; Chu C C, 1995, Acta Anaesthesiol Sin, V33, P149; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Dalchow S, 2013, INT J OBSTET ANESTH, V22, P217, DOI 10.1016/j.ijoa.2013.04.003; Eisenach JC, 2008, PAIN, V140, P87, DOI 10.1016/j.pain.2008.07.011; Ferouz F, 1997, ANESTH ANALG, V85, P1088; Giovannelli M, 2008, EUR J ANAESTH, V25, P118, DOI 10.1017/S0265021507001305; Goma HM, 2014, TOPICS SPINAL ANAEST; Grant GJ, 1996, J CLIN ANESTH, V8, P99, DOI 10.1016/0952-8180(95)00174-3; GRAVES DA, 1985, CLIN PHARMACY, V4, P41; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Jacques V, 2013, ANN FR ANESTH, V32, P142, DOI 10.1016/j.annfar.2013.01.016; Jaffee JB, 1997, INT J OBSTET ANESTH, V6, P182, DOI 10.1016/S0959-289X(97)80086-6; Kiran S, 2002, INT J OBSTET ANESTH, V11, P185, DOI 10.1054/ijoa.2002.0949; Kuczkowski KM, 2002, ANAESTHESIA, V57, P939; Marcus HE, 2011, ANAESTHESIST, V60, P916, DOI 10.1007/s00101-011-1931-y; Meininger D, 2003, ANESTH ANALG, V96, P852, DOI 10.1213/01.ANE.0000049685.38809.7E; Munishankar B, 2008, INT J OBSTET ANESTH, V17, P9, DOI 10.1016/j.ijoa.2007.06.006; Orbach-Zinger S, 2014, ISR MED ASSOC J, V16, P153; Pan PH, 2013, ANESTHESIOLOGY, V118, P1170, DOI 10.1097/ALN.0b013e31828e156f; RAYBURN WF, 1988, OBSTET GYNECOL, V72, P136; Rowe-Murray HJ, 2001, BRIT J OBSTET GYNAEC, V108, P1068, DOI 10.1016/S0306-5456(01)00242-X; Scavone BM, 2002, ANESTHESIOLOGY, V96, P1021, DOI 10.1097/00000542-200204000-00033; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Sibilla C, 1997, INT J OBSTET ANESTH, V6, P43, DOI 10.1016/S0959-289X(97)80051-9; Siti Salmah G, 2009, Med J Malaysia, V64, P71; TAMSEN A, 1979, ACTA ANAESTH SCAND, V23, P462, DOI 10.1111/j.1399-6576.1979.tb01475.x; Turk DC, 2008, PAIN, V139, P485, DOI 10.1016/j.pain.2008.06.025; Weigl Wojciech, 2009, Anestezjol Intens Ter, V41, P28; Wrench IJ, 2015, INT J OBSTET ANESTH, V24, P124, DOI 10.1016/j.ijoa.2015.01.003	39	7	7	3	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUN	2016	95	24							e3827	10.1097/MD.0000000000003827			7	Medicine, General & Internal	General & Internal Medicine	DO8SD	WOS:000378053000018	27310958	DOAJ Gold, Green Published			2020-06-30	J	Banik, S; Rath, GP				Banik, Sujoy; Rath, Girija Prasad			Dexmedetomidine Infusion may Cause Agitation During Procedural Sedation	PAIN PRACTICE			English	Letter									[Banik, Sujoy; Rath, Girija Prasad] All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, New Delhi, India	Rath, GP (reprint author), All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, New Delhi, India.	girijarath@yahoo.co.in	Rath, Girija Prasad/J-4046-2019	Rath, Girija Prasad/0000-0002-3985-8202; Banik, Sujoy/0000-0001-5649-7499			Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; Boyer J, 2010, NURS CRIT CARE, V5, P30; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Kim SY, 2013, BRIT J ANAESTH, V111, P222, DOI 10.1093/bja/aet056; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; tersBruggen FFJA, 2016, PAIN PRACT	6	3	3	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	JUN	2016	16	5					E89	E89		10.1111/papr.12434			1	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	DP3TP	WOS:000378418600003	27260117				2020-06-30	J	Ishida, T; Naito, T; Sato, H; Kawakami, J				Ishida, Takuya; Naito, Takafumi; Sato, Hikaru; Kawakami, Junichi			Relationship between the plasma fentanyl and serum 4 beta-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain	DRUG METABOLISM AND PHARMACOKINETICS			English	Article						Fentanyl; Transdermal system; 4 beta-Hydroxycholesterol; CYP3A5; Gender; Pharmacokinetics; Cancer pain	TRANSDERMAL FENTANYL; HALF-LIFE; ENDOGENOUS MARKER; PHARMACOKINETICS; CYP3A5-ASTERISK-3; POPULATION; INHIBITION; CLEARANCE; INDUCTION; HUMANS	This study aimed to evaluate the relationship between the concentrations of plasma fentanyl and serum 4 beta-hydroxycholesterol based on CYP3A5 genotype and gender in cancer patients. Thirty-three Japanese cancer patients treated with transdermal fentanyl were enrolled. The concentrations of plasma fentanyl and norfentanyl, and serum 4 beta-hydroxycholesterol and total cholesterol were determined at day 8 or later after starting the medication. The plasma fentanyl concentration was significantly higher in the CYP3A5*3/*3 group than in the *1 allele carrier group. The *3/*3 group had a lower metabolic ratio of fentanyl. The serum 4 beta-hydroxycholesterol concentration and its ratio to total cholesterol were significantly lower in the CYP3A5*3/*3 group than in the *1 allele carrier group. The concentrations of plasma fentanyl and serum 4 beta-hydroxycholesterol were significantly higher in women than in men. Gender did not affect the metabolic ratio of fentanyl or the concentration ratio of 4 beta-hydroxycholesterol. The plasma fentanyl concentration was not correlated with the serum 4 beta-hydroxycholesterol concentration, while the metabolic ratio of fentanyl was slightly correlated with the serum concentration ratio of 4 beta-hydroxycholesterol. In conclusion, CYP3A5*3 and gender affected the plasma fentanyl and serum 4 beta-hydroxycholesterol concentrations in cancer patients. However, the plasma disposition of fentanyl was not determined using the serum 4 beta-hydroxycholesterol concentration. (C) 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.	[Ishida, Takuya; Naito, Takafumi; Sato, Hikaru; Kawakami, Junichi] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Hamamatsu, Shizuoka 4313192, Japan	Naito, T (reprint author), Hamamatsu Univ Sch Med, Dept Hosp Pharm, Hamamatsu, Shizuoka 4313192, Japan.	naitou@hama-med.ac.jp		NAITO, TAKAFUMI/0000-0002-7447-3789	Takeda Science FoundationTakeda Science Foundation (TSF)	This work was supported by Takeda Science Foundation.	Barratt DT, 2014, PHARMACOGENET GENOM, V24, P185, DOI 10.1097/FPC.0000000000000032; Bodin K, 2002, J BIOL CHEM, V277, P31534, DOI 10.1074/jbc.M201712200; Charles KA, 2006, CLIN CANCER RES, V12, P7492, DOI 10.1158/1078-0432.CCR-06-0023; Chiba T, 2010, PALLIATIVE CARE RES, V5, P206; Diczfalusy U, 2008, PHARMACOGENET GENOM, V18, P201, DOI 10.1097/FPC.0b013e3282f50ee9; Diczfalusy U, 2011, BRIT J CLIN PHARMACO, V71, P183, DOI 10.1111/j.1365-2125.2010.03773.x; Diczfalusy U, 2009, BRIT J CLIN PHARMACO, V67, P38, DOI 10.1111/j.1365-2125.2008.03309.x; Fukuen S, 2002, PHARMACOGENETICS, V12, P331, DOI 10.1097/00008571-200206000-00009; Greenblatt DJ, 2008, J CLIN PHARMACOL, V48, P1350, DOI 10.1177/0091270008323754; He R, 2015, MED SCI MONITOR, V21, P396, DOI 10.12659/MSM.892044; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Josephson F, 2008, EUR J CLIN PHARMACOL, V64, P775, DOI 10.1007/s00228-008-0492-8; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kokubun Hideya, 2012, J Pain Palliat Care Pharmacother, V26, P98, DOI 10.3109/15360288.2012.679725; Kuroda K, 2007, UROLOGY, V69, P113, DOI 10.1016/j.urology.2006.09.039; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lutjohann D, 2009, INT J CLIN PHARM TH, V47, P709; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Meibohm B, 2002, CLIN PHARMACOKINET, V41, P329, DOI 10.2165/00003088-200241050-00002; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Seino S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131975; Suzuki Y, 2014, DRUG METAB DISPOS, V42, P105, DOI 10.1124/dmd.113.054171; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Tanaka N, 2014, THER DRUG MONIT, V36, P345, DOI 10.1097/FTD.0000000000000029; Wide K, 2008, BRIT J CLIN PHARMACO, V65, P708, DOI 10.1111/j.1365-2125.2007.03078.x; Yang Z, 2010, J CLIN PHARMACOL, V50, P1330, DOI 10.1177/0091270009360041; Ziesenitz VC, 2015, J CLIN PHARMACOL, V55, P708, DOI 10.1002/jcph.469	30	5	6	1	1	JAPANESE SOC STUDY XENOBIOTICS	TOKYO	INT MED INF CENTER SHINANOMACHI RENGAKAN, 35 SHINANO-MACHI SHINJUKU-KU, TOKYO, 160-0016, JAPAN	1347-4367	1880-0920		DRUG METAB PHARMACOK	Drug Metab. Pharmacokinet.	JUN	2016	31	3					242	248		10.1016/j.dmpk.2016.04.001			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DO4TH	WOS:000377776500009	27236640				2020-06-30	J	Corli, O; Floriani, I; Roberto, A; Montanari, M; Galli, F; Greco, MT; Caraceni, A; Kaasa, S; Dragani, TA; Azzarello, G; Luzzani, M; Cavanna, L; Bandieri, E; Gamucci, T; Lipari, G; Di Gregorio, R; Valenti, D; Reale, C; Pavesi, L; Iorno, V; Crispino, C; Pacchioni, M; Apolone, G				Corli, O.; Floriani, I.; Roberto, A.; Montanari, M.; Galli, F.; Greco, M. T.; Caraceni, A.; Kaasa, S.; Dragani, T. A.; Azzarello, G.; Luzzani, M.; Cavanna, L.; Bandieri, E.; Gamucci, T.; Lipari, G.; Di Gregorio, R.; Valenti, D.; Reale, C.; Pavesi, L.; Iorno, V.; Crispino, C.; Pacchioni, M.; Apolone, G.		CERP STUDY PAIN GRP	Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids	ANNALS OF ONCOLOGY			English	Article						opioids in cancer pain; variability of response; changes of therapy; neurotoxic effects	RELEASE ORAL MORPHINE; DOUBLE-BLIND; RECOMMENDATIONS; QUESTIONNAIRE; PALLIATION; GUIDELINES; MANAGEMENT; OXYCODONE; METHADONE; FENTANYL	Background: Guidelines tend to consider morphine and morphine-like opioids comparable and interchangeable in the treatment of chronic cancer pain, but individual responses can vary. This study compared the analgesic efficacy, changes of therapy and safety profile over time of four strong opioids given for cancer pain. In this four-arm multicenter, randomized, comparative, of superiority, phase IV trial, oncological patients with moderate to severe pain requiring WHO step III opioids were randomly assigned to receive oral morphine or oxycodone or transdermal fentanyl or buprenorphine for 28 days. At each visit, pain intensity, modifications of therapy and adverse drug reactions (ADRs) were recorded. The primary efficacy end point was the proportion of nonresponders, meaning patients with worse or unchanged average pain intensity (API) between the first and last visit, measured on a 0-10 numerical rating scale. (NCT01809106). Forty-four centers participated in the trial and recruited 520 patients. Worst pain intensity and API decreased over 4 weeks with no significant differences between drugs. Nonresponders ranged from 11.5% (morphine) to 14.4% (buprenorphine). Appreciable changes were made in the treatment schedules over time. Each group required increases in the daily dose, from 32.7% (morphine) to 121.2% (transdermal fentanyl). Patients requiring adjuvant analgesics ranged from 68.9% (morphine) to 81.6% (oxycodone), switches varied from 22.1% (morphine) to 12% (oxycodone), discontinuation of treatment from 27% ( morphine) to 14.5% (fentanyl). ADRs were similar except for effects on the nervous system, which significantly prevailed with morphine. The main findings were the similarity in pain control, response rates and main adverse reactions among opioids. Changes in therapy schedules were notable over time. A considerable proportion of patients were nonresponders or poor responders. NCT01809106 ().	[Corli, O.; Roberto, A.; Montanari, M.; Greco, M. T.] Ist Ric Farmacol Mario Negri, IRCCS, Dept Oncol, Unita Ric Dolore & Cure Palliat, I-20156 Milan, Italy; [Floriani, I.; Galli, F.] Ist Ric Farmacol Mario Negri, IRCCS, Lab Ric Clin, Oncol, I-20156 Milan, Italy; [Greco, M. T.] Univ Milan, Dept Stat, Milan, Italy; [Caraceni, A.] Ist Nazl Tumori, Fdn IRCCS, Palliat Care Complex Struct Terapia Dolore & Riab, Via Venezian 1, I-20133 Milan, Italy; [Kaasa, S.] Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, Oslo, Norway; [Dragani, T. A.] Ist Nazl Tumori, Fdn IRCCS, SSD Epidemiol Genet & Pharmacogen, Via Venezian 1, I-20133 Milan, Italy; [Azzarello, G.] Osped UOC Oncol Mirano ASL, Dept Hematol & Oncol, 13 Reg Veneto, Mirano, Italy; [Luzzani, M.] Osped Galliera, SSD Cure Palliat Riabilitaz & Stabilizzaz EO, Dept Orthogeriatr, Genoa, Italy; [Cavanna, L.] Osped Piacenza, Oncol Unit, Piacenza, Italy; [Bandieri, E.] Med Oncol Div USL, Unit Support & Simultaneous Care, Modena, Italy; [Gamucci, T.] Osped SS Trinita, UOC Med Oncol, Sora, Italy; [Lipari, G.] PO Salemi ASP 9, Palliat Care, Trapani, Italy; [Di Gregorio, R.] Opedale Sacro Cuore Gesu Fatebenefratelli, UOS Obstet Anasthesia & Pain Therapy, Benevento, Italy; [Valenti, D.] Azienda Osped Valtellina & Valchiavenna, Morbegno, Italy; [Reale, C.] Policlin Univ Umberto 1, Dept Cardiovasc Sci Resp Nephrol Anaesthet & Geri, Rome, Italy; [Pavesi, L.] RCCS Fdn Salvatore Maugeri, Unit Oncol, Pavia, Italy; [Iorno, V.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Ctr Pain Med M TIENGO, Milan, Italy; [Crispino, C.] AO Colli Monaldi Cotugno CTO Osped Monaldi, UOSD Treatment Lung Canc Complicat, Naples, Italy; [Pacchioni, M.] IRCCS, Osped San Raffaele, Dept Oncol, Milan, Italy; [Apolone, G.] Ist Nazl Tumori, Fdn IRCCS, Sci Direct, Via Venezian 1, I-20133 Milan, Italy	Corli, O (reprint author), Ist Ric Farmacol Mario Negri, IRCCS, Dept Oncol, Via G La Masa 19, I-20156 Milan, Italy.	oscar.corli@marionegri.it	Greco, Maria Teresa/K-2250-2018; Apolone, Giovanni/R-9799-2016; Caraceni, Augusto/C-1012-2017; Dragani, Tommaso A./K-4493-2016; Roberto, Anna/K-5040-2016; Cavanna, Luigi/AAL-5251-2020; Galli, Francesca/L-2724-2019	Greco, Maria Teresa/0000-0002-7114-8673; Apolone, Giovanni/0000-0001-5179-104X; Caraceni, Augusto/0000-0002-0375-6204; Dragani, Tommaso A./0000-0001-5915-4598; Roberto, Anna/0000-0002-6756-1297; Cavanna, Luigi/0000-0002-0303-3778; 	Grunenthal-Italia	This work was partially supported by Grunenthal-Italia. The founder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bouhassira D, 2005, PAIN, V114, P29, DOI 10.1016/j.pain.2004.12.010; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Corli O, 2013, EUR J PAIN, V17, P858, DOI 10.1002/j.1532-2149.2012.00257.x; Corli O, 2012, PAIN MED, V13, P897, DOI 10.1111/j.1526-4637.2012.01408.x; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Droney Joanne, 2007, J Opioid Manag, V3, P309; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Haddad A, 2007, SUPPORT CARE CANCER, V15, P251, DOI 10.1007/s00520-006-0127-5; Hanks G, 2005, SUPPORT CARE CANCER, V13, P145, DOI 10.1007/s00520-004-0730-2; Hanna Magdi, 2008, BMC Palliat Care, V7, P17, DOI 10.1186/1472-684X-7-17; Knudsen AK, 2012, PAIN, V153, P696, DOI 10.1016/j.pain.2011.12.005; Kress HG, 2014, PAIN PHYSICIAN, V17, P329; Marinangeli F, 2004, J PAIN SYMPTOM MANAG, V27, P409, DOI 10.1016/j.jpainsymman.2003.10.006; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P144, DOI 10.1016/S0885-3924(00)00228-1; Mercadante S, 1999, J PAIN SYMPTOM MANAG, V18, P347, DOI 10.1016/S0885-3924(99)00099-8; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Mercadante S, 2010, CLIN J PAIN, V26, P794, DOI 10.1097/AJP.0b013e3181ecd895; Pasternak GW, 2013, PHARMACOL REV, V65, P1257, DOI 10.1124/pr.112.007138; Pathan H, 2012, BRIT J PAIN, V6, P11, DOI 10.1177/2049463712438493; Pineyro G, 2007, CELL SIGNAL, V19, P8, DOI 10.1016/j.cellsig.2006.05.026; Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023; Rhee C, 2007, J PALLIAT MED, V10, P677, DOI 10.1089/jpm.2006.0246; Ross JR, 2008, CANCER-AM CANCER SOC, V112, P1390, DOI 10.1002/cncr.23292; Stamer UM, 2005, EUR J PAIN, V9, P101, DOI 10.1016/j.ejpain.2004.05.008; Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119; TAMBURINI M, 1992, ANN ONCOL, V3, P565, DOI 10.1093/oxfordjournals.annonc.a058263; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; World Health Organization, 1996, CANC PAIN REL	30	36	37	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	JUN	2016	27	6					1107	1115		10.1093/annonc/mdw097			9	Oncology	Oncology	DN9VD	WOS:000377427900022	26940689	Bronze			2020-06-30	J	Reddy, A; Yennurajalingam, S; Reddy, S; Wu, JM; Liu, D; Dev, R; Bruera, E				Reddy, Akhila; Yennurajalingam, Sriram; Reddy, Suresh; Wu, Jimin; Liu, Diane; Dev, Rony; Bruera, Eduardo			The Opioid Rotation Ratio From Transdermal Fentanyl to "Strong" Opioids in Patients With Cancer Pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Cancer; opioid rotation; morphine equivalent daily dose; fentanyl transdermal; supportive care; conversion ratio; cancer pain	DELIRIUM ASSESSMENT SCALE; DOSE RATIO; VALIDATION; METHADONE; WITHDRAWAL; FREQUENCY; MORPHINE	Context. One-third of cancer patients require opioid rotation (OR) to treat uncontrolled pain or opioid-induced neurotoxicity. Although fentanyl is the most frequently rotated opioid in cancer patients, the accurate opioid rotation ratio (ORR) from transdermal fentanyl (TDF) to other so-called "strong" opioids is unknown. Objectives. We aimed to determine the ORR of TDF to strong opioids, as measured by morphine equivalent daily dose (MEDD). Methods. We reviewed 2471 consecutive patient visits (938 patients) to our supportive care center for an OR from TDF to strong opioids. Information regarding demographics, symptoms, and MEDD was collected in patients who followed up within six weeks. Linear regression analysis was used to estimate the ORR between TDF dose and net MEDD (MEDD after OR minus MEDD of the breakthrough opioid used along with TDF before OR). Results. Among 47 eligible patients, the median age was 54 years, 53% were male, and 77% had advanced cancer. The median time to follow-up was 14 days. Uncontrolled pain (83%) was the most common reason for OR. In patients with OR and no worsening of pain at follow-up (n = 41), the median ORR (range) from TDF mg/day to net MEDD mg/day was 100 (12.5-217) and from TDF mcg/hour to net MEDD was 2.4 (0.3-5.2); the correlation of TDF dose to net MEDD was 0.60 (P < 0.0001). Conclusion. The median ORR from TDF mg/day to MEDD is 100 and from TDF mcg/hour to MEDD is 2.4, suggesting that TDF 100 mcg/hour is equivalent to an MEDD of 240 mg. (c) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.	[Reddy, Akhila; Yennurajalingam, Sriram; Reddy, Suresh; Dev, Rony; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA; [Wu, Jimin; Liu, Diane] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	Reddy, A (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA.	asreddy@mdanderson.org			National Institutes of Health through M. D. Anderson's Cancer Center Support Grant [CA016672]	This study was supported in part by the National Institutes of Health through M. D. Anderson's Cancer Center Support Grant #CA016672. The funding organization had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the article. The authors declare no conflicts of interest.	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Bradley AM, 2013, J PALLIAT MED, V16, P409, DOI 10.1089/jpm.2012.0424; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Breitbart W, 2000, ONCOLOGY WILLISTON P, V14, P9; Bruera E, 1991, J Palliat Care, V7, P6; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; Dalal S, 2015, MD ANDERSON SUPPORTI; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; HIGGS CMB, 1995, J PAIN SYMPTOM MANAG, V10, P4, DOI 10.1016/0885-3924(94)00060-X; Holmgaard R, 2013, SKIN PHARMACOL PHYS, V26, P155, DOI 10.1159/000348876; Hui D, 2016, J PAIN SYMPTOM MANAG, V51, P262, DOI 10.1016/j.jpainsymman.2015.10.004; Janssen Pharmaceuticals Inc, DUR FENT TRANSD SYST; Lawlor P, 1997, PAIN, V72, P79, DOI 10.1016/S0304-3959(97)00018-3; Lawlor PG, 2000, CANCER, V88, P2859, DOI 10.1002/1097-0142(20000615)88:12<2859::AID-CNCR29>3.3.CO;2-K; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V37, P632, DOI 10.1016/j.jpainsymman.2007.12.024; Parsons HA, 2010, CANCER-AM CANCER SOC, V116, P520, DOI 10.1002/cncr.24754; Reddy A, 2015, CANCER, V122, P149; Reddy A, 2014, ONCOLOGIST, V19, P1186, DOI 10.1634/theoncologist.2014-0130; Reddy A, 2013, ONCOLOGIST, V18, P212, DOI 10.1634/theoncologist.2012-0269; Ripamonti C, 1998, ANN ONCOL, V9, P79, DOI 10.1023/A:1008263910494; Solassol I, 2005, ONCOL REP, V14, P1029; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Tanco K, 2014, PALLIAT SUPPORT CARE, V12, P515, DOI 10.1017/S1478951514000091; Walker PW, 2008, J PALLIAT MED, V11, P1103, DOI 10.1089/jpm.2007.0285; Yennurajalingam S, 2012, J PAIN SYMPTOM MANAG, V44, P340, DOI 10.1016/j.jpainsymman.2011.09.014; Yennurajalingam S, 2011, J PAIN SYMPTOM MANAG, V41, P49, DOI 10.1016/j.jpainsymman.2010.03.017; ZENZ M, 1994, J PAIN SYMPTOM MANAG, V9, P54, DOI 10.1016/0885-3924(94)90149-X	32	10	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUN	2016	51	6					1040	1045		10.1016/j.jpainsymman.2015.12.312			6	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	DN8RS	WOS:000377347700012	26826675	Bronze			2020-06-30	J	Ruest, S; Anderson, A				Ruest, Stephanie; Anderson, Angela			Management of acute pediatric pain in the emergency department	CURRENT OPINION IN PEDIATRICS			English	Review						acute pain; analgesia; pediatric pain management	RANDOMIZED CONTROLLED-TRIAL; FEMORAL NERVE BLOCKS; KANGAROO MOTHER CARE; OF-THE-LITERATURE; INTRANASAL FENTANYL; PROCEDURAL PAIN; CHILDREN; ANALGESIA; INFANTS; DISTRACTION	Purpose of review This article provides a summary of recommendations for the multimodal and multidisciplinary approach to acute pediatric pain management and highlights recent research on this topic. Recent findings Recent literature has focused on updating recommendations for the use of various analgesics in the pediatric population. While codeine is no longer recommended due to increasing evidence of adverse effects, the more liberal use of intranasal fentanyl is now encouraged because of the ease of administration and rapid delivery. The evidence base for the use of ultrasound-guided regional nerve blocks by qualified providers in the acute pediatric pain setting continues to grow. Summary The pediatric emergency medicine provider should be able to assess pain and develop individualized pain plans by utilizing a range of nonpharmacologic and pharmacologic strategies. Knowledge of the most recent literature and changes in recommendations for various pain medications is essential.	[Ruest, Stephanie] Hasbro Childrens Hosp, Emergency Med, Sect Pediat Emergency Med, Providence, RI USA; [Anderson, Angela] Hasbro Childrens Hosp, Dept Pediat, Providence, RI USA; [Anderson, Angela] Hasbro Childrens Hosp, Dept Emergency Med, Providence, RI USA	Ruest, S (reprint author), 593 Eddy St, Providence, RI 02903 USA.	Stephanie.Ruest@lifespan.org					Amer Acad Pediat, 2006, PEDIATRICS, V118, P2231, DOI 10.1542/peds.2006-2277; [Anonymous], 2015, NEW PEDIAT LABELING; Baker MD, 2015, PEDIATR EMERG CARE, V31, P864, DOI 10.1097/PEC.0000000000000634; Balestracci A, 2015, PEDIATR NEPHROL, V30, P1873, DOI 10.1007/s00467-015-3105-7; Bruno A, 2014, BASIC CLIN PHARMACOL, V114, P56, DOI 10.1111/bcpt.12117; Chiaretti A, 2013, EUR REV MED PHARMACO, V17, P112; Choudhary M, 2016, J MATERN-FETAL NEO M, V29, P826, DOI 10.3109/14767058.2015.1020419; Cramton REM, 2012, CURR OPIN PEDIATR, V24, P530, DOI 10.1097/MOP.0b013e328355b2c5; Drendel AL, 2011, PEDIATR EMERG CARE, V27, P773, DOI 10.1097/PEC.0b013e31822877f7; Fein JA, 2012, PEDIATRICS, V130, pE1391, DOI 10.1542/peds.2012-2536; Frenkel O, 2015, PEDIATR EMERG CARE, V31, P255, DOI 10.1097/PEC.0000000000000398; Gao HX, 2015, INT J NURS STUD, V52, P1157, DOI 10.1016/j.ijnurstu.2015.04.006; Graudins A, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-208; Hagan JF, 2001, PEDIATRICS, V108, P793; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Harrison D, 2015, COCHRANE DB SYST REV, V5; Hartley KA, 2015, ADV NEONAT CARE, V15, P201, DOI 10.1097/ANC.0000000000000193; Huguet A, 2011, J PAIN, V12, P840, DOI 10.1016/j.jpain.2011.01.005; Ilicki J, 2015, J EMERG MED, V49, P799, DOI 10.1016/j.jemermed.2015.05.038; Karakaya A, 2016, PAIN MANAG NURS, V17, P47, DOI 10.1016/j.pmn.2015.08.005; Kennedy Robert M, 2008, Pediatrics, V122 Suppl 3, pS130, DOI 10.1542/peds.2008-1055e; Krauss BS, 2016, LANCET, V387, P83, DOI 10.1016/S0140-6736(14)61686-X; Kuehn BM, 2013, JAMA-J AM MED ASSOC, V309, P1100, DOI 10.1001/jama.2013.2403; Lazaryan M, 2015, ACTA PAEDIATR, V104, P550, DOI 10.1111/apa.13012; Liu M, 2015, CLIN EXP OBSTET GYN, V42, P304; Lonnqvist PA, 2005, BRIT J ANAESTH, V95, P59, DOI 10.1093/bja/aei065; Mak WY, 2011, EXPERT OPIN PHARMACO, V12, P865, DOI 10.1517/14656566.2011.542751; McGrath PJ, 2011, PAIN, V152, P2457, DOI 10.1016/j.pain.2011.07.018; Merritt Christopher, 2014, R I Med J (2013), V97, P31; Mitchell Anita, 2002, J Neurosci Nurs, V34, P228; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Niesters M, 2013, BRIT J ANAESTH, V110, P175, DOI 10.1093/bja/aes447; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Poonai N, 2015, PAIN MANAG, V5, P435, DOI 10.2217/pmt.15.41; Probst BD, 2005, PEDIATR EMERG CARE, V21, P298, DOI 10.1097/01.pec.0000159074.85808.14; Samuel N, 2015, AM J EMERG MED, V33, P451, DOI 10.1016/j.ajem.2014.12.012; Schaefer JA, 2015, AM J EMERG MED, V33, P1805, DOI 10.1016/j.ajem.2015.08.050; Scholten AC, 2015, INJURY, V46, P798, DOI 10.1016/j.injury.2014.10.045; Schultz-Machata AM, 2014, CURR OPIN ANESTHESIO, V27, P316, DOI 10.1097/ACO.0000000000000074; Scott LE, 2013, INT EMERG NURS, V21, P173, DOI 10.1016/j.ienj.2012.08.004; Shastri N, 2015, PEDIATR EMERG CARE, V31, P444, DOI 10.1097/PEC.0000000000000463; Standing JF, 2011, PEDIATR ANESTH, V21, P316, DOI 10.1111/j.1460-9592.2010.03509.x; Thakkar P, 2016, J PERINATOL, V36, P67, DOI 10.1038/jp.2015.122; Tobias JD, 2010, ASA REFRESHER COURSE, V38, P97; Tracey I, 2002, J NEUROSCI, V22, P2748, DOI 10.1523/JNEUROSCI.22-07-02748.2002; Turner AL, 2014, PEDIATR EMERG CARE, V30, P227, DOI 10.1097/PEC.0000000000000101; Valet M, 2004, PAIN, V109, P399, DOI 10.1016/j.pain.2004.02.033; Vandamme E, 2015, EUR J EMERG MED, DOI [10.1097/MEJ.0000000000000298, DOI 10.1097/MEJ.0000000000000298.]; Verghese Susan T, 2010, J Pain Res, V3, P105; Walker SM, 2015, CURR OPIN ANESTHESIO, V28, P570, DOI 10.1097/ACO.0000000000000227; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; Wente SJK, 2013, J EMERG NURS, V39, P140, DOI 10.1016/j.jen.2012.09.011; Yeaman F, 2013, EMERG MED AUSTRALAS, V25, P161, DOI 10.1111/1742-6723.12059	54	14	14	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-8703	1531-698X		CURR OPIN PEDIATR	CURR. OPIN. PEDIATR.	JUN	2016	28	3					298	304		10.1097/MOP.0000000000000347			7	Pediatrics	Pediatrics	DM5KF	WOS:000376387000006	26974975				2020-06-30	J	Yang, ZY; Yi, B				Yang, Zhiyong; Yi, Bin			Patient experience of sexual hallucinations after propofol-induced painless abortion may lead to violence against medical personnel	JOURNAL OF ANESTHESIA			English	Article						Medical violence; Painless abortion; Sexual performance	ANESTHESIA; DREAMS; MEMORY	Painless abortion is an outpatient surgical procedure performed under general anesthesia, which requires an appropriate anesthetic reagent that must be safe, comfortable for the patient, and highly controllable. At present, fentanyl and propofol are first-choice anesthetic reagents in clinical applications. However, both have various side effects, including the inhibition of respiration and circulation and the occurrence of postoperative sexual fantasies and amorous behavior. In this report, we will demonstrate three cases of allegations of assault and violence caused by sexual hallucinations in patients who were anesthetized with propofol and fentanyl during painless abortion surgery.	[Yang, Zhiyong; Yi, Bin] Third Mil Med Univ, Southwest Hosp, Dept Anaesthesiol, 30 Gaotanyan St, Chongqing 400038, Peoples R China	Yi, B (reprint author), Third Mil Med Univ, Southwest Hosp, Dept Anaesthesiol, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	yibin1974@163.com					Brandner B, 1997, ANAESTHESIA, V52, P750, DOI 10.1111/j.1365-2044.1997.161-az0171.x; Cork Randall C, 2006, J Perianesth Nurs, V21, P288, DOI 10.1016/j.jopan.2006.07.001; Cork RC, 1996, BRIT J ANAESTH, V76, P492; Hellwagner K, 2003, EUR J ANAESTH, V20, P282, DOI 10.1097/00003643-200304000-00002; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; Leslie K, 2005, ANAESTHESIA, V60, P239, DOI 10.1111/j.1365-2044.2004.04087.x; Leslie K, 2007, ANESTHESIOLOGY, V106, P33, DOI 10.1097/00000542-200701000-00010; Schacter Daniel L, 2013, Dialogues Clin Neurosci, V15, P393; Schacter DL, 1998, SCIENCE, V280, P59, DOI 10.1126/science.280.5360.59; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Toscano A, 2007, ANESTHESIOLOGY, V106, P952, DOI 10.1097/01.anes.0000265154.24685.47; Wu D, 2014, BMJ OPEN, V4, DOI [10.1136/bmjopen-2014006431, DOI 10.1136/BMJOPEN-2014006431]; YOUNG PN, 1988, ANAESTHESIA, V43, P170	13	1	1	0	7	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	JUN	2016	30	3					486	488		10.1007/s00540-016-2152-y			3	Anesthesiology	Anesthesiology	DM9HH	WOS:000376675600016	27017209				2020-06-30	J	Cassavaugh, JM; Oravitz, TM				Cassavaugh, Jessica M.; Oravitz, Todd M.			Multiple anesthetics for a patient with stiff-person syndrome	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						GABA signaling; Neuromuscular blockade; Stiff-person syndrome		Stiff-person syndrome is a progressive disease of muscle rigidity and spasticity due to a deficiency in the production of gamma-aminobutyric acid. Because of the rarity of the condition, little is known about effects of anesthesia on patients with stiff-person syndrome. This report describes the clinical course for a single patient with stiff-person syndrome who received general anesthesia on 3 separate occasions. Her anesthetics included use of both neuromuscular blockade and volatile agents. Unlike several previous reports regarding anesthesia and stiff-person syndrome, the postoperative period for this patient did not require prolonged intubation or result in any residual weakness. (C) 2016 Elsevier Inc. All rights reserved.	[Cassavaugh, Jessica M.; Oravitz, Todd M.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst Anesthesia Serv, Room 3N221B,Univ Dr C, Pittsburgh, PA 15240 USA	Oravitz, TM (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst Anesthesia Serv, Room 3N221B,Univ Dr C, Pittsburgh, PA 15240 USA.	cassavaughjm@upmc.edu; OravitzTM@anes.upmc.edu					Bouw J, 2003, ANESTH ANALG, V97, P486, DOI 10.1213/01.ANE.0000072701.97699.79; Dayalu P, 2012, SEMIN NEUROL, V32, P544, DOI 10.1055/s-0033-1334477; Ferrandis R, 2005, J CARDIOTHOR VASC AN, V19, P370, DOI 10.1053/j.jvca.2005.03.018; Hattan E, 2008, NEUROLOGY, V70, P1641, DOI 10.1212/01.wnl.0000284606.00074.f1; JOHNSON JO, 1995, ANESTH ANALG, V80, P612, DOI 10.1097/00000539-199503000-00032; Murinson BB, 2004, NEUROLOGIST, V10, P131, DOI 10.1097/01.nrl.0000126587.37087.1a; Nishikawa K, 2003, ANESTHESIOLOGY, V99, P678, DOI 10.1097/00000542-200309000-00024; Obara M, 2002, ANAESTHESIA, V57, P511; Piovano C, 2002, Minerva Anestesiol, V68, P861; Sugimura M, 2002, PHARMACOL BIOCHEM BE, V72, P111, DOI 10.1016/S0091-3057(01)00728-6	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	JUN	2016	31						197	199		10.1016/j.jclinane.2016.02.003			3	Anesthesiology	Anesthesiology	DN1FL	WOS:000376811600044	27185709				2020-06-30	J	El-Tahan, MR; Doyle, DJ; Telmesani, L; Al'Ghamdi, A; Khidr, AM; Abdeen, MM				El-Tahan, Mohamed R.; Doyle, D. John; Telmesani, Laila; Al'Ghamdi, Abdulmohsen; Khidr, Alaa M.; Abdeen, Mohamed Maher			Dexmedetomidine suppresses intractable hiccup during anesthesia for cochlear implantation	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						Anesthesia; Cochlear implantation; Dexmedetomidine; Hiccup	PHRENIC-NERVE BLOCK; GASTROINTESTINAL ENDOSCOPY; PROPOFOL; SEDATION; REFLEX; MIDAZOLAM; CHILDREN; THERAPY; ADULTS	We report on the successful use of dexmedetomidine to treat persistent intractable hiccup in a child who underwent cochlear implantation under sevoflurane-fentanyl anesthesia. (C) 2016 Elsevier Inc. All rights reserved.	[El-Tahan, Mohamed R.; Al'Ghamdi, Abdulmohsen; Khidr, Alaa M.; Abdeen, Mohamed Maher] Univ Dammam, King Fahd Hosp, Dept Anesthesiol, Dammam, Saudi Arabia; [El-Tahan, Mohamed R.; Telmesani, Laila; Al'Ghamdi, Abdulmohsen; Khidr, Alaa M.; Abdeen, Mohamed Maher] PO 40289, Al Khobar 31952, Saudi Arabia; [Doyle, D. John] Cleveland Clin, Dept Gen Anesthesiol, 9500 Euclid Ave,E31, Cleveland, OH 44195 USA; [Telmesani, Laila] Univ Dammam, King Fahd Hosp, ENT Dept, Otol & Cochlear Implant Unit, Dammam, Saudi Arabia	El-Tahan, MR (reprint author), Univ Dammam, King Fahd Hosp, Dept Anesthesiol, Dammam, Saudi Arabia.; El-Tahan, MR (reprint author), PO 40289, Al Khobar 31952, Saudi Arabia.	mohamedrefaateltahan@yahoo.com	Khidr, Alaa/A-4976-2015	Khidr, Alaa/0000-0001-9857-6750; El Tahan, Mohamed/0000-0002-9730-6406			Bagdure Dayanand N, 2011, Ann Pharmacother, V45, pe35, DOI 10.1345/aph.1P760; Bedirli N, 2012, PEDIATR ANESTH, V22, P150, DOI 10.1111/j.1460-9592.2011.03707.x; Beyaz SG, 2011, KOREAN J PAIN, V24, P105, DOI 10.3344/kjp.2011.24.2.105; Bilotta F, 2001, ANESTH ANALG, V93, P1358, DOI 10.1097/00000539-200111000-00066; Buehrer S, 2014, PEDIATR ANESTH, V24, P309, DOI 10.1111/pan.12276; Cohen SP, 2001, SOUTHERN MED J, V94, P1124, DOI 10.1097/00007611-200111000-00018; Cook-Sather SD, 2003, ANESTH ANALG, V96, P965, DOI 10.1213/01.ANE.0000055807.31411.8B; Dickerman RD, 2001, CLIN NEUROPHARMACOL, V24, P62, DOI 10.1097/00002826-200101000-00011; Goyal R, 2013, J ANESTH, V27, P461, DOI 10.1007/s00540-012-1538-8; Guven S, 2006, J LARYNGOL OTOL, V120, P10; JONES MV, 1995, J PHARMACOL EXP THER, V274, P962; Jover F, 2005, J CLIN PHARM THER, V30, P413, DOI 10.1111/j.1365-2710.2005.00660.x; Kang KN, 2010, KOREAN J PAIN, V23, P198, DOI 10.3344/kjp.2010.23.3.198; Kanniah SK, 2009, INT J OBSTET ANESTH, V18, P193, DOI 10.1016/j.ijoa.2008.12.004; Kim NY, 2014, YONSEI MED J, V55, P209, DOI 10.3349/ymj.2014.55.1.209; Kranke P, 2003, EUR J ANAESTH, V20, P239, DOI 10.1097/00003643-200303000-00010; LAUNOIS S, 1993, EUR RESPIR J, V6, P563; Leonetti J P, 1996, Ear Nose Throat J, V75, P489; Lierz P, 2002, ANESTH ANALG, V95, P494, DOI 10.1097/00000539-200208000-00050; Liu CC, 2012, WORLD J GASTROENTERO, V18, P3595, DOI 10.3748/wjg.v18.i27.3595; Mangar D, 1992, J Clin Anesth, V4, P86, DOI 10.1016/0952-8180(92)90125-K; Marhofer P, 1999, PAEDIATR ANAESTH, V9, P295, DOI 10.1046/j.1460-9592.1999.00378.x; Mason S, 2004, INT J AUDIOL, V43, pS33; Memis D, 2006, EUR J ANAESTH, V23, P700, DOI 10.1017/S0265021506000512; Nemoto C, 2013, J ANESTH, V27, P771, DOI 10.1007/s00540-013-1589-5; Oshima T, 2004, ANESTH ANALG, V98, P346, DOI 10.1213/01.ANE.0000097169.98992.E7; Peacock ME, 2013, CASE REP DENT, V2013, DOI 10.1155/2013/426178; Renes SH, 2010, REGION ANESTH PAIN M, V35, P455, DOI 10.1097/AAP.0b013e3181e8536f; Strate T, 2002, Surg Endosc, V16, P1109, DOI 10.1007/s00464-001-4248-0; Szibor-Kriesen U, 2008, ANASTH INTENSIV NOTF, V43, P674, DOI 10.1055/s-0028-1102984; Tobias D, 2008, PEDIATR CRIT CARE ME, V8, P115	31	2	2	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	JUN	2016	31						208	211		10.1016/j.jclinane.2016.02.013			4	Anesthesiology	Anesthesiology	DN1FL	WOS:000376811600048	27185713				2020-06-30	J	Som, A; Baidya, DK; Arora, MK; Maitra, S; Gupta, S				Som, Anirban; Baidya, Dalim K.; Arora, Mahesh K.; Maitra, Souvik; Gupta, Stuti			Rett syndrome: a concern for the anesthesiologists	JOURNAL OF CLINICAL ANESTHESIA			English	Letter									[Som, Anirban; Baidya, Dalim K.; Arora, Mahesh K.; Maitra, Souvik; Gupta, Stuti] All India Inst Med Sci, Dept Anaesthesiol Pain Med & Crit Care, 5th Floor,Teaching Block, New Delhi 110029, India	Maitra, S (reprint author), All India Inst Med Sci, Dept Anaesthesiol Pain Med & Crit Care, 5th Floor,Teaching Block, New Delhi 110029, India.	souvikmaitra@live.com	Som, Anirban/T-7027-2017	Som, Anirban/0000-0002-6646-679X; Maitra, Souvik/0000-0002-2328-9201			Acampa M, 2006, ARCH DIS CHILD, V91, P440, DOI 10.1136/adc.2005.090290; Chahrour M, 2007, NEURON, V56, P422, DOI 10.1016/j.neuron.2007.10.001; Ellaway CJ, 1999, ARCH DIS CHILD, V80, P470, DOI 10.1136/adc.80.5.470; Jian L, 2006, J PEDIATR-US, V149, P542, DOI 10.1016/j.jpeds.2006.06.015; Kako H, 2013, INT J CLIN EXP MED, V6, P393; KONARZEWSKI WH, 1994, ANAESTHESIA, V49, P357, DOI 10.1111/j.1365-2044.1994.tb14208.x; Nho JS, 2011, KOREAN J ANESTHESIOL, V61, P428, DOI 10.4097/kjae.2011.61.5.428	7	1	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	JUN	2016	31						247	248		10.1016/j.jclinane.2016.01.017			2	Anesthesiology	Anesthesiology	DN1FL	WOS:000376811600055	27185720				2020-06-30	J	Williams, SR; Belliveau, M; Brulotte, V; Ruel, MM				Williams, Stephan R.; Belliveau, Marc; Brulotte, Veronique; Ruel, Monique M.			Impact of thoracic epidural catheter threading distance on analgesia during the first 24 hours following thoracotomy: a randomized controlled trial	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							SPACE; PAIN; BUPIVACAINE; RESECTION; MORPHINE	The purpose of this prospective randomized controlled trial was to determine the impact of thoracic epidural catheter threading distance on analgesia quality after thoracotomy. We randomly assigned 120 elective thoracotomy patients to a thoracic epidural catheter threading distance of 3, 5, or 7 cm (groups 3CM, 5CM, and 7CM, respectively). Epidural bupivacaine 0.1% with fentanyl 2 A mu g center dot mL(-1) was administered according to a standardized protocol. Epidural analgesia quality was assessed at 60 min and 24 hr postoperatively for four measures: incidence of non-functioning epidurals; numerical rating score (NRS) < 4 at rest, while coughing, and during wound palpation; cold perception at the wound site; and cumulative dose of analgesic medication used. Our primary hypothesis was that, compared to threading distances of 3 and 5 cm, a threading distance of 7 cm was not inferior at providing an NRS < 4 while coughing at 60 min postoperatively, with a non-inferiority margin of 25% (absolute value) being significant. The incidence of NRS < 4 while coughing at 60 min was 74% (29/39) in group 7CM compared with 68% (54/80) in the combined 3CM and 5CM groups (absolute difference 7%; 95% confidence interval -11 to 23; P = 0.29). At both 60 min and 24 hr, differences between groups were similar regarding the number of non-functioning epidurals, NRS < 4, and suppressed cold sensation. Analgesic doses were similar in the three groups. This study found that a thoracic epidural catheter threading distance of 7 cm in the epidural space was not inferior to distances of 3 cm and 5 cm with respect to pain scores at 60 min postoperatively. This study was not powered to examine differences that could have clinical significance that were less than our a priori 25% non-inferiority margin.	[Williams, Stephan R.; Ruel, Monique M.] Ctr Hosp Univ Montreal, Montreal, PQ, Canada; [Belliveau, Marc; Brulotte, Veronique] Univ Montreal, Montreal, PQ, Canada	Williams, SR (reprint author), Ctr Hosp Univ Montreal, Montreal, PQ, Canada.	stephan.williams@umontreal.ca					Afshan G, 2011, ANAESTHESIA, V66, P913, DOI 10.1111/j.1365-2044.2011.06820.x; BEILIN Y, 1995, ANESTH ANALG, V81, P301; BISHTON IM, 1992, ANAESTHESIA, V47, P610, DOI 10.1111/j.1365-2044.1992.tb02337.x; DAngelo R, 1996, ANESTHESIOLOGY, V84, P88, DOI 10.1097/00000542-199601000-00011; DOUGHTY A, 1974, ANAESTHESIA, V29, P63, DOI 10.1111/j.1365-2044.1974.tb00584.x; Efron B, 1993, INTRO BOOTSTRAP, V13, P170; Hamilton CL, 1997, ANESTHESIOLOGY, V86, P778, DOI 10.1097/00000542-199704000-00007; Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; Hong D, 2008, ANESTH ANALG, V107, P1384, DOI 10.1213/ane.0b013e3181823efb; Huffnagle SL, 1998, ANESTH ANALG, V87, P326, DOI 10.1097/00000539-199808000-00017; Hughes R, 2005, BJA EDUC, V5, P56, DOI 10.1093/bjaceaccp/mki014; KEARNEY DJ, 1994, CHEST, V105, P753, DOI 10.1378/chest.105.3.753; Kim SY, 2012, KOREAN J ANESTHESIOL, V62, P251, DOI 10.4097/kjae.2012.62.3.251; KUMAR CM, 1985, ANAESTHESIA, V40, P1100, DOI 10.1111/j.1365-2044.1985.tb10610.x; Licker M, 1999, EUR J CARDIO-THORAC, V15, P314, DOI 10.1016/S1010-7940(99)00006-8; Mac TB, 2005, J CARDIOTHOR VASC AN, V19, P475, DOI 10.1053/j.jvca.2004.11.041; Merchant R, 2015, CAN J ANESTH, V62, P57, DOI 10.1007/s12630-014-0232-8; Mhyre JM, 2009, ANESTH ANALG, V108, P1232, DOI 10.1213/ane.0b013e318198f85e; PASCOE PJ, 1993, VET SURG, V22, P141, DOI 10.1111/j.1532-950X.1993.tb01689.x; SANCHEZ R, 1967, BRIT J ANAESTH, V39, P485, DOI 10.1093/bja/39.6.485; Schumi J, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-106; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; Slinger PD, 1999, J CARDIOTHOR VASC AN, V13, P350, DOI 10.1016/S1053-0770(99)90276-8; WATSON A, 1994, SURGERY, V115, P429; Yamauchi M, 2009, J ANESTH, V23, P605, DOI 10.1007/s00540-009-0813-9	26	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	JUN	2016	63	6					691	700		10.1007/s12630-016-0585-2			10	Anesthesiology	Anesthesiology	DL6DC	WOS:000375727500007	26830643	Bronze			2020-06-30	J	Venkat, A; Kim, D				Venkat, Arvind; Kim, David			Ethical Tensions in the Pain Management of an End-Stage Cancer Patient with Evidence of Opioid Medication Diversion	HEC FORUM			English	Review						End-of-life care; Opioid diversion; Clinical ethics; Virtue theory; Narrative/relationship theories; Proportionality		At the end of life, pain management is commonly a fundamental part of the treatment plan for patients where curative measures are no longer possible. However, the increased recognition of opioid diversion for secondary gain coupled with efforts to treat patients in the home environment towards the end of life creates the potential for ethical dilemmas in the palliative care management of terminal patients in need of continuous pain management. We present the case of an end-stage patient with rectal cancer who required a continuous residential narcotic infusion of fentanyl for pain control due to metastatic disease. His functional status was such that he had poor oral intake and ability to perform other activities of daily living, but was able to live at home with health agency nursing care. The patient presented to this institution with a highly suspect history of having lost his fentanyl infusion in a residential accident and asking for a refill to continue home therapy. The treating physicians had concerns of diversion of the infusion medication by caregivers and were reluctant to continue the therapeutic relationship with the patient. This case exemplifies the tension that can exist between wanting to continue with palliative care management of an end-stage patient and the fear of providers when confronted by evidence of potential diversion of opioid analgesic medications. We elucidate how an ethical framework based on a combination of virtue and narrative/relationship theories with reference to proportionality can guide physicians to a pragmatic resolution of these difficult situations.	[Venkat, Arvind] Allegheny Gen Hosp, Dept Emergency Med, 320 East North Ave, Pittsburgh, PA 15212 USA; [Kim, David] Allegheny Hlth Network, Dept Med, Pittsburgh, PA USA	Venkat, A (reprint author), Allegheny Gen Hosp, Dept Emergency Med, 320 East North Ave, Pittsburgh, PA 15212 USA.	avenkat@wpahs.org					DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Ferrell Betty, 2005, Pain Manag Nurs, V6, P83, DOI 10.1016/j.pmn.2005.06.001; Giordano James, 2006, Pain Physician, V9, P41; Hermeren G, 2012, MED HEALTH CARE PHIL, V15, P373, DOI 10.1007/s11019-011-9360-x; Parala-Metz A., 2014, CANC PAIN; Silver J. D., 2014, PITTSBURGH POSTGAZET; Venkat A, 2013, ACAD EMERG MED, V20, P716, DOI 10.1111/acem.12158; Walsh D, 2000, SEMIN ONCOL, V27, P45	9	2	2	0	6	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0956-2737	1572-8498		HEC FORUM	HEC Forum	JUN	2016	28	2					95	101		10.1007/s10730-014-9257-1			7	Ethics	Social Sciences - Other Topics	FG3AM	WOS:000410008700001	25381648				2020-06-30	J	Ruzycki, S; Yarema, M; Dunham, M; Sadrzadeh, H; Tremblay, A				Ruzycki, Shannon; Yarema, Mark; Dunham, Michael; Sadrzadeh, Hossein; Tremblay, Alain			Intranasal Fentanyl Intoxication Leading to Diffuse Alveolar Hemorrhage	JOURNAL OF MEDICAL TOXICOLOGY			English	Article						Fentanyl; Diffuse alveolar hemorrhage; Opioid toxicity; Pulmonary hemorrhage		Context Increasing rates of opioid abuse, particularly fentanyl, may lead to more presentations of unusual effects of opioid toxicity. Diffuse alveolar hemorrhage is a rare complication of fentanyl overdose. Case Details A 45-year-old male presented in hypoxic respiratory failure secondary to diffuse alveolar hemorrhage requiring intubation. Comprehensive drug screening detected fentanyl without exposure to cocaine. Further history upon the patient's recovery revealed exposure to snorted fentanyl powder immediately prior to presentation. Discussion Diffuse alveolar hemorrhage is a potential, though rare, presentation of opioid intoxication. Conclusions Recognition of less common complications of opioid abuse such as diffuse alveolar hemorrhage is important in proper management of overdoses.	[Ruzycki, Shannon; Yarema, Mark] Univ Calgary, Dept Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada; [Yarema, Mark] Univ Calgary, Dept Emergency Med, Calgary, AB, Canada; [Yarema, Mark] Alberta Hlth Serv, Poison & Drug Informat Serv, Calgary, AB, Canada; [Yarema, Mark; Dunham, Michael] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Dunham, Michael] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Sadrzadeh, Hossein] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Sadrzadeh, Hossein] Calgary Lab Serv, Calgary, AB, Canada; [Tremblay, Alain] Univ Calgary, Div Resp Med, Calgary, AB, Canada; [Tremblay, Alain] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada	Ruzycki, S (reprint author), Univ Calgary, Dept Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	sarro@ualberta.ca	Tremblay, Alain/F-3163-2011	Tremblay, Alain/0000-0002-0025-7426; Yarema, Mark/0000-0001-8714-9956			ALBERTSON TE, 1995, CHEST, V108, P1140, DOI 10.1378/chest.108.4.1140; CHATURVEDI AK, 1990, J ANAL TOXICOL, V14, P385, DOI 10.1093/jat/14.6.385; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Katz N, 2011, AM J DRUG ALCOHOL AB, V37, P205, DOI 10.3109/00952990.2011.569623; King NB, 2014, AM J PUBLIC HEALTH, V104, pE32, DOI 10.2105/AJPH.2014.301966; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Lara AR, 2010, CHEST, V137, P1164, DOI 10.1378/chest.08-2084; Megarbane B, 2013, CHEM-BIOL INTERACT, V206, P444, DOI 10.1016/j.cbi.2013.10.011; Mounteney J, 2015, INT J DRUG POLICY; Porter R, 2011, PEDIATR EMERG CARE, V27, P742, DOI 10.1097/PEC.0b013e318226df00; Safrai AE, 2007, ABSTRACTS FORENSIC S, V169S, pS10; Southwick R., 2015, CALGARY HERALD 2015; The Canadian Centre on Substance Abuse and Addiction and the Canadian Community Epidemiology Network on Drug Use, 2015, DEATHS INV FENT CAN; TOMASHEFSKI JF, 2004, [No title captured], V10, P413, DOI DOI 10.1016/J.CDIP.2004.04.009; Tseng W, 2014, CLIN REV ALLERG IMMU, V46, P82, DOI 10.1007/s12016-013-8376-9; Yamanaka T, 2013, RESPIROLOGY, V18, P255, DOI 10.1111/j.1440-1843.2012.02307.x	18	9	9	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1556-9039	1937-6995		J MED TOXICOL	J. Med. Toxicol.	JUN	2016	12	2					185	188		10.1007/s13181-015-0509-5			4	Toxicology	Toxicology	VF5ES	WOS:000443042500007	26503098	Green Published			2020-06-30	J							Amer Coll Med Toxicology	ACMT Position Statement: Safety Issues Regarding Prescription Fentanyl Products	JOURNAL OF MEDICAL TOXICOLOGY			English	Editorial Material						Fentanyl; Opioid; Toxicology; Position statement; Transmucosal										[Anonymous], TRANSM IMM REL FENT; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; Nalamachu SR, 2011, CURR MED RES OPIN, V27, P751, DOI 10.1185/03007995.2011.554808; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Shomaker TS, 2000, PAIN MED, V1, P225, DOI 10.1046/j.1526-4637.2000.00030.x; U. S. Food and Drug Administration, INF HEALTHC PROF FEN; U. S. Food and Drug Administration, FENT TRANSD PATCH IM; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231	12	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1556-9039	1937-6995		J MED TOXICOL	J. Med. Toxicol.	JUN	2016	12	2					211	212		10.1007/s13181-016-0535-y			2	Toxicology	Toxicology	VF5ES	WOS:000443042500013	26847376	Green Published			2020-06-30	J	Wiegand, TJ; Lait, MC; Bartelson, BB; Dart, RC; Green, JL				Wiegand, Timothy J.; Le Lait, Marie-Claire; Bartelson, Becki Bucher; Dart, Richard C.; Green, Jody L.			Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System	JOURNAL OF PAIN			English	Article						Buprenorphine; Butrans; opioid abuse; opioid diversion; RADARS	SURVEILLANCE RADARS(R); RESEARCHED ABUSE; NONMEDICAL USE; UNITED-STATES; ILLICIT USE; RELEASE; OPIOIDS; USERS	Prescription opioid abuse and diversion are major causes of morbidity and mortality in the United States. The buprenorphine transdermal delivery system (BTDS) is indicated for the treatment of moderate to severe chronic pain and provides a continuous dose of 5, 7.5, 10, 15, or 20 g/h buprenorphine for 7 days. Quarterly rates of abuse and diversion of BTDS were compared with 4 comparator groups: 1) other buprenorphine products, 2) fentanyl patches, 3) extended-release (ER) opioid tablets/capsules, and 4) ER tramadol. Data were obtained from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System Poison Center, Drug Diversion, Treatment Programs Combined (Opioid Treatment and Survey of Key Informants' Patients Programs), and College Survey Programs. Rates were calculated using case counts per population and mentions per prescriptions filled. Poisson regression analysis was used to compare mean rates over time across drug groups after allowing for drug group-specific dispersion parameters. Population adjusted abuse rates were low for BTDS in all of the RADARS System programs compared with the other comparator groups. Findings were similar for the prescription adjusted rates, with BTDS reported at the lowest rates in all programs. Route of abuse differed slightly for BTDS and the comparator groups depending on the program. BTDS was abused and diverted at low rates compared with the other opioid groups in 5 programs of the RADARS System using either population-based rates or prescription dispensed rates. Perspective: Data from the RADARS System show the BTDS is abused and diverted at low rates compared with other opioid groups including other forms of buprenorphine, fentanyl patches, ER opioid formulations, and ER tramadol. (C) 2016 by the American Pain Society	[Wiegand, Timothy J.] Univ Rochester, Dept Emergency Med, Med Ctr, Rochester, NY 14642 USA; [Le Lait, Marie-Claire; Bartelson, Becki Bucher; Dart, Richard C.; Green, Jody L.] Denver Hlth & Hosp Author, Res Dept, Rocky Mt Poison & Drug Ctr, Denver, CO USA; [Dart, Richard C.] Univ Colorado, Dept Emergency Med, Sch Med, Aurora, CO USA	Wiegand, TJ (reprint author), Univ Rochester, Med Ctr, Sch Med & Dent, 601 Elm Wood Ave,Box 655, Rochester, NY 14642 USA.	Timothy_Wiegand@URMC.Rochester.edu			RADARS System	This work was supported by the RADARS System, an independent nonprofit postmarketing surveillance system that is supported by subscription fees from pharmaceutical manufacturers, who use these data for pharmacovigilance activities and to meet regulatory obligations. None of the authors have a direct financial, commercial, or other relationship with any of the subscribers.	[Anonymous], 2015, BUTR; Bazazi AR, 2011, J ADDICT MED, V5, P175, DOI 10.1097/ADM.0b013e3182034e31; Cicero TJ, 2007, PAIN MED, V8, P157, DOI 10.1111/j.1526-4637.2006.00259.x; Daniulaityte R, 2012, DRUG ALCOHOL DEPEN, V122, P201, DOI 10.1016/j.drugalcdep.2011.09.029; Dart RC, 2014, CLIN J PAIN, V30, P685, DOI 10.1097/AJP.0000000000000001; Dasgupta N, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2810; Dasgupta N, 2010, PAIN MED, V11, P1078, DOI 10.1111/j.1526-4637.2010.00877.x; Davis JM, 2014, PHARMACOEPIDEM DR S, V23, P18, DOI 10.1002/pds.3533; Inciardi James A, 2007, Law Enforc Exec Forum, V7, P127; Lanier RK, 2008, PSYCHOPHARMACOLOGY, V198, P149, DOI 10.1007/s00213-008-1105-z; Lavonas EJ, 2014, J SUBST ABUSE TREAT, V47, P27, DOI 10.1016/j.jsat.2014.02.003; Paulozzi L, 2012, INJURY PREV, V18, P70, DOI 10.1136/injuryprev-2011-040294; Przeklasa-Muszynska A, 2011, CURR MED RES OPIN, V27, P1109, DOI 10.1185/03007995.2011.569017; Sansone Randy A, 2015, Innov Clin Neurosci, V12, P32; Sembower MA, 2013, J ADDICT DIS, V32, P26, DOI 10.1080/10550887.2012.759880; Severtson SG, 2013, J PAIN, V14, P1122, DOI 10.1016/j.jpain.2013.04.011; Sporer KA, 2004, ANN EMERG MED, V43, P580, DOI 10.1016/j.annemergmed.2003.11.006; Substance Abuse and Mental Health Services Administration, 2012, NSDUH SER H, V12-4713; Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, 2012, DAWN REP HIGHL 2010; Wadhwa R, 2015, INDIAN J PALLIAT CAR, V21, P49, DOI 10.4103/0973-1075.150180; *WHO, 2003, WHO TECH REP SER, V915, P1; Wightman R, 2012, J MED TOXICOL, V8, P335, DOI 10.1007/s13181-012-0263-x; Zosel A, 2013, J AM ACAD CHILD PSY, V52, P196, DOI 10.1016/j.jaac.2012.11.014	23	7	7	0	7	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	JUN	2016	17	6					745	752		10.1016/j.jpain.2016.02.015			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DO2RQ	WOS:000377628000012	26996928				2020-06-30	J	Finsterer, J; Dumser, M				Finsterer, J.; Dumser, M.			Allergy to transdermal fentanyl resulting in Staphylococcus aureus sepsis and fatal endocarditis with myocardial rupture	MEDECINE ET MALADIES INFECTIEUSES			English	Letter						Staphylococcus aureus; Endocarditis; Cutaneous allergy	BACTEREMIA; LESIONS		[Finsterer, J.] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria; [Dumser, M.] Krankenanstalt Rudolfstiftung Wien, Inst Pathol, Vienna, Austria	Finsterer, J (reprint author), Postfach 20, A-1180 Vienna, Austria.	fifigs1@yahoo.de		finsterer, josef/0000-0003-2839-7305			Dahl A, 2013, HEART LUNG, V42, P72, DOI 10.1016/j.hrtlng.2012.04.008; Furui M, 2010, ANN THORAC SURG, V89, P959, DOI 10.1016/j.athoracsur.2009.07.054; Incani A, 2013, EUR J CLIN MICROBIOL, V32, P1003, DOI 10.1007/s10096-013-1838-4; Okazaki S, 2013, CEREBROVASC DIS, V35, P155, DOI 10.1159/000346101; Thwaites GE, 2011, LANCET INFECT DIS, V11, P208, DOI 10.1016/S1473-3099(10)70285-1; Tisdell J, 2012, ARCH NEUROL-CHICAGO, V69, P1206, DOI 10.1001/archneurol.2011.3563; Yamamoto T, 2007, INTERNAL MED, V46, P571, DOI 10.2169/internalmedicine.46.6207	7	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0399-077X			MED MALADIES INFECT	Med. Mal. Infect.	JUN	2016	46	4					239	240		10.1016/j.medmal.2016.03.006			2	Infectious Diseases	Infectious Diseases	DS2RD	WOS:000380630300013	27132207				2020-06-30	J	Cheng, XY; Lun, XQ; Li, HB; Zhang, ZJ				Cheng, Xiao-Yan; Lun, Xiao-Qin; Li, Hong-Bo; Zhang, Zhi-Jie			Butorphanol suppresses fentanyl-induced cough during general anesthesia induction: A randomized, double-blinded, placebo-controlled clinical trial	MEDICINE			English	Article						butorphanol; cough; fentanyl; general anesthesia	INTRAVENOUS LIDOCAINE; OPIOID RECEPTORS; GUINEA-PIGS; DEZOCINE; BOLUS; PREMEDICATION; METAANALYSIS; PREVENTION; GUIDELINES; PROPOFOL	Fentanyl-induced cough (FIC) is unwanted in the patients requiring stable induction of general anesthesia. This study was designed to evaluate the suppressive effects of butorphanol pretreatment on the incidence and severity of FIC during the induction of general anesthesia. A total of 315 patients of American Society of Anesthesiologists physical status I and II, scheduled for elective surgery under general anesthesia were randomized into 3 equally sized groups (n = 0105). Two minutes before fentanyl bolus, group I received intravenously 5mL normal saline, groups II and III received butorphanol 0.015 and 0.03mg/kg (diluted with saline to 5mL), respectively. Patients were then administrated with fentanyl 2.5g/kg within 5s. The incidence and severity of FIC was recorded for 2minutes after fentanyl bolus. During experimental period, the mean arterial pressure, heart rate, and peripheral capillary oxygen saturation (SpO(2)) were recorded before the administration of butorphanol or normal saline (T0), 2minutes (T1) after butorphanol injection, and 2minutes (T2) after fentanyl injection. The incidence of FIC was 31.4% in group I, 11.4% in group II, and 3.8% in group III. Group III had a lowest incidence of FIC among 3 groups (P<0.001, vs group I; P<0.05, vs group II). The severe FIC was not observed in groups II and III, but was recoded from 6 patients in group I. At 2minutes after fentanyl injection (T2), the mean arterial pressure was significantly higher in group I than that in groups II and III (P<0.01, vs group II; P<0.05, vs group III), but the values remained within safe limits. In conclusion, pretreatment with butorphanol could effectively and safely suppress FIC during anesthesia induction.	[Cheng, Xiao-Yan; Lun, Xiao-Qin; Li, Hong-Bo] Weifang Peoples Hosp, Dept Anesthesiol, Weifang, Shandong, Peoples R China; [Zhang, Zhi-Jie] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Anesthesiol, 6 Beijing Rd West, Huaian 223300, Jiangsu, Peoples R China	Zhang, ZJ (reprint author), Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Anesthesiol, 6 Beijing Rd West, Huaian 223300, Jiangsu, Peoples R China.	hayy918@163.com					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ai Q, 2010, PHARMACOL REP, V62, P747, DOI 10.1016/S1734-1140(10)70333-9; Ambesh SP, 2009, KOREAN J ANESTHESIOL, P20; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; CAVANAGH RL, 1976, ARCH INT PHARMACOD T, V220, P258; CHANG KJ, 1981, P NATL ACAD SCI-BIOL, V78, P4141, DOI 10.1073/pnas.78.7.4141; CHRISTIE GJ, 1980, VET MED SM ANIM CLIN, V75, P1559; Commiskey S, 2005, J PHARMACOL SCI, V98, P109, DOI 10.1254/jphs.CRJ05001X; Du BX, 2014, INT J CLIN EXP MED, V7, P826; Firouzian Abolfazl, 2015, J Anaesthesiol Clin Pharmacol, V31, P522, DOI 10.4103/0970-9185.169082; Gecaj-Gashi Agreta, 2013, Cough, V9, P20, DOI 10.1186/1745-9974-9-20; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Hung KC, 2009, ACTA ANAESTH SCAND, V53, P1227, DOI 10.1111/j.1399-6576.2009.02027.x; KAMEI J, 1990, EUR J PHARMACOL, V187, P281, DOI 10.1016/0014-2999(90)90014-W; Kamei Junzo, 2013, Cough, V9, P3, DOI 10.1186/1745-9974-9-3; KARLSSON JA, 1990, J PHARMACOL EXP THER, V252, P863; Kim JE, 2014, J ANESTH, V28, P257, DOI 10.1007/s00540-013-1695-4; Kotzer CJ, 2000, J PHARMACOL EXP THER, V292, P803; Lim KJ, 2013, KOREAN J ANESTHESIOL, V65, P251, DOI 10.4097/kjae.2013.65.3.251; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2007, J FORMOS MED ASSOC, V106, P649, DOI 10.1016/S0929-6646(08)60022-4; Liu XS, 2015, PHARMACOL REP, V67, P52, DOI 10.1016/j.pharep.2014.08.004; Lui PW, 1996, CAN J ANAESTH, V43, P1216; McCool FD, 2006, CHEST, V129, p48S, DOI 10.1378/chest.129.1_suppl.48S; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; Sedighinejad Abbas, 2013, Anesth Pain Med, V2, P170, DOI 10.5812/aapm.8383; Sun ZT, 2011, J ANESTH, V25, P860, DOI 10.1007/s00540-011-1237-x; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Uvelin A, 2009, ACTA ANAESTH SCAND, V53, P1228, DOI 10.1111/j.1399-6576.2009.02041.x; Xu YJ, 2015, INT J CLIN EXP MED, V8, P6091; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021; Yu J, 2012, IRISH J MED SCI, V181, P517, DOI 10.1007/s11845-012-0807-8	36	5	6	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUN	2016	95	26							e3911	10.1097/MD.0000000000003911			5	Medicine, General & Internal	General & Internal Medicine	DS1PV	WOS:000380369300013	27367987	DOAJ Gold, Green Published			2020-06-30	J	Mick, I; Myers, J; Ramos, AC; Stokes, PRA; Erritzoe, D; Colasanti, A; Gunn, RN; Rabiner, EA; Searle, GE; Waldman, AD; Parkin, MC; Brailsford, AD; Galduroz, JCF; Bowden-Jones, H; Clark, L; Nutt, DJ; Lingford-Hughes, AR				Mick, Inge; Myers, Jim; Ramos, Anna C.; Stokes, Paul R. A.; Erritzoe, David; Colasanti, Alessandro; Gunn, Roger N.; Rabiner, Eugenii A.; Searle, Graham E.; Waldman, Adam D.; Parkin, Mark C.; Brailsford, Alan D.; Galduroz, Jose C. F.; Bowden-Jones, Henrietta; Clark, Luke; Nutt, David J.; Lingford-Hughes, Anne R.			Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers	NEUROPSYCHOPHARMACOLOGY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR-BINDING; ANTERIOR CINGULATE; EARLY ABSTINENCE; IN-VIVO; BRAIN; IMPULSIVITY; DOPAMINE; ADDICTION; PET	Pathological gambling is a psychiatric disorder and the first recognized behavioral addiction, with similarities to substance use disorders but without the confounding effects of drug-related brain changes. Pathophysiology within the opioid receptor system is increasingly recognized in substance dependence, with higher mu-opioid receptor (MOR) availability reported in alcohol, cocaine and opiate addiction. Impulsivity, a risk factor across the addictions, has also been found to be associated with higher MOR availability. The aim of this study was to characterize baseline MOR availability and endogenous opioid release in pathological gamblers (PG) using [C-11]carfentanil PET with an oral amphetamine challenge. Fourteen PG and 15 healthy volunteers (HV) underwent two [C-11]carfentanil PET scans, before and after an oral administration of 0.5 mg/kg of d-amphetamine. The change in [C-11]carfentanil binding between baseline and post-amphetamine scans (Delta BPND) was assessed in 10 regions of interest (ROI). MOR availability did not differ between PG and HV groups. As seen previously, oral amphetamine challenge led to significant reductions in [C-11]carfentanil BPND in 8/10 ROI in HV. PG demonstrated significant blunting of opioid release compared with HV. PG also showed blunted amphetamine-induced euphoria and alertness compared with HV. Exploratory analysis revealed that impulsivity positively correlated with caudate baseline BPND in PG only. This study provides the first evidence of blunted endogenous opioid release in PG. Our findings are consistent with growing evidence that dysregulation of endogenous opioids may have an important role in the pathophysiology of addictions.	[Mick, Inge; Myers, Jim; Ramos, Anna C.; Stokes, Paul R. A.; Erritzoe, David; Colasanti, Alessandro; Gunn, Roger N.; Nutt, David J.; Lingford-Hughes, Anne R.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Ctr Neuropsychopharmacol, Div Brain Sci, 160 Du Cane Rd, London W12 0NN, England; [Ramos, Anna C.; Galduroz, Jose C. F.] Univ Fed Sao Paulo, Dept Psychobiol, Sao Paulo, Brazil; [Stokes, Paul R. A.; Colasanti, Alessandro] Kings Coll London, Ctr Affect Disorders, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England; [Colasanti, Alessandro; Gunn, Roger N.; Rabiner, Eugenii A.; Searle, Graham E.] Imanova Ltd, Ctr Imaging Sci, London, England; [Rabiner, Eugenii A.] Kings Coll London, Inst Psychiat, Dept Neuroimaging, London, England; [Waldman, Adam D.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Dept Imaging, Div Expt Med, 160 Du Cane Rd, London W12 0NN, England; [Parkin, Mark C.; Brailsford, Alan D.] Kings Coll London, Drug Control Ctr, Analyt & Environm Sci, London, England; [Bowden-Jones, Henrietta] Univ London Imperial Coll Sci Technol & Med, CNWL NHS Fdn Trust, Natl Problem Gambling Clin, 160 Du Cane Rd, London W12 0NN, England; [Clark, Luke] Univ British Columbia, Dept Psychol, Ctr Gambling Res, Vancouver, BC V5Z 1M9, Canada	Lingford-Hughes, AR (reprint author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Ctr Neuropsychopharmacol, Div Brain Sci, 160 Du Cane Rd, London W12 0NN, England.	anne.lingford-hughes@imperial.ac.uk	Ramos, Anna/P-2600-2014	Ramos, Anna/0000-0003-1193-0652; Colasanti, Alessandro/0000-0001-6017-801X; Erritzoe, David/0000-0002-7022-6211; Waldman, Adam D/0000-0003-4398-6431; Mick, Inge Maria/0000-0002-0142-6156; Galduroz, Jose Carlos/0000-0002-2710-9693; Gunn, Roger/0000-0003-1181-5769; Brailsford, Alan/0000-0001-6198-4910; Clark, Luke/0000-0003-1103-2422	Medical Research Council-MRCMedical Research Council UK (MRC) [G1002226]; CAPESCAPES [PDSE 99999.014476/2013-04]; GSK/Wellcome Trust through Imperial College London; Responsible Gambling Trust; Province of British Columbia; British Columbia Lottery Corporation; LundbeckLundbeck Corporation; GSKGlaxoSmithKline; Medical Research CouncilMedical Research Council UK (MRC) [G1002226]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [2160]	This study was funded by the Medical Research Council-MRC G1002226. Anna Ramos has received financial support with a scholarship from CAPES (Process number: PDSE 99999.014476/2013-04). Dr Colasanti has been supported by a GSK/Wellcome Trust Fellowship in Translational Medicine and Therapeutics awarded through Imperial College London. The National Problem Gambling Clinic (Dr Bowden-Jones) receives some of its funding from the Responsible Gambling Trust. Dr Rabiner is a consultant for Lightlake Pharmaceutical, GSK, AbbVie, Teva, and a shareholder in GSK. Dr Waldman has received honoraria from Bayer, Novartis, and GSK, and has been a consultant for Bayer. Dr Stokes has received an honorarium from Indivior. Dr Clark has provided consultancy work for Cambridge Cognition Ltd, and the Centre for Gambling Research at UBC is funded by the Province of British Columbia and the British Columbia Lottery Corporation. Professor Gunn is a consultant for GSK, Abbvie, and UCB. Professor Lingford-Hughes has received research funding/support from Lundbeck, GSK, and honoraria for talks from Lundbeck. All the other authors report no conflict of interest.	Bartley CA, 2013, EXPERT REV NEUROTHER, V13, P887, DOI 10.1586/14737175.2013.814938; Blaszczynski APW, 1986, J GAMBLING BEHAVIOR, V2, P3; Boileau I, 2014, MOL PSYCHIATR, V19, P1305, DOI 10.1038/mp.2013.163; Bourdy R, 2012, TRENDS NEUROSCI, V35, P681, DOI 10.1016/j.tins.2012.06.007; Bowden-Jones H, 2011, BRIT J PSYCHIAT, V199, P87, DOI 10.1192/bjp.bp.110.088146; Clark L, 2013, CURR OPIN NEUROBIOL, V23, P655, DOI 10.1016/j.conb.2013.01.004; Clark L, 2012, NEUROIMAGE, V63, P40, DOI 10.1016/j.neuroimage.2012.06.067; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Cowlishaw S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008937.pub2; Cyders MA, 2007, PSYCHOL ASSESSMENT, V19, P107, DOI 10.1037/1040-3590.19.1.107; Doron R, 2006, NEUROREPORT, V17, P1633, DOI 10.1097/01.wnr.0000234755.88560.c7; Erritzoe D, 2014, NEUROPSYCHOPHARMACOL, V39, P1703, DOI 10.1038/npp.2014.18; Ferris J, 2001, CANADIAN PROBLEM GAM; Fethney J, 2010, AUST CRIT CARE, V23, P93, DOI 10.1016/j.aucc.2010.03.001; Forbush KT, 2008, CNS SPECTRUMS, V13, P306, DOI 10.1017/S1092852900016424; Fuentes D, 2006, J INT NEUROPSYCH SOC, V12, P907, DOI 10.1017/S1355617706061091; Ghitza UE, 2010, BIOL PSYCHIAT, V68, P697, DOI 10.1016/j.biopsych.2010.05.003; Gianoulakis C, 1996, ALCOHOL ALCOHOLISM, V31, P33; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Gorelick DA, 2008, PSYCHOPHARMACOLOGY, V200, P475, DOI 10.1007/s00213-008-1225-5; Grant JE, 2008, PSYCHOPHARMACOLOGY, V200, P521, DOI 10.1007/s00213-008-1235-3; Grant JE, 2014, BRIT J CLIN PHARMACO, V77, P375, DOI 10.1111/j.1365-2125.2012.04457.x; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Hodgins DC, 2011, LANCET, V378, P1874, DOI 10.1016/S0140-6736(10)62185-X; JOHNSON SW, 1992, J NEUROSCI, V12, P483; Lingford-Hughes AR, 2012, J PSYCHOPHARMACOL, V26, P899, DOI 10.1177/0269881112444324; Love TM, 2009, ARCH GEN PSYCHIAT, V66, P1124, DOI 10.1001/archgenpsychiatry.2009.134; Lubman DI, 2008, J PSYCHOPHARMACOL, V22, P836, DOI 10.1177/0269881107083846; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Meyer G, 2004, PSYCHONEUROENDOCRINO, V29, P1272, DOI 10.1016/j.psyneuen.2004.03.005; Michalczuk R, 2011, PSYCHOL MED, V41, P2625, DOI 10.1017/S003329171100095X; Mick I, 2014, INT J NEUROPSYCHOPH, V17, P2069, DOI 10.1017/S1461145714000704; Petrovic P, 2008, J NEUROSCI, V28, P10509, DOI 10.1523/JNEUROSCI.2807-08.2008; Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100; Shaffer H J, 1994, J Gambl Stud, V10, P339, DOI 10.1007/BF02104901; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shinohara Kikunori, 1999, Applied Human Science, V18, P37, DOI 10.2114/jpa.18.37; Soderman AR, 2009, BRAIN RES, V1296, P63, DOI 10.1016/j.brainres.2009.08.035; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Tziortzi AC, 2011, NEUROIMAGE, V54, P264, DOI 10.1016/j.neuroimage.2010.06.044; ULM RR, 1995, J CLIN PSYCHIAT, V56, P5; van Holst RJ, 2010, NEUROSCI BIOBEHAV R, V34, P87, DOI 10.1016/j.neubiorev.2009.07.007; VANKAMMEN DP, 1975, PSYCHOPHARMACOLOGIA, V44, P215, DOI 10.1007/BF00428897; Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32, P777, DOI 10.1016/j.neubiorev.2007.11.003; Votinov M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089954; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Williams TM, 2007, BRIT J PSYCHIAT, V191, P63, DOI 10.1192/bjp.bp.106.031120; Williams TM, 2009, EUR NEUROPSYCHOPHARM, V19, P740, DOI 10.1016/j.euroneuro.2009.06.007; Young MM, 2009, PSYCHOL ADDICT BEHAV, V23, P512, DOI 10.1037/a0015043; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225	53	34	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	JUN	2016	41	7					1742	1750		10.1038/npp.2015.340			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	DL9MY	WOS:000375968600006	26552847	Green Published, Other Gold, Green Accepted			2020-06-30	J	Windelov, JA; Pedersen, J; Holst, JJ				Windelov, Johanne A.; Pedersen, Jens; Holst, Jens J.			Use of anesthesia dramatically alters the oral glucose tolerance and insulin secretion in C57Bl/6 mice	PHYSIOLOGICAL REPORTS			English	Article						Anesthesia; metabolic test; oral glucose tolerance test	PLASMA-GLUCOSE; HYPERGLYCEMIA	Evaluation of the impact of anesthesia on oral glucose tolerance in mice. Anesthesia is often used when performing OGTT in mice to avoid the stress of gavage and blood sampling, although anesthesia may influence gastrointestinal motility, blood glucose, and plasma insulin dynamics. C57Bl/6 mice were anesthetized using the following commonly used regimens: (1) hypnorm/midazolam repetitive or single injection; (2) ketamine/xylazine; (3) isoflurane; (4) pentobarbital; and (5) A saline injected, nonanesthetized group. Oral glucose was administered at time 0 min and blood glucose measured in the time frame -15 to +150 min. Plasma insulin concentration was measured at time 0 and 20 min. All four anesthetic regimens resulted in impaired glucose tolerance compared to saline/no anesthesia. (1) hypnorm/midazolam increased insulin concentrations and caused an altered glucose tolerance; (2) ketamine/xylazine lowered insulin responses and resulted in severe hyperglycemia throughout the experiment; (3) isoflurane did not only alter the insulin secretion but also resulted in severe hyperglycemia; (4) pentobarbital resulted in both increased insulin secretion and impaired glucose tolerance. All four anesthetic regimens altered the oral glucose tolerance, and we conclude that anesthesia should not be used when performing metabolic studies in mice.	Univ Copenhagen, Novo Nordisk Fdn, Ctr Basic Metab Res, Translat Metab Physiol, Copenhagen, Denmark; Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark	Pedersen, J (reprint author), Univ Copenhagen, Novo Nordisk Fdn, Ctr Basic Metab Res, Ole Maaloesvej 3, DK-2200 Copenhagen N, Denmark.	jensp@sund.ku.dk		Windelov, johanne agerlin/0000-0002-9194-7886; Holst, Jens Juul/0000-0001-6853-3805	Danish Diabetes Academy by the Novo Nordisk Foundation	This work was supported by a PhD grant from the Danish Diabetes Academy supported by the Novo Nordisk Foundation.	Anderson DL, 2002, J NUCL MED, V43, P968; Ayala JE, 2010, DIS MODEL MECH, V3, P525, DOI 10.1242/dmm.006239; Brown ET, 2005, VISUAL NEUROSCI, V22, P615, DOI 10.1017/S0952523805225105; GOLDFINE ID, 1979, ENDOCRINOLOGY, V105, P920, DOI 10.1210/endo-105-4-920; Inada T, 2004, ANESTH ANALG, V99, P1102, DOI 10.1213/01.ANE.0000130852.53082.D5; JOHANSEN O, 1994, LAB ANIM, V28, P244, DOI 10.1258/002367794780681723; Pacini G, 2013, J DIABETES RES, DOI 10.1155/2013/986906; Pomplun D, 2004, HORM METAB RES, V36, P67, DOI 10.1055/s-2004-814104; Rodrigues SF, 2006, LIFE SCI, V79, P1630, DOI 10.1016/j.lfs.2006.05.019; Saha JK, 2005, EXP BIOL MED, V230, P777, DOI 10.1177/153537020523001012; Tanaka Tadashi, 2005, J Anesth, V19, P277, DOI 10.1007/s00540-005-0341-1; Yokomizo H, 2014, AM J PHYSIOL-ENDOC M, V306, pE1163, DOI 10.1152/ajpendo.00688.2013; Zuurbier CJ, 2008, ANESTH ANALG, V106, P135, DOI 10.1213/01.ane.0000297299.91527.74; Zuurbier CJ, 2014, EXP BIOL MED, V239, P737, DOI 10.1177/1535370214524877	14	21	21	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2051-817X			PHYSIOL REP	PHYSIOL. REP.	JUN	2016	4	11							UNSP e12824	10.14814/phy2.12824			6	Physiology	Physiology	DS0AG	WOS:000380256900018	27255361	DOAJ Gold, Green Published			2020-06-30	J	Wu, HY; Gong, CSA; Lin, SP; Chang, KY; Tsou, MY; Ting, CK				Wu, Hsin-Yun; Gong, Cihun-Siyong Alex; Lin, Shih-Pin; Chang, Kuang-Yi; Tsou, Mei-Yung; Ting, Chien-Kun			Predicting postoperative vomiting among orthopedic patients receiving patient-controlled epidural analgesia using SVM and LR	SCIENTIFIC REPORTS			English	Article							SUPPORT VECTOR MACHINE; ORTHOGNATHIC SURGERY; CATHETER INSERTION; RISK-FACTORS; NAUSEA; PAIN	Patient-controlled epidural analgesia (PCEA) has been applied to reduce postoperative pain in orthopedic surgical patients. Unfortunately, PCEA is occasionally accompanied by nausea and vomiting. The logistic regression (LR) model is widely used to predict vomiting, and recently support vector machines (SVM), a supervised machine learning method, has been used for classification and prediction. Unlike our previous work which compared Artificial Neural Networks (ANNs) with LR, this study uses a SVM-based predictive model to identify patients with high risk of vomiting during PCEA and comparing results with those derived from the LR-based model. From January to March 2007, data from 195 patients undergoing PCEA following orthopedic surgery were applied to develop two predictive models. 75% of the data were randomly selected for training, while the remainder was used for testing to validate predictive performance. The area under curve (AUC) was measured using the Receiver Operating Characteristic curve (ROC). The area under ROC curves of LR and SVM models were 0.734 and 0.929, respectively. A computer-based predictive model can be used to identify those who are at high risk for vomiting after PCEA, allowing for patient-specific therapeutic intervention or the use of alternative analgesic methods.	[Wu, Hsin-Yun] Taipei Med Univ, Shuang Ho Hosp, Dept Anesthesiol, 291 Zhongzheng Rd, Taipei 23561, Taiwan; [Wu, Hsin-Yun] Taipei Med Univ, Sch Med, Coll Med, Dept Anesthesiol, Taipei 23561, Taiwan; [Gong, Cihun-Siyong Alex] Chang Gung Univ, Dept Elect Engn, Taoyuan 33302, Taoyuan County, Taiwan; [Gong, Cihun-Siyong Alex; Lin, Shih-Pin] Chang Gung Univ, Coll Engn, Portable Energy Syst Grp, Green Technol Res Ctr, Taoyuan 33302, Taoyuan County, Taiwan; [Gong, Cihun-Siyong Alex] Chang Gung Mem Hosp, Taoyuan 33304, Taiwan; [Chang, Kuang-Yi; Tsou, Mei-Yung; Ting, Chien-Kun] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei 11217, Taiwan; [Chang, Kuang-Yi; Tsou, Mei-Yung; Ting, Chien-Kun] Natl Yang Ming Univ, Taipei 11217, Taiwan	Gong, CSA (reprint author), Chang Gung Univ, Dept Elect Engn, Taoyuan 33302, Taoyuan County, Taiwan.; Gong, CSA (reprint author), Chang Gung Univ, Coll Engn, Portable Energy Syst Grp, Green Technol Res Ctr, Taoyuan 33302, Taoyuan County, Taiwan.; Gong, CSA (reprint author), Chang Gung Mem Hosp, Taoyuan 33304, Taiwan.	alex.mlead@gmail.com	Ting, Chien-Kun/C-1389-2012	Ting, Chien-Kun/0000-0002-3156-8139	NATIONAL SCIENCE COUNCIL (NSC), TaiwanNational Science Council of Taiwan; MINISTRY OF SCIENCE AND TECHNOLOGY (MOST), Taiwan [NSC 102-2218-E-182-003-, MOST 103-2221-E-182-070-, MOST 103-2815-C-182-012-E, MOST 104-2815-C-182-052-E, MOST 104-2221-E-182-044, MOST 103-2221-E-075-003-]; CHANG GUNG UNIVERSITY (CGU); CHANG GUNG MEMORIAL HOSPITAL (CGMH)Chang Gung Memorial Hospital [UERPD2E0031, CMRPD2F0101, CMRPD2E0021]	This study was funded in part with grants from the NATIONAL SCIENCE COUNCIL (NSC), Taiwan, and MINISTRY OF SCIENCE AND TECHNOLOGY (MOST), Taiwan, under Grants NSC 102-2218-E-182-003-, MOST 103-2221-E-182-070-, MOST 103-2815-C-182-012-E, MOST 104-2815-C-182-052-E, MOST 104-2221-E-182-044, and MOST 103-2221-E-075-003-. This work is also supported in part by the CHANG GUNG UNIVERSITY (CGU) and CHANG GUNG MEMORIAL HOSPITAL (CGMH) under Contracts UERPD2E0031, CMRPD2F0101 and CMRPD2E0021.	Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Behera BK, 2008, J POSTGRAD MED, V54, P86; Cesur M, 2005, ANESTH ANALG, V101, P1501, DOI 10.1213/01.ANE.0000181005.50958.1E; Chen YJ, 2009, J CHIN MED ASSOC, V72, P183, DOI 10.1016/S1726-4901(09)70051-6; CHOI PT, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD003071, 10.1002/14651858.cd003071]; Crisler S, 2008, J NEUROSCI METH, V168, P524, DOI 10.1016/j.jneumeth.2007.10.027; DAngelo R, 1996, ANESTHESIOLOGY, V84, P88, DOI 10.1097/00000542-199601000-00011; Eberhart LHJ, 2000, ACTA ANAESTH SCAND, V44, P480, DOI 10.1034/j.1399-6576.2000.440422.x; Gan TJ, 2006, ANESTH ANALG, V102, P1884, DOI 10.1213/01.ANE.0000219597.16143.4D; Gedney JA, 1998, ANAESTHESIA, V53, P1148, DOI 10.1046/j.1365-2044.1998.00636.x; Golembiewski Julie, 2006, J Perianesth Nurs, V21, P385, DOI 10.1016/j.jopan.2006.09.004; Gong CSA, 2014, BIOMED RES INT, DOI 10.1155/2014/786418; Hu YJ, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-131; Jain A. K., 2000, IEEE T PATTERN ANAL, V22, P34; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005; Lee SY, 2014, J CHIN MED ASSOC, V77, P589, DOI 10.1016/j.jcma.2014.08.008; LERMAN J, 1992, BRIT J ANAESTH, V69, pS24, DOI 10.1093/bja/69.supplement_1.24S; Phillips C, 2015, INT J ORAL MAX SURG, V44, P745, DOI 10.1016/j.ijom.2015.01.006; Scuderi PE, 1999, ANESTHESIOLOGY, V90, P360, DOI 10.1097/00000542-199902000-00006; Silva AC, 2006, J ORAL MAXIL SURG, V64, P1385, DOI 10.1016/j.joms.2006.05.024; Tsui SL, 1997, ANAESTHESIA, V52, P1042, DOI 10.1111/j.1365-2044.1997.232-az0371.x; Xiao YP, 2008, NEURAL NETWORKS, V21, P341, DOI 10.1016/j.neunet.2007.12.022	23	6	6	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 1	2016	6								27041	10.1038/srep27041			7	Multidisciplinary Sciences	Science & Technology - Other Topics	DN6DT	WOS:000377163000001	27247165	DOAJ Gold, Green Published			2020-06-30	J	Minkowitz, H; Bull, J; Brownlow, RC; Parikh, N; Rauck, R				Minkowitz, Harold; Bull, Janet; Brownlow, R. Charles; Parikh, Neha; Rauck, Richard			Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain	SUPPORTIVE CARE IN CANCER			English	Article						Cancer pain; Breakthrough pain; Fentanyl sublingual spray; Opioids	PREVALENCE	Purpose The current study assessed the long-term safety of fentanyl sublingual spray for managing breakthrough cancer pain (BTCP). Methods This open-label, multicenter study enrolled both de novo and rollover patients who completed a double-blind, efficacy trial. Eligible patients were >= 18 years of age and experiencing pain that was being managed with an around-the-clock opioid yet were experiencing <= 4 BTCP episodes daily and were opioid-tolerant (i.e., receiving >= 60 mg/day oral morphine or an equivalent dose of another opioid for >= 1 week). De novo patients initially entered a 21-day titration period to identify an effective dose of fentanyl sublingual spray (100-1600 mu g), then entered a 90-day maintenance period. The incidence of adverse events (AEs), results of laboratory tests, vital sign assessments, and treatment satisfaction were assessed. Results Of the 269 patients (de novo, 179; rollover, 90) who entered the maintenance period, 163 (60.6 %) completed the study; the primary reason for discontinuation was an AE (22.3 %). Eighty percent of patients identified an effective dose of fentanyl sublingual spray (median dose, 600 mu g). The most common AEs differed from the titration period (nausea (13 %), vomiting (12 %), and somnolence (10 %)) to the maintenance period (malignant neoplasm progression (24 %), vomiting (16 %), and peripheral edema (12 %)). Few changes in laboratory parameters and vital sign assessments were observed. Patients generally reported being more satisfied with fentanyl sublingual spray than with their previous BTCP treatment. Conclusions This long-term maintenance study demonstrated that fentanyl sublingual spray was generally safe and well tolerated for managing BTCP over a 90-day period.	[Minkowitz, Harold] Mem Herman Mem City Med Ctr, Dept Anesthesiol, 921 Gessner Rd, Houston, TX 77024 USA; [Bull, Janet] Four Seasons Hosp & Palliat Care, Flat Rock, NC USA; [Brownlow, R. Charles] Better Hlth Clin Res, Newnan, GA USA; [Parikh, Neha] INSYS Therapeut Inc, Clin Operat, Chandler, AZ USA; [Rauck, Richard] Carolinas Pain Inst, Dept Med, Winston Salem, NC USA; [Rauck, Richard] Clin Res Ctr, Winston Salem, NC USA	Minkowitz, H (reprint author), Mem Herman Mem City Med Ctr, Dept Anesthesiol, 921 Gessner Rd, Houston, TX 77024 USA.	Harold@Minkowitzmd.com			INSYS Therapeutics, Inc.	This study was sponsored by INSYS Therapeutics, Inc.	[Anonymous], 2013, CII PACK INS; Atkinson Mark J, 2004, Health Qual Life Outcomes, V2, P12, DOI 10.1186/1477-7525-2-12; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Nalamachu SR, 2011, CURR MED RES OPIN, V27, P751, DOI 10.1185/03007995.2011.554808; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2010, EUR J PALLIAT CAR S3, V17, P4	17	3	3	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	JUN	2016	24	6					2669	2675		10.1007/s00520-015-3056-3			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	DK5TL	WOS:000374983300034	26780504				2020-06-30	J	Suarez, PM; Santotoribio, JD; Ramos, VR; Garcia, MAG; Ramos, SP; Huertas, DP; Hoyos, AM				Mesa Suarez, Pablo; Diego Santotoribio, Jose; Ramos Ramos, Victoria; Gonzalez Garcia, Maria Angela; Perez Ramos, Santiago; Portilla Huertas, David; Munoz Hoyos, Antonio			Brain damage after general anesthesia	MEDICINA CLINICA			Spanish	Article						S100B protein; General anaesthesia; Brain damage; Midazolam; Fentanyl; Propofol; Sevoflurane	S100-BETA PROTEIN; EARLY EXPOSURE; S100 PROTEINS; S-100B LEVELS; SERUM; CHILDREN; INJURY; SEVERITY; OUTCOMES; MARKER	Background and objective: S100B protein is a serum marker of cerebral damage. The objective was to evaluate the brain damage caused by general anaesthesia, by determining the concentration of serum S100B protein before and after of general anaesthesia. Patients and method: Patients with chronic adenotonsillar hypertrophy and indications for tonsillectomy were included. A venous blood sample was taken from the patients before general anaesthesia (basal sample). The patients were anaesthetised using the following intravenous anaesthetic drugs: midazolam, fentanyl and propofol; and inhaled sevoflurane. A second venous blood sample (postoperative sample) was taken from patients after the surgery, in the operating room. The concentration of serum S100B protein was determined in the basal sample (S100Bb) and postoperative sample (S100Bp) by immunoassay electro-chemiluminescence in MODULAR E-170 (Roche Diagnostics). Results: Seventy-six patients were included, 46 males and 30 females, aged between 3 to 14 (median 5 years). In all the patients, serum S100B protein levels increased after general anaesthesia. The values of S100Bp (median 164.0 ng/L) were significantly higher than the valus of S100Bb (median 94.5 ng/L). The median of the difference between S100Bp and S100Bb was 58.0 ng/L. There were statistically significant differences between S100Bb and S100Bp using the Wilcoxon test (P < .0001). Conclusions: The concentration of serum S100B protein increased significantly after general anaesthesia. This indicates that general anaesthesia may cause brain damage. (C) 2016 Elsevier Espana, S.L.U. All rights reserved.	[Mesa Suarez, Pablo; Portilla Huertas, David] Hosp Univ Puerto Real, Unidad Gest Clin Anestesiol, Cadiz, Spain; [Diego Santotoribio, Jose; Perez Ramos, Santiago] Hosp Univ Puerto Real, Unidad Gest Clin Lab, Cadiz, Spain; [Diego Santotoribio, Jose; Perez Ramos, Santiago] Univ Cadiz, Dept Biomed Biotecnol & Salud Publ, Cadiz, Spain; [Ramos Ramos, Victoria] Hosp Jerez Frontera de la Jerez, Unidad Gest Clin Pediat, Cadiz, Spain; [Gonzalez Garcia, Maria Angela] Hosp Jerez Frontera de la Jerez, Unidad Gest Clin Anal Clin, Cadiz, Spain; [Munoz Hoyos, Antonio] Univ Granada, Dept Pediat, Granada, Spain	Santotoribio, JD (reprint author), Hosp Univ Puerto Real, Unidad Gest Clin Lab, Cadiz, Spain.; Santotoribio, JD (reprint author), Univ Cadiz, Dept Biomed Biotecnol & Salud Publ, Cadiz, Spain.	jdsantotoribioc@gmail.com	Santotoribio, Jose D/L-8738-2016	Santotoribio, Jose D/0000-0002-8851-7551; Munoz-Hoyos, Antonio/0000-0002-8370-338X			Bartels M, 2009, TWIN RES HUM GENET, V12, P246, DOI 10.1375/twin.12.3.246; Bozkus F, 2014, EUR REV MED PHARMACO, V18, P1549; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Byrne MW, 2012, J NEUROSURG ANESTH, V24, P396, DOI 10.1097/ANA.0b013e31826a032d; Calik M, 2013, SEIZURE-EUR J EPILEP, V22, P99, DOI 10.1016/j.seizure.2012.10.012; Chiang LM, 2015, J CHIN MED ASSOC, V78, P610, DOI 10.1016/j.jcma.2015.06.009; Donato Rosario, 2010, Cardiovasc Psychiatry Neurol, V2010, P929712, DOI 10.1155/2010/929712; Donato R, 2013, EUR J APPL PHYSIOL, V113, P819, DOI 10.1007/s00421-012-2566-7; Egea-Guerrero JJ, 2014, MED INTENSIVA, V38, P218, DOI 10.1016/j.medin.2013.03.015; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Flick RP, 2011, PEDIATRICS, V128, pE1053, DOI 10.1542/peds.2011-0351; Fuertes Olivera A, 2014, ANESTESIOLOGIA REANI, P121; Laribi S, 2014, CLIN CHEM LAB MED, V52, P527, DOI 10.1515/cclm-2013-0621; Lee JY, 2015, J KOREAN NEUROSURG S, V58, P93, DOI 10.3340/jkns.2015.58.2.93; Lunardi N, 2015, MOL NEUROBIOL, V52, P942, DOI 10.1007/s12035-015-9246-7; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Piazza O, 2007, BRIT J ANAESTH, V99, P518, DOI 10.1093/bja/aem201; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Shakeril M, 2013, ARCH TRAUMA RES, V2, P76, DOI 10.5812/atr.8549; Sun L, 2010, BRIT J ANAESTH, V105, pI61, DOI 10.1093/bja/aeq302; Tomaszewski D, 2015, BIOMED RES INT, DOI 10.1155/2015/402959; Whiteley W, 2009, STROKE, V40, pE380, DOI 10.1161/STROKEAHA.108.528752; Ye H, 2015, J NEUROL SCI, V348, P81, DOI 10.1016/j.jns.2014.11.010	24	5	5	1	9	ELSEVIER ESPANA SLU	BARCELONA	AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN	0025-7753	1578-8989		MED CLIN-BARCELONA	Med. Clin.	MAY 6	2016	146	9					384	388		10.1016/j.medcli.2016.01.018			5	Medicine, General & Internal	General & Internal Medicine	DK9IB	WOS:000375243000002	26969427				2020-06-30	J	Mora, AG; Ganem, VJ; Ervin, AT; Maddry, JK; Bebarta, VS				Mora, Alejandra G.; Ganem, Victoria J.; Ervin, Alicia T.; Maddry, Joseph K.; Bebarta, Vikhyat S.			En Route Use of Analgesics in Nonintubated, Critically Ill Patients Transported by US Air Force Critical Care Air Transport Teams	MILITARY MEDICINE			English	Article; Proceedings Paper	Military Health System Research Symposium	AUG 17-21, 2014	Fort Lauderdale, FL				POSTTRAUMATIC-STRESS-DISORDER; AEROMEDICAL EVACUATION; SERVICE MEMBERS; PAIN; KETAMINE; IRAQ; OPERATIONS; MORPHINE; OUTCOMES; INJURY	Introduction: U.S. Critical Care Air Transport Teams (CCATTs) evacuate critically ill patients with acute pain in the combat setting. Limited data have been reported on analgesic administration en route, and no study has reported analgesic use by CCATTs. Our objective was to describe analgesics used by CCATTs for nonintubated, critically ill patients during evacuation from a combat setting. Methods: We conducted an institutional review board-approved, retrospective review of CCATT records. We included nonintubated, critically ill patients who were administered analgesics in flight and were evacuated out of theater (2007-2012). Demographics, injury description, analgesics and anesthetics, and predefined clinical adverse events were recorded. Data were presented as mean +/- standard deviation or percentage (%). Results: Of 1,128 records, we analyzed 381 subjects with the following characteristics: age 26 +/- 7.0 years; 98% male; and 97% trauma (70% blast, 17% penetrating, 11% blunt, and 3% burn). The injury severity score was 19 +/- 9. Fifty-one percent received morphine, 39% hydromorphone, 15% fentanyl, and 5% ketamine. Routes of delivery were 63% patient-controlled analgesia (PCA), 32% bolus intravenous (IV) administration, 24% epidural delivery, 21% continuous IV infusions, and 9% oral opioids. Patients that were administered local anesthetics (nerve block or epidural delivery) with IV opioids received a lower total dose of opioids than those who received opioids alone. No differences were associated between analgesics and frequency of complications in flight or postflight. Conclusion: About half of nonintubated, critically ill subjects evacuated out of combat by CCATT received morphine and more than half had a PCA. In our study, ketamine was not frequently used and pain scores were rarely recorded. However, we detected an opioid-sparing effect associated with local anesthetics (regional nerve blocks and epidural delivery).	[Mora, Alejandra G.; Ganem, Victoria J.; Ervin, Alicia T.; Maddry, Joseph K.; Bebarta, Vikhyat S.] US Army, Air Force Route Care Res Ctr, Inst Surg Res, 59th MDW,3698 Chambers Pass Rd,Bldg 3611, Ft Sam Houston, TX 78234 USA; [Maddry, Joseph K.; Bebarta, Vikhyat S.] San Antonio Mil Med Ctr, Dept Emergency Med, Brooke Army Med Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA	Mora, AG (reprint author), US Army, Air Force Route Care Res Ctr, Inst Surg Res, 59th MDW,3698 Chambers Pass Rd,Bldg 3611, Ft Sam Houston, TX 78234 USA.		Bebarta, Vikhyat S/M-1513-2015				Altshuler J, 2013, CRIT CARE NURS Q, V36, P356, DOI 10.1097/CNQ.0b013e3182a10dbf; Beninati W, 2008, CRIT CARE MED, V36, pS370, DOI 10.1097/CCM.0b013e31817e3143; Bridges E, 2015, MIL MED, V180, P44, DOI 10.7205/MILMED-D-14-00407; Bridges E, 2010, AACN ADV CRIT CARE, V21, P260, DOI 10.1097/NCI.0b013e3181e67385; Buckenmaier CC, 2009, PAIN MED, V10, P1487, DOI 10.1111/j.1526-4637.2009.00731.x; Clifford JL, 2014, J TRAUMA ACUTE CARE, V77, pS228, DOI 10.1097/TA.0000000000000403; Eastridge BJ, 2010, J TRAUMA, V69, pS5, DOI 10.1097/TA.0b013e3181e421f3; Flutter C, 2009, J R Army Med Corps, V155, P61; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; GRISSOM TE, 2005, [No title captured], V33, P13; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Hurd WW, 2006, AVIAT SPACE ENVIR MD, V77, P631; Ilfeld BM, 2011, ANESTH ANALG, V113, P904, DOI 10.1213/ANE.0b013e3182285e01; Ingalls N, 2014, JAMA SURG, V149, P807, DOI 10.1001/jamasurg.2014.621; Johannigman JA, 2007, J TRAUMA, V62, pS35, DOI 10.1097/TA.0b013e31806540f3; Kent ML, 2011, INT ANESTHESIOL CLIN, V49, P10, DOI 10.1097/AIA.0b013e318214d8f2; Lairet J, 2013, PREHOSP EMERG CARE, V17, P486, DOI 10.3109/10903127.2013.811564; Mason PE, 2011, J EMERG MED, V41, P8, DOI 10.1016/j.jemermed.2008.06.032; McGhee LL, 2008, J TRAUMA, V64, pS195, DOI 10.1097/TA.0b013e318160ba1d; Miller JP, 2015, AM J EMERG MED, V33, P402, DOI 10.1016/j.ajem.2014.12.058; O'Connor AB, 2010, AM J EMERG MED, V28, P1041, DOI 10.1016/j.ajem.2009.06.009; Rice DH, 2008, CRIT CARE, V12, DOI 10.1186/cc6782; Svenson JE, 2007, AM J EMERG MED, V25, P977, DOI 10.1016/j.ajem.2007.02.040	23	9	9	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	MAY	2016	181	5		S			145	151		10.7205/MILMED-D-15-00194			7	Medicine, General & Internal	General & Internal Medicine	DW5LJ	WOS:000383686400022	27168565	Bronze			2020-06-30	J	Ogawa, N; Furuishi, T; Nagase, H; Endo, T; Takahashi, C; Yamamoto, H; Kawashima, Y; Loftsson, T; Kobayashi, M; Ueda, H				Ogawa, Noriko; Furuishi, Takayuki; Nagase, Hiromasa; Endo, Tomohiro; Takahashi, Chisato; Yamamoto, Hiromitsu; Kawashima, Yoshiaki; Loftsson, Thorsteinn; Kobayashi, Masaru; Ueda, Haruhisa			Interaction of fentanyl with various cyclodextrins in aqueous solutions	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article						cyclodextrin; fentanyl base; fentanyl citrate; inclusion complex; nuclear magnetic resonance	BETA-CYCLODEXTRIN; CANCER PAIN; COMPLEXATION; INCLUSION; SYSTEM; NMR; PHARMACOKINETICS; H-1-NMR	Objectives Water-soluble fentanyl citrate salt has been used in sublingual or buccal formulations for the breakthrough pain treatment. However, fentanyl absorption through the lipid mucosal membrane may be improved by enhancing the non-ionic lipophilic fentanyl base solubility. Therefore, the interaction between cyclodextrins (CDs) and fentanyl base has been evaluated to obtain basic information for its application. Methods Parent CDs (alpha-, beta- and gamma-CD) as well as alpha-and beta-CD derivatives were used for solubility studies with fentanyl base. Nuclear magnetic resonance (NMR) studies were applied in a system including beta-CD or glucosyl-beta-CD (G1-beta-CD) with fentanyl base or fentanyl citrate. H-1- and C-13-NMR studies and a two-dimensional rotating frame Overhauser effect spectroscopy (ROESY) study were conducted to confirm inclusion complexes formation. Key findings Parent CDs displayed B-S type phase solubility diagrams; beta-CD exhibited a strong interaction with fentanyl base. Hydrophilic beta-CD derivatives, such as G1-beta-CD, displayed A(L) type phase diagrams and higher solubilizing effects compared with parent CDs. ROESY study suggested that fentanyl phenyl groups were included in beta-CD cavity. Conclusions This study revealed that hydrophilic beta-CD derivatives, such as G1-beta-CD, could be useful pharmaceutical additives for oral mucosal formulations because of the improved fentanyl base solubility via inclusion complexation.	[Ogawa, Noriko; Takahashi, Chisato; Yamamoto, Hiromitsu; Kawashima, Yoshiaki] Aichi Gakuin Univ, Sch Pharm, Dept Pharmaceut Engn, 1-100 Kusumoto Cho, Nagoya, Aichi 464, Japan; [Furuishi, Takayuki; Nagase, Hiromasa; Endo, Tomohiro] Hoshi Univ, Fac Pharmaceut Sci, Dept Phys Chem, Tokyo, Japan; [Loftsson, Thorsteinn] Univ Iceland, Fac Pharmaceut Sci, Reykjavik, Iceland; [Kobayashi, Masaru; Ueda, Haruhisa] Nihon Pharmaceut Univ, Dept Phys Chem, Saitama, Japan	Ogawa, N (reprint author), Aichi Gakuin Univ, Dept Pharmaceut Engn, Sch Pharm, Chikusa Ku, 1-100 Kusumoto Cho, Nagoya, Aichi 4648650, Japan.	noriko30@dpc.agu.ac.jp	Furuishi, Takayuki/Q-1762-2019	Furuishi, Takayuki/0000-0002-5085-4683	Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Hori Sciences and Arts Foundation	This study was supported in part by a research grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan and in part by the Hori Sciences and Arts Foundation.	Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; BACKENSFELD T, 1991, INT J PHARMACEUT, V74, P85, DOI 10.1016/0378-5173(91)90225-D; Brewster ME, 2007, ADV DRUG DELIVER REV, V59, P645, DOI 10.1016/j.addr.2007.05.012; CONNORS KA, 1980, J PHARM SCI, V69, P173, DOI 10.1002/jps.2600690215; Cruz JR, 2008, MAGN RESON CHEM, V46, P838, DOI 10.1002/mrc.2267; del Consuelo ID, 2007, J CONTROL RELEASE, V122, P135, DOI 10.1016/j.jconrel.2007.05.017; Frisch MJ, 2009, GAUSSIAN 09 REVISION; Hada S, 1999, J PHYS CHEM B, V103, P2579, DOI 10.1021/jp983873c; HALL GM, 1980, BRIT J ANAESTH, V52, P561, DOI 10.1093/bja/52.6.561; Hanks GW, 1998, OXFORD TXB PALLIATIV, P454; HARRISON JC, 1982, BIOPOLYMERS, V21, P1153, DOI 10.1002/bip.360210611; Higuchi T. K., 1965, ADV ANAL CHEM INSTRU, V4, P117; Holvoet C, 2003, INT J PHARM, V265, P13, DOI 10.1016/S0378-5173(03)00368-5; Ishizuka Y, 2005, CARBOHYD RES, V340, P1343, DOI 10.1016/j.carres.2005.02.019; Jimeno ML, 2003, CHEM PHARM BULL, V51, P929; KRISHNAMOORTHY R, 1996, INT J PHARM ADV, V1, P329; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Li HY, 2011, EUR J PHARM SCI, V42, P55, DOI 10.1016/j.ejps.2010.10.006; Liu L, 2002, J INCL PHENOM MACRO, V42, P1, DOI 10.1023/A:1014520830813; Loftsson T, 2012, J PHARM SCI-US, V101, P3019, DOI 10.1002/jps.23077; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; MULLER BW, 1991, J PHARM SCI, V80, P599, DOI 10.1002/jps.2600800620; Mystakidou K, 2004, IN VIVO, V18, P633; Ogawa N, 2010, J PHARM SCI-US, V99, P5019, DOI 10.1002/jps.22193; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Schneider HJ, 1998, CHEM REV, V98, P1755, DOI 10.1021/cr970019t; Serajuddin ATM, 2007, ADV DRUG DELIVER REV, V59, P603, DOI 10.1016/j.addr.2007.05.010; STANLEY TH, 1989, ANESTH ANALG, V69, P21; Sueishi Y, 2009, J INCL PHENOM MACRO, V64, P135, DOI 10.1007/s10847-009-9545-6; SUZUKI I, 1993, B CHEM SOC JPN, V66, P1472, DOI 10.1246/bcsj.66.1472; Szejtli J, 1998, CHEM REV, V98, P1743, DOI 10.1021/cr970022c; Uekama K, 1998, CHEM REV, V98, P2045, DOI 10.1021/cr970025p; Zia V, 2001, PHARMACEUT RES, V18, P667, DOI 10.1023/A:1011041628797	36	5	5	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	MAY	2016	68	5			SI		588	597		10.1111/jphp.12437			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DO9TM	WOS:000378129900005	26077960				2020-06-30	J	McKenzie, CP; Carvalho, B; Riley, ET				McKenzie, Christine P.; Carvalho, Brendan; Riley, Edward T.			The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia A Case Series of 5 Cesarean Deliveries Complicated by Paresthesias and Headaches	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							CESAREAN-SECTION; LABOR ANALGESIA; PARTURIENT; DELIVERY; COMPLICATIONS; BUPIVACAINE; SUFENTANIL; INJECTION	Intrathecal catheter devices using a catheter-over-needle design and softer flexible material have been introduced to clinical practice with the aim of reducing some of the complications such as postdural puncture headaches and paresthesias seen with previous versions of intrathecal catheters. We present a case series of 5 cesarean deliveries using the Wiley Spinal intrathecal system (Epimed, Johnstown, New York), which was recently approved by the US Food and Drug Administration. The intrathecal catheter system consists of a flexible 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle. The placement of the intrathecal catheter was successful in all 5 cases; however, paresthesias in 3 cases and postdural puncture headaches in 2 cases complicated the placement and use of the device. Although the unique catheter-over-needle design facilitates the use of smaller-gauge spinal needles for dural puncture and larger-gauge catheters for medication administration, this case series using the Wiley Spinal suggests that paresthesias and postdural puncture headaches may still limit its widespread utilization. Future studies are needed to determine the true incidence of complications and to determine the role of continuous spinal anesthesia in the obstetric population.	Stanford Univ, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA	Carvalho, B (reprint author), Stanford Univ, Sch Med, Dept Anesthesia, 300 Pasteur Ave, Stanford, CA 94305 USA.	bcarvalho@stanford.edu					Abboud TK, 1996, ACTA ANAESTH SCAND, V40, P210, DOI 10.1111/j.1399-6576.1996.tb04421.x; Alonso E, 2009, INT J OBSTET ANESTH, V18, P137, DOI 10.1016/j.ijoa.2008.11.001; Arkoosh VA, 2008, ANESTHESIOLOGY, V108, P286, DOI 10.1097/01.anes.0000299429.52105.e5; Banwell BR, 1998, CAN J ANAESTH, V45, P370, DOI 10.1007/BF03012031; BAYHI D, 1995, SOUTHERN MED J, V88, P1043, DOI 10.1097/00007611-199510000-00009; Bevacqua Brian K, 2003, Best Pract Res Clin Anaesthesiol, V17, P393, DOI 10.1016/S1521-6896(02)00117-9; BIZZARRI D, 1964, ANESTH ANALG, V43, P393; BLAISE GA, 1992, CAN J ANAESTH, V39, P633, DOI 10.1007/BF03008332; Choi PT, 2003, CAN J ANAESTH, V50, P460, DOI 10.1007/BF03021057; Coker Lanny L, 2002, AANA J, V70, P189; Dresner M, 2009, INT J OBSTET ANESTH, V18, P131, DOI [10.1016/j.ijoa.2008.09.009, 10.1016/j.ijoa.2009.04.004]; DRIPPS RD, 1950, NEW YORK STATE J MED, V50, P1595; GIUFFRIDA JG, 1972, ANESTH ANAL CURR RES, V51, P117; Graham C M, 1995, Int J Obstet Anesth, V4, P219, DOI 10.1016/0959-289X(95)82914-V; Holst D, 1998, REGION ANESTH PAIN M, V23, P463, DOI 10.1016/S1098-7339(98)90028-1; Horlocker TT, 1997, ANESTH ANALG, V84, P1063, DOI 10.1097/00000539-199705000-00020; HUCKABY T, 1991, REGION ANESTH, V16, P150; HURLEY RJ, 1990, ANESTH ANALG, V70, P97; HURLEY RJ, 1989, INT ANESTHESIOL CLIN, V27, P46, DOI 10.1097/00004311-198902710-00009; Imbelloni LE, 2006, INT J OBSTET ANESTH, V15, P171, DOI 10.1016/j.ijoa.2005.09.009; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; KESTIN IG, 1992, BRIT J ANAESTH, V68, P244, DOI 10.1093/bja/68.3.244; KESTIN IG, 1991, BRIT J ANAESTH, V66, P232, DOI 10.1093/bja/66.2.232; Koch Evan, 2002, AANA J, V70, P343; MCHALE S, 1992, BRIT J ANAESTH, V69, P634, DOI 10.1093/bja/69.6.634; Okutomi T, 2002, ACTA ANAESTH SCAND, V46, P329, DOI 10.1034/j.1399-6576.2002.t01-1-460317.x; Palmer CM, 2010, ANESTH ANALG, V111, P1476, DOI 10.1213/ANE.0b013e3181f7e3f4; RANSOM DM, 1995, ANESTH ANALG, V80, P418, DOI 10.1097/00000539-199502000-00038; RIGLER ML, 1991, ANESTH ANALG, V72, P275; ROBSON SC, 1993, BRIT J ANAESTH, V70, P634, DOI 10.1093/bja/70.6.634; Sultan P, 2012, CAN J ANESTH, V59, P473, DOI 10.1007/s12630-012-9681-0; Tao W, 2011, INT J OBSTET ANESTH, V20, P351, DOI 10.1016/j.ijoa.2011.07.010; TUOHY EB, 1950, SURG CLIN N AM, V30, P1797; Van de Velde M, 2003, INT J OBSTET ANESTH, V12, P51, DOI 10.1016/S0959-289X(02)00163-2; Velickovic IA, 2004, INT J OBSTET ANESTH, V13, P40, DOI 10.1016/S0959-289X(03)00052-9	35	9	10	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAY-JUN	2016	41	3					405	410		10.1097/AAP.0000000000000367			6	Anesthesiology	Anesthesiology	DP0CB	WOS:000378154200017	26909488				2020-06-30	J	Yurtlu, DA; Aslan, F; Ayvat, P; Isik, Y; Karakus, N; Unsal, B; Kizilkaya, M				Yurtlu, Derya Arslan; Aslan, Fatih; Ayvat, Pinar; Isik, Yasemin; Karakus, Nesli; Unsal, Belkis; Kizilkaya, Mehmet			Propofol-Based Sedation Versus General Anesthesia for Endoscopic Submucosal Dissection	MEDICINE			English	Article							ESD; EMR	The main objective of this study is to evaluate general anesthesia or propofol-based sedation methods at gastric endoscopic submucosal dissection (ESD) procedures. The anesthetic method administered to cases undergoing upper gastrointestinal ESD between 2013 and 2015 was retrospectively investigated. Procedure time, lesion size, dissection speed, anesthesia time, adverse effects such as gag reflex, nausea, vomiting, cough, number of desaturation episodes (SpO(2) < 90%), oropharyngeal suctioning requirements, hemorrhage, perforation, and amount of anesthetic medications were recorded. There were 54 and 37 patients who were administered sedation (group S) and general anesthesia (group G), respectively. The demographics of the groups were similar. The calculated dissection speed was significantly high in group G (36.02 +/- 20.96 mm(2)/min) compared with group S (26.04 +/- 17.56 mm(2)/min; P = 0.010). The incidence of nausea, cough, number of oropharyngeal suctioning, and desaturation episodes were significantly high in group S compared with that in group G (P < 0.5). While there was no difference between the groups in terms of hemodynamic parameters, in group S the use of propofol and in group G the use of midazolam and fentanyl were significantly higher (P < 0.05). Anesthesia time, postoperative anesthesia care unit, and hospital stay durations were not significantly different between the groups. General anesthesia increased dissection speed and enhanced endoscopist performance when compared with propofol-based sedation technique.	[Yurtlu, Derya Arslan; Ayvat, Pinar; Isik, Yasemin; Karakus, Nesli; Kizilkaya, Mehmet] Katip Celebi Univ, Anesthesiol & Reanimat Dept, Izmir Ataturk Educ & Res Hosp, Izmir, Turkey; [Aslan, Fatih; Unsal, Belkis] Katip Celebi Univ, Dept Gastroenterol, Izmir Ataturk Educ & Res Hosp, Izmir, Turkey	Yurtlu, DA (reprint author), Katip Celebi Univ, Basin Sitesi, TR-35260 Izmir, Turkey.	darslanyurtlu@yahoo.com					Akasaka T, 2011, DIGEST ENDOSC, V23, P73, DOI 10.1111/j.1443-1661.2010.01062.x; Alderette JA, 1970, ANESTH ANALG, V51, P543; Aldrete J A, 1998, J Perianesth Nurs, V13, P148, DOI 10.1016/S1089-9472(98)80044-0; Aslan F, 2015, SCAND J GASTROENTERO, V50, P368, DOI 10.3109/00365521.2014.999253; Lin JP, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0705-4; Nonaka S, 2015, DIGEST ENDOSC, V27, P665, DOI 10.1111/den.12457; Oka S, 2006, GASTROINTEST ENDOSC, V64, P877, DOI 10.1016/j.gie.2006.03.932; Othman MO, 2011, CLIN RES HEPATOL GAS, V35, P288, DOI 10.1016/j.clinre.2011.02.006; Park CH, 2015, PLOS ONE, V24; Rong QH, 2013, MED PRIN PRACT, V22, P280, DOI 10.1159/000344002; Rosow C, 2001, Anesthesiol Clin North Am, V19, P947; Sakamoto T, 2011, DIS COLON RECTUM, V54, P1307, DOI 10.1097/DCR.0b013e3182282ab0; Toyonaga T, 2010, Acta Chir Iugosl, V57, P41; Watari J, 2012, GASTROINTEST ENDOSC, V76, P1116, DOI 10.1016/j.gie.2012.07.043; Yoo YC, 2015, BRIT J ANAESTH, V115, P84, DOI 10.1093/bja/aeu555	15	4	8	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	MAY	2016	95	20							e3680	10.1097/MD.0000000000003680			5	Medicine, General & Internal	General & Internal Medicine	DO4TO	WOS:000377777200035	27196474	DOAJ Gold, Green Published			2020-06-30	J	Kim, JE; Choi, JB; Koo, BN; Jeong, HW; Lee, BH; Kim, SY				Kim, Ji Eun; Choi, Jong Bum; Koo, Bon-Nyeo; Jeong, Hae Won; Lee, Byung Ho; Kim, So Yeon			Efficacy of Intravenous Lidocaine During Endoscopic Submucosal Dissection for Gastric Neoplasm A Randomized, Double-Blind, Controlled Study	MEDICINE			English	Article							PAIN RELIEF; ANALGESIA; INFUSION; SEDATION; MAGNESIUM; CANCER	Endoscopic submucosal dissection (ESD) is an advanced therapy for early gastric neoplasm and requires sedation with adequate analgesia. Lidocaine is a short-acting local anesthetic, and intravenous lidocaine has been shown to have analgesic efficacy in surgical settings. The aim of this study was to assess the effects of intravenous lidocaine on analgesic and sedative requirements for ESD and pain after ESD. Sixty-six patients scheduled for ESD randomly received either intravenous lidocaine as a bolus of 1.5 mg/kg before sedation, followed by continuous infusion at a rate of 2 mg/kg/h during sedation (lidocaine group; n = 33) or the same bolus and infusion volumes of normal saline (control group; n = 33). Sedation was achieved with propofol and fentanyl. The primary outcome was fentanyl requirement during ESD. We recorded hemodynamics and any events during ESD and evaluated post-ESD epigastric and throat pain. Fentanyl requirement during ESD reduced by 24% in the lidocaine group compared with the control group (105 +/- 28 vs. 138 +/- 37 mu g, mean +/- SD; P<0.001). The lidocaine group reached sedation faster [40 (20-100) vs. 55 (30-120) s, median (range); P = 0.001], and incidence of patient movement during ESD decreased in the lidocaine group (3% vs. 26%, P = 0.026). Numerical rating scale for epigastric pain was significantly lower at 6 hours after ESD [2 (0-6) vs. 3 (0-8), median (range); P = 0.023] and incidence of throat pain was significantly lower in the lidocaine group (27% vs. 65%, P = 0.003). No adverse events associated with lidocaine were discovered. Administration of intravenous lidocaine reduced fentanyl requirement and decreased patient movement during ESD. Moreover, it alleviated epigastric and throat pain after ESD. Thus, we conclude that the use of intravenous adjuvant lidocaine is a new and safe sedative method during ESD.	[Kim, Ji Eun; Choi, Jong Bum; Jeong, Hae Won; Lee, Byung Ho] Ajou Univ, Sch Med, Dept Anesthesiol & Pain Med, Suwon 441749, South Korea; [Koo, Bon-Nyeo; Kim, So Yeon] Yonsei Univ, Coll Med, Severance Hosp, Dept Anesthesiol & Pain Med,Anesthesia & Pain Res, 50-1 Yonsei Ro, Seoul 03722, South Korea	Kim, SY (reprint author), Yonsei Univ, Coll Med, Severance Hosp, Dept Anesthesiol & Pain Med,Anesthesia & Pain Res, 50-1 Yonsei Ro, Seoul 03722, South Korea.	KIMSY326@yuhs.ac		Kim, So Yeon/0000-0001-5352-157X; Koo, Bon-Nyeo/0000-0002-3189-1673			de Oliveira CMB, 2010, REV BRAS ANESTESIOL, V60, P325, DOI 10.1016/S0034-7094(10)70041-6; Choi HS, 2012, DIGEST LIVER DIS, V44, P925, DOI 10.1016/j.dld.2012.06.015; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hans GA, 2010, BRIT J ANAESTH, V105, P471, DOI 10.1093/bja/aeq189; Jung DH, 2015, ENDOSCOPY, V47, P1119, DOI 10.1055/s-0034-1392537; Kaba A, 2007, ANESTHESIOLOGY, V106, P11, DOI 10.1097/00000542-200701000-00007; Kang JG, 2012, J CLIN ANESTH, V24, P465, DOI 10.1016/j.jclinane.2012.02.006; Kim B, 2015, SURG ENDOSC, V29, P714, DOI 10.1007/s00464-014-3730-4; Kim JE, 2015, SURG ENDOSC, V29, P3795, DOI 10.1007/s00464-015-4514-1; Kiriyama S, 2009, GASTRIC CANCER, V12, P142, DOI 10.1007/s10120-009-0514-y; Kranke P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009642.pub2; Kuo CP, 2006, BRIT J ANAESTH, V97, P640, DOI 10.1093/bja/ael217; Lauretti Gabriela Rocha, 2008, Rev. Bras. Anestesiol., V58, P280, DOI 10.1590/S0034-70942008000300011; Lee HW, 2014, SURG ENDOSC, V28, P2334, DOI 10.1007/s00464-014-3463-4; Lee H, 2012, GASTRIC CANCER, V15, P83, DOI 10.1007/s10120-011-0073-x; Lian JJ, 2012, GASTROINTEST ENDOSC, V76, P763, DOI 10.1016/j.gie.2012.06.014; McCarthy GC, 2010, DRUGS, V70, P1149, DOI 10.2165/10898560-000000000-00000; Muller M, 2011, NAT REV GASTRO HEPAT, V8, P481, DOI 10.1038/nrgastro.2011.122; Na SW, 2009, ANESTHESIOLOGY, V110, P38, DOI 10.1097/ALN.0b013e318190b56e; Park CH, 2013, SURG ENDOSC, V27, P2760, DOI 10.1007/s00464-013-2804-z; Peixoto RD, 2015, J PALLIAT MED, V18, P373, DOI 10.1089/jpm.2014.0279; Saadawy IM, 2010, ACTA ANAESTH SCAND, V54, P549, DOI 10.1111/j.1399-6576.2009.02165.x; Shin S, 2014, SURG ENDOSC, V28, P100, DOI 10.1007/s00464-013-3133-y; Tanaka Y, 2015, COCHRANE DB SYST REV, V7; TANELIAN DL, 1991, ANESTHESIOLOGY, V74, P934, DOI 10.1097/00000542-199105000-00020; Tremont-Lukats IW, 2005, ANESTH ANALG, V101, P1738, DOI 10.1213/01.ANE.0000186348.86792.38; Vigneault L, 2011, CAN J ANESTH, V58, P22, DOI 10.1007/s12630-010-9407-0; Yoo YC, 2015, BRIT J ANAESTH, V115, P84, DOI 10.1093/bja/aeu555	29	4	4	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	MAY	2016	95	18							e3593	10.1097/MD.0000000000003593			7	Medicine, General & Internal	General & Internal Medicine	DN2XJ	WOS:000376926000054	27149489	DOAJ Gold, Green Published			2020-06-30	J	Kim, SY; Kim, NK; Baik, SH; Min, BS; Hur, H; Lee, J; Noh, HY; Lee, JH; Koo, BN				Kim, So Yeon; Kim, Nam Kyu; Baik, Seung Hyuk; Min, Byung Soh; Hur, Hyuk; Lee, Jinae; Noh, Hyun-young; Lee, Jong Ho; Koo, Bon-Neyo			Effects of Postoperative Pain Management on Immune Function After Laparoscopic Resection of Colorectal Cancer: A Randomized Study	MEDICINE			English	Article							KILLER-CELL ACTIVITY; PATIENT-CONTROLLED ANALGESIA; RETROSPECTIVE ANALYSIS; ANESTHETIC TECHNIQUE; EPIDURAL ANALGESIA; TUMOR-METASTASIS; CLINICAL-TRIAL; COLON-CANCER; SURGERY; RECURRENCE	There has been a rising interest in the possible association between perioperative opioid use and postoperative outcomes in cancer patients. Continuous surgical wound infiltration with local anesthetics is a nonopioid analgesic technique that can be used as a postoperative pain management alternative to opioid-based intravenous patient-controlled analgesia (IV PCA). The aim of this study was to compare the effects of an opioid-based analgesic regimen versus a local anesthetic wound infiltration-based analgesic regimen on immune modulation and short-term cancer recurrence or metastasis in patients undergoing laparoscopic resection of colorectal cancer.Sixty patients undergoing laparoscopic resection of colorectal cancer were randomly assigned to either the opioid group or the ON-Q group. For postoperative analgesia during the first 48hours, the opioid group (n=30) received fentanyl via IV PCA, whereas the ON-Q group (n=30) received continuous wound infiltration of 0.5% ropivacaine with an ON-Q pump and tramadol via IV PCA. Pethidine for the opioid group and ketorolac or propacetamol for the ON-Q group were used as rescue analgesics. Anesthesia was induced and maintained with propofol and remifentanil. The primary outcome was postoperative immune function assessed by natural killer cell cytotoxicity (NKCC) and interleukin-2. Secondary outcomes were postoperative complications, cancer recurrence, or metastasis within 1 year after surgery, and postoperative inflammatory responses measured by white blood cell count, neutrophil percentage, and C-reactive protein. Immune function and inflammatory responses were measured before surgery and 24 and 48hours after surgery.Fifty-nine patients completed the study. In the circumstance of similar pain control efficacy between the opioid group and the ON-Q group, postoperative NKCC and interleukin-2 levels did not differ between the 2 groups. The incidence of postoperative complications and recurrence or metastasis within 1 year after surgery was comparable between the groups. Postoperative inflammatory responses were also similar between the groups.When compared with ropivacaine wound infiltration-based analgesia, fentanyl-based analgesia did not further decrease NKCC or affect short-term cancer recurrence or metastasis. Thus, a fentanyl-based analgesic regimen and a ropivacaine wound infiltration-based analgesic regimen can both be used for postoperative pain management in laparoscopic resection of colorectal cancer.	[Kim, So Yeon; Noh, Hyun-young; Koo, Bon-Neyo] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, Seoul 03722, South Korea; [Kim, Nam Kyu; Baik, Seung Hyuk; Min, Byung Soh; Hur, Hyuk] Yonsei Univ, Coll Med, Dept Surg, Div Colon & Rectal Surg, Seoul 03722, South Korea; [Lee, Jinae] Yonsei Univ, Coll Med, Biostat Collaborat Unit, Seoul 03722, South Korea; [Lee, Jong Ho] Yonsei Univ, Res Ctr Silver Sci,Brain Korea PLUS Project 21, Inst Symbiot Life TECH,Dept Food & Nutr,Coll Huma, Natl Leading Res Lab Clin Nutrigenet Nutrigenom, 50 Yonsei Ro, Seoul 03722, South Korea	Lee, JH (reprint author), Yonsei Univ, Res Ctr Silver Sci,Brain Korea PLUS Project 21, Inst Symbiot Life TECH,Dept Food & Nutr,Coll Huma, Natl Leading Res Lab Clin Nutrigenet Nutrigenom, 50 Yonsei Ro, Seoul 03722, South Korea.; Koo, BN (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Severance Hosp,Anesthesia & Pain Res Inst, 50-1 Yonsei Ro, Seoul 03722, South Korea.	jhleeb@younsei.ac.kr; KOOBN@yuhs.ac	Lee, Jinae/F-3805-2010	Hur, Hyuk/0000-0002-9864-7229; Koo, Bon-Nyeo/0000-0002-3189-1673; Baik, Seung Hyuk/0000-0003-4183-2332; Kim, So Yeon/0000-0001-5352-157X; Kim, Nam-Kyu/0000-0003-0639-5632	"Dongwha Holdings'' Faculty Research Assistance Program of Yonsei University College of Medicine [6-2014-0058]; National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [2014R1A2A2A01007289]; "Cooperative Research Program for Agriculture Science & Technology Development (Project title: Development of functional material for immune enhancement using Weissella cibaria" [PJ010835]; Rural Development Administration, Republic of KoreaRural Development Administration (RDA)	This study was financially supported by the "Dongwha Holdings'' Faculty Research Assistance Program of Yonsei University College of Medicine for 6-2014-0058 to So Yeon Kim, the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2014R1A2A2A01007289) to Bon Neyo Koo, and the "Cooperative Research Program for Agriculture Science & Technology Development (Project title: Development of functional material for immune enhancement using Weissella cibaria, Project No: PJ010835)'', Rural Development Administration, Republic of Korea to Jong Ho Lee.	Al-Hashimi M, 2013, BRIT J ANAESTH, V111, P80, DOI 10.1093/bja/aet153; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Bhat R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-367; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55; Cronin AJ, 2003, BRIT J ANAESTH, V91, P805, DOI 10.1093/bja/aeg273; Cummings KC, 2012, ANESTHESIOLOGY, V116, P797, DOI 10.1097/ALN.0b013e31824674f6; Day A, 2012, BRIT J ANAESTH, V109, P185, DOI 10.1093/bja/aes106; Evans C, 2006, ALIMENT PHARM THER, V24, P1163, DOI 10.1111/j.1365-2036.2006.03075.x; Forget P, 2010, EUR J ANAESTH, V27, P233, DOI 10.1097/EJA.0b013e32832d540e; Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0; Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Grocott MPW, 2007, J CLIN EPIDEMIOL, V60, P919, DOI 10.1016/j.jclinepi.2006.12.003; Gupta A, 2011, BRIT J ANAESTH, V107, P164, DOI 10.1093/bja/aer100; Heaney A, 2012, BRIT J ANAESTH, V109, pI17, DOI 10.1093/bja/aes421; Hubner M, 2015, ANN SURG, V261, P648, DOI 10.1097/SLA.0000000000000838; Jones OM, 2011, BMJ-BRIT MED J, V28, P343; Kwak JH, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-53; Lacy AM, 2002, LANCET, V359, P2224, DOI 10.1016/S0140-6736(02)09290-5; Lassen K, 2009, ARCH SURG-CHICAGO, V144, P961, DOI 10.1001/archsurg.2009.170; Levy BF, 2011, BRIT J SURG, V98, P1068, DOI 10.1002/bjs.7545; Levy BF, 2010, COLORECTAL DIS, V12, P5, DOI 10.1111/j.1463-1318.2009.01799.x; Lucchinetti E, 2012, ANESTHESIOLOGY, V116, P841, DOI 10.1097/ALN.0b013e31824babfe; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; Pries R, 2008, INT J ONCOL, V33, P993, DOI 10.3892/ijo_00000087; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Ventham NT, 2014, DIS COLON RECTUM, V57, P237, DOI 10.1097/DCR.0000000000000006; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Werdehausen R, 2012, EUR J ANAESTH, V29, P35, DOI 10.1097/EJA.0b013e32834cd6c4; Wichmann MW, 2005, ARCH SURG-CHICAGO, V140, P692, DOI 10.1001/archsurg.140.7.692; Yeager MP, 2002, ANESTH ANALG, V94, P94, DOI 10.1097/00000539-200201000-00018; Zamai L, 2007, J IMMUNOL, V178, P4011, DOI 10.4049/jimmunol.178.7.4011	35	8	14	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	MAY	2016	95	19							e3602	10.1097/MD.0000000000003602			8	Medicine, General & Internal	General & Internal Medicine	DN2XT	WOS:000376927000043	27175664	DOAJ Gold, Green Published			2020-06-30	J	Wang, XQ; Liu, WJ; Xu, Z; Wang, FM; Zhang, CF; Wang, BS; Wang, KG; Yu, JG				Wang, Xiuqin; Liu, Wenjuan; Xu, Zan; Wang, Fumei; Zhang, Chuanfeng; Wang, Baosheng; Wang, Kaiguo; Yu, Jingui			Effect of Dexmedetomidine Alone for Intravenous Patient-Controlled Analgesia After Gynecological Laparoscopic Surgery: A Consort-Prospective, Randomized, Controlled Trial	MEDICINE			English	Article							PAIN-MANAGEMENT; POSTOPERATIVE ANALGESIA; COLORECTAL SURGERY; EFFICACY; HUMANS; BLOCK	Gynecological laparoscopic surgery is minimally invasive compared with open surgical approaches, but postoperative pain is generally undermanaged. Pain management strategies related to the procedure-specific efficacy are needed. Many studies have shown that dexmedetomidine (DEX) has opioid-sparing properties. It is not clear whether DEX used alone for intravenous patient-controlled analgesia (PCA) could reduce postoperative pain after an invasive procedure. We hypothesized that DEX alone would reduce postoperative pain in women patients undergoing an elective gynecological laparoscopic procedure.This CONSORT-prospective randomized controlled clinical study aimed to investigate the effects of DEX alone for intravenous PCA after gynecological laparoscopic operation. Forty women patients scheduled for elective gynecological laparoscopy were enrolled into the study at Shandong Cancer Hospital and Institute and randomly allocated into two groups (n=20 each). In the DEX group (group D), the intravenous PCA protocol was DEX 0.25g/kg/h diluted to 100mL in 0.9% saline. In the fentanyl group (group F), the PCA protocol was fentanyl 20g/kg diluted to 100mL in 0.9% saline. The primary outcome was the mean pain score on a visual analogue scale (VAS) at 6hours after the operation. The secondary outcomes included the Ramsay sedation score, the incidence of postoperative nausea and vomiting (PONV), satisfaction with pain control, and time to recovery of gastrointestinal function.There were no significant differences in the patients' characteristics and intraoperative measurements (P>0.05). No patients received rescue analgesic. The mean VAS scores at 6hours post-operatively were not significantly different between the groups (P>0.05). The incidence of PONV was less in group D than in group F (P<0.05). The Ramsay sedation scores were not significantly between the groups (P>0.05). Satisfaction with pain control was higher and time to recovery of gastrointestinal function was lower in group D (P<0.05).DEX alone is effective for intravenous patient-controlled analgesia after gynecological laparoscopic surgery without a change in sedation and with fewer side effects, and this effect was associated with better satisfaction with postoperative pain control and earlier recovery of gastrointestinal function.	[Wang, Xiuqin; Yu, Jingui] Shandong Univ, Qilu Hosp, Dept Anesthesiol, 107 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Wang, Xiuqin; Xu, Zan; Wang, Fumei; Zhang, Chuanfeng; Wang, Baosheng; Wang, Kaiguo] Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Anesthesiol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China; [Liu, Wenjuan] Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Shandong Prov Key Lab Radiat Oncol, Jinan 250117, Shandong, Peoples R China	Yu, JG (reprint author), Shandong Univ, Qilu Hosp, Dept Anesthesiol, 107 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Wang, KG (reprint author), Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Anesthesiol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China.	982318162@qq.com			Shandong Medicine and Health Science Technology Development Foundation of China [2015WS0153]; Shandong Academy of Medical Sciences Foundation of China [2015-37]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81570241]	This work was supported by funding from Shandong Medicine and Health Science Technology Development Foundation of China (2015WS0153), and Shandong Academy of Medical Sciences Foundation of China (2015-37). It was also supported by grants from the National Natural Science Foundation of China (Grant no. 81570241).	Afonso J, 2012, REV BRAS ANESTESIOL, V62, P118, DOI 10.1016/S0034-7094(12)70110-1; Baba Y, 2012, EUR J PAIN, V16, P1137, DOI 10.1002/j.1532-2149.2012.00129.x; Berger NG, 2015, CLIN EXP GASTROENTER, V8, P231, DOI 10.2147/CEG.S64029; Chan AKM, 2010, EXPERT OPIN PHARMACO, V11, P2849, DOI 10.1517/14656566.2010.511613; Cheung CW, 2014, ANAESTHESIA, V6, P1; Choi YY, 2015, ANN SURG TREAT RES, V88, P86, DOI 10.4174/astr.2015.88.2.86; Collins SA, 2014, FEMALE PELVIC MED RE, V20, P310, DOI 10.1097/SPV.0000000000000134; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Elvir-Lazo Ofelia Loani, 2010, Anesthesiol Clin, V28, P217, DOI 10.1016/j.anclin.2010.02.011; Evans CJ, 2004, PAIN, V112, P254, DOI 10.1016/j.pain.2004.09.005; Evenson M, 2012, OBSTET GYNECOL, V119, P780, DOI 10.1097/AOG.0b013e31824bb15e; Favuzza J, 2013, DIS COLON RECTUM, V56, P389, DOI 10.1097/DCR.0b013e318280549b; Feld JM, 2006, J CLIN ANESTH, V18, P24, DOI 10.1016/j.jclinane.2005.05.009; Frolich MA, 2013, ANESTHESIOLOGY, V118, P611, DOI 10.1097/ALN.0b013e318281592d; Ge DJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001514; Grosu Irina, 2010, F1000 Med Rep, V2, P90, DOI 10.3410/M2-90; Holzer A, 2006, ANESTH ANALG, V102, P1480, DOI 10.1213/01.ane.0000204321.85599.0d; Hwang W, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0004-1; Joshi GP, 2013, ANESTHESIOLOGY, V118, P780, DOI 10.1097/ALN.0b013e31828866e1; Kim JY, 2013, KOREAN J ANESTHESIOL, V65, P544, DOI 10.4097/kjae.2013.65.6.544; Li M, 2012, ACTA ANAESTH SCAND, V56, P368, DOI 10.1111/j.1399-6576.2011.02603.x; Liang X, 2015, INT J CLIN EXP MED, V8, P12113; Liu SS, 2007, ANESTH ANALG, V104, P689, DOI 10.1213/01.ane.0000255040.71600.41; Nezhat CR, 2012, J MINIM INVAS GYN, V19, P238, DOI 10.1016/j.jmig.2011.12.026; Nie YY, 2014, EUR J ANAESTH, V31, P197, DOI 10.1097/EJA.0000000000000011; Niraj G, 2014, ANAESTHESIA, V69, P348, DOI 10.1111/anae.12546; Owesson CA, 2003, EUR J NEUROSCI, V18, P34, DOI 10.1046/j.1460-9568.2003.02724.x; Ramsay MAE, 2004, ANESTHESIOLOGY, V101, P787; Ren CG, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001348; Segerdahl M, 2008, ACTA ANAESTH SCAND, V52, P117, DOI 10.1111/j.1399-6576.2007.01472.x; Tsai Hsiao-Wen, 2011, Arch Surg, V146, P1360, DOI 10.1001/archsurg.2011.597; Zhang HF, 2012, INT J MED SCI, V9, P757, DOI 10.7150/ijms.4916	32	10	14	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	MAY	2016	95	19							e3639	10.1097/MD.0000000000003639			7	Medicine, General & Internal	General & Internal Medicine	DN2XT	WOS:000376927000059	27175680	DOAJ Gold, Green Published			2020-06-30	J	Karkera, MM; Harrison, DR; Aunspaugh, JP; Martin, TW				Karkera, Megha M.; Harrison, Dale R.; Aunspaugh, Jennifer P.; Martin, Timothy W.			Assessing Caudal Block Concentrations of Bupivacaine With and Without the Addition of Intravenous Fentanyl on Postoperative Outcomes in Pediatric Patients: A Retrospective Review	AMERICAN JOURNAL OF THERAPEUTICS			English	Article						caudal blocks; regional anesthesia; urologic procedures; pain management; pediatric	CHILDREN; CLONIDINE; ROPIVACAINE	Caudal blocks are a significant and efficacious aspect of pediatric anesthesia, especially in urologic and many general surgery cases. This type of regional anesthesia is common because it has a high success rate and provides between 6 and 8 hours of postoperative pain control. The aim of this study was to determine whether the concentration of bupivacaine or the addition of intravascular (i.v.) fentanyl affected the postanesthesia care unit (PACU) discharge time. A retrospective cohort study comparing the outcomes in pediatric patients who have received varying caudal concentrations with and without the addition of i.v. fentanyl was performed. A total of 849 consecutive patients undergoing hypospadias repairs or circumcisions were reviewed and placed in one of the following 3 groups: 0.125% bupivacaine (group 1), 0.25% bupivacaine (group 2), or one of these concentrations of bupivacaine + i.v. fentanyl intraoperatively (group 3). Total PACU time for each group was 46.1 minutes (group 1), 48.9 minutes (group 2), and 49.7 minutes (group 3). Our results revealed that there is no statistically significant difference between concentrations of bupivacaine administered in a caudal block with or without i.v. fentanyl with regard to the outcome of PACU duration (P = 0.16). Overall, based on the retrospective cohort design, there is no difference in primary and secondary outcomes based on the concentration of bupivacaine, when administered at a volume of 1 mL/kg.	[Karkera, Megha M.; Aunspaugh, Jennifer P.; Martin, Timothy W.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Div Pediat Anesthesiol, Little Rock, AR 72205 USA	Karkera, MM (reprint author), Arkansas Childrens Hosp, Div Pediat Anesthesiol, 1 Childrens Way,Slot 203, Little Rock, AR 72202 USA.	mmkarkera@uams.edu			Division of Pediatric Anesthesiology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital; Division of Pediatric Anesthesia	Supported by the Division of Pediatric Anesthesiology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital. This research was funded internally by the Division of Pediatric Anesthesia.	Barash PG, 2009, HDB CLIN ANESTHESIA, P839; Brenner L, 2011, BRIT J ANAESTH, V107, P229, DOI 10.1093/bja/aer128; de Beer DAH, 2003, BRIT J ANAESTH, V90, P487, DOI 10.1093/bja/aeg064; De Negri P, 2001, ANESTH ANALG, V93, P71; El-Hennawy AM, 2009, BRIT J ANAESTH, V103, P268, DOI 10.1093/bja/aep159; Invani G, 1998, BRIT J ANAESTH, P247; Ivani G, 2003, ANESTH ANALG, V97, P368, DOI 10.1213/01.ANE.0000068881.01031.09; Joshi W, 2004, PEDIATR ANESTH, V14, P483, DOI 10.1111/j.1460-9592.2004.01229.x; Khalil S, 1999, ANESTHESIOLOGY, V91, P1279, DOI 10.1097/00000542-199911000-00018; Klimscha W, 1998, ANESTH ANALG, V86, P54; Odes R, 2010, AGRI, V22, P53	11	0	0	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1075-2765	1536-3686		AM J THER	Am. J. Ther.	MAY-JUN	2016	23	3					e792	e798		10.1097/MJT.0000000000000076			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DM8KM	WOS:000376611500020	24832387				2020-06-30	J	Meijler, WJ				Meijler, Willem J.			The Influence of Low Salivary Flow Rates on Sublingual Fentanyl Absorption for Breakthrough Cancer Pain Reply	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter											w.j.meijler@planet.nl					Davies A, 2016, J PAIN SYMPTOM MANAG, V51, P538, DOI 10.1016/j.jpainsymman.2015.11.018	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAY	2016	51	5					E8	E8		10.1016/j.jpainsymman.2016.02.005			1	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	DM7CJ	WOS:000376510700004	27033157	Bronze			2020-06-30	J	Sahin, AS; Gulleroglu, A; Toker, MK; Karabay, AG; Adiyeke, O; Demiraran, Y				Sahin, Ayca S.; Gulleroglu, Aykan; Toker, Melike K.; Karabay, Ayse G.; Adiyeke, Ozal; Demiraran, Yavuz			Comparison of paracetamol and fentanyl for pain relief during and after suction termination	SAUDI MEDICAL JOURNAL			English	Article							INTRAVENOUS PARACETAMOL; ACETAMINOPHEN; MORPHINE; MANAGEMENT; CURETTAGE; EFFICACY; SURGERY	Objectives: To compare the combination of paracetamol (20 mg/kg) and propofol to fentanyl (1 mu g/kg) and propofol in terms of providing adequate analgesia and a comparable recovery profile in suction termination procedures. Methods: This is a prospective, randomized clinical study in which we obtained informed consents from 146 women (fentanyl group: 76 [52.1%], paracetamol group: 70 [47.9%]) who were scheduled for suction curettage at the Istanbul Kanuni Sultan Suleyman Education and Training Hospital, Istanbul, Turkey in January 2015. Patients were randomly allocated into a fentanyl group or a paracetamol group. Visual analogue scores, modified Aldrete scores, and hemodynamic parameters were recorded during and after the surgical procedure. A record was also maintained of any adverse events. Results: When the modified Aldrete scores at 60 minutes, systolic pressures at 0 minutes, oxygen saturation at 10, 15, 20 minutes, diastolic blood pressure at 10, 15, 20 minutes, heart rates, and visual analogue scores were compared, there was no significant difference between groups (p> 0.05). In the fentanyl group, systolic blood pressures at 5, 10, 15, 20 minutes and diastolic blood pressure at 5 minutes and oxygen saturation at 5 minutes were significantly lower (p< 0.05). Conclusion: Our study demonstrates that the analgesic properties and recovery profiles of intravenous paracetamol is as effective as fentanyl when used in suction termination procedures. Further larger studies are still required.	[Sahin, Ayca S.; Gulleroglu, Aykan; Toker, Melike K.; Karabay, Ayse G.; Adiyeke, Ozal; Demiraran, Yavuz] Istanbul Kanuni Sultan Suleyman Educ & Res Hosp, Dept Anesthesiol & Reanimat, Istanbul, Turkey	Sahin, AS (reprint author), Istanbul Kanuni Sultan Suleyman Educ & Res Hosp, Dept Anesthesiol & Reanimat, Istanbul, Turkey.	aycasultan@gmail.com	Sahin, Ayca Sultan/B-3345-2015; Toker, Melike/AAF-5969-2020; toker, melike/AAG-4329-2020				ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Alhashemi JA, 2006, CAN J ANAESTH, V53, P1200, DOI 10.1007/BF03021581; Ali Muhammad Asghar, 2015, J Anaesthesiol Clin Pharmacol, V31, P54, DOI 10.4103/0970-9185.150542; Arici S, 2009, AGRI, V21, P54; Blough ER, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00072; Craig M, 2012, EMERG MED J, V29, P37, DOI 10.1136/emj.2010.104687; Daabiss M, 2011, INDIAN J ANAESTH, V55, P111, DOI 10.4103/0019-5049.79879; Khan ZU, 2007, PAK J MED SCI, V23, P851; Kouchek M, 2013, IRAN J PHARM RES, V12, P193; Kucuk M, 2012, GYNECOL ENDOCRINOL, V28, P736, DOI 10.3109/09513590.2011.652248; Rattanachaiyanont M, 2005, OBSTET GYNECOL, V106, P533, DOI 10.1097/01.AOG.0000172424.09992.3e; Sinatra RS, 2005, ANESTHESIOLOGY, V102, P822, DOI 10.1097/00000542-200504000-00019; Tangsiriwatthana T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005056.pub2; Trolice MP, 2000, OBSTET GYNECOL, V95, P345, DOI 10.1016/S0029-7844(99)00557-8	14	1	1	0	2	SAUDI MED J	RIYADH	ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA	0379-5284			SAUDI MED J	Saudi Med. J.	MAY	2016	37	5					527	532		10.15537/smj.2016.5.15083			6	Medicine, General & Internal	General & Internal Medicine	DM8JI	WOS:000376607900007	27146615	DOAJ Gold, Green Published			2020-06-30	J	Goyal, R; Hasnain, S; Mittal, S; Shreevastava, S				Goyal, Rakhee; Hasnain, Shahbaz; Mittal, Saloni; Shreevastava, Sharad			A randomized, controlled trial to compare the efficacy and safety profile of a dexmedetomidine-ketamine combination with a propofol-fentanyl combination for ERCP	GASTROINTESTINAL ENDOSCOPY			English	Article							ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; SEDATION-RELATED COMPLICATIONS; CONSCIOUS SEDATION; GASTROINTESTINAL ENDOSCOPY; ANESTHESIA; GASTROENTEROLOGY	Background and Aims: Moderate to deep levels of sedation and analgesia are required for ERCP. Propofol-based sedation is simple, easy to use, and effective, but is not without cardiovascular and respiratory adverse effects. The combination of dexmedetomidine and ketamine (DK) has shown promising results for sedation in other similar scenarios. The aim of this study was to compare the efficacy and safety of a standard propofol-fentanyl (PF) regimen with a DK combination. Methods: After approval of the hospital ethics committee, 83 patients (18-75 years of age) were randomized and divided into 2 groups. Forty-two patients received a PF combination (group PF) and 41 patients received DK combination (group DK) for total intravenous anesthesia for ERCP as initial boluses followed by an infusion of PF and DK, respectively. The sedation-related adverse effects and recovery time were noted. Results: The mean values of the hemodynamic and respiratory parameters were in clinically acceptable ranges, but there were more episodes of hypotension (19%), bradycardia (4.7%), and decrease in oxygen saturation (SpO(2) < 80% in 11.9% and SpO(2) < 90% for > 10 s in 42.8%) in group PF. The procedure could be completed in all of the patients but was interrupted in 6 patients in group PF because of desaturation (5) or sudden patient movement (1). The recovery time was longer in group DK than in group PF. Conclusion: There were significantly fewer sedation-related adverse effects, but the recovery time was longer with DK.	[Goyal, Rakhee; Hasnain, Shahbaz; Mittal, Saloni] Pune & Command Hosp SC, Armed Forces Med Coll, Dept Anesthesia & Crit Care, Pune, Maharashtra, India; [Shreevastava, Sharad] Pune & Command Hosp SC, Armed Forces Med Coll, Dept Gastroenterol, Pune, Maharashtra, India	Goyal, R (reprint author), CHSC, Dept Anesthesia & Crit Care, Pune 411040, Maharashtra, India.						ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Amornyotin S, 2011, MED DEVICES-EVID RES, V4, P43, DOI 10.2147/MDER.S17236; Berzin TM, 2011, GASTROINTEST ENDOSC, V73, P710, DOI 10.1016/j.gie.2010.12.011; Cote GA, 2010, CLIN GASTROENTEROL H, V8, P137, DOI 10.1016/j.cgh.2009.07.008; Dawes J, 2014, PEDIATR ANESTH, V24, P1260, DOI 10.1111/pan.12468; Dumonceau JM, 2010, ENDOSCOPY, V42, P960, DOI 10.1055/s-0030-1255728; Fabbri LP, 2012, MED SCI MONITOR, V18, pCR575, DOI 10.12659/MSM.883354; Garewal D, 2013, CURR OPIN ANESTHESIO, V26, P475, DOI 10.1097/ACO.0b013e3283620139; Goyal R, 2013, J ANESTH, V27, P461, DOI 10.1007/s00540-012-1538-8; Jalowiecki P, 2005, ANESTHESIOLOGY, V103, P269, DOI 10.1097/00000542-200508000-00009; Jang SY, 2012, WORLD J GASTROENTERO, V18, P6284, DOI 10.3748/wjg.v18.i43.6284; Laurie T, 2005, GASTROINTEST ENDOSC, V61, pAB118, DOI 10.1016/S0016-5107(05)00724-8; LEVANEN J, 1995, ANESTHESIOLOGY, V82, P1117, DOI 10.1097/00000542-199505000-00005; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Lordan JT, 2011, HPB, V13, P174, DOI 10.1111/j.1477-2574.2010.00266.x; Mukhopadhyay Sandip, 2015, J Anaesthesiol Clin Pharmacol, V31, P201, DOI 10.4103/0970-9185.155149; Qadeer MA, 2009, GASTROENTEROLOGY, V136, P1568, DOI 10.1053/j.gastro.2009.02.004; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Raymondos K, 2002, ENDOSCOPY, V34, P721, DOI 10.1055/s-2002-33567; The Joint Royal Colleges of Anaesthetists (RCoA) and British Society of Gastroenterology (BSG) Working Party, 2011, GUID US PROP SED AD; Tobias JD, 2012, PEDIATR CRIT CARE ME, V13, P423, DOI 10.1097/PCC.0b013e318238b81c; von Delius S, 2012, ENDOSCOPY, V44, P258, DOI 10.1055/s-0031-1291485; Wani S, 2011, GASTROINTEST ENDOSC, V74, P1238, DOI 10.1016/j.gie.2011.09.006	23	5	7	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	MAY	2016	83	5					928	933		10.1016/j.gie.2015.08.077			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	DJ8CY	WOS:000374441300011	26364968				2020-06-30	J	Foley, EM; Wolfe, RE; Burstein, JL; Edlow, JA; Grossman, SA				Foley, Elizabeth M.; Wolfe, Richard E.; Burstein, Jonathan L.; Edlow, Jonathan A.; Grossman, Shamai A.			UTILITY OF PROCEDURAL SEDATION AS A MARKER FOR QUALITY ASSURANCE IN EMERGENCY MEDICINE	JOURNAL OF EMERGENCY MEDICINE			English	Article						procedural sedation; quality assurance; error; adverse event; conscious sedation	ADVERSE EVENTS; ERROR	Background: The Joint Commission requires health care organizations to monitor and evaluate procedural sedation. However, the utility of mandatory review of procedural sedation in evaluating health care quality is unknown. Objective: To determine whether procedural sedation is a useful marker for evaluating error in the emergency department (ED). Methods: We prospectively collected data for patients presenting to an urban, tertiary care, academic medical center ED between October 2013 and June 2015. We used an automated, electronic tracking system to identify patients who underwent procedural sedation. We randomly assigned cases to physician reviewers. Reviewers used a structured tool to determine the presence of error and adverse events. If a reviewer felt that the case had an error or adverse event, it was referred to a quality assurance (QA) committee, which made a final determination as to whether or not an error or adverse event occurred. Results: There were 166 cases of procedural sedation reviewed. Two errors were identified, for an error rate of 1.2% (95% confidence interval [CI] 0.003-0.043). Both errors occurred during the use of propofol to facilitate upper gastrointestinal endoscopy. Neither error resulted in an adverse event. One adverse event was identified that was unrelated to physician error (0.6%; 95% CI 0.001-0.033). Conclusion: Routine review of procedural sedation performed in the ED offers little advantage over existing QA markers. Directed review of high-risk cases, such as those involving endoscopy or other longer-duration procedures, may be more useful. Future studies focusing quality review on projected high-risk sedation cases may establish more valuable markers for QA review. (C) 2016 Elsevier Inc.	[Foley, Elizabeth M.; Wolfe, Richard E.; Burstein, Jonathan L.; Edlow, Jonathan A.; Grossman, Shamai A.] Harvard Univ, Dept Emergency Med, Sch Med, Beth Israel Deaconess Med Ctr, 1 Deaconess Rd, Boston, MA 02215 USA	Foley, EM (reprint author), Harvard Univ, Dept Emergency Med, Sch Med, Beth Israel Deaconess Med Ctr, 1 Deaconess Rd, Boston, MA 02215 USA.		Edlow, Jonathan A/F-7128-2016				Handler JA, 2000, ACAD EMERG MED, V7, P1183, DOI 10.1111/j.1553-2712.2000.tb00462.x; Klasco RS, 2015, AM J EMERG MED, V33, P1786, DOI 10.1016/j.ajem.2015.08.042; Kohn L., 2000, ERR IS HUMAN BUILDIN; Rothschild JM, 2005, CRIT CARE MED, V33, P1694, DOI 10.1097/01.CCM.0000171609.91035.BD; The Joint Commission, 1999, COMPR ACCR MAN HOSP, P73	5	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	MAY	2016	50	5					711	714		10.1016/j.jemermed.2016.02.007			4	Emergency Medicine	Emergency Medicine	DL2JS	WOS:000375461500010	26979347				2020-06-30	J	Lovas, K; Hadnagy, L; Jobban, E; Kullmann, T				Lovas Kornelia; Hadnagy Laszlo; Jobban Eszter; Kullmann Tamas			Analysis of the accessibility of short acting oral opioids in Hungary	ORVOSI HETILAP			Hungarian	Article						cancer pain; analgesia; morphine		Short acting oral formulas make part of optimal opioid analgesia. The use of short acting oral morphine has not widely spread in Hungary, and these drugs completely lacked from the market for three years. Since December 2015 short acting morphine-sulphate has again been commercialised. The causes of the market failure are analysed in this article. The aim of the retrospective analysis is to help the accessibility of the medicine to every patient in need. Prescription morphine use depends on the harmonised cooperation of a number of actors. Besides regulating and financing authorities and professional organisations, patients and the opinion forming media are also responsible for building up the right routine.	[Lovas Kornelia] Man O Bt, Budakeszi, Hungary; [Hadnagy Laszlo] Marosvasarhelyi Megyei Surgossegi Klin Korhaz, Radiol Osztaly, Marosvasarhely, Hungary; [Jobban Eszter] Misszio Egeszsegugyi Kozpont, Veresegyhaz, Hungary; [Kullmann Tamas] Petz Aladar Megyei Oktato Korhaz, Onkoradiol Osztaly, Gyor, Hungary	Kullmann, T (reprint author), Vasvari Pal U 2-4, H-9024 Gyor, Hungary.	kullmanndoki@hotmail.com					Biro E., 2012, KHARON THANATOLOGIAI, V16, P33; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Denisco RA, 2008, EXP CLIN PSYCHOPHARM, V16, P417, DOI 10.1037/a0013636; Embey-Isztin D., 2009, MANAGEMENT OF PAIN; Hungarian Hospice-Palliative Society in agreement with Professional Nursing Board and Professional Nutritional Board, 2002, EU KOZLONY, V52, P1458; Markus A., 2011, LEGE ARTIS MED, V21, P306; Radbruch L, 2014, ACCESS OPIOID MEDICA; Tamas K, 2015, ORVOSI HETILAP, V156, P1003, DOI 10.1556/650.2015.30171	8	0	0	0	1	AKADEMIAI KIADO ZRT	BUDAPEST	BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY	0030-6002	1788-6120		ORVOSI HETILAP	Orvosi Hetilap	MAY	2016	157	18					695	699		10.1556/650.2016.30411			5	Medicine, General & Internal	General & Internal Medicine	DK0YC	WOS:000374637600002	27106724	Green Accepted			2020-06-30	J	Kelly, HE; Shaw, GM; Brett, CN; Greenwood, FM; Huckabee, ML				Kelly, H. E.; Shaw, G. M.; Brett, C. N.; Greenwood, F. M.; Huckabee, M. L.			The effect of titrated fentanyl on suppressed cough reflex in healthy adult volunteers	ANAESTHESIA			English	Article						anaesthesia; cough reflex; opioids: fentanyl; pharmacology	ASPIRATION; PNEUMONIA; RISK; STROKE; PAIN	Cough suppression is part of the pharmacodynamic profile of opioids. We investigated the impact of clinical doses of fentanyl on suppressing the cough reflex. Thirteen volunteers received 2 g.kg(-1) of fentanyl in a divided administration protocol. Three minutes after each administration and at 10 min intervals during washout, suppressed cough reflex testing with nebulised citric acid was performed and compared with fentanyl effect-site concentration. Mean (SD) citric acid concentration provoking cough increased from 0.5 (0.28) mol.l(-1) at baseline to 1.2 (0.50) mol.l(-1) after 2 g.kg(-1) of fentanyl (p = 0.01). Mean (SD) fentanyl effect-site concentration after the final dose of fentanyl was 1.89 (0.05) ng.ml(-1). A strong positive correlation was found between suppressed cough reflex thresholds and fentanyl effect-site concentrations during both fentanyl administration and washout phases of the study (r(2) = 0.79, p = 0.01). The mean (SD) length of time for return of suppressed cough response was 44.6 (18.8) min. Clinically relevant doses of fentanyl produced cough reflex suppression in healthy volunteers.	[Kelly, H. E.] Univ Canterbury, Dept Commun Disorders, Christchurch 1, New Zealand; [Shaw, G. M.; Brett, C. N.; Greenwood, F. M.] Christchurch Hosp, Christchurch, New Zealand; [Huckabee, M. L.] Univ Canterbury, Rose Ctr Stroke Recovery & Res, Christchurch 1, New Zealand	Kelly, HE (reprint author), Univ Canterbury, Dept Commun Disorders, Christchurch 1, New Zealand.	helanakelly@gmail.com					Addington WR, 1999, STROKE, V30, P1203, DOI 10.1161/01.STR.30.6.1203; Canet J, 2010, ANESTHESIOLOGY, V113, P1338, DOI 10.1097/ALN.0b013e3181fc6e0a; Chung KF, 2002, PULM PHARMACOL THER, V15, P335, DOI 10.1006/pupt.2002.0342; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hammond CAS, 2001, NEUROLOGY, V56, P502, DOI 10.1212/WNL.56.4.502; Kallesen M, 2015, J CRIT CARE, V30, P758, DOI 10.1016/j.jcrc.2015.03.013; Miles A, 2013, PHYSIOL BEHAV, V118, P25, DOI 10.1016/j.physbeh.2013.05.004; Morice AH, 1996, PULM PHARMACOL THER, V9, P281, DOI 10.1006/pulp.1996.0036; Pikus L, 2003, AM J ROENTGENOL, V180, P1613, DOI 10.2214/ajr.180.6.1801613; Savilampi J, 2014, ANESTHESIOLOGY, V121, P52, DOI 10.1097/ALN.0000000000000202; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Shibutani K, 2005, BRIT J ANAESTH, V95, P377, DOI 10.1093/bja/aei195; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; STOELTING RK, 1999, [No title captured]; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; Wren SM, 2010, J AM COLL SURGEONS, V210, P491, DOI 10.1016/j.jamcollsurg.2010.01.009; Zhao SZ, 2004, J PAIN SYMPTOM MANAG, V28, P35, DOI 10.1016/j.jpainsymman.2003.11.001	17	8	8	2	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAY	2016	71	5					529	534		10.1111/anae.13410			6	Anesthesiology	Anesthesiology	DJ6PF	WOS:000374334700010	26919658	Bronze			2020-06-30	J	Naik, BI; Nemergut, EC; Kazemi, A; Fernandez, L; Cederholm, SK; McMurry, TL; Durieux, ME				Naik, Bhiken I.; Nemergut, Edward C.; Kazemi, Ali; Fernandez, Lucas; Cederholm, Sarah K.; McMurry, Timothy L.; Durieux, Marcel E.			The Effect of Dexmedetomidine on Postoperative Opioid Consumption and Pain After Major Spine Surgery	ANESTHESIA AND ANALGESIA			English	Article							PATIENT-CONTROLLED ANALGESIA; INDUCED HYPERALGESIA; MORPHINE; TOLERANCE; INFUSION; KETAMINE; RECOVERY	BACKGROUND: Adult deformity correction spine surgery can be associated with significant perioperative pain because of inflammatory, muscular, neuropathic, and postsurgical pain. alpha-2 Agonists have intrinsic antinociceptive and antihyperalgesic properties that can potentially reduce both postoperative opioid consumption and pain. We hypothesized that intraoperative dexmedetomidine would reduce postoperative opioid consumption and improve pain scores in deformity correction spine surgery. METHODS: Patients undergoing >3 levels of thoracic and/or lumbar spine surgery were enrolled in this prospective randomized double-blind study to receive either dexmedetomidine (1 mu g/kg load followed by a continuous infusion of 0.5 mu g/kg/h) or saline. Both groups received a single dose of 0.2 mg/kg (ideal body weight) of methadone at the start of surgery. Intraoperative fentanyl was administered based on the clinical and hemodynamic signs suggestive of increased nociception. Postoperative analgesia was provided with a hydromorphone patient-controlled analgesia pump. Opioid consumption and pain scores were recorded at 24, 48, and 72 hours after surgery. RESULTS: One hundred forty-two participants were enrolled with 131 completing the study. There was no significant difference in demographics (age, sex, weight, and ASA physical status), percentage of participants with preoperative opioid use, and daily median opioid consumption between the groups. The study was terminated early after interim analysis. Intraoperative opioid use was reduced in the dexmedetomidine arm (placebo versus dexmedetomidine, median [25%-75% interquartile range]: 7 [3-15] vs 3.5 [0-11] mg morphine equivalents, P = 0.04) but not at 24 hours: 49 (30-78) vs 61 (34-77) mg morphine equivalents, P = 0.65, or 48 hours: 41 (28-68) vs 40 (23-64) mg morphine equivalents, P = 0.60, or 72 hours: 29 (15-59) vs 30 (14-46) mg morphine equivalents, P = 0.58. The Wilcoxon-Mann-Whitney odds are 1.11 with 97.06% confidence interval (0.71-1.76) for opioid consumption. No difference in pain score, as measured by the 11-point visual analog scale, was seen at 24 hours (placebo versus dexmedetomidine, median [25%-75% interquartile range]: 7 [5-7] vs 6 [4-7], P = 0.12) and 48 hours (5 [3-7] vs 5 [3-6], P = 0.65). There was an increased incidence of bradycardia (placebo: 37% vs dexmedetomidine: 59% P = 0.02) and phenylephrine use in the dexmedetomidine group (placebo: 59% versus dexmedetomidine: 78%, P = 0.03). CONCLUSIONS: Intraoperative dexmedetomidine does not reduce postoperative opioid consumption or improve pain scores after multilevel deformity correction spine surgery.	[Naik, Bhiken I.; Nemergut, Edward C.; Kazemi, Ali; Fernandez, Lucas; Cederholm, Sarah K.; Durieux, Marcel E.] Univ Virginia, Dept Anesthesiol, Charlottesville, VA 22911 USA; [Naik, Bhiken I.; Nemergut, Edward C.; Durieux, Marcel E.] Univ Virginia, Dept Neurosurg, Charlottesville, VA 22911 USA; [McMurry, Timothy L.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA 22911 USA	Naik, BI (reprint author), Univ Virginia, POB 800710, Charlottesville, VA 22911 USA.	bin4n@virginia.edu	Naik, Bhiken/AAH-3831-2019	Durieux, Marcel/0000-0003-1479-7666			Bakhamees Hassan S., 2007, Middle East Journal of Anesthesiology, V19, P537; Bekker A, 2013, J NEUROSURG ANESTH, V25, P16, DOI 10.1097/ANA.0b013e31826318af; Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Chu LF, 2012, PAIN, V153, P1583, DOI 10.1016/j.pain.2012.02.028; Cui WH, 2009, J NEUROSURG ANESTH, V21, P318, DOI 10.1097/ANA.0b013e3181abbde5; Dexter F, 2013, ANESTH ANALG, V117, P537, DOI 10.1213/ANE.0b013e31829ed28f; Divine G, 2013, ANESTH ANALG, V117, P699, DOI 10.1213/ANE.0b013e31827f53d7; Chaparro LE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004959.pub4; Farag E, 2013, ANESTHESIOLOGY, V119, P932, DOI 10.1097/ALN.0b013e318297d4a5; Fu KMG, 2011, NEUROSURGERY, V69, P1181, DOI 10.1227/NEU.0b013e31822a9aeb; Gottschalk A, 2011, ANESTH ANALG, V112, P218, DOI 10.1213/ANE.0b013e3181d8a095; Grewal Anju, 2011, J Anaesthesiol Clin Pharmacol, V27, P297, DOI 10.4103/0970-9185.83670; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Gunes Y, 2008, NEUROSURG QUART, V18, P178, DOI 10.1097/WNQ.0b013e318182099d; Kimura M, 2012, NEUROSCI LETT, V529, P70, DOI 10.1016/j.neulet.2012.08.008; Koinig H, 1998, ANESTH ANALG, V87, P206, DOI 10.1097/00000539-199807000-00042; Lee HJ, 2014, KOREAN J ANESTHESIOL, V67, P299, DOI 10.4097/kjae.2014.67.5.299; Lee M, 2011, PAIN PHYSICIAN, V14, P145; Loftus RW, 2010, ANESTHESIOLOGY, V113, P639, DOI 10.1097/ALN.0b013e3181e90914; Luginbuhl M, 2003, ANESTH ANALG, V96, P726, DOI 10.1213/01.ANE.0000048086.58161.18; Mirza SK, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-53; Ozkose Z, 2006, TOHOKU J EXP MED, V210, P153, DOI 10.1620/tjem.210.153; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Sharma S, 2012, REGION ANESTH PAIN M, V37, P79, DOI 10.1097/AAP.0b013e3182340869; Tufanogullari B, 2008, ANESTH ANALG, V106, P1741, DOI 10.1213/ane.0b013e318172c47c; Turgut N, 2008, MINERVA ANESTESIOL, V74, P469; van der Tweel I, 2003, J CLIN EPIDEMIOL, V56, P610, DOI 10.1016/S0895-4356(03)00117-3; Yildiz Munise, 2006, Drugs R D, V7, P43, DOI 10.2165/00126839-200607010-00004; Zheng YG, 2012, BRAIN RES BULL, V87, P427, DOI 10.1016/j.brainresbull.2012.01.009	29	19	22	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2016	122	5					1646	1653		10.1213/ANE.0000000000001226			8	Anesthesiology	Anesthesiology	DK1HZ	WOS:000374664400058	27003917				2020-06-30	J	Dzikiti, BT; Ndawana, PS; Zeiler, G; Ferreira, JP; Dzikiti, LN				Dzikiti, Brighton T.; Ndawana, Patience S.; Zeiler, Gareth; Ferreira, Jacques P.; Dzikiti, Loveness N.			Determination of the minimum infusion rate of alfaxalone during its co-administration with fentanyl at three different doses by constant rate infusion intravenously in goats	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						alfaxalone; anaesthesia; fentanyl; goat; minimum infusion rate; total intravenous anaesthesia	ALVEOLAR CONCENTRATION; PROPOFOL; ISOFLURANE; ANESTHESIA; PHARMACOKINETICS; REQUIREMENT; MIDAZOLAM	ObjectiveTo determine the minimum infusion rate (MIR) of alfaxalone required to prevent purposeful movement of the extremities in response to standardized noxious stimulation during its co-administration with fentanyl at three different doses by constant rate infusion (CRI) intravenously (IV) in goats. Study designProspective, blinded, randomized crossover, experimental. AnimalsEight healthy goats; four does and four wethers. MethodsFor induction of anaesthesia, a bolus of fentanyl was administered at 0.005mgkg(-1) (LFent), 0.015mgkg(-1) (MFent) or 0.03mgkg(-1) (HFent) followed by alfaxalone at 2.0mgkg(-1). For maintenance, the goats received alfaxalone at an initial infusion rate of 9.6mgkg(-1)hour(-1) and one of three fentanyl treatments: 0.005mgkg(-1)hour(-1)(LFent), 0.015mgkg(-1)hour(-1) (MFent) or 0.03mgkg(-1) hour(-1) (HFent). The MIR of alfaxalone was determined during fentanyl CRI by testing for responses to stimulation (clamping on a digit with Vulsellum forceps) every 30minutes. Some cardiopulmonary parameters were measured. ResultsThe alfaxalone MIR median (range) was 6.7 (6.7-8.6), 2.9 (1.0-6.7) and 1.0 (1.0-4.8) mgkg(-1)hour(-1) during LFent, MFent and HFent, respectively. Alfaxalone MIR was significantly lower during MFENT and HFENT compared to LFENT. Significantly low oxygen haemoglobin saturation (SaO(2)) and arterial oxygen partial pressure (PaO2), observed 2minutes into anaesthesia after all fentanyl treatments, were the most remarkable adverse cardiopulmonary effects observed. Recovery from anaesthesia was severely affected by high doses of fentanyl with excitatory behavioural signs predominant for up to 2hours post-administration after MFent and HFent. Conclusions and clinical relevanceFentanyl reduces alfaxalone MIR in goats in a dose-dependent manner. Immediate oxygen supplementation after induction of general anaesthesia is recommended to prevent hypoxaemia. Doses of fentanyl equal to or greater than 0.015mgkg(-1)hour(-1) tend to be associated with severe excitatory behaviour and should be avoided when fentanyl is administered to goats.	[Dzikiti, Brighton T.; Ndawana, Patience S.; Zeiler, Gareth; Ferreira, Jacques P.] Univ Pretoria, Dept Compan Anim Clin Studies, P Bag X04, ZA-0110 Pretoria, South Africa; [Ndawana, Patience S.] Univ Zimbabwe, Dept Clin Vet Studies, Harare, Zimbabwe; [Dzikiti, Loveness N.] Univ Pretoria, Sch Hlth Syst & Publ Hlth, ZA-0110 Pretoria, South Africa	Dzikiti, BT (reprint author), Univ Pretoria, Dept Compan Anim Clin Studies, P Bag X04, ZA-0110 Pretoria, South Africa.	brighton.dzikiti@up.ac.za	Zeiler, Gareth/AAJ-7812-2020	Zeiler, Gareth/0000-0001-7653-7726; Dzikiti, Tarisai Brighton/0000-0002-8050-8597	University of Pretoria; National Research Foundation of South AfricaNational Research Foundation - South Africa	The study was jointly funded by the University of Pretoria and the National Research Foundation of South Africa. Mr Peter Tivenga is acknowledged for his assistance in data collection.	Bansal S, 2012, J NEUROSURG ANESTH, V24, P345, DOI 10.1097/ANA.0b013e318262282f; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Carroll GL, 1999, AM J VET RES, V60, P986; Carroll GL, 2007, INT J APPL RES VET M, V5, P77; Covey-Crump GL, 2008, VET ANAESTH ANALG, V35, P463, DOI 10.1111/j.1467-2995.2008.00408.x; Dzikiti TB, 2011, VET REC, V168, DOI 10.1136/vr.d999; Dzikiti TB, 2009, J S AFR VET ASSOC, V80, P10; Dzikiti TB, 2014, J S AFR VET ASSOC, V85, DOI 10.4102/jsava.v85i1.1047; Dzikiti TB, 2013, J S AFR VET ASSOC, V84, DOI 10.4102/jsava.v84i1.499; Ferre PJ, 2006, VET ANAESTH ANALG, V33, P229, DOI 10.1111/j.1467-2995.2005.00264.x; Kumar J, 2005, INDIAN J ANAESTH, V49, P421; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; Meredith James R, 2008, J Emerg Trauma Shock, V1, P88, DOI 10.4103/0974-2700.43189; MOON PF, 1995, ANESTHESIOLOGY, V83, P535, DOI 10.1097/00000542-199509000-00012; Muir W, 2008, VET ANAESTH ANALG, V35, P451, DOI 10.1111/j.1467-2995.2008.00406.x; Ndawana PS, 2015, VET ANAESTH ANALG, V42, P65, DOI 10.1111/vaa.12162; SEAR JW, 1983, ANAESTHESIA, V38, P931, DOI 10.1111/j.1365-2044.1983.tb12021.x; Suarez MA, 2012, VET ANAESTH ANALG, V39, P236, DOI 10.1111/j.1467-2995.2011.00700.x; Taylor PM, 1991, PRACTICE, V13, P31, DOI DOI 10.1136/INPRACT.13.1.31; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; Valverde A, 2005, J VET EMERG CRIT CAR, V15, P295, DOI 10.1111/j.1476-4431.2005.00168.x; Wilson D, 2006, JAVMA-J AM VET MED A, V228, P1042, DOI 10.2460/javma.228.7.1042	22	4	4	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2016	43	3					316	325		10.1111/vaa.12300			10	Veterinary Sciences	Veterinary Sciences	DJ5YV	WOS:000374287700009	26352513				2020-06-30	J	Colton, K; Yang, S; Hu, PF; Chen, HH; Bonds, B; Stansbury, LG; Scalea, TM; Stein, DM				Colton, Katharine; Yang, S.; Hu, P. F.; Chen, H. H.; Bonds, B.; Stansbury, L. G.; Scalea, T. M.; Stein, D. M.			Pharmacologic Treatment Reduces Pressure Times Time Dose and Relative Duration of Intracranial Hypertension	JOURNAL OF INTENSIVE CARE MEDICINE			English	Article						intracranial pressure; traumatic brain injury; hypertonic saline; hyperosmolar therapy	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; HYPERTONIC SALINE; PROPOFOL; FENTANYL; SUFENTANIL; INCREASES; MANNITOL; SEDATION; EDEMA	Introduction: Past work has shown the importance of the pressure times time dose (PTD) of intracranial hypertension (intracranial pressure [ICP] > 19 mm Hg) in predicting outcome after severe traumatic brain injury. We used automated data collection to measure the effect of common medications on the duration and dose of intracranial hypertension. Methods: Patients >17 years old, admitted and requiring ICP monitoring between 2008 and 2010 at a single, large urban tertiary care facility, were retrospectively enrolled. Timing and dose of ICP-directed therapy were recorded from paper and electronic medical records. The ICP data were collected automatically at 6-second intervals and averaged over 5 minutes. The percentage of time of intracranial hypertension (PTI) and PTD (mm Hg h) were calculated. Results: A total of 98 patients with 664 treatment instances were identified. Baseline PTD ranged from 27 (before administration of propofol and fentanyl) to 150 mm Hg h (before mannitol). A small dose of hypertonic saline (HTS; 250 mL 3%) reduced PTD by 38% in the first hour and 37% in the second hour and reduced the time with ICP >19 by 38% and 39% after 1 and 2 hours, respectively. A large dose of HTS reduced PTD by 40% in the first hour and 63% in the second (PTI reduction of 36% and 50%, respectively). An increased dose of propofol or fentanyl infusion failed to decrease PTD but reduced PTI between 14% (propofol alone) and 30% (combined increase in propofol and fentanyl, after 2 hours). Barbiturates failed to decrease PTD but decreased PTI by 30% up to 2 hours after administration. All reductions reported are significantly changed from baseline, P < .05. Conclusion: Baseline PTD values before drug administration reflects varied patient criticality, with much higher values seen before the use of mannitol or barbiturates. Treatment with HTS reduced PTD and PTI burden significantly more than escalation of sedation or pain management, and this effect remained significant at 2 hours after administration.	[Colton, Katharine; Yang, S.; Hu, P. F.; Chen, H. H.; Bonds, B.; Stansbury, L. G.; Scalea, T. M.; Stein, D. M.] Univ Maryland, Sch Med, Shock Trauma Anesthesia Res Organized Res Ctr, Baltimore, MD 21201 USA; [Colton, Katharine; Yang, S.; Hu, P. F.; Chen, H. H.; Bonds, B.; Stansbury, L. G.; Scalea, T. M.; Stein, D. M.] R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA; [Colton, Katharine] Duke Univ, Sch Med, Durham, NC USA	Colton, K (reprint author), Univ Maryland Med Syst, R Adams Cowley Shock Trauma Ctr, 22 South Greene St,T4M14, Baltimore, MD 21201 USA.	krcolton@gmail.com	Yang, Shiming/I-3695-2015	Yang, Shiming/0000-0003-0338-4268; Stein, Deborah/0000-0003-3683-3963	 [FA8650-11-2-6D06];  [FA8650-12-2-6D09];  [FA8650-13-2-6D15]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded in part by the grants FA8650-11-2-6D06, FA8650-12-2-6D09, and FA8650-13-2-6D15.	Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cai JS, 2011, NEUROCHEM RES, V36, P1724, DOI 10.1007/s11064-011-0487-1; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; Ding ZY, 2013, CELL BIOCHEM BIOPHYS, V67, P615, DOI 10.1007/s12013-013-9549-0; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Ghori Kamran A, 2007, Crit Care Resusc, V9, P166; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kawaguchi Masahiko, 2005, J Anesth, V19, P150, DOI 10.1007/s00540-005-0305-5; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Lauer KK, 1997, CAN J ANAESTH, V44, P929, DOI 10.1007/BF03011963; Lee JH, 2013, NEUROCHEM RES, V38, P2276, DOI 10.1007/s11064-013-1136-7; Leone M, 2004, ANESTH ANALG, V99, P1193, DOI 10.1213/01.ANE.0000132546.79769.91; Lu J, 2005, ACT NEUR S, V95, P281; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Rossaint J, 2009, CRIT CARE, V13, DOI 10.1186/cc7795; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; Sorani MD, 2008, J NEUROTRAUM, V25, P291, DOI 10.1089/neu.2007.0411; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; WHITE PF, 1982, ANESTHESIOLOGY, V57, P242, DOI 10.1097/00000542-198209000-00019	23	5	5	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0885-0666	1525-1489		J INTENSIVE CARE MED	J. Intensive Care Med.	MAY	2016	31	4					263	269		10.1177/0885066614555692			7	Critical Care Medicine	General & Internal Medicine	DJ4QT	WOS:000374193100006	25320157				2020-06-30	J	das Neves, JFNP; Araujo, MMPD; Araujo, FD; Ferreira, CM; Duarte, FBN; Pace, FH; Ornellas, LC; Baron, TH; Ferreira, LEVVD				Nunes Pereira das Neves, Jose Francisco; Pereira das Neves Araujo, Mariana Moraes; Araujo, Fernando de Paiva; Ferreira, Clarice Martins; Neves Duarte, Fabiana Baeta; Pace, Fabio Heleno; Ornellas, Laura Cotta; Baron, Todd H.; Vieira de Castro Ferreira, Lincoln Eduardo Villela			Colonoscopy sedation: clinical trial comparing propofol and fentanyl with or without midazolam	REVISTA BRASILEIRA DE ANESTESIOLOGIA			English	Article						Sedation; Colonoscopy; Propofol; Fentanil; Midazolam	MONITORED ANESTHESIA CARE; GASTROINTESTINAL ENDOSCOPY; COMBINATION; MEPERIDINE; CANCER; AGENTS	Colonoscopy is one of the most common procedures. Sedation and analgesia decrease anxiety and discomfort and minimize risks. Therefore, patients prefer to be sedated when undergoing examination, although the best combination of drugs has not been determined. The combination of opioids and benzodiazepines is used to relieve the patient's pain and discomfort. More recently, propofol has assumed a prominent position. This randomized prospective study is unique in medical literature that specifically compared the use of propofol and fentanyl with or without midazolam for colonoscopy sedation performed by anesthesiologists. The aim of this study was to evaluate the side effects of sedation, discharge conditions, quality of sedation, and propofol consumption during colonoscopy, with or without midazolam as preanesthetic. The study involved 140 patients who underwent colonoscopy at the University Hospital of the Federal University of Juiz de Fora. Patients were divided into two groups: Group I received intravenous midazolam as preanesthetic 5 min before sedation, followed by fentanyl and propofol; Group a received intravenous anesthesia with fentanyl and propofol. Patients in Group II had a higher incidence of reaction (motor or verbal) to the colonoscope introduction, bradycardia, hypotension, and increased propofol consumption. Patient satisfaction was higher in Group I. According to the methodology used, the combination of midazolam, fentanyl, and propofol for colonoscopy sedation reduces propofol consumption and provides greater patient satisfaction. (C) 2015 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.	[Nunes Pereira das Neves, Jose Francisco; Araujo, Fernando de Paiva; Ferreira, Clarice Martins; Neves Duarte, Fabiana Baeta; Pace, Fabio Heleno; Ornellas, Laura Cotta; Vieira de Castro Ferreira, Lincoln Eduardo Villela] Univ Fed Juiz De Fora UFJF, Juiz De Fora, MG, Brazil; [Pereira das Neves Araujo, Mariana Moraes] INTO, Rio De Janeiro, RJ, Brazil; [Baron, Todd H.] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA	Ferreira, LEVVD (reprint author), Univ Fed Juiz De Fora UFJF, Juiz De Fora, MG, Brazil.	lincoln.ferreira@ufjf.edu.br					Agostoni M, 2011, GASTROINTEST ENDOSC, V74, P266, DOI 10.1016/j.gie.2011.04.028; Pena REA, 2008, REV ESP ANEST REANIM, V55, P81, DOI 10.1016/S0034-9356(08)70514-0; Ahmadi A, 2009, WORLD J GASTROENTERO, V15, P61, DOI 10.3748/wjg.15.61; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Cappell MS, 2008, GASTROENTEROL CLIN N, V37, P129, DOI 10.1016/j.gtc.2007.12.003; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; de Villiers Willem J S, 2009, Anesthesiol Clin, V27, P57, DOI 10.1016/j.anclin.2008.10.007; Dumonceau JM, 2010, ENDOSCOPY, V42, P960, DOI 10.1055/s-0030-1255728; Edwards JK, 2004, J AM BOARD FAM PRACT, V17, P353, DOI 10.3122/jabfm.17.5.353; Gasparovic S, 2003, ACTA MED AUST, V30, P13, DOI 10.1046/j.1563-2571.2003.02050.x; Goulson Daniel T, 2009, Anesthesiol Clin, V27, P71, DOI 10.1016/j.anclin.2008.10.004; Greilich PE, 2001, ANESTH ANALG, V92, P80; Hartle A, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4024; Hsieh YH, 2009, J CLIN GASTROENTEROL, V43, P753, DOI 10.1097/MCG.0b013e3181862a8c; Jalowiecki P, 2005, ANESTHESIOLOGY, V103, P269, DOI 10.1097/00000542-200508000-00009; Lazaraki G, 2007, SURG ENDOSC, V21, P1631, DOI 10.1007/s00464-007-9215-y; Luginbuhl M, 2009, CURR OPIN ANESTHESIO, V22, P524, DOI 10.1097/ACO.0b013e32832dbb7c; Mandel JE, 2010, GASTROINTEST ENDOSC, V72, P112, DOI 10.1016/j.gie.2010.01.031; Padmanabhan U, 2009, ANESTH ANALG, V109, P1448, DOI 10.1213/ane.0b013e3181a6ad31; Qadeer MA, 2005, CLIN GASTROENTEROL H, V3, P1049, DOI 10.1016/S1542-3565(05)00742-1; Singh H, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006268.pub2; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Vargo JJ, 2007, J CLIN GASTROENTEROL, V41, P591, DOI 10.1097/01.mcg.0000225634.52780.0e	23	7	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	MAY-JUN	2016	66	3					231	236		10.1016/j.bjane.2014.09.014			6	Anesthesiology	Anesthesiology	DO2WC	WOS:000377640700002	27108817	DOAJ Gold, Green Published			2020-06-30	J	Lim, KI; Chiu, YC; Chen, CL; Wang, CH; Huang, CJ; Cheng, KW; Wu, SC; Shih, TH; Yang, SC; Juang, SE; Huang, CE; Jawan, B; Lee, YE				Lim, K. I.; Chiu, Y. C.; Chen, C. L.; Wang, C. H.; Huang, C. J.; Cheng, K. W.; Wu, S. C.; Shih, T. H.; Yang, S. C.; Juang, S. E.; Huang, C. E.; Jawan, B.; Lee, Y. E.			Effects of Pre-Existing Liver Disease on Acute Pain Management Using Patient-Controlled Analgesia Fentanyl With Parecoxib After Major Liver Resection: A Retrospective, Pragmatic Study	TRANSPLANTATION PROCEEDINGS			English	Article; Proceedings Paper	14th Congress of the Asian-Society-of-Transplantation	AUG 23-26, 2015	Singapore, SINGAPORE	Asian Soc Transplantat			HEPATOCELLULAR-CARCINOMA; SURGERY; DONORS; REQUIREMENTS; KETOROLAC; MORPHINE	Background. The aim of this study was to compare the outcomes of pain management with the use of patient-controlled analgesia (PCA) fentanyl with IV parecoxib between patients with healthy liver with patients with diseased liver undergoing major liver resection. Methods. Patients with healthy liver undergoing partial hepatectomy as liver donors for liver transplantation (group 1) and patients with liver cirrhosis (Child's criteria A) undergoing major liver resection for hepatoma (group 2) were identified retrospectively. Both groups routinely received post-operative IV PCA fentanyl and a single dose of parecoxib 40 mg. They were followed up for 3 days or until PCA fentanyl was discontinued post-operatively. Daily Visual Analog Scale, PCA fentanyl usage, rescue attempts, and common drug side effects were collected and analyzed with the use of SPSS version 20. Results. One hundred one patients were included in the study: 54 in group 1, and 47 in group 2. There were no statistical differences between the two groups in terms of the daily and total fentanyl usage, VAS resting, and incidence of itchiness. The rate of rescue analgesia on post-operative day (POD) 1 was lower in group 2, with a value of P = .045. VAS dynamics were better on POD 1 and 2 for group 2, with P = .05 and P = .012, respectively. Conclusions. We found that combining a single dose of IV parecoxib 40 mg with PCA fentanyl is an easy and effective method of acute pain control after major liver resection. We propose the careful usage of post-operative fentanyl and parecoxib in patients with diseased liver, given the difference in effect as compared with healthy liver.	[Lim, K. I.; Chiu, Y. C.; Wang, C. H.; Huang, C. J.; Cheng, K. W.; Wu, S. C.; Shih, T. H.; Yang, S. C.; Juang, S. E.; Huang, C. E.; Jawan, B.; Lee, Y. E.] Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung, Taiwan; [Chen, C. L.] Kaohsiung Chang Gung Mem Hosp, Dept Liver Transplantat Program & Surg, Kaohsiung, Taiwan; Chang Gung Univ, Coll Med, Kaohsiung, Taiwan	Lee, YE (reprint author), Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung, Taiwan.	entheodora@gmail.com					Beebe David, 2011, J Anaesthesiol Clin Pharmacol, V27, P362, DOI 10.4103/0970-9185.83683; Chen JP, 2010, TRANSPL P, V42, P701, DOI 10.1016/j.transproceed.2010.02.024; Chen JY, 2009, CLIN J PAIN, V25, P485, DOI 10.1097/AJP.0b013e31819a506b; Chiu CC, 2015, EJSO-EUR J SURG ONC, V41, P1170, DOI 10.1016/j.ejso.2015.04.023; Fan ST, 2000, ARCH SURG-CHICAGO, V135, P336, DOI 10.1001/archsurg.135.3.336; Garcia RM, 2013, J SPINAL DISORD TECH, V26, P291, DOI 10.1097/BSD.0b013e318246b0a6; Kao CW, 2012, TRANSPL P, V44, P360, DOI 10.1016/j.transproceed.2011.12.040; Ko JS, 2012, TRANSPL P, V44, P445, DOI 10.1016/j.transproceed.2012.01.017; New Zealand Medicines and Medical Devices Safety Authority, 2014, DAT DYN PAR SOD; Ng A, 2003, BRIT J ANAESTH, V90, P746, DOI 10.1093/bja/aeg139; Olthoff KM, 2015, LIVER TRANSPLANT, V21, P79, DOI 10.1002/lt.23966; The Electronic Medicines Compendium, 2015, DYN 40 MG POWD SOL I	12	1	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0041-1345	1873-2623		TRANSPL P	Transplant. Proc.	MAY	2016	48	4					1080	1082		10.1016/j.transproceed.2015.11.023			3	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	DP8PP	WOS:000378760400023	27320562				2020-06-30	J	Garnock-Jones, KP				Garnock-Jones, Karly P.			Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain	CLINICAL DRUG INVESTIGATION			English	Review							OPIOID-TOLERANT ADULTS; PHARMACOLOGICAL-PROPERTIES; DOSE PHARMACOKINETICS; THERAPEUTIC-EFFICACY; TRANSDERMAL FENTANYL; HEALTHY-SUBJECTS; OPEN-LABEL; MANAGEMENT; CROSSOVER; PATCH	Fentanyl buccal soluble film (Onsolis(A (R)), Breakyl(A (R)), Painkyl (TM)) comprises two layers: a mucoadhesive layer containing the active drug, and an inactive layer with the aim of preventing the diffusion of fentanyl into the oral cavity. It is approved in several countries worldwide, including the USA and those of the EU, for the management of breakthrough cancer pain in opioid-tolerant, adult patients with cancer. This article reviews the pharmacological properties of fentanyl buccal soluble film and its clinical efficacy and tolerability in these patients. Fentanyl buccal soluble film provides an additional option for transmucosal delivery of fentanyl, with approximately half of the dose undergoing an initial, rapid absorption via the buccal mucosa (accounting for its high bioavailability). In clinical trials, fentanyl buccal soluble film was associated with significant improvements in pain intensity scores versus placebo and was generally well tolerated. The most common adverse events were typical opioid-associated adverse events, such as nausea and vomiting. Fentanyl buccal soluble film is a useful option for the treatment of breakthrough cancer pain in opioid-tolerant patients.	[Garnock-Jones, Karly P.] Springer, Private Bag 65901, Auckland 0754, New Zealand	Garnock-Jones, KP (reprint author), Springer, Private Bag 65901, Auckland 0754, New Zealand.	demail@springer.com					[Anonymous], 2015, UK SUMMARY PRODUCT C; BioDelivery Sciences International, 2012, STUD SAF BEMA FENT U; Blick SKA, 2006, DRUGS, V66, P2387, DOI 10.2165/00003495-200666180-00013; Chang Andrew, 2015, J Pain Palliat Care Pharmacother, V29, P247, DOI 10.3109/15360288.2015.1063560; Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Davies A, 2011, CLIN DRUG INVEST, V31, P317, DOI 10.2165/11533540-000000000-00000; Finn AL, 2012, CLIN DRUG INVEST, V32, P63, DOI 10.2165/11594670-000000000-00000; Finn Andrew L, 2011, J Pain Res, V4, P245, DOI 10.2147/JPR.S22641; Hair PI, 2008, DRUGS, V68, P2001, DOI 10.2165/00003495-200868140-00005; Hoy SM, 2008, DRUGS, V68, P1711, DOI 10.2165/00003495-200868120-00008; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lyseng-Williamson KA, 2011, CNS DRUGS, V25, P511, DOI 10.2165/11207470-000000000-00000; Meda Pharmaceuticals, 2011, ONS FENT BUCC SOL FI; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; National Comprehensive Cancer Network, 2016, NCCN CLIN PRACT GUID; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Smith HS, 2013, J PAIN RES, V6, P189, DOI 10.2147/JPR.S40745; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Vasisht N, 2010, J CLIN PHARMACOL, V50, P785, DOI 10.1177/0091270010361354; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020; Zeppetella G, 2013, J NATL COMPR CANC NE, V11, pS37	24	10	10	1	17	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	MAY	2016	36	5					413	419		10.1007/s40261-016-0394-y			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DI7RW	WOS:000373700700009	27007271				2020-06-30	J	Kamat, PP; Ayestaran, FW; Gillespie, SE; Sanders, RD; Greenbaum, LA; Simon, HK; Stockwell, JA				Kamat, Pradip P.; Ayestaran, Frank W.; Gillespie, Scott E.; Sanders, Rebecca D.; Greenbaum, Larry A.; Simon, Harold K.; Stockwell, Jana A.			Deep procedural sedation by a sedationist team for outpatient pediatric renal biopsies	PEDIATRIC TRANSPLANTATION			English	Article						renal biopsy; native; transplant; outpatient; pediatric; sedation; adverse events	RESEARCH CONSORTIUM; ADVERSE EVENTS; PROPOFOL	To date, no study has analyzed the use of deep PS for pediatric renal biopsies by a dedicated sedation team in an outpatient setting. Retrospective analysis of renal biopsies performed at CHOA from 2009 to 2013. Patient demographics, procedure success, and sedation-related events were analyzed. Logistic regression techniques were applied to identify characteristics associated with procedure safety and success. A total of 174 biopsies from 136 patients, aged 2-21 yr, were reviewed. Of the 174 biopsies, 63 of 174 (36%) were from native, and 111 of 174 (64%) were from transplanted kidneys, respectively. No deaths, allograft losses, or unanticipated hospital admissions occurred. The most commonly utilized interventions during sedation were blow-by oxygen (29.9%) and CPAP (12.1%). Children receiving the combination of F + P had significantly higher biopsy success rates vs. other drug combinations (96.1% vs. 79%; p = 0.014). There was no difference in complication rates regardless of drug combination or biopsy type (transplanted vs. native). The combination of F + P yields a high procedural success rate for outpatient native and transplanted kidney biopsies. We identified a number of sedation-related events that can be easily managed by a well-trained sedationist team.	[Kamat, Pradip P.; Ayestaran, Frank W.; Gillespie, Scott E.; Sanders, Rebecca D.; Greenbaum, Larry A.; Simon, Harold K.; Stockwell, Jana A.] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Atlanta, GA USA; [Kamat, Pradip P.; Ayestaran, Frank W.; Gillespie, Scott E.; Sanders, Rebecca D.; Greenbaum, Larry A.; Simon, Harold K.; Stockwell, Jana A.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Kamat, Pradip P.; Stockwell, Jana A.] Emory Univ, Sch Med, Div Pediat Crit Care Med, Atlanta, GA USA; [Ayestaran, Frank W.; Greenbaum, Larry A.] Emory Univ, Sch Med, Div Pediat Nephrol, Atlanta, GA USA; [Gillespie, Scott E.] Emory Univ, Sch Med, Div Pediat Infect Dis, Atlanta, GA USA; [Simon, Harold K.] Emory Univ, Sch Med, Div Pediat Emergency Med, Atlanta, GA USA	Kamat, PP (reprint author), Childrens Healthcare Atlanta Egleston, 1405 Clifton Rd,NE, Atlanta, GA 30322 USA.	Pradip.kamat@choa.org	Kamat, Pradip/AAK-9374-2020	Kamat, Pradip/0000-0002-9633-0973			Birk PE, 2007, PEDIATR TRANSPLANT, V11, P196, DOI 10.1111/j.1399-3046.2006.00659.x; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Cote CJ, 2000, PEDIATRICS, V106, P633, DOI 10.1542/peds.106.4.633; Cravero JP, 2009, ANESTH ANALG, V108, P795, DOI 10.1213/ane.0b013e31818fc334; Green SM, 2011, ANN EMERG MED, V57, P470, DOI 10.1016/j.annemergmed.2011.03.014; Hussain F, 2003, PEDIATR NEPHROL, V18, P53, DOI 10.1007/s00467-002-1003-2; Kamat PP, 2015, PEDIATR CRIT CARE ME, V16, P11, DOI 10.1097/PCC.0000000000000273; Kudchadkar SR, 2015, PEDIATR CRIT CARE ME, V16, P77, DOI 10.1097/PCC.0000000000000293; Mallory MD, 2011, ANN EMERG MED, V57, P462, DOI 10.1016/j.annemergmed.2011.03.008; Mason KP, 2009, AM J ROENTGENOL, V192, P1261, DOI 10.2214/AJR.08.1743	10	3	3	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1397-3142	1399-3046		PEDIATR TRANSPLANT	Pediatr. Transplant.	MAY	2016	20	3					372	377		10.1111/petr.12680			6	Pediatrics; Transplantation	Pediatrics; Transplantation	DI7IO	WOS:000373673100005	26867508				2020-06-30	J	Li, SY; Yu, F; Zhu, HC; Yang, YT; Yang, LQ; Lian, JF				Li, Shiyang; Yu, Fang; Zhu, Huichen; Yang, Yuting; Yang, Liqun; Lian, Jianfeng			The median effective concentration (EC50) of propofol with different doses of fentanyl during colonoscopy in elderly patients	BMC ANESTHESIOLOGY			English	Article						EC50; Propofol; Fentanyl; Elderly patients	GASTROINTESTINAL ENDOSCOPY; SEDATION; CONSCIOUSNESS; DESFLURANE	Background: Propofol and fentanyl are the most widely administered anesthesia maintaining drugs during colonoscopy. In this study, we determined the median effective concentration (EC50) of propofol required for colonoscopy in elderly patients, and the purpose of this study was to describe the pharmacodynamic interaction between fentanyl and propofol when used in combination for colonoscopy in elderly patients. Methods: Ninety elderly patients scheduled for colonoscopy were allocated into three groups in a randomized, double-blinded manner as below, F0.5 group (0.5 mu g.kg(-1) fentanyl), F1.0 group (1.0 mu g. kg(-1) fentanyl) and saline control group. Anaesthesia was achieved by target-controlled infusion of propofol (Marsh model, with an initial plasma concentration of 2.0 mu g. ml(-1)) and fentanyl. Colonoscopy was started 3 min after the injection of fentanyl. The EC50 of propofol for colonoscopy with different doses of fentanyl was measured by using an up-and-down sequential method with an adjacent concentration gradient at 0.5 mu g. ml(-1) to inhibit purposeful movements. Anaesthesia associated adverse events and recovery characters were also recorded. Results: The EC50 of propofol for colonoscopy in elderly patients were 2.75 mu g. ml(-1) (95 % CI, 2.50-3.02 mu g. ml(-1)) in F0.5 group, 2.05 mu g. ml(-1) (95 % CI, 1.98-2.13 mu g. ml(-1)) in F1.0 group and 3.08 mu g. ml(-1) (95 % CI, 2.78-3.42 mu g. ml(-1)) in control group respectively (P < 0.05). Patients in the F1.0 group had a significantly longer awake time and length of hospital stay than those in control group (P < 0.05). Conclusion: Increasing doses of fentanyl up to 1.0 mu g. kg(-1) reduces the propofol EC50 required for elderly patients undergoing colonoscopy, and there was no significant difference in anaesthesia associated adverse events but prolonged awake and discharge time.	[Li, Shiyang; Lian, Jianfeng] Fujian Med Univ, Quanzhou Childrens Hosp, Dept Anesthesiol, Fujian 362000, Peoples R China; [Yu, Fang; Zhu, Huichen; Yang, Yuting; Yang, Liqun] Shanghai Jiao Tong Univ, Renji Hosp, Dept Anesthesiol, Sch Med, Shanghai 200136, Peoples R China	Yang, LQ (reprint author), Shanghai Jiao Tong Univ, Renji Hosp, Dept Anesthesiol, Sch Med, Shanghai 200136, Peoples R China.	lqyang72721@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81272066, 81471846]	Supported by National Natural Science Foundation of China (Grant No. 81272066 and No. 81471846).	Absalom AR, 2009, BRIT J ANAESTH, V103, P26, DOI 10.1093/bja/aep143; Adachi YU, 2013, KOREAN J ANESTHESIOL, V65, P121, DOI 10.4097/kjae.2013.65.2.121; Ellerkmann RK, 2013, BEST PRACT RES-CLIN, V27, P225, DOI 10.1016/j.bpa.2013.06.006; Fanti L, 2015, DIGEST LIVER DIS, V47, P566, DOI 10.1016/j.dld.2015.03.003; Ferreira AO, 2015, WORLD J GASTRO ENDOS, V7, P102, DOI 10.4253/wjge.v7.i2.102; Fu F, 2014, BRIT J ANAESTH, V112, P506, DOI 10.1093/bja/aet383; Hammer GB, 2009, PEDIATR ANESTH, V19, P138, DOI 10.1111/j.1460-9592.2008.02823.x; HANLEY C, 1965, CHILD DEV, V36, P437, DOI 10.2307/1126467; Higuchi H, 2002, ANESTH ANALG, V94, P886, DOI 10.1097/00000539-200204000-00021; Kim YS, 2015, ACTA ANAESTH SCAND, V59, P788, DOI 10.1111/aas.12494; Leslie K, 2008, COCHRANE DB SYST REV, V3; Li Min, 2011, Zhonghua Yi Xue Za Zhi, V91, P600; Moon SH, 2014, CLIN ENDOSC, V47, P135, DOI 10.5946/ce.2014.47.2.135; Muller PY, 2012, NAT REV DRUG DISCOV, V11, P751, DOI 10.1038/nrd3801; Pace NL, 2007, ANESTHESIOLOGY, V107, P144, DOI 10.1097/01.anes.0000267514.42592.2a; Park HJ, 2007, ANESTH ANALG, V105, P57, DOI 10.1213/01.ane.0000266447.23037.e4; RAMPIL IJ, 1991, ANESTHESIOLOGY, V74, P429, DOI 10.1097/00000542-199103000-00007; SCHELLER MS, 1988, CAN J ANAESTH, V35, P153, DOI 10.1007/BF03010656; Schilling D, 2014, DIGESTION, V89, P272, DOI 10.1159/000362541; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; Stanley T H, 2000, Proc (Bayl Univ Med Cent), V13, P7	21	8	8	1	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	APR 21	2016	16								24	10.1186/s12871-016-0189-y			5	Anesthesiology	Anesthesiology	DJ9TE	WOS:000374555000001	27106691	DOAJ Gold, Green Published			2020-06-30	J	Mayer, BP; DeHope, AJ; Mew, DA; Spackman, PE; Williams, AM				Mayer, Brian P.; DeHope, Alan J.; Mew, Daniel A.; Spackman, Paul E.; Williams, Audrey M.			Chemical Attribution of Fentanyl Using Multivariate Statistical Analysis of Orthogonal Mass Spectral Data	ANALYTICAL CHEMISTRY			English	Article							SELECTIVITY RATIO PLOT; IMPURITIES; PROFILES	Attribution of the origin of an illicit drug relies on identification of compounds indicative of its clandestine production and is a key component of many modern forensic investigations. The results of these studies can yield detailed information on method of manufacture, starting material source, and final product, all critical forensic evidence. In the present work, chemical attribution signatures (CAS) associated with the synthesis of the analgesic fentanyl, N-(1-phenylethylpiperidin-4-yl)-N-phenylpropanamide, were investigated. Six synthesis methods, all: previously published fentanyl synthetic routes or hybrid versions thereof, were studied in an effort to identify and classify route-specific signatures. A total of 160 distinct compounds and inorganic species were identified using gas and liquid chromatographies combined with mass spectrometric methods (gas chromatography/mass spectrometry (GC/MS) and liquid chromatography tandem mass spectrometry-time of (LC-MS/MS-TOF)) in conjunction with inductively coupled plasma mass spectrometry (ICPMS). The complexity of the resultant data matrix urged the use of multivariate statistical analysis. Using: partial least-squares-discriminant analysis (PLS-DA), 87 route specific CAS were classified and a statistical model capable of predicting the method of fentanyl synthesis was validated and tested against CAS profiles from crude fentanyl products deposited and later extracted from two operationally relevant surfaces: stainless steel and vinyl tile. This work provides the most detailed fentanyl CAS investigation to date by using orthogonal mass spectral data to identify CAS of forensic significance for illicit drug detection, profiling, and attribution.	[Mayer, Brian P.; Mew, Daniel A.; Spackman, Paul E.; Williams, Audrey M.] Lawrence Livermore Natl Lab, Forens Sci Ctr, 7000 East Ave L-091, Livermore, CA 94550 USA; [DeHope, Alan J.] Lawrence Livermore Natl Lab, Div Mat Sci, 7000 East Ave L-382, Livermore, CA 94550 USA	Williams, AM (reprint author), Lawrence Livermore Natl Lab, Forens Sci Ctr, 7000 East Ave L-091, Livermore, CA 94550 USA.	Williams259@llnl.gov	Williams, Audrey/P-9468-2017		Department of Homeland Security, Science and Technology Directorate, Chemical Forensic Program; U.S. Department of Energy, National Nuclear Security AdministrationNational Nuclear Security AdministrationUnited States Department of Energy (DOE) [DE-AC52-07NA27344]	The authors would like to thank the Department of Homeland Security, Science and Technology Directorate, Chemical Forensic Program for their funding of this work. Livermore National Laboratory is operated by Lawrence Livermore National Security, LLC, for the U.S. Department of Energy, National Nuclear Security Administration under Contract DE-AC52-07NA27344.	Fraga CG, 2011, ANAL CHEM, V83, P9564, DOI 10.1021/ac202340u; Fraga CG, 2011, FORENSIC SCI INT, V210, P164, DOI 10.1016/j.forsciint.2011.02.025; Garg A, 2010, J PHARMACEUT BIOMED, V53, P325, DOI 10.1016/j.jpba.2010.04.004; Grishina G. V., 1985, CHEM HETEROCYCL COMP, V21, P1355; Gupta PK, 2005, J CHEM RES, P452; Janssen A. J., 1964, US Patent, Patent No. [3,141,823, 3141823]; Kreuzer HW, 2012, J FORENSIC SCI, V57, P75, DOI 10.1111/j.1556-4029.2011.01946.x; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; LEONHART MM, 2008, FED REGISTER, V73, P43355; Lurie IS, 2012, FORENSIC SCI INT, V220, P191, DOI 10.1016/j.forsciint.2012.02.024; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; Lurie IS, 2005, J CHROMATOGR A, V1100, P168, DOI 10.1016/j.chroma.2005.09.054; Meier-Augenstein W., 2010, STABLE ISOTOPE FOREN; Mustazza C, 2006, CHEM PHARM BULL, V54, P611, DOI 10.1248/cpb.54.611; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Rajalahti T, 2009, CHEMOMETR INTELL LAB, V95, P35, DOI 10.1016/j.chemolab.2008.08.004; Rajalahti T, 2009, ANAL CHEM, V81, P2581, DOI 10.1021/ac802514y; Smilde AK, 2005, ANAL CHEM, V77, P6729, DOI 10.1021/ac051080y; Smith F., 2004, HDB FORENSIC DRUG AN; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250; Varmuza K., 2009, INTRO MULTIVARIATE S; Volpe AM, 2011, FORENSIC SCI INT, V209, P96, DOI 10.1016/j.forsciint.2011.01.005	22	19	19	3	39	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	APR 19	2016	88	8					4303	4310		10.1021/acs.analchem.5b04434			8	Chemistry, Analytical	Chemistry	DK1WP	WOS:000374706000021	27010913				2020-06-30	J	Ayad, S; Babazade, R; Elsharkawy, H; Nadar, V; Lokhande, C; Makarova, N; Khanna, R; Sessler, DI; Turan, A				Ayad, Sabry; Babazade, Rovnat; Elsharkawy, Hesham; Nadar, Vinayak; Lokhande, Chetan; Makarova, Natalya; Khanna, Rashi; Sessler, Daniel I.; Turan, Alparslan			Comparison of Transversus Abdominis Plane Infiltration with Liposomal Bupivacaine versus Continuous Epidural Analgesia versus Intravenous Opioid Analgesia	PLOS ONE			English	Article							COLORECTAL SURGERY; OPEN-LABEL; TAP BLOCK; EFFICACY; MOTOR; PAIN	Epidural analgesia is considered the standard of care but cannot be provided to all patients Liposomal bupivacaine has been approved for field blocks such as transversus abdominis plane (TAP) blocks but has not been clinically compared against other modalities. In this retrospective propensity matched cohort study we thus tested the primary hypothesis that TAP infiltration are noninferior (not worse) to continuous epidural analgesia and superior (better) to intravenous opioid analgesia in patients recovering from major lower abdominal surgery. 318 patients were propensity matched on 18 potential factors among three groups (106 per group): 1) TAP infiltration with bupivacaine liposome; 2) continuous Epidural analgesia with plain bupivacaine; and; 3) intravenous patient-controlled analgesia (IV PCA). We claimed TAP noninferior (not worse) over Epidural if TAP was noninferior (not worse) on total morphine-equivalent opioid and time-weighted average pain score (10-point scale) within first 72 hours after surgery with noninferiority deltas of 1 (10-point scale) for pain and an increase less of 20% in the mean morphine equivalent opioid consumption. We claimed TAP or Epidural groups superior (better) over IV PCA if TAP or Epidural was superior on opioid consumption and at least noninferior on pain outcome. Multivariable linear regressions within the propensity-matched cohorts were used to model total morphine-equivalent opioid dose and time-weighted average pain score within first 72 hours after surgery; joint hypothesis framework was used for formal testing. TAP infiltration were noninferior to Epidural on both primary outcomes (p<0.001). TAP infiltration were noninferior to IV PCA on pain scores (p = 0.001) but we did not find superiority on opioid consumption (p = 0.37). We did not find noninferiority of Epidural over IV PCA on pain scores (P = 0.13) and nor did we find superiority on opioid consumption (P = 0.98). TAP infiltration with liposomal bupivacaine and continuous epidural analgesia were similar in terms of pain and opioid consumption, and not worse in pain compared with IV PCA. TAP infiltrations might be a reasonable alternative to epidural analgesia in abdominal surgical patients. A large randomized trial comparing these techniques is justified.	[Ayad, Sabry] Fairview Hosp, Dept Anesthesiol & Pain Management, Cleveland, OH USA; [Ayad, Sabry] Cleveland Clin, Dept Outcomes Res, Anesthesiol Inst Cleveland, Cleveland, OH 44106 USA; [Babazade, Rovnat] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Babazade, Rovnat] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA; [Elsharkawy, Hesham] Cleveland Clin, Dept Gen Anesthesiol, Inst Anesthesiol, Cleveland, OH 44106 USA; [Elsharkawy, Hesham; Nadar, Vinayak; Lokhande, Chetan; Makarova, Natalya; Khanna, Rashi; Sessler, Daniel I.; Turan, Alparslan] Cleveland Clin, Dept Outcomes Res, Inst Anesthesiol, Cleveland, OH 44106 USA; [Makarova, Natalya] Cleveland Clin, Dept Qualitat Hlth Sci, Inst Anesthesiol, Cleveland, OH 44106 USA	Turan, A (reprint author), Cleveland Clin, Dept Outcomes Res, Inst Anesthesiol, Cleveland, OH 44106 USA.	turana@ccf.org	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	Pacira Pharmaceuticals, Inc.	The study was supported by Pacira Pharmaceuticals, Inc. The sponsor was not involved in data acquisition, analysis, nor interpretation of the results. This manuscript was written by the investigators. None of the authors has a personal financial interest in this research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], MAJ SURG PROC WER DE; Austin PC, 2009, BIOMETRICAL J, V51, P171, DOI 10.1002/bimj.200810488; CEDERHOLM I, 1994, REGION ANESTH, V19, P18; Chahar Praveen, 2012, J Pain Res, V5, P257, DOI 10.2147/JPR.S27894; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Findlay JM, 2012, SURG-J R COLL SURG E, V10, P361, DOI 10.1016/j.surge.2012.07.005; Finnerty O, 2013, MINERVA ANESTESIOL, V79, P1415; Finnerty O, 2012, CURR OPIN ANESTHESIO, V25, P610, DOI 10.1097/ACO.0b013e328357b165; Ganapathy S, 2015, EUR J ANAESTH, V32, P797, DOI 10.1097/EJA.0000000000000345; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Kadam VR, 2013, ANAESTH INTENS CARE, V41, P476, DOI 10.1177/0310057X1304100407; Kadam VR, 2011, J ANESTH, V25, P786, DOI 10.1007/s00540-011-1201-9; Konigsrainer I, 2009, ANAESTHESIA, V64, P27, DOI 10.1111/j.1365-2044.2008.05655.x; Marret E, 2007, BRIT J SURG, V94, P665, DOI 10.1002/bjs.5825; Mascha EJ, 2012, ANESTH ANALG, V114, P1304, DOI 10.1213/ANE.0b013e3182504435; Niraj G, 2014, ANAESTHESIA, V69, P348, DOI 10.1111/anae.12546; Niraj G, 2011, ANAESTHESIA, V66, P465, DOI 10.1111/j.1365-2044.2011.06700.x; Rosenbaum PR, 1983, CENTRAL ROLE PROPENS, DOI [10.1093/biomet/70.1.41, DOI 10.1093/BIOMET/70.1.41]; Spanjersberg WR, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007635.pub2; Turan A, 2013, CLIN J PAIN, V29, P1050, DOI 10.1097/AJP.0b013e318287a258; Vissers KCP, 2010, PAIN PRACT, V10, P85, DOI 10.1111/j.1533-2500.2009.00335.x; Wu YQ, 2013, ANESTH ANALG, V117, P507, DOI 10.1213/ANE.0b013e318297fcee	22	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2016	11	4							e0153675	10.1371/journal.pone.0153675			15	Multidisciplinary Sciences	Science & Technology - Other Topics	DJ6AH	WOS:000374291800043	27082959	DOAJ Gold, Green Published			2020-06-30	J	Sabir, H; Wood, T; Gill, H; Liu, X; Dingley, J; Thoresen, M				Sabir, Hemmen; Wood, Thomas; Gill, Hannah; Liu, Xun; Dingley, John; Thoresen, Marianne			Xenon depresses aEEG background voltage activity whilst maintaining cardiovascular stability in sedated healthy newborn pigs	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Xenon; Amplitude-integrated encephalography; Inhalation anaesthetics; Newborn	AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAM; BISPECTRAL INDEX; NEONATAL ENCEPHALOPATHY; BALANCED XENON; HYPNOTIC DEPTH; ANESTHESIA; HYPOTHERMIA; SEVOFLURANE; BRAIN; NEUROPROTECTION	Background: Changes in electroencephalography (EEG) voltage range are used to monitor the depth of anaesthesia, as well as predict outcome after hypoxia-ischaemia in neonates. Xenon is being investigated as a potential neuroprotectant after hypoxic-ischaemic brain injury, but the effect of Xenon on EEG parameters in children or neonates is not known. This study aimed to examine the effect of 50% inhaled Xenon on background amplitude-integrated EEG (aEEG) activity in sedated healthy newborn pigs. Methods: Five healthy newborn pigs, receiving intravenous fentanyl sedation, were ventilated for 24 h with 50%Xenon, 30%O-2 and 20%N-2 at normothermia. The upper and lower voltage-range of the aEEG was continuously monitored together with cardiovascular parameters throughout a 1 h baseline period with fentanyl sedation only, followed by 24 h of Xenon administration. Results: The median (IQR) upper and lower aEEG voltage during 1 h baseline was 48.0 mu V (46.0-50.0) and 25.0 mu V (23.0-26.0), respectively. The median (IQR) aEEG upper and lower voltage ranges were significantly depressed to 21.5 mu V (20.0-26.5) and 12.0 mu V (12.0-16.5) from 10 min after the onset of 50% Xenon administration (p = 0.002). After the initial Xenon induced depression in background aEEG voltage, no further aEEG changes were seen over the following 24 h of ventilation with 50% xenon under fentanyl sedation. Mean arterial blood pressure and heart rate remained stable. Conclusion: Mean arterial blood pressure and heart rate were not significantly influenced by 24 h Xenon ventilation. 50% Xenon rapidly depresses background aEEG voltage to a steady similar to 50% lower level in sedated healthy newborn pigs. Therefore, care must be taken when interpreting the background voltage in neonates also receiving Xenon. (C) 2016 Elsevier B.V. All rights reserved.	[Sabir, Hemmen; Gill, Hannah; Liu, Xun; Thoresen, Marianne] Univ Bristol, Sch Clin Sci, St Michaels Hosp, Bristol, Avon, England; [Sabir, Hemmen] Univ Dusseldorf, Univ Childrens Hosp, Dept Gen Pediat, Dusseldorf, Germany; [Sabir, Hemmen] Univ Dusseldorf, Univ Childrens Hosp, Dept Neonatol, Dusseldorf, Germany; [Sabir, Hemmen] Univ Dusseldorf, Univ Childrens Hosp, Dept Pediat Cardiol, Dusseldorf, Germany; [Wood, Thomas; Thoresen, Marianne] Univ Oslo, Inst Basic Med Sci, Dept Physiol, Oslo, Norway; [Dingley, John] Swansea Univ, Coll Med, Swansea, W Glam, Wales; [Thoresen, Marianne] Room 2366,Sognsvannsveien 9, N-0372 Oslo, Norway; [Thoresen, Marianne] PB 1103 Blindern, N-0317 Oslo, Norway	Thoresen, M (reprint author), Univ Oslo, Inst Basic Med Sci, Dept Physiol, Oslo, Norway.	marianne.thoresen@medisin.uio.no	Wood, Tommy/AAC-8252-2019; Gill, Hannah/J-4510-2014	Wood, Tommy/0000-0002-1130-2720; Gill, Hannah/0000-0002-4226-320X	Sport Aiding Medical Research for Kids (SPARKS (UK)); Laerdal Foundation for Acute Medicine (Norway); Norwegian Research CouncilResearch Council of Norway	This study was supported by Sport Aiding Medical Research for Kids (SPARKS (UK)), the Laerdal Foundation for Acute Medicine (Norway) and the Norwegian Research Council.	al Naqeeb N, 1999, PEDIATRICS, V103, P1263, DOI 10.1542/peds.103.6.1263; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Azzopardi D., 2015, LANCET NEUROL; Azzopardi D, 2013, ARCH DIS CHILD-FETAL, V98, pF437, DOI 10.1136/archdischild-2013-303786; Bernet V, 2010, PEDIATR RES, V67, P650, DOI 10.1203/PDR.0b013e3181da44ba; Chakkarapani E, 2009, ANESTH ANALG, V109, P451, DOI 10.1213/ane.0b013e3181aa9550; Chakkarapani E, 2012, INTENS CARE MED, V38, P316, DOI 10.1007/s00134-011-2442-7; Chakkarapani E, 2010, ANN NEUROL, V68, P330, DOI 10.1002/ana.22016; Creeley CE, 2010, ANESTH ANALG, V110, P442, DOI 10.1213/ANE.0b013e3181c6b9ca; CULLEN SC, 1969, ANESTHESIOLOGY, V31, P305, DOI 10.1097/00000542-196910000-00003; Dale MM, 2007, RANG DALES PHARM, P503; Davidson AJ, 2005, BRIT J ANAESTH, V95, P674, DOI 10.1093/bja/aei247; Dingley J, 2014, PEDIATRICS, V133, P809, DOI 10.1542/peds.2013-0787; Fahlenkamp AV, 2010, BRIT J ANAESTH, V105, P334, DOI 10.1093/bja/aeq163; Fahlenkamp AV, 2010, EUR J ANAESTH, V27, P906, DOI 10.1097/EJA.0b013e32833d1289; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Gamble C, 2012, PEDIATR EMERG CARE, V28, P1003, DOI 10.1097/PEC.0b013e31826ca956; Goto T, 2000, ANESTHESIOLOGY, V93, P1188, DOI 10.1097/00000542-200011000-00009; Hall RW, 2012, CLIN PERINATOL, V39, P239, DOI 10.1016/j.clp.2011.12.013; HARTMANN A, 1991, STROKE, V22, P182, DOI 10.1161/01.STR.22.2.182; HELLSTROMWESTAS L, 1995, ARCH DIS CHILD-FETAL, V72, pF34, DOI 10.1136/fn.72.1.F34; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Liu JJ, 2014, EUR J ANAESTH, V31, P669, DOI 10.1097/EJA.0000000000000073; Liu X, 2013, ACTA ANAESTH SCAND, V57, P646, DOI 10.1111/aas.12055; Loepke AW, 2008, ANESTH ANALG, V106, P1681, DOI 10.1213/ane.0b013e318167ad77; Mastrangelo M, 2013, SEIZURE-EUR J EPILEP, V22, P703, DOI 10.1016/j.seizure.2013.05.006; McKeever S, 2012, ANAESTH INTENS CARE, V40, P275, DOI 10.1177/0310057X1204000210; MORRIS LE, 1955, ANESTHESIOLOGY, V16, P312, DOI 10.1097/00000542-195505000-00003; Sabir H, 2013, ANESTHESIOLOGY, V119, P345, DOI 10.1097/ALN.0b013e318294934d; Shah DK, 2014, CURR PEDIATR REV, V10, P11, DOI 10.2174/157339631001140408115859; Stoppe C, 2012, BRIT J ANAESTH, V108, P80, DOI 10.1093/bja/aer393; Stuttmann R, 2010, BIOMED TECH, V55, P77, DOI 10.1515/BMT.2010.022; Thoresen M, 2010, PEDIATRICS, V126, pE131, DOI 10.1542/peds.2009-2938; Werther T, 2015, NEONATOLOGY, V107, P34, DOI 10.1159/000365277; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224	36	4	4	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	APR 15	2016	363						140	144		10.1016/j.jns.2016.02.051			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DJ3AW	WOS:000374078200029	27000239	Green Published			2020-06-30	J	Akhondzadeh, R; Ghomeishi, A; Nesioonpour, S; Nourizade, S				Akhondzadeh, Reza; Ghomeishi, Ali; Nesioonpour, Sholeh; Nourizade, Sanaz			A comparison between the effects of propofol-fentanyl with propofol-ketamine for sedation in patients undergoing endoscopic retrograde cholangiopancreatography outside the operating room	BIOMEDICAL JOURNAL			English	Article						Deep sedation; Endoscopic retrograde cholangiopancreatography; Fentanyl; Ketamine; Propofol	PROCEDURAL SEDATION; PEDIATRIC-PATIENTS; ANESTHESIA; REMIFENTANIL; ANALGESIA; CHILDREN; SURGERY; COMBINATION; INJECTION; QUALITY	Background: The efficient and secure techniques of anesthesia and sedation have always been needed for. One of these procedures is endoscopic retrograde cholangiopancreatography (ERCP), due to its painfulness and long duration, has high sensitivity. We compare the effects of propofolefentanyl (PF) with propofoleketamine (PK) to sedate patients undergoing ERCP. Methods: In this clinical trial, patients were divided into two groups of 49 people. A group received a pharmaceutical combination of PK, and another group received a pharmaceutical combination of PF. Vital signs of patients, Ramsey Sedation Score, and pain of patients were assessed. The total dosage of used propofol was also recorded. Results: There was no significant difference seen in the patients'hemodynamic characteristics in both groups. Pain at the end of surgery and an hour after it in the PK group was less that was not statistically significant. By Ramsey Sedation Score also significant differences were not seen between groups (p = 0.68). By using total dose of propofol used also a significant difference was not observed between the two groups (p = 0.36). Rate of apnea in PK group was 32% and in the PF group was 63%, which this difference was statistically significant (p < 0.05). Conclusion: A comparison between the two drugs combination shows that although in terms of hemodynamic and sedation criteria both groups were similar, but because of the lower amount of pain and apnea in the PK group, this combination may generally in the ERCP procedure is more efficient and safer.	[Akhondzadeh, Reza; Ghomeishi, Ali; Nesioonpour, Sholeh] Ahvaz Jundishapur Univ Med Sci, Imam Khomeini Hosp, Dept Anesthesiol, Pain Res Ctr, Box 1519, Ahwaz 6193673166, Iran; [Nourizade, Sanaz] Ahvaz Jundishapur Univ Med Sci, Razi Hosp, Dept Anesthesiol, Pain Res Ctr, Ahwaz, Iran	Akhondzadeh, R (reprint author), Ahvaz Jundishapur Univ Med Sci, Imam Khomeini Hosp, Dept Anesthesiol, Pain Res Ctr, Box 1519, Ahwaz 6193673166, Iran.	rezaakh@hotmail.com	nesioonpour, sholeh/R-7779-2017; ghomeishi, ali/O-3464-2017; akhondzadeh, raza/S-4834-2017	nesioonpour, sholeh/0000-0001-7462-1465; ghomeishi, ali/0000-0002-5929-4635; akhondzadeh, raza/0000-0002-5476-1505; akhondzadeh, reza/0000-0002-9170-1835	Ahvaz Jundishapur University of Medical Sciences; Pain Research Center, Imam Khomeini Hospital, Ahvaz, Iran	Financial support was provided by Ahvaz Jundishapur University of Medical Sciences and Pain Research Center, Imam Khomeini Hospital, Ahvaz, Iran.	Akcaboy ZN, 2006, ACTA ANAESTH SCAND, V50, P736, DOI 10.1111/j.1399-6576.2006.01047.x; Akhondzade R, 2014, PAK J MED SCI, V30, P942, DOI 10.12669/pjms.305.4775; Akhondzadeh R, 2014, EVALUATION ANALGESIC, V3, P72; Akin A, 2005, INT J PEDIATR OTORHI, V69, P1541, DOI 10.1016/j.ijporl.2005.04.011; Andolfatto G, 2012, ANN EMERG MED, V59, P504, DOI 10.1016/j.annemergmed.2012.01.017; David H, 2011, ANN EMERG MED, V57, P435, DOI 10.1016/j.annemergmed.2010.11.025; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; Friedberg BL, 1999, AESTHET PLAST SURG, V23, P70, DOI 10.1007/s002669900245; HUI TW, 1995, ANESTHESIOLOGY, V82, P641, DOI 10.1097/00000542-199503000-00005; Joo JD, 2012, KOREAN J ANESTHESIOL, V63, P431, DOI 10.4097/kjae.2012.63.5.431; Khutia SK, 2012, INDIAN J ANAESTH, V56, P145, DOI 10.4103/0019-5049.96313; Koo SW, 2006, ANESTH ANALG, V103, P1444, DOI 10.1213/01.ane.0000243334.83816.53; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; Li Lu, 2009, Practical Pharmacy and Clinical Remedies, V12, P175; Lichtenbelt BJ, 2004, CLIN PHARMACOKINET, V43, P577, DOI 10.2165/00003088-200443090-00002; Moerman AT, 2004, J CLIN ANESTH, V16, P237, DOI 10.1016/j.jclinane.2003.08.005; Nesioonpour S, 2014, ANESTH PAIN MED, V4, pe17350, DOI 10.5812/aapm.17350; Phillips William, 2010, J Pain Palliat Care Pharmacother, V24, P349, DOI 10.3109/15360288.2010.506503; Shah A, 2011, ANN EMERG MED, V57, P425, DOI 10.1016/j.annemergmed.2010.08.032; Vandervoort J, 2002, GASTROINTEST ENDOSC, V56, P652, DOI 10.1067/mge.2002.129086	20	4	4	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2319-4170	2320-2890		BIOMED J	Biomed. J.	APR	2016	39	2					145	149		10.1016/j.bj.2015.11.002			5	Biochemistry & Molecular Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Research & Experimental Medicine	DS3VN	WOS:000380710900008	27372170	DOAJ Gold, Green Published			2020-06-30	J	Prieto, I; Pardo, J; Luna, J; Marin, JP; Olivera, J; Garcia, AJ; Perez, AM				Prieto, Isabel; Pardo, Jose; Luna, Javier; Marin, Juan P.; Olivera, Jesus; Garcia, Antonio J.; Perez, Ana M.			Facilitation of accurate and effective radiation therapy using fentanyl pectin nasal spray (FPNS) to reduce incidental breakthrough pain due to procedure positioning	SCANDINAVIAN JOURNAL OF PAIN			English	Article						Radiotherapy; Procedure; Pain; Fentanyl; Intranasal; Visual analogue scale	PREVALENCE	Purpose: To provide effective and accurate radiotherapy (RT) for advanced cancer patients who experience breakthrough pain (BP) due to positioning manoeuvres, through the use of FPNS. Secondary endpoints were the dose and time required to achieve a 50% numeric rating scale (NRS) reduction and conduction of a pharmacoeconomic analysis. Patients and methods: Twenty-seven advanced cancer patients with moderate-severe BP associated with routine radiotherapy procedures and manoeuvres were selected to receive FPNS. Most patients (20/27) had bone metastases. The patients showed a low Karnovsky performance status (mean 54%; range: 30-80). BP intensity was scored with the NRS before and after the procedures that triggered it. All patients were already receiving opioid baseline treatment at a total dose equivalent to 40-160 mg oral morphine. Before the procedure, BP was treated with 100-400 mu g of FPNS. Data related to tolerance, pain relief, onset of the relief and efficient dose to allow RT to proceed were collected. Results: In 26 patients the BP score was reduced by at least 50% as determined in 15.5 min (range 8-35 min) after fentanyl pectin intranasal administration, and pain relief started after 7 min (range 3-15 min); p < 0.05 in both cases. The duration of pain reduction facilitated the proceeding of RT. The Mean NRS score before the procedure was 9 (95%CI: 8.6-9.4) and decreased during procedure to 3 (95%CI: 2.5-3.8). The average dose of FPNS for most patients was 100-200 mu g to achieve pain control, except in three patients who required progressive doses of up to 300-400 mu g. After receiving 300 mu g, one patient dropped out of the study due to severe adverse effects (nausea). Seven patients reported minor undesirable effects related to FPNS administration. Conclusions and implications: Certain necessary RT procedures in advanced cancer patients can cause severe BP episodes. A simple, safe, fast acting and strong analgesic is needed. FPNS is a rapidly absorbed opioid analgesic with a pain relief profile that would be particularly well suited for this patient population. By reducing BP, the drug enables the completion of necessary RT procedures without needless patient discomfort. When BP is attenuated, Department productivity is maintained and unnecessary delays are avoided. Further studies and clinical trials are needed to assess therapeutic FPNS dosages with a view to defining efficacy in the correct clinical context. (C) 2015 Scandinavian Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Prieto, Isabel; Luna, Javier; Marin, Juan P.; Olivera, Jesus; Perez, Ana M.] Univ Hosp, Fdn Jimenez Diaz, Dept Radiat Oncol, Madrid, Spain; [Pardo, Jose] Son Espases Univ Hosp, Dept Radiat Oncol, Palma De Mallorca, Spain; [Garcia, Antonio J.] Univ Med, Dept Pharmacol, Catedra Econ Salud & Uso Rat Medicamento, Malaga, Spain	Prieto, I (reprint author), Univ Hosp, Fdn Jimenez Diaz, Dept Radiat Oncol, Madrid, Spain.	iprieto@fjd.es; jose.pardo@ssib.es; jluna@fjd.es; jolivera@fjd.es; amperez@fjd.es					Bell BC, 2013, J PAIN RES, V6, P843, DOI 10.2147/JPR.S54788; Blanco B., 2013, Rev. Soc. Esp. Dolor, V20, P221, DOI 10.4321/S1134-80462013000500004; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; Lievens Y, 2003, INT J RADIAT ONCOL, V57, P522, DOI 10.1016/S0360-3016(03)00579-0; Luther W, 2013, ENCY RAD ONCOLOGY; Mercadante S, 2012, DRUGS, V72, P191; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Oddershede L, 2014, CLINICOECONOMIC OUTC, V6, P21, DOI 10.2147/CEOR.S55899; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2004, OXFORD TXB PALLIATIV, P438; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Taylor D, 2013, PAIN; Torres LM, 2014, J PALLIAT MED, V17, P1150, DOI 10.1089/jpm.2014.0089; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Zeppetella G, 2013, J PAIN SYMPTOM MANAG, V24; Zeppetella G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub3; Zeppetella G, 2013, J NATL COMPR CANC NE, V11, pS37	26	2	3	0	5	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1877-8860	1877-8879		SCAND J PAIN	Scand. J. Pain	APR	2016	11						52	58		10.1016/j.sjpain.2015.12.001			7	Clinical Neurology	Neurosciences & Neurology	DO9WI	WOS:000378138300010	28850470				2020-06-30	J	Breivik, H				Breivik, Harald			Transmucosal fentanyl for severe cancer pain: Nasal mucosa superior to oral mucosa?	SCANDINAVIAN JOURNAL OF PAIN			English	Editorial Material							BREAKTHROUGH PAIN; SPRAY		[Breivik, Harald] Univ Oslo, Fac Med, Oslo, Norway; [Breivik, Harald] Oslo Univ Hosp, Dept Pain Management & Res, POB 4950, N-0424 Oslo, Norway; [Breivik, Harald] Oslo Univ Hosp, Dept Anaesthesiol, N-0450 Oslo, Norway	Breivik, H (reprint author), Oslo Univ Hosp, Dept Pain Management & Res, POB 4950, N-0424 Oslo, Norway.	harald.breivik@medsin.uio.no	Breivik, Harald/AAG-2978-2020	Breivik, Harald/0000-0002-1738-9337			Kongsgaard UE, 2014, SUPPORT CARE CANCER, V22, P1655, DOI 10.1007/s00520-014-2128-0; Lyseng-Williamson KA, 2011, CNS DRUGS, V25, P511, DOI 10.2165/11207470-000000000-00000; Nalamachu S, 2013, PAIN THER, V2, P121, DOI 10.1007/s40122-013-0019-6; Prieto I, 2016, SCAND J PAIN, V11, P52, DOI 10.1016/j.sjpain.2015.12.001; Thronaes M, 2015, CLIN THER, V37, P585, DOI 10.1016/j.clinthera.2014.12.010; Thronas M, 2014, J Opioid Manag, V10, P21, DOI 10.5055/jom.2014.0188	6	0	0	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1877-8860	1877-8879		SCAND J PAIN	Scand. J. Pain	APR	2016	11						96	97		10.1016/j.sjpain.2015.12.008			2	Clinical Neurology	Neurosciences & Neurology	DO9WI	WOS:000378138300016	28850477				2020-06-30	J	Huang, RC; Hung, NK; Lu, CH; Wu, ZF				Huang, Ren-Chih; Hung, Nan-Kai; Lu, Chueng-He; Wu, Zhi-Fu			Removal of Laryngeal Mask Airway in Adults Under Target-Controlled, Propofol-Fentanyl Infusion Anesthesia Awake or Deep Anesthesia?	MEDICINE			English	Article							TIDAL SEVOFLURANE CONCENTRATION; GENERAL-ANESTHESIA; CHILDREN; INSERTION; END; COMPLICATIONS; INDUCTION; SURGERY; TUBE; LMA	After emergence from anesthesia, the incidence and severity of adverse airway effects caused by the laryngeal mask airway (LMA) can vary, depending on when the device was removed; nonetheless, reports differ regarding the exact optimal timing of LMA removal. The purpose of this study was to compare the rate of adverse events between 2 groups: those whose LMA was removed under general anesthesia ("deep" group) or under target-controlled infusion (TCI) of propofol ("awake" group). Institutional Review Board approval and written informed consent were obtained; 124 patients were then randomly allocated into either the "awake" group or the "deep" group. Anesthesia was induced and maintained using TCI of propofol, as well as intravenous fentanyl. In the "deep" group, the LMA was removed after surgery while the patients were deeply anesthetized using a target effect-site propofol concentration of 2mg/mL, whereas in the "awake" group, the device was removed while the patients followed verbal instructions. The incidence of the following adverse events was recorded: coughing, straining, bronchospasm, laryngospasm, clenching, breath holding, gross purposeful movement, airway obstruction, retching, vomiting, and oxygen desaturation. If any such event occurred, the LMA removal was considered a failure. Airway hyperreactivity was recorded and graded - based on the severity of cough, breath holding, and oxygen desaturation. The failure rate was higher in the "awake" group (15/61; 24.6%) than in the "deep" group (5/60; 8.3%). Airway hyperreactivity was mild (score, < 3) in both groups. Removal of the LMA under deep anesthesia using a target-controlled, effect-site propofol concentration of 2mg/mL may be safer and more successful than removal when patients are fully awake after surgery.	[Huang, Ren-Chih; Hung, Nan-Kai; Lu, Chueng-He] Natl Def Med Ctr, Dept Anesthesiol, Taipei 114, Taiwan; [Huang, Ren-Chih; Hung, Nan-Kai; Lu, Chueng-He] Triserv Gen Hosp, Taipei 114, Taiwan; [Wu, Zhi-Fu] Triserv Gen Hosp, Keelung Branch, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan; [Wu, Zhi-Fu] Triserv Gen Hosp, Dept Anesthesiol, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan; [Wu, Zhi-Fu] Natl Def Med Ctr, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan	Wu, ZF (reprint author), Triserv Gen Hosp, Keelung Branch, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan.; Wu, ZF (reprint author), Triserv Gen Hosp, Dept Anesthesiol, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan.; Wu, ZF (reprint author), Natl Def Med Ctr, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan.	aneswu@gmail.com	Hung, Nan-Kai/C-7178-2016	Hung, Nan-Kai/0000-0002-1853-0793			Batra YK, 2005, PEDIATR ANESTH, V15, P1094, DOI 10.1111/j.1460-9592.2005.01633.x; Brain AI, 1992, INTRAVENT LARYGEAL M; BRIMACOMBE J, 1995, CAN J ANAESTH, V42, P1017, DOI 10.1007/BF03011075; BRIMACOMBE J, 1996, LARYNGEAL MASK AIRWA; Chau SW, 2011, J CLIN ANESTH, V23, P588, DOI 10.1016/j.jclinane.2010.08.024; CHAUDHRI S, 1992, ANAESTHESIA, V47, P551, DOI 10.1111/j.1365-2044.1992.tb02321.x; DYER RA, 1995, BRIT J ANAESTH, V74, P123, DOI 10.1093/bja/74.2.123; Ganatra SB, 2002, EUR J ANAESTH, V19, P371, DOI 10.1017/S0265021502000601; GATAURE PS, 1995, CAN J ANAESTH, V42, P1113, DOI 10.1007/BF03015098; Gil ML, 1999, PAEDIATR ANAESTH, V9, P485, DOI 10.1046/j.1460-9592.1999.00404.x; Hans P, 2008, BRIT J ANAESTH, V101, P731, DOI 10.1093/bja/aen271; Heidari SM, 2005, J RES MED SCI, V10, P59; HICKEY S, 1990, ANAESTHESIA, V45, P629, DOI 10.1111/j.1365-2044.1990.tb14384.x; Hohlrieder M, 2007, BRIT J ANAESTH, V99, P587, DOI 10.1093/bja/aem203; Kati I, 2003, TOHOKU J EXP MED, V200, P111, DOI 10.1620/tjem.200.111; Kitching AJ, 1996, BRIT J ANAESTH, V76, P874; Laffon M, 1994, PAEDIATR ANAESTH, V4, P35, DOI DOI 10.1111/j.1460-9592.1994.tb00119.x; Lee JR, 2008, ANESTH ANALG, V106, P1122, DOI 10.1213/01.ane.0000286174.07844.e9; LEVY L, 1992, ANAESTHESIA, V47, P678, DOI 10.1111/j.1365-2044.1992.tb02389.x; Lim SI, 2006, PEDIATR ANESTH, V16, P1244, DOI 10.1111/j.1460-9592.2006.02005.x; Mathew PJ, 2015, COCHRANE DB SYST REV, V8; MCKEATING K, 1988, ANAESTHESIA, V43, P638, DOI 10.1111/j.1365-2044.1988.tb04146.x; Sahiner Y, 2011, EUR J ANAESTH, V28, P187, DOI 10.1097/EJA.0b013e3283433b83; Shim YH, 2005, ANESTH ANALG, V101, P1034, DOI 10.1213/01.ane.0000166977.17442.63; Sundman E, 2001, ANESTHESIOLOGY, V95, P1125, DOI 10.1097/00000542-200111000-00016; Taylor IN, 1998, ANAESTHESIA, V53, P222, DOI 10.1046/j.1365-2044.1998.00316.x; Ti LK, 1999, ANESTH ANALG, V88, P908, DOI 10.1097/00000539-199904000-00041; VARUGHESE A, 1994, ANESTHESIOLOGY, V81, pA1321; Yoo JY, 2015, YONSEI MED J, V56, P1128, DOI 10.3349/ymj.2015.56.4.1128	29	3	3	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	APR	2016	95	17							e3441	10.1097/MD.0000000000003441			5	Medicine, General & Internal	General & Internal Medicine	DN2XF	WOS:000376925600022	27124034	DOAJ Gold, Green Published			2020-06-30	J	Bishnoi, V; Kumar, B; Bhagat, H; Salunke, P; Bishnoi, S				Bishnoi, Vinod; Kumar, Bhupesh; Bhagat, Hemant; Salunke, Pravin; Bishnoi, Sonika			Comparison of Dexmedetomidine Versus Midazolam-Fentanyl Combination for Monitored Anesthesia Care During Burr-Hole Surgery for Chronic Subdural Hematoma	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						monitored anesthesia care; dexmedetomidine; fentanyl-midazolam; intraoperative movement	CONSCIOUS SEDATION; SURGICAL-TREATMENT; PROFILE	Background: Intraoperative movements are marker of inadequate level of sedation and are undesirable during burr-hole surgery under monitored anesthesia care (MAC). It distracts surgeon, hinders surgical procedure, and may lead to iatrogenic complication. Dexmedetomidine has shown to provide excellent analgesia, cooperative sedation with fewer fluctuations in sedation level during MAC. We compared the effect of dexmedetomidine on intraoperative patient movement, postoperative recovery time, and the surgeon and patient satisfaction scores with commonly used midazolam-fentanyl combination. Methods: Fifty-two patients undergoing burr-hole surgery for chronic subdural hematoma under MAC were randomly assigned to receive either IV dexmedetomidine 1 mu g/kg over 10 minutes followed by continuous infusion 0.03 to 0.07 mu g/kg/h (group D) or IV fentanyl 0.5 mu g/kg and midazolam 0.03 mu g/kg over 10 minutes followed by continuous infusion of 0.5 to 1.16 mu g/kg/h fentanyl and 0.03 to 0.07 mg/kg/h midazolam (group M/F) titrated to maintain Ramsay sedation scale 3. Total number of intraoperative patient movements, postoperative recovery time, and patient and surgeon satisfaction scores were recorded. Results: Demographic and baseline characteristics were comparable between the 2 groups. Intraoperative patient movements were significantly less in group D than group M/F (median interquartile range, 1.00 [0.00 to 2.00] vs. 3.00 [1.00 to 3.25], P = 0.007). Group D patients showed faster postoperative recovery (mean +/- SD, 7.00 +/- 6.96 vs. 13.69 +/- 6.18min, P = 0.000). Surgeon satisfaction scores were better in group D compared with group M/F (median interquartile range, 1.00 [1.00 to 1.25] vs. 2.00 [1.00 to 2.00], P = 0.014). However, patient satisfaction score and hemodynamic parameters were comparable (P > 0.05) between both the groups. Conclusions: Use of dexmedetomidine for MAC is associated with lesser number of intraoperative patient movements, faster postoperative recovery, better surgeon satisfaction score, and comparable patient's satisfaction compared with midazolam-fentanyl combination.	[Bishnoi, Vinod; Kumar, Bhupesh; Bhagat, Hemant] Post Grad Inst Med Educ & Res, Dept Anesthesia & Intens Care, Chandigarh 12, India; [Salunke, Pravin] Post Grad Inst Med Educ & Res, Dept Neurosurg, Chandigarh 12, India; [Bishnoi, Sonika] Postgrad Inst Med Sci, Rohtak, Haryana, India	Kumar, B (reprint author), Post Grad Inst Med Educ & Res, Dept Anesthesia & Intens Care, Chandigarh 12, India.	bhupeshkr@yahoo.com					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Alhashemi JA, 2006, BRIT J ANAESTH, V96, P722, DOI 10.1093/bja/ael080; Bekker AY, 2004, J NEUROSURG ANESTH, V16, P126, DOI 10.1097/00008506-200404000-00004; Candiotti KA, 2010, AMBUL ANESTHESIOL, V110, P327; Cheung CW, 2007, ANAESTHESIA, V62, P1132, DOI 10.1111/j.1365-2044.2007.05230.x; Dere K, 2010, EUR J ANAESTH, V27, P648, DOI 10.1097/EJA.0b013e3283347bfe; Gan TJ, 2006, CLIN PHARMACOKINET, V45, P855, DOI 10.2165/00003088-200645090-00001; Gelabert-Gonzalez M, 2005, CLIN NEUROL NEUROSUR, V107, P223, DOI 10.1016/j.clineuro.2004.09.015; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Gopalakrishna KN, 2015, J NEUROSURG ANESTH, V27, P209, DOI 10.1097/ANA.0000000000000144; Gupta N, 2013, J NEUROSURG ANESTH, V25, P271, DOI 10.1097/ANA.0b013e31828cb6c0; Guzel A, 2008, SWISS MED WKLY, V138, P398, DOI 2008/27/smw-12121; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; Oei-Lim VLB, 1998, EUR J ANAESTH, V15, P535, DOI 10.1046/j.1365-2346.1998.00349.x; Parikh Devangi A, 2013, J Anaesthesiol Clin Pharmacol, V29, P173, DOI 10.4103/0970-9185.111671; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Robin Christian, 2002, Anesth Prog, V49, P128; Streiner D. L., 1995, HLTH MEASUREMENT SCA, V2, P28; Xu XP, 2014, J NEUROSURG ANESTH, V26, P408, DOI 10.1097/ANA.0000000000000034	20	9	10	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2016	28	2					141	146		10.1097/ANA.0000000000000194			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	DM3HS	WOS:000376238100004	26018670				2020-06-30	J	Lian, M; Beckmen, KB; Bentzen, TW; Demma, DJ; Arnemo, JM				Lian, Marianne; Beckmen, Kimberlee B.; Bentzen, Torsten W.; Demma, Dominic J.; Arnemo, Jon M.			THIAFENTANIL-AZAPERONE-XYLAZINE AND CARFENTANIL-XYLAZINE IMMOBILIZATIONS OF FREE-RANGING CARIBOU (RANGIFER TARANDUS GRANTI) IN ALASKA, USA	JOURNAL OF WILDLIFE DISEASES			English	Article						Anesthesia; carfentanil; caribou; hypoxemia; immobilization; opioid; thiafentanil	CHEMICAL IMMOBILIZATION; PLUS XYLAZINE; ANESTHESIA; HYPOXEMIA; REINDEER; MOOSE; ETORPHINE; CALVES	Carfentanil-xylazine (CX) has been the primary drug combination used for immobilizing free-ranging ungulates in Alaska, US since 1986. We investigated the efficacy of a potential new drug of choice, thiafentanil (Investigational New Animal Drug A-3080). Captive trials indicated that thiafentanil-azaperone-medetomidine could provide good levels of immobilization. However, field trials conducted in October 2013 on free-ranging caribou (Rangifer tarandus granti) calves showed the combination too potent, causing three respiratory arrests and one mortality. The protocol was revised to thiafentanil-azaperone-xylazine (TAX), with good results. The induction time was not significantly different between the two combinations. However, the recovery time was significantly shorter for the TAX group than for the CX group. A physiologic evaluation was performed on 12 animals immobilized on CX and 15 animals on TAX. Arterial blood was collected after induction and again after 10 min of intranasal oxygen supplements (1 L/min). Both groups had significant increases in partial pressure of arterial oxygen after oxygen treatment. There was a concurrent significant increase in partial pressure of arterial carbon dioxide in both groups. Rectal temperature increased significantly in both groups during the downtime, which is consistent with other studies of potent opioids in ungulates. On the basis of our results, we found TAX to be a potential alternative for the current CX protocol for immobilizing free-ranging caribou calves via helicopter darting.	[Lian, Marianne; Arnemo, Jon M.] Hedmark Univ Coll, Fac Appl Ecol & Agr Sci, Dept Forestry & Wildlife Management, Campus Evenstad, NO-2480 Elverum, Norway; [Lian, Marianne; Beckmen, Kimberlee B.; Bentzen, Torsten W.] Alaska Dept Fish & Game, Div Wildlife Conservat, 1300 Coll Rd, Fairbanks, AK 99701 USA; [Demma, Dominic J.] Alaska Dept Fish & Game, Div Wildlife Conservat, 1800 Glenn Highway,Suite 2, Palmer, AK 99645 USA; [Arnemo, Jon M.] Swedish Univ Agr Sci, Fac Forest Sci, Dept Wildlife Fish & Environm Studies, SE-90183 Umea, Sweden	Lian, M (reprint author), Hedmark Univ Coll, Fac Appl Ecol & Agr Sci, Dept Forestry & Wildlife Management, Campus Evenstad, NO-2480 Elverum, Norway.; Lian, M (reprint author), Alaska Dept Fish & Game, Div Wildlife Conservat, 1300 Coll Rd, Fairbanks, AK 99701 USA.	mariannelian@gmail.com			Fulbright Foundation	This project was conducted in cooperation with William Lance of Wildlife Pharmaceuticals, Inc., Alaska Department of Fish and Game, and Hedmark University College. Quicksilver Air, Inc. performed helicopter support. We appreciate the assistance of William B. Collins for facilitating the captive caribou trials. Thanks also to the ADF&G biologists and technicians from the Fairbanks, Palmer, Tok, and Dillingham offices for their assistance. Stipend support was from the Fulbright Foundation.	Blix AS, 2011, J EXP BIOL, V214, P3850, DOI 10.1242/jeb.057455; CAULKETT NA, 1994, J ZOO WILDLIFE MED, V25, P376; Cote SD, 1998, J WILDLIFE MANAGE, V62, P745, DOI 10.2307/3802351; Evans AL, 2013, J WILDLIFE DIS, V49, P1037, DOI 10.7589/2013-03-049; Fahlman A, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P69; Fahlman A, 2012, J ZOO WILDLIFE MED, V43, P67, DOI 10.1638/2011-0064.1; Glenn LP, 1967, W15R1 FED AID WILDL; Haga HA, 2009, VET ANAESTH ANALG, V36, P555, DOI 10.1111/j.1467-2995.2009.00498.x; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; Hartsfield SM, 2007, LUMB JONES VET ANEST, P495; Ko JC, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P65; Kreeger T, 2012, HDB WILDLIFE CHEM IM, P448; Kreeger Terry J., 2005, Alces, V41, P121; Kreeger TJ, 2001, J WILDLIFE MANAGE, V65, P25, DOI 10.2307/3803272; Lance WR, 2011, FOWLERS ZOO WILD ANI, P589; LARSEN DG, 1989, J WILDLIFE MANAGE, V53, P564, DOI 10.2307/3809177; McDonell WC, 2007, LUMB JONES VET ANEST, P117; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; R Development Core Team, 2014, R LANG ENV STAT COMP; Read MR, 2003, J ZOO WILDLIFE MED, V34, P134, DOI 10.1638/1042-7260(2003)034[0134:AROAAA]2.0.CO;2; Risling TE, 2011, ANIM PROD SCI, V51, P355, DOI 10.1071/AN10190; Stanley TH, 1986, DAAK1184K0002 US DEP; Steffey E. P., 2001, Veterinary pharmacology and therapeutics, P172; Valkenburg P, 1999, WILDLIFE SOC B, V27, P894; Wolfe LL, 2004, J WILDLIFE DIS, V40, P282, DOI 10.7589/0090-3558-40.2.282	25	10	10	1	10	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558	1943-3700		J WILDLIFE DIS	J. Wildl. Dis.	APR	2016	52	2					327	334		10.7589/2015-04-101			8	Veterinary Sciences	Veterinary Sciences	DK8XP	WOS:000375213100016	26967141				2020-06-30	J	Ucar, M; Erdil, F; Sanli, M; Aydogan, MS; Durmus, M				Ucar, Muharrem; Erdil, Feray; Sanli, Mukadder; Aydogan, Mustafa Said; Durmus, Mahmut			Anesthesia Management in Aortic Dissection in Patients Undergoing Kidney Transplant	EXPERIMENTAL AND CLINICAL TRANSPLANTATION			English	Article						Anesthesia; Aortic surgery; Renal transplanted patients; Complications	CARDIOVASCULAR EVENTS; ISOFLURANE; INJURY	Kidney transplant is a last resort to increase the life expectancy and quality of life in patients with renal failure. Aortic dissection is a disease that requires emergency intervention; it is characterized by sudden life-threatening back or abdominal pain. In the case described, constant chest pain that increased with respiration was present on exam-ination of a 28-year-old man (85 kg, 173 cm) who presented at our emergency department complaining of severe back pain. He had undergone a kidney transplant in 2004 from his mother (live donor). He was diagnosed with acute Type II aortic dissection and was scheduled for emergent surgery. Because there were no surgical or anesthetic complications, the patient with 79 and 89 minutes aortic cross-clamping and cardiopulmonary bypass durations was sent, intubated, to intensive care unit. When nephrotoxic agents are avoided and blood flow is stabilized, cardiovascular surgery with cardiopulmonary bypass may be performed seamlessly in patients who have undergone a kidney transplant.	[Ucar, Muharrem; Erdil, Feray; Sanli, Mukadder; Aydogan, Mustafa Said; Durmus, Mahmut] Inonu Univ, Fac Med, Dept Anesthesiol & Reanimat, Malatya, Turkey	Aydogan, MS (reprint author), Inonu Univ, Anesthesiol & Reanimat, Sch Med, Dept Anesthesiol & Reanimat, Malatya, Turkey.	dr_mustafasaid@hotmail.com	Durmus, Mahmut/AAG-3377-2019				Aalten J, 2008, TRANSPL INT, V21, P985, DOI 10.1111/j.1432-2277.2008.00717.x; Arnaoutakis GJ, 2007, J THORAC CARDIOV SUR, V134, P1554, DOI 10.1016/j.jtcvs.2007.08.039; Boschiero L, 2009, TRANSPL P, V41, P1183, DOI 10.1016/j.transproceed.2009.02.047; Donmez A, 1998, TRANSPLANT P, V30, P790, DOI 10.1016/S0041-1345(98)00050-5; Englberger L, 2011, J THORAC CARDIOV SUR, V141, P552, DOI 10.1016/j.jtcvs.2010.02.045; GONSOWSKI CT, 1994, ANESTHESIOLOGY, V80, P556, DOI 10.1097/00000542-199403000-00012; Kara I, 2013, SELCUK TIP DERG, V29, P100; Kim WH, 2013, J CARDIOTHOR VASC AN, V27, P1158, DOI 10.1053/j.jvca.2013.04.007; Kucukarslan Nezihi, 2006, Anadolu Kardiyol Derg, V6, P193; Litz RJ, 2002, ANESTHESIOLOGY, V97, P1133, DOI 10.1097/00000542-200211000-00016; Moon IS, 2006, TRANSPL P, V38, P2022, DOI 10.1016/j.transproceed.2006.06.108; Musci M, 2007, TRANSPLANTATION, V84, P592, DOI 10.1097/01.tp.0000279005.85046.a6; Sear JW, 2005, BRIT J ANAESTH, V95, P20, DOI 10.1093/bja/aei018; Teixeira S, 2007, TRANSPL P, V39, P2486, DOI 10.1016/j.transproceed.2007.07.038; Tezcaner T, 1996, J TURKISH NEPHROLOGY, V3, P127; Wang LW, 2011, AM J KIDNEY DIS, V57, P476, DOI 10.1053/j.ajkd.2010.11.018; Yagmur F, 2010, DUZCE TIP DERGISI, V12, P68	17	1	1	0	2	BASKENT UNIV	ANKARA	TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY	1304-0855			EXP CLIN TRANSPLANT	Exp. Clin. Transplant.	APR	2016	14	2					227	229		10.6002/ect.2014.0100			3	Transplantation	Transplantation	DI4DX	WOS:000373451700017	25375956				2020-06-30	J	You, HJ; Lei, J; Xiao, Y; Ye, G; Sun, ZH; Yang, L; Niu, N				You, Hao-Jun; Lei, Jing; Xiao, Ying; Ye, Gang; Sun, Zhi-Hong; Yang, Lan; Niu, Nan			Pre-emptive analgesia and its supraspinal mechanisms: enhanced descending inhibition and decreased descending facilitation by dexmedetomidine	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							SPINAL WITHDRAWAL REFLEXES; OPIOID RECEPTORS; PAIN MODULATION; NOCICEPTION; RATS; STIMULATION; PATHWAYS; SEDATION; ANTINOCICEPTION; ANESTHESIA	We investigated and compared the antinociceptive effects of intraperitoneal administration of fentanyl (2-60gkg(-1)) and dexmedetomidine (Dex, 1-10gkg(-1); a highly selective 2-adrenoceptor agonist) in the regulation of nociception assessed by measuring noxious paw withdrawal reflexes in rats. Fentanyl elevated noxious mechanical paw withdrawal threshold and prolonged paw withdrawal heat latency within 1-1.5h (P<0.05). Dex failed to affect the mechanical paw withdrawal threshold, yet significantly prolonged the paw withdrawal heat latency in a bi-phasic manner; a short transient 1-1.5h period followed by a second, slowly developing increase in latency that persisted for at least 7days (P<0.05). Lesion of the dorsolateral funiculus (DLF) did not influence fentanyl-induced antinociceptive effects, indicating peripheral and spinal antinociceptive mechanisms. By contrast, the Dex-induced second, but not the first, phase of the prolonged paw withdrawal heat latency was significantly blocked by the lesion of either DLF or thalamic ventromedial (VM) nuclei, and was attenuated by intracerebral administration of either atipamezole (2-adrenoceptor antagonist) or WAY-100635 (5-HT1A receptor antagonist) into the VM nuclei (P<0.05). Upon intramuscular 5.8% saline-induced muscle nociception, pre-emptive injection of fentanyl enhanced mechanical hyperalgesia and blocked heat hypoalgesia, whereas Dex significantly prevented the occurrence of mechanical hyperalgesia and enhanced heat hypoalgesia. It is suggested that Dex, but not fentanyl, significantly enhances descending inhibition and/or decreases descending facilitation to modulate pain and nociception. The present study provides novel insight into thalamus-mediated mechanisms in pre-emptive analgesia.	[You, Hao-Jun; Lei, Jing; Xiao, Ying; Yang, Lan; Niu, Nan] Xi An Jiao Tong Univ, Coll Med, Ctr Biomed Res Pain, Xian 710061, Peoples R China; [Xiao, Ying] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Anesthesia, Xian 710061, Peoples R China; [Ye, Gang] Shanghai Tongji Univ, Tongji Hosp, Dept Pain, Shanghai 200065, Peoples R China; [Sun, Zhi-Hong] Yanan Univ, Coll Life Sci, Yanan 716000, Peoples R China	You, HJ (reprint author), Xi An Jiao Tong Univ, Coll Med, Ctr Biomed Res Pain, Xian 710061, Peoples R China.	yhj@mail.xjtu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81271228, 81473752]	The present work was supported by grants from the National Natural Science Foundation of China (81271228, 81473752) to H.-J.Y.	BASBAUM AI, 1979, J COMP NEUROL, V187, P513, DOI 10.1002/cne.901870304; BASBAUM AI, 1978, ANN NEUROL, V4, P451, DOI 10.1002/ana.410040511; BELCHER G, 1978, BRAIN RES, V151, P307, DOI 10.1016/0006-8993(78)90887-9; BESSON JM, 1987, PHYSIOL REV, V67, P67; Bol CJJG, 1997, J PHARMACOL EXP THER, V283, P1051; Buerkle H, 1998, BRIT J ANAESTH, V81, P208; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; CERVERO F, 1984, PAIN, V20, P125, DOI 10.1016/0304-3959(84)90094-0; Coggeshall RE, 1997, BRAIN RES, V764, P126, DOI 10.1016/S0006-8993(97)00446-0; Colpaert FC, 1996, PHARMACOL REV, V48, P355; Crile GW, 1913, LANCET, V2, P7; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Fields H L, 1976, Trans Am Neurol Assoc, V101, P208; FIELDS HL, 1992, APS J, V1, P71; Grundy D, 2015, J PHYSIOL-LONDON, V593, P2547, DOI 10.1113/JP270818; HABER LH, 1980, J NEUROPHYSIOL, V43, P1578; Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009; Henderson LA, 2013, J NEUROSCI, V33, P7574, DOI 10.1523/JNEUROSCI.0174-13.2013; Laux-Biehlmann A, 2013, NEUROSCIENCE, V233, P95, DOI 10.1016/j.neuroscience.2012.12.013; Lei J, 2013, EXP NEUROL, V248, P100, DOI 10.1016/j.expneurol.2013.06.001; Lei J, 2011, EXP NEUROL, V228, P206, DOI 10.1016/j.expneurol.2011.01.004; Malmberg AB, 2001, BRIT J PHARMACOL, V132, P1827, DOI 10.1038/sj.bjp.0704032; MANSOUR A, 1987, J NEUROSCI, V7, P2445; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; Ossipov MH, 2014, CURR OPIN SUPPORT PA, V8, P143, DOI 10.1097/SPC.0000000000000055; Paris A, 2005, CURR OPIN ANESTHESIO, V18, P412, DOI 10.1097/01.aco.0000174958.05383.d5; Paxinos G., 1998, RAT BRAIN STEREOTAXI; PERTOVAARA A, 1994, PAIN, V57, P207, DOI 10.1016/0304-3959(94)90225-9; Pertovaara A, 2013, EUR J PHARMACOL, V716, P2, DOI 10.1016/j.ejphar.2013.01.067; Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166-2236(02)02157-4; Ren K, 2009, SCI PAIN, P723; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; SAADE NE, 1990, PAIN, V42, P313, DOI 10.1016/0304-3959(90)91144-8; Sanders RD, 2005, ANESTH ANALG, V100, P1295, DOI 10.1213/01.ANE.0000149595.41576.B3; Stone LS, 1997, J NEUROSCI, V17, P7157; Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6; TJOLSEN A, 1991, ACTA PHYSIOL SCAND, V142, P229, DOI 10.1111/j.1748-1716.1991.tb09151.x; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; You HJ, 2013, NEUROSCIENCE, V232, P53, DOI 10.1016/j.neuroscience.2012.12.021; You HJ, 2014, J PHYSIOL-LONDON, V592, P4365, DOI 10.1113/jphysiol.2014.275800; You HJ, 2010, J PHYSIOL-LONDON, V588, P4177, DOI 10.1113/jphysiol.2010.196923; You HJ, 2005, EUR J NEUROSCI, V22, P354, DOI 10.1111/j.1460-9568.2005.04234.x; You HJ, 2003, NEUROSCIENCE, V121, P459, DOI 10.1016/S0306-4522(03)00296-3	43	6	9	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	APR 1	2016	594	7					1875	1890		10.1113/JP271991			16	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	DI7IT	WOS:000373673600007	26732231	Bronze, Green Published			2020-06-30	J	Scott, LJ				Scott, Lesley J.			Fentanyl Iontophoretic Transdermal System: A Review in Acute Postoperative Pain	CLINICAL DRUG INVESTIGATION			English	Review							PATIENT-CONTROLLED ANALGESIA; INTRAVENOUS MORPHINE PUMP; MANAGEMENT; EFFICACY; SAFETY; METAANALYSIS; DELIVERY; SURGERY; PATCH	Fentanyl iontophoretic transdermal system (ITS) [Ionsys (R)] is indicated for the management of acute postoperative pain in adults requiring opioid analgesia in the hospital setting. This article reviews the clinical use of fentanyl ITS for postoperative pain management, and summarizes the pharmacology of fentanyl and the characteristics of the two-component fentanyl ITS (Ionsys (R)) device. In well-designed, multicentre clinical trials, fentanyl ITS was an effective and generally well tolerated method for managing acute postoperative pain in inpatients who had undergone major abdominal, thoracic or orthopaedic surgery. Overall, fentanyl ITS provided equivalent analgesic efficacy to that with morphine patient-controlled intravenous analgesia (PCIA), but was perceived to be more convenient/easier to use than morphine PCIA by patients, nurses and physical therapists. Patients receiving fentanyl ITS also had a greater ability to mobilize after surgery than patients receiving morphine PCIA. In addition, relative to morphine PCIA, fentanyl ITS offers advantages in terms of the noninvasive administrative route (i.e. transdermal needle-free administration), pre-programmed delivery (no risk of programming errors/incorrect dosing) and improved tolerability with regard to the overall incidence of opioid-related adverse events (ORAEs) and some individual ORAEs. Hence, fentanyl ITS is a useful option for the management of acute postoperative pain in adults requiring opioid analgesia in the hospital setting.	[Scott, Lesley J.] Springer, Private Bag 65901, Auckland 0754, New Zealand	Scott, LJ (reprint author), Springer, Private Bag 65901, Auckland 0754, New Zealand.	demail@springer.com					Abraham J, 2015, VALUE HEALTH, V18, pA295, DOI 10.1016/j.jval.2015.03.1721; Abraham J, 2015, 69 ANN POSTGR ASS AN; Ahmad Shireen, 2007, Archives of Gynecology and Obstetrics, V276, P251, DOI 10.1007/s00404-007-0339-z; Argoff CE, 2014, PAIN PRACT, V14, P477, DOI 10.1111/papr.12108; Bourne MH, 2010, PHYS THER, V90, P707, DOI 10.2522/ptj.20080323; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Danesi H, 2015, 25 AM SOC PAIN MAN N; Eberhart Leopold, 2007, J Opioid Manag, V3, P249; European Medicines Agency, 2015, IONS 40 MICR PER DOS; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Grond S, 2015, EUR J ANAESTHESI S53, V32, P325; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Hair PI, 2008, DRUGS, V68, P2001, DOI 10.2165/00003495-200868140-00005; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hartrick CT, 2015, J OPIOID MANAG, DOI [10.5055/jom.2015.0000, DOI 10.5055/JOM.2015.0000]; Hoy SM, 2008, DRUGS, V68, P1711, DOI 10.2165/00003495-200868120-00008; Joshi N, 2016, PAIN MANAG, V6, P137, DOI 10.2217/pmt.15.70; Lane ME, 2013, EUR J PHARM BIOPHARM, V84, P449, DOI 10.1016/j.ejpb.2013.01.018; Langford R, 2015, EUR J ANAESTHESI S53, V32, P325; Langford R, 2014, ANN M AM SOC AN; Mattia C, 2010, EUR J ANAESTH, V27, P433, DOI 10.1097/EJA.0b013e3283349d82; Minkowitz H, 2014, ANESTH ANALG, V118, pS209; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Minkowitz HS, 2015, PAIN MANAG, V5, P327, DOI [10.2217/pmt.15.26, 10.2217/PMT.15.26]; Minkowitz Harold S, 2010, J Opioid Manag, V6, P203; Misiolek H, 2014, ANAESTH INTENSIVE TH, V46, P221, DOI [10.5603/AIT.2014.0041, 10.5603/AIT.2014.041]; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Oliasharizi A, 2015, AM AC PAIN MED AAPM; Phipps JB, 2015, EXPERT OPIN DRUG MET, V11, P481, DOI 10.1517/17425255.2015.1020296; Poon KH, 2009, ACUTE PAIN, V11, P65; Raders P van, 2007, Br J Nurs, V16, P312; Saffer CS, 2015, PAIN MANAG, V5, P339, DOI [10.2217/PMT.15.29, 10.2217/pmt.15.29]; Sathyan G, 2009, CURR MED RES OPIN, V25, P363, DOI 10.1185/03007990802594941 ; Schechter LN, 2015, J PERIANESTH NURS, V30, pe44; Sinatra RS, 2015, EXPERT OPIN PHARMACO, V16, P1607, DOI 10.1517/14656566.2015.1054279; The Medicines Company, 2015, IONS FENT IONT TRANS; Tongbram V, 2015, VALUE HEALTH, V18, pA346, DOI 10.1016/j.jval.2015.09.615; Viscusi E, 2015, 69 ANN POSTGR ASS AN; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2005, REGION ANESTH PAIN M, V30, P292, DOI 10.1016/j.rapm.2004.12.002; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Viscusi ER, 2016, PAIN MANAG, V6, P19, DOI 10.2217/pmt.15.49	44	6	7	0	6	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	APR	2016	36	4					321	330		10.1007/s40261-016-0387-x			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DH9GO	WOS:000373104600008	26968174				2020-06-30	J	Chalkiadis, GA; Sommerfield, D; Low, J; Orsini, F; Dowden, SJ; Tay, M; Penrose, S; Pirpiris, M; Graham, HK				Chalkiadis, George A.; Sommerfield, David; Low, Janette; Orsini, Francesca; Dowden, Stephanie J.; Tay, Michelle; Penrose, Sueann; Pirpiris, Marinis; Graham, H. Kerr			Comparison of lumbar epidural bupivacaine with fentanyl or clonidine for postoperative analgesia in children with cerebral palsy after single-event multilevel surgery	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							VENTILATORY RESPONSE; CARBON-DIOXIDE; ORAL CLONIDINE; ANESTHESIA; SPASTICITY; INFUSIONS; MORPHINE; DISEASE; HUMANS; INJURY	AimTo compare diazepam use, muscle spasm, analgesia, and side effects when clonidine or fentanyl are added to epidural bupivacaine in children with cerebral palsy after multilevel orthopaedic surgery. MethodFifty children were prospectively randomized to receive clonidine (n=24, mean age 10y 10mo [SD 2y 11mo]) or fentanyl (n=26, mean age 10y 11mo [SD 2y 10mo]). ResultsThere was no difference in primary outcome measures: median diazepam use (fentanyl 0, interquartile range [IQR] 0-0; clonidine 0, IQR 0-0; p=0.46), any muscle spasm (no muscle spasms in: fentanyl, 36%; clonidine, 62%; p=0.11), painful muscle spasm (fentanyl 40%; clonidine 25%; p=0.46), or pain score 6 (none: fentanyl 44%; clonidine 42%; p=0.29). There were differences in secondary outcome measures: no vomiting (clonidine 63%; fentanyl 20%); vomiting occurred more frequently with fentanyl (32% vomited more than three times; clonidine none; p=0.001). Fentanyl resulted in more oxygen desaturation (at least two episodes: fentanyl 20%; clonidine 0; p<0.001). Clonidine resulted in lower mean (SD) area under the curve for systolic blood pressure (fentanyl 106.5 [11.0]; clonidine 95.7mmHg [7.9]) and heart rate (fentanyl 104.9 beats per minute [13.6]; clonidine 85.3 [11.5]; p<0.001). InterpretationClonidine and fentanyl provide adequate analgesia with low rates of muscle spasm, resulting in low diazepam use. The choice of epidural additive should be based upon the most tolerable side-effect profile.	[Chalkiadis, George A.; Sommerfield, David; Low, Janette; Dowden, Stephanie J.; Tay, Michelle; Penrose, Sueann] Royal Childrens Hosp, Dept Paediat Anaesthesia & Pain Management, Flemington Rd, Melbourne, Vic 3052, Australia; [Chalkiadis, George A.; Orsini, Francesca; Pirpiris, Marinis; Graham, H. Kerr] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Chalkiadis, George A.; Pirpiris, Marinis; Graham, H. Kerr] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Pirpiris, Marinis; Graham, H. Kerr] Royal Childrens Hosp, Dept Orthopaed, Flemington Rd, Melbourne, Vic 3052, Australia	Chalkiadis, GA (reprint author), Royal Childrens Hosp, Dept Paediat Anaesthesia & Pain Management, Flemington Rd, Parkville, Vic 3052, Australia.	george.chalkiadis@rch.org.au	Pirpiris, Marinis/AAG-9789-2019; Graham, Kerr/AAK-4383-2020		Victorian Government's Operational Infrastructure Program, Australia	We thank Mary Sheedy for help with preparing this manuscript, Farah Abdullah for data collection, and Rory Wolfe, Katherine Smith, and Michelle Wiest for statistical help. This research was supported by the Victorian Government's Operational Infrastructure Program, Australia. HKG is on the Surgeon's Advisory Board Orthopaediatrics. The remaining authors have stated that they had no interests that could be perceived as posing a bias or conflict.	Aker John, 2007, AANA J, V75, P65; Baikie G, 2009, J PAEDIATR CHILD H, V45, P342, DOI 10.1111/j.1440-1754.2009.01496.x; BAILEY PL, 1991, ANESTHESIOLOGY, V74, P43, DOI 10.1097/00000542-199101000-00008; BONNET F, 1989, BRIT J ANAESTH, V63, P465, DOI 10.1093/bja/63.4.465; Brenn BR, 1998, CAN J ANAESTH, V45, P1156, DOI 10.1007/BF03012456; Cucchiaro G, 2003, PAEDIATR ANAESTH, V13, P318, DOI 10.1046/j.1460-9592.2003.01010.x; Cucchiaro G, 2006, ANESTH ANALG, V103, P322, DOI 10.1213/01.ane.0000221047.68114.ad; Dall JT, 1996, BRAIN INJURY, V10, P453; De Negri P, 2001, ANESTH ANALG, V93, P71; Disma N, 2011, PEDIATR ANESTH, V21, P128, DOI 10.1111/j.1460-9592.2010.03478.x; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; Fitzgerald DA, 2009, PAEDIATR RESPIR REV, V10, P18, DOI 10.1016/j.prrv.2008.10.003; Hall JE, 2001, BRIT J ANAESTH, V86, P5, DOI 10.1093/bja/86.1.5; JARVIS DA, 1992, ANESTHESIOLOGY, V76, P899, DOI 10.1097/00000542-199206000-00005; Klamt JG, 2003, J CLIN ANESTH, V15, P510, DOI 10.1016/j.jclinane.2003.02.005; Lovstad RZ, 2001, ACTA ANAESTH SCAND, V45, P482, DOI 10.1034/j.1399-6576.2001.045004482.x; Lubsch L, 2006, J CHILD NEUROL, V21, P1090, DOI 10.1177/7010.2006.00134; MIKAWA K, 1995, CAN J ANAESTH, V42, P977, DOI 10.1007/BF03011068; Nishina K, 2004, PEDIATR ANESTH, V14, P1001, DOI 10.1111/j.1460-9592.2004.01371.x; Nishina K, 1999, PAEDIATR ANAESTH, V9, P187; Nolan J, 2000, ANAESTHESIA, V55, P32, DOI 10.1046/j.1365-2044.2000.01065.x; Odding E, 2006, DISABIL REHABIL, V28, P183, DOI 10.1080/09638280500158422; OOI R, 1991, ANAESTHESIA, V46, P632, DOI 10.1111/j.1365-2044.1991.tb09709.x; PENON C, 1991, ANESTH ANALG, V72, P761; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Sankri-Tarbichi AG, 2013, RESP PHYSIOL NEUROBI, V185, P356, DOI 10.1016/j.resp.2012.09.005; Shukla Usha, 2011, J Anaesthesiol Clin Pharmacol, V27, P205, DOI 10.4103/0970-9185.81842; Thomason P, 2013, GAIT POSTURE, V37, P23, DOI 10.1016/j.gaitpost.2012.05.022; Thomason P, 2011, J BONE JOINT SURG AM, V93A, P451, DOI 10.2106/JBJS.J.00410; Tilton Ann H, 2004, Semin Pediatr Neurol, V11, P58, DOI 10.1016/j.spen.2004.01.008; Wass CT, 2012, J CHILD NEUROL, V27, P859, DOI 10.1177/0883073811428378; Wongprasartsuk P, 2002, PAEDIATR ANAESTH, V12, P296, DOI 10.1046/j.1460-9592.2002.00635.x; WOOLF CJ, 1985, NEUROSCIENCE, V16, P395, DOI 10.1016/0306-4522(85)90011-9	33	6	6	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	APR	2016	58	4					402	408		10.1111/dmcn.12930			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	DH6MM	WOS:000372904800018	26400818	Bronze			2020-06-30	J	Hayashi, N; Kanai, A; Suzuki, A; Nagahara, Y; Okamoto, H				Hayashi, Norihito; Kanai, Akifumi; Suzuki, Asaha; Nagahara, Yuki; Okamoto, Hirotsugu			Response to intravenous fentanyl infusion predicts subsequent response to transdermal fentanyl	JOURNAL OF ANESTHESIA			English	Article						Chronic pain; Intravenous; Transdermal fentanyl	CHRONIC NONCANCER PAIN; NEUROPATHIC PAIN; CONTROLLED-TRIALS; ANALGESIA; CROSSOVER; EFFICACY; THERAPY; OPIOIDS; SAFETY	Prediction of the response to transdermal fentanyl (FENtd) before its use for chronic pain is desirable. We tested the hypothesis that the response to intravenous fentanyl infusion (FENiv) can predict the response to FENtd, including the analgesic and adverse effects. The study subjects were 70 consecutive patients with chronic pain. The response to fentanyl at 0.1 mg diluted in 50 ml of physiological saline and infused over 30 min was tested. This was followed by treatment with FENtd (Durotep MT patch 2.1 mg) at a dose of 12.5 A mu g/h for 2 weeks. Pain intensity before and after FENiv and 2 weeks after FENtd, and the response to treatment, were assessed by the numerical rating scale (NRS), clinical global impression-improvement scale (CGI-I), satisfaction scale (SS), and adverse effects. The NRS score decreased significantly from 7 (4-9) [median (range)] at baseline to 3 (0-8) after FENiv (p < 0.001), and to 4 (1-8) after FENtd (p < 0.001). The effects of FENiv, as evaluated by Delta NRS, CGI-I, and SS, were significantly greater than those of FENtd (p < 0.001, each), but not by the frequency and the severity of adverse effects, with the exception of dizziness. Delta NRS, and severity of adverse effects (drowsiness, dizziness, nausea, dry mouth, and pruritus) of FENiv correlated significantly with those of FENtd (rs > 0.04, each). The analgesic and side effects after intravenous fentanyl infusion can be used to predict the response to short-term transdermal treatment with fentanyl.	[Hayashi, Norihito; Suzuki, Asaha; Nagahara, Yuki; Okamoto, Hirotsugu] Kitasato Univ, Sch Med, Dept Anesthesiol, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan; [Kanai, Akifumi] Kitasato Univ, Sch Med, Res & Dev Ctr New Med Frontiers, Sagamihara, Kanagawa 2520374, Japan	Hayashi, N (reprint author), Kitasato Univ, Sch Med, Dept Anesthesiol, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.	mininoriton@ybb.ne.jp					Attal N, 2002, NEUROLOGY, V58, P554, DOI 10.1212/WNL.58.4.554; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; Chapman CR, 2010, J PAIN, V11, P807, DOI 10.1016/j.jpain.2010.02.019; Cohen SP, 2009, ANESTHESIOLOGY, V111, P416, DOI 10.1097/ALN.0b013e3181ac1c47; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; DESMEULES J, 1991, EUR J CLIN PHARMACOL, V41, P23, DOI 10.1007/BF00280101; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; Gasche Y, 2004, NEW ENGL J MED, V351, P2827, DOI 10.1056/NEJMoa041888; Hedges DW, 2009, HUM PSYCHOPHARM CLIN, V24, P35, DOI 10.1002/hup.989; Huse E, 2001, PAIN, V90, P47, DOI 10.1016/S0304-3959(00)00385-7; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Kanai A, 2010, PAIN MED, V11, P609, DOI 10.1111/j.1526-4637.2010.00825.x; Saunders KW, 2010, J GEN INTERN MED, V25, P310, DOI 10.1007/s11606-009-1218-z; Soderberg KC, 2013, CNS DRUGS, V27, P155, DOI 10.1007/s40263-013-0038-1; Wasan AD, 2005, PAIN, V117, P450, DOI 10.1016/j.pain.2005.08.006	16	0	0	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2016	30	2					238	243		10.1007/s00540-015-2107-8			6	Anesthesiology	Anesthesiology	DI2BL	WOS:000373300600009	26661448				2020-06-30	J	Mohta, M; Kalra, B; Sethi, AK; Kaur, N				Mohta, Medha; Kalra, Bhumika; Sethi, Ashok K.; Kaur, Navneet			Efficacy of dexmedetomidine as an adjuvant in paravertebral block in breast cancer surgery	JOURNAL OF ANESTHESIA			English	Article						Bupivacaine; Paravertebral block; Breast surgery; Dexmedetomidine; Postoperative pain	PERIPHERAL-NERVE BLOCK; ALPHA-2-ADRENOCEPTOR AGONIST; BUPIVACAINE; ANALGESIA; NEUROTOXICITY; CLONIDINE; BLIND; LEVOBUPIVACAINE; ROPIVACAINE; COMBINATION	This study evaluated the analgesic efficacy of dexmedetomidine in combination with bupivacaine for single-shot paravertebral block (PVB) in patients undergoing major breast cancer surgery. This prospective, randomized double blind study was conducted in 45 ASA I/II/III females, aged a parts per thousand yen18 years, undergoing modified radical mastectomy or breast conservation surgery with axillary lymph node dissection. Patients in group PB (paravertebral-bupivacaine) received PVB with 0.5 % bupivacaine 0.3 ml/kg with 1 ml normal saline; group PBD (paravertebral-bupivacaine-dexmedetomidine) received PVB with 0.5 % bupivacaine 0.3 ml/kg and dexmedetomidine 1 mu g/kg in a volume of 1 ml; and group C (control) patients were given a sham block (a subcutaneous injection with 2 ml normal saline) before receiving general anesthesia (GA). All patients received analgesia by fentanyl intraoperatively and morphine patient-controlled analgesia postoperatively. The control group patients required more intraoperative fentanyl than the other two groups. Patients receiving dexmedetomidine had lower morphine consumption (p < 0.001), pain scores and incidence of postoperative nausea/vomiting (p = 0.011); longer time to first analgesic request; earlier time to mobilize; and better satisfaction scores. Heart rate and blood pressure values during the intraoperative period were also lower at many time points in this group. However, the incidence of hypotension and bradycardia were statistically similar in all groups. PVB using dexmedetomidine 1 A mu g/kg added to 0.5 % bupivacaine in patients undergoing major breast cancer surgery under GA provides analgesia of longer duration with decreased postoperative opioid consumption and lower incidence of nausea/vomiting compared to PVB with bupivacaine alone or no PVB.	[Mohta, Medha; Kalra, Bhumika; Sethi, Ashok K.] Univ Coll Med Sci, Dept Anaesthesiol & Crit Care, Delhi 110095, India; [Mohta, Medha; Kalra, Bhumika; Sethi, Ashok K.; Kaur, Navneet] Guru Teg Bahadur Hosp, Delhi 110095, India; [Kaur, Navneet] Univ Coll Med Sci, Dept Surg, Delhi 110095, India; [Mohta, Medha] 28-B,Pocket C,SFS Flats,Mayur Vihar Phase 3, Delhi 110096, India	Mohta, M (reprint author), Univ Coll Med Sci, Dept Anaesthesiol & Crit Care, Delhi 110095, India.; Mohta, M (reprint author), Guru Teg Bahadur Hosp, Delhi 110095, India.; Mohta, M (reprint author), 28-B,Pocket C,SFS Flats,Mayur Vihar Phase 3, Delhi 110096, India.	medhamohta@hotmail.com					Abdallah FW, 2013, BRIT J ANAESTH, V110, P915, DOI 10.1093/bja/aet066; Al-Mustafa MM, 2009, SAUDI MED J, V30, P365; Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; Bajwa SJS, 2011, SAUDI J ANAESTH, V5, P365, DOI 10.4103/1658-354X.87264; Biswas S, 2014, ETHIOP J HEALTH SCI, V24, P203, DOI 10.4314/ejhs.v24i3.3; Boughey JC, 2009, AM J SURG, V198, P720, DOI 10.1016/j.amjsurg.2008.11.043; Brummett CM, 2008, ANESTHESIOLOGY, V109, P502, DOI 10.1097/ALN.0b013e318182c26b; Burlacu CL, 2006, ANAESTHESIA, V61, P932, DOI 10.1111/j.1365-2044.2006.04793.x; Celik F, 2013, INT J SURG, V11, P414, DOI 10.1016/j.ijsu.2013.03.008; Duan X, 2014, ACTA ANAESTH SCAND, V58, P1121, DOI 10.1111/aas.12356; EASON MJ, 1979, ANAESTHESIA, V34, P638, DOI 10.1111/j.1365-2044.1979.tb06363.x; El-Hennawy AM, 2009, BRIT J ANAESTH, V103, P268, DOI 10.1093/bja/aep159; Esmaoglu A, 2010, ANESTH ANALG, V111, P1548, DOI 10.1213/ANE.0b013e3181fa3095; Fritsch G, 2014, REGION ANESTH PAIN M, V39, P37, DOI 10.1097/AAP.0000000000000033; Fujii Y, 1998, ACTA ANAESTH SCAND, V42, P1038, DOI 10.1111/j.1399-6576.1998.tb05373.x; Gartner R, 2009, JAMA-J AM MED ASSOC, V302, P1985, DOI 10.1001/jama.2009.1568; Grover VK, 2009, J POSTGRAD MED, V55, P257, DOI 10.4103/0022-3859.58928; Gupta R, 2011, INDIAN J ANAESTH, V55, P347, DOI 10.4103/0019-5049.84841; Gupta Rajni, 2011, J Anaesthesiol Clin Pharmacol, V27, P339, DOI 10.4103/0970-9185.83678; Kairaluoma PM, 2004, ANESTH ANALG, V99, P1837, DOI 10.1213/01.ANE.0000136775.15566.87; KALLIO A, 1989, CLIN PHARMACOL THER, V46, P33, DOI 10.1038/clpt.1989.103; Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x; Klein SM, 2000, ANESTH ANALG, V90, P1402, DOI 10.1097/00000539-200006000-00026; Koksal E, 2013, BALK MED J, V30, P355, DOI 10.5152/balkanmedj.2013.7747; Kol IO, 2009, CLIN DRUG INVEST, V29, P121, DOI 10.2165/0044011-200929020-00006; Konakci S, 2008, EUR J ANAESTH, V25, P403, DOI 10.1017/S0265021507003079; Marhofer D, 2013, BRIT J ANAESTH, V110, P438, DOI 10.1093/bja/aes400; Mohamed SA, 2014, PAIN PHYSICIAN, V17, pE589; Moller JF, 2007, ANESTH ANALG, V105, P1848, DOI 10.1213/01.ane.0000286135.21333.fd; Obayah GM, 2010, EUR J ANAESTH, V27, P280, DOI 10.1097/EJA.0b013e3283347c15; Poleshuck EL, 2006, J PAIN, V7, P626, DOI 10.1016/j.jpain.2006.02.007; Saadawy I, 2009, ACTA ANAESTH SCAND, V53, P251, DOI 10.1111/j.1399-6576.2008.01818.x; Sadhasivam S, 2012, PHARMACOGENOMICS, V13, P1719, DOI [10.2217/PGS.12.152, 10.2217/pgs.12.152]; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sinha S, 2012, ANAESTH PAIN INTENSI, V16, P38; Tufek A, 2013, CLIN INVEST MED, V36, pE95; VIRTANEN R, 1988, EUR J PHARMACOL, V150, P9, DOI 10.1016/0014-2999(88)90744-3; Zhang HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055556	38	24	29	1	10	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2016	30	2					252	260		10.1007/s00540-015-2123-8			9	Anesthesiology	Anesthesiology	DI2BL	WOS:000373300600011	26694929				2020-06-30	J	Kim, KM; Lee, KH; Kim, YH; Ko, MJ; Jung, JW; Kang, E				Kim, Kyung Mi; Lee, Ki Hwa; Kim, Yong Han; Ko, Myoung Jin; Jung, Jae-Wook; Kang, Eunsu			Comparison of effects of intravenous midazolam and ketamine on emergence agitation in children: Randomized controlled trial	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Child; ketamine; psychomotor agitation	SEVOFLURANE ANESTHESIA; DESFLURANE ANESTHESIA; PREOPERATIVE ANXIETY; POSTOPERATIVE PAIN; DELIRIUM; ADENOTONSILLECTOMY; ANALGESIA; HALOTHANE; RECOVERY; PROPOFOL	Objective A prospective, double-blind, randomized controlled trial to compare the effect of preoperative midazolam or ketamine on the incidence of emergence agitation (EA) following sevoflurane anaesthesia in children. Methods Paediatric patients (2-6 years old) undergoing ophthalmic surgery were allocated to receive premedication with either 0.1mg/kg midazolam or 1mg/kg ketamine. Incidence of EA and postoperative pain scores were recorded at 10-min intervals in the postanaesthetic care unit (PACU). The use of EA rescue medications (fentanyl or midazolam) was recorded. Results The incidence of EA was significantly lower in the ketamine group (n=33) than the midazolam group (n=34) at 10 and 20min after transfer to PACU. There was no significant difference in overall incidence of EA. The frequency of midazolam use as rescue medication was significantly lower in the katamine group than in the midazolam group. Conclusion Premedication with ketamine is more effective than midazolam in preventing EA during the early emergence period after sevoflurane anaesthesia in children.	[Kim, Kyung Mi] Hallym Univ Sacred Heart Hosp, Dept Anaesthesia & Pain Med, Anyang, South Korea; [Kim, Kyung Mi] Kangwon Natl Univ, Dept Anaesthesia & Pain Med, Chunchon, South Korea; [Lee, Ki Hwa; Kim, Yong Han; Ko, Myoung Jin; Jung, Jae-Wook; Kang, Eunsu] Haeundae Paik Hosp, Dept Anaesthesia & Pain Med, Busan, South Korea	Lee, KH (reprint author), Inje Univ 1435, Haeundae Paik Hosp, Dept Anaesthesia & Pain Med, Busan 612862, South Korea.	tedy333@paik.ac.kr			Inje University	This work was supported by the 2013 Inje University research grant.	Abdolahi M, 2013, J RES MED SCI, V18, P582; Ahmed Mohammad I., 2011, Middle East Journal of Anesthesiology, V21, P153; Aldrete J A, 1998, J Perianesth Nurs, V13, P148, DOI 10.1016/S1089-9472(98)80044-0; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aouad MT, 2005, CURR OPIN ANESTHESIO, V18, P614, DOI 10.1097/01.aco.0000188420.84763.35; Bell RF, 2005, ACTA ANAESTH SCAND, V49, P1405, DOI 10.1111/j.1399-6576.2005.00814.x; Breschan C, 2007, PEDIATR ANESTH, V17, P347, DOI 10.1111/j.1460-9592.2006.02101.x; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Chen JY, 2010, PEDIATR ANESTH, V20, P873, DOI 10.1111/j.1460-9592.2010.03375.x; Cohen IT, 2002, PAEDIATR ANAESTH, V12, P604, DOI 10.1046/j.1460-9592.2002.00903.x; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Dahmani S, 2014, CURR OPIN ANESTHESIO, V27, P309, DOI 10.1097/ACO.0000000000000076; Dilli D, 2009, CLIN J PAIN, V25, P349, DOI 10.1097/AJP.0b013e31818ecc52; Eghbal Mohammad Hossein, 2013, Middle East Journal of Anesthesiology, V22, P155; Elshammaa N, 2011, PEDIATR ANESTH, V21, P1009, DOI 10.1111/j.1460-9592.2011.03604.x; Jeong WJ, 2012, KOREAN J ANESTHESIOL, V63, P203, DOI 10.4097/kjae.2012.63.3.203; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Kararmaz A, 2004, PEDIATR ANESTH, V14, P477, DOI 10.1111/j.1460-9592.2004.01224.x; Kawaraguchi Yoshitaka, 2002, Masui, V51, P1343; Ko Y P, 2001, Acta Anaesthesiol Sin, V39, P169; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Oh AY, 2005, ACTA ANAESTH SCAND, V49, P297, DOI 10.1111/j.1399-6576.2005.00687.x; Reves JG, 2010, MILLERS ANESTHESIA, P742; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08	26	10	12	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	APR	2016	44	2					258	266		10.1177/0300060515621639			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	DI2CT	WOS:000373304000008	26880794	DOAJ Gold, Green Published			2020-06-30	J	Mutlu, H				Mutlu, Hasan			Can fentanyl transdermal patches prevent the cutaneous hyperpigmentation related to radiotherapy in patients with cancer?	JOURNAL OF ONCOLOGY PHARMACY PRACTICE			English	Article						Cancer; hyperpigmentation; melanosis; radiation therapy		Dermatologic adverse effects related to radiotherapy are one of the most important cosmetic problems and affect the quality of life in patients with cancer. In a male patient with non-small cell lung cancer who received palliative radiotherapy, the hyperpigmentation related to radiotherapy was examined two months later except for fentanyl transdermal patch area. The inhibitory effect of fentanyl on cell cycle may prevent hyperpigmentation related to radiotherapy.	[Mutlu, Hasan] Akdeniz Univ, Sch Med, Dept Med Oncol, TR-38000 Antalya, Turkey	Mutlu, H (reprint author), Akdeniz Univ, Tip Fak, Tibbi Onkol Bolumu, TR-38000 Antalya, Turkey.	doktorhasanmutlu@gmail.com					Cuperus E, 2013, EUR J DERMATOL, V23, P749, DOI 10.1684/ejd.2013.2106; Delogu G, 2004, J TRAUMA, V57, P75, DOI 10.1097/01.TA.0000075349.66640.3E; Ficklscherer A, 2013, ARCH MED SCI, V9, P576, DOI 10.5114/aoms.2013.35339; Kelemen G, 2012, PATHOL ONCOL RES, V18, P421, DOI 10.1007/s12253-011-9462-z; Liu Jian-hua, 2006, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V31, P91; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lynskey GE, 2013, J VASC INTERV RADIOL, V24, P1547, DOI 10.1016/j.jvir.2013.05.039; NASSIRI MR, 1991, PHARMACOL TOXICOL, V69, P17, DOI 10.1111/j.1600-0773.1991.tb00402.x; Oliveira G, 2012, TOXICOL IN VITRO, V26, P645, DOI 10.1016/j.tiv.2012.02.007; Ozyuvaci E, 2004, J PAIN SYMPTOM MANAG, V28, P277, DOI 10.1016/j.jpainsymman.2003.11.004; Qin Y, 2012, ONCOL RES, V20, P61, DOI 10.3727/096504012X13473664562501	11	0	0	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1078-1552	1477-092X		J ONCOL PHARM PRACT	J. Oncol. Pharm. Pract.	APR	2016	22	2					316	318		10.1177/1078155214551317			3	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	DH8MC	WOS:000373046300019	25233883				2020-06-30	J	Friesgaard, KD; Nikolajsen, L; Giebner, M; Rasmussen, CH; Riddervold, IS; Kirkegaard, H; Christensen, EF				Friesgaard, K. D.; Nikolajsen, L.; Giebner, M.; Rasmussen, C. -H.; Riddervold, I. S.; Kirkegaard, H.; Christensen, E. F.			Efficacy and safety of intravenous fentanyl administered by ambulance personnel	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							ADULT TRAUMA PATIENTS; PREHOSPITAL ANALGESIA; INTRANASAL FENTANYL; PAIN MANAGEMENT; EMERGENCY-MEDICINE; MORPHINE; UNDERTREATMENT	BackgroundManagement of pain in the pre-hospital setting is often inadequate. In 2011, ambulance personnel were authorized to administer intravenous fentanyl in the Central Denmark Region. The aim of this study was to evaluate the efficacy and safety of intravenous fentanyl administered by ambulance personnel. MethodsPre-hospital medical charts from 2348 adults treated with intravenous fentanyl by ambulance personnel during a 6-month period were reviewed. The primary outcome was the change in pain intensity on a numeric rating scale (NRS) from before fentanyl treatment to hospital arrival. Secondary outcomes included the number of patients with reduction in pain intensity during transport (NRS 2), the number of patients with NRS > 3 at hospital arrival, and potential fentanyl-related side effects. ResultsFentanyl reduced pain from before treatment (8, IQR 7-9) to hospital arrival (4, IQR 3-6) (NRS reduction: 3, IQR 2-5; P = 0.001), 79.3% of all patients had a reduction in > 2 on the NRS during transport, and 58.4% of patients experienced pain at hospital arrival (NRS > 3). Twenty-one patients (0.9%) had oxygen saturation < 90%. A decrease in Glasgow Coma Scale was seen in 31 patients (1.3%) and hypotension observed in 71 patients (3.0%). ConclusionIntravenous fentanyl caused clinically meaningful pain reduction in most patients and was safe in the hands of ambulance personnel. Many patients had moderate to severe pain at hospital arrival. As the protocol allowed higher doses of fentanyl, feedback on effect and safety should be part of continuous education of ambulance personnel.	[Friesgaard, K. D.; Riddervold, I. S.; Christensen, E. F.] Prehosp Emergency Med Serv, Cent Denmark Reg, Res Dept, Aarhus, Denmark; [Friesgaard, K. D.; Nikolajsen, L.] Aarhus Univ Hosp, Danish Pain Res Ctr, DK-8000 Aarhus, Denmark; [Friesgaard, K. D.; Nikolajsen, L.] Aarhus Univ Hosp, Dept Anesthesiol, DK-8000 Aarhus, Denmark; [Giebner, M.] Falck Danmark AS, Cent Denmark Reg, Kolding, Denmark; [Rasmussen, C. -H.] Responce, Cent Denmark Reg, Horsens, Denmark; [Kirkegaard, H.] Aarhus Univ Hosp, Res Ctr Emergency Med, DK-8000 Aarhus, Denmark	Friesgaard, KD (reprint author), Olof Palmes Alle 34,2 Sal, DK-8200 Aarhus N, Denmark.	k.friesgaard@me.com	Christensen, Erika/H-8753-2017	Nikolajsen, Lone/0000-0002-5261-806X; Christensen, Erika F./0000-0003-3673-9694; Nikolajsen, Lone/0000-0002-2705-7088			Albrecht E, 2013, BRIT J ANAESTH, V110, P96, DOI 10.1093/bja/aes355; Bakkelund KE, 2013, EUR J EMERG MED, V20, P428, DOI 10.1097/MEJ.0b013e32835c9fa3; Dahl JB, 2012, ACTA ANAESTH SCAND, V56, P669, DOI 10.1111/j.1399-6576.2012.02680.x; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Galinski M, 2010, PREHOSP EMERG CARE, V14, P334, DOI 10.3109/10903121003760218; Hansen MS, 2013, DAN MED J, V60; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Krauss WC, 2011, J EMERG MED, V40, P182, DOI 10.1016/j.jemermed.2009.02.009; Manterola C, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005660.pub3; McLean Samuel A, 2002, Prehosp Emerg Care, V6, P402, DOI 10.1080/10903120290938021; McManus JG, 2005, EMERG MED CLIN N AM, V23, P415, DOI 10.1016/j.emc.2004.12.009; Mehta SS, 2010, PAIN MED, V11, P1516, DOI 10.1111/j.1526-4637.2010.00950.x; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Smith MD, 2012, J EMERG MED, V43, P69, DOI 10.1016/j.jemermed.2011.05.018; Soriya GC, 2012, J TRAUMA ACUTE CARE, V72, P755, DOI 10.1097/TA.0b013e31823c4444; Thomas SH, 2008, J EMERG MED, V35, P47, DOI 10.1016/j.jemermed.2007.05.041; Walsh B, 2013, PREHOSP EMERG CARE, V17, P78, DOI 10.3109/10903127.2012.717167	24	11	11	1	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2016	60	4					537	543		10.1111/aas.12662			7	Anesthesiology	Anesthesiology	DG8XG	WOS:000372366300014	26612100				2020-06-30	J	Sayegh, RR; Sweet, JA; Miller, JP; Hayek, SM				Sayegh, Rony R.; Sweet, Jennifer A.; Miller, Jonathan P.; Hayek, Salim M.			Electrical Stimulation of the Trigeminal Ganglion and Intrathecal Drug Delivery Systems for the Management of Corneal Neuropathic Pain	CORNEA			English	Article						neuropathic pain; dry eye; intrathecal infusion; electrical stimulation; cornea	DRY EYE; LASIK	Purpose: This case study reports on 2 novel neuromodulatory approaches in the management of a particularly recalcitrant case of corneal neuropathic pain. Methods: Report of a case Results: A 32-year-old woman presented with intractable bilateral dry eye-like symptoms and corneal neuropathic pain after undergoing laser in situ keratomileusis surgery. Extensive ocular and systemic therapies were unsuccessful. Implantation of an electrode for the electrical stimulation of the trigeminal ganglion resulted in complete resolution of symptoms, but pain recurred after lead migration. Implantation of an intrathecal infusion system for fentanyl and bupivacaine delivery at the C1-C2 level resulted in control of her symptoms with excellent pain relief for more than 1 year. Conclusions: Electrical stimulation of the trigeminal ganglion and a high cervical intrathecal pain pump can be used in the management of corneal neuropathic pain unresponsive to ocular and systemic approaches.	[Sayegh, Rony R.] Univ Hosp Cleveland, Inst Eye, Dept Ophthalmol, Cleveland, OH 44106 USA; [Sweet, Jennifer A.; Miller, Jonathan P.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Dept Neurol Surg, Cleveland, OH 44106 USA; [Hayek, Salim M.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Dept Anesthesiol, Cleveland, OH 44106 USA	Sayegh, RR (reprint author), Univ Hosp Case Med Ctr, Dept Ophthalmol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	rony.sayegh@uhhospitals.org	Sayegh, Rony/G-8777-2013	Sayegh, Rony/0000-0002-0119-4201; Miller, Jonathan/0000-0001-5441-1751			Chao C, 2014, OCUL SURF, V12, P32, DOI 10.1016/j.jtos.2013.09.001; Deer TR, 2012, NEUROMODULATION, V15, P436, DOI 10.1111/j.1525-1403.2012.00476.x; Flack SH, 2011, ANESTH ANALG, V112, P460, DOI 10.1213/ANE.0b013e318203b7c0; Galor A, 2015, EYE, V29, P301, DOI 10.1038/eye.2014.263; Holsheimer J, 2001, Arch Physiol Biochem, V109, P304, DOI 10.1076/apab.109.3.304.9350; Levitt AE, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0020-7; Lundborg C, 2009, ACTA ANAESTH SCAND, V53, P908, DOI 10.1111/j.1399-6576.2009.01989.x; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Nettune GR, 2010, OCUL SURF, V8, P135, DOI 10.1016/S1542-0124(12)70224-0; Rosenthal P, 2016, BRIT J OPHTHALMOL, V100, P128, DOI 10.1136/bjophthalmol-2014-306280; Rosenthal P, 2012, OCUL SURF, V10, P2, DOI 10.1016/j.jtos.2012.01.002; Theophanous C, 2015, OPTOMETRY VISION SCI, V92, pE233, DOI 10.1097/OPX.0000000000000652; YOUNG RF, 1995, J NEUROSURG, V83, P72, DOI 10.3171/jns.1995.83.1.0072	13	4	5	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0277-3740	1536-4798		CORNEA	Cornea	APR	2016	35	4					576	577		10.1097/ICO.0000000000000751			2	Ophthalmology	Ophthalmology	DG8QZ	WOS:000372350000028	26807903				2020-06-30	J	Saccone, PA; Zelenock, KA; Lindsey, AM; Sulima, A; Rice, KC; Prinssen, EP; Wichmann, J; Woods, JH				Saccone, Phillip A.; Zelenock, Kathy A.; Lindsey, Angela M.; Sulima, Agnieszka; Rice, Kenner C.; Prinssen, Eric P.; Wichmann, Juergen; Woods, James H.			Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							NOCICEPTIN/ORPHANIN FQ RECEPTOR; SYNTHETIC AGONIST; PEPTIDE RECEPTORS; OPIOID RECEPTORS; ORPHANIN-FQ; DELTA; MU; ORL1; NOCICEPTION; RO64-6198	Nociceptin/orphanin FQ receptor (NOP) agonists have been reported to produce antinociceptive effects in rhesus monkeys with comparable efficacy to m-opioid receptor (MOP) agonists, but without their limiting side effects. There are also known to be species differences between rodents and nonhuman primates (NHPs) in the behavioral effects of NOP agonists. The aims of this study were the following: 1) to determine if the NOP agonist Ro 64-6198 could be trained as a discriminative stimulus; 2) to evaluate its pharmacological selectivity as a discriminative stimulus; and 3) to establish the order of potency with which Ro 64-6198 produces discriminative stimulus effects compared with analgesic effects in NHPs. Two groups of rhesus monkeys were trained to discriminate either fentanyl or Ro 646198 from vehicle. Four monkeys were trained in the warm-water tail-withdrawal procedure to measure antinociception. Ro 64-6198 produced discriminative stimulus effects that were blocked by the NOP antagonist J-113397 and not by naltrexone. The discriminative stimulus effects of Ro 64-6198 partially generalized to diazepam, but not to fentanyl, SNC 80, ketocyclazocine, buprenorphine, phencyclidine, or chlorpromazine. Fentanyl produced stimulus effects that were blocked by naltrexone and not by J-113397, and Ro 64-6198 did not produce fentanyl-appropriate responding in fentanyl-trained animals. In measures of antinociception, fentanyl, but not Ro 64-6198, produced dose-dependent increases in tail-withdrawal latency. Together, these results demonstrate that Ro 64-6198 produced stimulus effects in monkeys that are distinct from other opioid receptor agonists, but may be somewhat similar to diazepam. In contrast to previous findings, Ro 64-6198 did not produce antinociception in the majority of animals tested even at doses considerably greater than those that produced discriminative stimulus effects.	[Saccone, Phillip A.; Zelenock, Kathy A.; Lindsey, Angela M.; Woods, James H.] Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA; [Sulima, Agnieszka; Rice, Kenner C.] NIDA, Bethesda, MD 20892 USA; [Sulima, Agnieszka; Rice, Kenner C.] NIAAA, Bethesda, MD USA; [Prinssen, Eric P.; Wichmann, Juergen] Hoffman La Roche Ltd, Basel, Switzerland	Saccone, PA (reprint author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	sacconep@umich.edu			National Institutes of Health National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F31-DA038488, T32-DA007281]; National Institutes of Health National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health National Institute on Drug Abuse Intramural Research Programs; National Institutes of Health Intramural Research Programs of the National Institute on Drug Abuse; National Institute of Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	This study was supported by the National Institutes of Health National Institute on Drug Abuse [Grants F31-DA038488 and T32-DA007281]. A portion of this work was supported by the National Institutes of Health National Institute on Alcohol Abuse and Alcoholism and the National Institutes of Health National Institute on Drug Abuse Intramural Research Programs. The work of the Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, and National Institute of Alcohol Abuse and Alcoholism was supported by the National Institutes of Health Intramural Research Programs of the National Institute on Drug Abuse and National Institute of Alcohol Abuse and Alcoholism. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Institute on Drug Abuse.	Brandt MR, 1999, J PHARMACOL EXP THER, V290, P1157; Colpaert FC, 1999, PHARMACOL BIOCHEM BE, V64, P337, DOI 10.1016/S0091-3057(99)00047-7; Cremeans CM, 2012, J PHARMACOL EXP THER, V343, P72, DOI 10.1124/jpet.112.194308; Dykstra L A, 1988, Psychopharmacol Ser, V4, P107; FRANCE CP, 1992, PSYCHOPHARMACOLOGY, V109, P291, DOI 10.1007/BF02245876; GOAS JA, 1978, PHARMACOL BIOCHEM BE, V8, P235; Goeldner C, 2012, PSYCHOPHARMACOLOGY, V222, P203, DOI 10.1007/s00213-012-2636-x; HEIN DW, 1981, J PHARMACOL EXP THER, V218, P7; Higgins GA, 2001, NEUROPHARMACOLOGY, V41, P97, DOI 10.1016/S0028-3908(01)00048-X; Jenck F, 2000, P NATL ACAD SCI USA, V97, P4938, DOI 10.1073/pnas.090514397; Kangas BD, 2014, PAIN, V155, P1821, DOI 10.1016/j.pain.2014.06.010; Ko MC, 2009, J PAIN, V10, P509, DOI 10.1016/j.jpain.2008.11.006; Ko MC, 2009, NEUROPSYCHOPHARMACOL, V34, P2088, DOI 10.1038/npp.2009.33; Lambert DG, 2008, NAT REV DRUG DISCOV, V7, P694, DOI 10.1038/nrd2572; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Mogil JS, 2001, PHARMACOL REV, V53, P381; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; Podlesnik CA, 2011, PSYCHOPHARMACOLOGY, V213, P53, DOI 10.1007/s00213-010-2012-7; Recker MD, 2004, J PHARMACOL EXP THER, V311, P652, DOI 10.1124/jpet.104.071423; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Schroder W, 2014, BRIT J PHARMACOL, V171, P3777, DOI 10.1111/bph.12744; SOLOMON RE, 1982, NEUROPHARMACOLOGY, V21, P1329, DOI 10.1016/0028-3908(82)90142-3; Stevenson GW, 2003, J PHARMACOL EXP THER, V307, P1054, DOI 10.1124/jpet.103.056515; Sukhtankar DD, 2014, PSYCHOPHARMACOLOGY, V231, P1377, DOI 10.1007/s00213-013-3341-0; Suzuki T, 1997, EUR J PHARMACOL, V324, P21, DOI 10.1016/S0014-2999(97)00062-9; Suzuki T, 1997, EUR J PHARMACOL, V331, P1, DOI 10.1016/S0014-2999(97)01020-0; Varty GB, 2005, PSYCHOPHARMACOLOGY, V182, P132, DOI 10.1007/s00213-005-0041-4; Wichmann J, 2000, EUR J MED CHEM, V35, P839, DOI 10.1016/S0223-5234(00)00171-9; Woods J H, 1988, Psychopharmacol Ser, V4, P95	29	6	6	0	4	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	APR	2016	357	1					17	23		10.1124/jpet.115.231134			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DG5TX	WOS:000372142800003	26801398	Green Published, Bronze			2020-06-30	J	Welch, TP; Wallendorf, MJ; Kharasch, ED; Leonard, JR; Doctor, A; Pineda, JA				Welch, Timothy P.; Wallendorf, Michael J.; Kharasch, Evan D.; Leonard, Jeffrey R.; Doctor, Allan; Pineda, Jose A.			Fentanyl and Midazolam Are Ineffective in Reducing Episodic Intracranial Hypertension in Severe Pediatric Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						fentanyl; intracranial hypertension; midazolam; pressure-time exposure; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; NEUROCRITICAL CARE; UNITED-STATES; CHILDREN; HEMODYNAMICS; SUFENTANIL; ANALGESIA; SEDATION; MORPHINE	Objective: To evaluate the clinical effectiveness of bolus-dose fentanyl and midazolam to treat episodic intracranial hypertension in children with severe traumatic brain injury. Design: Retrospective cohort. Setting: PICU in a university-affiliated children's hospital level I trauma center. Patients: Thirty-one children 0-18 years of age with severe traumatic brain injury (Glasgow Coma Scale score of 8) who received bolus doses of fentanyl and/or midazolam for treatment of episodic intracranial hypertension. Interventions: None. Measurements and Main Results: The area under the curve from high-resolution intracranial pressure-time plots was calculated to represent cumulative intracranial hypertension exposure: area under the curve for intracranial pressure above 20 mm Hg (area under the curve-intracranial hypertension) was calculated in 15-minute epochs before and after administration of fentanyl and/or midazolam for the treatment of episodic intracranial hypertension. Our primary outcome measure, the difference between predrug and postdrug administration epochs (area under the curve-intracranial hypertension), was calculated for all occurrences. We examined potential covariates including age, injury severity, mechanism, and time after injury; time after injury correlated with area under the curve-intracranial hypertension. In a mixed-effects model, with patient as a random effect, drug/dose combination as a fixed effect, and time after injury as a covariate, intracranial hypertension increased after administration of fentanyl and/or midazolam (overall aggregate mean area under the curve-intracranial hypertension = +17 mm Hg x min, 95% CI, 0-34 mm Hg x min; p = 0.04). The mean area under the curve-intracranial hypertension increased significantly after administration of high-dose fentanyl (p = 0.02), low-dose midazolam (p = 0.006), and high-dose fentanyl plus low-dose midazolam (0.007). Secondary analysis using age-dependent thresholds showed no significant impact on cerebral perfusion pressure deficit (mean area under the curve-cerebral perfusion pressure). Conclusions: Bolus dosing of fentanyl and midazolam fails to reduce the intracranial hypertension burden when administered for episodic intracranial hypertension. Paradoxically, we observed an overall increase in intracranial hypertension burden following drug administration, even after accounting for within-subject effects and time after injury. Future work is needed to confirm these findings in a prospective study design.	[Welch, Timothy P.; Doctor, Allan; Pineda, Jose A.] Washington Univ, Sch Med, Dept Med, Div Crit Care Med, St Louis, MO 63110 USA; [Welch, Timothy P.; Kharasch, Evan D.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Wallendorf, Michael J.] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; [Leonard, Jeffrey R.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Dept Neurosurg, Columbus, OH 43210 USA	Pineda, JA (reprint author), Washington Univ, Sch Med, Dept Med, Div Crit Care Med, St Louis, MO 63110 USA.	pineda_j@wustl.edu	Pineda, Jose/W-2806-2019		St. Louis Children's Hospital Foundation; Sean Glanvill Foundation; Harold Amos Medical Faculty Development Program (Robert Wood Johnson Foundation); Intellectual and Developmental Disabilities Research Center at Washington University (National Institutes of Health [NIH]/National Institute of Child Health and Human Development [NICHD] [P30 HD062171]; Division of Biostatistics (Intellectual and Developmental Disabilities Research Center [IDDRC]); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; American Heart AssociationAmerican Heart Association; Children's Discovery Institute; Entegrion; Terumo BCT; Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF); Saint Louis Children's Hospital Foundation; NIH (Washington University IDDRC; NIH/National Institute of Child Health and Human Development [NICHD] [P30 HD062171]	Supported, in part, by the St. Louis Children's Hospital Foundation, the Sean Glanvill Foundation, the Harold Amos Medical Faculty Development Program (Robert Wood Johnson Foundation), and the Intellectual and Developmental Disabilities Research Center at Washington University (National Institutes of Health [NIH]/National Institute of Child Health and Human Development [NICHD] P30 HD062171).; Dr. Wallendorf is employed by the Washington University School of Medicine. His institution received grant support from the Division of Biostatistics (Intellectual and Developmental Disabilities Research Center [IDDRC]). Dr. Doctor consulted for Terumo BCT and Novartis and lectured for Terumo BCT. His institution received grant support from the National Institutes of Health (NIH), American Heart Association, Children's Discovery Institute, Entegrion, and Terumo BCT. Dr. Pineda's institution received grant support from the Robert Wood Johnson Foundation, Saint Louis Children's Hospital Foundation, Sean Glanvill Foundation, and the NIH (Washington University IDDRC; NIH/National Institute of Child Health and Human Development [NICHD] P30 HD062171). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS34; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS71; BUHRER M, 1990, CLIN PHARMACOL THER, V48, P555; de Nadal M, 1998, ACT NEUR S, V71, P10; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fong HK, 2006, ANESTH ANALG, V102, P1255, DOI 10.1213/01.ane.0000198602.29716.53; Gish Emily C, 2011, J Pediatr Pharmacol Ther, V16, P39; Haque IU, 2007, PEDIATR CRIT CARE ME, V8, P138, DOI 10.1097/01.PCC.0000257039.32593.DC; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Juul SE, 2011, PEDIATR RES, V69, P285, DOI 10.1203/PDR.0b013e31820bd165; Kahraman S, 2011, J TRAUMA, V70, P547, DOI 10.1097/TA.0b013e31820c768a; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lauer KK, 1997, CAN J ANAESTH, V44, P929, DOI 10.1007/BF03011963; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marx W, 1989, J Neurosurg Anesthesiol, V1, P3, DOI 10.1097/00008506-198903000-00002; PAPAZIAN L, 1993, BRIT J ANAESTH, V71, P267, DOI 10.1093/bja/71.2.267; Pineda JA, 2013, LANCET NEUROL, V12, P45, DOI 10.1016/S1474-4422(12)70269-7; ROSEN D A, 1991, Intensive Care Medicine, V17, pS15, DOI 10.1007/BF01731149; Schmittner MD, 2007, J NEUROSURG ANESTH, V19, P257, DOI 10.1097/ANA.0b013e31811f3feb; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; TOBIAS JD, 1994, PEDIATR EMERG CARE, V10, P89, DOI 10.1097/00006565-199404000-00007; Traudt CM, 2012, J NEUROSCI RES, V90, P307, DOI 10.1002/jnr.22750; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; WERNER C, 1995, ANESTHESIOLOGY, V83, P721, DOI 10.1097/00000542-199510000-00011; Young C, 2005, BRIT J PHARMACOL, V146, P189, DOI 10.1038/sj.bjp.0706301	40	9	11	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2016	44	4					809	818		10.1097/CCM.0000000000001558			10	Critical Care Medicine	General & Internal Medicine	DG1NU	WOS:000371835600019	26757162	Green Accepted			2020-06-30	J	Oosten, AW; Abrantes, JA; Jonsson, S; de Bruijn, P; Kuip, EJM; Falcao, A; van der Rijt, CCD; Mathijssen, RHJ				Oosten, Astrid W.; Abrantes, Joao A.; Jonsson, Siv; de Bruijn, Peter; Kuip, Evelien J. M.; Falcao, Amilcar; van der Rijt, Carin C. D.; Mathijssen, Ron H. J.			Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						Fentanyl; Pharmacokinetics; Subcutaneous; Transdermal; NONMEM	AVAILABLE RESERVOIR FORMULATION; RELEASE ORAL MORPHINE; DELIVERY-SYSTEM; PAIN; VOLUNTEERS; EFFICACY; NONMEM; BIOEQUIVALENCE; METAANALYSIS; CONVERSION	Transdermal fentanyl is effective for the treatment of moderate to severe cancer-related pain but is unsuitable for fast titration. In this setting, continuous subcutaneous fentanyl may be used. As data on the pharmacokinetics of continuous subcutaneous fentanyl are lacking, we studied the pharmacokinetics of subcutaneous and transdermal fentanyl. Furthermore, we evaluated rotations from the subcutaneous to the transdermal route. Fifty-two patients treated with subcutaneous and/or transdermal fentanyl for moderate to severe cancer-related pain participated. A population pharmacokinetic model was developed and evaluated using non-linear mixed-effects modelling. For rotations from subcutaneous to transdermal fentanyl, a 1:1 dose conversion ratio was used while the subcutaneous infusion was continued for 12 h (with a 50 % tapering after 6 h). A 6-h scheme with 50 % tapering after 3 h was simulated using the final model. A one-compartment model with first-order elimination and separate first-order absorption processes for each route adequately described the data. The estimated apparent clearance of fentanyl was 49.6 L/h; the absorption rate constant for subcutaneous and transdermal fentanyl was 0.0358 and 0.0135 h(-1), respectively. Moderate to large inter-individual and inter-occasion variability was found. Around rotation from subcutaneous to transdermal fentanyl, measured and simulated plasma fentanyl concentrations rose and increasing side effects were observed. We describe the pharmacokinetics of subcutaneous and transdermal fentanyl in one patient cohort and report several findings that are relevant for clinical practice. Further research is warranted to study the optimal scheme for rotations from the subcutaneous to the transdermal route.	[Oosten, Astrid W.; de Bruijn, Peter; Kuip, Evelien J. M.; van der Rijt, Carin C. D.; Mathijssen, Ron H. J.] Erasmus MC Canc Inst, Dept Med Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands; [Abrantes, Joao A.; Falcao, Amilcar] Univ Coimbra, Fac Pharm, Dept Pharmacol, Coimbra, Portugal; [Abrantes, Joao A.; Falcao, Amilcar] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal; [Abrantes, Joao A.; Jonsson, Siv] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden; [van der Rijt, Carin C. D.] Netherlands Comprehens Canc Org, Utrecht, Netherlands	Oosten, AW (reprint author), Erasmus MC Canc Inst, Dept Med Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.	a.oosten@erasmusmc.nl	Abrantes, Joao A./AAD-4422-2020; Falcao, Amilcar/G-6611-2013	Oosten, Astrid/0000-0003-2850-0501; Abrantes, Joao/0000-0002-7752-0229; Falcao, Amilcar/0000-0002-3854-6549	Netherlands Organisation for Health Research and Development (ZonMw)Netherlands Organization for Health Research and Development [1151.0014]; Cornelis Vrolijk Fund; Stichting Voorzieningenfonds Palliatieve Zorg Dirksland	This study was financially supported by the Netherlands Organisation for Health Research and Development (ZonMw project number 1151.0014), Cornelis Vrolijk Fund and Stichting Voorzieningenfonds Palliatieve Zorg Dirksland.	Beal SL, 1989, NONMEM 7 3 0 USERS G; Bergstrand M, 2011, AAPS J, V13, P143, DOI 10.1208/s12248-011-9255-z; Bista SR, 2015, J CLIN PHARM; Capper SJ, 2010, EUR J ANAESTH, V27, P241, DOI 10.1097/EJA.0b013e328331a361; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Jonsson EN, 1999, COMPUT METH PROG BIO, V58, P51; Justad M, 2009, HOME HLTH NURSE, V27; Justad Mindy, 2009, Home Healthc Nurse, V27, P140, DOI 10.1097/01.NHH.0000347677.15617.ff; Karlsson MO, 2007, CLIN PHARMACOL THER, V82, P17, DOI 10.1038/sj.clpt.6100241; KARLSSON MO, 1993, J PHARMACOKINET BIOP, V21, P735, DOI 10.1007/BF01113502; Kim DY, 2011, SUPPORT CARE CANCER, V19, P297, DOI 10.1007/s00520-010-0825-x; Kokubun Hideya, 2012, J Pain Palliat Care Pharmacother, V26, P98, DOI 10.3109/15360288.2012.679725; Kornick CA, 2001, CANCER, V92, P3056, DOI 10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H; Kress HG, 2010, EUR J PHARM BIOPHARM, V75, P225, DOI 10.1016/j.ejpb.2010.02.005; Lindbom L, 2005, COMPUT METH PROG BIO, V79, P241, DOI 10.1016/j.cmpb.2005.04.005; Lindbom L, 2004, COMPUT METH PROG BIO, V75, P85, DOI 10.1016/j.cmpb.2003.11.003; Liu J, 2014, INT J CLIN PHARM TH, V52, P175, DOI 10.5414/CP201901; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Miller RS, 1995, BRIT J CLIN PHARMACO, V40, P553; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Nomura M, 2013, CLIN J PAIN, V29, P487, DOI 10.1097/AJP.0b013e318266f6a5; Nomura M, 2011, SUPPORT CARE CANCER, V19, P691, DOI 10.1007/s00520-010-0890-1; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; VONCUBE B, 1969, N-S ARCH PHARMAKOL, V263, P199; Watanabe S, 1998, J PAIN SYMPTOM MANAG, V16, P323, DOI 10.1016/S0885-3924(98)00095-5; World Health Organization, WHOS PAIN LADD AD; Yang QO, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-67; Zecca E, 2015, BRIT J CLIN PHARMACO, V80, P110, DOI 10.1111/bcp.12595; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	39	8	10	0	10	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	APR	2016	72	4					459	467		10.1007/s00228-015-2005-x			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DG6DK	WOS:000372172200008	26762381	Green Published, Other Gold			2020-06-30	J	Pang, GS; Qu, LM; Tan, YY; Yee, ACP				Pang, G. S.; Qu, L. M.; Tan, Y. Y.; Yee, A. C. P.			Intravenous Fentanyl for Dyspnea at the End of Life: Lessons for Future Research in Dyspnea	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						fentanyl; opioid; intravenous; dyspnea; cancer; lessons	REFRACTORY BREATHLESSNESS; NEBULIZED FENTANYL; PALLIATIVE CARE; CANCER-PATIENTS; TRIAL DESIGN; MANAGEMENT; CITRATE; INTENSITY; OPIOIDS	Objectives: To determine the efficacy of intravenous (IV) Fentanyl in dyspnoeic patients with advanced cancer. Methods: Dyspnoeic patients with advanced cancer satisfying the selection criteria received (IV) Fentanyl and were evaluated for response 24 hours post-administration in a prospective observational study. Results: Altogether 36 patients were enrolled into the study. However, data from only 16 patients could be analysed as 20 patients had died or were too sick to self-report scores. Seven out of 16 patients responded to IV Fentanyl although the result was not statistically significant (non-responders versus responders: 56.3% vs 43.8%, p = 0.33). The strongest correlations for variables predictive of responder status were the absence of anxiety and lung metastases. Conclusions: This exploratory study shows that IV Fentanyl can alleviate dyspnea in some patients but is an example of the difficulties conducting dyspnea research. Future studies would benefit from novel developments in the areas of measuring dyspnea in dying patients and statistical analysis of small sample sizes.	[Pang, G. S.; Qu, L. M.; Tan, Y. Y.; Yee, A. C. P.] Natl Canc Ctr Singapore, Dept Palliat Med, 11 Hosp Dr, Singapore 169610, Singapore	Pang, GS (reprint author), Natl Canc Ctr Singapore, Dept Palliat Med, 11 Hosp Dr, Singapore 169610, Singapore.	grace.pang.su.yin@nccs.com.sg			National Cancer Centre Singapore Cancer Research Endowment Fund	We would like to acknowledge the National Cancer Centre Singapore Cancer Research Endowment Fund for funding to G.S. Pang and A.C.P. Yee for this study.	Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Ben-Aharon I, 2012, ACTA ONCOL, V51, P996, DOI 10.3109/0284186X.2012.709638; Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; Bruera E, 2013, PALLIATIVE MED, V27, P939, DOI 10.1177/0269216313477177; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Currow DC, 2007, J PALLIAT MED, V10, P1031, DOI 10.1089/jpm.2007.9912; Currow DC, 2010, J PAIN SYMPTOM MANAG, V39, P680, DOI 10.1016/j.jpainsymman.2009.09.017; Dorman S, 2007, PALLIATIVE MED, V21, P177, DOI 10.1177/0269216307076398; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Glare Paul, 2005, J Support Oncol, V3, P331; Hallenbeck J, 2012, J PALLIAT MED, V15, P848, DOI 10.1089/jpm.2011.0167; Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007; Johnson MJ, 2013, EUR RESPIR J, V42, P758, DOI 10.1183/09031936.00139812; Lang T, 2011, AM J TROP MED HYG, V85, P967, DOI 10.4269/ajtmh.2011.11-0151; Mahler DA, 2010, CHEST, V137, P674, DOI 10.1378/chest.09-1543; Mercadante S, 2000, J PAIN SYMPTOM MANAG, V20, P104, DOI 10.1016/S0885-3924(00)00160-3; Nelson NJ, 2010, J NATL CANCER I, V102, P1217, DOI 10.1093/jnci/djq319; Pinna MA, 2013, AM J HOSP PALLIAT CA; Preston NJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009007.pub2; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Smith TJ, 2009, J PALLIAT MED, V12, P771, DOI 10.1089/jpm.2009.0113; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1; Viola R, 2008, SUPPORT CARE CANCER, V16, P329, DOI 10.1007/s00520-007-0389-6	23	6	6	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	APR	2016	33	3					222	227		10.1177/1049909114559769			6	Health Care Sciences & Services	Health Care Sciences & Services	DF4LF	WOS:000371319000003	25425740				2020-06-30	J	Song, IK; Park, YH; Lee, JH; Kim, JT; Choi, IH; Kim, HS				Song, In-Kyung; Park, Yong-Hee; Lee, Ji-Hyun; Kim, Jin-Tae; Choi, In Ho; Kim, Hee-Soo			Randomized controlled trial on preemptive analgesia for acute postoperative pain management in children	PEDIATRIC ANESTHESIA			English	Article						acute pain; children; patient-controlled analgesia; pediatrics; postoperative pain	EMERGENCE DELIRIUM SCALE; EPIDURAL ANALGESIA; ANESTHESIA; EFFICACY; SURGERY; PHARMACOKINETICS; MORPHINE; INFANTS; RELIEF	BackgroundPreemptive analgesia is an anti-nociceptive treatment that starts before surgery and prevents the establishment of central sensitization. Whether preemptive analgesia is more effective than conventional regimens for managing postoperative pain remains controversial. This study evaluated the efficacy of intravenous preemptive analgesia for acute postoperative pain control in pediatric patients. MethodsIn this prospective randomized controlled trial, 51 children aged 3-7 years, scheduled for corrective osteotomy were randomized into control (group C) or preemptive (group P) group. Both groups received standardized general anesthesia, including intravenous patient-controlled analgesia (IV-PCA) with fentanyl, which was started before skin incision in group P or 5 min thereafter in group C. IV-PCA data, pain scores using verbal rating scale (VRS) and Wong-Baker FACES((R)) pain rating scale (WBFS), emergence agitation score (EAS) using the Pediatric Anesthesia Emergence Delirium (PAED) scale, analgesic requirements, and complications were recorded. ResultsThe primary outcome, pain score at postoperative 1 h, showed no difference between the groups. Both groups did not demonstrate emergence agitation (PAED cutoff value 12), although the EAS at admission to the postanesthetic care unit (PACU) was lower in group P than in group C (P = 0.002; mean difference 4.85, 95% CI 1.97-7.73). There were no differences in the delivered volume of IV-PCA, frequency of pushing the IV-PCA button, effective push attempts, VRS, WBFS, EAS at discharge from the PACU, additional analgesic requirements, and complications. ConclusionPreemptive analgesia using IV-PCA with fentanyl showed no significant advantages for postoperative analgesia after corrective osteotomy in pediatric patients.	[Song, In-Kyung; Lee, Ji-Hyun; Kim, Jin-Tae; Kim, Hee-Soo] Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, 101 Daehak Ro, Seoul 03080, South Korea; [Park, Yong-Hee] Chung Ang Univ Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Choi, In Ho] Seoul Natl Univ Hosp, Dept Orthoped Surg, Seoul 03080, South Korea	Kim, HS (reprint author), Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, 101 Daehak Ro, Seoul 03080, South Korea.	dami0605@snu.ac.kr	KIM, JIN TAE/D-5734-2012; Kim, Jin-Tae/T-7983-2019	KIM, JIN TAE/0000-0002-3738-0081; Kim, Jin-Tae/0000-0002-3738-0081			Aida S, 2000, PAIN, V84, P169, DOI 10.1016/S0304-3959(99)00196-7; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Bajwa SA, 2010, PEDIATR ANESTH, V20, P704, DOI 10.1111/j.1460-9592.2010.03328.x; Bong CL, 2009, PEDIATR ANESTH, V19, P593, DOI 10.1111/j.1460-9592.2009.03024.x; Bong CL, 2005, J CARDIOTHOR VASC AN, V19, P786, DOI 10.1053/j.jvca.2005.08.012; Brasher C, 2014, PEDIATR DRUGS, V16, P129, DOI 10.1007/s40272-013-0062-0; Chiaretti A, 2008, CHILD NERV SYST, V24, P119, DOI 10.1007/s00381-007-0429-z; Dahl JB, 2004, BRIT MED BULL, V71, P13, DOI 10.1093/bmb/ldh030; Dal D, 2007, PEDIATR ANESTH, V17, P263, DOI 10.1111/j.1460-9592.2006.02095.x; Fortier MA, 2011, J PEDIATR SURG, V46, P1700, DOI 10.1016/j.jpedsurg.2011.03.074; Hippard HK, 2012, ANESTH ANALG, V115, P356, DOI 10.1213/ANE.0b013e31825afef3; Howard RF, 2010, PEDIATR ANESTH, V20, P126, DOI 10.1111/j.1460-9592.2009.03242.x; Kart T, 1997, PAEDIATR ANAESTH, V7, P5, DOI 10.1046/j.1460-9592.1997.d01-30.x; Katz J, 2011, ANESTH ANALG, V113, P1242, DOI 10.1213/ANE.0b013e31822c9a59; Kelly DJ, 2001, CAN J ANAESTH, V48, P1091, DOI 10.1007/BF03020375; Kissin I, 1996, ANESTHESIOLOGY, V84, P1015, DOI 10.1097/00000542-199605000-00001; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Klasen J, 2005, ANAESTHESIA, V60, P118, DOI 10.1111/j.1365-2044.2004.03999.x; Mohammed BS, 2012, BRIT J ANAESTH, V108, P823, DOI 10.1093/bja/aes025; Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542-200203000-00032; Monitto CL, 2000, ANESTH ANALG, V91, P573, DOI 10.1213/00000539-200009000-00014; Ong CKS, 2005, ANESTH ANALG, V100, P757, DOI 10.1213/01.ANE.0000144428.98767.0E; Sethi S, 2013, PEDIATR ANESTH, V23, P1131, DOI 10.1111/pan.12260; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Taddio Anna, 2005, Paediatr Drugs, V7, P245, DOI 10.2165/00148581-200507040-00004	25	11	11	0	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	APR	2016	26	4					438	443		10.1111/pan.12864			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	DG7PL	WOS:000372276100017	26890267				2020-06-30	J	Bortolussi, R; Zotti, P; Matovic, M; Morabito, A; Bertuzzi, C; Caserta, M; Fabiani, F; Fracasso, A; Santantonio, C; Zanier, C; Roscetti, A; Polesel, J; Gussetti, D; Bedin, S; Colussi, AM; Fantin, D				Bortolussi, R.; Zotti, P.; Matovic, M.; Morabito, A.; Bertuzzi, C.; Caserta, M.; Fabiani, F.; Fracasso, A.; Santantonio, C.; Zanier, C.; Roscetti, A.; Polesel, J.; Gussetti, D.; Bedin, S.; Colussi, A. M.; Fantin, D.			A phase II study on the efficacy and safety of procedural analgesia with fentanyl buccal tablet in cancer patients for the placement of indwelling central venous access systems	SUPPORTIVE CARE IN CANCER			English	Article						Pain; Cancer; Anaesthesia	PAIN; INSERTION	Background Pain in cancer patients is often related to oncologic therapies and diagnostic procedures. The placement of fully implantable venous access systems is a very common procedure in oncology patients. Local anaesthesia is the method most commonly used to overcome pain related to this surgical procedure, but the local anaesthetic may be unable to completely eradicate all pain. This study investigates the effectiveness and safety of fentanyl buccal tablet (FBT), administered by OraVescent (R) technology, in reducing procedural pain related to the placement of indwelling central venous access systems (Ports) in opioid-naive cancer patients. Methods Inpatients who required an indwelling vascular access (Port) were preoperatively assessed with a self-assessment questionnaire on anxiety and pain. A 100 mu g FBT was administered 10 min before preparation of the operating field. A self-assessment scale for pain experienced during the procedure was administered at the end of the procedure. Vital signs and the presence of any side effects or bothersome symptoms were monitored during the procedure, at the end, and 4 h later. Results From October 2012 to June 2014, 65 patients were enrolled in the study. A total of 61 (93.9 %) patients perceived no or a little pain during the procedure. Four patients (6.2 %) reported a lot of pain. No patient reported very severe pain. This data is significant in terms of the lower than expected presence of pain (Fisher test p = 0.0018) as assessed in our previous experience without procedural analgesia. The most common side effects of FBT was drowsiness, experienced by 28 patients at the end of the procedure (43.1 %), significantly reduced (p < 0.01) to 8 patients after 4 h (12.5 %). Nausea was present in 6 cases at the end of the procedure (9.2 %) and in 7 cases 4 h later (10.9 %). Vomiting was present in 3 cases at the end (4.7 %) and in 2 other patients after 4 h (7.8 %). No significant change of vital parameters was observed between the baseline and the subsequent measurements in all patients studied. Conclusions The significant improvement in the number of patients experiencing little or no pain, accompanied by a lower number of non-severe side effects, suggests that FBT is a valid, practical and safe method of procedural analgesia. It will be necessary to perform further studies, taking into account the need for standard antiemetic pre-medication to minimise the incidence of nausea and vomiting.	[Bortolussi, R.] CRO Aviano Natl Canc Inst, Pain Therapy & Palliat Care Unit, Aviano, Italy; [Zotti, P.] CRO Aviano Natl Canc Inst, Psychooncol Unit, Aviano, Italy; [Matovic, M.; Morabito, A.; Bertuzzi, C.; Caserta, M.; Fabiani, F.; Fracasso, A.; Santantonio, C.; Zanier, C.; Roscetti, A.; Bedin, S.; Fantin, D.] CRO Aviano Natl Canc Inst, Anaesthesia & Intens Care Unit, Aviano, Italy; [Polesel, J.] CRO Aviano Natl Canc Inst, Dept Epidemiol & Biostat, Aviano, Italy; [Gussetti, D.; Colussi, A. M.] CRO Aviano Natl Canc Inst, Clin Trials Off, Sci Directorate, Aviano, Italy	Bortolussi, R (reprint author), CRO Aviano Natl Canc Inst, Pain Therapy & Palliat Care Unit, Aviano, Italy.	rbortolussi@cro.it	Polesel, Jerry/AAA-5750-2019; Zotti, Paola/AAB-9704-2020	Polesel, Jerry/0000-0001-9381-1520; Zotti, Paola/0000-0003-1068-0313			Agency for Health Care Policy and Research, 1992, AHCPR PUBL; Burlacu CL, 2011, J CLIN ANESTH, V23, P286, DOI 10.1016/j.jclinane.2010.12.007; Darwish M, 2010, PERSPECT MED CHEM, V4, P11; De Cicco M, 2009, ANN ONCOL, V20, P1936, DOI 10.1093/annonc/mdp235; De Cicco M, 2002, CRIT REV ONCOL HEMAT, V42, P189, DOI 10.1016/S1040-8428(01)00162-7; Elkhodair SM, 2014, EUR J EMERG MED, V12; FELICIANO DV, 1979, AM J SURG, V138, P869, DOI 10.1016/0002-9610(79)90313-1; Gavaruzzi T, 2010, BRIT J HEALTH PSYCH, V15, P253, DOI 10.1348/135910709X458305; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Kato Y, 2014, PEDIATR INT, V56, P354, DOI 10.1111/ped.12283; Kim TH, 2006, KOREAN J RADIOL, V7, P125, DOI 10.3348/kjr.2006.7.2.125; Lee TH, 2014, CLIN ENDOSC, V47, P141, DOI 10.5946/ce.2014.47.2.141; MIASKOWSKI C, 2005, [No title captured], V3; Morrison RS, 1998, J PAIN SYMPTOM MANAG, V15, P91, DOI 10.1016/S0885-3924(98)80006-7; Po' C, 2012, SUPPORT CARE CANCER, V20, P2407, DOI 10.1007/s00520-011-1347-x; Proud Carol, 2007, Clin J Oncol Nurs, V11, P561, DOI 10.1188/07.CJON.561-567; Puntillo KA, 2002, AM J CRIT CARE, V11, P415, DOI 10.4037/ajcc2002.11.5.415; Samantaray A, 2014, INDIAN J CRIT CARE M, V18, P421, DOI 10.4103/0972-5229.136069; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9; Skehan SJ, 2000, RADIOLOGY, V216, P653, DOI 10.1148/radiology.216.3.r00se09653; Spielberger CD, 1989, STATE TRAIT ANXIETY; Spruyt O, 2014, BMJ SUPPORT PALLIAT, V4, P342, DOI 10.1136/bmjspcare-2013-000447; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009	23	2	2	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	APR	2016	24	4					1537	1543		10.1007/s00520-015-2939-7			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	DI0BE	WOS:000373159000013	26377306	Other Gold, Green Published			2020-06-30	J	da Silva, PSL; Reis, ME; de Aguiar, VE; Fonseca, MCM				Lucas da Silva, Paulo Sergio; Reis, Maria Eunice; de Aguiar, Vania Euzebio; Machado Fonseca, Marcelo Cunio			Use of fentanyl and midazolam in mechanically ventilated children-Does the method of infusion matter?	JOURNAL OF CRITICAL CARE			English	Article						Benzodiazepine; Fentanyl; Midazolam; Opiate; Pediatric intensive care; Sedation	PEDIATRIC INTENSIVE-CARE; WITHDRAWAL SYMPTOMS SCALE; CRITICALLY III CHILDREN; CARDIAC-SURGERY; SEDATION; ANALGESIA; INFANTS; MULTICENTER; ANESTHETICS; TOLERANCE	Background and objective: Benzodiazepines and opioids are commonly used in pediatric intensive care unit. However, there is no previous study assessing the use of administering these drugs combined (single solution) or separately. We sought to evaluate the impact of these 2 different methods of providing sedation/analgesia in pediatric intensive care unit. Methods: One hundred twelve patients mechanically ventilated for more than 48 hours were randomized to receive a protocolized sedation regimecomprising midazolamand fentanyl either separately (group 1, 57 patients) or combined as a single solution (group 2, 55 patients). Primary end point variable was the cumulated dose of midazolam and fentanyl. Results: The median cumulated doses of both fentanyl (0.19 vs 0.37 mg/kg, P < .05) and midazolam (28.8 vs 45.6 mg/kg, P < .05) required in group 2 were higher when compared with those of group 1. Moreover, group 2 patients had a significantly longer time of vasopressor drugs requirement and a higher number of patients developing tolerance. Conclusion: Patients who received a single solution of midazolam and fentanyl had a higher cumulated dose of compared with those patients who did not. The potential risk for long-term neurologic effects on developing brains associated with this finding should be considered. (C) 2015 Elsevier Inc. All rights reserved.	[Lucas da Silva, Paulo Sergio; de Aguiar, Vania Euzebio] Hosp Serv Publ Municipal, Dept Pediat, Pediat Intens Care Unit, Rua Castro Alves 60, BR-01532900 Sao Paulo, Brazil; [Reis, Maria Eunice] Hosp & Maternidade Santa Joana, Sao Paulo, Brazil; [Machado Fonseca, Marcelo Cunio] Fed Univ Sao Paulo UNIFESP, Hlth Technol Assessment Unit, Sao Paulo, Brazil	da Silva, PSL (reprint author), Hosp Serv Publ Municipal, Dept Pediat, Pediat Intens Care Unit, Rua Castro Alves 60, BR-01532900 Sao Paulo, Brazil.	psls.nat@terra.com.br; eunice.resi@terra.com.br; vea@uol.com.br; marcelo.fonseca@axia.bio.br	Silva, Paulo Sergio L/P-5182-2018	Fonseca, Marcelo C M/0000-0003-0803-3715			Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Barr G, 2000, BRIT J ANAESTH, V84, P749; Benini F, 2010, ACTA PAEDIATR, V99, P758, DOI 10.1111/j.1651-2227.2010.01705.x; Dunser MW, 2006, CRIT CARE MED, V34, P1234, DOI 10.1097/01.CCM.0000208360.70835.87; Grant MJC, 2013, HEART LUNG, V42, P171, DOI 10.1016/j.hrtlng.2013.02.004; Gruber EM, 2001, ANESTH ANALG, V92, P882; Guerra GG, 2011, PEDIATR ANESTH, V21, P932, DOI 10.1111/j.1460-9592.2011.03581.x; Gupta K, 2012, PEDIATR CRIT CARE ME, V13, P131, DOI 10.1097/PCC.0b013e31820aba48; HARTWIG S, 1991, EUR J PEDIATR, V150, P784, DOI 10.1007/BF02026712; Ista Erwin, 2005, Pediatr Crit Care Med, V6, P58, DOI 10.1097/01.PCC.0000149318.40279.1A; Ista E, 2013, PEDIATR CRIT CARE ME, V14, P761, DOI 10.1097/PCC.0b013e31829f5be1; Ista E, 2009, INTENS CARE MED, V35, P1075, DOI 10.1007/s00134-009-1487-3; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Loepke AW, 2008, ANESTH ANALG, V106, P1681, DOI 10.1213/ane.0b013e318167ad77; Loepke AW, 2010, PEDIATR CRIT CARE ME, V11, P217, DOI 10.1097/PCC.0b013e3181b80383; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Merkel S I, 1997, Pediatr Nurs, V23, P293; Patsopoulos Nikolaos A, 2011, Dialogues Clin Neurosci, V13, P217; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Randolph AG, 2002, JAMA-J AM MED ASSOC, V288, P2561, DOI 10.1001/jama.288.20.2561; Rivenes SM, 2001, ANESTHESIOLOGY, V94, P223, DOI 10.1097/00000542-200102000-00010; Roze JC, 2008, ARCH PEDIAT ADOL MED, V162, P728, DOI 10.1001/archpedi.162.8.728; TURNAGE WS, 1993, CRIT CARE MED, V21, P1099, DOI 10.1097/00003246-199307000-00033; van Dijk M, 2012, INTENS CARE MED, V38, P531, DOI 10.1007/s00134-011-2434-7; van Zellem L, 2014, PEDIATR CRIT CARE ME, V15, P189, DOI 10.1097/PCC.0000000000000044; Vet NJ, 2013, INTENS CARE MED, V39, P1524, DOI 10.1007/s00134-013-2971-3; Wilson KM, 1998, J PAIN SYMPTOM MANAG, V16, P52, DOI 10.1016/S0885-3924(98)00024-4	29	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	APR	2016	32						108	113		10.1016/j.jcrc.2015.12.003			6	Critical Care Medicine	General & Internal Medicine	DE8DV	WOS:000370866900021	26775184				2020-06-30	J	Lee, WW; Ehm, G; Yang, HJ; Song, IH; Lim, YH; Kim, MR; Kim, YE; Hwang, JH; Park, HR; Lee, JM; Kim, JW; Kim, HJ; Kim, C; Kim, HC; Park, E; Kim, IY; Kim, DG; Jeon, B; Paek, SH				Lee, Woong-Woo; Ehm, Gwanhee; Yang, Hui-Jun; Song, In Ho; Lim, Yong Hoon; Kim, Mi-Ryoung; Kim, Young Eun; Hwang, Jae Ha; Park, Hye Ran; Lee, Jae Min; Kim, Jin Wook; Kim, Han-Joon; Kim, Cheolyoung; Kim, Hee Chan; Park, Eunkyoung; Kim, In Young; Kim, Dong Gyu; Jeon, Beomseok; Paek, Sun Ha			Bilateral Deep Brain Stimulation of the Subthalamic Nucleus under Sedation with Propofol and Fentanyl	PLOS ONE			English	Article							PARKINSON-DISEASE; GENERAL-ANESTHESIA; SURGERY; SHIFT; ACCURACY; FUSION	Awakening during deep brain stimulation (DBS) surgery may be stressful to patients. The aim of the current study was to evaluate the effect on MER signals and their applicability to subthalmic nucleus (STN) DBS surgery for patients with Parkinson's disease (PD) under sedation with propofol and fentanyl. Sixteen consecutive patients with PD underwent STN-DBS surgery with propofol and fentanyl. Their MER signals were achieved during the surgery. To identify the microelectrodes positions, the preoperative MRI and postoperative CT were used. Clinical profiles were also collected at the baseline and at 6 months after surgery. All the signals were slightly attenuated and contained only bursting patterns, compared with our previous report. All electrodes were mostly located in the middle one third part of the STN on both sides of the brain in the fused images. Six months later, the patients were improved significantly in the medication-off state and they met with less dyskinesia and less off-duration. Our study revealed that the sedation with propofol and fentanyl was applicable to STN-DBS surgery. There were no significant problems in precise positioning of bilateral electrodes. The surgery also improved significantly clinical outcomes in 6-month follow-up.	[Lee, Woong-Woo] Eulji Gen Hosp, Dept Neurol, Seoul, South Korea; [Ehm, Gwanhee] Myongji Hosp, Dept Neurol, Gyeonggi, South Korea; [Yang, Hui-Jun] Ulsan Univ Hosp, Dept Neurol, Ulsan, South Korea; [Song, In Ho] Osong Med Innovat Fdn, Med Device Dev Ctr, Chungcheong, South Korea; [Lim, Yong Hoon; Kim, Mi-Ryoung; Park, Hye Ran; Lee, Jae Min; Kim, Jin Wook; Kim, Dong Gyu; Paek, Sun Ha] Seoul Natl Univ Hosp, Dept Neurosurg, Seoul 110744, South Korea; [Kim, Young Eun] Hallym Univ, Sacred Heart Hosp, Dept Neurol, Gyeonggi, South Korea; [Hwang, Jae Ha] Daejeon Woori Hosp, Dept Neurosurg, Gyeonggi, South Korea; [Kim, Han-Joon; Jeon, Beomseok] Seoul Natl Univ Hosp, Dept Neurol, Seoul 110744, South Korea; [Kim, Cheolyoung] CyberMed Inc, Med Imaging Lab, Seoul, South Korea; [Kim, Hee Chan] Seoul Natl Univ, Coll Med, Dept Med Engn, Seoul, South Korea; [Park, Eunkyoung; Kim, In Young] Han Yang Univ, Dept Biomed Engn, Seoul, South Korea; [Kim, Dong Gyu; Paek, Sun Ha] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul, South Korea; [Jeon, Beomseok] Seoul Natl Univ, Coll Med, Dept Neurol, Seoul, South Korea	Paek, SH (reprint author), Seoul Natl Univ Hosp, Dept Neurosurg, Seoul 110744, South Korea.; Paek, SH (reprint author), Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.	paeksh@snu.ac.kr		Park, Eunkyoung/0000-0001-7700-0250; Kim, Han-Joon/0000-0001-8219-9663	Korea Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries, Republic of Korea [311011-05-3-SB020]; Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI09C13540100, HI10C14110400, HI11C21100200, HI12C02050101]; Technology Innovation Program - Ministry of Trade, industry & Energy (MI, Korea) [10050154]; Bio & Medical Technology Development Program of the NRF - the Korean government, MSIP [2015M3C7A1028926]; CyberMed Inc.	This work was partly supported by a grant from the Korea Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries, Republic of Korea (No. 311011-05-3-SB020), a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (No. HI09C13540100, HI10C14110400, HI11C21100200 and HI12C02050101), and a grant from the Technology Innovation Program (10050154, Business Model Development for Personalized Medicine Based on Integrated Genome and Clinical Information) funded By the Ministry of Trade, industry & Energy (MI, Korea), and a grant from the Bio & Medical Technology Development Program of the NRF funded by the Korean government, MSIP (2015M3C7A1028926). CyberMed Inc. provided support in the form of salaries for an author [CK], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	Benabid AL, 2003, CURR OPIN NEUROBIOL, V13, P696, DOI 10.1016/j.conb.2003.11.001; Benabid AL, 2009, LANCET NEUROL, V8, P67, DOI 10.1016/S1474-4422(08)70291-6; Benazzouz A, 2002, MOVEMENT DISORD, V17, pS145, DOI 10.1002/mds.10156; Burchiel KJ, 2013, J NEUROSURG, V119, P301, DOI 10.3171/2013.4.JNS122324; Chakrabarti R, 2014, N AM J MED SCI, V6, P359, DOI 10.4103/1947-2714.139281; Halpern CH, 2008, STEREOT FUNCT NEUROS, V86, P37, DOI 10.1159/000108587; Harries AM, 2012, J NEUROSURG, V116, P107, DOI 10.3171/2011.7.JNS11319; Hertel Frank, 2006, Neurosurgery, V59, pE1138; Houeto JL, 2003, ARCH NEUROL-CHICAGO, V60, P690, DOI 10.1001/archneur.60.5.690; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Hutchison WD, 1998, ANN NEUROL, V44, P622, DOI 10.1002/ana.410440407; Khan MF, 2008, STEREOT FUNCT NEUROS, V86, P44, DOI 10.1159/000108588; Kim W, 2014, J KOREAN MED SCI, V29, P1278, DOI 10.3346/jkms.2014.29.9.1278; Kocabicak E, 2013, J NEUROL SURG PART A, V74, P332, DOI 10.1055/s-0033-1342939; Lefaucheur JP, 2008, EUR NEUROL, V60, P186, DOI 10.1159/000148246; Lin SH, 2008, J NEUROSURG, V109, P238, DOI 10.3171/JNS/2008/109/8/0238; MacIver MB, 2011, ANESTHESIOLOGY, V115, P254, DOI 10.1097/ALN.0b013e3182217126; Magnin M, 2000, NEUROSCIENCE, V96, P549, DOI 10.1016/S0306-4522(99)00583-7; Maltete D, 2004, ARCH NEUROL-CHICAGO, V61, P390, DOI 10.1001/archneur.61.3.390; Martinez-Santiesteban FM, 2007, PHYS MED BIOL, V52, P2073, DOI 10.1088/0031-9155/52/8/003; Mirzadeh Z, 2014, MOVEMENT DISORD, V29, P1788, DOI 10.1002/mds.26056; Miyagi Y, 2007, J NEUROSURG, V107, P989, DOI 10.3171/JNS-07/11/0989; Moll Christian K E, 2013, Acta Neurochir Suppl, V117, P19, DOI 10.1007/978-3-7091-1482-7_4; Murata J, 2001, No To Shinkei, V53, P457; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Paek SH, 2008, NEUROSURGERY, V63, P925, DOI 10.1227/01.NEU.0000334045.43940.FB; Paek SH, 2011, WORLD NEUROSURG, V75, P517, DOI 10.1016/j.wneu.2010.12.003; Ponce FA, 2014, WORLD NEUROSURG, V81, P6, DOI 10.1016/j.wneu.2013.11.018; Raz A, 2010, ANESTH ANALG, V111, P1285, DOI 10.1213/ANE.0b013e3181f565f2; Rodriguez-Oroz MC, 2001, BRAIN, V124, P1777, DOI 10.1093/brain/124.9.1777; Santos P, 2004, Rev Esp Anestesiol Reanim, V51, P523; SCHALTENBRAND G, 1998, [No title captured]; Schrock LE, 2009, J NEUROPHYSIOL, V102, P3740, DOI 10.1152/jn.00544.2009; Sonkajarvi E, 2008, ACTA ANAESTH SCAND, V52, P274, DOI 10.1111/j.1399-6576.2007.01501.x; Starr PA, 2010, J NEUROSURG, V112, P479, DOI 10.3171/2009.6.JNS081161; Steigerwald F, 2008, J NEUROPHYSIOL, V100, P2515, DOI 10.1152/jn.90574.2008; Tao H, 2014, MED SCI MONITOR, V20, P1902, DOI [10.12659/MSM.892271, 10.12659/MSM.892485]; Velly LJ, 2007, ANESTHESIOLOGY, V107, P202, DOI 10.1097/01.anes.0000270734.99298.b4; Welter ML, 2014, NEUROLOGY, V82, P1352, DOI 10.1212/WNL.0000000000000315; Yamada K, 2007, PARKINSONISM RELAT D, V13, P101, DOI 10.1016/j.parkreldis.2006.07.008	40	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2016	11	3							e0152619	10.1371/journal.pone.0152619			12	Multidisciplinary Sciences	Science & Technology - Other Topics	DH5EH	WOS:000372807800064	27018855	DOAJ Gold, Green Published			2020-06-30	J	Mayer, BP; Kennedy, DJ; Lau, EY; Valdez, CA				Mayer, Brian P.; Kennedy, Daniel J.; Lau, Edmond Y.; Valdez, Carlos A.			Solution-State Structure and Affinities of Cyclodextrin:Fentanyl Complexes by Nuclear Magnetic Resonance Spectroscopy and Molecular Dynamics Simulation	JOURNAL OF PHYSICAL CHEMISTRY B			English	Article							INCLUSION COMPLEXES; WATER SUPPRESSION; BETA-CYCLODEXTRIN; FORCE-FIELD; THERMODYNAMICS; ANALGESIA; MODEL; PAIN	Cyclodextrins (CDs) ate investigated for their ability to form inclusion complexes with the analgesic fentanyl and three similar molecules: acetylfentanyl, thiofentanyl, and acetylthiofentanyl. Stoichiometry, binding strength, and complex structure are revealed through nuclear magnetic resonance (NMR) techniques and discussed in terms of molecular dynamics (MID) simulations. It was found that beta-cyclodextrin is generally capable of forming the strongest complexes with the fentanyl panel. Two-dimensional NMR data and computational chemical calculations are used to derive solution-state structures of the complexes. Binding of the fentanyls to the CDs occurs at the amide phenyl ring, leaving the majority of the molecule solvated by water, an observation common to all four fentanyls. This finding suggests a universal binding behavior, as the vast majority of previously synthesized fentanyl analogues contain this structural moiety. This baseline study serves as the most complete work on CD:fentanyl complexes to date and provides the insights into strategies for producing future generations of designer cyclodextrins capable of stronger and more selective complexation of fentanyl and its analogues.	[Mayer, Brian P.; Kennedy, Daniel J.; Valdez, Carlos A.] Lawrence Livermore Natl Lab, Forens Sci Ctr, Livermore, CA 94550 USA; [Lau, Edmond Y.] Lawrence Livermore Natl Lab, Phys & Life Sci Directorate, Biosci & Biotechnol Div, Livermore, CA 94550 USA	Valdez, CA (reprint author), Lawrence Livermore Natl Lab, Forens Sci Ctr, Livermore, CA 94550 USA.	valdez11@llnl.gov			LLNL's Laboratory Directed Research and Development Program [14-ERD-048]; U.S. Department of Energy, National Nuclear Security AdministrationNational Nuclear Security AdministrationUnited States Department of Energy (DOE) [DE-AC52-07NA27344]	This work was funded by LLNL's Laboratory Directed Research and Development Program (14-ERD-048). Livermore National Laboratory is operated by Lawrence Livermore National Security, LLC, for the U.S. Department of Energy, National Nuclear Security Administration, under Contract DE-AC52-07NA27344.	BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Brewster ME, 2007, ADV DRUG DELIVER REV, V59, P645, DOI 10.1016/j.addr.2007.05.012; Cameron KS, 2002, MAGN RESON CHEM, V40, pS106, DOI 10.1002/mrc.1083; Cameron KS, 2002, MAGN RESON CHEM, V40, P251, DOI 10.1002/mrc.1008; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Cezard C, 2011, PHYS CHEM CHEM PHYS, V13, P15103, DOI 10.1039/c1cp20854c; Challa R, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060243; Cohen-Adad R., 2003, EXPT DETERMINATION S, V6, P309; Connors KA, 1997, CHEM REV, V97, P1325, DOI 10.1021/cr960371r; Cooper A, 2005, ORG BIOMOL CHEM, V3, P1863, DOI 10.1039/b415903a; Cruz JR, 2008, MAGN RESON CHEM, V46, P838, DOI 10.1002/mrc.2267; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Del Valle EMM, 2004, PROCESS BIOCHEM, V39, P1033, DOI 10.1016/S0032-9592(03)00258-9; EASTON CJ, 1999, MODIFIED CYCLODEXTRI; Gould S, 2005, FOOD CHEM TOXICOL, V43, P1451, DOI 10.1016/j.fct.2005.03.007; Hirose K, 2001, J INCL PHENOM MACRO, V39, P193, DOI 10.1023/A:1011117412693; Hirose K., 2012, ANAL METHODS SUPRAMO, V1, P27; Hojsted J, 2007, EUR J PAIN, V11, P490, DOI 10.1016/j.ejpain.2006.08.004; Holvoet C, 2003, INT J PHARM, V265, P13, DOI 10.1016/S0378-5173(03)00368-5; HULL W, 1994, 2 DIMENSIONAL NMR SP; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.3.CO;2-G; Jeffrey GA, 1997, INTRO HYDROGEN BONDI; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; LEONHART MM, 2008, FED REGISTER, V73, P43355; Lipkowitz KB, 1998, CHEM REV, V98, P1829, DOI 10.1021/cr9700179; Mayer BP, 2012, MAGN RESON CHEM, V50, P229, DOI 10.1002/mrc.3803; Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h; Nachon F, 2013, CHEM-BIOL INTERACT, V206, P536, DOI 10.1016/j.cbi.2013.06.012; Ogawa N., 2015, J PHARM PHARMACOL, P12437; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Pettersen E. F., UCSF CHIMERA VISUALI; Rekharsky MV, 1998, CHEM REV, V98, P1875, DOI 10.1021/cr970015o; Ross PD, 1996, BIOPHYS J, V71, P2144, DOI 10.1016/S0006-3495(96)79415-8; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sehgal N, 2012, PAIN PHYSICIAN, V15, pES67; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Tang W, 2008, NAT PROTOC, V3, P691, DOI 10.1038/nprot.2008.37; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035	43	3	3	0	16	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1520-6106			J PHYS CHEM B	J. Phys. Chem. B	MAR 10	2016	120	9					2423	2433		10.1021/acs.jpcb.5b12333			11	Chemistry, Physical	Chemistry	DG4KV	WOS:000372042000039	26842886				2020-06-30	J	Huang, ZH; Liang, LN; Li, LY; Xu, M; Li, X; Sun, H; He, SW; Lin, LL; Zhang, YX; Song, YC; Yang, M; Luo, YL; Loh, HH; Law, PY; Zheng, DY; Zheng, H				Huang, Zhenhua; Liang, Lining; Li, Lingyu; Xu, Miao; Li, Xiang; Sun, Hao; He, Songwei; Lin, Lilong; Zhang, Yixin; Song, Yancheng; Yang, Man; Luo, Yuling; Loh, Horace H.; Law, Ping-Yee; Zheng, Dayong; Zheng, Hui			Opioid doses required for pain management in lung cancer patients with different cholesterol levels: negative correlation between opioid doses and cholesterol levels	LIPIDS IN HEALTH AND DISEASE			English	Article						Cholesterol level; Opioid; Analgesia; Lung cancer patients	HORMONE GNRH RECEPTOR; KNOCK-OUT MICE; LIPID RAFTS; NEURONAL CELLS; MEMBRANE RAFTS; AGONIST; MORPHINE; MICRODOMAINS; ANALGESIA; CAVEOLAE	Background: Pain management has been considered as significant contributor to broad quality-of-life improvement for cancer patients. Modulating serum cholesterol levels affects analgesia abilities of opioids, important pain killer for cancer patients, in mice system. Thus the correlation between opioids usages and cholesterol levels were investigated in human patients with lung cancer. Methods: Medical records of 282 patients were selected with following criteria, 1) signed inform consent, 2) full medical records on total serum cholesterol levels and opioid administration, 3) opioid- naive, 4) not received/ receiving cancer- related or cholesterol lowering treatment, 5) pain level at level 5- 8. The patients were divided into different groups basing on their gender and cholesterol levels. Since different opioids, morphine, oxycodone, and fentanyl, were all administrated at fixed low dose initially and increased gradually only if pain was not controlled, the percentages of patients in each group who did not respond to the initial doses of opioids and required higher doses for pain management were determined and compared. Results: Patients with relative low cholesterol levels have larger percentage (11 out of 28 in female and 31 out of 71 in male) to not respond to the initial dose of opioids than those with high cholesterol levels (0 out of 258 in female and 8 out of 74 in male). Similar differences were obtained when patients with different opioids were analyzed separately. After converting the doses of different opioids to equivalent doses of oxycodone, significant correlation between opioid usages and cholesterol levels was also observed. Conclusions: Therefore, more attention should be taken to those cancer patients with low cholesterol levels because they may require higher doses of opioids as pain killer.	[Huang, Zhenhua; Luo, Yuling; Zheng, Dayong] Southern Med Univ, Nanfang Hosp, Dept Oncol, 1838 Guangzhou Ave N, Guangzhou 510515, Guangdong, Peoples R China; [Liang, Lining; Li, Lingyu; Li, Xiang; Sun, Hao; He, Songwei; Lin, Lilong; Zhang, Yixin; Zheng, Hui] Chinese Acad Sci, CAS Key Lab Regenerat Biol, Guangdong Prov Key Lab Stem Cell & Regenerat Med, Guangzhou Inst Biomed & Hlth, A-131,190 Kaiyuan Ave, Guangzhou 510530, Guangdong, Peoples R China; [Li, Lingyu] Anhui Univ, Hefei 230601, Peoples R China; [Xu, Miao] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, 651 Dongfeng East Ave, Guangzhou 510060, Guangdong, Peoples R China; [Song, Yancheng] Southern Med Univ, Hosp 3, 183 Zhongshan Ave E, Guangzhou 510665, Guangdong, Peoples R China; [Yang, Man] Southern Med Univ, Nanfang Hosp, Dept Neurol, 1838 Guangzhou Ave N, Guangzhou 510515, Guangdong, Peoples R China; [Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA	Zheng, DY (reprint author), Southern Med Univ, Nanfang Hosp, Dept Oncol, 1838 Guangzhou Ave N, Guangzhou 510515, Guangdong, Peoples R China.; Zheng, H (reprint author), Chinese Acad Sci, CAS Key Lab Regenerat Biol, Guangdong Prov Key Lab Stem Cell & Regenerat Med, Guangzhou Inst Biomed & Hlth, A-131,190 Kaiyuan Ave, Guangzhou 510530, Guangdong, Peoples R China.	zhengdayong@hotmail.com; zheng_hui@gibh.ac.cn		Zheng, Hui/0000-0001-6801-0529	Guangdong Natural Science FoundationNational Natural Science Foundation of Guangdong Province [2014A030308002]; Guangdong Science and Technology Planning Project [2013B010404040]; Guangdong special support program [2014TQ01R157]; Guangzhou science and technology project [201508020250]; Special Foundation for National Clinical Specialties of China	This work has been supported by the "Guangdong Natural Science Foundation (2014A030308002)", the "Guangdong Science and Technology Planning Project 2013B010404040)", the "Guangdong special support program (2014TQ01R157)" the "Guangzhou science and technology project (201508020250)", and the Special Foundation for National Clinical Specialties of China (to Department of Oncology, Nanfang Hospital).	Abeatici S, 1989, Minerva Med, V80, P1085; Alfaro MJ, 1996, J PHARM PHARMACOL, V48, P433, DOI 10.1111/j.2042-7158.1996.tb05947.x; Andre A, 2008, BBA-BIOMEMBRANES, V1778, P1483, DOI 10.1016/j.bbamem.2008.03.017; Arslan D, 2014, ASIAN PAC J CANCER P, V15, P8557, DOI 10.7314/APJCP.2014.15.20.8557; Bari M, 2005, J BIOL CHEM, V280, P12212, DOI 10.1074/jbc.M411642200; Barnett-Norris J, 2005, LIFE SCI, V77, P1625, DOI 10.1016/j.lfs.2005.05.040; Bliss SP, 2007, MOL ENDOCRINOL, V21, P538, DOI 10.1210/me.2006-0289; CAMPS ES, 1998, AN MED INTERN, V15, P363; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; DUANE WC, 1988, HEPATOLOGY, V8, P1147, DOI 10.1002/hep.1840080531; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Eglen RM, 2009, METHODS MOL BIOL, V552, P1, DOI 10.1007/978-1-60327-317-6_1; Eglen RM, 2005, COMB CHEM HIGH T SCR, V8, P311, DOI 10.2174/1386207054020813; Fiorenza AM, 1996, INT J CLIN LAB RES, V26, P37, DOI 10.1007/BF02644772; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Gaibelet G, 2008, MOL MEMBR BIOL, V25, P423, DOI 10.1080/09687680802203380; Garcia-Sevilla JA, 2004, NEUROPHARMACOLOGY, V46, P519, DOI 10.1016/j.neuropharm.2003.10.006; Hong QY, 2015, CANCER-AM CANCER SOC, V121, P3080, DOI 10.1002/cncr.29584; Huang P, 2007, BRAIN RES, V1184, P46, DOI 10.1016/j.brainres.2007.09.096; Huang P, 2007, BIOCHEM PHARMACOL, V73, P534, DOI 10.1016/j.bcp.2006.10.032; Juni A, 2007, NEUROSCIENCE, V147, P439, DOI 10.1016/j.neuroscience.2007.04.030; Klein G, 2009, NEUROSCI LETT, V457, P115, DOI 10.1016/j.neulet.2009.04.012; Levitt ES, 2009, J BIOL CHEM, V284, P22108, DOI 10.1074/jbc.M109.030411; Lewington S, 2007, LANCET, V370, P1829; McNicol Ewan, 2008, J Pain Palliat Care Pharmacother, V22, P270, DOI 10.1080/15360280802537225; Mercadante S, 2015, EXPERT OPIN PHARMACO, V16, P389, DOI 10.1517/14656566.2015.989213; Morris DP, 2008, J BIOL CHEM, V283, P2973, DOI 10.1074/jbc.M705795200; Navratil AM, 2003, J BIOL CHEM, V278, P31593, DOI 10.1074/jbc.M304273200; Patel H. H., 2008, V186, P167, DOI 10.1007/978-3-540-72843-6_7; Qiu Y, 2011, MOL PHARMACOL, V80, P210, DOI 10.1124/mol.110.070870; Raish R, 1985, Iowa Med, V75, P506; Robson J, 2008, HEART, V94, P1331, DOI 10.1136/hrt.2008.150979; ROSSI GC, 1995, NEUROSCI LETT, V198, P99, DOI 10.1016/0304-3940(95)11977-5; Schug SA, 2015, EXPERT OPIN PHARMACO, V16, P5, DOI 10.1517/14656566.2015.980723; Shi YK, 2015, THORAC CANCER, V6, P10, DOI 10.1111/1759-7714.12168; Ware LJ, 2006, PAIN MANAG NURS, V7, P117, DOI 10.1016/j.pmn.2006.06.005; Whittaker Marianne R, 2013, J Pediatr Pharmacol Ther, V18, P269, DOI 10.5863/1551-6776-18.4.269; Yang WY, 2012, CIRCULATION, V125, P2212, DOI 10.1161/CIRCULATIONAHA.111.065904; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2012, J LIPID RES, V53, P1153, DOI 10.1194/jlr.M024455; Zheng H, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-6; Zheng H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.177089; Zheng H, 2010, IUBMB LIFE, V62, P112, DOI 10.1002/iub.293	46	7	8	0	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1476-511X			LIPIDS HEALTH DIS	Lipids Health Dis.	MAR 8	2016	15								47	10.1186/s12944-016-0212-9			9	Biochemistry & Molecular Biology; Nutrition & Dietetics	Biochemistry & Molecular Biology; Nutrition & Dietetics	DF6JF	WOS:000371461000001	26952011	DOAJ Gold, Green Published			2020-06-30	J	Bremer, PT; Kimishima, A; Schlosburg, JE; Zhou, B; Collins, KC; Janda, KD				Bremer, Paul T.; Kimishima, Atsushi; Schlosburg, Joel E.; Zhou, Bin; Collins, Karen C.; Janda, Kim D.			Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs	ANGEWANDTE CHEMIE-INTERNATIONAL EDITION			English	Article						antibody; biosensors; conjugate vaccines; fentanyls; immunology	HAPTEN; HEROIN; GLYCOPEPTIDES; AGONIST; BINDING; RELAPSE; IMPACT; TN	Fentanyl is an addictive prescription opioid that is over 80times more potent than morphine. The synthetic nature of fentanyl has enabled the creation of dangerous designer drug analogues that escape toxicology screening, yet display comparable potency to the parent drug. Alarmingly, a large number of fatalities have been linked to overdose of fentanyl derivatives. Herein, we report an effective immunotherapy for reducing the psychoactive effects of fentanyl class drugs. A single conjugate vaccine was created that elicited high levels of antibodies with cross-reactivity for a wide panel of fentanyl analogues. Moreover, vaccinated mice gained significant protection from lethal fentanyl doses. Lastly, a surface plasmon resonance (SPR)-based technique was established enabling drug-specificity profiling of antibodies derived directly from serum. Our newly developed fentanyl vaccine and analytical methods may assist in the battle against synthetic opioid abuse.	[Bremer, Paul T.; Kimishima, Atsushi; Schlosburg, Joel E.; Zhou, Bin; Collins, Karen C.; Janda, Kim D.] Scripps Res Inst, WIRM, Skaggs Inst Chem Biol, Dept Chem, 10550 N Torrey Pines Rd BCC 582, La Jolla, CA 92037 USA; [Bremer, Paul T.; Kimishima, Atsushi; Schlosburg, Joel E.; Zhou, Bin; Collins, Karen C.; Janda, Kim D.] Scripps Res Inst, WIRM, Skaggs Inst Chem Biol, Dept Immunol, 10550 N Torrey Pines Rd BCC 582, La Jolla, CA 92037 USA	Janda, KD (reprint author), Scripps Res Inst, WIRM, Skaggs Inst Chem Biol, Dept Chem, 10550 N Torrey Pines Rd BCC 582, La Jolla, CA 92037 USA.; Janda, KD (reprint author), Scripps Res Inst, WIRM, Skaggs Inst Chem Biol, Dept Immunol, 10550 N Torrey Pines Rd BCC 582, La Jolla, CA 92037 USA.	kdjanda@scripps.edu		Kimishima, Atsushi/0000-0002-8037-4293	National Institute on Drug Addiction [R21DA039634, F31DA037709]	We thank the National Institute on Drug Addiction for funding (grants R21DA039634, F31DA037709) and Dr. Michael Taffe for providing DEA licensing (RT0485537). This is manuscript number 29249 from TSRI.	Bannon Anthony W, 2007, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0809s41; Bremer PT, 2014, MOL PHARMACEUT, V11, P1075, DOI 10.1021/mp400631w; Bremer PT, 2012, J MED CHEM, V55, P10776, DOI 10.1021/jm301262z; Carrera MRA, 2000, P NATL ACAD SCI USA, V97, P6202, DOI 10.1073/pnas.97.11.6202; Carroll FI, 2012, ANN NY ACAD SCI, V1248, P18, DOI 10.1111/j.1749-6632.2011.06199.x; Collins KC, 2014, BIOCONJUGATE CHEM, V25, P593, DOI 10.1021/bc500016k; German CL, 2014, LIFE SCI, V97, P2, DOI 10.1016/j.lfs.2013.07.023; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Jalah R, 2015, BIOCONJUGATE CHEM, V26, P1041, DOI 10.1021/acs.bioconjchem.5b00085; Janda KD, 2012, NAT REV IMMUNOL, V12, P67, DOI 10.1038/nri3130; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; Klenkar G, 2008, ANAL BIOANAL CHEM, V391, P1679, DOI 10.1007/s00216-008-1839-9; KUNZ H, 1994, METHOD ENZYMOL, V247, P3; KUNZ H, 1990, CARBOHYD RES, V202, P207, DOI 10.1016/0008-6215(90)84081-5; KUNZ H, 1986, ANGEW CHEM INT EDIT, V25, P360, DOI 10.1002/anie.198603601; KUNZ H, 1986, ANGEW CHEM, V98, P354; Lockner JW, 2015, J MED CHEM, V58, P1005, DOI 10.1021/jm501625j; MAKOWSKI GS, 1995, ANN CLIN LAB SCI, V25, P169; Martell BA, 2005, BIOL PSYCHIAT, V58, P158, DOI 10.1016/j.biopsych.2005.04.032; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Moreno AY, 2011, J AM CHEM SOC, V133, P6587, DOI 10.1021/ja108807j; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; NIDA, 2015, EM TRENDS; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Pravetoni M, 2012, BIOCHEM PHARMACOL, V83, P543, DOI 10.1016/j.bcp.2011.11.004; Ruedi-Bettschen D, 2013, VACCINE, V31, P4596, DOI 10.1016/j.vaccine.2013.07.038; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Sakai G, 1998, SENSOR ACTUAT B-CHEM, V49, P5, DOI 10.1016/S0925-4005(98)00107-5; Schlosburg JE, 2013, P NATL ACAD SCI USA, V110, P9036, DOI 10.1073/pnas.1219159110; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Stowe GN, 2011, J MED CHEM, V54, P5195, DOI 10.1021/jm200461m; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; Vardanyan R, 2011, BIOORGAN MED CHEM, V19, P6135, DOI 10.1016/j.bmc.2011.08.027; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x	35	47	47	5	51	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1433-7851	1521-3773		ANGEW CHEM INT EDIT	Angew. Chem.-Int. Edit.	MAR 7	2016	55	11					3772	3775		10.1002/anie.201511654			4	Chemistry, Multidisciplinary	Chemistry	DF7EQ	WOS:000371521000043	26879590	Green Accepted			2020-06-30	J	van der Heijden, G; Jong, JAW; Ruijter, E; Orru, RVA				van der Heijden, Gydo; Jong, J. A. W. (Sjaak); Ruijter, Eelco; Orru, Romano V. A.			2-Bromo-6-isocyanopyridine as a Universal Convertible Isocyanide for Multicomponent Chemistry	ORGANIC LETTERS			English	Article							UGI 4-COMPONENT CONDENSATION; MOLECULAR DIVERSITY; ISONITRILE; HETEROCYCLES; CARBENES; COMPLEXES; VERSATILE; PROBES; ION	The development of 2-isocyanopyridines as novel convertible isocyanides for multicomponent chemistry is reported. Comparison of 12 representatives of this class revealed 2-bromo-6-isocyanopyridine as the optimal reagent in terms of stability and synthetic efficiency. It combines sufficient nucleophilicity with good leaving group capacity of the resulting amide moiety under both basic and acidic conditions. To demonstrate the practical utility of this reagent, an efficient two-step synthesis of the potent opioid carfentanil is presented.	[van der Heijden, Gydo; Jong, J. A. W. (Sjaak); Ruijter, Eelco; Orru, Romano V. A.] Vrije Univ Amsterdam, Dept Chem & Pharmaceut Sci, AIMMS, Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands	Ruijter, E; Orru, RVA (reprint author), Vrije Univ Amsterdam, Dept Chem & Pharmaceut Sci, AIMMS, Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	e.ruijter@vu.nl; r.v.a.orru@vu.nl		Orru, Romano V.A./0000-0003-1142-6798; Ruijter, Eelco/0000-0002-1105-3947	Innovative Medicines Initiative Joint Undertaking project CHEM21 [115360]; European UnionEuropean Union (EU); EFPIA companies' in kind contribution	We thank Elwin Janssen for technical assistance, Sanne Bouwman for HRMS measurements, and Dr. Andreas W. Ehlers for NMR maintenance (all VU Amsterdam). The research leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking project CHEM21 under Grant Agreement No. 115360, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.	Bartolome C, 2008, INORG CHEM, V47, P1616, DOI 10.1021/ic702201e; Bartolome C, 2010, INORG CHEM, V49, P9758, DOI 10.1021/ic101059c; Bartolome C, 2010, INORG CHIM ACTA, V363, P1864, DOI 10.1016/j.ica.2010.02.007; Beswick P. J., 2012, [No title captured], Patent No. [WO2012/4604 A1, 20124604]; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Domling A, 2006, CHEM REV, V106, P17, DOI 10.1021/cr0505728; Domling A, 2012, CHEM REV, V112, P3083, DOI 10.1021/cr100233r; Gilley CB, 2008, J ORG CHEM, V73, P4198, DOI 10.1021/jo800486k; Gilley CB, 2007, ORG LETT, V9, P3631, DOI 10.1021/ol701446y; Guo JH, 1997, INORG CHIM ACTA, V261, P141, DOI 10.1016/S0020-1693(97)05459-5; Hulme C, 2003, CURR OPIN DRUG DISC, V6, P921; KEATING TA, 1995, J AM CHEM SOC, V117, P7842, DOI 10.1021/ja00134a044; Keating TA, 1996, J AM CHEM SOC, V118, P2574, DOI 10.1021/ja953868b; Kobayashi G, 2011, SYNTHESIS-STUTTGART, P3225, DOI 10.1055/s-0030-1260211; Koopmanschap G, 2014, BEILSTEIN J ORG CHEM, V10, P544, DOI 10.3762/bjoc.10.50; Kruithof A, 2015, CHEM-ASIAN J, V10, P508, DOI 10.1002/asia.201403207; Lacerda RB, 2009, BIOORGAN MED CHEM, V17, P74, DOI 10.1016/j.bmc.2008.11.018; Linderman RJ, 1999, J ORG CHEM, V64, P336, DOI 10.1021/jo982186e; Lindhorst T, 1999, TETRAHEDRON, V55, P7411, DOI 10.1016/S0040-4020(99)00388-9; Maison W, 1999, BIOORG MED CHEM LETT, V9, P581, DOI 10.1016/S0960-894X(99)00024-4; Malaquin S, 2010, TETRAHEDRON LETT, V51, P2983, DOI 10.1016/j.tetlet.2010.03.120; Mironov M. A., 1999, RUSSIAN J ORGANIC CH, V35, P693; Neochoritis CG, 2015, ORG LETT, V17, P2002, DOI 10.1021/acs.orglett.5b00759; Neves RAW, 2012, TETRAHEDRON LETT, V53, P5360, DOI 10.1016/j.tetlet.2012.07.064; Pirrung MC, 2006, J AM CHEM SOC, V128, P11772, DOI 10.1021/ja0644374; Pirrung MC, 2009, J ORG CHEM, V74, P4110, DOI 10.1021/jo900414n; Ramakers BEI, 2014, CHEM SOC REV, V43, P2743, DOI 10.1039/c3cs60362h; Rotstein BH, 2014, CHEM REV, V114, P8323, DOI 10.1021/cr400615v; Shao N, 2011, J ORG CHEM, V76, P7458, DOI 10.1021/jo201273p; Shao N, 2010, TETRAHEDRON, V66, P7302, DOI 10.1016/j.tet.2010.06.096; Slobbe P, 2012, MEDCHEMCOMM, V3, P1189, DOI 10.1039/c2md20089a; Thompson MJ, 2009, J ORG CHEM, V74, P7084, DOI 10.1021/jo9014529; UGI I, 1963, [No title captured], V666, P65; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; Wessjohann LA, 2009, CHEM REV, V109, P796, DOI 10.1021/cr8003407; Zhu JP, 2003, EUR J ORG CHEM, V2003, P1133, DOI 10.1002/ejoc.200390167	36	25	25	1	47	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1523-7060	1523-7052		ORG LETT	Org. Lett.	MAR 4	2016	18	5					984	987		10.1021/acs.orglett.6b00091			4	Chemistry, Organic	Chemistry	DG0KP	WOS:000371754000025	26849150				2020-06-30	J	Fanelli, A; Sorella, MC; Chelly, JE				Fanelli, Andrea; Sorella, Maria Cristina; Chelly, Jacques E.			Iontophoretic transdermal fentanyl for the management of acute perioperative pain in hospitalized patients	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						acute postoperative pain; transdermal; patient controlled analgesia; iontophoretic system; Fentanyl	ACUTE POSTOPERATIVE PAIN; CONTROLLED ANALGESIA; SYSTEM; MORPHINE; EFFICACY; SAFETY; PHARMACOKINETICS; DELIVERY; EVENTS; COST	Introduction: Intravenous (I.V.) morphine administered through a patient-controlled system currently represents the gold standard treatment for moderate to severe acute postoperative pain. To fix the limitations showed by the available I.V. patient-controlled analgesia (PCA) systems that may restrict its use in the clinical practice a needle-free, iontophoretic, fentanyl patient-controlled transdermal system has been developed and recently approved by the United States Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). Areas covered: This review aims at describing the technology, pharmacology and clinical efficacy of fentanyl iontophoretic transdermal system (ITS) in the treatment of acute pain. A literature search was conducted in the PUBMED database using the term 'fentanyl iontophoretic transdermal system' through September 2015 and results from the main clinical trials are discussed. Expert opinion: In 2015, the appropriate treatment of acute pain after surgery is still a challenge and it represents a primary goal in the care of the surgical patient. When regional analgesia techniques are not applicable and systemic analgesia is required, patient controlled systems represent the standard of care for opioid administration. The fentanyl ITS presents several potential advantages compared to the currently used PCA devices. In particular, it does not require intravenous lines and eliminates the potential for drug administration errors, observed with manually programmed standard PCA devices. Nevertheless, further studies are needed to address eventual inter-individual variability especially for opioid tolerant patients.	[Fanelli, Andrea; Sorella, Maria Cristina] St Orsola Marcello Malpighi Hosp, Anesthesia & Intens Care Unit, Dept Med & Surg Sci, Via Albertoni 15, I-40138 Bologna, Italy; [Chelly, Jacques E.] Univ Pittsburgh, Div Acute Intervent Perioperat Pain & Reg Anesthe, Dept Anesthesiol, Med Ctr,Presbyterian Shadyside Hosp, Pittsburgh, PA USA	Fanelli, A (reprint author), St Orsola Marcello Malpighi Hosp, Anesthesia & Intens Care Unit, Dept Med & Surg Sci, Via Albertoni 15, I-40138 Bologna, Italy.	andrea.fanelli@aosp.bo.it		Fanelli, Andrea/0000-0001-9325-877X; Sorella, Maria Cristina/0000-0002-9885-9555			[Anonymous], 2012, ANESTHESIOLOGY, V116, P248, DOI DOI 10.1097/ALN.0B013E31823C1030; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Barry BW, 2001, EUR J PHARM SCI, V14, P101, DOI 10.1016/S0928-0987(01)00167-1; BOVILL JG, 1987, DRUGS, V33, P520, DOI 10.2165/00003495-198733050-00006; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Coluzzi F, 2009, MINERVA ANESTESIOL, V75, P622; Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Gupta SK, 1999, J PHARM SCI, V88, P835, DOI 10.1021/js980258b; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hartrick CT, 2007, FUTUR NEUROL, V2, P621, DOI 10.2217/14796708.2.6.621; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Kearns GL, 2003, PEDIATRICS, V112, P578, DOI 10.1542/peds.112.3.578; Mattia Consalvo, 2007, Ther Clin Risk Manag, V3, P19, DOI 10.2147/tcrm.2007.3.1.19; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Minkowitz Harold S, 2010, J Opioid Manag, V6, P203; Palmer P, 2014, CLINICOECONOMIC OUTC, V6, P311, DOI 10.2147/CEOR.S64077; Panchal SJ, 2007, ANESTH ANALG, V105, P1437, DOI 10.1213/01.ane.0000281442.36582.81; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Phipps JB, 2015, EXPERT OPIN DRUG MET, V11, P481, DOI 10.1517/17425255.2015.1020296; Rothman M, 2009, CURR MED RES OPIN, V25, P1433, DOI 10.1185/03007990902862032; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan G, 2009, CURR MED RES OPIN, V25, P363, DOI 10.1185/03007990802594941 ; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; Savoia G, 2010, MINERVA ANESTESIOL, V76, P657; Sinatra RS, 2015, EXPERT OPIN PHARMACO, V16, P1607, DOI 10.1517/14656566.2015.1054279; STEPHEN R, 1994, ARTIF ORGANS, V18, P461, DOI 10.1111/j.1525-1594.1994.tb02233.x; Stephens J, 2003, RHEUMATOLOGY, V42, P40, DOI 10.1093/rheumatology/keg497; Viscusi ER, 2006, AM J HEALTH-SYST PH, V63, pS3, DOI 10.2146/ajhp060011; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, AM J HEALTH-SYST PH, V61, pS11, DOI 10.1093/ajhp/61.suppl_1.S11; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2016, PAIN MANAG, V6, P19, DOI 10.2217/pmt.15.49; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x	41	2	2	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	MAR 3	2016	17	4					571	577		10.1517/14656566.2016.1146684			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DE6RB	WOS:000370760200003	26809270				2020-06-30	J	Heusler, P; Tardif, S; Cussac, D				Heusler, Peter; Tardif, Stephanie; Cussac, Didier			Agonist stimulation at human mu opioid receptors in a [S-35]GTP gamma S incorporation assay: observation of "bell-shaped" concentration-response relationships under conditions of strong receptor G protein coupling	JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION			English	Article						DAMGO; fentanyl; morphine; naloxone	GAMMA-S BINDING; CHO-CELLS; EFFICACY; ACTIVATION; MODULATION; POTENCY; SODIUM; AFFINITY; INVERSE; LINES	Context: The appearance of bell- (or inverted U-) shaped agonist concentration-response curves (CRCs) in in vitro pharmacological experiments is a frequently observed but poorly communicated phenomenon. In the context of G protein coupled receptor research, it is commonly attributed to the recruitment of secondary targets or to desensitization or feedback processes, but the concrete background of these observations often remains intriguing. Objective: Here, we addressed the subject of bell-shaped agonist CRCs at the mu opioid receptor (mu OR) by testing the impact of experimental conditions favoring G protein coupling. Methods: G protein activation by recombinant human mu ORs heterologously expressed in CHO cells was assessed in [S-35]GTPS binding assays using the opioid ligands DAMGO, morphine, fentanyl and naloxone. Experimental conditions were varied by changing the NaCl (10-300mM) and the GDP concentration (0.3-30 mu M). Results: Both the sodium and the GDP concentration were inversely related to G protein coupling, as evident by an increase in basal [S-35]GTPS incorporation at low sodium and low GDP levels and by the concomitant appearance of the partial agonist activity of the mu OR antagonist, naloxone. Bell-shaped CRCs were observed for the efficacious agonists DAMGO, fentanyl and morphine, and this phenomenon was promoted by low sodium as well as by low GDP concentrations. Conclusion: mu OR agonist CRCs show a non-monotonic behavior with a decline of maximal stimulation under conditions of strong receptor-G protein coupling, and this behavior is visible at the level of G protein activation itself.	[Heusler, Peter; Tardif, Stephanie; Cussac, Didier] Pierre Fabre Res Ctr, Dept Cellular & Mol Biol, 17 Ave Jean Moulin, F-81106 Castres, France	Heusler, P (reprint author), Pierre Fabre Res Ctr, Dept Cellular & Mol Biol, 17 Ave Jean Moulin, F-81106 Castres, France.	peter.heusler@pierre-fabre.com					Alt A, 2001, J PHARMACOL EXP THER, V298, P116; Bevan N, 1999, FEBS LETT, V462, P61, DOI 10.1016/S0014-5793(99)01467-2; Bindslev Niels, 2004, BMC Pharmacology, V4, P11, DOI 10.1186/1471-2210-4-11; Chen G, 2000, MOL PHARMACOL, V57, P125; Christopoulos A, 1999, BIOCHEM PHARMACOL, V58, P735, DOI 10.1016/S0006-2952(99)00087-8; Clark MJ, 2006, J PHARMACOL EXP THER, V317, P858, DOI 10.1124/jpet.105.096818; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; EASON MG, 1992, J BIOL CHEM, V267, P15795; Emmerson PJ, 2004, EUR J PHARMACOL, V494, P121, DOI 10.1016/j.ejphar.2004.04.050; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Ferguson SSG, 2007, TRENDS PHARMACOL SCI, V28, P173, DOI 10.1016/j.tips.2007.02.008; Fleysher L, 2013, NMR BIOMED, V26, P9, DOI 10.1002/nbm.2813; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; Heusler P, 2011, EUR J PHARMACOL, V669, P51, DOI 10.1016/j.ejphar.2011.07.031; Hommers LG, 2010, J BIOL CHEM, V285, P8227, DOI 10.1074/jbc.M109.015388; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Jacoby E, 2006, CHEMMEDCHEM, V1, P760, DOI 10.1002/cmdc.200600134; Katritch V, 2014, TRENDS BIOCHEM SCI, V39, P233, DOI 10.1016/j.tibs.2014.03.002; Kelly E, 2013, BRIT J PHARMACOL, V169, P1430, DOI 10.1111/bph.12222; Kelly E, 2015, PSYCHOPHARMACOLOGY, V232, P305, DOI 10.1007/s00213-014-3666-3; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518; Liu JG, 2001, MOL PHARMACOL, V60, P53; Livingston KE, 2014, P NATL ACAD SCI USA, V111, P18369, DOI 10.1073/pnas.1415013111; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Michal P, 2001, BRIT J PHARMACOL, V132, P1217, DOI 10.1038/sj.bjp.0703931; Newman-Tancredi A, 2002, MOL PHARMACOL, V62, P590, DOI 10.1124/mol.62.3.590; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Owen SC, 2014, ACS CHEM BIOL, V9, P777, DOI 10.1021/cb4007584; Pasternak GW, 2013, PHARMACOL REV, V65, P1257, DOI 10.1124/pr.112.007138; Pauwels PJ, 1997, N-S ARCH PHARMACOL, V356, P551, DOI 10.1007/PL00005090; Quirk K, 2007, BRIT J PHARMACOL, V151, P125, DOI 10.1038/sj.bjp.0707197; Rauly-Lestienne I, 2011, CELL SIGNAL, V23, P58, DOI 10.1016/j.cellsig.2010.08.002; ROVATI GE, 1994, TRENDS PHARMACOL SCI, V15, P140, DOI 10.1016/0165-6147(94)90073-6; Selley DE, 1997, MOL PHARMACOL, V51, P87; Selley DE, 2000, BRIT J PHARMACOL, V130, P987, DOI 10.1038/sj.bjp.0703382; Siehler Sandra, 2008, Biotechnology Journal, V3, P471, DOI 10.1002/biot.200800001; Strange PG, 2008, BRIT J PHARMACOL, V153, P1353, DOI 10.1038/sj.bjp.0707672; Strange PG, 2010, BRIT J PHARMACOL, V161, P1238, DOI 10.1111/j.1476-5381.2010.00963.x; Traynor JR, 2002, J PHARMACOL EXP THER, V300, P157, DOI 10.1124/jpet.300.1.157; Wade F, 2011, J BIOL CHEM, V286, P15252, DOI 10.1074/jbc.M110.184580; Wang DX, 2007, J PHARMACOL EXP THER, V321, P544, DOI 10.1124/jpet.106.118810; Wang DX, 2004, J PHARMACOL EXP THER, V308, P512, DOI 10.1124/jpet.103.054049; Wenzel-Seifert K, 2000, MOL PHARMACOL, V58, P954; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang QL, 2004, J BIOCHEM, V135, P589, DOI 10.1093/jb/mvh072; Zhang R, 2012, ACTA PHARMACOL SIN, V33, P372, DOI 10.1038/aps.2011.173	48	6	6	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-9893	1532-4281		J RECEPT SIG TRANSD	J. Recept. Signal Transduct.	MAR 3	2016	36	2					158	166		10.3109/10799893.2015.1069845			9	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	DC8YP	WOS:000369506800006	26466637				2020-06-30	J	Mambretti, EM; Kistner, K; Mayer, S; Massotte, D; Kieffer, BL; Hoffmann, C; Reeh, PW; Brack, A; Asan, E; Rittner, HL				Mambretti, Egle M.; Kistner, Katrin; Mayer, Stefanie; Massotte, Dominique; Kieffer, Brigitte L.; Hoffmann, Carsten; Reeh, Peter W.; Brack, Alexander; Asan, Esther; Rittner, Heike L.			Functional and structural characterization of axonal opioid receptors as targets for analgesia	MOLECULAR PAIN			English	Article						mu-Opioid receptor; internalization; peripheral nerve; ultrastructure; hypertonic solution; DAMGO; fentanyl; calcitonin gene-related peptide	INFLAMED TISSUE; MEDIATED ENDOCYTOSIS; MOLECULAR-MECHANISM; NERVE; PAIN; RAT; INFLAMMATION; INHIBITION; MORPHINE; PHOSPHORYLATION	Background: Opioids are the gold standard for the treatment of acute pain despite serious side effects in the central and enteric nervous system. mu-opioid receptors (MOPs) are expressed and functional at the terminals of sensory axons, when activated by exogenous or endogenous ligands. However, the presence and function of MOP along nociceptive axons remains controversial particularly in naive animals. Here, we characterized axonal MOPs by immunofluorescence, ultrastructural, and functional analyses. Furthermore, we evaluated hypertonic saline as a possible enhancer of opioid receptor function. Results: Comparative immunolabeling showed that, among several tested antibodies, which all provided specific MOP detection in the rat central nervous system (CNS), only one monoclonal MOP-antibody yielded specificity and reproducibility for MOP detection in the rat peripheral nervous system including the sciatic nerve. Double immunolabeling documented that MOP immunoreactivity was confined to calcitonin gene-related peptide (CGRP) positive fibers and fiber bundles. Almost identical labeling and double labeling patterns were found using mcherry-immunolabeling on sciatic nerves of mice producing a MOP-mcherry fusion protein (MOP-mcherry knock-in mice). Preembedding immunogold electron microscopy on MOP-mcherry knock-in sciatic nerves indicated presence of MOP in cytoplasm and at membranes of unmyelinated axons. Application of [ D-Ala(2), N-MePhe(4), Gly-ol]-enkephalin (DAMGO) or fentanyl dose-dependently inhibited depolarization-induced CGRP release from rat sciatic nerve axons ex vivo, which was blocked by naloxone. When the lipophilic opioid fentanyl was applied perisciatically in naive Wistar rats, mechanical nociceptive thresholds increased. Subthreshold doses of fentanyl or the hydrophilic opioid DAMGO were only effective if injected together with hypertonic saline. In vitro, using beta-arrestin-2/MOP double-transfected human embryonic kidney cells, DAMGO as well as fentanyl lead to a recruitment of beta-arrestin-2 to the membrane followed by a beta-arrestin-2 reappearance in the cytosol and MOP internalization. Pretreatment with hypertonic saline prevented MOP internalization. Conclusion: MOPs are present and functional in the axonal membrane from naive animals. Hypertonic saline acutely decreases ligand-induced internalization of MOP and thereby might improve MOP function. Further studies should explore potential clinical applications of opioids together with enhancers for regional analgesia.	[Mambretti, Egle M.; Brack, Alexander; Rittner, Heike L.] Univ Hosp Wuerzburg, Dept Anesthesiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany; [Mambretti, Egle M.; Asan, Esther] Univ Wurzburg, Inst Anat & Cell Biol, Wurzburg, Germany; [Kistner, Katrin; Reeh, Peter W.] Univ Erlangen Nurnberg, Inst Physiol & Pathophysiol, Erlangen, Germany; [Mayer, Stefanie; Hoffmann, Carsten] Univ Wurzburg, Inst Pharmacol & Toxicol, Wurzburg, Germany; [Mayer, Stefanie; Hoffmann, Carsten] Univ Wurzburg, Bioimaging Ctr, Rudolf Virchow Ctr, Wurzburg, Germany; [Massotte, Dominique] CNRS, Inst Neurosci Cellulaires & Integrat, UPR, Strasbourg, France; [Kieffer, Brigitte L.] McGill Univ, Fac Med, Dept Psychiat, Douglas Res Ctr, Montreal, PQ H3A 2T5, Canada; [Kieffer, Brigitte L.] Univ Strasbourg, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France	Rittner, HL (reprint author), Univ Hosp Wuerzburg, Dept Anesthesiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.	rittner_h@ukw.de	Reeh, Peter W./J-8981-2012; RIttner, Heike/AAC-6523-2019	Reeh, Peter W./0000-0002-4367-094X; RIttner, Heike/0000-0003-4867-0188; massotte, dominique/0000-0002-8758-1009	IZKF; Department of Anesthesiology, University Hospital of Wuerzburg; Wilhelm Sander-Stiftung; German Research Foundation (DFG)German Research Foundation (DFG); University of Wuerzburg	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the IZKF (to EMM, EA, HLR, and AB) and funds of the Department of Anesthesiology, University Hospital of Wuerzburg (to HLR and AB), as well as by the Wilhelm Sander-Stiftung (to KK and PWR). The publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding program Open Access Publishing.	Allouche S, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00280; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Baillie LD, 2015, NEUROPHARMACOLOGY, V93, P267, DOI 10.1016/j.neuropharm.2015.02.011; Bonn M, 2013, BRAIN STRUCT FUNCT, V218, P421, DOI 10.1007/s00429-012-0406-5; Brack A, 2004, PAIN, V108, P67, DOI 10.1016/j.pain.2003.12.008; BRETAG AH, 1969, LIFE SCI PT 1 PHYSI, V8, P319, DOI 10.1016/0024-3205(69)90283-5; Coggeshall RE, 1997, BRAIN RES, V764, P126, DOI 10.1016/S0006-8993(97)00446-0; Dabrowski S, 2015, ANTIOXID REDOX SIGN, V22, P1, DOI 10.1089/ars.2013.5706; Doll C, 2011, BRIT J PHARMACOL, V164, P298, DOI 10.1111/j.1476-5381.2011.01382.x; Erbs E, 2015, BRAIN STRUCT FUNCT, V220, P677, DOI 10.1007/s00429-014-0717-9; Fenalti G, 2014, NATURE, V506, P191, DOI 10.1038/nature12944; Flamer D, 2011, LOCAL REG ANESTH, V4, P57, DOI 10.2147/LRA.S16683; Frolich N, 2011, BIOCHEM PHARMACOL, V81, P1248, DOI 10.1016/j.bcp.2011.03.001; Gluck L, 2014, BIOL PSYCHIAT, V76, P767, DOI 10.1016/j.biopsych.2014.01.021; Grant GJ, 2001, ACTA ANAESTH SCAND, V45, P906, DOI 10.1034/j.1399-6576.2001.045007906.x; Hackel D, 2012, P NATL ACAD SCI USA, V109, pE2018, DOI 10.1073/pnas.1120800109; HASSAN AHS, 1993, NEUROSCIENCE, V55, P185, DOI 10.1016/0306-4522(93)90465-R; Heinke B, 2011, J NEUROSCI, V31, P1313, DOI 10.1523/JNEUROSCI.4060-10.2011; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hoffmann C, 2008, J BIOL CHEM, V283, P30933, DOI 10.1074/jbc.M801472200; Huang P, 2015, METHODS MOL BIOL, V1230, P141, DOI 10.1007/978-1-4939-1708-2_11; Jarousse N, 2000, TRAFFIC, V1, P378, DOI 10.1034/j.1600-0854.2000.010502.x; Katritch V, 2014, TRENDS BIOCHEM SCI, V39, P233, DOI 10.1016/j.tibs.2014.03.002; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Khalefa BI, 2012, EUR J PAIN, V16, P690, DOI 10.1002/j.1532-2149.2011.00070.x; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; Labuz D, 2013, J PHARMACOL EXP THER, V346, P535, DOI 10.1124/jpet.113.205344; Labuz D, 2009, J CLIN INVEST, V119, P1051, DOI [10.1172/JCI36246C1, 10.1172/JCI36246]; Lee LA, 2015, ANESTHESIOLOGY, V122, P659, DOI 10.1097/ALN.0000000000000564; Leffler A, 2012, ANESTHESIOLOGY, V116, P1335, DOI 10.1097/ALN.0b013e3182557917; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; Mousa SA, 2001, J NEUROIMMUNOL, V115, P71, DOI 10.1016/S0165-5728(01)00271-5; Niwa H, 2012, BRIT J ANAESTH, V108, P530, DOI 10.1093/bja/aes015; Nockemann D, 2013, EMBO MOL MED, V5, P1263, DOI 10.1002/emmm.201201980; Patierno S, 2011, GASTROENTEROLOGY, V140, P618, DOI 10.1053/j.gastro.2010.11.005; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; Pinard CR, 2012, NEUROSCIENCE, V205, P112, DOI 10.1016/j.neuroscience.2011.12.036; Puehler W, 2004, NEUROSCIENCE, V129, P473, DOI 10.1016/j.neuroscience.2004.06.086; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Rittner HL, 2009, BRAIN BEHAV IMMUN, V23, P548, DOI 10.1016/j.bbi.2009.02.007; Rittner HL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000362; Rittner HL, 2006, J LEUKOCYTE BIOL, V79, P1022, DOI 10.1189/jlb.0805452; Sauer RS, 2014, J CONTROL RELEASE, V185, P88, DOI 10.1016/j.jconrel.2014.04.029; Sauer SK, 1999, NEUROSCIENCE, V92, P319, DOI 10.1016/S0306-4522(98)00731-3; Schafer M, 1998, NEUROSCIENCE, V82, P603; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Schmidt Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079099; Schramm CL, 2010, PAIN, V151, P763, DOI 10.1016/j.pain.2010.09.009; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Truong W, 2003, ANN NEUROL, V53, P366, DOI 10.1002/ana.10465; Tsai YC, 2000, PAIN, V88, P155, DOI 10.1016/S0304-3959(00)00323-7; Vishnivetskiy SA, 2011, J BIOL CHEM, V286, P24288, DOI 10.1074/jbc.M110.213835; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	54	15	15	1	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1744-8069			MOL PAIN	Mol. Pain	MAR 1	2016	12								1744806916628734	10.1177/1744806916628734			17	Neurosciences	Neurosciences & Neurology	DM9XR	WOS:000376719500001	27030709	DOAJ Gold, Green Published			2020-06-30	J	da Silva, PSL; Reis, ME; Fonseca, TSM; Fonseca, MCM				Lucas da Silva, Paulo Sergio; Reis, Maria Eunice; Machado Fonseca, Thais Suelotto; Machado Fonseca, Marcelo Cunio			Opioid and Benzodiazepine Withdrawal Syndrome in PICU Patients: Which Risk Factors Matter?	JOURNAL OF ADDICTION MEDICINE			English	Article						benzodiazepine; fentanyl; midazolam; opiate; pediatric intensive care; withdrawal syndrome	CRITICALLY-ILL CHILDREN; PEDIATRIC-PATIENTS; III CHILDREN; FENTANYL; TOLERANCE; SYMPTOMS; MULTICENTER; ANALGESIA; METHADONE; SEDATION	Background and Aims:Although iatrogenic withdrawal syndrome (IWS) has been recognized in patients exposed to opioids and benzodiazepines, very few studies have used a validated tool for diagnosis and assessment of IWS in critically ill children. We sought to determine IWS rate, risk factors, and outcomes of IWS patients.Methods:Prospective observational study conducted in a pediatric intensive care unit. A total of 137 patients (31 with IWS and 106 with no IWS) received a continuous infusion of fentanyl and midazolam for 3 or more days. The Sophia Observation withdrawal Symptoms scale was repeatedly applied when children were weaned off sedation/analgesia.Results:The overall incidence of IWS was 22.6%. Of the 31 IWS patients, 6 showed IWS with less than 5 days sedation or analgesia. Logistic regression showed that the median peak dose of midazolam was associated with IWS development (odds ratio 1.4). Receiver-operating curve showed a cut-off value of 0.35mg/kg/h for midazolam peak dose (sensitivity 96.7%, specificity 51%, positive predictive value 36.6%, and negative predictive value 98.2%), with area under the curve of 0.80. IWS patients had a longer time on mechanical ventilation, prolonged pediatric intensive care unit, and hospital stays, and required prolonged period to have drugs discontinued.Conclusions:Although length of sedation/analgesia for at least5 days has been widely proposed for monitoring IWS, our data suggest that initiating monitoring after 3 sedation days is highly recommended. In addition, patients requiring infusion rates of midazolam above 0.35mg/kg/h should be considered at high risk for IWS.	[Lucas da Silva, Paulo Sergio] Hosp Servidor Publ Municipal, Dept Pediat, Pediat Intens Care Unit, Rua Castro Alves 60, BR-01532900 Sao Paulo, Brazil; [Reis, Maria Eunice] Hosp & Maternidade Santa Joana, Sao Paulo, Brazil; [Machado Fonseca, Thais Suelotto] Fac Med ABC, Santo Andre, Brazil; [Machado Fonseca, Marcelo Cunio] Univ Fed Sao Paulo, Hlth Technol Assessment Ctr, Sao Paulo, Brazil	da Silva, PSL (reprint author), Hosp Servidor Publ Municipal, Dept Pediat, Pediat Intens Care Unit, Rua Castro Alves 60, BR-01532900 Sao Paulo, Brazil.	psls.nat@terra.com.br	Silva, Paulo Sergio L/P-5182-2018	Fonseca, Marcelo C M/0000-0003-0803-3715			Amigoni A, 2014, ACTA PAEDIATR, V103, pE538, DOI 10.1111/apa.12777; Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Best KM, 2015, PEDIATR CRIT CARE ME, V16, P175, DOI 10.1097/PCC.0000000000000306; Burry L, 2014, COCHRANE DB SYST REV, V7; Cunliffe M, 2004, PEDIATR ANESTH, V14, P293, DOI 10.1046/j.1460-9592.2003.01219.x; Dominguez KD, 2006, ANN PHARMACOTHER, V40, P1035, DOI 10.1345/aph.1G701; Dominguez KD, 2003, ANN PHARMACOTHER, V37, P473, DOI 10.1345/aph.1C324; Fernandez-Carrion F, 2013, MED INTENSIVA, V37, P67, DOI 10.1016/j.medin.2012.02.009; Fisher D, 2013, HEART LUNG, V42, P407, DOI 10.1016/j.hrtlng.2013.07.008; Fletcher R, 2014, CLIN EPIDEMIOLOGY ES; Fonsmark L, 1999, CRIT CARE MED, V27, P196, DOI 10.1097/00003246-199901000-00052; Franck L S, 1998, Am J Crit Care, V7, P364; Franck LS, 2008, PEDIATR CRIT CARE ME, V9, P573, DOI 10.1097/PCC.0b013e31818c8328; Franck Linda S, 2004, Intensive Crit Care Nurs, V20, P344, DOI 10.1016/j.iccn.2004.07.008; Franck LS, 2012, PAIN, V153, P142, DOI 10.1016/j.pain.2011.10.003; Gupta K, 2012, PEDIATR CRIT CARE ME, V13, P131, DOI 10.1097/PCC.0b013e31820aba48; HUGHES J, 1994, ACTA PAEDIATR, V83, P1194; Ista Erwin, 2005, Pediatr Crit Care Med, V6, P58, DOI 10.1097/01.PCC.0000149318.40279.1A; Ista E, 2013, PEDIATR CRIT CARE ME, V14, P761, DOI 10.1097/PCC.0b013e31829f5be1; Ista E, 2009, INTENS CARE MED, V35, P1075, DOI 10.1007/s00134-009-1487-3; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Lugo RA, 2001, PHARMACOTHERAPY, V21, P1566, DOI 10.1592/phco.21.20.1566.34471; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Merkel S I, 1997, Pediatr Nurs, V23, P293; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Siddappa R, 2003, PAEDIATR ANAESTH, V13, P805, DOI 10.1046/j.1460-9592.2003.01153.x	30	10	10	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1932-0620	1935-3227		J ADDICT MED	J. Addict. Med.	MAR-APR	2016	10	2					110	116		10.1097/ADM.0000000000000197			7	Substance Abuse	Substance Abuse	DK2MN	WOS:000374748800006	26927302				2020-06-30	J	Barnett, S; Hung, A; Tsao, R; Sheehan, J; Bukoye, B; Sheth, SG; Leffler, DA				Barnett, Sheila; Hung, Adelina; Tsao, Roy; Sheehan, Julie; Bukoye, Bolanle; Sheth, Sunil G.; Leffler, Daniel A.			Capnographic Monitoring of Moderate Sedation During Low-Risk Screening Colonoscopy Does Not Improve Safety or Patient Satisfaction: A Prospective Cohort Study	AMERICAN JOURNAL OF GASTROENTEROLOGY			English	Article							PROCEDURAL SEDATION; RESPIRATORY EVENTS; ANESTHESIA; HYPOXEMIA	OBJECTIVES: Appropriate monitoring during sedation has been recognized as vital to patient safety in procedures outside of the operating room. Capnography can identify hypoventilation prior to hypoxemia; however, it is not clear whether the addition of capnography improves safety or is cost effective during routine colonoscopy, a high volume, low-risk procedure. Our aim was to evaluate the value of EtCO2 monitoring during colonoscopy with moderate sedation. METHODS: We conducted a prospective study of sedation safety and patient satisfaction before and after the introduction of EtCO2 monitoring during outpatient colonoscopy with midazolam and fentanyl using the validated PROcedural Sedation Assessment Survey (PROSAS). Complications of sedation and PROSAS scores were compared among colonoscopies with and without capnography. RESULTS: A total of 966 patients participated in our study, 465 in the pre-EtCO2 group and 501 in the EtCO2 group. On multivariate analysis, patients and nurses reported higher levels of procedural discomfort after adoption of capnography (1.71 vs. 1.00, P<0.001). No serious adverse events were seen, and minor sedation-related adverse events occurred with similar frequency in both groups (8.2% pre-EtCO2 vs. 11.2% EtCO2, P=0.115). The cost of implementing EtCO2 in our unit was $40,169.95 and added $11.68 per case. CONCLUSIONS: Colonoscopy with moderate sedation is a low-risk procedure, and the addition of EtCO2 did not improve safety or patient satisfaction but did increase cost. These data suggest that routine capnography in this setting may not be cost effective and that EtCO2 might be reserved for patients at higher risk of adverse events.	[Barnett, Sheila] Beth Israel Deaconess Med Ctr, Dept Anesthesiol, Boston, MA 02215 USA; [Hung, Adelina; Tsao, Roy; Sheehan, Julie; Bukoye, Bolanle; Sheth, Sunil G.; Leffler, Daniel A.] Beth Israel Deaconess Med Ctr, Dept Gastroenterol, 330 Brookline Ave, Boston, MA 02215 USA	Leffler, DA (reprint author), Beth Israel Deaconess Med Ctr, Dept Gastroenterol, 330 Brookline Ave, Boston, MA 02215 USA.	dleffler@caregroup.harvard.edu			Innovation Grant from the Center for Healthcare Delivery Science, at Beth Israel Deaconess Medical Center	This is work was supported by an Innovation Grant from the Center for Healthcare Delivery Science, at Beth Israel Deaconess Medical Center.	Beitz A, 2012, AM J GASTROENTEROL, V107, P1205, DOI 10.1038/ajg.2012.136; Burton JH, 2006, ACAD EMERG MED, V13, P500, DOI 10.1197/j.aem.2005.12.017; Cacho G, 2010, REV ESP ENFERM DIG, V102, P86, DOI 10.4321/s1130-01082010000200003; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Cooper GS, 2013, JAMA INTERN MED, V173, P551, DOI 10.1001/jamainternmed.2013.2908; Deitch K, 2010, ANN EMERG MED, V55, P258, DOI 10.1016/j.annemergmed.2009.07.030; Friedrich-Rust M, 2014, ENDOSCOPY, V46, P236, DOI 10.1055/s-0033-1359149; Hung A, 2015, J CLIN GASTROENTEROL; Koniaris LG, 2003, SURG ENDOSC, V17, P1261, DOI 10.1007/s00464-002-8789-7; Leffler DA, 2015, GASTROINTEST ENDOSC, V81, P194, DOI 10.1016/j.gie.2014.07.062; Lightdale JR, 2006, PEDIATRICS, V117, pE1170, DOI 10.1542/peds.2005-1709; Metzner J, 2010, CURR OPIN ANESTHESIO, V23, P523, DOI 10.1097/ACO.0b013e32833b7d7c; Qadeer MA, 2011, DIGESTION, V84, P37, DOI 10.1159/000321621; Qadeer MA, 2009, GASTROENTEROLOGY, V136, P1568, DOI 10.1053/j.gastro.2009.02.004; Seeff LC, 2004, GASTROENTEROLOGY, V127, P1670, DOI 10.1053/j.gastro.2004.09.051; Srinivasa Venkatesh, 2004, Curr Opin Anaesthesiol, V17, P517, DOI 10.1097/00001503-200412000-00013; Statement by the American Society of Gastrointestinal Endoscopy AmericanCollege of Gastroenterology and the American Gastroenterological Association, UN AD CAPN MOD SED A; Waugh JB, 2011, J CLIN ANESTH, V23, P189, DOI 10.1016/j.jclinane.2010.08.012; Weaver Joel, 2011, Anesth Prog, V58, P111, DOI 10.2344/0003-3006-58.3.111	19	10	10	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0002-9270	1572-0241		AM J GASTROENTEROL	Am. J. Gastroenterol.	MAR	2016	111	3					388	394		10.1038/ajg.2016.2			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	DL1OB	WOS:000375400500021	26832654				2020-06-30	J	Simoes, CR; Monteiro, ER; Rangel, JPP; Nunes, JS; Campagnol, D				Simoes, Clarissa R.; Monteiro, Eduardo R.; Rangel, Julia P. P.; Nunes-Junior, Juarez S.; Campagnol, Daniela			Effects of a prolonged infusion of fentanyl, with or without atropine, on the minimum alveolar concentration of isoflurane in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anticholinergic; inhalation anesthesia; opioid; phenylpiperidine derivative	CONSTANT RATE INFUSION; ANESTHETIZED DOGS; REMIFENTANIL; PHARMACOKINETICS; ANESTHESIA; HALOTHANE; ENFLURANE; COMBINATION; PROPOFOL; KETAMINE	Objectives To evaluate the effect of a prolonged constant rate infusion (CRI) of fentanyl on the minimum alveolar concentration (MAC) of isoflurane (ISOMAC) and to establish whether concurrent atropine administration influences ISOMAC in dogs. Study design Prospective, crossover study. Animals Six healthy dogs weighing 13.0 +/- 4.1 kg. Methods Dogs were anesthetized with isoflurane under conditions of normocapnia and normothermia. Arterial blood pressure was monitored invasively. Each dog was administered two treatments, on different occasions, in a crossover design. The dogs were administered intravenously (IV) an atropine bolus 0.02 mg kg(-1) and CRI at 0.04 mg kg(-1) hour(-1) (fentanyl-atropine treatment) or no atropine (fentanyl treatment). For each dog, baseline ISOMAC was measured in duplicate using a tail clamp technique. Subsequently, all dogs were administered a fentanyl bolus (5 mu g kg(-1)) and CRI (9 mu g kg(-1) hour(-1)) IV, and ISOMAC was redetermined at 120 and 300 minutes after initiation of the fentanyl CRI. Results Baseline ISOMAC values in the fentanyl and fentanyl-atropine treatments were 1.38 +/- 0.16% and 1.39 +/- 0.14%, respectively. Fentanyl significantly decreased the ISOMAC by 50 +/- 9% and 47 +/- 13% after 120 minutes and by 51 +/- 14% and 50 +/- 9% after 300 minutes (p < 0.001) in the fentanyl and fentanyl-atropine treatments, respectively. Compared with baseline, heart rate decreased significantly in the fentanyl treatment by 35% and 43% at 120 and 300 minutes, respectively. In the fentanyl-atropine treatment, heart rate did not change significantly over time. In both treatments, systolic arterial pressure increased from baseline after fentanyl. Conclusions and clinical relevance In this study, fentanyl reduced the ISOMAC by approximately 50%. The ISOMAC remained stable throughout the 300 minute CRI of fentanyl, suggesting no cumulative effect of the opioid. Atropine did not influence ISOMAC in dogs.	[Simoes, Clarissa R.; Monteiro, Eduardo R.; Rangel, Julia P. P.; Nunes-Junior, Juarez S.; Campagnol, Daniela] Univ Vila Velha, Sch Vet Med, Vila Velha, ES, Brazil; [Monteiro, Eduardo R.] Univ Fed Rio Grande do Sul, Fac Vet Med, Dept Anim Med, BR-91540000 Porto Alegre, RS, Brazil	Monteiro, ER (reprint author), Univ Fed Rio Grande do Sul, Fac Vet Med, Dept Anim Med, BR-91540000 Porto Alegre, RS, Brazil.	btraposo@hotmail.com		da Penha Piccoli Rangel, Julia/0000-0001-6239-4373	Fundacao de Amparo a Pesquisa do Espirito Santo (FAPES), ES, Brazil	Funding for this research was provided by the Fundacao de Amparo a Pesquisa do Espirito Santo (FAPES), ES, Brazil.	Allweiler S, 2007, VET ANAESTH ANALG, V34, P388, DOI 10.1111/j.1467-2995.2006.00308.x; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; Bufalari A, 2007, VET RES COMMUN, V31, P277, DOI 10.1007/s11259-007-0046-z; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; ELLINWOOD EH, 1990, J PHARMACOL EXP THER, V255, P1133; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; ILKIW JE, 1994, CAN J VET RES, V58, P248; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Kojima K, 2002, AM J VET RES, V63, P1671, DOI 10.2460/ajvr.2002.63.1671; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; LEMKE KA, 2007, LUMB JONES VET ANEST, P203; Luo LL, 2010, J CLIN ANESTH, V22, P527, DOI 10.1016/j.jclinane.2010.02.006; Mastrocinque S, 2003, VET ANAESTH ANALG, V30, P220, DOI 10.1046/j.1467-2995.2003.00090.x; Monteiro ER, 2010, AM J VET RES, V71, P1133, DOI 10.2460/ajvr.71.10.1133; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; PAGEL PS, 1991, ANESTHESIOLOGY, V74, P539, DOI 10.1097/00000542-199103000-00024; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; PROAKIS AG, 1978, ANESTHESIOLOGY, V48, P339, DOI 10.1097/00000542-197805000-00007; Pypendop BH, 2007, VET ANAESTH ANALG, V34, P209, DOI 10.1111/j.1467-2995.2006.00324.x; Queiroz-Williams P, 2014, VET ANAESTH ANALG, V41, P312, DOI 10.1111/vaa.12115; REITAN JA, 1978, ANESTH ANALG, V57, P31; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Solano AM, 2006, AM J VET RES, V67, P21, DOI 10.2460/ajvr.67.1.21; Ueyama Y, 2009, AM J VET RES, V70, P1459, DOI 10.2460/ajvr.70.12.1459; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; WEBB AI, 1987, AM J VET RES, V48, P1733	29	6	6	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAR	2016	43	2					136	144		10.1111/vaa.12282			9	Veterinary Sciences	Veterinary Sciences	DJ5ZE	WOS:000374288600003	26058733				2020-06-30	J	Davies, A; Mundin, G; Vriens, J; Webber, K; Buchanan, A; Waghorn, M				Davies, Andrew; Mundin, Gill; Vriens, Joanna; Webber, Kath; Buchanan, Alison; Waghorn, Melanie			The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Breakthrough cancer pain; opioid analgesic; fentanyl; oral transmucosal route; salivary gland hypofunction	OPIOID ANALGESICS; TOLERABILITY; MANAGEMENT; PHARMACOKINETICS; RECOMMENDATIONS; XEROSTOMIA; EFFICACY; SAFETY; TABLET	Context. Salivary gland hypofunction may affect the absorption of drugs through the oral mucosa, which in turn may affect their clinical efficacy (e.g., onset of action). Objectives. The aim of this study was to assess the pharmacokinetics of a sublingual fentanyl orally disintegrating tablet (Abstral (R), Prostrakan Inc.) in a group of cancer patients with salivary gland hypofunction. Methods. Nine cancer patients with salivary gland hypofunction underwent a series of three pharmacokinetic studies with the sublingual fentanyl orally disintegrating tablet. In the first phase, the patients received no pretreatment; in the second phase, the patients were allowed to moisten the oral cavity before dosing; in the third phase, the patients were given pilocarpine hydrochloride (saliva stimulant) before dosing. Fentanyl concentrations were measured using a method of high-performance liquid chromatography with validated tandem mass spectrometric detection. Results. The Tmax was longer, the Cmax was lower, the AUC0-30 lower, and the AUClast lower in the phase involving no pretreatment; the Tmax/Cmax/AUC0-30/AUClast were similar in the phase involving moistening of the oral cavity and the phase involving giving pilocarpine hydrochloride. Conclusion. The pharmacokinetics of the sublingual fentanyl orally disintegrating tablet appear to be negatively affected by the presence of salivary gland hypofunction, although the moistening of the oral cavity before dosing results in a pharmacokinetic profile similar to that seen with the giving of pilocarpine hydrochloride. J Pain Symptom Manage (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.	[Davies, Andrew; Webber, Kath; Buchanan, Alison; Waghorn, Melanie] Royal Surrey Cty Hosp, Guildford GU2 7XX, Surrey, England; [Mundin, Gill] Mundipharma Res Ltd, Cambridge, Cambs, England; [Vriens, Joanna] Princess Alice Hosp, Esher, Surrey, England	Davies, A (reprint author), Royal Surrey Cty Hosp, Guildford GU2 7XX, Surrey, England.	adavies12@nhs.net			Dr. Davies's Research Fund; ProStrakan Group Plc, Galashiels, UK	The study was funded by Dr. Davies's Research Fund, which has received unrestricted research funding from pharmaceutical companies with products with marketing authorizations for the management of breakthrough cancer pain (including ProStrakan Group Plc, Galashiels, UK). However, this was an investigator generated study, and not a pharmaceutical sponsored study.	[Anonymous], 2015, ACTIQ SUMMARY PRODUC; [Anonymous], 2015, SALAGEN SUMMARY PROD; [Anonymous], 2015, ABSTRAL PATIENT INFO; [Anonymous], 2015, ABSTRAL SUMMARY PROD; [Anonymous], 2015, EFFENTORA SUMMARY PR; BAILEY F, 2006, CANC RELATED BREAKTH, P43; Bedard G, 2013, SUPPORT CARE CANCER, V21, P2557, DOI 10.1007/s00520-013-1817-4; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Chaushu G, 2000, CANCER, V88, P984, DOI 10.1002/(SICI)1097-0142(20000301)88:5<984::AID-CNCR6>3.3.CO;2-S; Davies A., 2012, CANC RELATED BREAKTH; Davies A., 2010, ORAL COMPLICATIONS C; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 1998, PALLIATIVE MED, V12, P105, DOI 10.1191/026921698670435903; Davies AN, 2002, ORAL ONCOL, V38, P680, DOI 10.1016/S1368-8375(01)00133-6; Davies AN, 2001, J PAIN SYMPTOM MANAG, V22, P820, DOI 10.1016/S0885-3924(01)00318-9; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Hao JS, 2003, DRUG DEV IND PHARM, V29, P821, DOI 10.1081/DDC-120024178; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lister N, 2011, J CLIN PHARMACOL, V51, P1195, DOI 10.1177/0091270010379410; Lorch U, 2008, 13 INT PAIN CLIN C W; Moore N, 2012, CURR MED RES OPIN, V28, P1781, DOI 10.1185/03007995.2012.735227; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; ROBBINS LJ, 1983, NEW ENGL J MED, V309, P985; Sreebny L M, 1997, Gerodontology, V14, P33, DOI 10.1111/j.1741-2358.1997.00033.x; SREEBNY LM, 1996, [No title captured], P43; SREEBNY LM, 1992, [No title captured], V42, P291; Tranmer JE, 2003, J PAIN SYMPTOM MANAG, V25, P420, DOI 10.1016/S0885-3924(03)00074-5; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020	32	8	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAR	2016	51	3					538	545		10.1016/j.jpainsymman.2015.11.018			8	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	DI4ME	WOS:000373473200008	26706627	Bronze			2020-06-30	J	Hung, A; Marshall, J; Barnett, S; Falchuk, ZM; Sawhney, M; Leffler, DA				Hung, Adelina; Marshall, John; Barnett, Sheila; Falchuk, Zalman M.; Sawhney, Mandeep; Leffler, Daniel A.			Risk Factors and Outcomes of Reversal Agent Use in Moderate Sedation During Endoscopy and Colonoscopy	JOURNAL OF CLINICAL GASTROENTEROLOGY			English	Article						endoscopy; adverse events; moderate sedation; reversal agent; colonoscopy	GASTROINTESTINAL-ENDOSCOPY; NATIONWIDE SURVEY; GI ENDOSCOPY; ANESTHESIA; MIDAZOLAM; FENTANYL	Background: Moderate sedation has been standard for noninvasive gastrointestinal procedures for decades yet there are limited data on reversal agent use and outcomes associated with need for reversal of sedation. Aim: To determine prevalence and clinical significance of reversal agent use during endoscopies and colonoscopies. Methods: Individuals with adverse events requiring naloxone and/or flumazenil during endoscopy or colonoscopy from 2008 to 2013 were identified. A control group was obtained by random selection of patients matched by procedure type and date. Prevalence of reversal agent use and statistical comparison of patient demographics and risk factors against controls were determined. Results: Prevalence of reversal agent use was 0.03% [95% confidence interval (CI), 0.02-0.04]. Events triggering reversal use were oxygen desaturation (64.4%), respiration changes (24.4%), hypotension (8.9%), and bradycardia (6.7%). Two patients required escalation of care and the majority of patients were stabilized and discharged home. Compared with the control group, the reversal group was older (61 +/- 1.8 vs. 55 +/- 1.6, P=0.01), mostly female (82% vs. 50%, P < 0.01), and had lower body mass index (24 +/- 0.8 vs. 27 +/- 0.7, P=0.03) but received similar dosages of sedation. When adjusted for age, race, sex, and body mass index, the odds of reversal agent patients having a higher ASA score than controls was 4.7 (95% CI, 1.7-13.1), and the odds of having a higher Mallampati score than controls was 5.0 (95% CI, 2.1-11.7) with P < 0.01. Conclusions: Prevalence of reversal agent use during moderate sedation is low and outcomes are generally good. Several clinically relevant risk factors for reversal agent use were found suggesting that certain groups may benefit from closer monitoring.	[Hung, Adelina; Falchuk, Zalman M.; Sawhney, Mandeep; Leffler, Daniel A.] Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Boston, MA 02215 USA; [Barnett, Sheila] Beth Israel Deaconess Med Ctr, Dept Anesthesiol, Boston, MA 02215 USA; [Marshall, John] Beth Israel Deaconess Med Ctr, Div Pharma, Boston, MA 02215 USA	Hung, A (reprint author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA.	ahung@bidmc.harvard.edu					Al-Awabdy B, 2013, WORLD J GASTRO ENDOS, V5, P1, DOI 10.4253/wjge.v5.i1.1; Amornyotin S, 2013, WORLD J GASTRO ENDOS, V5, P527, DOI 10.4253/wjge.v5.i11.527; Barriga J, 2008, SOUTH MED J, V101, P362, DOI 10.1097/SMJ.0b013e318168521b; Bell GD, 2004, ENDOSCOPY, V36, P23; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Cohen Lawrence B, 2010, Gastrointest Endosc Clin N Am, V20, P615, DOI 10.1016/j.giec.2010.07.003; DANESHMEND TK, 1991, GUT, V32, P12, DOI 10.1136/gut.32.1.12; Hayee B, 2009, GASTROINTEST ENDOSC, V69, P681, DOI 10.1016/j.gie.2008.09.033; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Liu HS, 2012, JAMA-J AM MED ASSOC, V307, P1178, DOI 10.1001/jama.2012.270; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Rex DK, 2006, ALIMENT PHARM THER, V24, P163, DOI 10.1111/j.1365-2036.2006.02986.x; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; SILVIS SE, 1976, JAMA-J AM MED ASSOC, V235, P928, DOI 10.1001/jama.235.9.928; Triantafillidis JK, 2013, WORLD J GASTROENTERO, V19, P463, DOI 10.3748/wjg.v19.i4.463; Wang DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053311; Wang F, 2011, INT J COLORECTAL DIS, V26, P703, DOI 10.1007/s00384-011-1162-3; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4	19	8	8	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0192-0790	1539-2031		J CLIN GASTROENTEROL	J. Clin. Gastroenterol.	MAR	2016	50	3					E25	E29		10.1097/MCG.0000000000000291			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	DH5NX	WOS:000372837600001	25626630				2020-06-30	J	McIntyre, IM; Trochta, A; Gary, RD; Wright, J; Mena, O				McIntyre, Iain M.; Trochta, Amber; Gary, Ray D.; Wright, Jennifer; Mena, Othon			An Acute Butyr-Fentanyl Fatality: A Case Report with Postmortem Concentrations	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							REDISTRIBUTION; BUTYRFENTANYL; BLOOD; LIVER	In this case report, we present an evaluation of the distribution of postmortem concentrations of butyr-fentanyl in a fatality attributed principally to the drug. A man who had a history of intravenous drug abuse was found unresponsive on the bathroom floor of his home. Drug paraphernalia was located on the bathroom counter. Toxicology testing, which initially screened positive for fentanyl by enzyme-linked immunosorbent assay, subsequently confirmed butyr-fentanyl, which was then quantitated by gas chromatography-mass spectrometry-specific ion monitoring (GC-MS SIM) analysis following liquid-liquid extraction. The butyr-fentanyl peripheral blood concentration was quantitated at 58 ng/mL compared with the central blood concentration of 97 ng/mL. The liver concentration was 320 ng/g, the vitreous was 40 ng/mL, the urine was 670 ng/mL and the gastric contained 170 mg. Acetyl-fentanyl was also detected in all biological specimens tested. Peripheral blood concentration was quantitated at 38 ng/mL compared with the central blood concentration of 32 ng/mL. The liver concentration was 110 ng/g, the vitreous was 38 ng/mL, the urine was 540 ng/mL and the gastric contained < 70 mg. The only other drug detected was a relatively low concentration of benzoylecgonine. The cause of death was certified as acute butyr-fentanyl, acetyl-fentanyl and cocaine intoxication, and the manner of death was certified as accident.	[McIntyre, Iain M.; Trochta, Amber; Gary, Ray D.; Wright, Jennifer; Mena, Othon] Cty San Diego Med Examiners Off, 5570 Overland Ave,Suite 101, San Diego, CA 92123 USA	McIntyre, IM (reprint author), Cty San Diego Med Examiners Off, 5570 Overland Ave,Suite 101, San Diego, CA 92123 USA.	iain.mcintyre@sdcounty.ca.gov00		McIntyre, Iain/0000-0002-0284-6152			Alburges M.E., 1988, UTILIZATION RADIOREC; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Dalpe-Scott M, 1995, CAN SOC FORENSIC SCI, V28, P113; Drug Enforcement Administration, 2013, AC FENT N 1PHENETHYL; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; McIntyre IM, 2015, J ANAL TOXICOL, V39, P156, DOI 10.1093/jat/bku131; McIntyre IM, 2014, FORENSIC SCI MED PAT, V10, P91, DOI 10.1007/s12024-013-9503-x; McIntyre IM, 2014, INT J LEGAL MED, V128, P65, DOI 10.1007/s00414-013-0897-5; McIntyre IM, 2012, J ANAL TOXICOL, V36, P177, DOI 10.1093/jat/bks011; MMWR, 2013, MORBIDITY MORTALITY, V62, P703; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103	14	39	39	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAR	2016	40	2					162	166		10.1093/jat/bkv138			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	DG9VV	WOS:000372432800011	26683128	Bronze			2020-06-30	J	Adami, C; Casoni, D; Noussitou, F; Rytz, U; Spadavecchia, C				Adami, C.; Casoni, D.; Noussitou, F.; Rytz, U.; Spadavecchia, C.			Addition of magnesium sulphate to ropivacaine for spinal analgesia in dogs undergoing tibial plateau levelling osteotomy	VETERINARY JOURNAL			English	Article						Analgesia; Dog; Magnesium sulphate; Ropivacaine; Spinal anaesthesia	PAIN; BUPIVACAINE; AMANTADINE; MORPHINE	The aim of this blinded, randomised, prospective clinical trial was to determine whether the addition of magnesium sulphate to spinally-administered ropivacaine would improve peri-operative analgesia without impairing motor function in dogs undergoing orthopaedic surgery. Twenty client-owned dogs undergoing tibial plateau levelling osteotomy were randomly assigned to one of two treatment groups: group C (control, receiving hyperbaric ropivacaine by the spinal route) or group M (magnesium, receiving a hyperbaric combination of magnesium sulphate and ropivacaine by the spinal route). During surgery, changes in physiological variables above baseline were used to evaluate nociception. Arterial blood was collected before and after spinal injection, at four time points, to monitor plasma magnesium concentrations. Post-operatively, pain was assessed with a modified Sammarco pain score, a Glasgow pain scale and a visual analogue scale, while motor function was evaluated with a modified Tarlov scale. Assessments were performed at recovery and 1, 2 and 3 h thereafter. Fentanyl and buprenorphine were administered as rescue analgesics in the intra- and post-operative periods, respectively. Plasma magnesium concentrations did not increase after spinal injection compared to baseline. Group M required less intra-operative fentanyl, had lower Glasgow pain scores and experienced analgesia of longer duration than group C (527.0 +/- 341.0 min vs. 176.0 +/- 109.0 min). However, in group M the motor block was significantly longer, which limits the usefulness of magnesium for spinal analgesia at the investigated dose. Further research is needed to determine a clinically effective dose with shorter duration of motor block for magnesium used as an additive to spinal analgesic agents. (C) 2016 Elsevier Ltd. All rights reserved.	[Adami, C.] Univ London, Royal Vet Coll, Dept Clin Sci & Serv, Hawkshead Campus, Hatfield AL97TA, Herts, England; [Casoni, D.; Spadavecchia, C.] Univ Bern, Vetsuisse Fac, Anaesthesiol & Pain Therapy Div, Dept Vet Clin Sci, Langgassstr 124, CH-3012 Bern, Switzerland; [Noussitou, F.; Rytz, U.] Univ Bern, Vetsuisse Fac, Div Surg, Dept Vet Clin Sci, Langgassstr 124, CH-3012 Bern, Switzerland	Adami, C (reprint author), Univ London, Royal Vet Coll, Dept Clin Sci & Serv, Hawkshead Campus, Hatfield AL97TA, Herts, England.	c.adami@rvc.ac.uk					Adami C, 2012, VET J, V194, P229, DOI 10.1016/j.tvjl.2012.04.019; Arcioni R, 2007, ACTA ANAESTH SCAND, V51, P482, DOI 10.1111/j.1399-6576.2007.01263.x; Bahrenberg A, 2015, VET ANAESTH ANALG, V42, P319, DOI 10.1111/vaa.12211; Bilir A, 2007, BRIT J ANAESTH, V98, P519, DOI 10.1093/bja/aem029; BUSSELBERG D, 1994, J NEUROPHYSIOL, V71, P1491; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Crociolli GC, 2015, J VET MED SCI, V77, P1011, DOI 10.1292/jvms.14-0602; Elin R. J., 2010, Magnesium Research, V23, P194; Haghighi M., 2015, ANESTHESIOLOGY PAIN, V5; Holton L, 2001, VET REC, V148, P525, DOI 10.1136/vr.148.17.525; KuKanich B, 2013, VET CLIN N AM-SMALL, V43, P1109, DOI 10.1016/j.cvsm.2013.04.007; Levin A, 1998, ANESTH ANALG, V87, P624, DOI 10.1097/00000539-199809000-00025; Madden M, 2014, VET ANAESTH ANALG, V41, P440, DOI 10.1111/vaa.12141; Mills LR, 1998, J MEMBRANE BIOL, V166, P223, DOI 10.1007/s002329900464; Norkus C, 2015, J VET PHARMACOL THER, V38, P305, DOI 10.1111/jvp.12190; Ozalevli M, 2005, ACTA ANAESTH SCAND, V49, P1514, DOI 10.1111/j.1399-6576.2005.00793.x; Sammarco JL, 1996, VET SURG, V25, P59, DOI 10.1111/j.1532-950X.1996.tb01377.x; Sarotti D, 2011, VET ANAESTH ANALG, V38, P240, DOI 10.1111/j.1467-2995.2011.00608.x; Shahi Vaibhav, 2014, J Anaesthesiol Clin Pharmacol, V30, P538, DOI 10.4103/0970-9185.142852; SIMPSON JI, 1994, ANESTHESIOLOGY, V81, P1493, DOI 10.1097/00000542-199412000-00025; Steffey E., 2007, LUMB JONES VET ANEST; WAN X, 1995, J MEMBRANE BIOL, V145, P21; Yousef AA, 2010, INT J OBSTET ANESTH, V19, P401, DOI 10.1016/j.ijoa.2010.07.019	23	5	5	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-0233	1532-2971		VET J	Vet. J.	MAR	2016	209						163	168		10.1016/j.tvjl.2015.11.017			6	Veterinary Sciences	Veterinary Sciences	DG2YT	WOS:000371937400025	26831174	Green Accepted			2020-06-30	J	Shein, SL; Ferguson, NM; Kochanek, PM; Bayir, H; Clark, RSB; Fink, EL; Tyler-Kabara, EC; Wisniewski, SR; Tian, Y; Balasubramani, GK; Bell, MJ				Shein, Steven L.; Ferguson, Nikki M.; Kochanek, Patrick M.; Bayir, Huelya; Clark, Robert S. B.; Fink, Ericka L.; Tyler-Kabara, Elizabeth C.; Wisniewski, Stephen R.; Tian, Ye; Balasubramani, G. K.; Bell, Michael J.			Effectiveness of Pharmacological Therapies for Intracranial Hypertension in Children With Severe Traumatic Brain Injury-Results From an Automated Data Collection System Time-Synched to Drug Administration	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						intracranial hypertension; pediatrics; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; PEDIATRIC HEAD-INJURY; DEXAMETHASONE THERAPY; HYPERTONIC SALINE; BLOOD-PRESSURE; FENTANYL; METABOLISM	Objectives: To describe acute cerebral hemodynamic effects of medications commonly used to treat intracranial hypertension in children with traumatic brain injury. Currently, data supporting the efficacy of these medications are insufficient. Design: In this prospective observational study, intracranial hypertension (intracranial pressure 20 mm Hg for > 5 min) was treated by clinical protocol. Administration times of medications for intracranial hypertension (fentanyl, 3% hypertonic saline, mannitol, and pentobarbital) were prospectively recorded and synchronized with an automated database that collected intracranial pressure and cerebral perfusion pressure every 5 seconds. Intracranial pressure crises confounded by external stimulation or mechanical ventilator adjustments were excluded. Mean intracranial pressure and cerebral perfusion pressure from epochs following drug administration were compared with baseline values using Kruskal-Wallis analysis of variance and Dunn test. Frailty modeling was used to analyze the time to intracranial pressure crisis resolution. Mixed-effect models compared intracranial pressure and cerebral perfusion pressure 5 minutes after the medication versus baseline and rates of treatment failure. Setting: A tertiary care children's hospital. Patients: Children with severe traumatic brain injury (Glasgow Coma Scale score 8). Interventions: None. Measurements and Main Results: We analyzed 196 doses of fentanyl, hypertonic saline, mannitol, and pentobarbital administered to 16 children (median: 12 doses per patient). Overall, intracranial pressure significantly decreased following the administration of fentanyl, hypertonic saline, and pentobarbital. After controlling for administration of multiple medications, intracranial pressure was decreased following hypertonic saline and pentobarbital administration; cerebral perfusion pressure was decreased following fentanyl and was increased following hypertonic saline administration. After adjusting for significant covariates (including age, Glasgow Coma Scale score, and intracranial pressure), hypertonic saline was associated with a two-fold faster resolution of intracranial hypertension than either fentanyl or pentobarbital. Fentanyl was significantly associated with the most frequent treatment failure. Conclusions: Intracranial pressure decreased after multiple drug administrations, but hypertonic saline may warrant consideration as the first-line drug for treating intracranial hypertension, as it was associated with the most favorable cerebral hemodynamics and fastest resolution of intracranial hypertension.	[Shein, Steven L.; Ferguson, Nikki M.; Kochanek, Patrick M.; Bayir, Huelya; Clark, Robert S. B.; Fink, Ericka L.; Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Shein, Steven L.; Ferguson, Nikki M.; Kochanek, Patrick M.; Bayir, Huelya; Clark, Robert S. B.; Fink, Ericka L.; Bell, Michael J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Tyler-Kabara, Elizabeth C.; Bell, Michael J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.; Tian, Ye; Balasubramani, G. K.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA	Bell, MJ (reprint author), Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA.; Bell, MJ (reprint author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA.; Bell, MJ (reprint author), Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA.	bellmj4@upmc.edu	Shein, Steven/I-7763-2019; Ferguson, Nikki Miller/AAA-4548-2020; Tyler-Kabara, Elizabeth/H-4930-2013	Shein, Steven/0000-0003-3382-5159; Wisniewski, Stephen/0000-0002-3877-9860; Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Goundappa K, Balasubramani/0000-0001-7221-1825	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD 040686]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD 040686, NS 081041]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); PCORIPatient-Centered Outcomes Research Institute - PCORI; Laerdal Foundation;  [K23 NS065132]	Drs. Shein and Ferguson were supported by the National Institutes of Health (NIH) training grant (T32 HD 040686). Dr. Kochanek received salary support by an NIH grant (NS 081041). Dr. Fink was supported by K23 NS065132. Drs. Wisniewski and Bell received salary support by an NIH grant (NS 081041).; Dr. Bell received support for article research from the National Institutes of Health (NIH). His institution received funding: Drs. Shein and Ferguson were supported by NIH training grant (T32 HD 040686). Drs. Bell, Kochanek, and Wisniewski received salary support by an NIH grant (NS 081041). Dr. Fink was supported by K23 NS065132. Dr. Shein received support for article research from the NIH. His institution received funding from the NIH (T32 HD040686). Dr. Ferguson received support for article research from the NIH. Her institution received funding from the NIH/NICHD. Dr. Kochanek has multiple grants from federal agencies including the NIH and the U.S. Army, receives a stipend for serving as editor of Pediatric Critical Care Medicine, served as an expert witness on several cases over the past 36 months, received honoraria for numerous lectures at national meetings and/or as a guest professor at various institutions of higher education, and received support for article research from the NIH. His institution received funding from the NIH. Dr. Bayir received support for article research from the NIH. Dr. Clark received royalties from Elsevier. His institution received funding from NIH grants. Dr. Fink received support for article research from the NIH. Her institution received funding from the NIH, PCORI, and the Laerdal Foundation. Dr. Tyler-Kabara disclosed other support: TK Group LLC, member, consulting group for computer security, occasional medical legal work related to pediatric neurosurgery (none related to severe traumatic head injuries in the last 36 months). Dr. Wisniewski received support for article research from the Department of Defense. His institution received funding from the Department of Defense. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Bell MJ, 2009, NEUROCRIT CARE, V10, P4, DOI 10.1007/s12028-008-9061-3; Bramwell KJ, 2006, PEDIATR EMERG CARE, V22, P90, DOI 10.1097/01.pec.0000199563.64264.3a; CARLSSON C, 1982, ANESTHESIOLOGY, V57, P375, DOI 10.1097/00000542-198211000-00005; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; FANCONI S, 1988, INTENS CARE MED, V14, P163; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Hager H, 2009, OBES SURG, V19, P717, DOI 10.1007/s11695-008-9607-7; Huschak G, 2008, J NEUROSURG ANESTH, V20, P105, DOI 10.1097/ANA.0b013e31815f528c; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Mellion SA, 2013, PEDIATR CRIT CARE ME, V14, P239, DOI 10.1097/PCC.0b013e318271c3b2; MICHENFELDER JD, 1971, BRIT J ANAESTH, V43, P630, DOI 10.1093/bja/43.7.630; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; PITTMAN T, 1989, PEDIATR NEUROSCI, V15, P13, DOI 10.1159/000120433; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da	28	23	24	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2016	17	3					236	245		10.1097/PCC.0000000000000610			10	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	DG0IC	WOS:000371747500008	26673840	Green Accepted			2020-06-30	J	Lin, N; Han, RQ; Zhou, JX; Gelb, AW				Lin, Nan; Han, Ruquan; Zhou, Jianxin; Gelb, Adrian W.			Mild Sedation Exacerbates or Unmasks Focal Neurologic Dysfunction in Neurosurgical Patients with Supratentorial Brain Mass Lesions in a Drug-specific Manner	ANESTHESIOLOGY			English	Article							MONITORED CONSCIOUS SEDATION; MOTOR CORTEX ACTIVATION; HEALTH STROKE SCALE; ACETYLCHOLINE-RELEASE; NUCLEUS-ACCUMBENS; LOCAL-ANESTHESIA; RECOVERY; TUMORS; PROPOFOL; DEFICITS	Background: Sedation is commonly used in neurosurgical patients but has been reported to produce transient focal neurologic dysfunction. The authors hypothesized that in patients with frontal-parietal-temporal brain tumors, focal neurologic deficits are unmasked or exacerbated by nonspecific sedation independent of the drug used. Methods: This was a prospective, randomized, single-blind, self-controlled design with parallel arms. With institutional approval, patients were randomly assigned to one of the four groups: "propofol," "midazolam," "fentanyl," and "dexmedetomidine." The sedatives were titrated by ladder administration to mild sedation but fully cooperative, equivalent to Observer's Assessment of Alertness and Sedation score = 4. National Institutes of Health Stroke Scale (NIHSS) was used to evaluate the neurologic function before and after sedation. The study's primary outcome was the proportion of NIHSS-positive change in patients after sedation to Observer's Assessment of Alertness and Sedation = 4. Results: One hundred twenty-four patients were included. Ninety had no neurologic deficits at baseline. The proportion of NIHSS-positive change was midazolam 72%, propofol 52%, fentanyl 27%, and dexmedetomidine 23% (P less than 0.001 among groups). No statistical difference existed between propofol and midazolam groups (P = 0.108) or between fentanyl and dexmedetomidine groups (P = 0.542). Midazolam and propofol produced more sedative-induced focal neurologic deficits compared with fentanyl and dexmedetomidine. The neurologic function deficits were mainly limb motor weakness and ataxia. Patients with high-grade gliomas were more susceptible to the induced neurologic dysfunction regardless of the sedative. Conclusions: Midazolam and propofol augmented or revealed neurologic dysfunction more frequently than fentanyl and dexmedetomidine at equivalent sedation levels. Patients with high-grade gliomas were more susceptible than those with low-grade gliomas.	[Lin, Nan; Han, Ruquan] Capital Med Univ, Beijing Tiantan Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Zhou, Jianxin] Capital Med Univ, Beijing Tiantan Hosp, Dept Crit Care Med, Beijing, Peoples R China; [Gelb, Adrian W.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 521 Parnassus Ave,C450, San Francisco, CA 94143 USA	Gelb, AW (reprint author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 521 Parnassus Ave,C450, San Francisco, CA 94143 USA.	adrian.gelb@ucsf.edu	Han, Ruquan/K-2433-2019		Beijing Municipal Fund for Returning Scholars, Jointly doctoral degree education program in Capital Medical University, Beijing, China	Support for this work was received from Beijing Municipal Fund for Returning Scholars, Jointly doctoral degree education program in Capital Medical University, Beijing, China.	Afonso J, 2012, REV BRAS ANESTESIOL, V62, P118, DOI 10.1016/S0034-7094(12)70110-1; AHMED MS, 1989, LIFE SCI, V45, P2383, DOI 10.1016/0024-3205(89)90001-5; Berthier ML, 2005, DRUG AGING, V22, P163, DOI 10.2165/00002512-200522020-00006; Brian JE, 1996, ANESTHESIOLOGY, V85, pA29; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; Cechetto DF, 2001, ANESTH ANALG, V92, P934; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cheung RTF, 2010, INT J STROKE, V5, P74, DOI 10.1111/j.1747-4949.2010.00411.x; CUCCHIARA RF, 1992, ANESTH ANALG, V75, P467, DOI 10.1213/00000539-199209000-00036; Danks RA, 2000, J NEURO-ONCOL, V49, P131, DOI 10.1023/A:1026577518902; Duffau H, 2005, LANCET NEUROL, V4, P476, DOI 10.1016/S1474-4422(05)70140-X; Duffau H, 2014, CORTEX, V58, P325, DOI 10.1016/j.cortex.2013.08.005; Fabregas N, 2007, BEST PRACT RES-CLIN, V21, P431, DOI 10.1016/j.bpa.2007.06.006; Farag E, 2011, OCHSNER J, V11, P57; Floel A, 2005, NEUROLOGY, V65, P472, DOI 10.1212/01.wnl.0000172340.56307.5e; Floel A, 2005, ANN NEUROL, V58, P121, DOI 10.1002/ana.20536; Goldstein LB, 1997, STROKE, V28, P307, DOI 10.1161/01.STR.28.2.307; Goodwin H, 2012, CRIT CARE, V16, DOI 10.1186/cc11231; Hayashi Y, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.01.084; HEIJNA MH, 1990, EUR J PHARMACOL, V181, P267, DOI 10.1016/0014-2999(90)90088-N; Jang SH, 2002, AM J PHYS MED REHAB, V81, P844, DOI 10.1097/00002060-200211000-00007; Lazar RM, 2003, STROKE, V34, P794, DOI 10.1161/01.STR.0000056540.04159.F3; Lazar RM, 2002, STROKE, V33, P283, DOI 10.1161/hs0102.101222; Lotze M, 2012, NEUROREHAB NEURAL RE, V26, P594, DOI 10.1177/1545968311427706; Low D, 2007, ANN ACAD MED SINGAP, V36, P326; Mahanna EB, 2013, TXB NEUROINTENSIVE C, P856; MILLER RA, 1987, ANESTHESIOLOGY, V67, P844, DOI 10.1097/00000542-198711000-00046; Mirski MA, 2007, J NEUROL SCI, V261, P16, DOI 10.1016/j.jns.2007.04.028; Newman MF, 1996, CIRCULATION, V94, P74; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Osman NI, 2005, ANESTHESIOLOGY, V103, P779, DOI 10.1097/00000542-200510000-00016; Ott C, 2014, NEUROSURGERY, V75, P117, DOI 10.1227/NEU.0000000000000359; Pain L, 2002, ANESTH ANALG, V95, P915, DOI 10.1097/00000539-200210000-00022; Pang WW, 2009, BRIT J ANAESTH, V102, P720, DOI 10.1093/bja/aep074; Rosser N, 2008, ARCH PHYS MED REHAB, V89, P1633, DOI 10.1016/j.apmr.2008.02.030; Rosser N, 2008, NEUROREHABILITATION, V23, P95; Sahinovic MM, 2014, BRIT J ANAESTH, V112, P110, DOI 10.1093/bja/aet342; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Thal GD, 1996, ANESTHESIOLOGY, V85, P21, DOI 10.1097/00000542-199607000-00004; Tozakidou M, 2013, NEUROIMAGE-CLIN, V2, P221, DOI 10.1016/j.nicl.2013.01.002	41	13	14	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAR	2016	124	3					598	607		10.1097/ALN.0000000000000994			10	Anesthesiology	Anesthesiology	DE5US	WOS:000370698900014	26756518				2020-06-30	J	Ahn, S; Byun, SH; Park, K; Ha, JL; Kwon, B; Kim, JC				Ahn, Sowoon; Byun, Sung Hye; Park, Kibum; Ha, Jong Lin; Kwon, Byeonghun; Kim, Jong Chan			Analgesic efficacy of preemptive pregabalin administration in arthroscopic shoulder surgery: a randomized controlled trial	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							POSTOPERATIVE MORPHINE CONSUMPTION; BRACHIAL-PLEXUS BLOCK; DOUBLE-BLIND; PAIN RELIEF; GABAPENTIN; INFUSION	The purpose of the current study was to evaluate the effects of pregabalin administration as an adjunct to fentanyl-based intravenous patient-controlled analgesia on opioid consumption and postoperative pain following arthroscopic shoulder surgery. In this randomized controlled trial, 60 adult patients undergoing arthroscopic shoulder surgery were randomly assigned to receive either pregabalin 150 mg (Pregabalin group, n = 30) or placebo (Control group, n = 30) one hour before anesthetic induction. The primary outcome was the cumulative amount of fentanyl consumption during 48 hr postoperatively. Secondary outcomes were pain intensity, the number of rescue analgesics administered, and adverse effects related to the analgesic regimen, which were serially assessed during 48 hr postoperatively. The cumulative fentanyl consumption during 48 hr postoperatively was significantly lower in the Pregabalin group than in the Control group ([1,126.0 (283.6) mu g vs 1,641.4 (320.3) mu g, respectively; mean difference, 515.4 mu g; 95% confidence interval [CI], 359.0 to 671.8; P = < 0.001). Numeric rating scores for pain (0 to 10) were significantly lower in the Pregabalin group at six hours (mean difference, 2.9; 95% CI, 1.8 to 4.0), 24 hr (mean difference, 2.9; 95% CI, 1.9 to 3.8), and 48 hr (mean difference, 1.5; 95% CI, 0.6 to 2.3). The incidence of adverse effects related to the analgesic regimens, including nausea, sedation, and dizziness, were similar between the two groups. A preoperative dose of pregabalin 150 mg administered before arthroscopic shoulder surgery resulted in significant analgesic efficacy for 48 hr in terms of opioid-sparing effect and improved pain intensity scores without influencing complications. This trial was registered at: http://cris.nih.go.kr, number CT0000578.	[Ahn, Sowoon; Ha, Jong Lin; Kwon, Byeonghun; Kim, Jong Chan] CHA Univ, CHA Bundang Med Ctr, Dept Anesthesiol & Pain Med, 59 Yatap Ro, Songnam 463712, Gyeonggi Do, South Korea; [Byun, Sung Hye] Catholic Univ Daegu, Sch Med, Dept Anesthesiol & Pain Med, Daegu, South Korea; [Park, Kibum] Keimyung Univ, Sch Med, Dept Anesthesiol & Pain Med, Daegu, South Korea	Kim, JC (reprint author), CHA Univ, CHA Bundang Med Ctr, Dept Anesthesiol & Pain Med, 59 Yatap Ro, Songnam 463712, Gyeonggi Do, South Korea.	aescula72@hanmail.net					Agarwal A, 2008, BRIT J ANAESTH, V101, P700, DOI 10.1093/bja/aen244; Aida S, 2000, ANESTHESIOLOGY, V92, P1624, DOI 10.1097/00000542-200006000-00020; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Ben-Menachem E, 2004, EPILEPSIA, V45, P13, DOI 10.1111/j.0013-9580.2004.455003.x; Boezaart Andre P, 2002, Best Pract Res Clin Anaesthesiol, V16, P295, DOI 10.1053/bean.2002.0239; Chandrakantan A, 2011, BRIT J ANAESTH, V107, P27, DOI 10.1093/bja/aer358; Ciccone WJ, 2008, ARTHROSCOPY, V24, P14, DOI 10.1016/j.arthro.2007.07.021; Delaunay L, 2005, REGION ANESTH PAIN M, V30, P117, DOI 10.1016/j.rapm.2004.11.004; Dierking G, 2004, ACTA ANAESTH SCAND, V48, P322, DOI 10.1111/j.0001-5172.2004.0329.x; Fink K, 2002, NEUROPHARMACOLOGY, V42, P229, DOI 10.1016/S0028-3908(01)00172-1; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Frampton JE, 2005, DRUGS, V65, P111, DOI 10.2165/00003495-200565010-00011; Fredrickson MJ, 2010, ANAESTHESIA, V65, P608, DOI 10.1111/j.1365-2044.2009.06231.x; Hurley RW, 2002, ANESTHESIOLOGY, V97, P1263, DOI 10.1097/00000542-200211000-00033; Ilfeld BM, 2003, ANESTH ANALG, V96, P1089, DOI 10.1213/01.ANE.0000049824.51036.EF; Jokela R, 2008, BRIT J ANAESTH, V100, P834, DOI 10.1093/bja/aen098; Jokela R, 2008, PAIN, V134, P106, DOI 10.1016/j.pain.2007.04.002; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Klein SM, 2001, ANESTH ANALG, V93, P601, DOI 10.1097/00000539-200109000-00015; Obata H, 1999, CAN J ANAESTH, V46, P1127, DOI 10.1007/BF03015520; Paech MF, 2007, ANESTH ANALG, V105, P1449, DOI 10.1213/01.ane.0000286227.13306.d7; Pande AC, 2003, AM J PSYCHIAT, V160, P533, DOI 10.1176/appi.ajp.160.3.533; Pandey CK, 2004, CAN J ANAESTH, V51, P986, DOI 10.1007/BF03018484; Price DJ, 2007, ANAESTH INTENS CARE, V35, P575, DOI 10.1177/0310057X0703500418; Reuben SS, 2002, ANESTH ANALG, V94, P55, DOI 10.1097/00000539-200201000-00010; Shneker BF, 2005, ANN PHARMACOTHER, V39, P2029, DOI 10.1345/aph.1G078; Stacey BR, 2008, PAIN MED, V9, P1202, DOI 10.1111/j.1526-4637.2008.00423.x; Stahl SM, 2004, J CLIN PSYCHIAT, V65, P1033; Taylor Charles P, 2004, CNS Drug Rev, V10, P183; Van Elstraete AC, 2008, ANESTH ANALG, V106, P305, DOI 10.1213/01.ane.0000297417.05690.31; WILSON RJT, 1994, ANAESTHESIA, V49, P591; YaDeau JT, 2012, REGION ANESTH PAIN M, V37, P302, DOI 10.1097/AAP.0b013e31824c6846; Zhang J, 2011, BRIT J ANAESTH, V106, P454, DOI 10.1093/bja/aer027	33	7	7	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	MAR	2016	63	3					283	289		10.1007/s12630-015-0510-0			7	Anesthesiology	Anesthesiology	DD8IZ	WOS:000370171300008	26475164	Bronze			2020-06-30	J	Ahmed, SS; Hicks, SR; Slaven, JE; Nitu, ME				Ahmed, Sheikh Sohail; Hicks, Shawn R.; Slaven, James E.; Nitu, Mara E.			Deep Sedation for Pediatric Dental Procedures: Is this a Safe and Effective Option?	JOURNAL OF CLINICAL PEDIATRIC DENTISTRY			English	Article						Pediatric dental sedation; Propofol; Financial Implications	EMERGENCY-DEPARTMENT; CONTROLLED-TRIAL; PROPOFOL; ANALGESIA; KETAMINE; DISLOCATION; ANESTHESIA; REDUCTION; MIDAZOLAM; FENTANYL	Objective: Sedation may be needed for safe, effective completion of pediatric dental procedures. Procedural sedation is performed in a children's hospital based dental office. The three sedation approaches: a propofolonly (P-O) approach (2-3mg/kg titrated to the needed level of sedation), an approach that includes either IV ketamine (K+P) (0.25 or 0.5mg/kg) or IV fentanyl (F+P) (0.5- 1mcg/kg) prior to propofol administration. We sought to determine safety and efficacy of various propofol based sedation protocols. Study Design: Retrospective review of 222 patients receiving a propofol-only (P-O), ketamine+propofol (K+P) or fentanyl+propofol (F+P) approach. Results: There were 44 patients in P-O group, 154 in K+P group and 24 in F+P group with mean age (4.8 +/- 3.4y) and mean weight (19.7 +/- 6.7kg). All the patients completed procedures successfully. Mild hypoxemia occurred in 24% of cases and resolved with nasal cannula. Mean total dose of propofol was similar in all groups (P-O 8.2mg/kg, K+P 9.5mg/kg, F+P 9.6mg/kg, p=0.15). Although procedure and recovery times were similar in all groups, discharge times in K+P group were significantly shorter than P-O group and F+P group respectively (K+P 9.35 +/- 8.93.min, P-O 13.57 +/- 10.42min, F+P 10.42 +/- 4.40 p=0.002). Conclusion: Sedation can be accomplished safely and effectively in a children's hospital based dental office using propofol-based sedation.	[Ahmed, Sheikh Sohail] Indiana Univ Sch Med, James Whitcomb Riley Hosp Children, Pediat Crit Care Sect, IU Hlth,Pediat Sedat, Indianapolis, IN 46202 USA; [Hicks, Shawn R.] Indiana Univ Sch Med, James Whitcomb Riley Hosp Children, Pediat Crit Care Sect, Sedat Team,IU Hlth, Indianapolis, IN 46202 USA; [Slaven, James E.] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA; [Nitu, Mara E.] Indiana Univ Sch Med, James Whitcomb Riley Hosp Children, Pediat Crit Care Sect, IU Hlth, Indianapolis, IN 46202 USA	Ahmed, SS (reprint author), Indiana Univ Hlth, James Whitcomb Riley Hosp Children, Pediat Crit Care Sect, 705 Riley Hosp Dr RI 2117, Indianapolis, IN 46202 USA.	ssahmed@iupui.edu					Burton JH, 2006, ACAD EMERG MED, V13, P500, DOI 10.1197/j.aem.2005.12.017; Burton JH, 2002, ANN EMERG MED, V40, P496, DOI 10.1067/mem.2002.126607; Campbell R L, 1998, Anesth Prog, V45, P46; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Deitch K, 2007, ANN EMERG MED, V49, P1, DOI 10.1016/j.annemergmed.2006.06.013; Eltisur Y, 2000, ENDOSCOPY, V32, P788; Gottschalk A, 2001, AM FAM PHYSICIAN, V63, P1979; HUG CC, 1993, ANESTH ANALG, V77, pS21; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; Kavitha R, 2007, T CLIN PED DENT, V32, P1; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; LANGLEY MS, 1988, DRUGS, V35, P334, DOI 10.2165/00003495-198835040-00002; Loh G, 2007, ANN PHARMACOTHER, V41, P485, DOI 10.1345/aph.1H522; Mason KP, 2008, PEDIATR ANESTH, V18, P403, DOI 10.1111/j.1460-9592.2008.02468.x; Mathers LH, 2007, NELSON TXB PEDIAT; Messenger DW, 2007, CAN J EMERG MED, V9, P186; Miner JR, 2007, ANN EMERG MED, V50, P182, DOI 10.1016/j.annemergmed.2006.12.017; Miner JR, 2007, ACAD EMERG MED, V14, P170, DOI 10.1197/j.aem.2006.10.101; Miner JR, 2005, ACAD EMERG MED, V12, P491, DOI 10.1197/j.aem.2005.01.011; Miner JR, 2003, ACAD EMERG MED, V10, P931, DOI 10.1197/S1069-6563(03)00310-5; Morley K R, 1992, Ont Dent, V69, ppassim; Nathan J E, 1995, Dent Clin North Am, V39, P789; NEWSON C, 1995, ANESTH ANALG, V81, P486, DOI 10.1097/00000539-199509000-00010; Patel KN, 2009, PEDIATR EMERG CARE, V25, P133, DOI 10.1097/PEC.0b013e31819a7f75; Sidney B, 1991, CLIN PEDODONTICS, P114; TVERSKOY M, 1994, ANESTH ANALG, V78, P205, DOI 10.1213/00000539-199402000-00002; Willman EV, 2007, ANN EMERG MED, V49, P23, DOI 10.1016/j.annemergmed.2006.08.002; Worthington LM, 1998, BRIT J ANAESTH, V80, P131, DOI 10.1093/bja/80.2.131; Yagiela J A, 2001, J Dent Educ, V65, P1348	29	1	1	0	2	JOURNAL PEDODONTICS INC	BIRMINGHAM	5724 HIGHWAY 280 EAST, BIRMINGHAM, AL 35242 USA	1053-4628	1557-5268		J CLIN PEDIATR DENT	J. Clin. Pediatr. Dent.	SPR	2016	40	2					156	160		10.17796/1053-4628-40.2.156			5	Dentistry, Oral Surgery & Medicine; Pediatrics	Dentistry, Oral Surgery & Medicine; Pediatrics	DF6DJ	WOS:000371445800012	26950819				2020-06-30	J	Ives, SJ; Amann, M; Venturelli, M; Witman, MAH; Groot, HJ; Wray, DW; Morgan, DE; Stehlik, J; Richardson, RS				Ives, Stephen J.; Amann, Markus; Venturelli, Massimo; Witman, Melissa A. H.; Groot, H. Jonathan; Wray, D. Walter; Morgan, David E.; Stehlik, Josef; Richardson, Russell S.			The Mechanoreflex and Hemodynamic Response to Passive Leg Movement in Heart Failure	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						PASSIVE LEG MOVEMENT; MUSCLE AFFERENTS; BLOOD FLOW; MECHANORECEPTORS	EXERCISE PRESSOR REFLEX; SKELETAL-MUSCLE; RENAL VASOCONSTRICTION; CARDIAC-OUTPUT; STROKE VOLUME; HUMANS; AFFERENTS; BLOOD; FLOW; STRESS	Background Sensitization of mechanosensitive afferents, which contribute to the exercise pressor reflex, has been recognized as a characteristic of patients with heart failure (HF); however, the hemodynamic implications of this hypersensitivity are unclear. Objectives The present study used passive leg movement (PLM) and intrathecal injection of fentanyl to blunt the afferent portion of this reflex arc to better understand the role of the mechanoreflex on central and peripheral hemodynamics in HF. Methods Femoral blood flow (FBF), mean arterial pressure, femoral vascular conductance, HR, stroke volume, cardiac output, ventilation, and muscle oxygenation of the vastus lateralis were assessed in 10 patients with New York Heart Association class II HF at baseline and during 3 min of PLM both with fentanyl and without (control). Results Fentanyl had no effect on baseline measures but increased (control vs fentanyl, P < 0.05) the peak PLM-induced change in FBF (493 +/- 155 vs 804 +/- 198 Delta mL center dot min(-1)) and femoral vascular conductance (4.7 +/- 2 vs 8.5 +/- 3 Delta mL center dot min(-1)center dot mm Hg-1) while norepinephrine spillover (103% +/- 19% vs 58% +/- 17%Delta) and retrograde FBF (371 +/- 115 vs 260 +/- 68 Delta mL center dot min(-1)) tended to be reduced (P < 0.10). In addition, fentanyl administration resulted in greater PLM-induced increases in muscle oxygenation, suggestive of increased microvascular perfusion. Fentanyl had no effect on the ventilation, mean arterial pressure, HR, stroke volume, or cardiac output response to PLM. Conclusions Although movement-induced central hemodynamics were unchanged by afferent blockade, peripheral hemodynamic responses were significantly enhanced. Thus, in patients with HF, a heightened mechanoreflex seems to augment peripheral sympathetic vasoconstriction in response to movement, a phenomenon that may contribute to exercise intolerance in this population.	[Ives, Stephen J.; Amann, Markus; Venturelli, Massimo; Witman, Melissa A. H.; Groot, H. Jonathan; Wray, D. Walter; Richardson, Russell S.] George E Wahlen Dept Veteran Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA; [Ives, Stephen J.; Amann, Markus; Venturelli, Massimo; Witman, Melissa A. H.; Wray, D. Walter; Stehlik, Josef; Richardson, Russell S.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Ives, Stephen J.] Skidmore Coll, Hlth & Exercise Sci Dept, 815 N Broadway, Saratoga Springs, NY 12866 USA; [Amann, Markus; Groot, H. Jonathan; Wray, D. Walter; Richardson, Russell S.] Univ Utah, Dept Exercise & Sport Sci, Salt Lake City, UT USA; [Venturelli, Massimo] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy; [Witman, Melissa A. H.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [Morgan, David E.] Univ Utah, Dept Anesthesiol, Salt Lake City, UT USA	Ives, SJ (reprint author), Skidmore Coll, Hlth & Exercise Sci Dept, 815 N Broadway, Saratoga Springs, NY 12866 USA.	sives@skidmore.edu	Venturelli, Massimo/F-3235-2014; Venturelli, Massimo/AAQ-4613-2020	Venturelli, Massimo/0000-0002-2469-8787; Venturelli, Massimo/0000-0002-2469-8787; Stehlik, Josef/0000-0002-7362-0513; Amann, Markus/0000-0002-4012-8880	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 HL-091830, R01 HL118313, I21RX001572, HL116579, HL103786, AHA14-17770016]; VA RRD [1121RX001418-01]; VA Merit grant [E6910R]; Department of Veterans AffairsUS Department of Veterans Affairs	In addition, we would like to acknowledge financial support from NIH P01 HL-091830 (R. S. R), NIH R01 HL118313 (D. W. W.), I21RX001572 (M. A.), HL116579 (M. A.), HL103786 (M. A.), AHA14-17770016 (M. A.), VA RR&D 1121RX001418-01 (D. W. W.), and VA Merit grant E6910R (R. S. R.). Advanced Fellowships in Geriatrics from the Department of Veterans Affairs supported S. J. I. and M. A. H. W.	Amann M, 2014, INT J CARDIOL, V174, P368, DOI 10.1016/j.ijcard.2014.04.157; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794; BOS WJW, 1992, AM J HYPERTENS, V5, P529, DOI 10.1093/ajh/5.8.529; Carrington CA, 2004, CLIN SCI, V107, P197, DOI 10.1042/CS20040038; Coats Andrew J. S., 1994, British Heart Journal, V72, pS36; Critchley LA, 2010, ANESTH ANALG, V111, P1180, DOI 10.1213/ANE.0b013e3181f08a5b; Esposito F, 2010, J AM COLL CARDIOL, V55, P1945, DOI 10.1016/j.jacc.2009.11.086; Gonzalez-Alonso J, 2008, J PHYSIOL-LONDON, V586, P2405, DOI 10.1113/jphysiol.2008.152058; Gratton E, 1997, PHILOS T ROY SOC B, V352, P727, DOI 10.1098/rstb.1997.0055; Halliwill JR, 2010, AM J PHYSIOL-HEART C, V298, pH1126, DOI 10.1152/ajpheart.00174.2010; Harms MPM, 1999, CLIN SCI, V97, P291, DOI 10.1042/CS19990061; Koba S, 2008, AM J PHYSIOL-HEART C, V294, pH311, DOI 10.1152/ajpheart.00835.2007; Macefield VG, 2005, CLIN EXP PHARMACOL P, V32, P135, DOI 10.1111/j.1440-1681.2005.04143.x; McDaniel J, 2012, J APPL PHYSIOL, V112, P560, DOI 10.1152/japplphysiol.01223.2011; Middlekauff HR, 2004, AM J PHYSIOL-HEART C, V287, pH1937, DOI 10.1152/ajpheart.00330.2004; Middlekauff HR, 2001, J APPL PHYSIOL, V90, P1714; Middlekauff HR, 2000, CIRCULATION, V101, P784, DOI 10.1161/01.CIR.101.7.784; Mukkamala R, 2010, AM J PHYSIOL-HEART C, V299, pH584, DOI 10.1152/ajpheart.00303.2010; NOBREGA ACL, 1994, MED SCI SPORT EXER, V26, P709; Olson TP, 2014, EXP PHYSIOL, V99, P414, DOI 10.1113/expphysiol.2013.075937; Padilla J, 2010, AM J PHYSIOL-HEART C, V298, pH1128, DOI 10.1152/ajpheart.01133.2009; Piepoli MF, 2006, CIRCULATION, V114, P126, DOI 10.1161/CIRCULATIONAHA.105.605980; Ponikowski PP, 2001, CIRCULATION, V104, P2324, DOI 10.1161/hc4401.098491; Poole DC, 2012, AM J PHYSIOL-HEART C, V302, pH1050, DOI 10.1152/ajpheart.00943.2011; Reisner AT, 2011, BRIT J ANAESTH, V106, P23, DOI 10.1093/bja/aeq295; Scott AC, 2003, CIRCULATION, V107, P300, DOI 10.1161/01.CIR.0000042704.37387.29; Scott AC, 2000, J PHYSIOL-LONDON, V529, P863, DOI 10.1111/j.1469-7793.2000.00863.x; Smith SA, 2005, CIRCULATION, V112, P2293, DOI 10.1161/CIRCULATIONAHA.105.566745; Smith SA, 2003, CIRCULATION, V108, P1126, DOI 10.1161/01.CIR.0000084538.40542.56; STEBBINS CL, 1988, J APPL PHYSIOL, V65, P1539; STERNS DA, 1991, CIRCULATION, V84, P2034, DOI 10.1161/01.CIR.84.5.2034; Trinity JD, 2010, AM J PHYSIOL-HEART C, V299, pH1693, DOI 10.1152/ajpheart.00482.2010; Wang HJ, 2010, J PHYSIOL-LONDON, V588, P5033, DOI 10.1113/jphysiol.2010.199562; WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566; WILSON JR, 1984, CIRCULATION, V69, P1079, DOI 10.1161/01.CIR.69.6.1079; Witman MAH, 2015, INT J CARDIOL, V178, P232, DOI 10.1016/j.ijcard.2014.10.044; Witman MAH, 2012, AM J PHYSIOL-HEART C, V303, pH1237, DOI 10.1152/ajpheart.00568.2012	39	19	19	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	MAR	2016	48	3					368	376		10.1249/MSS.0000000000000782			9	Sport Sciences	Sport Sciences	DE2RW	WOS:000370475600005	26418560	Green Accepted			2020-06-30	J	Nguyen, MN; Zimmerman, LH; Meloche, K; Dolman, HS; Baylor, AE; Fuleihan, S; Wilson, RF; Tyburski, JG				Nguyen, Melissa N.; Zimmerman, Lisa Hall; Meloche, Kathy; Dolman, Heather S.; Baylor, Alfred E.; Fuleihan, Samir; Wilson, Robert F.; Tyburski, James G.			Hydromorphone vs fentanyl for epidural analgesia and anesthesia	AMERICAN JOURNAL OF SURGERY			English	Article						Analgesia; Epidural; Anesthesia; Hydromorphone; Fentanyl	SEDATION	BACKGROUND: Epidural analgesia/anesthesia is used during surgery because it dramatically relieves pain and attenuates the stress response. Because limited data exist regarding the relative merits of hydromorphone (HM) and fentanyl (FENT), the objective was to determine which was more safe and effective. METHODS: Prospective case-matched, observational study evaluated elective surgery patients: 30 HM and 60 FENT. Variables were measured perioperatively. RESULTS: Of the 90 patients, mean age was 52 years; simplified acute physiology score was 26 +/- 10; and American Society of Anesthesiologists score was 2.4 HM vs 2.7 FENT, P = .03. HM patients were more apt to be excessively sedated (16% HM vs 1% FENT, P = .007) and have poor mental unresponsiveness (6% HM vs 0% FENT, P = .04). The incidence of hypotension was not different, 76% HM vs 80% FENT, not significant. CONCLUSIONS: In a closely case-matched population, FENT caused less excessive sedation and un-responsiveness. FENT patients had better intraoperative urine output and tended to have less repeated episodes of hypotension. (C) 2016 Elsevier Inc. All rights reserved.	[Nguyen, Melissa N.; Zimmerman, Lisa Hall] Detroit Receiving Hosp & Univ Hlth Ctr, Dept Pharm Serv, 4201 St Antoine Blvd,UHC-1B, Detroit, MI 48201 USA; [Meloche, Kathy] Hutzel Womens Hosp, Harper Univ Hosp, Dept Anesthesia, Detroit, MI USA; [Dolman, Heather S.; Baylor, Alfred E.; Wilson, Robert F.; Tyburski, James G.] Wayne State Univ, Dept Surg, Detroit Receiving Hosp, Detroit, MI USA; [Fuleihan, Samir] Harper Univ Hosp, Detroit Med Ctr, Dept Anesthesiol, Detroit, MI USA	Zimmerman, LH (reprint author), Detroit Receiving Hosp & Univ Hlth Ctr, Dept Pharm Serv, 4201 St Antoine Blvd,UHC-1B, Detroit, MI 48201 USA.	lisahallzimmerman@gmail.com		Hall Zimmerman, Lisa/0000-0002-1064-178X			[Anonymous], 2012, ANESTHESIOLOGY, V116, P248, DOI DOI 10.1097/ALN.0B013E31823C1030; Bijker JB, 2007, ANESTHESIOLOGY, V107, P213, DOI 10.1097/01.anes.0000270724.40897.8e; deLeonCasasola OA, 1996, ANESTH ANALG, V83, P867, DOI 10.1097/00000539-199610000-00038; Gordon DB, 2008, JT COMM J QUAL PATIE, V34, P509, DOI 10.1016/S1553-7250(08)34065-3; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Grossman M, 1996, CLIN PHARMACOL THER, V60, P554, DOI 10.1016/S0009-9236(96)90151-4; Liu SS, 2007, ANESTH ANALG, V104, P689, DOI 10.1213/01.ane.0000255040.71600.41; Moraca RJ, 2003, ANN SURG, V238, P663, DOI 10.1097/01.sla.0000094300.36689.ad; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023	12	2	2	2	6	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	MAR	2016	211	3					565	569		10.1016/j.amjsurg.2015.12.003			5	Surgery	Surgery	DE5YR	WOS:000370709900027	26778766				2020-06-30	J	MacKenzie, M; Zed, PJ; Ensom, MHH				MacKenzie, Meghan; Zed, Peter J.; Ensom, Mary H. H.			Opioid Pharmacokinetics-Pharmacodynamics: Clinical Implications in Acute Pain Management in Trauma	ANNALS OF PHARMACOTHERAPY			English	Review						opioids; pharmacokinetics; pharmacodynamics; acute pain; trauma	EMERGENCY-DEPARTMENT PATIENTS; HYDROMORPHONE TITRATION PROTOCOL; INTRAVENOUS MORPHINE TITRATION; PLACEBO-CONTROLLED TRIAL; HEALTHY-VOLUNTEERS; USUAL CARE; RESPIRATORY DEPRESSION; PREHOSPITAL ANALGESIA; SEX-DIFFERENCES; 0.10 MG/KG	Objective: To evaluate acute traumatic pain protocols and to suggest optimization by characterizing opioid pharmacokinetics and pharmacodynamics (PK-PD). Data Sources: MEDLINE (1946 to November 2015), EMBASE (1974 to November 2015), International Pharmaceutical Abstracts (1970 to December 2014), and Cochrane Database of Systematic Reviews (2005 to November 2015). Keywords: morphine, hydromorphone, fentanyl, trauma, acute pain, intravenous, opioid, pharmacokinetics, and pharmacodynamics. Study Selection and Data Extraction: Literature characterizing opioid PK-PD was included. Additionally, studies evaluatingoutcomes of opioids for acute severe pain in adult trauma patients were selected. Data Synthesis: PK-PD literature suggests that morphine exhibits an effect delay of 1.6 to 4.8 hours; however, clinical significance is doubtful. The relative onset of morphine is approximately 6 minutes, and duration, 96 minutes. Morphine 0.1 mg/kg IV then 0.05 mg/kg every 5 minutes achieved pain control in 40% of patients at 10 minutes and 76% at 60 minutes. The effect delay of hydromorphone (orally) is 18 to 38 minutes; its relative onset (IV), 5 minutes; and duration, 120 minutes. Hydromorphone every 15 minutes achieved variable success in clinical trials. The effect delay of fentanyl IV is 16.4 minutes; relative onset, 2 minutes; and duration, 7 minutes. One randomized controlled trial used fentanyl 0.1 mu g/kg IV every 5 minutes. Conclusions: Further integration of opioid PK-PD into acutepain protocols is possible. One opioid should not be deemed more effective but rather titrated to effect. Morphine and hydromorphone can be titrated IV every 5 minutes until adequate pain control. Fentanyl can be titrated every 3 minutes.	[MacKenzie, Meghan] Dalhousie Univ, Coll Pharm, Nova Scotia Hlth Author, Cent Zone,Pharmacy Dept, Halifax, NS B3H 3A7, Canada; [Zed, Peter J.; Ensom, Mary H. H.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Ensom, Mary H. H.] Childrens & Womens Hlth Ctr British Columbia, Vancouver, BC, Canada	MacKenzie, M (reprint author), Dalhousie Univ, Coll Pharm, Halifax Infirm Pharm, Scotia Hlth Author,Pharm Dept, 1796 Summer St,Room 2416, Halifax, NS B3H 3A7, Canada.	Meghan.MacKenzie@nshealth.ca		Ensom, Mary/0000-0002-7802-0939			Albrecht E, 2013, BRIT J ANAESTH, V110, P96, DOI 10.1093/bja/aes355; Angst MS, 2001, ANESTHESIOLOGY, V94, P63, DOI 10.1097/00000542-200101000-00014; Aubrun F, 2012, BRIT J ANAESTH, V108, P193, DOI 10.1093/bja/aer458; Bijur PE, 2005, ANN EMERG MED, V46, P362, DOI 10.1016/j.annemergmed.2005.03.010; Bijur PE, 2012, AM J EMERG MED, V30, P1241, DOI 10.1016/j.ajem.2011.06.015; Birnbaum A, 2007, ANN EMERG MED, V49, P445, DOI 10.1016/j.annemergmed.2006.06.030; Bounes V, 2008, AM J EMERG MED, V26, P148, DOI 10.1016/j.ajem.2007.04.020; Chang AK, 2008, ACAD EMERG MED, V15, pS56; Chang AK, 2006, ANN EMERG MED, V48, P164, DOI 10.1016/j.annemergmed.2006.03.005; Chang AK, 2016, ANN EMERG MED, V67, P565, DOI 10.1016/j.annemergmed.2015.04.035; Chang AK, 2013, ANN EMERG MED, V62, P304, DOI 10.1016/j.annemergmed.2013.02.023; Chang AK, 2013, DRUG AGING, V30, P747, DOI 10.1007/s40266-013-0103-y; Chang AK, 2013, ACAD EMERG MED, V20, P185, DOI 10.1111/acem.12071; Chang AK, 2011, ANN EMERG MED, V58, P352, DOI 10.1016/j.annemergmed.2011.03.003; Chang AK, 2009, ANN EMERG MED, V54, P561, DOI 10.1016/j.annemergmed.2009.05.003; Chang AK, 2009, ANN EMERG MED, V54, P221, DOI 10.1016/j.annemergmed.2008.09.017; Chang AK, 2009, AM J GERIATR PHARMAC, V7, P1, DOI 10.1016/j.amjopharm.2009.02.002; CHAPMAN CR, 1990, PAIN, V43, P47, DOI 10.1016/0304-3959(90)90049-J; Coda B, 1997, PAIN, V71, P41, DOI 10.1016/S0304-3959(97)03336-8; Curtis KM, 2007, J TRAUMA, V63, P819, DOI 10.1097/01.ta.0000240979.31046.98; Dahan A, 2004, ANESTHESIOLOGY, V101, P1201, DOI 10.1097/00000542-200411000-00021; Dershwitz M, 2000, ANESTHESIOLOGY, V93, P619, DOI 10.1097/00000542-200009000-00009; Ducharme J, 2000, ANN EMERG MED, V35, P592, DOI 10.1016/S0196-0644(00)70033-3; Farsi D, 2013, ULUS TRAVMA ACIL CER, V19, P398, DOI 10.5505/tjtes.2013.86383; Felden L, 2011, BRIT J ANAESTH, V107, P319, DOI [10.1093/bja/aer232, 10.1093/bja/aer200]; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Fry Margaret, 2002, Emerg Med (Fremantle), V14, P249, DOI 10.1046/j.1442-2026.2002.00339.x; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Han A, 2007, CAN J EMERG MED, V9, P428; Harrison DW, 2006, CJEM, V8, pS223; Lotsch J, 2006, CLIN PHARMACOKINET, V45, P1051; Lotsch J, 2001, ANESTHESIOLOGY, V95, P1329; Lotsch JR, 2005, J PAIN SYMPTOM MANAG, V29, pS90, DOI 10.1016/j.jpainsymman.2005.01.012; Lvovschi V, 2008, AM J EMERG MED, V26, P676, DOI 10.1016/j.ajem.2007.10.025; Martini Christian, 2011, Expert Rev Clin Pharmacol, V4, P719, DOI 10.1586/ecp.11.59; Mazoit JX, 2007, ANESTH ANALG, V105, P70, DOI 10.1213/01.ane.0000265557.73688.32; Motov S., DOSING OPIOIDS OPTIM; Motov Sergey M, 2008, J Pain Res, V2, P5; O'Connor AB, 2010, AM J EMERG MED, V28, P1041, DOI 10.1016/j.ajem.2009.06.009; Olofsen E, 2010, ANESTHESIOLOGY, V112, P1417, DOI 10.1097/ALN.0b013e3181d5e29d; Romberg R, 2004, ANESTHESIOLOGY, V100, P120, DOI 10.1097/00000542-200401000-00021; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; Seth SD, 2009, TXB PHARM; Smith MD, 2012, J EMERG MED, V43, P69, DOI 10.1016/j.jemermed.2011.05.018; Sverrisdottir E, 2015, EUR J PHARM SCI, V74, P45, DOI 10.1016/j.ejps.2015.03.020; Upton RN, 1997, CLIN PHARMACOKINET, V33, P225, DOI 10.2165/00003088-199733030-00005; Wenderoth BR, 2013, J TRAUMA NURS, V20, P10, DOI 10.1097/JTN.0b013e31828660b5; Yassen A, 2007, CLIN PHARMACOL THER, V81, P50, DOI 10.1038/sj.clpt.6100025	48	13	13	2	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	MAR	2016	50	3					209	218		10.1177/1060028015625659			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DE5LG	WOS:000370671900008	26739277				2020-06-30	J	Matsumura, C; Yamada, M; Fujihara, S; Chisaki, Y; Takahashi, K; Yano, Y				Matsumura, Chikako; Yamada, Masami; Fujihara, Saki; Chisaki, Yugo; Takahashi, Kazushige; Yano, Yoshitaka			Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						opioid switching; transdermal fentanyl; oral oxycodone; pain control; conversion ratio; patients with cancer	PAIN; MORPHINE; CONVERSION; ROTATION	Objective: The present study aimed to examine affecting factors for conversion ratio and to predict adequate fentanyl dose for patients with cancer pain in opioid switching from oral oxycodone. Methods: Patient characteristics, biochemical parameters, daily oxycodone dose, and reasons for opioid switching were retrospectively collected. The effect of variables on the conversion ratio was analyzed by multiple regression analysis. Results: Regression analysis for the data from 122 patients suggested that the typical conversion ratio was 95:1; however, this ratio was significantly reduced in patients taking a daily oral morphine-equivalent dose of <45 mg/d and in patients with poor pain control to 52:1 and 64:1, respectively. Conclusion: We should carefully and rapidly control pain in opioid switching based on the adequate dose indicated in this study.	[Matsumura, Chikako; Fujihara, Saki; Chisaki, Yugo; Yano, Yoshitaka] Kyoto Pharmaceut Univ, Educ & Res Ctr Clin Pharm, Kyoto 607, Japan; [Matsumura, Chikako; Yamada, Masami; Takahashi, Kazushige] Osaka Fu Saiseikai Noe Hosp, Dept Pharm, Osaka, Japan	Matsumura, C (reprint author), 5 Nakauchi Cho, Kyoto 6078414, Japan.	chika-matsumura@mb.kyoto-phu.ac.jp					Akiyama Yasuko, 2007, Masui, V56, P317; [Anonymous], 2008, DUR FENT TRANSD SYST; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Indelicato RA, 2002, J CLIN ONCOL, V20, P348, DOI 10.1200/JCO.2002.20.1.348; Kanbayashi Y, 2011, CLIN J PAIN, V27, P664, DOI 10.1097/AJP.0b013e3182168fed; Kato K, 2004, YAKUGAKU ZASSHI, V124, P287, DOI 10.1248/yakushi.124.287; Maltoni M, 2005, SUPPORT CARE CANCER, V13, P888, DOI 10.1007/s00520-005-0807-6; Menten J, 2002, CURR MED RES OPIN, V18, P488, DOI 10.1185/030079902125001272; Mercadante S, 2001, J CLIN ONCOL, V19, P2898, DOI 10.1200/JCO.2001.19.11.2898; Mercadante S, 2011, PALLIATIVE MED, V25, P504, DOI 10.1177/0269216311406577; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Nalamachu SR, 2012, ADV THER, V29, P849, DOI 10.1007/s12325-012-0051-7; Ogawa J, 2009, YAKUGAKU ZASSHI, V129, P335, DOI 10.1248/yakushi.129.335; ROWBOTHAM DJ, 1989, BRIT J ANAESTH, V63, P56, DOI 10.1093/bja/63.1.56; Solassol I, 2005, ONCOL REP, V14, P1029	19	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	MAR	2016	33	2					109	114		10.1177/1049909114554413			6	Health Care Sciences & Services	Health Care Sciences & Services	DD8TW	WOS:000370200800001	25324418				2020-06-30	J	Rogers, JS; Rehrer, SJ; Hoot, NR				Rogers, Jeremy S.; Rehrer, Seth J.; Hoot, Nathan R.			ACETYLFENTANYL: AN EMERGING DRUG OF ABUSE	JOURNAL OF EMERGENCY MEDICINE			English	Article						opioid analgesics; drug overdose; street drugs; naloxone		Background: Opioid analgesics are widely used in health care, yet have significant potential for abuse. High doses are associated with potentially fatal respiratory depression, which caused 21,314 deaths in the United States in 2011. Acetylfentanyl, a synthetic opioid agonist closely related to fentanyl, recently emerged as a drug of abuse linked to numerous deaths in North America. Case Report: A 36-year-old male developed the habit of using a propylene glycol electronic cigarette filled with acetylfentanyl to aid relaxation. He purchased the drug online in a manner that appeared legal to him, which compromised his insight about the danger of the substance. He had been using the e-cigarette with increasing frequency while on medical leave, and his wife reported finding him weakly responsive on more than one occasion. At approximately 3 AM, the family activated 911 for altered mental status. His presentation included respiratory depression, pinpoint pupils, hypoxemia, and a Glasgow Coma Scale score of 6. He responded to serial doses of intravenous naloxone with improvement in his mental status and respiratory condition. Due to the need for repeated dosing, he was placed on a naloxone infusion and recovered uneventfully in intensive care. Why Should an Emergency Physician Be Aware of This?: Complications from emerging drugs of abuse, like acetylfentanyl, frequently present first to emergency departments. Prompt recognition and treatment can help avoid morbidity and mortality. Acetylfentanyl can be managed effectively with naloxone, although higher than conventional dosing may be required to achieve therapeutic effect. (C) 2016 Elsevier Inc.	[Rogers, Jeremy S.; Rehrer, Seth J.; Hoot, Nathan R.] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, Houston, TX 77030 USA	Hoot, NR (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, Jesse Jones Lib, 6431 Fannin,4th Floor, Houston, TX 77030 USA.						[Anonymous], 2014, J SENTINEL; [Anonymous], 2012, DAWN REP HIGHL 2011; [Anonymous], 2013, AC N 1 PHEN 4 YL N P; CBC, 2013, CBC NEWS; Counselman FL, 2014, ACAD EMERG MED, V21, P574, DOI 10.1111/acem.12373; Eisen Jeffrey S, 2004, CJEM, V6, P104; Keary CJ, 2012, PRIM CARE COMPANION, P14; Nelson LS, 2011, GOLDFRANKS TOXICOLOG; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Skulska Agnieszka, 2005, Przegl Lek, V62, P581; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017	13	19	19	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	MAR	2016	50	3					433	436		10.1016/j.jemermed.2015.10.014			4	Emergency Medicine	Emergency Medicine	DI2BV	WOS:000373301600028	26589567				2020-06-30	J	Kerai, S; Saxena, KN; Sehrawat, L; Taneja, B				Kerai, Sukhyanti; Saxena, Kirti Nath; Sehrawat, Lalit; Taneja, Bharti			Anesthesia for noncardiac intervention in a patient with total anomalous systemic venous return	PEDIATRIC ANESTHESIA			English	Letter							DRAINAGE		[Kerai, Sukhyanti] Dr RML Hosp, Post Grad Inst Med Educ & Res, Dept Anaesthesiol, New Delhi, India; [Saxena, Kirti Nath; Sehrawat, Lalit; Taneja, Bharti] Maulana Azad Med Coll, Dept Anaesthesiol, New Delhi, India; [Saxena, Kirti Nath; Sehrawat, Lalit; Taneja, Bharti] Associated Lok Nayak Hosp, New Delhi, India	Kerai, S (reprint author), Dr RML Hosp, Post Grad Inst Med Educ & Res, Dept Anaesthesiol, New Delhi, India.	drsukhi25@gmail.com					Devendran V, 2013, PEDIATR CARDIOL, V34, P1918, DOI 10.1007/s00246-012-0458-6; SCHICK EC, 1985, J AM COLL CARDIOL, V5, P374, DOI 10.1016/S0735-1097(85)80063-2; Williams GD, 2010, J CARDIOTHOR VASC AN, V24, P834, DOI 10.1053/j.jvca.2010.02.012; Zhang ZW, 2009, ANN THORAC SURG, V87, P1599, DOI 10.1016/j.athoracsur.2008.09.025	4	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	MAR	2016	26	3					324	325		10.1111/pan.12804			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	DC3XM	WOS:000369152900017	26814041				2020-06-30	J	Koike, K; Terui, T; Nagasako, T; Horiuchi, I; Machino, T; Kusakabe, T; Hirayama, Y; Mihara, H; Yamakage, M; Kato, J; Nishisato, T; Ishitani, K				Koike, Kazuhiko; Terui, Takeshi; Nagasako, Tomokazu; Horiuchi, Iori; Machino, Takayuki; Kusakabe, Toshiro; Hirayama, Yasuo; Mihara, Hiroyoshi; Yamakage, Michiaki; Kato, Junji; Nishisato, Takuji; Ishitani, Kunihiko			A new once-a-day fentanyl citrate patch (FentosA (R) Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch	SUPPORTIVE CARE IN CANCER			English	Article						End-of-dose failure; Transdermal fentanyl; Fentanyl citrate; Breakthrough cancer pain; Opioid switch	LONG-TERM TREATMENT; CANCER PAIN; BREAKTHROUGH PAIN; MANAGEMENT; RECOMMENDATIONS; OPIOIDS	The recommended dosing interval for transdermal fentanyl is every 72 h. However, some patients will have "end-of-dose failure," which may be seen as an increase of episodes of severe pain flares at the third day after application of the patch. A new once-a-day fentanyl patch was developed in Japan since 2010. This study aimed to assess the efficacy of the once-a-day fentanyl citrate patch for patients with cancer-related pain receiving the 72-h transdermal fentanyl not lasting 72 h. We performed a cross-sectional retrospective analysis of 445 inpatients with the 72-h transdermal fentanyl at Higashi Sapporo Hospital. We could switch to the once-a-day fentanyl citrate patch if patients reported inadequate pain relief beyond 48 h after application of the 72-h transdermal fentanyl. Patients recorded baseline scores for background pain intensity (PI) and the frequency of use of daily rescue medication for breakthrough cancer pain (BTcP). Of all patients, 10.1 % showed the increase in PI of 30 % or more baseline PI on the third day after application of the 72-h transdermal fentanyl. Of patients, 84.4 % were converted from equivalent dose of the 72-h transdermal fentanyl to the once-a-day fentanyl citrate patch. On the third day after switching, 60.5 % of patients showed a reduction of more than 30 % from baseline PI. Switching to the once-a-day fentanyl citrate patch significantly reduced the mean frequency of daily rescue dose for BTcP. A once-a-day fentanyl citrate patch provided stable pain control. Its use may be considered as the dominant strategy for patients receiving a 72-h transdermal fentanyl not lasting 72 h.	[Koike, Kazuhiko; Nishisato, Takuji] Sapporo Kiyota Hosp, Div Palliat Med, Kiyota Ku, 1-1-1-1 Shinei, Sapporo, Hokkaido 0040831, Japan; [Nagasako, Tomokazu; Horiuchi, Iori; Machino, Takayuki; Ishitani, Kunihiko] Higashi Sapporo Hosp, Div Palliat Med, Sapporo, Hokkaido, Japan; [Terui, Takeshi; Kusakabe, Toshiro; Hirayama, Yasuo; Mihara, Hiroyoshi] Higashi Sapporo Hosp, Div Internal Med, Sapporo, Hokkaido, Japan; [Yamakage, Michiaki] Sapporo Med Univ Hosp, Dept Anesthesiol, Sapporo, Hokkaido, Japan; [Kato, Junji] Sapporo Med Univ Hosp, Dept Med Oncol & Hematol, Sapporo, Hokkaido, Japan	Koike, K (reprint author), Sapporo Kiyota Hosp, Div Palliat Med, Kiyota Ku, 1-1-1-1 Shinei, Sapporo, Hokkaido 0040831, Japan.	kkoikekyh@gmail.com					Caraceni A, 2013, J NATL COMPR CANC NE, V11, pS29; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Hall Levi M, 2012, J Pharm Pract, V25, P503; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Kim DY, 2011, SUPPORT CARE CANCER, V19, P297, DOI 10.1007/s00520-010-0825-x; Kokubun H, 2007, J PHARM HLTH CARE SC, V33, P200; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; Mercadante S, 2011, CURR PAIN HEADACHE R, V15, P244, DOI 10.1007/s11916-011-0191-5; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; National Comprehensive Cancer Network, 2014, NNCN CLIN PRACT GUID; Payne R, 1998, SEMIN ONCOL, V25, P47; Takakuwa O, 2013, AM J HOSP PALLIAT ME, V30, P726, DOI 10.1177/1049909112470020; Uchida E, 2010, J CLIN THERAPEUTICS, V26, P335; US Food and Drug Administration, 2007, INF HEALTHC PROF FEN; Zeppetella G, 2011, CLIN ONCOL-UK, V23, P393, DOI 10.1016/j.clon.2010.12.002	20	2	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	MAR	2016	24	3					1053	1059		10.1007/s00520-015-2880-9			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	DC1WY	WOS:000369010000007	26248654				2020-06-30	J	Onk, D; Ayazoglu, TA; Kuyrukluyildiz, U; Aksut, M; Bedir, Z; Kupeli, I; Onk, OA; Alagol, A				Onk, Didem; Ayazoglu, Tulin Akarsu; Kuyrukluyildiz, Ufuk; Aksut, Mehmet; Bedir, Zehra; Kupeli, Ilke; Onk, Oruc Alper; Alagol, Aysin			Effects of Fentanyl and Morphine on Shivering During Spinal Anesthesia in Patients Undergoing Endovenous Ablation of Varicose Veins	MEDICAL SCIENCE MONITOR			English	Article						Anesthesia; Spinal; Fentanyl; Morphine Dependence	INTRATHECAL MORPHINE; EPIDURAL-ANESTHESIA; HYPOTHERMIA	Background: We sought to investigate the effect of morphine and fentanyl on shivering when used adjunctively with bupivacaine during spinal anesthesia in patients undergoing varicose vein surgery on an outpatient basis. Material/Methods: The study included a total of 90 patients, aged 25-45 years, ASA I-II, scheduled to undergo endovenous laser ablation under spinal anesthesia for lower extremity venous insufficiency/varicose vein disease. Patients were randomly allocated into 3 groups: Group M (morphine group) received 5 mg 0.5% hyperbaric bupivacaine + 0.1 mg morphine, Group F (fentanyl group) received 5 mg 0.5% hyperbaric bupivacaine + 25 mu g fentanyl, and Group C (control group) received 5 mg 0.5% hyperbaric bupivacaine + physiologic saline. The level of sensory blockade was assessed with pin-prick test and the level of motor blockade was assessed with Bromage scale at 5-min intervals. Shivering grade and time to first postoperative analgesic requirement was recorded. Results: Level and time of sensory block showed a slight but insignificant increase in the Morphine Group and Fentanyl Group. Time of postoperative analgesic requirement was significantly longer in patients who received morphine (p<0.05). Shivering was significantly less common in patients who received morphine and fentanyl than in patients who are in the Control Group (p<0.02). Conclusions: Morphine or fentanyl may be used as adjunctives to spinal anesthesia to prevent shivering in patients undergoing venous surgery.	[Onk, Didem; Kuyrukluyildiz, Ufuk; Bedir, Zehra; Kupeli, Ilke; Alagol, Aysin] Erzincan Univ, Dept Anesthesiol & Reanimat, Erzincan, Turkey; [Ayazoglu, Tulin Akarsu] Goztepe Training & Res Hosp, Dept Anesthesiol, Istanbul, Turkey; [Aksut, Mehmet; Onk, Oruc Alper] Erzincan Univ, Dept Cardiovasc Surg, Erzincan, Turkey	Onk, D (reprint author), Erzincan Univ, Dept Anesthesiol & Reanimat, Erzincan, Turkey.	d.hesapdar@gmail.com	KUPELI, ILKE/B-9305-2017	KUPELI, ILKE/0000-0003-3518-7365			ABOULEISH E, 1988, ANESTH ANALG, V67, P370; Adkinson GH, 1993, ANAETH ANALG, V76, P52; Berti M, 1998, ANAESTHESIA, V53, P46; Chow T C, 1994, Acta Anaesthesiol Sin, V32, P165; Chu C C, 1995, Acta Anaesthesiol Sin, V33, P149; CLARK WG, 1979, PHARMACOL BIOCHEM BE, V10, P609, DOI 10.1016/0091-3057(79)90241-7; CROSSLEY AWA, 1994, ANAESTHESIA, V49, P205; Dal D, 2005, BRIT J ANAESTH, V95, P189, DOI 10.1093/bja/aei148; Hong JY, 2005, ANAESTHESIA, V60, P1168, DOI 10.1111/j.1365-2044.2005.04158.x; Ishiyama T, 2001, J Anesth, V15, P69, DOI 10.1007/s005400170029; Isik A, 2015, CIR ESPAN, V93, P580, DOI 10.1016/j.ciresp.2015.02.014; Isik A, 2014, MED SCI MONITOR, V20, P1369, DOI 10.12659/MSM.890804; Isik A, 2014, INT J CLIN EXP MED, V7, P1047; JORIS J, 1994, ANESTHESIOLOGY, V80, P268, DOI 10.1097/00000542-199402000-00006; KURZ A, 1993, ANESTH ANALG, V77, P721; LOTTI VJ, 1965, J PHARMACOL EXP THER, V150, P135; ROSOW CE, 1980, J PHARMACOL EXP THER, V213, P273; Sadegh Ali, 2012, Med J Islam Repub Iran, V26, P85; Sellden E, 1999, ANESTH ANALG, V89, P1551, DOI 10.1097/00000539-199912000-00045; Techanivate Anchalee, 2005, Journal of the Medical Association of Thailand, V88, P1214	20	1	1	0	6	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	FEB 12	2016	22						469	473		10.12659/MSM.897256			5	Medicine, Research & Experimental	Research & Experimental Medicine	DD4SL	WOS:000369912800002	26871238	Green Published			2020-06-30	J	Palmer, GM				Palmer, Greta M.			Pain management in the acute care setting: Update and debates	JOURNAL OF PAEDIATRICS AND CHILD HEALTH			English	Review						analgesia; children; codeine; emergency department; fentanyl intranasal; opioid; pain	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PEDIATRIC EMERGENCY-DEPARTMENT; INTRANASAL FENTANYL; MAJOR SURGERY; ANALGESIA; CHILDREN; PARACETAMOL; CELECOXIB; MORPHINE; INJURY	Pain management in the paediatric acute care setting is underutilised and can be improved. An awareness of the analgesic options available and their limitations is an important starting point. This article describes the evolving understanding of relevant pharmacogenomics and safety data of the various analgesic agents with a focus on agents available in Australia and New Zealand. It highlights the concerns with the use of codeine in children and discusses alternative oral opioids. Key features of oral, parenteral, inhaled and intranasal analgesic agents are discussed, as well as evidence supported use of sweet tasting solutions and non-pharmacological interventions. One of the biggest changes in acute care pain management has been the advent of intranasal fentanyl providing reliable potent analgesia without the need for intravenous access. The article will also address the issue of multimodal analgesia where a single agent is insufficient.	[Palmer, Greta M.] Royal Childrens Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Palmer, Greta M.] Univ Melbourne, Fac Med Dent & Hlth Sci, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Palmer, Greta M.] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Paediat, Melbourne, Vic, Australia	Palmer, GM (reprint author), Royal Childrens Hosp Melbourne, Dept Anaesthesia & Pain Management, 50 Flemington Rd, Parkville, Vic 3052, Australia.	greta.palmer@rch.org.au					Alexander J, 2003, ANN EMERG MED, V41, P617, DOI 10.1067/mem.2003.138; Ali S, 2014, PAED CHILD HEALT-CAN, V19, P190, DOI 10.1093/pch/19.4.190; Anderson BJ, 2014, OXFORD TXB PAEDIAT P, P436; Bendall JC, 2011, PREHOSP DISASTER MED, V26, P422, DOI 10.1017/S1049023X12000180; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Bueno M, 2013, PAIN RES MANAG, V18, P153, DOI 10.1155/2013/956549; Capici F, 2008, BRIT J ANAESTH, V100, P251, DOI 10.1093/bja/aem377; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Dodwell ER, 2010, CALCIFIED TISSUE INT, V87, P193, DOI 10.1007/s00223-010-9379-7; Fein JA, 2012, PEDIATRICS, V130, pE1391, DOI 10.1542/peds.2012-2536; Forrester MB, 2009, HUM EXP TOXICOL, V28, P191, DOI 10.1177/0960327109104500; Friedrichsdorf Stefan J, 2013, J Opioid Manag, V9, P151, DOI 10.5055/jom.2013.0156; Graham GG, 2013, INFLAMMOPHARMACOLOGY, V21, P201, DOI 10.1007/s10787-013-0172-x; Grindlay J, 2009, EMERG MED AUSTRALAS, V21, P4, DOI 10.1111/j.1742-6723.2009.01153.x; Hansen MS, 2013, DAN MED J, V60; Harrison D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008408.pub3; Herd DW, 2009, EMERG MED AUSTRALAS, V21, P210, DOI 10.1111/j.1742-6723.2009.01184.x; Howard RF, 2010, PEDIATR ANESTH, V20, P126, DOI 10.1111/j.1460-9592.2009.03242.x; Hoyle JD, 2011, ACAD EMERG MED, V18, P140, DOI 10.1111/j.1553-2712.2010.00970.x; Kassab M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008411.pub2; Kelly LE, 2012, PEDIATRICS, V129, pE1343, DOI 10.1542/peds.2011-2538; Kennedy Robert M, 2008, Pediatrics, V122 Suppl 3, pS130, DOI 10.1542/peds.2008-1055e; Koller D, 2012, J PEDIATR NURS, V27, P652, DOI 10.1016/j.pedn.2011.08.001; Kurmis AP, 2012, J BONE JOINT SURG AM, V94A, P815, DOI 10.2106/JBJS.J.01743; Lavonas EJ, 2010, PEDIATRICS, V126, pE1430, DOI 10.1542/peds.2009-3352; Lewis SR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003591.pub3; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; MacLean S, 2007, PEDIATR EMERG CARE, V23, P87, DOI 10.1097/PEC.0b013e31803; Madadi P, 2007, CAN FAM PHYSICIAN, V53, P33; Maund E, 2011, BRIT J ANAESTH, V106, P292, DOI 10.1093/bja/aeq406; Misurac JM, 2013, J PEDIATR-US, V162, P1153, DOI 10.1016/j.jpeds.2012.11.069; Misurac JM, 2013, J PEDIAT, V162; Morton NS, 2010, PEDIATR ANESTH, V20, P119, DOI 10.1111/j.1460-9592.2009.03187.x; Murto K, 2015, CAN J ANESTH, V62, P785, DOI 10.1007/s12630-015-0376-1; Musu M, 2011, EUR REV MED PHARMACO, V15, P1461; Rattray B, 2006, HAEMOPHILIA, V12, P514, DOI 10.1111/j.1365-2516.2006.01311.x; Riddell RRP, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006275.pub3; Schug SA, ACUTE PAIN MANAGEMEN, P409; Southey ER, 2009, CURR MED RES OPIN, V25, P2207, DOI 10.1185/03007990903116255; Stevens B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001069.pub4; Taddio A, 2009, CLIN THER, V31, pS48, DOI 10.1016/j.clinthera.2009.07.024; Tremlett MR, 2013, PEDIATR ANESTH, V23, P677, DOI 10.1111/pan.12190; Uman LS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005179; Wente SJK, 2013, J EMERG NURS, V39, P140, DOI 10.1016/j.jen.2012.09.011; Wong I, 2013, PEDIATR ANESTH, V23, P475, DOI 10.1111/pan.12163; World Health Organization, 2012, WHO GUID PHARM TREAT; Yeaman F, 2013, EMERG MED AUSTRALAS, V25, P161, DOI 10.1111/1742-6723.12059	48	5	5	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1034-4810	1440-1754		J PAEDIATR CHILD H	J. Paediatr. Child Health	FEB	2016	52	2					213	220		10.1111/jpc.13134			8	Pediatrics	Pediatrics	DJ0YI	WOS:000373929900020	27062626				2020-06-30	J	Cheng, SQ; Ouyang, DS; Tang, YJ; Wu, K; Xiao, J				Cheng, Shu-Qiao; Ouyang, Dong-Sheng; Tang, Yong-Jun; Wu, Kai; Xiao, Jian			A rapid, simple and sensitive method for the determination and bioequivalence study of transdermal fentanyl in human plasma using liquid chromatography-electrospray ionization tandem mass spectrometry	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						fentanyl; LC-MS/MS; human plasma; bioequivalence	SAMPLE PREPARATION TECHNIQUES; CANCER PAIN; WHOLE-BLOOD; VALIDATION; FORMULATIONS; EXTRACTION; URINE; PHARMACOKINETICS; IDENTIFICATION; BUPRENORPHINE	Objective: Since the 1960s, fentanyl has been used to replace morphine and other opioids due to its higher potency in the treatment of acute pain; since the 1990s, it has also been administrated to control chronic pain by using transdermal fentanyl device system. It is crucial and of utmost importance and crucial to validate a sensitive method for the quantification of trans dermal fentanyl in human plasma. Materials and methods: A rapid, simple and sensitive high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method has been established and validated for the determination of transdermal fentanyl in human plasma using fentanyl-D5 as an internal standard (IS). Following liquid-liquid extraction (LLE) with n-hexane, the extracts were separated on a Thermo Hypersil ODS(C18) column (2.1 x 150 mm i.d., 5 gm) interfaced with a triple-quadrupole tandem mass spectrometer using positive electrospray ionization. Results and conclusions: Quantification of fentanyl was carried out by multiple reaction monitoring (MRM) of the transitions at m/z 337.1 -> 188.0 for fentanyl and 341.9 -> 187.9 for IS. The lower limit of quantification was 9.75 pgxmL(-1), and the test showed a linear range of 9.75 - 10,000 pgxmL(-1). The validated method was subsequently applied to a bioequivalence (BE) study in 24 healthy Chinese volunteers by using transdermal fentanyl patches.	[Cheng, Shu-Qiao; Xiao, Jian] Cent S Univ, Xiangya Hosp, Dept Pharm, Changsha 410008, Hunan, Peoples R China; [Ouyang, Dong-Sheng; Tang, Yong-Jun] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China; [Ouyang, Dong-Sheng; Tang, Yong-Jun] Cent S Univ, Xiangya Hosp, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410008, Hunan, Peoples R China; [Wu, Kai] Cent S Univ, Xiangya Hosp, Physiatry Dept, Changsha 410008, Hunan, Peoples R China	Xiao, J (reprint author), Cent S Univ, Xiangya Hosp, Dept Pharm, Changsha 410008, Hunan, Peoples R China.	admanoas@163.com	Chen, Yao/AAJ-5658-2020		National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81300204]; Changsha Science and Technology Key Project [K1406004-31, K1308032-31]	This work was supported by the National Natural Science Foundation of China (No. 81300204 to J. Xiao), Changsha Science and Technology Key Project (K1406004-31, K1308032-31).	Almousa AA, 2011, J CHROMATOGR B, V879, P2941, DOI 10.1016/j.jchromb.2011.08.029; Alnajjar A, 2007, J CHROMATOGR B, V856, P62, DOI 10.1016/j.jchromb.2007.05.038; Bagheri H, 2007, J PHARMACEUT BIOMED, V43, P1763, DOI 10.1016/j.jpba.2006.12.016; Berg T, 2013, J ANAL TOXICOL, V37, P159, DOI 10.1093/jat/bkt005; Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; Bylda C, 2014, ANALYST, V139, P2265, DOI 10.1039/c4an00094c; Chen ML, 2014, AAPS ADV PHARM SCI, P29, DOI 10.1007/978-1-4939-1252-0_2; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Corli O, 2014, MINERVA ANESTESIOL, V80, P1123; Devine JW, 2013, MIL MED, V178, P1241, DOI 10.7205/MILMED-D-13-00184; Goldberger BA, 2010, METHODS MOL BIOL, V603, P245, DOI 10.1007/978-1-60761-459-3_22; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; GROSSE CM, 1994, J PHARMACEUT BIOMED, V12, P195, DOI 10.1016/0731-7085(94)90030-2; HERBST LH, 1992, J PAIN SYMPTOM MANAG, V7, pS54, DOI 10.1016/0885-3924(92)90056-N; Hisada T, 2013, BIOL PHARM BULL, V36, P412, DOI 10.1248/bpb.b12-00825; Huang WH, 2014, ANAL METHODS-UK, V6, P8258, DOI [10.1039/c4ay01783h, 10.1039/C4AY01783H]; Ibrahim WAW, 2014, CRIT REV ANAL CHEM, V44, P233, DOI 10.1080/10408347.2013.855607; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kole PL, 2011, BIOMED CHROMATOGR, V25, P199, DOI 10.1002/bmc.1560; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; Lane ME, 2013, EUR J PHARM BIOPHARM, V84, P449, DOI 10.1016/j.ejpb.2013.01.018; Liang LL, 2011, J PHARMACEUT BIOMED, V54, P838, DOI 10.1016/j.jpba.2010.11.016; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; Manfio JL, 2011, J AOAC INT, V94, P136; McWilliams K, 2013, QJM-INT J MED, V106, P887, DOI 10.1093/qjmed/hct092; Meriggi F, 2013, REV RECENT CLIN TRIA, V8, P42, DOI 10.2174/15748871112079990039; Moore N, 2012, CURR MED RES OPIN, V28, P1781, DOI 10.1185/03007995.2012.735227; Naito T, 2012, CHEM PHARM BULL, V60, P56, DOI 10.1248/cpb.60.56; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Paci A., 2001, European Journal of Cancer, V37, pS64, DOI 10.1016/S0959-8049(01)80717-6; PATT RB, 1992, J PAIN SYMPTOM MANAG, V7, pS51, DOI 10.1016/0885-3924(92)90055-M; PAYNE R, 1992, J PAIN SYMPTOM MANAG, V7, pS40, DOI 10.1016/0885-3924(92)90052-J; Rittgen J, 2012, ELECTROPHORESIS, V33, P1595, DOI 10.1002/elps.201100655; Ross JR, 2003, EUR J PAIN, V7, P481, DOI 10.1016/S1090-3801(02)00148-9; Sachs H, 1996, INT J LEGAL MED, V109, P213, DOI 10.1007/BF01225521; SIMMONDS MA, 1992, J PAIN SYMPTOM MANAG, V7, pS36, DOI 10.1016/0885-3924(92)90051-I; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; SINGH AK, 1989, J CHROMATOGR, V473, P215, DOI 10.1016/S0021-9673(00)91303-7; Skaer TL, 2014, J PAIN RES, V7, P495, DOI 10.2147/JPR.S36446; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Strano-Rossi S, 2011, ANAL BIOANAL CHEM, V399, P1623, DOI 10.1007/s00216-010-4471-4; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Wiffen PJ, 2014, COCHRANE DB SYST REV, V5; Wolf CE, 2005, J ANAL TOXICOL, V29, P711, DOI 10.1093/jat/29.7.711	46	1	2	0	17	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	FEB	2016	54	2					144	156		10.5414/CP202431			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DF5ER	WOS:000371375100010	26754304				2020-06-30	J	Armitage, MC; Woolfield, KI; Page, CB				Armitage, Melanie C.; Woolfield, Kathryn I.; Page, Colin B.			Serotonin toxicity caused by the interaction of fentanyl and serotonergic medications	EMERGENCY MEDICINE AUSTRALASIA			English	Letter									[Armitage, Melanie C.; Woolfield, Kathryn I.; Page, Colin B.] Princess Alexandra Hosp, Emergency Dept, Brisbane, Qld 4102, Australia; [Page, Colin B.] Univ Newcastle, Clin Toxicol Res Grp, Newcastle, NSW 2300, Australia; [Page, Colin B.] Univ Queensland, Sch Med, Brisbane, Qld, Australia	Armitage, MC (reprint author), Princess Alexandra Hosp, Emergency Dept, Brisbane, Qld 4102, Australia.						Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; Buckley NA, 2015, MED J AUSTRALIA, V202, P438, DOI 10.5694/mja14.01116; Buckley NA, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1626; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; Koury KM, 2015, PAIN PHYSICIAN, V18, pE27; Rang ST, 2008, CAN J ANAESTH, V55, P521, DOI 10.1007/BF03016672	6	2	2	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-6731	1742-6723		EMERG MED AUSTRALAS	Emerg. Med. Australas.	FEB	2016	28	1					119	120		10.1111/1742-6723.12521			2	Emergency Medicine	Emergency Medicine	DD9SN	WOS:000370266000021	26679218				2020-06-30	J	Yanagimoto, Y; Takiguchi, S; Miyazaki, Y; Mikami, J; Makino, T; Takahashi, T; Kurokawa, Y; Yamasaki, M; Miyata, H; Nakajima, K; Mori, M; Doki, Y				Yanagimoto, Yoshitomo; Takiguchi, Shuji; Miyazaki, Yasuhiro; Mikami, Jota; Makino, Tomoki; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Mori, Masaki; Doki, Yuichiro			Comparison of pain management after laparoscopic distal gastrectomy with and without epidural analgesia	SURGERY TODAY			English	Article						Laparoscopic distal gastrectomy; Epidural anesthesia; Urinary retention	RANDOMIZED CONTROLLED-TRIAL; EARLY GASTRIC-CANCER; POSTOPERATIVE ANALGESIA; COLORECTAL SURGERY; BOWEL FUNCTION; BALANCED ANALGESIA; ANESTHESIA; ROPIVACAINE; INFUSION; BLOCK	Purpose The optimal analgesia following laparoscopic distal gastrectomy (LDG) has not been determined; moreover, it has been unclear whether epidural anesthesia has benefits for laparoscopic surgery. In this study, we evaluated the effectiveness of epidural analgesia after LDG. Methods This retrospective study included 84 patients who underwent LDG for gastric cancer. Patients received either combined thoracic epidural and general anesthesia (Epidural group, n = 34) or general anesthesia alone (No epidural group, n = 50). We recorded data on the patients, surgery, postoperative outcomes and anesthesia-related complications. Results In the Epidural group, the first day of flatus was significantly earlier (2.21 vs. 2.44 days, p = 0.045) and the number of additional doses of analgesics was significantly lower (2.85 vs. 4.86 doses, p = 0.007) than in the No epidural group. Postoperative urinary retention occurred at a significantly higher rate in the Epidural group (n = 7; 20.6 %) than in the No epidural group (p < 0.001). Conclusion Epidural anesthesia may reduce the need for additional analgesics after LDG, but increases the risk of urinary retention.	[Yanagimoto, Yoshitomo; Takiguchi, Shuji; Miyazaki, Yasuhiro; Mikami, Jota; Makino, Tomoki; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Mori, Masaki; Doki, Yuichiro] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, 2-2,E-2 Yamadaoka, Suita, Osaka 5650871, Japan	Takiguchi, S (reprint author), Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, 2-2,E-2 Yamadaoka, Suita, Osaka 5650871, Japan.	stakiguchi@gesurg.med.osaka-u.ac.jp					Baig MK, 2004, DIS COLON RECTUM, V47, P516, DOI 10.1007/s10350-003-0067-9; Basse L, 2000, REGION ANESTH PAIN M, V25, P498, DOI 10.1053/rapm.2000.9537; Carli F, 2001, DIS COLON RECTUM, V44, P1083, DOI 10.1007/BF02234626; Casati L, 2002, ANESTH ANALG, V94, P1331, DOI 10.1097/00000539-200205000-00053; Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2; Freise H, 2009, CURR OPIN ANESTHESIO, V22, P644, DOI 10.1097/ACO.0b013e32832eb7e8; Hamabe A, 2012, SURG ENDOSC, V26, P1702, DOI 10.1007/s00464-011-2096-0; Henriksen MG, 2002, NUTRITION, V18, P147, DOI 10.1016/S0899-9007(01)00748-1; Joshi GP, 2013, COLORECTAL DIS, V15, P146, DOI 10.1111/j.1463-1318.2012.03062.x; Kehlet H, 1999, DRUGS, V58, P793, DOI 10.2165/00003495-199958050-00002; Khan SA, 2013, SURG ENDOSC, V27, P2581, DOI 10.1007/s00464-013-2794-x; Kim BS, 2011, J LAPAROENDOSC ADV S, V21, P387, DOI 10.1089/lap.2010.0515; Kim DG, 2013, SURG ENDOSC, V27, P3153, DOI 10.1007/s00464-013-2869-8; Kinoshita T, 2011, SURG ENDOSC, V25, P1395, DOI 10.1007/s00464-010-1402-6; Kitano S, 2002, SURGERY, V131, pS306, DOI 10.1067/msy.2002.120115; Kobayashi R, 2013, SURG TODAY, V43, P963, DOI 10.1007/s00595-012-0485-1; Levy BF, 2011, BRIT J SURG, V98, P1068, DOI 10.1002/bjs.7545; Matsutani N, 2014, SURG TODAY, V44, P712, DOI 10.1007/s00595-013-0743-x; Schug SA, 1996, BRIT J ANAESTH, V76, P487; SCOTT DA, 1995, ANESTH ANALG, V81, P982, DOI 10.1097/00000539-199511000-00015; Senagore AJ, 2001, SURGERY, V129, P672, DOI 10.1067/msy.2001.114648; Stubbs BM, 2013, COLORECTAL DIS, V15, P733, DOI 10.1111/codi.12124; Takayama T, 2014, SURG TODAY, V44, P2332, DOI 10.1007/s00595-014-0928-y; Taqi A, 2007, SURG ENDOSC, V21, P247, DOI 10.1007/s00464-006-0069-5; Walter CJ, 2013, SURG ENDOSC, V27, P2366, DOI 10.1007/s00464-013-2791-0; Yamashita K, 2013, SURG TODAY, V43, P1013, DOI 10.1007/s00595-012-0388-1; Yano H, 2001, Gastric Cancer, V4, P93, DOI 10.1007/PL00011730	27	4	6	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	FEB	2016	46	2					229	234		10.1007/s00595-015-1162-y			6	Surgery	Surgery	DD4TH	WOS:000369915000014	25861994				2020-06-30	J	Eggers, A; Latham, GJ; Geiduschek, J; Yung, D; Chen, JM; Joffe, DC				Eggers, Ashley; Latham, Gregory J.; Geiduschek, Jeremy; Yung, Delphine; Chen, Jonathan M.; Joffe, Denise C.			Anesthesia for Potts Shunt in a Child with Severe Refractory Idiopathic Pulmonary Arterial Hypertension	A & A CASE REPORTS			English	Article							SURVIVAL	Childhood idiopathic pulmonary arterial hypertension is a progressive and fatal disease. When pulmonary artery pressures become suprasystemic and refractory to medical management, atrial septostomy can be recommended for bridging patients to lung transplantation. Recently, a surgical Potts shunt has been recommended as an alternative rescue therapy, and initial outcome data are promising. The placement of a Potts shunt converts the child to Eisenmenger physiology, which is anticipated to provide an improved quality and duration of life. We present the first description of anesthetic management of a child undergoing surgical Potts shunt for pulmonary arterial hypertension and summarize the multiple, unique intraoperative considerations.	[Eggers, Ashley; Latham, Gregory J.; Geiduschek, Jeremy; Joffe, Denise C.] Univ Washington, Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, MB 11-500,Sand Point Way NE, Seattle, WA 98105 USA; [Yung, Delphine] Univ Washington, Seattle Childrens Hosp, Dept Pediat Cardiol, Seattle, WA 98105 USA; [Chen, Jonathan M.] Univ Washington, Seattle Childrens Hosp, Dept Pediat Cardiovasc Surg, Seattle, WA 98105 USA	Eggers, A (reprint author), Univ Washington, Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, MB 11-500,Sand Point Way NE, Seattle, WA 98105 USA.	ashley.eggers@seattlechildrens.org	Latham, Gregory J/U-9744-2019	Latham, Gregory J/0000-0002-1440-9742			Barst RJ, 2012, CIRCULATION, V125, P113, DOI 10.1161/CIRCULATIONAHA.111.026591; Baruteau AE, 2015, EUR J CARDIO-THORAC, V47, pE105, DOI 10.1093/ejcts/ezu445; Baruteau AE, 2012, ANN THORAC SURG, V94, P817, DOI 10.1016/j.athoracsur.2012.03.099; Blanc J, 2004, NEW ENGL J MED, V350, P623, DOI 10.1056/NEJM200402053500623; Carmosino MJ, 2007, ANESTH ANALG, V104, P521, DOI 10.1213/01.ane.0000255732.16057.1c; Hopkins WE, 1996, J HEART LUNG TRANSPL, V15, P100; Ivy DD, 2013, J AM COLL CARDIOL, V62, pD117, DOI 10.1016/j.jacc.2013.10.028; Labombarda F, 2009, PEDIATR CARDIOL, V30, P1143, DOI 10.1007/s00246-009-9485-3; McLaughlin VV, 2009, CIRCULATION, V119, P2250, DOI 10.1161/CIRCULATIONAHA.109.192230; Micheletti A, 2006, HEART, V92, P969, DOI 10.1136/hrt.2005.077669; MURPHY JG, 1993, NEW ENGL J MED, V329, P593, DOI 10.1056/NEJM199308263290901; POTTS WJ, 1946, JAMA-J AM MED ASSOC, V132, P627, DOI 10.1001/jama.1946.02870460017005; Schaellibaum G, 2011, PEDIATR PULM, V46, P1121, DOI 10.1002/ppul.21484; Taylor K, 2015, ANESTH ANALG, V120, P420, DOI 10.1213/ANE.0000000000000547	14	1	2	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237			A A CASE REP	A A Case Rep.	FEB 1	2016	6	3					56	60		10.1213/XAA.0000000000000268			5	Anesthesiology	Anesthesiology	DD0FG	WOS:000369595200005	26579614				2020-06-30	J	Song, Y; Shim, JK; Song, JW; Kim, EK; Kwak, YL				Song, Young; Shim, Jae-Kwang; Song, Jong-Wook; Kim, Eui-Kyung; Kwak, Young-Lan			Dexmedetomidine added to an opioid-based analgesic regimen for the prevention of postoperative nausea and vomiting in highly susceptible patients A randomised controlled trial	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article							SIMPLIFIED RISK SCORE; PAIN; MORPHINE; SURGERY; REMIFENTANIL; HYPERALGESIA; ONDANSETRON; CONSUMPTION; MANAGEMENT; RECEPTORS	BACKGROUNDDexmedetomidine, an 2 adrenergic receptor agonist, has analgesic, sedative and sympatholytic properties, with a lack of respiratory depression. It is licensed only for intensive care sedation.OBJECTIVEThe objective of this study is to investigate whether intravenous (i.v.) patient-controlled analgesia (PCA) with dexmedetomidine added to a fentanyl-based drug mixture could reduce postoperative nausea and vomiting (PONV) in highly susceptible patients undergoing lumbar spinal surgery.DESIGNA randomised, double-blinded study.SETTINGAt a tertiary university hospital between September 2012 and September 2013.PATIENTSOne hundred and eight patients undergoing level 1 or 2 posterior lumbar spinal fusion who had at least three risk factors for PONV (female, nonsmoker, use of postoperative opioids) were randomised into two groups. Three patients were excluded from analysis and 105 patients completed the study.METHODSPatients received either dexmedetomidine 0.5gkg(-1) i.v. (dexmedetomidine group) or 0.9% normal saline (control group) 30min before the completion of surgery followed by fentanyl 0.5gkg(-1) and 4mg ondansetron. Postoperatively, the PCA (fentanyl 10gkg(-1) with 120mg ketorolac, with or without dexmedetomidine 10gkg(-1) made up to a total volume of 100ml) was programmed to deliver 1ml bolus (lockout 15min) with a continuous background infusion of 2mlh(-1). The PCA was used for the first 48h postoperatively.MAIN OUTCOME MEASURESThe incidence and severity of PONV, cumulative dose of PCA fentanyl consumed and pain scores were assessed for 48h.RESULTSThe dexmedetomidine group experienced less nausea during the time interval 1 to 3h postoperatively compared with the control group [odds ratio (OR) 0.32; 95% confidence interval (CI) 0.13 to 0.77; P=0.019]. The intensity of nausea between the groups during the first 48h was comparable, but the dexmedetomidine group had a lower incidence of moderate to severe nausea (OR 0.28; 95% CI 0.12 to 0.67; P<0.003). Pain scores were not significantly different between the groups, but patients in the dexmedetomidine group required less fentanyl and less rescue analgesia in the first 12h. Compared with the control group, patients in the dexmedetomidine group experienced almost twice as many episodes of hypotension and bradycardia, but this failed to reach statistical significance.CONCLUSIONAdding dexmedetomidine to a fentanyl-based PCA drug mixture reduces the frequency and severity of acute postoperative nausea in highly susceptible patients.TRIAL REGISTRATIONClinicaltrials.gov identifier: NCT01840254.	[Song, Young; Shim, Jae-Kwang; Song, Jong-Wook; Kim, Eui-Kyung; Kwak, Young-Lan] Yonsei Univ Hlth Syst, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 134 Shinchon Dong, Seoul 120725, South Korea	Kwak, YL (reprint author), Yonsei Univ Hlth Syst, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 134 Shinchon Dong, Seoul 120725, South Korea.; Kwak, YL (reprint author), Yonsei Univ Hlth Syst, Dept Anesthesiol & Pain Med, 134 Shinchon Dong, Seoul 120725, South Korea.	ylkwak@yuhs.ac		Shim, Jae-Kwang/0000-0001-9093-9692; Kwak, Young-Lan/0000-0002-2984-9927; Song, Jong Wook/0000-0001-7518-2070; Song, Young/0000-0003-4597-387X			Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Carstensen M, 2010, BRIT J ANAESTH, V104, P401, DOI 10.1093/bja/aeq041; Choi YS, 2008, SPINE, V33, pE602, DOI 10.1097/BRS.0b013e31817c6bde; Clarke H, 2009, ACTA ANAESTH SCAND, V53, P1073, DOI 10.1111/j.1399-6576.2009.02039.x; COHEN MM, 1994, ANESTH ANALG, V78, P7; Cortinez LI, 2004, ANESTHESIOLOGY, V101, P1077, DOI 10.1097/00000542-200411000-00006; Costantini R, 2011, INT J CLIN PHARM TH, V49, P116, DOI 10.5414/CP201401; Elia N, 2005, ANESTHESIOLOGY, V103, P1296, DOI 10.1097/00000542-200512000-00025; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Gerlach Anthony T, 2009, Pharmacotherapy, V29, P1492, DOI 10.1592/phco.29.12.1492; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Hill RP, 2000, ANESTHESIOLOGY, V92, P958, DOI 10.1097/00000542-200004000-00012; Iirola T, 2012, BRIT J ANAESTH, V108, P460, DOI 10.1093/bja/aer441; KAUPPILA T, 1991, ANESTHESIOLOGY, V74, P3, DOI 10.1097/00000542-199101000-00002; Kim SH, 2013, YONSEI MED J, V54, P1273, DOI 10.3349/ymj.2013.54.5.1273; Klinger RY, 2012, J CLIN ANESTH, V24, P212, DOI 10.1016/j.jclinane.2011.07.016; Lichtor JL, 2012, CURR OPIN ANESTHESIO, V25, P673, DOI 10.1097/ACO.0b013e32835956d8; Lin TF, 2009, BRIT J ANAESTH, V102, P117, DOI 10.1093/bja/aen320; Malviya S, 2004, ANESTHESIOLOGY, V100, P218, DOI 10.1097/00000542-200402000-00007; Mansikka H, 2002, NEUROSCIENCE, V113, P339, DOI 10.1016/S0306-4522(02)00189-6; Song JW, 2013, BRIT J ANAESTH, V111, P630, DOI 10.1093/bja/aet192; Ulger F, 2009, ANESTH ANALG, V109, P616, DOI 10.1213/ane.0b013e3181a9fae2; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; Zhang X, 2014, NEUROSCI LETT, V561, P7, DOI 10.1016/j.neulet.2013.12.039; Zheng YG, 2012, BRAIN RES BULL, V87, P427, DOI 10.1016/j.brainresbull.2012.01.009	27	27	31	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	FEB	2016	33	2					75	83		10.1097/EJA.0000000000000327			9	Anesthesiology	Anesthesiology	DD0IT	WOS:000369604300003	26258655				2020-06-30	J	Ham, SY; Shim, YH; Kim, EH; Son, MJ; Park, WS; Lee, JS				Ham, Sung Yeon; Shim, Yon Hee; Kim, Eun Ho; Son, Min Ji; Park, Won Sun; Lee, Jeong Soo			Aprepitant for antiemesis after laparoscopic gynaecological surgery A randomised controlled trial	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article							SIMPLIFIED RISK SCORE; POSTOPERATIVE NAUSEA; PREVENTION; ONDANSETRON; ANTAGONIST; CASOPITANT; EMESIS; SINGLE; PAY	BACKGROUNDOndansetron, a 5-HT3 receptor antagonist, and aprepitant, a neurokinin-1 receptor antagonist, block the emetic effect of serotonin and neurokinin, respectively. Aprepitant combined with ondansetron can be more effective for preventing emesis in patients at high risk of postoperative nausea and vomiting (PONV).OBJECTIVETo investigate the prophylactic effect of combining aprepitant with ondansetron compared with ondansetron alone on PONV in patients with fentanyl-based patient-controlled analgesia (PCA) after laparoscopic gynaecological surgery.DESIGNSingle-centre, double-blinded randomised controlled trial.SETTINGA major university hospital in Seoul, Korea, between July 2012 and April 2013.PATIENTSOne hundred and twenty-five female patients (American Society of Anesthesiologists' physical status 1 or 2) with fentanyl-based intravenous PCA after gynaecological laparoscopy were recruited to the study, and 110 completed the protocol.INTERVENTIONSOral aprepitant 80mg or placebo was given 1h before anaesthesia. In all patients, ondansetron 4mg was administered intravenously at the end of surgery and 12mg was added to the PCA solution.MAIN OUTCOME MEASURESThe primary outcome measure was complete response (no PONV and no rescue antiemetics) up to 48h postoperatively.RESULTSThere was no difference in the proportion of complete responses to 48h between the groups (P=0.05), but in the post-anaesthesia care unit and up to 24h postoperatively, the proportion was significantly higher in the aprepitant and ondansetron group than in the ondansetron only group (76 vs. 50%, P=0.004 and 38 vs. 16%, P=0.011, respectively). In the aprepitant and ondansetron group, the time to first PONV was delayed (P=0.014) and the incidence of nausea up to 24h postoperatively was lower (P=0.014). However, there were no differences in the incidences of retching or vomiting, the severity of nausea, use of rescue antiemetics or the incidence of side-effects.CONCLUSIONAprepitant 80mg orally with ondansetron is effective in suppressing early PONV up to 24h postoperatively and delays the time to first PONV in patients with fentanyl-based intravenous PCA after gynaecological laparoscopy. However, the combination prophylaxis with aprepitant and ondansetron failed to reach the predefined primary study outcome when compared with ondansetron alone.	[Ham, Sung Yeon; Kim, Eun Ho] Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, 211 Eonju Ro, Seoul 135720, South Korea; [Shim, Yon Hee; Lee, Jeong Soo] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Anaesthesia & Pain Res Inst,Dept Anaesthesiol & P, 211 Eonju Ro, Seoul 135720, South Korea; [Son, Min Ji] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; [Park, Won Sun] Yonsei Univ, Yongin Severance Hosp, Coll Med, Anaesthesia & Pain Res Inst,Dept Anaesthesiol & P, 211 Eonju Ro, Seoul 135720, South Korea	Lee, JS (reprint author), Yonsei Univ, Gangnam Severance Hosp, Coll Med, Anaesthesia & Pain Res Inst,Dept Anaesthesiol & P, 211 Eonju Ro, Seoul 135720, South Korea.	ration99@yuhs.ac		Ham, Sung Yeon/0000-0001-8619-4595; Lee, Jeong Soo/0000-0002-8947-3706; PARK, WON SUN/0000-0003-3856-3987; Shim, Yon Hee/0000-0003-1921-3391			Altorjay A, 2011, ARCH SURG-CHICAGO, V146, P201, DOI 10.1001/archsurg.2010.327; ANDREWS PLR, 1993, NEUROPHARMACOLOGY, V32, P799, DOI 10.1016/0028-3908(93)90189-A; [Anonymous], 2006, EMEND CAPSULES MERCK; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Bradshaw WA, 2002, SURG ENDOSC, V16, P777, DOI 10.1007/s00464-001-8342-0; Diemunsch P, 2007, BRIT J ANAESTH, V99, P202, DOI 10.1093/bja/aem133; Diemunsch P, 2009, BRIT J ANAESTH, V103, P7, DOI 10.1093/bja/aep125; Dzwonczyk R, 2012, AM J THER, V19, P11, DOI 10.1097/MJT.0b013e3181e7a512; Eriksson H, 1996, ANESTH ANALG, V82, P533, DOI 10.1097/00000539-199603000-00019; Gan TJ, 2001, ANESTH ANALG, V92, P393, DOI 10.1213/00000539-200102000-00022; Gan TJ, 2007, ANESTH ANALG, V104, P1082, DOI 10.1213/01.ane.0000263277.35140.a3; Green MS, 2012, BRIT J ANAESTH, V109, P716, DOI 10.1093/bja/aes233; Gutierrez-Williams Gabriella, 2008, Conn Med, V72, P21; Kakuta N, 2011, J MED INVESTIG, V58, P246, DOI 10.2152/jmi.58.246; Kerger H, 2007, ACTA ANAESTH SCAND, V51, P38, DOI 10.1111/j.1399-6576.2006.01171.x; Kim SH, 2013, YONSEI MED J, V54, P1273, DOI 10.3349/ymj.2013.54.5.1273; Lim CS, 2013, KOREAN J ANESTHESIOL, V64, P212, DOI 10.4097/kjae.2013.64.3.212; Majumdar AK, 2006, J CLIN PHARMACOL, V46, P291, DOI 10.1177/0091270005283467; Myles PS, 2000, BRIT J ANAESTH, V84, P6; Navari RM, 1999, NEW ENGL J MED, V340, P190, DOI 10.1056/NEJM199901213400304; Parra-Sanchez I, 2012, CAN J ANESTH, V59, P366, DOI 10.1007/s12630-011-9660-x; Roila F, 2010, ANN ONCOL, V21, pv232, DOI 10.1093/annonc/mdq194; Singla NK, 2010, ANESTHESIOLOGY, V113, P74, DOI 10.1097/ALN.0b013e3181d7b13a; Vallejo MC, 2012, PLAST RECONSTR SURG, V129, P519, DOI 10.1097/PRS.0b013e31822b6932	24	8	8	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	FEB	2016	33	2					90	95		10.1097/EJA.0000000000000242			6	Anesthesiology	Anesthesiology	DD0IT	WOS:000369604300005	26694939				2020-06-30	J	Soaida, SM; ElSheemy, MS; Shouman, AM; Shoukry, AI; Morsi, HA; Salah, DM; Fadel, FI; Bazaraa, HM				Soaida, Sherif M.; ElSheemy, Mohammed S.; Shouman, Ahmed M.; Shoukry, Ahmed I.; Morsi, Hany A.; Salah, Doaa M.; Fadel, Fatina I.; Bazaraa, Hafez M.			Caudal extradural catheterization in pediatric renal transplant and its effect on perioperative hemodynamics and pain scoring: a prospective randomized study	JOURNAL OF ANESTHESIA			English	Article						Anesthesia; Transplant; Pediatrics; Caudal; Epidural; Renal	THORACIC EPIDURAL-ANESTHESIA; CHILDREN; INFANTS; ANALGESIA; LUMBAR	'Hockey stick incision' used in renal transplant is large enough to cause severe postoperative morbidity especially in pediatric recipients. Although epidural analgesia is known to be effective in pain control, the resulting sympathectomy might affect hemodynamics interfering with the transplant process. In our study, we evaluated the feasibility and safety of inserting an epidural catheter to the thoracic level via the caudal route, and the effect of using epidural local anesthetics at low concentrations on hemodynamics. After approval from the ethical committee at Kasr Al Ainy University Hospital and consent from parents/legal guardians, sixty patients aged 3-12 years who were scheduled for renal transplant were randomly divided into two equal groups. Group I (epidural group) received continuous caudal epidural bupivacaine 0.125 % with fentanyl together with intravenous (IV) fentanyl and paracetamol. Group II (control group) received only IV fentanyl and paracetamol. Intraoperative data included heart rate (HR), mean arterial blood pressure (MAP) and central venous pressure (CVP). Postoperative variables included HR, MAP, CVP, pain score and complications. Threading failure via the caudal route occurred in 6.67 % of cases. Intraoperative differences in hemodynamics and CVP were not clinically significant between groups. Postoperative HR, MAP, and CVP were generally higher in the control group. Pain control was more satisfactory and postoperative complications were less in the epidural group. Caudal epidural anesthesia in pediatric renal transplant is a valuable addition to general anesthesia as it provides stable perioperative hemodynamics, excellent postoperative analgesia and is associated with fewer complications than narcotic-dependent analgesia. Clinical trial registration number: NCT02037802.	[Soaida, Sherif M.] Cairo Univ, Fac Med, Div Pediat Anesthesia, Dept Anesthesia ICU & Pain Management,Abu ElReesh, Cairo, Egypt; [ElSheemy, Mohammed S.; Shouman, Ahmed M.; Shoukry, Ahmed I.; Morsi, Hany A.] Cairo Univ, Fac Med, Div Pediat Urol, Abu El Reesh Childrens Hosp, Cairo, Egypt; [Salah, Doaa M.; Fadel, Fatina I.; Bazaraa, Hafez M.] Cairo Univ, Fac Med, Pediat Nephrol, Abu El Reesh Childrens Hosp, Cairo, Egypt; [Soaida, Sherif M.] Cairo Univ, Kasr al Ainy Hosp, Dept Anesthesia, Kasr al Ainy St, Cairo 11562, Egypt	Soaida, SM (reprint author), Cairo Univ, Fac Med, Div Pediat Anesthesia, Dept Anesthesia ICU & Pain Management,Abu ElReesh, Cairo, Egypt.; Soaida, SM (reprint author), Cairo Univ, Kasr al Ainy Hosp, Dept Anesthesia, Kasr al Ainy St, Cairo 11562, Egypt.	sherif_soaida@hotmail.com	ElSheemy, Mohammed Said/A-2620-2016	ElSheemy, Mohammed Said/0000-0002-1029-1417; Shoukry, Ahmed/0000-0003-2418-8012			Bhandal N, 2006, ANAESTHESIA, V61, P277, DOI 10.1111/j.1365-2044.2005.04515.x; Blanco D, 1996, ANESTHESIOLOGY, V84, P1312, DOI 10.1097/00000542-199606000-00006; Blanco D, 1994, Rev Esp Anestesiol Reanim, V41, P214; BOSENBERG AT, 1988, ANESTHESIOLOGY, V69, P265; Dauri M, 2003, Minerva Anestesiol, V69, P873; FLANDINBLETY C, 1995, PAEDIATR ANAESTH, V5, P41, DOI 10.1111/j.1460-9592.1995.tb00239.x; GUNTER JB, 1992, ANESTHESIOLOGY, V76, P935, DOI 10.1097/00000542-199206000-00010; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Kasai T, 2003, ANESTH ANALG, V96, P65, DOI 10.1097/00000539-200301000-00014; Peutrell JM, 1997, REGIONAL ANAESTHESIA, P187; RASCH DK, 1990, CAN J ANAESTH, V37, P359, DOI 10.1007/BF03005591; Rowney DA, 1998, ANAESTHESIA, V53, P980, DOI 10.1046/j.1365-2044.1998.00527.x; Shah VR, 2008, TRANSPL P, V40, P3451, DOI 10.1016/j.transproceed.2008.06.065; TOBIAS JD, 1993, CAN J ANAESTH, V40, P879, DOI 10.1007/BF03009262	14	3	3	0	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2016	30	1					47	54		10.1007/s00540-015-2087-8			8	Anesthesiology	Anesthesiology	DC9ML	WOS:000369545600008	26493396				2020-06-30	J	Gurunathan, U; Rapchuk, IL; King, G; Barnett, AG; Fraser, JF				Gurunathan, Usha; Rapchuk, Ivan L.; King, Gillian; Barnett, Adrian G.; Fraser, John F.			The effect of pregabalin and celecoxib on the analgesic requirements after laparoscopic cholecystectomy: a randomized controlled trial	JOURNAL OF ANESTHESIA			English	Article						Laparoscopic cholecystectomy; Pregabalin; Celecoxib; Postoperative pain	POSTOPERATIVE PAIN; SHOULDER PAIN; DOUBLE-BLIND; PREEMPTIVE ANALGESIA; PREOPERATIVE USE; GABAPENTIN; MANAGEMENT; EFFICACY; SURGERY; DEXAMETHASONE	Early postoperative pain is a common complaint after elective laparoscopic cholecystectomy. The use of non-opioid medications as a part of multimodal analgesia has been increasingly advocated in the management of acute post-surgical pain. This randomized, double-blinded, placebo-controlled study evaluated the efficacy of pregabalin, celecoxib, and their combination in the management of acute postoperative pain in patients undergoing elective laparoscopic cholecystectomy. One hundred ASA I/II patients scheduled to undergo elective laparoscopic cholecystectomy were assigned to receive two perioperative doses, 12 h apart, of either pregabalin alone, celecoxib alone, their combination, or a placebo. Standard anesthetic protocol was followed. The primary outcomes were postoperative pain at rest and with movement. Secondary outcomes were fentanyl requirements and side effects, which were assessed at 1, 2, 4, 8, 12, and 24 h following surgery. Patient satisfaction with pain relief was recorded at discharge. Differences in main outcomes were analyzed using an intention-to-treat approach. There was no statistically significant difference (p > 0.05) between the four groups in terms of outcomes such as rest pain, movement pain, postoperative fentanyl requirements, or changes in anxiety scores. Patients who had only celecoxib had significantly higher satisfaction with pain management (p = 0.013). Patients who had only pregabalin were at three-times-higher odds of having drowsiness (p = 0.040) and four-times-higher odds of having lightheadedness (p = 0.019) when compared with the placebo group. Pregabalin, celecoxib alone, or in combination offers no analgesic superiority over standard opioid care in the treatment of postoperative pain following laparoscopic cholecystectomy.	[Gurunathan, Usha; Rapchuk, Ivan L.] Univ Queensland, Dept Anesthesia & Perfus Serv, Prince Charles Hosp, Brisbane, Qld, Australia; [Gurunathan, Usha; Rapchuk, Ivan L.] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [King, Gillian] Prince Charles Hosp, Surg Preadmiss Clin, Brisbane, Qld 4032, Australia; [Barnett, Adrian G.] Queensland Univ Technol, Brisbane, Qld 4001, Australia; [Fraser, John F.] Univ Queensland, Intens Care Unit, CCRG, Prince Charles Hosp, Brisbane, Qld, Australia	Gurunathan, U (reprint author), Univ Queensland, Dept Anesthesia & Perfus Serv, Prince Charles Hosp, Brisbane, Qld, Australia.; Gurunathan, U (reprint author), Univ Queensland, Sch Med, Brisbane, Qld, Australia.	usha.gurunathan@health.qld.gov.au	Barnett, Adrian/I-9850-2012; Rapchuk, Ivan/E-2243-2011	Barnett, Adrian/0000-0001-6339-0374; Rapchuk, Ivan/0000-0001-5644-2543	Prince Charles Hospital Foundation [NR2012-126]	This research was funded by a grant from The Prince Charles Hospital Foundation, Grant No. NR2012-126.	Agarwal A, 2008, BRIT J ANAESTH, V101, P700, DOI 10.1093/bja/aen244; Alanoglu Z, 2005, SURG ENDOSC, V19, P1182, DOI 10.1007/s00464-004-8254-x; Alimian Mahzad, 2012, Anesth Pain Med, V2, P12, DOI 10.5812/aapm.4300; Aynehchi BB, 2014, JAMA FACIAL PLAST SU, V16, P306, DOI 10.1001/jamafacial.2014.351; Balaban F, 2012, J CLIN ANESTH, V24, P175, DOI 10.1016/j.jclinane.2011.06.027; Bannister K, 2011, ANESTHESIOLOGY, V115, P144, DOI 10.1097/ALN.0b013e31821f6545; Bekawi MS, 2014, CLIN J PAIN, V30, P944, DOI 10.1097/AJP.0000000000000060; Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Schulmeyer MCC, 2010, OBES SURG, V20, P1678, DOI 10.1007/s11695-009-9944-1; Carmichael NME, 2013, PAIN RES MANAG, V18, P127, DOI 10.1155/2013/258714; Chang SH, 2009, ANESTH ANALG, V109, P1284, DOI 10.1213/ane.0b013e3181b4874d; Chaparro LE, 2012, J ANESTH, V26, P829, DOI 10.1007/s00540-012-1447-x; Dahl JB, 2004, ACTA ANAESTH SCAND, V48, P1130, DOI 10.1111/j.1399-6576.2004.00484.x; Demirhan A, 2013, AESTHET PLAST SURG, V37, P1100, DOI 10.1007/s00266-013-0207-0; Derry S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004233.pub4; Durkin B, 2010, EXPERT OPIN PHARMACO, V11, P2751, DOI 10.1517/14656566.2010.526106; Gilron I, 2009, ANESTH ANALG, V108, P623, DOI 10.1213/ane.0b013e318193cd1b; Gonano C, 2011, J PSYCHOPHARMACOL, V25, P249, DOI 10.1177/0269881109106928; Gurusamy KS, 2014, COCHRANE DB SYST REV, V28; Fuertes MJ, 2015, CIR ESPAN, V93, P181, DOI 10.1016/j.ciresp.2013.04.026; Jokela R, 2008, BRIT J ANAESTH, V100, P834, DOI 10.1093/bja/aen098; Jokela R, 2008, PAIN, V134, P106, DOI 10.1016/j.pain.2007.04.002; Joshi GP, 2004, ANESTH ANALG, V98, P336, DOI 10.1213/01.ANE.0000093390.94921.4A; Kandil TS, 2010, J LAPAROENDOSC ADV S, V20, P677, DOI 10.1089/lap.2010.0112; Kim JH, 2014, CLIN EXP OTORHINOLAR, V7, P102, DOI 10.3342/ceo.2014.7.2.102; Kumar KP, 2013, J PAIN RES, V6, P471, DOI 10.2147/JPR.S43613; Kumar V, 2013, RECENT PATENTS INFLA, V7, P124, DOI 10.2174/1872213X11307020004; Lee C, 2013, KOREAN J ANESTHESIOL, V64, P19, DOI 10.4097/kjae.2013.64.1.19; Mardani-Kivi M, 2013, ARCH ORTHOP TRAUM SU, V133, P1561, DOI 10.1007/s00402-013-1852-0; Martinotti G, 2013, CURR PHARM DESIGN, V19, P6367; Mathiesen O, 2008, BRIT J ANAESTH, V101, P535, DOI 10.1093/bja/aen215; Mehta A, 2013, J UROLOGY, V190, P1834, DOI 10.1016/j.juro.2013.04.058; Mishriky BM, 2015, BRIT J ANAESTH, V114, P10, DOI 10.1093/bja/aeu293; Nutthachote P, 2014, J MINIM INVAS GYN, V21, P669, DOI 10.1016/j.jmig.2014.01.018; Pandey CK, 2004, CAN J ANAESTH, V51, P358, DOI 10.1007/BF03018240; Parsa AA, 2009, AESTHET PLAST SURG, V33, P98, DOI 10.1007/s00266-008-9230-y; Peng PWH, 2010, BRIT J ANAESTH, V105, P155, DOI 10.1093/bja/aeq116; Phinchantra Pitcha, 2004, Journal of the Medical Association of Thailand, V87, P283; Sarakatsianou C, 2013, SURG ENDOSC, V27, P2504, DOI 10.1007/s00464-012-2769-3; Schmidt PC, 2013, ANESTHESIOLOGY, V119, P1215, DOI 10.1097/ALN.0b013e3182a9a896; Stahl SM, 2013, TRENDS PHARMACOL SCI, V34, P332, DOI 10.1016/j.tips.2013.04.001; White PF, 2007, CAN J ANAESTH, V54, P342, DOI 10.1007/BF03022655; Zhang Zhenxiang, 2014, Eur J Orthop Surg Traumatol, V24, P919, DOI 10.1007/s00590-013-1359-y	43	10	11	1	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2016	30	1					64	71		10.1007/s00540-015-2078-9			8	Anesthesiology	Anesthesiology	DC9ML	WOS:000369545600010	26419487				2020-06-30	J	Kitamura, S; Kawano, T; Kaminaga, S; Yamanaka, D; Tateiwa, H; Locatelli, FM; Yokoyama, M				Kitamura, Sonoe; Kawano, Takashi; Kaminaga, Satomi; Yamanaka, Daiki; Tateiwa, Hiroki; Locatelli, Fabricio M.; Yokoyama, Masataka			Effects of fentanyl on serotonin syndrome-like behaviors in rats	JOURNAL OF ANESTHESIA			English	Article						Serotonin syndrome; Fentanyl; Opioid receptor		Emerging evidence from case reports suggests that fentanyl may precipitate potentially life-threatening serotonin syndrome in patients taking serotonergic drugs. However, the underlying mechanism of the association between serotonin syndrome and fentanyl remains under investigation. We therefore investigated the pharmacological effects of an analgesic dose of fentanyl (0.2 mg/kg) injected subcutaneously (s.c.) on serotonergic toxicity-like responses in rats. Rats were s.c. injected with 0.75 mg/kg 8-OH-DPAT, a full 5-HT1A agonist, as an animal model of serotonin syndrome. The 8-OH-DPAT-treated rats showed well-characterized serotonin syndrome-like behaviors (low body posture, forepaw treading), hyperlocomotion, and decreased body temperature. Rats injected s.c. with fentanyl alone showed no significant changes in any of the parameters measured, while concomitant administration of fentanyl + 8-OH-DPAT resulted in exaggerated 8-OH-DPAT-induced serototoxic responses. A separate dose-response experiment showed that the serototoxic effect of fentanyl was dose-dependent. Pretreatment with naloxone [2.0 mg/kg, intraperitoneal (i.p.) injection], an opioid receptor antagonist, failed to antagonize the fentanyl-induced exaggerated serotonin syndrome-like behaviors. In contrast, pretreatment with WAY-100653, a serotonin 5-HT1A receptor antagonist (0.5 mg/kg, i.p. injection) completely inhibited all responses. Our findings provide preclinical proof-of-concept that an analgesic dose of fentanyl enhances serotonin toxicity, likely via its serotonin-reuptake inhibitory activity, independently of interaction with the opioid receptors.	[Kitamura, Sonoe; Kawano, Takashi; Kaminaga, Satomi; Yamanaka, Daiki; Tateiwa, Hiroki; Locatelli, Fabricio M.; Yokoyama, Masataka] Kochi Med Sch, Dept Anesthesiol & Intens Care Med, Oko Cho, Nankoku, Kochi 7838505, Japan	Kawano, T (reprint author), Kochi Med Sch, Dept Anesthesiol & Intens Care Med, Oko Cho, Nankoku, Kochi 7838505, Japan.	takashika@kochi-u.ac.jp					Ables AZ, 2010, AM FAM PHYSICIAN, V81, P1139; Altman CS, 2010, ANESTH ANALG, V110, P526, DOI 10.1213/ANE.0b013e3181c76be9; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Campos AR, 2006, BIOL PHARM BULL, V29, P86, DOI 10.1248/bpb.29.86; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Gnanadesigan Nallini, 2005, J Am Med Dir Assoc, V6, P265, DOI 10.1016/j.jamda.2005.04.012; Greenier Ewa, 2014, AANA J, V82, P340; Gudjonsson SV, 1932, J PHYSIOL-LONDON, V74, P73, DOI 10.1113/jphysiol.1932.sp002830; Haberzettl R, 2013, BEHAV BRAIN RES, V256, P328, DOI 10.1016/j.bbr.2013.08.045; Health Canada, 2012, CANADIAN ADVERSE REA, V22; Kawano T, 2015, J ANESTH, V29, P631, DOI 10.1007/s00540-014-1973-9; Koury KM, 2015, PAIN PHYSICIAN, V18, pE27; Nisijima K, 2001, BRAIN RES, V890, P23, DOI 10.1016/S0006-8993(00)03020-1; Paquette MA, 2009, PSYCHOPHARMACOLOGY, V204, P743, DOI 10.1007/s00213-009-1505-8; Rastogi R, 2011, ANESTHESIOLOGY, V115, P1291, DOI 10.1097/ALN.0b013e31823940c0; SPANOS LJ, 1989, PHARMACOL BIOCHEM BE, V32, P835, DOI 10.1016/0091-3057(89)90044-0	16	3	3	0	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2016	30	1					178	182		10.1007/s00540-015-2092-y			5	Anesthesiology	Anesthesiology	DC9ML	WOS:000369545600027	26499475				2020-06-30	J	Chen, Q; Shang, Y; Xu, Y; Li, P; Li, P; Liu, GL				Chen, Quan; Shang, You; Xu, Yong; Li, Ping; Li, Ping; Liu, Guo-Li			Analgesic effect and pharmacological mechanism of fentanyl and butorphanol in a rat model of incisional pain	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Fentanyl; Butorphanol; Median effective dose; Pharmacological effect; Response rate; Rat model	BREAKTHROUGH CANCER PAIN; OPIOID ANALGESICS; BUPRENORPHINE; MORPHINE; COMBINATION; SEDATION	Objectives: To explore analgesic effects of fentanyl and butorphanol on incisional pain in rats and to investigate the pharmacological mechanism of combination. Methods: Seventy rats were randomly divided into control group (group N, n = 10), fentanyl group (group F, n = 30), and butorphanol group (group B, n = 30), to determine median effective dose (ED50) in fentanyl and butorphanol. Another 50 rats were treated with both fentanyl and butorphanol (joint group) to quantitatively detect response rate of joint application. Ninety rats were randomly divided into 1/4 ED50 fentanyl (group 1, n = 30), 1/2 ED50 fentanyl (group 2, n = 30), and 3/4 ED50 fentanyl (group 3, n = 30), to detect the correlation between combined pharmacological effects of 2 drugs and their dose proportionality. Statistical analysis was performed using SPSS 17.0. Results: Probit analysis revealed that ED50 of fentanyl was 4.1 mu g/kg, whereas ED50 of butorphanol was 295 mu g/kg. The qualitative response rate of combination (P-o) was 0.84, and expected qualitative response rate (P-e) was 0.75, with no statistical significance (P = 0.3). Furthermore, probit analysis showed that 155 mu g/kg butorphanol with 1/4 ED50 fentanyl could reach experimental ED50 of combination of 2 drugs; 115 mu g/kg butorphanol with 1/2 ED50 fentanyl could reach experimental combination ED50; and 88 mu g/kg butorphanol with 3/4 ED50 fentanyl could reach experimental combination ED50. Conclusion: Both fentanyl and butorphanol showed good analgesic effect on incisional pain in rats, but fentanyl was superior to butorphanol. The pharmacological mechanism of combination with ED50 of fentanyl and butorphanol showed independent joint action, and the combination efficacy was related to the dosage. (C) 2016 Elsevier Inc. All rights reserved.	[Chen, Quan; Shang, You; Xu, Yong; Li, Ping; Liu, Guo-Li] Liaoning Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Renmin St,Abschnitt 5,2, Jinzhou 121001, Peoples R China; [Li, Ping; Li, Ping] Liaoning Med Univ, Affiliated Hosp 1, Dept Oncol, Renmin St,Abschnitt 5,2, Jinzhou 121001, Peoples R China	Liu, GL (reprint author), Liaoning Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Renmin St,Abschnitt 5,2, Jinzhou 121001, Peoples R China.; Li, P (reprint author), Liaoning Med Univ, Affiliated Hosp 1, Dept Oncol, Renmin St,Abschnitt 5,2, Jinzhou 121001, Peoples R China.	liping826_222@126.com; liuguoli_lgl@126.com			general education scientific research project of Liaoning Province [L2013324]	We would like to acknowledge the reviewers for their helpful comments on this paper. This article was funded by the general education scientific research project of Liaoning Province (no. L2013324).	Abrisham SMJ, 2014, KNEE SURG SPORT TR A, V22, P1580, DOI 10.1007/s00167-012-2287-9; Arora Vikramjeet, 2012, Int J Appl Basic Med Res, V2, P97, DOI 10.4103/2229-516X.106350; Bilotta F, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-170; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Brennan MC, 2012, BIRTH DEFECTS RES A, V94, P620, DOI 10.1002/bdra.23064; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Chari P, 2006, J CLIN ANESTH, V18, P8, DOI 10.1016/j.jclinane.2005.04.007; Chaudhury K, 2013, J TURK-GER GYNECOL A, V14, P225, DOI 10.5152/jtgga.2013.00378; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Fernandez-Duenas V, 2011, PHARMACOL BIOCHEM BE, V98, P331, DOI 10.1016/j.pbb.2011.01.023; Hwang IC, 2014, AM J HOSP PALLIAT ME, V31, P109, DOI 10.1177/1049909112474112; Kapfhamer KA, 2014, OBSTET GYNECOL, V123, p58S, DOI 10.1097/01.AOG.0000447358.78867.9c; Kaur J, 2014, SAUDI J ANAESTH, V8, P167, DOI 10.4103/1658-354X.130687; Kaur Jasleen, 2013, Saudi J Anaesth, V7, P128, DOI 10.4103/1658-354X.114052; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Michetti CP, 2012, J TRAUMA ACUTE CARE, V72, P924, DOI 10.1097/TA.0b013e3182479884; Miller M, 2011, J AM GERIATR SOC, V59, P430, DOI 10.1111/j.1532-5415.2011.03318.x; Niesters M, 2013, BRIT J ANAESTH, V110, P842, DOI 10.1093/bja/aet084; Ong CKS, 2010, ANESTH ANALG, V110, P1170, DOI 10.1213/ANE.0b013e3181cf9281; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; Salla K, 2014, VET ANAESTH ANALG, V41, P567, DOI 10.1111/vaa.12158; Schug SA, 2006, CLIN RHEUMATOL, V25, pS16, DOI 10.1007/s10067; Sibille KT, 2011, PAIN MED, V12, P1076, DOI 10.1111/j.1526-4637.2011.01157.x; Sinha Chandni, 2012, J Anaesthesiol Clin Pharmacol, V28, P32, DOI 10.4103/0970-9185.92431; Smith MA, 2009, J PHARMACOL EXP THER, V330, P468, DOI 10.1124/jpet.108.150011; Szabova Alexandra, 2010, J Opioid Manag, V6, P401; Tosun Z, 2008, PEDIATR ANESTH, V18, P43, DOI 10.1111/j.1460-9592.2007.02380.x; Troster A, 2012, CLIN J PAIN, V28, P705, DOI 10.1097/AJP.0b013e318241d948; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1346, DOI 10.1001/jama.2011.369; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Wolfert MZ, 2010, PAIN MED, V11, P425, DOI 10.1111/j.1526-4637.2009.00761.x; Wolff RF, 2012, PAIN MANAG, V2, P351, DOI [10.2217/PMT.12.22, 10.2217/pmt.12.22]; Younger JW, 2011, PAIN, V152, P1803, DOI 10.1016/j.pain.2011.03.028; Zhang W, 2011, MINERVA ANESTESIOL, V77, P33	34	4	5	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2016	28						67	73		10.1016/j.jclinane.2015.08.010			7	Anesthesiology	Anesthesiology	DC4MF	WOS:000369194300014	26440441				2020-06-30	J	Barletta, M; Kleine, SA; Hofmeister, EH; Thoresen, M; Peroni, JF; Knych, HK; Scharf, AM; Quandt, JE				Barletta, Michele; Kleine, Stephanie A.; Hofmeister, Erik H.; Thoresen, Merrilee; Peroni, John F.; Knych, Heather K.; Scharf, Alexandra M.; Quandt, Jane E.			Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							TRANSDERMALLY ADMINISTERED FENTANYL; MECHANICALLY VENTILATED GOATS; MAC-BAR; CARDIOVASCULAR-RESPONSES; SYMPATHETIC RESPONSES; ORTHOPEDIC-SURGERY; URINARY-BLADDER; SKIN INCISION; SEVOFLURANE; DOGS	OBJECTIVE To determine the minimum alveolar concentration that blunts adrenergic responses (MACBAR) for isoflurane and evaluate effects of fentanyl on isoflurane MACBAR in sheep. ANIMALS 13 healthy adult Dorset-cross adult ewes. PROCEDURES In a crossover design, each ewe was anesthetized 2 times for determination of isoflurane MACBAR. Anesthesia was induced with propofol administered IV. Sheep initially received fentanyl (5 mu g/kg, IV, followed by a constant rate infusion of 5 mu g/kg/h) or an equivalent volume of saline (0.9% NaCl) solution (control treatment). After a washout period of at least 8 days, the other treatment was administered. For MACBAR determination, a mechanical nociceptive stimulus (ie, sponge forceps) was applied at the coronary band for 1 minute. The MACBAR values of the 2 treatments were compared by means of a paired t test. During MACBAR determination, blood samples were collected for measurement of plasma fentanyl concentration. RESULTS Mean +/- SD isoflurane MACBAR of the fentanyl and control treatments was 1.70 +/- 0.28% and 1.79 +/- 0.35%, respectively; no significant difference was found between the 2 treatments. Plasma concentration of fentanyl reached a median steady-state concentration of 1.69 ng/mL (interquartile range [25th to 75th percentile], 1.47 to 1.79 ng/mL), which was maintained throughout the study. CONCLUSIONS AND CLINICAL RELEVANCE Administration of fentanyl at 5 mu g/kg, IV, followed by a constant rate infusion of the drug at 5 mu g/kg/h did not decrease isoflurane MACBAR. Further studies to determine the effect of higher doses of fentanyl on inhalation anesthetic agents and their potential adverse effects are warranted.	[Barletta, Michele; Thoresen, Merrilee; Peroni, John F.; Scharf, Alexandra M.] Univ Georgia, Dept Large Anim Med, Coll Vet Med, Athens, GA 30602 USA; [Kleine, Stephanie A.; Hofmeister, Erik H.; Quandt, Jane E.] Univ Georgia, Small Anim Med & Surg, Coll Vet Med, Athens, GA 30602 USA; [Knych, Heather K.] Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Davis, CA 95616 USA	Barletta, M (reprint author), Univ Georgia, Dept Large Anim Med, Coll Vet Med, Athens, GA 30602 USA.	mbarlett@uga.edu		Scharf, Alexandra/0000-0003-1270-0998; Kleine, Stephanie/0000-0002-2432-7492			Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; Ahern BJ, 2009, AM J VET RES, V70, P418, DOI 10.2460/ajvr.70.3.418; Albertin A, 2004, ANESTHESIOLOGY, V100, P255, DOI 10.1097/00000542-200402000-00012; ANTOGNINI JF, 1995, ANESTH ANALG, V81, P843, DOI 10.1097/00000539-199510000-00032; Bernards CM, 1996, ANESTHESIOLOGY, V85, P91, DOI 10.1097/00000542-199607000-00013; Bokesch PM, 2000, ANESTHESIOLOGY, V93, P202, DOI 10.1097/00000542-200007000-00031; Boscan P, 2010, BRIT J ANAESTH, V104, P330, DOI 10.1093/bja/aep377; BRETT CM, 1987, ANESTHESIOLOGY, V67, P60, DOI 10.1097/00000542-198707000-00011; CLABOUGH DL, 1989, AM J PHYSIOL, V257, pR1303; Criado AB, 2003, VET ANAESTH ANALG, V30, P250, DOI 10.1046/j.1467-2995.2003.00123.x; DALY MD, 1993, J PHYSIOL-LONDON, V463, P545, DOI 10.1113/jphysiol.1993.sp019610; Daniel M, 1998, ANESTHESIOLOGY, V88, P43, DOI 10.1097/00000542-199801000-00009; Davidson CD, 2004, JAVMA-J AM VET MED A, V224, P700, DOI 10.2460/javma.2004.224.700; Dixon MJ, 2010, LAB ANIM-UK, V44, P247, DOI 10.1258/la.2010.009080; Dzikiti BT, 2011, VET ANAESTH ANALG, V38, P44, DOI 10.1111/j.1467-2995.2010.00585.x; Dzikiti TB, 2011, VET REC, V168, DOI 10.1136/vr.d999; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; Hall LW, 2014, VET ANESTHESIA, P345; HASSAN AAM, 1987, Q J EXP PHYSIOL CMS, V72, P1; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; Katoh T, 2000, BRIT J ANAESTH, V84, P63; Knych HKD, 2009, AM J VET RES, V70, P1193, DOI 10.2460/ajvr.70.10.1193; Koch HJ, 2001, INT J CLIN PRACT, V55, P323; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; LEEK BF, 1983, VET REC, V113, P10, DOI 10.1136/vr.113.1.10; Love L, 2011, VET ANAESTH ANALG, V38, P292, DOI 10.1111/j.1467-2995.2011.00616.x; Luis-Delgado OE, 2006, J PAIN, V7, P32, DOI 10.1016/j.jpain.2005.07.011; March PA, 2003, AM J VET RES, V64, P1528, DOI 10.2460/ajvr.2003.64.1528; MCGUIRK SM, 1990, J AM VET MED ASSOC, V196, P894; Musk GC, 2014, VET ANAESTH ANALG, V41, P305, DOI 10.1111/vaa.12103; NOLAN A, 1987, J PHARMACOL METHOD, V17, P39, DOI 10.1016/0160-5402(87)90035-0; Okutomi T, 2009, J ANESTH, V23, P392, DOI 10.1007/s00540-009-0763-2; PALAHNIUK RJ, 1974, ANESTHESIOLOGY, V41, P82, DOI 10.1097/00000542-197407000-00021; Puri GD, 2011, J CLIN MONIT COMPUT, V25, P309, DOI 10.1007/s10877-011-9309-x; RIEBOLD TW, 2007, [No title captured], P731; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ROIZEN MF, 1981, ANESTHESIOLOGY, V54, P390, DOI 10.1097/00000542-198105000-00008; RUCKEBUSCH Y, 1984, LIFE SCI, V35, P1731, DOI 10.1016/0024-3205(84)90269-8; Rudolff AS, 2014, VET ANAESTH ANALG, V41, P386, DOI 10.1111/vaa.12118; Seddighi R, 2012, AM J VET RES, V73, P341, DOI 10.2460/ajvr.73.3.341; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; Trumpatori BJ, 2010, VET SURG, V39, P785, DOI 10.1111/j.1532-950X.2010.00712.x; Ueyama Y, 2009, AM J VET RES, V70, P1459, DOI 10.2460/ajvr.70.12.1459; WATERMAN AE, 1990, VET ANAESTH ANALG, V17, P20; Wilson D, 2006, JAVMA-J AM VET MED A, V228, P1042, DOI 10.2460/javma.228.7.1042; Yackey M, 2004, VET ANAESTH ANALG, V31, P183, DOI 10.1111/j.1467-2987.2004.00125.x; YAMAGUCHI YOICHI, 1964, KEIO J MED, V13, P87; Yamashita K, 2012, J VET MED SCI, V74, P507, DOI 10.1292/jvms.11-0274	52	2	2	0	14	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	FEB	2016	77	2					119	126		10.2460/ajvr.77.2.119			8	Veterinary Sciences	Veterinary Sciences	DC4CM	WOS:000369167600011	27027704				2020-06-30	J	Robleda, G; Roche-Campo, F; Sendra, MA; Navarro, M; Castillo, A; Rodriguez-Arias, A; Juanes-Borrego, E; Gich, I; Urrutia, G; Nicolas-Arfelis, JM; Puntillo, K; Mancebo, J; Banos, JE				Robleda, Gemma; Roche-Campo, Ferran; Sendra, Maria-Angels; Navarro, Marta; Castillo, Ana; Rodriguez-Arias, Ainhoa; Juanes-Borrego, Elena; Gich, Ignasi; Urrutia, Gerard; Nicolas-Arfelis, Jose M.; Puntillo, Kathleen; Mancebo, Jordi; Banos, Josep-E.			Fentanyl as pre-emptive treatment of pain associated with turning mechanically ventilated patients: a randomized controlled feasibility study	INTENSIVE CARE MEDICINE			English	Article						Turning; Pain; Pre-emptive analgesia; Behavioral pain scale; Mechanical ventilation; Intensive care unit	INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; CONTROLLED-TRIAL; ANALGESIA; BOLUS; SEDATION; SUCTION; ADULTS; ICU	Purpose: To compare pain incidence and changes in pain scores with fentanyl versus placebo as pre-emptive treatment during turning and 30 min post-turning in mechanically ventilated critically ill patients. Methods: We performed a randomized, double-blind, parallel-group, placebo-controlled clinical trial in the intensive care unit of a university hospital. Seventy-five mechanically ventilated patients were randomized to an intervention group (fentanyl) or a control group (placebo). Patients in the intervention group received 1 A mu g/kg (medical patients) or 1.5 A mu g/kg (surgical patients) of fentanyl 10 min before turning. Pain indicators were assessed using the behavioral pain scale. Safety was assessed by determining the frequency and severity of pre-defined adverse events. Pain was evaluated at rest (T0), at turn start and end (T1 and T2) and at 5, 15 and 30 min post-turning (T3, T4 and T5). Results: The two groups had similar baseline characteristics. The area under the curve for BPS values was significantly smaller in the fentanyl group than in the control group [median and interquartile range (IQR): 132 (108-150) vs. 147 (125-180); p = 0.016, respectively]. Nineteen non-serious adverse events were recorded in 14 patients, with no significant between-group differences (23 % fentanyl group vs. 14 % control group; p = 0.381). Conclusions: These results suggest an intravenous bolus of fentanyl of 1 A mu g/kg for medical patients or 1.5 A mu g/kg for surgical patients reduces the incidence of turning-associated pain in critically ill patients on mechanical ventilation.	[Robleda, Gemma] Hosp Santa Creu & Sant Pau, Dept Nursing Res, St Antoni Ma Claret 167, Barcelona 08025, Spain; [Roche-Campo, Ferran; Sendra, Maria-Angels; Navarro, Marta; Castillo, Ana; Mancebo, Jordi] Hosp Santa Creu & Sant Pau, Intens Care Unit, Barcelona, Spain; [Roche-Campo, Ferran] Hosp Tortosa Verge Cinta, Intens Care Unit, Tarragona, Spain; [Rodriguez-Arias, Ainhoa; Juanes-Borrego, Elena] Hosp Santa Creu & Sant Pau, Dept Pharm, Barcelona, Spain; [Gich, Ignasi; Urrutia, Gerard] IIB St Pau, Dept Clin Epidemiol & Publ Hlth, Barcelona, Spain; [Gich, Ignasi; Urrutia, Gerard] CIBERESP, Barcelona, Spain; [Gich, Ignasi] Univ Autonoma Barcelona, E-08193 Barcelona, Spain; [Nicolas-Arfelis, Jose M.] Hosp Clin Barcelona, Intens Care Unit, Barcelona, Spain; [Puntillo, Kathleen] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA; [Banos, Josep-E.] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain	Robleda, G (reprint author), Hosp Santa Creu & Sant Pau, Dept Nursing Res, St Antoni Ma Claret 167, Barcelona 08025, Spain.	grobleda@santpau.cat	Banos, Josep-E/D-8118-2014; Robleda, Gemma/AAG-4467-2020	Robleda, Gemma/0000-0003-3301-1171; Urrutia, Gerard/0000-0002-8850-0960; banos, josep-e/0000-0001-8202-6893; Gich, Ignasi/0000-0003-3975-6588			Ahlers SJGM, 2012, ANAESTH INTENS CARE, V40, P417, DOI 10.1177/0310057X1204000306; Arroyo-Novoa Carmen Mabel, 2008, Intensive Crit Care Nurs, V24, P20, DOI 10.1016/j.iccn.2007.05.002; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Brocas E, 2002, INTENS CARE MED, V28, P211, DOI 10.1007/s00134-001-1189-y; Casey E, 2010, INTENS CARE MED, V36, P1380, DOI 10.1007/s00134-010-1836-2; Celis-Rodriguez E, 2013, MED INTENSIVA, V37, P519, DOI 10.1016/j.medin.2013.04.001; Chanques G, 2007, ANESTHESIOLOGY, V107, P858, DOI 10.1097/01.anes.0000287211.98642.51; Chaveron D, 2012, EUR J ANAESTH, V29, P280, DOI 10.1097/EJA.0b013e328352234d; de Jong A, 2013, CRIT CARE, V17, DOI 10.1186/cc12683; Fulton T R, 2000, Am J Crit Care, V9, P125; Gelinas C, 2014, INTENS CARE MED, V40, P1009, DOI 10.1007/s00134-014-3299-3; Gelinas C, 2013, SEMIN RESP CRIT CARE, V34, P153, DOI 10.1055/s-0033-1342970; Granja C, 2008, CRIT CARE MED, V36, P2801, DOI 10.1097/CCM.0b013e318186a3e7; Haynes JM, 2015, RESP CARE, V60, P1, DOI 10.4187/respcare.03312; Martin J, 2006, INTENS CARE MED, V32, P1137, DOI 10.1007/s00134-006-0214-6; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Payen JF, 2009, ANESTHESIOLOGY, V111, P1308, DOI 10.1097/ALN.0b013e3181c0d4f0; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Puntillo K A, 2001, Am J Crit Care, V10, P238; Puntillo KA, 2002, AM J CRIT CARE, V11, P415, DOI 10.4037/ajcc2002.11.5.415; Puntillo KA, 2002, HEART LUNG, V31, P303, DOI 10.1067/mhl.2002.125652; Puntillo KA, 2014, AM J RESP CRIT CARE, V189, P39, DOI 10.1164/rccm.201306-1174OC; Robleda G, 2016, MED INTENSIVA, V40, P96, DOI 10.1016/j.medin.2015.03.004; Vazquez M, 2011, NURS CRIT CARE, V16, P178, DOI 10.1111/j.1478-5153.2011.00436.x; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; Yiannakopoulos CK, 2004, ORTHOPEDICS, V27, P412; Young Jeanne, 2006, Intensive Crit Care Nurs, V22, P32, DOI 10.1016/j.iccn.2005.04.004	27	10	13	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	FEB	2016	42	2					183	191		10.1007/s00134-015-4112-7			9	Critical Care Medicine	General & Internal Medicine	DB7UM	WOS:000368722000005	26556618				2020-06-30	J	Prin, M; Guglielminotti, J; Moitra, V; Li, GH				Prin, Meghan; Guglielminotti, Jean; Moitra, Vivek; Li, Guohua			Prophylactic Ondansetron for the Prevention of Intrathecal Fentanyl- or Sufentanil-Mediated Pruritus: A Meta-Analysis of Randomized Trials	ANESTHESIA AND ANALGESIA			English	Article							LOW-DOSE BUPIVACAINE; OPIOID-INDUCED PRURITUS; SPINAL-ANESTHESIA; CESAREAN DELIVERY; TRANSURETHRAL RESECTION; RECEPTOR ANTAGONISTS; MORPHINE; COMBINATION; SURGERY; LEVOBUPIVACAINE	BACKGROUND: Pruritus is a common side effect of intrathecal fentanyl or sufentanil that decreases patient satisfaction and may delay hospital discharge. There are conflicting reports about the efficacy of prophylactic ondansetron in reducing the incidence of pruritus. This meta-analysis aimed to assess the effect of prophylactic ondansetron on the incidence of intrathecal fentanyl- or sufentanil-mediated pruritus and the need for rescue treatment. METHODS: A systematic search on PubMed, Medline, and the Cochrane Central Register of Controlled Trials from January 1, 1994, to January 1, 2014, was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Randomized controlled trials evaluating the efficacy of prophylactic ondansetron on pruritus associated with intrathecal fentanyl or sufentanil were included. The primary outcome was the incidence of pruritus, and the secondary outcome was patients' need for rescue therapy. Sensitivity analyses were conducted to assess the outcomes in obstetric and nonobstetric patients and in patients who received ondansetron before or after intrathecal opioid injection. Analyses used random-effect models. RESULTS: Six randomized controlled trials involving 555 patients were included. In the overall analysis, prophylactic ondansetron did not significantly decrease the incidence of pruritus, but there was a trend toward reduced rescue medication use (risk ratio [RR], 0.57; 95% confidence interval [CI], 0.35-0.91; I-2 = 0%; P = 0.02). Exploratory subgroups, including nonobstetric surgery patients and patients who received ondansetron before spinal opioid administration, also suggest a trend toward less rescue medication use (RR, 0.47; 95% CI, 0.26-0.85; P = 0.01; and RR, 0.62; 95% CI, 0.38-1.00; P = 0.05). CONCLUSIONS: IV 8 mg prophylactic ondansetron does not decrease the incidence of fentanyl- or sufentanil-mediated pruritus but may decrease the need for pruritus rescue medication, particularly in specific subgroups. Randomized trials are needed to confirm these results.	[Prin, Meghan; Guglielminotti, Jean; Moitra, Vivek; Li, Guohua] Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, 622 West 168th St,PH 5-527D, New York, NY 10032 USA; [Guglielminotti, Jean] Hop Bichat Claude Bernard, AP HP, Dept Anesthesie Reanimat, F-75877 Paris 18, France; [Guglielminotti, Jean] INSERM, IAME, UMR 1137, Paris, France; [Li, Guohua] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	Prin, M (reprint author), Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, 622 West 168th St,PH 5-527D, New York, NY 10032 USA.	mep9042@nyp.org					Akan B, 2013, J RES MED SCI, V18, P378; Akcaboy ZN, 2012, REV BRAS ANESTESIOL, V62, P753, DOI 10.1016/S0034-7094(12)70176-9; Akkamahadevi P, 2012, INDIAN J ANAESTH, V56, P365, DOI 10.4103/0019-5049.100819; Alley Elizabeth A, 2014, Anesthesiol Clin, V32, P357, DOI 10.1016/j.anclin.2014.02.007; American Hospital Association, 2006, TREND WATCH; Arzola C, 2011, BRIT J ANAESTH, V107, P308, DOI 10.1093/bja/aer200; Bachmann M, 2012, EUR J ANAESTH, V29, P22, DOI 10.1097/EJA.0b013e32834a11be; BALLANTYNE JC, 1988, PAIN, V33, P149, DOI 10.1016/0304-3959(88)90085-1; Bernards CM, 2003, ANESTHESIOLOGY, V99, P455, DOI 10.1097/00000542-200308000-00029; Bogra J, 2005, BMC ANESTHESIOL, V5, P5, DOI DOI 10.1186/1471-2253-5-5; Bonnet MP, 2008, BRIT J ANAESTH, V101, P311, DOI 10.1093/bja/aen202; Bozdogan Ozyilkan Nesrin, 2013, Curr Ther Res Clin Exp, V75, P64, DOI 10.1016/j.curtheres.2013.09.003; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Cohen SE, 1998, ANESTHESIOLOGY, V89, P1559, DOI 10.1097/00000542-199812000-00036; Colbert S, 1999, ANAESTHESIA, V54, P948, DOI 10.1046/j.1365-2044.1999.01066.x; Forster JG, 2014, CURR OPIN ANESTHESIO, V27, P597, DOI 10.1097/ACO.0000000000000126; Gebhardt V, 2013, ACTA ANAESTH SCAND, V57, P249, DOI 10.1111/aas.12031; George RB, 2009, ANESTH ANALG, V109, P174, DOI 10.1213/ane.0b013e3181a45a6b; Gulhas N, 2007, J ANESTH, V21, P159, DOI 10.1007/s00540-007-0503-4; Gupta Shikha, 2013, J Anaesthesiol Clin Pharmacol, V29, P509, DOI 10.4103/0970-9185.119158; Gurkan Y, 2002, ANESTH ANALG, V95, P1763, DOI 10.1213/01.ANE.0000033097.30674.02; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Hindle A, 2008, BJA EDUC, V8, P81, DOI 10.1093/bjaceaccp/mkn016; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Koenig L, 2009, ANAL RECENT GROWTH A; Kolm André, 2006, Rev. Bras. Anestesiol., V56, P28, DOI 10.1590/S0034-70942006000100004; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P1292, DOI 10.1046/j.1399-6576.2003.00206.x; Kumar Kamal, 2013, J Anaesthesiol Clin Pharmacol, V29, P303, DOI 10.4103/0970-9185.117045; Kyriakides K, 1999, BRIT J ANAESTH, V82, P439, DOI 10.1093/bja/82.3.439; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Motiani Poonam, 2011, J Anaesthesiol Clin Pharmacol, V27, P67; Bujedo BM, 2014, PAIN PRACT, V14, P350, DOI 10.1111/papr.12099; Nair GS, 2009, BRIT J ANAESTH, V102, P307, DOI 10.1093/bja/aen389; Popping DM, 2013, PAIN, V154, P1383, DOI 10.1016/j.pain.2013.04.023; Rimoin LP, 2013, DERMATOL THER, V26, P157, DOI 10.1111/dth.12034; Roofthooft E, 2008, CURR OPIN ANESTHESIO, V21, P259, DOI 10.1097/ACO.0b013e3282ff5e41; Sarvela PJ, 2006, ACTA ANAESTH SCAND, V50, P239, DOI 10.1111/j.1399-6576.2006.00934.x; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; Toomey Matthew, 2006, AANA J, V74, P379; TORN K, 1994, BRIT J ANAESTH, V73, P411, DOI 10.1093/bja/73.3.411; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; Unal D, 2012, J PAK MED ASSOC, V62, P313; Waxler B, 2004, CAN J ANAESTH, V51, P685, DOI 10.1007/BF03018426; Wells J, 2004, INT J OBSTET ANESTH, V13, P35, DOI 10.1016/j.ijoa.2003.07.001; Yazigi A, 2002, J CLIN ANESTH, V14, P183, DOI 10.1016/S0952-8180(01)00381-6; Youssef N, 2014, ANESTH ANALG, V119, P965, DOI 10.1213/ANE.0000000000000377; Zand F, 2015, PAIN PRACT, V15, P348, DOI 10.1111/papr.12185	47	3	5	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2016	122	2					402	409		10.1213/ANE.0000000000001046			8	Anesthesiology	Anesthesiology	DB6SU	WOS:000368646100003	26505578				2020-06-30	J	Mauermann, E; Filitz, J; Dolder, P; Rentsch, KM; Bandschapp, O; Ruppen, W				Mauermann, Eckhard; Filitz, Joerg; Dolder, Patrick; Rentsch, Katharina M.; Bandschapp, Oliver; Ruppen, Wilhelm			Does Fentanyl Lead to Opioid-induced Hyperalgesia in Healthy Volunteers? A Double-blind, Randomized, Crossover Trial	ANESTHESIOLOGY			English	Article							REMIFENTANIL-INDUCED ANALGESIA; INDUCED POSTOPERATIVE HYPERALGESIA; SHORT-TERM INFUSION; SMALL-DOSE KETAMINE; HUMAN PAIN MODEL; CENTRAL SENSITIZATION; ACUTE TOLERANCE; HUMAN SKIN; POSTINFUSION HYPERALGESIA; WITHDRAWAL HYPERALGESIA	Background: Although opioids in general and remifentanil in particular have been shown to induce hyperalgesia, data regarding fentanyl are scarce. Thus, the authors investigated the effect of fentanyl dosing on pain perception and central sensitization in healthy volunteers using established pain models. Methods: Twenty-one healthy, male volunteers were included in this randomized, double-blind, crossover study and received either intravenous low-dose (1 g/kg) or high-dose (10 g/kg) fentanyl. Pain intensities and hyperalgesia were assessed by intracutaneous electrical stimulation, and cold pressor pain was used as an additional measure of acute pain. The primary outcome was hyperalgesia from 4.5 to 6.5 h after fentanyl administration. Results: A higher dose of fentanyl led to significantly decreased pain scores as measured by the numeric rating scale (0.83 units lower [95% CI, 0.63 to 1.02]; P < 0.001) but increased areas of hyperalgesia (+30.5% [95% CI, 16.6 to 44.4%]; P < 0.001) from 4.5 to 6.5 h after fentanyl administration. Allodynia did not differ between groups (+4.0% [95% CI, -15.4 to 23.5%]; P = 0.682).The high dose also led to both increased cold pressor pain threshold (+43.0% [95% CI, 29.7 to 56.3%]; P < 0.001) and tolerance (+32.5% [95% CI, 21.7 to 43.4%]; P < 0.001) at 4.5 to 6.5h. In the high-dose group, 19 volunteers (90%) required reminders to breathe, 8 (38%) required supplemental oxygen, and 12 (57%) experienced nausea. Conclusions: A higher dose of fentanyl increased hyperalgesia from 4.5 to 6.5 h in healthy volunteers while simultaneously decreasing pain scores.	[Mauermann, Eckhard; Bandschapp, Oliver; Ruppen, Wilhelm] Univ Basel Hosp, Dept Anesthesia Surg Intens Care Prehosp Emergenc, Spitalstr 21, CH-4031 Basel, Switzerland; [Filitz, Joerg] Univ Hosp Hannover, Dept Anesthesiol, Hannover, Germany; [Dolder, Patrick; Rentsch, Katharina M.] Univ Basel Hosp, Dept Lab Med, CH-4031 Basel, Switzerland	Mauermann, E (reprint author), Univ Basel Hosp, Dept Anesthesia Surg Intens Care Prehosp Emergenc, Spitalstr 21, CH-4031 Basel, Switzerland.	eckhard.mauermann@usb.ch		Dolder, Patrick/0000-0002-0952-3356	Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital of Basel, Basel, Switzerland	Support was provided solely from institutional and/or departmental sources (Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital of Basel, Basel, Switzerland).	Angst MS, 2015, J CARDIOTHOR VASC AN, V29, pS16, DOI 10.1053/j.jvca.2015.01.026; Angst MS, 2012, PAIN, V153, P1397, DOI 10.1016/j.pain.2012.02.022; Angst MS, 2009, PAIN, V142, P17, DOI 10.1016/j.pain.2008.11.001; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; ARNER S, 1988, ACTA ANAESTH SCAND, V32, P253, DOI 10.1111/j.1399-6576.1988.tb02725.x; Bandschapp O, 2011, PAIN, V152, P1304, DOI 10.1016/j.pain.2011.02.003; Bandschapp O, 2010, ANESTHESIOLOGY, V113, P421, DOI 10.1097/ALN.0b013e3181e33ac8; Bartley EJ, 2013, BRIT J ANAESTH, V111, P52, DOI 10.1093/bja/aet127; Bekhit MH, 2010, AM J THER, V17, P498, DOI 10.1097/MJT.0b013e3181ed83a0; Bodnar RJ, 2010, HORM BEHAV, V58, P72, DOI 10.1016/j.yhbeh.2009.09.012; Burke SM, 2010, ANESTH ANALG, V110, P1180, DOI 10.1213/ANE.0b013e3181cf949a; Carvalho B, 2012, INT J OBSTET ANESTH, V21, P29, DOI 10.1016/j.ijoa.2011.09.002; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; CHERYCROZE S, 1983, PAIN, V15, P265, DOI 10.1016/0304-3959(83)90061-1; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Cintron A, 2006, J PALLIAT MED, V9, P1454, DOI 10.1089/jpm.2006.9.1454; Collard V, 2007, ANESTH ANALG, V105, P1255, DOI 10.1213/01.ane.0000282822.07437.02; Compton P, 2004, PHARMACOL BIOCHEM BE, V77, P263, DOI 10.1016/j.pbb.2003.10.017; Compton P, 2003, J PAIN, V4, P511, DOI 10.1016/j.jpain.2003.08.003; Compton P, 2012, J PAIN, V13, P401, DOI 10.1016/j.jpain.2012.01.001; Cooper DW, 1997, BRIT J ANAESTH, V78, P311; Cooper DW, 2002, ANAESTHESIA, V57, P266, DOI 10.1046/j.1365-2044.2002.2366_1.x; Cortinez LI, 2001, BRIT J ANAESTH, V87, P866, DOI 10.1093/bja/87.6.866; De Kock M, 2005, ANESTH ANALG, V101, P566, DOI 10.1213/01.ANE.0000157121.71808.04; De Kock M, 2001, PAIN, V92, P373, DOI 10.1016/S0304-3959(01)00278-0; DEJALON PDG, 1985, PAIN, V22, P183, DOI 10.1016/0304-3959(85)90178-2; Dolder PC, 2015, ANAL BIOANAL CHEM, V407, P1577, DOI 10.1007/s00216-014-8388-1; Eisenach JC, 2006, REGION ANESTH PAIN M, V31, P1, DOI 10.1016/j.rapm.2005.11.008; Farrell MJ, 2012, PAIN MED, V13, pS37, DOI 10.1111/j.1526-4637.2011.01287.x; Fishbain DA, 2009, PAIN MED, V10, P829, DOI 10.1111/j.1526-4637.2009.00653.x; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Gagliese L, 2009, J PAIN, V10, P343, DOI 10.1016/j.jpain.2008.10.013; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Gustorff B, 2002, ANESTH ANALG, V94, P1223, DOI 10.1097/00000539-200205000-00032; Hansen EG, 2005, ACTA ANAESTH SCAND, V49, P1464, DOI 10.1111/j.1399-6576.2005.00861.x; Hood DD, 2003, ANESTH ANALG, V97, P810, DOI 10.1213/01.ANE.0000078811.80093.88; Hwang IC, 2014, ANESTHESIOLOGY, V121, P825, DOI 10.1097/ALN.0000000000000405; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Kim SH, 2013, ANESTHESIOLOGY, V118, P337, DOI 10.1097/ALN.0b013e31827bd108; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Koppert W, 2003, PAIN, V106, P91, DOI 10.1016/S0304-3959(03)00294-X; Koppert W, 2001, ANESTHESIOLOGY, V95, P395, DOI 10.1097/00000542-200108000-00022; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Laulin JP, 1999, NEUROSCIENCE, V89, P631, DOI 10.1016/S0306-4522(98)00652-6; Lavand'homme P, 2005, ANESTHESIOLOGY, V103, P813, DOI 10.1097/00000542-200510000-00020; Lee A, 1997, ANAESTH INTENS CARE, V25, P665, DOI 10.1177/0310057X9702500613; Lee LHY, 2005, ANESTHESIOLOGY, V102, P398, DOI 10.1097/00000542-200502000-00024; Li XQ, 2001, MOL BRAIN RES, V86, P56, DOI 10.1016/S0169-328X(00)00260-6; Luginbuhl M, 2003, ANESTH ANALG, V96, P726, DOI 10.1213/01.ANE.0000048086.58161.18; Mathiesen O, 2009, ACTA ANAESTH SCAND, V53, P227, DOI 10.1111/j.1399-6576.2008.01821.x; Orstavik K, 2003, BRAIN, V126, P567, DOI 10.1093/brain/awg060; Paller CJ, 2009, PAIN MED, V10, P289, DOI 10.1111/j.1526-4637.2008.00558.x; Petersen KL, 2001, ANESTHESIOLOGY, V94, P15, DOI 10.1097/00000542-200101000-00008; Remerand F, 2009, ANESTH ANALG, V109, P1963, DOI 10.1213/ANE.0b013e3181bdc8a0; Richebe P, 2011, J CARDIOTHOR VASC AN, V25, P917, DOI 10.1053/j.jvca.2011.03.185; Richebe P, 2009, CAN J ANAESTH, V56, P126, DOI 10.1007/s12630-008-9023-4; Sadhasivam S, 2012, PHARMACOGENOMICS, V13, P1719, DOI [10.2217/PGS.12.152, 10.2217/pgs.12.152]; Salengros JC, 2010, J CARDIOTHOR VASC AN, V24, P608, DOI 10.1053/j.jvca.2009.10.006; SCHMELZ M, 1994, J PHYSIOL-LONDON, V480, P389, DOI 10.1113/jphysiol.1994.sp020368; Sen H, 2009, EUR J ANAESTH, V26, P772, DOI 10.1097/EJA.0b013e32832ad2fa; Sen H, 2009, ANESTH ANALG, V109, P1645, DOI 10.1213/ANE.0b013e3181b65ea0; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Singla A, 2007, ANESTH ANALG, V105, P1816, DOI 10.1213/01.ane.0000290338.39037.38; Song JW, 2011, ANESTH ANALG, V113, P390, DOI 10.1213/ANE.0b013e31821d72bc; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P1124, DOI 10.1111/j.1399-6576.1997.tb04854.x; Suzan E, 2013, PAIN PHYSICIAN, V16, P65; Troster A, 2006, ANESTHESIOLOGY, V105, P1016; Troster A, 2012, CLIN J PAIN, V28, P705, DOI 10.1097/AJP.0b013e318241d948; Van Elstraete AC, 2008, ANESTHESIOLOGY, V108, P484, DOI 10.1097/ALN.0b013e318164cf85; Van Elstraete AC, 2011, ANESTH ANALG, V113, P634, DOI 10.1213/ANE.0b013e3182222b59; van Gulik L, 2012, BRIT J ANAESTH, V109, P616, DOI 10.1093/bja/aes247; Weidner C, 1999, J NEUROSCI, V19, P10184; White PF, 2003, ANESTH ANALG, V97, P1633, DOI 10.1213/01.ANE.0000085296.07006.BA; Wilder-Smith OHG, 2005, EUR J PAIN, V9, P137, DOI 10.1016/j.ejpain.2004.07.011; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Zollner C, 2010, ANAESTHESIST, V59, P983, DOI 10.1007/s00101-010-1803-x	77	31	33	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	FEB	2016	124	2					453	463		10.1097/ALN.0000000000000976			11	Anesthesiology	Anesthesiology	DB5FP	WOS:000368540300022	26655493				2020-06-30	J	Chatterjee, D; Agarwal, R; Bajaj, L; Teng, SN; Prager, JD				Chatterjee, Debnath; Agarwal, Rita; Bajaj, Lalit; Teng, Sarena N.; Prager, Jeremy D.			Airway management in laryngotracheal injuries from blunt neck trauma in children	PEDIATRIC ANESTHESIA			English	Review						pediatric laryngotracheal injuries; blunt neck trauma; tracheal transection; laryngotracheal separation; airway management		Pediatric laryngotracheal injuries from blunt neck trauma are extremely rare, but can be potentially catastrophic. Early diagnosis and skillful airway management is critical in avoiding significant morbidity and mortality associated with these cases. We present a case of a patient who suffered a complete tracheal transection and cervical spine fracture following a clothesline injury to the anterior neck. A review of the mechanisms of injury, clinical presentation, initial airway management, and anesthetic considerations in laryngotracheal injuries from blunt neck trauma in children are presented.	[Chatterjee, Debnath] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Anesthesiol, Aurora, CO 80045 USA; [Agarwal, Rita] Stanford Univ, Lucile Packard Childrens Hosp, Dept Anesthesiol, Palo Alto, CA 94304 USA; [Bajaj, Lalit] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Emergency Med, Aurora, CO 80045 USA; [Teng, Sarena N.] Ochsner Hosp Children, Dept Anesthesiol, New Orleans, LA USA; [Prager, Jeremy D.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Otolaryngol, Aurora, CO 80045 USA	Chatterjee, D (reprint author), Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Anesthesiol, 13123 East 16th Ave,B090, Aurora, CO 80045 USA.	debnath.chatterjee@childrenscolorado.org	Agarwal, Rita/AAB-2378-2020				Breckwoldt J, 2011, RESUSCITATION, V82, P1519, DOI 10.1016/j.resuscitation.2011.06.028; Deakin C D, 1996, Eur J Emerg Med, V3, P233, DOI 10.1097/00063110-199612000-00004; FUHRMAN GM, 1990, J TRAUMA, V30, P87, DOI 10.1097/00005373-199001000-00014; Gold SM, 1997, ARCH OTOLARYNGOL, V123, P83; GUSSACK GS, 1986, LARYNGOSCOPE, V96, P660; Hamid Umar Imran, 2013, J Emerg Trauma Shock, V6, P117, DOI 10.4103/0974-2700.110774; KIRSH MM, 1976, ANN THORAC SURG, V22, P93, DOI 10.1016/S0003-4975(10)63961-6; Mandell DL, 2005, CLIN PEDIATR EMERG M, V6, P41, DOI 10.1016/j.cpem.2004.12.004; Oosthuizen J C, 2011, Int J Otolaryngol, V2011, P183047, DOI 10.1155/2011/183047; SCHAEFER SD, 1982, ANN OTO RHINOL LARYN, V91, P399, DOI 10.1177/000348948209100416; SCHAEFER SD, 1992, ARCH OTOLARYNGOL, V118, P598; Schaefer SD, 2014, LARYNGOSCOPE, V124, P233, DOI 10.1002/lary.24068; Sidell D, 2011, ANN OTO RHINOL LARYN, V120, P787, DOI 10.1177/000348941112001204; Wootten CT, 2009, INT J PEDIATR OTORHI, V73, P1071, DOI 10.1016/j.ijporl.2009.02.025	14	3	3	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	FEB	2016	26	2					132	138		10.1111/pan.12791			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	DA4RT	WOS:000367788700003	26530711				2020-06-30	J	Bobeck, EN; Ingram, SL; Hermes, SM; Aicher, SA; Morgan, MM				Bobeck, Erin N.; Ingram, Susan L.; Hermes, Sam M.; Aicher, Sue A.; Morgan, Michael M.			Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance	BEHAVIOURAL BRAIN RESEARCH			English	Article						Analgesia; Periaqueductal gray; Functional selectivity; ERK1/2	VENTROLATERAL PERIAQUEDUCTAL GRAY; NEUROBLASTOMA SH-SY5Y CELLS; ELEMENT-BINDING-PROTEIN; MORPHINE-WITHDRAWAL; BETA-2-ADRENERGIC RECEPTOR; ANALGESIC TOLERANCE; DIFFERENT EFFICACY; CHOLERA TOXINS; ERK ACTIVATION; MU	Opioids produce antinociception by activation of G protein signaling linked to the mu-opioid receptor (MOPr). However, opioid binding to the MOPr also activates beta-arrestin signaling. Opioids such as DAMGO and fentanyl differ in their relative efficacy for activation of these signaling cascades, but the behavioral consequences of this differential signaling are not known. The purpose of this study was to evaluate the behavioral significance of G protein and internalization dependent signaling within ventrolateral periaqueductal gray (v1PAG). Antinociception induced by microinjecting DAMGO into the v1PAG was attenuated by blocking G alpha(i/o) protein signaling with administration of pertussis toxin (PTX), preventing internalization with administration of dynamin dominant-negative inhibitory peptide (dyn-DN) or direct inhibition of ERK1/2 with administration of the MEK inhibitor, U0126. In contrast, the antinociceptive effect of microinjecting fentanyl into the v1PAG was not altered by administration of PTX or U0126, and was enhanced by administration of dyn-DN. Microinjection of DAMGO, but not fentanyl, into the vIPAG induced phosphorylation of ERK1/2, which was blocked by inhibiting receptor internalization with administration of dyn-DN, but not by inhibition of G alpha(i/o) proteins. ERK1/2 inhibition also prevented the development and expression of tolerance to repeated DAMGO microinjections, but had no effect on fentanyl tolerance. These data reveal that ERK1/2 activation following MOPr internalization contributes to the antinociceptive effect of some (e.g., DAMGO), but not all opioids (e.g., fentanyl) despite the known similarities for these agonists to induce beta-arrestin recruitment and internalization. (C) 2015 Elsevier B.V. All rights reserved.	[Bobeck, Erin N.; Morgan, Michael M.] Washington State Univ, Dept Psychol, Vancouver, WA 98686 USA; [Ingram, Susan L.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA; [Hermes, Sam M.; Aicher, Sue A.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA	Bobeck, EN (reprint author), Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, One Gustave L Levy Pl, New York, NY 10029 USA.	erin.bobeck@mssm.edu	Bobeck, Erin/I-8839-2019	Bobeck, Erin/0000-0001-8421-883X	National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA015498, DA027625]; State of Washington Initiative Measure [171]	This study was supported in part by the National Institute of Drug Abuse (DA015498; DA027625) and by funds provided for medical and biological research by the State of Washington Initiative Measure No. 171. The authors would like to thank Shauna Schoo, Rachel Reid, and Davina Fitzgibbon for technical assistance.	AMMER H, 1993, BIOCHEM J, V295, P263, DOI 10.1042/bj2950263; Belcheva MM, 2005, J BIOL CHEM, V280, P27662, DOI 10.1074/jbc.M502593200; Bilecki W, 2005, CELL MOL LIFE SCI, V62, P2369, DOI 10.1007/s00018-005-5277-y; Bobeck EN, 2012, J PAIN, V13, P799, DOI 10.1016/j.jpain.2012.05.005; Bobeck EN, 2009, PAIN, V147, P210, DOI 10.1016/j.pain.2009.09.008; BODNAR RJ, 1990, BRAIN RES, V529, P324, DOI 10.1016/0006-8993(90)90845-3; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; Cao JL, 2010, P NATL ACAD SCI USA, V107, P17011, DOI 10.1073/pnas.1010077107; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Christie MJ, 2008, BRIT J PHARMACOL, V154, P384, DOI 10.1038/bjp.2008.100; Ciccarelli A, 2013, NEUROPHARMACOLOGY, V70, P168, DOI 10.1016/j.neuropharm.2012.12.010; Costantino CM, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/erm.2012.5; DEPAULIS A, 1987, BRAIN RES, V436, P223, DOI 10.1016/0006-8993(87)91665-9; Drake MT, 2008, J BIOL CHEM, V283, P5669, DOI 10.1074/jbc.M708118200; Duraffourd C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110230; Eitan S, 2003, J NEUROSCI, V23, P8360; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Goode TL, 1997, LIFE SCI, V60, pPL107, DOI 10.1016/S0024-3205(96)00684-4; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hull LC, 2010, J PHARMACOL EXP THER, V332, P1127, DOI 10.1124/jpet.109.161455; Kelly E, 2013, BRIT J PHARMACOL, V169, P1430, DOI 10.1111/bph.12222; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Macey TA, 2010, NEUROSCIENCE, V168, P543, DOI 10.1016/j.neuroscience.2010.04.003; Macey T.A., 2014, BRIT J PHARMACOL, V172, P549; Macey TA, 2006, J BIOL CHEM, V281, P34515, DOI 10.1074/jbc.M604278200; Macey TA, 2009, J PHARMACOL EXP THER, V331, P412, DOI 10.1124/jpet.109.152157; Madia PA, 2012, PHARMACOL BIOCHEM BE, V101, P155, DOI 10.1016/j.pbb.2011.11.001; Madia PA, 2009, PSYCHOPHARMACOLOGY, V207, P413, DOI 10.1007/s00213-009-1673-6; Martin F, 2011, BRIT J PHARMACOL, V163, P857, DOI 10.1111/j.1476-5381.2011.01287.x; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Meyer PJ, 2007, NEUROPHARMACOLOGY, V52, P1580, DOI 10.1016/j.neuropharm.2007.03.002; MJANGER E, 1991, J PHARMACOL EXP THER, V258, P544; Molinari P, 2010, J BIOL CHEM, V285, P12522, DOI 10.1074/jbc.M109.059410; Morgan MM, 2006, PHARMACOL BIOCHEM BE, V85, P214, DOI 10.1016/j.pbb.2006.08.003; Morgan MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114269; Morgan MM, 2003, NEUROSCIENCE, V118, P227, DOI 10.1016/S0306-4522(02)00822-9; Mouledous L, 2007, PHARMACOL BIOCHEM BE, V88, P39, DOI 10.1016/j.pbb.2007.07.002; Oldfield S, 2008, J NEUROCHEM, V104, P937, DOI 10.1111/j.1471-4159.2007.05057.x; Pan YX, 2009, P NATL ACAD SCI USA, V106, P4917, DOI 10.1073/pnas.0811586106; Paxinos G, 2005, RAT BRAIN STEREOTAXI; RAFFA RB, 1994, EUR J PHARMACOL, V258, pR5, DOI 10.1016/0014-2999(94)90073-6; Rozenfeld R, 2007, FASEB J, V21, P2455, DOI 10.1096/fj.06-7793com; Sanchez-Blazquez P, 2001, BRAIN RES BULL, V54, P229, DOI 10.1016/S0361-9230(00)00448-2; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Shenoy Sudha K, 2005, Sci STKE, V2005, pcm10, DOI 10.1126/stke.2005/308/cm10; Subramanian J, 2011, J NEUROSCI, V31, P4755, DOI 10.1523/JNEUROSCI.6594-10.2011; Thompson GL, 2015, BRIT J PHARMACOL, V172, P287, DOI 10.1111/bph.12600; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Wang WS, 2012, J NEUROSCI, V32, P13763, DOI 10.1523/JNEUROSCI.1991-12.2012; Wang ZY, 2010, PAIN, V151, P194, DOI 10.1016/j.pain.2010.07.006; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; Williams JT, 2001, PHYSIOL REV, V81, P299; Xu J, 2014, SYNAPSE, V68, P144, DOI 10.1002/syn.21727; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.177089	59	11	11	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 1	2016	298		B				17	24		10.1016/j.bbr.2015.10.032			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CZ9JM	WOS:000367413900003	26497105	Green Accepted			2020-06-30	J	Smith, RL; Siddiqui, N; Henderson, T; Teresi, J; Downey, K; Carvalho, JCA				Smith, Rebecca-Lea; Siddiqui, Naveed; Henderson, Tamara; Teresi, James; Downey, Kristi; Carvalho, Jose C. A.			Analgesia for Medically Induced Second Trimester Termination of Pregnancy: A Randomized Trial	JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA			English	Article						Analgesia; intravenous analgesia; epidural analgesia; obstetrics; termination of pregnancy		Objective: To compare the efficacy between intravenous patient-controlled analgesia (IVPCA) and patient-controlled epidural analgesia (PCEA) in women undergoing medically induced second trimester termination of pregnancy (TOP). Methods: We conducted a randomized trial in a Canadian quaternary care hospital. We included in the study women of gestational age 12 weeks to 23+6 weeks who were undergoing second trimester induction of labour between June 2012 and January 2014. Participants were computer-randomized to receive either IVPCA with fentanyl or PCEA with bupivacaine and fentanyl, with the option to cross over between treatment groups. We administered Quality of Recovery-40 (QoR-40) questionnaires pre-procedure, at the time of discharge, and 24 hours after discharge. Pain scores, satisfaction scores, and obstetrical complications also were noted. Results: One hundred thirty-eight women were approached for participation in the study; 80 declined and 16 were ineligible, leaving 42 participants. Three women subsequently withdrew consent, and two were not included in the results because of protocol violations. A total of 37 women completed the study. Twenty (54%) were allocated to the IVPCA group and 17 (46%) to the PCEA group. Although the QoR-40 values at the time of discharge and at 24 hours after discharge were significantly higher in the PCEA group, they also were significantly higher before the procedure in that group. The within-group differences in QoR-40 (betweenQoR-40 at discharge and QoR pre-procedure, and betweenQoR-40 at 24 hours after discharge and QoR pre-procedure), maximum pain scores, satisfaction, and obstetrical complication rates did not differ significantly between the two groups. Conclusion: IVPCA and PCEA provide similar quality of recovery, quality of analgesia, and satisfaction for women undergoing second trimester TOP. Copyright (C) 2016 The Society of Obstetricians and Gynaecologists of Canada/La Societe des obstetriciens et gynecologues du Canada. Published by Elsevier Inc. All rights reserved.	[Smith, Rebecca-Lea; Siddiqui, Naveed; Henderson, Tamara; Teresi, James; Downey, Kristi; Carvalho, Jose C. A.] Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON, Canada	Smith, RL (reprint author), Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON, Canada.		Siddiqui, Naveed T/L-9437-2017	Siddiqui, Naveed T/0000-0001-6757-0057			Ashok PW, 2004, CONTRACEPTION, V69, P51, DOI 10.1016/j.contraception.2003.09.006; Castro C, 2003, CAN J ANAESTH, V50, P1039, DOI 10.1007/BF03018370; Davis VJ, 2006, SOGC CLIN PRACTICE G; Dubar G, 2010, INT J OBSTET ANESTH, V19, P395, DOI 10.1016/j.ijoa.2010.05.005; Fiala C, 2005, HUM REPROD, V20, P3072, DOI 10.1093/humrep/dei216; Gornall BF, 2013, BRIT J ANAESTH, V111, P161, DOI 10.1093/bja/aet014; Hamoda H, 2004, BJOG-INT J OBSTET GY, V111, P996, DOI 10.1111/j.1471-0528.2004.00235.x; Herrera FJ, 2007, ANESTH ANALG, V105, P63, DOI 10.1213/01.ane.0000265534.73169.95; Jackson E, 2011, CONTRACEPTION, V83, P116, DOI 10.1016/j.contraception.2010.07.014; Lavand'homme PM, 2010, ANESTHESIOLOGY, V113, P1186, DOI 10.1097/ALN.0b013e3181f5d32d; Mazouni C, 2007, INT J OBSTET ANESTH, V16, P383, DOI 10.1016/j.ijoa.2006.11.003; ROSENBLATT WH, 1992, ANESTH ANALG, V75, P760; ROSENBLATT WH, 1991, ANESTH ANALG, V73, P553; Viviand X, 2003, INT J OBSTET ANESTH, V12, P83, DOI 10.1016/S0959-289X(02)00155-3	14	3	3	0	0	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	1701-2163			J OBSTET GYNAECOL CA	J. Obstet. Gynaecol. Can.	FEB	2016	38	2					147	153		10.1016/j.jogc.2015.12.015			7	Obstetrics & Gynecology	Obstetrics & Gynecology	VF7NN	WOS:000443514400009	27032739				2020-06-30	J	Barbosa, TC; Vianna, LC; Fernandes, IA; Prodel, E; Rocha, HNM; Garcia, VP; Rocha, NG; Secher, NH; Nobrega, ACL				Barbosa, Thales C.; Vianna, Lauro C.; Fernandes, Igor A.; Prodel, Eliza; Rocha, Helena N. M.; Garcia, Vinicius P.; Rocha, Natalia G.; Secher, Niels H.; Nobrega, Antonio C. L.			Intrathecal fentanyl abolishes the exaggerated blood pressure response to cycling in hypertensive men	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							NITRIC-OXIDE SYNTHASE; IV MUSCLE AFFERENTS; FUNCTIONAL SYMPATHOLYSIS; SKELETAL-MUSCLE; RESPIRATORY RESPONSES; RHYTHMIC EXERCISE; CENTRAL COMMAND; HEART-RATE; GROUP-III; REFLEX	Hypertensive patients present an exaggerated increase in blood pressure and an elevated cardiovascular risk during exercise. Although controversial, human studies suggest that group III and IV skeletal muscle afferents might contribute to this abnormal response. In the present study, we investigated whether attenuation of the group III and IV muscle afferent signal of hypertensive men eliminates the exaggerated increase in blood pressure occurring during exercise. Eight hypertensive men performed two sessions of 5min of cycling exercise at 40W. Between sessions, the subjects were provided with a lumbar intrathecal injection of fentanyl, a -opioid receptor agonist, aiming to attenuate the central projection of opioid-sensitive group III and IV muscle afferent nerves. The cardiovascular response to exercise of these subjects was compared with that of six normotensive men. During cycling, the hypertensive group demonstrated an exaggerated increase in blood pressure compared to the normotensive group (meanSEM: +173vs. +81mmHg, respectively; P<0.05), whereas the increase in heart rate, stroke volume, cardiac output and vascular conductance was similar (P>0.05). Fentanyl inhibited the blood pressure response to exercise in the hypertensive group (+112mmHg) to a level comparable to that of the normotensive group (P>0.05). Moreover, fentanyl increased the responses of vascular conductance and stroke volume to exercise (P<0.05), whereas the heart rate response was attenuated (P<0.05) and the cardiac output response was maintained (P>0.05). The results of the present study show that attenuation of the exercise pressor reflex normalizes the blood pressure response to cycling exercise in hypertensive individuals.	[Barbosa, Thales C.; Fernandes, Igor A.; Prodel, Eliza; Rocha, Helena N. M.; Garcia, Vinicius P.; Rocha, Natalia G.; Nobrega, Antonio C. L.] Univ Fed Fluminense, Dept Physiol & Pharmacol, Lab Exercise Sci, BR-24210130 Niteroi, RJ, Brazil; [Vianna, Lauro C.] Univ Brasilia, Fac Phys Educ, BR-70910900 Brasilia, DF, Brazil; [Secher, Niels H.] Univ Copenhagen, Dept Anaesthesiol, Copenhagen Muscle Res Ctr, DK-1168 Copenhagen, Denmark	Nobrega, ACL (reprint author), Univ Fed Fluminense, Dept Physiol & Pharmacol, 101 Hernani Pires de Melo St,Suite 106, BR-24210130 Niteroi, RJ, Brazil.	anobrega@id.uff.br	da Nobrega, Antonio Claudio Lucas/O-5107-2019; Vianna, Lauro/A-8188-2008; Rocha, Natalia Galito/AAN-7903-2020; Fernandes, Igor A/G-9589-2012; Rocha, Helena/AAO-9239-2020; Nobrega, Antonio Claudio/F-4825-2012; Rocha, Helena/B-9530-2018	da Nobrega, Antonio Claudio Lucas/0000-0002-3830-2886; Vianna, Lauro/0000-0002-5747-0295; Fernandes, Igor A/0000-0003-3873-2656; Nobrega, Antonio Claudio/0000-0002-3830-2886; Rocha, Helena/0000-0002-4741-7343; Rocha, Natalia Galito/0000-0002-1990-9834; Fernandes, Igor Alexandre/0000-0002-0206-6316	Brazilian National Council of Scientific and Technological Development (CNPq)National Council for Scientific and Technological Development (CNPq) [87584/2013-9]; Foundation for Research Support of Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ) [E-26/110.097/2013]; Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES)CAPES [99999.008878/2014-05]; Brazilian Funding Agency for Studies and Projects (FINEP) [MCT/FINEP/CT-INFRA-PROINFRA-01/2007]; program Science without Borders (CNPq/CAPES) [PVE 051/2012]	This study was supported by grants and scholarships from the Brazilian National Council of Scientific and Technological Development (CNPq - 87584/2013-9), the Foundation for Research Support of Rio de Janeiro (FAPERJ - E-26/110.097/2013), Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES - 99999.008878/2014-05) and the Brazilian Funding Agency for Studies and Projects (FINEP - MCT/FINEP/CT-INFRA-PROINFRA-01/2007). NHS was sponsored by the program Science without Borders (PVE 051/2012 - CNPq/CAPES).	Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; Amann M, 2014, INT J CARDIOL, V174, P368, DOI 10.1016/j.ijcard.2014.04.157; Amann M, 2011, J PHYSIOL-LONDON, V589, P3855, DOI 10.1113/jphysiol.2011.209353; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Barbosa TC, 2015, EXP PHYSIOL, V100, P302, DOI 10.1113/expphysiol.2014.083857; Caringi D, 1998, AM J PHYSIOL-HEART C, V274, pH139; Felix JVC, 2007, HYPERTENSION, V50, P780, DOI 10.1161/HYPERTENSIONAHA.107.094474; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; COOTE JH, 1971, J PHYSIOL-LONDON, V215, P789, DOI 10.1113/jphysiol.1971.sp009498; da Nobrega ACL, 2005, EXERC SPORT SCI REV, V33, P84; DANGELO R, 1994, ANESTHESIOLOGY, V80, P1209, DOI 10.1097/00000542-199406000-00007; Delaney EP, 2010, AM J PHYSIOL-HEART C, V299, pH1318, DOI 10.1152/ajpheart.00556.2010; Fadel PJ, 2012, EXP PHYSIOL, V97, P39, DOI 10.1113/expphysiol.2011.057554; Fisher JP, 2015, COMPR PHYSIOL, V5, P475, DOI 10.1002/cphy.c140022; GISSEN AJ, 1987, ANESTH ANALG, V66, P1272; Gladwell VF, 2002, J PHYSIOL-LONDON, V540, P1095, DOI 10.1113/jphysiol.2001.013486; GOODWIN GM, 1972, J PHYSIOL-LONDON, V226, P173, DOI 10.1113/jphysiol.1972.sp009979; Greaney JL, 2015, J HUM HYPERTENS, V29, P402, DOI 10.1038/jhh.2014.106; Halliwill JR, 2013, EXP PHYSIOL, V98, P7, DOI 10.1113/expphysiol.2011.058065; Huang CJ, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00314; Ives SJ, 2016, MED SCI SPORT EXER, V48, P368, DOI 10.1249/MSS.0000000000000782; Kikuya M, 2007, CIRCULATION, V115, P2145, DOI 10.1161/CIRCULATIONAHA.106.662254; Kishi T, 2002, HYPERTENSION, V39, P264, DOI 10.1161/hy0202.102701; Kishi T, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00335; Kokkinos Peter F, 2002, J Cardiopulm Rehabil, V22, P178, DOI 10.1097/00008483-200205000-00009; Kurl S, 2001, STROKE, V32, P2036, DOI 10.1161/hs0901.095395; Leal AK, 2008, AM J PHYSIOL-HEART C, V295, pH1429, DOI 10.1152/ajpheart.01365.2007; Leal AK, 2013, AM J PHYSIOL-HEART C, V305, pH1246, DOI 10.1152/ajpheart.00116.2013; Leal AK, 2013, EXP PHYSIOL, V98, P1337, DOI 10.1113/expphysiol.2012.071563; LI SJ, 1984, EUR J PHARMACOL, V99, P91, DOI 10.1016/0014-2999(84)90436-9; Mancia G, 2013, J HYPERTENS, V31, P1281, DOI [10.1097/01.hjh.0000431740.32696.cc, 10.1093/eurheartj/eht151]; MCCLOSKE.DI, 1972, J PHYSIOL-LONDON, V224, P173, DOI 10.1113/jphysiol.1972.sp009887; MEINTJES AF, 1995, CIRC RES, V77, P326, DOI 10.1161/01.RES.77.2.326; Mizuno M, 2014, AM J PHYSIOL-HEART C, V307, pH242, DOI 10.1152/ajpheart.00103.2014; Mizuno M, 2011, J PHYSIOL-LONDON, V589, P6191, DOI 10.1113/jphysiol.2011.214429; Mortensen SP, 2014, J PHYSIOL-LONDON, V592, P3063, DOI 10.1113/jphysiol.2014.273722; Mundal R, 1996, HYPERTENSION, V27, P324, DOI 10.1161/01.HYP.27.3.324; Murphy MN, 2013, AM J PHYSIOL-HEART C, V304, pH1547, DOI 10.1152/ajpheart.00235.2012; NOBLE BJ, 1983, MED SCI SPORT EXER, V15, P523; O'Brien E, 2013, J HYPERTENS, V31, P1731, DOI 10.1097/HJH.0b013e328363e964; Olson TP, 2014, EXP PHYSIOL, V99, P414, DOI 10.1113/expphysiol.2013.075937; PAPADEMETRIOU V, 1989, AM J HYPERTENS, V2, P114, DOI 10.1093/ajh/2.2.114; Pescatello LS, 2015, MAYO CLIN PROC, V90, P801, DOI 10.1016/j.mayocp.2015.04.008; POWER I, 1991, REGION ANESTH, V16, P204; REMENSNYDER JP, 1962, CIRC RES, V11, P370, DOI 10.1161/01.RES.11.3.370; Rondon MUPB, 2006, AM J HYPERTENS, V19, P951, DOI 10.1016/j.amjhyper.2006.02.001; Sausen MT, 2009, EUR J APPL PHYSIOL, V105, P351, DOI 10.1007/s00421-008-0910-8; Sidhu SK, 2015, AM J PHYSIOL-HEART C, V309, pH1479, DOI 10.1152/ajpheart.00433.2015; Smith SA, 2015, AUTON NEUROSCI-BASIC, V188, P58, DOI 10.1016/j.autneu.2014.12.004; Thomas GD, 2015, AUTON NEUROSCI-BASIC, V188, P64, DOI 10.1016/j.autneu.2014.10.019; Thompson PD, 2007, CIRCULATION, V115, P2358, DOI 10.1161/CIRCULATIONAHA.107.181485; Trinity JD, 2010, AM J PHYSIOL-HEART C, V299, pH1693, DOI 10.1152/ajpheart.00482.2010; Vongpatanasin W, 2011, J PHYSIOL-LONDON, V589, P1209, DOI 10.1113/jphysiol.2010.203026; WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566; WILLIAMSON JW, 1995, J APPL PHYSIOL, V78, P1273; Zhao WY, 2006, HYPERTENSION, V48, P637, DOI 10.1161/01.HYP.0000240347.51386.ea	57	26	26	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	FEB 1	2016	594	3					715	725		10.1113/JP271335			11	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	DD3YT	WOS:000369860100014	26659384	Green Published, Bronze			2020-06-30	J	Tan, Y; Shi, YS; Ding, H; Kong, XB; Zhou, HJ; Tian, JH				Tan, Yuan; Shi, Yisa; Ding, Hui; Kong, Xiangbin; Zhou, Haijiao; Tian, Jinhui			mu-Opioid agonists for preventing emergence agitation under sevoflurane anesthesia in children: a meta-analysis of randomized controlled trials	PEDIATRIC ANESTHESIA			English	Review						fentanyl; remifentanil; sufentanil; alfentanil; sevoflurane; emergence agitation	PEDIATRIC-PATIENTS; INTRANASAL FENTANYL; GREATER INCIDENCE; DOSE FENTANYL; CAUDAL BLOCK; DOUBLE-BLIND; HALOTHANE; REMIFENTANIL; DELIRIUM; DEXMEDETOMIDINE	Background: Emergence agitation (EA) is an adverse effect after sevoflurane anesthesia in pediatric patients. The effectiveness of prophylactic mu-opioid agonists fentanyl, remifentanil, sufentanil, and alfentanil in preventing EA is debatable. Methods: A literature search was conducted to identify clinical trials that observed the effect of mu-opioid agonists fentanyl, remifentanil, sufentanil, and alfentanil on preventing EA in pediatric patients under sevoflurane anesthesia. The statistical software RevMan 5.3 was used for meta-analysis. Data from each study were combined using the relative ratio (RR), weighted mean differences, and their associated 95% confidence intervals. I-2 was used to evaluate heterogeneity. Subgroup analysis was conducted to investigate the possible influences of patient age, adenotonsillectomy, premedication, N2O, propofol, and regional block/local anesthetics on preventing EA with prophylactic administration of mu-opioid agonists. Publication bias was checked using funnel plots and Begg's test. Results: This meta-analysis showed the inclusion of 19 randomized controlled trials with 1528 patients (857 patients received mu-opioid agonists therapy and 671 patients had placebo). The pooled data indicated that prophylactic mu-opioid agonists fentanyl, remifentanil, sufentanil, and alfentanil significantly decreased the incidence of EA [RR = 0.49 (0.38, 0.64), I-2 = 42%, P = 0.04; RR = 0.57 (0.33, 0.99), I-2 = 37%, P = 0.19; RR = 0.18 (0.08, 0.39), I-2 = 0%, P = 0.98; and RR = 0.56 (0.40, 0.78), I-2 = 6%, P = 0.34, respectively]. All subgroup analyses strengthened the proof for lower incidence of EA under sevoflurane anesthesia after fentanyl administration. A possibility of publication bias was detected in the fentanyl group. Conclusions: This meta-analysis suggested that prophylactic mu-opioid agonists fentanyl, remifentanil, sufentanil, and alfentanil could significantly decrease the incidence of EA under sevoflurane anesthesia in children compared to placebo. Considering the limitations of the included studies, more clinical studies are required.	[Tan, Yuan; Shi, Yisa; Zhou, Haijiao] Lanzhou Univ, Hosp 2, Dept Anesthesiol, Lanzhou 730030, Gansu, Peoples R China; [Ding, Hui; Kong, Xiangbin] Lanzhou Univ, Hosp 2, Dept Urol, Lanzhou 730030, Gansu, Peoples R China; [Tian, Jinhui] Lanzhou Univ, Evidence Based Med Ctr, Lanzhou 730030, Gansu, Peoples R China	Shi, YS (reprint author), Lanzhou Univ, Hosp 2, Dept Anesthesiol, Cuiyingmen 82, Lanzhou 730030, Gansu, Peoples R China.	shiys@lzu.edu.cn					Abdelhalim Ashraf Arafat, 2013, Saudi J Anaesth, V7, P392, DOI 10.4103/1658-354X.121047; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aouad MT, 2005, CURR OPIN ANESTHESIO, V18, P614, DOI 10.1097/01.aco.0000188420.84763.35; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Asaad OM, 2011, EGYPT J ANAESTH, V27, P233, DOI [10.1016/j.egja.2011.07.006, 10.1016/j.egja.2010.12.005]; Bakhamees HS, 2009, SAUDI MED J, V30, P500; Bilgen S, 2014, J INT MED RES, V42, P1262, DOI 10.1177/0300060514543039; Binstock W, 2004, PEDIATR ANESTH, V14, P759, DOI 10.1111/j.1460-9592.2004.01296.x; Bortone L, 2006, PEDIATR ANESTH, V16, P1138, DOI 10.1111/j.1460-9592.2006.01954.x; Bortone L, 2014, PEDIATR ANESTH, V24, P614, DOI 10.1111/pan.12388; Choi HR, 2011, KOREAN J ANESTHESIOL, V61, P148, DOI 10.4097/kjae.2011.61.2.148; Cohen IT, 2003, PAEDIATR ANAESTH, V13, P63, DOI 10.1046/j.1460-9592.2003.00948.x; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; Dong YX, 2010, ANAESTH INTENS CARE, V38, P718, DOI 10.1177/0310057X1003800416; Eger EI, 2004, AM J HEALTH-SYST PH, V61, pS3, DOI 10.1093/ajhp/61.suppl_4.S3; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Ghosh SM, 2011, EUR J ANAESTH, V28, P329, DOI 10.1097/EJA.0b013e3283416754; Higgins JP, 2008, COCHRANE HDB SYSTEMA, P187, DOI [DOI 10.1002/9780470712184, 10.1002/9780470712184]; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Kanaya A, 2014, J ANESTH, V28, P4, DOI 10.1007/s00540-013-1656-y; Kim D, 2013, KOREAN J ANESTHESIOL, V64, P240, DOI 10.4097/kjae.2013.64.3.240; Kim JY, 2009, ACTA ANAESTH SCAND, V53, P678, DOI 10.1111/j.1399-6576.2009.01943.x; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Kuratani N, 2008, ANESTHESIOLOGY, V109, P225, DOI 10.1097/ALN.0b013e31817f5c18; Li J, 2011, CHINESE MED J-PEKING, V124, P3682, DOI 10.3760/cma.j.issn.0366-6999.2011.22.015; Li XZ, 2013, SAUDI MED J, V34, P40; Li Y, 2008, J NEUROSCI, V28, P2814, DOI 10.1523/JNEUROSCI.5447-07.2008; Liang P, 2014, PAK J MED SCI, V30, P1059, DOI 10.12669/pjms.305.4483; Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI 10.7326/0003-4819-151-4-200908180-00136; Makharita MY, 2009, EGYPTIAN JOURNAL OF, V25, P319; Michel F, 2009, EXPERT OPIN PHARMACO, V10, P861, DOI [10.1517/14656560902798752, 10.1517/14656560902798752 ]; Moore JK, 2003, BRIT J ANAESTH, V90, P461, DOI 10.1093/bja/aeg098; Na HS, 2013, ACTA ANAESTH SCAND, V57, P100, DOI 10.1111/aas.12006; Ozturk T, 2009, EUR J ANAESTH, V26, P338, DOI 10.1097/EJA.0b013e32831de50d; Petroz GC, 2006, ANESTHESIOLOGY, V105, P1098, DOI 10.1097/00000542-200612000-00009; Przybylo HJ, 2003, PAEDIATR ANAESTH, V13, P609, DOI 10.1046/j.1460-9592.2003.01099.x; Rampersad S, 2010, PEDIATR ANESTH, V20, P1028, DOI 10.1111/j.1460-9592.2010.03427.x; Schmidt B, 2010, KLIN PADIATR, V222, P62, DOI 10.1055/s-0029-1225348; SCHWAGMEIER R, 1995, J CLIN ANESTH, V7, P109, DOI 10.1016/0952-8180(94)00023-W; Shen X, 2012, PEDIATR ANESTH, V22, P1179, DOI 10.1111/j.1460-9592.2012.03906.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Sinha A, 2012, SAUDI J ANAESTH, V6, P403, DOI 10.4103/1658-354X.105887; Sun L, 2014, ACTA ANAESTH SCAND, V58, P642, DOI 10.1111/aas.12292; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08; Yamashita M, 2003, PAEDIATR ANAESTH, V13, P641, DOI 10.1046/j.1460-9592.2003.00986_2.x; Zhang CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099718; Zhang CM, 2013, CLIN THER, V35, P1622, DOI 10.1016/j.clinthera.2013.08.016	53	12	12	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	FEB	2016	26	2					139	150		10.1111/pan.12815			12	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	DA4RT	WOS:000367788700004	26614352				2020-06-30	J	Mercadante, S; Marchetti, P; Cuomo, A; Mammucari, M; Caraceni, A				Mercadante, Sebastiano; Marchetti, Paolo; Cuomo, Arturo; Mammucari, Massimo; Caraceni, Augusto		IOPS MS Study Grp	Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group	SUPPORTIVE CARE IN CANCER			English	Article						Breakthrough pain; Opioids; Fentanyl; Morphine	FENTANYL BUCCAL TABLET; OPIOID BASAL REGIMEN; CANCER-PAIN; ASSESSMENT-TOOL; EPISODIC PAIN; PREVALENCE; VALIDATION; MANAGEMENT; ADMISSION; TITRATION	Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.	[Marchetti, Paolo] Univ Roma La Sapienza, Mol & Clin Med Med Oncol, I-00185 Rome, Italy; [Cuomo, Arturo] Natl Canc Inst Pascale, Abdominal Med Oncol, Naples, Italy; [Mammucari, Massimo] ASL RME, Primary Care Unit, Rome, Italy; [Caraceni, Augusto] Natl Canc Inst, Palliat Care Pain Therapy & Rehabil, I-20133 Milan, Italy; [Mercadante, Sebastiano] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy		terapiadeldolore@lamaddalenanet.it	Marchetti, Paolo/K-1469-2016; mammucari, massimo/AAB-9899-2020; Marchetti, Paolo/J-9890-2018; cuomo, arturo/AAL-4416-2020; Dekel, Boaz G Samolsky/M-3027-2016; Caraceni, Augusto/C-1012-2017	mammucari, massimo/0000-0002-9515-3549; Marchetti, Paolo/0000-0002-9064-8761; Dekel, Boaz G Samolsky/0000-0002-9954-4117; Caraceni, Augusto/0000-0002-0375-6204	Molteni Pharmaceutical, Italy	IOPS activity is sponsored by an unrestricted grant of Molteni Pharmaceutical, Italy.	Bedard G, 2013, SUPPORT CARE CANCER, V21, P2557, DOI 10.1007/s00520-013-1817-4; BENNETT D, 2005, [No title captured], V30, P354; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; England Ruth, 2011, BMJ Support Palliat Care, V1, P349, DOI 10.1136/bmjspcare-2011-000037; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250; Hagen NA, 2008, J PAIN SYMPTOM MANAG, V35, P136, DOI 10.1016/j.jpainsymman.2007.03.016; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V28, P505, DOI 10.1016/j.jpainsymman.2004.02.024; Mercadante S, 2014, CLIN ONCOL-UK, V26, P806, DOI 10.1016/j.clon.2014.09.003; Mercadante S., 2011, EUR J PAIN S, P443; Mercadante S, 2009, SUPPORT CARE CANCER, V38, P554; Mercadante S, 2010, J PAIN SYMPTOM MANAG, V40, P183, DOI 10.1016/j.jpainsymman.2010.01.010; Mercadante S, 2006, DRUGS, V66, P2394, DOI 10.2165/00003495-200666180-00015; Mercadante S, 2015, CLIN J PAIN, V31, P214, DOI 10.1097/AJP.0000000000000161; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mercadante S, 2014, CLIN J PAIN, V30, P510, DOI 10.1097/AJP.0000000000000004; Mercadante S, 2013, CURR MED RES OPIN, V29, P1527, DOI 10.1185/03007995.2013.826640; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2013, CURR MED RES OPIN, V29, P667, DOI 10.1185/03007995.2013.792247; Mercadante S, 2013, CURR MED RES OPIN, V29, P93, DOI 10.1185/03007995.2012.755120; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; Petzke F, 1999, J PAIN SYMPTOM MANAG, V17, P391, DOI 10.1016/S0885-3924(99)00023-8; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Swanwick M, 2001, PALLIATIVE MED, V15, P9, DOI 10.1191/026921601668030190; Webber K, 2014, J PAIN SYMPTOM MANAG, V48, P619, DOI 10.1016/j.jpainsymman.2013.10.026; Webber K, 2011, SUPPORT CARE CANCER, V19, P2041, DOI 10.1007/s00520-010-1062-z; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub3; Zeppetella G, 2013, J NATL COMPR CANC NE, V11, pS37	44	27	30	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	FEB	2016	24	2					961	968		10.1007/s00520-015-2951-y			8	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	DA0AD	WOS:000367458200055	26438145				2020-06-30	J	Rose, L; Burry, L; Mallick, R; Luk, E; Cook, D; Fergusson, D; Dodek, P; Burns, K; Granton, J; Ferguson, N; Devlin, JW; Steinberg, M; Keenan, S; Reynolds, S; Tanios, M; Fowler, RA; Jacka, M; Olafson, K; Skrobik, Y; Mehta, S				Rose, Louise; Burry, Lisa; Mallick, Ranjeeta; Luk, Elena; Cook, Deborah; Fergusson, Dean; Dodek, Peter; Burns, Karen; Granton, John; Ferguson, Niall; Devlin, John W.; Steinberg, Marilyn; Keenan, Sean; Reynolds, Stephen; Tanios, Maged; Fowler, Robert A.; Jacka, Michael; Olafson, Kendiss; Skrobik, Yoanna; Mehta, Sangeeta			Prevalence, risk factors, and outcomes associated with physical restraint use in mechanically ventilated adults	JOURNAL OF CRITICAL CARE			English	Article						Physical restraint; Chemical restraint; Sedation protocol; Daily sedation interruption; Intensive care	INTENSIVE-CARE PATIENTS; UNPLANNED EXTUBATION; SEDATION; DELIRIUM; SCALE; UNITS	Purpose: The purpose was to describe characteristics and outcomes of restrained and nonrestrained patients enrolled in a randomized trial of protocolized sedation compared with protocolized sedation plus daily sedation interruption and to identify patient and treatment factors associated with physical restraint. Methods: This was a post hoc secondary analysis using Cox proportional hazards modeling adjusted for center- and time-varying covariates to evaluate predictors of restraint use. Results: A total of 328 (76%) of 430 patients were restrained for a median of 4 days. Restrained patients received higher daily doses of benzodiazepines (105 vs 41 mg midazolam equivalent, P < .0001) and opioids (1524 919 mu g fentanyl equivalents, P < .0001), more days of infusions (benzodiazepines 6 vs 4, P < .0001; opioids 7 vs 5, P = .02), and more daily benzodiazepine boluses (0.2 vs 0.1, P < .0001). More restrained patients received haloperidol (23% vs 12%, P = .02) and atypical antipsychotics (17% vs 4%, P = .003). More restrained patients experienced unintentional device removal (26% vs 3%, P < .001) and required reintubation (8% vs 1%, P = .01). In the multivariable analysis, alcohol use was associated with decreased risk of restraint (hazard ratio, 0.22; 95% confidence interval, 0.08-0.58). Conclusions: Physical restraint was common in mechanically ventilated adults managed with a sedation protocol. Restrained patients received more opioids and benzodiazepines. Except for alcohol use, patient characteristics and treatment factors did not predict restraint use. (C) 2015 Elsevier Inc. All rights reserved.	[Rose, Louise; Fowler, Robert A.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Rose, Louise; Luk, Elena] Univ Toronto, Lawrence S Bloomberg Fac Nursing, Toronto, ON M5T 1P8, Canada; [Burry, Lisa] Mt Sinai Hosp, Dept Pharm & Med, Toronto, ON M5G 1X5, Canada; [Burry, Lisa] Univ Toronto, Toronto, ON, Canada; [Mallick, Ranjeeta; Fergusson, Dean] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON K1Y 4E9, Canada; [Mallick, Ranjeeta; Fergusson, Dean] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Cook, Deborah] St Josephs Healthcare, Hamilton, ON L8N 4A6, Canada; [Cook, Deborah] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Cook, Deborah] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Dodek, Peter] St Pauls Hosp, Div Crit Care Med, Vancouver, BC V6Z 1Y6, Canada; [Dodek, Peter] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada; [Dodek, Peter] Univ British Columbia, Vancouver, BC V6Z 1Y6, Canada; [Burns, Karen] St Michaels Hosp, Dept Crit Care, Toronto, ON M5B 1W8, Canada; [Burns, Karen] Interdepartmental Div Crit Care Med, Toronto, ON, Canada; [Burns, Karen] Li Ka Shing Inst, Toronto, ON, Canada; [Granton, John] Univ Hlth Network, Div Respirol, Dept Med, Toronto, ON M5G 2C4, Canada; [Granton, John] Gen Res Inst, Toronto, ON M5G 2C4, Canada; [Granton, John] Univ Toronto, Inst Hlth Policy Management & Evaluat, Interdepartmental Div Crit Care Med, Toronto, ON, Canada; [Granton, John] Univ Toronto, Dept Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Granton, John] Univ Toronto, Inst Hlth Policy Management & Evaluat, Dept Physiol, Toronto, ON, Canada; [Ferguson, Niall] Univ Hlth Network, Crit Care & Pulm Med, Toronto, ON M5G 2C4, Canada; [Ferguson, Niall] Univ Toronto, Interdepartmental Div Crit Care Med, Toronto, ON, Canada; [Devlin, John W.] Northeastern Univ, Sch Pharm, Boston, MA 02115 USA; [Steinberg, Marilyn] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Keenan, Sean] Royal Columbia Hosp, Div Crit Care, Dept Crit Care, New Westminster, BC V3L 3W7, Canada; [Keenan, Sean; Reynolds, Stephen] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Tanios, Maged] Long Beach Mem Med Ctr, Dept Med, Long Beach, CA 90806 USA; [Fowler, Robert A.] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada; [Jacka, Michael] Univ Alberta Hosp, Dept Anesthesiol, Edmonton, AB T6G 2B7, Canada; [Olafson, Kendiss] Univ Manitoba, Dept Med, Sect Crit Care, Winnipeg, MB R3T 2N2, Canada; [Skrobik, Yoanna] McGill Univ, Dept Med, Montreal, PQ H3G 2M1, Canada; [Mehta, Sangeeta] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Mehta, Sangeeta] Mt Sinai Hosp, Interdepartmental Div Crit Care Med, Toronto, ON M5G 1X5, Canada	Mehta, S (reprint author), Mt Sinai Hosp, 600 Univ Ave,RM 18-216, Toronto, ON M5G 1X5, Canada.	Geeta.mehta@utoronto.ca	Rose, Louise/F-4723-2011; Ferguson, Niall/D-7619-2019; Burry, Lisa D/C-6546-2017; Skrobik, Yoanna/J-6393-2013; Mehta, Sangeeta/C-4623-2015; Skrobik, Yoanna/K-8165-2014	Ferguson, Niall/0000-0002-6213-5264; Burry, Lisa D/0000-0002-6545-3890; Skrobik, Yoanna/0000-0002-5315-6020; Rose, Louise/0000-0003-1700-3972; Fergusson, Dean/0000-0002-3389-2485	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Canadian Association of Critical Care Nurses; Sigma Theta Tau International Lambda Pi-At-Large Research Seed Grant; Mount Sinai Hospital Department of Medicine	The SLEAP trial was funded by the Canadian Institutes of Health Research. The secondary analysis of restraint use was funded by the Canadian Association of Critical Care Nurses and a Sigma Theta Tau International Lambda Pi-At-Large Research Seed Grant and the Mount Sinai Hospital Department of Medicine.	Benbenbishty Julie, 2010, Intensive Crit Care Nurs, V26, P241, DOI 10.1016/j.iccn.2010.08.003; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Bray Kate, 2004, Nurs Crit Care, V9, P199, DOI 10.1111/j.1362-1017.2004.00074.x; Burry LD, 2014, CAN J ANESTH, V61, P619, DOI 10.1007/s12630-014-0174-1; Chang LY, 2008, AM J CRIT CARE, V17, P408; Chevron V, 1998, CRIT CARE MED, V26, P1049, DOI 10.1097/00003246-199806000-00026; De Jonghe B, 2013, INTENS CARE MED, V39, P31, DOI 10.1007/s00134-012-2715-9; Evans D, 2003, J ADV NURS, V41, P274, DOI 10.1046/j.1365-2648.2003.02501.x; Frezza EE, 2000, AM J MED QUAL, V15, P221, DOI 10.1177/106286060001500507; Government of Ontario, 2001, PAT RESTR MIN ACT; Hatchett C, 2010, SOUTH AFR J CRIT CAR, V26, P52; Jones C, 2007, INTENS CARE MED, V33, P978, DOI 10.1007/s00134-007-0600-8; da Silva PSL, 2012, ANESTH ANALG, V114, P1003, DOI 10.1213/ANE.0b013e31824b0296; Luk E, 2014, CRIT CARE, V18, DOI 10.1186/cc13789; Maccioli GA, 2003, CRIT CARE MED, V31, P2665, DOI 10.1097/01.CCM.0000095463.72353.AD; Mehta S, 2015, CRIT CARE MED, V43, P557, DOI 10.1097/CCM.0000000000000727; Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872; Micek ST, 2005, CRIT CARE MED, V33, P1260, DOI 10.1097/01.CCM.0000164540.58515.BF; Mion LC, 2007, CRIT CARE MED, V35, P2714, DOI 10.1097/01.CCM.0000291651.12767.52; Mion LC, 2008, GERIATR NURS, V29, P421, DOI 10.1016/j.gerinurse.2008.09.006; Pesiri A J, 1994, Crit Care Nurs Q, V17, P35; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Rose L, 2015, J CRIT CARE, V30, P348, DOI 10.1016/j.jcrc.2014.10.021; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892	25	18	20	1	26	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	FEB	2016	31	1					31	35		10.1016/j.jcrc.2015.09.011			5	Critical Care Medicine	General & Internal Medicine	CY8HX	WOS:000366650500007	26489482				2020-06-30	J	Weldon, ER; Ariano, RE; Grierson, RA				Weldon, Erin R.; Ariano, Robert E.; Grierson, Robert A.			COMPARISON OF FENTANYL AND MORPHINE IN THE PREHOSPITAL TREATMENT OF ISCHEMIC TYPE CHEST PAIN	PREHOSPITAL EMERGENCY CARE			English	Article						chest pain; prehospital; morphine; fentanyl; acute pain	ACUTE CORONARY SYNDROMES; INTRAVENOUS MORPHINE; ANALGESIA; ASSOCIATION; SAFETY	In the treatment of acute coronary syndromes, reduction of sympathetic stress and catecholamine release is an important therapeutic goal. One method used to achieve this goal is pain reduction through the systemic administration of analgesia. Historically, morphine has been the analgesic of choice in ischemic cardiac pain. This randomized double-blind controlled trial seeks to prove the utility of fentanyl as an alternate first-line analgesic for ischemic-type chest pain in the prehospital setting. Successive patients who were treated for suspected ischemic chest pain in the emergency medical services system were considered eligible. Once chest pain was confirmed, patients received oxygen, aspirin, and nitroglycerin therapy. If the ischemic-type chest pain continued the patient was randomized in a double-blinded fashion to treatment with either morphine or fentanyl. Pain scale scores, necessity for additional dosing, and rate of adverse events between the groups were assessed every 5 minutes and were compared using t-testing, Fisher's Exact test, or Analysis of Variance (ANOVA) where appropriate. The primary outcome of the study was incidence of hypotension and the secondary outcome was pain reduction as measured by the visual analog score and numeric rating score. A total of 207 patients were randomized with 187 patients included in the final analysis. Of the 187 patients, 99 were in the morphine group and 88 in the fentanyl group. No statistically significant difference between the two groups with respect to hypotension was found (morphine 5.1% vs. fentanyl 0%, p = 0.06). Baseline characteristics, necessity for additional dosing, and other adverse events between the two groups were not statistically different. There were no significant differences between the changes in visual analog scores and numeric rating scale scores for pain between the two groups (p = 0.16 and p = 0.15, respectively). This study supports that fentanyl and morphine are comparable in providing analgesia for ischemic-type chest pain. Fentanyl appears to be a safe and effective alternative to morphine for the management of chest pain in the prehospital setting.	[Weldon, Erin R.; Grierson, Robert A.] Univ Manitoba, Emergency Med, Winnipeg, MB, Canada; [Ariano, Robert E.] St Boniface Gen Hosp, Pharm, Winnipeg, MB, Canada	Weldon, ER (reprint author), Univ Manitoba, Emergency Med, Winnipeg, MB, Canada.	eweldon@winnipeg.ca		Ariano, Robert/0000-0001-7021-4336			[Anonymous], 2011, MORPH MON LEX COMP I; BARKE KE, 1993, LIFE SCI, V53, P1391, DOI 10.1016/0024-3205(93)90581-M; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Everts B, 1998, EUR J PAIN-LONDON, V2, P115, DOI 10.1016/S1090-3801(98)90004-0; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Headrick JP, 2015, BRIT J PHARMACOL, V172, P2026, DOI 10.1111/bph.13042; Herlitz J, 2011, INT J CARDIOL, V149, P147, DOI 10.1016/j.ijcard.2010.10.012; Hjalte L, 2007, EUR J EMERG MED, V14, P134; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Meine TJ, 2005, AM HEART J, V149, P1043, DOI 10.1016/j.ahj.2005.02.010; O'Connor RE, 2010, CIRCULATION, V122, pS787, DOI 10.1161/CIRCULATIONAHA.110.971028; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; Silfvast T, 2001, Eur J Emerg Med, V8, P275, DOI 10.1097/00063110-200112000-00005; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; Van de Werf F, 2008, EUR HEART J, V29, P2909, DOI 10.1093/eurheartj/ehn416	18	5	5	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	JAN 2	2016	20	1					45	51		10.3109/10903127.2015.1056893			7	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	DA1DI	WOS:000367536100007	26727338				2020-06-30	J	Kilickaya, R; Orak, Y; Balci, MA; Balci, F; Unal, I				Kilickaya, Refika; Orak, Yavuz; Balci, Mehtap Arda; Balci, Fatih; Unal, Ilker			Comparison of the Effects of Intrathecal Fentanyl and Intrathecal Morphine on Pain in Elective Total Knee Replacement Surgery	PAIN RESEARCH & MANAGEMENT			English	Article							POSTOPERATIVE ANALGESIA; MULTIMODAL ANALGESIA; SPINAL-ANESTHESIA; ARTHROPLASTY; BUPIVACAINE	Objective. Total knee replacement is one of the most painful orthopedic surgical procedures. In this study, our goal was to compare the intraoperative and postoperative hemodynamic effects, the side effects, the effect on the duration of pain start, the 24-hour VAS, and the amount of additional analgesia used, of the fentanyl and morphine we added to the local anesthetic in the spinal anesthesia we administered in cases of elective knee replacement. Materials and Methods. After obtaining the approval of the Erciyes University Medical Faculty Clinical Drug Trials Ethics Committee, as well as the verbal and written consent of the patients, we included 50 patients in our prospective, randomized study. Results. In our study, the morphine group (Group M) had lower pain scores in the 2nd, 6th, 12th, and 24th hours compared to the fentanyl group (Group F). When additional analgesic requirements were compared, it was found that in the 2nd, 6th, and 24th hours fewer Group M patients needed more analgesics than did Group F patients. Conclusion. The fentanyl group also had lower first analgesic requirement times than did the morphine group. In terms of nausea and vomiting, there was no statistically significant difference between the two groups.	[Kilickaya, Refika; Balci, Mehtap Arda] Bor State Hosp, Anesthesiol & Reanimat Clin, Nigde, Turkey; [Orak, Yavuz] Mardin State Hosp, Anesthesiol & Reanimat Clin, Mardin, Turkey; [Balci, Fatih] Nigde State Hosp, Anesthesiol & Reanimat Clin, Nigde, Turkey; [Unal, Ilker] Cukurova Univ, Med Biostat Dept, Adana, Turkey	Orak, Y (reprint author), Mardin State Hosp, Anesthesiol & Reanimat Clin, Mardin, Turkey.	dryavuzorak@hotmail.com	Unal, Ilker/E-5071-2018	Unal, Ilker/0000-0002-9485-3295			Acar P, 2010, AGRI, V22, P151; Agrawal Amit, 2016, Anesth Essays Res, V10, P420; Andrieu G, 2009, ANESTH ANALG, V108, P1954, DOI 10.1213/ane.0b013e3181a30182; Attari MA, 2016, J NEUROSURG ANESTH, V28, P38, DOI 10.1097/ANA.0000000000000232; BAILEY PL, 1986, ANESTHESIA, P745; BONICA JJ, 1990, MANAGEMENT PAIN, P461; dos Santos LM, 2009, CLINICS, V64, P279, DOI 10.1590/S1807-59322009000400003; Gupta A, 2003, TECH REG ANESTH PAIN, V7, P155; Gurbet A, 2008, EUR SPINE J, V17, P1237, DOI 10.1007/s00586-008-0676-z; Gurkan Y, 2004, ACTA ANAESTH SCAND, V48, P513, DOI 10.1111/j.1399-6576.2004.00353.x; GUSTAFSSON LL, 1988, DRUGS, V35, P597, DOI 10.2165/00003495-198835060-00001; Maheshwari AV, 2009, CLIN ORTHOP RELAT R, V467, P1418, DOI 10.1007/s11999-009-0728-7; MITCHELL RWD, 1989, BRIT J ANAESTH, V63, P147, DOI 10.1093/bja/63.2.147; Priebe HJ, 2000, BRIT J ANAESTH, V85, P763, DOI 10.1093/bja/85.5.763; Rathmell JP, 2003, ANESTH ANALG, V97, P1452, DOI 10.1213/01.ANE.0000083374.44039.9E; Rosaeg OP, 2001, REGION ANESTH PAIN M, V26, P125, DOI 10.1053/rapm.2001.20982; Salmah G. S., 2009, MED J MALAYSIA, V64, P71; Saracoglu A, 2011, ARCH MED SCI, V7, P694, DOI 10.5114/aoms.2011.24141; Stephens J, 2003, RHEUMATOLOGY, V42, P40, DOI 10.1093/rheumatology/keg497; Vendittoli PA, 2006, J BONE JOINT SURG AM, V88A, P282, DOI 10.2106/JBJS.E.00173	20	2	3	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1203-6765	1918-1523		PAIN RES MANAG	Pain Res. Manag.		2016	2016								3256583	10.1155/2016/3256583			5	Clinical Neurology	Neurosciences & Neurology	EH6AM	WOS:000391854600001	28115877	DOAJ Gold, Green Published			2020-06-30	J	Islam, MR; Yang, L; Lee, YS; Hruby, VJ; Karamyan, VT; Abbruscato, TJ				Islam, Mohammad Rashedul; Yang, Li; Lee, Yeon Sun; Hruby, Victor J.; Karamyan, Vardan T.; Abbruscato, Thomas J.			Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment	CURRENT PHARMACEUTICAL DESIGN			English	Article						Ischemic stroke; Neuroprotection; Biphalin; Enkephalin-fentanyl conjugates; multifunctional opioids	METHYL-D-ASPARTATE; AMERICAN-HEART-ASSOCIATION; TRANSIENT MCA OCCLUSION; NEURONAL CELL-DEATH; CEREBRAL-ISCHEMIA; RAT-BRAIN; IN-VITRO; RECEPTOR ACTIVATION; LIPID-PEROXIDATION; MOUSE MODEL	Background: Ischemic stroke is one of the leading causes of mortality and morbidity in the world and effective neuroprotectants are yet to be developed. Recent studies have demonstrated excellent neuroprotective effects of a bivalent enkephalin opioid agonist, biphalin in multiple stroke models. Methods: The purpose of this study is to evaluate novel multifunctional enkephalin-fentanyl opioid agonists, LYS436, LYS739 and LYS416 for their neuroprotective potential using in vitro and in vivo ischemic stroke models and to compare the effect to that of biphalin. Results: In general, all non-selective opioid agonists significantly decreased neuronal cell death and levels of reactive oxygen species in primary neurons subjescted to hypoxia-aglycemia/re-oxygenation or NMDA neurotoxicity. Fluorinated enkephalin-fentanyl conjugate, LYS739 showed enhanced neuroprotection in both in vitro models compared to biphalin. Based on further in vitro screening and comparative studies to biphalin, LYS739 was selected as a lead for in vivo experimentation. A mouse middle cerebral artery occlusion (MCAO) stroke model was utilized to study biphalin and the lead analog, LYS739. Both agonists significantly decreased brain infarct and edema ratios compared to saline treated group. Neurological impairment after stroke was statistically significantly improved in terms of neurological score and locomotor activities with LYS739 and biphalin treatment. Importantly, LYS739 and biphalin demonstrated better neuroprotection compared to fentanyl, and this effect was reversed by non-selective opioid antagonist naltrexone. Conclusion: In summary, the results of this study suggest that the multifunctional fluorinated enkephalin analog, LYS739 can be considered as a potential lead for ischemic stroke research and may provide advantages given the multimeric peptide-opiate structure.	[Islam, Mohammad Rashedul; Yang, Li; Karamyan, Vardan T.; Abbruscato, Thomas J.] Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX 79106 USA; [Lee, Yeon Sun; Hruby, Victor J.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA	Abbruscato, TJ (reprint author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.	thomas.abbruscato@ttuhsc.edu			National Institution of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS076012, R01DA13449]	This work was supported by National Institution of Health Grants R01NS076012 to Thomas J. Abbruscato, and R01DA13449 to Victor J. Hruby.	Abbruscato TJ, 1996, J PHARMACOL EXP THER, V276, P1049; ADAMS HP, 1986, STROKE, V17, P404, DOI 10.1161/01.STR.17.3.404; Balkaya M, 2013, J CEREBR BLOOD F MET, V33, P330, DOI 10.1038/jcbfm.2012.185; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Caplan L., 2000, A CLIN APPROACH; Chao D, 2015, NEURAL FUNCTIONS DEL, P247; Chao DM, 2007, J CELL PHYSIOL, V212, P60, DOI 10.1002/jcp.21000; Cheng Yu Dennis, 2004, NeuroRx, V1, P36, DOI 10.1007/BF03206566; CHOI DW, 1987, J NEUROSCI, V7, P369; Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715; Cui JK, 2000, FASEB J, V14, P955; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; El Mouedden M, 2005, PHARMACOL BIOCHEM BE, V82, P109, DOI 10.1016/j.pbb.2005.07.016; Feliciani F, 2013, MINI-REV MED CHEM, V13, P11, DOI 10.2174/138955713804484776; Feng Y, 2008, LIFE SCI, V82, P752, DOI 10.1016/j.lfs.2008.01.004; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fonarow GC, 2011, CIRCULATION, V123, P750, DOI 10.1161/CIRCULATIONAHA.110.974675; GANNON RL, 1991, BRAIN RES, V548, P242, DOI 10.1016/0006-8993(91)91127-M; Garbuz O, 2015, PEPTIDES, V63, P1, DOI 10.1016/j.peptides.2014.09.027; Gorgulu A, 2000, ACTA NEUROCHIR, V142, P1287, DOI 10.1007/s007010070027; Haj-Mirzaian A, 2014, EUR J PHARMACOL, V735, P26, DOI 10.1016/j.ejphar.2014.03.053; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Hayashi T, 1999, BRAIN RES, V832, P159, DOI 10.1016/S0006-8993(99)01409-2; HORAN PJ, 1993, J PHARMACOL EXP THER, V265, P1446; HOSOBUCHI Y, 1982, SCIENCE, V215, P69, DOI 10.1126/science.6274019; Kawalec M, 2011, NEUROCHEM RES, V36, P2091, DOI 10.1007/s11064-011-0568-1; Kochanek K.D., 2013, NCHS DATA BRIEF, V2014, P1; Krause D. N, 2002, CEREBRAL BLOOD FLOW; Lazarczyk M, 2010, PEPTIDES, V31, P1606, DOI 10.1016/j.peptides.2010.05.002; Lee YS, 2007, BIOORG MED CHEM LETT, V17, P2161, DOI 10.1016/j.bmcl.2007.01.114; Lee YS, 2011, J MED CHEM, V54, P382, DOI 10.1021/jm100982d; Lesniak A, 2016, NEUROPHARMACOLOGY, V101, P506, DOI 10.1016/j.neuropharm.2015.10.014; Lo A, 2003, AM J PHYSIOL-HEART C, V285, pH955, DOI 10.1152/ajpheart.00278.2003; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lobner D, 2000, J NEUROSCI METH, V96, P147, DOI 10.1016/S0165-0270(99)00193-4; Lopez E, 2006, FREE RADICAL BIO MED, V40, P940, DOI 10.1016/j.freeradbiomed.2005.10.062; Marutani E, 2012, J BIOL CHEM, V287, P32124, DOI 10.1074/jbc.M112.374124; Mehrotra S, 2002, IMMUNOPHARM IMMUNOT, V24, P83, DOI 10.1081/IPH-120003405; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Petrov RR, 2006, BIOORG MED CHEM LETT, V16, P4946, DOI 10.1016/j.bmcl.2006.06.040; Rashid M, 2010, J PHARMACOL EXP THER, V335, P754, DOI 10.1124/jpet.110.171439; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SAKAMOTO A, 1991, BRAIN RES, V554, P186, DOI 10.1016/0006-8993(91)90187-Z; Sobczak M, 2014, PEPTIDES, V60, P102, DOI 10.1016/j.peptides.2014.08.005; Stewart LSA, 2003, COMPARATIVE MED, V53, P29; Sydserff SG, 1996, NEURODEGENERATION, V5, P81, DOI 10.1006/neur.1996.0011; Tang JL, 1998, INT J IMMUNOPHARMACO, V20, P457, DOI 10.1016/S0192-0561(98)00052-6; Tian XS, 2013, INT J MOL SCI, V14, P15959, DOI 10.3390/ijms140815959; Traystman RJ, 2010, STROKE, V41, pS63, DOI 10.1161/STROKEAHA.110.598557; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Wang ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041724; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; Yang L, 2015, BRAIN RES, V1609, P1, DOI 10.1016/j.brainres.2015.03.022; Yang L, 2011, J PHARMACOL EXP THER, V339, P499, DOI 10.1124/jpet.111.184127; Yang L, 2011, BRAIN RES, V1383, P307, DOI 10.1016/j.brainres.2011.01.083; Yang YL, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-55	63	10	10	0	3	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2016	22	42					6459	6468		10.2174/1381612822666160720170124			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EG9ZZ	WOS:000391423200014	27510489				2020-06-30	J	Gaszynski, T; Czarnik, K; Lazinski, L; Gaszynski, W				Gaszynski, Tomasz; Czarnik, Klaudia; Lazinski, Lukasz; Gaszynski, Wojciech			Dexmedetomidine for attenuating haemodynamic response to intubation stimuli in morbidly obese patients anaesthetised using low-opioid technique: comparison with fentanyl-based general anaesthesia	ANAESTHESIOLOGY INTENSIVE THERAPY			English	Article						dexmedetomidine; fentanyl; intubation; obesity	TOTAL INTRAVENOUS ANESTHESIA; BARIATRIC SURGERY; HYPERALGESIA	Background: Anaesthesiologists are facing the problem of an increasing population of morbidly obese patients. In order to minimize the risk of opioid-induced postoperative respiratory failure, the intraoperative administration of opioids should be reduced or replaced with other drugs. The purpose of this study was to compare haemodynamic response elicited by intubation in morbidly obese patients between two variants of anaesthesia induction: fentanylbased or low-opioid using dexmedetomidine. Methods: Forty-two morbidly obese patients scheduled for bariatric surgery were randomly assigned to two groups: low-opioid using dexmedetomidine (DEX) or fentanyl-based (FNT) anaesthesia. Patients were premedicated with 100 mu g of fentanyl i. v. In the DEX group, a 10 minute infusion of a loading dose of 200 mu g of dexmedetomidine was started. In the FNT group, 2 mg of intravenous midazolam was given. Thereafter, propofol was used in both groups. In the FNT group, patients received a dose of fentanyl up to 5 mu g kg(-1) of ideal body weight. Following administration of rocuronium, laryngoscopy and tracheal intubation were performed. Haemodynamic parameters, including systolic (SBP), diastolic (DBP) and mean arterial (MAP) blood pressure, as well as heart rate (HR), were recorded before and after intubation. Patients who were not intubated at first attempt were excluded from the study. Results: Data from 33 patients were analysed. There were no statistically significant differences between the DEX and FNT groups regarding demographic data. Haemodynamic response to intubation was defined as mean change (d) in values of analysed parameters that occurred during intubation. The following differences were observed: dSBP FNT + 11.6 mm Hg vs. DEX + 0.4 mm Hg (P = 0.15); dDBP FNT + 3.7 mm Hg vs. DEX + 3.5 mm Hg (P = 0.98); dMAP FNT + 8.6 mm Hg vs. DEX + 1.4 mm Hg (P = 0.36); dHR FNT + 2 beats min-1 vs. DEX-1 beat min(-1) (P = 0.30). None of these comparisons yielded significant differences. Conclusions: The study revealed no advantage of fentanyl over low opioid dexmedetomidine-based induction of general anaesthesia in attenuating cardiovascular response to intubation in morbidly obese patients.	[Gaszynski, Tomasz; Czarnik, Klaudia; Lazinski, Lukasz; Gaszynski, Wojciech] Med Univ Lodz, Al Kosciuszki 4, PL-90419 Lodz, Poland	Gaszynski, T (reprint author), Med Univ Lodz, Al Kosciuszki 4, PL-90419 Lodz, Poland.	tomasz.gaszynski@umed.lodz.pl		Czarnik, Klaudia/0000-0002-0065-558X			Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Bakan M, 2015, REV BRAS ANESTESIOL, V65, P191, DOI [10.1016/j.bjane.2014.05.001, 10.1016/j.bjan.2014.05.006]; Bakhamees Hassan S., 2007, Middle East Journal of Anesthesiology, V19, P537; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; CAMPBELL BC, 1984, BRIT J ANAESTH, V56, P257, DOI 10.1093/bja/56.3.257; Feld JM, 2006, J CLIN ANESTH, V18, P24, DOI 10.1016/j.jclinane.2005.05.009; Gaszynski T, 2002, ANESTEZJOL INTENS TE, V34, P291; Gaszynski T, 2003, TWOJ MAGAZYN MED CHI, V3, P55; Hofer RE, 2005, CAN J ANAESTH, V52, P176, DOI 10.1007/BF03027725; LACOUMENTA S, 1987, BRIT J ANAESTH, V59, P713, DOI 10.1093/bja/59.6.713; Lee MH, 2014, KOREAN J ANESTHESIOL, V66, P222, DOI 10.4097/kjae.2014.66.3.222; Mansour Mohamed Ahmed, 2013, Saudi J Anaesth, V7, P387, DOI 10.4103/1658-354X.121045; Misiolek H, 2014, ANAESTH INTENSIVE TH, V46, P221, DOI [10.5603/AIT.2014.0041, 10.5603/AIT.2014.041]; Mulier JP, OPIOID FREE ANAESTHE; Naranjo-Gonzalez M, 2015, REV MEX ANEST, V38; Rasmus A, 1994, ANESTEZJOL INTENS TE, V26, P145; Tufanogullari B, 2008, ANESTH ANALG, V106, P1741, DOI 10.1213/ane.0b013e318172c47c; Weinbroum AA, 2015, EUR J ANAESTH, V32, P230, DOI 10.1097/EJA.0000000000000231; Ziemann-Gimmel P, 2014, BRIT J ANAESTH, V112, P906, DOI 10.1093/bja/aet551	19	2	2	0	1	VIA MEDICA	GDANSK	UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND	1642-5758	1731-2531		ANAESTH INTENSIVE TH	Anaesth. Intensive Ther.		2016	48	5					275	279		10.5603/AIT.a2016.0058			5	Anesthesiology	Anesthesiology	EG2IX	WOS:000390868100001	27869287	DOAJ Gold			2020-06-30	J	Kabukcu, HK; Sahin, N; Ozkaloglu, K; Golbasi, I; Titiz, TA				Kabukcu, Hanife Karakaya; Sahin, Nursel; Ozkaloglu, Kezban; Golbasi, Ilhan; Titiz, Tulin Aydogdu			Bispectral Index Monitoring in Patients Undergoing Open Heart Surgery	BRAZILIAN JOURNAL OF CARDIOVASCULAR SURGERY			English	Article						Cardiopulmonary Bypass; Anesthesia; Monitoring, Intraoperative	GLUCOSE METABOLIC-RATE; CARDIAC ANESTHESIA; AWARENESS; PROPOFOL; INFORMATION; ALFENTANIL	Introduction: To obtain the optimal anesthesia depth is not easy in cardiovascular surgery patients where the haemodynamic reserve is limited, due to reasons such as not being able to give the desired dose of anesthetic agent, or the change in the pharmacokinetics of the agent in the heart-lung machine. This study was planned to assess the contribution of bispectral index (BIS) monitoring in the depth of anesthesia. Methods: The patients were divided into 2 groups, and BIS monitoring was used for each patient. Group 1 (G1 n=35): keeping the BIS monitor screen open, the anesthesia need was set. Group 2 (G2 n=35): BIS monitor was tied to the patient and the monitor screen was closed in such a way that the anaesthesist couldn't see the BIS value. When the recording time came, the data on the monitor was recorded. The need for the anesthetic agent was set according to the parameters such as haemodynamics or follow up of pupils, instead of BIS value, by titrating the anesthetic infusion doses. Results: BIS values were similar in both groups before the induction, BIS values in both groups showed a decrease, showing no significant statistical difference (P>0.05). One patient in each group said that he dreamt, and one patient in G2 said that he had heard a noise and felt that he was taken from one place to another. Conclusion: The management should be done with clinical evaluation, haemodynamics and other monitorization methods and BIS monitoring findings together.	[Kabukcu, Hanife Karakaya; Sahin, Nursel; Ozkaloglu, Kezban; Golbasi, Ilhan; Titiz, Tulin Aydogdu] Akdeniz Univ, Fac Med, Antalya, Turkey	Kabukcu, HK (reprint author), Akdeniz Univ, Tip Fak, Dumlupinar Kampusu Anesteziyol & Reanimasyon AD, TR-07070 Antalya, Turkey.	hanifekabukcu@akdeniz.edu.tr		ozkaloglu erdem, kezban tuna/0000-0002-6657-6243			Alkire MT, 1998, ANESTHESIOLOGY, V89, P323, DOI 10.1097/00000542-199808000-00007; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; Goddard N, 2013, BJA EDUC, V13, P213, DOI 10.1093/bjaceaccp/mkt016; GRADY CL, 1991, J CEREBR BLOOD F MET, V11, pA57, DOI 10.1038/jcbfm.1991.38; Ma G, 2013, J CARDIOTHOR VASC AN, V27, P510, DOI 10.1053/j.jvca.2012.10.013; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Olivier P, 2000, J CARDIOTHOR VASC AN, V14, P29, DOI 10.1016/S1053-0770(00)90052-1; Orser BA, 2008, CAN MED ASSOC J, V178, P185, DOI 10.1503/cmaj.071761; Pinto Jr. Valdester Cavalcante, 2003, Braz. J. Cardiovasc. Surg., V18, P53, DOI 10.1590/S0102-76382003000100011; Ranta S, 1996, ACTA ANAESTH SCAND, V40, P554, DOI 10.1111/j.1399-6576.1996.tb04487.x; Ranta SOV, 2002, J CARDIOTHOR VASC AN, V16, P426, DOI 10.1053/jcan.2002.125149; Schwender D, 1998, BRIT J ANAESTH, V80, P133, DOI 10.1093/bja/80.2.133; Sebel PS, 1997, CAN J ANAESTH, V44, pR124, DOI 10.1007/BF03022271; Shapiro BA, 1999, CRIT CARE MED, V27, P1663, DOI 10.1097/00003246-199908000-00056; Shimizu T, 1997, CAN J ANAESTH, V44, P1162, DOI 10.1007/BF03013338; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; SKACEL M, 1986, BRIT J ANAESTH, V58, P947, DOI 10.1093/bja/58.9.947; Tiren C, 2005, ANAESTHESIA, V60, P189, DOI 10.1111/j.1365-2044.2004.04063.x; VICKERS MD, 1992, ANAESTHESIA, V47, P291, DOI 10.1111/j.1365-2044.1992.tb02166.x; Vretzakis G, 2005, J CLIN ANESTH, V17, P509, DOI 10.1016/j.jclinane.2004.12.018	21	0	0	0	7	SOC BRASIL CIRURGIA CARDIOVASC	SAO PAULO SP	RUA BEIRA RIO, 45, 7 ANDAR-CJ 72 VILA OLIMPIA, SAO PAULO SP, CEP04548-050, BRAZIL	0102-7638	1678-9741		BRAZ J CARDIOVA SURG	Braz. J. Cardiovasc. Surg.		2016	31	2					178	182		10.5935/1678-9741.20160038			5	Cardiac & Cardiovascular Systems; Surgery	Cardiovascular System & Cardiology; Surgery	EF1MV	WOS:000390089800018	27556320	DOAJ Gold, Green Published			2020-06-30	J	Derry, S; Stannard, C; Cole, P; Wiffen, PJ; Knaggs, R; Aldington, D; Moore, RA				Derry, Sheena; Stannard, Cathy; Cole, Peter; Wiffen, Philip J.; Knaggs, Roger; Aldington, Dominic; Moore, R. Andrew			Fentanyl for neuropathic pain in adults	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							RELEASE ORAL MORPHINE; OPIOID-NAIVE PATIENTS; QUALITY-OF-LIFE; TRANSDERMAL FENTANYL; RANDOMIZED WITHDRAWAL; TRIGEMINAL NEURALGIA; ENRICHED ENROLLMENT; GENERAL-POPULATION; TREATMENT OUTCOMES; EFFICACY	Background Opioid drugs, including fentanyl, are commonly used to treat neuropathic pain, and are considered effective by some professionals. Most reviews have examined all opioids together. This review sought evidence specifically for fentanyl, at any dose, and by any route of administration. Other opioids are considered in separate reviews. Objectives To assess the analgesic efficacy of fentanyl for chronic neuropathic pain in adults, and the adverse events associated with its use in clinical trials. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase from inception to June 2016, together with the reference lists of retrieved articles, and two online study registries. Selection criteria We included randomised, double-blind studies of two weeks' duration or longer, comparing fentanyl (in any dose, administered by any route, and in any formulation) with placebo or another active treatment in chronic neuropathic pain. Data collection and analysis Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality and potential bias. We did not carry out any pooled analyses. We assessed the quality of the evidence using GRADE. Main results Only one study met our inclusion criteria. Participants were men and women (mean age 67 years), with postherpetic neuralgia, complex regional pain syndrome, or chronic postoperative pain. They were experiencing inadequate relief from non-opioid analgesics, and had not previously taken opioids for their neuropathic pain. The study used an enriched enrolment randomised withdrawal design. It was adequately blinded, but we judged it at unclear risk of bias for other criteria. Transdermal fentanyl (one-day fentanyl patch) was titrated over 10 to 29 days to establish the maximum tolerated and effective dose (12.5 to 50 mu g/h). Participants who achieved a prespecified good level of pain relief with a stable dose of fentanyl, without excessive use of rescue medication or intolerable adverse events ('responders'), were randomised to continue with fentanyl or switch to placebo for 12 weeks, under double-blind conditions. Our prespecified primary outcomes were not appropriate for this study design, but the measures reported do give an indication of the efficacy of fentanyl in this condition. In the titration phase, 1 in 3 participants withdrew because of adverse events or inadequate pain relief, and almost 90% experienced adverse events. Of 258 participants who underwent open-label titration, 163 were 'responders' and entered the randomised withdrawal phase. The number of participants completing the study (and therefore continuing on treatment) without an increase of pain by more than 15/100 was 47/84 (56%) with fentanyl and 28/79 (35%) with placebo. Because only 63% responded sufficiently to enter the randomised withdrawal phase, this implies that only a maximum of 35% of participants entering the study would have had useful pain relief and tolerability with transdermal fentanyl, compared with 22% with placebo. Almost 60% of participants taking fentanyl were 'satisfied' and 'very satisfied' with their treatment at the end of the study, compared with about 40% with placebo. This outcome approximates to our primary outcome of moderate benefit using the Patient Global Impression of Change scale, but the group was enriched for responders and the method of analysis was not clear. The most common adverse events were constipation, nausea, somnolence, and dizziness. There was no information about other types of neuropathic pain, other routes of administration, or comparisons with other treatments. We downgraded the quality of the evidence to very low because there was only one study, with few participants and events, and there was no information about how data from people who withdrew were analysed. Authors' conclusions There is insufficient evidence to support or refute the suggestion that fentanyl works in any neuropathic pain condition.	[Derry, Sheena; Wiffen, Philip J.; Moore, R. Andrew] Univ Oxford, Pain Res, Oxford, England; [Derry, Sheena; Wiffen, Philip J.; Moore, R. Andrew] Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Div Anaesthet, Oxford, England; [Stannard, Cathy] Frenchay Hosp, Pain Clin, Macmillan Ctr, Bristol, Avon, England; [Cole, Peter] Oxford Univ Hosp NHS Trust, Oxford Pain ReliefUnit, Churchill Hosp, Oxford, England; [Knaggs, Roger] Univ Nottingham, Sch Pharm, Nottingham, England; [Aldington, Dominic] Royal Hampshire Cty Hosp, Winchester, Hants, England	Derry, S (reprint author), Univ Oxford, Churchill Hosp, Pain Res Unit, Pain Res, Oxford OX3 7LE, Oxon, England.; Derry, S (reprint author), Univ Oxford, Churchill Hosp, Nuffield Dept Clin Neurosci, Nuffield Div Anaesthet,Pain Res Unit, Oxford OX3 7LE, Oxon, England.	sheena.derry@ndcn.ox.ac.uk		Aldington, Dominic/0000-0001-6253-1649	Oxford Pain Relief Trust, UK; National Institute for Health Research (NIHR), UKNational Institute for Health Research (NIHR); NIHR Cochrane Programme [13/89/29]	Internal sources; Oxford Pain Relief Trust, UK.; General institutional support; External sources; The National Institute for Health Research (NIHR), UK.; NIHR Cochrane Programme Grant: 13/89/29 - Addressing the unmet need of chronic pain: providing the evidence for treatments of pain	Agarwal S, 2007, PAIN MED, V8, P554, DOI 10.1111/j.1526-4637.2006.00246.x; Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Arai T, 2015, CURR MED RES OPIN, V31, P2207, DOI 10.1185/03007995.2015.1092127; Baron R, 2012, LANCET NEUROL, V11, P19, DOI 10.1016/S1474-4422(11)70281-2; Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5; Bouhassira D, 2008, PAIN, V136, P380, DOI 10.1016/j.pain.2007.08.013; BULLINGHAM RES, 1984, LIFE SCI, V34, P2047, DOI 10.1016/0024-3205(84)90369-2; Cachia Elaine, 2011, Curr Opin Support Palliat Care, V5, P15, DOI 10.1097/SPC.0b013e3283437a39; Canneti A, 2013, MINERVA ANESTESIOL, V79, P871; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Derry S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010958.pub2; Derry S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007393.pub3; Derry S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010111; Di Franco M, 2010, CLIN EXP RHEUMATOL, V28, pS110; [丁远远 Ding Yuanyuan], 2014, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V41, P1307; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Franco ML, 2002, PAIN CLINIC, V14, P99, DOI 10.1163/156856902760196315; Franklin GM, 2014, NEUROLOGY, V83, P1277, DOI 10.1212/WNL.0000000000000839; Gaskell H, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010692.pub2; Gustorff B, 2008, ACTA ANAESTH SCAND, V52, P132, DOI 10.1111/j.1399-6576.2007.01486.x; Guyatt G, 2013, J CLIN EPIDEMIOL, V66, P151, DOI 10.1016/j.jclinepi.2012.01.006; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Hall GC, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-28; Hall GC, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-26; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hoffman DL, 2010, PAIN, V149, P194, DOI 10.1016/j.pain.2009.09.017; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Janssen Pharmaceutical KK (Sponsors), CONF STUD FENT PART; Jensen TS, 2011, PAIN, V152, P2204, DOI 10.1016/j.pain.2011.06.017; Kalso E, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7339; Kalso E, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-39; KATUSIC S, 1991, NEUROEPIDEMIOLOGY, V10, P276, DOI 10.1159/000110284; Koopman JSHA, 2009, PAIN, V147, P122, DOI 10.1016/j.pain.2009.08.023; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Lange B, 2010, ADV THER, V27, P381, DOI 10.1007/s12325-010-0036-3; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lunn MPT, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007115.pub3; McNicol ED, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006146.pub2; MCQUAY H, 1998, EVIDENCE BASED RESOU; MCQUAY HJ, 1979, BRIT J ANAESTH, V51, P543, DOI 10.1093/bja/51.6.543; McQuay HJ, 2007, HLTH CARE NEEDS ASSE, P519; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Mitra F, 2011, AUSTR PAIN SOC C DAR, V39, P747; Moisset X, 2007, NEUROIMAGE, V37, pS80, DOI 10.1016/j.neuroimage.2007.03.054; Moore A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2690; Moore RA, 2014, EUR J PAIN, V18, P67, DOI 10.1002/j.1532-2149.2013.00341.x; Moore RA, 2013, ANAESTHESIA, V68, P400, DOI 10.1111/anae.12148; Moore RA, 2010, ANN RHEUM DIS, V69, P374, DOI 10.1136/ard.2009.107805; Moore RA, 2015, PAIN, V156, P1382, DOI 10.1097/j.pain.0000000000000088; Moore RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007076.pub2; Moore RA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007938.pub3; Moore R Andrew, 2012, Cochrane Database Syst Rev, V12, pCD008242, DOI 10.1002/14651858.CD008242.pub2; Moore RA, 2012, PAIN, V153, P265, DOI 10.1016/j.pain.2011.10.004; Moore RA, 2011, PAIN, V152, P982, DOI 10.1016/j.pain.2010.11.030; Moore RA, 2010, PAIN, V151, P592, DOI 10.1016/j.pain.2010.07.013; Moore RA, 2010, PAIN, V150, P386, DOI 10.1016/j.pain.2010.05.011; Moore RA, 2010, PAIN, V149, P431, DOI 10.1016/j.pain.2010.02.032; Moore RA, 2010, PAIN, V149, P360, DOI 10.1016/j.pain.2010.02.039; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; Moore RA, 2008, SYSTEMATIC REV PAIN, V1, P15; Moore RA, 2014, PAIN PRACT, V14, P79, DOI 10.1111/papr.12050; Moore RA, 2011, EUR J ANAESTH, V28, P427, DOI 10.1097/EJA.0b013e328343c569; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; National Institute for Health and Care Excellence (NICE), 2013, NEUR PAIN PHARM MAN; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Nordic Cochrane Centre, 2014, REV MAN REVMAN VERS; O'Brien EM, 2010, PAIN MED, V11, P6, DOI 10.1111/j.1526-4637.2009.00685.x; O'Connor AB, 2009, AM J MED, V122, pS22, DOI 10.1016/j.amjmed.2009.04.007; Park JH, 2011, ACTA NEUROCHIR, V153, P181, DOI 10.1007/s00701-010-0785-4; [Prescribing and Medicines Team Health and Social Care Information Centre], 2014, PRESCR COST AN, P309; RAPPAPORT ZH, 1994, PAIN, V56, P127, DOI 10.1016/0304-3959(94)90086-8; Raptis E, 2014, PAIN PRACT, V14, P32, DOI 10.1111/papr.12045; Soni A, 2013, ARTHRITIS RHEUM-US, V65, P1942, DOI 10.1002/art.37962; Straube S, 2008, BRIT J CLIN PHARMACO, V66, P266, DOI 10.1111/j.1365-2125.2008.03200.x; Straube S, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-150; Sultan A, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-29; Torrance N, 2006, J PAIN, V7, P281, DOI 10.1016/j.jpain.2005.11.008; Tracey I, 2011, NAT REV NEUROL, V7, P173, DOI 10.1038/nrneurol.2011.4; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; van Hecke O, 2014, PAIN, V155, P654, DOI 10.1016/j.pain.2013.11.013; Vo T, 2009, PAIN, V143, P169, DOI 10.1016/j.pain.2009.03.013; von Hehn CA, 2012, NEURON, V73, P638, DOI 10.1016/j.neuron.2012.02.008; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Weisberg DF, 2014, INT J DRUG POLICY, V25, P1124, DOI 10.1016/j.drugpo.2014.07.009; Wiffen PJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011603.pub2; Wiffen PJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010567.pub2; Zin CS, 2014, EUR J PAIN, V18, P1343, DOI 10.1002/j.1532-2149.2014.496.x	92	16	16	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2016		10							CD011605	10.1002/14651858.CD011605.pub2			35	Medicine, General & Internal	General & Internal Medicine	EE4UD	WOS:000389599900021		Green Published			2020-06-30	J	Daszkiewicz, A; Janik, A; Sliwczynska, M; Karpe, J; Misiolek, H				Daszkiewicz, Andrzej; Janik, Andrzej; Sliwczynska, Magdalena; Karpe, Jacek; Misiolek, Hanna			A comparison of selective and conventional spinal anaesthesia for ambulatory surgery	ANAESTHESIOLOGY INTENSIVE THERAPY			English	Article						ambulatory surgery; anaesthesia; spinal anaesthesia; selective spinal anaesthesia; local anaesthetics; lidocaine; opioids; fentanyl	OUTPATIENT KNEE ARTHROSCOPY; MINIDOSE LIDOCAINE-FENTANYL; INGUINAL HERNIORRHAPHY; DISCHARGE; RECOVERY; MANAGEMENT; CRITERIA; PAIN	Background: Selective spinal anaesthesia is the practice of employing minimal doses of intrathecal agents so that only the nerve roots supplying a specific area and only the modalities that require to be anaesthetised are affected.. The study is based on the hypothesis that small dose lidocaine spinal anaesthesia may be adequate for elective surgical procedures, providing limited motor and sensory block, and thus enabling earlier patient's discharge. The aim of this study was the comparison of the low and the conventional dose of lidocaine spinal anaesthesia discharge time. Methods: The study was a prospective, randomized controlled single-blind trial, with 84 patients enrolled. Patients in study group (SS-L, Selective Spinal Lidocaine) were administered 3 mL of a 0.8% lidocaine solution containing 24 mg of lidocaine and 15 mu g of fentanyl into the subarachnoid space. Patients in the control group (CD-L, Conventional Dose Lidocaine) received 5 mL of a 1% lidocaine solution containing 50 mg of lidocaine and 25 mu g of fentanyl into the subarachnoid space. Discharge time was evaluated. Results: In the SS-L group time to discharge were shorter (P < 0.01) compared to the CD-L group. Conclusion: Selective spinal anaesthesia with low dose of lidocaine decreases the time of patient discharge compared with conventional lidocaine dose spinal anaesthesia.	[Daszkiewicz, Andrzej] Med Univ Silesia, Sch Hlth Sci, Sch Med, Dept Res & Treatment Pain,Div Dent Zabrze, Katowice, Poland; [Janik, Andrzej] Reg Hosp, Dept Internal Diseases, Staszow, Poland; [Sliwczynska, Magdalena] Med Univ Silesia, Dept Anaesthesiol & Crit Care Zabrze, Sch Hlth Sci, Katowice Students Sci Club, Katowice, Poland; [Karpe, Jacek; Misiolek, Hanna] Med Univ Silesia, Sch Hlth Sci, Sch Med, Dept Anaesthesiol & Crit Care,Div Dent Zabrze, Katowice, Poland	Misiolek, H (reprint author), SPSK 1 Zabrzu, Klin Anestezjol & Intensywnej Terapii, 3 Maja 13-15, PL-41800 Zabrze, Poland.	hanna.misiolek@gmail.com					Awad IT, 2006, CAN J ANAESTH, V53, P858, DOI 10.1007/BF03022828; Baldini G, 2009, ANESTHESIOLOGY, V110, P1139, DOI 10.1097/ALN.0b013e31819f7aea; Ben-David B, 2000, ANESTH ANALG, V91, P865, DOI 10.1097/00000539-200010000-00018; Ben-David B, 2001, ANESTH ANALG, V93, P319, DOI 10.1097/00000539-200108000-00016; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Casati A, 2007, ANESTH ANALG, V104, P959, DOI 10.1213/01.ane.0000258766.73612.d8; CHUNG F, 1995, J CLIN ANESTH, V7, P500, DOI 10.1016/0952-8180(95)00130-A; Elvir-Lazo OL, 2010, CURR OPIN ANESTHESIO, V23, P697, DOI 10.1097/ACO.0b013e32833fad0a; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; Hocking G, 2007, UPDATE ANAESTHESIA, V22, P23; Korhonen AM, 2006, CURR OPIN ANESTHESIO, V19, P612, DOI 10.1097/ACO.0b013e32801042c7; Lamonerie L, 2004, BRIT J ANAESTH, V92, P544, DOI 10.1093/bja/aeh099; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Marshall SI, 1999, ANESTH ANALG, V88, P508, DOI 10.1097/00000539-199903000-00008; Marshall SI, 1997, CURR OPIN ANAESTH, V10, P445, DOI [DOI 10.1097/00001503-1997112000-00011, 10.1097/00001503-1997112000-00011]; McGrath Brid, 2003, Anesthesiol Clin North Am, V21, P367, DOI 10.1016/S0889-8537(02)00080-9; Mulroy MF, 2002, ANESTHESIOLOGY, V97, P315, DOI 10.1097/00000542-200208000-00005; Mulroy MF, 2009, ANESTHESIOLOGY, V111, P1388, DOI 10.1097/ALN.0b013e3181bfa8d3; Pavlin DJ, 1999, ANESTH ANALG, V89, P90, DOI 10.1097/00000539-199907000-00016; Pavlin DJ, 1998, ANESTH ANALG, V87, P816, DOI 10.1097/00000539-199810000-00014; Pavlin DJ, 1999, ANESTHESIOLOGY, V91, P42, DOI 10.1097/00000542-199907000-00010; PETERSENFELIX S, 1993, ANESTHESIOLOGY, V79, P959, DOI 10.1097/00000542-199311000-00014; PFLUG AE, 1978, CAN ANAESTH SOC J, V25, P133, DOI 10.1007/BF03005071; Roberts L, 1998, AMBUL SURG, V6, P3; Sethi N, 2007, INTERNET J ANESTHESI, V15, DOI [10.5580/1e8, DOI 10.5580/1E8]; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; Urmey William F, 2003, Best Pract Res Clin Anaesthesiol, V17, P335, DOI 10.1016/S1521-6896(03)00015-6; Vaghadia H, 1998, CAN J ANAESTH, V45, pR64, DOI 10.1007/BF03019208; Vaghadia H, 1997, ANESTH ANALG, V84, P59, DOI 10.1097/00000539-199701000-00011; WANG JK, 1979, ANESTHESIOLOGY, V50, P149, DOI 10.1097/00000542-197902000-00013; ZBINDEN AM, 1994, ANESTHESIOLOGY, V80, P253, DOI 10.1097/00000542-199402000-00004; Zoellner C, 2007, HDB EXP PHARM, V177, P31	32	2	2	0	0	VIA MEDICA	GDANSK	UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND	1642-5758	1731-2531		ANAESTH INTENSIVE TH	Anaesth. Intensive Ther.		2016	48	4					220	227		10.5603/AIT.2016.0046			8	Anesthesiology	Anesthesiology	EB6DD	WOS:000387470400003	27797093	DOAJ Gold			2020-06-30	J	Khan, I; Chatterjee, AB; Bellinger, CR; Haponik, E				Khan, Irtaza; Chatterjee, Arjun B.; Bellinger, Christina R.; Haponik, Edward			Sedation for Bronchoscopy and Complications in Obese Patients	RESPIRATION			English	Article						Bronchoscopy; Sedation; Obesity; Complications	FLEXIBLE FIBEROPTIC BRONCHOSCOPY; SAGITTAL ABDOMINAL DIAMETER; DRUG REQUIREMENTS; OXYGEN-SATURATION; US ADULTS; PREVALENCE; ACCURACY; SAFETY; TRENDS; RISK	Background: Bronchoscopy is a safe and minimally invasive diagnostic tool, but no studies have reported prospectively on sedation and outcomes in patients with objectively defined obesity. Objectives: The purpose of the study is to determine if obese patients require more sedation or had more procedural complications during bronchoscopy under moderate sedation than non-obese patients. Methods: We evaluated complications and sedation requirements in non-obese versus obese patients, defined by multiple criteria including body mass index (BMI), neck circumference, abdominal height, and Mallampati scores. Results: Data were collected prospectively in 258 patients undergoing bronchoscopy under moderate sedation. By varying criteria, there were the following proportions of obese patients: 30% by BMI >30, 39% by neck circumference >40 cm, and 35% by abdominal height >22 cm in males and >20 cm in females. Sedative and analgesic dosing was not clinically significantly higher in obese patients than in non-obese patients. There was no difference in complications or procedural success based on obesity criteria. Hemoglobin oxygen desaturations occurred more often during bronchoscopy in patients with increasing Mallampati scores (p = 0.04), but this had no effect on bronchoscopy time or successful completion of the procedure. A subset of patients with previous polysomnogram-proven obstructive sleep apnea were more likely to have earlier termination of their procedure (15.8%) than patients with no diagnosed sleep apnea (2.3%; p = 0.002). Conclusion: In this prospective assessment of patients with obesity, we found neither clinically significant differences in sedation needs nor increases in complications in obese versus non-obese patients using a variety of indices of obesity. (C) 2016 S. Karger AG, Basel	[Khan, Irtaza] Salem Chest Specialists, Winston Salem, NC USA; [Chatterjee, Arjun B.; Bellinger, Christina R.; Haponik, Edward] Wake Forest Baptist Hlth, Winston Salem, NC USA	Bellinger, CR (reprint author), Wake Forest Baptist Hlth, Dept Pulm Crit Care, Med Ctr Blvd, Winston Salem, NC 27157 USA.	cbelling@wakehealth.edu	chatterjee, arjun B/H-2689-2013	chatterjee, arjun B/0000-0001-8221-873X			Bellinger CR, J BRONCHOL IN PRESS; Blouin RA, 1999, J PHARM SCI, V88, P1, DOI 10.1021/js980173a; Chhajed PN, 2005, RESPIRATION, V72, P617, DOI 10.1159/000089577; Chhajed PN, 2005, TRANSPLANTATION, V80, P1081, DOI 10.1097/01.tp.0000176925.13074.90; Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4; Cillo JE, 2005, J ORAL MAXIL SURG, V63, P752, DOI 10.1016/j.joms.2005.02.004; CREDLE WF, 1974, AM REV RESPIR DIS, V109, P67; Dang D, 2012, INTERN MED J, V42, P300, DOI 10.1111/j.1445-5994.2010.02261.x; DHARIWAL A, 1992, GASTROINTEST ENDOSC, V38, P684, DOI 10.1016/S0016-5107(92)70564-1; DREISIN RB, 1978, CHEST, V74, P144, DOI 10.1378/chest.74.2.144; Eikermann Matthias, 2010, Open Respir Med J, V4, P58, DOI 10.2174/1874306401004010058; Empana JP, 2004, CIRCULATION, V110, P2781, DOI 10.1161/01.CIR.0000146395.64065.BA; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Geraci G, 2007, ANN ITAL CHIR, V78, P183; Iribarren C, 2006, AM J EPIDEMIOL, V164, P1150, DOI 10.1093/aje/kwj341; IWAO T, 1994, GASTROINTEST ENDOSC, V40, P277, DOI 10.1016/S0016-5107(94)70055-9; Jin FG, 2008, RESPIRATION, V76, P429, DOI 10.1159/000151656; Kaparianos A, 2008, EUR REV MED PHARMACO, V12, P355; KATZ I, 1990, AM REV RESPIR DIS, V141, P1228, DOI 10.1164/ajrccm/141.5_Pt_1.1228; Khan I, 2010, CLIN PULM MED, V17, P244; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; Maltais F, 1996, CHEST, V109, P1195, DOI 10.1378/chest.109.5.1195; Meghjee SPL, 2001, RESP MED, V95, P5, DOI 10.1053/rmed.2000.0925; Moore WC, 2011, J ALLERGY CLIN IMMUN, V128, P328, DOI 10.1016/j.jaci.2011.02.042; Ochs-Balcom HM, 2006, CHEST, V129, P853, DOI 10.1378/chest.129.4.853; Passannante Anthony N, 2005, Anesthesiol Clin North Am, V23, P479, DOI 10.1016/j.atc.2005.02.005; PEREIRA W, 1978, CHEST, V73, P813, DOI 10.1378/chest.73.6.813; PUE CA, 1995, CHEST, V107, P430, DOI 10.1378/chest.107.2.430; Putinati S, 1999, CHEST, V115, P1437, DOI 10.1378/chest.115.5.1437; Riserus U, 2010, J OBES, V2010, DOI 10.1155/2010/757939; Romero-Corral A, 2008, INT J OBESITY, V32, P959, DOI 10.1038/ijo.2008.11; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; SURATT PM, 1976, CHEST, V69, P747, DOI 10.1378/chest.69.6.747; Sweitzer BJ, 2009, MED CLIN N AM, V93, P1017, DOI 10.1016/j.mcna.2009.05.009	35	6	6	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0025-7931	1423-0356		RESPIRATION	Respiration		2016	92	3					158	165		10.1159/000448250			8	Respiratory System	Respiratory System	DX9GO	WOS:000384701800006	27595264				2020-06-30	J	Oishi, N; Herrero, R; Martin, A; Basterra, J; Zapater, E				Oishi, Natsuki; Herrero, Ricard; Martin, Ana; Basterra, Jorge; Zapater, Enrique			Is testing the voice under sedation reliable in medialization thyroplasty?	LOGOPEDICS PHONIATRICS VOCOLOGY			English	Article						Acoustic analysis; medialization thyroplasty; position; sedation	VOCAL FOLD MEDIALIZATION; GENERAL-ANESTHESIA; LARYNGEAL MASK; LARYNGOPLASTY; EXPERIENCE; SURGERY	Objectives. Medialization thyroplasty is an accepted method for improving non-compensated unilateral vocal cord palsy. Most surgeons decide the depth of penetration of the prosthesis by monitoring the voice changes in the patient during the surgical procedure. General anesthesia with intubation is incompatible with this procedure. Sedation is recommended. In this study we want to objectivize and quantify the influence of sedation and position on voice in order to know if this anesthetic procedure is justified in medialization thyroplasties.Study design. A prospective study.Methods. This study involved 15 adult patients who underwent sedation. Voice recordings were performed in each patient in three different positions and conditions: the seated position without sedation, the supine position without sedation, and the supine position under the effects of sedation. The sedation drugs used were midazolam, fentanyl, and propofol. The level of sedation was monitored using the observational scale and the bispectral index.Results. The acoustic data obtained from sustained vowel sounds from patient recordings showed that sedation significantly affected the values of pitch. Compared to recordings from patients without sedation, pitch values in patients under sedation were significantly higher for jitter local and shimmer local recordings and significantly lower for pitch and harmonics-to-noise ratio. The supine position was shown not to influence on the voice.Conclusions. Sedation exerts an important influence on voice quality. General anesthesia could be an alternative, focusing our attention on monitoring the glottis with a fibrolaryngoscope during the surgical procedure. No sedation at all can also be an alternative.	[Oishi, Natsuki; Herrero, Ricard; Basterra, Jorge; Zapater, Enrique] Univ Gen Hosp, ENT Dept, Valencia, Spain; [Martin, Ana] Univ Gen Hosp, Dept Anesthesiol, Valencia, Spain	Oishi, N (reprint author), Hosp Gen Univ Valencia, ENT Dept, Avda Tres Cruces, Valencia 46014, Spain.	dramiriamoishi@gmail.com	Oishi, Natsuki/E-3785-2019	Oishi, Natsuki/0000-0002-0920-3483	Spanish Ministry of Economy and Competitiveness; FEDEREuropean Union (EU) [FFI2013-46987-C3-1P]	The acoustic analysis of the second author (R.H.) has been supported by the Spanish Ministry of Economy and Competitiveness and the FEDER [project number FFI2013-46987-C3-1P].	ARNOLD GE, 1962, ARCHIV OTOLARYNGOL, V76, P358; Boersma P., 2001, GLOT INT, V5, P341, DOI DOI 10.1097/AUD.0B013E31821473F7; Carrau RL, 1998, LARYNGOSCOPE, V108, P769, DOI 10.1097/00005537-199805000-00026; CUMMINGS CW, 1993, ANN OTO RHINOL LARYN, V102, P843, DOI 10.1177/000348949310201104; Friedrich G, 1999, ANN OTO RHINOL LARYN, V108, P79, DOI 10.1177/000348949910800112; Friedrich G, 2007, EUR ARCH OTO-RHINO-L, V264, P1191, DOI 10.1007/s00405-007-0333-x; Giovanni A, 1999, LARYNGOSCOPE, V109, P284, DOI 10.1097/00005537-199902000-00020; Griffin M, 1998, ANAESTHESIA, V53, P1202, DOI 10.1046/j.1365-2044.1998.00609.x; Grundler S, 1999, CAN J ANAESTH, V46, P460, DOI 10.1007/BF03012945; Harries ML, 1996, J OTOLARYNGOL, V105, P280; Ibrahim AE, 2001, ANESTHESIOLOGY, V95, P1151, DOI 10.1097/00000542-200111000-00019; Kanazawa T, 2014, ACTA OTO-LARYNGOL, V134, P193, DOI 10.3109/00016489.2013.847283; Michel F, 2003, Ann Otolaryngol Chir Cervicofac, V120, P259; MONTGOMERY WW, 1993, ANN OTO RHINOL LARYN, V102, P571, DOI 10.1177/000348949310200801; Montgomery WW, 1997, ANN OTO RHINOL LARYN, V106, P1; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Razzaq I, 2000, BRIT J ANAESTH, V85, P547, DOI 10.1093/bja/85.4.547; Rosen CA, 1998, LARYNGOSCOPE, V108, P1697, DOI 10.1097/00005537-199811000-00020; Tokashiki R, 2007, ACTA OTO-LARYNGOL, V127, P328, DOI 10.1080/00016480600746289; Woo P, 2001, OTOLARYNG HEAD NECK, V124, P615, DOI 10.1067/mhn.2001.116021; Zapater E, 2014, LARYNGOSCOPE, V124, P1659, DOI 10.1002/lary.24545	21	0	0	1	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1401-5439	1651-2022		LOGOP PHONIATR VOCO	Logop. Phoniatr. Vocology.		2016	41	4					149	153		10.3109/14015439.2015.1054306			5	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	DW3CO	WOS:000383519900002	26134182				2020-06-30	J	Meesters, NJ; van Dijk, M; Knibbe, CAJ; Keyzer-Dekker, CMG; Tibboel, D; Simons, SHP				Meesters, Naomi J.; van Dijk, Monique; Knibbe, Catherijne A. J.; Keyzer-Dekker, Claudia M. G.; Tibboel, Dick; Simons, Sinno H. P.			Infants Operated on for Necrotizing Enterocolitis: Towards Evidence-Based Pain Guidelines	NEONATOLOGY			English	Article						Necrotizing enterocolitis; Analgesia; Pain management; Premature infants	PRETERM INFANTS; PROLONGED PAIN; OUTCOMES; SCALE; MANAGEMENT	Background: Necrotizing enterocolitis (NEC) is known as an extremely painful childhood condition. Objectives: The objective of this study was to explore pain management around NEC-related surgery in our neonatal intensive care unit (NICU) from a chart review of prospectively collected data on 60 operated NEC patients admitted between 2008 and 2013 with a median (IQR) gestational age of 28.3 (25.5-31.6) weeks. Methods: Pain medication data and pain scores (i.e. COMFORTneo and Numerical Rating Scale pain and distress scores) from 72 h before until 72 h after surgery were collected. Results: Preoperatively, 95% of the patients received morphine versus 100% postoperatively, with a median dosage of 10.0 (IQR 9.7-14.5) and 16.9 (IQR 10.1-20.0) mu g/kg/h, respectively. Postoperatively, 28 patients (46.7%) received additional fentanyl intermittently and 14 (23.3%) received midazolam, which was part of palliative treatment for 6 patients (42.9%). In patients receiving pain medication, median COMFORTneo scores were 10 (IQR 10-11) preoperatively and 11 (10-12) postoperatively. The pain scores were comparable with those of other patients admitted to the NICU in the same time period. Conclusions: Continuous morphine of 10 mu g/kg/h preoperatively, with an increase to 15 g/kg/h postoperatively, seems to constitute a good starting dose for further individualized pain management guided by pain scores. (C) 2016 The Author(s) Published by S. Karger AG, Basel	[Meesters, Naomi J.; van Dijk, Monique; Simons, Sinno H. P.] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Div Neonatol,Dept Pediat, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands; [van Dijk, Monique; Keyzer-Dekker, Claudia M. G.; Tibboel, Dick] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Intens Care, Rotterdam, Netherlands; [van Dijk, Monique; Keyzer-Dekker, Claudia M. G.; Tibboel, Dick] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat Surg, Rotterdam, Netherlands; [Knibbe, Catherijne A. J.] Leiden Univ, LACDR, Div Pharmacol, Leiden, Netherlands	Meesters, NJ (reprint author), Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Div Neonatol,Dept Pediat, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	n.meesters@erasmusmc.nl	simons, sinno/AAC-7442-2019	van Dijk, Monique/0000-0002-9856-0318; Simons, Sinno/0000-0001-5219-5696			Amer Acad Pediat, 2006, PEDIATRICS, V118, P2231, DOI 10.1542/peds.2006-2277; Bradshaw WT, 2009, J PERINAT NEONAT NUR, V23, P87, DOI 10.1097/JPN.0b013e318196fefb; Ceelie I, 2013, JAMA-J AM MED ASSOC, V309, P149, DOI 10.1001/jama.2012.148050; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; Coit AK, 1999, J PERINAT NEONAT NUR, V12, P53, DOI 10.1097/00005237-199903000-00006; Debillon T, 2001, ARCH DIS CHILD-FETAL, V85, pF36, DOI 10.1136/fn.85.1.F36; Downard CD, 2012, J PEDIATR SURG, V47, P2111, DOI 10.1016/j.jpedsurg.2012.08.011; Gibbins S, 2006, NEONATAL NETW, V25, P339, DOI 10.1891/0730-0832.25.5.339; Gordon PV, 2009, PEDIATR RES, V65, P138, DOI 10.1203/PDR.0b013e31818c7920; Gregory Katherine E, 2011, Adv Neonatal Care, V11, P155, DOI 10.1097/ANC.0b013e31821baaf4; Gregory KE, 2011, ADV NEONATAL CARE, V11, P165; Grunau RE, 2004, PEDIATRICS, V114, pE77, DOI 10.1542/peds.114.1.e77; Grunau RE, 2006, SEMIN FETAL NEONAT M, V11, P268, DOI 10.1016/j.siny.2006.02.007; Hall NJ, 2013, J PEDIATR SURG, V48, P2359, DOI 10.1016/j.jpedsurg.2013.08.006; Henry MCW, 2004, SEMIN PERINATOL, V28, P221, DOI 10.1053/j.semperi.2004.03.010; Huda Shehzad, 2014, Pathophysiology, V21, P3, DOI 10.1016/j.pathophys.2013.11.009; KISSIN I, 1990, ANESTH ANALG, V71, P137; Krekels EHJ, 2014, CLIN PHARMACOKINET, V53, P553, DOI 10.1007/s40262-014-0135-4; Murthy K, 2014, J PERINATOL, V34, P736, DOI 10.1038/jp.2014.153; Noerr Barbara, 2003, Adv Neonatal Care, V3, P107; Pike K, 2012, ARCH DIS CHILD-FETAL, V97, pF318, DOI 10.1136/fetalneonatal-2011-300244; Schechter NL, 2003, PAIN INFANTS CHILDRE; Thiagarajah S, 2007, ANESTHESIOLOGYNEWS; van Dijk M, 2009, CLIN J PAIN, V25, P607, DOI 10.1097/AJP.0b013e3181a5b52a	24	6	6	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1661-7800	1661-7819		NEONATOLOGY	Neonatology		2016	110	3					190	197		10.1159/000445284			8	Pediatrics	Pediatrics	DX0EO	WOS:000384034800004	27198526	Other Gold, Green Published			2020-06-30	J	Onk, D; Ayazoglu, TA; Onk, OA; Aksut, M; Gunay, M; Turkmen, K; Ozensoy, A; Ersoy, CY; Coban, A				Onk, Didem; Ayazoglu, Tulin Akarsu; Onk, Oruc Alper; Aksut, Mehmet; Gunay, Murat; Turkmen, Kultigin; Ozensoy, Aynur; Ersoy, Cigdem Yazici; Coban, Abdulkadir			Comparison of TIVA and Desflurane Added to a Subanaesthetic Dose of Propofol in Patients Undergoing Coronary Artery Bypass Surgery: Evaluation of Haemodynamic and Stress Hormone Changes	BIOMED RESEARCH INTERNATIONAL			English	Article							TOTAL INTRAVENOUS ANESTHESIA; CARDIOPULMONARY BYPASS; CARDIAC ANESTHESIA; REMIFENTANIL; SEVOFLURANE; INDUCTION; RESPONSES; VOLATILE; CORTISOL	Introduction. Increased levels of stress hormones are associated with mortality in patients undergoing coronary artery bypass grafting (CABG). Aim. To compare total intravenous anaesthesia (TIVA) and desflurane added to a subanaesthetic dose of propofol. Material and Methods. Fifty patients were enrolled in this study. Fentanyl (3-5mcg/kg/h) was started in both groups. Patients were divided into two groups. The PD group (n = 25) received 1 minimum alveolar concentration (MAC) desflurane anaesthesia in addition to propofol infusion (2-3 mg/kg/h), while P group (n = 25) received propofol infusion (5-6 mg/kg/h) only. Biochemical data, cortisol, and insulin levels were measured preoperatively (T0), after initiation of CPB but before cross-clamping the aorta (T1), after removal of the cross-clamp (T2), and at the 24th postoperative hour (T3). Results. Systolic, diastolic, and mean arterial pressure levels were significantly higher in PD group than those in P group in T1 and T2 measurements (p <= 0.05). CK-MB showed a significant decrease in group P (p <= 0.05). When we compared both groups, cortisol levels were significantly higher in PD group than P group (p <= 0.05). Conclusion. Stress and haemodynamic responses were better controlled using TIVA than desflurane inhalation added to a subanaesthetic dose of propofol in patients undergoing CABG.	[Onk, Didem] Erzincan Univ, Dept Anesthesiol, TR-24030 Erzincan, Turkey; [Ayazoglu, Tulin Akarsu] Goztepe Training & Res Hosp, Dept Anesthesiol, TR-34722 Istanbul, Turkey; [Onk, Oruc Alper] Erzincan Univ, Dept Cardiovasc Surg, TR-24030 Erzincan, Turkey; [Aksut, Mehmet] Kartal Kosuyolu High Specializat Training & Res H, Dept Cardiovasc Surg, TR-34865 Istanbul, Turkey; [Gunay, Murat; Coban, Abdulkadir] Erzincan Univ, Dept Biochem, TR-24030 Erzincan, Turkey; [Turkmen, Kultigin] Necmettin Erbakan Univ, Meram Sch Med, Div Nephrol, Dept Internal Med, TR-42080 Konya, Turkey; [Ozensoy, Aynur] Kartal Kosuyolu High Specializat Training & Res H, Dept Anesthesiol, TR-34865 Istanbul, Turkey; [Ersoy, Cigdem Yazici] Sisli Etfal Training & Res Hosp, Dept Internal Med, TR-34363 Istanbul, Turkey	Onk, D (reprint author), Erzincan Univ, Dept Anesthesiol, TR-24030 Erzincan, Turkey.	d.hesapdar@gmail.com					Burton D, 2004, CEACCP, V4, P144, DOI DOI 10.1093/BJACEACCP/MKH040; Carvalho G, 2009, J CARDIOTHOR VASC AN, V23, P901, DOI 10.1053/j.jvca.2009.04.015; Desborough J. P., 1993, ANAESTHESIA REV, V10, P131; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; DESBOROUGH JP, 1989, BAILLIERE CLIN ANAES, V3, P317, DOI 10.1016/S0950-3501(89)80003-0; Eagle Kim A, 2004, Circulation, V110, pe340; Henzen C, 2003, EUR J ENDOCRINOL, V148, P663, DOI 10.1530/eje.0.1480663; Ihn CH, 2009, J INT MED RES, V37, P1760, DOI 10.1177/147323000903700612; Jezova D, 2008, ANN NY ACAD SCI, V1148, P495, DOI 10.1196/annals.1410.050; Kostopanagiotou G, 2010, HORM-INT J ENDOCRINO, V9, P67, DOI 10.14310/horm.2002.1255; Landoni G, 2011, ACTA ANAESTH SCAND, V55, P259, DOI 10.1111/j.1399-6576.2010.02381.x; LARIJANI GE, 1989, DICP ANN PHARMAC, V23, P743, DOI 10.1177/106002808902301001; Lehmann A, 1999, J CARDIOTHOR VASC AN, V13, P15, DOI 10.1016/S1053-0770(99)90166-0; MALATINSKY J, 1984, RESUSCITATION, V11, P57, DOI 10.1016/0300-9572(84)90034-0; Malhotra V., 2005, MILLERS ANESTHESIA, P1962; NAGAOKA H, 1989, ANN THORAC SURG, V48, P798, DOI 10.1016/0003-4975(89)90673-5; NEWBY LK, 1995, CLIN CHEM, V41, P1263; Ouattara A, 2003, BRIT J ANAESTH, V90, P617, DOI 10.1093/bja/aeg124; PIAT V, 1994, ANESTH ANALG, V79, P840; Rassias AJ, 2006, SEMIN THORAC CARDIOV, V18, P330, DOI 10.1053/j.semtcvs.2006.05.002; Roth-Isigkeit AK, 2000, STEROIDS, V65, P513, DOI 10.1016/S0039-128X(00)00133-1; Schoffmann G, 2009, LAB ANIM-UK, V43, P243, DOI 10.1258/la.2008.0080026; Silver Marc A, 2004, Congest Heart Fail, V10, P1, DOI 10.1111/j.1527-5299.2004.03271.x; WEISKOPF RB, 1994, ANESTHESIOLOGY, V80, P1035	24	3	4	0	6	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2016	2016								3272530	10.1155/2016/3272530			6	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	DT0CQ	WOS:000381150500001	27547757	DOAJ Gold, Green Published			2020-06-30	J	Borgaonkar, MR; Pace, D; Lougheed, M; Marcoux, C; Evans, B; Hickey, N; O'Leary, M; McGrath, J				Borgaonkar, Mark R.; Pace, David; Lougheed, Muna; Marcoux, Curtis; Evans, Bradley; Hickey, Nikita; O'Leary, Meghan; McGrath, Jerry			Canadian Association of Gastroenterology Indicators of Safety Compromise following Colonoscopy in Clinical Practice	CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article							COLORECTAL-CANCER; CONTROLLED-TRIAL; DELIVERY SYSTEM; ADVERSE EVENTS; RISK-FACTORS; COMPLICATIONS; ENDOSCOPY; QUALITY; POSTCOLONOSCOPY; PERFORATION	In 2012 the Canadian Association of Gastroenterology published 19 indicators of safety compromise. We studied the incidence of these indicators by reviewing all colonoscopies performed in St. John's, NL, between January 1, 2012, and June 30, 2012. Results. A total of 3235 colonoscopies were included. Adverse events are as follows. Medication-related includes use of reversal agents 0.1%, hypoxia 9.9%, hypotension 15.4%, and hypertension 0.9%. No patients required CPR or experienced allergic reactions or laryngospasm/bronchospasm. The indicator, "sedation dosages in patients older than 70," showed lower usage of fentanyl and midazolamin elderly patients. Procedure-related immediate includes perforation 0.2%, immediate postpolypectomy bleeding 0.3%, need for hospital admission or transfer to the emergency department 0.1%, and severe persistent abdominal pain proven not to be perforation 0.4%. Instrument impaction was not seen. Procedure-related delayed includes death within 14 days 0.1%, unplanned health care visit within 14 days of the colonoscopy 1.8%, unplanned hospitalization within 14 days of the colonoscopy 0.6%, bleeding within 14 days of colonoscopy 0.2%, infection 0.03%, and metabolic complication 0.03%. Conclusions. The most common adverse events were mild and sedation related. Rates of serious adverse events were in keeping with published reports.	[Borgaonkar, Mark R.; McGrath, Jerry] Mem Univ Newfoundland, Dept Med, St John, NF A1B 3V6, Canada; [Pace, David] Mem Univ Newfoundland, Dept Surg, St John, NF A1B 3V6, Canada; [Lougheed, Muna; Marcoux, Curtis; Evans, Bradley] Mem Univ Newfoundland, Fac Med, St John, NF A1B 3V6, Canada; [Hickey, Nikita] Dalhousie Univ, Dept Surg, Halifax, NS B3H 4R2, Canada; [O'Leary, Meghan] Queens Univ, Dept Obstet & Gynecol, Kingston, ON K7L 3 3N62, Canada	Borgaonkar, MR (reprint author), Mem Univ Newfoundland, Dept Med, St John, NF A1B 3V6, Canada.	markb@mun.ca					Armstrong D, 2012, CAN J GASTROENTEROL, V26, P17, DOI 10.1155/2012/173739; Azalgara VM, 2014, CAN J GASTROENTEROL, V28, P595, DOI 10.1155/2014/750587; Borgaonkar MR, 2012, CAN J GASTROENTEROL, V26, P71, DOI 10.1155/2012/782790; Bowles CJA, 2004, GUT, V53, P277, DOI 10.1136/gut.2003.016436; Cotton PB, 2010, GASTROINTEST ENDOSC, V71, P446, DOI 10.1016/j.gie.2009.10.027; Fehmi SMA, 2009, GASTROENTEROLOGY, V136, pA39; Froehlich F, 2006, ENDOSCOPY, V38, P461, DOI 10.1055/s-2006-925368; Gavin DR, 2013, GUT, V62, P242, DOI 10.1136/gutjnl-2011-301848; Kim HS, 2006, AM J GASTROENTEROL, V101, P1333, DOI 10.1111/j.1572-0241.2006.00638.x; Ko CW, 2010, CLIN GASTROENTEROL H, V8, P166, DOI 10.1016/j.cgh.2009.10.007; Levin TR, 2006, ANN INTERN MED, V145, P880, DOI 10.7326/0003-4819-145-12-200612190-00004; Lugay M, 1996, Gastroenterol Nurs, V19, P194, DOI 10.1097/00001610-199611000-00002; MacIntosh D, 2013, CAN J GASTROENTEROL, V27, P74, DOI 10.1155/2013/165804; Nelson DB, 2002, GASTROINTEST ENDOSC, V55, P307, DOI 10.1067/mge.2002.121883; NIVATVONGS S, 1988, AM SURGEON, V54, P61; Rabeneck L, 2008, GASTROENTEROLOGY, V135, P1899, DOI 10.1053/j.gastro.2008.08.058; Rex DK, 2009, AM J GASTROENTEROL, V104, P739, DOI 10.1038/ajg.2009.104; Robinson MHE, 1999, GUT, V45, P588, DOI 10.1136/gut.45.4.588; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; Singh H, 2009, GASTROINTEST ENDOSC, V69, P665, DOI 10.1016/j.gie.2008.09.046; Sumanac K, 2002, GASTROINTEST ENDOSC, V56, P190, DOI 10.1067/mge.2002.126391	21	2	2	0	2	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2291-2789	2291-2797		CAN J GASTROENTEROL	Can. J. Gastroenterol. Hepatol.		2016	2016								2729871	10.1155/2016/2729871			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	DQ2ST	WOS:000379054000001	27446832	DOAJ Gold, Green Published			2020-06-30	J	Francis, C; Vitalis, M; Thikra, S				Francis, Codero; Vitalis, Mung'ayi; Thikra, Sharif			A randomised controlled trial comparing the effect of adjuvant intrathecal 2 mg midazolam to 20 micrograms fentanyl on postoperative pain for patients undergoing lower limb orthopaedic surgery under spinal anaesthesia	AFRICAN HEALTH SCIENCES			English	Article						Midazolam fentanyl; lower limb; orthopaedic surgery; spinal anaesthesia	OPIOID-INDUCED PRURITUS; ANALGESIA; MANAGEMENT; PREVALENCE; EXPERIENCE; EFFICACY; REFLEXES; SAFETY	Background: Intrathecal adjuvants are added to local anaesthetics to improve the quality of neuraxial blockade and prolong the duration of analgesia during spinal anaesthesia. Used intrathecally, fentanyl improves the quality of spinal blockade as compared to plain bupivacaine and confers a short duration of post-operative analgesia. Intrathecal midazolam as an adjuvant has been used and shown to improve the quality of spinal anaesthesia and prolong the duration of post-operative analgesia. No studies have been done comparing intrathecal fentanyl with bupivacaine and intrathecal 2 mg midazolam with bupivacaine. Objective: To compare the effect of intrathecal 2mg midazolam to intrathecal 20 micrograms fentanyl when added to 2.6 ml of 0.5% hyperbaric bupivacaine, on post-operative pain, in patients undergoing lower limb orthopaedic surgery under spinal anaesthesia. Methods: A total of 40 patients undergoing lower limb orthopaedic surgery under spinal anaesthesia were randomized to two groups. Group 1: 2.6mls 0.5% hyperbaric bupivacaine with 0.4mls (20micrograms) fentanyl Group 2: 2.6mls of 0.5% hyperbaric bupivacaine with 0.4mls (2mg) midazolam Results: The duration of effective analgesia was longer in the midazolam group (384.05 minutes) as compared to the fentanyl group (342.6 minutes). There was no significant difference (P 0.4047). The time to onset was significantly longer in midazolam group 17.1 minutes as compared to the fentanyl group 13.2 minutes (P 0.023). The visual analogue score at rescue was significantly lower in the midazolam group (5.55) as compared to the fentanyl group 6.35 (P - 0.043). Conclusion: On the basis of the results of this study, there was no significant difference in the duration of effective analgesia between adjuvant intrathecal 2 mg midazolam as compared to intrathecal 20 micrograms fentanyl for patients undergoing lower limb orthopaedic surgery.	[Francis, Codero; Vitalis, Mung'ayi; Thikra, Sharif] Aga Khan Univ, Dept Anaesthesia, Karachi, East Africa, Pakistan	Vitalis, M (reprint author), Aga Khan Univ, Dept Anaesthesia, Karachi, East Africa, Pakistan.	vitalis.mung'ayi@aku.edu					Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Borg PAJ, 1996, CLIN J PAIN, V12, P63, DOI 10.1097/00002508-199603000-00012; Breivik H, 1998, EUR J ANAESTH, V15, P748, DOI 10.1097/00003643-199811000-00022; Carr DB, 1999, ANN REV NURSING RES, V353, P107; Dureja GP, 2010, PAIN PHYSICIAN, V13, P213; GOODCHILD CS, 1987, BRIT J CLIN PHARMACO, V23, P279, DOI 10.1111/j.1365-2125.1987.tb03046.x; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Ho KM, 2008, ANAESTH INTENS CARE, V36, P365, DOI 10.1177/0310057X0803600307; International Association for the Study of Pain, 1986, PAIN S, pS1; Kim MH, 2001, BRIT J ANAESTH, V86, P77, DOI 10.1093/bja/86.1.77; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; Kyriakides K, 1999, BRIT J ANAESTH, V82, P439, DOI 10.1093/bja/82.3.439; Mwaka G, 2013, AFR HEALTH SCI, V13, P768, DOI 10.4314/ahs.v13i3.36; NIV D, 1983, BRIT J ANAESTH, V55, P541, DOI 10.1093/bja/55.6.541; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; RUDRA P, 2004, [No title captured], V48, P461; Safari F, 2012, KOREAN J ANESTHESIOL, V63, P521, DOI 10.4097/kjae.2012.63.6.521; SCOTT PV, 1982, POSTGRAD MED J, V58, P531, DOI 10.1136/pgmj.58.683.531; Sen A, 2001, J Indian Med Assoc, V99, P683; Sen A, 2001, J INDIAN MED ASSOC, V99, P686; Shadangi BK, 2011, SINGAP MED J, V52, P432; Sommer M, 2008, EUR J ANAESTH, V25, P267, DOI 10.1017/S0265021507003031; Talwar V, 2008, ANESTHESIA ANALGESIA, V24, P447; Tucker AP, 2004, ANESTH ANALG, V98, P1512; Tucker AP, 2004, ANESTH ANALG, V98, P1521; Valentine JMJ, 1996, EUR J ANAESTH, V13, P589, DOI 10.1046/j.1365-2346.1996.00044.x; Wang JJ, 1998, REGION ANESTH PAIN M, V23, P479, DOI 10.1016/S1098-7339(98)90031-1; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652; Yaksh TL, 2004, ANESTH ANALG, V98, P1536	31	5	5	0	0	MAKERERE UNIV, FAC MED	KAMPALA	PO BOX 7072, KAMPALA, 00000, UGANDA	1680-6905	1729-0503		AFR HEALTH SCI	Afr. Health Sci.		2016	16	1					282	291		10.4314/ahs.v16i1.37			10	Medicine, General & Internal	General & Internal Medicine	DP9WE	WOS:000378847700037	27358643	Green Published, Other Gold			2020-06-30	J	Attari, MA; Najafabadi, FM; Talakoob, R; Abrishamkar, S; Taravati, H				Attari, Moahammad A.; Najafabadi, Fereidoun Mortazavi; Talakoob, Reyhanak; Abrishamkar, Saeid; Taravati, Hosein			Comparison of the Effects of 3 Methods of Intrathecal Bupivacaine, Bupivacaine-Fentanyl, and Bupivacaine-Fentanyl-Magnesium Sulfate on Sensory Motor Blocks and Postoperative Pain in Patients Undergoing Lumbar Disk Herniation Surgery	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						spinal anesthesia; bupivacaine; fentanyl; magnesium sulfate; postoperative pain	SPINAL-ANESTHESIA; ANALGESIC REQUIREMENTS; CENTRAL SENSITIZATION; KNEE ARTHROSCOPY; CONTROLLED-TRIAL; KETAMINE; SECTION; INJURY; LEVEL; CORD	Background: The aim of this study was to investigate the effects of adding intrathecal (IT) fentanyl and magnesium sulfate (MgSO4) to bupivacaine on sensory motor blocks and postoperative pain in patients undergoing lumbar disk herniation surgery. Methods: In a double-blind randomized clinical trial, the patients undergoing lumbar disk herniation surgery were allocated to receive hyperbaric bupivacaine (A), or hyperbaric bupivacaine and fentanyl (B), hyperbaric bupivacaine, fentanyl and MgSO4 (C) IT. Data were collected regarding the onset of sensory block and time to regression to T10, time to complete motor block and full motor recovery, time to first analgesic requirement, postoperative pain score, and analgesic consumption and side effects. P< 0.05 was considered to be statistically significant. Results: A total of 105 patients were randomized and assigned to 3 groups (n= 35 in each groups). There were no significant differences between groups in regard to time to reach the T10 level of sensory block (P= 0.82), time to regression to T10 (P= 0.11), and the time to complete motor block (P= 0.58). Meanwhile, the time to complete recovery of motor function was significantly longer in group C (116.4 +/- 18.4, 126.4 +/- 25.5, 130.2 +/- 15.7 min, respectively, P= 0.016). Time to first analgesic requirement was also significantly longer in group C (3.26 +/- 1.12, 5.57 +/- 0.92, 6.91 +/- 1.27 h, respectively, P< 0.001). Total morphine consumption was significantly less in group C (14.3 +/- 4.3, 8.3 +/- 3.5, 6 +/- 3.6 mg, respectively, P< 0.001). The severity of pain was significantly less in C group (P< 0.001). Conclusion: In patients undergoing lumbar disk herniation surgery, IT MgSO4 in combination with bupivacaine-fentanyl can decrease severity of postoperative pain and analgesic consumption without additional side effect.	[Attari, Moahammad A.; Talakoob, Reyhanak] Isfahan Univ Med Sci, Sch Med, Alzahra Hosp, Dept Anesthesiol, Esfahan, Iran; [Najafabadi, Fereidoun Mortazavi] Isfahan Univ Med Sci, Sch Med, Alzahra Hosp, Dept Neuroanesthesia, Esfahan, Iran; [Abrishamkar, Saeid] Isfahan Univ Med Sci, Sch Med, Alzahra Hosp, Dept Neurosurg, Esfahan, Iran; [Taravati, Hosein] Kerman Univ Med Sci, Sch Med, Dept Anesthesiol, Kerman, Iran	Najafabadi, FM (reprint author), Alzahra Hosp, Dept Neuroanesthesia, Sofe Blvd, Esfahan 8174675731, Iran.	mortazavi54@gmail.com	Abrishamkar, Saeid/A-1437-2018; Attari, Mohammad Ali/W-5021-2017; Talakoub, Reihanak/D-8669-2018	Abrishamkar, Saeid/0000-0001-8860-5204; Attari, Mohammad Ali/0000-0003-4430-8333; Talakoub, Reihanak/0000-0002-0212-3608	Isfahan University of Medical Sciences	Supported by Isfahan University of Medical Sciences.	Arcioni R, 2007, ACTA ANAESTH SCAND, V51, P482, DOI 10.1111/j.1399-6576.2007.01263.x; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; Attari MA, 2011, J RES MED SCI, V16, P524; BOGRA J, 2005, BMC ANESTHESIOL, V5, DOI DOI 10.1186/1471-2253-5-5); Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Chanimov M, 1997, ANAESTHESIA, V52, P223, DOI 10.1111/j.1365-2044.1997.034-az0057.x; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Dayioglu H, 2009, J ANESTH, V23, P19, DOI 10.1007/s00540-008-0677-4; Edgcombe H, 2008, BRIT J ANAESTH, V100, P165, DOI 10.1093/bja/aem380; Fassoulaki A, 1999, ANESTH ANALG, V88, P398, DOI 10.1097/00000539-199902000-00033; Ghrab BE, 2009, ANN FR ANESTH, V28, P454, DOI 10.1016/j.annfar.2009.03.004; Haubold HA, 1906, J AMER MED ASSOC, V46, P647; Jabalameli Mitra, 2012, Adv Biomed Res, V1, P7, DOI 10.4103/2277-9175.94430; Khalili G, 2011, J ANESTH, V25, P892, DOI 10.1007/s00540-011-1227-z; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; LEJUSTE MJLR, 1985, S AFR MED J, V68, P367; Liu HT, 2001, ANESTH ANALG, V92, P1173; Menigaux C, 2001, ANESTH ANALG, V93, P606, DOI 10.1097/00000539-200109000-00016; Morrison AP, 2013, BRIT J ANAESTH, V110, P702, DOI 10.1093/bja/aet064; Ozalevli M, 2005, ACTA ANAESTH SCAND, V49, P1514, DOI 10.1111/j.1399-6576.2005.00793.x; Pierre C, 2000, RADIOL CLIN N AM, V38, P22; Saeki H, 2004, ANESTH ANALG, V99, P1805, DOI 10.1213/01.ANE.0000138039.04548.3D; SIMPSON JI, 1994, ANESTHESIOLOGY, V81, P1493, DOI 10.1097/00000542-199412000-00025; THURNAU GR, 1987, AM J OBSTET GYNECOL, V157, P1435, DOI 10.1016/S0002-9378(87)80239-9; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; XIAO WH, 1994, BRAIN RES, V666, P168, DOI 10.1016/0006-8993(94)90768-4	28	5	5	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2016	28	1					38	43		10.1097/ANA.0000000000000232			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	DM3FY	WOS:000376233400007	26465641				2020-06-30	J	Galgano, M; Briggs, D; Marawar, S; Calancie, B				Galgano, Michael; Briggs, Dana; Marawar, Satya; Calancie, Blair			A Case of Malignant Hyperthermia Captured by Neuromonitoring During a Lumbar Endoscopic Discectomy	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Letter									[Galgano, Michael; Briggs, Dana; Marawar, Satya; Calancie, Blair] SUNY Upstate Med Univ, Syracuse, NY 13210 USA	Galgano, M (reprint author), SUNY Upstate Med Univ, Syracuse, NY 13210 USA.						Klingler W, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-8; URWYLER A, 1994, ANAESTHESIST, V43, P557, DOI 10.1007/s001010050093	2	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2016	28	1					86	87		10.1097/ANA.0000000000000216			3	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	DM3FY	WOS:000376233400017	26291728				2020-06-30	J	Almustafa, MM; Al-Oweidi, AS; Al-Zaben, KR; Qudaisat, IY; Abu-Halaweh, S; Alghanem, SM; Massad, IM; Samarah, W; Al-Shaer, RA; Ismail, S; Khazawla, F				Almustafa, Mahmoud M.; Al-Oweidi, Abdelkareem S.; Al-Zaben, Khaled R.; Qudaisat, Ibraheem Y.; Abu-Halaweh, Sami; Alghanem, Subhi M.; Massad, Islam M.; Samarah, Walid; Al-Shaer, Reem A.; Ismail, Said; Khazawla, Fawaz			Ephedrine requirements during spinal anesthesia for cesarean delivery in Jordanian parturients: association with beta 2-adrenoceptor gene variants	ANNALS OF SAUDI MEDICINE			English	Article							VASOPRESSOR REQUIREMENTS; RECEPTOR GENE; HYPOTENSION; MANAGEMENT; HAPLOTYPE; SECTION; POLYMORPHISMS; PHENYLEPHRINE; CAUCASIANS; GENOTYPE	BACKGROUND: Maternal hypotension after spinal anesthesia for cesarean delivery is common. Many studies performed on the beta 2-adrenoceptor (beta 2AR) gene variants and their association with vasopressor requirements during and after neuroaxial block have contradictory conclusions. OBJECTIVES: The aim of the study was to evaluate the influence of the beta 2AR in codons 16 and 27 on the incidence of maternal hypotension and ephedrine consumption after spinal anesthesia for cesarean delivery in an Arab ethnic group. DESIGN: A prospective gene association study. SETTING: Jordan University Hospital from 1 July 2013 to 31 January 2014. PATIENTS AND METHODS: We enrolled parturients who underwent cesarean delivery under spinal anesthesia. Spinal anesthesia was performed with 10 mg plain bupivacaine along with 25 mu g fentanyl. Hypotension was treated with ephedrine and the amount consumed in the first 30 minutes after spinal anesthesia was calculated. The beta 2AR genotype at codons 16 and 27 was determined. We studied the correlation between the beta 2AR genotype and the amount of ephedrine consumption after spinal anesthesia. MAIN OUTCOME MEASURES: Amount of ephederine used. RESULTS: Of 250 patients enrolled in the study, genotype and clinical data were available for 234 cases. Ephedrine was used in 94% of patients. There was a significant effect of beta 2AR genotype on ephedrine dose in the first 30 minutes after spinal anesthesia in codon 16 and 27. Arg16 homozygotes received less ephedrine (14.0 [11.2] mg) than Gly16 homozygotes (38.6 [25.7] mg) and Arg16Gly heterozygotes (33.42 [22.70] mg) (P<.0001). Gln27 homozygotes received less ephedrine (18.2 [12.8] mg) than Glu 27 homozygotes (47.5 [27.0] mg) and Gln27Glu heterozygotes (48.2 [23.7] mg). (P<.0001). CONCLUSION: In an Arab ethnic group, the beta 2AR gene has a role in maternal hypotension after spinal anesthesia. The Gly16 and Glu27 alleles have a higher incidence of arterial hypotension and required a greater amount of vasopressor to treat hypotension compared with homozygous Arg16 and Gln27 carriers. LIMITATIONS: Fasting time and hydration protocol, the use of a fixed dose of ephedrine, and relatively small sample size.	[Almustafa, Mahmoud M.; Al-Oweidi, Abdelkareem S.; Al-Zaben, Khaled R.; Qudaisat, Ibraheem Y.; Abu-Halaweh, Sami; Alghanem, Subhi M.; Massad, Islam M.; Samarah, Walid] Jordan Univ Hosp, Dept Anesthesia, Amman, Jordan; [Al-Shaer, Reem A.; Ismail, Said] Jordan Univ Hosp, Dept Biochem, Amman, Jordan; [Khazawla, Fawaz] OB GYN Jordan, Amman, Jordan	Almustafa, MM (reprint author), King Faisal Specialist Hosp & Res Ctr, Dept Anesthesia, MBC 22 POB 3354, Riyadh 11211, Saudi Arabia.	mahmoud_juh@hotmail.com	almustafa, mahmoud m/F-3651-2016; Al-mustafa, Mahmoud/AAP-4092-2020; QUDAISAT, Ibraheem/D-7838-2015	almustafa, mahmoud m/0000-0003-2835-0777; Al-mustafa, Mahmoud/0000-0003-2835-0777; QUDAISAT, Ibraheem/0000-0001-6907-5164	deanship of scientific research, The University of Jordan	This study was funded by the deanship of scientific research, The University of Jordan. It was conducted during sabbatical leave at King Faisal Specialist Hospital and Research Center, Riyadh.	Allen TK, 2009, INT J OBSTET ANESTH, V18, P356, DOI 10.1016/j.ijoa.2009.03.014; Belfer I, 2005, EUR J HUM GENET, V13, P341, DOI 10.1038/sj.ejhg.5201313; CARPENTER RL, 1992, ANESTHESIOLOGY, V76, P906, DOI 10.1097/00000542-199206000-00006; Daher M, 2012, ANAESTHESIA, V67, P1251, DOI 10.1111/j.1365-2044.2012.07296.x; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Frey UH, 2014, BRIT J ANAESTH, V112, P477, DOI 10.1093/bja/aet404; Gratze G, 1999, HYPERTENSION, V33, P1425, DOI 10.1161/01.HYP.33.6.1425; Hawkins GA, 2006, AM J RESP CRIT CARE, V174, P1101, DOI 10.1164/rccm.200509-1405OC; Kumar Amit, 2014, BMC Res Notes, V7, P396, DOI 10.1186/1756-0500-7-396; Kundra P, 2007, ANAESTHESIA, V62, P460, DOI 10.1111/j.1365-2044.2007.05025.x; Landau R, 2011, ANESTH ANALG, V112, P1432, DOI 10.1213/ANE.0b013e3182179424; Lee A, 2002, ANESTH ANALG, V94, P920, DOI 10.1097/00000539-200204000-00028; Lin FQ, 2012, CNS NEUROSCI THER, V18, P591, DOI 10.1111/j.1755-5949.2012.00345.x; Magalhaes E, 2010, REV BRAS ANESTESIOL, V60, P228, DOI 10.1016/S0034-7094(10)70031-3; Maxwell TJ, 2005, INT J MOL MED, V16, P573; Mercier FJ, 2013, MINERVA ANESTESIOL, V79, P62; Mitra JK, 2013, J POSTGRAD MED, V59, P121, DOI 10.4103/0022-3859.113840; Smiley RM, 2006, ANESTHESIOLOGY, V104, P644, DOI 10.1097/00000542-200604000-00006; Xie HG, 1999, PHARMACOGENETICS, V9, P511	19	2	2	0	1	K FAISAL SPEC HOSP RES CENTRE	RIYADH	PUBLICATIONS OFFICE PO BOX 3354, RIYADH 11211, SAUDI ARABIA	0256-4947	1319-9226		ANN SAUDI MED	Ann. Saudi Med.	JAN-FEB	2016	36	1					29	36		10.5144/0256-4947.2016.29			8	Medicine, General & Internal	General & Internal Medicine	DK8XW	WOS:000375214000005	26922685	DOAJ Gold, Green Published			2020-06-30	J	Keating, S; Kerr, C; McDonell, W; Valverde, A; Johnson, R; Knych, H; Edginton, A				Keating, Stephanie; Kerr, Carolyn; McDonell, Wayne; Valverde, Alexander; Johnson, Ron; Knych, Heather; Edginton, Andrea			Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						acepromazine; anesthesia; dexmedetomidine; dog; fentanyl; recovery	CONSTANT RATE INFUSION; ORGAN BLOOD-FLOW; TRANSDERMAL FENTANYL; INTRAVENOUS FENTANYL; PHARMACOKINETICS; COMBINATION; LIDOCAINE; MEDETOMIDINE; ALFENTANIL; METABOLISM	Objective To describe fentanyl pharmacokinetics during isoflurane anesthesia and on recovery from anesthesia with concurrent administration of acepromazine, dexmedetomidine or saline in dogs. Study design Experimental blinded, randomized, crossover study. Animals Seven adult hound dogs. Methods Dogs were administered intravenous (IV) fentanyl as a bolus (5 mu g kg(-1)) followed by an infusion (5 mu g kg(-1) hour(-1)) for 120 minutes during isoflurane anesthesia and emergence from anesthesia, and for 60 minutes after extubation during recovery from anesthesia. At the time of extubation, dexmedetomidine (2.5 mu g kg(-1)), acepromazine (0.05 mg kg(-1)) or saline were administered IV. Venous blood was sampled during the maintenance and recovery periods. Fentanyl plasma concentrations were measured using high-performance liquid chromatography-mass spectrometry and population pharmacokinetic analyses were performed. Results Mean fentanyl plasma concentrations were 1.6-4.5 ng mL(-1) during isoflurane anesthesia and 1.6-2.0 ng mL(-1) during recovery from anesthesia. Recovery from isoflurane anesthesia without sedation was associated with an increase in the volume of the central compartment from 0.80 to 1.02 L kg(-1). After administration of acepromazine, systemic clearance of fentanyl increased from 31.5 to 40.3 mL minute(-1) kg(-1) and the volume of the central compartment increased from 0.70 to 0.94 L kg(-1). Administration of dexmedetomidine did not significantly change fentanyl pharmacokinetics. Inter-individual variability for fentanyl parameter estimates in all treatments ranged from 2.2% to 54.5%, and residual error ranged from 6.3% to 13.4%. Conclusions and clinical relevance The dose rates of fentanyl used in this study achieved previously established analgesic plasma concentrations for the duration of the infusion. Despite alterations in fentanyl pharmacokinetics, differences in fentanyl plasma concentrations among treatments during recovery from anesthesia were small and were unlikely to be of clinical significance.	[Keating, Stephanie; Kerr, Carolyn; McDonell, Wayne; Valverde, Alexander] Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON N1G 4S7, Canada; [Johnson, Ron] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 4S7, Canada; [Knych, Heather] Univ Calif Davis, Dept Vet Mol Biosci, Sch Vet Med, Davis, CA 95616 USA; [Edginton, Andrea] Univ Waterloo, Sch Pharm, Waterloo, ON N2L 3G1, Canada	Keating, S (reprint author), Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON N1G 4S7, Canada.	stephkeating@yahoo.ca		Valverde, Alexander/0000-0002-8356-0104	Ontario Veterinary College Pet Trust Fund	This study was funded by the Ontario Veterinary College Pet Trust Fund, and has been published online in part as a copyrighted DVSc thesis (https://dspace.lib.uoguelph.ca/xmlui/bitstream/handle/10214/6548/Keating_Stephanie_201304_DVSc.	Anderson MK, 2008, VET ANAESTH ANALG, V35, P528, DOI 10.1111/j.1467-2995.2008.00413.x; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; Bjorkman S, 2000, J PHARM PHARMACOL, V52, P1065, DOI 10.1211/0022357001774985; Dyson DH, 1998, J AM ANIM HOSP ASSOC, V34, P325, DOI 10.5326/15473317-34-4-325; Egger CM, 2007, VET ANAESTH ANALG, V34, P200, DOI 10.1111/j.1467-2995.2006.00310.x; Feary DJ, 2005, AM J VET RES, V66, P574, DOI 10.2460/ajvr.2005.66.574; Grimm KA, 2005, AM J VET RES, V66, P1222, DOI 10.2460/ajvr.2005.66.1222; HARTMAN JC, 1992, CAN J ANAESTH, V39, P877, DOI 10.1007/BF03008300; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; ILKIW JE, 1994, CAN J VET RES, V58, P248; JACOBSON JD, 1994, VET SURG, V23, P299, DOI 10.1111/j.1532-950X.1994.tb00488.x; Karol M. D., 2000, BEST PRACT RES CL AN, V14, P261, DOI DOI 10.1053/BEAN.2000.0081; Keating SCJ, 2013, THESIS U GUELPH, P114; Keating SCJ, 2013, AM J VET RES, V74, P672, DOI 10.2460/ajvr.74.5.672; KHARASCH ED, 1992, ANESTHESIOLOGY, V77, P1208, DOI 10.1097/00000542-199212000-00023; KHARASCH ED, 1991, ANESTHESIOLOGY, V75, P520, DOI 10.1097/00000542-199109000-00020; Lawrence CJ, 1996, ANESTH ANALG, V83, P1160, DOI 10.1097/00000539-199612000-00005; Monteiro ER, 2008, VET ANAESTH ANALG, V35, P519, DOI 10.1111/j.1467-2995.2008.00412.x; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P917, DOI 10.1016/S0195-5616(08)70015-9; Pypendop BH, 2008, AM J VET RES, V69, P531, DOI 10.2460/ajvr.69.4.531; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; SALMENPERA MT, 1994, ANESTHESIOLOGY, V80, P837, DOI 10.1097/00000542-199404000-00017; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Sear JW, 1998, BRIT J ANAESTH, V81, P38; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Talke PO, 2000, ANESTH ANALG, V90, P1060, DOI 10.1097/00000539-200005000-00011; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Thomasy SM, 2005, AM J VET RES, V66, P1162, DOI 10.2460/ajvr.2005.66.1162; Ueyama Y, 2009, AM J VET RES, V70, P1459, DOI 10.2460/ajvr.70.12.1459	30	0	0	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2016	43	1					35	43		10.1111/vaa.12271			9	Veterinary Sciences	Veterinary Sciences	DJ5YZ	WOS:000374288100005	25943714				2020-06-30	J	Li, CC; Chen, SS; Huang, CH				Li, C. C.; Chen, S. S.; Huang, C. H.			Evidence appraisal of Li CC, Chen SS, Huang CH, et al. Fentanyl-induced cough is a risk factor for postoperative nausea and vomiting	AORN JOURNAL			English	Editorial Material																	0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0001-2092			ASSOC OPER ROOM NURS	AORN J.	JAN	2016	103	1					124	129		10.1016/j.aorn.2015.11.021			6	Nursing	Nursing	DI4GR	WOS:000373458900026					2020-06-30	J	Prabhakar, H; Singh, GP; Ali, Z; Kalaivani, M; Smith, MA				Prabhakar, Hemanshu; Singh, Gyaninder Pal; Ali, Zulfiqar; Kalaivani, Mani; Smith, Martha A.			Pharmacological and non-pharmacological interventions for reducing rocuroniumbromide induced pain on injection in children and adults	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							PREVENTING WITHDRAWAL MOVEMENT; DOUBLE-BLIND; SODIUM-BICARBONATE; INTRAVENOUS-INJECTION; MAGNESIUM-SULFATE; NITROUS-OXIDE; PRETREATMENT; REMIFENTANIL; LIDOCAINE; KETAMINE	Background Rocuronium bromide is a routinely used muscle relaxant in anaesthetic practice. Its use, however, is associated with intense pain on injection. While it is well established that rocuronium bromide injection causes pain in awake patients, anaesthetized patients also tend to show withdrawal movements of the limbs when this muscle relaxant is administered. Various strategies, both pharmacological and non-pharmacological, have been studied to reduce the incidence and severity of pain on rocuronium bromide injection. We wanted to find out which of the existing modalities was best to reduce pain on rocuronium injection. Objectives The objectives of this review were to assess the ability of both pharmacological and non-pharmacological interventions to reduce or eliminate the pain that accompanies rocuronium bromide administration. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2013, Issue 7), MEDLINE via Ovid SP (1966 to July 2013) and EMBASE via Ovid SP (1980 to July 2013). We also searched specific websites. We reran the searches in February 2015 and will deal with the 11 studies of interest found through this search when we update the review. Selection criteria We included all randomized controlled trials (RCTs) that compared the use of any drug or a non-pharmacological method with control patients, or those receiving no treatment to reduce the severity of pain with rocuronium injection. Our primary outcome was pain on rocuronium bromide injection measured by a pain score assessment. Our secondary outcomes were rise in heart rate and blood pressure following administration of rocuronium and adverse events related to the interventions. Data collection and analysis We used the standardized methods for conducting a systematic review as described in the Cochrane Handbook for Systematic Reviews of Interventions. Two authors independently extracted details of trial methodology and outcome data from reports of all trials considered eligible for inclusion. We made all analyses on an intention-to-treat basis. We used a fixed-effect model where there was no evidence of significant heterogeneity between studies and a random-effects model if heterogeneity was likely. Main results We included 66 studies with 7840 participants in the review, though most analyses were based on data from fewer participants. In total there are 17 studies awaiting classification. No studies were at a low risk of bias. We noted substantial statistical and clinical heterogeneity between trials. Most of the studies reported the primary outcome pain as assessed by verbal response from participants in an awake state but some trials reported withdrawal of the injected limb as a proxy for pain after induction of anaesthesia in response to rocuronium administration. Few studies reported adverse events and no study reported heart rate and blood pressure changes after administration of rocuronium. Lidocaine was the most commonly studied intervention drug, used in 29 trials with 2256 participants. The risk ratio (RR) of pain on injection if given lidocaine compared to placebo was 0.23 (95% confidence interval (CI) 0.17 to 0.31; I-2 = 65%, low quality of evidence). The RR of pain on injection if fentanyl and remifentanil were given compared to placebo was 0.42 (95% CI 0.26 to 0.70; I-2 = 79%, low quality of evidence) and (RR 0.10, 95% CI 0.04 to 0.26; I-2 = 74%, low quality of evidence), respectively. Pain on injection of intervention drugs was reported with the use of lidocaine and acetaminophen in one study. Cough was reported with the use of fentanyl (one study), remifentanil (five studies, low quality evidence) and alfentanil (one study). Breath holding and chest tightness were reported with the use of remifentanil in two studies (very low quality evidence) and one study (very low quality evidence), respectively. The overall rate of complications was low. Authors' conclusions The evidence to suggest that the most commonly investigated pharmacological interventions reduce pain on injection of rocuronium is of low quality due to risk of bias and inconsistency. There is low or very low quality evidence for adverse events, due to risk of bias, inconsistency and imprecision of effect. We did not compare the various interventions with one another and so cannot comment on the superiority of one intervention over another. Complications were reported more often with use of opioids.	[Prabhakar, Hemanshu; Singh, Gyaninder Pal] All India Inst Med Sci, Dept Neuroanaesthesiol, New Delhi 110029, India; [Ali, Zulfiqar] Govt Med Coll, Dept Anaesthesia & Intens Care, Srinagar, Jammu & Kashmir, India; [Kalaivani, Mani] All India Inst Med Sci, Dept Biostat, New Delhi 110029, India; [Smith, Martha A.] Newcastle Univ, Sch Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Prabhakar, H (reprint author), All India Inst Med Sci, Dept Neuroanaesthesiol, New Delhi 110029, India.	prabhakaraiims@yahoo.co.in	SINGH, GYANINDER/K-8621-2019; SINGH, GYANINDER/T-7976-2017	SINGH, GYANINDER/0000-0002-6702-6892	All India Institute of Medical Sciences, New Delhi, India	Internal sources; All India Institute of Medical Sciences, New Delhi, India.	Abbas Nighat, 2009, JPMA Journal of the Pakistan Medical Association, V59, P847; Abdusoglu MN, 2011, EUR J ANAESTH, V28, P229, DOI 10.1097/EJA.0b013e3283425603; Abu-Halaweh SA, 2014, J ANESTH, V28, P886, DOI 10.1007/s00540-014-1836-4; Abu-Halaweh S. A., 2013, Middle East Journal of Anesthesiology, V22, P87; Ahmad N, 2005, ANESTH ANALG, V100, P987, DOI 10.1213/01.ANE.0000147790.76114.3A; Akcaboy ZN, 2012, MED PRIN PRACT, V21, P323, DOI 10.1159/000336582; Akkaya T, 2008, TURK J MED SCI, V38, P577; Alanoglu Z, 2007, ANESTEZIYOLOJI VE RE, V15, P34; [Anonymous], 2014, REV MAN REVMAN VERS; ASIDA SM, 2009, EGYPTIAN J ANAESTHES, V25, P31; Ates G, 2014, J CLIN ANAL MED, V5, P507, DOI 10.4328/JCAM.1632; Aydin GB, 2014, J ANESTH, V28, P471, DOI 10.1007/s00540-013-1743-0; Ayoglu H, 2007, EUR J ANAESTH, V24, P541, DOI 10.1017/S0265021506002250; Baek SH, 2008, PEDIATR ANESTH, V18, P515, DOI 10.1111/j.1460-9592.2008.02465.x; 황선호, 2003, Korean Journal of Anesthesiology, V45, P451; Borgeat A, 1997, J CLIN ANESTH, V9, P650, DOI 10.1016/S0952-8180(97)00192-X; Cheong KF, 2000, BRIT J ANAESTH, V84, P106; Cheong Soon Ho, 2003, Korean Journal of Anesthesiology, V45, P447; Chiarella A. B., 2003, British Journal of Anaesthesia, V90, P377, DOI 10.1093/bja/aeg054; Cho KR, 2014, KOREAN J ANESTHESIOL, V66, P23, DOI 10.4097/kjae.2014.66.1.23; Choi BI, 2008, YONSEI MED J, V49, P211, DOI 10.3349/ymj.2008.49.2.211; Choi YJ, 2012, KOREAN J ANESTHESIOL, V63, P413, DOI 10.4097/kjae.2012.63.5.413; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dogru K, 2002, TURK ANESTEZIYOLOJI, V30, P350; Ertugrul F, 2006, J INT MED RES, V34, P665, DOI 10.1177/147323000603400612; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Han DW, 2007, J CLIN ANESTH, V19, P418, DOI 10.1016/j.jclinane.2007.02.012; Han DW, 2003, KOREAN J ANESTHESIOL, V45, P697; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Honca M, 2013, TURK J MED SCI, V43, P79, DOI 10.3906/sag-1202-77; Ikram M, 2008, APMC, V2, P113; Jeon Y, 2013, KOREAN J ANESTHESIOL, V64, P25, DOI 10.4097/kjae.2013.64.1.25; Jeon YH, 2010, KOREAN J ANESTHESIOL, V59, P13, DOI 10.4097/kjae.2010.59.1.13; Jung KT, 2014, KOREAN J ANESTHESIOL, V67, P175, DOI 10.4097/kjae.2014.67.3.175; Jung SS, 2005, KOREAN J ANESTHESIOL, V49, P131; Kang Wha-Ja, 2005, Korean Journal of Anesthesiology, V49, P35; Kaya G, 2004, TURK ANESTEZIYOLOJI, V32, P344; Ki HS, 2005, KOREAN J ANESTHESIOL, V48, P145; Kilicaslan A, 2010, ARASTIRMA YAZISI SEL, V26, P128; 최형규, 2006, Korean Journal of Anesthesiology, V51, P162; Kim E, 2013, J ANESTH, V27, P868, DOI 10.1007/s00540-013-1655-z; Kim JY, 2007, BRIT J ANAESTH, V98, P120, DOI 10.1093/bja/ael285; Kim JH, 2009, J CLIN ANESTH, V21, P9, DOI 10.1016/j.jclinane.2008.06.016; Kim JY, 2008, PEDIATR ANESTH, V18, P245, DOI 10.1111/j.1460-9592.2007.02390.x; Kim KS, 2006, J CLIN ANESTH, V18, P334, DOI 10.1016/j.jclinane.2005.12.001; Kim SK, 2008, J CLIN ANESTH, V20, P629, DOI 10.1016/j.jclinane.2008.08.002; Kim YH, 2010, J ANESTH, V24, P549, DOI 10.1007/s00540-010-0964-8; Kirpit P, 2010, TURK ANESTEZIYOLOJI, V38, P428; Kwak HJ, 2010, KOREAN J ANESTHESIOL, V58, P446, DOI 10.4097/kjae.2010.58.5.446; Lee HJ, 2009, J KOREAN MED SCI, V24, P879, DOI 10.3346/jkms.2009.24.5.879; Lee Jae In, 2009, Korean J Anesthesiol, V56, P628, DOI 10.4097/kjae.2009.56.6.628; Lee SH, 2011, CURR THER RES CLIN E, V72, P36, DOI 10.1016/j.curtheres.2011.02.001; Lee Su-Kyung, 2004, Korean Journal of Anesthesiology, V46, P151; Lee SS, 2009, J KOREAN ACAD NURS, V39, P270, DOI 10.4040/jkan.2009.39.2.270; Lee YC, 2009, J CLIN ANESTH, V21, P427, DOI 10.1016/j.jclinane.2008.11.011; Lefebvre C, 2011, COCHRANE COLLABORATI; Liou JT, 2003, ANESTH ANALG, V97, P1294, DOI 10.1213/01.ANE.0000082247.39704.79; LOCKEY D, 1995, ANAESTHESIA, V50, P474, DOI 10.1111/j.1365-2044.1995.tb06019.x; Mahajan C, 2010, J ANESTH, V24, P845, DOI 10.1007/s00540-010-1014-2; Mahajan R, 2005, CAN J ANAESTH, V52, P111, DOI 10.1007/BF03018591; Memis D, 2002, ANESTH ANALG, V94, P1517, DOI 10.1097/00000539-200206000-00026; Memis D, 2005, CAN J ANAESTH, V52, P437, DOI 10.1007/BF03016292; Min SK, 2011, J INT MED RES, V39, P1408, DOI 10.1177/147323001103900427; Oh AY, 2007, ACTA ANAESTH SCAND, V51, P1190, DOI 10.1111/j.1399-6576.2007.01371.x; Orebaugh SL, 1999, AM J EMERG MED, V17, P715, DOI 10.1016/S0735-6757(99)90168-7; Park JT, 2005, YONSEI MED J, V46, P765, DOI 10.3349/ymj.2005.46.6.765; Park SH, 2011, ACTA ANAESTH SCAND, V55, P87, DOI 10.1111/j.1399-6576.2010.02317.x; PARK SJ, 2006, KOREAN J ANESTHESIOL, V51, P157; Prabhakar H, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009346, DOI 10.1002/14651858.CD009346]; Prasanna M, 2005, J ANAESTH CLIN PHARM, V21, P59; Reddy MS, 2001, ANAESTHESIA, V56, P902, DOI 10.1046/j.1365-2044.2001.02059-6.x; Sari M, 2008, SAUDI MED J, V29, P374; SEONG LIM CHAE, 2006, Korean Journal of Anesthesiology, V50, P637; Shabana AM, 2011, EGYPT J ANAESTH, V27, P141, DOI 10.1016/j.egja.2011.04.008; Sharma S, 2010, INDIAN J ANAESTH, V54, P142, DOI 10.4103/0019-5049.63660; Shevchenko Y, 1999, ANESTH ANALG, V88, P746, DOI 10.1097/00000539-199904000-00011; Shin，Yong-Sup, 2005, Korean Journal of Anesthesiology, V49, P30; Shin YH, 2011, KOREAN J ANESTHESIOL, V60, P329, DOI 10.4097/kjae.2011.60.5.329; Singh M, 2007, J ANESTH, V21, P510, DOI 10.1007/s00540-007-0560-8; Tuncali B, 2004, ANESTH ANALG, V99, P740, DOI 10.1213/01.ANE.0000130005.94395.B2; Turan A, 2003, ANAESTH INTENS CARE, V31, P277, DOI 10.1177/0310057X0303100306; Wee SW, 2004, KOREAN J ANESTHESIOL, V47, P327; Yavascaoglu B, 2007, J CLIN ANESTH, V19, P413, DOI 10.1016/j.jclinane.2007.02.011; Yoon JR, 2010, J INT MED RES, V38, P1795, DOI 10.1177/147323001003800526; Yoon JY, 2010, J ANESTH, V24, P182, DOI 10.1007/s00540-010-0868-7; Yoon JS, 2011, KOREAN J ANESTHESIOL, V61, P367, DOI 10.4097/kjae.2011.61.5.367; Zeidan Ahed, 2006, Middle East Journal of Anesthesiology, V18, P879; Zhang YH, 2012, J CLIN ANESTH, V24, P456, DOI 10.1016/j.jclinane.2011.12.006; 정성미, 2005, Korean Journal of Anesthesiology, V48, P483; 황성미, 2004, Korean Journal of Anesthesiology, V46, P160; 곽현정, 2004, Korean Journal of Anesthesiology, V46, P675; 안태훈, 2005, Korean Journal of Anesthesiology, V48, P20; 안태훈, 2004, Korean Journal of Anesthesiology, V47, P331; 정성미, 2005, Korean Journal of Anesthesiology, V48, P514; 김경식, 2002, Korean Journal of Anesthesiology, V43, P572	96	3	4	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2016		2							CD009346	10.1002/14651858.CD009346.pub2			143	Medicine, General & Internal	General & Internal Medicine	DI1VP	WOS:000373285000049	26871982				2020-06-30	J	Joshi, N; Lemke, J; Danesi, H				Joshi, Nitin; Lemke, John; Danesi, Hassan			Design and functionality of a smart fentanyl iontophoretic transdermal system for the treatment of moderate-to-severe postoperative pain	PAIN MANAGEMENT			English	Article						design; fentanyl; IONSYS; iontophoretic transdermal system; patient-controlled analgesia	PATIENT-CONTROLLED ANALGESIA; PLACEBO-CONTROLLED TRIAL; MORPHINE; MANAGEMENT; PHARMACOKINETICS; EFFICACY; DELIVERY; SURGERY; SAFETY; IV	Fentanyl iontophoretic transdermal system (ITS) is a patient-controlled analgesia system used for the management of acute postoperative pain. The first-generation fentanyl ITS was an integrated one-piece system; however, corrosion that could limit reliability was detected in a small number of systems. A second-generation fentanyl ITS was designed to separate the hydrogels in the Drug Unit from the electronic circuit of the Controller during manufacture and storage, removing the primary cause of corrosion and thereby improving reliability. No evidence of corrosion has been observed in over 10,000 systems tested in real-time aging studies for the second generation fentanyl ITS. The second generation fentanyl ITS design features combine to ensure safe operation of the system with high reliability.	[Joshi, Nitin; Lemke, John; Danesi, Hassan] Medicines Co, Parsippany, NJ 07054 USA	Danesi, H (reprint author), Medicines Co, Parsippany, NJ 07054 USA.	hassan.danesi@THEMEDCO.com			Medicines Company	The authors wish to thank S Grundy of SD Scientific, Inc. for her technical writing contribution to the manuscript, funded by The Medicines Company.	[Anonymous], 2015, IONSYS FENT IONT TRA; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; ECHOLS DF, 1975, ARCH OTOLARYNGOL, V101, P418; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Phipps JB, 2015, EXPERT OPIN DRUG MET, V11, P481, DOI 10.1517/17425255.2015.1020296; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	12	6	6	0	1	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1758-1869	1758-1877		PAIN MANAG	Pain Manag.		2016	6	2					137	145		10.2217/pmt.15.70			9	Clinical Neurology	Neurosciences & Neurology	DH7TB	WOS:000372995600009	26805009	Bronze			2020-06-30	J	Jin, SJ; Lim, HS; Kwon, YJ; Park, SU; Yi, JM; Chin, JH; Hwang, JH; Kim, YK				Jin, Seok-Joon; Lim, Hyeong-Seok; Kwon, Youn-Ju; Park, Se-Ung; Yi, Jung-Min; Chin, Ji-Hyun; Hwang, Jai-Hyun; Kim, Young-Kug			Comparison of the Efficacy and Safety of a Pharmacokinetic Model-Based Dosing Scheme Versus a Conventional Fentanyl Dosing Regimen For Patient-Controlled Analgesia Immediately Following Robot-Assisted Laparoscopic Prostatectomy A Randomized Clinical Trial	MEDICINE			English	Article							COMPUTER-CONTROLLED INFUSION; POSTOPERATIVE PAIN; MORPHINE; REQUIREMENTS; ALFENTANIL; SURGERY; NAUSEA	Conventional, intravenous, patient-controlled analgesia, which is only administered by demand bolus without basal continuous infusion, is closely associated with inappropriate analgesia. Pharmacokinetic model-based dosing schemes can quantitatively describe the time course of drug effects and achieve optimal drug therapy. We compared the efficacy and safety of a conventional dosing regimen for intravenous patient-controlled analgesia that was administered by demand bolus without basal continuous infusion (group A) versus a pharmacokinetic model-based dosing scheme performed by decreasing the dosage of basal continuous infusion according to the model-based simulation used to achieve a targeted concentration (group B) following robot-assisted laparoscopic prostatectomy. In total, 70 patients were analyzed: 34 patients in group A and 36 patients in group B. The postoperative opioid requirements, pain scores assessed by the visual analog scale, and adverse events (eg, nausea, vomiting, pruritis, respiratory depression, desaturation, sedation, confusion, and urinary retention) were compared on admission to the postanesthesia care unit and at 0.5, 1, 4, 24, and 48 h after surgery between the 2 groups. All patients were kept for close observation in the postanesthesia care unit for 1 h, and then transferred to the general ward. The fentanyl requirements in the postanesthesia care unit for groups A and B were 110.0 +/- 46.4 mu g and 77.5 +/- 35.3 mu g, respectively. The pain scores assessed by visual analog scale at 0.5, 1, 4, and 24 h after surgery in group B were significantly lower than in group A (all P < 0.05). There were no differences in the adverse events between the 2 groups. We found that the pharmacokinetic model-based dosing scheme resulted in lower opioid requirements, lower pain scores, and no significant adverse events in the postanesthesia care unit following robot-assisted laparoscopic prostatectomy in comparison with conventional dosing regimen.	[Jin, Seok-Joon; Park, Se-Ung; Yi, Jung-Min; Chin, Ji-Hyun; Hwang, Jai-Hyun; Kim, Young-Kug] Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Lim, Hyeong-Seok] Asan Med Ctr, Dept Clin Pharmacol & Therapeut, Seoul, South Korea; [Kwon, Youn-Ju] Asan Med Ctr, Dept Nursing, Seoul, South Korea	Kim, YK (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, 88 Olympic Ro 43 Gil, Seoul 05505, South Korea.	kyk@amc.seoul.kr	Kim, Young-Kug/V-4877-2018	Kim, Young-Kug/0000-0002-1982-3053			Bhattaram VA, 2007, CLIN PHARMACOL THER, V81, P213, DOI 10.1038/sj.clpt.6100051; BROWN CR, 1990, PHARMACOTHERAPY, V10, pS116; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; Ekstein P, 2006, ANN SURG, V243, P41, DOI 10.1097/01.sla.0000193806.81428.6f; Ginsberg B, 1996, ANESTHESIOLOGY, V85, P1268, DOI 10.1097/00000542-199612000-00007; GLASS PSA, 1992, ANESTH ANALG, V74, P345; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hagle Mary E, 2004, Orthop Nurs, V23, P18, DOI 10.1097/00006416-200401000-00007; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Kim SH, 2013, YONSEI MED J, V54, P1273, DOI 10.3349/ymj.2013.54.5.1273; LAITINEN J, 1992, ANESTHESIOLOGY, V76, P194, DOI 10.1097/00000542-199202000-00006; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Muller M, 2001, WIEN KLIN WOCHENSCHR, V113, P566; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Sheiner LB, 2000, ANNU REV PHARMACOL, V40, P67, DOI 10.1146/annurev.pharmtox.40.1.67; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; Shin S, 2014, YONSEI MED J, V55, P800, DOI 10.3349/ymj.2014.55.3.800; Sidebotham D, 1997, J PAIN SYMPTOM MANAG, V14, P202, DOI 10.1016/S0885-3924(97)00182-6; Song JW, 2011, ANAESTHESIA, V66, P263, DOI 10.1111/j.1365-2044.2011.06648.x; SUNSHINE A, 1975, CLIN PHARMACOL THER, V18, P530; VANDENNIEUWENHUYZEN MCO, 1995, ANESTH ANALG, V81, P671, DOI 10.1097/00000539-199510000-00003; VANDERCAR DH, 1991, ANESTHESIOLOGY, V74, P623, DOI 10.1097/00000542-199103000-00036; VANLERSBERGHE C, 1994, J CLIN ANESTH, V6, P308, DOI 10.1016/0952-8180(94)90078-7; Weinbroum AA, 2003, ANESTH ANALG, V96, P789; Weinbroum AA, 2001, ANAESTHESIA, V56, P616, DOI 10.1046/j.1365-2044.2001.02088.x	29	1	1	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JAN	2016	95	2							e2542	10.1097/MD.0000000000002542			6	Medicine, General & Internal	General & Internal Medicine	DE4YG	WOS:000370636200001	26765479	DOAJ Gold, Green Published			2020-06-30	J	Peng, K; Liu, HY; Liu, SL; Ji, FH				Peng, Ke; Liu, Hua-yue; Liu, Si-lan; Ji, Fu-hai			Dexmedetomidine-fentanyl Compared With Midazolam-fentanyl for Conscious Sedation in Patients Undergoing Lumbar Disc Surgery	CLINICAL THERAPEUTICS			English	Article						analgesia; dexmedetomidine; discectomy; laminotomy; midazolam; sedation	RANDOMIZED CONTROLLED-TRIALS; UPPER GASTROINTESTINAL ENDOSCOPY; UNITED-STATES; METAANALYSIS; AGONISTS; PAIN; ALPHA(2)-ADRENOCEPTOR; LAMINECTOMY; COMBINATION; MORPHINE	Purpose: Patients undergoing awake lumbar disc surgery need adequate sedation and analgesia. This study investigated whether use of a dexmedetomidine-fentanyl (DF) regimen could be superior to midazolam-fentanyl (MF) for these patients. Methods: Sixty patients scheduled for elective lumbar laminotomy and discectomy were randomly assigned to receive either DF or MF for conscious sedation. Patient-controlled intravenous analgesia with fentanyl was used for postoperative pain management. Hemodynamic and respiratory changes,. sedation scores, pain scores, fentanyl consumption, patient satisfaction, postoperative hospital stay, and adverse events were assessed. Findings: The patient and surgical characteristics, sedation levels, and pain scores were similar in the 2 groups. Compared with the MF group, heart rate was lower in the DF group at six time points from skin incision to 15 minutes in the postanesthesia care unit (PACU), they are skin incision, 15 min after the beginning of surgery, 30 min after the, beginning of surgery, skin closure, entering PACU,. and 15 min in PACU (P = 0.016, 0.002, 0.000, 0.000, 0.000, and 0.001, respectively), whereas pulse oxygen saturation was higher at 3 time points from 15 minutes, after the beginning of surgery to skin closure (P = 0.022, 0.026, and 0.025, respectively). The intraoperative, postoperative, and total consumption of fentanyl were lower in the DF group (total: mean difference = -69.3 mu g; 95% CI, = -114.3 to -24.4;. P = 0.003). No significant differences were found for adverse events, postoperative hospital' stay, or satisfaction between the 2 groups. Implications: Although awake lumbar disc surgery can be performed successfully under sedation with either MF or DF combination, the latter may be a better alternative because of less consumption of opioid analgesics. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.	[Peng, Ke; Liu, Hua-yue; Liu, Si-lan; Ji, Fu-hai] Soochow Univ, Affiliated Hosp 1, Dept Anesthesiol, 188 Shizi St, Suzhou 215006, Peoples R China	Ji, FH (reprint author), Soochow Univ, Affiliated Hosp 1, Dept Anesthesiol, 188 Shizi St, Suzhou 215006, Peoples R China.	jifuhaisuda@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81471835]	This work was supported, in part, by the National Natural Science Foundation of China grant 81471835. We thank the surgical teams for technical help and the nurses at the Department of Anesthesiology and Orthopedics for helpful assistance. We thank Medjaden Bioscience Limited for assisting in the preparation of this manuscript. The Medjaden Bioscience Limited group provided only a language editing service for this paper, and they are not qualified as authors. All authors contributed equally.	ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; Biccard BM, 2008, ANAESTHESIA, V63, P4, DOI 10.1111/j.1365-2044.2007.05306.x; Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Cheung CW, 2015, ACTA ANAESTH SCAND, V59, P215, DOI 10.1111/aas.12445; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Dere K, 2010, EUR J ANAESTH, V27, P648, DOI 10.1097/EJA.0b013e3283347bfe; Duger C, 2012, J CLIN NEUROSCI, V19, P406, DOI 10.1016/j.jocn.2011.04.042; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Hsu YW, 2004, ANESTHESIOLOGY, V101, P1066, DOI 10.1097/00000542-200411000-00005; Jellish WS, 1996, ANESTH ANALG, V83, P559, DOI 10.1097/00000539-199609000-00021; Ji FH, 2014, J CARDIOTHOR VASC AN, V28, P267, DOI 10.1053/j.jvca.2013.06.022; Ji FH, 2013, CIRCULATION, V127, P1576, DOI 10.1161/CIRCULATIONAHA.112.000936; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Lazzaroni M, 2005, ENDOSCOPY, V37, P101, DOI 10.1055/s-2004-826149; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; OSSIPOV MH, 1989, ANESTH ANALG, V68, P194; Peng K, 2014, J CLIN NEUROSCI, V21, P1951, DOI 10.1016/j.jocn.2014.02.023; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Robin Christian, 2002, Anesth Prog, V49, P128; Schnabel A, 2013, PAIN, V154, P1140, DOI 10.1016/j.pain.2013.03.029; Taoda M, 2001, NEUROCHEM INT, V38, P317, DOI 10.1016/S0197-0186(00)00096-6; Torres HM, 2009, P R HEALTH SCI J, V28, P354; Tosteson ANA, 2008, SPINE, V33, P2108, DOI 10.1097/BRS.0b013e318182e390; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; Wang YL, 2015, J SURG RES, V194, P147, DOI 10.1016/j.jss.2014.10.008; Weinbroum AA, 2001, EUR J SURG, V167, P563; West BT, 2009, EVAL HEALTH PROF, V32, P207, DOI 10.1177/0163278709338554; Wu W, 2014, J INT MED RES, V42, P516, DOI 10.1177/0300060513515437; Yu C, 2014, INT J ORAL MAX SURG, V43, P1148, DOI 10.1016/j.ijom.2014.03.019	32	10	10	0	4	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	JAN	2016	38	1					192	201		10.1016/j.clinthera.2015.11.016			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DC4NZ	WOS:000369198900016	26699739				2020-06-30	J	Cunningham, SM; Haikal, NA; Kraner, JC				Cunningham, Susan M.; Haikal, Nabila A.; Kraner, James C.			Fatal Intoxication with Acetyl Fentanyl	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; forensic toxicology; acetyl fentanyl; intoxication; postmortem; opioid; fatal	LC-MS/MS; OPIOID TOLERANCE; NORFENTANYL; BLOOD; POSTMORTEM; PERSPECTIVE; METABOLISM; LIVER	Among the new psychoactive substances encountered in forensic investigations is the opioid, acetyl fentanyl. The death of a 28-year-old man from recreational use of this compound is reported. The decedent was found in the bathroom of his residence with a tourniquet secured around his arm and a syringe nearby. Postmortem examination findings included marked pulmonary and cerebral edema and needle track marks. Toxicological analysis revealed acetyl fentanyl in subclavian blood, liver, vitreous fluid, and urine at concentrations of 235 ng/mL, 2400 ng/g, 131 ng/mL, and 234 ng/mL, respectively. Acetyl fentanyl was also detected in the accompanying syringe. Death was attributed to recreational acetyl fentanyl abuse, likely through intravenous administration. The blood acetyl fentanyl concentration is considerably higher than typically found in fatal fentanyl intoxications. Analysis of this case underscores the need for consideration of a wide range of compounds with potential opioid-agonist activity when investigating apparent recreational drug-related deaths.	[Cunningham, Susan M.; Haikal, Nabila A.; Kraner, James C.] Off Chief Med Examiner, 619 Virginia St West, Charleston, WV 25302 USA	Kraner, JC (reprint author), Off Chief Med Examiner, 619 Virginia St West, Charleston, WV 25302 USA.	james.c.kraner@wv.gov					Aceto M, 1988, NIDA RES MONOGR, V81; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; [Anonymous], 2013, REC LAB TEST AC FENT; [Anonymous], 2013, AC N 1 PHEN 4 YL N P; Barceloux DG, 2012, MED TOXICOLOGY DRUG, P275; Barceloux DG, 2012, MED TOXICOLOGY DRUG, P539; Baselt R.C., 2014, DISPOSITION TOXIC DR; Bono JP., 2007, DRUG ABUSE HDB, P21; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; Collett BJ, 1998, BRIT J ANAESTH, V81, P58; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Drug Enforcement Administration, 2010, FED REG, V75; Dumas EO, 2008, AAPS J, V10, P537, DOI 10.1208/s12248-008-9056-1; Evers AS, 2008, GOODMAN GILMANS MANU, P240; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Garg A, 2010, J PHARMACEUT BIOMED, V53, P325, DOI 10.1016/j.jpba.2010.04.004; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Immunalysis Corporation, 2013, FENT ENZ IMM IMM PRO; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; Molina DK, 2013, AM J FOREN MED PATH, V34, P155, DOI 10.1097/PAF.0b013e318288b0d5; Ogilivie L., 2013, TOXTALK, V37, P14; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; United Nations Office of Drugs and Crime, 2013, CHALL NEW PSYCH SUBS	29	41	42	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	JAN	2016	61			1			S276	S280		10.1111/1556-4029.12953			5	Medicine, Legal	Legal Medicine	DC7ZC	WOS:000369438700042	26389815				2020-06-30	J	Moore, A; el-Bahrawy, A; Hatzakorzian, R; Li-Pi-Shan, W				Moore, Albert; el-Bahrawy, Aly; Hatzakorzian, Roupen; Li-Pi-Shan, William			Maternal Epidural Fentanyl Administered for Labor Analgesia Is Found in Neonatal Urine 24 Hours After Birth	BREASTFEEDING MEDICINE			English	Letter									[Moore, Albert; el-Bahrawy, Aly; Hatzakorzian, Roupen; Li-Pi-Shan, William] Royal Victoria Hosp, Dept Anesthesia, 1001 Decaire Blvd, Montreal, PQ H4A 3J1, Canada	Moore, A (reprint author), Royal Victoria Hosp, Dept Anesthesia, 1001 Decaire Blvd, Montreal, PQ H4A 3J1, Canada.	moore_albert@hotmail.com		Elbahrawy, Aly/0000-0001-9152-3218			Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Brimdyr K, 2015, BIRTH-ISS PERINAT C, V42, P319, DOI 10.1111/birt.12186; GAMBLING DR, 1993, CAN J ANAESTH, V40, P211, DOI 10.1007/BF03037032; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; STEER PL, 1992, CAN J ANAESTH, V39, P231, DOI 10.1007/BF03008782; Van Nimmen NFJ, 2010, J CLIN PHARMACOL, V50, P667, DOI 10.1177/0091270009347872	7	2	2	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1556-8253	1556-8342		BREASTFEED MED	Breastfeed. Med.	JAN 1	2016	11	1					40	41		10.1089/bfm.2015.0173			2	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	DB7DW	WOS:000368675800008	26701799				2020-06-30	J	Reddy, A; Tayjasanant, S; Haider, A; Heung, Y; Wu, JM; Liu, D; Yennurajalingam, S; Reddy, S; de la Cruz, M; Rodriguez, EM; Waletich, J; Vidal, M; Arthur, J; Holmes, C; Tallie, K; Wong, A; Dev, R; Williams, J; Bruera, E				Reddy, Akhila; Tayjasanant, Supakarn; Haider, Ali; Heung, Yvonne; Wu, Jimin; Liu, Diane; Yennurajalingam, Sriram; Reddy, Suresh; de la Cruz, Maxine; Rodriguez, Eden Mae; Waletich, Jessica; Vidal, Marieberta; Arthur, Joseph; Holmes, Carolyn; Tallie, Kimmie; Wong, Angelique; Dev, Rony; Williams, Janet; Bruera, Eduardo			The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients	CANCER			English	Article						cancer pain; cancer patients; conversion ratio; fentanyl transdermal; morphine equivalent daily dose; opioid rotation; supportive care	QUALITY-OF-LIFE; ORAL MORPHINE; PALLIATIVE CARE; PAIN MANAGEMENT; SUBSTITUTION; CONVERSION; TOXICITY; THERAPY; METABOLITES; PREDICTORS	BACKGROUNDTransdermal fentanyl (TDF) is 1 of the most common opioids prescribed to patients with cancer. However, the accurate opioid rotation ratio (ORR) from other opioids to TDF is unknown, and various currently used methods result in wide variation of the ORR. The objective of this study was to determine the ORR of the oral morphine equivalent daily dose (MEDD) to the TDF dose when correcting for the MEDD of breakthrough opioids (the net MEDD) in cancer outpatients. METHODSThe records of 6790 consecutive patients were reviewed at the authors' supportive care center from 2010 to 2013 to identify those who underwent rotation from other opioids to TDF. Data regarding Edmonton Symptom Assessment Scale scores and MEDDs were collected for patients who returned for a follow-up visit within 5 weeks. Linear regression analysis was used to estimate the ORR between the TDF dose and the net MEDD (the MEDD before opioid rotation [OR] minus the MEDD of the breakthrough opioid used along with TDF after OR). RESULTSIn total, 129 patients underwent OR from other opioids to TDF. The mean patient age was 56 years, 59% were men, and 88% had advanced cancer. Uncontrolled pain (80%) was the most frequent reason for OR. In 101 patients who underwent OR and had no worsening of pain at follow-up, the median ORR from net MEDD to TDF (in mg per day) was 0.01 (range, -0.02 to 0.04), and the correlation coefficient of the TDF dose to the net MEDD was 0.77 (P<.0001). The ORR was not significantly impacted by body mass index or serum albumin. The ORR of 0.01 suggests that an MEDD of 100mg is equivalent to 1mg TDF daily or approximately 40 micrograms per hour of TDF (1000micrograms/24 hours). CONCLUSIONSThe median ORR from MEDD to TDF in mg per day was 0.01. These results warrant further studies Cancer 2016;122:149-156. (c) 2015 American Cancer Society.	[Reddy, Akhila; Haider, Ali; Heung, Yvonne; Yennurajalingam, Sriram; Reddy, Suresh; de la Cruz, Maxine; Rodriguez, Eden Mae; Waletich, Jessica; Vidal, Marieberta; Arthur, Joseph; Holmes, Carolyn; Tallie, Kimmie; Wong, Angelique; Dev, Rony; Williams, Janet; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA; [Tayjasanant, Supakarn] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand; [Wu, Jimin; Liu, Diane] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	Reddy, A (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 1414,1515 Holcombe Blvd, Houston, TX 77030 USA.	asreddy@mdanderson.org	Arthur, Joseph/J-8123-2016	Arthur, Joseph/0000-0002-9185-6108; Heung, Yvonne/0000-0003-0929-9021	University of Texas MD Anderson Cancer Center from the National Cancer Institute [CA016672]	This study was supported in part by The University of Texas MD Anderson Cancer Center support grant (CA016672) from the National Cancer Institute.	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Ashby MA, 1999, MED J AUSTRALIA, V170, P68, DOI 10.5694/j.1326-5377.1999.tb126885.x; Bradley AM, 2013, J PALLIAT MED, V16, P409, DOI 10.1089/jpm.2012.0424; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Bruera E, 1991, J Palliat Care, V7, P6; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; Cancer pain relief and palliative care, 1990, WHO TECH REP SER, V804, P1; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Carvajal A, 2011, EUR J CANCER, V47, P1863, DOI 10.1016/j.ejca.2011.03.027; Coller J, 2009, EUR J CLIN PHARMACOL, V65, P121, DOI 10.1007/s00228-008-0570-y; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Dev R, 2011, CANCER-AM CANCER SOC, V117, P4551, DOI 10.1002/cncr.26082; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Elsayem A., 2008, MD ANDERSON SYMPTOM; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Hayashi T, 2014, BIOL PHARM BULL, V37, P1860, DOI 10.1248/bpb.b14-00119; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Hewitt DJ, 2000, ONCOLOGY-NY, V14, P705; HIGGS CMB, 1995, J PAIN SYMPTOM MANAG, V10, P4, DOI 10.1016/0885-3924(94)00060-X; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Ikeda Masahiko, 2012, Gan To Kagaku Ryoho, V39, P599; Janssen Pharmaceuticals Inc, DUR FENT TRANSD SYST; Kloke M, 2000, SUPPORT CARE CANCER, V8, P479, DOI 10.1007/s005200000153; Kwon JH, 2013, ONCOLOGIST, V18, P768, DOI 10.1634/theoncologist.2013-0001; Lotsch J, 2005, J PAIN SYMPTOM MANAG, V29, pS10, DOI 10.1016/j.jpainsymman.2005.01.004; MACDONALD N, 1993, PAIN, V53, P353, DOI 10.1016/0304-3959(93)90232-E; Maddocks I, 1996, J PAIN SYMPTOM MANAG, V12, P182, DOI 10.1016/0885-3924(96)00050-4; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Mercadante S, 2011, PALLIATIVE MED, V25, P504, DOI 10.1177/0269216311406577; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V37, P632, DOI 10.1016/j.jpainsymman.2007.12.024; Miyoshi Takanori, 2014, Gan To Kagaku Ryoho, V41, P1401; Morita T, 2005, J PAIN SYMPTOM MANAG, V30, P96, DOI 10.1016/j.jpainsymman.2004.12.010; Nomura M, 2013, CLIN J PAIN, V29, P487, DOI 10.1097/AJP.0b013e318266f6a5; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Parsons HA, 2008, J PALLIAT MED, V11, P964, DOI 10.1089/jpm.2008.0037; Parsons HA, 2010, CANCER-AM CANCER SOC, V116, P520, DOI 10.1002/cncr.24754; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Reddy A, 2014, ONCOLOGIST, V19, P1186, DOI 10.1634/theoncologist.2014-0130; Reddy A, 2013, ONCOLOGIST, V18, P212, DOI 10.1634/theoncologist.2012-0269; SJOGREN P, 1994, PAIN, V59, P313, DOI 10.1016/0304-3959(94)90084-1; Skaer TL, 2004, DRUGS, V64, P2629, DOI 10.2165/00003495-200464230-00002; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; Walker PW, 2008, J PALLIAT MED, V11, P1103, DOI 10.1089/jpm.2007.0285; Webster LR, 2012, PAIN MED, V13, P562, DOI 10.1111/j.1526-4637.2012.01357.x; Webster LR, 2012, PAIN MED, V13, P571, DOI 10.1111/j.1526-4637.2012.01356.x; Xing SZ, 2015, SUPPORT CARE CANCER, V23, P753, DOI 10.1007/s00520-014-2419-5; Yennurajalingam S, 2011, J PAIN SYMPTOM MANAG, V41, P49, DOI 10.1016/j.jpainsymman.2010.03.017; ZENZ M, 1994, J PAIN SYMPTOM MANAG, V9, P54, DOI 10.1016/0885-3924(94)90149-X	53	14	14	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0008-543X	1097-0142		CANCER-AM CANCER SOC	Cancer	JAN 1	2016	122	1					149	156		10.1002/cncr.29688			8	Oncology	Oncology	DA7LF	WOS:000367984900021	26451687	Bronze			2020-06-30	J	Kucuk, HO; Kucuk, U; Kolcu, Z; Balta, S; Demirkol, S				Kucuk, H. O.; Kucuk, U.; Kolcu, Z.; Balta, S.; Demirkol, S.			Misuse of fentanyl transdermal patch mixed with acute coronary syndrome	HUMAN & EXPERIMENTAL TOXICOLOGY			English	Article						Fentanyl; acute coronary syndrome; coronary angiography		Fentanyl transdermal patches have long been used in the palliative care of patients with chronic pain with a favorable safety profile. However, intoxications secondary to intentional and unintentional misuse have been widely reported. In this study, we report an otherwise healthy woman presented to emergency department who used three patches of fentanyl to alleviate her knee pain and with a picture mimicking acute coronary syndrome.	[Kucuk, H. O.; Kolcu, Z.] Van Educ & Res Hosp, Dept Cardiol, Van, Turkey; [Kucuk, U.] Van Army Dist Hosp, Dept Cardiol, TR-65100 Van, Turkey; [Balta, S.; Demirkol, S.] Gulhane Mil Med Acad Hosp, Dept Cardiol, Ankara, Turkey	Kucuk, U (reprint author), Van Army Dist Hosp, Dept Cardiol, TR-65100 Van, Turkey.	drugurkucuk@gmail.com		Balta, Sevket/0000-0002-6657-7334			BLAIR JR, 1987, ANESTHESIOLOGY, V67, P442, DOI 10.1097/00000542-198709000-00033; FREEMAN AB, 1985, CAN ANAESTH SOC J, V32, P654, DOI 10.1007/BF03011415; Moon JM, 2011, J EMERG MED, V40, P37, DOI 10.1016/j.jemermed.2007.10.075; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; ODEN RV, 1991, ANESTHESIOLOGY, V74, P941, DOI 10.1097/00000542-199105000-00023	5	4	5	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0960-3271	1477-0903		HUM EXP TOXICOL	Hum. Exp. Toxicol.	JAN	2016	35	1					51	52		10.1177/0960327115577516			2	Toxicology	Toxicology	CZ8EG	WOS:000367332400007	25736329				2020-06-30	J	Ahiskalioglu, A; Ince, I; Aksoy, M; Yalcin, E; Ahiskalioglu, EO; Kilinc, A				Ahiskalioglu, Ali; Ince, Ilker; Aksoy, Mehmet; Yalcin, Ertan; Ahiskalioglu, Elif Oral; Kilinc, Adnan			Effects of a Single-Dose of Pre-Emptive Pregabalin on Postoperative Pain and Opioid Consumption After Double-Jaw Surgery: A Randomized Controlled Trial	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							ORTHOGNATHIC SURGERY; ANALGESIA; GABAPENTIN; INTENSITY; OSTEOTOMY	Purpose: The effect of a single-dose of pre-emptive pregabalin is still unknown, although it is used as an adjuvant in controlling acute postoperative pain. The purpose of this study was to evaluate the effects of pre-emptive single-dose pregabalin on postoperative acute pain and 24-hour opioid consumption in patients who underwent double-jaw surgery. Patients and Methods: Forty patients (18 to 45 yr old; American Society of Anesthesiologists status I to II) for whom elective double-jaw surgery was planned under general anesthesia were included in this study, which had been planned as a prospective, randomized, and double-blinded study. Patients were randomly divided into 2 groups: the pregabalin group (n = 20) was given pregabalin 150 mg orally 1 hour before general anesthesia and the placebo group (n = 20) was given an oral placebo capsule. The groups were administered the routine general anesthesia protocol. Postoperative analgesia was performed intravenously in the 2 groups twice a day with dexketoprofen trometamol 50 mg and patient-controlled analgesia with fentanyl. Postoperative analgesia was evaluated using the visual analog scale (VAS). Fentanyl consumption, additional analgesia requirement, and side-effects were recorded during the first 24 hours after surgery. Descriptive and bivariate statistics were computed, and significance was set at a P value less than .05. Results: Compared with placebo, the VAS score was statistically lower in the pregabalin group during the early postoperative period (P < .05). The 24-hour opioid consumption was significantly higher in the placebo group compared with the pregabalin group (509.40 +/- 261.56 vs 260.10 +/- 246.53 mu q, respectively; P = .004). In addition, the analgesia requirement was statistically lower in the pregabalin group (P <. 05). Nausea or vomiting was observed more often in the placebo group, whereas other side-effects were similar for the 2 groups. Conclusion: A single 150-mg dose of pre-emptive pregabalin decreased postoperative opioid consumption in the first 24 hours after double-jaw surgery. Multimodal analgesia techniques that contain pre-emptive analgesia can be used successfully in preventing postoperative pain caused by orthognathic surgery. (C) 2016 American Association of Oral and Maxillofacial Surgeons	[Ahiskalioglu, Ali; Ince, Ilker; Aksoy, Mehmet] Ataturk Univ, Dept Anesthesiol & Reanimat, Sch Med, TR-25070 Erzurum, Turkey; [Yalcin, Ertan; Kilinc, Adnan] Ataturk Univ, Fac Dent, Dept Oral & Maxillofacial Surg, TR-25070 Erzurum, Turkey; [Ahiskalioglu, Elif Oral] Reg Training & Res Hosp, Dept Anesthesiol, Erzurum, Turkey	Ahiskalioglu, A (reprint author), Ataturk Univ, Dept Anesthesiol & Reanimat, Sch Med, Yakutiye Res Hosp, TR-25070 Erzurum, Turkey.	aliahiskalioglu@hotmail.com	Ahiskalioglu, Ali/K-5343-2019; Ahiskalioglu, Ali/B-7473-2016	Ahiskalioglu, Ali/0000-0002-8467-8171; Ahiskalioglu, Ali/0000-0002-8467-8171			Agarwal A, 2008, BRIT J ANAESTH, V101, P700, DOI 10.1093/bja/aen244; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Aziz SR, 2004, J ORAL MAXIL SURG, V62, P1303, DOI 10.1016/j.joms.2003.08.044; Balaban F, 2012, J CLIN ANESTH, V24, P175, DOI 10.1016/j.jclinane.2011.06.027; Bornemann-Cimenti H, 2012, BRIT J ANAESTH, V108, P845, DOI 10.1093/bja/aes004; Busby Bret R, 2002, Int J Adult Orthodon Orthognath Surg, V17, P159; Cheung CW, 2012, J ORAL MAXIL SURG, V70, P25, DOI 10.1016/j.joms.2011.03.056; Cillo JE, 2014, J ORAL MAXIL SURG, V72, P1909, DOI 10.1016/j.joms.2014.05.014; D'Agostino A, 2010, J CRANIOFAC SURG, V21, P1189, DOI 10.1097/SCS.0b013e3181e1b5ff; Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036; Fassoulaki A, 2012, EUR J ANAESTH, V29, P531, DOI 10.1097/EJA.0b013e32835800e0; Frampton JE, 2005, DRUGS, V65, P111, DOI 10.2165/00003495-200565010-00011; Hill CM, 2001, EUR J PAIN, V5, P119, DOI 10.1053/eujp.2001.0235; Kelly DJ, 2001, CAN J ANAESTH, V48, P1000, DOI 10.1007/BF03016591; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Lyseng-Williamson KA, 2008, DRUGS, V68, P2205, DOI 10.2165/00003495-200868150-00009; Mixter CG, 1998, ARCH SURG-CHICAGO, V133, P432, DOI 10.1001/archsurg.133.4.432; Nagatsuka C, 2000, Anesth Prog, V47, P119; Nesari S, 2005, INT J ORAL MAX SURG, V34, P495, DOI 10.1016/j.ijom.2004.10.021; Peng PWH, 2007, PAIN RES MANAG, V12, P85, DOI 10.1155/2007/840572; Phillips C, 2008, J ORAL MAXIL SURG, V66, P2110, DOI 10.1016/j.joms.2008.06.080; Politis C, 2014, OR SURG OR MED OR PA, V117, pE102, DOI 10.1016/j.oooo.2013.08.001; Sagit M, 2013, J CRANIOFAC SURG, V24, P373, DOI 10.1097/SCS.0b013e31827fece5; Sarakatsianou C, 2013, SURG ENDOSC, V27, P2504, DOI 10.1007/s00464-012-2769-3; Seib RK, 2006, CAN J ANAESTH, V53, P461, DOI 10.1007/BF03022618; Sen H, 2009, EUR J ANAESTH, V26, P772, DOI 10.1097/EJA.0b013e32832ad2fa; Tuzuner AM, 2007, J ORAL MAXIL SURG, V65, P2453, DOI 10.1016/j.joms.2007.06.622; Widar F, 2015, INT J ORAL MAX SURG, V44, P252, DOI 10.1016/j.ijom.2014.08.002; WOOLF CJ, 1995, BRIT J ANAESTH, V75, P169, DOI 10.1093/bja/75.2.169; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	30	10	10	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JAN	2016	74	1								10.1016/j.joms.2015.09.008			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CZ8OB	WOS:000367357900008	26433040				2020-06-30	J	Buck, D; Subramanyam, R; Varughese, A				Buck, David; Subramanyam, Rajeev; Varughese, Anna			A quality improvement project to reduce the intraoperative use of single-dose fentanyl vials across multiple patients in a pediatric institution	PEDIATRIC ANESTHESIA			English	Article						quality improvement; patient safety; anesthesiology; pediatrics; infection control		ObjectiveThe use of a single-dose vial across multiple patients presents a risk to sterility and is against CDC guidelines. We initiated a quality improvement (QI) project to reduce the intraoperative use of single-dose vials of fentanyl across multiple patients at Cincinnati Children's Hospital Medical Center (CCHMC). MethodsThe initial step of the improvement project was the development of a Key Driver Diagram. The diagram has the SMART aim of the project, key drivers inherent to the process we are trying to improve, and specific interventions targeting the key drivers. The number of patients each week receiving an IV dose of fentanyl, from a vial previously accessed for another patient was tracked in a high turnover operating room (OR). The improvement model used was based on the concept of building Plan-Do-Study-Act (PDSA) cycles. Tests of change included provider education, provision of an increased number of fentanyl vials, alternate wasting processes, and provision of single-use fentanyl syringes by the pharmacy. ResultsPrior to initiation of this project, it was common for a single fentanyl vial to be accessed for multiple patients. Our data showed an average percentage of failures of just over 50%. During the end of the project, after 7 months, the mean percentage failures had dropped to 5%. Preparation of 20 mcg single-use fentanyl syringes by pharmacy, combined with education of providers on appropriate use, was successful in reducing failures to below our goal of 25%. ConclusionsAppropriately sized fentanyl syringes prepared by pharmacy, education on correct use of single-dose vials, and reminders in the OR, reduced the percentage of patients receiving a dose of fentanyl from a vial previously accessed for another patient in a high-volume otolaryngology room.	[Buck, David; Subramanyam, Rajeev; Varughese, Anna] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA	Buck, D (reprint author), Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, 3333 Burnet Ave,MLC 2001, Cincinnati, OH 45229 USA.	David.Buck@cchmc.org					[Anonymous], 2008, US PHARMACOPEIAL CON, p[5, 13]; [Anonymous], 2012, SINGLE DOSE SINGLE U; [Anonymous], 2011, RECOMMENDATIONS INFE; Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1; CDC, 2011, CDC SINGLE DOSE SING; Fent K, 2006, AQUAT TOXICOL, V76, P122, DOI 10.1016/j.aquatox.2005.09.009; Gounder P, 2013, J CLIN ANESTH, V25, P521, DOI 10.1016/j.jclinane.2013.04.013; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pE573; Meyer T, 2015, OFFICIAL J ANESTHESI; Siegel JD, 2007, 2007 GUIDELINE ISOLA; Tallis GF, 2003, J VIRAL HEPATITIS, V10, P234, DOI 10.1046/j.1365-2893.2003.00424.x; 2003, MMWR MORB MORTAL WKL, V52, P901	12	0	0	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	JAN	2016	26	1					92	101		10.1111/pan.12774			10	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	CY4TU	WOS:000366402200011	26566703				2020-06-30	J	Choi, L; Ferrell, BA; Vasilevskis, EE; Pandharipande, PP; Heltsley, R; Ely, EW; Stein, CM; Girard, TD				Choi, Leena; Ferrell, Benjamin A.; Vasilevskis, Eduard E.; Pandharipande, Pratik P.; Heltsley, Rebecca; Ely, E. Wesley; Stein, C. Michael; Girard, Timothy D.			Population Pharmacokinetics of Fentanyl in the Critically Ill	CRITICAL CARE MEDICINE			English	Article						fentanyl; intensive care; mechanical ventilation; pharmacokinetics; sedation	TERM CONTINUOUS-INFUSION; SEDATION; VALIDATION; DEXMEDETOMIDINE; IMPAIRMENT; ANALGESICS; ALFENTANIL; PATIENT	Objective: To characterize fentanyl population pharmacokinetics in patients with critical illness and identify patient characteristics associated with altered fentanyl concentrations. Design: Prospective cohort study. Setting: Medical and surgical ICUs in a large tertiary care hospital in the United States. Patients: Patients with acute respiratory failure and/or shock who received fentanyl during the first 5 days of their ICU stay. Measurements and Main Results: We collected clinical and hourly drug administration data and measured fentanyl concentrations in plasma collected once daily for up to 5 days after enrollment. Among 337 patients, the mean duration of infusion was 58 hours at a median rate of 100 g/hr. Using a nonlinear mixed-effects model implemented by NONMEM, we found that fentanyl pharmacokinetics were best described by a two-compartment model in which weight, severe liver disease, and congestive heart failure most affected fentanyl concentrations. For a patient population with a mean weight of 92kg and no history of severe liver disease or congestive heart failure, the final model, which performed well in repeated 10-fold cross-validation, estimated total clearance, intercompartmental clearance (Q), and volumes of distribution for the central (V-1) and peripheral compartments (V-2) to be 35L/hr (95% CI, 32-39L/hr), 55L/hr (95% CI, 42-68L/hr), 203L (95% CI, 140-266L), and 523L (95% CI, 428-618L), respectively. Severity of illness was marginally associated with fentanyl pharmacokinetics but did not improve the model fit after liver and heart diseases were included. Conclusions: In this study, fentanyl pharmacokinetics during critical illness were strongly influenced by severe liver disease, congestive heart failure, and weight, factors that should be considered when dosing fentanyl in the ICU. Future studies are needed to determine if data-driven fentanyl dosing algorithms can improve outcomes for ICU patients.	[Choi, Leena] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Ferrell, Benjamin A.; Ely, E. Wesley; Girard, Timothy D.] Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37212 USA; [Vasilevskis, Eduard E.] Vanderbilt Univ, Sch Med, Dept Med, Div Gen Internal Med & Publ Hlth, Nashville, TN 37212 USA; [Vasilevskis, Eduard E.; Ely, E. Wesley; Girard, Timothy D.] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN 37212 USA; [Vasilevskis, Eduard E.; Ely, E. Wesley; Girard, Timothy D.] Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, Educ & Clin Ctr Serv, Geriatr Res, Nashville, TN USA; [Pandharipande, Pratik P.] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Div Crit Care, Nashville, TN 37212 USA; [Pandharipande, Pratik P.] Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, Anesthesia Serv, Nashville, TN USA; [Heltsley, Rebecca] Aegis Sci Corp, Nashville, TN USA; [Ely, E. Wesley; Girard, Timothy D.] Vanderbilt Univ, Sch Med, Ctr Qual Aging, Nashville, TN 37212 USA; [Stein, C. Michael] Vanderbilt Univ, Sch Med, Dept Med, Div Clin Pharmacol, Nashville, TN 37212 USA; [Stein, C. Michael] Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol, Nashville, TN 37212 USA	Girard, TD (reprint author), Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.	timothy.girard@vanderbilt.edu	Girard, Timothy/I-3008-2019; Vasilevskis, Eduard/AAA-3065-2019; Ely, E. Wesley/Z-2018-2019	Girard, Timothy/0000-0002-9833-4871; Vasilevskis, Eduard/0000-0001-8165-5321; Ely, E. Wesley/0000-0003-3957-2172; Pandharipande, Pratik/0000-0002-1389-8580	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG034412, AG027472, TR000445, AG040157, HL111111, AG035117, GM109145, AG034257]; VA Clinical Science Research and Development Service (VA Career Development Award); VA Clinical Science Research and Development Service (VA Merit Review Award); Veterans Affairs Tennessee Valley Geriatric Research, Education and Clinical Center (GRECC); Hospira, Inc.	This study was supported by the National Institutes of Health (AG034412, AG027472, and TR000445). In addition, Drs. Vasilevskis, Pandharipande, Ely, Stein, and Girard received support from the National Institutes of Health (AG040157, HL111111, AG035117, GM109145, and AG034257). Drs. Pandharipande and Ely also received support from the VA Clinical Science Research and Development Service (VA Career Development Award and VA Merit Review Award, respectively) and Drs. Vasilevskis, Ely, and Girard received support from the Veterans Affairs Tennessee Valley Geriatric Research, Education and Clinical Center (GRECC). Dr. Pandharipande has received a research grant from Hospira, Inc. Dr. Ely has received honoraria from Abbott Laboratories, Hospira, Inc., and Orion Corporation. Dr. Girard has received honoraria from Hospira, Inc. The remaining authors have disclosed that they have no potential conflicts of interest.	Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663; BAILIE GR, 1992, BRIT J ANAESTH, V68, P486, DOI 10.1093/bja/68.5.486; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Beal SL, 2009, NONMEM USERS GUIDES; Bosilkovska M, 2012, DRUGS, V72, P1645, DOI 10.2165/11635500-000000000-00000; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; Casati A, 2005, J CLIN ANESTH, V17, P134, DOI 10.1016/j.jclinane.2004.01.009; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Choi L, 2011, J PHARMACOKINET PHAR, V38, P613, DOI 10.1007/s10928-011-9211-7; DePriest A, 2010, J ANAL TOXICOL, V34, P444, DOI 10.1093/jat/34.8.444; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; GREENBLATT DJ, 1991, CLIN PHARMACOKINET, V21, P262, DOI 10.2165/00003088-199121040-00003; HABERER JP, 1982, BRIT J ANAESTH, V54, P1267, DOI 10.1093/bja/54.12.1267; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; Heltsley R, 2011, J ANAL TOXICOL, V35, P529, DOI 10.1093/anatox/35.8.529; Hudson RJ, 2002, CAN J ANAESTH, V49, P388, DOI 10.1007/BF03017328; Jin SJ, 2011, CLIN PHARMACOL THER, V90, P423, DOI 10.1038/clpt.2011.133; Kaneda K, 2009, BURNS, V35, P790, DOI 10.1016/j.burns.2008.12.006; Kim JH, 2009, COMPUT STAT DATA AN, V53, P3735, DOI 10.1016/j.csda.2009.04.009; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kohli U, 2012, EUR J CLIN PHARMACOL, V68, P937, DOI 10.1007/s00228-011-1208-z; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mercadante S, 2004, J PAIN, V5, P2, DOI 10.1016/j.jpain.2003.09.007; Molinaro AM, 2005, BIOINFORMATICS, V21, P3301, DOI 10.1093/bioinformatics/bti499; Niscola P, 2010, CURR DRUG TARGETS, V11, P752, DOI 10.2174/138945010791170879; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; R Core Team, 2014, R LANG ENV STAT COMP; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; SINGLETON MA, 1988, BRIT J ANAESTH, V60, P619, DOI 10.1093/bja/60.6.619; Swart EL, 2004, BRIT J CLIN PHARMACO, V57, P135, DOI 10.1046/j.1365-2125.2003.01957.x; U.S. Food and Drug Administration, DRUG DEV DRUG INT TA; Valitalo PA, 2013, CLIN DRUG INVEST, V33, P579, DOI 10.1007/s40261-013-0101-1; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156	39	15	17	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2016	44	1					64	72		10.1097/CCM.0000000000001347			9	Critical Care Medicine	General & Internal Medicine	CY7QZ	WOS:000366605100008	26491862	Green Accepted			2020-06-30	J	Droege, CA; Mueller, EW				Droege, Chris A.; Mueller, Eric W.			Fentanyl Pharmacokinetics in Critically Ill Patients: A Demonstration of Mixed Effects	CRITICAL CARE MEDICINE			English	Editorial Material						critical illness; drug dosing; pharmacodynamics; pharmacology; pharmacokinetics	THERAPY; BURNS; PAIN		[Droege, Chris A.; Mueller, Eric W.] Univ Cincinnati, Med Ctr, Dept Pharm Serv, Cincinnati, OH 45267 USA	Droege, CA (reprint author), Univ Cincinnati, Med Ctr, Dept Pharm Serv, Cincinnati, OH 45267 USA.						Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Choi G, 2009, CRIT CARE MED, V37, P2268, DOI 10.1097/CCM.0b013e3181aab3d0; Choi L, 2016, CRIT CARE MED, V44, P64, DOI 10.1097/CCM.0000000000001347; Chu LF, 2006, J PAIN, V7, P43, DOI 10.1016/j.jpain.2005.08.001; Danhof M, 2005, PHARM RES, V22, P1432, DOI 10.1007/s11095-005-5882-3; Duffull SB, 2011, BRIT J CLIN PHARMACO, V71, P807, DOI 10.1111/j.1365-2125.2010.03891.x; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Han TH, 2007, J CLIN PHARMACOL, V47, P674, DOI 10.1177/0091270007299756; Kaneda K, 2009, BURNS, V35, P790, DOI 10.1016/j.burns.2008.12.006; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Lat I, 2011, J CRIT CARE, V26, P89, DOI 10.1016/j.jcrc.2010.06.012; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Power BM, 1998, CLIN PHARMACOKINET, V34, P25, DOI 10.2165/00003088-199834010-00002; Roberts JA, 2009, CRIT CARE MED, V37, P840, DOI 10.1097/CCM.0b013e3181961bff; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Smith BS, 2012, CHEST, V141, P1327, DOI 10.1378/chest.11-1396; Smithburger PL, 2015, CRIT CARE MED, V43, P1612, DOI 10.1097/CCM.0000000000001022; Valitalo P, 2014, ACTA ANAESTH SCAND, V58, P143, DOI 10.1111/aas.12253	18	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2016	44	1					240	242		10.1097/CCM.0000000000001444			3	Critical Care Medicine	General & Internal Medicine	CY7QZ	WOS:000366605100032	26672932				2020-06-30	J	Viscusi, ER; Grond, S; Ding, L; Danesi, H; Jones, JB; Sinatra, RS				Viscusi, Eugene R.; Grond, Stefan; Ding, Li; Danesi, Hassan; Jones, James B.; Sinatra, Raymond S.			A comparison of opioid-related adverse events with fentanyl iontophoretic transdermal system versus morphine intravenous patient-controlled analgesia in acute postoperative pain	PAIN MANAGEMENT			English	Article						fentanyl; iontophoretic transdermal system; morphine; opioid-related adverse drug events; patient-controlled analgesia; postoperative pain	DRUG EVENTS; MANAGEMENT; EFFICACY; SAFETY; COST	Objective: This analysis compared opioid-related adverse events (ORADEs) observed with fentanyl iontophoretic transdermal system (ITS) versus morphine intravenous (iv.) patient-controlled analgesia (PCA) in the management of postoperative pain. Methods: Safety data from four Phase IIIB randomized, active-comparator trials were pooled for this analysis (n = 1288 fentanyl ITS and 1313 morphine iv. PCA patients). Treatment-emergent adverse events were collected via spontaneous report. In this post hoc analysis, ORADEs were defined as apnea, confusion, constipation, dyspnea, hypotension, hypoventilation, hypoxia, ileus, nausea, pruritus, somnolence, tachycardia, urinary retention and vomiting. Odds ratios (OR) and 95% CI were calculated for all ORADEs and p-values were based on logistic regression with treatment as effect. Results: There were fewer patients in the fentanyl ITS group compared with the morphine iv. PCA group who experienced at least one ORADE (52.7 vs 59.1%, respectively; OR: 0.772: 95% CI: 0.661-0.901; p = 0.0011). The ORADEs that occurred less frequently in the fentanyl ITS group than in the morphine iv. PCA group included hypotension (3.7 vs 5.5%, respectively; OR: 0.667; 95% CI: 0.459-0.969; p = 0.0338), hypoventilation (0.9 vs 1.9%, respectively; OR: 0.444; 95% CI: 0.217-0.906; p = 0.0256), nausea (40.3 vs 44.5%, respectively; OR: 0.842; 95% CI: 0.721-0.984; p = 0.0310), pruritus (5.5 vs 9.4%, respectively; OR: 0.559; 95% CI: 0.413-0.757; p = 0.0002) and tachycardia (1.6 vs 2.8%, respectively; OR: 0.489; 95% CI: 0.277-0.863; p = 0.0136). No ORADEs occurred more frequently in the fentanyl ITS group compared with the morphine iv. PCA group. Conclusion: Fentanyl ITS, in the management of acute postoperative pain, offered safety advantages in terms of ORADEs compared with morphine iv. PCA.	[Viscusi, Eugene R.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Grond, Stefan] Klinikum Detmold Lippe, D-32756 Detmold, Germany; [Ding, Li; Danesi, Hassan; Jones, James B.] Medicines Co, Parsippany, NJ 07054 USA; [Sinatra, Raymond S.] West Haven VA Med Ctr, West Haven, CT 06516 USA	Danesi, H (reprint author), Medicines Co, 8 Sylvan Way, Parsippany, NJ 07054 USA.	hassan.danesi@THEMEDCO.com					Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Barletta JF, 2012, PHARMACOTHERAPY, V32, p12S, DOI 10.1002/j.1875-9114.2012.01178.x; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Kessler ER, 2013, PHARMACOTHERAPY, V33, P383, DOI 10.1002/phar.1223; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Minkowitz HS, 2014, AM J HEALTH-SYST PH, V71, P1556, DOI 10.2146/ajhp130031; Minkowitz Harold S, 2014, J Manag Care Spec Pharm, V20, P948; Minkowitz Harold S, 2010, J Opioid Manag, V6, P203; Oderda G, 2012, PHARMACOTHERAPY, V32, p6S, DOI 10.1002/j.1875-9114.2012.01177.x; Oderda GM, 2003, J PAIN SYMPTOM MANAG, V25, P276, DOI 10.1016/S0885-3924(02)00691-7; Overdyk F, 2014, PAIN MANAG, V4, P317, DOI [10.2217/pmt.14.19, 10.2217/PMT.14.19]; Strassels SA, 2005, AM J HEALTH-SYST PH, V62, P1904, DOI 10.2146/ajhp040490.p1; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd	16	15	18	1	5	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1758-1869	1758-1877		PAIN MANAG	Pain Manag.		2016	6	1					19	24		10.2217/pmt.15.49			6	Clinical Neurology	Neurosciences & Neurology	CY9TB	WOS:000366748100005	26376128	Bronze			2020-06-30	J	Reynolds, SL; Studnek, JR; Bryant, K; VanderHave, K; Grossman, E; Moore, CG; Young, J; Hogg, M; Runyon, MS				Reynolds, Stacy L.; Studnek, Jonathan R.; Bryant, Kathleen; VanderHave, Kelly; Grossman, Eric; Moore, Charity G.; Young, James; Hogg, Melanie; Runyon, Michael S.			Study protocol of a randomised controlled trial of intranasal ketamine compared with intranasal fentanyl for analgesia in children with suspected, isolated extremity fractures in the paediatric emergency department	BMJ OPEN			English	Article							REPORT PAIN SCALES; PREHOSPITAL ANALGESIA; MANAGEMENT; NORKETAMINE; MORPHINE; RELIEF	Introduction: Fentanyl is the most widely studied intranasal (IN) analgesic in children. IN subdissociative (INSD) ketamine may offer a safe and efficacious alternative to IN fentanyl and may decrease overall opioid use during the emergency department (ED) stay. This study examines the feasibility of a larger, multicentre clinical trial comparing the safety and efficacy of INSD ketamine to IN fentanyl and the potential role for INSD ketamine in reducing total opioid medication usage. Methods and analysis: This double-blind, randomised controlled, pilot trial will compare INSD ketamine (1 mg/kg) to IN fentanyl (1.5 mu g/kg) for analgesia in 80 children aged 4-17 years with acute pain from a suspected, single extremity fracture. The primary safety outcome for this pilot trial will be the frequency of cumulative side effects and adverse events at 60 min after drug administration. The primary efficacy outcome will be exploratory and will be the mean reduction of pain scale scores at 20 min. The study is not powered to examine efficacy. Secondary outcome measures will include the total dose of opioid pain medication in morphine equivalents/kg/hour (excluding study drug) required during the ED stay, number and reason for screen failures, time to consent, and the number and type of protocol deviations. Patients may receive up to 2 doses of study drug. Ethics and dissemination: This study was approved by the US Food and Drug Administration, the local institutional review board and the study data safety monitoring board. This study data will be submitted for publication regardless of results and will be used to establish feasibility for a multicentre, non-inferiority trial.	[Reynolds, Stacy L.] Carolinas Med Ctr, Dept Emergency Med, Div Pediat Emergency Med, Charlotte, NC 28203 USA; [Studnek, Jonathan R.] Mecklenberg EMS Agcy Med, Charlotte, NC USA; [Bryant, Kathleen; Young, James; Hogg, Melanie; Runyon, Michael S.] Carolinas Med Ctr, Dept Emergency Med, Charlotte, NC 28203 USA; [VanderHave, Kelly] Carolinas Med Ctr, Dept Orthoped, Charlotte, NC 28203 USA; [Grossman, Eric] Levine Childrens Hosp, Dept Pediat Surg, Concord, NC USA; [Moore, Charity G.] Carolinas Healthcare Syst, Dickson Adv Analyt, Charlotte, NC USA	Reynolds, SL (reprint author), Carolinas Med Ctr, Dept Emergency Med, Div Pediat Emergency Med, Charlotte, NC 28203 USA.	Stacy.Reynolds@carolinas.org		Moore, Charity/0000-0002-0060-0124	Carolinas Trauma Network Research Center of Excellence at Carolinas Healthcare System; Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB), Emergency Medical Services for Children (EMSC) [H34MC26201]	This work was supported by an internal grant from the Carolinas Trauma Network Research Center of Excellence at Carolinas Healthcare System. This project is supported in part by the Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB), Emergency Medical Services for Children (EMSC) Targeted Issues grant programme, Grant No. H34MC26201 for $900 000.	Andolfatto G, 2013, ACAD EMERG MED, V20, P1050, DOI 10.1111/acem.12229; Bailey B, 2007, ANN EMERG MED, V50, P379, DOI 10.1016/j.annemergmed.2007.04.021; Bell RF, 2012, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Bulloch B, 2002, ACAD EMERG MED, V9, P199, DOI 10.1197/aemj.9.3.199; Dong L, 2012, PEDIATR EMERG CARE, V28, P109, DOI 10.1097/PEC.0b013e3182442c25; Gausche-Hill M, 2014, PREHOSP EMERG CARE, V18, P25, DOI 10.3109/10903127.2013.844873; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Iyer SB, 2011, PEDIATRICS, V127, pE219, DOI 10.1542/peds.2010-0632; Kerr C, 2011, J PALLIAT MED, V14, P1074, DOI 10.1089/jpm.2010.0424; Kircher J, 2014, CAN J EMERG MED, V16, P449, DOI 10.2310/8000.2013.131211; Mabry R, 2008, CRIT CARE MED, V36, pS258, DOI 10.1097/CCM.0b013e31817da674; Malinovsky JM, 1996, BRIT J ANAESTH, V77, P203, DOI 10.1093/bja/77.2.203; Moore CG, 2011, CTS-CLIN TRANSL SCI, V4, P332, DOI 10.1111/j.1752-8062.2011.00347.x; Motov S, 2015, ANN EMERG MED, V66, P222, DOI 10.1016/j.annemergmed.2015.03.004; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Neri CM, 2013, PEDIATR ANESTH, V23, P684, DOI 10.1111/pan.12172; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Shikanai H, 2014, J ANESTH, V28, P390, DOI 10.1007/s00540-013-1722-5; Stang AS, 2014, PAIN RES MANAG, V19, pE179, DOI 10.1155/2014/269140; Swor Robert, 2005, Prehosp Emerg Care, V9, P40, DOI 10.1080/10903120590891930; Truba N, 2014, J PAIN MANAG, V7, P235; Tsze DS, 2015, ACAD EMERG MED, V22, P415, DOI 10.1111/acem.12620; Tsze DS, 2013, PEDIATRICS, V132, pE971, DOI 10.1542/peds.2013-1509; Uprety D, 2014, ANN HEMATOL, V93, P769, DOI 10.1007/s00277-013-1954-3; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; Williams DM, 2012, PREHOSP EMERG CARE, V16, P519, DOI 10.3109/10903127.2012.695436; Yanagihara Y, 2003, BIOPHARM DRUG DISPOS, V24, P37, DOI 10.1002/bdd.336; Yeaman F, 2013, EMERG MED AUSTRALAS, V25, P161, DOI 10.1111/1742-6723.12059	31	4	4	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2016	6	9							e012190	10.1136/bmjopen-2016-012190			6	Medicine, General & Internal	General & Internal Medicine	EG8JL	WOS:000391302900161	27609854	DOAJ Gold, Green Published			2020-06-30	J	Helander, A; Backberg, M; Beck, O				Helander, Anders; Backberg, Matilda; Beck, Olof			Intoxications involving the fentanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfentanyl: results from the Swedish STRIDA project	CLINICAL TOXICOLOGY			English	Article						Acetylfentanyl; butyrfentanyl; fentanyl analog; 4-fluorobutyrfentanyl; furanylfentanyl; Internet drug; mass spectrometry method; 4-methoxybutyrfentanyl; new psychoactive substances; opioid analgesic drug	DRUG-RELATED DEATHS; ACETYL FENTANYL; LEGAL-HIGHS; LC-MS/MS; IDENTIFICATION; SWEDEN; URINE; 3-METHYLFENTANYL; DERIVATIVES; FATALITY	Background: Potent and potentially harmful new psychoactive substances (NPS) are continuously introduced on the recreational drugs market. This report from the Swedish STRIDA project describes analytically confirmed cases of intoxication involving the fentanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl, and furanylfentanyl. Methods: Patients with suspected NPS exposure presenting in emergency departments and intensive care units in Sweden and requiring hospital care are invited to the STRIDA project. Toxicological analysis of serum and urine samples was performed by multi-component liquid chromatographic-mass spectrometric methods. Data on clinical features were retrieved from telephone consultations with the Swedish Poisons Information Centre and from medical records. Results: Between April and November 2015, 14 analytically confirmed intoxications involving acetylfentanyl (nine cases), 4-methoxybutyrfentanyl (3), furanylfentanyl (1), and 4-methoxybutyrfentanyl together with furanylfentanyl (1) were identified. The patients were aged 20-40 (mean 28.5) years and 86% were men. Twelve patients (86%) were admitted to intensive care, where two required intubation and mechanical ventilation. Typical clinical features were decreased consciousness, respiratory depression, and miosis. In eight cases, the antidote naloxone was administered to counter the effects. The serum acetylfentanyl concentration (N=7) was 0.6-51.6 (mean 18.3 and median 14.8) ng/mL, and in urine (N=8) 0.1-686 (mean 155 and median 66.6) ng/mmol creatinine. The serum 4-methoxybutyrfentanyl concentration (N=2) was 1.3 and 3.1ng/mL, and 5.1-51.3ng/mmol creatinine in urine (N=3). For furanylfentanyl, the serum concentrations were 4.4 and 148ng/mL and in urine 9.2 and 85ng/mmol creatinine, respectively. In 13 cases (93%), other NPS and/or classical drugs were also detected. Drug products brought to hospital by patients contained acetylfentanyl (nasal spray and pink tablet), 4-methoxybutyrfentanyl (green tablet), furanylfentanyl/traces of 4-methoxybutyrfentanyl (nasal spray), and 4-fluorobutyrfentanyl (purple tablet). Conclusion: Potentially life-threatening opioid toxicity was seen in acute intoxications involving acetylfentanyl, 4-methoxybutyrfentanyl, and furanylfentanyl. Intensive care treatment for one month was necessary in one acetylfentanyl case and one acetylfentanyl patient died from cerebral hemorrhage.	[Helander, Anders; Beck, Olof] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Helander, Anders; Beck, Olof] Karolinska Univ Lab, Dept Clin Pharmacol, C1 74, SE-14186 Stockholm, Sweden; [Backberg, Matilda] Swedish Poisons Informat Ctr, Stockholm, Sweden	Helander, A (reprint author), Karolinska Univ Lab, Dept Clin Pharmacol, C1 74, SE-14186 Stockholm, Sweden.	anders.helander@ki.se					Al-Saffar Y, 2013, J CHROMATOGR B, V930, P112, DOI 10.1016/j.jchromb.2013.04.043; Backberg M, 2015, CLIN TOXICOL, V53, P856, DOI 10.3109/15563650.2015.1079325; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Backberg M, 2015, CLIN TOXICOL, V53, P46, DOI 10.3109/15563650.2014.981823; Baron M, 2011, DRUG TEST ANAL, V3, P576, DOI 10.1002/dta.274; Bazckberg M, 2014, CLIN TOXICOL, V52, P618, DOI 10.3109/15563650.2014.920088; Beck O, 2015, CLIN TOXICOL, V53, P865, DOI 10.3109/15563650.2015.1089576; Bluelight.org, NOV OP 4 METH 4 MEO; Bluelight.org, NOV OP FUR; Bluelight.org, BIG DAND FENT AN THR; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Davies S, 2010, QJM-INT J MED, V103, P489, DOI 10.1093/qjmed/hcq056; Drugs-Forum.com, DRUG NEED INF ACETYL; EMCDDA, 2015, NEW PSYCH SUBST EUR; EMCDDA, 2015, EUR DRUG REP 2015 TR; EMCDDA, 2012, FENT IN EUR; Flashback.org, 4 MEO BF; Flashback.org, AC; Flashback.org, FUR; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2015, CLIN TOXICOL, V53, P446, DOI 10.3109/15563650.2015.1033630; Helander A, 2014, FORENSIC SCI INT, V243, P23, DOI 10.1016/j.forsciint.2014.02.022; Helander A, 2013, SCAND J CLIN LAB INV, V73, P400, DOI 10.3109/00365513.2013.793817; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Johansson M, 2014, J PHARMACEUT BIOMED, V100, P215, DOI 10.1016/j.jpba.2014.07.026; Kamijo Y, 2014, INTERNAL MED, V53, P2439, DOI 10.2169/internalmedicine.53.2344; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Kronstrand R, 2014, J ANAL TOXICOL, V38, P599, DOI 10.1093/jat/bku057; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Melent'ev A, 2015, J ANAL CHEM+, V70, P240, DOI 10.1134/S1061934815020124; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Persson HE, 1998, J TOXICOL-CLIN TOXIC, V36, P205, DOI 10.3109/15563659809028940; Poklis A., 1995, REV CLIN ANAL TOXICO, V33, P439; Prosser JM, 2012, J MED TOXICOL, V8, P33, DOI 10.1007/s13181-011-0193-z; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Simonsen KW, 2015, FORENSIC SCI INT, V248, P172, DOI 10.1016/j.forsciint.2015.01.003; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; UNODC, UNODC EARL WARN ADV; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vorce SP, 2014, J ANAL TOXICOL, V38, P226, DOI 10.1093/jat/bku011; WHO, 2014, COMM MAN OP OV	49	56	59	0	32	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.		2016	54	4					324	332		10.3109/15563650.2016.1139715			9	Toxicology	Toxicology	DK5ZM	WOS:000374999800006	26850293				2020-06-30	J	Burns, G; DeRienz, RT; Baker, DD; Casavant, M; Spiller, HA				Burns, Glenn; DeRienz, Rebecca T.; Baker, Daniel D.; Casavant, Marcel; Spiller, Henry A.			Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?	CLINICAL TOXICOLOGY			English	Article						Chest wall rigidity; fentanyl; heroin; norfentanyl; opioids; overdose	INDUCED MUSCULAR RIGIDITY; HEROIN; INVOLVEMENT; ANESTHESIA; OXYGEN	Background: There has been a significant spike in fentanyl-related deaths from illicit fentanyl supplied via the heroin trade. Past fentanyl access was primarily oral or dermal via prescription fentanyl patch diversion. One factor potentially driving this increase in fatalities is the change in route of administration. Rapid intravenous (IV) fentanyl can produce chest wall rigidity. We evaluated post-mortem fentanyl and norfentanyl concentrations in a recent surge of lethal fentanyl intoxications. Methods: Fentanyl related deaths from the Franklin County coroner's office from January to September 2015 were identified. Presumptive positive fentanyl results were confirmed by quantitative analysis using liquid chromatography tandem mass spectrometry (LC/MS/MS) and were able to quantify fentanyl, norfentanyl, alfentanyl, and sufentanyl. Results: 48 fentanyl deaths were identified. Mean fentanyl concentrations were 12.5 ng/ml, (range 0.5 ng/ml to >40 ng/ml). Mean norfentanyl concentrations were 1.9 ng/ml (range none detected to 8.3 ng/ml). No appreciable concentrations of norfentanyl could be detected in 20 of 48 cases (42%) and were less than 1 ng/ml in 25 cases (52%). Elevated fentanyl concentrations did not correlate with rises in norfentanyl levels. In several cases fentanyl concentrations were strikingly high (22 ng/ml and 20 ng/ml) with no norfentanyl detected. Discussion: The lack of any measurable norfentanyl in half of our cases suggests a very rapid death, consistent with acute chest rigidity. An alternate explanation could be a dose-related rapid onset of respiratory arrest. Deaths occurred with low levels of fentanyl in the therapeutic range (1-2 ng/ml) in apparent non-naive opiate abusers. Acute chest wall rigidity is a well-recognized complication in the medical community but unknown within the drug abuse community. The average abuser of illicit opioids may be unaware of the increasing fentanyl content of their illicit opioid purchase. Conclusion: In summary we believe sudden onset chest wall rigidity may be a significant and previously unreported factor leading to an increased mortality, from illicit IV fentanyl use. Fentanyl and norfentanyl ratios and concentrations suggest a more rapid onset of death given the finding of fentanyl without norfentanyl in many of the fatalities. Chest wall rigidity may help explain the cause of death in these instances, in contrast to the typical opioid-related overdose deaths. Intravenous heroin users should be educated regarding this potentially fatal complication given the increasingly common substitution and combination with heroin of fentanyl.	[Burns, Glenn] Ohio State Univ, Cent Ohio Poison Ctr, Med Toxicol, Columbus, OH 43210 USA; [DeRienz, Rebecca T.; Baker, Daniel D.] Off Franklin Cty Coroner, Div Forens Toxicol, Columbus, OH USA; [Casavant, Marcel; Spiller, Henry A.] Ohio State Univ, Coll Med, Cent Ohio Poison Ctr, Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA	Spiller, HA (reprint author), Ohio State Univ, Coll Med, Cent Ohio Poison Ctr, Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.	haspiller5@gmail.com	Casavant, Marcel J/E-2848-2011	Casavant, Marcel J/0000-0001-8513-4144			Ackerman W E, 1990, Anesth Prog, V37, P46; COMSTOCK MK, 1981, ANESTH ANALG, V60, P362; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Darke S, 2000, DRUG ALCOHOL DEPEN, V60, P141, DOI 10.1016/S0376-8716(99)00147-7; Dewhirst E, 2012, PEDIATR EMERG CARE, V28, P465, DOI 10.1097/PEC.0b013e3182535a2a; Dimitriou Vassilios, 2014, Middle East Journal of Anesthesiology, V22, P619; Drug enforcement administration US department of justice, 2008, FED REGISTER, V73, P43355; GARRIOTT JC, 1973, NEW ENGL J MED, V289, P1276, DOI 10.1056/NEJM197312132892404; GOLDBERGER BA, 1994, J ANAL TOXICOL, V18, P22, DOI 10.1093/jat/18.1.22; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; JACKSON FW, 1994, GASTROENTEROLOGY, V106, P820, DOI 10.1016/0016-5085(94)90729-3; Jolley CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140995; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Launiainen T, 2014, DRUG TEST ANAL, V6, P308, DOI 10.1002/dta.1507; LEE TY, 1995, NEUROSCI LETT, V199, P195, DOI 10.1016/0304-3940(95)12049-A; LUI PW, 1990, NEUROSCI LETT, V108, P183, DOI 10.1016/0304-3940(90)90728-R; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003; Tanus-Santos JE., 1998, BMJ-BRIT MED J, V317, P1386; TORNETTA FJ, 1969, ANESTH ANAL CURR RES, V48, P850; Vaughn R L, 1981, Anesth Prog, V28, P50; WALLER JL, 1981, ANESTHESIOLOGY, V55, P212, DOI 10.1097/00000542-198109000-00005	26	45	45	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.		2016	54	5					420	423		10.3109/15563650.2016.1157722			4	Toxicology	Toxicology	DL4OQ	WOS:000375617500005	26999038				2020-06-30	J	Lundorf, LJ; Nedergaard, HK; Moller, AM				Lundorf, Luise Jessen; Nedergaard, Helene Korvenius; Moller, Ann Merete			Perioperative dexmedetomidine for acute pain after abdominal surgery in adults	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							INTRAVENOUS DEXMEDETOMIDINE; POSTOPERATIVE PAIN; DOUBLE-BLIND; DOSE DEXMEDETOMIDINE; BARIATRIC SURGERY; ALPHA-2 AGONISTS; METAANALYSIS; ANESTHESIA; EFFICACY; ANALGESIA	Background Acute postoperative pain is still an issue in patients undergoing abdominal surgery. Postoperative pain and side effects of analgesic treatment, in particular those of opioids, need to be minimized. Opioid-sparing analgesics, possibly including dexmedetomidine, seem a promising avenue by which to improve postoperative outcomes. Objectives Our primary aim was to determine the analgesic efficacy and opioid-sparing effect of perioperative dexmedetomidine for acute pain after abdominal surgery in adults. Secondary aims were to establish effects of dexmedetomidine on postoperative nausea and vomiting (PONV), gastrointestinal function and mobilization, together with the side effect profile of dexmedetomidine. Search methods We searched the following databases: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Institute for Scientific Information (ISI), Web of Science and Cumulative Index to Nursing and Allied Health Literature (CINAHL), and reference lists of articles to May 2014. We searched the Science Citation Index, ClinicalTrials.gov and Current Controlled Trials, and we contacted pharmaceutical companies to identify unpublished and ongoing studies. We applied no language restrictions. We reran the search in May 2015 and found nine studies of interest. We will deal with the studies of interest when we update the review. Selection criteria We included randomized, controlled trials of perioperative dexmedetomidine versus placebo or other drug during abdominal surgery in adults. Trials included one of the following outcomes: amount of 'rescue' opioid, postoperative pain, time to 'rescue' analgesia, participants requiring 'rescue' analgesia, postoperative sedation, PONV, time to first passage of flatus and stool or time to first out-of-bed mobilization. Data collection and analysis Two review authors independently screened the titles and abstracts for eligibility. We retrieved full trial reports if necessary, and we extracted relevant data from the included studies using a data collection form and assessed risk of bias. We resolved disagreements by discussion with the third review author. We sought additional information of relevance for risk of bias assessment or extraction of data by contacting study authors or, if necessary, co-authors from present or former studies. Main results Our systematic review included seven studies with a total of 492 participants. We included 422 participants in our analysis. Thirteen studies are awaiting classification. For the comparison dexmedetomidine versus placebo (six studies, 402 participants), most studies found a reduction in 'rescue' opioid consumption in the first 24 hours after surgery, together with in general no clinically important differences in postoperative pain (visual analogue scale (VAS) 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain) in the first 24 hours after surgery - except for one study (80 participants) with a reduction in VAS pain at two hours after surgery in favour of dexmedetomidine, with a mean difference of -30.00 mm (95% confidence interval (CI) -38.25 to -21.75). As the result of substantial heterogeneity, pooling of data in statistical meta-analyses was not appropriate. The quality of evidence was very low for our primary outcomes because of imprecision of results and risk of bias. Regarding our secondary aims, evidence was too scant in general to allow robust conclusions, or the estimates too imprecise or of poor methodological quality. Regarding adverse effects, low quality data (one study, 80 participants) suggest that the proportion of participants with hypotension requiring intervention was slightly higher in the high-dose dexmedetomidine group with a risk ratio of 2.50 (95% CI 0.94 to 6.66), but lower doses of dexmedetomidine led to no differences compared with control. Evidence for the comparison dexmedetomidine versus fentanyl was insufficient to permit robust conclusions (one study, 20 participants). Authors' conclusions Dexmedetomidine, when administered perioperatively for acute pain after abdominal surgery in adults, seemed to have some opioid-sparing effect together with in general no important differences in postoperative pain when compared with placebo. However the quality of the evidence was very low as the result of imprecision, methodological limitations and substantial heterogeneity among the seven included studies. The clinical importance for patients is uncertain, in as much as the influence of dexmedetomidine on patient-important outcomes such as gastrointestinal function, mobilization and adverse effects could not be satisfactorily determined. All included studies were relatively small, and publication bias could not be ruled out. Applicability of evidence was limited to middle-aged participants who were relatively free of co-morbidity and were undergoing elective abdominal surgery. A potential bias was a considerable quantity of unobtainable data from studies with mixed surgery. To detect and investigate patient-important outcomes, larger studies with longer periods of follow-up are needed.	[Lundorf, Luise Jessen] Herlev Univ Hosp, Rotat, Herlev Ringvej 75, DK-2730 Herlev, Denmark; [Nedergaard, Helene Korvenius] Lillebaelt Hosp, Dept Anaesthesiol & Intens Care, Kolding, Denmark; [Moller, Ann Merete] Univ Copenhagen, Herlev Hosp, Cochrane Anaesthesia Crit & Emergency Care Grp, DK-2730 Herlev, Denmark	Lundorf, LJ (reprint author), Herlev Univ Hosp, Rotat, Herlev Ringvej 75, DK-2730 Herlev, Denmark.	hansenluise@hotmail.com			Herlev University Hospital, Denmark	Internal sources; Herlev University Hospital, Denmark.	Abdalla N, 2003, EGYPTIAN J ANAESTHES, V19, P283; Akinci HA, 2011, EUROPEAN J ANAESTHES; Aldehayat G, 2011, RAWAL MED J, V36, P274; Altindis NT, 2008, NEUROSCIENCES, V13, P117; [Anonymous], 2008, MULTIMODAL ANALGESIC; [Anonymous], 2007, J PAIN PALLIATIVE CA, V21, P124; Anvaroglu R, 2008, ANESTEZI DERGISI, V16, P201; Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; Awad M, INTRAVENOUS DEXMEDET; Bakhamees Hassan S., 2007, Middle East Journal of Anesthesiology, V19, P537; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Basar H, 2008, J CLIN ANESTH, V20, P431, DOI 10.1016/j.jclinane.2008.04.007; Bergese SD, 2010, AM J THER, V17, P586, DOI 10.1097/MJT.0b013e3181d69072; BHATTACHARJEE DP, 2010, [No title captured], V26, P45; Biccard BM, 2008, ANAESTHESIA, V63, P4, DOI 10.1111/j.1365-2044.2007.05306.x; Bicer C, 2006, EUR J ANAESTH, V23, P149, DOI 10.1017/S0265021505002061; Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Bonnet F, 2007, BEST PRACT RES-CLIN, V21, P99, DOI 10.1016/j.bpa.2006.12.007; Candiotti KA, 2010, ANESTH ANALG, V110, P47, DOI 10.1213/ane.0b013e3181ae0856; Ceballos Caballero M, 2011, NEUROLOGIA NEUROCIRU, V44, P114; Chan AKM, 2010, EXPERT OPIN PHARMACO, V11, P2849, DOI 10.1517/14656566.2010.511613; Chen JJ, 2013, EXP THER MED, V5, P489, DOI 10.3892/etm.2012.811; Cho K, 2014, EUR J ANAESTH, V31, P228, DOI 10.1097/00003643-201406001-00657; Chrysostomou C, 2008, EXPERT OPIN DRUG MET, V4, P619, DOI [10.1517/17425255.4.5.619, 10.1517/17425255.4.5.619 ]; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elcicek K, 2010, J ANESTH, V24, P544, DOI 10.1007/s00540-010-0939-9; European Medicines Agency, DEXD PROD INF; Feld JM, 2006, J CLIN ANESTH, V18, P24, DOI 10.1016/j.jclinane.2005.05.009; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Gupta M, 2014, J CLIN DIAGN RES, V8, P114, DOI 10.7860/JCDR/2014/7883.4023; Gupta P, 2014, INDIAN J ANAESTH, V58, P154, DOI 10.4103/0019-5049.130816; Gupta Rajni, 2011, J Anaesthesiol Clin Pharmacol, V27, P339, DOI 10.4103/0970-9185.83678; Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622; Gutyanov V. A. p, 2013, Anesteziologiya i Reanimatologiya, P21; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Harsoor S S, 2014, J Anaesthesiol Clin Pharmacol, V30, P25, DOI 10.4103/0970-9185.125693; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hospira Inc, PREC PRESCR INF; Ibacache M, 2014, EUR J ANAESTH, V31, P150, DOI 10.1097/00003643-201406001-00424; Iwakiri H, 2012, EUR J ANAESTH, V29, P251, DOI 10.1097/EJA.0b013e3283529ba8; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; Jun GW, 2014, KOREAN J ANESTHESIOL, V67, P246, DOI 10.4097/kjae.2014.67.4.246; Jung KT, EFFECT DEXMEDETOMIDI; Kaya FN, 2010, CAN J ANAESTH, V57, P39, DOI 10.1007/s12630-009-9231-6; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Keniya VM, 2011, INDIAN J ANAESTH, V55, P352, DOI 10.4103/0019-5049.84846; Khanduja Suchit, 2014, J Anaesthesiol Clin Pharmacol, V30, P208, DOI 10.4103/0970-9185.130022; Kilicaslan N, 2006, ANESTEZI DERGISI, V14, P237; Kim JM, 2014, EUR J ANAESTH, V31, P34, DOI 10.1097/00003643-201406001-00096; Kim YC, EFFECT DEXMEDETOMIDI; Kordan A, 2006, ANESTEZI DERGISI, V14, P95; Lawrence CJ, 1997, ANAESTHESIA, V52, P736, DOI 10.1111/j.1365-2044.1997.169-az0303.x; Le Guen M, 2014, ANESTH ANALG, V118, P946, DOI 10.1213/ANE.0000000000000185; Lin TF, 2009, BRIT J ANAESTH, V102, P117, DOI 10.1093/bja/aen320; Lin YY, 2012, CRIT CARE, V16, DOI 10.1186/cc11646; Liu SS, 2007, ANESTH ANALG, V104, P689, DOI 10.1213/01.ane.0000255040.71600.41; Lundorf LJ, 2013, COCHRANE DB SYST REV, V2013, DOI [10.1002/14651858.cd010358, DOI 10.1002/14651858.CD010358]; Malek J, 2010, Rozhl Chir, V89, P275; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mantz J, 2011, EUR J ANAESTH, V28, P3, DOI 10.1097/EJA.0b013e32833e266d; Marangoni Marco Aurélio, 2005, Rev. Bras. Anestesiol., V55, P19, DOI 10.1590/S0034-70942005000100003; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; Mizrak A, 2010, J SURG RES, V159, pE11, DOI 10.1016/j.jss.2009.07.031; Mohamed AA, 2012, PAIN PHYSICIAN, V15, P339; Naja ZM, 2014, MEDKNOW PUBLICATIONS, V8, P57; Nordic Cochrane Centre, 2014, REV MAN REVMAN VERS; Ohtani N, 2008, ANESTH ANALG, V107, P1871, DOI 10.1213/ane.0b013e3181887fcc; Ozbakis Akkurt BC, 2008, ANESTEZI DERGIS, V16, P183; Padma L, 2013, INT J BASIC CLIN PHA, V2, P804, DOI [10.5455/2319-2003.ijbcp20131225, DOI 10.5455/2319-2003.IJBCP20131225]; Park JK, 2012, KOREAN J ANESTHESIOL, V63, P436, DOI 10.4097/kjae.2012.63.5.436; SCHEININ B, 1992, BRIT J ANAESTH, V68, P126, DOI 10.1093/bja/68.2.126; Schnabel A, 2013, PAIN, V154, P1140, DOI 10.1016/j.pain.2013.03.029; Shukla Deepika, 2011, J Anaesthesiol Clin Pharmacol, V27, P495, DOI 10.4103/0970-9185.86594; Singh S, 2014, 7 WORLD C WORLD I PA, P95; Subasi H, 2011, EUROPEAN J ANAESTHES; Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6; Tasdogan M, 2009, J CLIN ANESTH, V21, P394, DOI 10.1016/j.jclinane.2008.10.010; Tufanogullari B, 2008, ANESTH ANALG, V106, P1741, DOI 10.1213/ane.0b013e318172c47c; Unlugenc H, 2005, EUR J ANAESTH, V22, P386, DOI 10.1017/S0265021505000669; Vandermeulen E, 2006, ACTA ANAESTH BELG, V57, P113; Villela Nivaldo Ribeiro, 2003, Rev. Bras. Anestesiol., V53, P97, DOI 10.1590/S0034-70942003000100013; Wan Lin-jun, 2011, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V23, P543; Wang YL, 2015, J SURG RES, V194, P147, DOI 10.1016/j.jss.2014.10.008; Way CC, MULTIMODAL ANALGESIC; White PF, 2010, ANESTHESIOLOGY, V112, P220, DOI 10.1097/ALN.0b013e3181c6316e; Wijeysundera DN, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004126.pub2; Xiao Chun, 2013, Zhonghua Yi Xue Za Zhi, V93, P44; Yacout AG, 2012, ALEX J MED, V48, P3, DOI 10.1016/j.ajme.2011.11.001; Yektas A, 2011, REGIONAL ANESTHESIA; Yildiz Munise, 2006, Drugs R D, V7, P43, DOI 10.2165/00126839-200607010-00004; Zeeni C, DEXMEDETOMIDINE POST; Zeng XZ, 2014, ANAESTH INTENS CARE, V42, P185, DOI 10.1177/0310057X1404200204; Ziemann-Gimmel P, 2014, BRIT J ANAESTH, V112, P906, DOI 10.1093/bja/aet551	95	29	30	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2016		2							CD010358	10.1002/14651858.CD010358.pub2			97	Medicine, General & Internal	General & Internal Medicine	DI1VP	WOS:000373285000061	26889627	Green Published			2020-06-30	J	Song, JH; Kang, C; Hwang, DS; Hwang, JM; Shin, BK				Song, Jae-Hwang; Kang, Chan; Hwang, Deuk-Soo; Hwang, Jung-Mo; Shin, Byung-Kon			Fentanyl Patches to Supplement Ultrasound-Guided Nerve Blocks for Improving Pain Control After Foot and Ankle Surgery: A Prospective Study	JOURNAL OF FOOT & ANKLE SURGERY			English	Article						local anesthesia; postoperative analgesia; sciatic nerve; surgery; transdermal fentanyl		The analgesic effects of preoperative ultrasound-guided nerve blocks wear off after about 12 hours, leaving some patients in substantial pain. Transdermal fentanyl concentrations peak at 12 to 24 hours after application and maintain this concentration for approximately 72 hours. We sought to determine whether combining the use of a transdermal fentanyl patch with either a sciatic or femoral-sciatic nerve block would improve pain control in patients undergoing foot and/or ankle surgery. Consecutive patients in the no-patch control group (n = 104) were enrolled from July 2011 to October 2011, and those in the treatment group (n = 232) were enrolled from November 2011 to May 2012 and received a transdermal patch (4.125 mg/7.5 cm(2) releasing 25 mg of fentanyl per hour) applied to their chest postoperatively. Pain was assessed using a visual analog scale at 6, 12, 24, and 48 hours after surgery. The primary outcome measure was the number of requests for additional postoperative pain medication. Additional postoperative analgesia was requested by 49 of the 104 control patients (47.1%) and 63 of the 232 treated patients (27.1%; p = .002). The mean pain scores were also lower in the treatment group, with a statistically significant difference (p < .05) at 12, 24, and 48 hours. Thus, patients receiving a fentanyl patch combined with an ultrasound-guided nerve block required less supplemental analgesia to maintain adequate pain control than did those receiving a nerve block alone. In conclusion, a fentanyl patch is a useful adjunct to an ultrasound-guided nerve block in foot and ankle surgery. (C) 2016 by the American College of Foot and Ankle Surgeons. All rights reserved.	[Song, Jae-Hwang; Kang, Chan; Hwang, Deuk-Soo; Hwang, Jung-Mo; Shin, Byung-Kon] Chungnam Natl Univ, Sch Med, Dept Orthoped Surg, Daejeon 301721, South Korea	Kang, C (reprint author), Chungnam Natl Univ, Sch Med, Dept Orthoped Surg, 282 Munwha Ro, Daejeon 301721, South Korea.	faschan@hanmail.net		Kang, Chan/0000-0002-6651-0340; Hwang, Deuk-Soo/0000-0003-1009-3784			CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Domingo-Triado V, 2007, ANESTH ANALG, V104, P1270, DOI 10.1213/01.ane.0000221469.24319.49; Fredrickson MJ, 2009, ANAESTHESIA, V64, P836, DOI 10.1111/j.1365-2044.2009.05938.x; Helayel PE, 2007, REGION ANESTH PAIN M, V32, P221, DOI 10.1016/j.rapm.2007.01.006; Jeng CL, 2010, BRIT J ANAESTH, V105, pI97, DOI 10.1093/bja/aeq273; Kang C, 2010, J KOREAN ORTHOP US S, V2, P74; 강찬, 2011, [journal of korean foot and ankle society, 대한족부족관절학회지], V15, P97; Lehmann LJ, 1997, REGION ANESTH, V22, P24, DOI 10.1016/S1098-7339(06)80052-0; Marhofer P, 2005, BRIT J ANAESTH, V94, P7, DOI 10.1093/bja/aei002; Pasero Chris, 2005, J Perianesth Nurs, V20, P279, DOI 10.1016/j.jopan.2005.03.007; Sathitkarnmanee T, 2014, J PAIN RES, V7, P449, DOI 10.2147/JPR.S66741; YASTER M, 1990, PEDIATRICS, V86, P463; 강찬, 2010, [journal of korean foot and ankle society, 대한족부족관절학회지], V14, P90	14	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1067-2516	1542-2224		J FOOT ANKLE SURG	J. Foot Ankle Surg.	JAN-FEB	2016	55	1					121	124		10.1053/j.jfas.2015.08.009			4	Orthopedics; Surgery	Orthopedics; Surgery	CZ4KF	WOS:000367071200027	26422649				2020-06-30	J	Maeda, T; Hayakawa, T				Maeda, Tsuyoshi; Hayakawa, Toru			Combined Effect of Opioids and Corticosteroids for Alleviating Dyspnea in Terminal Cancer Patients: A Retrospective Review	JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY			English	Review						corticosteroid; dyspnea; opioid; terminal care	PALLIATIVE CARE; ILL CANCER; MORPHINE; INTERVENTIONS; PREDICTION; MANAGEMENT; SURVIVAL; INFUSION; FENTANYL; THERAPY	Dyspnea is a prognostic factor that affects the quality of life of terminal cancer patients, and many reports have described opioid treatment for dyspnea alleviation. Here, we retrospectively evaluated differences in the effects of various opioids administered concomitantly with corticosteroids on dyspnea in 20 terminal-stage cancer patients (13 men, 7 women; mean age [range]: 71 [49-94] years) who received opioids concomitantly with corticosteroids. Effectiveness was assessed throughout administration using the Support Team Assessment Schedule, Japanese version (STAS-J), particularly the subscale indicating how strongly a patient is affected by symptoms. The effectiveness of combined opioid and corticosteroid therapy against dyspnea and the opioid dose comprised the primary and secondary foci, respectively. Among concomitantly treated patients, STAS-J scores at initiation (mean +/- SD: 3.1 +/- 0.24) and lowest recorded STAS-J scores (1.4 +/- 0.22) differed significantly (P = .0034) among those receiving morphine, but not among those receiving oxycodone (P = .068) or fentanyl (P = .18). Concomitant opioid and corticosteroid treatment was associated with >= 2-point STAS-J score improvement in 14/20 patients (effectiveness: 70%). The opioid dose did not significantly affect dyspnea alleviation. We conclude that concomitant opioid and corticosteroid treatment can effectively alleviate dyspnea in terminal cancer patients.	[Maeda, Tsuyoshi] Kasugai Municipal Hosp, Dept Pharm, 1-1-1 Takaki Cho, Kasugai, Aichi 4868510, Japan; [Hayakawa, Toru] Hokkaido Pharmaceut Univ, Sch Pharm, Dept Pharmacotherapy, Sapporo, Hokkaido, Japan	Maeda, T (reprint author), Kasugai Municipal Hosp, Dept Pharm, 1-1-1 Takaki Cho, Kasugai, Aichi 4868510, Japan.	maeda@hospital.kasugai.aichi.jp					Allard P, 1999, J PAIN SYMPTOM MANAG, V17, P256, DOI 10.1016/S0885-3924(98)00157-2; Ben-Aharon I, 2008, J CLIN ONCOL, V26, P2396, DOI 10.1200/JCO.2007.15.5796; Ben-Aharon I, 2012, ACTA ONCOL, V51, P996, DOI 10.3109/0284186X.2012.709638; Boyd KJ, 1997, PALLIATIVE MED, V11, P277, DOI 10.1177/026921639701100403; Bruera E, 1998, CAN MED ASSOC J, V158, P1717; Bruera E, 1990, J Pain Symptom Manage, V5, P341, DOI 10.1016/0885-3924(90)90027-H; Clemens KE, 2007, J PAIN SYMPTOM MANAG, V33, P473, DOI 10.1016/j.jpainsymman.2006.09.015; COHEN MH, 1991, SOUTHERN MED J, V84, P229, DOI 10.1097/00007611-199102000-00019; Gamborg Helle, 2013, J Opioid Manag, V9, P269, DOI 10.5055/jom.2013.0168; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Guirimand F, 2015, CANCER MED-US, V4, P532, DOI 10.1002/cam4.419; Japanese Society for Palliative Medicine, 2011, CLIN GUID RESP SYMPT, P52; Japanese Society for Palliative Medicine, 2011, CLIN GUID RESP SYMPT, P57; Kawabata M, 2013, AM J HOSP PALLIAT ME, V30, P305, DOI 10.1177/1049909112448924; MALTONI M, 1995, CANCER-AM CANCER SOC, V75, P2613, DOI 10.1002/1097-0142(19950515)75:10<2613::AID-CNCR2820751032>3.0.CO;2-1; Mazzocato C, 1999, ANN ONCOL, V10, P1511, DOI 10.1023/A:1008337624200; Miura T, 2014, JPN J CLIN ONCOL, V44, P1082, DOI 10.1093/jjco/hyu137; Miyashita Mitsunori, 2004, Palliat Support Care, V2, P379; Simon ST, 2012, SCHMERZ, V26, P515, DOI 10.1007/s00482-012-1228-3; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Simon ST, 2009, WIEN MED WOCHENSCHR, V159, P591, DOI 10.1007/s10354-009-0728-y; Thomas JR, 2002, ONCOLOGY-NY, V16, P745; Thomas JR, 2002, LANCET ONCOL, V3, P223, DOI 10.1016/S1470-2045(02)00713-1; THOMAS JR, 2002, ONCOLOGY WILLISTON P, V16, P758; THOMAS JR, 2002, [No title captured], V16, P755; THOMAS JR, 2002, ONCOLOGY WILLISTON P, V16, P750; Tsuyoshi M, 2014, JPN J PHARM PALLIAT, V7, P111; Vigano A, 2000, PALLIATIVE MED, V14, P363, DOI 10.1191/026921600701536192; Zebraski SE, 2000, LIFE SCI, V66, P2221, DOI 10.1016/S0024-3205(00)00434-3	29	3	3	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1536-0288	1536-0539		J PAIN PALLIAT CARE	J. Pain Palliat. Care Pharmacother.		2016	30	2					106	110		10.3109/15360288.2016.1167803			5	Anesthesiology; Pharmacology & Pharmacy	Anesthesiology; Pharmacology & Pharmacy	DQ7AE	WOS:000379357900005	27093633				2020-06-30	J	Naeem, M; Al Alem, H; Al Shehri, A; Al-Jeraisy, M				Naeem, Mohammed; Al Alem, Hala; Al Shehri, Ali; Al-Jeraisy, Majed			Effect of N-Methyl-D-Aspartate Receptor Antagonist Dextromethorphan on Opioid Analgesia in Pediatric Intensive Care Unit	PAIN RESEARCH & MANAGEMENT			English	Article							PREOPERATIVE ORAL DEXTROMETHORPHAN; MORPHINE CONSUMPTION; POSTOPERATIVE PAIN; MANAGEMENT; DEPENDENCE	Objective. Pain control is an essential goal in the management of critical children. Narcotics are the mainstay for pain control. Patients frequently need escalating doses of narcotics. In such cases an adjunctive therapy may be beneficial. Dextromethorphan (DM) is NMDA receptor antagonist and may prevent tolerance to narcotics; however, its definitive role is still unclear. We sought whether dextromethorphan addition could decrease the requirements of fentanyl to control pain in critical children. Design. Double-blind, randomized control trial (RCT). Setting. Pediatric multidisciplinary ICU in tertiary care center. Patients. Thirtysix pediatric patients 2-14 years of age in a multidisciplinary PICU requiring analgesia were randomized into dextromethorphan and placebo. The subjects in both groups showed similarity in most of the characteristics. Interventions. Subjects while receiving fentanyl for pain control received dextromethorphan or placebo through nasogastric/orogastric tubes for 96 hours. Pain was assessed using FLACC and faces scales. Measurements and Main Results. This study found no statistical significant difference in fentanyl requirements between subjects receiving dextromethorphan and those receiving placebo (p = 0.127). Conclusions. Dextromethorphan has no effect on opioid requirement for control of acute pain in children admitted with acute critical care illness in PICU.	[Naeem, Mohammed; Al Alem, Hala; Al Shehri, Ali] King Abdul Aziz Med City, Div PICU, Dept Pediat, Riyadh, Saudi Arabia; [Naeem, Mohammed; Al Alem, Hala; Al Shehri, Ali; Al-Jeraisy, Majed] King Saud Bin Abdulaziz Univ Hlth Sci KSAU HS, Riyadh, Saudi Arabia; [Naeem, Mohammed; Al Alem, Hala; Al Shehri, Ali; Al-Jeraisy, Majed] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Al-Jeraisy, Majed] King Abdul Aziz Med City, Dept Pharm, Riyadh, Saudi Arabia	Naeem, M (reprint author), King Abdul Aziz Med City, Div PICU, Dept Pediat, Riyadh, Saudi Arabia.; Naeem, M (reprint author), King Saud Bin Abdulaziz Univ Hlth Sci KSAU HS, Riyadh, Saudi Arabia.; Naeem, M (reprint author), King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia.	naeem.mdpicu@yahoo.com					Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Boomershine C. S., ADJUVANT NONOPIOIDME; Capon DA, 1996, CLIN PHARMACOL THER, V60, P295, DOI 10.1016/S0009-9236(96)90056-9; Chau-In W, 2007, PAIN MED, V8, P462, DOI 10.1111/j.1526-4637.2006.00226.x; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; ELIOTT K, 1994, PAIN, V59, P361, DOI 10.1016/0304-3959(94)90022-1; Erstad BL, 2009, CHEST, V135, P1075, DOI 10.1378/chest.08-2264; FLEMING PM, 1986, BRIT MED J, V293, P597, DOI 10.1136/bmj.293.6547.597; Goldstein Frederick J., 2002, Journal of the American Osteopathic Association, V102, pS15; HOLLANDER D, 1994, ANN NEUROL, V36, P920, DOI 10.1002/ana.410360619; Ilkjaer S, 2000, PAIN, V86, P19, DOI 10.1016/S0304-3959(99)00305-X; King MR, 2016, ANESTHESIOLOGY, V124, P696, DOI 10.1097/ALN.0000000000000950; Mahmoodzadeh Hossein, 2010, Middle East Journal of Anesthesiology, V20, P559; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Mao JR, 1996, PAIN, V67, P361, DOI 10.1016/0304-3959(96)03120-X; Memis D, 2010, J CRIT CARE, V25, P458, DOI 10.1016/j.jcrc.2009.12.012; Nilsson S, 2008, PEDIATR ANESTH, V18, P767, DOI 10.1111/j.1460-9592.2008.02655.x; PRICE DD, 1994, PAIN, V59, P165, DOI 10.1016/0304-3959(94)90069-8; Saarto T, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005454, 10.1002/14651858.CD005454.pub2]; Savage S, 2001, DEFINITIONS RELATED; Sindrup SH, 2005, BASIC CLIN PHARMACOL, V96, P399, DOI 10.1111/j.1742-7843.2005.pto_96696601.x; Singla N, 2010, PAIN MED, V11, P1284, DOI 10.1111/j.1526-4637.2010.00896.x; Tomlinson D, 2010, PEDIATRICS, V126, pE1168, DOI 10.1542/peds.2010-1609; Wiffen P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001133.pub2	24	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1203-6765	1918-1523		PAIN RES MANAG	Pain Res. Manag.		2016	2016								1658172	10.1155/2016/1658172			7	Clinical Neurology	Neurosciences & Neurology	EB5OR	WOS:000387424900001	27867308	DOAJ Gold, Green Published			2020-06-30	J	Mieda, T; Nishizawa, D; Nakagawa, H; Tsujita, M; Imanishi, H; Terao, K; Yoshikawa, H; Itoh, K; Amano, K; Tashiro, J; Ishii, T; Ariyama, J; Yamaguchi, S; Kasai, S; Hasegawa, J; Ikeda, K; Kitamura, A; Hayashida, M				Mieda, Tsutomu; Nishizawa, Daisuke; Nakagawa, Hideyuki; Tsujita, Miki; Imanishi, Hirokazu; Terao, Kazuhisa; Yoshikawa, Hiroaki; Itoh, Kazushi; Amano, Kojiro; Tashiro, Jo; Ishii, Toshimasa; Ariyama, Jun; Yamaguchi, Shigeki; Kasai, Shinya; Hasegawa, Junko; Ikeda, Kazutaka; Kitamura, Akira; Hayashida, Masakazu			Genome-wide association study identifies candidate loci associated with postoperative fentanyl requirements after laparoscopic-assisted colectomy	PHARMACOGENOMICS			English	Article						analgesia; laparoscopic-assisted colectomy; opioids; pain; pharmacogenetics	ANALGESIC REQUIREMENTS; GENE; PAIN; POLYMORPHISM; RECEPTOR; SENSITIVITY; SURGERY	Aims: Opioids are widely used as effective analgesics, but opioid sensitivity is well known to vary widely among individuals and the underlying genetic factors are not fully understood, thus hampering efficient pain treatment. We explored the genetic factors that contribute to individual differences in opioid sensitivity by performing a genome-wide association study. Methods: We conducted a multistage genome-wide association study in subjects who underwent laparoscopic-assisted colectomy (LAC). Results: A nonsynonymous SNP in the LAMB3 gene region, rs2076222, was strongly associated with postoperative opioid requirements. The C allele of this best-candidate SNP was associated with lower opioid sensitivity and/or higher pain sensitivity in the patient subjects. Conclusion: Our findings provide valuable information for personalized pain treatment after LAC, in which the C allele of the rs2076222 SNP is associated with lower opioid sensitivity and requires more opioid analgesic after LAC.	[Mieda, Tsutomu; Nakagawa, Hideyuki; Tsujita, Miki; Imanishi, Hirokazu; Terao, Kazuhisa; Yoshikawa, Hiroaki; Itoh, Kazushi; Ariyama, Jun; Kitamura, Akira; Hayashida, Masakazu] Saitama Med Univ, Int Med Ctr, Dept Anesthesiol, Hidaka, Saitama 3501298, Japan; [Nishizawa, Daisuke; Amano, Kojiro; Kasai, Shinya; Hasegawa, Junko; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Setagaya Ku, Tokyo 1568506, Japan; [Amano, Kojiro; Hayashida, Masakazu] Juntendo Univ, Sch Med, Dept Anesthesiol & Pain Med, Bunkyo Ku, Tokyo 1138421, Japan; [Tashiro, Jo; Ishii, Toshimasa; Yamaguchi, Shigeki] Saitama Med Univ, Int Med Ctr, Dept Gastroenterol, Hidaka, Saitama 3501298, Japan	Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.	ikeda-kz@igakuken.or.jp		Yamaguchi, Shigeki/0000-0003-3850-2818	Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22790518, 23390377, 24659549, 24790544, 25116532, 26293347, 26860360]; Ministry of Health, Labour and Welfare (MHLW) of JapanMinistry of Health, Labour and Welfare, Japan [H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020, H26-Kakushintekigan-ippan-060, 14524680]; Smoking Research Foundation (Tokyo, Japan); Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan); Taisho Pharmaceutical Co., Ltd; Japan Tobacco, Inc.Japan Tobacco Inc.	This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI (no. 22790518, 23390377, 24659549, 24790544, 25116532, 26293347 and 26860360), Ministry of Health, Labour and Welfare (MHLW) of Japan (no. H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020, H26-Kakushintekigan-ippan-060 and 14524680), Smoking Research Foundation (Tokyo, Japan) and Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan). The funding agencies had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. K Ikeda has received support from Eisai for a project unrelated to this research and speaker's fees from The authors have no other relevant affiliations or financial involvementTaisho Pharmaceutical Co., Ltd, and Japan Tobacco, Inc. with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.; The authors acknowledge M Arends for his assistance with editing the manuscript, which was funded by a grant from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI (no. 26293347).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Alexander JI, 1997, BRIT J ANAESTH, V79, P369, DOI 10.1093/bja/79.3.369; Aoki Y, 2015, J PHARMACOL SCI, V127, P391, DOI 10.1016/j.jphs.2015.02.005; Aoki Y, 2013, NEUROSCI LETT, V542, P1, DOI 10.1016/j.neulet.2013.02.039; Aumailley Monique, 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000123; Ballantyne G H, 1995, Gastroenterologist, V3, P75; Basse L, 2005, ANN SURG, V241, P416, DOI 10.1097/01.sla.0000154149.85506.36; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Candiotti KA, 2011, ANESTHESIOLOGY, V114, P1162, DOI 10.1097/ALN.0b013e318216e9cb; Chiang LY, 2011, NAT NEUROSCI, V14, P993, DOI 10.1038/nn.2873; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Daly AK, 2010, NAT REV GENET, V11, P241, DOI 10.1038/nrg2751; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Hayashida M, 2008, PHARMACOGENOMICS, V9, P1605, DOI 10.2217/14622416.9.11.1605; Hill AG, 2006, ANZ J SURG, V76, P282, DOI 10.1111/j.1445-2197.2006.03711.x; Ide S, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-75; Ide S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070694; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; Lotsch J, 2009, PHARMACOL THERAPEUT, V124, P168, DOI 10.1016/j.pharmthera.2009.06.010; Moriyama A, 2013, J PHARMACOL SCI, V121, P48, DOI 10.1254/jphs.12159FP; Nishizawa D, 2014, MOL PSYCHIATR, V19, P55, DOI 10.1038/mp.2012.164; Nishizawa D, 2014, J PHARMACOL SCI, V126, P253, DOI 10.1254/jphs.14189FP; Nishizawa D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007060; RAMOS JM, 1995, DIS COLON RECTUM, V38, P494, DOI 10.1007/BF02148849; Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600; Weeks JC, 2002, JAMA-J AM MED ASSOC, V287, P321, DOI 10.1001/jama.287.3.321; Wills VL, 2000, BRIT J SURG, V87, P273, DOI 10.1046/j.1365-2168.2000.01374.x; Xu ZL, 2009, NUCLEIC ACIDS RES, V37, pW600, DOI 10.1093/nar/gkp290	28	7	8	0	5	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1462-2416	1744-8042		PHARMACOGENOMICS	Pharmacogenomics		2016	17	2					133	145		10.2217/pgs.15.151			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CZ6DY	WOS:000367192600006	26566055				2020-06-30	J	Dreher, M; Cornelissen, CG; Reddemann, MA; Muller, A; Hubel, C; Muller, T				Dreher, Michael; Cornelissen, Christian Gabriel; Reddemann, Manuel Armin; Mueller, Annegret; Huebel, Christian; Mueller, Tobias			Nebulized versus Standard Local Application of Lidocaine during Flexible Bronchoscopy: A Randomized Controlled Trial	RESPIRATION			English	Article						Flexible bronchoscopy; Sedation; Lidocaine; Nebulizer	TOPICAL ANESTHESIA; SEDATION; CRYOBIOPSY; MIDAZOLAM; PROPOFOL	Background: Endobronchial administration of local anesthetics such as lidocaine is often used for cough suppression during bronchoscopy. To achieve a better distribution of lidocaine in the tracheobronchial tree, spray catheters have been developed, allowing nebulization of the local anesthetic solution. However, there are little data on the efficacy and safety of this approach, or on the consumption of sedative drugs and lidocaine during nebulized administration. Objectives: To investigate the tolerability of nebulized lidocaine compared to conventional lidocaine administration via syringe through the working channel of the bronchoscope in patients undergoing bronchoscopy. Consumption of sedative drugs and lidocaine was also compared between the two lidocaine administration approaches. Methods: Patients requiring bronchoscopy with endobronchial or trans-bronchial biopsy were randomly assigned to receive topical lidocaine either via syringe or via nebulizer. Endpoints were consumption of lidocaine and sedative drugs, as well as patient tolerance and safety. Results: Thirty patients were included, 15 in each group. Patients in the nebulizer group required lower doses of endobronchial lidocaine (184.7 +/- 67.98 vs. 250.7 +/- 21.65 mg, p = 0.0045) and intravenous fentanyl (0.033 +/- 0.041 vs. 0.067 +/- 0.045 mg, p = 0.0236) than those in the syringe group; midazolam or propofol dosages did not differ between the two groups. In addition, there were no between-group differences in patient tolerance or safety (all p > 0.05). Conclusion: Endobronchial administration of lidocaine during bronchoscopy via nebulizer was found to be well tolerated and safe and was associated with reduced lidocaine and fentanyl dosages compared to administration via syringe. (C) 2016 S. Karger AG, Basel	[Dreher, Michael; Cornelissen, Christian Gabriel; Mueller, Annegret; Huebel, Christian; Mueller, Tobias] Univ Hosp RWTH Aachen, Div Pneumol, Pauwelsstr 30, DE-52074 Aachen, Germany; [Reddemann, Manuel Armin] Rhein Westfal TH Aachen, Inst Heat & Mass Transfer, Aachen, Germany	Muller, T (reprint author), Univ Hosp RWTH Aachen, Div Pneumol, Pauwelsstr 30, DE-52074 Aachen, Germany.	tobmueller@ukaachen.de		Muller, Tobias/0000-0002-9801-3496			Akyuz U, 2010, HEPATO-GASTROENTEROL, V57, P685; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Antoniades N, 2009, RESPIROLOGY, V14, P873, DOI 10.1111/j.1440-1843.2009.01587.x; Babiak A, 2009, RESPIRATION, V78, P203, DOI 10.1159/000203987; Dreher M, 2010, RESPIRATION, V79, P307, DOI 10.1159/000267227; Du Rand IA, 2013, THORAX, V68, P1, DOI 10.1136/thoraxjnl-2013-203618; Hetzel J, 2012, EUR RESPIR J, V39, P685, DOI 10.1183/09031936.00033011; MacDougall M, 2011, J BRONCHOL INTERN PU, V18, P144, DOI 10.1097/LBR.0b013e318216da26; Mak PHK, 2002, ANAESTH INTENS CARE, V30, P633, DOI 10.1177/0310057X0203000516; Malcharek MJ, 2015, EUR J ANAESTH, V32, P615, DOI 10.1097/EJA.0000000000000285; PEACOCK AJ, 1990, THORAX, V45, P38, DOI 10.1136/thx.45.1.38; Piepho T, 2009, EUR J ANAESTH, V26, P328, DOI 10.1097/EJA.0b013e32831ac4ce; Putinati S, 1999, CHEST, V115, P1437, DOI 10.1378/chest.115.5.1437; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Schlatter L, 2011, EUR RESPIR J, V38, P529, DOI 10.1183/09031936.00121610; Stolz D, 2005, CHEST, V128, P1756, DOI 10.1016/S0012-3692(15)52214-9; Thiebes AL, 2016, TISSUE ENG PART C-ME, V22, P322, DOI [10.1089/ten.TEC.2015.0381, 10.1089/ten.tec.2015.0381]; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361; WU FL, 1993, PHARMACOTHERAPY, V13, P72	19	8	8	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0025-7931	1423-0356		RESPIRATION	Respiration		2016	92	4					266	273		10.1159/000449135			8	Respiratory System	Respiratory System	DZ7PJ	WOS:000386058000011	27614989				2020-06-30	J	do Vale, AHB; Videira, RLD; Gomez, DS; Carmona, MJC; Tsuchie, SY; Florio, C; Vane, MF; Posso, ID				Barbosa do Vale, Arthur Halley; da Rocha Videira, Rogerio Luiz; Gomez, David Souza; Carvalho Carmona, Maria Jose; Tsuchie, Sara Yume; Florio, Claudia; Vane, Matheus Fachini; Posso, Irimar de Paula			Effect of nitrous oxide on fentanyl consumption in burned patients undergoing dressing change	REVISTA BRASILEIRA DE ANESTESIOLOGIA			English	Article						Pain; Nitrous oxide; Burns; Debridement	SEDATION; ANALGESIA	Background and objectives: Thermal injuries and injured areas management are important causes of pain in burned patients, requiring that these patients are constantly undergoing general anesthesia for dressing change. Nitrous oxide (N2O) has analgesic and sedative properties; it is easy to use and widely available. Thus, the aim of this study was to evaluate the analgesic effect of N2O combined with fentanyl in burned patients during dressing change. Method: After approval by the institutional Ethics Committee, 15 adult burned patients requiring daily dressing change were evaluated. Patient analgesia was controlled with fentanyl 0.0005% administered by intravenous pump infusion on-demand. Randomly, in one of the days a mixture of 65% N2O in oxygen (O-2) was associated via mask, with a flow of 10 L/min (N2O group) and on the other day only O-2 under the same flow (control group). Results: No significant pain reduction was seen in N2O group compared to control group. VAS score before dressing change was 4.07 and 3.4, respectively, in N2O and control groups. Regarding pain at the end of the dressing, patients in N2O group reported pain severity of 2.8; while the control group reported 2.87. There was no significant difference in fentanyl consumption in both groups. Conclusions: The association of N2O was not effective in reducing opioid consumption during dressing changes. (C) 2014 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.	[Barbosa do Vale, Arthur Halley; da Rocha Videira, Rogerio Luiz; Gomez, David Souza; Carvalho Carmona, Maria Jose; Tsuchie, Sara Yume; Florio, Claudia; Vane, Matheus Fachini; Posso, Irimar de Paula] Univ Sao Paulo, Fac Med, Discipline Anesthesiol, Inst Cent HCFMUSP, Sao Paulo, SP, Brazil	do Vale, AHB (reprint author), Univ Sao Paulo, Fac Med, Discipline Anesthesiol, Inst Cent HCFMUSP, Sao Paulo, SP, Brazil.	arthurhattey@gmail.com	POSSO, Irimar/AAA-7842-2020; CARMONA, MARIA JOSE CARVALHO/G-3653-2014; Videira, Rogerio L R/C-8896-2017; Vane, Matheus F/B-7991-2015	CARMONA, MARIA JOSE CARVALHO/0000-0002-3031-2924; Vane, Matheus F/0000-0003-3062-1484			Annequin D, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e47; Baden JM, 1994, ANESTHESIA, P157; Berge TI, 1999, ACTA ODONTOL SCAND, V57, P201, DOI 10.1080/000163599428788; Castera L, 2001, AM J GASTROENTEROL, V96, P1553; Coimbra C, 2003, ANESTH ANALG, V97, P839, DOI 10.1213/01.ANE.0000074236.76333.53; Corboy J M, 1984, J Am Intraocul Implant Soc, V10, P232; Fink DA, 1985, NITROUS OXIDE N2O, P41; Gallagher G, 2000, ANAESTHESIA, V55, P1159, DOI 10.1046/j.1365-2044.2000.01712.x; Girtler R, 2011, ANAESTHESIST, V60, P243, DOI 10.1007/s00101-010-1835-2; Hurford WE, 1997, CLIN ANESTHESIA PROC, P174; KEIDAN I, 2003, ACUTE PAIN, V5, P25; KLUGER MT, 1990, ANAESTHESIA, V45, P1072, DOI 10.1111/j.1365-2044.1990.tb14893.x; Luhmann JD, 2001, ANN EMERG MED, V37, P20, DOI 10.1067/mem.2001.112003; Pedersen RS, 2013, DAN MED J, V60; Prakash S, 2004, ANESTH ANALG, V99, P552, DOI 10.1213/01.ANE.0000125110.56886.90; Sanders RD, 2008, ANESTHESIOLOGY, V109, P707, DOI 10.1097/ALN.0b013e3181870a17; Sim KM, 1996, BURNS, V22, P238, DOI 10.1016/0305-4179(95)00121-2; Videira RLR, 2011, TRATADO ANESTESIOLOG, P2157; Zier JL, 2011, PEDIATR EMERG CARE, V27, P1107, DOI 10.1097/PEC.0b013e31823aff6d	19	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	JAN-FEB	2016	66	1					7	11		10.1016/j.bjane.2014.07.016			5	Anesthesiology	Anesthesiology	DF1DX	WOS:000371080100002	26768923	DOAJ Gold, Green Published			2020-06-30	J	Romano, M; Portela, DA; Breghi, G; Otero, PE				Romano, Marta; Portela, Diego A.; Breghi, Gloria; Otero, Pablo E.			Stress-related biomarkers in dogs administered regional anaesthesia or fentanyl for analgesia during stifle surgery	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						dog; peripheral nerve block; regional anaesthesia; spinal anaesthesia; stress	OPIOID-INDUCED HYPERALGESIA; EPIDURAL-ANESTHESIA; NERVE BLOCK; BUPIVACAINE; PAIN; RESPONSES; MORPHINE; COMPLICATIONS	Objectives To compare the effects of regional anaesthesia and opioid administration on adrenocortical and glycaemic responses, postoperative pain and recovery quality in dogs undergoing stifle surgery. Study design Prospective, blinded clinical study. Animals Forty-five dogs anaesthetized for tibial tuberosity advancement or tibial plateau levelling osteotomy, and 15 healthy dogs undergoing noninvasive orthopaedic diagnostic procedures. Methods The baseline behaviour of each dog was classified on a descriptive scale before anaesthesia. Dogs were anaesthetized using a standard protocol. Those undergoing surgery were randomly assigned to one of three intraoperative analgesia protocols: 1) peripheral (femoral and sciatic) nerve block (bupivacaine 0.5%; 0.15 mL kg(-1) in each nerve; group PNB); 2) spinal anaesthesia (isobaric bupivacaine 0.5%; 0.05 mL kg(-1); group SPI); and 3) intravenous fentanyl variable rate infusion and postoperative methadone (0.2 mg kg(-1); group FEN). Blood samples were collected for measurement of cortisol and glucose concentrations on arrival (T-AR), at induction (T-IND), at tracheal extubation (T-EXT), and 1 hour post-extubation (T-PEX). After extubation, a researcher unaware of the dog's group assignment evaluated pain and recovery quality using the Glasgow Composite Measure Pain Scale (Short-Form) and a descriptive scale, respectively. Results Median recovery quality was significantly worse in group FEN (p < 0.0001) compared with all other groups. Postoperative pain scores were lower in group PNB compared with groups SPI and FEN. Cortisol and glucose concentrations increased significantly from T-AR at T-EXT and T-PEX (p < 0.0001) in group FEN, and were unchanged from T-AR in the other groups. Conclusions and clinical relevance Analgesia with a peripheral nerve block or spinal anaesthesia prevented the glycaemic and cortisol responses to surgery, promoted better recovery quality, and decreased postoperative pain scores compared with FEN. In the present study, the regional anaesthesia techniques used were found to be excellent alternatives to fentanyl administration.	[Romano, Marta; Portela, Diego A.; Breghi, Gloria] Univ Pisa, Dept Vet Clin, Vet Teaching Hosp Mario Modenato, Pisa, Italy; [Romano, Marta] Clin Vet Apuana, Marina Di Carrara, MS, Italy; [Portela, Diego A.] Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA; [Otero, Pablo E.] Univ Buenos Aires, Fac Vet Sci, Dept Anesthesiol, Buenos Aires, DF, Argentina	Romano, M (reprint author), Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA.	marta.romano@me.com	Portela, Diego A./I-2025-2019; Otero, Pablo Ezequiel/I-4638-2019	Portela, Diego A./0000-0002-1796-9710; breghi, gloria/0000-0002-1097-8331			ABRAM SE, 1994, ANESTHESIOLOGY, V80, P1114, DOI 10.1097/00000542-199405000-00020; Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; Becker WM, 2013, VET SURG, V42, P302, DOI 10.1111/j.1532-950X.2012.01080.x; Bekhit MH, 2010, AM J THER, V17, P498, DOI 10.1097/MJT.0b013e3181ed83a0; Campoy L, 2012, VET ANAESTH ANALG, V39, P91, DOI 10.1111/j.1467-2995.2011.00673.x; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Devitt CM, 2005, JAVMA-J AM VET MED A, V227, P921, DOI 10.2460/javma.2005.227.921; Ecoffey C, 2010, PEDIATR ANESTH, V20, P1061, DOI 10.1111/j.1460-9592.2010.03448.x; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Keating SCJ, 2013, AM J VET RES, V74, P672, DOI 10.2460/ajvr.74.5.672; KEHLET H, 1989, BRIT J ANAESTH, V63, P189, DOI 10.1093/bja/63.2.189; Kettner SC, 2011, BRIT J ANAESTH, V107, P90, DOI 10.1093/bja/aer340; Kona-Boun JJ, 2006, JAVMA-J AM VET MED A, V229, P1103, DOI 10.2460/javma.229.7.1103; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; Lamont LA, 2008, VET CLIN N AM-SMALL, V38, P1173, DOI 10.1016/j.cvsm.2008.06.005; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Meissner A, 1997, ANESTH ANALG, V85, P517; Naitoh T, 2002, SURG ENDOSC, V16, P1627, DOI 10.1007/s00464-002-0007-0; Nelson R, 2006, MED INTERNA CANE GAT, P797; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Portela DA, 2013, VET ANAESTH ANALG, V40, P194, DOI 10.1111/j.1467-2995.2012.00765.x; Portela DA, 2010, VET ANAESTH ANALG, V37, P531, DOI 10.1111/j.1467-2995.2010.00572.x; Reid J, 2007, ANIM WELFARE, V16, P97; Sarotti D, 2013, VET ANAESTH ANALG, V40, P220, DOI 10.1111/j.1467-2995.2012.00787.x; Sarotti D, 2011, VET ANAESTH ANALG, V38, P240, DOI 10.1111/j.1467-2995.2011.00608.x; Sibanda S, 2006, VET ANAESTH ANALG, V33, P246, DOI 10.1111/j.1467-2995.2005.00261.x; Vaisanen MAM, 2005, VET ANAESTH ANALG, V32, P158, DOI 10.1111/j.1467-2995.2005.00188.x; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vettorato E, 2013, J SMALL ANIM PRACT, V54, P630, DOI 10.1111/jsap.12146; Wolf AR, 2012, PEDIATR ANESTH, V22, P19, DOI 10.1111/j.1460-9592.2011.03714.x; Wolf AR, 1998, PAEDIATR ANAESTH, V8, P305, DOI 10.1046/j.1460-9592.1998.00239.x; WOLF AR, 1993, BRIT J ANAESTH, V70, P654, DOI 10.1093/bja/70.6.654; Zhang J, 2007, ANESTH ANALG, V104, P984, DOI 10.1213/01.ane.0000258765.16164.27	33	26	26	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2016	43	1					44	54		10.1111/vaa.12275			11	Veterinary Sciences	Veterinary Sciences	DJ5YZ	WOS:000374288100006	25996102				2020-06-30	J	Sandroni, C; Soar, J; Friberg, H				Sandroni, Claudio; Soar, Jasmeet; Friberg, Hans			Does this comatose survivor of cardiac arrest have a poor prognosis?	INTENSIVE CARE MEDICINE			English	Editorial Material							TARGETED TEMPERATURE MANAGEMENT; NEURON-SPECIFIC ENOLASE; THERAPEUTIC HYPOTHERMIA; PROGNOSTICATION; RESUSCITATION; 36-DEGREES-C; 33-DEGREES-C; PREDICTION; DEATH		[Sandroni, Claudio] Univ Cattolica Sacro Cuore, Sch Med, Dept Anaesthesiol & Intens Care, I-00168 Rome, Italy; [Soar, Jasmeet] Southmead Hosp, Dept Anaesthesia & Intens Care Med, Bristol, Avon, England; [Friberg, Hans] Lund Univ, Skane Univ Hosp, Dept Anaesthesiol & Intens Care Med, Lund, Sweden	Sandroni, C (reprint author), Univ Cattolica Sacro Cuore, Sch Med, Dept Anaesthesiol & Intens Care, Largo Gemelli 8, I-00168 Rome, Italy.	sandroni@rm.unicatt.it	Sandroni, Claudio/A-7320-2019	Sandroni, Claudio/0000-0002-8878-2611			Cronberg T, 2011, NEUROLOGY, V77, P623, DOI 10.1212/WNL.0b013e31822a276d; Dragancea I, 2013, RESUSCITATION, V84, P337, DOI 10.1016/j.resuscitation.2012.09.015; Grossestreuer AV, 2013, RESUSCITATION, V84, P1741, DOI 10.1016/j.resuscitation.2013.07.009; Hofmeijer J, 2015, NEUROLOGY, V85, P137, DOI 10.1212/WNL.0000000000001742; Kamps MJA, 2013, INTENS CARE MED, V39, P1671, DOI 10.1007/s00134-013-3004-y; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Sandroni C, 2014, INTENS CARE MED, V40, P1816, DOI 10.1007/s00134-014-3470-x; Sandroni C, 2013, RESUSCITATION, V84, P1324, DOI 10.1016/j.resuscitation.2013.06.020; Sharshar T, 2014, INTENS CARE MED, V40, P484, DOI 10.1007/s00134-014-3214-y; Stammet P, 2015, J AM COLL CARDIOL, V65, P2104, DOI 10.1016/j.jacc.2015.03.538; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd	11	3	3	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JAN	2016	42	1					104	106		10.1007/s00134-015-4082-9			3	Critical Care Medicine	General & Internal Medicine	CX5AS	WOS:000365713400014	26527197				2020-06-30	J	Wei, W; Tian, YL; Zhao, CL; Sui, ZF; Liu, C; Wang, CM; Yang, RY				Wei, Wei; Tian, Yanli; Zhao, Chunlei; Sui, Zhifu; Liu, Chang; Wang, Congmin; Yang, Rongya			Correlation of ADRB1 rs1801253 Polymorphism with Analgesic Effect of Fentanyl After Cancer Surgeries	MEDICAL SCIENCE MONITOR			English	Article						Analgesics; Fentanyl; Pain, Postoperative; Polymorphism, Genetic	BETA(1)-ADRENERGIC RECEPTOR; POSTOPERATIVE PAIN; BETA-1-ADRENERGIC RECEPTOR; GENETIC POLYMORPHISMS; ATRIAL-FIBRILLATION; BETA-ADRENOCEPTOR; HEART-FAILURE; ASSOCIATION; SUFENTANIL; METABOLISM	Background: Our study aimed to explore the association between beta(1)-adrenoceptor (ADRB1) rs1801253 polymorphism and analgesic effect of fentanyl after cancer surgeries in Chinese Han populations. Material/Methods: Postoperative fentanyl consumption of 120 patients for analgesia was recorded. Genotype distributions were detected by allele specific amplification-polymerase chain reaction (ASA-PCR) method. Postoperative pain was measured by visual analogue scale (VAS) method. Differences in postoperative VAS score and postoperative fentanyl consumption for analgesia in different genotype groups were compared by analysis of variance (ANOVA). Preoperative cold pressor-induced pain test was also performed to test the analgesic effect of fentanyl. Results: Frequencies of Gly/Gly, Gly/Arg, Arg/Arg genotypes were 45.0%, 38.3%, and 16.7%, respectively, and passed the Hardy-Weinberg Equilibrium (HWE) test. The mean arterial pressure (MAP) and the heart rate (HR) had no significant differences at different times. After surgery, the VAS score and fentanyl consumption in Arg/Arg group were significantly higher than in other groups at the postoperative 2nd hour, but the differences were not obvious at the 4th hour, 24th hour, and the 48th hour. The results suggest that the Arg/Arg homozygote increased susceptibility to postoperative pain. The preoperative cold pressor-induced pain test suggested that individuals with Arg/Arg genotype showed worse analgesic effect of fentanyl compared to other genotypes. Conclusions: In Chinese Han populations, ADRB1 rs1801253 polymorphism might be associated with the analgesic effect of fentanyl after cancer surgery.	[Wei, Wei; Tian, Yanli; Sui, Zhifu; Liu, Chang; Wang, Congmin; Yang, Rongya] Beijing Mil Command, Gen Hosp, Dept Dermatol, Beijing, Peoples R China; [Zhao, Chunlei] Hengshui Cardiovasc Hosp, Hengshui, Hebei, Peoples R China	Yang, RY (reprint author), Beijing Mil Command, Gen Hosp, Dept Dermatol, Beijing, Peoples R China.	yangrnogya@126.com					ADLERGRASCHINSK.E, 1975, BRIT J PHARMACOL, V53, P43, DOI 10.1111/j.1476-5381.1975.tb07328.x; AHLQUIST RP, 1948, AM J PHYSIOL, V153, P586; Aleong RG, 2013, JACC-HEART FAIL, V1, P338, DOI 10.1016/j.jchf.2013.04.002; Amanfu RK, 2014, MOL PHARMACOL, V86, P222, DOI 10.1124/mol.113.090951; Beitelshees AL, 2006, PHARMACOGENOMICS J, V6, P174, DOI 10.1038/sj.tpj.6500354; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Brodde OE, 2008, PHARMACOL THERAPEUT, V117, P1, DOI 10.1016/j.pharmthera.2007.07.002; Bruck H, 2005, J AM COLL CARDIOL, V46, P2111, DOI 10.1016/j.jacc.2005.08.041; Burguete-Garcia AI, 2014, NUTR HOSP, V29, P1327, DOI 10.3305/nh.2014.29.6.7367; Chia YY, 2004, BRIT J ANAESTH, V93, P799, DOI 10.1093/bja/aeh268; Davidson EM, 2001, CAN J ANAESTH, V48, P59, DOI 10.1007/BF03019816; Doi K, 2007, J ANESTH, V21, P439, DOI 10.1007/s00540-007-0519-9; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Hu YC, 2014, SCI REP-UK, V4, DOI 10.1038/srep07208; Hu YC, 2014, SCI REP-UK, V4, DOI 10.1038/srep06984; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Jeff JM, 2014, AM HEART J, V167, P101, DOI 10.1016/j.ahj.2013.09.016; Jing W, 2014, MOL CANCER THER, V13, P2127, DOI 10.1158/1535-7163.MCT-14-0175; Kang S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0402-7; Kim MK, 2007, BRIT J ANAESTH, V99, P270, DOI 10.1093/bja/aem146; Kuang D, 2014, ASIAN PAC J CANCER P, V15, P6855, DOI 10.7314/APJCP.2014.15.16.6855; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lamothe-Molina Paul J, 2014, Rev Med Inst Mex Seguro Soc, V52, P494; Lanfear DE, 2005, JAMA-J AM MED ASSOC, V294, P1526, DOI 10.1001/jama.294.12.1526; Leineweber K, 2004, N-S ARCH PHARMACOL, V369, P1, DOI 10.1007/s00210-003-0824-2; Liggett SB, 2006, P NATL ACAD SCI USA, V103, P11288, DOI 10.1073/pnas.0509937103; Liu J, 2006, CLIN PHARMACOL THER, V80, P23, DOI 10.1016/j.clpt.2006.03.004; Maqbool A, 1999, LANCET, V353, P897, DOI 10.1016/S0140-6736(99)00549-8; Martikainen IK, 2004, NEUROSCI LETT, V361, P140, DOI 10.1016/j.neulet.2003.12.060; McLean RC, 2011, CARDIOVASC DRUG THER, V25, P251, DOI 10.1007/s10557-011-6307-7; Moriyama A, 2013, J PHARMACOL SCI, V121, P48, DOI 10.1254/jphs.12159FP; Ohlin B, 2008, J HYPERTENS, V26, P1583, DOI 10.1097/HJH.0b013e328303df5f; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Philipp M, 2004, PHARMACOL THERAPEUT, V101, P65, DOI 10.1016/j.pharmthera.2003.10.004; Raeder J, 2014, EXPERT OPIN PHARMACO, V15, P449, DOI 10.1517/14656566.2014.879292; Schutz M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095592; Smith HS, 2014, POSTGRAD MED, V126, P98, DOI 10.3810/pgm.2014.07.2788; Sweeney BP, 2007, EUR J ANAESTH, V24, P209, DOI 10.1017/S0265021506002316; Tateishi T, 1996, ANESTH ANALG, V82, P167; Zhu X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105995; Zill P, 2003, AM J MED GENET B, V120B, P85, DOI 10.1002/ajmg.b.20017	44	6	7	1	9	INT SCIENTIFIC LITERATURE, INC	SMITHTOWN	361 FOREST LANE, SMITHTOWN, NY 11787 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	DEC 22	2015	21						4000	4005		10.12659/MSM.894060			6	Medicine, Research & Experimental	Research & Experimental Medicine	CZ8VA	WOS:000367376000002	26694722	Green Published			2020-06-30	J	Van Iterson, EH; Snyder, EM; Joyner, MJ; Johnson, BD; Olson, TP				Van Iterson, Erik H.; Snyder, Eric M.; Joyner, Michael J.; Johnson, Bruce D.; Olson, Thomas P.			Intrathecal fentanyl blockade of afferent neural feedback from skeletal muscle during exercise in heart failure patients: Influence on circulatory power and pulmonary vascular capacitance	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Article						Ergoreceptors; Metaboreceptor; Mechanoreceptor; Pulmonary hypertension; Fentanyl	METABOREFLEX-INDUCED INCREASES; CARDIAC PUMPING CAPACITY; DORSAL-HORN; VENTILATORY RESPONSE; CARBON-DIOXIDE; HYPERTENSION; BLOOD; INTOLERANCE; DIAGNOSIS; SECONDARY	Background: Secondary pulmonary hypertension is common in heart failure (HF) patients. We hypothesized that inhibition of feedback from locomotor muscle group III/IV neurons contributes to reduced pulmonary vascular pressures independent of changes in cardiac function during exercise in HF. Methods: 9 HF patients (ages, 60 +/- 2; EF, 26.7 +/- 1.9%; New York Heart Association classes, I-III) and 9 age/gender matched controls (ages, 63 +/- 2) completed five-minutes of constant-load cycling (65% Workload(peak)) with intrathecal fentanyl or placebo on randomized separate days. Mean arterial pressure (MAP), heart rate (HR), end-tidal partial pressure of CO2 (PETCO2), and oxygen consumption (VO2) were measured at rest and exercise. Non-invasive surrogates for cardiac power (circulatory power, CircP = VO2 x MAP), stroke volume (oxygen pulse, O(2)pulse = VO2/HR), and pulmonary arterial pressure (GX(CAP) = O(2)pulse x PETCO2) were calculated. Results: At rest and end-exercise, differences between fentanyl versus placebo were not significant for CircP in HF or controls. Differences between fentanyl versus placebo for GX(CAP) were not significant at rest in HF or controls. At end-exercise, GX(CAP) was significantly higher with fentanyl versus placebo in HF (691 +/- 59 versus 549 +/- 38 mL/beat x mm Hg), but not controls (536 +/- 59 versus 474 +/- 43 mL/beat x mm Hg). Slopes (rest to end-exercise) for GX(CAP) were significantly higher with fentanyl versus placebo in HF (95.1 +/- 9.8 versus 71.6 +/- 6.0 mL/beat x mm Hg), but not controls (74.3 +/- 9.5 versus 60.8 +/- 6.5 mL/beat x mm Hg). CircP slopes did not differ between fentanyl versus placebo in HF or controls (p > 0.05). Conclusion: We conclude that feedback from locomotor muscle group III/IV neurons may evoke increases in pulmonary vascular pressures independent of changes in cardiac function during exercise in HF. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Van Iterson, Erik H.; Snyder, Eric M.] Univ Minnesota, Dept Kinesiol, Minneapolis, MN 55455 USA; [Joyner, Michael J.; Johnson, Bruce D.; Olson, Thomas P.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA	Van Iterson, EH (reprint author), Univ Minnesota, Dept Kinesiol, Cooke Hall,1900 Univ Ave SE, Minneapolis, MN 55455 USA.	vanit001@umn.edu		Van Iterson, Erik/0000-0003-0576-3229	American Heart Association (AHA)American Heart Association [12GRNT1160027]; National Center for Advancing Translational Sciences (NCATS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000136]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL71478, HL46493]	This work was supported by American Heart Association (AHA) grant 12GRNT1160027 (T.P.O.), National Center for Advancing Translational Sciences (NCATS) grant KL2TR000136 (T.P.O.), National Institutes of Health grants HL71478 (B.D.J.) and HL46493 (M.J.J.) and the Frank R. and Shari Caywood Professorship (M.J.J.).	ABRAMSON SV, 1992, ANN INTERN MED, V116, P888, DOI 10.7326/0003-4819-116-11-888; Amann M, 2014, INT J CARDIOL, V174, P368, DOI 10.1016/j.ijcard.2014.04.157; Amann M, 2011, J PHYSIOL-LONDON, V589, P5299, DOI 10.1113/jphysiol.2011.213769; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Aronson D, 2011, CIRC-HEART FAIL, V4, P644, DOI 10.1161/CIRCHEARTFAILURE.110.960864; BESSE D, 1990, BRAIN RES, V521, P15, DOI 10.1016/0006-8993(90)91519-M; BESSE D, 1991, BRAIN RES, V548, P287, DOI 10.1016/0006-8993(91)91134-M; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; Butler J, 1999, J AM COLL CARDIOL, V34, P1802, DOI 10.1016/S0735-1097(99)00408-8; Cohen-Solal A, 2002, EUR HEART J, V23, P806, DOI 10.1053/euhj.2001.2966; COOTE JH, 1971, J PHYSIOL-LONDON, V215, P789, DOI 10.1113/jphysiol.1971.sp009498; Crisafulli A, 2003, MED SCI SPORT EXER, V35, P221, DOI 10.1249/01.MSS.0000048639.02548.24; Crisafulli A, 2011, J PHYSIOL SCI, V61, P385, DOI 10.1007/s12576-011-0163-x; Dickstein K, 2008, EUR J HEART FAIL, V10, P933, DOI 10.1016/j.ejheart.2008.08.005; Eisenhofer G, 1996, CIRCULATION, V93, P1667, DOI 10.1161/01.CIR.93.9.1667; Fisher JP, 2010, J PHYSIOL-LONDON, V588, P1117, DOI 10.1113/jphysiol.2009.185470; Galie N, 2009, EUR HEART J, V30, P2493, DOI 10.1093/eurheartj/ehp297; Ghio S, 2001, J AM COLL CARDIOL, V37, P183, DOI 10.1016/S0735-1097(00)01102-5; Higuchi H, 2004, ANESTHESIOLOGY, V100, P106, DOI 10.1097/00000542-200401000-00019; Keller-Ross ML, 2014, AM HEART J, V167, P521, DOI 10.1016/j.ahj.2013.12.021; KOMAMURA K, 1993, AM J PHYSIOL, V265, pH1119; Lang CC, 2009, CIRC-HEART FAIL, V2, P33, DOI 10.1161/CIRCHEARTFAILURE.108.798611; LEIGH MD, 1957, ANESTHESIOLOGY, V18, P878, DOI 10.1097/00000542-195711000-00009; Lykidis CK, 2008, EXP PHYSIOL, V93, P247, DOI 10.1113/expphysiol.2007.09487; Maslow A, 2001, ANESTH ANALG, V92, P306, DOI 10.1213/00000539-200102000-00004; MCCLOSKE.DI, 1972, J PHYSIOL-LONDON, V224, P173, DOI 10.1113/jphysiol.1972.sp009887; MEINTJES AF, 1995, CIRC RES, V77, P326, DOI 10.1161/01.RES.77.2.326; Moraes DL, 2000, CIRCULATION, V102, P1718, DOI 10.1161/01.CIR.102.14.1718; O'Leary DS, 2004, AM J PHYSIOL-HEART C, V287, pH2612, DOI 10.1152/ajpheart.00604.2004; O'Leary DS, 1999, AM J PHYSIOL-HEART C, V276, pH1399; Olson TP, 2014, EXP PHYSIOL, V99, P414, DOI 10.1113/expphysiol.2013.075937; Olson TP, 2010, CIRC-HEART FAIL, V3, P212, DOI 10.1161/CIRCHEARTFAILURE.109.879684; Piepoli M, 1999, AM HEART J, V137, P1050, DOI 10.1016/S0002-8703(99)70361-3; POMEROY G, 1986, BRAIN RES, V381, P385, DOI 10.1016/0006-8993(86)90095-8; Rich S, 2008, CIRCULATION, V118, P2190, DOI 10.1161/CIRCULATIONAHA.107.723007; ROSE CP, 1983, CIRCULATION, V68, P241, DOI 10.1161/01.CIR.68.2.241; Sala-Mercado JA, 2006, AM J PHYSIOL-HEART C, V290, pH751, DOI 10.1152/ajpheart.00869.2005; Scharf C, 2002, CHEST, V122, P1333, DOI 10.1378/chest.122.4.1333; SCHWINGER RHG, 1994, CIRC RES, V74, P959, DOI 10.1161/01.RES.74.5.959; SHIBUTANI K, 1994, ANESTH ANALG, V79, P829; Stromberg Anna, 2003, Eur J Cardiovasc Nurs, V2, P7; Taylor BJ, 2013, CLIN MED INSIGHTS-CI, V7, P53, DOI 10.4137/CCRPM.S12178; White MJ, 2013, EXP PHYSIOL, V98, P758, DOI 10.1113/expphysiol.2012.068528; Williams SG, 2005, AM J CARDIOL, V96, P1149, DOI 10.1016/j.amjcard.2005.06.051; WILSON JR, 1984, CIRCULATION, V69, P1079, DOI 10.1161/01.CIR.69.6.1079; ZELIS R, 1969, CIRC RES, V24, P799, DOI 10.1161/01.RES.24.6.799	46	2	2	1	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273	1874-1754		INT J CARDIOL	Int. J. Cardiol.	DEC 15	2015	201						384	393		10.1016/j.ijcard.2015.08.101			10	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CY1CL	WOS:000366144200117	26310984	Green Accepted			2020-06-30	J	Haddad, SH; Gonzales, CB; Deeb, AM; Tamim, HM; AlDawood, AS; Al Babtain, I; Naidu, BS; Arabi, YM				Haddad, Samir H.; Gonzales, Catherine B.; Deeb, Ahmad M.; Tamim, Hani M.; AlDawood, Abdulaziz S.; Al Babtain, Ibrahim; Naidu, Brintha S.; Arabi, Yaseen M.			Computerized physician order entry of a sedation protocol is not associated with improved sedation practice or outcomes in critically ill patients	BMC ANESTHESIOLOGY			English	Article						Sedation; Protocol; Computerized physician order entry; Guidelines; Analgesics; Sedatives; Critically ill	INTENSIVE-CARE-UNIT; IMPLEMENTATION; DURATION; SCALE	Background: Computerized Physician Order Entry (CPOE) analgesia-sedation protocols may improve sedation practice and patients' outcomes. We aimed to evaluate the impact of the introduction of CPOE protocol. Methods: This was a prospective, observational cohort study of adult patients receiving mechanical ventilation, requiring intravenous infusion of analgesics and/or sedatives, and expected to stay in the intensive care unit (ICU) >= 24 h. As a quality improvement project, the study had three phases: phase 1, no protocol, July 1st to September 30th, 2010; phase 2, post implementation of CPOE protocol, October 1st to December 31st, 2010; and phase 3, revised (age, kidney and liver function adjusted) CPOE protocol, August 1st to October 31st, 2011. Multivariate analyses were performed to determine the independent predictors of mortality. Results: Two hundred seventy nine patients were included (no protocol = 91, CPOE protocol = 97, revised CPOE protocol = 91). Implementation of CPOE protocol was associated with increase of the average daily dose of fentanyl (3720 +/- 3286 vs. 2647 +/- 2212 mcg/day; p = 0.009) and decrease of hospital length of stay (40 +/- 37 vs. 63 +/- 85 days, p = 0.02). The revised CPOE protocol was associated with, compared to the CPOE protocol, a decrease of the average daily dose of fentanyl (2208 +/- 2115 vs. 3720 +/- 3286 mcg/day, p = 0.0002) and lorazepam (0 +/- 0 vs. 0.06 +/- 0.26 mg/day, p = 0.04), sedation-related complications during ICU stay (3.3 % vs. 29.9 %, p < 0.0001), and ICU mortality (18 % vs. 39 %, p = 0.001). The impact of the revised CPOE protocol was more evident on patients aged > 70 years or with severe kidney or liver impairment. Both the original CPOE protocol and the revised CPOE protocol were not independent predictors of ICU (adjusted odds ratio [aOR] = 1.85, confidence interval [CI] = 0.90-3.78; p = 0.09; aOR = 0.70, CI = 0.32-1.53, p = 0.37; respectively) or hospital mortality (aOR = 1.12, CI = 0.57-2.21, p = 0.74; aOR = 0.80, CI = 0.40-1.59, p = 0.52; respectively). Conclusions: The implementation of a CPOE analgesia-sedation protocol was not associated with improved sedation practices or patients' outcome but with unpredicted increases of an analgesic dose. However, the revised CPOE protocol (age, kidney and liver function adjusted) was associated with improved sedation practices. This study highlights the importance of carefully evaluating the impact of changes in practice to detect unanticipated outcomes.	[Haddad, Samir H.; Gonzales, Catherine B.; Deeb, Ahmad M.; Tamim, Hani M.; AlDawood, Abdulaziz S.; Al Babtain, Ibrahim; Naidu, Brintha S.; Arabi, Yaseen M.] KAMC, Riyadh, Saudi Arabia; [Haddad, Samir H.; Arabi, Yaseen M.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia; [Deeb, Ahmad M.; Tamim, Hani M.; Arabi, Yaseen M.] KAMC, KAIMRC, Riyadh, Saudi Arabia; [Tamim, Hani M.] Amer Univ Beirut, Med Ctr, Dept Internal Med, Clin Res Inst, Beirut, Lebanon; [AlDawood, Abdulaziz S.; Al Babtain, Ibrahim; Arabi, Yaseen M.] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Haddad, Samir H.] King Abdul Aziz Med City, Dept Intens Care, Surg Intens Care Unit, Riyadh 11426, Saudi Arabia; [Gonzales, Catherine B.; Naidu, Brintha S.] KAMC, Nursing Serv, Riyadh, Saudi Arabia; [Haddad, Samir H.; AlDawood, Abdulaziz S.; Arabi, Yaseen M.] KAMC, Intens Care Dept, Riyadh, Saudi Arabia; [Al Babtain, Ibrahim] KAMC, Dept Surg, Trauma & Acute Care Surg, Riyadh, Saudi Arabia	Haddad, SH (reprint author), KAMC, Riyadh, Saudi Arabia.	haddads55@yahoo.com		Arabi, Yaseen/0000-0001-5735-6241; Deeb, Ahmad/0000-0002-3680-7338			Arabi Yaseen, 2007, Middle East Journal of Anesthesiology, V19, P429; Armstrong R, 2007, HEALTH PROMOT INT, V22, P254, DOI 10.1093/heapro/dam017; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Brattebo G, 2002, BRIT MED J, V324, P1386, DOI 10.1136/bmj.324.7350.1386; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Bucknall TK, 2008, CRIT CARE MED, V36, P1444, DOI 10.1097/CCM.0b013e318168f82d; Del Beccaro MA, 2006, PEDIATRICS, V118, P290, DOI 10.1542/peds.2006-0367; Fraser GL, 2006, CRIT CARE MED, V35, P635, DOI 10.1097/01.CCM.0000254072.83323.4E; Haddad Samir, 2009, Middle East Journal of Anesthesiology, V20, P389; Han YY, 2005, PEDIATRICS, V116, P1506, DOI 10.1542/peds.2005-1287; Hutton P, 2002, FUNDAMENTAL PRINCIPL; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; McCaffery M, 1998, PAIN CLIN MANUAL NUR; McCaffery M, 1999, PAIN CLIN MANUAL; Meehan D A, 1995, Am J Crit Care, V4, P435; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Pun BT, 2005, CRIT CARE MED, V33, P1199, DOI 10.1097/01.CCM.0000166867.78320.AC; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022	20	2	2	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	DEC 7	2015	15								177	10.1186/s12871-015-0161-2			10	Anesthesiology	Anesthesiology	CX8HB	WOS:000365942200001	26644114	DOAJ Gold, Green Published			2020-06-30	J	Xie, JD; Huang, Y; Chen, DT; Pan, JH; Bi, BT; Feng, KY; Huang, W; Zeng, WA				Xie, Jing-Dun; Huang, Yang; Chen, Dong-Tai; Pan, Jia-Hao; Bi, Bing-Tian; Feng, Kun-Yao; Huang, Wan; Zeng, Wei-An			Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice	PLOS ONE			English	Article							REVERSES MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; DRUG-INTERACTIONS; IN-VITRO; CLINICAL-IMPLICATIONS; OVEREXPRESSING CELLS; CYTOCHROME-P450 3A; PHARMACOKINETICS; BINDING; VIVO	Fentanyl, a potent opioid analgesic that is used to treat cancer pain, is commonly administered with paclitaxel in advanced tumors. However, the effect of fentanyl on the hepatotoxicity of paclitaxel and its potential mechanism of action is not well studied. The purpose of this study was to investigate the effect of fentanyl on the hepatotoxicity of paclitaxel and its potential mechanisms of action. Pharmacokinetic parameters of paclitaxel were tested using reversed phase high-performance liquid chromatography (RP-HPLC). Aspartate transaminase (AST), alanine aminotransferase (ALT), and mouse liver histopathology were examined. Moreover, the cytotoxicity of anti-carcinogens was examined using 1-(4, 5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT), and the intracellular accumulation of doxorubicin and rhodamine 123 was detected by flow cytometry. Furthermore, the expression of ABCB1 and the activity of ABCB1 ATPase and CYP3A4 were also examined. In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t(1/2)) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice. Fentanyl significantly increased the levels of ALT in mice to 88.2 U/L, which is more than 2-fold higher than the level detected in the control group, and it increased the histological damage in mouse livers. Furthermore, fentanyl enhanced the cytotoxicity of anti-carcinogens that are ABCB1 substrates and increased the accumulation of doxorubicin and rhodamine 123. Additionally, fentanyl stimulated ABCB1 ATPase activity and inhibited CYP3A4 activity in the liver microsomes of mice. Our study indicates that the obvious hepatotoxicity during this co-administration was due to the inhibition of CYP3A4 activity and ABCB1 transport activity. These findings suggested that the accumulation-induced hepatotoxicity of paclitaxel when it is combined with fentanyl should be avoided.	[Xie, Jing-Dun; Huang, Yang; Chen, Dong-Tai; Pan, Jia-Hao; Huang, Wan; Zeng, Wei-An] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol,Canc Ctr, Guangzhou 510275, Guangdong, Peoples R China; [Bi, Bing-Tian; Feng, Kun-Yao] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Clin Trial Ctr,Canc Ctr, Guangzhou 510275, Guangdong, Peoples R China	Zeng, WA (reprint author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol,Canc Ctr, Guangzhou 510275, Guangdong, Peoples R China.	zengwa@mail.sysu.edu.cn			Natural Science Foundation of ChinaNational Natural Science Foundation of China [81271246]	Grant (No. 81271246) from the Natural Science Foundation of China (http://www.nsfc.gov.cn/).	Al-Farsi A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00157; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Andersen Anders, 2006, BMC Clin Pharmacol, V6, P2, DOI 10.1186/1472-6904-6-2; Brozik A, 2011, EXPERT OPIN DRUG MET, V7, P623, DOI 10.1517/17425255.2011.562892; Bujedo Borja Mugabure, 2012, J Opioid Manag, V8, P177, DOI 10.5055/jom.2012.0114; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; Dai CL, 2009, BIOCHEM PHARMACOL, V78, P355, DOI 10.1016/j.bcp.2009.04.023; Dreher MR, 2006, JNCI-J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070; Englund G, 2014, DRUG METAB DISPOS, V42, P441, DOI 10.1124/dmd.113.054932; Fromm MF, 2004, TRENDS PHARMACOL SCI, V25, P423, DOI 10.1016/j.tips.2004.06.002; Fu LW, 2004, CANCER CHEMOTH PHARM, V53, P349, DOI 10.1007/s00280-003-0742-5; Goh IXW, 2013, SINGAP MED J, V54, P131, DOI 10.11622/smedj.2013044; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Honjo Y, 2001, CANCER RES, V61, P6635; Hsu PW, 2013, J AGR FOOD CHEM, V61, P4464, DOI 10.1021/jf3052384; King S, 2011, PALLIATIVE MED, V25, P525, DOI 10.1177/0269216311406313; KLEIN HO, 1982, CIRCULATION, V65, P998, DOI 10.1161/01.CIR.65.5.998; Lee CK, 2011, BIOPHARM DRUG DISPOS, V32, P245, DOI 10.1002/bdd.754; Lin JH, 2003, CLIN PHARMACOKINET, V42, P59, DOI 10.2165/00003088-200342010-00003; Lin JH, 1998, CLIN PHARMACOKINET, V35, P361, DOI 10.2165/00003088-199835050-00003; Ling SY, 2014, BRIT J CLIN PHARMACO, V77, P1039, DOI 10.1111/bcp.12309; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mercer SL, 2011, CURR TOP MED CHEM, V11, P1157; Miller AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060685; MORDEL A, 1993, CLIN PHARMACOL THER, V53, P457, DOI 10.1038/clpt.1993.51; Park BK, 2005, ANNU REV PHARMACOL, V45, P177, DOI 10.1146/annurev.pharmtox.45.120403.100058; Pawar M, 2007, EUR J PHARMACOL, V563, P92, DOI 10.1016/j.ejphar.2007.01.059; Perez-Tomas R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077; Rabindran SK, 2000, CANCER RES, V60, P47; Shi S, 2010, INT J PHARMACEUT, V383, P264, DOI 10.1016/j.ijpharm.2009.09.025; Tang R, 2004, LEUKEMIA, V18, P1246, DOI 10.1038/sj.leu.2403390; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723; Yang XN, 2008, J ETHNOPHARMACOL, V117, P408, DOI 10.1016/j.jep.2008.02.021; Zanger UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/j.pharmthera.2012.12.007; Zhang JY, 2007, CANCER BIOL THER, V6, P1413; Zhao F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113478; Zhao XQ, 2012, MOL PHARMACOL, V82, P47, DOI 10.1124/mol.111.076299; Zhou WJ, 2012, BRIT J PHARMACOL, V166, P1669, DOI 10.1111/j.1476-5381.2012.01849.x	39	15	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2015	10	12							e0143701	10.1371/journal.pone.0143701			15	Multidisciplinary Sciences	Science & Technology - Other Topics	CX9QI	WOS:000366040000020	26633878	DOAJ Gold, Green Published			2020-06-30	J	Skledar, SJ; Lachell, CM; Chelly, JE				Skledar, Susan J.; Lachell, Carsten M.; Chelly, Jacques E.			Pharmacodynamics and clinical efficacy of fentanyl iontophoretic transdermal system for post-operative pain in hospitalized patients	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY			English	Review						fentanyl; iontophoretic system; opioid; pain management; patient-controlled; postoperative analgesia; transdermal	PLACEBO-CONTROLLED TRIAL; CONTROLLED ANALGESIA; DELIVERY-SYSTEM; DRUG-DELIVERY; IV-PCA; MANAGEMENT; MORPHINE; PHARMACOKINETICS; SAFETY; FORMULATIONS	Introduction: The fentanyl iontophoretic transdermal system (ITS) is a patient-controlled transdermal system allowing needle-free administration of on-demand doses of Fentanyl of 40 mu g over a 10-min period up to 80 doses or over a 24-h period. It is indicated in opioid naive patients for the treatment of acute postoperative pain in the hospitalized patients for up to 72h.Areas covered: It has been demonstrated to be effective and safe in randomized trials and to provide comparable analgesia versus morphine intravenous (i.v.) patient-controlled analgesia (PCA) with adverse events similar between groups.Expert opinion: Fentanyl ITS has shown high patient satisfaction rates, and was described by patients and investigators as easy and convenient to use. These properties make this technology interesting when considering perioperative pain management. In the present health care environment additional data are required to establish the cost-benefit ratio of this technology in optimizing patient's recovery from surgery.	[Skledar, Susan J.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA; [Skledar, Susan J.] Univ Pittsburgh, Med Ctr, Hlth Syst Formulary Management & Drug Use Policy, Dept Pharm, Pittsburgh, PA 15213 USA; [Lachell, Carsten M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA; [Chelly, Jacques E.] Univ Pittsburgh, Med Ctr, Div Acute Intervent Perioperat Pain & Reg Anesthe, UPMC Presbyterian Shadyside Hosp,Dept Anesthesiol, Pittsburgh, PA 15232 USA	Chelly, JE (reprint author), Univ Pittsburgh, Med Ctr, Div Acute Intervent Perioperat Pain & Reg Anesthe, UPMC Presbyterian Shadyside Hosp,Dept Anesthesiol, Suite M140 Posner Pain Ctr,5230 Ctr Ave, Pittsburgh, PA 15232 USA.	chelje@anes.upmc.edu					[Anonymous], 2015, IONSYS PACK INS; [Anonymous], 2015, FENT IONT TRAND SYST; [Anonymous], 2015, HCAHPS HOSP CONSUMER; [Anonymous], 2014, DUR PACK INS; [Anonymous], 2015, HOSP VALUE BASED PUR; [Anonymous], 2009, ASS REP IONSYS; [Anonymous], 2015, PAIN MAN JOINT COMM; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; ASHBURN MA, 1995, ANESTHESIOLOGY, V82, P1146, DOI 10.1097/00000542-199505000-00009; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Bonnet F, 2009, CURR MED RES OPIN, V25, P293, DOI 10.1185/03007990802631321 ; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Herndon CM, 2007, PHARMACOTHERAPY, V27, P745, DOI 10.1592/phco.27.5.745; Lindley P, 2009, J ADV NURS, V65, P1370, DOI 10.1111/j.1365-2648.2009.04991.x; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lotsch J, 2009, PHARMACOGENET GENOM, V19, P429, DOI 10.1097/FPC.0b013e32832b89da; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mattia C, 2010, EUR J ANAESTH, V27, P433, DOI 10.1097/EJA.0b013e3283349d82; Miaskowski C, 2008, AM PAIN SOC PRINCIPL; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; Panchal SJ, 2007, ANESTH ANALG, V105, P1437, DOI 10.1213/01.ane.0000281442.36582.81; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Phipps JB, 2015, EXPERT OPIN DRUG MET, V11, P481, DOI 10.1517/17425255.2015.1020296; Polomano RC, 2008, PAIN MANAG NURS, V9, pS33, DOI 10.1016/j.pmn.2007.11.005; Power I, 2008, MED DEVICES-EVID RES, V1, P49; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; Sommer M, 2008, EUR J ANAESTH, V25, P267, DOI 10.1017/S0265021507003031; THYSMAN S, 1993, ANESTH ANALG, V77, P61; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Viscusi ER, 2008, REGION ANESTH PAIN M, V33, P146, DOI 10.1016/j.rapm.2007.11.005; Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6; Wu WD, 2009, MOL DIAGN THER, V13, P331, DOI 10.2165/11317320-000000000-00000; Zhang W, 2010, ANAESTHESIA, V65, P130, DOI 10.1111/j.1365-2044.2009.06193.x; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	45	1	1	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1742-5255	1744-7607		EXPERT OPIN DRUG MET	Expert Opin. Drug Metab. Toxicol.	DEC 2	2015	11	12					1925	1935		10.1517/17425255.2015.1112788			11	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	CX5XI	WOS:000365775400002	26565744				2020-06-30	J	Arai, T; Kashimoto, Y; Ukyo, Y; Tominaga, Y; Imanaka, K				Arai, Tsutomu; Kashimoto, Yuji; Ukyo, Yoshifumi; Tominaga, Yushin; Imanaka, Keiichiro			Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-naive patients with chronic pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						1 day patch; Chronic pain; Fentanyl; Opioid	OXYMORPHONE EXTENDED-RELEASE; BACK-PAIN; EFFICACY; 12-WEEK; SAFETY	Objective:To evaluate the efficacy and safety of fentanyl 1 day patch in opioid-naive patients with non-cancer chronic pain insufficiently relieved by non-opioid analgesics.Research design and methods:Two phase III placebo-controlled, double-blind, group-comparison, randomized withdrawal studies were conducted in patients with osteoarthritis and/or low back pain (N01 study) and post-herpetic neuralgia, complex regional pain syndrome, or chronic postoperative pain (N02) in Japan. Both studies consisted of period I (10-29 days of titration, fentanyl 12.5-50.0 mu g/h) and period II (12 weeks double-blind).Clinical trial registration:N01, NCT01008618; N02, NCT01008553Main outcome measures:The primary endpoint was the number of days until study discontinuation due to insufficient pain relief in period II, and secondary endpoints included pain scored on visual analog scale (VAS), subject's overall assessment, the number of rescue dose, brief pain inventory short form score, score on short-form 36-item health survey version 2.0, physician's overall assessment, and assessment of adverse events.Results:Of the 218 (N01) and 258 (N02) subjects who entered period I, 150 and 163 subjects entered period II, respectively. In the N01 study, the between-group difference was significant in the VAS score (95% CI: 7.3 [1.1, 13.5] mm, P=0.0215) but not in the primary endpoint (P=0.0846, log-rank test). In the N02 study, both primary efficacy (P=0.0003) and VAS (8.7 [2.4, 15.0] mm, P=0.0071) results showed that fentanyl was more effective than placebo. The major adverse events were nervous system and gastrointestinal disorders typically associated with opioid analgesic use. The incidence of adverse events in the fentanyl group was 68.5% to 85.7%.Conclusions:Although the primary efficacy results showed significant effects of fentanyl in the N02 but not the N01 study, overall results showed that fentanyl 1 day patch is effective and well tolerated.	[Arai, Tsutomu; Kashimoto, Yuji; Ukyo, Yoshifumi; Tominaga, Yushin; Imanaka, Keiichiro] Janssen Pharmaceut KK, Tokyo 1010065, Japan	Arai, T (reprint author), Janssen Pharmaceut KK, Chiyoda Ku, 5-2,Nishi Kanda 3 Chome, Tokyo 1010065, Japan.	tarai@its.jnj.com			Janssen Pharmaceutical KK	Editorial support was funded by Janssen Pharmaceutical KK.	Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Hale ME, 2007, J PAIN, V8, P175, DOI 10.1016/j.jpain.2006.09.011; Hanaoka Kazuo, 2011, Masui, V60, P147; Hanaoka Kazuo, 2011, Masui, V60, P157; Imanaka K, 2014, PAIN CLINIC, V35, P781; Katz N, 2007, CURR MED RES OPIN, V23, P117, DOI 10.1185/030079906X162692; Knop C, 2001, UNFALLCHIRURG, V104, P488, DOI 10.1007/s001130170111; Lemmens HJM, 2006, CONTEMP CLIN TRIALS, V27, P165, DOI 10.1016/j.cct.2005.10.005; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; Miyazaki T, 2010, J NEW REM CLIN, V59, P157; Suzuki T, 2003, J PAIN CLIN MED, V3, P199; Wesson DR, 2003, J PSYCHOACTIVE DRUGS, V35, P253, DOI 10.1080/02791072.2003.10400007	12	6	6	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	DEC 2	2015	31	12					2207	2218		10.1185/03007995.2015.1092127			12	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	CW9NV	WOS:000365326400002	26359327	Bronze			2020-06-30	J	Sutter, ME; Wintemute, GJ; Clarke, SO; Roche, BM; Chenoweth, JA; Gutierrez, R; Albertson, TE				Sutter, Mark E.; Wintemute, Garen J.; Clarke, Samuel O.; Roche, Bailey M.; Chenoweth, James A.; Gutierrez, Rory; Albertson, Timothy E.			The Changing Use of Intravenous Opioids in an Emergency Department	WESTERN JOURNAL OF EMERGENCY MEDICINE			English	Article						Opioids; Medication Safety	RENAL-FAILURE; CARE; ERRORS	Introduction: Government agencies are increasingly emphasizing opioid safety in hospitals. In 2012, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) started a sentinel event program, the "Safe Use of Opioids in Hospitals." We sought to determine if opioid use patterns in our emergency department (ED) changed from 2011, before the program began, to 2013, after start of the program. Methods: This was a retrospective study of all adult ED patients who received an intravenous opioid and had a serum creatinine measured. We recorded opioids used, dose prescribed, and serum creatinine. As an index of the safety of opioids, uses of naloxone after administration of an opioid was recorded. Results: Morphine is still the most commonly used opioid by doses given, but its percentage of opioids used decreased from 68.9% in 2011 to 52.8% in 2013. During the same period, use of hydromorphone increased from 27.5% to 42.9%, while the use of fentanyl changed little (3.6% to 4.3%). Naloxone administration was rare after an opioid had been given. Opioids were not dosed in an equipotent manner. Conclusion: The use of hydromorphone in our ED increased by 56% (absolute increase of 15.4%), while the use of morphine decreased by 30.5% (absolute decrease 16.1%) of total opioid use from 2011 to 2013. The JCAHO program likely was at least indirectly responsible for this change in relative dosing of the opioids. Based on frequency of naloxone administered after administration of an opioid, the use of opioids was safe.	[Wintemute, Garen J.; Clarke, Samuel O.] Univ Calif Davis, Dept Emergency Med, Sacramento, CA 95817 USA; [Sutter, Mark E.; Roche, Bailey M.; Chenoweth, James A.; Albertson, Timothy E.] Univ Calif Davis, Dept Emergency Med, Div Med Toxicol, Sacramento, CA 95817 USA; [Sutter, Mark E.; Roche, Bailey M.; Chenoweth, James A.; Albertson, Timothy E.] VA Northern Calif Hlth Care Syst, Mather, CA USA; [Gutierrez, Rory] Univ Calif Davis, Dept Pharm, Sacramento, CA 95817 USA; [Albertson, Timothy E.] Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA	Sutter, ME (reprint author), Univ Calif Davis, Med Ctr, 2315 Stockton Blvd, Sacramento, CA 95817 USA.	mesutter@ucdavis.edu			National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000002]	The Clinical Translational Science Center at our institution provided data abstraction and statistical support. The project was supported financially by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1 TR000002. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Klopotowska JE, 2010, CRIT CARE, V14, DOI 10.1186/cc9278; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Moyen E, 2008, CRIT CARE, V12, DOI 10.1186/cc6813; Murray A, 2005, J PAIN SYMPTOM MANAG, V29, pS57, DOI 10.1016/j.jpainsymman.2005.01.007; OSBORNE RJ, 1986, BRIT MED J, V292, P1548, DOI 10.1136/bmj.292.6535.1548; Patanwala AE, 2007, ANN PHARMACOTHER, V41, P255, DOI 10.1345/aph.1H421; Randolph TC, 2009, AM J HEALTH-SYST PH, V66, P1484, DOI 10.2146/ajhp080698; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Smith HS, 2009, MAYO CLIN PROC, V84, P613, DOI 10.1016/S0025-6196(11)60750-7	10	6	6	0	0	WESTJEM	ORANGE	C/O SHAHRAM LOTFIPOUR, MD, MPH, 333 CITY BLVD W STE 640, RT 128-01, ORANGE, CA 92868 USA	1936-900X	1936-9018		WEST J EMERG MED	West. J. Emerg. Med.	DEC	2015	16	7					1079	1083		10.5811/westjem.2015.10.28454			5	Emergency Medicine	Emergency Medicine	DH9OX	WOS:000373126600020	26759658	DOAJ Gold, Green Published			2020-06-30	J	Li, Y; Flood, P; Cornes, S				Li, Yi; Flood, Pamela; Cornes, Susannah			Electroencephalography of Seizure-Like Movements During General Anesthesia with Propofol: Seizures or Nonepileptic Events?	A & A CASE REPORTS			English	Article							SEVOFLURANE	Seizure-like behavior is an uncommon yet worrisome phenomenon during anesthesia with propofol. The current case report describes a 23-year-old man admitted for elective surgery who experienced several seizure-like episodes after induction with propofol and during a desflurane-based general anesthetic that were so severe it was not possible to complete the procedure. A second surgery was rescheduled 2 days later with simultaneous scalp electroencephalographic (EEG) recording and general anesthesia with propofol and fentanyl. During the second operation, he again experienced numerous episodes of generalized shaking movements. Simultaneous intraoperative EEG recording showed a background of diffuse beta and alpha frequencies interspersed with periods of pseudoperiodic delta activity; electrographic seizures were not apparent. With this information, muscle relaxants were given and the procedure was performed without difficulty. This is the first report of apparent seizure-like activity during anesthesia with propofol of an otherwise relatively healthy adult, in which concurrent EEG recording demonstrates the nonepileptic nature. The current case demonstrates that, at least in some instances, these concerning movements are not seizure related. Concurrent EEG monitoring may be helpful to evaluate the nature of the episodes in select cases.	[Li, Yi] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Li, Yi] Cent S Univ, Xiangya Hosp, Dept Neurol, Changsha, Hunan, Peoples R China; [Flood, Pamela] Stanford Hosp & Clin, Dept Anesthesiol Perioperat & Pain Med, 300 Pasteur Ave, Palo Alto, CA 94140 USA; [Cornes, Susannah] UCSF Comprehens Epilepsy Ctr, Dept Neurol, San Francisco, CA USA	Flood, P (reprint author), Stanford Hosp & Clin, Dept Anesthesiol Perioperat & Pain Med, 300 Pasteur Ave, Palo Alto, CA 94140 USA.	pflood@stanford.edu		Li, Yi/0000-0003-0392-6661			BORGEAT A, 1993, BRIT J ANAESTH, V70, P459, DOI 10.1093/bja/70.4.459; DOLIN SJ, 1992, BRIT J ANAESTH, V68, P523, DOI 10.1093/bja/68.5.523; Hirsch Lawrence J, 2013, Continuum (Minneap Minn), V19, P767, DOI 10.1212/01.CON.0000431395.16229.5a; Hoyer C, 2013, EUR ARCH PSY CLIN N, V264, P255; Jaaskelainen SK, 2003, NEUROLOGY, V61, P1073, DOI 10.1212/01.WNL.0000090565.15739.8D; Jones PJ, 2007, J PHARMACOL EXP THER, V320, P828, DOI 10.1124/jpet.106.11542; McCarthy Michelle M, 2008, J Neurosci, V28, P13488, DOI 10.1523/JNEUROSCI.3536-08.2008; Mhuircheartaigh RN, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006007; Pilge S, 2013, ANESTHESIOLOGY, V119, P447, DOI 10.1097/ALN.0b013e31827335b9; San-juan D, 2010, CLIN NEUROPHYSIOL, V121, P998, DOI 10.1016/j.clinph.2009.12.016; Walder B, 2002, NEUROLOGY, V58, P1327, DOI 10.1212/WNL.58.9.1327; Zeiler SR, 2008, SEIZURE-EUR J EPILEP, V17, P665, DOI 10.1016/j.seizure.2008.03.004	12	5	5	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237			A A CASE REP	A A Case Rep.	DEC 1	2015	5	11					195	198		10.1213/XAA.0000000000000212			4	Anesthesiology	Anesthesiology	DC7VD	WOS:000369427700003	26588032				2020-06-30	J	Brimdyr, K; Cadwell, K; Widstrom, AM; Svensson, K; Neumann, M; Hart, EA; Harrington, S; Phillips, R				Brimdyr, Kajsa; Cadwell, Karin; Widstrom, Ann-Marie; Svensson, Kristin; Neumann, Monica; Hart, Elaine A.; Harrington, Sarah; Phillips, Raylene			The Association Between Common Labor Drugs and Suckling When Skin-to-Skin During the First Hour After Birth	BIRTH-ISSUES IN PERINATAL CARE			English	Article						skin-to-skin; epidural; fentanyl	RANDOMIZED CONTROLLED-TRIAL; BREAST-FEEDING BEHAVIOR; EPIDURAL ANALGESIA; RETROSPECTIVE COHORT; PLACENTAL-TRANSFER; NEWBORN BEHAVIOR; OXYTOCIN USE; FENTANYL; TERM; ANESTHESIA	Background: Intrapartum drugs, including fentanyl administered via epidural and synthetic oxytocin, have been previously studied in relation to neonatal outcomes, especially breastfeeding, with conflicting results. We examined the normal neonatal behavior of suckling within the first hour after a vaginal birth while in skin-to-skin contact with mother in relation to these commonly used drugs. Suckling in the first hour after birth has been shown in other studies to increase desirable breastfeeding outcomes. Method: Prospective comparative design. Sixty-three low-risk mothers self-selected to labor with intrapartum analgesia/anesthesia or not. Video recordings of infants during the first hour after birth while being held skin-to-skin with their mother were coded and analyzed to ascertain whether or not they achieved Stage 8 (suckling) of Widstrom's 9 Stages of newborn behavior during the first hour after birth. Results: A strong inverse correlation was found between the amount and duration of exposure to epidural fentanyl and the amount of synthetic oxytocin against the likelihood of achieving suckling during the first hour after a vaginal birth. Conclusions: Results suggest that intrapartum exposure to the drugs fentanyl and synthetic oxytocin significantly decreased the likelihood of the baby suckling while skin-to-skin with its mother during the first hour after birth. (BIRTH 42:4 December 2015)	[Brimdyr, Kajsa; Cadwell, Karin] Hlth Children Project Inc, 327 Quaker Meeting House Rd, East Sandwich, MA 02639 USA; [Brimdyr, Kajsa] Union Inst & Univ, Maternal Child Hlth, Cincinnati, OH USA; [Cadwell, Karin] Union Inst & Univ, Maternal Child Hlth, Grad Program Hlth & Wellness, Cincinnati, OH USA; [Widstrom, Ann-Marie; Svensson, Kristin] Karolinska Inst, Div Reprod Hlth, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Neumann, Monica] Loma Linda Univ, Med Ctr, Childrens Hosp, Sch Med,Dept Anesthesiol Obstetr Anesthesiol, Loma Linda, CA USA; [Hart, Elaine A.] Loma Linda Univ, Med Ctr, Childrens Hosp, Sch Med,Dept Obstet & Gynecol, Loma Linda, CA USA; [Harrington, Sarah] Kern Med Ctr, Bakersfield, CA USA; [Harrington, Sarah] Loma Linda Univ, Sch Med, Loma Linda, CA USA; [Phillips, Raylene] Loma Linda Univ, Med Ctr, Childrens Hosp, Sch Med,Dept Pediat, Loma Linda, CA USA	Brimdyr, K (reprint author), Hlth Children Project Inc, 327 Quaker Meeting House Rd, East Sandwich, MA 02639 USA.			Brimdyr, Kajsa/0000-0003-3789-635X; svensson, kristin/0000-0002-7138-6209	Loma Linda University Medical Center; Healthy Children Project, Inc.	We thank the delightful mothers and babies who so graciously participated in this study, as well as the hardworking and dedicated nurses and doctors. We thank the research assistants, Judy Blatchford, Natasha Mishchenko, Aisha Stewart, Cynthia Mach, and Allysa Erskine. Thank you to Jocelyn Pitman, Glenn Bush and Ann-Sofie Mattiesen for their statistical expertise. Funding for this project was provided by Loma Linda University Medical Center and Healthy Children Project, Inc.	Aghdas K, 2014, WOMEN BIRTH, V27, P37, DOI 10.1016/j.wombi.2013.09.004; Baumgarder DJ, 2003, J AM BOARD FAM PRACT, V16, P7, DOI 10.3122/jabfm.16.1.7; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Bell AF, 2013, EARLY HUM DEV, V89, P137, DOI 10.1016/j.earlhumdev.2012.09.017; Berglund S, 2008, ACTA PAEDIATR, V97, P714, DOI 10.1111/j.1651-2227.2008.00803.x; Brimdyr K, 2011, SKIN TO SKIN 1 HOUR; Brimdyr K, 2012, J PERINAT EDUC, V21, P149, DOI 10.1891/1058-1243.21.3.149; Buchanan SL, 2012, AUST NZ J OBSTET GYN, V52, P173, DOI 10.1111/j.1479-828X.2011.01403.x; Cadwell K, 2009, BREASTFEED MED, V4, P240; Carberry AE, 2013, BREASTFEED MED, V8, P513, DOI 10.1089/bfm.2013.0041; CHRISTENSSON K, 1995, ACTA PAEDIATR, V84, P468, DOI 10.1111/j.1651-2227.1995.tb13676.x; Cooper J, 1999, BRIT J ANAESTH, V82, P929; Costley PL, 2013, COCHRANE DB SYST REV, V7; Crenshaw JT, 2012, BREASTFEED MED, V7, P69, DOI 10.1089/bfm.2011.0040; DECHATEAU P, 1977, ACTA PAEDIATR SCAND, V66, P145, DOI 10.1111/j.1651-2227.1977.tb07826.x; Dozier AM, 2013, MATERN CHILD HLTH J, V17, P689, DOI 10.1007/s10995-012-1045-4; Edmond KM, 2006, PEDIATRICS, V117, pE380, DOI 10.1542/peds.2005-1496; Garcia-Fortea P, 2014, J MATERN-FETAL NEO M, V27, P1598, DOI 10.3109/14767058.2013.871255; Gialloreti LE, 2014, MED HYPOTHESES, V82, P713, DOI 10.1016/j.mehy.2014.03.011; Halpern SH, 1999, BIRTH-ISS PERINAT C, V26, P83, DOI 10.1046/j.1523-536x.1999.00083.x; Hayes EJ, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2008.01.039; Jonas W, 2009, BREASTFEED MED, V4, P71, DOI 10.1089/bfm.2008.0002; Jonsson M, 2008, ACTA OBSTET GYN SCAN, V87, P745, DOI 10.1080/00016340802220352; Jordan S, 2005, BJOG-INT J OBSTET GY, V112, P927, DOI 10.1111/j.1471-0528.2005.00548.x; Kurth L, 2011, J ATTEN DISORD, V15, P423, DOI 10.1177/1087054710397800; Lieberman E, 2000, PEDIATRICS, V105, P8, DOI 10.1542/peds.105.1.8; Lind JN, 2014, J HUM LACT, V30, P167, DOI 10.1177/0890334413520189; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; Mahmood I, 2011, JCPSP-J COLL PHYSICI, V21, P601, DOI 10.2011/JCPSP.601605; Martin Joyce A, 2013, Natl Vital Stat Rep, V62, P1; Mealing NM, 2009, AUST NZ J OBSTET GYN, V49, P599, DOI 10.1111/j.1479-828X.2009.01086.x; Moises ECD, 2005, EUR J CLIN PHARMACOL, V61, P517, DOI 10.1007/s00228-005-0967-9; Moore ER, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub3; NISSEN E, 1995, ACTA PAEDIATR, V84, P140, DOI 10.1111/j.1651-2227.1995.tb13596.x; Nystedt A, 2004, J CLIN NURS, V13, P455, DOI 10.1046/j.1365-2702.2003.00849.x; Fernandez IO, 2012, ACTA PAEDIATR, V101, P749, DOI 10.1111/j.1651-2227.2012.02668.x; Phaneuf S, 2000, J REPROD FERTIL, V120, P91, DOI 10.1530/reprod/120.1.91; Radzyminski S, 2005, JOGNN-J OBST GYN NEO, V34, P335, DOI 10.1177/0884217505276283; Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x; RIGHARD L, 1992, BIRTH-ISS PERINAT C, V19, P185, DOI 10.1111/j.1523-536X.1992.tb00399.x; Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103; Selin L, 2009, ACTA OBSTET GYN SCAN, V88, P1352, DOI 10.3109/00016340903358812; SEPKOSKI CM, 1992, DEV MED CHILD NEUROL, V34, P1072; Szabo AL, 2013, ANESTH ANALG, V116, P399, DOI 10.1213/ANE.0b013e318273f63c; Torvaldsen S, 2006, INT BREASTFEED J, V1, DOI 10.1186/1746-4358-1-24; Volmanen P, 2004, INT J OBSTET ANESTH, V13, P25, DOI 10.1016/S0959-289X(03)00104-3; Wiberg-Itzel E, 2014, ACTA OBSTET GYN SCAN, V93, P80, DOI 10.1111/aogs.12261; Widstrom AM, 2011, ACTA PAEDIATR, V100, P79, DOI 10.1111/j.1651-2227.2010.01983.x; WIDSTROM AM, 1990, EARLY HUM DEV, V21, P153, DOI 10.1016/0378-3782(90)90114-X; Wiklund I, 2009, MIDWIFERY, V25, pE31, DOI 10.1016/j.midw.2007.07.005; Wilson MJA, 2010, ANAESTHESIA, V65, P145, DOI 10.1111/j.1365-2044.2009.06136.x	51	22	23	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0730-7659	1523-536X		BIRTH-ISS PERINAT C	Birth-Issue Perinat. Care	DEC	2015	42	4					319	328		10.1111/birt.12186			10	Nursing; Obstetrics & Gynecology; Pediatrics	Nursing; Obstetrics & Gynecology; Pediatrics	DB3XI	WOS:000368446400005	26463582	Other Gold, Green Published			2020-06-30	J	Poklis, J; Poklis, A; Wolf, C; Mainland, M; Hair, L; Devers, K; Chrostowski, L; Arbefeville, E; Merves, M; Pearson, J				Poklis, Justin; Poklis, Alphonse; Wolf, Carl; Mainland, Mary; Hair, Laura; Devers, Kelly; Chrostowski, Leszek; Arbefeville, Elise; Merves, Michele; Pearson, Julia			Postmortem tissue distribution of acetyl fentanyl, fentanyl and their respective nor-metabolites analyzed by ultrahigh performance liquid chromatography with tandem mass spectrometry	FORENSIC SCIENCE INTERNATIONAL			English	Article						Postmortem tissue distribution; Acetyl fentanyl; Fentanyl; UPLC/MS/MS	DEATHS; CIRCUMSTANCES	In the last two years, an epidemic of fatal narcotic overdose cases has occurred in the Tampa area of Florida. Fourteen of these deaths involved fentanyl and/or the new designer drug, acetyl fentanyl. Victim demographics, case histories, toxicology findings and causes and manners of death, as well as, disposition of fentanyl derivatives and their nor-metabolites in postmortem heart blood, peripheral blood, bile, brain, liver, urine and vitreous humor are presented. In the cases involving only acetyl fentanyl (without fentanyl, n = 4), the average peripheral blood acetyl fentanyl concentration was 0.467 mg/L (range 0.31 to 0.60 mg/L) and average acetyl norfentanyl concentration was 0.053 mg/L (range 0.002 to 0.086 mg/L). In the cases involving fentanyl (without acetyl fentanyl, n = 7), the average peripheral blood fentanyl concentration was 0.012 mg/L (range 0.004 to 0.027 mg/L) and average norfentanyl blood concentration was 0.001 mg/L (range 0.0002 to 0.003 mg/L). In the cases involving both acetyl fentanyl and fentanyl (n = 3), the average peripheral blood acetyl fentanyl concentration was 0.008 mg/L (range 0.006 to 0.012 mg/L), the average peripheral blood acetyl norfentanyl concentration was 0.001 mg/L (range 0.001 to 0.002 mg/L), the average peripheral blood fentanyl concentration was 0.018 mg/L (range 0.015 to 0.021 mg/L) and the average peripheral blood norfentanyl concentration was 0.002 mg/L (range 0.001 mg/L to 0.003 mg/L). Based on the toxicology results, it is evident that when fentanyl and/or acetyl fentanyl were present, they contributed to the cause of death. A novel ultrahigh performance liquid chromatography (UPLC) tandem mass spectrometry (MS/MS) method to identify and quantify acetyl fentanyl, acetyl norfentanyl, fentanyl and norfentanyl in postmortem fluids and tissues is also presented. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Poklis, Justin; Poklis, Alphonse] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA USA; [Poklis, Alphonse; Wolf, Carl] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA USA; [Poklis, Alphonse; Wolf, Carl] Virginia Commonwealth Univ, Dept Forens Sci, Richmond, VA USA; [Mainland, Mary; Hair, Laura; Devers, Kelly; Chrostowski, Leszek; Arbefeville, Elise; Merves, Michele; Pearson, Julia] Hillsborough Cty Med Examiner Dept, Tampa, FL 33617 USA	Pearson, J (reprint author), Hillsborough Cty Med Examiner Dept, Tampa, FL 33617 USA.	jlpoklis@vcu.edu; apoklis@mcvh-vcu.edu; cewolf@vcu.edu; mainlandm@hillsboroughcounty.org; hairl@hillsboroughcounty.org; deversk@hillsboroughcounty.org; chrostowskil@hillsboroughcounty.org; arbefevillee@hillsboroughcounty.org; mervesm@hillsboroughcounty.org; pearsonjm@hillsboroughcounty.org			National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30DA033934]	This project was supported in part by the National Institute of Health (NIH) grant P30DA033934.	Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; [Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Flammia DD, 2004, J ANAL TOXICOL, V28, P533, DOI 10.1093/jat/28.6.533; HENDERSON GL, 1983, P W PHARMACOL SOC, V26, P287; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Stogner JM, 2015, AM J DRUG ALCOHOL AB, V41, P519, DOI 10.3109/00952990.2014.998367; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; US Food and Drug Administration, 2001, GUID IND BIOAN METH	18	49	49	1	30	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	DEC	2015	257						435	441		10.1016/j.forsciint.2015.10.021			7	Medicine, Legal	Legal Medicine	DA7VA	WOS:000368011500068	26583960	Green Accepted			2020-06-30	J	Fischer, B; Russell, C; Murphy, Y; Kurdyak, P				Fischer, Benedikt; Russell, Cayley; Murphy, Yoko; Kurdyak, Paul			Prescription opioids, abuse and public health in Canada: is fentanyl the new centre of the opioid crisis?	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Editorial Material							OVERDOSE DEATHS; TRENDS; MORTALITY; ANALGESICS; EPIDEMIC; ONTARIO; HARMS; FOCUS		[Fischer, Benedikt; Russell, Cayley; Murphy, Yoko; Kurdyak, Paul] Ctr Addict & Mental Hlth, Dept Social & Epidemiol Res, Toronto, ON M5S 2S1, Canada; [Fischer, Benedikt; Kurdyak, Paul] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Fischer, Benedikt; Kurdyak, Paul] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Fischer, Benedikt] Simon Fraser Univ, Fac Hlth Sci, Ctr Appl Res Mental Hlth & Addict, Vancouver, BC, Canada; [Kurdyak, Paul] Inst Clin Evaluat Sci, Toronto, ON, Canada	Fischer, B (reprint author), Univ Toronto, Ctr Addict & Mental Hlth CAMH, Dept Social & Epidemiol Res, 33 Russell St, Toronto, ON M5S 2S1, Canada.	benedikt.fischer@utoronto.ca		Fischer, B/0000-0002-2186-4030; Kurdyak, Paul/0000-0001-8115-7437	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [SAF-94814]		Burgmann T., 2015, GLOBE MAIL; Calcaterra S, 2013, DRUG ALCOHOL DEPEN, V131, P263, DOI 10.1016/j.drugalcdep.2012.11.018; Canadian Centre on Substance Abuse (CCSA), 2015, CCENDU B DEATHS VOLV; Carter A., 2014, CBC NEWS; Chief Coroner of Ontario, 2015, NUMB OP TOX DEATHS D; Cotter J., 2015, CTV NEWS; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Degenhardt L, 2005, ADDICTION, V100, P908, DOI 10.1111/j.1360-0443.2005.01094.x; Department of Health and Human Services, 2012, FENT PATCH MIS SER I; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Fischer B, 2015, PAIN PHYSICIAN, V18, pE659; Fischer B, 2015, DRUG-EDUC PREV POLIC, V22, P60, DOI 10.3109/09687637.2014.936827; Fischer B, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-90; Fischer B, 2014, DRUG ALCOHOL REV, V33, P19, DOI 10.1111/dar.12089; Fischer B, 2012, INT J DRUG POLICY, V23, P495, DOI 10.1016/j.drugpo.2012.07.008; Fischer B, 2012, PAIN PHYSICIAN, V15, pES191; Fishman SM, 2006, PHARMACOEPIDEM DR S, V15, P628, DOI 10.1002/pds.1292; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; International Narcotics Control Board (INCB), 2014, NARC DRUGS EST WORLD; Jones G., 2015, COMMUNICATION   0505; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; King NB, 2014, AM J PUBLIC HEALTH, V104, pE32, DOI 10.2105/AJPH.2014.301966; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Mastropietro DJ, 2013, DRUG DEV IND PHARM, V39, P611, DOI 10.3109/03639045.2012.680468; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Paulozzi LJ, 2006, AM J PREV MED, V31, P506, DOI 10.1016/j.amepre.2006.08.017; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Simonsen KW, 2015, FORENSIC SCI INT, V248, P172, DOI 10.1016/j.forsciint.2015.01.003; Talmazan Y., 2015, GLOBAL NEWS; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x	35	18	18	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	DEC	2015	24	12					1334	1336		10.1002/pds.3901			3	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	DA3CI	WOS:000367673100012	26502744				2020-06-30	J	Ruan, XL				Ruan, Xiulu			Iron Chelation in Thalassemia Major Caterina Borgna-Pignatti and Maria Marsella	CLINICAL THERAPEUTICS			English	Letter									[Ruan, Xiulu] Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesiol, New Orleans, LA 70112 USA	Ruan, XL (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesiol, New Orleans, LA 70112 USA.						Bista SR, 2015, CLIN THER, V37, P2468, DOI 10.1016/j.clinthera.2015.09.002; Deer TR, 2015, PAIN PHYSICIAN, V18, pE157; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Kowalczyk B, INSTABILITY STABLE D; REILLY CS, 1985, ANAESTHESIA, V40, P837, DOI 10.1111/j.1365-2044.1985.tb11043.x; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Upton RN, 2007, CLIN EXP PHARMACOL P, V34, P695, DOI 10.1111/j.1440-1681.2007.04649.x; Voigt I, 2013, CASE REP CRIT CARE, V2013, DOI 10.1155/2013/154143	8	1	1	0	4	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	DEC	2015	37	12					2880	2881		10.1016/j.clinthera.2015.11.003			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CZ9MF	WOS:000367421000025	26621629	Bronze			2020-06-30	J	Bista, SR; Haywood, A; Norris, R; Good, P; Tapuni, A; Lobb, M; Hardy, J				Bista, Sudeep R.; Haywood, Alison; Norris, Ross; Good, Phillip; Tapuni, Angela; Lobb, Michael; Hardy, Janet			Iron Chelation in Thalassemia Major	CLINICAL THERAPEUTICS			English	Letter									[Bista, Sudeep R.; Haywood, Alison; Norris, Ross] Griffith Univ, Sch Pharm, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia; [Bista, Sudeep R.; Haywood, Alison; Norris, Ross; Good, Phillip; Hardy, Janet] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia; [Bista, Sudeep R.; Haywood, Alison; Norris, Ross] St Vincents Hosp, SydPath, Sydney, NSW 2010, Australia; [Bista, Sudeep R.; Haywood, Alison; Norris, Ross] Univ New S Wales, St Vincents Clin Sch, Sydney, NSW, Australia; [Good, Phillip; Hardy, Janet] Mater Hlth Serv, Dept Palliat & Support Care, Brisbane, Qld, Australia; [Good, Phillip] St Vincents Private Hosp, Palliat Care, Brisbane, Qld, Australia; [Tapuni, Angela] Mater Hlth Serv, Dept Palliat & Support Care, Brisbane, Qld, Australia; [Lobb, Michael] Mater Pathol Serv, South Brisbane, Qld, Australia	Bista, SR (reprint author), Griffith Univ, Sch Pharm, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia.		Good, Phillip/B-4004-2008	Good, Phillip/0000-0002-8198-0375; Haywood, Alison/0000-0002-5354-8868			Bista SR, 2015, CLIN THER, V37, P2468, DOI 10.1016/j.clinthera.2015.09.002	1	5	5	0	2	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	DEC	2015	37	12					2882	2883		10.1016/j.clinthera.2015.11.002			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CZ9MF	WOS:000367421000026	26621625	Bronze			2020-06-30	J	Schaefer, JA; Mlekoday, TJ				Schaefer, Jared A.; Mlekoday, Tamara J.			Time to opioid administration after implementation of an intranasal fentanyl protocol	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							PEDIATRIC EMERGENCY-DEPARTMENT; RANDOMIZED CONTROLLED-TRIAL; PAIN MANAGEMENT; ACUTE ANALGESIA; CHILDREN; PHARMACOKINETICS; EFFICACY; MORPHINE	Background: Prompt and effective analgesia is a mainstay of emergency department (ED) medicine; however, it is often delayed in times of overcrowding and by the need to establish intravenous (IV) access. Thus, noninvasive analgesic administration by means of the intranasal route could potentially reduce time to analgesic administration by eliminating IV line insertion. Methods: This retrospective study evaluated time from physician entry into patient's room to opioid administration after implementation of an intranasal fentanyl protocol. Data were collected on pediatric patients who received intranasal fentanyl in the ED 225 days after protocol implementation. Time to opioid administration was then evaluated against historical controls given IV opioids in the same ED 90 days before protocol implementation. Results: Seven patients were included in the intranasal fentanyl group and were evaluated against 47 patients given IV opioids. Time from physician entry into patient's room to opioid administration was significantly reduced for intranasal fentanyl (20.43 +/- 11.54 minutes) vs IV opioids (42.04 +/- 31.55 minutes; P = .002), and IV line insertion was avoided in all 7 intranasal fentanyl patients. No significant differences in adverse events were noted. Conclusion: This study provides evidence that administration of fentanyl via the intranasal route in the ED decreases time to administration of opioids in pediatric patients. (C) 2015 Elsevier Inc. All rights reserved.	[Schaefer, Jared A.; Mlekoday, Tamara J.] INTEGRIS Baptist Med Ctr, Oklahoma City, OK 73112 USA	Schaefer, JA (reprint author), INTEGRIS Baptist Med Ctr, Oklahoma City, OK 73112 USA.	jared.a.schaefer@gmail.com; tamara.mlekoday@integrisok.com					Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Brown JC, 2003, ANN EMERG MED, V42, P197, DOI 10.1067/mem.2003.275; Casalino E, 2014, EMERG MED J, V31, P361, DOI 10.1136/emermed-2012-202155; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; MacLean S, 2007, PEDIATR EMERG CARE, V23, P87, DOI 10.1097/PEC.0b013e31803; Microsoft Office, 2010, MICR OFF 2010 EXC VE; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711	16	7	7	1	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	DEC	2015	33	12					1805	1807		10.1016/j.ajem.2015.08.050			3	Emergency Medicine	Emergency Medicine	CY1IC	WOS:000366158900018	26452510				2020-06-30	J	Wang, HT; Cai, YH; Liu, JC; Dong, Y; Lai, J				Wang, Haitang; Cai, Yehua; Liu, Jingchen; Dong, Yinv; Lai, Jian			Pain sensitivity: a feasible way to predict the intensity of stress reaction caused by endotracheal intubation and skin incision?	JOURNAL OF ANESTHESIA			English	Article						Pain sensitivity; Stress response; Intubation; Skin incision	COSMETIC DAY SURGERY; BODY-MASS INDEX; CEREBROSPINAL-FLUID; POSTOPERATIVE PAIN; SURGICAL STRESS; RISK PREDICTOR; ANESTHESIA; TOLERANCE; ANXIETY; PLASMA	Recent studies have shown that pain sensitivity has a significant relationship with clinical pain and may also predict the intensity of pain and analgesic consumption after surgery. However, the correlation between pre-operative pain sensitivity and stress response during anesthesia has not been investigated. Therefore, we aimed to explore the relationship between pre-operative pain sensitivity and stress responses during intubation and skin incision in this study. Fifty women (ASA I-II) aged 20-55 years, undergoing elective abdominal surgery requiring at least a 10-cm-long skin incision were studied. Pain sensitivity, including pain threshold and pain tolerance was measured before surgery. In this study, experimental pain was induced by potassium ion conducted via continuous current. When patients reported feeling pain or acted to stop pain, the intensity of the current was recorded to register pain threshold and pain tolerance. The State-Trait Anxiety Inventory (STAI) was used to examine the pre-operative mental status. General anesthesia was induced with intravenous fentanyl and a target-controlled infusion of propofol. Blood samples for norepinephrine (NE) detection were collected at 10 min after entering the operating theater, immediately before intubation, 2 min after intubation, immediately before skin incision and 2 min after incision. Mean arterial blood pressure (MAP) and heart rate (HR) were recorded at the same time. Pearson's correlation test (SPSS 13.0) was then used to analyze the relationship between pain sensitivity and the changes in MAP, HR and NE level. A total of fifty women were enrolled in the study. Their pre-operative pain threshold and pain tolerance were 0.90 +/- A 0.40 mA and 2.53 +/- A 0.77 mA,respectively. Changes in MAP, HR and NE before and after intubation or skin incision were significantly related with pre-operative pain tolerance (P < 0.05); however, pain threshold was not correlated with changes in MAP, HR and NE (P > 0.05). The STAI score did not correlate with the stress response either (P > 0.05). Pain tolerance had a significant relationship with stress response during intubation and skin incision. We may initially use pain tolerance to direct opioid usage in the future.	[Wang, Haitang; Dong, Yinv] Southern Med Univ, Nanfang Hosp, Dept Anesthesiol, Guangzhou 510515, Guangdong, Peoples R China; [Cai, Yehua] Southern Med Univ, Zhujiang Hosp, Dept Anesthesiol, Guangzhou 510515, Guangdong, Peoples R China; [Liu, Jingchen; Lai, Jian] Guangxi Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanning, Peoples R China	Wang, HT (reprint author), Southern Med Univ, Nanfang Hosp, Dept Anesthesiol, 1838 Guangzhoudadaobei, Guangzhou 510515, Guangdong, Peoples R China.	wanght1981@gmail.com					ARNTZ A, 1991, BEHAV RES THER, V29, P41, DOI 10.1016/S0005-7967(09)80006-5; Coghill R, 2001, NEUROIMAGE, V13, pS873; De Cosmo G, 2008, CLIN J PAIN, V24, P399, DOI 10.1097/AJP.0b013e3181671a08; de Jong RH, 2001, PLAST RECONSTR SURG, V108, P556, DOI 10.1097/00006534-200108000-00044; de Jong RH, 2001, PLAST RECONSTR SURG, V108, P562; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Duschek S, 2008, J PSYCHOPHYSIOL, V22, P20, DOI 10.1027/0269-8803.22.1.20; Edwards RR, 2006, ANESTHESIOLOGY, V104, P1243, DOI 10.1097/00000542-200606000-00020; Edwards RR, 2001, PSYCHOSOM MED, V63, P316, DOI 10.1097/00006842-200103000-00018; Granot M, 2003, ANESTHESIOLOGY, V98, P1422, DOI 10.1097/00000542-200306000-00018; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; HAMBERGER B, 1983, ACTA ANAESTH SCAND, V27, P307, DOI 10.1111/j.1399-6576.1983.tb01957.x; James JE, 2002, BRIT J HEALTH PSYCH, V7, P149, DOI 10.1348/135910702169411; Jones Allan, 2002, J Am Med Womens Assoc (1972), V57, P91; KANTO J, 1991, BRIT J ANAESTH, V66, P587, DOI 10.1093/bja/66.5.587; KONO K, 1981, ANESTH ANALG, V60, P552; Ledowski T, 2010, ANAESTHESIA, V65, P1001, DOI 10.1111/j.1365-2044.2010.06480.x; Lund Irene, 2005, Physiotherapy Theory and Practice, V21, P81, DOI 10.1080/09593980590922307; Mitchell S, 2003, OCCUP ENVIRON MED, V60, P217, DOI 10.1136/oem.60.3.217; Munafo MR, 2001, J PSYCHOSOM RES, V51, P589, DOI 10.1016/S0022-3999(01)00258-6; Nie YY, 2014, EUR J ANAESTH, V31, P197, DOI 10.1097/EJA.0000000000000011; Oehmke MJ, 2008, ACTA ANAESTH SCAND, V52, P487, DOI 10.1111/j.1399-6576.2007.01551.x; Ozalp G, 2003, ACTA ANAESTH SCAND, V47, P26, DOI 10.1034/j.1399-6576.2003.470105.x; PARKER SD, 1995, CRIT CARE MED, V23, P1954, DOI 10.1097/00003246-199512000-00003; PHILBIN DM, 1990, ANESTHESIOLOGY, V73, P5, DOI 10.1097/00000542-199007000-00002; ROSA C, 1988, CLIN EXP HYPERTENS A, V10, P383, DOI 10.3109/10641968809075994; Salinas AS, 1999, UROL INT, V63, P92, DOI 10.1159/000030425; Tao KM, 2014, ANESTHESIOLOGY, V121, P127, DOI 10.1097/ALN.0000000000000210; Thompson T, 2008, PAIN, V134, P187, DOI 10.1016/j.pain.2007.04.018; Zheng Z, 2005, SHANGHAI ARCH PSYCHI, V17, P331	30	3	4	0	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2015	29	6					904	911		10.1007/s00540-015-2040-x			8	Anesthesiology	Anesthesiology	CY1GX	WOS:000366155800015	26187542				2020-06-30	J	Guitart, J; Vargas, MI; De Sanctis, V; Folch, J; Salazar, R; Fuentes, J; Coma, J; Ferreras, J; Moya, J; Tomas, A; Estivill, P; Rodelas, F; Jimenez, AJ				Guitart, Jordi; Isabel Vargas, Maria; De Sanctis, Vicente; Folch, Jordi; Salazar, Rafael; Fuentes, Jose; Coma, Jordi; Ferreras, Julia; Moya, Jordi; Tomas, Albert; Estivill, Pere; Rodelas, Francisco; Javier Jimenez, Antonio			Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes	CLINICAL DRUG INVESTIGATION			English	Article							FORM HEALTH SURVEY; HOSPITAL ANXIETY; DEPRESSION SCALE; PREVALENCE; EFFICACY; SAFETY; TOLERABILITY	Background and Objective Breakthrough pain (BTP) is highly prevalent in patients with cancer and is strongly associated with adverse outcomes related to health status, mood, anxiety and depression. However, studies on the effect of BTP medication on quality of life (QOL) are lacking. The purpose of this study was to provide a qualitative evaluation of the effect of sublingual fentanyl tablets (SFT), a therapy specifically developed for BTP, on the QOL of cancer pain patients. Methods We conducted a multicentre, prospective observation post-authorisation, open-label study between March and December 2013. The study consisted of a screening visit and four assessment points at 3, 7, 15 and 30 days. Pain intensity (PI), frequency of BTP, onset of pain relief and adverse events (AEs) were assessed at each visit. Anxiety and depression were evaluated using the validated Hospital Anxiety and Depression Scale (HADS) and health status using the Short Form 12, version 2 (SF-12v2) Health Survey. Results Of the 102 patients considered eligible, 81 (79.4 %) were enrolled; of these, 69 (85.1 %) completed the study. Significant pain reduction was achieved for average PI (p < 0.001) compared with baseline. At the end of the observational period, HADS scores showed significant improvement in the depression subscale (p = 0.005) and the anxiety subscale (p < 0.001). Similarly, SF-12 scores showed significant improvement, both in the mental component score (p < 0.001) and the physical component score (p = 0.002). SFT was well-tolerated and only one patient withdrew from the study due to drug-related AEs. Conclusion SFT represents an effective, well-tolerated treatment for cancer BTP. Results provide consistent evidence for the positive impact of SFT on health-related QOL and physical functioning as well as other co-morbidities of cancer BTP such as anxiety and depression.	[Guitart, Jordi; Folch, Jordi] Hosp Plato, Dept Anesthesiol, Barcelona 08006, Spain; [Isabel Vargas, Maria; Estivill, Pere] Parc Sanitari Sant Joan de Deu, Dept Anesthesiol, Barcelona, Spain; [De Sanctis, Vicente] Hosp Univ Sagrat Cor, Pain Unit, Dept Anesthesiol, Barcelona, Spain; [Salazar, Rafael; Rodelas, Francisco] Hosp Comarcal Inca, Dept Anesthesiol, Palma De Mallorca, Spain; [Fuentes, Jose] Pius Hosp Valls, Dept Anesthesiol, Tarragona, Spain; [Coma, Jordi] Hosp Gen Hosp, Dept Anesthesiol, Barcelona, Spain; [Ferreras, Julia] Hosp Residencia St Camil, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Moya, Jordi] Hosp Mateu Orfila, Pain Unit, Dept Anesthesiol, Minorca, Spain; [Tomas, Albert] Fundacio Hosp St Bernabe, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Javier Jimenez, Antonio] Lab ProStrakan SLU, Madrid, Spain	Guitart, J (reprint author), Hosp Plato, Dept Anesthesiol, C Plato 21, Barcelona 08006, Spain.	jordi.guitart@hospitalplato.com			ProStrakan SLU	The clinical study was sponsored by ProStrakan SLU. Medical writing and editorial assistance were provided by M.J. Sanchez and were funded by ProStrakan SLU. The authors received research funding from ProStrakan SLU for this study.	Bennett SJ, 2003, NURS RES, V52, P207, DOI 10.1097/00006199-200307000-00001; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Canovas-Martinez L, 2015, CLIN DRUG INVEST, V35, P169, DOI 10.1007/s40261-015-0268-8; Cohen J, 1988, STAT POWER ANAL BEHA; Davies A, 2015, SUPPORT CARE CANCER, V23, P2135, DOI 10.1007/s00520-014-2590-8; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Elsner F, 2011, CLIN DRUG INVEST, V31, P605, DOI 10.2165/11592910-000000000-00000; England Ruth, 2011, BMJ Support Palliat Care, V1, P349, DOI 10.1136/bmjspcare-2011-000037; Guitart J, 2013, CLIN DRUG INVEST, V33, P675, DOI 10.1007/s40261-013-0111-z; Herrero MJ, 2003, GEN HOSP PSYCHIAT, V25, P277, DOI 10.1016/S0163-8343(03)00043-4; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Nalamachu S, 2013, PAIN THER, V2, P121, DOI 10.1007/s40122-013-0019-6; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; Narayana A, 2015, PAIN, V156, P252, DOI 10.1097/01.j.pain.0000460305.41078.7d; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Schmidt S, 2012, MED CLIN-BARCELONA, V139, P613, DOI 10.1016/j.medcli.2011.10.024; Simon Steven M, 2014, J Opioid Manag, V10, P207, DOI 10.5055/jom.2014.0209; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; Torres LM, 2014, J PALLIAT MED, V17, P1150, DOI 10.1089/jpm.2014.0089; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Ware J. E., 2002, USERS MANUAL SF 12V2; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Webster Lynn R, 2011, J Opioid Manag, V7, P297; Zeppetella G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub3; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	8	13	0	6	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	DEC	2015	35	12					815	822		10.1007/s40261-015-0344-0			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CX2TR	WOS:000365550200005	26507617				2020-06-30	J	Bucher, J; Koyfman, A				Bucher, Joshua; Koyfman, Alex			INTUBATION OF THE NEUROLOGICALLY INJURED PATIENT	JOURNAL OF EMERGENCY MEDICINE			English	Article						airway management; intracerebral hemorrhage; neurologically injured patients; rapid sequence intubation; traumatic brain injury	RAPID-SEQUENCE INTUBATION; CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID PRESSURE; CRITICALLY-ILL PATIENTS; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; ENDOTRACHEAL INTUBATION; TRACHEAL INTUBATION; HEMODYNAMIC-RESPONSES	Background: Intubation of the neurologically injured patient is a critical procedure that must be done in a manner to prevent further neurologic injury. Although many different medications and techniques have been used to meet specific needs, there is little to no evidence to support many claims. Objective: To review the literature regarding important topics relating to intubating patients with neurologic injury. Discussion: Airway management requires ideal preoxygenation and airway maneuvers to minimize manipulation of the larynx and to maximize first-pass success. There is no evidence that lidocaine pretreatment decreases intracerebral pressure (ICP). Fentanyl can be used to help blunt the hemodynamic response to intubation. Esmolol is another medication that can blunt the hemodynamic response. Ketamine can be used and is possibly the ideal agent, having a neutral hemodynamic profile. A prefasciculation dose for neuromuscular blockade has not been shown to have any effect on ICP. Conclusions: Ideal intubation conditions should be obtained through the use of airway manipulation techniques and appropriate medication choice for rapid sequence intubation in patients who are neurologically injured. (C) 2015 Elsevier Inc.	[Bucher, Joshua] Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA; [Koyfman, Alex] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA	Bucher, J (reprint author), Rutgers Robert Wood Johnson Med Sch, Dept Emergency Med, 1 RWJ Plaza MEB 103, New Brunswick, NJ 08901 USA.			Bucher, Joshua/0000-0003-2761-3387			Abbasivash R, 2014, J CLIN ANESTH, V26, P628, DOI 10.1016/j.jclinane.2014.05.014; Adachi YU, 2002, ANESTH ANALG, V95, P233, DOI 10.1097/00000539-200207000-00043; Agbeko RS, 2012, PEDIATR CRIT CARE ME, V13, pE39, DOI 10.1097/PCC.0b013e31820ac2ad; Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; Baillard C, 2006, AM J RESP CRIT CARE, V174, P171, DOI 10.1164/rccm.200509-1507OC; Blissitt PA, 2006, AM J CRIT CARE, V15, P206; Bourgoin A, 2005, CRIT CARE MED, V33, P1109, DOI 10.1097/01.CCM.0000162491.26292.98; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; Brezina A, 2010, PHYSIOL RES, V59, P703; Brown MM, 1996, EUR J ANAESTH, V13, P474, DOI 10.1046/j.1365-2346.1996.00973.x; Caricato A, 2013, CRIT CARE, V17, DOI 10.1186/cc13097; Cheung AT, 1999, ANESTH ANALG, V89, P1116, DOI 10.1213/00000539-199911000-00008; CHUNG KS, 1992, CAN J ANAESTH, V39, P774, DOI 10.1007/BF03008287; Clancy M, 2001, EMERG MED J, V18, P373, DOI 10.1136/emj.18.5.373; Cohen L, 2015, ANN EMERG MED, V65, P43, DOI 10.1016/j.annemergmed.2014.06.018; CORK RC, 1984, ANESTH ANALG, V63, P60; Curran MP, 2006, DRUGS, V66, P1755, DOI 10.2165/00003495-200666130-00010; DAHLGREN N, 1981, ANAESTHESIA, V36, P1022, DOI 10.1111/j.1365-2044.1981.tb08676.x; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Dixon BJ, 2005, ANESTHESIOLOGY, V102, P1110, DOI 10.1097/00000542-200506000-00009; El-Khatib ME, 2007, CAN J ANAESTH, V54, P744, DOI 10.1007/BF03026871; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Feng C K, 1996, Acta Anaesthesiol Sin, V34, P61; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; Garg K, 2013, J CLIN DIAGN RES, V7, P2548, DOI 10.7860/JCDR/2013/6860.3607; GIBBS JM, 1972, BRIT J ANAESTH, V44, P1298, DOI 10.1093/bja/44.12.1298; GOLD MI, 1986, ANESTHESIOLOGY, V64, P718, DOI 10.1097/00000542-198606000-00007; Gregoretti C, 1998, INTENS CARE MED, V24, P785, DOI 10.1007/s001340050666; Gurulingappa, 2012, J CLIN DIAGN RES, V6, P1749, DOI 10.7860/JCDR/2012/4070.2619; Habibi Mohammad Reza, 2014, J Clin Diagn Res, V8, pGC01, DOI 10.7860/JCDR/2014/10237.5006; Hamaya Y, 2000, ANESTHESIOLOGY, V93, P95, DOI 10.1097/00000542-200007000-00018; HASSAN HG, 1991, ACTA ANAESTH SCAND, V35, P442, DOI 10.1111/j.1399-6576.1991.tb03325.x; Hassani Valiallah, 2013, Anesth Pain Med, V2, P115, DOI 10.5812/aapm.6442; Hayakawa-Fujii Y, 2001, J Anesth, V15, P191, DOI 10.1007/s005400170001; HELFMAN SM, 1991, ANESTH ANALG, V72, P482; Hosseinzadeh H, 2013, J CARDIOVASC THORAC, V5, P51, DOI 10.5681/jcvtr.2013.011; Hovda DA, 2006, CRIT CARE MED, V35, P663, DOI 10.1097/01.CCM.0000254442.66789.52; Jabre P, 2009, LANCET, V374, P293, DOI 10.1016/S0140-6736(09)60949-1; KOENIG KL, 1992, ANN EMERG MED, V21, P929, DOI 10.1016/S0196-0644(05)82930-0; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; KORPINEN R, 1995, CAN J ANAESTH, V42, P298, DOI 10.1007/BF03010706; KOVARIK WD, 1994, ANESTH ANALG, V78, P469; Lin CC, 2012, AM J EMERG MED, V30, P1782, DOI 10.1016/j.ajem.2012.02.013; Lopera JL, 2006, AM J RESP CRIT CARE, V174, P1274, DOI 10.1164/ajrccm.174.11.1274; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; McSwain NE, 2004, J TRAUMA, V57, P8; MINTON MD, 1986, ANESTHESIOLOGY, V65, P165, DOI 10.1097/00000542-198608000-00006; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Monro A, 1783, OBSERVATIONS STRUCTU; Moon YE, 2012, J CLIN ANESTH, V24, P8, DOI 10.1016/j.jclinane.2010.12.010; Mort TC, 2005, CRIT CARE MED, V33, P2672, DOI 10.1097/01.CCM.0000187131.67594.9E; Mort TC, 2009, CRIT CARE MED, V37, P68, DOI 10.1097/CCM.0b013e318192845e; Nishimura M, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0084-5; Perkins ZB, 2013, J TRAUMA ACUTE CARE, V74, P1074, DOI 10.1097/TA.0b013e3182827305; Pouraghaei Mahboob, 2014, Anesth Pain Med, V4, pe14618, DOI 10.5812/aapm.14618; Price B, 2013, AM J EMERG MED, V31, P1124, DOI 10.1016/j.ajem.2013.03.041; Prys-Roberts C, 1998, BRIT J ANAESTH, V80, P106; Prys-Roberts C, 1998, BRIT J ANAESTH, V80, P104; Robinson N, 2001, EMERG MED J, V18, P453, DOI 10.1136/emj.18.6.453; Schmittner MD, 2007, J NEUROSURG ANESTH, V19, P257, DOI 10.1097/ANA.0b013e31811f3feb; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; SINGH H, 1995, J CLIN ANESTH, V7, P5, DOI 10.1016/0952-8180(94)00013-T; STRANDGAARD S, 1989, AM J HYPERTENS, V2, P486, DOI 10.1093/ajh/2.6.486; Ugur B, 2007, CLIN DRUG INVEST, V27, P269, DOI 10.2165/00044011-200727040-00006; Walz M, 1998, UNFALLCHIRURG, V101, P527, DOI 10.1007/s001130050305; Wang X, 2014, J ANESTH, V28, P821, DOI 10.1007/s00540-014-1845-3; Weingart SD, 2015, ANN EMERG MED, V65, P349, DOI 10.1016/j.annemergmed.2014.09.025; Weingart SD, 2012, ANN EMERG MED, V59, P165, DOI 10.1016/j.annemergmed.2011.10.002; WIEBER J, 1975, ANAESTHESIST, V24, P260; Wimalasena Y, 2015, ANN EMERG MED, V65, P371, DOI 10.1016/j.annemergmed.2014.11.014; Wright D, 2011, TINTINALLIS EMERGENC, P1692; Zhang GH, 2009, CHINESE MED J-PEKING, V122, P2330, DOI 10.3760/cma.j.issn.0366-6999.2009.19.026	72	7	7	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	DEC	2015	49	6					920	927		10.1016/j.jemermed.2015.06.078			8	Emergency Medicine	Emergency Medicine	CX0TC	WOS:000365408800028	26416129				2020-06-30	J	Patel, R; Clayton, S; Quintero, E; Gill, J				Patel, Rupal; Clayton, Steven; Quintero, Eduardo; Gill, Jeffrey			Chronic Opioid Users Are More Difficult to Sedate than Alcoholics and Controls	SOUTHERN MEDICAL JOURNAL			English	Article						colonoscopy; conscious sedation; substance abuse	COLONOSCOPY	Objectives Diagnostic and therapeutic colonoscopy is performed using conscious sedation. Excessive alcohol users, chronic benzodiazepine and opioid users, and polysubstance users are commonly cited as difficult to sedate. Few studies have compared and analyzed medication dosages to achieve sedation in these groups. Methods The endoscopic database was searched for patients who underwent colonoscopy. A retrospective chart review was performed to determine whether each patient was an abuser/chronic user of opioids, benzodiazepines, marijuana, alcohol, or a combination of the above. The mean dose of fentanyl and versed administered in each group was compared. Results A total of 239 patients were enrolled. Compared with the alcohol and control groups, the opioid group used a statistically higher mean medication dosage to achieve sedation. The mean dose of fentanyl in the opioid group was 124 g, the mean dose in the alcohol group was 101 g, and the mean dose in the control group was 101 g. The mean dose of midazolam in the opioid group was 4.1 mg, the mean dose in the alcohol group was 3.3 mg, and the mean dose in the control group was 3.3 mg. Conclusions Identifying patients who are difficult to sedate before colonoscopy is important because adequate sedation is associated with better adenoma detection, a better procedural completion rate, and patient satisfaction. In patients using daily opioids, it is important to anticipate the need for higher doses of medication to achieve adequate sedation.	Univ S Florida, Dept Internal Med, Tampa, FL 33620 USA; Univ S Florida, Dept Gastroenterol, Tampa, FL 33620 USA; Univ S Carolina, Dept Gastroenterol, Greenville, SC USA	Patel, R (reprint author), Univ S Florida, Tampa, FL 33620 USA.	rpatel19@health.usf.edu					COOK PJ, 1984, BRIT MED J, V289, P351, DOI 10.1136/bmj.289.6441.351; de Wit Marjolein, 2007, BMC Anesthesiol, V7, P3, DOI 10.1186/1471-2253-7-3; Department of Veterans Affairs, QUICK FACTS; Eberl S, 2014, TECH COLOPROCTOL, V18, P745, DOI 10.1007/s10151-014-1188-y; Eberl S, 2012, TECH COLOPROCTOL, V16, P271, DOI 10.1007/s10151-012-0834-5; Eisen GM, 2000, GASTROINTEST ENDOSC, V51, P777, DOI 10.1053/ge.2000.v51.age516777; Green BB, 2014, AM J PUBLIC HEALTH, V104, P982, DOI 10.2105/AJPH.2014.301877; Inadomi JM, 2010, GASTROINTEST ENDOSC, V72, P580, DOI 10.1016/j.gie.2010.04.040; Jamison RN, 2015, MAYO CLIN PROC, V90, P957, DOI 10.1016/j.mayocp.2015.04.010; Kelly JP, 2008, PAIN, V138, P507, DOI 10.1016/j.pain.2008.01.027; *NIH, ALC US ALC US DIS US; Osborn Timothy M, 2004, Anesth Prog, V51, P46; Radaelli F, 2008, AM J GASTROENTEROL, V103, P1122, DOI 10.1111/j.1572-0241.2007.01778.x; Rex D K, 2000, Gastrointest Endosc Clin N Am, V10, P135; Saper JR, 2010, HEADACHE, V50, P1175, DOI 10.1111/j.1526-4610.2010.01733.x; Substance Abuse and Mental Health Services Administration, SUBST US MENT HLTH E; Vijan S, 2004, ALIMENT PHARM THERAP, V20, P507, DOI 10.1111/j.1365-2036.2004.01960.x; Zandstra SM, 2002, SOC PSYCH PSYCH EPID, V37, P139, DOI 10.1007/s001270200006	18	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0038-4348	1541-8243		SOUTH MED J	South.Med.J.	DEC	2015	108	12					744	747		10.14423/SMJ.0000000000000384			4	Medicine, General & Internal	General & Internal Medicine	CX5AF	WOS:000365711800011	26630896				2020-06-30	J	McPherson, C; Haslam, M; Pineda, R; Rogers, C; Neil, JJ; Inder, TE				McPherson, Christopher; Haslam, Matthew; Pineda, Roberta; Rogers, Cynthia; Neil, Jeffrey J.; Inder, Terrie E.			Brain Injury and Development in Preterm Infants Exposed to Fentanyl	ANNALS OF PHARMACOTHERAPY			English	Article						premature infant; magnetic resonance imaging; neonatal intensive care; analgesics; opioid analgesics	INTENSIVE-CARE-UNIT; MEDICATION USE; IN-VITRO; MORPHINE; INFUSION; RISK; PAIN; ANALGESIA; OUTCOMES; TRIAL	Background: Fentanyl is commonly used in preterm infants. Relatively little is known regarding the neurodevelopmental outcomes of preterm infants exposed to fentanyl. Objective: To investigate the association between cumulative fentanyl dose and brain injury and diameters in a cohort of preterm infants. Methods: Data on demographics, perinatal course, and neonatal course, including total fentanyl exposure prior to term equivalent age, were retrospectively evaluated for 103 infants born at 30 weeks gestational age (mean gestational age 26.9 +/- 1.8 weeks) who underwent magnetic resonance imaging at term equivalent age. Magnetic resonance images were evaluated for brain injury and regional brain diameters. Developmental testing was conducted at term equivalent and 2 years of age. Results: Seventy-eight infants (76%) received fentanyl (median cumulative dose 3 mu g/kg, interquartile range 1-441 mu g/kg). Cumulative fentanyl dose in the first week of life correlated with the incidence of cerebellar hemorrhage after correction for covariates (odds ratio 2.1, 95% confidence interval 1.1-4.1). Cumulative fentanyl dose before term equivalent age correlated with reductions in transverse cerebellar diameter after correction for covariates, including the presence of cerebellar hemorrhage (r = 0.461, P = 0.002). No correlation was detected between cumulative fentanyl dose and development at 2 years of age. Conclusions: Higher cumulative fentanyl dose in preterm infants correlated with a higher incidence of cerebellar injury and lower cerebellar diameter at term equivalent age. Our findings must be taken with caution, but emphasize the need for future prospective trials examining the risks and benefits of commonly used analgesic agents in preterm infants.	[McPherson, Christopher; Inder, Terrie E.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Haslam, Matthew; Pineda, Roberta; Rogers, Cynthia] Washington Univ, Sch Med, St Louis, MO USA; [Neil, Jeffrey J.] Boston Childrens Hosp, Boston, MA USA	McPherson, C (reprint author), Brigham & Womens Hosp, Dept Pediat Newborn Med, 75 Francis St,CWN418, Boston, MA 02115 USA.	ccmcpherson@partners.org	Rogers, Cynthia/O-1466-2017	Rogers, Cynthia/0000-0001-6251-8436; Haslam, Matthew/0000-0001-5922-9334	National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD057098]; Intellectual and Developmental Disabilities Research Center at Washington University [NIH/NICHD P30 HD062171]; Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF)	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institute of Child Health and Development (R01 HD057098); the Intellectual and Developmental Disabilities Research Center at Washington University (NIH/NICHD P30 HD062171); and the Doris Duke Charitable Foundation.	Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; Clark RH, 2006, PEDIATRICS, V117, P1979, DOI 10.1542/peds.2005-1707; Durrmeyer X, 2010, PEDIATR RES, V67, P117, DOI 10.1203/PDR.0b013e3181c8eef3; Engelhardt E, 2015, ANN NEUROL, V77, P154, DOI 10.1002/ana.24313; Fitzgerald M, 2005, NAT REV NEUROSCI, V6, P507, DOI 10.1038/nrn1701; Garel C., 2004, MR IMAGING FETAL BRA; Golalipour MJ, 2012, ANAT CELL BIOL, V45, P121, DOI 10.5115/acb.2012.45.2.121; Grunau RE, 2006, SEMIN FETAL NEONAT M, V11, P268, DOI 10.1016/j.siny.2006.02.007; HAMMER RP, 1989, NEUROTOXICOLOGY, V10, P475; Harris SR, 2005, DEV MED CHILD NEUROL, V47, P820, DOI 10.1017/S0012162205001738; Hauser KF, 1998, EXP NEUROL, V151, P70, DOI 10.1006/exnr.1998.6788; Hauser KF, 2000, EUR J NEUROSCI, V12, P1281, DOI 10.1046/j.1460-9568.2000.01015.x; HAUSER KF, 1994, EXP NEUROL, V130, P95, DOI 10.1006/exnr.1994.1188; Kidokoro H, 2013, AM J NEURORADIOL, V34, P2208, DOI 10.3174/ajnr.A3521; Kumar P, 2008, J PEDIATR, V152, P412, DOI 10.1016/j.jpeds.2007.07.050; Lago P, 1998, ARCH DIS CHILD-FETAL, V79, pF194, DOI 10.1136/fn.79.3.F194; Lammers EM, 2014, ANN PHARMACOTHER, V48, P335, DOI 10.1177/1060028013514026; Limperopoulos C, 2005, PEDIATRICS, V116, P717, DOI 10.1542/peds.2005-0556; McPherson C, 2015, PEDIATR RES, V78, P198, DOI 10.1038/pr.2015.72; Miall Lawrence S, 2003, J Perinatol, V23, P396, DOI 10.1038/sj.jp.7210941; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; STEELE WJ, 1975, ACTA PHARMACOL TOX, V37, P265; Thompson DK, 2007, BRAIN, V130, P667, DOI 10.1093/brain/awl277; Tich SNT, 2009, AM J NEURORADIOL, V30, P125, DOI 10.3174/ajnr.A1309; Volpe JJ, 2009, J CHILD NEUROL, V24, P1085, DOI 10.1177/0883073809338067; ZAGON IS, 1977, PHARMACOLOGY, V15, P276, DOI 10.1159/000136699; Zwicker JG, 2012, PED AC SOC ANN M APR	29	21	23	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	DEC	2015	49	12					1291	1297		10.1177/1060028015606732			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CW5KI	WOS:000365033900003	26369570	Green Accepted			2020-06-30	J	Choi, YJ; Park, SW; Kwon, HJ; Choi, JM; Lee, YM				Choi, Yoon-Ji; Park, Sang-Wook; Kwon, Hyun-Jung; Choi, Jae-Moon; Lee, Yu-Mi			Efficacy of early intravenous bolus oxycodone or fentanyl in emergence from general anaesthesia and postoperative analgesia following laparoscopic cholecystectomy: A randomized trial	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Oxycodone; postoperative pain; laparoscopic cholecystectomy	ABDOMINAL-SURGERY; LYSINE ACETYLSALICYLATE; LOCAL-ANESTHETICS; CANCER PAIN; LIDOCAINE; MORPHINE; PHARMACOKINETICS; REMIFENTANIL; DICLOFENAC; MAGNESIUM	Objectives To compare prospectively the efficacy of early intravenous bolus of oxycodone or fentanyl in providing analgesia at emergence from general anaesthesia following laparoscopic cholecystectomy. Methods Patients were randomly assigned to receive either 0.08mg/kg oxycodone (Group O) or 1 mu g/kg fentanyl (Group F), 20min before the end of surgery. Postoperative pain was evaluated using a visual analogue scale (VAS). The time to first postoperative analgesic dose, requirement for analgesia and side-effects were assessed in the postanaesthesia care unit (PACU). Results The VAS scores at 0min and 30min and requirement for analgesia were significantly lower in Group O (n=28) than in Group F (n=26). The time to first analgesia dose was significantly longer in Group O than Group F. There were no significant between-group differences in the incidence of side-effects. Conclusions Oxycodone relieves immediate postoperative pain significantly better than fentanyl, and is not associated with an increase in side-effects in patients undergoing laparoscopic cholecystectomy.	[Choi, Yoon-Ji] Seoul Natl Univ, Dent Hosp, Dept Dent Anaesthesiol, Seoul, South Korea; [Park, Sang-Wook; Kwon, Hyun-Jung; Choi, Jae-Moon; Lee, Yu-Mi] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anaesthesiol & Pain Med, Seoul 138736, South Korea	Lee, YM (reprint author), Univ Ulsan, Coll Med, Dept Anaesthesiol & Pain Med, Asan Med Ctr 88,Olymp Ro 43 Gil, Seoul 138736, South Korea.	ylee@amc.seoul.kr		Choi, Jae Moon/0000-0002-1161-6586			American Society of Anesthesiologists, 2014, PHYS STAT CLASS SYST; Bhaskar SB, 2013, INDIAN J ANAESTH, V57, P1, DOI 10.4103/0019-5049.108549; Chung F, 1997, ANESTH ANALG, V85, P808, DOI 10.1097/00000539-199710000-00017; Coluzzi F, 2005, Minerva Anestesiol, V71, P451; Dirks J, 2000, ANESTH ANALG, V91, P967, DOI 10.1097/00000539-200010000-00037; EDWARDS ND, 1991, ANAESTHESIA, V46, P1077, DOI 10.1111/j.1365-2044.1991.tb09930.x; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Gallego AO, 2007, CLIN TRANSL ONCOL, V9, P298, DOI 10.1007/s12094-007-0057-9; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; JORIS J, 1995, ANESTH ANALG, V81, P379, DOI 10.1097/00000539-199508000-00029; KALSO E, 1991, ACTA ANAESTH SCAND, V35, P642, DOI 10.1111/j.1399-6576.1991.tb03364.x; Kim Dal Yong, 2009, Korean J Anesthesiol, V57, P327, DOI 10.4097/kjae.2009.57.3.327; Kim SH, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00108; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; Koppert W, 2004, ANESTH ANALG, V98, P1050, DOI 10.1213/01.ANE.0000104582.71710.EE; KORTTILA K, 1980, BRIT J ANAESTH, V52, P613, DOI 10.1093/bja/52.6.613; Lee B, 2009, BRIT J ANAESTH, V102, P775, DOI 10.1093/bja/aep090; LEOW KP, 1995, ANESTH ANALG, V80, P296, DOI 10.1097/00000539-199502000-00016; Lepner U, 2003, Scand J Surg, V92, P121; Loizides S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007049.pub2; Michaloliakou C, 1996, ANESTH ANALG, V82, P44, DOI 10.1097/00000539-199601000-00009; MORRISON JD, 1971, BMJ-BRIT MED J, V3, P287, DOI 10.1136/bmj.3.5769.287; NUUTINEN LS, 1986, ACTA ANAESTH SCAND, V30, P620, DOI 10.1111/j.1399-6576.1986.tb02487.x; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; POYHIA R, 1991, BRIT J CLIN PHARMACO, V32, P516, DOI 10.1111/j.1365-2125.1991.tb03942.x; Saadawy IM, 2010, ACTA ANAESTH SCAND, V54, P549, DOI 10.1111/j.1399-6576.2009.02165.x; Soares LGL, 2003, J PAIN SYMPTOM MANAG, V26, P876, DOI 10.1016/S0885-3924(03)00314-2; Staahl C, 2006, PAIN, V123, P28, DOI 10.1016/j.pain.2006.02.006; Sugimoto M, 2003, BRIT J PHARMACOL, V138, P876, DOI 10.1038/sj.bjp.0705107; TAMMISTO T, 1980, ANN CHIR GYNAECOL FE, V69, P287; TIGERSTEDT I, 1981, ACTA ANAESTH SCAND, V25, P543, DOI 10.1111/j.1399-6576.1981.tb01702.x; URE BM, 1994, SURG ENDOSC-ULTRAS, V8, P90, DOI 10.1007/BF00316616; Wallace DH, 1997, BRIT J SURG, V84, P455; Wilding JR, 2009, J PERIANESTH NURS, V24, P233, DOI 10.1016/j.jopan.2009.03.013	34	3	8	1	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	DEC	2015	43	6					809	818		10.1177/0300060515594194			10	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	CY7MK	WOS:000366592500009	26378067	DOAJ Gold			2020-06-30	J	Chen, Z; Lin, S; Shao, W				Chen, Z.; Lin, S.; Shao, W.			Effects on somatosensory and motor evoked potentials of senile patients using different doses of dexmedetomidine during spine surgery	IRISH JOURNAL OF MEDICAL SCIENCE			English	Article						Anesthesia; General; Senile; Intravenous; Evoked potentials; Medetomidine; Propofol	BISPECTRAL INDEX; ANESTHESIA	The aim of this study was to evaluate the effects of different doses of dexmedetomidine (Dex) compounded propofol and fentanyl on intraoperative somatosensory evoked potential (SEP) and motor evoked potential (MEP) monitoring on senile patients. Forty-five patients undergoing elective spinal surgery were randomly divided into three groups: group C, group D-1 (Dex, 0.3 mu g kg(-1) h(-1)), and group D-2 (Dex, 0.8 mu g kg(-1) h(-1)). Anesthesia administration: midazolam, propofol, fentanyl, and cisatracurium. Anesthesia maintenance: propofol and fentanyl. No muscle relaxant was used throughout the operation. When muscle relaxation was T (4)/T (1) > 75 %, SEPs and MEPs were monitored for the baseline. In group D-1, Dex (0.3 mu g/kg, loading dose) was administered, followed by a 0.3 mu g kg(-1) h(-1) infusion of said drug until the end of surgery. In group D-2, Dex (0.8 mu g/kg, loading dose) was injected, followed by a 0.8 mu g kg(-1) h(-1) infusion of said drug. Compared with group C, no significant difference was observed in the amplitude and latency of SEP (P-15-N-20) waves in groups D-1 and D-2 (P > 0.05). In groups C and D-1, the MEP waveform did not disappear at every stage. In group D-2, three patients lost the MEP waveform after the Dex loading dose, while four patients lost it during the Dex infusion stage. A significant difference was observed between groups C and D-1. The median time to recover the MEP waveform was 47 min. Dex did not affect SEPs of senile patients, but inhibited MEPs when larger doses were administered.	[Chen, Z.; Lin, S.; Shao, W.] Yantaishan Hosp, Dept Anesthesiol, Yantai 264001, Peoples R China	Lin, S (reprint author), Yantaishan Hosp, Dept Anesthesiol, 91 Jiefang Rd, Yantai 264001, Peoples R China.	linsheng760401@163.com					American Clinical Neurophysiology Society, 2006, Am J Electroneurodiagnostic Technol, V46, P240; American Clinical Neurophysiology Society, 2006, Am J Electroneurodiagnostic Technol, V46, P301; American Clinical Neurophysiology Society, 2006, Am J Electroneurodiagnostic Technol, V46, P287; Bala E, 2008, ANESTHESIOLOGY, V109, P417, DOI 10.1097/ALN.0b013e318182a467; Bronson WH, 2012, ORTHOPEDICS, V35, pE1453, DOI 10.3928/01477447-20120822-40; Gurses E, 2004, ANESTH ANALG, V98, P128, DOI 10.1213/01.ANE.0000090314.43496.1D; Kim SM, 2012, CLIN NEUROPHYSIOL, V123, P1465, DOI 10.1016/j.clinph.2011.11.035; Mahmoud M, 2010, ANESTHESIOLOGY, V112, P1364, DOI 10.1097/ALN.0b013e3181d74f55; Monk TG, 2011, CURR OPIN ANESTHESIO, V24, P665, DOI 10.1097/ACO.0b013e32834c7acf; Ravasio G, 2012, JAVMA-J AM VET MED A, V241, P1307, DOI 10.2460/javma.241.10.1307; Rouche O, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-5; Schmidt GN, 2005, ANAESTHESIA, V60, P228, DOI 10.1111/j.1365-2044.2004.04120.x; Schwartz DM, 2007, J BONE JOINT SURG AM, V89A, P2440, DOI 10.2106/Jl3JS.F01476; Shida Y, 2012, J NEUROSURG ANESTH, V24, P113, DOI 10.1097/ANA.0b013e318237fa41; Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006; Stone LS, 2004, NEUROSCI LETT, V361, P265, DOI 10.1016/j.neulet.2003.12.065; Tamkus AA, 2014, SPINE J, V14, P1440, DOI 10.1016/j.spinee.2013.08.037; Thornton C, 1999, BRIT J ANAESTH, V83, P381; Tobias JD, 2008, PEDIATR ANESTH, V18, P1082, DOI 10.1111/j.1460-9592.2008.02733.x	19	7	8	1	11	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0021-1265	1863-4362		IRISH J MED SCI	Irish J. Med. Sci.	DEC	2015	184	4					813	818		10.1007/s11845-014-1178-0			6	Medicine, General & Internal	General & Internal Medicine	CU0ZK	WOS:000363248100014	25183287				2020-06-30	J	Garah, J; Adiv, OE; Rosen, I; Shaoul, R				Garah, Jamal; Adiv, Orly Eshach; Rosen, Irit; Shaoul, Ron			The value of Integrated Pulmonary Index (IPI) monitoring during endoscopies in children	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Endoscopy; Monitoring; Children; Safety; Sedation; End tidal CO2	TIDAL CARBON-DIOXIDE; RESPIRATORY DEPRESSION; CONSCIOUS SEDATION; MODERATE SEDATION; PROPOFOL SEDATION; PULSE OXIMETRY; CAPNOGRAPHY; GASTROENTEROLOGY; ANESTHESIA; GUIDELINES	The Integrated Pulmonary Index (IPI) is an algorithm included in commercially available monitors that constitutes a representation of 4 parameters: EtCO2, RR, SpO2 and PR. The IPI index has been validated for adults and children older than 1 year of age. In this study we aimed to study the value of IPI monitoring during pediatric endoscopic procedures. Our data consisted of 124 measurements of 109 patients undergoing different procedures (upper endoscopy 84 patients, colonoscopy 6 patients, both 9 patients). The data was divided into 3 groups based on the drug type used: propofol only, 5 patients (group 1); propofol & midazolam, 89 patients (group 2); propofol, midazolam and Fentanyl, 15 patients (group 3). Patients in group 2 and 3 had significantly higher IPI levels than group 1. Significantly lower IPI values were found between ages 4-6 compared to 7-12 years old. High midazolam dose was associated with lower IPI levels during the procedure. No significant differences were found for propofol doses. Patients who had an anesthetist present had lower IPI levels during the procedure compared to those who did not. No differences were noted between the different procedures. IPI alerted all apnea episodes (58 events, IPI = 1) and hypoxia (26 events, IPI a parts per thousand currency sign 3) episodes, whereas pulse oximetry captured only the hypoxia episodes (IPI sensitivity = 1, specificity 0.98, positive predictive value 0.95). Younger patient age, use of propofol alone, higher midazolam doses and presence of anesthetist are all associated with lower IPI levels.	[Garah, Jamal; Adiv, Orly Eshach; Rosen, Irit; Shaoul, Ron] Meyer Childrens Hosp Haifa, Rambam Med Ctr, Pediat Gastroenterol & Nutr Unit, IL-31096 Haifa, Israel; [Garah, Jamal; Adiv, Orly Eshach; Rosen, Irit; Shaoul, Ron] Technion Israel Inst Technol, Fac Med, Haifa, Israel	Shaoul, R (reprint author), Meyer Childrens Hosp Haifa, Rambam Med Ctr, Pediat Gastroenterol & Nutr Unit, POB 9602, IL-31096 Haifa, Israel.	shaoul_r@012.net.il		Shaoul, Ron/0000-0001-5667-8759	Oridion	Funding for this study was available from a research grant from Oridion.	[Anonymous], 1987, PEDIATRICS, V79, P292; Beitz A, 2012, AM J GASTROENTEROL, V107, P1205, DOI 10.1038/ajg.2012.136; Berkenbosch JW, 2001, ANESTH ANALG, V92, P1427; Berkenstadt H, 2012, J CLIN MONIT COMPUT, V26, P177, DOI 10.1007/s10877-012-9357-x; Bhende M S, 2001, J Postgrad Med, V47, P153; Cacho G, 2010, REV ESP ENFERM DIG, V102, P86, DOI 10.4321/s1130-01082010000200003; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cote CJ, 2008, PEDIATR ANESTH, V18, P9, DOI 10.1111/j.1460-9592.2007.02404.x; Dar AQ, 2010, WORLD J GASTRO ENDOS, V2, P257, DOI 10.4253/wjge.v2.i7.257; Elitsur Y, 2000, ENDOSCOPY, V32, P788, DOI 10.1055/s-2000-7713; Gozal Y, 2009, RELIABILITY INTEGRAT; Gozal Y, 2009, INTEGRATED PULMONARY; Hart LS, 1997, PEDIATR EMERG CARE, V13, P189, DOI 10.1097/00006565-199706000-00004; Heuss LT, 2004, DIGESTION, V70, P152, DOI 10.1159/000081515; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Koniaris LG, 2003, SURG ENDOSC, V17, P1261, DOI 10.1007/s00464-002-8789-7; Kunkov S, 2005, PEDIATR EMERG CARE, V21, P574, DOI 10.1097/01.pec.0000177197.83655.d8; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Lightdale JR, 2006, PEDIATRICS, V117, pE1170, DOI 10.1542/peds.2005-1709; Lightdale JR, 2010, GASTROINTEST ENDOSC, V71, pAB255, DOI 10.1016/j.gie.2010.03.564; McQuillen KK, 2000, PEDIATR EMERG CARE, V16, P401, DOI 10.1097/00006565-200012000-00005; Nagler J, 2006, PEDIATRICS, V118, P260, DOI 10.1542/peds.2005-2723; Nelson DB, 2000, GASTROINTEST ENDOSC, V51, P288, DOI 10.1016/S0016-5107(00)70357-9; Radaelli Franco, 2004, Gastrointest Endosc Clin N Am, V14, P335, DOI 10.1016/j.giec.2004.01.008; RUSCONI F, 1994, PEDIATRICS, V94, P350; Sabbatani P, 2013, INT J CARDIOL, V169, P430, DOI 10.1016/j.ijcard.2013.10.015; Sullivan KJ, 2005, PEDIATR EMERG CARE, V21, P327, DOI 10.1097/01.pec.0000159064.24820.bd; Thakkar K, 2007, GASTROINTEST ENDOSC, V65, P213, DOI 10.1016/j.gie.2006.03.015; Tirosh E, 2001, CLIN PHYSIOL, V21, P150, DOI 10.1046/j.1365-2281.2001.00319.x; Tobias JD, 1997, ANESTH ANALG, V85, P55, DOI 10.1097/00000539-199707000-00010; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Vargo JJ, 2002, GASTROINTEST ENDOSC, V55, P826, DOI 10.1067/mge.2002.124208; Vargo JJ, 2009, GASTROENTEROLOGY, V137, P2161, DOI 10.1053/j.gastro.2009.09.050; Wallis LA, 2005, ARCH DIS CHILD, V90, P1117, DOI 10.1136/adc.2004.068718; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Waugh JB, 2011, J CLIN ANESTH; Wilson John, 2005, J Intensive Care Med, V20, P291, DOI 10.1177/0885066605278652; Yarchi D, 2009, GASTROINTEST ENDOSC, V69, P877, DOI 10.1016/j.gie.2008.05.054; Yildizdas D, 2004, PEDIATR EMERG CARE, V20, P162, DOI 10.1097/01.pec.0000117922.65522.26	40	8	8	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	DEC	2015	29	6					773	778		10.1007/s10877-015-9665-z			6	Anesthesiology	Anesthesiology	CU5EH	WOS:000363554100015	25666393				2020-06-30	J	Asouhidou, I; Trikoupi, A				Asouhidou, Irene; Trikoupi, Anastasia			Esmolol reduces anesthetic requirements thereby facilitating early extubation; a prospective controlled study in patients undergoing intracranial surgery	BMC ANESTHESIOLOGY			English	Article						Craniotomy; Esmolol; Neuroanesthesia; Propofol; Sevoflurane	CEREBRAL-BLOOD-FLOW; POSTOPERATIVE COGNITIVE RECOVERY; NEUROSURGICAL PATIENTS; BALANCED ANESTHESIA; PROPOFOL ANESTHESIA; SEVOFLURANE; CRANIOTOMY; REMIFENTANIL; DESFLURANE; PRESSURE	Background: Adequate cerebral perfusion pressure with quick and smooth emergence from anesthesia is a major concern of the neuroanesthesiologist. Anesthesia techniques that minimize anesthetic requirements and their effects may be beneficial. Esmolol, a short acting hyperselective beta-adrenergic blocker is effective in blunting adrenergic response to several perioperative stimuli and so it might interfere in the effect of the anesthetic drugs on the brain. This study was designed to investigate the effect of esmolol on the consumption of propofol and sevoflurane in patients undergoing craniotomy. Method: Forty-two patients that underwent craniotomy for aneurysm clipping or tumour dissection were randomly divided in two groups (four subgroups). Anesthesia was induced with propofol, fentanyl and a single dose of cis-atracurium, followed by continuous infusion of remifentanil and either propofol or sevoflurane. Patients in the esmolol group received 500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by additional 200 mcg/kg/min of esmolol. Monitoring of the depth of anesthesia was also performed using the Bispectral Index-BIS and cardiac output. The inspired concentration of sevoflurane and the infusion rate of propofol were adjusted in order to maintain a BIS value between 40-50. Intraoperative emergence was detected by the elevation of BIS value, HR or MAP. Results: The initial and the intraoperative doses of propofol and sevoflurane were 18-50 mcg/kg/min and 0.2-0.5 MAC respectively in the esmolol group, whereas in the control group they where 100-150 mcg/kg/ and 0.9-2.0 MAC respectively (p = 0.000 for both groups). All procedures were anesthesiologically uneventful with no episodes of intraoperative emerge. Conclusions: Esmolol is effective not only in attenuating intraoperative hemodynamic changes related to sympathetic overdrive but also in minimizing significant propofol and sevoflurane requirements without compromising the hemodynamic status.	[Asouhidou, Irene; Trikoupi, Anastasia] G Papanikolaou Gen Hosp, Dept Anesthesiol, Thessaloniki 55133, Greece	Asouhidou, I (reprint author), G Papanikolaou Gen Hosp, Dept Anesthesiol, 15-17 Agiou Evgeniou St, Thessaloniki 55133, Greece.	iasouh@aol.com	Asouhidou, Irene/AAK-3417-2020				ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; ANGARAN DM, 1986, CLIN PHARMACY, V5, P288; Berridge CW, 1996, J NEUROSCI, V16, P6999; Bilotta F, 2007, EUR J ANAESTH, V24, P122, DOI 10.1017/S0265021506001244; Bilotta F, 2009, J NEUROSURG ANESTH, V21, P207, DOI 10.1097/ANA.0b013e3181a19c52; Bloomfield EL, 1996, J NEUROSURG ANESTH, V8, P101, DOI 10.1097/00008506-199604000-00001; Bruder N, 1999, ANESTH ANALG, V89, P674, DOI 10.1097/00000539-199909000-00027; Bundgaard H, 1998, ACTA ANAESTH SCAND, V42, P621, DOI 10.1111/j.1399-6576.1998.tb05292.x; Chia YY, 2004, BRIT J ANAESTH, V93, P799, DOI 10.1093/bja/aeh268; Collard V, 2007, ANESTH ANALG, V105, P1255, DOI 10.1213/01.ane.0000282822.07437.02; Coloma M, 2001, ANESTH ANALG, V92, P352, DOI 10.1213/00000539-200102000-00014; Davidson EM, 2001, CAN J ANAESTH, V48, P59, DOI 10.1007/BF03019816; DUBOIS M, 1992, J NEUROSURG ANESTH, V4, P176, DOI 10.1097/00008506-199207000-00005; Fraga M, 2003, ANESTHESIOLOGY, V98, P1085, DOI 10.1097/00000542-200305000-00010; Grillo P, 2003, ANESTH ANALG, V96, P1145, DOI 10.1213/01.ANE.0000055647.54957.77; Hans P, 2006, CURR OPIN ANESTHESIO, V19, P498, DOI 10.1097/01.aco.0000245274.69292.ad; Johansen JW, 2001, ANESTH ANALG, V93, P1526, DOI 10.1097/00000539-200112000-00039; Johansen JW, 1997, ANESTHESIOLOGY, V86, P364, DOI 10.1097/00000542-199702000-00011; Kolbitsch C, 2000, ANESTH ANALG, V91, P156, DOI 10.1097/00000539-200007000-00029; Magni G, 2005, J NEUROSURG ANESTH, V17, P134, DOI 10.1097/01.ana.0000167447.33969.16; Magni G, 2007, J NEUROSURG ANESTH, V19, P229, DOI 10.1097/ANA.0b013e31806e5f5a; Menigaux C, 2002, BRIT J ANAESTH, V89, P857, DOI 10.1093/bja/aef275; MILLER RD, 1968, ANESTHESIOLOGY, V29, P1153, DOI 10.1097/00000542-196811000-00012; Ogawa Y, 2006, ANESTH ANALG, V102, P552, DOI 10.1213/01.ane.0000189056.96273.48; Orme R, 2002, ANESTH ANALG, V94, P112, DOI 10.1097/00000539-200201000-00021; Ture H, 2009, ANESTH ANALG, V109, P1625, DOI 10.1213/ane.0b013e3181b0f18b; Wilson ES, 2004, ANAESTHESIA, V59, P122, DOI 10.1111/j.1365-2044.2004.03460.x; WOOD AJJ, 1983, CLIN PHARMACOKINET, V8, P253, DOI 10.2165/00003088-198308030-00004; Yang H, 2003, CAN J ANAESTH, V50, P627, DOI 10.1007/BF03018700; Zaugg M, 1999, ANESTHESIOLOGY, V91, P1674, DOI 10.1097/00000542-199912000-00020	30	9	9	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	NOV 28	2015	15								172	10.1186/s12871-015-0154-1			8	Anesthesiology	Anesthesiology	CX3HN	WOS:000365588100001	26615516	DOAJ Gold, Green Published			2020-06-30	J	Sadowski, SM; Andres, A; Morel, P; Schiffer, E; Frossard, JL; Platon, A; Poletti, PA; Buhler, L				Sadowski, Samira M.; Andres, Axel; Morel, Philippe; Schiffer, Eduardo; Frossard, Jean-Louis; Platon, Alexandra; Poletti, Pierre-Alexandre; Buehler, Leo			Epidural anesthesia improves pancreatic perfusion and decreases the severity of acute pancreatitis	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article						Severe acute pancreatitis; Epidural anesthesia; Pancreatic necrosectomy; Pancreatic perfusion; Computed tomography	ACUTE NECROTIZING PANCREATITIS; NECROSIS; COMPLICATIONS; MICROCIRCULATION; MORTALITY; ANALGESIA; RATS; FLOW	AIM: To study the safety of epidural anesthesia (EA), its effect on pancreatic perfusion and the outcome of patients with acute pancreatitis (AP). METHODS: From 2005 to August 2010, patients with predicted severe AP [Ranson score >= 2, C-reactive protein > 100 or necrosis on computed tomography (CT)] were prospectively randomized to either a group receiving EA or a control group treated by patient controlled intravenous analgesia. Pain management was evaluated in the two groups every eight hours using the visual analog pain scale (VAS). Parameters for clinical severity such as length of hospital stay, use of antibiotics, admission to the intensive care unit, radiological/clinical complications and the need for surgical necrosectomy including biochemical data were recorded. A CT scan using a perfusion protocol was performed on admission and at 72 h to evaluate pancreatic blood flow. A significant variation in blood flow was defined as a 20% difference in pancreatic perfusion between admission and 72 h and was measured in the head, body and tail of the pancreas. RESULTS: We enrolled 35 patients. Thirteen were randomized to the EA group and 22 to the control group. There were no differences in demographic characteristics between the two groups. The Balthazar radiological severity score on admission was higher in the EA group than in the control group (mean score 4.15 +/- 2.54 vs 3.38 +/- 1.75, respectively, P = 0.347) and the median Ranson scores were 3.4 and 2.7 respectively (P = NS). The median duration of EA was 5.7 d, and no complications of the epidural procedure were reported. An improvement in perfusion of the pancreas was observed in 13/30 (43%) of measurements in the EA group vs 2/27 (7%) in the control group (P = 0.0025). Necrosectomy was performed in 1/13 patients in the EA group vs 4/22 patients in the control group (P = 0.63). The VAS improved during the first ten days in the EA group compared to the control group (0.2 vs 2.33, P = 0.034 at 10 d). Length of stay and mortality were not statistically different between the 2 groups (26 d vs 30 d, P = 0.65, and 0% for both respectively). CONCLUSION: Our study demonstrates that EA increases arterial perfusion of the pancreas and improves the clinical outcome of patients with AP.	[Sadowski, Samira M.; Andres, Axel; Morel, Philippe; Buehler, Leo] Univ Hosp Geneva, Dept Visceral & Transplantat Surg, CH-1211 Geneva 14, Switzerland; [Schiffer, Eduardo] Univ Hosp Geneva, Dept Anesthesiol, CH-1211 Geneva 14, Switzerland; [Frossard, Jean-Louis] Univ Hosp Geneva, Dept Gastroenterol, CH-1211 Geneva 14, Switzerland; [Platon, Alexandra; Poletti, Pierre-Alexandre] Univ Hosp Geneva, Dept Radiol, CH-1211 Geneva 14, Switzerland	Buhler, L (reprint author), Univ Hosp Geneva, Dept Visceral & Transplantat Surg, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland.	leo.buhler@hcuge.ch	Eduardo, Schiffer/I-4968-2019	Buhler, Leo/0000-0002-9461-8498	University Hospitals of Geneva	Supported by a research grant of the University Hospitals of Geneva (to Buhler L).	Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; Balthazar EJ, 2002, RADIOL CLIN N AM, V40, P1199, DOI 10.1016/S0033-8389(02)00047-7; Banks PA, 2006, AM J GASTROENTEROL, V101, P2379, DOI 10.1111/j.1572-0241.2006.00856.x; Beger H G, 2001, J Hepatobiliary Pancreat Surg, V8, P140; Beger HG, 1997, WORLD J SURG, V21, P130, DOI 10.1007/s002689900204; Bernhardt A, 2002, Anaesthesiol Reanim, V27, P16; Bize PE, 2006, AM J ROENTGENOL, V186, P114, DOI 10.2214/AJR.04.1416; BUCHLER M, 1992, EUR SURG RES, V24, P85, DOI 10.1159/000129243; Buchler MW, 2000, ANN SURG, V232, P619; Connor S, 2005, SURGERY, V137, P499, DOI 10.1016/j.surg.2005.01.003; Demirag A, 2006, WORLD J GASTROENTERO, V12, P915, DOI 10.3748/wjg.v12.i6.915; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Freise H, 2005, ANESTH ANALG, V100, P255, DOI 10.1213/01.ANE.0000140253.65577.1C; Freise H, 2011, BRIT J ANAESTH, V107, P859, DOI 10.1093/bja/aer339; Freise H, 2006, ANESTHESIOLOGY, V105, P354, DOI 10.1097/00000542-200608000-00019; Frossard JL, 2008, LANCET, V371, P143, DOI 10.1016/S0140-6736(08)60107-5; Gloor B, 2001, BRIT J SURG, V88, P975, DOI 10.1046/j.0007-1323.2001.01813.x; Hayes MH, 1921, PSYCHOL BULL, V18, P98, DOI DOI 10.1037/H0064147; Isenmann R, 2001, PANCREATOLOGY, V1, P63, DOI 10.1159/000055794; KLAR E, 1994, DIGEST DIS SCI, V39, P2639, DOI 10.1007/BF02087702; KUSTERER K, 1993, AM J PHYSIOL, V265, pG165; Niesel H C, 1991, Reg Anaesth, V14, P97; RANSON JHC, 1981, SURG CLIN N AM, V61, P55; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Schilling MK, 1999, PANCREAS, V19, P21, DOI 10.1097/00006676-199907000-00003; Sielenkamper AW, 2000, ANESTHESIOLOGY, V93, P844, DOI 10.1097/00000542-200009000-00036; STEINBERG W, 1994, NEW ENGL J MED, V330, P1198, DOI 10.1056/NEJM199404283301706; Takeda K, 2005, PANCREAS, V30, P40; Tenner S, 1997, GASTROENTEROLOGY, V113, P899, DOI 10.1016/S0016-5085(97)70185-9; Tsuji Y, 2007, CLIN GASTROENTEROL H, V5, P1484, DOI 10.1016/j.cgh.2007.07.014; Tsuji Y, 2010, J GASTROENTEROL, V45, P1155, DOI 10.1007/s00535-010-0267-8; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; Tziavrangos E, 2006, CURR OPIN ANESTHESIO, V19, P521, DOI 10.1097/01.aco.0000245278.22658.1e; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x; Yang AL, 2008, ARCH INTERN MED, V168, P649, DOI 10.1001/archinte.168.6.649	35	15	17	0	10	BAISHIDENG PUBLISHING GROUP INC	PLEASANTON	8226 REGENCY DR, PLEASANTON, CA 94588 USA	1007-9327	2219-2840		WORLD J GASTROENTERO	World J. Gastroenterol.	NOV 21	2015	21	43					12448	12456		10.3748/wjg.v21.i43.12448			9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CW5HH	WOS:000365025800022	26604652	Green Published, Other Gold			2020-06-30	J	Tuominen, L; Tuulari, J; Karlsson, H; Hirvonen, J; Helina, S; Salminen, P; Parkkola, R; Hietala, J; Nuutila, P; Nummenmaa, L				Tuominen, Lauri; Tuulari, Jetro; Karlsson, Henry; Hirvonen, Jussi; Helina, Semi; Salminen, Paulina; Parkkola, Riitta; Hietala, Jarmo; Nuutila, Pirjo; Nummenmaa, Lauri			Aberrant mesolimbic dopamine-opiate interaction in obesity	NEUROIMAGE			English	Article						Opioid; Dopamine; Obesity; Interaction; PET	MU-OPIOID RECEPTORS; IN-VIVO; HUMAN-BRAIN; NUCLEUS-ACCUMBENS; MESSENGER-RNA; BINDING; PET; D2; AMPHETAMINE; ADDICTION	Dopamine and opioid neurotransmitter systems share many functions such as regulation of reward and pleasure. mu-Opioid receptors (MOR) modulate the mesolimbic dopamine system in ventral tegmental area and striatum, key areas implicated in reward. We hypothesized that dopamine and opioid receptor availabilities correlate in vivo and that this correlation is altered in obesity, a disease with altered reward processing. Twenty lean females (mean BMI 22) and 25 non-binge eating morbidly obese females (mean BMI 41) underwent two positron emission tomography scans with [C-11] carfentanil and [C-11]raclopride to measure the MOR and dopamine D2 receptor (DRD2) availability, respectively. In lean subjects, the MOR and DRD2 availabilities were positively associated in the ventral striatum(r=0.62, p=0.003) and dorsal caudate nucleus (r=0.62, p=0.004). Moreover, DRD2 availability in the ventral striatum was associated with MOR availability in other regions of the reward circuitry, particularly in the ventral tegmental area. In morbidly obese subjects, this receptor interaction was significantly weaker in ventral striatum but unaltered in the caudate nucleus. Finally, the association between DRD2 availability in the ventral striatum and MOR availability in the ventral tegmental area was abolished in the morbidly obese. The study demonstrates a link between DRD2 and MOR availabilities in living human brain. This interaction is selectively disrupted in mesolimbic dopamine system in morbid obesity. We propose that interaction between the dopamine and opioid systems is a prerequisite for normal reward processing and that disrupted cross-talk may underlie altered reward processing in obesity. (C) 2015 Elsevier Inc. All rights reserved.	[Tuominen, Lauri; Tuulari, Jetro; Karlsson, Henry; Hirvonen, Jussi; Helina, Semi; Hietala, Jarmo; Nuutila, Pirjo; Nummenmaa, Lauri] Univ Turku, Turku PET Ctr, FIN-20520 Turku, Finland; [Tuominen, Lauri; Hietala, Jarmo] Univ Turku, Dept Psychiat, Turku 20700, Finland; [Salminen, Paulina] Turku Univ Hosp, Dept Surg, FIN-20520 Turku, Finland; [Parkkola, Riitta] Turku Univ Hosp, Dept Radiol, FIN-20520 Turku, Finland; [Parkkola, Riitta] Turku Univ, Turku, Finland; [Nummenmaa, Lauri] Aalto Univ, Sch Sci, Dept Biomed Engn & Computat Sci BECS, Mind Brain Lab, Aalto 00076, Finland; [Nummenmaa, Lauri] Aalto Univ, Sch Sci, Low Temp Lab, BRU, Aalto 00076, Finland	Tuominen, L (reprint author), Univ Turku, Turku PET Ctr, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.	ljtuom@utu.fi	Nummenmaa, Lauri/G-6910-2012; Hirvonen, Jussi/AAC-1864-2020	Nummenmaa, Lauri/0000-0002-2497-9757; Tuulari, Jetro/0000-0002-1797-8000; Karlsson, Hasse/0000-0002-4992-1893; Hietala, Jarmo/0000-0002-3179-6780	Academy of FinlandAcademy of Finland [283320, 265917, 251125, 121031]; Sigrid Juselius FoundationSigrid Juselius Foundation; University of Turku; Turku University Hospital and Abo Akademi University [13503]; Finnish Diabetes Foundation and Finnish Foundation for cardiovascular research; Maud Kuistila Memorial Foundation	We thank the staff at the Turku PET Centre for assistance and Juha Lahnakoski for the help with the visualizations. The study was conducted within the Finnish Centre of Excellence in Cardiovascular and Metabolic Diseases supported by the Academy of Finland (grants (#283320; #265917; #251125 and #121031), Sigrid Juselius Foundation, University of Turku, Turku University Hospital and Abo Akademi University (grant #13503), and Finnish Diabetes Foundation and Finnish Foundation for cardiovascular research. The work of Dr. Tuominen was supported by the Maud Kuistila Memorial Foundation. Funding sources had no involvement in the conduct of the research or preparation of the article.	Alakurtti K, 2011, J CEREBR BLOOD F MET, V31, P155, DOI 10.1038/jcbfm.2010.64; Ambrose LM, 2004, ANAT REC PART A, V279A, P583, DOI 10.1002/ar.a.20054; ANDERSEN PH, 1988, EUR J PHARMACOL, V146, P113, DOI 10.1016/0014-2999(88)90492-X; Atalayer D, 2014, NEUROIMAGE, V100, P405, DOI 10.1016/j.neuroimage.2014.05.054; Azaryan AV, 1996, NEUROCHEM RES, V21, P1411, DOI 10.1007/BF02532382; Balodis IM, 2013, BIOL PSYCHIAT, V73, P877, DOI 10.1016/j.biopsych.2013.01.014; Bencherif B, 2005, J NUCL MED, V46, P1349; Bettinardi V, 2011, MED PHYS, V38, P5394, DOI 10.1118/1.3635220; Brady KT, 1999, PSYCHIAT CLIN N AM, V22, P241, DOI 10.1016/S0193-953X(05)70074-5; BRENT PJ, 1994, BRAIN RES, V654, P191, DOI 10.1016/0006-8993(94)90479-0; Brooks SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060393; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; COMETTAMORINI C, 1992, MOL PHARMACOL, V41, P185; DEVINE DP, 1993, J PHARMACOL EXP THER, V266, P1236; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; FARDE L, 1986, SCIENCE, V231, P258, DOI 10.1126/science.2867601; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; Garcia-Garcia I, 2014, OBES REV, V15, P853, DOI 10.1111/obr.12221; Gonzalez-Nicolini MV, 2003, NEUROSCIENCE, V121, P387, DOI 10.1016/S0306-4522(03)00488-3; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Greenway FL, 2010, LANCET, V376, P595, DOI 10.1016/S0140-6736(10)60888-4; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Hagelberg N, 2002, SYNAPSE, V45, P25, DOI 10.1002/syn.10078; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255; HIETALA J, 1994, PSYCHOPHARMACOLOGY, V116, P285, DOI 10.1007/BF02245330; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Jalabert M, 2011, P NATL ACAD SCI USA, V108, P16446, DOI 10.1073/pnas.1105418108; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Kennedy J, 2014, APPETITE, V75, P103, DOI 10.1016/j.appet.2013.12.017; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Laviolette SR, 2002, BEHAV BRAIN RES, V129, P17, DOI 10.1016/S0166-4328(01)00327-8; Mick I, 2014, INT J NEUROPSYCHOPH, V7, P1; Morgane PJ, 2005, PROG NEUROBIOL, V75, P143, DOI 10.1016/j.pneurobio.2005.01.001; Moulton EA, 2014, ADDICT BIOL, V19, P317, DOI 10.1111/adb.12101; Penttila J, 2004, INT J NEUROPSYCHOPH, V7, P431, DOI 10.1017/S146114570400450X; POLLARD H, 1977, NATURE, V268, P745, DOI 10.1038/268745a0; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Salokangas RKR, 2000, AM J PSYCHIAT, V157, P632, DOI 10.1176/appi.ajp.157.4.632; Schott BH, 2008, J NEUROSCI, V28, P14311, DOI 10.1523/JNEUROSCI.2058-08.2008; Small DM, 2003, NEUROIMAGE, V19, P1709, DOI 10.1016/S1053-8119(03)00253-2; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Tomasi D, 2015, HUM BRAIN MAPP, V36, P120, DOI 10.1002/hbm.22617; Tuominen L, 2014, HUM BRAIN MAPP, V35, P1875, DOI 10.1002/hbm.22298; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Volkow ND, 2013, BIOL PSYCHIAT, V73, P811, DOI 10.1016/j.biopsych.2012.12.020; Volkow ND, 2012, ANNU REV PHARMACOL, V52, P321, DOI 10.1146/annurev-pharmtox-010611-134625; Wiskerke J, 2011, J NEUROSCI, V31, P262, DOI 10.1523/JNEUROSCI.4794-10.2011	49	32	32	0	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	NOV 15	2015	122						80	86		10.1016/j.neuroimage.2015.08.001			7	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CT9GO	WOS:000363125200009	26260431				2020-06-30	J	Amlani, A; McKee, G; Khamis, N; Raghukumar, G; Tsang, E; Buxton, JA				Amlani, Ashraf; McKee, Geoff; Khamis, Noren; Raghukumar, Geetha; Tsang, Erica; Buxton, Jane A.			Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada	HARM REDUCTION JOURNAL			English	Article						Survey; People who use drugs; Fentanyl; Overdose; Opioids	DEATHS	Background: Fentanyl-detected illicit drug overdose deaths in British Columbia (BC) recently increased dramatically from 13 deaths in 2012 to 90 deaths in 2014, signaling an emerging public health concern. Illicit fentanyl is sold as pills or powders, often mixed with other substances like heroin or oxycodone; reports from coroners suggested that fentanyl was frequently taken unknowingly by people who use drugs. This study aimed to assess the prevalence and characteristics of fentanyl use among clients accessing harm reduction (HR) services in BC. Methods: Participants attending HR services at 17 sites across BC were invited to complete an anonymous questionnaire describing drugs they have used within the last 3 days and provide a urine sample to test for fentanyl. Data from eligible participants were analyzed using descriptive, bivariate, and multivariate statistical methods. Results: Surveys from 17 HR sites were received, resulting in analysis of responses from 242 eligible participants. Most participants used multiple substances (median = 3), with crystal meth (59 %) and heroin (52 %) use most frequently reported. Seventy participants (29 %) tested positive for fentanyl, 73 % of whom did not report using fentanyl. Controlling for age, gender, and health authority, reported use of fentanyl (odds ratio (OR) = 6.13, 95 % confidence interval (CI) = [2.52, 15.78], p < 0.001) and crystal methamphetamine (OR = 3.82, 95 % CI = [1.79, 8.63], p < 0.001) use were significantly associated with fentanyl detection. Conclusions: The proportion of those testing positive who did not report knowingly using fentanyl represents a considerable public health concern. The risk of overdose among this vulnerable population highlights the need for targeted HR strategies, such as increased accessibility to naloxone, overdose education, and urine screens.	[Amlani, Ashraf; Buxton, Jane A.] British Columbia Ctr Dis Control, Vancouver, BC V5Z 4R4, Canada; [Khamis, Noren; Raghukumar, Geetha; Tsang, Erica; Buxton, Jane A.] Univ British Columbia, Fac Med, Vancouver, BC V5Z 1M9, Canada; [McKee, Geoff] Univ British Columbia, Sch Publ & Populat Hlth, Vancouver, BC V5Z 1M9, Canada	Amlani, A (reprint author), British Columbia Ctr Dis Control, 655 West 12th Ave, Vancouver, BC V5Z 4R4, Canada.	ashraf.amlani@bccdc.ca	Tsang, Erica/AAN-3395-2020	Tsang, Erica/0000-0003-2317-2721; McKee, Geoff/0000-0002-0329-2454	BC Centre for Disease Control	The authors would like to thank the peers from the Vancouver Area Network of Drug Users for their input on the study design, as well as the health authority regional harm reduction representatives and participating sites, including the staff and participants, for their assistance in the recruitment and data collection. We acknowledge the contributions of Robert Balshaw, Senior Statistician, BCCDC, as well as medical students Jennifer Campbell and Hugh Guan on their early work designing the study. Funding for this project was provided through BC Centre for Disease Control.	[Anonymous], 2015, STRAT PLAN RHOD ISL; [Anonymous], 2015, INCR FENT DRUG CONF; Banjo Oluwajenyo, 2014, CMAJ Open, V2, pE153, DOI 10.9778/cmajo.20140008; British Columbia Center for Disease Control, 2014, COMM DRUG AL CDA TIP; British Columbia Coroners Service, 2014, INF B BC COR SERV WA; BTNX Inc, 2013, RAP RESP FENT FYL TE; Canadian Centre on Substance Abuse, 2015, CCENDU B DEATHS INV; Canadian Centre on Substance Abuse Canadian Community Epidemiology Network on Drug Use, 2014, CCENDU DRUG AL INCR; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; Jafari S, 2015, CAN J ADDICT, V6, P4; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Kuo M, 2014, HARM REDUCT J, V11, DOI 10.1186/1477-7517-11-13; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Sorge J., 2015, SUBSTANCE USE TRENDS; STILLER RL, 1990, FORENSIC SCI INT, V44, P1, DOI 10.1016/0379-0738(90)90160-Z; Walsh J., 2015, COMMUNICATION; Wheeler Eliza, 2012, Morbidity and Mortality Weekly Report, V61, P101	20	63	62	2	16	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1477-7517			HARM REDUCT J	Harm Reduct. J.	NOV 14	2015	12								54	10.1186/s12954-015-0088-4			7	Substance Abuse	Substance Abuse	CW2FJ	WOS:000364806200001	26577516	DOAJ Gold, Green Published	Y	N	2020-06-30	J	Koh, JC; Lee, J; Kim, SY; Choi, S; Han, DW				Koh, Jae Chul; Lee, Jinae; Kim, So Yeon; Choi, Sumin; Han, Dong Woo			Postoperative Pain and Intravenous Patient-Controlled Analgesia-Related Adverse Effects in Young and Elderly Patients A Retrospective Analysis of 10,575 Patients	MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BACKGROUND INFUSION; CARDIAC-SURGERY; DOUBLE-BLIND; NAUSEA; FENTANYL; MANAGEMENT; MORPHINE; KETOROLAC; EFFICACY	In this retrospective analysis of 10,575 patients who used fentanyl-based intravenous patient-controlled analgesia (IV-PCA) after surgery, we evaluated difference between young and elderly patients on their characteristic of adverse effects.We reviewed the data collected from the patients who were provided IV-PCA for pain control following elective surgery under either general or spinal anesthesia between September 2010 and March 2014. Postoperative pain, incidence of PCA-related adverse effects, and risk factors for the need of rescue analgesics and antiemetics for postoperative 48hours were analyzed.Pain intensity (numerical rating scale [NRS]) at postoperative 6 to 12 hours (4.68 vs 4.58, P<0.01) and incidence of nausea or vomiting (23.8% vs 20.6%, P<0.001) were higher in young patients, while incidence of PCA discontinuation (9.9% vs 11.5%, P<0.01) and sedation (0.1% vs 0.7%, P<0.001) was higher in elderly patients. Despite larger fentanyl dose used, a greater proportion of young patients required rescue analgesics (53.8% vs 47.9%, P<0.001) while addition of ketorolac was effective in reducing postoperative pain. Despite lower incidence of postoperative nausea and vomiting (PONV), a larger proportion of elderly patients required rescue antiemetics (10.1% vs 12.2%, P<0.001) while addition of ramosetron was effective in reducing PONV.In conclusion, when fentanyl-based IV-PCA is used for postoperative pain control, a larger proportion of young patients may require rescue analgesics while elderly patients may require more rescue antiemetics. The addition of ketorolac or ramosetron to the PCA of young and elderly patients can be effective to prevent rescue analgesics or antiemetics use.	[Koh, Jae Chul; Kim, So Yeon; Choi, Sumin] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul 135720, South Korea; [Lee, Jinae] Yonsei Univ, Coll Med, Biostat Collaborat Unit, Seoul 135720, South Korea	Han, DW (reprint author), Yonsei Univ, Anesthesia & Pain Res Inst, Gangnam Severance Hosp, Dept Anesthesiol & Pain Med,Coll Med, 211 Eonju Ro, Seoul 135720, South Korea.	hanesth@yuhs.ac	Lee, Jinae/F-3805-2010	Han, Dong Woo/0000-0002-8757-663X; Kim, So Yeon/0000-0001-5352-157X; Koh, Jae Chul/0000-0002-1625-8650			Aubrun F, 2007, BEST PRACT RES-CLIN, V21, P109, DOI 10.1016/j.bpa.2006.12.005; Aydogan MS, 2013, J ANESTH, V27, P569, DOI 10.1007/s00540-013-1565-0; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Barkin RL, 2010, DRUG AGING, V27, P775, DOI 10.2165/11539430-000000000-00000; BELLVILL.JW, 1971, J AMER MED ASSOC, V217, P1835, DOI 10.1001/jama.217.13.1835; BELLVILLE JW, 1960, ANESTHESIOLOGY, V21, P186, DOI 10.1097/00000542-196003000-00009; Cepeda MS, 2005, ANESTHESIOLOGY, V103, P1225, DOI 10.1097/00000542-200512010-00018; Choi JB, 2014, YONSEI MED J, V55, P1430, DOI [10.3349/ymj.2014.55.5.1430, 10.3349/YMJ.2014.55.5.1430]; Cornally Nicola, 2011, Br J Community Nurs, V16, P90; Davis MP, 2003, DRUG AGING, V20, P23, DOI 10.2165/00002512-200320010-00003; ERGINA PL, 1993, WORLD J SURG, V17, P192, DOI 10.1007/BF01658926; FERRELL BA, 1995, ANN INTERN MED, V123, P681, DOI 10.7326/0003-4819-123-9-199511010-00007; Gan TJ, 2001, ANESTH ANALG, V92, P393, DOI 10.1213/00000539-200102000-00022; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Guler T, 2004, CAN J ANAESTH, V51, P718, DOI 10.1007/BF03018432; Horn CC, 2014, EUR J PHARMACOL, V722, P55, DOI 10.1016/j.ejphar.2013.10.037; HUTCHISON RW, 2006, [No title captured], V41, P659; Kim K, 2014, J INT MED RES, V42, P684, DOI 10.1177/0300060514525351; Kim SH, 2013, YONSEI MED J, V54, P1273, DOI 10.3349/ymj.2013.54.5.1273; KORTTILA K, 1992, BRIT J ANAESTH, V69, pS20, DOI 10.1093/bja/69.supplement_1.20S; Lee JH, 2013, KOREAN J PAIN, V26, P361, DOI 10.3344/kjp.2013.26.4.361; LERMAN J, 1992, BRIT J ANAESTH, V69, pS24, DOI 10.1093/bja/69.supplement_1.24S; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Macario A, 2001, PAIN MED, V2, P336, DOI 10.1046/j.1526-4637.2001.01043.x; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Mortimer M, 2003, SCAND J PUBLIC HEALT, V31, P194, DOI 10.1080/14034940210134086; OBERLE K, 1990, CAN J AGING, V9, P13, DOI 10.1017/S0714980800016056; Obrink E, 2015, INT J SURG, V15, P100, DOI 10.1016/j.ijsu.2015.01.024; Odom-Forren J, 2015, CLIN J PAIN, V31, P845, DOI 10.1097/AJP.0000000000000170; PALAZZO MGA, 1984, CAN ANAESTH SOC J, V31, P178, DOI 10.1007/BF03015257; Palmer Pamela P, 2010, Anesthesiol Clin, V28, P587, DOI 10.1016/j.anclin.2010.08.010; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Picard P, 1997, PAIN, V73, P401, DOI 10.1016/S0304-3959(97)00128-0; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Shin S, 2014, YONSEI MED J, V55, P800, DOI 10.3349/ymj.2014.55.3.800; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; Sofaer-Bennett B, 2007, PAIN MED, V8, P271, DOI 10.1111/j.1526-4637.2007.00297.x; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; White I, 2012, PHARMACOL RES, V66, P185, DOI 10.1016/j.phrs.2012.03.016; Wiesenfeld-Hallin Zsuzsanna, 2005, Gend Med, V2, P137, DOI 10.1016/S1550-8579(05)80042-7	41	8	8	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	NOV	2015	94	45							e2008	10.1097/MD.0000000000002008			7	Medicine, General & Internal	General & Internal Medicine	DC9JJ	WOS:000369537400052	26559296	DOAJ Gold, Green Published			2020-06-30	J	Iwamoto, M; Higashi, T; Miura, H; Kawaguchi, T; Tanaka, S; Yamashita, I; Yoshimoto, T; Yoshida, S; Matoba, M				Iwamoto, Momoko; Higashi, Takahiro; Miura, Hiroki; Kawaguchi, Takahiro; Tanaka, Shigeyuki; Yamashita, Itsuku; Yoshimoto, Tetsusuke; Yoshida, Shigeaki; Matoba, Motohiro			Accuracy of using Diagnosis Procedure Combination administrative claims data for estimating the amount of opioid consumption among cancer patients in Japan	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						palliative care; analgesics; opioid; pain	EXTERNAL VALIDATION; ANALGESICS; CARE	Objective: The state of opioid consumption among cancer patients has never been comprehensively investigated in Japan. The Diagnosis Procedure Combination claims data may be used to measure and monitor opioid consumption among cancer patients, but the accuracy of using the Diagnosis Procedure Combination data for this purpose has never been tested. Methods: We aimed to ascertain the accuracy of using the Diagnosis Procedure Combination claims data for estimating total opioid analgesic consumption by cancer patients compared with electronic medical records at Aomori Prefectural Central Hospital. We calculated percent differences between estimates obtained from electronic medical records and Diagnosis Procedure Combination claims data by month and drug type (morphine, oxycodone, fentanyl, buprenorphine, codeine and tramadol) between 1 October 2012 and 30 September 2013, and further examined the causes of discrepancy by reviewing medical and administrative charts between April and July 2013. Results: Percent differences varied by month for drug types with small prescription volumes, but less so for drugs with larger prescription volumes. Differences also tended to diminish when consumption was compared for a year instead of a month. Total percent difference between electronic medical records and Diagnosis Procedure Combination data during the study period was -0.1% (4721 mg per year per hospital), as electronic medical records as baseline. Half of the discrepancy was caused by errors in data entry. Conclusion: Our study showed that Diagnosis Procedure Combination claims data can be used to accurately estimate opioid consumption among a population of cancer patients, although the same conclusion cannot be made for individual estimates or when making estimates for a group of patients over a short period of time.	[Iwamoto, Momoko; Higashi, Takahiro] Natl Canc Ctr, Div Hlth Serv Res, Ctr Canc Control & Informat Serv, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan; [Miura, Hiroki; Kawaguchi, Takahiro; Tanaka, Shigeyuki; Yamashita, Itsuku; Yoshida, Shigeaki] Aomori Prefectural Cent Hosp, Dept Palliat Care, Aomori, Aomori, Japan; [Yoshimoto, Tetsusuke] Chukyo Hosp, Dept Palliat & Support Care, Minami Ku, Nagoya, Aichi, Japan; [Matoba, Motohiro] Japanese Red Cross Med Ctr, Dept Palliat Care, Shibuya Ku, Tokyo, Japan	Iwamoto, M (reprint author), Natl Canc Ctr, Div Hlth Serv Res, Ctr Canc Control & Informat Serv, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	moiwamot@ncc.go.jp			Ministry of Health, Labor and Welfare, JapanMinistry of Health, Labour and Welfare, Japan	This study was funded by grant-in-aid from the Ministry of Health, Labor and Welfare, Japan.	[Anonymous], 2013, GUID SUBM DPC SURV D; [Anonymous], 2011, WORLD MED SITUATION; Du XLL, 2006, MED CARE, V44, P124, DOI 10.1097/01.mlr.0000196978.34283.a6; Fisher J, 2013, J PAIN SYMPTOM MANAG, V46, P20, DOI 10.1016/j.jpainsymman.2012.07.006; Higashi T, 2013, JPN J CLIN ONCOL, V43, P225, DOI 10.1093/jjco/hyt001; Jarlbaek L, 2004, J PAIN SYMPTOM MANAG, V27, P36, DOI 10.1016/j.jpainsymman.2003.05.002; [Labour and Welfare Pharmaceutical and Food Safety Bureau Compliance and Narcotics Division Ministry of Health], GUID APPR US MED OP; Lamont EB, 2002, MED CARE, V40, P201, DOI 10.1097/00005650-200203000-00004; Lund JL, 2013, MED CARE, V51, pE27, DOI 10.1097/MLR.0b013e31823ab60f; Matsuda S., 2008, Eurohealth, V14, P25; Miller DC, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-92; Pan HH, 2013, J PAIN SYMPTOM MANAG, V45, P272, DOI 10.1016/j.jpainsymman.2012.02.014	12	2	2	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	NOV	2015	45	11					1036	1041		10.1093/jjco/hyv130			6	Oncology	Oncology	DB3IV	WOS:000368405300006	26358712	Bronze			2020-06-30	J	Drees, R; Johnson, RA; Stepien, RL; Del Rio, AM; Saunders, JH; Franccois, CJ				Drees, Randi; Johnson, Rebecca A.; Stepien, Rebecca L.; Del Rio, Alejandro Munoz; Saunders, Jimmy H.; Franccois, Christopher J.			QUANTITATIVE PLANAR AND VOLUMETRIC CARDIAC MEASUREMENTS USING 64 MDCT AND 3T MRI VS. STANDARD 2D AND M-MODE ECHOCARDIOGRAPHY: DOES ANESTHETIC PROTOCOL MATTER?	VETERINARY RADIOLOGY & ULTRASOUND			English	Article						cardiac function; cardiac size; computed tomography; dog; magnetic resonance imaging	LEFT-VENTRICULAR MASS; COMPUTED-TOMOGRAPHY; HEALTHY DOGS; REAL-TIME; 3-DIMENSIONAL ECHOCARDIOGRAPHY; ANATOMIC VALIDATION; EJECTION FRACTION; HEART-RATE; CT; ANGIOGRAPHY	Cross-sectional imaging of the heart utilizing computed tomography and magnetic resonance imaging (MRI) has been shown to be superior for the evaluation of cardiac morphology and systolic function in humans compared to echocardiography. The purpose of this prospective study was to test the effects of two different anesthetic protocols on cardiac measurements in 10 healthy beagle dogs using 64-multidetector row computed tomographic angiography (64-MDCTA), 3T magnetic resonance (MRI) and standard awake echocardiography. Both anesthetic protocols used propofol for induction and isoflourane for anesthetic maintenance. In addition, protocol A used midazolam/fentanyl and protocol B used dexmedetomedine as premedication and constant rate infusion during the procedure. Significant elevations in systolic and mean blood pressure were present when using protocol B. There was overall good agreement between the variables of cardiac size and systolic function generated from the MDCTA and MRI exams and no significant difference was found when comparing the variables acquired using either anesthetic protocol within each modality. Systolic function variables generated using 64-MDCTA and 3T MRI were only able to predict the left ventricular end diastolic volume as measured during awake echocardiogram when using protocol B and 64-MDCTA. For all other systolic function variables, prediction of awake echocardiographic results was not possible (P = 1). Planar variables acquired using MDCTA or MRI did not allow prediction of the corresponding measurements generated using echocardiography in the awake patients (P = 1). Future studies are needed to validate this approach in a more varied population and clinically affected dogs. (C) 2015 American College of Veterinary Radiology.	[Drees, Randi; Johnson, Rebecca A.] Univ Wisconsin, VMTH DSS, Madison, WI 53706 USA; [Stepien, Rebecca L.] Univ Wisconsin, DSS, Madison, WI 53706 USA; [Del Rio, Alejandro Munoz] UW Madison, Dept Med Phys, Madison, WI 53792 USA; [Saunders, Jimmy H.] UGent, Fac Vet Med, B-9820 Merelbeke, Belgium; [Del Rio, Alejandro Munoz; Franccois, Christopher J.] UW Madison, Sch Med & Publ Hlth, Dept Radiol, Madison, WI 53792 USA	Drees, R (reprint author), Univ London Royal Vet Coll, Dept Clin Sci & Serv, London AL9 7TA, Herts, England.	rdrees@rvc.ac.uk		Francois, Christopher/0000-0001-5254-1181	Clinical and Translational Science Award (CTSA) program through the National Center for Research Resources (NCRR) grant [1UL1RR025011]; Clinical and Translational Science Award (CTSA) program through NIH National Center for Advancing Translational Sciences (NCATS) grant [9U54TR000021]; Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]	The project was supported by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR) grant 1UL1RR025011, and now by the NIH National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021 and Dr. Johnson was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427.	Achenbach S, 2012, ROFO-FORTSCHR RONTG, V184, P345, DOI 10.1055/s-0031-1299400; Al-Mohaissen MA, 2013, ECHOCARDIOGR-J CARD, V30, P1135, DOI 10.1111/echo.12253; Armbrust LJ, 2012, JAVMA-J AM VET MED A, V240, P1088, DOI 10.2460/javma.240.9.1088; Asferg C, 2012, EUR J RADIOL, V81, pE757, DOI 10.1016/j.ejrad.2012.02.002; Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422; Buchanan JW, 1965, VET RADIOL ULTRASOUN, V6, P21; Buchanan JW, 1965, VET RADIOL ULTRASOUN, V6, P5; Chetboul V, 2010, VET CLIN N AM-SMALL, V40, P529, DOI 10.1016/j.cvsm.2010.03.007; Contreras S, 2008, VET J, V178, P130, DOI 10.1016/j.tvjl.2007.06.027; Coon PD, 2012, ULTRASOUND MED BIOL, V38, P1853, DOI 10.1016/j.ultrasmedbio.2012.07.001; Cornell CC, 2004, J VET INTERN MED, V18, P311, DOI 10.1892/0891-6640(2004)18&lt;311:ASOMCM&gt;2.0.CO;2; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1987, [No title captured], V9, P9; FOLLAND ED, 1979, CIRCULATION, V60, P760, DOI 10.1161/01.CIR.60.4.760; Alberti JFF, 2012, REV ESP CARDIOL, V65, P24, DOI 10.1016/j.recesp.2011.11.015; Francois CJ, 2004, RADIOLOGY, V230, P389, DOI 10.1148/radiol.2302020761; Fratz S, 2009, AM J CARDIOL, V103, P1764, DOI 10.1016/j.amjcard.2009.02.030; Gilbert SH, 2010, VET J, V183, P124, DOI 10.1016/j.tvjl.2008.11.018; Henjes CR, 2012, AM J VET RES, V73, P393, DOI 10.2460/ajvr.73.3.393; Henninger W, 2003, J SMALL ANIM PRACT, V44, P56, DOI 10.1111/j.1748-5827.2003.tb00121.x; Hergan K, 2008, EUR J RADIOL, V65, P270, DOI 10.1016/j.ejrad.2007.03.031; Hettrick DA, 1996, ANESTH ANALG, V83, P1166, DOI 10.1097/00000539-199612000-00006; Hezzell MJ, 2013, J SMALL ANIM PRACT, V54, P318, DOI 10.1111/jsap.12079; Holm S., 1979, SCAND J STAT, V17, P571; Hou DJ, 2013, EUR J RADIOL, V82, P1793, DOI 10.1016/j.ejrad.2013.05.003; Juergens KU, 2008, AM J ROENTGENOL, V190, P308, DOI 10.2214/AJR.07.2283; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; Lee M, 2013, AM J VET RES, V74, P62, DOI 10.2460/ajvr.74.1.62; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MacDonald KA, 2006, J VET INTERN MED, V20, P627, DOI 10.1892/0891-6640(2006)20[627:TDIAGE]2.0.CO;2; Mahabadi AA, 2010, RADIOLOGY, V257, P614, DOI 10.1148/radiol.10100140; Mai W, 2010, VET RADIOL ULTRASOUN, V51, P428, DOI 10.1111/j.1740-8261.2010.01673.x; Marolf AJ, 2011, VET RADIOL ULTRASOUN, V52, P168, DOI 10.1111/j.1740-8261.2010.01759.x; McDonald K M, 1998, J Card Fail, V4, P203, DOI 10.1016/S1071-9164(98)80007-9; Menke J, 2013, AM HEART J, V165, P154, DOI 10.1016/j.ahj.2012.10.026; MERIN RG, 1991, ANESTHESIOLOGY, V74, P568, DOI 10.1097/00000542-199103000-00027; Meyer J, 2013, AM J VET RES, V74, P1223, DOI 10.2460/ajvr.74.9.1223; Nasis A, 2013, RADIOLOGY, V267, P11, DOI 10.1148/radiol.13111196; Peters J, 2010, LECT NOTES COMPUT SC, V6361, P400; Petite A., 2011, Veterinary computed tomography, P249; Prather AB, 2005, VET RADIOL ULTRASOUN, V46, P114, DOI 10.1111/j.1740-8261.2005.00023.x; R Development Core Team, 2012, R LANG ENV STAT COMP; Reetz JA, 2012, VET RADIOL ULTRASOUN, V53, P121, DOI 10.1111/j.1740-8261.2011.01883.x; Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6; Sanz J, 2012, CARDIOL CLIN, V30, P189, DOI 10.1016/j.ccl.2012.03.001; Saremi F, 2008, RADIOGRAPHICS, V28, P1161, DOI 10.1148/rg.284065718; Schuller S, 2005, BERL MUNCH TIERARZTL, V118, P76; Shors SM, 2004, RADIOLOGY, V230, P383, DOI 10.1148/radiol.2302021309; Sieslack AK, 2013, AM J VET RES, V74, P990, DOI 10.2460/ajvr.74.7.990; Sousa MG, 2008, VET ANAESTH ANALG, V35, P185, DOI 10.1111/j.1467-2995.2007.00370.x; Stepien RL, 1998, J APPL PHYSIOL, V85, P1368; THOMAS WP, 1984, VET RADIOLOGY, V25, P50, DOI 10.1111/j.1740-8261.1984.tb01910.x; Tsang W, 2012, HEART, V98, P1146, DOI 10.1136/heartjnl-2012-302074; Wess G, 2010, J VET INTERN MED, V24, P1069, DOI 10.1111/j.1939-1676.2010.0575.x	54	7	7	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8183	1740-8261		VET RADIOL ULTRASOUN	Vet. Radiol. Ultrasound	NOV-DEC	2015	56	6					638	657		10.1111/vru.12269			20	Veterinary Sciences	Veterinary Sciences	DA7XX	WOS:000368020000009	26082285	Green Accepted			2020-06-30	J	Dalton, BGA; Gonzalez, KW; Millspaugh, DL; Desai, AA; Sharp, SW; St Peter, SD				Dalton, Brian G. A.; Gonzalez, Katherine W.; Millspaugh, Daniel L.; Desai, Amita A.; Sharp, Susan W.; St Peter, Shawn D.			Pectus excavatum: Benefit of randomization	JOURNAL OF PEDIATRIC SURGERY			English	Article						Pectus Excavatum; Randomization; Benefit; Epidural; Patient controlled analgesia; Length of Stay	CLINICAL-RESEARCH; NUSS PROCEDURE; EXPERIENCE; REPAIR; MANAGEMENT	Background: Minimally invasive bar repair for pectus patients produces substantial pain which dictates the postoperative hospital course. We have data from 2 randomized trials comparing epidural catheter placement to patient controlled analgesia. The purpose of this study was to compare the outcomes of patients who were enrolled in the trials to those that did not participate in the trials. Methods: A retrospective chart review was performed on patients not enrolled in the trials to compare to the prospective datasets from October 2006 to June 2014. Perioperative outcomes were examined. Results: There were 135 patients in a study protocol (IS) and 195 patients that were not enrolled in a study (OS). Comparing the entire IS and OS groups, length of stay was less in the IS group, as was time to regular diet. Average pain scores, operative time and complication rates were not significantly different between the groups. Of the IS patients a significantly lower number of patients had epidural failure, requiring substitution of a PCA for pain control. Conclusions: There are benefits derived from participating in our randomized trials comparing epidural to patient controlled analgesia after bar placement for pectus excavatum regardless of which arm is utilized. (c) 2015 Elsevier Inc. All rights reserved.	[Dalton, Brian G. A.; Gonzalez, Katherine W.; Desai, Amita A.; Sharp, Susan W.; St Peter, Shawn D.] Childrens Mercy Hosp, Dept Pediat Surg, Kansas City, MO 64108 USA; [Millspaugh, Daniel L.] Childrens Mercy Hosp, Dept Anesthesiol, Kansas City, MO 64108 USA	St Peter, SD (reprint author), Childrens Mercy Hosp, Dept Surg, 2401 Gillham Rd, Kansas City, MO 64108 USA.	sspeter@cmh.edu					Croitoru DP, 2002, J PEDIATR SURG, V37, P437, DOI 10.1053/jpsu.2002.30851; Fonkalsrud EW, 2003, WORLD J SURG, V27, P502, DOI 10.1007/s00268-003-7025-5; Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214; Hoberman A, 2013, JAMA PEDIATR, V167, P561, DOI 10.1001/jamapediatrics.2013.1050; Holcomb III GW, 2010, PEDIAT SURG, P245; Miller KA, 2001, SURGERY, V130, P652, DOI 10.1067/msy.2001.116917; Molik KA, 2001, J PEDIATR SURG, V36, P324, DOI 10.1053/jpsu.2001.20707; Park HJ, 2004, ANN THORAC SURG, V77, P289, DOI 10.1016/S0003-4975(03)01330-4; Peter SDS, 2010, J PEDIATR SURG, V45, P1361, DOI 10.1016/j.jpedsurg.2010.02.115; St Peter SD, 2012, J PEDIATR SURG, V47, P148, DOI 10.1016/j.jpedsurg.2011.10.040; Swoveland B, 2001, AORN J, V74, P828; Tait AR, 2003, ANESTHESIOLOGY, V99, P819, DOI 10.1097/00000542-200310000-00012; Uemura S, 2003, PEDIATR SURG INT, V19, P186, DOI 10.1007/s00383-002-0915-z	13	3	4	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	NOV	2015	50	11					1937	1939		10.1016/j.jpedsurg.2015.05.009			3	Pediatrics; Surgery	Pediatrics; Surgery	DA1UG	WOS:000367580400026	26100690				2020-06-30	J	Goudra, B; Nuzat, A; Singh, PM; Gouda, GB; Carlin, A; Manjunath, AK				Goudra, Basavana; Nuzat, Ahmad; Singh, Preet M.; Gouda, Gowri B.; Carlin, Augustus; Manjunath, Amit K.			Cardiac Arrests in Patients Undergoing Gastrointestinal Endoscopy: A Retrospective Analysis of 73,029 Procedures	SAUDI JOURNAL OF GASTROENTEROLOGY			English	Article						Cardiac arrest; death; endoscopy; Endoscopc retrograde cholangiopancreatogrphy; Esophagoduodenoscopy; propofol	ADMINISTERED PROPOFOL SEDATION; ANESTHESIA; EUS; MIDAZOLAM; SAFETY; RISK	Background/Aims: Airway difficulties leading to cardiac arrest are frequently encountered during propofol sedation in patients undergoing gastrointestinal (GI) endoscopy. With a noticeable increase in the use of propofol for endoscopic sedation, we decided to examine the incidence and outcome of cardiac arrests in patients undergoing gastrointestinal (GI) endoscopy with sedation. Patients and Methods: In this retrospective study, cardiac arrest data obtained from the clinical quality improvement and local registry over 5 years was analyzed. The information of patients who sustained cardiac arrest attributable to sedation was studied in detail. Analysis included comparison of cardiac arrests due to all causes until discharge (or death) versus the cardiac arrests and death occurring during the procedure and in the recovery area. Results: The incidence of cardiac arrest and death (all causes, until discharge) was 6.07 and 4.28 per 10,000 in patients sedated with propofol, compared with non-propofol-based sedation (0.67 and 0.44). The incidence of cardiac arrest during and immediately after the procedure (recovery area) for all endoscopies was 3.92 per 10,000; of which, 72% were airway management related. About 90.0% of all peri-procedural cardiac arrests occurred in patients who received propofol. Conclusions: The incidence of cardiac arrest and death is about 10 times higher in patients receiving propofol-based sedation compared with those receiving midazolam-fentanyl sedation. More than two thirds of these events occur during EGD and ERCP.	[Goudra, Basavana] Hosp Univ Penn, Dept Clin Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Nuzat, Ahmad] Hosp Univ Penn, Dept Med, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA; [Singh, Preet M.] All India Inst Med Sci, Dept Anesthesiol & Crtical Care Med, New Delhi, India; [Gouda, Gowri B.; Carlin, Augustus; Manjunath, Amit K.] Perelman Sch Med, Dept Clin Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Goudra, B (reprint author), Dept Anesthesiol & Crit Care Med, 680 Dulles Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	goudrab@uphs.upenn.edu	Singh, Preet Mohinder/V-3471-2017	Singh, Preet Mohinder/0000-0001-7642-529X			Cote GA, 2010, CLIN GASTROENTEROL H, V8, P137, DOI 10.1016/j.cgh.2009.07.008; DeWitt J, 2008, GASTROINTEST ENDOSC, V68, P499, DOI 10.1016/j.gie.2008.02.092; Fanti L, 2007, DIGEST LIVER DIS, V39, P81, DOI 10.1016/j.dld.2006.09.004; Fatima H, 2008, AM J GASTROENTEROL, V103, P1649, DOI 10.1111/j.1572-0241.2008.01906.x; Friedrich K, 2012, J GASTROINTEST LIVER, V21, P259; Goudra BGB, 2013, JAMA INTERN MED, V173, P1659, DOI 10.1001/jamainternmed.2013.8756; Khan HA, 2014, ARAB J GASTROENTEROL, V15, P32, DOI 10.1016/j.ajg.2014.01.011; Kopp SL, 2005, ANESTH ANALG, V100, P855, DOI 10.1213/01.ANE.0000144066.72932.B1; Metzner J, 2009, CURR OPIN ANESTHESIO, V22, P502, DOI 10.1097/ACO.0b013e32832dba50; Redondo-Cerezo E, 2012, EUR J GASTROEN HEPAT, V24, P506, DOI 10.1097/MEG.0b013e328350fcbd; Rex DK, 2009, TECH GASTROINTEST EN, V11, P177, DOI 10.1016/j.tgie.2009.09.003; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Sprung J, 2008, SIGNA VITAE, V3, P8, DOI 10.22514/SV32.102008.2; Yusoff IF, 2004, GASTROINTEST ENDOSC, V60, P356, DOI 10.1016/S0016-5107(04)01711-0	14	25	25	0	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1319-3767	1998-4049		SAUDI J GASTROENTERO	Saudi J. Gastroenterol.	NOV-DEC	2015	21	6					400	+		10.4103/1319-3767.164202			12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CZ4RB	WOS:000367089300011	26655137	DOAJ Gold, Green Published			2020-06-30	J	Hsu, CD; Huang, JM; Chuang, YP; Wei, HY; Su, YC; Wu, JY; Wang, WM; Hsu, HT; Huang, HF; Lu, IC; Lu, DV				Hsu, Chiung-Dan; Huang, Jui-Mei; Chuang, Ya-Ping; Wei, Hua-Yi; Su, Yu-Chung; Wu, Jeng-Yih; Wang, Wen-Ming; Hsu, Hung-Te; Huang, Hui-Fang; Lu, I-Cheng; Lu, David Vi			Propofol target-controlled infusion for sedated gastrointestinal endoscopy: A comparison of propofol alone versus propofol-fentanyl-midazolam	KAOHSIUNG JOURNAL OF MEDICAL SCIENCES			English	Article						Gastrointestinal endoscopy; Propofol; Target-controlled infusion	OUTPATIENT COLONOSCOPY; DEEP SEDATION; MEPERIDINE; TRIAL; BENZODIAZEPINES; COMBINATION; ANALGESIA; QUALITY	Gastrointestinal (GI) endoscopy is the major technique for diagnosis of GI disease and treatment. Various sedation and analgesia regimens such as midazolam, fentanyl, and propofol can be used during GI endoscopy. The purpose of the study was to compare propofol alone and propofol combination with midazolam and fentanyl in moderate sedation for GI endoscopy. One hundred patients undergoing GI endoscopy were enrolled in this study. All patients received a propofol target-controlled infusion (TCI) to maintain sedation during the procedure. Patients were randomly allocated into either Group P (propofol TCI alone) or Group C (combination of propofol TCI plus midazolam and fentanyl). Dermographic data, anesthetic parameters (sedation regimen, blood pressure, heart rate, and oxygen saturation), procedure parameters (procedure time, colonoscopy, or panendoscopy), propofol consumption, and adverse events (hypoxia, hypotension, and bradycardia) were all recorded. Postprocedural records included recovery time, postoperative adverse events (nausea, vomiting, dizziness, recall, and pain) and satisfaction. The average propofol consumption was 251 perpendicular to 83 mg in Group P and 159 +/- 73 mg in Group C (p < 0.001). The incidence of transient hypotension was higher in Group P (p = 0.009). The recovery time and discharge time were both shorter in Group C (p < 0.001 and p = 0.006 respectively). Overall, postprocedural adverse events were similar in both groups. The postanesthetic satisfaction was comparable in both groups. TCI of propofol combined with midazolam and fentanyl achieved sedation with fewer hypotension episodes and shorter recovery and discharge time than propofol TCI alone in patients undergoing GI endoscopy. Copyright (C) 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.	[Hsu, Chiung-Dan; Lu, I-Cheng; Lu, David Vi] Kaohsiung Municipal Hsiaokang Hosp, Dept Anesthesiol, Kaohsiung 812, Taiwan; [Huang, Jui-Mei; Chuang, Ya-Ping; Wei, Hua-Yi; Hsu, Hung-Te; Huang, Hui-Fang] Kaohsiung Municipal Tatung Hosp, Dept Anesthesiol, Kaohsiung, Taiwan; [Su, Yu-Chung; Wu, Jeng-Yih; Wang, Wen-Ming] Kaohsiung Municipal Tatung Hosp, Dept Internal Med, Kaohsiung, Taiwan	Lu, DV (reprint author), Kaohsiung Municipal Hsiaokang Hosp, Dept Anesthesiol, 482 Shanming Rd, Kaohsiung 812, Taiwan.	davidlu@kmu.edu.tw		Hsu, Hung-Te/0000-0002-2140-3146			Chan WH, 2014, J DIGEST DIS, V15, P18, DOI 10.1111/1751-2980.12101; DeWitt J, 2008, GASTROINTEST ENDOSC, V68, P499, DOI 10.1016/j.gie.2008.02.092; Frolich MA, 2005, BRIT J ANAESTH, V94, P434, DOI 10.1093/bja/aei081; Gras S, 2010, ANESTH ANALG, V110, P89, DOI 10.1213/ANE.0b013e3181c5bd11; Heuss LT, 2005, ENDOSCOPY, V37, P161, DOI 10.1055/s-2004-826143; Hsieh YH, 2009, J CLIN GASTROENTEROL, V43, P753, DOI 10.1097/MCG.0b013e3181862a8c; Hsu WH, 2013, J DIGEST DIS, V14, P147, DOI 10.1111/1751-2980.12020; Lam Fai, 2013, Acta Anaesthesiol Taiwan, V51, P53, DOI 10.1016/j.aat.2013.06.009; Liu SYW, 2009, ENDOSCOPY, V41, P522, DOI 10.1055/s-0029-1214711; Mandel JE, 2008, ANESTH ANALG, V106, P434, DOI 10.1213/01.ane.0000297300.33441.32; Meining A, 2007, ENDOSCOPY, V39, P345, DOI 10.1055/s-2006-945195; Moerman AT, 2004, J CLIN ANESTH, V16, P237, DOI 10.1016/j.jclinane.2003.08.005; Olkkola K. T., 2008, V182, P335, DOI 10.1007/978-3-540-74806-9_16; Pao Yun-Ying, 2014, Acta Anaesthesiol Taiwan, V52, P13, DOI 10.1016/j.aat.2014.05.003; Robertson DJ, 2009, ALIMENT PHARM THER, V29, P817, DOI 10.1111/j.1365-2036.2009.03943.x; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Triantafillidis JK, 2013, WORLD J GASTROENTERO, V19, P463, DOI 10.3748/wjg.v19.i4.463; Tsai CJ, 2010, ANAESTHESIA, V65, P254, DOI 10.1111/j.1365-2044.2009.06226.x; van den Nieuwenhuyzen MCO, 2000, CLIN PHARMACOKINET, V38, P181, DOI 10.2165/00003088-200038020-00003; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Wang DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053311; Wang DR, 2013, SCAND J GASTROENTERO, V48, P101, DOI 10.3109/00365521.2012.737360; Xu CX, 2013, WORLD J GASTROENTERO, V19, P4791, DOI 10.3748/wjg.v19.i29.4791	23	8	9	0	3	ELSEVIER TAIWAN	TAIPEI	RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN	1607-551X			KAOHSIUNG J MED SCI	Kaohsiung J. Med. Sci.	NOV	2015	31	11					580	584		10.1016/j.kjms.2015.09.004			5	Medicine, Research & Experimental	Research & Experimental Medicine	CY6XX	WOS:000366553200005	26678938	DOAJ Gold			2020-06-30	J	Bista, SR; Haywood, A; Norris, R; Good, P; Tapuni, A; Lobb, M; Hardy, J				Bista, Sudeep R.; Haywood, Alison; Norris, Ross; Good, Phillip; Tapuni, Angela; Lobb, Michael; Hardy, Janet			Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer	CLINICAL THERAPEUTICS			English	Article						cancer pain; fentanyl; opioid; pharmacokinetics; plasma; saliva	NOR-FENTANYL; PAIN; MORPHINE; METABOLITES; MORPHINE-6-GLUCURONIDE; VALIDATION; MANAGEMENT; ANALGESIA; TRANSPORT; METHADONE	Purpose: Fentanyl is widely used to relieve cancer pain. However there is great interpatient variation in the dose required to relieve pain and little knowledge about the pharmacokinetic and pharmacodynamic (PK/PD) relationship of fentanyl and pain control. Patients with cancer are fragile and there is reluctance on the part of health professionals to take multiple plasma samples for PK/PD studies. The relationship between plasma and saliva fentanyl concentrations was investigated to determine whether saliva could be a valid substitute for plasma in PK/PD studies. Methods: One hundred sixty-three paired plasma and saliva samples were collected from 56 patients prescribed transdermal fentanyl (Durogesic, Janssen-Cilag Pty Limited, NSW, Australia) at varying doses (12-200 mu g/h). Pain scores were recorded at the time of sampling. Fentanyl and norfentanyl concentrations in plasma and saliva were quantified using HPLC-MS/MS. Findings: Saliva concentrations of fentanyl (mean = 4.84 mu g/L) were much higher than paired plasma concentrations of fentanyl (mean = 0.877 mu g/L). Both plasma and saliva mean concentrations of fentanyl were well correlated with dose with considerable interpatient variation at each dose. The relationship between fentanyl and norfentanyl concentrations was poor in both plasma and saliva. No correlation was observed between fentanyl concentration in plasma and saliva (r(2) = 0.3743) or free fentanyl in plasma and total saliva concentrations (r(2) = 0.1374). Pain scores and fentanyl concentration in either of the matrices were also not correlated. (C) 2015 Elsevier HS Journals, Inc. All rights reserved.	[Bista, Sudeep R.; Haywood, Alison; Norris, Ross] Griffith Univ, Menzies Hlth Inst Queensland, Sch Pharm, Gold Coast, NSW, Australia; [Haywood, Alison; Norris, Ross; Good, Phillip; Hardy, Janet] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia; [Norris, Ross] St Vincents Hosp, SydPath, Sydney, NSW 2010, Australia; [Norris, Ross] Univ New S Wales, St Vincents Clin Sch, Sydney, NSW, Australia; [Good, Phillip; Tapuni, Angela; Hardy, Janet] Mater Hlth Serv, Dept Palliat & Support Care, Brisbane, Qld, Australia; [Good, Phillip] St Vincents Private Hosp, Palliat Care, Brisbane, Qld, Australia; [Lobb, Michael] Mater Pathol Serv, South Brisbane, Qld, Australia	Bista, SR (reprint author), Sch Pharm, Gold Coast Campus, Griffith, Qld 4222, Australia.	s.bista@griffith.edu.au	Hardy, Janet/F-2501-2012; Good, Phillip/B-4004-2008	Good, Phillip/0000-0002-8198-0375; Haywood, Alison/0000-0002-5354-8868	Menzies Health Institute Queensland; Mater Medical Research Institute; Griffith UniversityGriffith University	The authors thank Menzies Health Institute Queensland, Griffith University, and Mater Medical Research Institute for partially funding this study and for the patients who contributed.	Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; Bista SR, 2015, J PAIN SYMPTOM MANAG, V49, P934, DOI 10.1016/j.jpainsymman.2014.09.017; Bista SR, 2015, XENOBIOTICA, V45, P207, DOI 10.3109/00498254.2014.971093; Charles BG, 1999, AUS J HOSP PHARM, P88; DANHOF M, 1978, CLIN PHARMACOKINET, V3, P39, DOI 10.2165/00003088-197803010-00003; Faura CC, 1996, J PAIN SYMPTOM MANAG, V11, P95, DOI 10.1016/0885-3924(95)00148-4; Food and Drug Administration, GUID FENT FOOD DRUG; Gandia P, 2003, J CLIN PHARMACOL, V43, P1235, DOI 10.1177/0091270003257229; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Gretton SK, 2013, J PAIN SYMPTOM MANAG, V45, P670, DOI 10.1016/j.jpainsymman.2012.03.015; Haeckel R, 1996, EUR J CLIN CHEM CLIN, V34, P171; Hardy J, 2012, SUPPORT CARE CANCER, V20, P767, DOI 10.1007/s00520-011-1147-3; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Hold KM, 1999, INT J DRUG TESTING, V1, P1; Kopecky EA, 1997, THER DRUG MONIT, V19, P530, DOI 10.1097/00007691-199710000-00008; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Loo JA, 2010, J DENT RES, V89, P1016, DOI 10.1177/0022034510380414; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MATIN SB, 1974, CLIN PHARMACOL THER, V16, P1052; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Moolchan ET, 2001, J ADDICT DIS, V20, P55, DOI 10.1300/J069v20n02_05; Navarro M, 2001, CLIN CHEM, V47, P1788; O'Neal CL, 1999, J ANAL TOXICOL, V23, P452, DOI 10.1093/jat/23.6.452; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Pourzitaki C, 2006, REV CLIN PHARM PHARM, V20, P108; Quigley C, 2003, PALLIATIVE MED, V17, P185, DOI 10.1191/0269216303pm658oa; RITSCHEL WA, 1987, J CLIN PHARMACOL, V27, P647, DOI 10.1002/j.1552-4604.1987.tb03082.x; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; Shiran MR, 2005, THER DRUG MONIT, V27, P580, DOI 10.1097/01.ftd.0000164392.01779.db; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Skopp G, 2001, INT J LEGAL MED, V114, P133, DOI 10.1007/PL00007717; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Tesseromatis C, ACUTE PHASE PROTEINS; TROUPIN AS, 1975, EPILEPSIA, V16, P223, DOI 10.1111/j.1528-1157.1975.tb06051.x; Wokovich AM, 2006, EUR J PHARM BIOPHARM, V64, P1, DOI 10.1016/j.ejpb.2006.03.009	36	7	8	0	9	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	NOV	2015	37	11					2468	2475		10.1016/j.clinthera.2015.09.002			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CY2MN	WOS:000366242900010	26404396				2020-06-30	J	Isik, IA; Iyilikci, L; Ozturk, Y; Adiyaman, E				Isik, Ishak A.; Iyilikci, Leyla; Ozturk, Yesim; Adiyaman, Esma			Sedation Practice Outside the Operating Room for Pediatric Gastrointestinal Endoscopy	INDIAN PEDIATRICS			English	Letter						Anesthesia; Complication; Endoscopy; Sedation	ADVERSE EVENTS; PROPOFOL; SEDATION/ANESTHESIA; MIDAZOLAM	Medical records of the 575 children who underwent gastrointestinal endoscopy outside the operating room were investigated retrospectively. The most frequently used combinations were propofol-midazolam-fentanyl in 83.2% of the procedures and propofol-midazolam in 13.8% of the procedures. 24 (3.4%) of 703 procedures had complications due to sedation anesthesia; 11 had hypoxia and 8 had pain in the injection area. Sedation anesthesia practice provided by an anesthesiologist outside the operating room enables gastrointestional endoscopic procedures to be carried out more safely.	[Isik, Ishak A.; Ozturk, Yesim] Dokuz Eylul Univ, Sch Med Hepatol & Nutr, Dept Pediat Gastroenterol, Yzmir, Turkey; [Iyilikci, Leyla; Adiyaman, Esma] Dokuz Eylul Univ, Dept Anesthesiol & Reanimatol, Yzmir, Turkey	Isik, IA (reprint author), Dokuz Eylul Univ, Sch Med Hepatol & Nutr, Dept Pediat Gastroenterol, Yzmir, Turkey.	Yshaksik02@yahoo.com.tr	iyilikci, leyla/Q-1633-2019				BENDIG DW, 1991, J PEDIATR GASTR NUTR, V12, P39, DOI 10.1097/00005176-199101000-00008; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Cravero JP, 2006, PEDIATRICS, V118, P1087, DOI 10.1542/peds.2006-0313; Cravero JP, 2009, ANESTH ANALG, V108, P795, DOI 10.1213/ane.0b013e31818fc334; Dumonceau JM, 2010, EUR J ANAESTH, V27, P1016, DOI 10.1097/EJA.0b013e32834136bf; Julian-Gomez L, 2010, REV ESP ENFERM DIG, V102, P100, DOI 10.4321/s1130-01082010000200005; Martinez JL, 2002, J PEDIATR GASTR NUTR, V35, P51, DOI 10.1097/00005176-200207000-00012; Miqdady MIS, 2011, WORLD J GASTROENTERO, V17, P3630, DOI 10.3748/wjg.v17.i31.3630; Nguyen VX, 2010, INT J GEN MED, V3, P345, DOI 10.2147/IJGM.S14555; Redondo-Cerezo E, 2012, EUR J GASTROEN HEPAT, V24, P506, DOI 10.1097/MEG.0b013e328350fcbd	10	3	3	0	2	SPRINGER INDIA	NEW DELHI	7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA	0019-6061	0974-7559		INDIAN PEDIATR	Indian Pediatrics	NOV	2015	52	11					989	990		10.1007/s13312-015-0761-4			2	Pediatrics	Pediatrics	CX2WK	WOS:000365557300018	26615354				2020-06-30	J	Fava, M				Fava, Maurizio			Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder	JAMA Psychiatry			English	Editorial Material							CLINICAL-TRIALS		[Fava, Maurizio] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Fava, Maurizio] Harvard Univ, Sch Med, Boston, MA USA	Fava, M (reprint author), Massachusetts Gen Hosp, Div Clin Res, MGH Res Inst, Dept Psychiat,CTNI, 55 Fruit St,Bulfinch 351, Boston, MA 02114 USA.	mfava@mgh.harvard.edu	Fava, Maurizio/AAH-3548-2020		Abbott LaboratoriesAbbott Laboratories; Adamed Co; Advanced Meeting Partners; Affectis Pharmaceuticals AG; Alkermes Inc; Amarin Pharma Inc; American Cyanamid; American Psychiatric Association; American Society of Clinical Psychopharmacology; Aspect Medical Systems; AstraZenecaAstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AGBayer AG; Belvoir Media Group; Best Practice Project Management Inc; BioMarin Pharmaceuticals Inc; BioResearch; Biovail Corp; Boehringer Ingelheim GmbHBoehringer Ingelheim; BrainCells Inc; Bristol-Myers SquibbBristol-Myers Squibb; CeNeRx BioPharma; Cephalon Inc; Cerecor; Clintara LLC; CME Institute/Physicians Postgraduate Press Inc; CNS Response Inc; Compellis Pharmaceuticals; Covance; Covidien; Cypress Pharmaceutical Inc; DiagnoSearch Life Sciences Ltd; Dinippon Sumitomo Pharma Co Inc; Dov Pharmaceuticals Inc; Edgemont Pharmaceuticals Inc; Eisai IncEisai Inc; Eli Lilly and CoEli Lilly; EnVivo Pharmaceuticals Inc; ePharmaSolutions; EPIX Pharmaceuticals Inc; Euthymics Bioscience Inc; Fabre-Kramer Pharmaceuticals Inc; Forest Pharmaceuticals Inc; Forum Pharmaceuticals; Ganeden Biotech Inc; GenOmind LLC; GlaxoSmithKlineGlaxoSmithKline; Grunenthal GmbH; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenis; Imedex LLC; Janssen PharmaceuticaJohnson & Johnson USAJanssen Biotech Inc; Jazz Pharmaceuticals Inc; Jed Foundation; Johnson and Johnson Pharmaceutical Research Development LLC; Knoll Pharmaceuticals Corp; Labopharm Inc; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck IncLundbeck Corporation; MedAvante Inc; Merck Co IncMerck & Company; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; MSI Methylation Sciences Inc; National Alliance for Research on Schizophrenia DepressionNARSAD; National Center for Complementary and Alternative MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); Naurex Inc; Nestle Health Sciences; Neuralstem Inc; Neuronetics Inc; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics Inc; Organon Pharmaceuticals; Otsuka PharmaceuticalsOtsuka Pharmaceutical; Pamlab LLC; Pfizer IncPfizer; Pharmacia and Upjohn; Pharmaceutical Research Associates Inc; PharmaStar; Pharmavite LLC; PharmoRx Therapeutics; Photothera; Precision Human Biolaboratory; Prexa Pharmaceuticals Inc; PPD; Puretech Ventures; PsychoGenics; Psylin Neurosciences Inc; RCT Logic LLC; Reckitt Benckiser; Rexahn Pharmaceuticals Inc; Ridge Diagnostics Inc; RocheRoche Holding; Sanofi US LLC; Sepracor Inc; Servier Laboratories; Schering-Plough CorpMerck & CompanySchering Plough Corporation; Shire; Solvay Pharmaceuticals Inc; Somaxon Pharmaceuticals Inc; Somerset Pharmaceuticals Inc; Stanley Medical Research Institute; Sunovion Pharmaceuticals; Supernus Pharmaceuticals Inc; Synthelabo; Takeda Pharmaceutical Co LtdTakeda Pharmaceutical Company Ltd; Tal Medical Inc; Tetragenex Pharmaceuticals Inc; TransForm Pharmaceuticals Inc; Transcept Pharmaceuticals Inc; United BioSource Corp; Vanda Pharmaceuticals Inc; Wyeth-Ayerst LaboratoriesCanadian Institutes of Health Research (CIHR)	Dr Fava has received research support from, has served on the advisory board for, has served as a consultant for, and/or has been involved with speaking/publishing for Abbott Laboratories; Adamed Co; Advanced Meeting Partners; Affectis Pharmaceuticals AG; Alkermes Inc; Amarin Pharma Inc; American Cyanamid; American Psychiatric Association; American Society of Clinical Psychopharmacology; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AG; Belvoir Media Group; Best Practice Project Management Inc; BioMarin Pharmaceuticals Inc; BioResearch; Biovail Corp; Boehringer Ingelheim GmbH; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon Inc; Cerecor; Clintara LLC; CME Institute/Physicians Postgraduate Press Inc; CNS Response Inc; Compellis Pharmaceuticals; Covance; Covidien; Cypress Pharmaceutical Inc; DiagnoSearch Life Sciences Ltd; Dinippon Sumitomo Pharma Co Inc; Dov Pharmaceuticals Inc; Edgemont Pharmaceuticals Inc; Eisai Inc; Eli Lilly and Co; EnVivo Pharmaceuticals Inc; ePharmaSolutions; EPIX Pharmaceuticals Inc; Euthymics Bioscience Inc; Fabre-Kramer Pharmaceuticals Inc; Forest Pharmaceuticals Inc; Forum Pharmaceuticals; Ganeden Biotech Inc; GenOmind LLC; GlaxoSmithKline; Grunenthal GmbH; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenis; Imedex LLC; Janssen Pharmaceutica; Jazz Pharmaceuticals Inc; Jed Foundation; Johnson and Johnson Pharmaceutical Research Development LLC; Knoll Pharmaceuticals Corp; Labopharm Inc; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc; MedAvante Inc; Merck Co Inc; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; MSI Methylation Sciences Inc; National Alliance for Research on Schizophrenia Depression; National Center for Complementary and Alternative Medicine; National Institute on Drug Abuse; Naurex Inc; Nestle Health Sciences; Neuralstem Inc; Neuronetics Inc; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics Inc; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab LLC; Pfizer Inc; Pharmacia and Upjohn; Pharmaceutical Research Associates Inc; PharmaStar; Pharmavite LLC; PharmoRx Therapeutics; Photothera; Precision Human Biolaboratory; Prexa Pharmaceuticals Inc; PPD; Puretech Ventures; PsychoGenics; Psylin Neurosciences Inc; RCT Logic LLC, formerly Clinical Trials Solutions LLC; Reckitt Benckiser; Rexahn Pharmaceuticals Inc; Ridge Diagnostics Inc; Roche; Sanofi US LLC; Sepracor Inc; Servier Laboratories; Schering-Plough Corp; Shire; Solvay Pharmaceuticals Inc; Somaxon Pharmaceuticals Inc; Somerset Pharmaceuticals Inc; Stanley Medical Research Institute; Sunovion Pharmaceuticals; Supernus Pharmaceuticals Inc; Synthelabo; Takeda Pharmaceutical Co Ltd; Tal Medical Inc; Tetragenex Pharmaceuticals Inc; TransForm Pharmaceuticals Inc; Transcept Pharmaceuticals Inc; United BioSource Corp; Vanda Pharmaceuticals Inc; and Wyeth-Ayerst Laboratories. He has equity holdings in Compellis and PsyBrain Inc and royalty/other income from patents for sequential parallel comparison design licensed by Massachusetts General Hospital to Pharmaceutical Product Development LLC PPD and a patent application for a combination of ketamine plus scopolamine in major depressive disorder licensed by Massachusetts General Hospital to Biohaven.	Borsook D, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.43; BROWN WA, 1994, NEUROPSYCHOPHARMACOL, V10, P265, DOI 10.1038/npp.1994.53; Fava M, 2003, BIOL PSYCHIAT, V53, P649, DOI 10.1016/S0006-3223(03)00231-2; Fava M, 2003, PSYCHOTHER PSYCHOSOM, V72, P115, DOI 10.1159/000069738; Kelley JM, 2012, PSYCHOTHER PSYCHOSOM, V81, P312, DOI 10.1159/000337053; Papakostas GI, 2009, EUR NEUROPSYCHOPHARM, V19, P34, DOI 10.1016/j.euroneuro.2008.08.009; Pecina M, 2015, JAMA PSYCHIAT, V72, P1087, DOI 10.1001/jamapsychiatry.2015.1335	7	5	5	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	NOV	2015	72	11					1073	1074		10.1001/jamapsychiatry.2015.1727			2	Psychiatry	Psychiatry	CV6YG	WOS:000364417600004	26421499				2020-06-30	J	Sidhu, SK; Weavil, JC; Venturelli, M; Rossman, MJ; Gmelch, BS; Bledsoe, AD; Richardson, RS; Amann, M				Sidhu, Simranjit K.; Weavil, Joshua C.; Venturelli, Massimo; Rossman, Matthew J.; Gmelch, Benjamin S.; Bledsoe, Amber D.; Richardson, Russell S.; Amann, Markus			Aging alters muscle reflex control of autonomic cardiovascular responses to rhythmic contractions in humans	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						afferent feedback; dynamic exercise; exercise pressor reflex	CAROTID BAROREFLEX CONTROL; EXERCISE PRESSOR REFLEX; ARTERIAL-BLOOD PRESSURE; DYNAMIC EXERCISE; CARDIAC-OUTPUT; AFFERENTS CONTRIBUTE; METABOLIC-RESPONSE; ADVANCING AGE; FIBER-TYPE; GROUP-III	We investigated the influence of aging on the group III/IV muscle afferents in the exercise pressor reflex-mediated cardiovascular response to rhythmic exercise. Nine old (OLD; 68 +/- 2 yr) and nine young (YNG; 24 +/- 2 yr) males performed single-leg knee extensor exercise (15 W, 30 W, 80% max) under control conditions and with lumbar intrathecal fentanyl impairing feedback from group III/IV leg muscle afferents. Mean arterial pressure (MAP), cardiac output, leg blood flow (QL), systemic (SVC) and leg vascular conductance (LVC) were continuously determined. With no hemodynamic effect at rest, fentanyl blockade during exercise attenuated both cardiac output and QL similar to 17% in YNG, while the decrease in cardiac output in OLD (similar to 5%) was significantly smaller with no impact on QL (P = 0.8). Therefore, in the face of similar significant similar to 7% reduction in MAP during exercise with fentanyl blockade in both groups, LVC significantly increased similar to 11% in OLD, but decreased similar to 8% in YNG. The opposing direction of change was reflected in SVC with a significant similar to 5% increase in OLD and a similar to 12% decrease in YNG. Thus while cardiac output seems to account for the majority of group III/IV-mediated MAP responses in YNG, the impact of neural feedback on the heart may decrease with age and alterations in SVC become more prominent in mediating the similar exercise pressor reflex in OLD. Interestingly, in terms of peripheral hemodynamics, while group III/IV-mediated feedback plays a clear role in increasing LVC during exercise in the YNG, these afferents seem to actually reduce LVC in OLD. These peripheral findings may help explain the limited exercise-induced peripheral vasodilation often associated with aging.	[Sidhu, Simranjit K.; Venturelli, Massimo; Richardson, Russell S.; Amann, Markus] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Weavil, Joshua C.; Rossman, Matthew J.; Richardson, Russell S.; Amann, Markus] Univ Utah, Dept Exercise & Sport Sci, Salt Lake City, UT USA; [Richardson, Russell S.; Amann, Markus] Univ Utah, Vet Affairs Med Ctr, Geriatr Res Educ Ctr, Salt Lake City, UT USA; [Richardson, Russell S.; Amann, Markus] Univ Utah, Vet Affairs Med Ctr, Ctr Clin, Salt Lake City, UT USA; [Gmelch, Benjamin S.; Bledsoe, Amber D.; Amann, Markus] Univ Utah, Dept Anesthesiol, Salt Lake City, UT USA; [Sidhu, Simranjit K.] Univ Adelaide, Sch Med, Discipline Physiol, Adelaide, SA 5005, Australia; [Venturelli, Massimo] Univ Milan, Dept Biomed Sci Hlth, I-20122 Milan, Italy	Sidhu, SK (reprint author), Univ Adelaide, Med Sch North, N404, Adelaide, SA 5005, Australia.	simran.sidhu@adelaide.edu.au	Sidhu, Simranjit/A-5478-2012; Venturelli, Massimo/AAQ-4613-2020; Venturelli, Massimo/F-3235-2014	Sidhu, Simranjit/0000-0002-4797-8298; Venturelli, Massimo/0000-0002-2469-8787; Venturelli, Massimo/0000-0002-2469-8787; Amann, Markus/0000-0002-4012-8880; Weavil, Joshua/0000-0002-2032-8498	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-103786, HL-116579, HL-091830]; American Heart AssociationAmerican Heart Association [14POST17770016]; Veteran Affairs Merit Grant [E6910R]	This study was supported by National Heart, Lung, and Blood Institute Grants HL-103786, HL-116579, and HL-091830; American Heart Association Grant 14POST17770016; and Veteran Affairs Merit Grant E6910R.	Amann M, 2015, AUTON NEUROSCI-BASIC, V188, P19, DOI 10.1016/j.autneu.2014.10.018; Amann M, 2011, J PHYSIOL-LONDON, V589, P3855, DOI 10.1113/jphysiol.2011.209353; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Barrett-O'Keefe Z, 2015, J GERONTOL A-BIOL, V70, P554, DOI 10.1093/gerona/glu065; BERKENBOSCH A, 1989, J PHYSIOL-LONDON, V411, P367, DOI 10.1113/jphysiol.1989.sp017578; Bogert LWJ, 2005, EXP PHYSIOL, V90, P437, DOI 10.1113/expphysiol.2005.030262; Boushel R, 2010, ACTA PHYSIOL, V199, P367, DOI 10.1111/j.1748-1716.2010.02133.x; COOTE JH, 1971, J PHYSIOL-LONDON, V215, P789, DOI 10.1113/jphysiol.1971.sp009498; Credeur DP, 2014, AM J PHYSIOL-HEART C, V306, pH1417, DOI 10.1152/ajpheart.00036.2014; Dinenno FA, 2005, J PHYSIOL-LONDON, V567, P311, DOI 10.1113/jphysiol.2005.087668; Donato AJ, 2006, AM J PHYSIOL-HEART C, V290, pH272, DOI 10.1152/ajpheart.00405.2005; Fadel PJ, 2012, EXP PHYSIOL, V97, P39, DOI 10.1113/expphysiol.2011.057554; Ferrara N, 2014, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00396; Ferrari AU, 2003, J APPL PHYSIOL, V95, P2591, DOI 10.1152/japplphysiol.00601.2003; Fisher JP, 2007, AM J PHYSIOL-HEART C, V293, pH777, DOI 10.1152/ajpheart.00199.2007; Fisher JP, 2012, AUTON NEUROSCI-BASIC, V172, P13, DOI 10.1016/j.autneu.2012.10.013; Fisher JP, 2010, AM J PHYSIOL-REG I, V299, pR1241, DOI 10.1152/ajpregu.00462.2010; Gonzalez-Alonso J, 2001, J PHYSIOL-LONDON, V530, P331, DOI 10.1111/j.1469-7793.2001.0331l.x; HIGGINBOTHAM MB, 1986, AM J CARDIOL, V57, P1374, DOI 10.1016/0002-9149(86)90221-3; HILL JM, 1990, J APPL PHYSIOL, V68, P2466; Hilty L, 2011, EXP PHYSIOL, V96, P505, DOI 10.1113/expphysiol.2010.056226; Hoskins DL, 1998, BRAIN RES, V791, P299, DOI 10.1016/S0006-8993(98)00034-1; Houssiere A, 2006, MED SCI SPORT EXER, V38, P305, DOI 10.1249/01.mss.0000187426.93464.81; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; KAUFMAN MP, 1996, HDB PHYSIOL 12, P381; Kim A, 2011, AM J PHYSIOL-HEART C, V301, pH2454, DOI 10.1152/ajpheart.00772.2011; Laitinen T, 2004, J APPL PHYSIOL, V96, P2333, DOI 10.1152/japplphysiol.00444.2003; Lakatta EG, 2000, CLIN GERIATR MED, V16, P419, DOI 10.1016/S0749-0690(05)70021-5; Lalande S, 2014, J APPL PHYSIOL, V116, P222, DOI 10.1152/japplphysiol.01022.2013; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Lawrenson L, 2003, AM J PHYSIOL-HEART C, V285, pH1023, DOI 10.1152/ajpheart.00135.2003; LEXELL J, 1995, J GERONTOL A-BIOL, V50, P11; Markel TA, 2003, CIRCULATION, V107, P675, DOI 10.1161/01.CIR.0000055190.81716.AB; MCCLOSKE.DI, 1972, J PHYSIOL-LONDON, V224, P173, DOI 10.1113/jphysiol.1972.sp009887; MEINTJES AF, 1995, CIRC RES, V77, P326, DOI 10.1161/01.RES.77.2.326; Mitchell GF, 2008, J APPL PHYSIOL, V105, P1652, DOI 10.1152/japplphysiol.90549.2008; MITCHELL JH, 1977, AM J PHYSIOL, V233, pH374; MITCHELL JH, 1983, ANNU REV PHYSIOL, V45, P229, DOI 10.1146/annurev.ph.45.030183.001305; Mortensen SP, 2012, J PHYSIOL-LONDON, V590, P6227, DOI 10.1113/jphysiol.2012.240093; O'Leary DS, 1998, AM J PHYSIOL-HEART C, V275, pH220; OGAWA T, 1992, CIRCULATION, V86, P494, DOI 10.1161/01.CIR.86.2.494; Olson TP, 2014, EXP PHYSIOL, V99, P414, DOI 10.1113/expphysiol.2013.075937; POMEROY G, 1986, BRAIN RES, V381, P385, DOI 10.1016/0006-8993(86)90095-8; Poole JG, 2003, AM J PHYSIOL-HEART C, V284, pH1251, DOI 10.1152/ajpheart.00790.2002; Proctor DN, 1998, J APPL PHYSIOL, V84, P599; Proctor DN, 2003, J APPL PHYSIOL, V95, P1963, DOI 10.1152/japplphysiol.00472.2003; Proctor DN, 1998, J APPL PHYSIOL, V85, P68; Purves-Smith FM, 2014, EXERC SPORT SCI REV, V42, P45, DOI 10.1249/JES.0000000000000012; RODEHEFFER RJ, 1984, CIRCULATION, V69, P203, DOI 10.1161/01.CIR.69.2.203; Seals DR, 2000, J PHYSIOL-LONDON, V528, P407, DOI 10.1111/j.1469-7793.2000.00407.x; Secher NH, 2012, EXP PHYSIOL, V97, P59, DOI 10.1113/expphysiol.2011.057679; Smith SA, 2003, J PHYSIOL-LONDON, V551, P1013, DOI 10.1113/jphysiol.2003.044925; THOMAS SG, 1993, CAN J PHYSIOL PHARM, V71, P136, DOI 10.1139/y93-019; Vianna LC, 2012, AM J PHYSIOL-HEART C, V302, pH2419, DOI 10.1152/ajpheart.01105.2011; Wilson L B, 1995, Adv Exp Med Biol, V381, P187; WILSON LB, 1995, J APPL PHYSIOL, V79, P1744; Wray DW, 2015, EXP PHYSIOL, V100, P589, DOI 10.1113/EP085076	58	16	16	0	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135	1522-1539		AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	NOV 1	2015	309	9					H1479	H1489		10.1152/ajpheart.00433.2015			11	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Physiology	CV2NH	WOS:000364092900009	26386110	Green Published			2020-06-30	J	Elfil, H; Crowley, L; Segurado, R; Spring, A				Elfil, H.; Crowley, L.; Segurado, R.; Spring, A.			A randomised controlled trial of the effect of a head-elevation pillow on intrathecal local anaesthetic spread in caesarean section	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Combined spinal-epidural anaesthesia; Caesarean section; Head elevation pillow	POSITION	Background: A head-elevation pillow places a patient in a ramped posture, which maximises the view of the larynx during laryngoscopy, particularly in obese parturients. In our institution an elevation pillow is used pre-emptively for neuraxial anaesthesia. We hypothesised that head-elevation may impair cephalad spread of local anaesthetic before caesarean section resulting in a lower block or longer time to achieve a T6 level. We aimed to investigate the effect of head-elevation on spread of intrathecal local anaesthetics during anaesthesia for caesarean section. Methods: One-hundred parturients presenting for caesarean section under combined spinal-epidural anaesthesia were randomised to either the standard supine position with lateral displacement or in the supine position with lateral displacement on an head-elevation pillow. Each patient received intrathecal hyperbaric bupivacaine 11 mg, morphine 100 mu g and fentanyl 15 mu g. Patients were assessed for adequacy of sensory block (T6 or higher) at 10 min. Results: Sensory block to T6 was achieved within 10 mm in 65.9% of parturients in the Elevation Pillow Group compared to 95.7% in the Control Group (P<0.05). Compared to the Control Group, patients in the Elevation Pillow Group had greater requirements for epidural supplementation (43.5% vs 2.1%, P<0.001) or conversion to general anaesthesia (9.3% vs 0%, P<0.04). Conclusions: Use of a ramped position with an head-elevation pillow following injection of the intrathecal component of a combined spinal-epidural anaesthetic for scheduled caesarean section was associated with a significantly lower block height at 10 min. (C) 2015 Elsevier Ltd. All rights reserved.	[Elfil, H.; Crowley, L.; Spring, A.] Natl Matern Hosp, Dept Anaesthesia, Dublin 2, Ireland; [Segurado, R.] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Dublin 2, Ireland	Elfil, H (reprint author), Natl Matern Hosp, Dept Anaesthesia, Dublin 2, Ireland.	asmak33@hotmail.com	Segurado, Ricardo/K-6116-2014	Segurado, Ricardo/0000-0002-3547-6733			Benumof JL, 1996, AIRWAY MANAGEMENT PR, P261; Cheesman K, 2014, INT J OBSTET ANESTH, V23, P106, DOI 10.1016/j.ijoa.2014.01.002; El-Orbany M, 2011, ANESTH ANALG, V113, P103, DOI 10.1213/ANE.0b013e31821c7e9c; Levitan R, 2001, JEMS, V26, P36; Lucas DN, 2000, J ROY SOC MED, V93, P346, DOI 10.1177/014107680009300703; Panni MK, 2006, BRIT J ANAESTH, V96, P106, DOI 10.1093/bja/aei284; Pinchalk Mark, 2003, Prehosp Emerg Care, V7, P252, DOI 10.1080/10903120390936897; Russell IF, 2004, INT J OBSTET ANESTH, V13, P146, DOI 10.1016/j.ijoa.2003.12.007; Schmitt HJ, 2002, J CLIN ANESTH, V14, P335, DOI 10.1016/S0952-8180(02)00368-9	9	3	3	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	NOV	2015	24	4					303	307		10.1016/j.ijoa.2015.08.004			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	CV4RX	WOS:000364255300003	26421700				2020-06-30	J	Moaveni, D; Cohn, J; Brodt, J; Hoctor, K; Ranasinghe, J				Moaveni, D.; Cohn, J.; Brodt, J.; Hoctor, K.; Ranasinghe, J.			Scleroderma and pulmonary hypertension complicating two pregnancies: use of neuraxial anesthesia, general anesthesia, epoprostenol and a multidisciplinary approach for cesarean delivery	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Anesthesia; Obstetric; Scleroderma; CREST syndrome; Pulmonary hypertension; Epoprostenol; Cesarean delivery	IVA MORQUIO-BRAILSFORD; MUCOPOLYSACCHARIDOSIS; CHILDREN; CARE; DIAGNOSIS	Literature regarding the anesthetic care of patients with scleroderma during labor and delivery is limited to remote case reports. No recent publications provide information on the anesthetic management of patients with coexisting pulmonary hypertension. This report describe's the anesthetic and multidisciplinary management of two pregnant patients with concomitant scleroderma and pulmonary hypertension undergoing cesarean delivery; one with neuraxial anesthesia and one with general anesthesia. Considerations for neuraxial and general anesthesia in patients with concurrent scleroderma and pulmonary hypertension are discussed. (C) 2015 Elsevier Ltd. All rights reserved.	[Moaveni, D.; Cohn, J.; Brodt, J.; Hoctor, K.; Ranasinghe, J.] Univ Miami, Miller Sch Med, Jackson Mem Hosp, Miami, FL 33136 USA	Moaveni, D (reprint author), Jackson Mem Hosp, 1611 NW 12th Ave,Cent 301, Miami, FL 33136 USA.	dmoaveni@med.miami.edu					BELANI KG, 1993, J PEDIATR SURG, V28, P403, DOI 10.1016/0022-3468(93)90240-L; Cerda SE, 2007, SOC OBST AN PER 39 A; Hendriksz CJ, 2013, MOL GENET METAB, V110, P54, DOI 10.1016/j.ymgme.2013.04.002; Lankester BJA, 2006, CURR ORTHOPAED, V20, P128, DOI 10.1016/j.cuor.2005.12.003; Montano AM, 2007, J INHERIT METAB DIS, V30, P165, DOI 10.1007/s10545-007-0529-7; Northover H, 1996, J INHERIT METAB DIS, V19, P357, DOI 10.1007/BF01799267; Pagel PS, 2009, J CARDIOTHOR VASC AN, V23, P855, DOI 10.1053/j.jvca.2008.12.009; Sawicki AK, 2011, SOC OBST AN PER 43 A; Solanki GA, 2013, J INHERIT METAB DIS, V36, P329, DOI 10.1007/s10545-013-9585-3; Solanki GA, 2013, J INHERIT METAB DIS, V36, P339, DOI 10.1007/s10545-013-9586-2; Theroux MC, 2012, PEDIATR ANESTH, V22, P901, DOI 10.1111/j.1460-9592.2012.03904.x; Tobias JD, 1999, J CLIN ANESTH, V11, P242, DOI 10.1016/S0952-8180(99)00007-0; Tomatsu S, 2011, CURR PHARM BIOTECHNO, V12, P931, DOI 1389-2010/11 $58.00+.00	13	3	3	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	NOV	2015	24	4					375	387		10.1016/j.ijoa.2015.05.001			13	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	CV4RX	WOS:000364255300011	26119257				2020-06-30	J	Coffman, JC; Fiorini, K; Small, RH				Coffman, J. C.; Fiorini, K.; Small, R. H.			Ilioinguinal-iliohypogastric block used to rescue ineffective transversus abdominis plane block after cesarean delivery	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							NERVE BLOCK; ANALGESIA; MORPHINE		[Coffman, J. C.; Fiorini, K.; Small, R. H.] Ohio State Univ, Wexner Med Ctr, Dept Anesthesiol, Columbus, OH 43210 USA	Coffman, JC (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Anesthesiol, Columbus, OH 43210 USA.	John.coffman@osumc.edu	Small, Robert/E-4106-2011	Small, Robert/0000-0001-6362-9437			Bell EA, 2002, CAN J ANAESTH, V49, P694, DOI 10.1007/BF03017448; Demirci A, 2014, REV BRAS ANESTESIOL, V64, P350, DOI [10.1016/j.bjane.2014.01.001, 10.1016/j.bjan.2014.01.001]; Lee THW, 2010, ANAESTH INTENS CARE, V38, P452, DOI 10.1177/0310057X1003800307; McDermott G, 2012, BRIT J ANAESTH, V108, P499, DOI 10.1093/bja/aer422; Mei W, 2011, ANESTH ANALG, V113, P134, DOI 10.1213/ANE.0b013e31821891e2; Mirza F, 2013, CAN J ANESTH, V60, P299, DOI 10.1007/s12630-012-9866-6; Mishriky BM, 2012, CAN J ANESTH, V59, P766, DOI 10.1007/s12630-012-9729-1; Vallejo MC, 2012, SCI WORLD J, DOI 10.1100/2012/107316; Williams DJ, 2014, ANAESTHESIA, V69, P847, DOI 10.1111/anae.12679; Wolfson A, 2012, J CLIN ANESTH, V24, P298, DOI 10.1016/j.jclinane.2011.09.007	10	3	3	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	NOV	2015	24	4					394	395		10.1016/j.ijoa.2015.05.003			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	CV4RX	WOS:000364255300017	26119256				2020-06-30	J	Aksenov, DP; Li, LM; Miller, MJ; Iordanescu, G; Wyrwicz, AM				Aksenov, Daniil P.; Li, Limin; Miller, Michael J.; Iordanescu, Gheorghe; Wyrwicz, Alice M.			Effects of anesthesia on BOLD signal and neuronal activity in the somatosensory cortex	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						anesthesia; barrel cortex; BOLD contrast; electrophysiology; functional MRI (fMRI)	CEREBRAL-BLOOD-FLOW; SYNAPTIC TRANSMISSION; HEMODYNAMIC-RESPONSE; VOLATILE ANESTHETICS; FUNCTIONAL MRI; BARREL CORTEX; FMRI SIGNAL; RAT; ISOFLURANE; SEVOFLURANE	Most functional magnetic resonance imaging (fMRI) animal studies rely on anesthesia, which can induce a variety of drug-dependent physiological changes, including depression of neuronal activity and cerebral metabolism as well as direct effects on the vasculature. The goal of this study was to characterize the effects of anesthesia on the BOLD signal and neuronal activity. Simultaneous fMRI and electrophysiology were used to measure changes in single units (SU), multi-unit activity (MUA), local field potentials (LFP), and the blood oxygenation level-dependent (BOLD) response in the somatosensory cortex during whisker stimulation of rabbits before, during and after anesthesia with fentanyl or isoflurane. Our results indicate that anesthesia modulates the BOLD signal as well as both baseline and stimulus-evoked neuronal activity, and, most significantly, that the relationship between the BOLD and electrophysiological signals depends on the type of anesthetic. Specifically, the behavior of LFP observed under isoflurane did not parallel the behavior of BOLD, SU, or MUA. These findings suggest that the relationship between these signals may not be straightforward. BOLD may scale more closely with the best measure of the excitatory subcomponents of the underlying neuronal activity, which may vary according to experimental conditions that alter the excitatory/inhibitory balance in the cortex.	[Aksenov, Daniil P.; Li, Limin; Miller, Michael J.; Iordanescu, Gheorghe; Wyrwicz, Alice M.] NorthShore Univ HealthSyst, Res Inst, Evanston, IL 60201 USA	Wyrwicz, AM (reprint author), NorthShore Univ HealthSyst, Res Inst, Ctr Basic MR Res, 1033 Univ Pl,Suite 100, Evanston, IL 60201 USA.	a-wyrwicz@northwestern.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS44617, S10 RR15685]	This work was supported by National Institute of Health (R01 NS44617, S10 RR15685).	ALADJ LJ, 1991, ANESTH ANALG, V72, P48; Antkowiak B, 1998, ANESTHESIOLOGY, V88, P1592, DOI 10.1097/00000542-199806000-00024; ARMSTRONGJAMES M, 1988, EXP NEUROL, V99, P369, DOI 10.1016/0014-4886(88)90155-0; Austin VC, 2005, NEUROIMAGE, V24, P92, DOI 10.1016/j.neuroimage.2004.08.011; Berwick J, 2002, J CEREBR BLOOD F MET, V22, P670, DOI 10.1097/00004647-200206000-00005; Burns SP, 2010, J NEUROSCI, V30, P13739, DOI 10.1523/JNEUROSCI.0743-10.2010; Buzsaki G, 2012, NAT REV NEUROSCI, V13, P407, DOI 10.1038/nrn3241; COLANTUONI A, 1984, INT J MICROCIRC, V3, P13; Drake CT, 1999, BRAIN RES, V849, P203, DOI 10.1016/S0006-8993(99)01910-1; Ekstrom A, 2007, HIPPOCAMPUS, V17, P606, DOI 10.1002/hipo.20300; Ekstrom A, 2010, BRAIN RES REV, V62, P233, DOI 10.1016/j.brainresrev.2009.12.004; ELBEHEIRY H, 1989, EXP BRAIN RES, V77, P87; Friedberg MH, 1999, J NEUROPHYSIOL, V81, P2243; Goodarzi M, 1996, SPINE, V21, P1565, DOI 10.1097/00007632-199607010-00016; Hara K, 2002, ANESTH ANALG, V94, P313, DOI 10.1097/00000539-200202000-00015; Hyder F, 2002, P NATL ACAD SCI USA, V99, P10771; Ibanez L., 2005, ITK SOFTWARE GUIDE; JONES MV, 1992, J PHYSIOL-LONDON, V449, P279, DOI 10.1113/jphysiol.1992.sp019086; Kerssens C, 2005, ANESTHESIOLOGY, V103, P11, DOI 10.1097/00000542-200507000-00006; Li LM, 2012, J NEUROSCI METH, V205, P305, DOI 10.1016/j.jneumeth.2012.01.014; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Martin C, 2006, NEUROIMAGE, V32, P33, DOI 10.1016/j.neuroimage.2006.02.021; Masamoto K, 2007, CEREB CORTEX, V17, P942, DOI 10.1093/cercor/bhl005; Masamoto K, 2012, J CEREBR BLOOD F MET, V32, P1233, DOI 10.1038/jcbfm.2012.50; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; MCPHERSON RW, 1984, ANESTHESIOLOGY, V60, P180, DOI 10.1097/00000542-198403000-00002; Peeters RR, 2001, MAGN RESON IMAGING, V19, P821, DOI 10.1016/S0730-725X(01)00391-5; Petersen CCH, 2001, J NEUROSCI, V21, P8435; Petersen RS, 2000, J NEUROSCI, V20, P6135, DOI 10.1523/JNEUROSCI.20-16-06135.2000; Plourde G, 2006, ANESTHESIOLOGY, V104, P448, DOI 10.1097/00000542-200603000-00011; Pratt W, 1991, MORPHOLOGICAL IMAGE; Rauch A, 2008, P NATL ACAD SCI USA, V105, P6759, DOI 10.1073/pnas.0800312105; RICHARDS CD, 1983, BRIT J ANAESTH, V55, P201, DOI 10.1093/bja/55.3.201; Richards CD, 2002, BRIT J ANAESTH, V89, P79, DOI 10.1093/bja/aef162; Ruskin K. J., 2013, FUNDAMENTALS NEUROAN; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; SCHELLER MS, 1988, ANESTHESIOLOGY, V68, P548, DOI 10.1097/00000542-198804000-00012; Sicard K, 2003, J CEREBR BLOOD F MET, V23, P472, DOI 10.1097/01.WCB.0000054755.93668.20; Song XM, 2010, NEUROIMAGE, V51, P775, DOI 10.1016/j.neuroimage.2010.02.030; Tallent Melanie K., 2008, V44, P177, DOI 10.1007/400_2007_037; Viswanathan A, 2007, NAT NEUROSCI, V10, P1308, DOI 10.1038/nn1977; Wyrwicz AM, 2000, MAGNET RESON MED, V44, P474, DOI 10.1002/1522-2594(200009)44:3<474::AID-MRM19>3.0.CO;2-I; Yang Y, 2012, J NEUROSCI, V32, P15142, DOI 10.1523/JNEUROSCI.1411-12.2012	43	31	31	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2015	35	11					1819	1826		10.1038/jcbfm.2015.130			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CV4TR	WOS:000364259900014	26104288	Green Published, Bronze			2020-06-30	J	Sato, Y; Oshiro, M; Takemoto, K; Hosono, H; Saito, A; Kondo, T; Aizu, K; Matsusawa, M; Futamura, Y; Asami, T; Terasaki, H; Hayakawa, M				Sato, Y.; Oshiro, M.; Takemoto, K.; Hosono, H.; Saito, A.; Kondo, T.; Aizu, K.; Matsusawa, M.; Futamura, Y.; Asami, T.; Terasaki, H.; Hayakawa, M.			Multicenter observational study comparing sedation/analgesia protocols for laser photocoagulation treatment of retinopathy of prematurity	JOURNAL OF PERINATOLOGY			English	Article							NEONATAL CIRCUMCISION; ANESTHESIA; PAIN; ANALGESIA; YOUNG	OBJECTIVE: The aim of this study was to identify the best sedation/analgesia protocol for laser photocoagulation (PC) of retinopathy of prematurity (ROP). STUDY DESIGN: This multicenter observational study included five hospitals, each using a specific sedation/analgesia protocol: local anesthesia with oxybuprocaine hydrochloride (Group L); intravenous pentazocine (Group P); intravenous fentanyl (Group F); air, oxygen and sevoflurane (AOS) inhalation (Group I). The groups were compared for pain responses, vital signs and adverse events. RESULTS: Heart rates and systemic blood pressures were elevated by PC in Groups L and P and Groups L, P and F, respectively. Moreover, poor analgesic efficacy was recognized in Groups L, P and F. In contrast, Group I experienced hypothermia, enteral feeding intolerance and apnea more frequently. CONCLUSION: From the viewpoint of sedation/pain relief, AOS anesthesia should be the best protocol. However, considering all the various factors together, the most reasonable one can be varied based on the patient's condition and hospital.	[Sato, Y.; Saito, A.; Kondo, T.; Hayakawa, M.] Nagoya Univ Hosp, Ctr Maternal Neonatal Care, Div Neonatol, Nagoya, Aichi 4668550, Japan; [Oshiro, M.; Saito, A.] Japanese Red Cross Nagoya Daiichi Hosp, Dept Pediat, Nagoya, Aichi, Japan; [Takemoto, K.] Anjo Kosei Hosp, Dept Pediat, Anjo, Aichi, Japan; [Takemoto, K.; Hosono, H.] Konan Kosei Hosp, Dept Pediat, Konan, Aichi, Japan; [Kondo, T.] Ogaki Municipal Hosp, Dept Pediat Cardiol & Neonatol, Ogaki, Gifu, Japan; [Aizu, K.] Toyota Mem Hosp, Dept Neonatol, Toyota, Aichi, Japan; [Matsusawa, M.] Okazaki City Hosp, Dept Pediat, Okazaki, Aichi, Japan; [Futamura, Y.; Asami, T.; Terasaki, H.] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4648601, Japan	Sato, Y (reprint author), Nagoya Univ Hosp, Ctr Maternal Neonatal Care, Div Neonatol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	yoshiaki@med.nagoya-u.ac.jp	asami, tetsu/A-2052-2016; Sato, Yoshiaki/I-7414-2014	Sato, Yoshiaki/0000-0001-6320-9176			Amer Acad Pediat, 2006, PEDIATRICS, V118, P2231, DOI 10.1542/peds.2006-2277; ANAND KJS, 1989, PEDIATR CLIN N AM, V36, P795; Chen SDM, 2007, EYE, V21, P1033, DOI 10.1038/sj.eye.6702499; Dilli D, 2014, ACTA PAEDIATR, V103, pE76, DOI 10.1111/apa.12454; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991, DOI 10.1001/archopht.123.7.991; Haigh PM, 1997, BRIT J OPHTHALMOL, V81, P283, DOI 10.1136/bjo.81.4.283; Kirwan C, 2007, ACTA OPHTHALMOL SCAN, V85, P644, DOI 10.1111/j.1600-0420.2007.00900.x; Laudenbach V, 2001, J CLIN INVEST, V107, P457, DOI 10.1172/JCI9716; Lawrence J, 1993, Neonatal Netw, V12, P59; Loepke AW, 2008, ANESTH ANALG, V106, P1681, DOI 10.1213/ane.0b013e318167ad77; Mellon RD, 2007, ANESTH ANALG, V104, P509, DOI 10.1213/01.ane.0000255729.96438.b0; Parulekar MV, 2008, EYE, V22, P375, DOI 10.1038/sj.eye.6702642; SCHULENBURG WE, 1995, ACTA OPHTHALMOL SCAN, V73, P14; TADDIO A, 1995, LANCET, V345, P291, DOI 10.1016/S0140-6736(95)90278-3; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Woodhead DD, 2007, J PERINATOL, V27, P209, DOI 10.1038/sj.jp.7211675; Zhu CL, 2010, J CEREBR BLOOD F MET, V30, P1017, DOI 10.1038/jcbfm.2009.274	18	5	5	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	NOV	2015	35	11					965	969		10.1038/jp.2015.112			5	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	CV0XB	WOS:000363976000015	26355942				2020-06-30	J	Kurita, K; Mochizuki, Y; Kokubun, H; Atsuta, K				Kurita, Kaoru; Mochizuki, Yuka; Kokubun, Hideya; Atsuta, Kouichirou			Evaluation of Detachment and Clinical Usability of Transdermal Fentanyl Patches in Healthy Volunteers	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						transdermal fentanyl; detachment; clinical usability	MORPHINE	The dose of a transdermal fentanyl patch is proportional to its application site area. Therefore, the absorption of fentanyl may decrease if the patch detaches, leading to insufficient analgesia. Sixteen healthy volunteers were enrolled in a study to investigate the appropriate application sites and clinical utility of three transdermal fentanyl patches available in Japan. Three placebos, Fentanyl 1-day (Fentos; Fen), Fentanyl 3-day (Durotep; Dur), and Generic Fentanyl 3-day (HMT) were administered using a crossover study design. The placebos were applied to 11 different sites, including both sides of the upper arm, abdomen, back, thigh, chest, and the middle of the chest. We determined the patch detachment area and incidence of patch-induced itching every 24 h and evaluated differences between each application site using the Wilcoxon signed-rank test. Significant patch detachment was observed on the abdomen and upper arms with Fen, on the abdomen and chest with Dur, and on the chest with HMT compared with that at other sites (p<0.005). Although no significant difference in itching was observed between regions when administering Fen, itching significantly increased on the chest and back when using Dur and on the abdomen when using HMT as compared with that at other sites (p<0.05). Our results indicate that the three transdermal Fen patches exhibit different adhesive properties and local adverse events, indicating that the application site should be cautiously selected for each patch type.	[Kurita, Kaoru] Kitasato Univ Hosp, Dept Nursing, Minami Ku, Sagamihara, Kanagawa 2520375, Japan; [Mochizuki, Yuka; Atsuta, Kouichirou] Kitasato Univ, Sch Pharm, Minato Ku, Tokyo 1088641, Japan; [Kokubun, Hideya; Atsuta, Kouichirou] Kitasato Univ Hosp, Dept Pharm, Minami Ku, Sagamihara, Kanagawa 2520375, Japan	Kurita, K (reprint author), Kitasato Univ Hosp, Dept Nursing, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520375, Japan.	k.kurita@kitasato-u.ac.jp					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; [Anonymous], 2011, DUR MT PATCH INT FOR; [Anonymous], 2011, FENT TAP INT FORM; [Anonymous], 2012, FENT 3 DAYS TAP HMT; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Genf World Health Organization, 1986, CANC PAIN REL; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Hattori S., 2010, J NEW REMEDIES CLIN, V59, P1425; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Image J, IM ANAL SOFTW; Ooi K, 2008, JPN PHARMACOL THER, V36, P589; Oshima S, 2012, JPN J PHARM PALLIAT, V5, P7; Yoshimaru K., 2010, AUTONOMIC NERVOUS SY, V47, P138	14	1	1	0	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1307	1315		10.1248/yakushi.15-00080			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500012	26521880	Bronze			2020-06-30	J	Bakovic, M; Nestic, M; Mayer, D				Bakovic, Marija; Nestic, Marina; Mayer, Davor			Death by band-aid: fatal misuse of transdermal fentanyl patch	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Child fatality; Fatal intoxication; Transdermal fentanyl patch; Postmortem; Skin abrasion	AMERICAN ASSOCIATION; POSTMORTEM; OPIOIDS; CHILD	We present a case of fatal intoxication by the application of a transdermal fentanyl patch upon a superficial bleeding abrasion of a 2-year-old girl. The grandmother discovered the body of the child in bed at approximately 7 a.m. External examination revealed a properly developed, nourished, and hydrated child, with some vomit in the nostrils and inside the mouth. There was no evidence of trauma besides small contusions and abrasions on the knees, with a patch placed over the largest abrasion. Closer inspection revealed that this was transdermal fentanyl patch. Internal examination and microscopic analysis revealed regurgitation of stomach content, cerebral and pulmonary edema, and liver congestion. Toxicology analysis revealed trace levels of fentanyl in the blood just above the limit of detection (2 ng/mL), while concentrations in the urine, liver, and kidney were approximately 102, 28, and 10 ng/mL, respectively. Investigation discovered that the child injured her knee while playing the evening before. The grandmother applied the patch to cover the injury, unaware that she had used a fentanyl transdermal patch instead of simple band-aid. Although fatal intoxications are uncommon among young children in high-income countries, it is of major interest to raise awareness of such events especially since a great majority of these are preventable. The presented case points at the need for more thorough education of users and more strict rules in prescribing and handling of this potent medicine. As well, we find this case to be a useful contribution to the evaluation of postmortem fentanyl concentrations in fatal intoxication in a small child.	[Bakovic, Marija; Nestic, Marina; Mayer, Davor] Univ Zagreb, Sch Med, Inst Forens Med & Criminalist, Zagreb 10000, Croatia	Mayer, D (reprint author), Univ Zagreb, Sch Med, Inst Forens Med & Criminalist, Salata 11, Zagreb 10000, Croatia.	dmayer@mef.hr					Anderson B, 2013, COTE LERMANS PRACTIC, P77; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; [Anonymous], 2005, FDA ISSUES PUBLIC HL; [Anonymous], 2011, CAUSES DEATH 2008 SU; [Anonymous], 2012, FENTANYL PATCH CAN B; [Anonymous], 2007, 2 SAFETY WARNING FEN; Bond GR, 2012, J PEDIATR-US, V160, P265, DOI 10.1016/j.jpeds.2011.07.042; Bronstein AC, 2012, CLIN TOXICOL, V50, P911, DOI 10.3109/15563650.2012.746424; Bronstein AC, 2011, CLIN TOXICOL, V49, P910, DOI 10.3109/15563650.2011.635149; Foy L, 2011, PEDIATR EMERG CARE, V27, P854, DOI 10.1097/PEC.0b013e31822c281f; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Hardwick WE, 1997, SOUTH MED J, V90, P962, DOI 10.1097/00007611-199709000-00023; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lyttle MD, 2012, PEDIATR EMERG CARE, V28, P463, DOI 10.1097/PEC.0b013e31825358b4; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Mather L. E., 1991, TRANSDERMAL FENTANYL, P73; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Meyer D, 2005, CLIN PEDIATR, V44, P499, DOI 10.1177/000992280504400605; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Watson WA, 2003, AM J EMERG MED, V21, P353, DOI 10.1016/S0735-6757(03)00088-3	23	13	13	1	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	NOV	2015	129	6					1247	1252		10.1007/s00414-015-1209-z			6	Medicine, Legal	Legal Medicine	CT5ZG	WOS:000362889200009	26055040	Green Accepted			2020-06-30	J	Li, Z; Tian, M; Zhang, CY; Li, AZ; Huang, AJ; Shi, CX; Xin, DQ; Qi, J; Li, KZ				Li, Z.; Tian, M.; Zhang, C. -Y.; Li, A. -Z.; Huang, A. -J.; Shi, C. -X.; Xin, D-Q.; Qi, J.; Li, K. -Z.			A Randomised Controlled Trial to Evaluate the Effectiveness of Intrathecal Bupivacaine Combined with Different Adjuvants (Fentanyl, Clonidine and Dexmedetomidine) in Caesarean Section	DRUG RESEARCH			English	Article						spinal anesthesia; bupivacaine; fentanyl; clonidine; dexmedetomidine; sensory block; motor block; caesarean section; labour analgesia	HYPERBARIC BUPIVACAINE; SPINAL-ANESTHESIA; ANALGESIA; SUFENTANIL; SURGERY; BLOCK; CORD; ANTINOCICEPTION; OBSTETRICS; INJECTION	Purpose: The purpose of this study was to evaluate comparatively, in women undergoing caesarean section under spinal anesthesia, the effectiveness of hyperbaric bupivacaine combined with 3 different adjuvants (fentanyl, clonidine, and dexmedtomidine) on quality of blockade and maternal and neonatal repercussions. Method: 84 patients undergoing elective surgeries under spinal anesthesia were randomized into 4 groups of 21 each, gB, gBF, gBC and gBD. Patients in groups gb, gBF, gBC and gBD were given bupivacaine alone, bupivacaine plus fentanyl (15.0 mu g), bupivacaine plus fentanyl plus clonidine (75 mu g), and bupivacaine plus dexmedetomidine (10 mu g), respectively. Hemodynamic parameters evaluated were the onset and level of sensory block, perioperative analgesia, degree and recovery time of motor block, duration of analgesia, sedation, and maternal-foetal repercussions. Results: The onset of blockade was significantly faster in groups with adjuvants clonidine and dexmedetomidine compared with gB and gBF. Patients in Groups gB and gBF reported pain during the perioperative period. Duration of analgesia was significantly higher in Group gBD and was comparable to gBC and time to motor block recovery was significantly higher in Group gBD. Sedation was significant in Group gBD and gBC. Conclusion: Addition of dexmedetomidine and clonidine as adjuvants to hyperbaric bupivacaine provided adequate anesthesia and postoperative analgesia compared to fentanyl adjuvant without causing any significant side effects.	[Li, Z.; Tian, M.; Li, K. -Z.] Shandong Univ, Sch Med, Jinan 250100, Peoples R China; [Li, Z.; Tian, M.; Zhang, C. -Y.; Li, A. -Z.; Huang, A. -J.; Shi, C. -X.; Xin, D-Q.; Qi, J.; Li, K. -Z.] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Anesthesiol,Yantai Yuhuangding Hosp, 20 East Yuhuangding Rd, Yantai 264000, Shandong, Peoples R China	Li, KZ (reprint author), Qingdao Univ, Coll Med, Affiliated Hosp, Dept Anesthesiol,Yantai Yuhuangding Hosp, 20 East Yuhuangding Rd, Yantai 264000, Shandong, Peoples R China.	lkz112004@hotmail.com					Agarwal K, ANESTHESIA ESSAYS RE, DOI [10.4103/0259-1162.103367, DOI 10.4103/0259-1162.103367]; Akcaboy ZN, 2012, REV BRAS ANESTESIOL, V62, P753, DOI 10.1016/S0034-7094(12)70176-9; Al-Ghanem SM, 2009, AM J APPL SCI, V6, P882, DOI DOI 10.3844/AJASSP.2009.882.887; Al-Mustafa Mahmoud M., 2009, Middle East Journal of Anesthesiology, V20, P225; Alves BJ, 2000, REV BRAS ANESTESIOL, V50, P396; Bajwa Sukhminder Jit Singh, 2012, Int J Crit Illn Inj Sci, V2, P63, DOI 10.4103/2229-5151.97269; Benhamou D, 1998, ANESTH ANALG, V87, P609, DOI 10.1097/00000539-199809000-00022; Braga ADFD, 2003, EUR J ANAESTH, V20, P631; BRANDT SA, 1990, PAIN, V42, P323, DOI 10.1016/0304-3959(90)91145-9; Chiari A, 1999, ANESTHESIOLOGY, V91, P388, DOI 10.1097/00000542-199908000-00012; Côrtes Carlos Alberto de Figueiredo, 2007, Rev. Bras. Anestesiol., V57, P39, DOI 10.1590/S0034-70942007000100005; Côrtes Carlos Alberto Figueiredo, 2003, Rev. Bras. Anestesiol., V53, P177, DOI 10.1590/S0034-70942003000200005; Côrtes Carlos Alberto Figueiredo, 2006, Rev. Bras. Anestesiol., V56, P16, DOI 10.1590/S0034-70942006000100003; Braga ADD, 2010, REV BRAS ANESTESIOL, V60, P121, DOI 10.1590/S0034-70942010000200003; Delfino J, 2001, REV BRAS ANESTESIOL, V51, P474; Dinesh CN, 2014, SAUDI J ANAESTH, V8, P202, DOI 10.4103/1658-354X.130719; Duarte Nádia Maria da Conceição, 2008, Rev. Bras. Anestesiol., V58, P5, DOI 10.1590/S0034-70942008000100002; Dyer Robert A, 2004, Curr Opin Anaesthesiol, V17, P301, DOI 10.1097/01.aco.0000137088.29861.64; Elia N, 2008, REGION ANESTH PAIN M, V33, P159, DOI 10.1016/j.rapm.2007.10.008; Gonçalves Rosane Fossatti, 2003, Rev. Bras. Anestesiol., V53, P169, DOI 10.1590/S0034-70942003000200004; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; HUNT CO, 1989, INT ANESTHESIOL CLIN, V27, P26, DOI 10.1097/00004311-198902710-00006; Inanoglu K, 2010, J ANESTH, V24, P700, DOI 10.1007/s00540-010-0979-1; Ishii H, 2008, EUR J NEUROSCI, V27, P3182, DOI 10.1111/j.1460-9568.2008.06260.x; Juliao MCC, 2000, J CLIN ANESTH, V12, P357, DOI 10.1016/S0952-8180(00)00171-9; KALSO EA, 1991, PHARMACOL TOXICOL, V68, P140, DOI 10.1111/j.1600-0773.1991.tb02052.x; Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x; Kothari N, 2011, SAUDI J ANAESTH, V5, P31, DOI 10.4103/1658-354X.76499; Lavand'homme PM, 2008, ANESTH ANALG, V107, P948, DOI 10.1213/ane.0b013e31817f1595; Liu SS, 2005, ANESTH ANALG, V101, P1634, DOI 10.1213/01.ANE.0000180829.70036.4F; POST C, 1987, ANESTH ANALG, V66, P317; REDDY SVR, 1980, BRAIN RES, V189, P391; Roelants F, 2006, CURR OPIN ANESTHESIO, V19, P233, DOI 10.1097/01.aco.0000192812.56161.f8; Saxena AK, 2004, INDIAN J ANAESTH, V48, P13; Shukry M, 2010, THER CLIN RISK MANAG, V6, P111; Sia ATH, 2000, CAN J ANAESTH, V47, P875, DOI 10.1007/BF03019667; Simon L, 2000, INT J OBSTET ANESTH, V9, P10, DOI 10.1054/ijoa.1999.0348; Singh Ranju, 2013, Saudi J Anaesth, V7, P283, DOI 10.4103/1658-354X.115360; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; Tekin M, 2007, CURR THER RES CLIN E, V68, P313, DOI 10.1016/j.curtheres.2007.10.006; van Tuijl I, 2006, BRIT J ANAESTH, V97, P365, DOI 10.1093/bja/ael182; Whizar-Lugo V, 2007, ANESTESIA MEXICO, V19, P143	42	22	23	0	18	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	2194-9379	2194-9387		DRUG RES	Drug Res.	NOV	2015	65	11					581	586		10.1055/s-0034-1395614			6	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CV6JR	WOS:000364377000004	25504002				2020-06-30	J	Pecina, M; Bohnert, ASB; Sikora, M; Avery, ET; Langenecker, SA; Mickey, BJ; Zubieta, JK				Pecina, Marta; Bohnert, Amy S. B.; Sikora, Magdalena; Avery, Erich T.; Langenecker, Scott A.; Mickey, Brian J.; Zubieta, Jon-Kar			Association Between Placebo-Activated Neural Systems and Antidepressant Responses Neurochemistry of Placebo Effects in Major Depression	JAMA PSYCHIATRY			English	Article							TRICYCLIC ANTIDEPRESSANT; FUNCTIONAL NEUROANATOMY; EMOTION PERCEPTION; OPIOID ANALGESIA; REWARD; DYSREGULATION; MODEL; NEUROBIOLOGY; METAANALYSIS; MODULATION	IMPORTANCE High placebo responses have been observed across a wide range of pathologies, severely impacting drug development. OBJECTIVE To examine neurochemical mechanisms underlying the formation of placebo effects in patients with major depressive disorder (MDD). DESIGN, SETTING, AND PARTICIPANTS In this study involving 2 placebo lead-in phases followed by an open antidepressant administration, we performed a single-blinded 2-week crossover randomized clinical trial of 2 identical oral placebos (described as having either active or inactive fast-acting antidepressant-like effects) followed by a 10-week open-label treatment with a selective serotonin reuptake inhibitor or, in some cases, another agent as clinically indicated. The volunteers (35 medication-free patients with MDD at a university health system) were studied with positron emission tomography and the mu-opioid receptor-selective radiotracer [C-11]carfentanil after each 1-week inactive and active oral placebo treatment. In addition, 1 mL of isotonic saline was administered intravenously within sight of the volunteer during positron emission tomographic scanning every 4 minutes over 20 minutes only after the 1-week active placebo treatment, with instructions that the compound may be associated with the activation of brain systems involved in mood improvement. This challenge stimulus was used to test the individual capacity to acutely activate endogenous opioid neurotransmision under expectations of antidepressant effect. MAIN OUTCOMES AND MEASURES Changes in depressive symptoms in response to active placebo and antidepressant. Baseline and activation measures of mu-opioid receptor binding. RESULTS Higher baseline mu-opioid receptor binding in the nucleus accumbens was associated with better response to antidepressant treatment (r = 0.48; P = .02). Reductions in depressive symptoms after 1 week of active placebo treatment, compared with the inactive, were associated with increased placebo-induced mu-opioid neurotransmission in a network of regions implicated in emotion, stress regulation, and the pathophysiology of MDD, namely, the subgenual anterior cingulate cortex, nucleus accumbens, midline thalamus, and amygdala (nucleus accumbens: r = 0.6; P < .001). Placebo-induced endogenous opioid release in these regions was associated with better antidepressant treatment response, predicting 43% of the variance in symptom improvement at the end of the antidepressant trial. CONCLUSIONS AND RELEVANCE These data demonstrate that placebo-induced activation of the mu-opioid system is implicated in the formation of placebo antidepressant effects in patients with MDD and also participate in antidepressant responses, conferring illness resiliency, during open administration.	[Pecina, Marta; Bohnert, Amy S. B.; Sikora, Magdalena; Avery, Erich T.; Mickey, Brian J.; Zubieta, Jon-Kar] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA; [Bohnert, Amy S. B.] US Dept Vet Affairs, Ann Arbor, MI USA; [Langenecker, Scott A.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; [Zubieta, Jon-Kar] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI USA	Zubieta, JK (reprint author), Univ Michigan, Sch Med, Dept Psychiat, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu	Mickey, Brian/J-1756-2014; Pecina, Marta/W-7135-2019; Langenecker, Scott/F-3548-2012	Mickey, Brian/0000-0002-7847-7680; Langenecker, Scott/0000-0002-7932-5494	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH086858]; Phil F. Jenkins Foundation; Michigan Institute for Clinical & Health Research grant [CTSA UL1RR024986]	This work was supported by National Institutes of Health grant R01 MH086858 (Dr Zubieta), the Phil F. Jenkins Foundation, and a Michigan Institute for Clinical & Health Research grant (CTSA UL1RR024986).	Agid O, 2013, AM J PSYCHIAT, V170, P1335, DOI 10.1176/appi.ajp.2013.12030315; AGREN H, 1982, ANN NY ACAD SCI, V398, P388, DOI 10.1111/j.1749-6632.1982.tb39510.x; Amanzio M, 1999, J NEUROSCI, V19, P484; Benbouzid M, 2008, EUR J PAIN, V12, P1008, DOI 10.1016/j.ejpain.2008.01.010; Benbouzid M, 2008, BIOL PSYCHIAT, V63, P633, DOI 10.1016/j.biopsych.2007.06.016; Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; Benedetti F, 1996, PAIN, V64, P535, DOI 10.1016/0304-3959(95)00179-4; BIEGON A, 1980, BIOCHEM PHARMACOL, V29, P460, DOI 10.1016/0006-2952(80)90531-6; Buchel C, 2014, NEURON, V81, P1223, DOI 10.1016/j.neuron.2014.02.042; Cressey D, 2011, NATURE, DOI [10.1038/news.2011.367, DOI 10.1038/NEWS.2011.367]; Drevets WC, 1998, MOL PSYCHIATR, V3, P220, DOI 10.1038/sj.mp.4000370; Ehrich E, 2015, NEUROPSYCHOPHARMACOL, V40, P1448, DOI 10.1038/npp.2014.330; Ellingsen DM, 2013, P NATL ACAD SCI USA, V110, P17993, DOI 10.1073/pnas.1305050110; EMRICH HM, 1982, ANN NY ACAD SCI, V398, P108, DOI 10.1111/j.1749-6632.1982.tb39483.x; Fava M, 2003, PSYCHOTHER PSYCHOSOM, V72, P115, DOI 10.1159/000069738; Gotlib IH, 2005, NEUROREPORT, V16, P1731, DOI 10.1097/01.wnr.0000183901.70030.82; Gray AM, 1998, BRIT J PHARMACOL, V124, P669, DOI 10.1038/sj.bjp.0701882; Hall KT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048135; Hamani C, 2011, BIOL PSYCHIAT, V69, P301, DOI 10.1016/j.biopsych.2010.09.034; Hamani C, 2009, J NEUROSURG, V111, P1209, DOI 10.3171/2008.10.JNS08763; HAMON M, 1987, NEUROPHARMACOLOGY, V26, P531, DOI 10.1016/0028-3908(87)90144-4; Hsu DT, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00073; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-8716(98)00064-7; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; Marchand F, 2003, PAIN, V103, P229, DOI 10.1016/S0304-3959(03)00168-4; Mayberg HS, 2003, NEUROIMAG CLIN N AM, V13, P805, DOI 10.1016/S1052-5149(03)00104-7; Mayberg HS, 2002, AM J PSYCHIAT, V159, P728, DOI 10.1176/appi.ajp.159.5.728; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Meissner K, 2013, JAMA INTERN MED, V173, P1941, DOI 10.1001/jamainternmed.2013.10391; Mestre TA, 2014, NEUROLOGY, V82, P1402, DOI 10.1212/WNL.0000000000000340; Mico JA, 2006, TRENDS PHARMACOL SCI, V27, P348, DOI 10.1016/j.tips.2006.05.004; Nutt David, 2011, Eur Neuropsychopharmacol, V21, P495, DOI 10.1016/j.euroneuro.2011.05.004; Pecina M, 2014, MOL PSYCHIATR, V19, P385, DOI 10.1038/mp.2013.124; Pecina M, 2013, MOL PSYCHIATR, V18, P135, DOI 10.1038/mp.2012.16; Pecina M, 2014, SOC COGN AFFECT NEUR, V9, P1013, DOI 10.1093/scan/nst079; Pecina M, 2014, J NEUROSCI, V34, P5874, DOI 10.1523/JNEUROSCI.2152-13.2014; Peduzzi P, 2002, EPIDEMIOL REV, V24, P26, DOI 10.1093/epirev/24.1.26; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Phillips ML, 2003, BIOL PSYCHIAT, V54, P515, DOI 10.1016/S0006-3223(03)00171-9; Price JL, 2012, TRENDS COGN SCI, V16, P61, DOI 10.1016/j.tics.2011.12.011; Price JL, 2010, NEUROPSYCHOPHARMACOL, V35, P192, DOI 10.1038/npp.2009.104; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; Schmidt L, 2014, NAT NEUROSCI, V17, P1793, DOI 10.1038/nn.3842; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Stolk P, 2003, ANN PHARMACOTHER, V37, P1891, DOI 10.1345/aph.1D172; TEJEDORREAL P, 1995, PHARMACOL BIOCHEM BE, V52, P145, DOI 10.1016/0091-3057(95)00067-7; Vaccarino AL, 2000, PEPTIDES, V21, P1975, DOI 10.1016/S0196-9781(00)00345-4; Van Ree JM, 1999, PHARMACOL REV, V51, P341; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; Wanigasekera V, 2012, P NATL ACAD SCI USA, V109, P17705, DOI 10.1073/pnas.1120201109; Zubieta JK, 2006, BRAIN BEHAV IMMUN, V20, P15, DOI 10.1016/j.bbi.2005.08.006; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005	59	61	62	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	NOV	2015	72	11					1087	1094		10.1001/jamapsychiatry.2015.1335			8	Psychiatry	Psychiatry	CV6YG	WOS:000364417600007	26421634	Green Accepted, Bronze			2020-06-30	J	Mercadante, S; Adile, C; Cuomo, A; Aielli, F; Cortegiani, A; Casuccio, A; Porzio, G				Mercadante, Sebastiano; Adile, Claudio; Cuomo, Arturo; Aielli, Federica; Cortegiani, Andrea; Casuccio, Alessandra; Porzio, Giampiero			Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Cancer pain; breakthrough pain; fentanyl buccal tablet; oral morphine	IMMEDIATE-RELEASE OXYCODONE; PALLIATIVE CARE-UNIT; PECTIN NASAL SPRAY; INTRAVENOUS MORPHINE; TRANSMUCOSAL FENTANYL; TOLERANT PATIENTS; DOUBLE-BLIND; EFFICACY; SAFETY; INTENSITY	Context. Fentanyl products have shown superiority to oral opioids for the management of breakthrough cancer pain (BTcP). However, these studies did not use appropriate patient selection, and drugs have been compared by using different rationales. Objectives. The aim of this randomized, crossover, controlled study was to compare efficacy and safety of fentanyl buccal tablets (FBTs) and oral morphine (OM), given in doses proportional to opioid daily doses. Methods. Cancer patients with pain receiving >= 60 mg or more of oral morphine equivalents per day and presenting with <= 3 episodes of BTcP per day were included. In a randomized, crossover manner, patients received FBT or OM at doses proportional to the daily opioid regimen in four consecutive episodes of BTcP. Pain intensity was measured before (T0) and 15 (T15) and 30 minutes (T30), after study drugs. Results. In total, 263 episodes of BTcP were treated. A statistical difference in changes in pain intensity-decrease of >= 33% and >= 50%-between the two groups was observed at T15 and T30 (P < 0.0005). No severe adverse effects after study drug administration were observed. Conclusion. When used in doses proportional to the basal opioid regimen, FBT showed a clear superiority and was well tolerated when compared with OM during the first 30 minutes, which is the approximate target for a timely intervention required for a BTcP medication. (C) 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.	[Mercadante, Sebastiano; Adile, Claudio] La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, I-90145 Palermo, Italy; [Mercadante, Sebastiano; Adile, Claudio] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90145 Palermo, Italy; [Cuomo, Arturo] Natl Canc Inst Pascale, Anesthesia & Pain Therapy, Naples, Italy; [Aielli, Federica; Porzio, Giampiero] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy; [Cortegiani, Andrea] Univ Palermo, Dept Biopathol Med & Forens Biotechnol, Sect Anesthesia Analgesia Intens Care & Emergency, Policlin P Giaccone, Palermo, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Via San Lorenzo 312, I-90145 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	Cortegiani, Andrea/H-4902-2016; casuccio, alessandra/B-1730-2013; cuomo, arturo/AAL-4416-2020	Cortegiani, Andrea/0000-0003-1416-9993; casuccio, alessandra/0000-0002-5676-9535; Porzio, Giampiero/0000-0002-9875-9220; Adile, Claudio/0000-0002-0664-3520; AIELLI, Federica/0000-0003-2785-0702; mercadante, sebastiano/0000-0001-9859-6487			Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Bailey PL, 2003, ANESTHESIOLOGY, V99, pA967; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2010, ANESTHESIOLOGY, V112, P1464, DOI 10.1097/ALN.0b013e3181de0e6d; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Kosugi T, 2014, J PAIN SYMPTOM MANAG, V47, P990, DOI 10.1016/j.jpainsymman.2013.07.006; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2011, EUR J PAIN, V5, P443; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Mercadante S, 2015, CLIN J PAIN, V31, P214, DOI 10.1097/AJP.0000000000000161; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mercadante S, 2013, CURR MED RES OPIN, V29, P1527, DOI 10.1185/03007995.2013.826640; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2013, CURR MED RES OPIN, V29, P667, DOI 10.1185/03007995.2013.792247; Mercadante S, 2013, CURR MED RES OPIN, V29, P93, DOI 10.1185/03007995.2012.755120; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Webster LR, 2013, PAIN MED, V14, P1332, DOI 10.1111/pme.12184; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020	39	23	24	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	NOV	2015	50	5					579	586		10.1016/j.jpainsymman.2015.05.016			8	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	CU3NX	WOS:000363433200002	26303188	Bronze			2020-06-30	J	Garcia, NN; Coronado, LIR; Chacon, AB; Cayuela, JMG				Navarro Garcia, N.; Ripoll Coronado, L. I.; Bastida Chacon, A.; Garcia Cayuela, J. M.			Anesthetic management for biliary atresia (procedure Kasai)	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION			Spanish	Editorial Material									[Navarro Garcia, N.; Ripoll Coronado, L. I.; Bastida Chacon, A.; Garcia Cayuela, J. M.] Hosp Gen Univ Santa Lucia, Serv Anestesiol & Reanimac, Murcia, Spain	Garcia, NN (reprint author), Hosp Gen Univ Santa Lucia, Serv Anestesiol & Reanimac, Murcia, Spain.	nathaly5749@hotmail.com						0	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0034-9356	2340-3284		REV ESP ANEST REANIM	Rev. Esp. Anestesiol. Reanim.	NOV	2015	62	9					546	546		10.1016/j.redar.2014.11.003			1	Anesthesiology	Anesthesiology	VH0EZ	WOS:000449608100014					2020-06-30	J	Schauer, CKMW; Shand, JAD; Reynolds, TM				Schauer, Cameron K. M. W.; Shand, James A. D.; Reynolds, Thomas M.			The Fentanyl Patch Boil-Up - A Novel Method of Opioid Abuse	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article							MISUSE	Fentanyl is a potent opioid analgesic used in the treatment of pain. Transdermal fentanyl patches are now widely utilized as an acceptable and efficacious method of medication delivery. Unfortunately, the potential for their abuse is well recognized. Previous case reports have documented deaths after intravenous (IV) misuse of fentanyl which had been extracted from Duragesic (liquid reservoir type) patches. We present a case of IV fentanyl abuse after the extraction from a Mylan (matrix type) patch. This method of abuse has not previously been described in the literature.	[Schauer, Cameron K. M. W.; Shand, James A. D.] Whangarei Hosp, Dept Gen Med, Whangarei 0148, New Zealand; [Reynolds, Thomas M.] Whangarei Hosp, Dept Emergency Med, Whangarei 0148, New Zealand	Schauer, CKMW (reprint author), Whangarei Hosp, Dept Gen Med, Private Bag 9742, Whangarei 0148, New Zealand.	cameron.schauer@gmail.com					Jost U, 2004, DEUT MED WOCHENSCHR, V129, P313, DOI 10.1055/s-2004-818627; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Purucker M, 2000, ANN EMERG MED, V35, P314, DOI 10.1016/S0196-0644(00)70091-6; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11	7	10	10	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7835	1742-7843		BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	NOV	2015	117	5					358	359		10.1111/bcpt.12412			2	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	CT2QG	WOS:000362647600010	25892448				2020-06-30	J	Yousef, AAA; Atef, AM; Awais, WM				Yousef, Ayman Abd Al-Maksoud; Atef, Ashraf Mohamed; Awais, Waleed Mohamed			Comparison of fentanyl versus meperidine as supplements to epidural clonidine-bupivacaine in patients with lower limb orthopedic surgery under combined spinal epidural anesthesia	BMC ANESTHESIOLOGY			English	Article							POSTOPERATIVE ANALGESIA; INTRAVENOUS FENTANYL; PAIN; PHARMACODYNAMICS; PHARMACOKINETICS; PETHIDINE; DELIVERY	Background: The analgesic and sedative effect of clonidine explain its common use as adjuvant in regional anesthesia, however the hemodynamic instability associated with its neuroaxial administration is the major drawback. Our study hypothesis is to compare the hemodynamic and analgesic effect of epidural fentanyl in comparison to meperidine when added to clonidine in patients undergoing lower limbs orthopedic surgery using combined spinal-epidural anesthesia. Methods: One hundred thirty five ASA physical status I or II patients were recruited for lower limb orthopedic surgery. All received 2 mL intrathecal 0.5 % hyperbaric bupivacaine, 10 mL epidural 0.25 % plain bupivacaine, and 1 mL epidural clonidine 2 mu g/kg (Clonidine group) and then either 1 ml fentanyl 25 mu g (Fentanyl Group) or 1 ml meperidine 25 mg (Meperidine Group). The quality of surgical anesthesia, incidence of hypotension and bradycardia, intra-operative pain assessment, and onset of postoperative pain, sedation scores and side effects in the postoperative period were recorded. Results: The 1st analgesic requirement in the postoperative period was significantly prolonged in the meperidine group (p = 0.001). Significant decrease in the mean arterial blood pressure in fentanyl group was at 15, 30, 45, 60 and 90 min (p = 0.035, 0.019, 0.027, 0.032 and 0.039) respectively, significant decrease in meperdine group was at 15 and 30 min (p = 0.038 and 0.043), while in clonidine group a significant decrease was at 15, 30, 45, and 60 min (p = 0.025, 0.028, 0.036 and 0.042) respectively. Among group changes, the mean arterial blood pressure was significantly higher in meperdine group at 30, 45, 60 and 90 min (p = 0.007, 0.015, 0.029 and 0.033) respectively. A significant decrease in the heart rate in fentanyl group at 15, 30 and 45 min (p = 0.035, 0.018 and 0.029), in meperdine group a significant decrease in the heart rate was at 15 min (p = 0.038), while in clonidine group a significant decrease was at 15, and 30 min (p = 0.016 and 0.003). Among group changes, the heart rate was significantly higher in meperdine group at 30, 45 and 60 min (p = 0.021, 0.017 and 0.011). VAS were significantly lower in meperdine group in comparison to fentanyl and clonidine groups at 2 h, 3 h and 4 h post-operative period (p = 0.024, 0.001 and 0.039). Conclusion: The combined administration of epidural clonidine and meperidine provided better intraoperative hemodynamics and prolonged postoperative analgesia than epidural clonidine fentanyl combination in patients undergoing lower limb orthopedic surgery.	[Yousef, Ayman Abd Al-Maksoud] Tanta Univ, Fac Med, Anesthesia Dept, Tanta, Egypt; [Atef, Ashraf Mohamed; Awais, Waleed Mohamed] Tanta Univ, Fac Med, Dept Orthoped Surg, Tanta, Egypt	Yousef, AAA (reprint author), Tanta Univ, Fac Med, Anesthesia Dept, Alguish St, Tanta, Egypt.	ayman.yousef@rocketmail.com		Atef, Ashraf/0000-0003-0158-0644			BARAKA A, 1982, ANESTH ANALG, V61, P652; CHRUBASIK S, 1995, BRIT J ANAESTH, V74, P121, DOI 10.1093/bja/74.2.121; Cox CR, 1996, ANAESTHESIA, V5, P695; Eichenberger U, 2003, BRIT J ANAESTH, V90, P467, DOI 10.1093/bja/aeg100; Ferrante FM, 1993, ANESTH ANALG, V7711, P79; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Goh JL, 1996, ANAESTH INTENS CARE, V24, P45, DOI 10.1177/0310057X9602400108; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Khaw KS, 2000, CAN J ANAESTH, V47, P155, DOI 10.1007/BF03018852; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Lauretti GR, 1996, ANESTH ANALG, V83, P766, DOI 10.1097/00000539-199610000-00019; LOPER KA, 1990, ANESTH ANALG, V70, P72; Lysakowski C, 2007, ANESTH ANALG, V104, P1532, DOI 10.1213/01.ane.0000261250.59984.cd; PAECH MJ, 1989, ANAESTH INTENS CARE, V17, P157, DOI 10.1177/0310057X8901700206; Reuben SS, 2007, J BONE JOINT SURG AM, V89A, P1343, DOI 10.2106/JBJS.F.00906; ROBINSON RJS, 1986, CAN J ANAESTH, V33, P550, DOI 10.1007/BF03014259; StOnge S, 1997, CAN J ANAESTH, V44, P360, DOI 10.1007/BF03014454; Yousef AA, 2010, INT J OBSTET ANESTH, V19, P401, DOI 10.1016/j.ijoa.2010.07.019	18	2	2	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	OCT 14	2015	15								146	10.1186/s12871-015-0126-5			8	Anesthesiology	Anesthesiology	CT4WD	WOS:000362807200001	26468074	DOAJ Gold, Green Published			2020-06-30	J	Ryu, T; Kil, BT; Kim, JH				Ryu, Taeha; Kil, Byung Tae; Kim, Jong Hae			Comparison Between Ultrasound-Guided Supraclavicular and Interscalene Brachial Plexus Blocks in Patients Undergoing Arthroscopic Shoulder Surgery	MEDICINE			English	Article							REGIONAL ANESTHESIA; INFRACLAVICULAR BLOCK; GUIDANCE IMPROVES; NERVE-STIMULATION; UPPER EXTREMITY; SUCCESS RATE; ANALGESIA; ESSENTIALS; LOCATION	Although supraclavicular brachial plexus block (SCBPB) was repopularized by the introduction of ultrasound, its usefulness in shoulder surgery has not been widely reported. The objective of this study was to compare motor and sensory blockades, the incidence of side effects, and intraoperative opioid analgesic requirements between SCBPB and interscalene brachial plexus block (ISBPB) in patients undergoing arthroscopic shoulder surgery.Patients were randomly assigned to 1 of 2 groups (ISBPB group: n=47; SCBPB group: n=46). The side effects of the brachial plexus block (Horner's syndrome, hoarseness, and subjective dyspnea), the sensory block score (graded from 0 [no cold sensation] to 100 [intact sensation] using an alcohol swab) for each of the 5 dermatomes (C5-C8 and T1), and the motor block score (graded from 0 [complete paralysis] to 6 [normal muscle force]) for muscle forces corresponding to the radial, ulnar, median, and musculocutaneous nerves were evaluated 20 min after the brachial plexus block. Fentanyl was administered in 50 g increments when the patients complained of pain that was not relieved by the brachial plexus block.There were no conversions to general anesthesia due to a failed brachial plexus block. The sensory block scores for the C5 to C8 dermatomes were significantly lower in the ISBPB group. However, the percentage of patients who received fentanyl was comparable between the 2 groups (27.7% [ISBPB group] and 30.4% [SCBPB group], P=0.77). SCBPB produced significantly lower motor block scores for the radial, ulnar, and median nerves than did ISBPB. A significantly higher incidence of Horner's syndrome was observed in the ISBPB group (59.6% [ISBPB group] and 19.6% [SCBPB group], P<0.001). No patient complained of subjective dyspnea.Despite the weaker degree of sensory blockade provided by SCBPB in comparison to ISBPB, opioid analgesic requirements are similar during arthroscopic shoulder surgery under both brachial plexus blocks. However, SCBPB produces a better motor blockade and a lower incidence of Horner's syndrome than ISBPB.	[Ryu, Taeha; Kil, Byung Tae; Kim, Jong Hae] Catholic Univ Daegu, Sch Med, Dept Anesthesiol & Pain Med, 33 Duryugongwon Ro 17 Gil, Daegu 42472, South Korea	Kim, JH (reprint author), Catholic Univ Daegu, Sch Med, Dept Anesthesiol & Pain Med, 33 Duryugongwon Ro 17 Gil, Daegu 42472, South Korea.	usmed@cu.ac.kr		Kim, Jong Hae/0000-0003-1222-0054; Ryu, Taeha/0000-0002-5973-7715	Research Institute of Medical Science, Catholic University of Daegu	This work was supported by the grant from the Research Institute of Medical Science, Catholic University of Daegu.	Arad E, 2014, PLAST RECONSTR SURG, V133, p20E, DOI 10.1097/01.prs.0000436825.49580.82; Bigeleisen PE, 2009, ANESTHESIOLOGY, V110, P1235, DOI 10.1097/ALN.0b013e3181a59891; Chan VWS, 2007, CAN J ANAESTH, V54, P176, DOI 10.1007/BF03022637; Cohen JM, 2010, REGION ANESTH PAIN M, V35, P397, DOI 10.1097/AAP.0b013e3181e8a35f; Cornish P, 2009, REGION ANESTH PAIN M, V34, P607, DOI 10.1097/AAP.0b013e3181ada5af; Dewees Janet L, 2006, AANA J, V74, P201; Dingemans E, 2007, ANESTH ANALG, V104, P1275, DOI 10.1213/01.ane.0000226101.63736.20; Fredrickson MJ, 2010, ANAESTHESIA, V65, P608, DOI 10.1111/j.1365-2044.2009.06231.x; Gadsden J, 2011, ANESTH ANALG, V112, P471, DOI 10.1213/ANE.0b013e3182042f7f; Gautier P, 2011, ANESTH ANALG, V113, P951, DOI 10.1213/ANE.0b013e31822b876f; Gonano C, 2009, BRIT J ANAESTH, V103, P428, DOI 10.1093/bja/aep173; Gurkan Y, 2010, ACTA ANAESTH SCAND, V54, P403, DOI 10.1111/j.1399-6576.2009.02206.x; Hanumanthaiah D, 2013, MED ULTRASON, V15, P224, DOI 10.11152/mu.2013.2066.153.dh1mg2; HICKEY R, 1989, ANESTH ANALG, V68, P767; Kakazu C, 2014, BRIT J ANAESTH, V113, P190, DOI 10.1093/bja/aeu214; KAPRAL S, 1994, ANESTH ANALG, V78, P507; Kapral S, 2008, REGION ANESTH PAIN M, V33, P253, DOI 10.1016/j.rapm.2007.10.011; KEEGAN JJ, 1948, ANAT REC, V102, P409, DOI 10.1002/ar.1091020403; Kessler J, 2015, BRIT J ANAESTH, V114, P728, DOI 10.1093/bja/aeu559; Kessler J, 2008, REGION ANESTH PAIN M, V33, P545, DOI 10.1016/j.rapm.2008.04.004; LANZ E, 1983, ANESTH ANALG, V62, P55; Liguori GA, 1998, ANESTH ANALG, V87, P1320, DOI 10.1097/00000539-199812000-00020; Liu SS, 2010, ANESTH ANALG, V111, P617, DOI 10.1213/ANE.0b013e3181ea5f5d; Martinoli C, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790699; MOORE DC, 1965, ARCH SURG-CHICAGO, V90, P68; Moore KL, 1999, CLIN ORIENTED ANATOM; Munirama S, 2015, ANAESTHESIA, V70, P1084, DOI 10.1111/anae.13098; Neal J.M., 2009, NEURAL BLOCKADE CLIN, P316; Neal JM, 2002, REGION ANESTH PAIN M, V27, P402, DOI 10.1053/rapm.2002.34377; Neal JM, 2009, REGION ANESTH PAIN M, V34, P134, DOI 10.1097/AAP.0b013e31819624eb; Netter F. H., 2006, ATLAS HUMAN ANATOMY; Perlas A, 2009, REGION ANESTH PAIN M, V34, P171, DOI 10.1097/AAP.0b013e31819a3f81; Reiss W, 2010, REGION ANESTH PAIN M, V35, P400, DOI 10.1097/AAP.0b013e3181e90ec9; Royse CF, 2006, ANAESTH INTENS CARE, V34, P203, DOI 10.1177/0310057X0603400212; Sadowski M, 2014, ANAESTH INTENSIVE TH, V46, P37, DOI 10.5603/AIT.2014.0008; Seo KC, 2010, KOREAN J ANESTHESIOL, V58, P38, DOI 10.4097/kjae.2010.58.1.38; Sites BD, 2009, REGION ANESTH PAIN M, V34, P508, DOI 10.1097/AAP.0b013e3181ae7306; Song JG, 2013, KOREAN J ANESTHESIOL, V65, P37, DOI 10.4097/kjae.2013.65.1.37; VESTERANDERSEN T, 1981, ACTA ANAESTH SCAND, V25, P81, DOI 10.1111/j.1399-6576.1981.tb01612.x; Warren JA, 2008, ANESTH ANALG, V106, P1578, DOI 10.1213/01.ane.0000281434.80883.88	40	20	23	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	OCT	2015	94	40							e1726	10.1097/MD.0000000000001726			7	Medicine, General & Internal	General & Internal Medicine	DC7SC	WOS:000369419700001	26448030	DOAJ Gold, Green Published			2020-06-30	J	Kim, SH; Hwang, JH				Kim, Sung-Hoon; Hwang, Jai-Hyun			Preoperative glycosylated haemoglobin as a predictor of postoperative analgesic requirements in diabetic patients A prospective observational study	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article							ACUTE MYOCARDIAL-INFARCTION; GLYCEMIC CONTROL; GLUCOSE CONTROL; CARDIAC-SURGERY; HYPERGLYCEMIA; MELLITUS; MORPHINE; PAIN; MANAGEMENT; RATS	BACKGROUNDIn diabetic individuals undergoing surgery, the analgesic effect of opioids on postoperative pain may be different from normal. Although the ability of glycosylated haemoglobin (HbA1c) to predict adverse events and outcomes after major surgery has recently been assessed, the ability of HbA1c to predict the need for postoperative analgesia has not been determined.OBJECTIVESThe objective of this study is to evaluate the relationship between preoperative glycaemic control in diabetic individuals and the opioid requirement for postoperative pain treatment.DESIGNA prospective observational study.SETTINGSingle university hospital.PATIENTSFifty-two diabetic patients undergoing open nephrectomy surgery.MAIN OUTCOME MEASURESTo evaluate the effect of long-term glucose control on postoperative analgesia requirements, the patients were divided into those with good glycaemic control (HbA1c <6.5%) and those with poor glycaemic control (HbA1c 6.5%). The amount of postoperative opioid received, the pain scores and satisfaction with analgesia were compared between these two groups. The two groups were compared using univariate and multivariate analyses to investigate possible independent predictors of postoperative analgesic opioid consumption.RESULTSThe total fentanyl consumption during the first 48h after surgery was 20% higher in the HbA1c at least 6.5% group than in the HbA1c less than 6.5% group (P=0.007). Compared with the HbA1c less than 6.5% group, there was a higher proportion of patients with inadequate analgesia during the early postoperative period (89.3 vs. 66.7% on moving; 71.4 vs. 37.5% while resting, P<0.05) and lower satisfaction with analgesia (3.41.0 vs. 4.1 +/- 1.0) on a 5-point Likert Scale (P=0.008) in the HbA1c at least 6.5% group. Univariate analysis revealed a significant correlation between preoperative HbA1c level and postoperative fentanyl requirements during the first 48h after surgery (r=0.455, P=0.001). Using a multivariate analysis, independent predictors of postoperative fentanyl requirement were HbA1c and weight (adjusted R-2=0.274).CONCLUSIONThis study demonstrated that in diabetic patients, the preoperative level of HbA1c was associated with the postoperative fentanyl consumption. In diabetic patients, the HbA1c level prior to surgery may be useful in anticipating postoperative analgesic requirements and help to improve patient counselling regarding postoperative pain.	Univ Ulsan Coll Med, Dept Anesthesiol & Pain Med, Asan Med Ctr, Seoul, South Korea; [Kim, Sung-Hoon; Hwang, Jai-Hyun] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul 138736, South Korea	Kim, SH (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, 86 Asanbyeongwon Gil, Seoul 138736, South Korea.	jhhwang@amc.seoul.kr					ALBERTI KGMM, 1979, BRIT J ANAESTH, V51, P693, DOI 10.1093/bja/51.7.693; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Courteix C, 1998, J PHARMACOL EXP THER, V285, P63; Cunha JM, 2009, BRAZ J MED BIOL RES, V42, P197, DOI 10.1590/S0100-879X2009000200008; Dronge AS, 2006, ARCH SURG-CHICAGO, V141, P375, DOI 10.1001/archsurg.141.4.375; Estrada CA, 2003, ANN THORAC SURG, V75, P1392, DOI 10.1016/S0003-4975(02)04997-4; Gerbershagen HJ, 2009, EUR J PAIN, V13, P853, DOI 10.1016/j.ejpain.2008.10.001; Gul H, 2000, PAIN, V89, P39, DOI 10.1016/S0304-3959(00)00343-2; Gullapalli S, 2002, EUR J PHARMACOL, V435, P187, DOI 10.1016/S0014-2999(01)01593-X; Gustafsson UO, 2009, BRIT J SURG, V96, P1358, DOI 10.1002/bjs.6724; GWILT PR, 1991, CLIN PHARMACOKINET, V20, P477, DOI 10.2165/00003088-199120060-00004; Hadjadj S, 2004, DIABETIC MED, V21, P305, DOI 10.1111/j.1464-5491.2004.01112.x; Halkos ME, 2008, J THORAC CARDIOV SUR, V136, P631, DOI 10.1016/j.jtcvs.2008.02.091; Hudson CCC, 2010, CAN J ANAESTH, V57, P565, DOI 10.1007/s12630-010-9294-4; Ibironke G F, 2006, Afr J Med Med Sci, V35, P443; Kadoi Y, 2010, J ANESTH, V24, P748, DOI 10.1007/s00540-010-0988-0; KAMEI J, 1993, LIFE SCI, V52, P53, DOI 10.1016/0024-3205(93)90288-E; Kang H, 2012, KOREAN J ANESTHESIOL, V63, P195, DOI 10.4097/kjae.2012.63.3.195; Karci A, 2004, ACTA ANAESTH SCAND, V48, P619, DOI 10.1111/j.1399-6576.2004.00387.x; KOENIG RJ, 1976, NEW ENGL J MED, V295, P417, DOI 10.1056/NEJM197608192950804; Kosiborod M, 2008, CIRCULATION, V117, P1018, DOI 10.1161/CIRCULATIONAHA.107.740498; Labuzek K, 2013, INT J CLIN PHARM TH, V51, P517, DOI 10.5414/CP201878; Lavand'homme P, 2006, CURR OPIN ANESTHESIO, V19, P556, DOI 10.1097/01.aco.0000245284.53152.1f; Lipshutz AKM, 2009, ANESTHESIOLOGY, V110, P408, DOI 10.1097/ALN.0b013e3181948a80; MACKENZIE RG, 1978, J NEUROCHEM, V30, P205, DOI 10.1111/j.1471-4159.1978.tb07053.x; Moitra VK, 2010, CAN J ANAESTH, V57, P322, DOI 10.1007/s12630-010-9266-8; Nathan DM, 2006, DIABETES CARE, V29, P1963, DOI 10.2337/dc06-9912; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033; Ouattara A, 2005, ANESTHESIOLOGY, V103, P687, DOI 10.1097/00000542-200510000-00006; Park SH, 2011, KOREAN J ANESTHESIOL, V61, P419, DOI 10.4097/kjae.2011.61.5.419; Perna M, 2012, SURG OBES RELAT DIS, V8, P685, DOI 10.1016/j.soard.2011.08.002; Pieper GM, 2000, EUR J PHARMACOL, V401, P375, DOI 10.1016/S0014-2999(00)00459-3; RAZ I, 1988, DIABETES, V37, P1253, DOI 10.2337/diabetes.37.9.1253; Ross-Huot MC, 2011, ANESTHESIOLOGY, V115, P614, DOI 10.1097/ALN.0b013e31822a63c9; Sato H, 2010, J CLIN ENDOCR METAB, V95, P4338, DOI 10.1210/jc.2010-0135; Sheehy Ann M, 2009, J Diabetes Sci Technol, V3, P1261; Taylor A, 2013, J PAIN RES, V6, P755, DOI 10.2147/JPR.S52205; Thorell A, 1999, Curr Opin Clin Nutr Metab Care, V2, P69, DOI 10.1097/00075197-199901000-00012; Turina M, 2005, CRIT CARE MED, V33, P1624, DOI 10.1097/01.CCM.0000170106.61978.D8; Wile DJ, 2010, DIABETES CARE, V33, P156, DOI 10.2337/dc09-0606; Yue WS, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-113	41	4	4	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	OCT	2015	32	10					705	711		10.1097/EJA.0000000000000282			7	Anesthesiology	Anesthesiology	CW9XG	WOS:000365350900007	26086279				2020-06-30	J	Soga, T; Kume, K; Kakuta, N; Hamaguchi, E; Tsutsumi, R; Kawanishi, R; Fukuta, K; Tanaka, K; Tsutsumi, YM				Soga, Tomohiro; Kume, Katsuyoshi; Kakuta, Nami; Hamaguchi, Eisuke; Tsutsumi, Rie; Kawanishi, Ryosuke; Fukuta, Kohei; Tanaka, Katsuya; Tsutsumi, Yasuo M.			Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study	JOURNAL OF ANESTHESIA			English	Article						Fosaprepitant; Gynecologic abdominal surgery; Ondansetron; Patient-controlled epidural analgesia; Postoperative nausea and vomiting	RECEPTOR ANTAGONIST; APREPITANT; EFFICACY; EMESIS; SAFETY; TRIAL	Postoperative nausea and vomiting (PONV) is the most common postoperative complication. The postoperative use of opioids is known to increase the incidence. We compared fosaprepitant, a neurokinin-1 (NK1) receptor antagonist, and ondansetron for their preventive effects on PONV in patients who underwent gynecologic abdominal surgery with patient-controlled epidural analgesia. This prospective, double-blind, randomized study comprised 44 patients who underwent gynecologic abdominal surgery. They were randomly allocated to receive 150 mg intravenous fosaprepitant (n = 24; NKI group) or 4 mg ondansetron (n = 20; ONS group) before anesthesia, which was maintained with volatile anesthetics, remifentanil, fentanyl, and rocuronium. All patients received postoperative fentanyl by patient-controlled epidural anesthesia. The incidence of nausea and vomiting, complete response rate (i.e., no vomiting and no rescue antiemetic use), rescue antiemetic use, nausea score (0-3), and visual analog scale score (VAS 0-10) for pain were recorded at 2, 24, 48, and 72 h after surgery. No (0 %) patient in the NKI group experienced vomiting after surgery; however, 4-6 (20-30 %) of 20 patients in the ONS group experienced vomiting. This difference was significant at 0-24, 0-48, and 0-72 h. During the study period, no significant differences existed between the NK1 and ONS groups in the incidence of PONV, complete response rate, rescue antiemetic use, nausea score, and VAS score for pain. Compared to ondansetron, fosaprepitant more effectively decreased the incidence of vomiting in patients who underwent gynecologic abdominal surgery with patient-controlled epidural analgesia.	[Soga, Tomohiro; Kume, Katsuyoshi; Kakuta, Nami; Hamaguchi, Eisuke; Kawanishi, Ryosuke; Fukuta, Kohei; Tanaka, Katsuya; Tsutsumi, Yasuo M.] Univ Tokushima, Grad Sch, Dept Anesthesiol, Tokushima 7708503, Japan; [Tsutsumi, Rie] Univ Tokushima, Grad Sch, Dept Nutr, Tokushima 7708503, Japan	Tsutsumi, YM (reprint author), Univ Tokushima, Grad Sch, Dept Anesthesiol, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	tsutsumi@tokushima-u.ac.jp		Tsutsumi, Yasuo/0000-0002-1997-082X	JSPS KAKENHI from Japan Society for the Promotion of Science, Tokyo [25861378]	Supported by JSPS KAKENHI Number 25861378 from Japan Society for the Promotion of Science, Tokyo.	Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Behera BK, 2008, J POSTGRAD MED, V54, P86; Diemunsch P, 2007, BRIT J ANAESTH, V99, P202, DOI 10.1093/bja/aem133; Diernunsch P, 2007, CURR MED RES OPIN, V23, P2559, DOI 10.1185/030079907X233115; Gan TJ, 1996, ANESTHESIOLOGY, V85, P1036, DOI 10.1097/00000542-199611000-00011; Gan TJ, 2007, ANESTH ANALG, V104, P1082, DOI 10.1213/01.ane.0000263277.35140.a3; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gonsalves S, 1996, EUR J PHARMACOL, V305, P181, DOI 10.1016/0014-2999(96)00216-6; Grunberg S, 2011, J CLIN ONCOL, V29, P1495, DOI 10.1200/JCO.2010.31.7859; Jung WS, 2013, J ANESTH, V27, P396, DOI 10.1007/s00540-012-1529-9; Kakuta N, 2011, J MED INVESTIG, V58, P246, DOI 10.2152/jmi.58.246; Kawano H, 2014, MINERVA ANE IN PRESS; Koivuranta M, 1997, ANAESTHESIA, V52, P443, DOI 10.1111/j.1365-2044.1997.117-az0113.x; Lasseter KC, 2007, J CLIN PHARMACOL, V47, P834, DOI 10.1177/0091270007301800; Marbury TC, 2011, J CLIN PHARMACOL, V51, P1712, DOI 10.1177/0091270010387792; RUST M, 1994, ANAESTHESIA, V49, P16, DOI 10.1111/j.1365-2044.1994.tb03578.x; Saito H, 2013, ANN ONCOL, V24, P1067, DOI 10.1093/annonc/mds541; Scuderi PE, 2011, ANESTH ANALG, V112, P750, DOI 10.1213/ANE.0b013e31820d979c; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; TATTERSALL FD, 1994, NEUROPHARMACOLOGY, V33, P259, DOI 10.1016/0028-3908(94)90018-3; Tramer MR, 1997, ANESTHESIOLOGY, V87, P1277, DOI 10.1097/00000542-199712000-00004; Tsutsumi YM, 2014, BIOMED RES INT, DOI 10.1155/2014/307025	22	6	6	0	6	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	OCT	2015	29	5					696	701		10.1007/s00540-015-2006-z			6	Anesthesiology	Anesthesiology	CT7YV	WOS:000363032600009	25801542				2020-06-30	J	Yousef, AA; Salem, HA; Moustafa, MZ				Yousef, Ayman Abdelmaksoud; Salem, Hesham Abdalaziz; Moustafa, Mostafa Zein			Effect of mini-dose epidural dexmedetomidine in elective cesarean section using combined spinal-epidural anesthesia: a randomized double-blinded controlled study	JOURNAL OF ANESTHESIA			English	Article						Dexmedetomidine; Combined spinal-epidural anesthesia	LABOR ANALGESIA; PAIN; BUPIVACAINE; CLONIDINE; BLOCK; FENTANYL; PATIENT	Combined spinal-epidural anesthesia is commonly used for elective cesarean section. Our study aimed to evaluate the effect of adding dexmedetomidine to epidural bupivacaine and fentanyl in patients undergoing elective cesarean section using combined spinal-epidural anesthesia. Eighty healthy women at term were randomly assigned to two groups: a control group (n = 40; "Bup/Fen group") received combined spinal-epidural anesthesia with intrathecal hyperbaric bupivacaine 5 mg and an epidural mixture of 10 mL plain bupivacaine 0.25 % and fentanyl 50 mu g, whereas the study group (n = 40; "Dex/Bup/Fen group") received 1 mL epidural dexmedetomidine 0.5 A mu g/kg in addition. The primary outcome measure was the difference between the groups in the supplementary fentanyl analgesic required. The quality of surgical anesthesia, incidences of hypotension and bradycardia, APGAR scores, intraoperative pain assessment, and onset of postoperative pain, sedation score, and side effects were recorded. There was no statistically significant difference between the groups regarding block characteristics. Significantly less intraoperative and postoperative fentanyl were required by the Dex/Bup/Fen group (P = 0.015 and P = 0.0011, respectively). There was no statistically significant difference between the groups regarding sedation score or the incidences of hypotension, nausea and vomiting, dizziness, and pruritus. The addition of mini-dose epidural dexmedetomidine 0.5 A mu g/kg as a single injection to bupivacaine fentanyl in women undergoing elective cesarean section with combined spinal-epidural anesthesia improved intraoperative conditions and the quality of postoperative analgesia.	[Yousef, Ayman Abdelmaksoud] Tanta Univ, Fac Med, Dept Anesthesia, Tanta, Egypt; [Salem, Hesham Abdalaziz; Moustafa, Mostafa Zein] Tanta Univ, Dept Gynecol & Obstet, Fac Med, Tanta, Egypt	Yousef, AA (reprint author), Tanta Univ, Fac Med, Dept Anesthesia, Tanta, Egypt.	ayman.yousef@rocketmail.com					Abu-Halaweh SA, 2009, EUR J ANAESTH, V26, P86, DOI 10.1097/EJA.0b000e000000f3fb; Bajwa SJ, 2012, J OBSTET ANAESTH CRI, V2, P57, DOI DOI 10.4103/2249-4472.99337; Bajwa SJS, 2011, INDIAN J ANAESTH, V55, P116, DOI 10.4103/0019-5049.79883; Brummett CM, 2005, SEMIN ANESTH PERIO M, V25, P41, DOI DOI 10.1053/j.sane.2006.03.001; CARRIE LES, 1990, BRIT J ANAESTH, V65, P225, DOI 10.1093/bja/65.2.225; Cooper DW, 1999, BRIT J ANAESTH, V82, P366, DOI 10.1093/bja/82.3.366; El-Hennawy AM, 2009, BRIT J ANAESTH, V103, P268, DOI 10.1093/bja/aep159; Elhakim M, 2010, ACTA ANAESTH SCAND, V54, P703, DOI 10.1111/j.1399-6576.2009.02199.x; FAN SZ, 1994, ANESTH ANALG, V78, P474; Goodman SR, 2009, ANESTH ANALG, V108, P246, DOI 10.1213/ane.0b013e31818f896f; Graham AC, 2001, ANAESTHESIA, V56, P470, DOI 10.1046/j.1365-2044.2001.01524-6.x; Jain D, 2012, SOUTH AFR J ANAESTH, V18, P105, DOI 10.1080/22201173.2012.10872835; Konakci S, 2008, EUR J ANAESTH, V25, P403, DOI 10.1017/S0265021507003079; Mantz J, 2011, EUR J ANAESTH, V28, P3, DOI 10.1097/EJA.0b013e32833e266d; NAULTY JS, 1985, ANESTHESIOLOGY, V63, P694, DOI 10.1097/00000542-198512000-00025; POCKETT S, 1995, ANESTH ANALG, V80, P173, DOI 10.1097/00000539-199501000-00026; WAGNER DS, 2006, [No title captured], V25, P77, DOI DOI 10.1053/j.sane.2006.02.003; Wallet F, 2010, EUR J ANAESTH, V27, P441, DOI 10.1097/EJA.0b013e3283365944; Yoshitomi T, 2008, ANESTH ANALG, V107, P96, DOI 10.1213/ane.0b013e318176be73; Zeng XZ, 2014, ANAESTH INTENS CARE, V42, P185, DOI 10.1177/0310057X1404200204	20	14	18	0	10	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	OCT	2015	29	5					708	714		10.1007/s00540-015-2027-7			7	Anesthesiology	Anesthesiology	CT7YV	WOS:000363032600011	26006222				2020-06-30	J	Kassir, M; Kassas, MC; Ajine, M; Hammoud, M; Mahmoud, W				Kassir, M.; Kassas, M. C.; Ajine, M.; Hammoud, M.; Mahmoud, W.			Role of deep sedation phacoemulsificat ion with scleral tunnel	JOURNAL FRANCAIS D OPHTALMOLOGIE			French	Article						Deep sedation; Dexmedetomidine; Phacoemulsification; Scleral tunnel; Pain; Comfort; Safety	MONITORED ANESTHESIA CARE; CATARACT-SURGERY; DEXMEDETOMIDINE SEDATION; INTRAVENOUS SEDATION; TOPICAL ANESTHESIA; MIDAZOLAM	Purpose. - To describe a method of deep sedation without adjunctive periocular injection in phacoemulsification with a scleral tunnel technique. Methods. - All patients undergoing phacoemulsification with a scleral tunnel and foldable intraocular lens for cataract between May 2011 and November 2014 received deep sedation including a bolus of midazolam and fentanyl followed by a continuous perfusion of dexmedetomidine throughout the surgical procedure. The patients and medical team evaluated pain, sedation, clinical status of the patient, and surgeon comfort. Results. - One thousand and five hundred patients were included, representing 1763 eyes. Ramsay's sedation score was 2 in 7.13% of cases and 3 in 86.3%, which allowed surgery to be performed under very satisfactory conditions. On a scale of 1 to 10, intraoperative pain was less than or equal to 1 in 81.2% of cases. The bradycardic and hypotensive effects of dexmedetomidine were appreciable, while respiratory depression was not observed. Only 1 case of severe agitation during surgery directly resulted in a vitreous issue. Some simple precautions allow optimization of the advantages of this method of anesthesia. Conclusion. - The deep sedation method including bolus injections of midazolam and fentanyl and continuous perfusion of dexmedetomidine affords a certain comfort to the patient as well as the surgeon in phacoemulsification of cataract through a scleral tunnel without adjunctive periocular injection. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Kassir, M.] Labib Med Ctr, Serv Ophtalmol, Saida, Lebanon; [Kassas, M. C.] Victoria Hosp, Serv Anesthesie Reanimat, Riyadh, Saudi Arabia; [Kassas, M. C.; Ajine, M.; Hammoud, M.; Mahmoud, W.] Labib Med Ctr, Serv Anesthesie Reanimat, Saida, Lebanon	Kassir, M (reprint author), Labib Med Ctr, Serv Ophtalmol, Rond Point ELIA,Immeuble Dandachli Plaza,BP 644, Saida, Lebanon.	domoukas@hotmail.com					Alhashemi JA, 2006, BRIT J ANAESTH, V96, P722, DOI 10.1093/bja/ael080; Apan A, 2009, MINERVA ANESTESIOL, V75, P239; Aydin ON, 2002, J CATARACT REFR SURG, V28, P1968, DOI 10.1016/S0886-3350(02)01429-3; Ayoglu H, 2007, BRIT J ANAESTH, V99, P448, DOI 10.1093/bja/aem226; Candiotti KA, 2010, ANESTH ANALG, V110, P47, DOI 10.1213/ane.0b013e3181ae0856; Erdurmus M, 2008, EUR J OPHTHALMOL, V18, P361; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; JAAKOLA ML, 1992, BRIT J ANAESTH, V68, P570, DOI 10.1093/bja/68.6.570; SALMON JF, 1992, BRIT J OPHTHALMOL, V76, P598, DOI 10.1136/bjo.76.10.598; VIRKKILA M, 1994, ANAESTHESIA, V49, P853, DOI 10.1111/j.1365-2044.1994.tb04257.x; Wong DHW, 1996, CAN J ANAESTH, V43, P1115, DOI 10.1007/BF03011837	11	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0181-5512	1773-0597		J FR OPHTALMOL	J. Fr. Ophthamol.	OCT	2015	38	8					752	757		10.1016/j.jfo.2015.03.007			6	Ophthalmology	Ophthalmology	CT6ZX	WOS:000362963800017	26341020				2020-06-30	J	Shimokaze, T; Saito, E; Akaba, K				Shimokaze, Tomoyuki; Saito, Emi; Akaba, Kazuhiro			Increased Incidence of Late-Onset Circulatory Collapse after Changing Clinical Practice: A Retrospective Investigation of Causative Factors	AMERICAN JOURNAL OF PERINATOLOGY			English	Article						adrenal insufficiency; fentanyl; glucocorticoid; hyponatremia; opioid	LOW-BIRTH-WEIGHT; PRETERM INFANTS; PREMATURE-INFANTS; INSUFFICIENCY; MORPHINE; OUTCOMES; DYSFUNCTION; STRESS; TRIAL; JAPAN	Objective Acute primary profound circulatory failure responsive to glucocorticoid therapy after the first week of age in preterm infants is termed late-onset circulatory collapse (LCC). This study was performed to identify factors that notably increased the incidence of LCC after various management practices were changed. Study Design We retrospectively studied the clinical characteristics of infants (<29 weeks' gestation) before (n = 26) and after (n = 35) implementing the following practice changes: stress reduction, conservative replacement of thyroid hormone, positive antenatal glucocorticoid administration, sedation with fentanyl (<7 days after birth), and hydrocortisone therapy for hypotension. Results After the aforementioned changes, the incidence of LCC increased from 4 to 43%, and that of intraventricular hemorrhage decreased from 42 to 9%. Antenatal glucocorticoids (75 vs. 20%), fentanyl (94 vs. 53%), and hydrocortisone (63 vs. 31%) (<2 weeks of age) were given to infants with LCC and non-LCC. After the practice changes, infants with LCC had lower serum sodium levels than did infants without LCC at 7 to 14 days of age. Conclusion Relative hyponatremia was an early sign of imminent LCC. In addition to adrenal prematurity, the antenatal administration of glucocorticoids and fentanyl, which influence adrenal function, might increase the incidence of LCC.	[Shimokaze, Tomoyuki; Saito, Emi; Akaba, Kazuhiro] Saiseikai Yamagata Hosp, Dept Pediat, Yamagata 9908545, Japan	Shimokaze, T (reprint author), Saiseikai Yamagata Hosp, Dept Pediat, 79-1 Okimachi, Yamagata 9908545, Japan.	tkaze@hotmail.com	Shimokaze, Tomoyuki/I-4822-2019	Shimokaze, Tomoyuki/0000-0001-8490-475X			Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; BALLARD PL, 1980, PEDIATR RES, V14, P122, DOI 10.1203/00006450-198002000-00011; Bellu R, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004212.pub3; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; Davis EP, 2006, J PERINATOL, V26, P147, DOI 10.1038/sj.jp.7211447; Efird Meica M, 2005, J Perinatol, V25, P119, DOI 10.1038/sj.jp.7211193; Hall RW, 2005, PEDIATRICS, V115, P1351, DOI 10.1542/peds.2004-1398; Houshyar H, 2001, J NEUROENDOCRINOL, V13, P862, DOI 10.1046/j.1365-2826.2001.00713.x; Kawai M, 2012, PEDIATR INT, V54, P177, DOI 10.1111/j.1442-200X.2011.03518.x; 이진아, 2011, Neonatal medicine, V18, P211; 최창원, 2011, Neonatal medicine, V18, P82; Kobayashi S, 2006, TOHOKU J EXP MED, V210, P333, DOI 10.1620/tjem.210.333; Kusuda S, 2006, PEDIATRICS, V118, pE1130, DOI 10.1542/peds.2005-2724; Masumoto K, 2008, PEDIATR RES, V63, P686, DOI 10.1203/PDR.0b013e31816c8fcc; Mussig K, 2007, CLIN ENDOCRINOL, V66, P604, DOI 10.1111/j.1365-2265.2007.02779.x; Nakanishi H, 2010, J PERINATOL, V30, P751, DOI 10.1038/jp.2010.41; Oltmanns KM, 2005, J INTERN MED, V257, P478, DOI 10.1111/j.1365-2796.2005.01483.x; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Takizawa F, 2010, PEDIATR INT, V52, pe154, DOI 10.1111/j.1442-200X.2010.03072.x; Toyoshima K, 2013, J FORMOS MED ASSOC, V112, P510, DOI 10.1016/j.jfma.2013.02.011; Vuong C, 2010, ENDOCR REV, V31, P98, DOI 10.1210/er.2009-0009; Washio Y, 2013, PEDIATR INT, V55, P582, DOI 10.1111/ped.12114; Yagasaki H, 2010, J PEDIATR ENDOCR MET, V23, P153	23	4	4	0	1	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0735-1631	1098-8785		AM J PERINAT	Am. J. Perinatol.	OCT	2015	32	12					1169	1176		10.1055/s-0035-1552933			8	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	CT3IH	WOS:000362699900013	26007315				2020-06-30	J	Kim, TK; Niklewski, PJ; Martin, JF; Obara, S; Egan, TD				Kim, T. K.; Niklewski, P. J.; Martin, J. F.; Obara, S.; Egan, T. D.			Enhancing a sedation score to include truly noxious stimulation: the Extended Observer's Assessment of Alertness and Sedation (EOAA/S)	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics i.v.; propofol; sedation; sedation scale	NITROUS-OXIDE ANESTHESIA; POPULATION PHARMACODYNAMICS; CONTROLLED INFUSION; PROPOFOL; REMIFENTANIL; SURGERY; PHARMACOKINETICS; MODELS; SEVOFLURANE; VOLUNTEERS	Background: Although the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) is frequently used in sedation-related drug and device studies, a major shortcoming is that it does not differentiate between lighter and deeper levels of general anaesthesia because the only noxious stimulus of the MOAA/S is a trapezius squeeze. The primary aim of this investigation was to expand the MOAA/S score to include truly noxious stimulation, thereby extending the dynamic range of the assessment to include sedation states consistent with deeper levels of general anaesthesia. Methods: Twenty healthy volunteers received target controlled infusions of fentanyl (target.0.8 ng ml(-1)) and propofol (starting at 0.5 mu g ml(-1) and gradually increasing to 5 mu g ml(-1)). At each propofol concentration, a MOAA/S score was obtained before and after tetanic electrical stimulation. The tetanic electrical stimulation current was gradually increased until the subject responded or until 50 mA was delivered without a response. A pharmacodynamic model was constructed to characterize the concentration-effect relationship between propofol and the MOAA/S scores. Results: All subjects required a significantly higher propofol concentration to produce unresponsiveness to tetanic electrical stimulation at 50 mA compared with a standardized trapezius squeeze. The pharmacodynamic model adequately characterized the concentration-effect relationship. Conclusions: The Extended Observer's Assessment of Alertness and Sedation (or EOAA/S) extends the range of the widely used MOAA/S score to include truly noxious stimulation, thereby enabling the identification of drug-induced central nervous system depression representative of surgical anaesthesia.	[Kim, T. K.; Obara, S.; Egan, T. D.] Univ Utah, Sch Med, Dept Anesthesiol SOM 3C444, Salt Lake City, UT USA; [Niklewski, P. J.] Pusan Natl Univ, Dept Anesthesia & Pain Med, Busan, South Korea; [Niklewski, P. J.] Ethicon Endo Surg Inc, Cincinnati, OH USA; [Niklewski, P. J.] Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; [Obara, S.] Fukushima Med Univ, Sch Med, Dept Anesthesiol, Fukushima 9601295, Japan	Egan, TD (reprint author), Univ Utah, Sch Med, Dept Anesthesiol SOM 3C444, 30 North 1900 East, Salt Lake City, UT USA.	talmage.egan@hsc.utah.edu			Ethicon Endo-Surgery; University of Utah	Ethicon Endo-Surgery; University of Utah Dr K. C. Wong Presidential Endowed Chair Professorship (held by T.D.E.).	AUSEMS ME, 1986, ANESTHESIOLOGY, V65, P362, DOI 10.1097/00000542-198610000-00004; Bouillon T, 2004, ANESTHESIOLOGY, V100, P240, DOI 10.1097/00000542-200402000-00010; Brendel K, 2007, CLIN PHARMACOKINET, V46, P221, DOI 10.2165/00003088-200746030-00003; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cohen LB, 2008, ALIMENT PHARM THERAP, V27, P597, DOI 10.1111/j.1365-2036.2008.03598.x; Dosani M, 2010, PEDIATR ANESTH, V20, P1001, DOI 10.1111/j.1460-9592.2010.03398.x; Drover DR, 1998, ANESTHESIOLOGY, V89, P869, DOI 10.1097/00000542-199810000-00011; Egan TD, 2003, ANESTHESIOLOGY, V99, P1214, DOI 10.1097/00000542-200311000-00031; GALLA SJ, 1958, ANESTHESIOLOGY, V19, P328, DOI 10.1097/00000542-195805000-00003; Heyse B, 2012, ANESTHESIOLOGY, V116, P311, DOI 10.1097/ALN.0b013e318242a2ec; Jordan D, 2010, ANESTH ANALG, V111, P1416, DOI 10.1213/ANE.0b013e3181fb919e; Kern SE, 2004, ANESTHESIOLOGY, V100, P1373, DOI 10.1097/00000542-200406000-00007; LaPierre CD, 2012, ANESTHESIOLOGY, V117, P252, DOI 10.1097/ALN.0b013e31825fb1b2; LaPierre CD, 2011, ANESTH ANALG, V113, P490, DOI 10.1213/ANE.0b013e318210fc45; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; Pambianco DJ, 2011, GASTROINTEST ENDOSC, V73, P765, DOI 10.1016/j.gie.2010.10.031; PETERSENFELIX S, 1993, ANESTHESIOLOGY, V79, P959, DOI 10.1097/00000542-199311000-00014; Ropcke H, 2001, ANESTHESIOLOGY, V94, P390; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Smith WD, 1996, ANESTHESIOLOGY, V84, P38, DOI 10.1097/00000542-199601000-00005; Somma J, 1998, ANESTHESIOLOGY, V89, P1430, DOI 10.1097/00000542-199812000-00021; Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895-4356(03)00047-7; Struys MMRF, 2005, ANESTHESIOLOGY, V103, P730, DOI 10.1097/00000542-200510000-00011; YASUDA N, 1991, ANESTH ANALG, V73, P175; ZBINDEN AM, 1994, ANESTHESIOLOGY, V80, P261, DOI 10.1097/00000542-199402000-00005	26	7	7	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	OCT	2015	115	4					569	577		10.1093/bja/aev306			9	Anesthesiology	Anesthesiology	CS7ZO	WOS:000362305700014	26385665	Bronze			2020-06-30	J	Kokki, M; Heikkinen, AT; Raatikainen, K; Ranta, VP; Hautajarvi, H; Kokki, H				Kokki, M.; Heikkinen, A. T.; Raatikainen, K.; Ranta, V. -P.; Hautajarvi, H.; Kokki, H.			Pharmacokinetics of intranasal fentanyl in parturient	BRITISH JOURNAL OF ANAESTHESIA			English	Letter											merja.kokki@kuh.fi					Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Heikkinen EM, 2015, BASIC CLIN PHARMACOL, V117, P156, DOI 10.1111/bcpt.12382	3	3	3	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	OCT	2015	115	4					635	636		10.1093/bja/aev313			2	Anesthesiology	Anesthesiology	CS7ZO	WOS:000362305700026	26385675	Bronze			2020-06-30	J	Kokki, M; Westeren-Punnonen, S; Hautajarvi, H; Heinonen, S; Mazzei, M; Maatta, S; Paalanen, E; Kokki, H				Kokki, M.; Westeren-Punnonen, S.; Hautajarvi, H.; Heinonen, S.; Mazzei, M.; Maatta, S.; Paalanen, E.; Kokki, H.			Neonatal safety of maternal fentanyl during labour	BRITISH JOURNAL OF ANAESTHESIA			English	Letter							PHARMACOKINETICS				merja.kokki@kuh.fi					AMIELTISON C, 1982, ANESTHESIOLOGY, V56, P492, DOI 10.1097/00000542-198206000-00031; Heikkinen EM, 2015, BASIC CLIN PHARMACOL, V117, P156, DOI 10.1111/bcpt.12382; Kokki M, 2012, BASIC CLIN PHARMACOL, V111, P182, DOI 10.1111/j.1742-7843.2012.00884.x; Norman E, 2013, PEDIATR RES, V73, P87, DOI 10.1038/pr.2012.153	4	4	4	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	OCT	2015	115	4					636	638		10.1093/bja/aev314			3	Anesthesiology	Anesthesiology	CS7ZO	WOS:000362305700027	26385676	Bronze			2020-06-30	J	Heiskanen, T; Langel, K; Gunnar, T; Lillsunde, P; Kalso, EA				Heiskanen, Tarja; Langel, Kaarina; Gunnar, Teemu; Lillsunde, Pirjo; Kalso, Eija A.			Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Opioid; oral fluid; plasma; concentration	BRAIN-BARRIER TRANSPORT; P-GLYCOPROTEIN; OXYCODONE; MORPHINE; DRUGS; ABUSE; BLOOD; SALIVA; PHARMACOKINETICS; PHARMACODYNAMICS	Context. Measuring opioid concentrations in pain treatment is warranted in situations where optimal opioid analgesia is difficult to reach. Objectives. To assess the usefulness of oral fluid (OFL) as an alternative to plasma in opioid concentration monitoring in cancer patients on chronic opioid therapy. Methods. We collected OFL and plasma samples from 64 cancer patients on controlled-release (CR) oral morphine, CR oral oxycodone, or transdermal (TD) fentanyl for pain. Samples were obtained on up to five separate days. Results. A total of 213 OFL and plasma samples were evaluable. All patients had detectable amounts of the CR or TD opioid in both plasma and OFL samples. The plasma concentrations of oxycodone and fentanyl (determination coefficient R-2 = 0.628 and 0.700, respectively), but not morphine (R-2 = 0.292), were moderately well correlated to the daily opioid doses. In contrast to morphine and fentanyl (mean OFL/plasma ratio 2.0 and 3.0, respectively), the OFL oxycodone concentrations were significantly higher than the respective plasma concentrations (mean OFL/plasma ratio 14.9). An active transporter could explain the much higher OFL vs. plasma concentrations of oxycodone compared with morphine and fentanyl. Conclusion. OFL analysis is well suited for detecting the studied opioids. For morphine and fentanyl, an approximation of the plasma opioid concentrations is obtainable, whereas for oxycodone, the OFL/plasma concentration relationship is too variable for reliable approximation results. (C) 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.	[Heiskanen, Tarja; Kalso, Eija A.] Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Pain Clin, Helsinki 00029, Finland; [Langel, Kaarina; Gunnar, Teemu] Univ Helsinki, Alcohol & Drug Analyt Unit, Helsinki 00029, Finland; [Lillsunde, Pirjo] Univ Helsinki, Injury Prevent Unit, Natl Inst Hlth & Welf, Helsinki 00029, Finland; [Kalso, Eija A.] Univ Helsinki, Inst Clin Med, Helsinki 00029, Finland	Heiskanen, T (reprint author), Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Pain Clin, POB 140, Helsinki 00029, Finland.	tarja.heiskanen@hus.fi		Kalso, Eija/0000-0002-4899-605X	Cancer Society of Finland; Research Funds of the Helsinki University Central Hospital [T10200066]	The study was supported by a grant from the Cancer Society of Finland and a grant from the Research Funds of the Helsinki University Central Hospital (T10200066). The authors declare no conflicts of interest.	Andreassen TN, 2011, EUR J CLIN PHARMACOL, V67, P493, DOI 10.1007/s00228-010-0948-5; AVIRAM M, 1987, PEDIATRICS, V80, P894; Bosker WM, 2009, CLIN CHEM, V55, P1910, DOI 10.1373/clinchem.2008.108670; Bostrom E, 2005, J PHARM SCI-US, V94, P1060, DOI 10.1002/jps.20327; Bostrom E, 2006, DRUG METAB DISPOS, V34, P1624, DOI 10.1124/dmd.106.009746; Chu M, 2012, FORENSIC SCI INT, V215, P28, DOI 10.1016/j.forsciint.2011.05.012; Coluzzi F, 2005, Minerva Anestesiol, V71, P451; CONE EJ, 1993, ANN NY ACAD SCI, V694, P91, DOI 10.1111/j.1749-6632.1993.tb18346.x; Dams R, 2007, DRUG ALCOHOL DEPEN, V87, P258, DOI 10.1016/j.drugalcdep.2006.08.020; Darke S, 1997, DRUG ALCOHOL DEPEN, V47, P45, DOI 10.1016/S0376-8716(97)00070-7; Darke S, 2011, J FORENSIC SCI, V56, P690, DOI 10.1111/j.1556-4029.2011.01703.x; Gunnar T, 2005, J MASS SPECTROM, V40, P739, DOI 10.1002/jms.846; Haanpaa M, 2011, PAIN, V152, P14, DOI 10.1016/j.pain.2010.07.031; Hagen NA, 2005, J PAIN SYMPTOM MANAG, V29, P80, DOI 10.1016/j.jpainsymman.2004.04.015; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; Hardy J, 2012, SUPPORT CARE CANCER, V20, P767, DOI 10.1007/s00520-011-1147-3; Hardy JR, 2001, PALLIATIVE MED, V15, P3, DOI 10.1191/026921601673324846; Hassan HE, 2007, J PHARM SCI-US, V96, P2494, DOI 10.1002/jps.20893; Hassan HE, 2009, J PHARM SCI-US, V98, P4928, DOI 10.1002/jps.21770; Heiskanen TE, 2000, ACTA ONCOL, V39, P941; Katz N, 2010, PHARMACOEPIDEM DR S, V19, P115, DOI 10.1002/pds.1878; Kharasch ED, 2003, CLIN PHARMACOL THER, V74, P543, DOI 10.1016/j.clpt.2003.08.011; Kim I, 2002, CLIN CHEM, V48, P1486; Kopecky EA, 1997, THER DRUG MONIT, V19, P530, DOI 10.1097/00007691-199710000-00008; Langel K, 2008, J ANAL TOXICOL, V32, P393, DOI 10.1093/jat/32.6.393; Langel K, 2014, DRUG TEST ANAL, V6, P461, DOI 10.1002/dta.1532; Langel K, 2011, J CHROMATOGR B, V879, P859, DOI 10.1016/j.jchromb.2011.02.027; Moore Christine, 2012, J Opioid Manag, V8, P161, DOI 10.5055/jom.2012.0112; MUCKLOW JC, 1982, THER DRUG MONIT, V4, P229, DOI 10.1097/00007691-198208000-00001; Nieminen TH, 2009, ANESTHESIOLOGY, V110, P1371, DOI 10.1097/ALN.0b013e31819faa54; Okura T, 2008, DRUG METAB DISPOS, V36, P2005, DOI 10.1124/dmd.108.022087; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; POYHIA R, 1994, PHARMACOL TOXICOL, V74, P23; Rohrig TP, 2003, J ANAL TOXICOL, V27, P449, DOI 10.1093/jat/27.7.449; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; Samyn N, 1999, Forensic Sci Rev, V11, P1; Thurlkill RL, 2005, J CARDIOTHOR VASC AN, V19, P759, DOI 10.1053/j.jvca.2004.11.039; Toennes SW, 2005, J ANAL TOXICOL, V29, P22, DOI 10.1093/jat/29.1.22; UMSTEAD G S, 1982, Clinical Pharmacy, V1, P54; Wille SMR, 2009, THER DRUG MONIT, V31, P511, DOI 10.1097/FTD.0b013e3181ae46ea	40	13	13	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	OCT	2015	50	4					524	532		10.1016/j.jpainsymman.2014.09.004			9	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	CS5CN	WOS:000362093800014	25242020	Bronze			2020-06-30	J	Cahill, K; Shehab, RM; Hassan, A; Lowney, A; McQuillan, R				Cahill, Kathleen; Shehab, Ruqaya Mohsen; Hassan, Ali; Lowney, Aoife; McQuillan, Regina			Addiction to transmucosal fentanyl: Is it a cause for concern in cancer pain management?	PALLIATIVE MEDICINE			English	Letter									[Cahill, Kathleen; McQuillan, Regina] St Francis Hosp, Dublin 5, Ireland; [Shehab, Ruqaya Mohsen] RCSI Bahrain, Sch Med, Busaiteen, Bahrain; [Lowney, Aoife] St Lukes Hosp, Dublin, Ireland; [Lowney, Aoife] Our Ladys Childrens Hosp, Dublin, Ireland; [Hassan, Ali] Univ Jordan, Amman, Jordan	Cahill, K (reprint author), St Francis Hosp, Dublin 5, Ireland.	cahillkp@gmail.com					Nunez-Olarte JM, 2011, J PAIN SYMPTOM MANAG, V42, pE6, DOI 10.1016/j.jpainsymman.2011.07.006; Passik SD, 2007, PAIN MED, V8, P130, DOI 10.1111/j.1526-4637.2006.00295.x; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Twycross R, 2012, J PAIN SYMPTOM MANAG, V44, P131, DOI 10.1016/j.jpainsymman.2012.05.001	4	0	0	1	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163	1477-030X		PALLIATIVE MED	Palliat. Med.	OCT	2015	29	9					861	862		10.1177/0269216315593452			2	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	CR6XN	WOS:000361491800011	26130412				2020-06-30	J	Kapoor, PM; Taneja, S; Kiran, U; Rajashekhar, P				Kapoor, Poonam Malhotra; Taneja, Sameer; Kiran, Usha; Rajashekhar, P.			Comparison of the effects of inhalational anesthesia with desflurane and total intravenous anesthesia on cardiac biomarkers after aortic valve replacement	ANNALS OF CARDIAC ANAESTHESIA			English	Article						Aortic stenosis; Cardiac biomarkers; Cardiopulmonary bypass; Desflurane; Ischemia-modified albumin; Total intravenous anesthesia; Troponin I		Objective (s): The aim of this study was to compare the effects of using inhalational anesthesia with desflurane with that of a total intravenous (iv) anesthetic technique using midazolam-fentanyl-propofol on the release of cardiac biomarkers after aortic valve replacement (AVR) for aortic stenosis (AS). The specific objectives included (a) determination of the levels of ischemia-modified albumin (IMA) and cardiac troponin I (cTnI) as markers of myocardial injury, (b) effect on mortality, morbidity, duration of mechanical ventilation, length of Intensive Care Unit (ICU) and hospital stay, incidence of arrhythmias, pacing, cardioversion, urine output, and serum creatinine. Methodology and Design: Prospective randomized clinical study. Setting: Operation room of a cardiac surgery center of a tertiary teaching hospital. Participants: Seventy-six patients in New York Heart Association classification II to III presenting electively for AVR for severe symptomatic AS. Interventions: Patients included in the study were randomized into two groups and subjected to either a desflurane-fentanyl based technique or total IV anesthesia (TIVA). Blood samples were drawn at preordained intervals to determine the levels of IMA, cTnI, and serum creatinine. Measurements and Main Results: The IMA and cTnI levels were not found to be significantly different between both the study groups. Patients in the desflurane group were found to had significantly lower ICU and hospital stays and duration of postoperative mechanical ventilation as compared to those in the TIVA group. There was no difference found in mean heart rate, urine output, serum creatinine, incidence of arrhythmias, need for cardioversion, and 30-day mortality between both groups. The patients in the TIVA group had higher mean arterial pressures on weaning off cardiopulmonary bypass as well as postoperatively in the ICU and recorded lower inotrope usage. Conclusion: The result of our study remains ambiguous regarding the overall protective effect of desflurane in patients undergoing AVR although some benefit in terms of shorter duration of postoperative mechanical ventilation, ICU and hospital stays, as well as cTnI, were seen. However, no difference in overall outcome could be clearly established between patients who received desflurane and those that were managed solely with IV anesthetic technique using propofol.	[Kapoor, Poonam Malhotra; Taneja, Sameer; Kiran, Usha] All India Inst Med Sci, Dept Cardiac Anesthesiol, New Delhi 110029, India; [Rajashekhar, P.] All India Inst Med Sci, Dept Cardiothorac Surg, New Delhi, India	Taneja, S (reprint author), All India Inst Med Sci, Dept Cardiac Anesthesiol, New Delhi 110029, India.	sameertaneja09@gmail.com					Belhomme D, 1999, CIRCULATION, V100, P340; Cason BA, 1997, ANESTHESIOLOGY, V87, P1182, DOI 10.1097/00000542-199711000-00023; Conzen PF, 2003, ANESTHESIOLOGY, V99, P826, DOI 10.1097/00000542-200310000-00013; Cromheecke S, 2006, ANESTH ANALG, V103, P289, DOI 10.1213/01.ane.0000226097.22384.f4; De Hert SG, 2005, ANESTH ANALG, V100, P1584, DOI 10.1213/01.ANE.0000153483.61170.0C; De Hert SG, 2004, ANESTHESIOLOGY, V101, P9, DOI 10.1097/00000542-200407000-00005; De Hert SG, 2003, ANESTHESIOLOGY, V99, P314, DOI 10.1097/00000542-200308000-00013; De Hert SG, 2002, ANESTHESIOLOGY, V97, P42, DOI 10.1097/00000542-200207000-00007; de Peppo AP, 1999, ANN THORAC SURG, V68, P112, DOI 10.1016/S0003-4975(99)00466-X; Greeley WJ, 2010, MILLERS ANAESTHESIA, P2617; Guarracino F, 2006, J CARDIOTHOR VASC AN, V20, P477, DOI 10.1053/j.jvca.2006.05.012; Julier K, 2003, ANESTHESIOLOGY, V98, P1315, DOI 10.1097/00000542-200306000-00004; Kanko M, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-3; Landoni G, 2007, J CARDIOTHOR VASC AN, V21, P672, DOI 10.1053/j.jvca.2006.11.017; Landoni G, 2007, J CARDIOTHOR VASC AN, V21, P502, DOI 10.1053/j.jvca.2007.02.013; Landoni G, 2009, ANN CARD ANAESTH, V12, P4, DOI 10.4103/0971-9784.45006; Malhotra Poonam, 2013, Anesth Pain Med, V3, P191, DOI 10.5812/aapm.9511; Nader ND, 2004, J CARDIOTHOR VASC AN, V18, P269, DOI 10.1053/j.jvca.2004.03.004; Sedlic F, 2007, FASEB J, V21, pA867; SMILEY RM, 1991, CAN J ANAESTH, V38, P965, DOI 10.1007/BF03008612	20	4	4	0	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0971-9784	0974-5181		ANN CARD ANAESTH	Ann. Card. Anaesth.	OCT-DEC	2015	18	4					502	509		10.4103/0971-9784.166455			8	Anesthesiology	Anesthesiology	V4B6R	WOS:000218784800009	26440236	DOAJ Gold, Green Published			2020-06-30	J	da Luz, VF; Otsuki, DA; Gonzalez, MMC; Negri, EM; Caldini, EG; Damaceno-Rodrigues, NR; Malbouisson, LMS; Viana, BG; Vane, MF; Carmona, MJC				da Luz, Vinicius Fernando; Otsuki, Denise Aya; Castro Gonzalez, Maria Margarita; Negri, Elnara Marcia; Caldini, Elia Garcia; Damaceno-Rodrigues, Nilsa Regina; Sa Malbouisson, Luiz Marcelo; Viana, Bruno Goncalves; Vane, Matheus Fachini; Carvalho Carmona, Maria Jose			Myocardial protection induced by fentanyl in pigs exposed to high-dose adrenaline	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article						adrenaline; analgesics; animals; cardioprotection; catecholamines; fentanyl; myocardial preconditioning; opioid; swine	ISCHEMIA-REPERFUSION INJURY; OPIOID RECEPTOR STIMULATION; HOSPITAL CARDIAC-ARREST; PROTEIN-KINASE-C; CARDIOPULMONARY-RESUSCITATION; TAKOTSUBO CARDIOMYOPATHY; RAT-HEART; PEPTIDE RECEPTOR; CROSS-TALK; EPINEPHRINE	The use of high doses of adrenaline is common in critical patients, especially during cardiac arrest. During these situations, myocardial dysfunction can be a result of multiple factors, including adrenaline use. In addition, opioids have been shown to have anti-arrhythmic and anti-ischemic mechanisms that may confer cardiac protection. This study aimed to evaluate the effects of fentanyl on myocardial function in pigs exposed to high-dose adrenaline. After institutional ethics committee approval, 26 pigs were randomly allocated to receive either 20 mu g/kg fentanyl (n = 10; fentanyl group) administered 5 min before five doses of adrenaline (20 mu g/kg), equivalent-volume saline (n = 10; saline group) using the same adrenaline dosing protocol, or neither fentanyl nor adrenaline (n = 6; sham group). The fentanyl group showed lower levels of troponin at the end of the sixth hour compared with the saline group (1.91 +/- 1.47 vs 5.44 +/- 5.35 ng/mL, P = 0.019). Transmission electron microscopy and immunohistochemistry also showed less myocardial injury in the fentanyl group. The conclusion was reached that fentanyl attenuates myocardial injury caused by high-dose adrenaline without blunting the hemodynamic effect of adrenaline.	[da Luz, Vinicius Fernando; Sa Malbouisson, Luiz Marcelo; Vane, Matheus Fachini; Carvalho Carmona, Maria Jose] Univ Sao Paulo, Sch Med, Dept Anesthesiol, Sao Paulo, SP, Brazil; [Otsuki, Denise Aya] Univ Sao Paulo, Sch Med, Lab Anaesthesiol LIM 8, Dept Anaesthesiol, Sao Paulo, SP, Brazil; [Castro Gonzalez, Maria Margarita] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, SP, Brazil; [Negri, Elnara Marcia; Caldini, Elia Garcia] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, SP, Brazil; [Damaceno-Rodrigues, Nilsa Regina] Univ Sao Paulo, Sch Med, Lab Cell Biol LIM 59, Sao Paulo, SP, Brazil; [Vane, Matheus Fachini] Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil	da Luz, VF (reprint author), Univ Sao Paulo, Sch Med, Dept Anesthesiol, Sao Paulo, SP, Brazil.	viniciusfernando@usp.br	CARMONA, MARIA JOSE CARVALHO/G-3653-2014; Vane, Matheus F/B-7991-2015; Damaceno-Rodrigues, Nilsa Regina/AAJ-7953-2020; Caldini, Elia G/F-1105-2011; Malbouisson, Luiz Marcelo/F-4819-2012	CARMONA, MARIA JOSE CARVALHO/0000-0002-3031-2924; Vane, Matheus F/0000-0003-3062-1484; Malbouisson, Luiz Marcelo/0000-0002-3261-5603; caldini, elia/0000-0001-5322-3812	Foundation for Research Support of the State of Sao Paulo - FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/09885-0]	This study was supported by a grant from the Foundation for Research Support of the State of Sao Paulo - FAPESP (2011/09885-0). We thank Inter-Biotech for English language editing.	Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Attaran RR, 2010, FUTUR CARDIOL, V6, P473, DOI 10.2217/FCA.10.24; Bach JF, 2008, VET CLIN N AM-SMALL, V38, P423, DOI 10.1016/j.cvsm.2008.02.001; Bian JS, 1998, BRIT J PHARMACOL, V124, P600, DOI 10.1038/sj.bjp.0701857; Brinjikji W, 2012, AM HEART J, V164, P215, DOI 10.1016/j.ahj.2012.04.010; Callaway CW, 2012, JAMA-J AM MED ASSOC, V307, P1198, DOI 10.1001/jama.2012.313; Cariou A, 2008, INTENS CARE MED, V34, P917, DOI 10.1007/s00134-008-1022-y; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Ducrocq N, 2012, ANESTHESIOLOGY, V116, P1083, DOI 10.1097/ALN.0b013e31824f9669; Fries M, 2006, CRIT CARE MED, V34, pS454, DOI 10.1097/01.CCM.0000247717.81480.B2; Gavish D, 2006, ANESTHESIOLOGY, V105, P621, DOI 10.1097/00000542-200609000-00029; Gross ER, 2004, CIRC RES, V94, P960, DOI 10.1161/01.RES.0000122392.33172.09; Hagihara A, 2012, JAMA-J AM MED ASSOC, V307, P1161, DOI 10.1001/jama.2012.294; Halperin HR, 2010, AM J EMERG MED, V28, P195, DOI 10.1016/j.ajem.2009.10.006; HOLADAY JW, 1983, ANNU REV PHARMACOL, V23, P541, DOI 10.1146/annurev.pa.23.040183.002545; Holmberg M, 2002, RESUSCITATION, V54, P37, DOI 10.1016/S0300-9572(02)00048-5; Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217; Huh J, 2001, AM J PHYSIOL-HEART C, V280, pH377; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Karck M, 2001, J THORAC CARDIOV SUR, V122, P986, DOI 10.1067/mtc.2001.116950; Khoueiry G, 2013, J EMERG MED, V44, P96, DOI 10.1016/j.jemermed.2011.09.032; Kim HS, 2012, J SURG RES, V174, P231, DOI 10.1016/j.jss.2011.01.018; Lessa MA, 2004, ACTA ANAESTH SCAND, V48, P1115, DOI 10.1111/j.1399-6576.2004.00472.x; Ma Y, 2012, REGION ANESTH PAIN M, V37, P99, DOI 10.1097/AAP.0b013e31823ebc74; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; Minguet G, 2012, ACTA ANAESTH BELG, V63, P23; O'Rourke B, 2004, CIRC RES, V94, P420, DOI 10.1161/01.RES.0000117583.66950.43; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; Peart JN, 2005, VASC PHARMACOL, V42, P211, DOI 10.1016/j.vph.2005.02.003; Pepe S, 2004, CARDIOVASC RES, V63, P414, DOI 10.1016/j.cardiores.2004.04.022; Pepe S, 1997, CIRCULATION, V95, P2122, DOI 10.1161/01.CIR.95.8.2122; Richard C, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-39; Sato Y, 2000, ANESTHESIOLOGY, V92, P615, DOI 10.1097/00000542-200002000-00048; Schultz JE, 2001, PHARMACOL THERAPEUT, V89, P123, DOI 10.1016/S0163-7258(00)00106-6; Sheng JZ, 1996, LIFE SCI, V59, P2181, DOI 10.1016/S0024-3205(96)00575-9; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; STRATTON JR, 1985, J APPL PHYSIOL, V58, P1199; Stub D, 2011, CIRCULATION, V123, P1428, DOI 10.1161/CIRCULATIONAHA.110.988725; Sun SJ, 2010, CRIT CARE MED, V38, P2175, DOI 10.1097/CCM.0b013e3181eedad6; TANG WC, 1995, CIRCULATION, V92, P3089, DOI 10.1161/01.CIR.92.10.3089; Tedders KM, 2014, PHARMACOTHERAPY, V34, P643, DOI 10.1002/phar.1429; Tomai F, 1999, J AM COLL CARDIOL, V33, P1863, DOI 10.1016/S0735-1097(99)00095-9; Tran KA, 2012, J PEDIATR INTENSIVE, V1, P221, DOI 10.3233/PIC-12037; Turer AT, 2010, AM J CARDIOL, V106, P360, DOI 10.1016/j.amjcard.2010.03.032; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; Wong GTC, 2010, ACTA ANAESTH SCAND, V54, P510, DOI 10.1111/j.1399-6576.2009.02145.x; Xiao RP, 1999, CIRC RES, V84, P43; Xiao RP, 1997, AM J PHYSIOL-HEART C, V272, pH797; Ye S, 2012, CIRCULATION, V125, P123, DOI 10.1161/CIRCULATIONAHA.111.062257; Zhang SZ, 2006, ANESTHESIOLOGY, V105, P550, DOI 10.1097/00000542-200609000-00019; Zhang YY, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-20	51	8	8	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1440-1681			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	OCT	2015	42	10					1098	1107		10.1111/1440-1681.12456			10	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	CT2PD	WOS:000362644300012	26173999				2020-06-30	J	Scholes, C; Palmer, AR; Sumner, CJ				Scholes, Chris; Palmer, Alan R.; Sumner, Christian J.			Stream segregation in the anesthetized auditory cortex	HEARING RESEARCH			English	Article						Auditory cortex; Neuron; Auditory stream segregation; Adaptation; Anesthesia	VENTRAL COCHLEAR NUCLEUS; PERCEPTUAL ORGANIZATION; TONE SEQUENCES; SONGBIRD FOREBRAIN; CORTICAL REPRESENTATION; SELECTIVE ATTENTION; SCENE ANALYSIS; RESPONSES; FREQUENCY; NEURONS	Auditory stream segregation describes the way that sounds are perceptually segregated into groups or streams on the basis of perceptual attributes such as pitch or spectral content. For sequences of pure tones, segregation depends on the tones' proximity in frequency and time. In the auditory cortex (and elsewhere) responses to sequences of tones are dependent on stimulus conditions in a similar way to the perception of these stimuli. However, although highly dependent on stimulus conditions, perception is also clearly influenced by factors unrelated to the stimulus, such as attention. Exactly how 'bottom-up' sensory processes and non-sensory 'top-down' influences interact is still not clear. Here, we recorded responses to alternating tones (ABAB ... ) of varying frequency difference (FD) and rate of presentation (PR) in the auditory cortex of anesthetized guinea-pigs. These data complement previous studies, in that top-down processing resulting from conscious perception should be absent or at least considerably attenuated. Under anesthesia, the responses of cortical neurons to the tone sequences adapted rapidly, in a manner sensitive to both the FD and PR of the sequences. While the responses to tones at frequencies more distant from neuron best frequencies (BFs) decreased as the FD increased, the responses to tones near to BF increased, consistent with a release from adaptation, or forward suppression. Increases in PR resulted in reductions in responses to all tones, but the reduction was greater for tones further from BE Although asymptotically adapted responses to tones showed behavior that was qualitatively consistent with perceptual stream segregation, responses reached asymptote within 2 s, and responses to all tones were very weak at high PRs (>12 tones per second). A signal-detection model, driven by the cortical population response, made decisions that were dependent on both FD and PR in ways consistent with perceptual stream segregation. This included showing a range of conditions over which decisions could be made either in favor of perceptual integration or segregation, depending on the model 'decision criterion'. However, the rate of 'build-up' was more rapid than seen perceptually, and at high PR responses to tones were sometimes so weak as to be undetectable by the model. Under anesthesia, adaptation occurs rapidly, and at high PRs tones are generally poorly represented, which compromises the interpretation of the experiment. However, within these limitations, these results complement experiments in awake animals and humans. They generally support the hypothesis that 'bottom-up' sensory processing plays a major role in perceptual organization, and that processes underlying stream segregation are active in the absence of attention. (C) 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Scholes, Chris; Palmer, Alan R.; Sumner, Christian J.] MRC, Inst Hearing Res, Nottingham NG7 2RD, England; [Scholes, Chris] Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England	Scholes, C (reprint author), Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England.	Chris.Scholes@nottingham.ac.uk	Sumner, Christian/AAB-8624-2020; Scholes, Chris/A-1437-2019	Scholes, Chris/0000-0002-1597-3070; Palmer, Alan/0000-0001-5893-4525; Sumner, Christian/0000-0002-2573-7418	Medical Research CouncilMedical Research Council UK (MRC) [U135097127]; Medical Research CouncilMedical Research Council UK (MRC) [MC_U135097127, MC_U135097126]	We thank Angie Killoran for assistance with formatting and bibliography and two anonymous reviewers for their constructive comments. This work was funded by the Medical Research Council (U135097127).	ALAIN C, 1994, PERCEPT PSYCHOPHYS, V56, P501, DOI 10.3758/BF03206947; ALBRECHT D, 1989, BRAIN RES BULL, V22, P923, DOI 10.1016/0361-9230(89)90001-4; ANSTIS S, 1985, J EXP PSYCHOL HUMAN, V11, P257, DOI 10.1037/0096-1523.11.3.257; Bee MA, 2005, BRAIN BEHAV EVOLUT, V66, P197, DOI 10.1159/000087854; Bee MA, 2004, J NEUROPHYSIOL, V92, P1088, DOI 10.1152/jn.00884.2003; Bee MA, 2010, J COMP PHYSIOL A, V196, P543, DOI 10.1007/s00359-010-0542-4; Bidet-Caulet A, 2007, J NEUROSCI, V27, P9252, DOI 10.1523/JNEUROSCI.1402-07.2007; Bregman A.S., 1990, AUDITORY SCENE ANAL; BREGMAN AS, 1978, J EXP PSYCHOL HUMAN, V4, P380, DOI 10.1037/0096-1523.4.3.380; Brosch M, 1997, J NEUROPHYSIOL, V77, P923; BUUNEN TJF, 1978, J ACOUST SOC AM, V64, P772, DOI 10.1121/1.382042; Capsius B, 1996, HEARING RES, V96, P59, DOI 10.1016/0378-5955(96)00038-X; Carlyon RP, 2003, PERCEPTION, V32, P1393, DOI 10.1068/p5035; Carlyon RP, 2001, J EXP PSYCHOL HUMAN, V27, P115, DOI 10.1037/0096-1523.27.1.115; Carlyon RP, 2004, TRENDS COGN SCI, V8, P465, DOI 10.1016/j.tics.2004.08.008; Christison-Lagay KL, 2015, INT J PSYCHOPHYSIOL, V95, P238, DOI 10.1016/j.ijpsycho.2014.03.004; Cusack R, 2005, J COGNITIVE NEUROSCI, V17, P641, DOI 10.1162/0898929053467541; Denham SL, 2006, J PHYSIOL-PARIS, V100, P154, DOI 10.1016/j.jphysparis.2006.09.012; Elhilali M, 2009, NEURON, V61, P317, DOI 10.1016/j.neuron.2008.12.005; Fishman YI, 2004, J ACOUST SOC AM, V116, P1656, DOI 10.1121/1.1778903; Fishman YI, 2001, HEARING RES, V151, P167, DOI 10.1016/S0378-5955(00)00224-0; Fritz J, 2003, NAT NEUROSCI, V6, P1216, DOI 10.1038/nn1141; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613; Gutschalk A, 2005, J NEUROSCI, V25, P5382, DOI 10.1523/JNEUROSCI.0347-05.2005; Hara K, 2002, ANESTH ANALG, V94, P313, DOI 10.1097/00000539-200202000-00015; HARRIS DM, 1979, J NEUROPHYSIOL, V42, P1083; Hill KT, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-85; HILLYARD SA, 1973, SCIENCE, V182, P177, DOI 10.1126/science.182.4108.177; Itatani N, 2014, P NATL ACAD SCI USA, V111, P10738, DOI 10.1073/pnas.1321487111; Kanwal JS, 2003, NETWORK-COMP NEURAL, V14, P413, DOI 10.1088/0954-898X/14/3/303; Kiang NYS, 1965, DISCHARGE PATTERNS S; Lakatos P, 2013, NEURON, V77, P750, DOI 10.1016/j.neuron.2012.11.034; Macken WJ, 2003, J EXP PSYCHOL HUMAN, V29, P43, DOI 10.1037/0096-1523.29.1.43; MARDIA KV, 2000, DIRECTIONAL STAT; MAY BJ, 1992, J NEUROPHYSIOL, V68, P1589; Mesgarani N, 2012, NATURE, V485, P233, DOI 10.1038/nature11020; Micheyl C, 2005, NEURON, V48, P139, DOI 10.1016/j.neuron.2005.08.039; Paltoglou AE, 2011, EUR J NEUROSCI, V33, P1733, DOI 10.1111/j.1460-9568.2011.07656.x; Pressnitzer D, 2008, CURR BIOL, V18, P1124, DOI 10.1016/j.cub.2008.06.053; Pressnitzer D, 2006, CURR BIOL, V16, P1351, DOI 10.1016/j.cub.2006.05.054; Rennaker RL, 2007, NEUROSCIENCE, V145, P357, DOI 10.1016/j.neuroscience.2006.11.043; Rose MM, 2000, J ACOUST SOC AM, V108, P1209, DOI 10.1121/1.1287708; Scholes C, 2011, EUR J NEUROSCI, V33, P1240, DOI 10.1111/j.1460-9568.2010.07568.x; Shamma SA, 2010, CURR OPIN NEUROBIOL, V20, P361, DOI 10.1016/j.conb.2010.03.009; Shore SE, 1998, J ACOUST SOC AM, V104, P378, DOI 10.1121/1.423294; SMITH RL, 1979, J ACOUST SOC AM, V65, P166, DOI 10.1121/1.382260; Snyder JS, 2007, PSYCHOL BULL, V133, P780, DOI 10.1037/0033-2909.133.5.780; Snyder JS, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00015; Snyder JS, 2006, J COGNITIVE NEUROSCI, V18, P1, DOI 10.1162/089892906775250021; Spielmann MI, 2014, PSYCHOL RES-PSYCH FO, V78, P361, DOI 10.1007/s00426-014-0547-7; SRIDHAR TS, 1995, J NEUROSCI, V15, P3667; Sussman ES, 2007, PERCEPT PSYCHOPHYS, V69, P136, DOI 10.3758/BF03194460; Syka J, 2005, HEARING RES, V206, P177, DOI 10.1016/j.heares.2005.01.013; Taaseh N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023369; Thompson SK, 2011, J EXP PSYCHOL HUMAN, V37, P1253, DOI 10.1037/a0021925; Ulanovsky N, 2004, J NEUROSCI, V24, P10440, DOI 10.1523/JNEUROSCI.1905-04.2004; Ulanovsky N, 2003, NAT NEUROSCI, V6, P391, DOI 10.1038/nn1032; VANNOORDEN LPAS, 1977, J ACOUST SOC AM, V61, P1041, DOI 10.1121/1.381388; Winkler I, 2009, TRENDS COGN SCI, V13, P532, DOI 10.1016/j.tics.2009.09.003	59	16	16	2	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5955	1878-5891		HEARING RES	Hear. Res.	OCT	2015	328						48	58		10.1016/j.heares.2015.07.004			11	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	CS5XQ	WOS:000362152000005	26163899	Green Published, Green Accepted, Other Gold			2020-06-30	J	Konopka-Filippow, M; Zabrocka, E; Wojtowicz, A; Skalij, P; Wojtukiewicz, MZ; Sierko, E				Konopka-Filippow, Monika; Zabrocka, Ewa; Wojtowicz, Aleksandra; Skalij, Piotr; Wojtukiewicz, Marek Z.; Sierko, Ewa			Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience	INTERNATIONAL DENTAL JOURNAL			English	Article						Pain; oropharyngeal cancer (OPC); radiotherapy; radiochemotherapy	QUALITY-OF-LIFE; NECK-CANCER; POSTOPERATIVE RADIOTHERAPY; RADIATION-THERAPY; HEAD; CHEMOTHERAPY; MUCOSITIS; TRIAL	Aim of the study: Radiotherapy (RT) is a radical therapeutic option for patients with oropharyngeal cancer (OPC). It induces an acute postradiation reaction that may cause significant pain. The aim of this study was to analyse pain occurrence and intensity, as well as type and effectiveness of analgesic treatment, in OPC patients undergoing RT or radiochemotherapy (RT-CT). Material and methods: Retrospective data were obtained for 42 OPC patients at clinical stages I-IVA, treated with adjuvant RT or RT-CT or definite RT or RT-CcT at the Comprehensive Cancer Center in Bialystok, Poland. Pain intensity and type of analgesic treatment during the therapy were analysed and compared with the intensity of the radiation-induced acute reaction, assessed weekly according to the Dische score. Results: Thirty-nine (92.9%) patients received analgesic treatment. Analgesic therapy was started in 27 (64.3%) patients with administration of non-steroidal anti-inflammatory drugs (NSAIDs) and/or paracetamol, in seven (16.7%) with mild opioids and in five (11.9%) with strong opioids. Strong opioids were used during therapy in 21 (50%) patients. Co-analgesics were administered to six patients. Breakthrough pain was observed in 10 (23.8%) patients. Conclusions: High incidence of pain during RT and RT-CT calls for increased awareness of the importance of pain monitoring and treatment during RT of OPC patients. The analgesic treatment had to be adjusted individually.	[Konopka-Filippow, Monika; Sierko, Ewa] Comprehens Canc Ctr Bialystok, Dept Radiotherapy, Bialystok, Poland; [Zabrocka, Ewa; Wojtowicz, Aleksandra; Skalij, Piotr; Wojtukiewicz, Marek Z.] Med Univ, Dept Oncol, PL-15027 Bialystok, Poland; [Skalij, Piotr; Wojtukiewicz, Marek Z.; Sierko, Ewa] Comprehens Canc Ctr Bialystok, Dept Clin Oncol, Bialystok, Poland	Sierko, E (reprint author), Med Univ, Dept Oncol, 12 Ogrodowa St, PL-15027 Bialystok, Poland.	ewa.sierko@iq.pl	Sierko, Ewa/U-7244-2018; Wojtukiewicz, Marek/T-1114-2018	Sierko, Ewa/0000-0001-6661-3182; Wojtukiewicz, Marek/0000-0002-7604-8188			Armstrong Judith A, 2006, Clin J Oncol Nurs, V10, P53, DOI 10.1188/06.CJON.53-56; Bar Ad V, 2010, HEAD NECK-J SCI SPEC, V32, P173, DOI 10.1002/hed.21165; Benedetti C, 2012, J MED PERS, V10, P10; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Buntzel J, 2014, TRACE ELEM ELECTROLY, V31, P1, DOI 10.5414/TEX01310; Chang JTC, 2010, JPN J CLIN ONCOL, V40, P307, DOI 10.1093/jjco/hyp166; Czreninski R., 2005, Topics in Clinical Nutrition, V20, P229; Epstein JB, 2007, J DENT RES, V86, P506, DOI 10.1177/154405910708600605; Epstein JB, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-26; Genf World Health Organization, 1986, CANC PAIN REL; Golen M, 2005, REP PRACT ONCOL RADI, V10, P179, DOI 10.1016/S1507-1367(05)71091-9; Katz N, 2002, J PAIN SYMPTOM MANAG, V24, pS38, DOI 10.1016/S0885-3924(02)00411-6; Lalla Rajesh V, 2008, Dent Clin North Am, V52, P61, DOI 10.1016/j.cden.2007.10.002; Lalla RV, 2010, SUPPORT CARE CANCER, V18, P985, DOI 10.1007/s00520-010-0892-z; Lawrence TS, 2003, SEMIN RADIAT ONCOL, V13, P13, DOI 10.1053/srao.2003.50002; Ling IS, 2011, SUPPORT CARE CANCER, V19, P1343, DOI 10.1007/s00520-010-0955-1; Lybak S, 2011, EUR ARCH OTO-RHINO-L, V268, P449, DOI 10.1007/s00405-010-1344-6; Maguire PD, 2011, INT J RADIAT ONCOL, V79, P1081, DOI 10.1016/j.ijrobp.2009.12.046; McNicol ED, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006332.pub2; McNicol ED, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006146.pub2; Nguyen NP, 2002, CANCER, V94, P1131, DOI 10.1002/cncr.10257; O'Hara J, 2011, EUR ARCH OTO-RHINO-L, V268, P437, DOI 10.1007/s00405-010-1362-4; Petersen PE, 2005, COMMUNITY DENT ORAL, V33, P397, DOI 10.1111/j.1600-0528.2005.00251.x; Potter J, 2003, J ROY SOC MED, V96, P379, DOI 10.1258/jrsm.96.8.379; Redding Spencer W, 2005, J Dent Educ, V69, P919; Seiwert TY, 2007, NAT CLIN PRACT ONCOL, V4, P156, DOI 10.1038/ncponc0750; Sherman AC, 2000, ARCH OTOLARYNGOL, V126, P459, DOI 10.1001/archotol.126.4.459; Sonis ST, 2004, NAT REV CANCER, V4, P277, DOI 10.1038/nrc1318; Thibault K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091297; Treister Nathaniel, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P123, DOI 10.1097/MOO.0b013e3280523ad6; Vissink A, 2003, CRIT REV ORAL BIOL M, V14, P199, DOI 10.1177/154411130301400305; Wojciechowska U, 2014, MALIGNANT TUMORS POL; Yom SS, 2004, NAT CLIN PRACT ONCOL, V1, P14, DOI 10.1038/ncponc0009	34	7	7	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-6539	1875-595X		INT DENT J	Int. Dent. J.	OCT	2015	65	5					242	248		10.1111/idj.12181			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CT5KP	WOS:000362848900003	26362241				2020-06-30	J	Kavanagh, PL; Sprinz, PG; Wolfgang, TL; Killius, K; Champigny, M; Sobota, A; Dorfman, D; Barry, K; Miner, R; Moses, JM				Kavanagh, Patricia L.; Sprinz, Philippa G.; Wolfgang, Tahlia L.; Killius, Kelly; Champigny, Maria; Sobota, Amy; Dorfman, David; Barry, Karan; Miner, Renee; Moses, James M.			Improving the Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department	PEDIATRICS			English	Article							SICKLE-CELL-DISEASE; RANDOMIZED CONTROLLED-TRIAL; STATISTICAL PROCESS-CONTROL; INTRANASAL FENTANYL; HEALTH-CARE; INTRAVENOUS MORPHINE; UNITED-STATES; ACUTE PAIN; CHILDREN; CRISIS	OBJECTIVES: Vaso-occlusive episodes (VOEs) account for the majority of emergency department (ED) visits for children with sickle cell disease (SCD). We hypothesized that addressing key barriers to VOE care would improve receipt of analgesics and outcomes. METHODS: A quality improvement (QI) initiative was conducted from September 2010 to April 2014 to streamline VOE care in an urban pediatric ED. Four interventions were used: a standardized time-specific VOE protocol; intranasal fentanyl as the first parenteral pain medication; an SCD pain medication calculator; and provider and patient/family education. Data were collected for 3 outcome measures (mean time from triage to first parenteral opioid and admission/discharge decision, and proportion discharged from the ED); 1 process measure (mean time from triage to initiation of patient-controlled analgesia); and 4 balancing measures (mean time from triage to second intravenous opioid dose, 24-hour ED readmission, respiratory depression, and length of stay). RESULTS: There were 289 ED visits in the study period. Improvements were seen in mean time to: first dose of parenteral opioid (56 to 23 minutes); second opiate intravenous dose (106 to 83 minutes); admission and discharge decisions (163 to 109 minutes and 271 to 178 minutes, respectively); and initiation of patient-controlled analgesia (216 to 141 minutes). The proportion discharged from the ED increased from 32% to 48% (chi(2) = 6.5402, P =.01). No increase in 24-hour readmission, respiratory depression, or inpatient length of stay was observed. CONCLUSIONS: Using VOE-specific interventions, we significantly improved VOE care for children. Studies are needed to determine if these results can be replicated.	[Kavanagh, Patricia L.; Sprinz, Philippa G.; Wolfgang, Tahlia L.; Sobota, Amy; Dorfman, David; Moses, James M.] Boston Univ, Sch Med, Boston Med Ctr, Dept Pediat, Boston, MA 02118 USA; [Killius, Kelly] Boston Med Ctr, Dept Pharm, Boston, MA USA; [Champigny, Maria] Boston Med Ctr, Dept Social Work, Boston, MA USA; [Barry, Karan; Miner, Renee] Boston Med Ctr, Dept Nursing, Boston, MA USA	Kavanagh, PL (reprint author), Boston Univ, Sch Med, Boston Med Ctr, 88 E Newton St,Vose Hall,3rd Floor, Boston, MA 02118 USA.	patricia.kavanagh@bmc.org		Moses, James/0000-0002-5366-7816	Health Resources and Services Administration's Sickle Cell Disease Newborn Screening Program [U38MC22215]	Supported by grant U38MC22215 from the Health Resources and Services Administration's Sickle Cell Disease Newborn Screening Program.	Barrett MJ, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-74; Benjamin LJ, 1999, GUIDELINE MANAGEMENT; Benneyan JC, 2003, QUAL SAF HEALTH CARE, V12, P458, DOI 10.1136/qhc.12.6.458; Booker MJ, 2006, CHRONIC ILLN, V2, P39, DOI 10.1179/174592006X93860; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Brousseau DC, 2010, AM J HEMATOL, V85, P77, DOI 10.1002/ajh.21570; Drendel AL, 2006, PEDIATRICS, V117, P1511, DOI 10.1542/peds.2005-2046; Givens M, 2007, J EMERG MED, V32, P239, DOI 10.1016/j.jemermed.2006.07.022; Gordon DB, 2008, JT COMM J QUAL PATIE, V34, P509, DOI 10.1016/S1553-7250(08)34065-3; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; Kenyon CC, 2012, J NATL MED ASSOC, V104, P337, DOI 10.1016/S0027-9684(15)30174-7; KREMER E, 1981, PAIN, V10, P241, DOI 10.1016/0304-3959(81)90199-8; Langley GJ, 2009, IMPROVEMENT GUIDE PR; Melzer-Lange MD, 2004, PEDIATR EMERG CARE, V20, P2, DOI 10.1097/01.pec.0000106235.72265.29; Mohammed MA, 2004, QUAL SAF HEALTH CARE, V13, P243, DOI 10.1136/qshc.2004.011650; Morrissey LK, 2009, PEDIATR BLOOD CANCER, V52, P369, DOI 10.1002/pbc.21847; Mvundura M, 2009, PEDIATR BLOOD CANCER, V53, P642, DOI 10.1002/pbc.22069; National Heart Lung and Blood Institute, 2014, EV BAS MAN SICKL CEL; Shenoi R, 2011, PEDIATR EMERG CARE, V27, P911, DOI 10.1097/PEC.0b013e3182302871; Smith WR, 2008, ANN INTERN MED, V148, P94, DOI 10.7326/0003-4819-148-2-200801150-00004; Telfer P, 2014, BRIT J HAEMATOL, V166, P157, DOI 10.1111/bjh.12879; Todd KH, 2006, J PAIN, V7, P453, DOI 10.1016/j.jpain.2006.05.004; Wang CJ, 2011, PEDIATRICS, V128, P484, DOI 10.1542/peds.2010-1791; Yusuf HR, 2010, AM J PREV MED, V38, pS536, DOI 10.1016/j.amepre.2010.01.001; Zempsky WT, 2010, J EMERG MED, V39, P691, DOI 10.1016/j.jemermed.2009.06.003; Zempsky WT, 2009, JAMA-J AM MED ASSOC, V302, P2479, DOI 10.1001/jama.2009.1811	30	24	24	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2015	136	4					E1016	E1025		10.1542/peds.2014-3470			10	Pediatrics	Pediatrics	CT6TC	WOS:000362944300028	26391933	Bronze			2020-06-30	J	Andres, MAA; Echarte, OZ; Errea, JDC; Rodriguez, MP; de Zabalza, RLP; Calahorra, MAA				Arteche Andres, M. A.; Zugasti Echarte, O.; de Carlos Errea, J.; Perez Rodriguez, M.; Perez de Zabalza, R. Leyun; Azcona Calahorra, M. A.			Anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma: Description of a case and anesthetic implications	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION			Spanish	Article						Encephalitis; N-methyt-D-aspartate receptor antibodies; Anesthesia; Ovarian teratoma		N-methyl-D-aspartate receptor encephalitis is an autoimmune encephalitis reladonated or not with a neoplasm. Although its incidence is unknown, probably remains underdiagnosed. Epidemiological studies place it as the second cause of immune-mediated encephalitis and the first in patients aged Less of 30 years. It shows neuropsychiatric symptoms and autonomic instability. After diagnosis, based on the detection of antibodies in serum or cerebrospinal fluid, an occult malignancy must be investigated. While increasing number of cases have been diagnosed and the important role of this receptor in general anesthesia mechanisms, the interaction of the disease with anesthetic agents and perioperative stress is unknown. We describe the case of a patient with encephalitis associated to ovarian teratoma that underwent gynaecological laparoscopy. (C) 2014 Sociedad Espanola de Anestesiologia, Reanimacion y Terapeutica del Dolor. Published by Elsevier Espana, S.L.U. All rights reserved.	[Arteche Andres, M. A.; Zugasti Echarte, O.; de Carlos Errea, J.; Perez Rodriguez, M.; Perez de Zabalza, R. Leyun; Azcona Calahorra, M. A.] Complejo Hosp Navarra, Serv Anestesiol Reanimac & Tratamiento Dolor, Navarra, Spain	Andres, MAA (reprint author), Complejo Hosp Navarra, Serv Anestesiol Reanimac & Tratamiento Dolor, Navarra, Spain.	aartetxa@cfnavarra.es					Batistaki C, 2014, J ANESTH, V28, P475, DOI 10.1007/s00540-013-1723-4; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Gumbinger C, 2013, NEUROLOGY, V80, P1997, DOI 10.1212/WNL.0b013e318293e334; Kawano H, 2011, ANAESTHESIA, V66, P515, DOI 10.1111/j.1365-2044.2011.06707.x; Kruse JL, 2014, ANN CLIN PSYCHIATRY, V26, P111; Lang Y, 2014, CHINESE MED J-PEKING, V127, P2197, DOI 10.3760/cma.j.issn.0366-6999.20132818; Lapebie FX, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-5; Pascual-Ramirez J, 2011, INT J GYNECOL OBSTET, V115, P291, DOI 10.1016/j.ijgo.2011.07.028; Pryzbylkowski PG, 2011, ANESTH ANALG, V113, P1188, DOI 10.1213/ANE.0b013e31822b8a7d; Splinter WM, 2009, PEDIATR ANESTH, V19, P911, DOI 10.1111/j.1460-9592.2009.03085.x; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1	11	1	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0034-9356	2340-3284		REV ESP ANEST REANIM	Rev. Esp. Anestesiol. Reanim.	OCT	2015	62	8					468	471		10.1016/j.redar.2015.01.001			4	Anesthesiology	Anesthesiology	VH0EX	WOS:000449607900008	25804681				2020-06-30	J	Li, AX; Xin, WQ; Ma, CG				Li, Ai-xiang; Xin, Wen-qi; Ma, Chuan-gen			Fentanyl inhibits the invasion and migration of colorectal cancer cells via inhibiting the negative regulation of Ets-1 on BANCR	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						Colorectal cancer; Fentanyl; Ets-1; BRAF-activated lncRNA	LONG NONCODING RNA; NF-KAPPA-B; DOWN-REGULATION; PROGRESSION; METASTASIS; HOTAIR; GROWTH	Background: Recent studies have shown the potential anti-tumor effect of fentanyl on colorectal cancer (CRC). However, its underling mechanism is still unclear. Since studies indicates the abnormal expression of transcription factor Ets-1 and BRAF-activated lncRNA (BANCR) in CRC progress, the relationship between Ets-1 and BANCR was investigated here to illustrate the fentanyl-induced mechanism on CRC in vitro. Methods: The expression levels of Ets-1 and BANCR were first detected in fentanyl-treated CRC cells. The interaction between Ets-1 and BANCR promoter was verified with chromatin immunoprecipitation assays, as well as corresponding acetylation of histones. The regulation of Ets-1 on BANCR expression was confirmed through luciferase assays and RT-PCR analysis. And, cell clone formation, cell migration and invasion were observed to evaluate the anti-tumor effects of fentanyl. Ets-1 overexpression or co-overexpression with BANCR was further performed by plasmids transfection to show the regulatory role of Ets-1 in fentanyl-induced mechanism. Results: Fentanyl induced BANCR upregulation and Ets-1 downregulation in CRC cells. Further studies showed that Ets-1 negatively regulated BANCR expression via the deacetylation of histones H3 within BANCR promoter. Moreover, fentanyl induced less cell clone formation, as well as inhibited cell migration and invasion in vitro, while Ets-1 overexpression inhibited fentanyl-induced effects that could be reversed by BANCR co-overexpression. Conclusion: Fentanyl showed anti-tumor like effects on CRC cells, including less cell clone formation and inhibited cell migration and invasion. Furthermore, the regulatory role of Ets-1 on BANCR influenced fentanyl-induced mechanism, indicating their potential application in the therapeutic treatment of CRC. (C) 2015 Elsevier Inc. All rights reserved.	[Li, Ai-xiang; Xin, Wen-qi; Ma, Chuan-gen] Henan Univ, Huaihe Hosp, Dept Anesthesiol, Kaifeng 475000, Henan Province, Peoples R China	Li, AX (reprint author), Henan Univ, Huaihe Hosp, Dept Anesthesiol, 8 Baobei Rd, Kaifeng 475000, Henan Province, Peoples R China.	axianglx@163.com					Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; CHEN WQ, 2014, ANN TRANSL MED, V2; Davis M.P., 2011, FENTANYL BREAKTHROUG; Flockhart RJ, 2012, GENOME RES, V22, P1006, DOI 10.1101/gr.140061.112; Globocan W., 2014, ESTIMATED CANC INCID; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Kavurma MM, 2010, J BIOL CHEM, V285, P21902, DOI 10.1074/jbc.A110.200463; Kim DH, 2008, P NATL ACAD SCI USA, V105, P16230, DOI 10.1073/pnas.0808830105; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Lennon FE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091577; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Nie Y, 2013, CANCER SCI, V104, P458, DOI 10.1111/cas.12092; Park YH, 2008, BIOCHEM BIOPH RES CO, V377, P389, DOI 10.1016/j.bbrc.2008.09.135; Peng C, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-53; Qi P, 2013, MODERN PATHOL, V26, P155, DOI 10.1038/modpathol.2012.160; Qin Y, 2012, ONCOL RES, V20, P61, DOI 10.3727/096504012X13473664562501; Quo QH, 2014, ONCOL LETT, V8, P869, DOI 10.3892/ol.2014.2154; Seton-Rogers S, 2014, NAT REV CANCER, V14, P764, DOI 10.1038/nrc3865; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sun M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-68; Wish TA, 2010, CANCER EPIDEM BIOMAR, V19, P1831, DOI 10.1158/1055-9965.EPI-10-0055; Xu CA, 2011, INT J ONCOL, V39, P169, DOI 10.3892/ijo.2011.1007; Zhang XL, 2015, INT J CLIN EXP PATHO, V8, P227; Zhang XL, 2014, ASIAN PAC J CANCER P, V15, P10015, DOI 10.7314/APJCP.2014.15.22.10015; Zhang YJ, 2012, ONCOL REP, V27, P685, DOI 10.3892/or.2011.1561	26	19	23	1	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	SEP 25	2015	465	3					594	600		10.1016/j.bbrc.2015.08.068			7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CR5XS	WOS:000361418300045	26296467				2020-06-30	J	Janecka-Placek, A; Lisowska, G; Paradysz, A; Misiolek, H				Janecka-Placek, Agata; Lisowska, Grazyna; Paradysz, Andrzej; Misiolek, Hanna			Cochlear Function Monitoring After Spinal Anesthesia	MEDICAL SCIENCE MONITOR			English	Article						Otoacoustic Emissions, Spontaneous; Urologic Surgical Procedures	SENSORINEURAL HEARING-LOSS; OTOACOUSTIC EMISSIONS; AUDITORY FUNCTION; LUMBAR PUNCTURE; IMPAIRMENT; NEEDLES; YOUNG	Background: The aim of the study was to examine the effect of spinal anesthesia on the function of cochlear outer hair cells (OHCs), determined by means of objective distortion product otoacoustic emissions (DPOAE) testing. To the best of our knowledge, our study was the second OAE-based analysis of cochlear function during spinal anesthesia, and the only experiment including such a large group of patients. Material/Methods: The study included 20 patients (18 men and 2 women) subjected to a scheduled uretherorenoscopic lithotripsy with routine spinal anesthesia with 10 mg (2 ml) of 0.5% hyperbaric bupivacaine and 50 mu g (1 ml) of fentanyl. The levels of DPOAEs and background noise at 1000-6000 Hz were recorded prior to and immediately after the anesthesia, and on the postoperative day 2. Results: We did not find significant differences between DPOAEs values recorded prior to and immediately after the anesthesia. The only exception pertained to 5652 Hz, at which a significantly higher level of DPOAEs was observed immediately after the anesthesia. The levels of DPOAEs at 2002 Hz and 2380 Hz collected on the postoperative day 2 were significantly higher than the respective baseline values. Irrespective of the frequency and time of testing, we did not find any significant differences between the recorded levels of background noise. Conclusions: Our findings point to the lack of a detrimental effect of spinal anesthesia on objectively evaluated cochlear function, and thus suggest that this method is safe, even for OHCs, which are extremely susceptible to exogenous and endogenous injuries.	[Janecka-Placek, Agata; Misiolek, Hanna] Med Univ Silesia, Dept Anesthesiol & Intens Therapy Zabrze, Zabrze, Poland; [Lisowska, Grazyna] Med Univ Silesia, Dept Otolaryngol Zabrze, Zabrze, Poland; [Paradysz, Andrzej] Med Univ Silesia, Dept Urol Zabrze, Zabrze, Poland	Lisowska, G (reprint author), Med Univ Silesia, Dept Otolaryngol Zabrze, Zabrze, Poland.	grazyna.lisowska@onet.pl		Misiolek, Hanna/0000-0002-9333-9155			Cooper NP, 2003, J PHYSIOL-LONDON, V548, P307, DOI 10.1113/jphysiol.2003.039081; Cosar A, 2004, ACTA OTO-LARYNGOL, V124, P1159, DOI 10.1080/00016480410017143; Duniec L, 2013, ANAESTH INTENSIVE TH, V45, P1, DOI 10.5603/AIT.2013.0001; Erol A, 2009, EUR J ANAESTH, V26, P416, DOI 10.1097/EJA.0b013e32831c89d4; Finegold H, 2002, ANESTH ANALG, V95, P198, DOI 10.1097/00000539-200207000-00035; Glowatzki E, 2000, SCIENCE, V288, P2366, DOI 10.1126/science.288.5475.2366; Gultekin S, 2002, ANESTH ANALG, V94, P1318; Hajduk Agata, 2006, Otolaryngol Pol, V60, P61; Karatas E, 2006, EUR ARCH OTO-RHINO-L, V263, P705, DOI 10.1007/s00405-006-0049-3; Kilickan L, 2002, ACTA ANAESTH SCAND, V46, P1155, DOI 10.1034/j.1399-6576.2002.460916.x; Lamberg T, 1997, REGION ANESTH, V22, P539; Lisowska G, 2002, ACTA OTO-LARYNGOL, V122, P613, DOI 10.1080/000164802320396286; Lisowska G, 2001, OTOL NEUROTOL, V22, P316, DOI 10.1097/00129492-200105000-00008; Lisowska G, 2014, CLIN INTERV AGING, V9, P901, DOI 10.2147/CIA.S61934; Malhotra S K, 2007, Minerva Anestesiol, V73, P395; Malhotra SK, 2002, EUR J ANAESTH, V19, P69; MICHEL O, 1992, ANN OTO RHINOL LARYN, V101, P390, DOI 10.1177/000348949210100503; MICHEL O, 1990, HNO, V38, P71; Morawski K, 2003, LARYNGOSCOPE, V113, P1615, DOI 10.1097/00005537-200309000-00039; Ok G, 2004, REGION ANESTH PAIN M, V29, P430, DOI 10.1016/j.rapm.2004.06.005; ONCEL S, 1992, J LARYNGOL OTOL, V106, P783, DOI 10.1017/S0022215100120882; PANNING B, 1983, LANCET, V2, P581; PAPARELLA MM, 1991, ACTA OTO-LARYNGOL, P26; Probst R, 1990, Adv Otorhinolaryngol, V44, P1; Schaffartzik W, 2000, ANESTH ANALG, V91, P1466, DOI 10.1097/00000539-200012000-00032; WALSTED A, 1991, SCAND AUDIOL, V20, P211, DOI 10.3109/01050399109045965; Yildiz TS, 2007, OTOLARYNG HEAD NECK, V137, P79, DOI 10.1016/j.otohns.2007.02.018	27	1	1	0	2	INT SCIENTIFIC LITERATURE, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	SEP 17	2015	21						2767	2773		10.12659/MSM.893718			7	Medicine, Research & Experimental	Research & Experimental Medicine	CR6FW	WOS:000361441100001	26377393	Green Published			2020-06-30	J	Poon, CS; Song, G				Poon, Chi-Sang; Song, Gang			Type III-IV muscle afferents are not required for steady-state exercise hyperpnea in healthy subjects and patients with COPD or heart failure	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Control of breathing; Exercise hyperpnea; Heart failure; COPD; Cardiopulmonary disease; Muscle afferents; Homeostasis; Cardiopulmonary disease; Dead space; Ventilatory efficiency; Real-feel metabolic CO2 load; mu-opioid; Fentanyl; Sherringtonian reflex; Internal model; Optimization hypothesis; Cardiovascular regulation	CAROTID-BODY RESECTION; VENTILATORY RESPONSE; DEAD SPACE; SENSORIMOTOR INTEGRATION; GAS-EXCHANGE; POTENTIATION; MECHANISM; REFLEX; OUTPUT; DRIVE	Blockade of group III-IV muscle afferents by intrathecal injection of the mu-opioid agonist fentanyl (IF) in humans has been variously reported to depress exercise hyperpnea in some studies but not others. A key unanswered question is whether such an effect is transient or persists in the steady state. Here we show that in healthy subjects undergoing constant-load cycling exercise IF significantly slows the transient exercise ventilatory kinetics but has no discernible effect on the ventilatory response when exercise is sufficiently prolonged. Thus, the ventilatory response to group III-IV muscle afferents input in healthy subjects is not a simple reflex but acts like a high-pass filter with maximum sensitivity during early-phase exercise and is reset in the late phase. In patients with chronic heart failure (CHF) IF causes sustained CO2 retention not only during exercise but also in the resting state, where muscle afferents feedback is minimal. In patients with chronic obstructive pulmonary disease (COPD), IF also elicits sustained decreases in the exercise ventilatory response but with little or no resultant CO2 retention due to concomitant decreases in physiological V-D/V-T (dead space-to-ventilation ratio). These results support the proposition that optimal long-term regulation of exercise hyperpnea in health and in disease is determined centrally by the respiratory controller through the continuing adaptation of an internal model which dynamically tracks the metabolic CO2 load and the ventilatory inefficiency [1/(1 - V-D/V-T)] that must be overcome for the maintenance of arterial PCO2 homeostasis, rather than being reflexively driven by group III-IV muscle afferents feedback per se. (C) 2015 Elsevier B.V. All rights reserved.	[Poon, Chi-Sang; Song, Gang] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA	Poon, CS (reprint author), MIT, Inst Med Engn & Sci, Bldg E25-250,77 Massachusetts Ave, Cambridge, MA 02139 USA.	cpoon@mit.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL093225, HL067966]	This work was supported by National Institutes of Health grants HL093225 and HL067966.	Neder JA, 2015, EUR RESPIR J, V45, P377, DOI 10.1183/09031936.00135514; Amann M, 2011, J PHYSIOL-LONDON, V589, P5299, DOI 10.1113/jphysiol.2011.213769; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; DEJOURS P, 1964, HANDBOOK PHYSIOLOG 3, V1, P631; Dempsey JA, 2014, J PHYSIOL-LONDON, V592, P463, DOI 10.1113/jphysiol.2013.261925; Duffin J, 2014, J PHYSIOL-LONDON, V592, P445, DOI 10.1113/jphysiol.2013.258897; Gagnon P, 2012, AM J RESP CRIT CARE, V186, P606, DOI 10.1164/rccm.201203-0404OC; Gozal D, 1996, AM J RESP CRIT CARE, V153, P761, DOI 10.1164/ajrccm.153.2.8564130; Joyner MJ, 2006, EXP PHYSIOL, V91, P27, DOI 10.1113/expphysiol.2005.032102; Krogh A, 1913, J PHYSIOL-LONDON, V47, P112; LUGLIANI R, 1971, NEW ENGL J MED, V285, P1105, DOI 10.1056/NEJM197111112852002; MacDonald SM, 2009, EXP PHYSIOL, V94, P269, DOI 10.1113/expphysiol.2008.045344; Olson TP, 2014, EXP PHYSIOL, V99, P414, DOI 10.1113/expphysiol.2013.075937; Paoletti P, 2011, RESP PHYSIOL NEUROBI, V179, P167, DOI 10.1016/j.resp.2011.07.013; Paterson DJ, 2014, J PHYSIOL-LONDON, V592, P433, DOI 10.1113/jphysiol.2013.261586; Poon C.S, 2015, RESP PHYSL IN PRESS; Poon C.-S., 2005, J NEURAL ENG, V2, DOI [10.1088/1741-2552/1082/1083/E1001, DOI 10.1088/1741-2552/1082/1083/E1001]; Poon CS, 2008, J APPL PHYSIOL, V105, P390, DOI 10.1152/japplphysiol.90543.2008; Poon CS, 2007, RESP PHYSIOL NEUROBI, V159, P1, DOI 10.1016/j.resp.2007.02.020; Poon Chi-Sang, 2006, Behav Brain Funct, V2, P29, DOI 10.1186/1744-9081-2-29; Poon CS, 2015, J APPL PHYSIOL, V118, P1558; Poon CS, 2014, RESP CARE, V59, P1157, DOI 10.4187/respcare.03433; Poon CS, 2014, PROG BRAIN RES, V209, P235, DOI 10.1016/B978-0-444-63274-6.00012-6; Poon CS, 2013, RESP PHYSIOL NEUROBI, V186, P114, DOI 10.1016/j.resp.2012.12.004; Poon CS, 2009, RESP PHYSIOL NEUROBI, V169, P234, DOI 10.1016/j.resp.2009.09.006; POON CS, 1992, J APPL PHYSIOL, V73, P591; Poon CS, 2000, NEUROSCI LETT, V284, P5, DOI 10.1016/S0304-3940(00)00993-9; Poon CS, 2001, CIRCULATION, V104, pE131; Raven PB, 2006, EXP PHYSIOL, V91, P37, DOI 10.1113/expphysiol.2005.032250; Riley MS, 2002, MED SCI SPORT EXER, V34, P98, DOI 10.1097/00005768-200201000-00016; Scott AC, 2000, J PHYSIOL-LONDON, V529, P863, DOI 10.1111/j.1469-7793.2000.00863.x; Siniaia MS, 2000, J PHYSIOL-LONDON, V523, P479, DOI 10.1111/j.1469-7793.2000.t01-1-00479.x; Song G., 2015, BRAIN STRUC IN PRESS; Sun XG, 2002, AM J RESP CRIT CARE, V166, P1443, DOI 10.1164/rccm.2202033; Teopompi E, 2014, RESP CARE, V59, P1034, DOI 10.4187/respcare.02629; Tin C., 2014, ENCY COMPUTATIONAL N; Tin C, 2005, J NEURAL ENG, V2, DOI 10.1088/1741-2560/2/3/S01; WARD SA, 1980, J APPL PHYSIOL, V48, P225; WASSERMAN K, 1975, J APPL PHYSIOL, V39, P354; Wasserman K, 1997, CIRCULATION, V96, P2221, DOI 10.1161/01.cir.96.7.2221; WHIPP BJ, 1972, J APPL PHYSIOL, V33, P351; Whipp BJ, 2008, ADV EXP MED BIOL, V605, P16; Wood HE, 2011, RESP PHYSIOL NEUROBI, V179, P235, DOI 10.1016/j.resp.2011.08.011; Young DL, 2003, J APPL PHYSIOL, V94, P1213, DOI 10.1152/japplphysiol.00639.2002	44	6	6	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048	1878-1519		RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	SEP 15	2015	216						78	85		10.1016/j.resp.2015.04.007			8	Physiology; Respiratory System	Physiology; Respiratory System	CQ7HP	WOS:000360773900011	25911558	Green Accepted			2020-06-30	J	Barratt, DT; Klepstad, P; Dale, O; Kaasa, S; Somogyi, AA				Barratt, Daniel T.; Klepstad, Pal; Dale, Ola; Kaasa, Stein; Somogyi, Andrew A.			Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl	PLOS ONE			English	Article							MINI-MENTAL-STATE; PRIMARY-CARE; ASSOCIATION; PHARMACOKINETICS; MECHANISM; DEMENTIA; SURGERY; QUALITY; OPIOIDS; MYD88	Common adverse symptoms of cancer and chemotherapy are a major health burden; chief among these is pain, with opioids including transdermal fentanyl the mainstay of treatment. Innate immune activation has been implicated generally in pain, opioid analgesia, cognitive dysfunction, and sickness type symptoms reported by cancer patients. We aimed to determine if genetic polymorphisms in neuroimmune activation pathways alter the serum fentanyl concentration-response relationships for pain control, cognitive dysfunction, and other adverse symptoms, in cancer pain patients. Cancer pain patients (468) receiving transdermal fentanyl were genotyped for 31 single nucleotide polymorphisms in 19 genes: CASP1, BDNF, CRP, LY96, IL6, IL1B, TGFB1, TNF, IL10, IL2, TLR2, TLR4, MYD88, IL6R, OPRM1, ARRB2, COMT, STAT6 and ABCB1. Lasso and backward stepwise generalised linear regression were used to identify non-genetic and genetic predictors, respectively, of pain control (average Brief Pain Inventory < 4), cognitive dysfunction (Mini-Mental State Examination <= 23), sickness response and opioid adverse event complaint. Serum fentanyl concentrations did not predict between-patient variability in these outcomes, nor did genetic factors predict pain control, sickness response or opioid adverse event complaint. Carriers of the MYD88 rs6853 variant were half as likely to have cognitive dysfunction (11/111) than wild-type patients (69/325), with a relative risk of 0.45 (95% CI: 0.27 to 0.76) when accounting for major non-genetic predictors (age, Karnofsky functional score). This supports the involvement of innate immune signalling in cognitive dysfunction, and identifies MyD88 signalling pathways as a potential focus for predicting and reducing the burden of cognitive dysfunction in cancer pain patients.	[Barratt, Daniel T.; Somogyi, Andrew A.] Univ Adelaide, Sch Med, Discipline Pharmacol, Adelaide, SA, Australia; [Klepstad, Pal] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway; [Klepstad, Pal; Dale, Ola] St Olavs Univ Hosp, Dept Anaesthesiol & Intens Care Med, Trondheim, Norway; [Dale, Ola; Kaasa, Stein] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, European Palliat Care Res Ctr, N-7034 Trondheim, Norway; [Somogyi, Andrew A.] Royal Adelaide Hosp, Dept Clin Pharmacol, Adelaide, SA 5000, Australia; [Barratt, Daniel T.; Somogyi, Andrew A.] Univ Adelaide, Ctr Personalised Canc Med, Adelaide, SA, Australia	Barratt, DT (reprint author), Univ Adelaide, Sch Med, Discipline Pharmacol, Adelaide, SA, Australia.	daniel.barratt@adelaide.edu.au		Barratt, Daniel/0000-0001-6261-353X	Norwegian Research CouncilResearch Council of Norway; European UnionEuropean Union (EU) [037777]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1011521]; EPOS study	The Norwegian Research Council and the European Union's 6th framework (Contract No. 037777; http://www.forskningsradet.no/en/Home_page/1177315753906; PK OD SK) and the National Health and Medical Research Council of Australia (Project Grant 1011521; https://www.nhmrc.gov.au/; AAS) financially supported the EPOS study.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Barratt DT, 2014, PHARMACOGENET GENOM, V24, P185, DOI 10.1097/FPC.0000000000000032; Capparelli R, 2013, GENES IMMUN, V14, P504, DOI 10.1038/gene.2013.48; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Cleeland CS, 2000, SEMIN RADIAT ONCOL, V10, P175, DOI 10.1053/srao.2000.6590; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Deguine Jacques, 2014, F1000Prime Rep, V6, P97, DOI 10.12703/P6-97; Dhiman N, 2008, VACCINE, V26, P1731, DOI 10.1016/j.vaccine.2008.01.017; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Fayers PM, 2005, J PAIN SYMPTOM MANAG, V30, P41, DOI 10.1016/j.jpainsymman.2005.05.001; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galvan A, 2012, PHARMACOGENOMICS J, V12, P412, DOI 10.1038/tpj.2011.27; Grace PM, 2014, NAT REV IMMUNOL, V14, P217, DOI 10.1038/nri3621; Gunma University Hospital Department of Anesthesiology, PREV EFF MIN POST CO; Hutchinson MR, 2011, PHARMACOL REV, V63, P772, DOI 10.1124/pr.110.004135; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Iracleous P, 2010, INT J GERIATR PSYCH, V25, P23, DOI 10.1002/gps.2293; Ismail Z, 2010, INT J GERIATR PSYCH, V25, P111, DOI 10.1002/gps.2306; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; Klepstad P, 2005, PALLIATIVE MED, V19, P477, DOI 10.1191/0269216305pm1054oa; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Klepstad P, 2003, PALLIATIVE MED, V17, P679, DOI 10.1191/0269216303pm835oa; Kurita GP, 2011, J CLIN ONCOL, V29, P1297, DOI 10.1200/JCO.2010.32.6884; Lee BN, 2004, NEUROIMMUNOMODULAT, V11, P279, DOI 10.1159/000079408; Lonie JA, 2009, INT J GERIATR PSYCH, V24, P902, DOI 10.1002/gps.2208; Lu SM, 2015, BRAIN BEHAV IMMUN, V44, P221, DOI 10.1016/j.bbi.2014.10.011; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Milne A, 2008, INT PSYCHOGERIATR, V20, P911, DOI 10.1017/S1041610208007394; Mitchell AJ, 2009, J PSYCHIATR RES, V43, P411, DOI 10.1016/j.jpsychires.2008.04.014; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Mulholland CV, 2014, J MOL NEUROSCI, V52, P497, DOI 10.1007/s12031-013-0201-7; Mystakidou K, 2007, PSYCHO-ONCOLOGY, V16, P352, DOI 10.1002/pon.1090; R Core Team, 2013, R LANG ENV STAT COMP; Ripamonti CI, 2012, ANN ONCOL, V23, P294, DOI 10.1093/annonc/mds360; Shulman KI, 2006, INT PSYCHOGERIATR, V18, P281, DOI 10.1017/S1041610205002693; Skaer TL, 2014, J PAIN RES, V7, P495, DOI 10.2147/JPR.S36446; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; Stevens CW, 2013, BRIT J PHARMACOL, V168, P1421, DOI 10.1111/bph.12028; Tassinari D, 2011, PALLIATIVE MED, V25, P478, DOI 10.1177/0269216311404274; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Venables W. N., 2002, MODERN APPL STAT S; Wang Y, 2013, MOL MED REP, V7, P1137, DOI 10.3892/mmr.2013.1322; WHO, 2013, WHOS PAIN LADD AD	46	10	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2015	10	9							e0137179	10.1371/journal.pone.0137179			13	Multidisciplinary Sciences	Science & Technology - Other Topics	CQ4ZT	WOS:000360613800105	26332828	DOAJ Gold, Green Published			2020-06-30	J	Lindley, EM; Milligan, K; Farmer, R; Burger, EL; Patel, VV				Lindley, Emily M.; Milligan, Kenneth; Farmer, Ryan; Burger, Evalina L.; Patel, Vikas V.			Patient-Controlled Transdermal Fentanyl Versus Intravenous Morphine Pump After Spine Surgery	ORTHOPEDICS			English	Article							POSTOPERATIVE PAIN; CONTROLLED ANALGESIA; SYSTEM; MANAGEMENT; EFFICACY; SAFETY; PHARMACOKINETICS	Patient-controlled analgesia (PCA) is regularly used to manage pain following major surgery. The fentanyl hydrochloride iontophoretic transdermal system (ITS) was developed to overcome some of the limitations of intravenous (IV) PCA. The small, self-adhesive, needle-free disposable system is applied to the skin on the upper arm or chest and is controlled by patients clicking a button on the device. The authors identified patients who were underwent spinal surgery from 2 prior multicenter, randomized studies and analyzed their data. Of the 1296 patients in the original trials, 170 underwent spine surgery procedures: 90 were randomized to the fentanyl ITS (40 mcg/activation) and 80 to IV PCA morphine (1 mg/dose). More patients treated with the fentanyl ITS rated their method of pain control as "excellent" across all time points, but differences did not reach statistical significance. However, investigators' ratings of "excellent" satisfaction with study treatment were significantly higher for the fentanyl ITS. Discontinuation rates and overall adverse event rates were similar between groups. The only significant difference was that patients treated with the fentanyl ITS had a higher rate of application site reactions than infusion site reactions in the IV PCA morphine group; the reactions were typically mild-to-moderate erythema that resolved shortly after removal of the fentanyl ITS device and did not require further treatment. Ratings of satisfaction with pain control method were consistently higher for the fentanyl ITS than the IV PCA morphine. The 2 groups had a similar safety profile. These results suggest that the fentanyl ITS appears to be a safe, efficacious alternative to IV PCA in spine surgery patients.	[Lindley, Emily M.; Milligan, Kenneth; Farmer, Ryan; Burger, Evalina L.; Patel, Vikas V.] Univ Colorado, Dept Orthoped, Denver, CO 80202 USA	Lindley, EM (reprint author), Univ Colorado, Dept Orthoped, Anschutz Med Campus,13001 E 17th Pl,Mail Stop F43, Aurora, CO 80045 USA.	Emily.lindley@ucdenver.edu					Breivik H, 1998, EUR J ANAESTH, V15, P748, DOI 10.1097/00003643-199811000-00022; Breivik H, 2008, PAIN, V137, P233, DOI 10.1016/j.pain.2008.04.014; Buvanendran A, 2010, SPINE, V35, pS274, DOI 10.1097/BRS.0b013e31820240f8; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Gepstein R, 2007, SURG NEUROL, V67, P360, DOI 10.1016/j.surneu.2006.09.033; Gottschalk A, 2004, ANESTHESIOLOGY, V101, P175, DOI 10.1097/00000542-200407000-00027; GRONBLAD M, 1984, ANAT REC, V209, P297, DOI 10.1002/ar.1092090306; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Ritter III HTM, 2011, PENNSYLVANIA PATIENT, V8, P94; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, AM J HEALTH-SYST PH, V61, pS11, DOI 10.1093/ajhp/61.suppl_1.S11; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Wong M, 2013, SOC AN SLEEP MED SAS; Yukawa Y, 2005, SPINE, V30, P2357, DOI 10.1097/01.brs.0000184377.31427.fa	23	7	7	0	2	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0147-7447	1938-2367		ORTHOPEDICS	Orthopedics	SEP	2015	38	9					E819	E824		10.3928/01477447-20150902-61			6	Orthopedics	Orthopedics	CX0NL	WOS:000365393600012	26375541				2020-06-30	J	Robles, LA				Robles, Luis A.			Serotonin Syndrome Induced by Fentanyl in a Child: Case Report	CLINICAL NEUROPHARMACOLOGY			English	Review						serotonin syndrome; fentanyl; intracerebral hemorrhage	SERTRALINE; TOXICITY; PAROXETINE; DIAGNOSIS	Serotonin syndrome (SS) is a potentially fatal condition associated with increased serotonergic activity in the central nervous system that can be attributed to certain drugs or interactions between drugs. There are some published articles reporting this syndrome caused by the combination of fentanyl and selective serotonin reuptake inhibitors antidepressants in adult patients; however, there are no reports of SS associated to the use of fentanyl as a single causative agent. The author reports a case of a 7-year-old boy who was admitted to the emergency department with neurological deterioration secondary to an intracerebral hemorrhage. The patient was operated to remove the bleeding. Postoperatively, he experienced a diversity of progressive neurological signs (shivering, tremor, hypertonia, hyperreflexia, clonus, bilateral mydriasis, and intracranial hypertension), which were initially considered to be signs of neurological deterioration, but finally, it was proved that they were part of a SS caused by fentanyl. The absence of concomitant use of another medications known to induce SS and the dramatic improving observed after stopping fentanyl strongly indicates that fentanyl was the causative agent in this case of SS. Fentanyl is a medication used frequently, and therefore, clinicians should be aware of this potential adverse effect when this drug is administered.	[Robles, Luis A.] Hosp CMQ Premiere, Sect Neurosurg Neurocrit Care, Puerto Vallarta, Jalisco, Mexico	Robles, LA (reprint author), Av Francisco Villa 1479, Puerto Vallarta 48300, Jalisco, Mexico.	larob@prodigy.net.mx					Ables AZ, 2010, AM FAM PHYSICIAN, V81, P1139; Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; Alkhatib AA, 2010, DIGEST DIS SCI, V55, P215, DOI 10.1007/s10620-009-0711-x; Altman CS, 2010, ANESTH ANALG, V110, P526, DOI 10.1213/ANE.0b013e3181c76be9; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; CARR DB, 1994, CRIT CARE MED, V22, P725; Choudhury Minati, 2011, J Anaesthesiol Clin Pharmacol, V27, P233, DOI 10.4103/0970-9185.81825; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; Gill M, 1999, ANN EMERG MED, V33, P457, DOI 10.1016/S0196-0644(99)70313-6; Gollapudy S, 2012, J CLIN ANESTH, V24, P251, DOI 10.1016/j.jclinane.2011.04.017; Hillman AD, 2015, PHARMACOTHERAPY, V35, P112, DOI 10.1002/phar.1528; Horowitz BZ, 1999, PEDIATR EMERG CARE, V15, P325, DOI 10.1097/00006565-199910000-00006; Iqbal MM, 2012, ANN CLIN PSYCHIATRY, V24, P310; Isbister GK, 2007, MED J AUSTRALIA, V187, P361, DOI 10.5694/j.1326-5377.2007.tb01282.x; KAMINSKI CA, 1994, ANN EMERG MED, V23, P1371, DOI 10.1016/S0196-0644(94)70364-7; Kirschner R, 2010, J EMERG MED, V38, P477, DOI 10.1016/j.jemermed.2008.01.003; Lee DO, 1999, PHARMACOTHERAPY, V19, P894, DOI 10.1592/phco.19.10.894.31561; Pao M, 1997, ARCH PEDIAT ADOL MED, V151, P1064, DOI 10.1001/archpedi.1997.02170470098028; Rang ST, 2008, CAN J ANAESTH, V55, P521, DOI 10.1007/BF03016672; Rastogi R, 2011, ANESTHESIOLOGY, V115, P1291, DOI 10.1097/ALN.0b013e31823940c0; STERNBACH H, 1991, AM J PSYCHIAT, V148, P705; Thomas CR, 2004, J AM ACAD CHILD PSY, V43, P790, DOI 10.1097/01.chi.0000128830.13997.aa	22	2	2	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-5664	1537-162X		CLIN NEUROPHARMACOL	Clin. Neuropharmacol.	SEP-OCT	2015	38	5					206	208		10.1097/WNF.0000000000000100			3	Clinical Neurology; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CS5HF	WOS:000362107900008	26366964				2020-06-30	J	Varadi, A; Palmer, TC; Haselton, N; Afonin, D; Subrath, JJ; Le Rouzic, V; Hunkele, A; Pasternak, GW; Marrone, GF; Borics, A; Majumdar, S				Varadi, Andras; Palmer, Travis C.; Haselton, Nathan; Afonin, Daniel; Subrath, Joan J.; Le Rouzic, Valerie; Hunkele, Amanda; Pasternak, Gavril W.; Marrone, Gina F.; Borics, Attila; Majumdar, Susruta			Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction	ACS CHEMICAL NEUROSCIENCE			English	Article						Ugi reaction; multicomponent reactions; mu-delta; opioid analgesics; carfentanil	MU-AGONIST/DELTA-ANTAGONIST; PHYSICAL-DEPENDENCE; RECEPTOR AGONISTS; ACUTE TOLERANCE; RHESUS-MONKEYS; DELTA; MORPHINE; ANTINOCICEPTION; LIGANDS; POTENT	We report a novel approach to synthesize carfentanil amide analogues utilizing the isocyanide-based four-component Ugi multicomponent reaction. A small library of bis-amide analogues of carfentanil was created using N-alkylpiperidones, aniline, propionic acid, and various aliphatic isocyanides. Our lead compound showed high affinity for mu (MOR) and delta opioid receptors (DOR) with no appreciable affinity for kappa (KOR) receptors in radioligand binding assays. The compound was found to be a mixed MOR agonist/partial DOR agonist in [S-35]GTP gamma S functional assays, and it showed moderate analgesic potency in vivo. The compound showed no visible signs of physical dependence or constipation in mice. In addition, it produced less respiratory depression than morphine. Most mixed MOR/DOR opioids reported in the literature are peptides and thereby systemically inactive. Our approach utilizing a multicomponent reaction has the promise to deliver potent and efficacious small-molecule analgesics with potential clinical utility.	[Varadi, Andras; Palmer, Travis C.; Haselton, Nathan; Afonin, Daniel; Subrath, Joan J.; Le Rouzic, Valerie; Hunkele, Amanda; Pasternak, Gavril W.; Marrone, Gina F.; Majumdar, Susruta] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10065 USA; [Borics, Attila] Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, H-6726 Szeged, Hungary	Majumdar, S (reprint author), Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10065 USA.	majumdas@mskcc.org		Palmer, Travis/0000-0002-1335-775X; Varadi, Andras/0000-0001-5591-377X	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA034106, DA06241]; National Science FoundationNational Science Foundation (NSF) [DGE-1257284]; European UnionEuropean Union (EU); State of Hungary - European Social Fund [TAMOP 4.2.4. A/2-11-1-2012-0001]	This work was supported by research grants from the National Institute on Drug Abuse (DA034106) to S.M. and (DA06241) to G.W.P., National Science Foundation Graduate Research Fellowship (DGE-1257284) to G.F.M. Research of A.B. was supported by the European Union and the State of Hungary, cofinanced by the European Social Fund in the framework of TAMOP 4.2.4. A/2-11-1-2012-0001 "National Excellence Program".	Ananthan S, 1999, J MED CHEM, V42, P3527, DOI 10.1021/jm990039i; Ananthan S, 2006, AAPS J, V8, pE118, DOI 10.1208/aapsj080114; Balboni G, 2002, J MED CHEM, V45, P713, DOI 10.1021/jm010449i; Balboni G, 2010, ACS CHEM NEUROSCI, V1, P155, DOI 10.1021/cn900025j; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Bishop MJ, 2003, J MED CHEM, V46, P623, DOI 10.1021/jm020395s; Bolan EA, 2004, SYNAPSE, V51, P11, DOI 10.1002/syn.10277; Bot G, 1998, J NEUROCHEM, V70, P358; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Coats SJ, 2004, BIOORG MED CHEM LETT, V14, P5493, DOI 10.1016/j.bmcl.2004.09.004; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Corbett AD, 2006, BRIT J PHARMACOL, V147, pS153, DOI 10.1038/sj.bjp.0706435; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.0.CO;2-M; Do Carmo GP, 2008, J PHARMACOL EXP THER, V326, P939, DOI 10.1124/jpet.108.138180; Eguchi M, 2004, MED RES REV, V24, P182, DOI 10.1002/med.10059; Granier S, 2012, NATURE, V485, P400, DOI 10.1038/nature11111; He L, 1998, J PHARMACOL EXP THER, V285, P1181; HORAN P, 1992, LIFE SCI, V50, P1535, DOI 10.1016/0024-3205(92)90144-E; Hulme C, 2003, CURR MED CHEM, V10, P51, DOI 10.2174/0929867033368600; KOLESNIKOV YA, 1993, P NATL ACAD SCI USA, V90, P5162, DOI 10.1073/pnas.90.11.5162; Lowery JJ, 2011, J PHARMACOL EXP THER, V336, P767, DOI 10.1124/jpet.110.172866; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Majumdar S, 2011, P NATL ACAD SCI USA, V108, P19778, DOI 10.1073/pnas.1115231108; Majumdar S, 2011, BIOORG MED CHEM LETT, V21, P4001, DOI 10.1016/j.bmcl.2011.05.008; Malaquin S, 2010, TETRAHEDRON LETT, V51, P2983, DOI 10.1016/j.tetlet.2010.03.120; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Mosberg HI, 2014, J MED CHEM, V57, P3148, DOI 10.1021/jm5002088; Mosberg HI, 2013, J MED CHEM, V56, P2139, DOI 10.1021/jm400050y; Pentel P.R., 2014, Compositions and Methods of Treating Opioid Addiction, Patent No. [US 20140093525 A1, 20140093525, US20140093525A1]; PORRECA F, 1992, J PHARMACOL EXP THER, V263, P147; Portoghese P., 2014, Analgesic Conjugates, Patent No. [WO2014124317A1, 2014124317, WO 2014124317 A1]; Purington LC, 2009, J MED CHEM, V52, P7724, DOI 10.1021/jm9007483; Schafer B, 2013, BIOCONJUGATE CHEM, V24, P1684, DOI 10.1021/bc4002135; Schiller PW, 1999, J MED CHEM, V42, P3520, DOI 10.1021/jm980724+; Shim J, 2013, J PHYS CHEM B, V117, P7907, DOI 10.1021/jp404238n; Srulevitch D B, 1989, Prog Clin Biol Res, V291, P377; SRULEVITCH DB, 1991, ACTA PHARM JUGOSL, V41, P89; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Varadi A, 2014, ORG LETT, V16, P1668, DOI 10.1021/ol500328t; Varadi A, 2013, EUR J MED CHEM, V69, P786, DOI 10.1016/j.ejmech.2013.09.031; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; VAUGHT JL, 1979, J PHARMACOL EXP THER, V208, P86; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; Wells JL, 2001, J PHARMACOL EXP THER, V297, P597; Yekkirala AS, 2012, ACS CHEM NEUROSCI, V3, P720, DOI 10.1021/cn300049m	46	15	15	0	24	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	SEP	2015	6	9					1570	1577		10.1021/acschemneuro.5b00137			8	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	CR7CI	WOS:000361505100008	26148793	Green Accepted			2020-06-30	J	Li, CC; Chen, SS; Huang, CH; Chien, KL; Yang, HJ; Fan, SZ; Leighton, BL; Chen, LK				Li, C. C.; Chen, S. S.; Huang, C. H.; Chien, K. L.; Yang, H. J.; Fan, S. Z.; Leighton, B. L.; Chen, L. K.			Fentanyl-induced cough is a risk factor for postoperative nausea and vomiting	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesics opioid, fentanyl; cough; postoperative nausea and vomiting	HISTAMINE-RELEASE; PREVENTION; SURGERY; DIMENHYDRINATE; METAANALYSIS; ONDANSETRON; INJECTION; CENTERS; TRIAL; SCORE	Background: Postoperative nausea and vomiting (PONV) and fentanyl-induced cough (FIC) are two common anaesthesia-related events, which seem to have common risk factors. In this prospective cohort study, we investigate whether patients who have FIC during induction of anaesthesia have an increased incidence of PONV. Methods: We studied adult non-smoking gynaecological surgical patients enrolled between July 1, 2011 and July 30, 2012. The presence of FIC during induction and the occurrence of PONV were recorded. Fentanyl-induced cough and other perioperative variables were subjected to multivariate analysis to determine the association between FIC and PONV. Results: All 502 patients enrolled in this study had at least two risk factors for PONV, and 154 (31%) developed FIC. The incidence of PONV in the FIC group was higher than in the non-FIC group (56.5 vs 38.2%; P<0.0001). Multivariate logistic regression analysis found FIC to be a predictive risk factor for the development of PONV (adjusted odds ratio 2.08, 95% confidence interval 1.41-3.07). Conclusions: Non-smoking women undergoing gynaecological surgery who develop FIC during induction of anaesthesia have a higher incidence of PONV.	[Li, C. C.] Taipei Med Univ, Shuang Ho Hosp, Dept Anesthesiol, Taipei, Taiwan; [Chen, S. S.] Natl Yang Ming Univ, Sch Med, Dept Urol, Taipei 112, Taiwan; [Chen, S. S.] Taipei City Hosp, Renai Branch, Dept Surg, Taipei, Taiwan; [Huang, C. H.; Fan, S. Z.] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Anesthesiol, Taipei 10764, Taiwan; [Chien, K. L.] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan; [Yang, H. J.] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Internal Med, Hsinchu, Taiwan; [Leighton, B. L.; Chen, L. K.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Chen, L. K.] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Anesthesiol, Hsinchu, Taiwan	Chen, LK (reprint author), Washington Univ, Sch Med, Dept Anesthesiol, Campus Box 8054,660 South Euclid Ave, St Louis, MO 63110 USA.	chenl@anest.wustl.edu		Fan, Shou-Zen/0000-0002-6849-8453; HUANG, CHI-HSIANG/0000-0001-5357-0451; CHIEN, KUO-LIONG/0000-0003-4979-8351; CHEN, LI-KUEI/0000-0003-1946-4828	Anesthesiology Department of National Taiwan University Hospital	Anesthesiology Department of National Taiwan University Hospital.	Apfel CC, 2002, BRIT J ANAESTH, V88, P234, DOI 10.1093/bja/88.2.234; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; CARROLL NV, 1994, J CLIN ANESTH, V6, P364, DOI 10.1016/S0952-8180(05)80004-2; Cholwill JM, 1999, BRIT J ANAESTH, V83, P611; Franck M, 2010, J INT MED RES, V38, P1034, DOI 10.1177/147323001003800330; Hung KC, 2010, ANAESTHESIA, V65, P4, DOI 10.1111/j.1365-2044.2009.06109.x; Kamei Junzo, 2013, Cough, V9, P3, DOI 10.1186/1745-9974-9-3; Kim JE, 2014, J ANESTH, V28, P257, DOI 10.1007/s00540-013-1695-4; Kimura K, 2004, INFLAMM RES, V53, pS148, DOI 10.1007/s00011-004-0356-3; Kranke P, 2002, ACTA ANAESTH SCAND, V46, P238, DOI 10.1034/j.1399-6576.2002.t01-1-460303.x; Lehmann M, 2010, J CLIN ANESTH, V22, P13, DOI 10.1016/j.jclinane.2009.02.015; LERMAN J, 1992, BRIT J ANAESTH, V69, pS24, DOI 10.1093/bja/69.supplement_1.24S; Lim KJ, 2013, KOREAN J ANESTHESIOL, V65, P251, DOI 10.4097/kjae.2013.65.3.251; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lin TF, 2005, BRIT J ANAESTH, V94, P835, DOI 10.1093/bja/aei137; Nies C, 1997, INFLAMM RES, V46, pS83; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Parra-Sanchez I, 2012, CAN J ANESTH, V59, P366, DOI 10.1007/s12630-011-9660-x; Pierre S, 2002, CAN J ANAESTH, V49, P237, DOI 10.1007/BF03020521; Piwko C, 2005, PEDIATR ANESTH, V15, P755, DOI 10.1111/j.1460-9592.2004.01528.x; Tweed WA, 2001, ANESTH ANALG, V92, P1442; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023	24	4	7	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	SEP	2015	115	3					444	448		10.1093/bja/aev157			5	Anesthesiology	Anesthesiology	CR2WL	WOS:000361191400018	26034022	Bronze			2020-06-30	J	Blanco, ME; Encinas, E; Gonzalez, O; Rico, E; Vozmediano, V; Suarez, E; Alonso, RM				Blanco, M. E.; Encinas, E.; Gonzalez, O.; Rico, E.; Vozmediano, V.; Suarez, E.; Alonso, R. M.			Quantitative determination of fentanyl in newborn pig plasma and cerebrospinal fluid samples by HPLC-MS/MS	DRUG TESTING AND ANALYSIS			English	Article						fentanyl; newborn pig; plasma; cerebrospinal fluid; HPLC-MS; MS	PERFORMANCE LIQUID-CHROMATOGRAPHY; GAS-CHROMATOGRAPHY; LIVER-MICROSOMES; CANCER PAIN; MORPHINE; PHARMACOKINETICS; CYTOCHROME-P450; MODEL; ASSAY; FORMULATIONS	In this study, a selective and sensitive high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method requiring low sample volume (100L) was developed and validated for the quantitative determination of the opioid drug fentanyl in plasma and cerebrospinal fluid (CSF). A protein precipitation extraction with acetonitrile was used for plasma samples whereas CSF samples were injected directly on the HPLC column. Fentanyl and C-13(6)-fentanyl (Internal Standard) were analyzed in an electrospray ionization source in positive mode, with multiple reaction monitoring (MRM) of the transitions m/z 337.0/188.0 and m/z 337.0/105.0 for quantification and confirmation of fentanyl, and m/z 343.0/188.0 for C-13(6)-fentanyl. The respective lowest limits of quantification for plasma and CSF were 0.2 and 0.25ng/mL. Intra- and inter-assay precision and accuracy did not exceed 15%, in accordance with bioanalytical validation guidelines. The described analytical method was proven to be robust and was successfully applied to the determination of fentanyl in plasma and CSF samples from a pharmacokinetic and pharmacodynamic study in newborn piglets receiving intravenous fentanyl (5 mu g/kg bolus immediately followed by a 90-min infusion of 3 mu g/kg/h). Copyright (c) 2015 John Wiley & Sons, Ltd.	[Blanco, M. E.; Gonzalez, O.; Rico, E.; Alonso, R. M.] Univ Basque Country UPV EHU, Dept Analyt Chem, Fac Sci & Technol, Bilbao 48080, Basque Country, Spain; [Encinas, E.; Suarez, E.] Univ Basque Country UPV EHU, Fac Med, Dept Pharmacol, Bilbao 48080, Basque Country, Spain; [Gonzalez, O.] Leiden Univ, LACDR, Analyt Biosci Div, Leiden, Netherlands; [Vozmediano, V.] Dynakin SL, Drug Modeling & Consulting, Bilbao, Basque Country, Spain	Blanco, ME (reprint author), Univ Basque Country UPV EHU, Dept Analyt Chem, Fac Sci & Technol, POB 644, Bilbao 48080, Basque Country, Spain.	mariaencarnacion.blanco@ehu.es	Blanco, Maria Encarnacion/K-9059-2017; Blanco, Maria Encarnacion/L-3391-2019; Gonzalez, Oskar/G-7649-2015	Blanco, Maria Encarnacion/0000-0003-4032-8003; Blanco, Maria Encarnacion/0000-0003-4032-8003; Gonzalez, Oskar/0000-0001-6495-1815; Suarez, Elena/0000-0002-6683-4847; ALONSO ROJAS, ROSA M./0000-0001-9046-6602	Spanish Ministry of Science and InnovationSpanish Government [CTQ2013-46179-R]; Spanish Ministry of Science and Innovation (INNPACTO by FEDER Fund) [ITP-09000-2010-002]; University of the Basque CountryUniversity of Basque Country [UFI 11/23, PPM12/06]; Basque Country GovernmentBasque Government [IT789/13]; Basque Country GovernmentBasque Government; UPV/EHUUniversity of Basque Country	Authors thank the Spanish Ministry of Science and Innovation (Project CTQ2013-46179-R and INNPACTO Project, ITP-09000-2010-002, which is financed by the FEDER Fund), University of the Basque Country (UFI 11/23 and Project PPM12/06) and Basque Country Government (Project IT789/13) for financial support and the SGIker technical support (UPV/ EHU, MICINN, GV/EJ, ERDF and ESF). E. Encinas, E. Rico, M.E. Blanco and O. Gonzalez also thank Basque Country Government and UPV/EHU for their predoctoral and postdoctoral grants. We also want to thank the staff of the Research Unit for Experimental Neonatal Respiratory Physiology at Cruces University Hospital (Barakaldo, Biscay, Basque Country) for executing the experimental phase in piglets.	Almousa AA, 2011, J CHROMATOGR B, V879, P2941, DOI 10.1016/j.jchromb.2011.08.029; Anzenbacher P, 1998, DRUG METAB DISPOS, V26, P56; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Bagheri H, 2007, J PHARMACEUT BIOMED, V43, P1763, DOI 10.1016/j.jpba.2006.12.016; Bonfiglio R, 1999, RAPID COMMUN MASS SP, V13, P1175, DOI 10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0; Buddington RK, 2012, J ANIM SCI, V90, P290, DOI 10.2527/jas.54604; Caminita F, 2015, AM J PHYSIOL-LUNG C, V308, pL118, DOI 10.1152/ajplung.00173.2014; Chang YW, 2007, J CHROMATOGR B, V857, P195, DOI 10.1016/j.jchromb.2007.07.014; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; de Lange ECM, 2002, CLIN PHARMACOKINET, V41, P691, DOI 10.2165/00003088-200241100-00001; Dotsikas Y, 2002, ANAL CHIM ACTA, V459, P177, DOI 10.1016/S0003-2670(02)00133-2; Eiby YA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068763; Encinas E, 2013, PEDIATR DRUGS, V15, P247, DOI 10.1007/s40272-013-0029-1; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; *FOOD DRUG ADM CTR, 2001, GUID IND BIOAN METH; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Gottas A, 2012, J PHARMACOL TOX MET, V66, P14, DOI 10.1016/j.vascn.2012.04.009; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hisada T, 2013, BIOL PHARM BULL, V36, P412, DOI 10.1248/bpb.b12-00825; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Kim Jin Hyung, 2013, Korean J Ophthalmol, V27, P229, DOI 10.3341/kjo.2013.27.4.229; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; KROLL MH, 1994, CLIN CHEM, V40, P1996; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Lin JH, 2008, CURR DRUG METAB, V9, P46, DOI 10.2174/138920008783331077; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; Modanlou HCD, 1996, J INVEST MED, V44, P362; Nagaya Y, 2014, DRUG METAB PHARMACOK, V29, P419, DOI 10.2133/dmpk.DMPK-14-RG-026; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Rey-Santano C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090728; Roth WJ, 2013, AAPS J, V15, P763, DOI 10.1208/s12248-013-9482-6; SCHIEBER RA, 1985, ANESTHESIOLOGY, V63, P166, DOI 10.1097/00000542-198508000-00009; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; Shankaran H, 2013, TOXICOL APPL PHARM, V273, P464, DOI 10.1016/j.taap.2013.05.024; Shen DD, 2004, ADV DRUG DELIVER REV, V56, P1825, DOI 10.1016/j.addr.2004.07.011; Skaanild MT, 2006, CURR PHARM DESIGN, V12, P1421, DOI 10.2174/138161206776361183; Snyder ML, 2011, CLIN CHIM ACTA, V412, P946, DOI 10.1016/j.cca.2011.01.029; Swindle MM, 2012, VET PATHOL, V49, P344, DOI 10.1177/0300985811402846; Szeitz A, 1996, J CHROMATOGR B, V675, P33, DOI 10.1016/0378-4347(95)00350-9; Twite Mark D, 2004, Pediatr Crit Care Med, V5, P521, DOI 10.1097/01.PCC.0000144710.13710.2E; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Wang GH, 2011, FORENSIC SCI INT, V206, P127, DOI 10.1016/j.forsciint.2010.07.022; WANG WL, 1993, FORENSIC SCI INT, V61, P65, DOI 10.1016/0379-0738(93)90250-E; Ziesenitz VC, 2013, BASIC CLIN PHARMACOL, V113, P43, DOI 10.1111/bcpt.12066	50	2	3	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	SEP	2015	7	9					804	811		10.1002/dta.1778			8	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	CQ7FP	WOS:000360768700009	25755165				2020-06-30	J	Pimentel, MPT; Bobb, LE; Shimada, YJ; Gerhard-Herman, M; Katz, JE; Palanisamy, A				Pimentel, Marc Philip T.; Bobb, Lesley E.; Shimada, Yuichi J.; Gerhard-Herman, Marie; Katz, Jeffrey E.; Palanisamy, Arvind			Anesthetic Management of Peripartum Right Ventricular Outflow Tract Tachycardia	A & A CASE REPORTS			English	Article							SPINAL-ANESTHESIA; ARRHYTHMIAS; PREGNANCY; PALPITATIONS; FENTANYL	Arrhythmia and palpitation are common during pregnancy. Right ventricular outflow tract tachycardia, a rare cause of palpitations occurring even in the absence of structural heart disease, is uncommon during pregnancy. Nevertheless, the presence of right ventricular outflow tract tachycardia in pregnancy requires careful cardiac evaluation with a focus on managing arrhythmogenic activity while maintaining patient comfort and safety. We report a case of right ventricular outflow tract tachycardia in a pregnant 32-year-old woman, whose arrhythmia was detected 2 weeks before labor and persisted through the peripartum period.	[Pimentel, Marc Philip T.; Bobb, Lesley E.; Palanisamy, Arvind] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Katz, Jeffrey E.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA; [Shimada, Yuichi J.; Gerhard-Herman, Marie] Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA	Pimentel, MPT (reprint author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St,CWN-L1, Boston, MA 02115 USA.	mppimentel@partners.org		Shimada, Yuichi/0000-0002-3494-307X			Adamson DL, 2007, HEART, V93, P1630, DOI 10.1136/hrt.2006.098822; BRODSKY M, 1992, AM HEART J, V123, P933, DOI 10.1016/0002-8703(92)90699-V; Goli AK, 2009, REV CARDIOVASC MED, V10, P171, DOI 10.3909/ricm0469; Gowda RM, 2003, INT J CARDIOL, V88, P129, DOI 10.1016/S0167-5273(02)00601-0; Hogarth Andrew J, 2014, Indian Pacing Electrophysiol J, V14, P79; Hosokawa Y, 2012, J ANESTH, V26, P219, DOI 10.1007/s00540-011-1292-3; Joglar JA, 2001, CURR OPIN CARDIOL, V16, P40, DOI 10.1097/00001573-200101000-00006; Langesaeter E, 2011, CURR OPIN ANESTHESIO, V24, P242, DOI 10.1097/ACO.0b013e32834588c5; MORRIS GF, 1994, CAN J ANAESTH, V41, P667, DOI 10.1007/BF03015618; Mulroy M, 1998, ANESTH ANALG, V86, P923, DOI 10.1097/00000539-199805000-00001; MURAD SHN, 1985, ANESTH ANALG, V64, P7; Murphy J, 2008, INT J OBSTET ANESTH, V17, P275, DOI 10.1016/j.ijoa.2007.09.016; Shotan A, 1997, AM J CARDIOL, V79, P1061, DOI 10.1016/S0002-9149(97)00047-7; Srivathsan Komandoor, 2005, Indian Pacing Electrophysiol J, V5, P106; Trappe Hans-Joachim, 2010, J Emerg Trauma Shock, V3, P153, DOI 10.4103/0974-2700.62116; Watson E, 2014, INT J OBSTET ANESTH, V23, P293, DOI 10.1016/j.ijoa.2014.03.002; WAXMAN MB, 1980, CIRCULATION, V62, P843, DOI 10.1161/01.CIR.62.4.843; YOSHII WY, 1993, REGION ANESTH, V18, P296	18	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA		2575-3126		A A CASE REP	A A Case Rep.	SEP 1	2015	5	5					72	74		10.1213/XAA.0000000000000178			3	Anesthesiology	Anesthesiology	CQ5SU	WOS:000360666800002	26323033				2020-06-30	J	Sun, Y; Xu, Y; Wang, GN				Sun, Y.; Xu, Y.; Wang, G-N.			Comparative Evaluation of Intrathecal Bupivacaine Alone, Bupivacaine-fentanyl, and Bupivacaine-dexmedetomidine in Caesarean Section	DRUG RESEARCH			English	Article						bupivacaine; fentanyl; dexmedetomidine; post-operative analgesia; cesarean section; sensory block; motor block	RANDOMIZED CONTROLLED-TRIALS; SPINAL-ANESTHESIA; HYPERBARIC BUPIVACAINE; ANALGESIA; OPIOIDS; SUFENTANIL; CLONIDINE; MORPHINE; BLOCK; LABOR	Purpose: In this study, we aimed to compare the effects of bupivacaine alone, bupivacaine plus fentanyl, and bupivacaine plus dexmedetomidine for postoperative analgesia in women undergoing cesarean section under spinal anesthesia. Material and methods: 90 term parturients scheduled to have elective cesarean section and ASA physical status I or II were allocated randomly into 3 groups to receive either bupivacaine (Bv group) or bupivacaine plus fentanyl (BvF group) or bupivacaine plus dexmedetomidine (BvD group). The onset time of sensory block, maximum sensory block level, duration of motor and sensory block, onset of post-operative pain, sedation scores, Apgar scores and side effects were recorded and statistically compared across 3 groups. Results: Regression time to T10 was significantly longer in BvD group, sensory block was also prolonged in BvD group without any difference in duration of motor block. Onset of post-operative pain was delayed in BvD group. Sedation scores (VAS) were improved in case of BvD with least values of 0-3 followed by BvF (1-4). There was no significant difference in Apgar scores and neonatal arterial gas pressures across 3 groups. Conclusion: The use of dexmedtomidine as an adjuvant to bupivacaine in cesarean surgeries provides better intra-operative and post-operative analgesia without having significant impact on Apgar scores or incidence of side effects.	[Sun, Y.] Heilongjiang Prov Hosp, Dept Anesthesia, Harbin, Heilongjiang Pr, Peoples R China; [Xu, Y.; Wang, G-N.] Harbin Med Univ, Affiliated Hosp 3, Dept Anesthesia, 150 Haping Rd, Harbin 150000, Heilongjiang, Peoples R China	Wang, GN (reprint author), Harbin Med Univ, Affiliated Hosp 3, Dept Anesthesia, 150 Haping Rd, Harbin 150000, Heilongjiang, Peoples R China.	guonian30301@gmail.com					Abu-Halaweh SA, 2009, EUR J ANAESTH, V26, P86, DOI 10.1097/EJA.0b000e000000f3fb; Al-Ghanem SM, 2009, AM J APPL SCI, V6, P882, DOI DOI 10.3844/AJASSP.2009.882.887; Al-Mustafa MM, 2009, SAUDI MED J, V30, P365; ALAHUHTA S, 1990, ACTA ANAESTH SCAND, V34, P95, DOI 10.1111/j.1399-6576.1990.tb03050.x; Benhamou D, INTRAHECAL CLONIDINE; Bogra J, 2005, BMC ANESTHESIOL, V5, P5, DOI DOI 10.1186/1471-2253-5-5; Braga ADFD, 2003, EUR J ANAESTH, V20, P631; Bremerich DH, 2007, CURR MED RES OPIN, V23, P3047, DOI 10.1185/030079907X242764; Carollo DS, 2008, CURR OPIN ANESTHESIO, V21, P457, DOI 10.1097/ACO.0b013e328305e3ef; CARTER J, 1994, CONT ANESTHESIA, V4, P11; Chestnut DH, 1997, ANESTHESIOLOGY, V86, P273, DOI 10.1097/00000542-199702000-00001; COVINO BG, 1989, INT ANESTHESIOL CLIN, V27, P8, DOI 10.1097/00004311-198902710-00003; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Dresner MR, 2001, BEST PRACT RES CL OB, V15, P127, DOI 10.1053/beog.2000.0153; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; Gogarten Wiebke, 2003, Best Pract Res Clin Anaesthesiol, V17, P377; Gupta Rajni, 2011, J Anaesthesiol Clin Pharmacol, V27, P339, DOI 10.4103/0970-9185.83678; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Hamber EA, 1998, ANESTH ANALG, V87, P609; Hunt CO, 1987, ANESTHESIOLOGY, P67; Ishii H, 2008, EUR J NEUROSCI, V27, P3182, DOI 10.1111/j.1460-9568.2008.06260.x; KALSO EA, 1991, PHARMACOL TOXICOL, V68, P140, DOI 10.1111/j.1600-0773.1991.tb02052.x; Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x; Karaman S, 2006, EUR J ANAESTH, V23, P285, DOI 10.1017/S0265021505001869; Lee A, 2002, ANESTH ANALG, V94, P920, DOI 10.1097/00000539-200204000-00028; McKinlay J, 2002, INT J OBSTET ANESTH, V11, P117, DOI 10.1054/ijoa.2001.0926; Neumann MM, 2009, INT J OBSTET ANESTH, V18, P403, DOI 10.1016/j.ijoa.2009.05.002; Paech MJ, 2004, ANESTH ANALG, V98, P1460, DOI 10.1213/01.ANE.0000111208.08867.3C; Palanisamy A, 2009, INT J OBSTET ANESTH, V18, P258, DOI 10.1016/j.ijoa.2008.10.002; ROBINSON JO, 1980, ANAESTHESIA, V35, P1173, DOI 10.1111/j.1365-2044.1980.tb05074.x; Rubin AP, 1998, PRINCIPLES PRACTICE, P70; Salgado PF, 2005, ANESTHESIOLOGY, V103, pA974; Sapate M, 2013, ANAESTH PAIN INTENSI, V17, P145; Shetty PS, 2006, ANAEST INTENS CARE M, V7, P407, DOI 10.1053/j.mpaic.2006.08.004; Sibilla C, 1997, INT J OBSTET ANESTH, V6, P43, DOI 10.1016/S0959-289X(97)80051-9; Taittonen MT, 1997, BRIT J ANAESTH, V78, P400; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; Vercauteren M, 2003, CURR OPIN ANESTHESIO, V16, P503, DOI 10.1097/00001503-200310000-00010	39	22	23	0	12	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	2194-9379	2194-9387		DRUG RES	Drug Res.	SEP	2015	65	9					468	472		10.1055/s-0034-1387740			5	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CQ3KS	WOS:000360501600004	25207707				2020-06-30	J	Knych, HK; Steffey, EP; Casbeer, HC; Mitchell, MM				Knych, H. K.; Steffey, E. P.; Casbeer, H. C.; Mitchell, M. M.			Disposition, behavioural and physiological effects of escalating doses of intravenously administered fentanyl to young foals	EQUINE VETERINARY JOURNAL			English	Article						horse; analgesic; fentanyl; foals; opioid	INDUCED MUSCULAR RIGIDITY; MINIMUM ALVEOLAR CONCENTRATION; INDUCED MUSCLE RIGIDITY; HORSES; PHARMACOKINETICS; RATS; INVOLVEMENT; ISOFLURANE; ANALGESICS; METABOLITE	Reasons for performing studyFoal responses to a broader range of plasma fentanyl concentrations than currently reported are desirable to support (or not) clinical use. ObjectivesTo describe fentanyl plasma concentrations following an escalating i.v. fentanyl dosing schedule in foals aged 5-13 days and describe selected, associated dose- and time-related behavioural and physiological responses to plasma fentanyl concentration. Study designExperimental. MethodsFentanyl was administered i.v. in an escalating fashion (2, 4, 8, 16 and 32g/kg bwt) at 10-min intervals. Blood samples were collected before and at selected times until 24h post administration. Blood samples were analysed for fentanyl and metabolite concentrations and correlated with behavioural and physiological observations and selected blood analytes. ResultsFoals mostly appeared to be unaffected following 2g/kg bwt (1.09 0.41g/l; average maximal plasma concentration) of fentanyl, but 6 of the 8 foals appeared to be sedated following 4g/kg bwt (3.07 +/- 1.11g/l). Ataxia with increased locomotor activity, muscle rigidity and head pressing posture was observed in many foals at 8 (7.24 +/- 3.22g/l) and 16g/kg bwt (17.4 +/- 5.67g/l). All foals were heavily sedated after 32g/kg bwt (34.5 +/- 10.3g/l); 3 of the 8 foals became recumbent. The average (+/- s.d.) terminal half-life following administration of the final dose was 44.2 +/- 9.85min. ConclusionsBehavioural and physiological responses to i.v. fentanyl in young foals are dose related. As with mature horses, the window of fentanyl plasma concentrations related to possible clinically desirable actions appears relatively narrow.	[Knych, H. K.; Steffey, E. P.; Casbeer, H. C.; Mitchell, M. M.] Univ Calif Davis, Sch Vet Med, KL Maddy Equine Analyt Chem Lab, Davis, CA 95616 USA; [Knych, H. K.] Univ Calif Davis, Sch Vet Med, Dept Vet Mol Biosci, Davis, CA 95616 USA; [Steffey, E. P.] Univ Calif Davis, Sch Vet Med, Dept Vet Surg & Radiol, Davis, CA 95616 USA	Knych, HK (reprint author), Univ Calif Davis, Sch Vet Med, KL Maddy Equine Analyt Chem Lab, Davis, CA 95616 USA.	hkknych@ucdavis.edu					Arguedas MG, 2008, J VET INTERN MED, V22, P1417, DOI 10.1111/j.1939-1676.2008.0200.x; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; Eberspacher E, 2008, VET ANAESTH ANALG, V35, P249, DOI 10.1111/j.1467-2987.2007.00378.x; FRINCKE JM, 1980, DRUG METAB DISPOS, V8, P425; JAFFE TB, 1983, ANESTHESIOLOGY, V58, P562, DOI 10.1097/00000542-198306000-00015; JERUSSI TP, 1987, PHARMACOL BIOCHEM BE, V28, P283, DOI 10.1016/0091-3057(87)90226-7; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; Knych HK, 2015, EQUINE VET J, V47, P72, DOI 10.1111/evj.12246; Knych HKD, 2009, AM J VET RES, V70, P1193, DOI 10.2460/ajvr.70.10.1193; LUI PW, 1989, ANESTHESIOLOGY, V70, P984, DOI 10.1097/00000542-198906000-00017; LUI PW, 1990, NEUROSCI LETT, V108, P183, DOI 10.1016/0304-3940(90)90728-R; Mama K. R., 1992, CAN J VET RES, V57, P106; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Sanchez LC, 2007, J VET INTERN MED, V21, P1067; STEFFEY EP, 1976, AM J VET RES, V37, P959; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; TOBIN T, 1979, J EQUINE MED SURG, V3, P284; TSOU MY, 1989, NEUROPHARMACOLOGY, V28, P1163, DOI 10.1016/0028-3908(89)90206-2; Vankova ME, 1996, ANESTHESIOLOGY, V85, P574, DOI 10.1097/00000542-199609000-00017; WECKMAN TJ, 1989, AM J VET RES, V50, P502	22	5	5	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0425-1644	2042-3306		EQUINE VET J	Equine Vet. J.	SEP	2015	47	5					592	598		10.1111/evj.12318			7	Veterinary Sciences	Veterinary Sciences	CP5DS	WOS:000359902100017	24978306				2020-06-30	J	Matsumoto, S; Matsumoto, K; Iida, H				Matsumoto, Shigemi; Matsumoto, Kazu; Iida, Hiroki			Transdermal fentanyl patch improves post-operative pain relief and promotes early functional recovery in patients undergoing primary total knee arthroplasty: a prospective, randomised, controlled trial	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Transdermal fentanyl patch; Post-operative pain; Total knee arthroplasty; Early functional recovery; NSAIDs	QUALITY-OF-LIFE; DOUBLE-BLIND; CONTROLLED ANALGESIA; INFILTRATION; MORPHINE; HIP; REHABILITATION; REPLACEMENT; CONSUMPTION; PREDICTORS	The aim of the present study was to evaluate the efficacy and safety of a 12.5 mu g/h transdermal fentanyl patch (TFP). Fifty-two patients scheduled for primary total knee arthroplasty (TKA) were recruited in the study. They were randomly divided into two groups: patients provided with a transdermal fentanyl patch (Group TFP) and those provided with non-steroid anti-inflammatory drugs (Group NSAID). The patients in the TFP and NSAID groups had mean ages of 70.1 years (range 36-86 years) and 73.5 years (range 32-86 years), respectively. Post-operative pain intensity was measured using the visual analogue scale both at rest and during movement (mVAS). We also evaluated lower leg functional recovery and adverse events. The mean mVAS scores were not different between the two groups on post-operative day 4, but were significantly smaller in the TFP group than in the NSAID group on post-operative days 7 (p = 0.0026) and 14 (p = 0.007). Muscle strength recovered faster in the TFP group than in the NSAID group, the percentage of pre-operative strength being significantly greater in the former than in the latter on post-operative days 7 (p = 0.027) and 14 (p = 0.047). Furthermore, there were no remarkable adverse events in patients using TFP. We conclude that a 12.5 mu g/h TFP can improve post-operative pain relief and promotes early functional recovery following total knee arthroplasty.	[Matsumoto, Shigemi; Iida, Hiroki] Gifu Univ, Dept Anesthesiol & Pain Med, Grad Sch Med, Gifu 5011194, Japan; [Matsumoto, Kazu] Gifu Univ, Dept Orthopaed Surg, Grad Sch Med, Gifu 5011194, Japan	Iida, H (reprint author), Gifu Univ, Dept Anesthesiol & Pain Med, Grad Sch Med, 1-1 Yanagido, Gifu 5011194, Japan.	iida@gifu-u.ac.jp					Abrisham SMJ, 2014, KNEE SURG SPORT TR A, V22, P1580, DOI 10.1007/s00167-012-2287-9; Andersen KV, 2010, ACTA ORTHOP, V81, P606, DOI 10.3109/17453674.2010.519165; Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; BROOME IJ, 1995, ANAESTHESIA, V50, P300, DOI 10.1111/j.1365-2044.1995.tb04603.x; Carli F, 2010, BRIT J ANAESTH, V105, P185, DOI 10.1093/bja/aeq112; Chelly JE, 2003, ORTHOPEDICS, V26, pS865, DOI 10.3928/0147-7447-20030802-08; Cheville A, 2001, J BONE JOINT SURG AM, V83A, P572, DOI 10.2106/00004623-200104000-00013; Fischer HBJ, 2008, ANAESTHESIA, V63, P1105, DOI 10.1111/j.1365-2044.2008.05565.x; Fu PL, 2009, KNEE, V16, P280, DOI 10.1016/j.knee.2008.12.012; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; Harden RN, 2003, PAIN, V106, P393, DOI 10.1016/j.pain.2003.08.009; Hawker G, 1998, J BONE JOINT SURG AM, V80A, P163, DOI 10.2106/00004623-199802000-00003; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; KILBRIDE M, 1994, DIS COLON RECTUM, V37, P1070, DOI 10.1007/BF02049805; Koh IJ, 2012, KNEE, V19, P253, DOI 10.1016/j.knee.2011.03.007; LEHMANN KA, 1991, EUR J CLIN PHARMACOL, V41, P17, DOI 10.1007/BF00280100; Lombardi AV, 2004, CLIN ORTHOP RELAT R, P125, DOI 10.1097/01.blo.000147701.24029.cc; Maheshwari AV, 2009, CLIN ORTHOP RELAT R, V467, P1418, DOI 10.1007/s11999-009-0728-7; Meding JB, 2012, CLIN ORTHOP RELAT R, V470, P144, DOI 10.1007/s11999-011-2123-4; MIGUEL R, 1995, ANESTHESIOLOGY, V83, P470, DOI 10.1097/00000542-199509000-00005; Minville V, 2008, J CLIN ANESTH, V20, P280, DOI 10.1016/j.jclinane.2007.12.013; MODIG J, 1983, ANESTH ANALG, V62, P174; NormanTaylor FH, 1996, J BONE JOINT SURG BR, V78B, P74; Parker DA, 2009, J ARTHROPLASTY, V24, P918, DOI 10.1016/j.arth.2008.05.001; Parvataneni Hari K, 2007, Instr Course Lect, V56, P125; Parvizi J, 2012, J BONE JOINT SURG AM, V94A, P1441, DOI 10.2106/JBJS.9416edit; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; SEBEL PS, 1987, EUR J CLIN PHARMACOL, V32, P529, DOI 10.1007/BF00637682; Singelyn FJ, 1998, ANESTH ANALG, V87, P88, DOI 10.1097/00000539-199807000-00019; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T	32	6	6	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	SEP	2015	135	9					1291	1297		10.1007/s00402-015-2265-z			7	Orthopedics; Surgery	Orthopedics; Surgery	CP3XI	WOS:000359815800013	26112273				2020-06-30	J	Childers, RE; Williams, JL; Sonnenberg, A				Childers, Ryan E.; Williams, J. Lucas; Sonnenberg, Amnon			Practice patterns of sedation for colonoscopy	GASTROINTESTINAL ENDOSCOPY			English	Article							UPPER GASTROINTESTINAL ENDOSCOPY; COLORECTAL-CANCER; UNITED-STATES; RACIAL/ETHNIC DISPARITIES; MEDICARE BENEFICIARIES; CONSCIOUS SEDATION; RACIAL-DIFFERENCES; DIAGNOSTIC YIELD; AFRICAN-AMERICAN; WEB SURVEY	Background: Sedative and analgesic medications have been used routinely for decades to provide patient comfort, reduce procedure time, and improve examination quality during colonoscopy. Objective: To evaluate trends of sedation during colonoscopy in the United States. Setting: Endoscopic data repository of U.S. gastroenterology practices (Clinical Outcomes Research Initiative, CORI database from 2000 until 2013). Patients: The study population was made up of patients undergoing a total of 1,385,436 colonoscopies. Interventions: Colonoscopy without any intervention or with mucosal biopsy, polypectomy, various means of hemostasis, luminal dilation, stent placement, or ablation. Main Outcome Measurements: Dose of midazolam, diazepam, fentanyl, meperidine, diphenhydramine, promethazine, and propofol used for sedation during colonoscopy. Results: During the past 14 years, midazolam, fentanyl, and propofol have become the most commonly used sedatives for colonoscopy. Except for benzodiazepines, which were dosed higher in women than men, equal doses of sedation were given to female and male patients. White patients were given higher doses than other ethnic groups undergoing sedation for colonoscopy. Except for histamine-1 receptor antagonists, all sedative medications were given at lower doses to patients with increasing age. The dose of sedatives was higher in colonoscopies associated with procedural interventions or of long duration. Limitations: Potential for incomplete or incorrect documentation in the database. Conclusion: The findings reflect on colonoscopy practice in the United States during the last 14 years and provide an incentive for future research on how sex and ethnicity influence sedation practices.	Portland VA Med Ctr, Div Gastroenterol & Hepatol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Sonnenberg, A (reprint author), Portland VA Med Ctr, Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.				NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [UO1 CA 89389-01, U01 DK057132, R33-DK61778-01]	This project was supported with funding from NIDDK UO1 CA 89389-01, NIDDK U01 DK057132, and R33-DK61778-01. In addition, the practice network (Clinical Outcomes Research Initiative) has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Novartis, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon. All authors disclosed no financial relationships relevant to this article.	Abotchie PN, 2012, J WOMENS HEALTH, V21, P393, DOI 10.1089/jwh.2011.2992; Abraham NS, 2004, AM J GASTROENTEROL, V99, P1692, DOI 10.1111/j.1572-0241.2004.40157.x; Agrawal S, 2005, AM J GASTROENTEROL, V100, P515, DOI 10.1111/j.1572-0241.2005.41829.x; Ahmed NU, 2013, AM J PUBLIC HEALTH, V103, pE91, DOI 10.2105/AJPH.2012.301034; Aisenberg James, 2006, Gastrointest Endosc Clin N Am, V16, P695, DOI 10.1016/j.giec.2006.08.004; Akhtar AJ, 2011, ETHNIC DIS, V21, P412; Arora A, 2004, GASTROINTEST ENDOSC, V60, P408, DOI 10.1016/S0016-5107(04)01715-8; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; BARDHAN KD, 1984, BRIT MED J, V288, P1046, DOI 10.1136/bmj.288.6423.1046; Burgess DJ, 2013, CLIN J PAIN, V29, P118, DOI 10.1097/AJP.0b013e31826a86ae; Campo R, 2000, EUR J GASTROEN HEPAT, V12, P187, DOI 10.1097/00042737-200012020-00009; Carlos RC, 2005, ACAD RADIOL, V12, P451, DOI 10.1016/j.acra.2004.12.024; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; COLE SG, 1983, GASTROINTEST ENDOSC, V29, P219, DOI 10.1016/S0016-5107(83)72588-5; Cooper GS, 2004, CANCER-AM CANCER SOC, V100, P418, DOI 10.1002/cncr.20014; Fanti L, 2011, DIGEST LIVER DIS, V43, P726, DOI 10.1016/j.dld.2011.04.012; Farraye FA, 2004, AM J GASTROENTEROL, V99, P341, DOI 10.1111/j.1572-0241.2004.04045.x; Faulx AL, 2005, GASTROINTEST ENDOSC, V62, P9, DOI 10.1016/S0016-5107(05)00518-3; FIRTH J D, 1960, Anesth Analg, V39, P175; Froehlich F, 1997, GASTROINTEST ENDOSC, V45, P1, DOI 10.1016/S0016-5107(97)70295-5; Griffin JM, 2009, PREV MED, V49, P436, DOI 10.1016/j.ypmed.2009.09.013; Inadomi JM, 2010, GASTROINTEST ENDOSC, V72, P580, DOI 10.1016/j.gie.2010.04.040; Irby K, 2006, CANCER EPIDEM BIOMAR, V15, P792, DOI 10.1158/1055-9965.EPI-05-0879; Johnson-Jennings MD, 2014, CANCER-AM CANCER SOC, V120, P3192, DOI 10.1002/cncr.28855; Karajeh MA, 2006, ENDOSCOPY, V38, P226, DOI 10.1055/s-2005-921209; KEEFFE EB, 1990, GASTROINTEST ENDOSC, V36, P541, DOI 10.1016/S0016-5107(90)71146-7; Lazzaroni M, 2005, ENDOSCOPY, V37, P101, DOI 10.1055/s-2004-826149; Lee E, 2013, JAMA SURG, V148, P91, DOI 10.1001/jamasurg.2013.682; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Liss DT, 2014, AM J PREV MED, V46, P228, DOI 10.1016/j.amepre.2013.10.023; Liu HS, 2012, JAMA-J AM MED ASSOC, V307, P1178, DOI 10.1001/jama.2012.270; LUDLAM R, 1971, LANCET, V2, P1397; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Miranda PY, 2012, PREV MED, V55, P131, DOI 10.1016/j.ypmed.2012.05.016; Natarajan A, 2011, ANAESTHESIA, V66, P15, DOI 10.1111/j.1365-2044.2010.06568.x; NELIS GF, 1980, LANCET, V2, P861; Paspatis GA, 2009, DIGEST LIVER DIS, V41, P807, DOI 10.1016/j.dld.2009.03.003; Percac-Lima S, 2008, J GEN INTERN MED, V23, P237, DOI 10.1007/s11606-008-0864-x; Qureshi WA, 2006, GASTROINTEST ENDOSC, V63, P566, DOI 10.1016/j.gie.2006.02.001; Rex DK, 2009, AM J GASTROENTEROL, V104, P739, DOI 10.1038/ajg.2009.104; Richards RJ, 2002, DIGEST DIS SCI, V47, P2715, DOI 10.1023/A:1021001121026; Ristikankare M, 2000, GASTROINTEST ENDOSC, V52, P48, DOI 10.1067/mge.2000.105982; Singhal Shashideep, 2011, J Gastrointest Cancer, V42, P212, DOI 10.1007/s12029-010-9190-8; Sly JR, 2013, HEALTH EDUC BEHAV, V40, P449, DOI 10.1177/1090198112459514; Tamayo-Sarver JH, 2003, AM J PUBLIC HEALTH, V93, P2067, DOI 10.2105/AJPH.93.12.2067; Travis AC, 2012, AM J GASTROENTEROL, V107, P1495, DOI 10.1038/ajg.2012.246; Vale Nilton Bezerra do, 2003, Rev Bras Anestesiol, V53, P401; Wilson FA, J CANC ED; Yen YH, 2011, J FORMOS MED ASSOC, V110, P44, DOI 10.1016/S0929-6646(11)60007-7; Yi SY, 2005, J GASTROEN HEPATOL, V20, P1873, DOI 10.1111/j.1440-1746.2004.04081.x	50	21	21	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	SEP	2015	82	3					503	511		10.1016/j.gie.2015.01.041			9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP0XX	WOS:000359601300013	25851159	Green Accepted			2020-06-30	J	Kuhar, JR; Bedini, A; Melief, EJ; Chiu, YC; Striegel, HN; Chavkin, C				Kuhar, Jamie Rose; Bedini, Andrea; Melief, Erica J.; Chiu, Yen-Chen; Striegel, Heather N.; Chavkin, Charles			Mu opioid receptor stimulation activates c-Jun N-terminal kinase 2 by distinct arrestin-dependent and independent mechanisms	CELLULAR SIGNALLING			English	Article						Arrestin; JNK; Tolerance; Opioid; Morphine; Fentanyl	LOCUS-CERULEUS NEURONS; FOCAL ADHESION KINASE; PROTEIN-KINASE; BETA-ARRESTIN; PERIAQUEDUCTAL GRAY; SIGNAL-TRANSDUCTION; DESENSITIZATION; MORPHINE; TOLERANCE; SRC	G protein-coupled receptor desensitization is typically mediated by receptor phosphorylation by G protein-coupled receptor kinase (GRK) and subsequent arrestin binding; morphine, however, was previously found to activate a c-Jun N-terminal kinase (JNK)-dependent, GRK/arrestin-independent pathway to produce mu opioid receptor (MOR) inactivation in spinally-mediated, acute anti-nociceptive responses [Melief et al.] [1]. In the current study, we determined that JNK2 was also required for centrally-mediated analgesic tolerance to morphine using the hotplate assay. We compared JNK activation by morphine and fentanyl in JNK1(-/-), JNK2(-/-), JNK3(-/-), and GRK3(-/-) mice and found that both compounds specifically activate JNK2 in vivo; however, fentanyl activation of JNK2 was GRK3-dependent, whereas morphine activation of JNK2 was GRK3-independent. In MOR-GFP expressing HEK293 cells, treatment with either arrestin siRNA, the Src family kinase inhibitor PP2, or the protein kinase C (PKC) inhibitor Go6976 indicated that morphine activated JNK2 through an arrestin-independent Src- and PKC-dependent mechanism, whereas fentanyl activated JNK2 through a Src-GRK3/arrestin-2-dependent and PKC-independent mechanism. This study resolves distinct ligand-directed mechanisms of JNK activation by mu opioid agonists and understanding ligand-directed signaling at MOR may improve opioid therapeutics. (C) 2015 Elsevier Inc All rights reserved.	[Kuhar, Jamie Rose; Bedini, Andrea; Melief, Erica J.; Chiu, Yen-Chen; Striegel, Heather N.; Chavkin, Charles] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; [Bedini, Andrea] Univ Bologna, Dept Pharm & Biotechnol FaBiT, I-40126 Bologna, Italy; [Melief, Erica J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Chavkin, C (reprint author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	cchavkin@u.washington.edu			USPHS from the National Institute on Drug Abuse [R37-DA11672, T32-DA07278, K05-DA020570, P01-DA035764]	This work was supported by USPHS grants R37-DA11672, T32-DA07278, K05-DA020570, and P01-DA035764 from the National Institute on Drug Abuse.	Bailey CP, 2009, BRIT J PHARMACOL, V158, P157, DOI 10.1111/j.1476-5381.2009.00140.x; Bailey CP, 2009, EUR J NEUROSCI, V29, P307, DOI 10.1111/j.1460-9568.2008.06573.x; Bailey CP, 2004, MOL PHARMACOL, V66, P1592, DOI 10.1124/mol.104.004747; Bruchas MR, 2007, J BIOL CHEM, V282, P29803, DOI 10.1074/jbc.M705540200; Dang VC, 2009, J NEUROSCI, V29, P3322, DOI 10.1523/JNEUROSCI.4749-08.2009; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hanson SM, 2007, J MOL BIOL, V368, P375, DOI 10.1016/j.jmb.2007.02.053; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hull LC, 2010, J PHARMACOL EXP THER, V332, P1127, DOI 10.1124/jpet.109.161455; IRWIN S, 1951, J PHARMACOL EXP THER, V101, P132; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kam AYF, 2004, J PHARMACOL EXP THER, V310, P301, DOI 10.1124/jpet.104.065078; Kam AYF, 2004, J NEUROCHEM, V89, P391, DOI 10.1111/j.1471-4159.2004.02338.x; Kam AYF, 2003, J NEUROCHEM, V84, P503, DOI 10.1046/j.1471-4159.2003.01535.x; Kenakin T, 2007, MOL PHARMACOL, V72, P1393, DOI 10.1124/mol.107.040352; Kobayashi H, 2005, CELL SIGNAL, V17, P1248, DOI 10.1016/j.cellsig.2004.12.014; Kook S, 2013, J BIOL CHEM, V288, P37332, DOI 10.1074/jbc.M113.510412; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Le Bars D, 2001, PHARMACOL REV, V53, P597; Levitt ES, 2012, MOL PHARMACOL, V82, P983, DOI 10.1124/mol.112.081547; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2010, PHARMACOL REV, V62, P305, DOI 10.1124/pr.109.002436; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Melief EJ, 2011, MOL PHARMACOL, V80, P920, DOI 10.1124/mol.111.074195; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Mittal N, 2012, NEUROPSYCHOPHARMACOL, V37, P1953, DOI 10.1038/npp.2012.42; Rey A, 2006, J BIOL CHEM, V281, P38181, DOI 10.1074/jbc.M606762200; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Shenoy SK, 2011, TRENDS PHARMACOL SCI, V32, P521, DOI 10.1016/j.tips.2011.05.002; Terman GW, 2004, BRIT J PHARMACOL, V141, P55, DOI 10.1038/sj.bjp.0705595; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tortorici V, 2001, PAIN, V89, P237, DOI 10.1016/S0304-3959(00)00367-5; TSOU K, 1964, SCI SINICA, V13, P1099; Walwyn W, 2007, J NEUROSCI, V27, P5092, DOI 10.1523/JNEUROSCI.1157-07.2007; YAKSH TL, 1976, BRAIN RES, V114, P83, DOI 10.1016/0006-8993(76)91009-X; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhan XZ, 2014, CELL SIGNAL, V26, P766, DOI 10.1016/j.cellsig.2014.01.001; Zhan XZ, 2013, J BIOL CHEM, V288, P28535, DOI 10.1074/jbc.M113.508085; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 2009, J BIOL CHEM, V284, P1990, DOI 10.1074/jbc.M807971200	46	26	26	1	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0898-6568	1873-3913		CELL SIGNAL	Cell. Signal.	SEP	2015	27	9					1799	1806		10.1016/j.cellsig.2015.05.019			8	Cell Biology	Cell Biology	CN4HC	WOS:000358390200014	26056051	Green Accepted			2020-06-30	J	Nummenmaa, L; Manninen, S; Tuominen, L; Hirvonen, J; Kalliokoski, KK; Nuutila, P; Jaaskelainen, IP; Hari, R; Dunbar, RIM; Sams, M				Nummenmaa, Lauri; Manninen, Sandra; Tuominen, Lauri; Hirvonen, Jussi; Kalliokoski, Kari K.; Nuutila, Pirjo; Jaaskelainen, Iiro P.; Hari, Riitta; Dunbar, Robin I. M.; Sams, Mikko			Adult attachment style is associated with cerebral mu-opioid receptor availability in humans	HUMAN BRAIN MAPPING			English	Article						attachment; emotion; opioids; neurotransmitters; social interaction; positron emission tomography	SOCIAL NETWORK SIZE; GENE OPRM1; A118G POLYMORPHISM; PAIN; DIMENSIONS; BEHAVIOR; ACTIVATION; MECHANISMS; REJECTION; RESPONSES	Human attachment behavior mediates establishment and maintenance of social relationships. Adult attachment characteristically varies on anxiety and avoidance dimensions, reflecting the tendencies to worry about the partner breaking the social bond (anxiety) and feeling uncomfortable about depending on others (avoidance). In primates and other mammals, the endogenous -opioid system is linked to long-term social bonding, but evidence of its role in human adult attachment remains more limited. We used in vivo positron emission tomography to reveal how variability in -opioid receptor (MOR) availability is associated with adult attachment in humans. We scanned 49 healthy subjects using a MOR-specific ligand [C-11]carfentanil and measured their attachment avoidance and anxiety with the Experiences in Close Relationships-Revised scale. The avoidance dimension of attachment correlated negatively with MOR availability in the thalamus and anterior cingulate cortex, as well as the frontal cortex, amygdala, and insula. No associations were observed between MOR availability and the anxiety dimension of attachment. Our results suggest that the endogenous opioid system may underlie interindividual differences in avoidant attachment style in human adults, and that differences in MOR availability are associated with the individuals' social relationships and psychosocial well-being. Hum Brain Mapp 36:3621-3628, 2015. (c) 2015 Wiley Periodicals, Inc.	[Nummenmaa, Lauri; Manninen, Sandra; Tuominen, Lauri; Hirvonen, Jussi; Kalliokoski, Kari K.; Nuutila, Pirjo] Univ Turku, Turku PET Ctr, FIN-20520 Turku, Finland; [Nummenmaa, Lauri; Tuominen, Lauri; Jaaskelainen, Iiro P.; Hari, Riitta; Dunbar, Robin I. M.; Sams, Mikko] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, AALTO, FI-00076 Espoo, Finland; [Nummenmaa, Lauri] Univ Turku, Dept Psychol, Turku 20014, Finland; [Nuutila, Pirjo] Turku Univ Hosp, Dept Endocrinol, Turku 20521, Finland; [Dunbar, Robin I. M.] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	Nummenmaa, L (reprint author), Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, AALTO, FI-00076 Espoo, Finland.	lauri.nummenmaa@aalto.fi	Nummenmaa, Lauri/G-6910-2012; Jaaskelainen, Iiro P/C-7392-2012; Hirvonen, Jussi/AAC-1864-2020; Hari, Riitta K/J-1880-2012; Sams, Mikko E/G-7060-2012	Nummenmaa, Lauri/0000-0002-2497-9757; Jaaskelainen, Iiro P/0000-0001-6001-6950; Hari, Riitta K/0000-0002-3142-2703; Kalliokoski, Kari/0000-0002-8893-7126	aivoAALTO Project of the Aalto University; Academy of FinlandAcademy of Finland [265917, 138145, 131483]; European Research Council (ERC)European Research Council (ERC) [313000, 232946, 295663]	Contract grant sponsor: aivoAALTO Project of the Aalto University; Contract grant sponsor: Academy of Finland; Contract grant numbers: 265917 (to L.N.), 138145 (to I.P.J.), and 131483 (to R.H.); Contract grant sponsor: European Research Council (ERC); Contract grant numbers: 313000 (to L.N.), 232946 (to R.H.), and 295663 (to R.D.)	Alenius S, 1997, EUR J NUCL MED, V24, P258, DOI 10.1007/s002590050050; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Barr CS, 2008, P NATL ACAD SCI USA, V105, P5277, DOI 10.1073/pnas.0710225105; BARTHOLOMEW K, 1990, J SOC PERS RELAT, V7, P147, DOI 10.1177/0265407590072001; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bowlby J, 1982, ATTACHMENT LOSS; Brennan K. A., 1998, ATTACHMENT THEORY CL, P46, DOI DOI 10.1037/T03763-000; BRENNAN KA, 1995, PERS SOC PSYCHOL B, V21, P267, DOI 10.1177/0146167295213008; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; Burkett JP, 2011, NEUROPSYCHOPHARMACOL, V36, P2200, DOI 10.1038/npp.2011.117; Cerda M, 2014, DRUG ALCOHOL DEPEN, V142, P231, DOI 10.1016/j.drugalcdep.2014.06.026; Colasanti A, 2011, J PSYCHOPHARMACOL, V25, P1415, DOI 10.1177/0269881110367726; DeWall CN, 2012, SOC COGN AFFECT NEUR, V7, P184, DOI 10.1093/scan/nsq107; Dunbar RIM, 2012, P ROY SOC B-BIOL SCI, V279, P1161, DOI 10.1098/rspb.2011.1373; Dunbar RIM, 2010, BEHAVIOUR, V147, P775, DOI 10.1163/000579510X501151; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Eisenberger NI, 2012, NAT REV NEUROSCI, V13, P421, DOI 10.1038/nrn3231; FABRENYS C, 1982, PHARMACOL BIOCHEM BE, V16, P653, DOI 10.1016/0091-3057(82)90432-4; Fiori KL, 2011, RES AGING, V33, P465, DOI 10.1177/0164027511401038; Fraley RC, 2002, PERS SOC PSYCHOL REV, V6, P123, DOI 10.1207/S15327957PSPR0602_03; Fraley RC, 2000, J PERS SOC PSYCHOL, V78, P350, DOI 10.1037/0022-3514.78.2.350; Graves FC, 2002, BEHAV NEUROSCI, V116, P489, DOI 10.1037//0735-7044.116.3.489; GRIFFIN D, 1994, J PERS SOC PSYCHOL, V67, P430, DOI 10.1037/0022-3514.67.3.430; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037/0022-3514.52.3.511; Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316; Hsu DT, 2013, MOL PSYCHIATR, V18, P1211, DOI [10.1038/mp.2013.96, 10.1038/mp.2013.139]; Johnson ZV, 2015, CURR OPIN BEHAV SCI, V3, P38, DOI 10.1016/j.cobeha.2015.01.009; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Kassel JD, 2007, ADDICT BEHAV, V32, P1164, DOI 10.1016/j.addbeh.2006.08.005; KEVERNE EB, 1989, PSYCHONEUROENDOCRINO, V14, P155, DOI 10.1016/0306-4530(89)90065-6; Koch T, 2008, PHARMACOL THERAPEUT, V117, P199, DOI 10.1016/j.pharmthera.2007.10.003; Lewis PA, 2011, NEUROIMAGE, V57, P1624, DOI 10.1016/j.neuroimage.2011.05.030; Lutz PE, 2013, TRENDS NEUROSCI, V36, P195, DOI 10.1016/j.tins.2012.11.002; Machin AJ, 2011, BEHAVIOUR, V148, P985, DOI 10.1163/000579511X596624; Mague SD, 2009, P NATL ACAD SCI USA, V106, P10847, DOI 10.1073/pnas.0901800106; Mikulincer M., 2007, ATTACHMENT ADULTHOOD; Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943; Nelson EE, 1998, NEUROSCI BIOBEHAV R, V22, P437, DOI 10.1016/S0149-7634(97)00052-3; Norman L, 2015, SOC COGN AFFECT NEUR, V10, P832, DOI 10.1093/scan/nsu127; Panksepp J, 2003, SCIENCE, V302, P237, DOI 10.1126/science.1091062; PANKSEPP J, 1978, BIOL PSYCHIAT, V13, P607; PANKSEPP J, 1980, NEUROSCI BIOBEHAV R, V4, P473, DOI 10.1016/0149-7634(80)90036-6; Pecina M, 2015, NEUROPSYCHOPHARMACOL, V40, P957, DOI 10.1038/npp.2014.272; Powell J, 2012, P ROY SOC B-BIOL SCI, V279, P2157, DOI 10.1098/rspb.2011.2574; Resendez SL, 2013, J NEUROSCI, V33, P9140, DOI 10.1523/JNEUROSCI.4123-12.2013; Ross J, 2005, DRUG ALCOHOL REV, V24, P411, DOI 10.1080/09595230500286039; Schindler A, 2005, ATTACH HUM DEV, V7, P207, DOI 10.1080/14616730500173918; Schindler A, 2009, ATTACH HUM DEV, V11, P307, DOI 10.1080/14616730902815009; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shultz S, 2010, P NATL ACAD SCI USA, V107, P21582, DOI 10.1073/pnas.1005246107; Spielberger C., 1983, MANUAL STATE TRAIT A; Troisi A, 2011, SOC NEUROSCI-UK, V6, P88, DOI 10.1080/17470919.2010.482786; Troisi A, 2010, PERS INDIV DIFFER, V48, P640, DOI 10.1016/j.paid.2010.01.002; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Van Ree JM, 2000, EUR J PHARMACOL, V405, P89, DOI 10.1016/S0014-2999(00)00544-6; Vrticka P, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00212; Vrticka P, 2012, J SOC PERS RELAT, V29, P530, DOI 10.1177/0265407512443451; Vrticka P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002868; Way BM, 2009, P NATL ACAD SCI USA, V106, P15079, DOI 10.1073/pnas.0812612106; Weerts EM, 2013, INT J NEUROPSYCHOPH, V16, P47, DOI 10.1017/S146114571200017X; Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	65	42	42	2	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	SEP	2015	36	9					3621	3628		10.1002/hbm.22866			8	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CP9IY	WOS:000360209000022	26046928	Green Published			2020-06-30	J	Smith, SR; Draganic, B; Pockney, P; Holz, P; Holmes, R; Mcmanus, B; Carroll, R				Smith, Stephen Ridley; Draganic, Brian; Pockney, Peter; Holz, Phillip; Holmes, Ryan; Mcmanus, Brendan; Carroll, Rosemary			Transversus abdominis plane blockade in laparoscopic colorectal surgery: a double-blind randomized clinical trial	INTERNATIONAL JOURNAL OF COLORECTAL DISEASE			English	Article						TAP blocks; Transversus abdominis plane blocks; Pain; Laparoscopic colorectal; Surgery; Postoperative analgesia	POSTOPERATIVE ANALGESIA; STRESS-RESPONSE; EFFICACY; MOBILITY; INFUSION; CARE	A prospective double-blind randomized clinical trial, involving 226 consecutive patients having laparoscopic colorectal surgery, was performed by a university colorectal surgical department. Patients were randomized to either TAP blockade using ultrasound guidance, or control, with the primary outcome being postoperative pain, as measured by analgesic consumption. Secondary outcomes assessed were pain visual analogue score (VAS), respiratory function, time to return of gut function, length of hospital stay, postoperative complications, and patient satisfaction. A total of 142 patients were followed up to trial completion (74 controls, 68 interventions). Patients were well matched with regard to demographics. No complications occurred as a result of the intervention of TAP blockade. There was no difference between groups with regards to analgesic consumption (161 mEq morphine control vs 175 mEq morphine TAP; p = 0.596). There was no difference between the two groups with regards to the secondary outcomes of daily VAS, respiratory outcome, time to return of gut function, length of hospital stay, postoperative complications, and patient satisfaction. We conclude that TAP blockade appears to be a safe intervention but confers no specific advantage following laparoscopic colorectal surgery.	[Smith, Stephen Ridley; Draganic, Brian; Pockney, Peter; Holz, Phillip] Univ Newcastle, John Hunter Hosp, Div Surg, Hunter Reg Mail Ctr, Newcastle, NSW 2310, Australia; [Smith, Stephen Ridley; Draganic, Brian; Pockney, Peter; Holmes, Ryan] Univ Newcastle, Newcastle, NSW 2310, Australia; [Mcmanus, Brendan; Carroll, Rosemary] John Hunter Hosp, Newcastle, NSW 2310, Australia	Smith, SR (reprint author), Univ Newcastle, John Hunter Hosp, Div Surg, Hunter Reg Mail Ctr, Locked Bag 1, Newcastle, NSW 2310, Australia.	steve_srs@hotmail.com	Carroll, Rosemary/W-5427-2018; Smith, Stephen/W-5590-2018	Carroll, Rosemary/0000-0002-2162-2744; Smith, Stephen/0000-0002-1104-133X; Pockney, Peter/0000-0002-7648-4916; McManus, Brendan/0000-0002-8021-9525			Abdallah FW, 2012, REGION ANESTH PAIN M, V37, P193, DOI 10.1097/AAP.0b013e3182429531; Bonnet F, 2005, BRIT J ANAESTH, V95, P52, DOI 10.1093/bja/aei038; Carney J, 2008, ANESTH ANALG, V107, P2056, DOI 10.1213/ane.0b013e3181871313; Charlton S, 2010, PERIOPERATIVE TRANSV; Clarke A, 2001, EUR J PUBLIC HEALTH, V11, P166, DOI 10.1093/eurpub/11.2.166; de Morton NA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-63; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; El-Dawlatly AA, 2009, BRIT J ANAESTH, V102, P763, DOI 10.1093/bja/aep067; Griffiths JD, 2010, ANESTH ANALG, V111, P797, DOI 10.1213/ANE.0b013e3181e53517; Johns N, 2012, COLORECTAL DIS, V14, pE635, DOI 10.1111/j.1463-1318.2012.03104.x; Lee THW, 2010, ANAESTH INTENS CARE, V38, P452, DOI 10.1177/0310057X1003800307; Levy BF, 2010, COLORECTAL DIS, V12, P5, DOI 10.1111/j.1463-1318.2009.01799.x; McDermott G, 2012, BRIT J ANAESTH, V108, P499, DOI 10.1093/bja/aer422; McDonnell JG, 2007, ANESTH ANALG, V104, P193, DOI 10.1213/01.ane.0000250223.49963.0f; Moore SE, 2012, TECH COLOPROCTOL, V16, P431, DOI 10.1007/s10151-012-0845-2; Moraca RJ, 2003, ANN SURG, V238, P663, DOI 10.1097/01.sla.0000094300.36689.ad; Mukhtar K, 2009, BRIT J ANAESTH, V102, P143, DOI 10.1093/bja/aen338; Niraj G, 2009, BRIT J ANAESTH, V103, P601, DOI 10.1093/bja/aep175; Petersen P, 2013, ACTA ANAESTH SCAND, V57, P24; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Rafi AN, 2001, ANAESTHESIA, V56, P1024, DOI 10.1046/j.1365-2044.2001.02279-40.x; Schwenk W, 2008, SHORT TERM BENEFITS; Tran TMN, 2009, BRIT J ANAESTH, V102, P123, DOI 10.1093/bja/aen344; Veenhof AAFA, 2012, ANN SURG, V255, P216, DOI 10.1097/SLA.0b013e31824336e2	24	22	22	1	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-1958	1432-1262		INT J COLORECTAL DIS	Int. J. Colorectal Dis.	SEP	2015	30	9					1237	1245		10.1007/s00384-015-2286-7			9	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CQ3YY	WOS:000360542000013	26099316				2020-06-30	J	Kurita, GP; Lundstrom, S; Sjogren, P; Ekholm, O; Christrup, L; Davies, A; Kaasa, S; Klepstad, P; Dale, O				Kurita, G. P.; Lundstrom, S.; Sjogren, P.; Ekholm, O.; Christrup, L.; Davies, A.; Kaasa, S.; Klepstad, P.; Dale, O.			Renal function and symptoms/adverse effects in opioid-treated patients with cancer	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							QUALITY-OF-LIFE; COCKCROFT-GAULT; SERUM CONCENTRATIONS; MORPHINE-METABOLISM; PALLIATIVE CARE; PREDICTING GFR; PAIN; DIET; MORPHINE-6-GLUCURONIDE; MORPHINE-3-GLUCURONIDE	BackgroundRenal impairment and the risk of toxicity caused by accumulation of opioids and/or active metabolites is an under-investigated issue. This study aimed at analysing if symptoms/adverse effects in opioid-treated patients with cancer were associated with renal function. MethodsCross-sectional multicentre study (European Pharmacogenetic Opioid Study, 2005-2008), in which 1147 adult patients treated exclusively with only one of the most frequently reported opioids (morphine/oxycodone/fentanyl) for at least 3days were analysed. Fatigue, nausea/vomiting, pain, loss of appetite, constipation and cognitive dysfunction were assessed (EORTC QLQ-C30). Glomerular filtration rate (GFR) was estimated using Cockcroft-Gault (CG), Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI Creatinine) equations. ResultsMild to severe low GFR was observed among 40-54% of patients. CG equation showed that patients with mild and moderate/severe low GFR on morphine treatment had higher odds of having severe constipation (P<0.01) than patients with normal GFR. In addition, patients with moderate/severe low GFR on morphine treatment were more likely to have loss of appetite (P=0.04). No other significant associations were found. ConclusionOnly severe constipation and loss of appetite were associated with low GFR in patients treated with morphine. Oxycodone and fentanyl, in relation to the symptoms studied, seem to be safe as used and titrated in routine cancer pain care.	[Kurita, G. P.; Sjogren, P.] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Copenhagen, Denmark; [Kurita, G. P.] Copenhagen Univ Hosp, Rigshosp, Dept Neuroanaesthesiol, Ctr Multidisciplinary Pain, Copenhagen, Denmark; [Lundstrom, S.] Karolinska Inst, Stockholms Sjukhem Fdn, Stockholm, Sweden; [Lundstrom, S.] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Sjogren, P.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark; [Ekholm, O.] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark; [Christrup, L.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, Copenhagen, Denmark; [Davies, A.] Royal Surrey Cty Hosp, Guildford, Surrey, England; [Kaasa, S.] Univ Trondheim Hosp, Dept Oncol, St Olav Hosp, N-7006 Trondheim, Norway; [Kaasa, S.] Norwegian Univ Sci & Technol, DMF, European Palliat Care Res Ctr, N-7034 Trondheim, Norway; [Klepstad, P.] St Olavs Univ Hosp, Dept Intens Care Med, Trondheim, Norway; [Klepstad, P.; Dale, O.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway	Kurita, GP (reprint author), Rigshosp, Sect Palliat Med, Dept 4111, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	geana.kurita@regionh.dk		Christrup, Lona/0000-0002-4128-7373	European Palliative Care Research Collaborative 6th EU Framework ProgrammeEuropean Union (EU); Norwegian Research CouncilResearch Council of Norway	This study was supported by European Palliative Care Research Collaborative 6th EU Framework Programme and Norwegian Research Council.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Andersen G, 2004, EUR J PAIN, V8, P263, DOI 10.1016/j.ejpain.2003.09.003; Andreassen TN, 2012, J PAIN SYMPTOM MANAG, V43, P694, DOI 10.1016/j.jpainsymman.2011.05.008; Andreassen TN, 2011, EUR J CLIN PHARMACOL, V67, P493, DOI 10.1007/s00228-010-0948-5; Botev R, 2009, CLIN J AM SOC NEPHRO, V4, P899, DOI 10.2215/CJN.05371008; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; DADGAR D, 1995, J PHARMACEUT BIOMED, V13, P89, DOI 10.1016/0731-7085(94)00106-C; Daeninck PJ, 1999, ACTA ANAESTH SCAND, V43, P924, DOI 10.1034/j.1399-6576.1999.430910.x; Dale O, 2009, J PAIN SYMPTOM MANAG, V37, P68, DOI 10.1016/j.jpainsymman.2007.12.016; de Lusignan S, 2005, FAM PRACT, V22, P234, DOI 10.1093/fampra/cmi026; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Drenth-van Maanen AC, 2013, BRIT J CLIN PHARMACO, V76, P616, DOI 10.1111/bcp.12199; Droney Joanne, 2007, J Opioid Manag, V3, P309; Edwards SR, 2007, J CHROMATOGR B, V848, P264, DOI 10.1016/j.jchromb.2006.10.039; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Fitzgerald J, 1991, Conn Med, V55, P701; Fladvad T, 2013, PHARMACOGENET GENOM, V23, P117, DOI 10.1097/FPC.0b013e32835ce485; Ibrahim H, 2005, J AM SOC NEPHROL, V16, P1051, DOI 10.1681/ASN.2004080692; Johnsen AT, 2009, EUR J HAEMATOL, V83, P139, DOI 10.1111/j.1600-0609.2009.01250.x; Kaiko R., 1996, Clinical Pharmacology and Therapeutics, V59, P130, DOI 10.1038/sj.clpt.1996.19; King S, 2011, PALLIATIVE MED, V25, P525, DOI 10.1177/0269216311406313; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Klepstad P, 2003, PALLIATIVE MED, V17, P679, DOI 10.1191/0269216303pm835oa; Launay-Vacher V, 2007, CANCER-AM CANCER SOC, V110, P1376, DOI 10.1002/cncr.22904; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; National Kidney Foundation, 2014, FREQ ASK QUEST GFR E; Niscola P, 2010, CURR DRUG TARGETS, V11, P752, DOI 10.2174/138945010791170879; Pierrat A, 2003, KIDNEY INT, V64, P1425, DOI 10.1046/j.1523-1755.2003.00208.x; SHAH VP, 1991, EUR J DRUG METAB PH, V16, P249; Sjogren P, 1998, ACTA ANAESTH SCAND, V42, P1070, DOI 10.1111/j.1399-6576.1998.tb05378.x; SOMOGYI AA, 1993, CLIN PHARMACOKINET, V24, P413, DOI 10.2165/00003088-199324050-00005; Stromgren AS, 2002, CANCER, V94, P512, DOI 10.1002/cncr.10222; Van Pottelbergh G, 2010, AGE AGEING, V39, P542, DOI 10.1093/ageing/afq091	33	12	12	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2015	59	8					1049	1059		10.1111/aas.12521			11	Anesthesiology	Anesthesiology	CO8LP	WOS:000359421100012	25943005				2020-06-30	J	Heikkinen, EM; Voipio, HM; Laaksonen, S; Haapala, L; Rasanen, J; Acharya, G; Erkinaro, T; Haapsamo, M; Hautajarvi, H; Kokki, H; Kokki, M; Heikkinen, AT				Heikkinen, Emma M.; Voipio, Hanna-Marja; Laaksonen, Sakari; Haapala, Linnea; Rasanen, Juha; Acharya, Ganesh; Erkinaro, Tiina; Haapsamo, Mervi; Hautajarvi, Heidi; Kokki, Hannu; Kokki, Merja; Heikkinen, Aki T.			Fentanyl Pharmacokinetics in Pregnant Sheep after Intravenous and Transdermal Administration to the Ewe	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article							DOGS; DISPOSITION; PLASMA; HORSES	Fentanyl is used for pain treatment during pregnancy in human beings and animals. However, fentanyl pharmacokinetics during pregnancy has not been fully established. The aim of this study was to characterize fentanyl pharmacokinetics in pregnant sheep after intravenous and transdermal dosing during surgical procedure performed to ewe and foetus. Pharmacokinetic parameters reported for non-pregnant sheep and nominal transdermal dose rate were utilized for a priori calculation to achieve analgesic fentanyl concentration (0.5-2ng/ml) in maternal plasma. A total of 20 Aland landrace ewes at 118-127 gestational days were used. In the first protocol, 1week before surgery, 10 animals received 2g/kg fentanyl intravenous bolus, and on the operation day, transdermal fentanyl patches at nominal dose rate of 2g/kg/hr were applied to antebrachium, and ewes were then given a 2g/kg intravenous bolus followed by an intra-operative 2.5g/kg/hr infusion. In the second protocol, 10 animals received fentanyl only as transdermal patches on the operation day and oxycodone for rescue analgesia. The data were analysed with population pharmacokinetic modelling. Intra- and post-operative fentanyl concentrations were similar and slightly lower than the a priori predictions, and elimination and distribution clearances appeared slower during than before or after the surgery. Transdermal patches provided sustained fentanyl absorption for up to 5days, but the absorption rate was slower than the nominal dose rate and showed a high interindividual variability. Further research is warranted to evaluate the clinical relevance of the observations made in sheep.	[Heikkinen, Emma M.; Heikkinen, Aki T.] Univ Eastern Finland, Sch Pharm, Kuopio, Finland; [Voipio, Hanna-Marja; Laaksonen, Sakari; Haapala, Linnea] Univ Oulu, Dept Expt Surg, Lab Anim Ctr, Kuopio, Finland; [Voipio, Hanna-Marja; Laaksonen, Sakari; Haapala, Linnea] Univ Hosp Oulu, Oulu, Finland; [Rasanen, Juha; Kokki, Merja] Univ Eastern Finland, Sch Med, Kuopio, Finland; [Rasanen, Juha; Kokki, Merja] Kuopio Univ Hosp, Dept Obstet & Gynecol, SF-70210 Kuopio, Finland; [Rasanen, Juha; Haapsamo, Mervi] Univ Hosp Oulu, Dept Obstet & Gynecol, Oulu, Finland; [Acharya, Ganesh] UiT Arctic Univ Norway, Dept Clin Med, Womens Hlth & Perinatol Res Grp, Tromso, Norway; [Erkinaro, Tiina] Univ Hosp, Dept Anesthesiol, Oulu, Finland; [Hautajarvi, Heidi] Admescope Ltd, FI-90620 Oulu, Finland; [Kokki, Hannu; Kokki, Merja] Kuopio Univ Hosp, Anesthesia & Operat Serv, SF-70210 Kuopio, Finland	Heikkinen, AT (reprint author), Admescope Ltd, Typpitie 1, FI-90620 Oulu, Finland.	aki.heikkinen@admescope.com		Heikkinen, Emma/0000-0001-5923-7289	governmental VTR-fund, Kuopio University Hospital, Kuopio, Finland; Orion Farmos Research Foundation	The authors gratefully acknowledge Dr. Pyry Valitalo for useful discussions on population pharmacokinetic analysis. The study was financially supported by the governmental VTR-fund, Kuopio University Hospital, Kuopio, Finland (Hannu Kokki, Merja Kokki), and by Orion Farmos Research Foundation (Aki Heikkinen). This study is a part of the KuBi-Co (Kuopio Birth Control) consortium (www.KuBiCo.fi) for Hannu Kokki and Merja Kokki.	Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; Anderson D, 2011, J MIDWIFERY WOM HEAL, V56, P222, DOI 10.1111/j.1542-2011.2011.00061.x; CRAFT JB, 1983, ANESTH ANALG, V62, P894; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Erkinaro T, 2006, BRIT J ANAESTH, V96, P231, DOI 10.1093/bja/aei305; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; Grubb TL, 2005, AM J VET RES, V66, P907, DOI 10.2460/ajvr.2005.66.907; Keizer RJ, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.24; Kyles AE, 1996, AM J VET RES, V57, P715; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; Margetts L, 2007, BJA EDUC, V7, P171, DOI 10.1093/bjaceaccp/mkm033; MATHER LE, 1986, BRIT J ANAESTH, V58, P888, DOI 10.1093/bja/58.8.888; Orsini JA, 2006, J VET PHARMACOL THER, V29, P539, DOI 10.1111/j.1365-2885.2006.00796.x; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Thomasy SM, 2008, J ANAL TOXICOL, V32, P754, DOI 10.1093/jat/32.9.754; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12	18	8	8	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7835	1742-7843		BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	SEP	2015	117	3					156	163		10.1111/bcpt.12382			8	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	CO6IC	WOS:000359259400003	25626156				2020-06-30	J	Yu, M; Han, CB; Jiang, X; Wu, XH; Yu, L; Ding, ZN				Yu, Min; Han, Chuanbao; Jiang, Xiuhong; Wu, Xia; Yu, Li; Ding, Zhengnian			Effect and Placental Transfer of Dexmedetomidine During Caesarean SectionUnder General Anaesthesia	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article							CLONIDINE; REMIFENTANIL; EFFICACY; DELIVERY; CHILDREN	Many drugs can pass through the placenta and cause adverse effects on the foetus. Thus, during Caesarean section for puerperas who have contraindications for intravertebral anaesthesia, the use of proper drugs that have sedative, analgesic effects on the puerperas without adverse effects on the foetus is important. In this study, we investigated the effect and placental transfer of dexmedetomidine during Caesarean section under general anaesthesia. Thirty-eight puerperas were randomly divided to receive dexmedetomidine or saline before anaesthesia induction and during the operation. The dexmedetomidine-treated parturients had lower mean arterial pressure and heart rate at the delivery and at the end of the operation. The dexmedetomidine-treated parturients also needed 5.5% less propofol and 8.4% less fentanyl than the saline-treated ones. Between the dexmedetomidine-treated and saline-treated parturients, there was no difference in the maternal artery, umbilical vein, umbilical artery blood gas analysis results and the Apgar scores at 1 and 5min. after delivery. The placental transfer rate of dexmedetomidine was 0.76. We concluded that dexmedetomidine was effective in maintaining the haemodynamic stability in the parturients during Caesarean section under general anaesthesia without adverse neonatal effects. Dexmedetomidine can pass through the placenta with a placental transfer rate of 0.76.	[Yu, Min; Han, Chuanbao; Jiang, Xiuhong; Wu, Xia; Yu, Li; Ding, Zhengnian] Nanjing Med Univ, Affiliated Hosp 1, Dept Anaesthesiol, Nanjing 210029, Jiangsu, Peoples R China	Han, CB (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Anaesthesiol, Nanjing 210029, Jiangsu, Peoples R China.	mzkhcb@hotmail.com		Ding, zhengnian/0000-0003-4108-6034	Priority Academic Program Development of Jiangsu Higher Education Institutions	This project was supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions.	AlaKokko TI, 1997, ACTA ANAESTH SCAND, V41, P313, DOI 10.1111/j.1399-6576.1997.tb04685.x; Bilotta F, 2009, CURR OPIN ANESTHESIO, V22, P560, DOI 10.1097/ACO.0b013e3283302339; Calzada BC, 2001, PHARMACOL RES, V44, P195, DOI 10.1006/phrs.2001.0857; Chrysostomou C, 2014, J PEDIATR-US, V164, P276, DOI 10.1016/j.jpeds.2013.10.002; DAILLAND P, 1989, ANESTHESIOLOGY, V71, P827, DOI 10.1097/00000542-198912000-00003; El-Tahan MR, 2012, INT J OBSTET ANESTH, V21, P222, DOI 10.1016/j.ijoa.2012.04.006; Heesen M, 2013, ACTA ANAESTH SCAND, V57, P29, DOI 10.1111/j.1399-6576.2012.02723.x; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; Koroglu A, 2005, BRIT J ANAESTH, V94, P821, DOI 10.1093/bja/aei119; Lesage S, 2014, CAN J ANESTH, V61, P489, DOI 10.1007/s12630-014-0125-x; Neumann MM, 2009, INT J OBSTET ANESTH, V18, P403, DOI 10.1016/j.ijoa.2009.05.002; Palanisamy A, 2009, INT J OBSTET ANESTH, V18, P258, DOI 10.1016/j.ijoa.2008.10.002; Patel CR, 2012, INDIAN J ANAESTH, V56, P542, DOI 10.4103/0019-5049.104571; Potts AL, 2010, PEDIATR ANESTH, V20, P425, DOI 10.1111/j.1460-9592.2010.03285.x; Sia AT, 2005, INT J OBSTET ANESTH, V14, P104, DOI 10.1016/j.ijoa.2004.11.004; Taittonen MT, 1997, BRIT J ANAESTH, V78, P400; Tariq M, 2008, BASIC CLIN PHARMACOL, V103, P180, DOI 10.1111/j.1742-7843.2008.00282.x; Ueyama Hiroshi, 2010, Masui, V59, P357	19	18	22	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7835	1742-7843		BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	SEP	2015	117	3					204	208		10.1111/bcpt.12389			5	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	CO6IC	WOS:000359259400009	25652672				2020-06-30	J	Vizseralek, G; Berko, S; Toth, G; Balogh, R; Budai-Szucs, M; Csanyi, E; Sinko, B; Takacs-Novak, K				Vizseralek, Gabor; Berko, Szilvia; Toth, Gergo; Balogh, Reka; Budai-Szucs, Maria; Csanyi, Erzsebet; Sinko, Balint; Takacs-Novak, Krisztina			Permeability test for transdermal and local therapeutic patches using Skin PAMPA method	EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						Permeability; Skin PAMPA; Transdermal drug delivery; Transdermal patch; Artificial membrane permeability assay	PERCUTANEOUS-ABSORPTION; PERMEATION	Using the skin as absorption site presents unique advantages that have facilitated the progression of transdermal drug delivery in the past decades. Efforts in drug research have been devoted to find a quick and reproducible model for predicting the skin permeation of molecules. The Parallel Artificial Membrane Permeability Assay (PAMPA) has been extended for prediction of transdermal permeation by developing a model with completely artificial membrane, which can mimic the permeation through the stratum corneum. The present study aims to extend the Skin PAMPA method for testing transdermal and local therapeutic patches. The original method was modified and seven commercially available transdermal and local therapeutic patches with four different active pharmaceutical ingredients (nicotine, fentanyl, rivastigmine and ketoprofen) were studied. Data were compared to the declared delivery rates that are indicated by the manufacturers. Ex vivo permeation study was also performed in order to compare the permeated amount of the released drugs obtained by the two methods. The flux across the artificial membrane as well as the human skin (ex vivo) has been calculated and compared to the in vivo flux deduced from the labelled delivery rate and the active area of the patches. The results suggest that Skin PAMPA system can serve as a useful tool for evaluation and classification of the transdermal patches. (C) 2015 Elsevier B.V. All rights reserved.	[Vizseralek, Gabor; Toth, Gergo; Balogh, Reka; Sinko, Balint; Takacs-Novak, Krisztina] Semmelweis Univ, Dept Pharmaceut Chem, H-1092 Budapest, Hungary; [Berko, Szilvia; Budai-Szucs, Maria; Csanyi, Erzsebet] Univ Szeged, Dept Pharmaceut Technol, H-6720 Szeged, Hungary; [Sinko, Balint] SinkoLAB Sci, H-9400 Sopron, Hungary	Takacs-Novak, K (reprint author), Semmelweis Univ, Dept Pharmaceut Chem, 9 Hogyes Endre St, H-1092 Budapest, Hungary.	novak.krisztina@pharma.semmelweis-univ.hu	Toth, Gergo/S-1085-2017	Toth, Gergo/0000-0001-5341-319X			[Anonymous], 2005, VAL AN PROC TEXT MET; FRANZ TJ, 1975, J INVEST DERMATOL, V64, P190, DOI 10.1111/1523-1747.ep12533356; Frum Y, 2007, EUR J PHARM BIOPHARM, V67, P434, DOI 10.1016/j.ejpb.2007.03.012; Guy R. H., 2009, TRANSDERMAL DRUG DEL; Hadgraft J, 2005, INT J PHARMACEUT, V305, P2, DOI 10.1016/j.ijpharm.2005.07.014; Hadgraft J, 2004, EUR J PHARM BIOPHARM, V58, P291, DOI 10.1016/j.ejpb.2004.03.002; HADGRAFT J, 1991, INT J PHARM, V73, P125, DOI 10.1016/0378-5173(91)90035-M; Howes D, 1996, ATLA-ALTERN LAB ANIM, V24, P81; Kansy M, 1998, J MED CHEM, V41, P1007, DOI 10.1021/jm970530e; Khan GM, 2005, INT J PHARMACEUT, V303, P81, DOI 10.1016/j.ijpharm.2005.07.005; Kligman A., 1963, ARCH DERMATOL RES, P702; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Lee PH, 2010, BIOORG MED CHEM LETT, V20, P69, DOI 10.1016/j.bmcl.2009.11.039; Olivier JC, 2003, INT J PHARM, V252, P133, DOI 10.1016/S0378-5173(02)00637-3; POTTS RO, 1992, PHARMACEUT RES, V9, P663, DOI 10.1023/A:1015810312465; Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504; Salerno C, 2010, AAPS PHARMSCITECH, V11, P986, DOI 10.1208/s12249-010-9457-1; Sinko B, 2014, ADMET DMPK, V2, P191, DOI 10.5599/admet.2.4.150; Sinko B, 2012, EUR J PHARM SCI, V45, P698, DOI 10.1016/j.ejps.2012.01.011; Thomas BJ, 2004, DRUG DISCOV TODAY, V9, P697, DOI 10.1016/S1359-6446(04)03180-0; Vizseralek G, 2014, EUR J PHARM SCI, V53, P45, DOI 10.1016/j.ejps.2013.12.008; Wiedersberg S, 2014, J CONTROL RELEASE, V190, P150, DOI 10.1016/j.jconrel.2014.05.022; Zendzian RP, 2000, AIHAJ, V61, P473, DOI 10.1202/0002-8894(2000)061&lt;0473:DAOPIT&gt;2.0.CO;2	23	12	13	3	58	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0928-0987	1879-0720		EUR J PHARM SCI	Eur. J. Pharm. Sci.	AUG 30	2015	76						165	172		10.1016/j.ejps.2015.05.004			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL5DP	WOS:000356980300019	25957747				2020-06-30	J	Fechtner, L; El Ali, M; Sattar, A; Moore, M; Strohl, KP				Fechtner, Linnea; El Ali, Mazen; Sattar, Abdus; Moore, Michael; Strohl, Kingman P.			Fentanyl effects on breath generation in C57BL/6J and A/J mouse strains	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Ventilatory control; Hypoxia; Apnea; Genetic background	INDUCED RESPIRATORY DEPRESSION; NITRIC-OXIDE; VENTILATORY BEHAVIOR; MALE-MICE; RECTAL TEMPERATURE; CIRCADIAN PATTERN; PAIN MANAGEMENT; MORPHINE; OPIOIDS; EXPRESSION	We examined the effect of fentanyl on chemoresponsiveness in mouse strains divergent in the expression of spontaneous and post-hypoxic pauses. Frequency and tidal volume were recorded with plethysmography in A/J and C57BL/6J (B6) male mice. Mice selected at random received an intraperitoneal (IP) injection of either saline, low dose fentanyl (LDF = 0.04 mg/kg), or high dose fentanyl (HDF = 0.4 mg/kg) under hypoxia (8%O-2) or hyperoxia (100%O-2). LDF produced a decrease in frequency during hypoxia in B6, but not A/J, mice. HDF significantly decreased frequency and tidal volume in both strains under hypoxia and hyperoxia (p < 0.01); naloxone, an opioid antagonist, reversed this response. The acute administration of fentanyl at any dose did not promote apneas in strains of mice exhibiting regular or irregular respiratory patterns. However, higher doses depressed respiratory frequency in both strains. The B6 mice responded with a depressive response to hypoxia that did not recover with reoxygenation, but did recover with time or naloxone. Published by Elsevier B.V.	[Fechtner, Linnea; Sattar, Abdus] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [El Ali, Mazen; Moore, Michael; Strohl, Kingman P.] Louis Stokes Dept Veteran Affairs Med Ctr, Cleveland, OH USA; [El Ali, Mazen; Strohl, Kingman P.] Case Western Reserve Univ, Dept Med, Div Pulm Crit Care & Sleep Med, Cleveland, OH 44106 USA	Strohl, KP (reprint author), 111 J W VAMC 10801 E Blvd, Cleveland, OH 44106 USA.	kpstrohl@aol.com			VA Research Service Merit Award; Case Western Reserve University School of Medicine	This work is supported in part by the VA Research Service Merit Award and by Case Western Reserve University School of Medicine.	ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Bailey A, 2010, EUR J NEUROSCI, V31, P742, DOI 10.1111/j.1460-9568.2010.07104.x; Barletta JF, 2012, PHARMACOTHERAPY, V32, p12S, DOI 10.1002/j.1875-9114.2012.01178.x; Bodnar RJ, 2013, PEPTIDES, V50, P55, DOI 10.1016/j.peptides.2013.10.001; Boom M, 2012, CURR PHARM DESIGN, V18, P5994, DOI 10.2174/138161212803582469; Chai S, 2011, RESP PHYSIOL NEUROBI, V177, P265, DOI 10.1016/j.resp.2011.04.021; CROSFILL ML, 1961, J PHYSIOL-LONDON, V158, P1, DOI 10.1113/jphysiol.1961.sp006750; Fong AY, 2009, RESP PHYSIOL NEUROBI, V168, P179, DOI 10.1016/j.resp.2009.05.012; Golder FJ, 2013, RESP PHYSIOL NEUROBI, V189, P395, DOI 10.1016/j.resp.2013.06.010; Gonsenhauser I, 2004, J APPL PHYSIOL, V97, P888, DOI 10.1152/japplphysiol.01346.2003; Han F, 2002, J APPL PHYSIOL, V92, P1133, DOI 10.1152/japplphysiol.00785.2001; Han F, 2001, J APPL PHYSIOL, V91, P1962; Hey E.N., 1966, RESP PHYSL, V1, P1205; Jarzyna D, 2011, PAIN MANAG NURS, V12, P118, DOI 10.1016/j.pmn.2011.06.008; Jungquist CR, 2011, PAIN MANAG NURS, V12, P180, DOI 10.1016/j.pmn.2010.02.001; Karami M, 2014, INDIAN J PHARMACOL, V46, P57, DOI 10.4103/0253-7613.125169; Liu WX, 2012, MED RES REV, V32, P536, DOI 10.1002/med.20222; Ma P, 2014, NEUROREPORT, V25, P641, DOI 10.1097/WNR.0000000000000146; Makuch W, 2013, NEUROPHARMACOLOGY, V75, P445, DOI 10.1016/j.neuropharm.2013.08.031; MANSOUR A, 1994, BRAIN RES, V643, P245, DOI 10.1016/0006-8993(94)90031-0; Mellen NM, 2003, NEURON, V37, P821, DOI 10.1016/S0896-6273(03)00092-8; Mortola JP, 2004, COMP BIOCHEM PHYS A, V139, P83, DOI 10.1016/j.cbpb.2004.07.007; Mortola JP, 2004, EUR J APPL PHYSIOL, V91, P119, DOI 10.1007/s00421-003-0978-0; Mortola JP, 2002, RESP PHYSIOL NEUROBI, V131, P91, DOI 10.1016/S1569-9048(02)00040-X; MURAKI T, 1985, PSYCHOPHARMACOLOGY, V85, P162, DOI 10.1007/BF00428407; MURAKI T, 1986, PSYCHOPHARMACOLOGY, V89, P60; MURAKI T, 1988, PEPTIDES, V9, P777, DOI 10.1016/0196-9781(88)90121-0; Niesters M, 2013, BRIT J ANAESTH, V110, P175, DOI 10.1093/bja/aes447; Panagiotou I, 2012, CURR PHARM DESIGN, V18, P6025, DOI 10.2174/138161212803582450; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Price ER, 2003, J APPL PHYSIOL, V95, P1097, DOI 10.1152/japplphysiol.00166.2003; Rodriguez-Munoz M, 2013, MOL NEUROBIOL, V48, P769, DOI 10.1007/s12035-013-8465-z; Sadhasivam S, 2012, PHARMACOGENOMICS, V13, P1719, DOI [10.2217/PGS.12.152, 10.2217/pgs.12.152]; Sugino S, 2012, NEUROSCI LETT, V517, P107, DOI 10.1016/j.neulet.2012.04.038; van der Schier Rutger, 2014, F1000Prime Rep, V6, P79, DOI 10.12703/P6-79; Whittaker Marianne R, 2013, J Pediatr Pharmacol Ther, V18, P269, DOI 10.5863/1551-6776-18.4.269; Yamauchi M, 2008, RESP PHYSIOL NEUROBI, V162, P117, DOI 10.1016/j.resp.2008.05.003; Yamauchi M, 2010, ADV EXP MED BIOL, V669, P303, DOI 10.1007/978-1-4419-5692-7_62; Zutler M, 2011, CURR PHARM DESIGN, V17, P1443, DOI 10.2174/138161211796197070	39	3	3	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048	1878-1519		RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	AUG 15	2015	215						20	29		10.1016/j.resp.2015.04.011			10	Physiology; Respiratory System	Physiology; Respiratory System	CN2QX	WOS:000358268100003	25936679	Green Accepted			2020-06-30	J	Shi, FM; Xiao, Y; Xiong, W; Zhou, Q; Yang, P; Huang, XQ				Shi, Fenmei; Xiao, Ying; Xiong, Wei; Zhou, Qin; Yang, Peng; Huang, Xiongqing			Effects of Fentanyl on Emergence Agitation in Children under Sevoflurane Anesthesia: Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Article							INTRANASAL FENTANYL; PEDIATRIC-PATIENTS; DOSE FENTANYL; BILATERAL MYRINGOTOMY; DELIRIUM; DESFLURANE; PREVENTION; HALOTHANE; PROPOFOL; SURGERY	Background and Objectives The goal of this meta-analysis study was to assess the effects of fentanyl on emergence agitation (EA) under sevoflurane anesthesia in children. Subjects and Methods We searched electronic databases (PubMed, Embase, Web of Science and the Cochrane Central Register of Controlled Trials) for articles published until December 2014. Randomized controlled trials (RCTs) that assessed the effects of fentanyl and placebo on EA under sevoflurane anesthesia in children that the outcome were the incidence of EA, postoperative pain, emergence time or adverse effects were included in this meta-analysis. Results A total of 16 studies, including 1362 patients (737 patients for the fentanyl group and 625 for the placebo group), were evaluated in final analysis. We found that administration of fentanyl decreased the incidences of EA (RR = 0.37, 95% CI 0.27 similar to 0.49, P<0.00001) and postoperative pain (RR = 0.59, 95% CI 0.41 similar to 0.85, P = 0.004) but increased the incidence of postoperative nausea and vomiting (PONV) (RR = 2.23, 95% CI 1.33 similar to 3.77, P = 0.003). The extubation time (WMD = 0.71 min, 95% CI 0.12 similar to 1.3, P = 0.02), emergence time (WMD = 4.90 min, 95% CI 2.49 similar to 7.30, P<0.0001), and time in the postanesthesia care unit (PACU) (WMD = 2.65 min, 95% CI 0.76 similar to 4.53, P = 0.006) were slightly increased. There were no significant differences in the time to discharge of day patients (WMD = 3.72 min, 95% CI -2.80 similar to 10.24, P = 0.26). Conclusion Our meta-analysis suggests that fentanyl decreases the incidence of EA under sevoflurane anesthesia in children and postoperative pain, but has a higher incidence of PONV. Considering the inherent limitations of the included studies, more RCTs with extensive follow-up should be performed to validate our findings in the future.	[Shi, Fenmei] Sun Yat Sen Univ, Dept Anaesthesiol, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China; [Xiao, Ying; Xiong, Wei; Zhou, Qin; Yang, Peng; Huang, Xiongqing] Sun Yat Sen Univ, Dept Anaesthesiol, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China	Huang, XQ (reprint author), Sun Yat Sen Univ, Dept Anaesthesiol, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.	hxiongqing@163.com					Abdelhalim Ashraf Arafat, 2013, Saudi J Anaesth, V7, P392, DOI 10.4103/1658-354X.121047; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Bajwa SA, 2010, PEDIATR ANESTH, V20, P704, DOI 10.1111/j.1460-9592.2010.03328.x; Bakhamees HS, 2009, SAUDI MED J, V30, P500; Binstock W, 2004, PEDIATR ANESTH, V14, P759, DOI 10.1111/j.1460-9592.2004.01296.x; Bortone L, 2014, PEDIATR ANESTH, V24, P614, DOI 10.1111/pan.12388; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Costi D, 2014, COCHRANE DB SYST REV, V9, pD7084; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Cravero JP, 2001, AN ABSTR SCI PAP ANN, P1222; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; [DEM S MM R], 2014, EGYPTIAN J ANAESTHES, P2; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; [DY K CH K YJ K MJ I], 2004, KOREAN J ANESTHESIOL, P1; ECKENHOFF J, 1961, ANESTHESIOLOGY, V22, P667, DOI 10.1097/00000542-196109000-00002; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3; Finkel J, 2000, AN ABSTR SCI PAP ANN, P1252; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Galinkin JL, 2000, AN ABSTR SCI PAP ANN, P1253; [关雷 GUAN Lei], 2011, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V27, P644; Hedges LV, 2001, PSYCHOL METHODS, V6, P203, DOI 10.1037/1082-989X.6.3.203; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hippard HK, 2012, ANESTH ANALG, V115, P356, DOI 10.1213/ANE.0b013e31825afef3; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Hung WT, 2005, J CLIN ANESTH, V17, P494, DOI 10.1016/j.jclinane.2004.09.014; Inomata S, 2010, BRIT J ANAESTH, V105, P361, DOI 10.1093/bja/aeq168; JIN HEE CHEOL, 2004, Korean Journal of Anesthesiology, V46, P524; Jung HJ, 2010, KOREAN J ANESTHESIOL, V58, P148, DOI 10.4097/kjae.2010.58.2.148; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; 박성용, 2005, Korean Journal of Anesthesiology, V49, P502; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Kuratani N, 2008, ANESTHESIOLOGY, V109, P225, DOI 10.1097/ALN.0b013e31817f5c18; Li J, 2011, CHINESE MED J-PEKING, V124, P3682, DOI 10.3760/cma.j.issn.0366-6999.2011.22.015; Li XZ, 2013, SAUDI MED J, V34, P40; Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100; Locatelli BG, 2013, PEDIATR ANESTH, V23, P301, DOI 10.1111/pan.12038; Lynch EP, 1998, ANESTH ANALG, V86, P781; [M A G E H E AA R BS E MY M], 2009, EGYPTIAN J ANAESTHES, P4; [M A AT D O K B I], 2005, TURK ANESTEZIYOLOJI, P5; [M H MY M SS E OM A], 2011, EGYPTIAN J ANAESTHES, P1; Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007; Oh AY, 2005, ACTA ANAESTH SCAND, V49, P297, DOI 10.1111/j.1399-6576.2005.00687.x; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; [裴春明 Pei Chunming], 2012, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V28, P17; Pestieau SR, 2011, PEDIATR ANESTH, V21, P1128, DOI 10.1111/j.1460-9592.2011.03615.x; Rampersad S, 2010, PEDIATR ANESTH, V20, P1028, DOI 10.1111/j.1460-9592.2010.03427.x; [沈霞 Shen Xia], 2010, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V30, P303; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; SM A, 2008, EGYPTIAN J ANAESTHES, P1; Somaini M, 2015, PEDIATR ANESTH, V25, P524, DOI 10.1111/pan.12580; Veyckemans F, 2001, Curr Opin Anaesthesiol, V14, P339, DOI 10.1097/00001503-200106000-00010; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005; Zhang CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099718; Zhang CM, 2013, CLIN THER, V35, P1622, DOI 10.1016/j.clinthera.2013.08.016; ZHANG YY, 2012, SHIP ELECT ENG, V32, P12; 김치효, 2007, Korean Journal of Anesthesiology, V53, P609; 김혜경, 2005, Korean Journal of Anesthesiology, V49, P370	63	7	9	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2015	10	8							e0135244	10.1371/journal.pone.0135244			18	Multidisciplinary Sciences	Science & Technology - Other Topics	CO9KD	WOS:000359493600058	26275039	DOAJ Gold, Green Published			2020-06-30	J	Burghardt, PR; Rothberg, AE; Dykhuis, KE; Burant, CF; Zubieta, JK				Burghardt, Paul R.; Rothberg, Amy E.; Dykhuis, Kate E.; Burant, Charles F.; Zubieta, Jon-Kar			Endogenous Opioid Mechanisms Are Implicated in Obesity and Weight Loss in Humans	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR AVAILABILITY; FOOD-INTAKE; STRESS; BINDING; IMPACT; REWARD; CARFENTANIL; NALTREXONE; SELECTION	Context: Successful long-term weight loss is challenging. Brain endogenous opioid systems regulate associated processes; however, their role in the maintenance of weight loss has not been adequately explored in humans. Objective: In a preliminary study, the objective was to assess central mu-opioid receptor (MOR) system involvement in eating behaviors and their relationship to long-term maintenance of weight loss. Design: This was a case-control study with follow-up of the treatment group at 1 year after intervention. Setting: The study was conducted at a tertiary care university medical center. Participants: Lean healthy (n = 7) and chronically obese (n = 7) men matched for age and ethnicity participated in the study. Interventions: MOR availability measures were acquired with positron emission tomography and [C-11] carfentanil. Lean healthy men were scanned twice under both fasted and fed conditions. Obese men were placed on a very low-calorie diet to achieve 15% weight loss from baseline weight and underwent two positron emission tomography scans before and two after weight loss, incorporating both fasted and fed states. Main Outcome Measures: Brain MORavailability and activation were measured by reductions in MOR availability (nondisplaceable binding potential) from the fed compared with the fasted-state scans. Results: Baseline MOR nondisplaceable binding potential was reduced in obese compared with the lean and partially recovered obese after weight loss in regions that regulate homeostatic, hedonic, and emotional responses to feeding. Reductions in negative affect and feeding-induced MOR system activation in the right temporal pole were highly correlated in leans but not in obese men. A trend for an association between MOR activation in the right temporal pole before weight loss and weight regain 1 year was found. Conclusions: Although these preliminary studies have a small sample size, these results suggest that obesity and diet-induced weight loss impact central MOR binding and endogenous opioid system function. MOR system activation in response to an acute meal may be related to the risk of weight regain.	[Burghardt, Paul R.; Zubieta, Jon-Kar] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Rothberg, Amy E.; Burant, Charles F.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Dykhuis, Kate E.; Zubieta, Jon-Kar] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Burghardt, Paul R.] Wayne State Univ, Dept Nutr & Food Sci, Detroit, MI 48202 USA	Burghardt, PR (reprint author), Wayne State Univ, Nutr & Food Sci, 5000 Gullen Mall, Detroit, MI 48202 USA.	paul.burghardt@wayne.edu		Burant, Charles/0000-0001-9189-5003	National Institute of Diabetes and Digestive and Kidney Diseases Grant [DK092322]; Brain and Behavior Research Foundation National Alliance for Research on Schizophrenia and Depression Young Investigator Award; National Institute of Diabetes and Digestive and Kidney Diseases GrantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK089503, P30DK092926, DK089503, DK020572]; National Center for Research Resources GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024986]; Robert C. and Veronica Adkins Foundation; A. Alfred Taubman Medical Institute; Phil Jenkins Foundation; Blue Care Network of Michigan	This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant DK092322; the Brain and Behavior Research Foundation National Alliance for Research on Schizophrenia and Depression Young Investigator Award (to P.R.B.); National Institute of Diabetes and Digestive and Kidney Diseases Grants P30DK089503, P30DK092926 (Michigan Center for Diabetes Translational Research), DK089503, DK020572, and National Center for Research Resources Grant UL1RR024986; the Robert C. and Veronica Adkins Foundation (to C.F.B.); the A. Alfred Taubman Medical Institute (to C.F.B. and J.-K.Z.); The Phil Jenkins Foundation (to J.-K.Z.); and Blue Care Network of Michigan.	Barfield ET, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00019; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bencherif B, 2005, J NUCL MED, V46, P1349; Berthoud HR, 2002, NEUROSCI BIOBEHAV R, V26, P393, DOI 10.1016/S0149-7634(02)00014-3; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; Flint A, 2000, INT J OBESITY, V24, P38, DOI 10.1038/sj.ijo.0801083; Friedman JM, 2003, SCIENCE, V299, P856, DOI 10.1126/science.1079856; Glass M, 1996, AM J PHYSIOL, V271, P21; Glass MJ, 1999, NEUROPEPTIDES, V33, P360, DOI 10.1054/npep.1999.0050; Gosnell B, 2005, INT J OBES S2, V33, P8; GOSNELL BA, 1990, PHARMACOL BIOCHEM BE, V37, P207, DOI 10.1016/0091-3057(90)90322-9; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Kelley AE, 2005, PHYSIOL BEHAV, V86, P773, DOI 10.1016/j.physbeh.2005.08.066; Kelley AE, 2002, PHYSIOL BEHAV, V76, P365, DOI 10.1016/S0031-9384(02)00751-5; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Kranzler HR, 2004, J CONSULT CLIN PSYCH, V72, P317, DOI 10.1037/0022-006X.72.2.317; Larsen JK, 2006, J PSYCHOSOM RES, V60, P237, DOI 10.1016/j.jpsychores.2005.07.006; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Meyer C R, 1997, Med Image Anal, V1, P195, DOI 10.1016/S1361-8415(97)85010-4; MINOSHIMA S, 1993, J NUCL MED, V34, P322; Narendran R, 2008, SYNAPSE, V62, P851, DOI 10.1002/syn.20566; Oliver G, 1999, PHYSIOL BEHAV, V66, P511, DOI 10.1016/S0031-9384(98)00322-9; Oliver G, 2000, PSYCHOSOM MED, V62, P853, DOI 10.1097/00006842-200011000-00016; Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052; Quelch DR, 2014, J CEREBR BLOOD F MET, V34, P1604, DOI 10.1038/jcbfm.2014.117; Rothberg AE, 2013, OBESITY, V21, P2157, DOI 10.1002/oby.20597; Scott DJ, 2007, SYNAPSE, V61, P707, DOI 10.1002/syn.20404; SLOCHOWER J, 1981, APPETITE, V2, P115, DOI 10.1016/S0195-6663(81)80005-0; Smith KS, 2007, J NEUROSCI, V27, P1594, DOI 10.1523/JNEUROSCI.4205-06.2007; Taut D, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00359; Umberg EN, 2011, PHYSIOL BEHAV, V104, P69, DOI 10.1016/j.physbeh.2011.04.045; Walsh Z, 2008, J ADDICT DIS, V27, P65, DOI 10.1300/J069v27n01_07; Wang GJ, 1997, NEUROPSYCHOPHARMACOL, V16, P174, DOI 10.1016/S0893-133X(96)00184-4; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Weerts EM, 2011, ALCOHOL CLIN EXP RES, V35, P2162, DOI 10.1111/j.1530-0277.2011.01565.x; Zellner DA, 2006, PHYSIOL BEHAV, V87, P789, DOI 10.1016/j.physbeh.2006.01.014; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	40	18	18	0	13	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	AUG	2015	100	8					3193	3201		10.1210/jc.2015-1783			9	Endocrinology & Metabolism	Endocrinology & Metabolism	CW2XH	WOS:000364855900066	26108093	Green Published, Bronze			2020-06-30	J	Purwar, B; Ismail, KM; Turner, N; Farrell, A; Verzune, M; Annappa, M; Smith, I; El-Gizawy, Z; Cooper, JC				Purwar, B.; Ismail, K. M.; Turner, N.; Farrell, A.; Verzune, M.; Annappa, M.; Smith, I.; El-Gizawy, Zeiad; Cooper, J. C.			General or Spinal Anaesthetic for Vaginal Surgery in Pelvic Floor Disorders (GOSSIP): a feasibility randomised controlled trial	INTERNATIONAL UROGYNECOLOGY JOURNAL			English	Article						General anaesthesia; Spinal anaesthesia; Transvaginal tape; Vaginal hysterectomy; Vaginal repair	ABDOMINAL HYSTERECTOMY; URINARY-INCONTINENCE; REGIONAL ANESTHESIA; ORGAN PROLAPSE; TOTAL HIP; RECOVERY; KNEE; EPIDEMIOLOGY; ARTHROPLASTY; REPLACEMENT	Introduction and hypothesis Spinal anaesthesia (SA) and general anaesthesia (GA) are widely used techniques for vaginal surgery for pelvic floor disorders with inconclusive evidence of the superiority of either. We conducted a randomised controlled trial (RCT) to assess the feasibility of a full scale RCT aiming to examine the effect of anaesthetic mode for vaginal surgery on operative, patient reported and length of hospital stay (LOHS) outcomes. Methods Patients undergoing vaginal surgery, recruited through a urogynaecology service in a University teaching hospital, were randomised to receive either GA or SA. Patients were followed up for 12 weeks postoperatively. Pain was measured on a visual analogue scale; nausea was assessed with a four-point verbal rating scale. Patient's subjective perception of treatment outcome, quality of life (QoL) and functional outcomes were assessed using the International Consultation on Incontinence Modular Questionnaire (ICIQ) on vaginal symptoms and the SF-36 questionnaire. Results Sixty women were randomised, 29 to GA and 31 to SA. The groups were similar in terms of age and type of vaginal surgery performed. No statistically significant differences were noted between the groups with regard to pain, nausea, quality of life (QoL), functional outcomes as well as length of stay in the postoperative recovery room, use of analgesia postoperatively and LOHS. Conclusion This study has demonstrated that a full RCT is feasible and should focus on the length of hospital stay in a subgroup of patients undergoing vaginal surgery where SA may help to facilitate enhanced recovery or day surgery.	[Purwar, B.; Verzune, M.; El-Gizawy, Zeiad; Cooper, J. C.] Royal Stoke Univ Hosp, Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England; [Ismail, K. M.] Univ Birmingham, Birmingham Ctr Womens & Childrens Hlth, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Ismail, K. M.] Birmingham Womens NHS Fdn Trust, Acad Unit, Birmingham B15 2TG, W Midlands, England; [Turner, N.; Farrell, A.; Smith, I.] Royal Stoke Univ Hosp, Dept Anaesthesia, Stoke On Trent ST4 6QG, Staffs, England; [Annappa, M.] Prince Wales Hosp, Dept ofObstetr & Gynaecol, Bridgend, Wales	Cooper, JC (reprint author), Royal Stoke Univ Hosp, Dept Obstet & Gynaecol, Newcastle Rd, Stoke On Trent ST4 6QG, Staffs, England.	jasoncooper@doctors.org.uk	Ismail, Khaled/Z-5530-2019	Ismail, Khaled/0000-0001-9449-0706	North Staffordshire Medical Institute, UK	This study was funded by a Research Award from the North Staffordshire Medical Institute, UK.	[Anonymous], 2013, 36 ROYAL COLL OBST G; Barber MD, 2013, INT UROGYNECOL J, V24, P1783, DOI 10.1007/s00192-013-2169-9; Battantyne JC, 2005, J CLIN ANESTH, V17, P382, DOI 10.1016/j.jclinane.2004.10.005; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Chang CC, 2010, ANESTHESIOLOGY, V113, P279, DOI 10.1097/ALN.0b013e3181e2c1c3; Deval B, 2002, J UROLOGY, V167, P2093, DOI 10.1016/S0022-5347(05)65092-6; Ellerkmann RM, 2001, AM J OBSTET GYNECOL, V185, P1332, DOI 10.1067/mob.2001.119078; Food Drug Administration, 2011, UR SURG MESH UPD SER; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Harsten A, 2013, BRIT J ANAESTH, V111, P391, DOI 10.1093/bja/aet104; Hu S, 2009, J BONE JOINT SURG BR, V91B, P935, DOI 10.1302/0301-620X.91B7.21538; Hunskaar S, 2000, INT UROGYNECOL J, V11, P301, DOI 10.1007/s001920070021; Korhonen AM, 2006, CURR OPIN ANESTHESIO, V19, P612, DOI 10.1097/ACO.0b013e32801042c7; Luger TJ, 2010, OSTEOPOROSIS INT, V21, pS555, DOI 10.1007/s00198-010-1399-7; Macfarlane AJR, 2009, BRIT J ANAESTH, V103, P335, DOI 10.1093/bja/aep208; Massicotte L, 2009, ACTA ANAESTH SCAND, V53, P641, DOI 10.1111/j.1399-6576.2009.01930.x; Matthey PW, 2004, REGION ANESTH PAIN M, V29, P96, DOI 10.1016/j.rapm.2003.10.017; Pradhan A, 2013, BJOG-INT J OBSTET GY, V120, P200, DOI 10.1111/1471-0528.12076; Price N, 2006, BJOG-INT J OBSTET GY, V113, P700, DOI 10.1111/j.1471-0528.2006.00938.x; RCOG, 2013, 36 RCOG; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Schmittner MD, 2010, BRIT J SURG, V97, P12, DOI 10.1002/bjs.6792; Sessler DI, 2009, ANESTHESIOLOGY, V111, P1, DOI 10.1097/ALN.0b013e3181a913e1; Smith I, 2006, ANAESTHESIA, V61, P1191, DOI 10.1111/j.1365-2044.2006.04875.x; Sprung J, 2006, CAN J ANAESTH, V53, P690, DOI 10.1007/BF03021628; Stewart AVG, 2001, BRIT J ANAESTH, V86, P570, DOI 10.1093/bja/86.4.570; TESSLER MJ, 1995, ANESTH ANALG, V81, P694, DOI 10.1097/00000539-199510000-00006; Vaghadia H, 1998, CAN J ANAESTH, V45, pR64, DOI 10.1007/BF03019208; Wodlin NB, 2011, BJOG-INT J OBSTET GY, V118, P299, DOI 10.1111/j.1471-0528.2010.02697.x	29	4	4	0	2	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-3462	1433-3023		INT UROGYNECOL J	Int. Urogynecol. J.	AUG	2015	26	8					1171	1178		10.1007/s00192-015-2670-4			8	Obstetrics & Gynecology; Urology & Nephrology	Obstetrics & Gynecology; Urology & Nephrology	CR3JU	WOS:000361229500012	25792351				2020-06-30	J	Jirapinyo, P; Kumar, N; Thompson, CC				Jirapinyo, Pichamol; Kumar, Nitin; Thompson, Christopher C.			Patients With Roux-en-Y Gastric Bypass Require Increased Sedation During Upper Endoscopy	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY			English	Article						Endoscopic Sedation; Weight-loss Surgery; Obesity; Bariatric Endoscopy	FATTY LIVER-DISEASE; UPPER GASTROINTESTINAL ENDOSCOPY; BARIATRIC SURGERY; EVENTS	BACKGROUND & AIMS: After Roux-en-Y gastric bypass (RYGB), many patients experience changes in metabolism that could affect the amount of sedative they require. We assessed whether patients who have vs have not received RYGB have different sedation requirements during esophagogas-troduodenoscopy (EGD). METHODS: In a retrospective study, we collected data from patients who had received RYGB (n = 200; mean age, 45 years; 188 women; body mass index [BMI], 34.0 +/- 7.1 kg/m(2)) or had not (controls, n [200; mean age, 45 years; 188 women; BMI, 34.1 +/- 7.2 kg/m(2)) and underwent EGD under conscious sedation from 2005 through 2010; groups were matched for age, sex, and BMI. Sedative doses were compared by using the Student t test. Multivariate linear regression was used to identify factors associated with sedation dose. We performed a subgroup analysis of RYGB patients who underwent EGD before and after RYGB, comparing sedative doses with a paired t test. RESULTS: Patients with RYGB were given 132.4 +/- 40.4 mu g fentanyl and 5.4 +/- 1.5 mu g midazolam, whereas controls received 108.6 +/- 31.6 mu g fentanyl (P < .001) and 4.3 +/- 1.2 mu g midazolam (P < .001). Increased time from RYGB, higher American Society of Anesthesiologists class, and therapeutic procedure were associated with higher doses of sedation (P < .05). Thirty-two patients underwent EGD before and after RYGB. Patients were given 95.0 +/- 39.0 mu g fentanyl before RYGB and 130.5 +/- 41.3 mu g fentanyl afterward (P < .05); they were given 4.0 +/- 1.0 mu g midazolam before RYGB and 5.5 +/- 1.7 mu g midazolam afterward (P < .05). CONCLUSIONS: Patients with RYGB require larger amounts of fentanyl and midazolam during EGD than patients without RYGB, despite similar age, sex, and BMI. Among patients who underwent EGD before and after RYGB, levels of drugs required for sedation increased after gastric bypass, despite weight loss.	[Jirapinyo, Pichamol] Yale New Haven Med Ctr, Dept Internal Med, New Haven, CT 06504 USA; [Kumar, Nitin; Thompson, Christopher C.] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA; [Kumar, Nitin; Thompson, Christopher C.] Harvard Univ, Sch Med, Dept Internal Med, Boston, MA USA	Thompson, CC (reprint author), Brigham & Womens Hosp, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA.	ccthompson@partners.org	Kumar, Nitin/E-1320-2016	Kumar, Nitin/0000-0002-9876-2884	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK034854]		Cote GA, 2010, CLIN GASTROENTEROL H, V8, P660, DOI 10.1016/j.cgh.2010.05.015; DANESHMEND TK, 1991, GUT, V32, P12, DOI 10.1136/gut.32.1.12; DHARIWAL A, 1992, GASTROINTEST ENDOSC, V38, P684, DOI 10.1016/S0016-5107(92)70564-1; Enestvedt BK, 2013, GASTROINTEST ENDOSC, V77, P464, DOI 10.1016/j.gie.2012.11.039; Furuya CK, 2007, J GASTROEN HEPATOL, V22, P510, DOI 10.1111/j.1440-1746.2007.04833.x; Jirapinyo P, 2014, DIGEST DIS SCI, V59, P2173, DOI 10.1007/s10620-014-3140-4; KEEFFE E B, 1990, Gastrointestinal Endoscopy, V36, pS13; Khalaf KI, 2013, CURR DIABETES REP, V13, P245, DOI 10.1007/s11892-013-0364-1; Khiani VS, 2009, GASTROINTEST ENDOSC, V70, P1116, DOI 10.1016/j.gie.2009.05.036; Klein S, 2006, GASTROENTEROLOGY, V130, P1564, DOI 10.1053/j.gastro.2006.01.042; Kumar N, 2013, CLIN GASTROENTEROL H, V11, P343, DOI 10.1016/j.cgh.2012.10.043; Manthurin P, 2009, GASTROENTEROLOGY, V137, P532; Manthurin P, 2006, GASTROENTEROLOGY, V130, P1617; Mummadi RR, 2008, CLIN GASTROENTEROL H, V6, P1396, DOI 10.1016/j.cgh.2008.08.012; Santry HP, 2005, JAMA-J AM MED ASSOC, V294, P1909, DOI 10.1001/jama.294.15.1909; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254; Tai CM, 2012, OBES SURG, V22, P1016, DOI 10.1007/s11695-011-0579-7	19	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1542-3565	1542-7714		CLIN GASTROENTEROL H	Clin. Gastroenterol. Hepatol.	AUG	2015	13	8					1432	1436		10.1016/j.cgh.2015.02.042			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP7SQ	WOS:000360088800014	25769410				2020-06-30	J	Backberg, M; Beck, O; Jonsson, KH; Helander, A				Backberg, Matilda; Beck, Olof; Jonsson, Karl-Henrik; Helander, Anders			Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project	CLINICAL TOXICOLOGY			English	Article						Butyrfentanyl; Butyrylfentanyl; Fentanyl analogue; Internet drugs; Mass spectrometry methods; New psychoactive substances; NPS; Opioid analgesic drug; para-Fluorobutyrfentanyl	LEGAL-HIGHS; FUTURE-PROSPECTS; DESIGNER DRUGS; 3-METHYLFENTANYL; IDENTIFICATION; EXPERIENCE; EMERGENCY; EPIDEMIC; ESTONIA; DEATHS	Background. The supply of unregulated "new psychoactive substances" (NPS) has shown a steady increase over the past six years. This report from the Swedish STRIDA project describes analytically confirmed non-fatal intoxications involving butyrfentanyl (butyrylfentanyl) or 4-fluorobutyrfentanyl (para-fluorobutyrfentanyl), two fentanyl analogues recently introduced as NPS opioids. Study design. Observational case series of consecutive patients with suspected acute NPS exposure and requiring hospital care from all over Sweden. Patients and methods. From May 2014 to January 2015, blood and urine samples were obtained from four intoxication cases involving butyrfentanyl and one case involving 4-fluorobutyrfentanyl (men, 19-30 years) presenting in emergency departments (ED) or intensive care units (ICU). Laboratory analysis of serum and/or urine samples was performed by multi-component liquid chromatography mass spectrometry methods. Data on clinical features were collected during consultations with the Poisons Information Centre and retrieved from medical records. Case details. Of the five patients, two were discharged home from the ED and three were admitted to the ICU, of whom two required intubation and mechanical ventilation. Clinical features included typical opioid symptoms such as unconsciousness, respiratory depression, and apnea. In one case, naloxone successfully countered the effects. All patients were discharged the same or the following day. Butyrfentanyl was detected in two serum (0.6 and 0.9 ng/mL) and three urine (2.0-65.6 ng/mL) samples from three of four cases; three cases also contained fentanyl. In the 4-fluorobutyrfentanyl case, the substance was detected in serum (similar to 15 ng/mL) and urine (similar to 10 ng/mL). In four cases, other NPS and/or classical drugs were also detected. Analysis of two "butyrfentanyl" NPS products (nasal spray and powder) brought to hospital by patients showed that the 10-fold more potent fentanyl was the main active ingredient (similar to 7.5-10-fold higher amount) in both. Conclusion. Typical and potentially life-threatening opioid toxicity was seen in acute intoxications involving butyrfentanyl, 4F-butyrfentanyl, and fentanyl. The incorrect labelling of butyrfentanyl NPS products which instead mainly contained fentanyl is alarming, given the narrow range between a safe and a lethal dose for opioids.	[Backberg, Matilda] Swedish Poisons Informat Ctr, Stockholm, Sweden; [Beck, Olof; Helander, Anders] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Beck, Olof; Helander, Anders] Karolinska Univ Lab, Dept Clin Pharmacol, Stockholm, Sweden; [Jonsson, Karl-Henrik] Med Prod Agcy, Uppsala, Sweden	Helander, A (reprint author), Karolinska Univ Lab Huddinge, Dept Lab Med, C1 74, SE-14186 Stockholm, Sweden.	anders.helander@ki.se					Al-Saffar Y, 2013, J CHROMATOGR B, V930, P112, DOI 10.1016/j.jchromb.2013.04.043; Backberg M, 2015, CLIN TOXICOL, V53, P46, DOI 10.3109/15563650.2014.981823; Baron M, 2011, DRUG TEST ANAL, V3, P576, DOI 10.1002/dta.274; Bazckberg M, 2014, CLIN TOXICOL, V52, P618, DOI 10.3109/15563650.2014.920088; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Davies S, 2010, QJM-INT J MED, V103, P489, DOI 10.1093/qjmed/hcq056; de Boer D, 2003, J PHARMACEUT BIOMED, V31, P557, DOI 10.1016/S0731-7085(02)00684-2; EMCDDA, 2012, EMCDDA TRENDSP STUD; EMCDDA, 2015, NEW PSYCH SUBST EUR; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), EUR DRUG REP 2014 TR; European Monitoring Centre for Drugs Drug Addiction (EMCDDA), 2003, REP RISK ASS PMMA FR; Garg A, 2010, J PHARMACEUT BIOMED, V53, P325, DOI 10.1016/j.jpba.2010.04.004; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2014, FORENSIC SCI INT, V243, P23, DOI 10.1016/j.forsciint.2014.02.022; Helander A, 2013, SCAND J CLIN LAB INV, V73, P400, DOI 10.3109/00365513.2013.793817; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; Johansson M, 2014, J PHARMACEUT BIOMED, V100, P215, DOI 10.1016/j.jpba.2014.07.026; Kram TC, 1981, ANAL CHEM, V53, p1379A; Kronstrand R, 2014, J ANAL TOXICOL, V38, P599, DOI 10.1093/jat/bku057; Lane ME, 2013, EUR J PHARM BIOPHARM, V84, P449, DOI 10.1016/j.ejpb.2013.01.018; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Persson HE, 1998, J TOXICOL-CLIN TOXIC, V36, P205, DOI 10.3109/15563659809028940; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Simonsen KW, 2015, FORENSIC SCI INT, V248, P172, DOI 10.1016/j.forsciint.2015.01.003; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vevelstad M, 2012, FORENSIC SCI INT, V219, DOI 10.1016/j.forsciint.2011.12.014; Wermeling DP, 2015, THER ADV DRUG SAF, V6, P20, DOI 10.1177/2042098614564776; World Health Organization, 2014, COMM MAN OP OV 2014; Zamengo L, 2014, TOXICOL LETT, V229, P220, DOI 10.1016/j.toxlet.2014.06.012; Zuba D, 2013, DRUG TEST ANAL, V5, P420, DOI 10.1002/dta.1365	43	61	63	1	37	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	AUG	2015	53	7					609	617		10.3109/15563650.2015.1054505			9	Toxicology	Toxicology	CP4WN	WOS:000359883400004	26083809				2020-06-30	J	Xu, YC; Li, RP; Xue, FS; Cui, XL; Wang, SY; Liu, GP; Yang, GZ; Sun, C; Liao, X				Xu, Ya-Chao; Li, Rui-Ping; Xue, Fu-Shan; Cui, Xin-Long; Wang, Shi-Yu; Liu, Gao-Pu; Yang, Gui-Zhen; Sun, Chao; Liao, Xu			kappa-Opioid receptors are involved in enhanced cardioprotection by combined fentanyl and limb remote ischemic postconditioning	JOURNAL OF ANESTHESIA			English	Article						Ischemia reperfusion injury; Cardioprotection; Remote ischemic postconditioning; Pharmacological postconditioning; Opioid receptors	PROTEIN-KINASE-C; MYOCARDIAL REPERFUSION INJURY; ISCHAEMIA/REPERFUSION INJURY; PRECONDITIONING PROTECTS; DEPENDENT MECHANISM; INFARCTION; RAT; HEARTS; MODEL	The combination of various interventions to obtain enhanced cardioprotection is always an important area of research focus. This randomized experiment was designed to assess whether combined fentanyl and limb remote ischemic postconditioning produced enhanced protection against myocardial ischemia/reperfusion injury in an in vivo rat model, and to determine if kappa-opioid receptors were implicated in the cardioprotection of these interventions. Seventy-two rats were exposed to a 30-min myocardial ischemia followed by a 180-min reperfusion. Half of the rats (36) were randomized into four different groups receiving control treatment, fentanyl postconditioning, limb remote ischemic postconditioning, and combined fentanyl and limb remote ischemic postconditioning. The remaining 36 rats were also randomized into four groups receiving the same interventions as the above groups following the intravenous administration of a kappa-opioid receptor antagonist, nor-binaltorphimine, before myocardial ischemia. At the end of reperfusion, both serum cardiac troponin I and infarct size were determined. Both fentanyl postconditioning and limb remote ischemic postconditioning significantly decreased the infarct size and serum cardiac troponin I level, and combined fentanyl and limb remote ischemic postconditioning produced enhanced cardioprotection on the infarct size-sparing effect. The use of nor-binaltorphimin to block kappa-opioid receptors eliminated cardioprotection by fentanyl postconditioning and enhanced cardioprotection by combined fentanyl and limb remote ischemic postconditioning, but did not change cardioprotection by limb remote ischemic postconditioning. Combined fentanyl and limb remote ischemic postconditioning produced enhanced protection against myocardial ischemia/reperfusion injury. kappa-Opioid receptors are essential for cardioprotection by fentanyl postconditioning and enhanced cardioprotection by combined fentanyl and limb remote ischemic postconditioning; however, they do not play a pivotal role in cardioprotection by limb remote ischemic postconditioning.	[Xu, Ya-Chao] Capital Med Univ, Xuanwu Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Li, Rui-Ping; Xue, Fu-Shan; Cui, Xin-Long; Wang, Shi-Yu; Liu, Gao-Pu; Yang, Gui-Zhen; Sun, Chao; Liao, Xu] Chinese Acad Med Sci, Plast Surg Hosp, Dept Anesthesiol, Beijing 100730, Peoples R China; [Li, Rui-Ping; Xue, Fu-Shan; Cui, Xin-Long; Wang, Shi-Yu; Liu, Gao-Pu; Yang, Gui-Zhen; Sun, Chao; Liao, Xu] Peking Union Med Coll, Beijing 100021, Peoples R China	Xue, FS (reprint author), Chinese Acad Med Sci, Plast Surg Hosp, Dept Anesthesiol, 33 Ba Da Chu Rd, Beijing 100730, Peoples R China.	diagnosis@126.com; liruiping1987@yeah.net; xuefushan@aliyun.com; playcs_1.7@163.com; yucandy178@163.com; lgp_0608@outlook.com; yang-pan-xiaoyu@foxmail.com; sunchao0101@126.com; liaoxu_vip@aliyun.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [30972836]	This research was funded by the National Natural Science Foundation of China (No. 30972836). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Botker HE, 2010, LANCET, V375, P727, DOI 10.1016/S0140-6736(09)62001-8; Buja LM, 2010, CARDIOVASC PATHOL, V19, P29, DOI 10.1016/j.carpath.2008.10.001; Chen ZL, 2008, J SURG RES, V145, P287, DOI 10.1016/j.jss.2007.07.020; Frassdorf J, 2009, BRIT J ANAESTH, V103, P89, DOI 10.1093/bja/aep141; Gross ER, 2006, CARDIOVASC RES, V70, P212, DOI 10.1016/j.cardiores.2005.12.019; Guo HT, 2011, J CARDIOVASC PHARM, V58, P207, DOI 10.1097/FJC.0b013e318220e37f; Kaneda K, 2008, ANESTH ANALG, V106, P9, DOI 10.1213/01.ane.0000297298.93627.36; Kato R, 2000, BRIT J ANAESTH, V84, P608, DOI 10.1093/bja/84.5.608; Kim JM, 2011, KOREAN J ANESTHESIOL, V61, P358, DOI 10.4097/kjae.2011.61.5.358; Lessa MA, 2004, ACTA ANAESTH SCAND, V48, P1115, DOI 10.1111/j.1399-6576.2004.00472.x; Li CM, 2006, SCAND CARDIOVASC J, V40, P312, DOI 10.1080/14017430600925292; Loukogeorgakis SP, 2007, CIRCULATION, V116, P1386, DOI 10.1161/CIRCULATIONAHA.106.653782; Minamino T, 2012, CIRC J, V76, P1074, DOI 10.1253/circj.CJ-12-0132; Ortiz-Vilchis P, 2014, EUR J PHARMACOL, V744, P76, DOI 10.1016/j.ejphar.2014.09.042; Pasupathy S, 2005, EUR J VASC ENDOVASC, V29, P106, DOI 10.1016/j.ejvs.2004.11.005; Peart JN, 2008, BASIC RES CARDIOL, V103, P454, DOI 10.1007/s00395-008-0726-z; Peart JN, 2005, VASC PHARMACOL, V42, P211, DOI 10.1016/j.vph.2005.02.003; Ren C, 2008, NEUROSCIENCE, V151, P1099, DOI 10.1016/j.neuroscience.2007.11.056; Sandhu R, 1997, CIRCULATION, V96, P984; Schmidt MR, 2007, AM J PHYSIOL-HEART C, V292, pH1883, DOI 10.1152/ajpheart.00617.2006; VENTURA C, 1989, BIOCHIM BIOPHYS ACTA, V987, P69, DOI 10.1016/0005-2736(89)90456-2; Wang WL, 2011, MED HYPOTHESES, V77, P734, DOI 10.1016/j.mehy.2011.07.026; Wei M, 2011, CIRC RES, V108, P1220, DOI 10.1161/CIRCRESAHA.110.236190; White WB, 1999, AM J HYPERTENS, V12, p50S, DOI 10.1016/S0895-7061(98)00280-5; Xin P, 2010, AM J PHYSIOL-HEART C, V298, pH1819, DOI 10.1152/ajpheart.01102.2009; Xiong J, 2011, CHINESE MED J-PEKING, V124, P2209, DOI 10.3760/cma.j.issn.0366-6999.2011.14.023; Xiong J, 2011, INFLAMM RES, V60, P547, DOI 10.1007/s00011-010-0303-4; Yao LN, 2009, J SURG RES, V155, P25, DOI 10.1016/j.jss.2008.07.012; Zatta AJ, 2006, CARDIOVASC RES, V70, P315, DOI 10.1016/j.cardiores.2005.11.030; Zhang SZ, 2006, ANESTHESIOLOGY, V105, P550, DOI 10.1097/00000542-200609000-00019	30	9	12	0	7	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	AUG	2015	29	4					535	543		10.1007/s00540-015-1998-8			9	Anesthesiology	Anesthesiology	CP7QK	WOS:000360082800009	25808344				2020-06-30	J	Song, L; Wu, CR; Liu, J; Zuo, YX; Volinn, E; Yao, JX				Song, Li; Wu, Chaoran; Liu, Jin; Zuo, Yunxia; Volinn, Ernest; Yao, Jiaxiang			Potential advantages of an additional forearm rubber tourniquet in intravenous regional anesthesia: a randomized clinical trial	JOURNAL OF ANESTHESIA			English	Article						Intravenous regional anesthesia; Additional forearm tourniquet	BIERS BLOCK; LIDOCAINE; 0.5-PERCENT; REDUCTION; FRACTURES	Although the usefulness of an additional forearm tourniquet to conventional intravenous regional anesthesia (IVRA) has been reported, the forearm cuff may disturb the surgical field to some degree, especially in wrist surgery. In the present study, we assessed the clinical efficacy of a temporary additional forearm rubber tourniquet to the conventional upper arm tourniquet on the quality of IVRA. The study included 32 ASA physical status I and II adult patients undergoing elective hand surgery who were randomly allocated to either an additional forearm tourniquet group (Group F) or to a conventional upper arm tourniquet group (Group C). Upper arm tourniquet IVRA was established using 40 mL of 0.5 % lidocaine in Group C. Hypothetically enhanced forearm tourniquet IVRA was established using 10 mL of 0.5 % lidocaine with an additional forearm rubber tourniquet and then administering 30 mL of 0.25 % lidocaine after removing the forearm tourniquet in Group F. The sensory and motor block onset and recovery times, onset time of tourniquet pain, intraoperative fentanyl consumption, and incidence of local anesthetic toxicity were recorded. The numerical rating score (NRS) of perioperative and postoperative pain and quality of anesthesia were also assessed. Although the total dose of lidocaine in Group F was less and the sensory and motor block onset times were significantly shorter in Group F than those in Group C (P < 0.05), there was no difference regarding sensory and motor block recovery times, onset time of tourniquet pain, intraoperative fentanyl consumption, NRS of perioperative and postoperative pain, and the quality of anesthesia in the two groups (P > 0.05). Compared with Group C, the incidence of local anesthetic toxicity (i.e., dizziness, 43.8 vs 6.2 %, P = 0.02) was significantly decreased in Group F. The combination of the additional forearm and upper arm tourniquets with a smaller amount of local anesthetic achieved more rapid onset of sensory and motor block, a similar quality of anesthesia and a lower incidence of local anesthetic toxicity compared with the conventional technique.	[Song, Li; Wu, Chaoran; Liu, Jin; Zuo, Yunxia] Sichuan Univ, Dept Anesthesiol, Translat Med Neurosci Ctr, West China Hosp, Chengdu 610041, Sichuan, Peoples R China; [Volinn, Ernest] Univ Utah, Dept Anesthesiol, Pain Res Ctr, Salt Lake City, UT 84108 USA; [Yao, Jiaxiang] Kunming Med Univ, Dept Anesthesiol, Affiliated Hosp 1, Kunming 650032, Yunnan, Peoples R China	Liu, J (reprint author), Sichuan Univ, Dept Anesthesiol, Translat Med Neurosci Ctr, West China Hosp, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.	huaxisongli@hotmail.com; scujinliu@gmail.com			National Nature Science Foundation of ChinaNational Natural Science Foundation of China [30772084]	This work was supported in part by Grant 30772084 from the National Nature Science Foundation of China.	ACALOVSCHI I, 1995, ANESTH ANALG, V81, P539, DOI 10.1097/00000539-199509000-00020; Asik I, 2009, J CLIN ANESTH, V21, P401, DOI 10.1016/j.jclinane.2008.10.011; Chong AKS, 2007, J HAND SURG-BRIT EUR, V32E, P57, DOI 10.1016/j.jhsb.2006.10.002; Davis Roger, 2002, AANA J, V70, P295; Fletcher SJ, 2011, EUR J ANAESTH, V28, P133, DOI 10.1097/EJA.0b013e3283410131; Guay J, 2009, J CLIN ANESTH, V21, P585, DOI 10.1016/j.jclinane.2009.01.015; Reuben SS, 2002, ANESTH ANALG, V95, P457, DOI 10.1097/00000539-200208000-00041; Rosenberg P. H., 1993, REGIONAL ANESTHESIA, V18, P1; ROSENBERG PH, 1983, ANESTHESIOLOGY, V58, P95, DOI 10.1097/00000542-198301000-00014; Singh R, 2010, MINERVA ANESTESIOL, V76, P109; Turan A, 2002, ANESTH ANALG, V95, P1419, DOI 10.1097/00000539-200211000-00058; van Zundert A, 2008, REGION ANESTH PAIN M, V33, P483, DOI 10.1016/j.rapm.2008.04.011; Werk LN, 2008, J PEDIATR ORTHOPED, V28, P410, DOI 10.1097/BPO.0b013e31816d7235; Ye L, 2006, ANESTH ANALG, V103, P257, DOI 10.1213/01.ANE.0000215220.95927.3F	14	1	1	0	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	AUG	2015	29	4					551	556		10.1007/s00540-015-1988-x			6	Anesthesiology	Anesthesiology	CP7QK	WOS:000360082800011	25771759				2020-06-30	J	Kim, SH; Oh, CS; Lee, SJ				Kim, Seong-Hyop; Oh, Chung-Sik; Lee, Sun Joo			Efficacy of palonosetron and ramosetron on postoperative nausea and vomiting related to intravenous patient-controlled analgesia with opioids after gynecological laparoscopic surgery (double-blinded prospective randomized controlled trial)	JOURNAL OF ANESTHESIA			English	Article						Postoperative nausea and vomiting; Patient-controlled analgesia; Opioids	ONDANSETRON; CHEMOTHERAPY; GUIDELINES; PREVENTION; EVALUATE; PLACEBO; EMESIS; SAFETY	The study was designed to assess the efficacy of palonosetron and ramosetron in preventing postoperative nausea and vomiting (PONV) related to intravenous (IV) patient-controlled analgesia (PCA) with opioids after gynecological laparoscopic surgery. Patients were randomly allocated to 4 groups-C, P, R0.3 and R-PCA. At the end of surgery, group C received an infusion of 50 ml normal saline, group P received palonosetron 75 mu g mixed in 50 ml normal saline, and groups R0.3 and R-PCA received ramosetron 0.3 mg mixed in 50 ml normal saline. A PCA pump containing fentanyl was connected for all groups; however, ramosetron 0.6 mg was mixed with the PCA regimen for the R-PCA group. PONV and postoperative pain were assessed. PONV incidence and scale, and Rhodes index in R-PCA group between 24 and 72 h after discharge from the post-anesthetic care unit (PACU) showed significantly lower values, compared with the other groups. PONV incidence and scale, and Rhodes index in P group and R0.3 group were lower than the corresponding values in C group at all times, without statistical significance. A single dose of palonosetron 75 mu g or ramosetron 0.3 mg was unable to prevent PONV related to IV PCA with opioids in patients undergoing gynecological laparoscopic surgery. The combination of a single dose of ramosetron 0.3 mg, followed by ramosetron 0.6 mg mixed with PCA, significantly decreased PONV compared with a single dose of palonosetron 75 mu g or ramosetron 0.3 mg.	[Kim, Seong-Hyop; Oh, Chung-Sik] Konkuk Univ, Sch Med, Med Ctr, Dept Anesthesiol & Pain Med, Seoul 143729, South Korea; [Kim, Seong-Hyop] Konkuk Univ, Sch Med, Inst Biomed Sci & Technol, Seoul 143729, South Korea; [Lee, Sun Joo] Konkuk Univ, Sch Med, Med Ctr, Dept Obstet & Gynecol, Seoul 143729, South Korea	Kim, SH (reprint author), Konkuk Univ, Sch Med, Med Ctr, Dept Anesthesiol & Pain Med, 120-1 Neungdong Ro Hwayang Dong, Seoul 143729, South Korea.	yshkim75@daum.net			National Research Foundation of Korea (NRF) - Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of KoreaNational Research Foundation of Korea [2012R1A1A1001819]	This research was supported by the Basic Science Research Programme through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (grant number: 2012R1A1A1001819). It was presented as an oral presentation in Anesthesiology (TM) 2014 annual meeting.	Bajwa SS, 2011, SAUDI J ANAESTH, V5, P19, DOI 10.4103/1658-354X.76484; Candiotti KA, 2008, ANESTH ANALG, V107, P445, DOI 10.1213/ane.0b013e31817b5ebb; Carlisle JB, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004125.pub2; Cherian VT, 2001, BRIT J ANAESTH, V87, P502, DOI 10.1093/bja/87.3.502; Choi DK, 2010, ACTA ANAESTH SCAND, V54, P962, DOI 10.1111/j.1399-6576.2010.02275.x; Choi DH, 2005, J KOREAN MED SCI, V20, P811, DOI 10.3346/jkms.2005.20.5.811; Chung F, 1999, EUR J ANAESTH, V16, P669, DOI 10.1046/j.1365-2346.1999.00547.x; De Leon Andrew, 2006, Proc (Bayl Univ Med Cent), V19, P413; Dresner M, 1998, BRIT J ANAESTH, V81, P384, DOI 10.1093/bja/81.3.384; Gan TJ, 2006, ANESTH ANALG, V102, P1884, DOI 10.1213/01.ANE.0000219597.16143.4D; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gomez-Hernandez J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-692; Gralla RJ, 1999, J CLIN ONCOL, V17, P2971, DOI 10.1200/JCO.1999.17.9.2971; Habib AS, 2003, EXPERT OPIN PHARMACO, V4, P457, DOI 10.1517/14656566.4.4.457; Herrstedt J, 2011, SUPPORT CARE CANCER, V19, pS15, DOI 10.1007/s00520-010-0951-5; Jordan K, 2005, EUR J CANCER, V41, P199, DOI 10.1016/j.ejca.2004.09.026; Kim SI, 2009, BRIT J ANAESTH, V103, P549, DOI 10.1093/bja/aep209; Koeller JM, 2002, SUPPORT CARE CANCER, V10, P519, DOI 10.1007/s00520-001-0335-y; Kovac AL, 2008, ANESTH ANALG, V107, P439, DOI 10.1213/ane.0b013e31817abcd3; Kris MG, 2005, SUPPORT CARE CANCER, V13, P85, DOI 10.1007/s00520-004-0699-x; Millo J, 2001, ANAESTHESIA, V56, P60, DOI 10.1046/j.1365-2044.2001.01763-4.x; Moon YE, 2012, BRIT J ANAESTH, V108, P417, DOI 10.1093/bja/aer423; Park SK, 2013, KOREAN J ANESTHESIOL, V64, P133, DOI 10.4097/kjae.2013.64.2.133; Rhodes V A, 1999, Oncol Nurs Forum, V26, P889; Scuderi PE, 2010, ANESTH ANALG, V110, P410, DOI 10.1213/ANE.0b013e3181c5bcfc; White PF, 2005, ANESTHESIOLOGY, V103, pA703	26	9	9	0	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	AUG	2015	29	4					585	592		10.1007/s00540-015-1981-4			8	Anesthesiology	Anesthesiology	CP7QK	WOS:000360082800016	25735497				2020-06-30	J	Schacherer, NM; Ramirez, DE; Frazier, SB; Perkins, AM				Schacherer, Nicole Marie; Ramirez, Dana Erikson; Frazier, Steven Barron; Perkins, Amy M.			Expedited Delivery of Pain Medication for Long-Bone Fractures Using an Intranasal Fentanyl Clinical Pathway	PEDIATRIC EMERGENCY CARE			English	Article						intranasal; fentanyl; pain; pathway; morphine	EMERGENCY-DEPARTMENT; CHILDREN	Objective This study aims to determine whether a pathway designed to facilitate the use of intranasal (IN) fentanyl for long-bone fractures will expedite the delivery of pain medication, decrease the total length of emergency department (ED) stay, and provide faster analgesia compared with intravenous (IV) morphine. Methods A pain pathway for IN fentanyl in long-bone fractures was instituted in our ED in July 2011. We performed a retrospective and prospective chart review of patients aged 3 to 21 years who presented to the ED with a clinically suspected long-bone fracture and either received IV morphine or were placed on IN fentanyl pain pathway. Results A total of 94 patients met our inclusion criteria; 71 received IV morphine, and 23 received IN fentanyl, per pathway protocol. The mean length of time to pain medication administration was statistically significantly faster for IN fentanyl (37 minutes) than for IV morphine (62 minutes) (P = 0.002). The mean total length of stay for patients who received IN fentanyl versus patients who received IV morphine was not statistically significantly different after excluding patients who needed reduction or surgery. Effectiveness of pain control was not statistically significantly different between the IN fentanyl group and the IV morphine group. Conclusions Use of the IN fentanyl pain pathway significantly decreases time to pain medication administration in pediatric patients with suspected long-bone fractures.	[Schacherer, Nicole Marie; Ramirez, Dana Erikson; Perkins, Amy M.] Childrens Hosp Kings Daughters, Norfolk, VA 23507 USA; [Schacherer, Nicole Marie; Ramirez, Dana Erikson; Frazier, Steven Barron; Perkins, Amy M.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA	Schacherer, NM (reprint author), Childrens Hosp Kings Daughters, Pediat Emergency Med, 601 Childrens Lane, Norfolk, VA 23507 USA.	nicole.schacherer@chkd.org					Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Bulloch B, 2002, ACAD EMERG MED, V9, P199, DOI 10.1197/aemj.9.3.199; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Cummings EA, 1996, PAIN, V68, P25, DOI 10.1016/S0304-3959(96)03163-6; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Zand DJ, 2008, PEDIATRICS, V122, P1191, DOI 10.1542/peds.2008-0205	9	9	9	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	AUG	2015	31	8					560	563		10.1097/PEC.0000000000000435			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	CP0ZL	WOS:000359605500004	25875994				2020-06-30	J	Stroumpoulis, K; Stamatakis, E; Koutroumanis, P; Loukeri, A; Valsamidis, D				Stroumpoulis, K.; Stamatakis, E.; Koutroumanis, P.; Loukeri, A.; Valsamidis, D.			Pencil-point needle bevel direction influences ED50 of isobaric ropivacaine with fentanyl in spinal anesthesia for cesarean delivery: a prospective, double-blind sequential allocation study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Bevel direction; Pencil-point; ED50; Cesarean delivery; Spinal anesthesia; Ropivacaine	TERM PARTURIENT; INTRATHECAL BUPIVACAINE; HYPERBARIC BUPIVACAINE; SPREAD; SECTION; INJECTION; LEVOBUPIVACAINE; ANALGESIA; BARICITY; DURATION	Background: There is little evidence on the influence of bevel direction of a pencil-point needle on the median effective dose (ED50) of isobaric ropivacaine and fentanyl in spinal anesthesia for cesarean delivery. Methods: In this prospective, double-blind, sequential allocation study, 82 parturients scheduled for elective cesarean delivery under combined spinal-epidural anesthesia were included. We sought to determine the median effective dose of intrathecal 0.75% isobaric ropivacaine plus fentanyl 15 mu g with two different bevel directions of a 26-gauge Whitacre needle using up-down sequential allocation. Parturients were randomly allocated to either Group Ce (needle aperture oriented in a cephalad direction) or Group Ca (aperture directed caudally). The initial dose was 0.75% ropivacaine 11.25 mg plus fentanyl 151.tg in both groups. Each dose was classified as effective if, after 15 min and during the next 60 min, there was inability to appreciate pin-prick as sharp at T4, a visual analogue pain score <2 and no requirement for an epidural rescue bolus. Results: Eighty patients were included in the analysis. The ED50 in group Ca was significantly higher (13.09 mg, 95% CI 12.19-14.00) than in group Ce (10.10 mg, 95% CI 9.54-10.65, P <0.001). Conclusion: The orientation of the distal aperture of a 26-gauge Whitacre needle during induction of spinal anesthesia for cesarean delivery influences the ED50 of 0.75% ropivacaine. (C) 2015 Elsevier Ltd. All rights reserved.	[Stroumpoulis, K.; Stamatakis, E.; Loukeri, A.; Valsamidis, D.] Alexandra Gen Hosp Athens, Dept Anesthesiol, Athens 11528, Greece; [Koutroumanis, P.] Univ Athens, Sch Med, Alexandra Gen Hosp Athens, Dept Obstet & Gynecol 1, GR-10679 Athens, Greece	Stroumpoulis, K (reprint author), Alexandra Gen Hosp Athens, Dept Anesthesiol, Lourou 1 Str, Athens 11528, Greece.	arkaskostas@yahoo.gr	Stamatakis, Emmanuel/C-4958-2009	Stamatakis, Emmanuel/0000-0001-7323-3225; Stroumpoulis, Konstantinos/0000-0003-3234-3772			BEARDSLEY D, 1995, ANESTH ANALG, V81, P314, DOI 10.1097/00000539-199508000-00019; Camorcia M, 2006, EUR J ANAESTH, V23, P611, DOI 10.1017/S0265021506000421; Casati A, 1998, ANESTH ANALG, V87, P355, DOI 10.1097/00000539-199808000-00022; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Columb MO, 2006, INT J OBSTET ANESTH, V15, P129, DOI 10.1016/j.ijoa.2005.09.010; Dixon WJ, 1983, INTRO STAT ANAL, P426; Ekelof NP, 1997, ACTA ANAESTH SCAND, V41, P884, DOI 10.1111/j.1399-6576.1997.tb04804.x; Gautier P, 2003, BRIT J ANAESTH, V91, P684, DOI 10.1093/bja/aeg251; GRAHAM CW, 1978, ANAESTHESIA, V33, P192, DOI 10.1111/j.1365-2044.1978.tb08350.x; GREENE NM, 1985, ANESTH ANALG, V64, P715; Hallworth SP, 2005, ANESTH ANALG, V100, P1159, DOI 10.1213/01.ANE.0000149548.88029.A2; HARTWELL BL, 1991, REGION ANESTH, V16, P17; Hocking G, 2004, BRIT J ANAESTH, V93, P568, DOI 10.1093/bja/aeh204; Holman SJ, 1997, ANESTHESIOLOGY, V86, P966, DOI 10.1097/00000542-199704000-00027; Husain T, 2013, INT J OBSTET ANESTH, V22, P298, DOI 10.1016/j.ijoa.2013.07.002; James KS, 1996, BRIT J ANAESTH, V77, P150, DOI 10.1093/bja/77.2.150; Khaw KS, 2001, ANESTHESIOLOGY, V95, P1346, DOI 10.1097/00000542-200112000-00011; Kirschner M, 1932, SURG GYNECOL OBSTET, V5, P317; Law ACS, 2003, ANESTH ANALG, V97, P1795, DOI 10.1213/01.ANE.0000086733.92150.47; Loubert C, 2011, ANESTH ANALG, V113, P811, DOI 10.1213/ANE.0b013e3182288bf2; NEIGH JL, 1970, ANESTH ANAL CURR RES, V49, P912; NORRIS MC, 1990, ANESTHESIOLOGY, V72, P478, DOI 10.1097/00000542-199003000-00015; Parpaglioni R, 2006, ANAESTHESIA, V61, P110, DOI 10.1111/j.1365-2044.2005.04380.x; Siddik-Sayyid SM, 2002, ANESTH ANALG, V95, P209, DOI 10.1097/00000539-200207000-00037; Teoh WHL, 2006, INT J OBSTET ANESTH, V15, P273, DOI 10.1016/j.ijoa.2006.03.004; Urmey WF, 1997, ANESTH ANALG, V84, P337, DOI 10.1097/00000539-199702000-00017; Valsamidis D, 2007, EUR J ANAESTH, V29, pS142; Wang LZ, 2014, INT J OBSTET ANESTH, V23, P40, DOI 10.1016/j.ijoa.2013.08.009; Wong CA, 2003, CAN J ANAESTH, V50, P689, DOI 10.1007/BF03018711; Zar JH, 1984, BIOSTAT ANAL, V2nd, P586	30	4	5	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	AUG	2015	24	3					225	229		10.1016/j.ijoa.2015.03.005			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	CN9YO	WOS:000358807300005	25936784				2020-06-30	J	Coffman, JC; Fiorini, K; Mathew, P; Small, RH				Coffman, J. C.; Fiorini, K.; Mathew, P.; Small, R. H.			Pocket warming of epidural medications	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							ANALGESIA; LABOR		[Coffman, J. C.; Fiorini, K.; Mathew, P.; Small, R. H.] Ohio State Univ, Dept Anesthesiol, Wexner Med Ctr, Columbus, OH 43210 USA	Coffman, JC (reprint author), Ohio State Univ, Dept Anesthesiol, Wexner Med Ctr, Columbus, OH 43210 USA.	john.coffman@osumc.edu	Small, Robert/E-4106-2011	Small, Robert/0000-0001-6362-9437			Care Fusion, MAT SAF DAT SHEET HO; Gambling D, 2013, ANESTH ANALG, V116, P636, DOI 10.1213/ANE.0b013e31827e4e29; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Sviggum HP, 2015, INT J OBSTET ANESTH, V24, P15, DOI 10.1016/j.ijoa.2014.07.001	4	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	AUG	2015	24	3					290	291		10.1016/j.ijoa.2015.04.006			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	CN9YO	WOS:000358807300017	26116285				2020-06-30	J	Fareed, A; Buchanan-Cummings, AM; Crampton, K; Grant, A; Drexler, K				Fareed, Ayman; Buchanan-Cummings, Ann Marie; Crampton, Kelli; Grant, Angela; Drexler, Karen			Reversal of overdose on fentanyl being illicitly sold as heroin with naloxone nasal spray: A case report	AMERICAN JOURNAL ON ADDICTIONS			English	Article							RHODE-ISLAND	BackgroundThis is a case report describing a reversal of fentanyl overdose with naloxone nasal spray. The patient was not aware that he overdosed on fentanyl being sold as heroin. MethodsThe Veterans Health Administration (VHA) has implemented an initiative to provide education for veterans, their families, friends and significant others about opioid overdose and use of naloxone reversal kits. The Atlanta VA Medical Center adopted this program to reduce the risk of opioid overdose in high risk patients. ResultsOver the past year, we provided educational sessions for 63 veterans and their families. We also prescribed 41 naloxone kits. We have received three reports of opioid overdose reversal with use of naloxone kits prescribed by the Atlanta VA Medical Center. Conclusions and Scientific significanceThe authors recommend that public health administrators and policy makers advocate for the implementation of these programs to reduce the rising number of overdose death in the United States and worldwide. (Am J Addict 2015;24:388 -390)	[Fareed, Ayman; Buchanan-Cummings, Ann Marie; Crampton, Kelli; Grant, Angela; Drexler, Karen] Atlanta VA Med Ctr, Decatur, GA USA; [Fareed, Ayman; Drexler, Karen] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA	Fareed, A (reprint author), Emory Univ, Sch Med, Dept Psychiat, Atlanta VA Med Ctr 116A, 1670 Clairmont Rd, Decatur, GA 30033 USA.	ayman.fareed@va.gov			Reckitt Benckiser (pharmaceutical company)	Dr. Fareed received honorarium for serving on a clinical advisory board for Orexo, AB (pharmaceutical company). He was a paid consultant to Reckitt Benckiser (pharmaceutical company).	Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Drug Enforcement Administration US Department of Justice, 2008, FED REG, V73, P43355; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Pennsylvania Department of Drug and Alcohol Programs, 2013, DEP DRUG ALC PROGR W; Substance Abuse and Mental Health Services Administration (SAMHSA), 2013, HHS PUBL, V(SMA) 13-4760; Welsh C, 2008, ADDICTION, V103, P1226, DOI 10.1111/j.1360-0443.2008.02244.x; Williams AV, 2014, ADDICTION, V109, P250, DOI 10.1111/add.12360; Yokell Michael A, 2012, J Opioid Manag, V8, P63	9	7	7	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1055-0496	1521-0391		AM J ADDICTION	Am. J. Addict.	AUG	2015	24	5					388	390		10.1111/ajad.12230			3	Substance Abuse	Substance Abuse	CN7ND	WOS:000358620400001	26039379				2020-06-30	J	Sinatra, RS; Viscusi, ER; Ding, L; Danesi, H; Jones, JB; Grond, S				Sinatra, Raymond S.; Viscusi, Eugene R.; Ding, Li; Danesi, Hassan; Jones, James B.; Grond, Stefan			Meta-analysis of the efficacy of the fentanyl iontophoretic transdermal system versus intravenous patient-controlled analgesia in postoperative pain management	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						fentanyl; iontophoretic transdermal system; morphine; patient-controlled analgesia; patient global assessment of the method of pain control; postoperative pain	CONTROLLED OPIOID ANALGESIA; IV-PCA; MORPHINE; SAFETY; MODALITIES	Objective: This meta-analysis was conducted to analyze and compare the efficacy outcomes associated with the fentanyl iontophoretic transdermal system (ITS) and morphine intravenous (IV) patient-controlled analgesia (PCA) in the management of postoperative pain. Research design and methods: This meta-analysis assessed the efficacy of the fentanyl ITS versus morphine IV PCA using data from four randomized, active-controlled trials (n = 1271 fentanyl ITS and 1298 morphine IV PCA patients). Main outcome measures were patient global assessment (PGA) of the method of pain control at 24 h. Results: Fentanyl ITS and morphine IV PCA did not significantly differ regarding 'good' and 'excellent' ratings on the PGA of the method of pain control at 24 h (odds ratio = 0.95, p = 0.66), however, fentanyl ITS was superior in terms of 'excellent' PGA ratings at that time point (odds ratio = 1.53, p < 0.0001). No significant differences were found in weighted mean pain intensity scores at 24, 48 and 72 h. Conclusions: In this meta-analysis, fentanyl ITS was as efficacious as morphine IV PCA and may offer additional benefits as demonstrated by its 'excellent' PGA ratings.	[Sinatra, Raymond S.] West Haven VA Med Ctr, West Haven, CT USA; [Viscusi, Eugene R.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Ding, Li; Danesi, Hassan; Jones, James B.] Med Co, Parsippany, NJ 07054 USA; [Grond, Stefan] Klinikum Lippe, Detmold, Germany	Danesi, H (reprint author), Med Co, 8 Sylvan Way, Parsippany, NJ 07054 USA.	hassan.danesi@THEMEDCO.com			Medicines Company (Parsippany, NJ, USA); AcelRx; piacere; MedtronicMedtronic; Medicines Company	The Medicines Company (Parsippany, NJ, USA) sponsored the analysis and writing of this paper. RS Sinatra serves as consultant to The Medicines Company and Pacira Pharmaceuticals (San Diego, CA, USA). ER Viscusi has research funded to his institution by AcelRx, piacere, Medtronic. He has consulted for AcelRx, Pacira The Medicines Company, Mallinckrodt, Cubist, Trevena, Pacira and has received speaking honoraria from AstraZeneca, Mallinckrodt, Cubist, Salix and Pacira. S Groud serves as a consultant to The Medicines Company and Jansen-Cilag. L Ding and JB Jones and H Danesi are employees of The Medicines Company. S Grundy of SD Scientific, Inc. provided technical writing assistance and was funded by The Medicines Company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Batheja Priya, 2006, Expert Opin Drug Deliv, V3, P127; Bonnet F, 2009, CURR MED RES OPIN, V25, P293, DOI 10.1185/03007990802631321 ; Evans C, 2007, PAIN MANAG NURS, V8, P86, DOI 10.1016/j.pmn.2007.03.004; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Petrie A., 2009, MED STAT GLANCE; Rothman M, 2009, CURR MED RES OPIN, V25, P1433, DOI 10.1185/03007990902862032; Viscusi ER, 2006, AM J HEALTH-SYST PH, V63, pS3, DOI 10.2146/ajhp060011; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x	14	9	9	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	AUG	2015	16	11					1607	1613		10.1517/14656566.2015.1054279			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CN5GS	WOS:000358458400005	26050870				2020-06-30	J	Marashi, SM; Sharifnia, HR; Azimaraghi, O; Aghajani, Y; Barzin, G; Movafegh, A				Marashi, S. M.; Sharifnia, H. R.; Azimaraghi, O.; Aghajani, Y.; Barzin, G.; Movafegh, A.			Naloxone added to bupivacaine or bupivacaine-fentanyl prolongs motor and sensory block during supraclavicular brachial plexus blockade: a randomized clinical trial	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							LOW-DOSE NALOXONE; EPIDURAL NALOXONE; SPINAL-CORD; ANALGESIA; MORPHINE; NAUSEA; PRURITUS; INFUSION; HYPERALGESIA; SUFENTANIL	BackgroundIn this study, the effect of naloxone on duration of supraclavicular brachial plexus block was evaluated. It was hypothesized that naloxone can increase the duration of neural blockade. MethodsSixty-eight patients scheduled for surgery under supraclavicular brachial plexus block were randomly assigned to receive 30ml bupivacaine (Group C); 30ml bupivacaine with 100g of fentanyl (Group F); 30ml bupivacaine with 100ng naloxone (Group N); or 30ml bupivacaine with 100g of fentanyl and 100ng naloxone (Group N+F). Sensory and motor blockade were recorded at 5, 15, and 30min following the block, and every 10min following the end of surgery. Duration of sensory and motor block was considered to be the time interval between the complete block and the first postoperative pain and complete recovery of motor functions. ResultsSensory and motor onset times were the same in all groups. The duration of sensory and motor block in Group C (11.31.7h and 4.56 +/- 1.0h) and Group F (12.8 +/- 3.3h and 5.1 +/- 2.0h) were less than in the other groups (18.1 +/- 2.2h and 6.18 +/- 1.0h in Group N, and 15.8 +/- 2.9h and 6.53 +/- 1.1h in Group N+F, P<0.0001). ConclusionAddition of naloxone to bupivacaine in supraclavicular brachial plexus block prolonged the duration of the neural blockade.	[Marashi, S. M.; Sharifnia, H. R.; Azimaraghi, O.; Aghajani, Y.; Barzin, G.; Movafegh, A.] Univ Tehran Med Sci, Shariati Hosp, Dept Anesthesiol, Tehran 1411713135, Iran	Movafegh, A (reprint author), Univ Tehran Med Sci, Dept Anesthesiol & Crit Care, Dr Ali Shariati Hosp, Jalal Al Ahmad St, Tehran 1411713135, Iran.	movafegh@sina.tums.ac.ir		Movafegh, Ali/0000-0002-6346-3657; Azimaraghi, Omid/0000-0001-8367-741X			Alayurt S, 2004, ANAESTH INTENS CARE, V32, P22, DOI 10.1177/0310057X0403200103; BOURKE DL, 1993, J CLIN ANESTH, V5, P114, DOI 10.1016/0952-8180(93)90137-4; Brummett CM, 2011, INT ANESTHESIOL CLIN, V49, P104, DOI 10.1097/AIA.0b013e31820e4a49; Burns LH, 2010, CLIN MED INSIGHTS-TH, V2, P857, DOI 10.4137/CMT.S4870; Choi JH, 2000, CAN J ANAESTH, V47, P33, DOI 10.1007/BF03020728; Comelon M, 2013, ACTA ANAESTH SCAND, V57, P509, DOI 10.1111/aas.12051; Crain SM, 2000, PAIN, V84, P121, DOI 10.1016/S0304-3959(99)00223-7; Gan TJ, 1997, ANESTHESIOLOGY, V87, P1075, DOI 10.1097/00000542-199711000-00011; Jeon Y, 2005, INT J OBSTET ANESTH, V14, P22, DOI 10.1016/j.ijoa.2004.06.001; Jia DL, 2010, CHINESE MED J-PEKING, V123, P1695, DOI 10.3760/cma.j.issn.0366-6999.2010.13.015; Kakinohana M, 2003, ANESTHESIOLOGY, V98, P862, DOI 10.1097/00000542-200304000-00012; Kehlet H, 1997, BRIT J ANAESTH, V78, P606; Kim ES, 2004, CAN J ANAESTH, V51, P1048, DOI 10.1007/BF03018499; Kim MK, 2007, BRIT J ANAESTH, V99, P270, DOI 10.1093/bja/aem146; Lee J, 2001, CAN J ANAESTH, V48, P54, DOI 10.1007/BF03019815; LEVINE JD, 1979, NATURE, V278, P740, DOI 10.1038/278740a0; LEVINE JD, 1986, BRAIN RES, V365, P377, DOI 10.1016/0006-8993(86)91653-7; Meissner W, 2009, EUR J PAIN, V13, P56, DOI 10.1016/j.ejpain.2008.06.012; Movafegh A, 2009, ANESTH ANALG, V109, P1679, DOI 10.1213/ANE.0b013e3181b9e904; Murphy DB, 2000, ANESTH ANALG, V90, P1122, DOI 10.1097/00000539-200005000-00023; Nishikawa K, 2000, ANESTH ANALG, V91, P384, DOI 10.1097/00000539-200008000-00028; Okutomi T, 2003, CAN J ANAESTH, V50, P961, DOI 10.1007/BF03018748; Tsai RY, 2009, NEUROSCIENCE, V159, P1244, DOI 10.1016/j.neuroscience.2009.01.058; Wang HY, 2005, NEUROSCIENCE, V135, P247, DOI 10.1016/j.neuroscience.2005.06.003; WOOLF CJ, 1980, BRAIN RES, V189, P593, DOI 10.1016/0006-8993(80)90375-3; WRIGHT PMC, 1992, ACTA ANAESTH SCAND, V36, P230, DOI 10.1111/j.1399-6576.1992.tb03455.x; Yang CP, 2011, ANESTH ANALG, V113, P1490, DOI 10.1213/ANE.0b013e31822d39c1; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209	28	4	5	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	AUG	2015	59	7					921	927		10.1111/aas.12527			7	Anesthesiology	Anesthesiology	CM8RN	WOS:000357969800011	25922978				2020-06-30	J	Oh, CS; Jung, E; Lee, SJ; Kim, SH				Oh, Chung-Sik; Jung, Eugene; Lee, Sun Joo; Kim, Seong-Hyop			Effect of nefopam- versus fentanyl-based patient-controlled analgesia on postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery: a prospective double-blind randomized controlled trial	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Fentanyl; Nefopam; Patient-controlled analgesia; Postoperative nausea and vomiting	PAIN; EFFICACY; MORPHINE; INVOLVEMENT; DOPAMINE; SAFETY; MODEL	Objective: This study comparatively evaluated the effect of patient-controlled analgesia (PCA) regimens using equipotent doses of nefopam or fentanyl during laparoscopic gynecological surgery on postoperative nausea and vomiting (PONV). Research design and methods: Patients undergoing gynecological laparoscopic surgery were randomly allocated to receive either nefopam(non-opioid; N group) or fentanyl-based (F group) PCA. PONV and postoperative pain were assessed during the 72 hours following discharge from the post-anesthetic care unit ACU). The adverse effects of nefopam were also evaluated. Clinical trial registration: Cris.nih.go.kr ID KCT0000783. Results: In total, 94 patients were included in the final analysis. The PONV incidence and scale and the Rhodes index scores were significantly lower in the N group than the F group at all measured times. The N group exhibited a significantly lower incidence of PONV (15/47 [31.9%] vs. 27/47 [57.4%], respectively; P= 0.022) and severity of PONV (0 [1] vs. 1 [2], respectively; P= 0.005) 24 hours after PACU discharge and a significantly lower Rhodes index score (0 [3] vs. 5 [9], respectively; P= 0.002) from 30 minutes after PACU arrival to 24 hours after PACU discharge than did the F group. There was no significant difference in postoperative pain at any time between the two groups. Dry mouth on PACU arrival was significantly more frequent in the N group. However, the frequency of dry mouth decreased after PACU arrival in the N group, resulting in a significantly lower incidence 24 hours after PACU discharge. Conclusions: Use of a PCA regimen with nefopam for analgesia was associated with a similar degree of pain control and superior PONV outcomes 24 hours after PACU discharge and no adverse events compared with a PCA regimen using an equipotent dose of fentanyl.	[Oh, Chung-Sik; Jung, Eugene; Kim, Seong-Hyop] Konkuk Univ, Sch Med, Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Lee, Sun Joo] Konkuk Univ, Sch Med, Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea; [Kim, Seong-Hyop] Konkuk Univ, Sch Med, Res Inst Med Sci, Seoul, South Korea	Kim, SH (reprint author), Konkuk Univ Med Ctr, Dept Anesthesiol & Pain Med, 120-1,Neungdong Ro Hwayang Dong, Seoul 143729, South Korea.	yshkim75@daum.net			Konkuk University	This study was supported by Konkuk University.	Beloeil H, 2004, ANESTH ANALG, V98, P395, DOI 10.1213/01.ANE.0000093780.67532.95; Bures J, 2002, Cas Lek Cesk, V141, P673; Choi DH, 2005, J KOREAN MED SCI, V20, P811, DOI 10.3346/jkms.2005.20.5.811; Du Manoir B, 2003, BRIT J ANAESTH, V91, P836, DOI 10.1093/bja/aeg264; ESPOSITO E, 1986, EUR J PHARMACOL, V128, P157, DOI 10.1016/0014-2999(86)90762-4; Evans MS, 2008, BRIT J ANAESTH, V101, P610, DOI 10.1093/bja/aen267; FULLER RW, 1993, NEUROPHARMACOLOGY, V32, P995, DOI 10.1016/0028-3908(93)90064-A; Gan TJ, 2006, ANESTH ANALG, V102, P1884, DOI 10.1213/01.ANE.0000219597.16143.4D; Gomez-Hernandez J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-692; Gray AM, 1999, EUR J PHARMACOL, V365, P149, DOI 10.1016/S0014-2999(98)00837-1; HEEL RC, 1980, DRUGS, V19, P249, DOI 10.2165/00003495-198019040-00001; Kapfer B, 2005, ANESTH ANALG, V100, P169, DOI 10.1213/01.ANE.0000138037.19757.ED; Merle JC, 2005, ANN FR ANESTH, V24, P13, DOI 10.1016/j.annfar.2004.11.008; Mimoz O, 2001, ANAESTHESIA, V56, P520, DOI 10.1046/j.1365-2044.2001.01980.x; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Reynolds JEF, 1989, MARTINDALE EXTRA PHA, P30; Rhodes V A, 1999, Oncol Nurs Forum, V26, P889; ROSLAND JH, 1990, J PHARM PHARMACOL, V42, P437, DOI 10.1111/j.2042-7158.1990.tb06587.x; SUNSHINE A, 1975, CLIN PHARMACOL THER, V18, P530; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Woodhouse A, 1996, PAIN, V64, P115, DOI 10.1016/0304-3959(95)00082-8	21	9	10	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	AUG	2015	31	8					1599	1607		10.1185/03007995.2015.1058251			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	CR3WR	WOS:000361264300017	26047392				2020-06-30	J	Karas-Trzeciak, M; Grabowski, T; Woloszczuk-Gebicka, B; Borucka, B				Karas-Trzeciak, Magdalena; Grabowski, Tomasz; Woloszczuk-Gebicka, Bogumila; Borucka, Beata			Fentanyl with ropivacaine infusion for postoperative pain relief in infants and children. Kinetics of epidural fentanyl	PEDIATRIC ANESTHESIA			English	Article						pharmacokinetics: fentanyl; anesthesia; epidural; anesthetics; local; infant; child	PLASMA-CONCENTRATIONS; PHARMACOKINETICS; SUFENTANIL; ANALGESIA; EFFICACY; OPIOIDS	ObjectivesThe aim of the study was to evaluate pharmacokinetics of fentanyl administered as continuous epidural infusion with 0.2% ropivacaine for postoperative pain relief in infants and toddlers, and older children undergoing major abdominal and urological procedures. MethodsThirteen infants and toddlers (median age 14 [range 3-36]months, 11 [5-17]kg, Group I) and 11 children (68 [45-131]months, 21 [16-52] kg, Group II) participated in the study. Epidural catheter was placed under general anesthesia in the L1-L2, L2-L3, or L3-L4 epidural space and threaded up to 4cm into the epidural space. Bolus dose of 0.2% ropivacaine, 0.5mlkg(-1) and fentanyl, 2gkg(-1) was given, then followed by continuous infusion of 0.2% ropivacaine, 0.15mlkg(-1)h(-1) with fentanyl 1.12gkg(-1)h(-1). In the postoperative period, fentanyl dose was reduced to 0.375gkg(-1)h(-1). ResultsWith this dosing regimen, fentanyl concentration in plasma was within the range of analgesic concentrations, and did not exceed 1.0ngml(-1). After discontinuation of epidural infusion, pharmacokinetics of fentanyl was complicated by a slight increase in plasma concentration during the elimination phase. Both elimination half-life of fentanyl (t(1/2,MRT)) and mean residence time (MRT) were much longer than those observed after single IV bolus dose, and longer in Group I than in Group II (t(1/2MRT) 15.9 [3.6-31.5]h vs 8.0 [7.1-13.3]h, P<0.05, MRTstop-last 22.9 [5.1-45.5]h vs 11.5 [10.2-19.1]h, P<0.05). Therefore, monitoring of vital signs seems warranted for several hours after the termination of the epidural infusion because risk of respiratory depression may persist, especially in the younger age group.	[Karas-Trzeciak, Magdalena] Med Univ Warsaw, Dept Pediat Anesthesiol & Intens Care, Warsaw, Poland; [Grabowski, Tomasz] Polpharma Biol, Gdansk, Poland; [Woloszczuk-Gebicka, Bogumila] Univ Rzeszow, Fac Med, PL-35309 Rzeszow, Poland; [Borucka, Beata] Filab Pharmacokinet Res Ctr, Lajski, Poland	Woloszczuk-Gebicka, B (reprint author), Univ Rzeszow, Inst Midwifery & Med Lifesaving, Fac Med, Ul Pigonia 6, PL-35309 Rzeszow, Poland.	bogumila.gebicka@wum.edu.pl	Grabowski, Tomasz/AAE-6300-2020	Grabowski, Tomasz/0000-0002-3077-9698	National Centre for Science (Poland) [N407 098363]	The study was supported by the research grant from the National Centre for Science (Poland), grant No N407 098363 to Bogumila Woloszczuk-Gebicka.	[Anonymous], 2013, SUBLIMAZE INJECTION; Bailey JM, 2002, CLIN PHARMACOKINET, V41, P793, DOI 10.2165/00003088-200241110-00001; Bernards CM, 2003, ANESTHESIOLOGY, V99, P455, DOI 10.1097/00000542-200308000-00029; Bosenberg AT, 2005, PEDIATR ANESTH, V15, P739, DOI 10.1111/j.1460-9592.2004.01550.x; GELLER E, 1993, ANESTH ANALG, V76, P1243, DOI 10.1213/00000539-199376060-00011; Ginsberg B, 1996, ANESTHESIOLOGY, V85, P1268, DOI 10.1097/00000542-199612000-00007; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; Grabowski T, 2012, ARZNEIMITTELFORSCH, V62, P682, DOI 10.1055/s-0032-1331194; Horlocker TT, 2009, ANESTHESIOLOGY, V110, P218, DOI 10.1097/ALN.0b013e31818ec946; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Konigsrainer I, 2009, ANAESTHESIA, V64, P27, DOI 10.1111/j.1365-2044.2008.05655.x; Lejus C, 2000, BRIT J ANAESTH, V85, P615, DOI 10.1093/bja/85.4.615; Lerman J, 2003, ANESTHESIOLOGY, V99, P1166, DOI 10.1097/00000542-200311000-00025; Liu J, 2008, NEUROPHARMACOLOGY, V55, P812, DOI 10.1016/j.neuropharm.2008.06.034; Lonnqvist PA, 2002, PAEDIATR ANAESTH, V12, P747, DOI 10.1046/j.1460-9592.2002.00953.x; Niesters M, 2013, BRIT J ANAESTH, V110, P175, DOI 10.1093/bja/aes447; RENAUD B, 1988, ANESTH ANALG, V67, P971; Schug SA, 2006, CNS DRUGS, V20, P917, DOI 10.2165/00023210-200620110-00005; SINGLETON MA, 1987, CAN J ANAESTH, V34, P152, DOI 10.1007/BF03015333; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; Woloszczuk-Gebicka B, 2011, ANESTH ANALG, V28, P155; Woloszczuk-Gebicka B, 2014, PEDIATR ANESTH, V24, P962, DOI 10.1111/pan.12440	24	4	4	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	AUG	2015	25	8					818	823		10.1111/pan.12648			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	CM5LY	WOS:000357730600009	25904383				2020-06-30	J	Thomas, B				Thomas, Berlet			Remifentanil versus fentanyl in total intravenous anesthesia for lumbar spine surgery: a retrospective cohort study	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Anesthesia; Intravenous; Outcome assessment; Spine/surgery	POSTANESTHESIA RECOVERY; GENERAL-ANESTHESIA; COGNITIVE FUNCTION; SURGICAL-PATIENTS; PROPOFOL; POPULATION; INFUSION; TIME	Study objective: The aim of this study was to compare the speed of anesthetic recovery and the perioperative analgesic requirements in patients who received total intravenous anesthesia (TIVA) with either remifentanil-propofol or fentanyl-propofol for lumbar spine surgery. Design: Retrospective cohort study. Setting: Operating room, postanesthesia care unit, and general surgical ward. Patients: One hundred six patients (53 in each group) with American Society of Anesthesiologists status I, II, or III who received either remifentanil-propofol TIVA or fentanyl-propofol TIVA for elective lumbar vertebral disc surgery. Measurements: Patient demographics, total duration of anesthesia relative to surgical duration, time to emergence from anesthesia after completion of surgery, length of stay in the postanesthesia care unit, and requirements for opioid analgesia, nonopioid analgesia, and antiemetics in the perioperative period. Main results: No differences in anesthesia time, emergence time, or length of stay in the postanesthesia care unit were found between the remifentanil-propofol and fentanyl-propofol groups. Postoperative opioid and nonopioid analgesic use was significantly higher in the remifentanil-propofol group. Conclusions: Remifentanil and fentanyl are equally efficient with regard to the speed of patient turnover when used as part of TIVA for lumbar disc surgery, but remifentanil use is associated with increased perioperative analgesic requirements. (C) 2015 Elsevier Inc. All rights reserved.	[Thomas, Berlet] Gemeinschaftskrankenhaus Herdecke, Dept Anesthesia, D-58313 Herdecke, Germany	Thomas, B (reprint author), Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland.	thomas.berlet@insel.ch		Berlet, Thomas/0000-0001-9535-508X			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Bouillon T, 1999, ANESTHESIOLOGY, V90, P7, DOI 10.1097/00000542-199901000-00004; Coskun D, 2010, J ANESTH, V24, P373, DOI 10.1007/s00540-010-0898-1; Del Gaudio A, 2006, MINERVA ANESTESIOL, V72, P309; Dexter F, 2007, ANN SURG, V245, P336, DOI 10.1097/01.sla.0000253097.64557.7a; Gaszynski TM, 2004, OBES SURG, V14, P498, DOI 10.1381/096089204323013488; Gorina Y, 2012, COMP RATES ALL LISTE; Horrichs-Haermeyer G, 2002, ANASTH INTENSIVMED, V43, P517; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Kostopanagiotou G, 2005, J CLIN ANESTH, V17, P16, DOI 10.1016/j.jclinane.2004.03.008; Lacombe GF, 2006, J ORAL MAXIL SURG, V64, P215, DOI 10.1016/j.joms.2005.10.026; Naito Aya, 2009, Masui, V58, P77; Nakada T, 2010, J ANESTH, V24, P832, DOI 10.1007/s00540-010-1006-2; Takayama A, 2012, J ANESTH, V26, P34, DOI 10.1007/s00540-011-1266-5; Twersky RS, 2001, J CLIN ANESTH, V13, P407, DOI 10.1016/S0952-8180(01)00292-6; Williams BA, 2000, ANESTHESIOLOGY, V93, P529, DOI 10.1097/00000542-200008000-00033; World Health Organization, 2004, ICD 10 INT STAT CLAS	17	1	1	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	AUG	2015	27	5					391	395		10.1016/j.jclinane.2015.03.024			5	Anesthesiology	Anesthesiology	CL5KJ	WOS:000356998500005	25912730				2020-06-30	J	Sharp, PS; Shaw, K; Boorman, L; Harris, S; Kennerley, AJ; Azzouz, M; Berwick, J				Sharp, Paul S.; Shaw, Kira; Boorman, Luke; Harris, Samuel; Kennerley, Aneurin J.; Azzouz, Mimoun; Berwick, Jason			Comparison of stimulus-evoked cerebral hemodynamics in the awake mouse and under a novel anesthetic regime	SCIENTIFIC REPORTS			English	Article							OPTICAL IMAGING SPECTROSCOPY; CORTEX IN-VIVO; BLOOD-FLOW; BOLD SIGNAL; VISUAL-CORTEX; INDUCED VASODILATION; SENSORY STIMULATION; ALZHEIMERS-DISEASE; GENERAL-ANESTHESIA; RESPONSE FUNCTION	Neural activity is closely followed by a localised change in cerebral blood flow, a process termed neurovascular coupling. These hemodynamic changes form the basis of contrast in functional magnetic resonance imaging (fMRI) and are used as a correlate for neural activity. Anesthesia is widely employed in animal fMRI and neurovascular studies, however anesthetics are known to profoundly affect neural and vascular physiology, particularly in mice. Therefore, we investigated the efficacy of a novel 'modular' anesthesia that combined injectable (fentanyl-fluanisone/midazolam) and volatile (isoflurane) anesthetics in mice. To characterize sensory-evoked cortical hemodynamic responses, we used optical imaging spectroscopy to produce functional maps of changes in tissue oxygenation and blood volume in response to mechanical whisker stimulation. Following fine-tuning of the anesthetic regime, stimulation elicited large and robust hemodynamic responses in the somatosensory cortex, characterized by fast arterial activation, increases in total and oxygenated hemoglobin, and decreases in deoxygenated hemoglobin. Overall, the magnitude and speed of evoked hemodynamic responses under anesthesia resembled those in the awake state, indicating that the novel anesthetic combination significantly minimizes the impact of anesthesia. Our findings have broad implications for both neurovascular research and longitudinal fMRI studies that increasingly require the use of genetically engineered mice.	[Sharp, Paul S.; Shaw, Kira; Boorman, Luke; Harris, Samuel; Kennerley, Aneurin J.; Berwick, Jason] Univ Sheffield, Dept Psychol, Sheffield S10 2TN, S Yorkshire, England; [Sharp, Paul S.; Azzouz, Mimoun] Univ Sheffield, Dept Neurosci, Sheffield Inst Translat Neurosci, Sheffield S10 2TN, S Yorkshire, England	Sharp, PS (reprint author), Univ Sheffield, Dept Psychol, Sheffield S10 2TN, S Yorkshire, England.	p.sharp@sheffield.ac.uk	Berwick, Jason/P-6950-2017; Azzouz, Mimoun/B-3979-2009	Berwick, Jason/0000-0003-4026-0088; Harris, Samuel/0000-0001-6666-9485; Azzouz, Mimoun/0000-0001-6564-5967; Shaw, Kira/0000-0003-3889-1171	Medical Research Council UKMedical Research Council UK (MRC) [G1002194]; Alzheimer's Research UK (ARUK-IRG); Alzheimers Research UKAlzheimer's Research UK (ARUK) [ARUK-IRG2014-10]; Medical Research CouncilMedical Research Council UK (MRC) [G1002194]	This work was funded by the Medical Research Council UK (G1002194) and the Alzheimer's Research UK (ARUK-IRG2014). The authors would like to thank Michael Port for his technical assistance.	Adamczak JM, 2010, NEUROIMAGE, V51, P704, DOI 10.1016/j.neuroimage.2010.02.083; Ahrens ET, 2001, NMR BIOMED, V14, P318, DOI 10.1002/nbm.709; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P744, DOI 10.1097/01.WCB.0000122745.72175.D5; Berwick J, 2008, J NEUROPHYSIOL, V99, P787, DOI 10.1152/jn.00658.2007; Berwick J, 2005, EUR J NEUROSCI, V22, P1655, DOI 10.1111/j.1460-9568.2005.04347.x; Bonder DE, 2014, J NEUROSCI, V34, P13139, DOI 10.1523/JNEUROSCI.2591-14.2014; Boorman L, 2010, J NEUROSCI, V30, P4285, DOI 10.1523/JNEUROSCI.6063-09.2010; Bosshard SC, 2010, PAIN, V151, P655, DOI 10.1016/j.pain.2010.08.025; Buxton RB, 1998, MAGNET RESON MED, V39, P855, DOI 10.1002/mrm.1910390602; Buxton RB, 1997, J CEREBR BLOOD F MET, V17, P64, DOI 10.1097/00004647-199701000-00009; Castro-Alamancos MA, 2004, NEURON, V41, P455, DOI 10.1016/S0896-6273(03)00853-5; Cesarovic N, 2012, J AM ASSOC LAB ANIM, V51, P209; Colussi GL, 2011, HYPERTENS RES, V34, P929, DOI 10.1038/hr.2011.62; Dombeck DA, 2007, NEURON, V56, P43, DOI 10.1016/j.neuron.2007.08.003; Drew PJ, 2010, NAT METHODS, V7, P981, DOI 10.1038/NMETH.1530; Enderle AK, 2008, VET ANAESTH ANALG, V35, P297, DOI 10.1111/j.1467-2995.2007.00391.x; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Grandjean J, 2014, NEUROIMAGE, V102, P838, DOI 10.1016/j.neuroimage.2014.08.043; GRINVALD A, 1991, P NATL ACAD SCI USA, V88, P11559, DOI 10.1073/pnas.88.24.11559; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Hall CN, 2014, NATURE, V508, P55, DOI 10.1038/nature13165; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; Hillman EMC, 2014, ANNU REV NEUROSCI, V37, P161, DOI 10.1146/annurev-neuro-071013-014111; Hoge RD, 1999, MAGNET RESON MED, V42, P849, DOI 10.1002/(SICI)1522-2594(199911)42:5<849::AID-MRM4>3.0.CO;2-Z; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Iadecola C, 2013, NEURON, V80, P844, DOI 10.1016/j.neuron.2013.10.008; Jonckers E, 2014, MAGN RESON MED, V72, P1103, DOI 10.1002/mrm.24990; Kahn I, 2011, J NEUROSCI, V31, P15086, DOI 10.1523/JNEUROSCI.0007-11.2011; Kenner AJ, 2012, NEUROIMAGE, V61, P10, DOI 10.1016/j.neuroimage.2012.03.015; Kennerley AJ, 2005, MAGN RESON MED, V54, P354, DOI 10.1002/mrm.20511; Kennerley AJ, 2009, NEUROIMAGE, V47, P1608, DOI 10.1016/j.neuroimage.2009.05.092; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Lind BL, 2013, P NATL ACAD SCI USA, V110, pE4678, DOI 10.1073/pnas.1310065110; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Logothetis NK, 1999, NAT NEUROSCI, V2, P555, DOI 10.1038/9210; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Malonek D, 1997, P NATL ACAD SCI USA, V94, P14826, DOI 10.1073/pnas.94.26.14826; Martin C, 2006, NEUROIMAGE, V32, P33, DOI 10.1016/j.neuroimage.2006.02.021; Martin C, 2013, NEUROIMAGE, V66, P1, DOI 10.1016/j.neuroimage.2012.10.006; Martindale J, 2008, MAGN RESON MED, V59, P607, DOI 10.1002/mrm.21512; Masamoto K, 2012, J CEREBR BLOOD F MET, V32, P1233, DOI 10.1038/jcbfm.2012.50; Masamoto K, 2009, EUR J NEUROSCI, V30, P242, DOI 10.1111/j.1460-9568.2009.06812.x; Nair G, 2004, MAGN RESON MED, V52, P430, DOI 10.1002/mrm.20158; Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P1354, DOI 10.1038/jcbfm.2011.43; Niwa K, 2000, P NATL ACAD SCI USA, V97, P9735, DOI 10.1073/pnas.97.17.9735; Nizar K, 2013, J NEUROSCI, V33, P8411, DOI 10.1523/JNEUROSCI.3285-12.2013; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Otsu Y, 2015, NAT NEUROSCI, V18, P210, DOI 10.1038/nn.3906; Peeters RR, 2001, MAGN RESON IMAGING, V19, P821, DOI 10.1016/S0730-725X(01)00391-5; Pisauro MA, 2013, J NEUROSCI, V33, P18343, DOI 10.1523/JNEUROSCI.2130-13.2013; Prakash N, 2007, NEUROIMAGE, V37, pS27, DOI 10.1016/j.neuroimage.2007.04.063; Schaffer CB, 2006, PLOS BIOL, V4, P258, DOI 10.1371/journal.pbio.0040022; Schroeter A, 2014, NEUROIMAGE, V94, P372, DOI 10.1016/j.neuroimage.2014.01.046; Schulte ML, 2006, NEUROSCI LETT, V394, P63, DOI 10.1016/j.neulet.2005.10.008; Shtoyerman E, 2000, J NEUROSCI, V20, P8111; Takuwa H, 2011, BRAIN RES, V1369, P103, DOI 10.1016/j.brainres.2010.11.007; Thrane AS, 2012, P NATL ACAD SCI USA, V109, P18974, DOI 10.1073/pnas.1209448109; Tian PF, 2010, P NATL ACAD SCI USA, V107, P15246, DOI 10.1073/pnas.1006735107; Urban A, 2014, NEUROIMAGE, V101, P138, DOI 10.1016/j.neuroimage.2014.06.063; Wang XH, 2006, NAT NEUROSCI, V9, P816, DOI 10.1038/nn1703	61	16	16	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 28	2015	5								12621	10.1038/srep12621			12	Multidisciplinary Sciences	Science & Technology - Other Topics	CN6ZT	WOS:000358584000001	26218081	DOAJ Gold, Green Published, Green Accepted			2020-06-30	J	Martikainen, IK; Nuechterlein, EB; Pecina, M; Love, TM; Cummiford, CM; Green, CR; Stohler, CS; Zubieta, JK				Martikainen, Ilkka K.; Nuechterlein, Emily B.; Pecina, Marta; Love, Tiffany M.; Cummiford, Chelsea M.; Green, Carmen R.; Stohler, Christian S.; Zubieta, Jon-Kar			Chronic Back Pain Is Associated with Alterations in Dopamine Neurotransmission in the Ventral Striatum	JOURNAL OF NEUROSCIENCE			English	Article						amygdala; chronic pain; dopamine; endogenous opioid; striatum	D2 RECEPTOR-BINDING; NUCLEUS-ACCUMBENS; AFFECTIVE DIMENSIONS; CONTINUOUS-INFUSION; NOXIOUS STIMULI; POSITIVE AFFECT; BASAL GANGLIA; FORMALIN TEST; HUMAN BRAIN; ANALGESIA	Back pain is common in the general population, but only a subgroup of back pain patients develops a disabling chronic pain state. The reasons for this are incompletely understood, but recent evidence implies that both preexisting and pain-related variations in the structure and function of the nervous system may contribute significantly to the development of chronic pain. Here, we addressed the role of striatal dopamine (DA) D2/D3 receptor (D2/D3R) function in chronic non-neuropathic back pain (CNBP) by comparing CNBP patients and healthy controls using PET and the D2/D3R-selective radioligand [C-11]raclopride. D2/D3R availability was measured at baseline and during a pain challenge, yielding in vivo measures of receptor availability (binding potential, BPND) and DA release (change in BPND from baseline to activated state). At baseline, CNBP patients demonstrated reductions in D2/D3R BPND in the ventral striatum compared with controls. These reductions were associated with greater positive affect scores and pain tolerance measures. The reductions in D2/D3R BPND were also correlated with mu-opioid receptor BPND and pain-induced endogenous opioid system activation in the amygdala, further associated with measures of positive affect, the affective component of back pain and pain tolerance. During the pain challenge, lower magnitudes of DA release, and therefore D2/D3R activation, were also found in the ventral striatum in the CNBP sample compared with controls. Our results show that CNBP is associated with adaptations in ventral striatal D2/D3R function, which, together with endogenous opioid system function, contribute to the sensory and affective-motivational features of CNBP.	[Martikainen, Ilkka K.; Nuechterlein, Emily B.; Pecina, Marta; Love, Tiffany M.; Cummiford, Chelsea M.; Zubieta, Jon-Kar] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Pecina, Marta; Love, Tiffany M.; Zubieta, Jon-Kar] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Green, Carmen R.] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA; [Green, Carmen R.] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; [Green, Carmen R.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Nuechterlein, Emily B.] Univ Michigan, Neurosci Grad Program, Ann Arbor, MI 48104 USA; [Stohler, Christian S.] Columbia Univ, Coll Dent Med, New York, NY 10032 USA	Zubieta, JK (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu	Love, Tiffany/W-8427-2019; STOHLER, CHRISTIAN/AAQ-7539-2020; Pecina, Marta/W-7135-2019	Love, Tiffany/0000-0001-9299-3190; Kaplan, Chelsea/0000-0001-9324-655X	National Institute on Drug Abuse-National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA 022520, R01 027494]; Phil F. Jenkins Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32EY017878, 5T32DA007281]	This work was supported by the National Institute on Drug Abuse-National Institutes of Health (Grants R01 DA 022520 and R01 027494) and the Phil F. Jenkins Foundation. E.B.N. was supported in part by the National Institutes of Health (Grants 5T32EY017878 and 5T32DA007281). We thank nurses Kathleen Singer and Laurie Carr for patient screening and recruitment and the nuclear medicine technologists at the Positron Emission Tomography Center at the University of Michigan for the assistance in PET data acquisition and reconstruction.	ABERCROMBIE ED, 1989, J NEUROCHEM, V52, P1655, DOI 10.1111/j.1471-4159.1989.tb09224.x; Altier N, 1999, LIFE SCI, V65, P2269, DOI 10.1016/S0024-3205(99)00298-2; Austin PJ, 2010, NEUROSCIENCE, V171, P329, DOI 10.1016/j.neuroscience.2010.08.040; Baliki MN, 2012, NAT NEUROSCI, V15, P1117, DOI 10.1038/nn.3153; Baliki MN, 2010, NEURON, V66, P149, DOI 10.1016/j.neuron.2010.03.002; Becker S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080766; Brischoux F, 2009, P NATL ACAD SCI USA, V106, P4894, DOI 10.1073/pnas.0811507106; Burgdorf J, 2006, NEUROSCI BIOBEHAV R, V30, P173, DOI 10.1016/j.neubiorev.2005.06.001; Carson RE, 1997, J CEREBR BLOOD F MET, V17, P437, DOI 10.1097/00004647-199704000-00009; Chang PC, 2014, PAIN, V155, P1128, DOI 10.1016/j.pain.2014.02.019; CHEN JF, 1993, NEUROSCIENCE, V54, P669, DOI 10.1016/0306-4522(93)90238-B; Clark L. A., 1999, MANUAL POSITIVE NEGA; Clauw DJ, 1999, SPINE, V24, P2035, DOI 10.1097/00007632-199910010-00013; Coghill RC, 1999, J NEUROPHYSIOL, V82, P1934; Edwards RR, 2003, PAIN, V106, P419, DOI 10.1016/j.pain.2003.09.004; Fudge JL, 2000, NEUROSCIENCE, V97, P479, DOI 10.1016/S0306-4522(00)00092-0; Gear RW, 1999, J NEUROSCI, V19, P7175, DOI 10.1523/JNEUROSCI.19-16-07175.1999; Giesecke T, 2004, ARTHRITIS RHEUM-US, V50, P613, DOI 10.1002/art.20063; Haber SN, 2003, J CHEM NEUROANAT, V26, P317, DOI 10.1016/j.jchemneu.2003.10.003; Haber SN, 2011, NEUROBIOLOGY SENSATI; Hagelberg N, 2003, PAIN, V106, P43, DOI 10.1016/S0304-3959(03)00275-6; Hagelberg N, 2003, PAIN, V101, P149, DOI 10.1016/S0304-3959(02)00323-8; Hagelberg N, 2002, PAIN, V99, P273, DOI 10.1016/S0304-3959(02)00121-5; Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1; Jaaskelainen SK, 2014, PAIN, V155, P2180, DOI 10.1016/j.pain.2014.08.029; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; KELLEY AE, 1982, NEUROSCIENCE, V7, P615, DOI 10.1016/0306-4522(82)90067-7; Ladouceur A, 2012, PAIN, V153, P1755, DOI 10.1016/j.pain.2012.05.019; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Magnusson JE, 2000, BRAIN RES, V855, P260, DOI 10.1016/S0006-8993(99)02396-3; Martikainen IK, 2013, J NEUROSCI, V33, P14729, DOI 10.1523/JNEUROSCI.1400-13.2013; McNair DM, 1992, EDITS MANUAL PROFILE; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; MINOSHIMA S, 1993, J NUCL MED, V34, P322; MORGAN MJ, 1991, PHARMACOL BIOCHEM BE, V40, P317, DOI 10.1016/0091-3057(91)90560-O; MORGAN MJ, 1990, BRAIN RES, V519, P144, DOI 10.1016/0006-8993(90)90072-J; O'Neill S, 2007, EUR J PAIN, V11, P415, DOI 10.1016/j.ejpain.2006.05.009; Phillips AG, 2003, NEUROSCI BIOBEHAV R, V27, P543, DOI 10.1016/j.neubiorev.2003.09.002; Rouge Pont F, 1993, BRAIN RES, V602, P169; Salamone JD, 2012, NEURON, V76, P470, DOI 10.1016/j.neuron.2012.10.021; Schmidt BL, 2002, J NEUROSCI, V22, P6773; Schwartz N, 2014, SCIENCE, V345, P535, DOI 10.1126/science.1253994; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, SYNAPSE, V61, P707, DOI 10.1002/syn.20404; Scott DJ, 2006, J NEUROSCI, V26, P10789, DOI 10.1523/JNEUROSCI.2577-06.2006; Seeman P, 2006, SYNAPSE, V60, P205, DOI 10.1002/syn.20298; Soderman AR, 2009, BRAIN RES, V1296, P63, DOI 10.1016/j.brainres.2009.08.035; Sowman PF, 2011, EUR J PAIN, V15, P139, DOI 10.1016/j.ejpain.2010.06.009; Steiner H, 1998, EXP BRAIN RES, V123, P60, DOI 10.1007/s002210050545; Stohler CS, 1999, PAIN, V79, P165, DOI 10.1016/S0304-3959(98)00171-7; Strand EB, 2006, J PSYCHOSOM RES, V60, P477, DOI 10.1016/j.jpsychores.2005.08.010; Tang NKY, 2008, PAIN, V138, P392, DOI 10.1016/j.pain.2008.01.018; Taylor BK, 2003, BRAIN RES, V987, P135, DOI 10.1016/S0006-8993(03)03318-3; Tiemann L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096167; Treister R, 2009, PAIN, V147, P187, DOI 10.1016/j.pain.2009.09.001; Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575; Von Korff M, 2005, PAIN, V117, P304, DOI 10.1016/j.pain.2005.06.017; Watabe H, 2000, J NUCL MED, V41, P522; Wood PB, 2007, EUR J NEUROSCI, V25, P3576, DOI 10.1111/j.1460-9568.2007.05623.x; Zautra AJ, 2005, J CONSULT CLIN PSYCH, V73, P212, DOI 10.1037/0022-006X.73.2.212; ZHANG X, 1993, IEEE T BIO-MED ENG, V40, P344, DOI 10.1109/10.222327; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	62	58	59	1	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 8	2015	35	27					9957	9965		10.1523/JNEUROSCI.4605-14.2015			9	Neurosciences	Neurosciences & Neurology	CN2LT	WOS:000358253400016	26156996	Green Published, Bronze			2020-06-30	J	Cai, B; Engqvist, H; Bredenberg, S				Cai, Bing; Engqvist, Hakan; Bredenberg, Susanne			Development and evaluation of a tampering resistant transdermal fentanyl patch	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Transdermal patch; Tamper-resistance; Geopolymer; Fentanyl; Abuse; Drug delivery	NARCOTIC ANALGESICS; SOLUBILITY; SYSTEM; ABUSE	With the increasing number of misuse and abuse of opioids, the resistance to tampering becomes an important attribute for transdermal opioid patches. In this study, drug-containing geopolymer granules were integrated into an adhesive matrix to improve the resistance of fast drug release against some common abuse techniques. Bench testing showed that fentanyl loaded geopolymer granules had better resistance to tampering compared to a commercial fentanyl patch. Moreover, in a pilot in vivo study on a few rats, the granules showed potential to give similar drug plasma concentrations as the commercial fentanyl patch. After integrating geopolymer granules into an adhesive matrix, the new patch showed a better resistance against the investigated tampering tests compared with the commercially available patch. In this study, we showed that incorporating drug loaded geopolymer granules into a patch adhesive has potential to improve the resistance of the fentanyl patch against tampering without compromising the drug release. (C) 2015 Elsevier B.V. All rights reserved.	[Cai, Bing; Engqvist, Hakan; Bredenberg, Susanne] Uppsala Univ, Angstrom Lab, Dept Engn Sci, Div Appl Mat Sci, SE-75121 Uppsala, Sweden	Engqvist, H (reprint author), Uppsala Univ, Angstrom Lab, Dept Engn Sci, Div Appl Mat Sci, Box 534, SE-75121 Uppsala, Sweden.	hakan.engqvist@angstrom.uu.se			Sweden's Innovation Agency (VINNOVA)Vinnova; Swedish Research CouncilSwedish Research Council [2011-3399, 2011-4444]	This work has received support from Orexo AB for kind contribution of the materials and Sweden's Innovation Agency (VINNOVA) and the Swedish Research Council (2011-3399 and 2011-4444) for financial contributions. Karin Soderkvist, Anders Sagstrom, Cecilia Coupland, Sari Obrink, Ulrica Roos are acknowledged for some of the experimental works.	[Anonymous], 2010, The DAWN Report: Trends in Emergency Department Visits Involving Nonmedical Use of Narcotic Pain Relievers, Patent No. [20050002997, US 20050002997 Al]; [Anonymous], 2013, GUIDANCE IND ABUSE D; [Anonymous], 2010, GUIDANCE IND ASSESSM; [Anonymous], 2010, Guidance for Industry Assessment of Abuse Potential of Drugs, Patent No. [US20070065365 Al, 20070065365]; [Anonymous], 2010, DAWN REPORT TRENDS E; [Anonymous], 2013, Guidance for Industry Abuse-Deterrent Opioids - Evaluation and Labeling, Draft Guidance, Patent No. [WO 2004098567 A3, 2004098567]; Butler S. F., 2011, HARM REDUCT J, V19, P8, DOI DOI 10.1186/1477-7517-8-29; Cai B, 2014, INT J PHARMACEUT, V465, P169, DOI 10.1016/j.ijpharm.2014.02.029; Carson HJ, 2010, LEGAL MED, V12, P157, DOI 10.1016/j.legalmed.2010.03.001; Goliber P.A., 2005, BENCHTOP EVALUATIONS; Howard S.A., 2005, Patent No. [WO 2004098567 A3, 2062573]; Howard S.A., 2004, Patent No. [US 20050002997 Al, 7182955, US 7182955 B2]; Jamstorp Erik, 2012, Results Pharma Sci, V2, P23, DOI 10.1016/j.rinphs.2012.02.001; Jamstorp E, 2011, J PHARM SCI-US, V100, P4338, DOI 10.1002/jps.22636; Jamstorp E, 2010, J CONTROL RELEASE, V146, P370, DOI 10.1016/j.jconrel.2010.05.029; Katz NP, 2006, DRUG DEV IND PHARM, V32, P727, DOI 10.1080/03639040500529093; Kugelmann H., 2006, Patent No. [US20070065365 Al, 20090156814, US 20090156814 Al]; Margetts L, 2007, BJA EDUC, V7, P171, DOI 10.1093/bjaceaccp/mkm033; Mastropietro DJ, 2013, DRUG DEV IND PHARM, V39, P611, DOI 10.3109/03639045.2012.680468; Moon JM, 2011, J EMERG MED, V40, P37, DOI 10.1016/j.jemermed.2007.10.075; Prosser JM, 2010, J MED TOXICOL, V6, P443, DOI 10.1007/s13181-010-0092-8; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	25	6	6	0	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173	1873-3476		INT J PHARMACEUT	Int. J. Pharm.	JUL 5	2015	488	1-2					102	107		10.1016/j.ijpharm.2015.04.061			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CK0HU	WOS:000355887100013	25913120				2020-06-30	J	McIntyre, IM; Trochta, A; Gary, RD; Malamatos, M; Lucas, JR				McIntyre, Iain M.; Trochta, Amber; Gary, Ray D.; Malamatos, Mark; Lucas, Jonathan R.			An Acute Acetyl Fentanyl Fatality: A Case Report With Postmortem Concentrations	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							REDISTRIBUTION; BLOOD; LIVER	In this case report, we present an evaluation of the distribution of postmortem concentrations of acetyl fentanyl in a fatality attributed to the drug. A young man who had a history of heroin abuse was found deceased at his parents' home. Toxicology testing, which initially screened positive for fentanyl by ELISA, subsequently confirmed acetyl fentanyl by gas chromatography-mass spectrometry specific ion monitoring (GC-MS SIM) analysis following liquid-liquid extraction. No other drugs or medications, including fentanyl, were detected. The acetyl fentanyl peripheral blood concentration was quantified at 260 ng/mL compared with the central blood concentration of 250 ng/mL. The liver concentration was 1,000 ng/kg, the vitreous was 240 ng/mL and the urine was 2,600 ng/mL. The cause of death was certified due to acute acetyl fentanyl intoxication, and the manner of death was certified as an accident.	[McIntyre, Iain M.; Trochta, Amber; Gary, Ray D.; Malamatos, Mark; Lucas, Jonathan R.] Cty San Diego Med Examiners Off, San Diego, CA 92123 USA	McIntyre, IM (reprint author), Cty San Diego Med Examiners Off, 5570 Overland Ave,Suite 101, San Diego, CA 92123 USA.	iain.mcintyre@sdcounty.ca.gov		McIntyre, Iain/0000-0002-0284-6152			Baselt R., PREPARATION DISPOSIT; Dalpe-Scott M, 1995, CAN SOC FORENSIC SCI, V28, P113; Drug Enforcement Administration, 2013, AC FENT N 1PHEN 4 YL; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; McIntyre IM, 2015, J ANAL TOXICOL, V39, P156, DOI 10.1093/jat/bku131; McIntyre IM, 2014, FORENSIC SCI MED PAT, V10, P91, DOI 10.1007/s12024-013-9503-x; McIntyre IM, 2014, INT J LEGAL MED, V128, P65, DOI 10.1007/s00414-013-0897-5; McIntyre IM, 2012, J ANAL TOXICOL, V36, P177, DOI 10.1093/jat/bks011; North Carolina Department of Health and Human Services, 2014, DHHS ISS HLTH ADV DE; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Pennsylvania Department of Drug and Alcohol Programs, 2013, DEP DRUG ALC PROGR W; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103	17	48	49	0	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUL-AUG	2015	39	6					490	494		10.1093/jat/bkv043			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	CP2TM	WOS:000359730100011	25917447	Bronze			2020-06-30	J	Wen, YY; Wang, MD; Yang, JF; Wang, YC; Sun, HP; Zhao, JH; Liu, WZ; Zhou, ZY; Deng, HW; Castillo-Pedraza, C; Zhang, Y; Candiotti, KA				Wen, Yiyun; Wang, Mingde; Yang, Jinfeng; Wang, Yichun; Sun, Huiping; Zhao, Jianghong; Liu, Weizhen; Zhou, Zhengyu; Deng, Hongwu; Castillo-Pedraza, Catalina; Zhang, Yi; Candiotti, Keith A.			A Comparison of Fentanyl and Flurbiprofen Axetil on Serum VEGF-C, TNF-alpha, and IL-1 beta Concentrations in Women Undergoing Surgery for Breast Cancer	PAIN PRACTICE			English	Article						analgesia; postoperative pain; immunologic factors	ENDOTHELIAL GROWTH-FACTOR; POSTOPERATIVE PAIN; GENERAL-ANESTHESIA; TUMOR-METASTASIS; INFLAMMATION; ANGIOGENESIS; EXPRESSION; INTERLEUKIN-1-BETA; LYMPHANGIOGENESIS; TUMORIGENESIS	Background: Vascular endothelial growth factor-C (VEGF-C), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 beta(IL-1 beta) have been shown to be associated with the recurrence and metastasis of breast cancer after surgery. This study tested the hypothesis that patients undergoing surgery for breast cancer, who received postoperative analgesia with flurbiprofen axetil combined with small doses of fentanyl (FA), exhibited reduced levels of VEGF-C, TNF-alpha, and IL-1 beta compared with those patients receiving fentanyl alone (F). Method: Forty-women with primary breast cancer undergoing a modified radical mastectomy were randomized to receive postoperative analgesia with flurbiprofen axetil combined with fentanyl or fentanyl alone. Venous blood was sampled before anesthesia, at the end of surgery, and at 48 hours after surgery, and the serum was analyzed. The primary endpoint was changes in the VEGF-C concentrations in serum. Results: Group FA patients reported similar analgesic effects as group F patients at 2, 24, and 48 hours. At 48 hours, mean postoperative concentrations of VEGF-C in group F patients were higher than in group FA patients, 730.9 versus. 354.1 pg/mL (P = 0.003), respectively. The mean postoperative concentrations of TNF-alpha in group F patients were also higher compared with group FA patients 27.1 vs. 15.8 pg/mL (P = 0.005). Finally, the mean postoperative concentrations of IL-1 beta in group F were also significantly higher than in group FA 497.5 vs. 197.7 pg/mL (P = 0.001). Conclusion: In patients undergoing a mastectomy, postoperative analgesia with flurbiprofen axetil, combined with fentanyl, were associated with decreases in serum concentrations of VEGF-C, TNF-alpha, and IL-1 beta compared with patients receiving doses of only fentanyl.	[Wen, Yiyun; Wang, Mingde; Yang, Jinfeng; Sun, Huiping; Zhao, Jianghong; Liu, Weizhen] Cent S Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Dept Anesthesiol,Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China; [Wang, Yichun] Cent S Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Dept ICU,Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China; [Zhou, Zhengyu; Deng, Hongwu; Zhang, Yi] Cent S Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Care Cent Breast Canc,Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China; [Castillo-Pedraza, Catalina; Candiotti, Keith A.] Univ Miami, Miller Sch Med, Dept Anesthesiol Perioperat Med & Pain Management, Miami, FL 33136 USA	Candiotti, KA (reprint author), Univ Miami, Miller Sch Med, Dept Anesthesiol, 1611 Northwest 12th Ave,Cent 130 R-370, Miami, FL 33136 USA.	KCandiot@med.miami.edu					Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Bendre MS, 2002, CANCER RES, V62, P5571; Brand JM, 1997, CLIN IMMUNOL IMMUNOP, V83, P190, DOI 10.1006/clin.1997.4351; Brand JM, 2003, SHOCK, V20, P213, DOI 10.1097/00024382-200309000-00003; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; DAHL JB, 1991, BRIT J ANAESTH, V66, P703, DOI 10.1093/bja/66.6.703; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Delogu G, 2004, J TRAUMA, V57, P75, DOI 10.1097/01.TA.0000075349.66640.3E; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Foekens JA, 2001, CANCER RES, V61, P5407; Heer K, 1998, BRIT J CANCER, V78, P1203, DOI 10.1038/bjc.1998.655; Hussain SP, 2007, INT J CANCER, V121, P2373, DOI 10.1002/ijc.23173; Jin L, 1997, CANCER-AM CANCER SOC, V80, P421, DOI 10.1002/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z; MIZUSHIMA Y, 1986, J PHARM PHARMACOL, V38, P132, DOI 10.1111/j.2042-7158.1986.tb04527.x; Ng A, 2002, BRIT J ANAESTH, V88, P714, DOI 10.1093/bja/88.5.714; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pinto MP, 2010, CANCER RES, V70, P2655, DOI 10.1158/0008-5472.CAN-09-4373; Rao VSR, 2006, ONCOL REP, V15, P179; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Shaheen RM, 1999, CANCER RES, V59, P5412; Shakhar G, 2003, ANN SURG ONCOL, V10, P972, DOI 10.1245/ASO.2003.02.007; Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Timoshenko AV, 2006, BRIT J CANCER, V94, P1154, DOI 10.1038/sj.bjc.6603067; Tsuchiya Y, 2003, SURGERY, V133, P547, DOI 10.1067/msy.2003.141; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Washington C, 1996, ADV DRUG DELIVER REV, V20, P131, DOI 10.1016/0169-409X(95)00116-O	34	10	11	4	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	JUL	2015	15	6					530	537		10.1111/papr.12206			8	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	CP4AJ	WOS:000359824100008	24807396				2020-06-30	J	Rauck, R; Parikh, N; Dillaha, L; Barker, J; Stearns, L				Rauck, Richard; Parikh, Neha; Dillaha, Larry; Barker, Jerry; Stearns, Lisa			Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain	PAIN PRACTICE			English	Article						breakthrough pain; cancer; fentanyl; opioid; patient satisfaction; sublingual	DOUBLE-BLIND; DOSE-TITRATION; CITRATE; PREVALENCE; MULTICENTER; XEROSTOMIA; EFFICACY; IMPACT	Objectives: Breakthrough cancer pain (BTCP) is associated with decreased satisfaction with around-the-clock opioid therapy. This analysis examined patient satisfaction with fentanyl sublingual spray for BTCP during the open-label titration period of a randomized, placebo-controlled study. Methods: Opioid-tolerant patients with 1 to 4 daily BTCP episodes were included. During a 26-day, open-label titration phase, a successful dose (100 to 1600 mcg) of fentanyl sublingual spray was established that provided effective analgesia for 2 consecutive BTCP episodes with tolerable side effects. The Treatment Satisfaction Questionnaire for Medication (TSQM) was administered at baseline to assess satisfaction with previous BTCP medication and at the end of the titration to assess satisfaction with fentanyl sublingual spray. Results: Of 130 enrolled patients, 115 (88.5%) had a TSQM measure at baseline and at the end of their titration period. Scores on all 4 TSQM domains increased from baseline to end of the titration, with mean (standard error [SE]) improvements of 22.3 (2.3) for effectiveness, 7.7 (3.2) for side effects, 6.8 (2.2) for convenience, and 12.9 (2.8) for global satisfaction (P < 0.05 for all). Satisfaction with symptom relief (26.1% to 77.4%) and onset of action (21.7% to 82.6%) also improved from baseline to end of titration. At least one adverse event (AE) was reported by 78 patients (60.0%). The most common AEs considered possibly or probably related to study medication were dizziness, somnolence, and nausea (n = 10 [7.7%] each). Discussion: These data indicate markedly improved satisfaction among patients receiving fentanyl sublingual spray relative to previous BTCP medications.	[Rauck, Richard] Clin Res Ctr, Winston Salem, NC USA; [Parikh, Neha; Dillaha, Larry] INSYS Therapeut Inc, Chandler, AZ USA; [Barker, Jerry] Baylor Res Inst, Ft Worth, TX USA; [Stearns, Lisa] Ctr Pain & Support Care, Scottsdale, AZ USA	Rauck, R (reprint author), Carolinas Pain Inst, Clin Res Ctr, 145 Kimel Pk Dr, Winston Salem, NC 27103 USA.	rrauck@ccrpain.org			Insys Therapeutics, Inc., Chandler, AZ, U.S.A.	This research was presented in part at the American Pain Society 31st Annual Scientific Meeting, May 16 to 19, 2012, Honolulu, HI. The authors were involved in conceptualizing the article as study sponsors or subinvestigators and were also involved in drafting the article. Additionally, they were familiar with the content and approved submission of the final version. The decision to publish this report was made by all of the authors. Technical editorial and medical writing assistance was provided by Nancy Holland, PhD, Synchrony Medical Communications, LLC, West Chester, PA. Funding for this support was provided by Insys Therapeutics, Inc., Chandler, AZ, U.S.A.	Atkinson Mark J, 2004, Health Qual Life Outcomes, V2, P12, DOI 10.1186/1477-7525-2-12; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 2001, J PAIN SYMPTOM MANAG, V22, P820, DOI 10.1016/S0885-3924(01)00318-9; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; INSYS Therapeutics Inc., 2013, SUBS FENT SUBL SPRAY; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Taylor Donald, 2010, J Support Oncol, V8, P184; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; Veldhorst-Janssen NML, 2012, J PALLIAT MED, V15, P631, DOI 10.1089/jpm.2012.0013; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2010, EUR J PALLIAT CAR S3, V17, P4; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658	27	3	4	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	JUL	2015	15	6					554	563		10.1111/papr.12225			10	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	CP4AJ	WOS:000359824100011	25060406				2020-06-30	J	Muniraman, HK; Yaari, J; Hand, I				Muniraman, Hemananda K.; Yaari, Jonathan; Hand, Ivan			Premedication Use Before Nonemergent Intubation in the Newborn Infant	AMERICAN JOURNAL OF PERINATOLOGY			English	Article						intubation; premedication; neonatologist; neonatal intensive care	NEONATAL ENDOTRACHEAL INTUBATION; RANDOMIZED CONTROLLED-TRIAL; NASOTRACHEAL INTUBATION; PRESSURE; ATROPINE; FACILITATION; MIVACURIUM; MANAGEMENT; RESPONSES; EFFICACY	Objective In 2010, an American Academy of Pediatrics (AAP) clinical report recommended that except for emergent situations, premedication should be used for all endotracheal intubations in newborns. The purpose of this study is to ascertain the current practice of premedication before elective intubation. Study Design An online, survey-based questionnaire on the practice of premedication before nonemergent intubations was distributed via e-mail to neonatologists who are members of the Perinatal Section of the AAP. Results Although 72% of respondents believed premedication should be used in nonemergent intubations, only 34% of the respondents report frequently premedicating before intubation with significant variation among the neonatal units (46% among level 4 units and 27% in level 3 and 2 units) p = 0.000. About 44% of respondents report having a written protocol or guideline on premedication which significantly correlated with the use of premedication (62% in level 4, 33% in level 3, and 16% in level 2 units), p = 0.000. Conclusion Despite a recent AAP clinical report recommending the use of premedication before nonemergent endotracheal intubation, only one-third of neonatologists report frequent use of premedication and less than half of the institutions have a written protocol on premedication.	[Muniraman, Hemananda K.; Yaari, Jonathan; Hand, Ivan] Suny Downstate Med Ctr, Sch Med, Dept Pediat, Brooklyn, NY USA	Hand, I (reprint author), Kings Cty Hosp Ctr, Dept Neonatol, 451 Clarkson Ave, Brooklyn, NY 11203 USA.	handi@nychhc.org	Muniraman, Hemananda Kumar/I-4878-2019	Muniraman, Hemananda Kumar/0000-0003-0254-2607; Hand, Ivan/0000-0002-6262-0980			Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Barrington KJ, 2011, PAED CHILD HEALT-CAN, V16, P159, DOI 10.1093/pch/16.3.159; Bhutada A, 2000, ARCH DIS CHILD-FETAL, V82, pF34, DOI 10.1136/fn.82.1.F34; Bonow Fernanda P., 2004, J. Pediatr. (Rio J.), V80, P355, DOI 10.1590/S0021-75572004000600005; Carbajal R, 2007, SEMIN PERINATOL, V31, P309, DOI 10.1053/j.semperi.2007.07.006; Chaudhary R, 2009, PEDIATR ANESTH, V19, P653, DOI 10.1111/j.1460-9592.2008.02829.x; de Kort EHM, 2013, BIOMED RES INT, DOI 10.1155/2013/892974; Dempsey EM, 2006, ARCH DIS CHILD-FETAL, V91, pF279, DOI 10.1136/adc.2005.087213; FRIESEN RH, 1987, ANESTH ANALG, V66, P874; Ghanta S, 2007, PEDIATRICS, V119, pE1248, DOI 10.1542/peds.2006-2708; GOLDBERG ME, 1989, ANESTH ANALG, V69, P93; Greenwood C S, 2009, NEOREVIEWS, V10, pe31; Hassid S, 2007, PEDIATR ANESTH, V17, P1053, DOI 10.1111/j.1460-9592.2007.02214.x; HICKEY PR, 1985, ANESTH ANALG, V64, P1137; KELLY MA, 1984, J PEDIATR-US, V105, P303, DOI 10.1016/S0022-3476(84)80137-7; Kumar P, 2010, PEDIATRICS, V125, P608, DOI 10.1542/peds.2009-2863; Le CN, 2014, J PERINATOL, V34, P458, DOI 10.1038/jp.2014.32; Lemyre B, 2009, ARCH DIS CHILD-FETAL, V94, pF439, DOI 10.1136/adc.2008.146068; MARSHALL TA, 1984, CRIT CARE MED, V12, P501, DOI 10.1097/00003246-198406000-00006; MILLAR C, 1994, CAN J ANAESTH, V41, P281, DOI 10.1007/BF03009904; Mosalli R, 2012, SAUDI J ANAESTH, V6, P385, DOI 10.4103/1658-354X.105878; O'Donnell CPF, 2006, PEDIATRICS, V117, pE16, DOI 10.1542/peds.2005-0901; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; Porter FL, 1997, PEDIATRICS, V100, P626, DOI 10.1542/peds.100.4.626; RAJU TNK, 1980, J PEDIATR-US, V96, P860, DOI 10.1016/S0022-3476(80)80558-0; Roberts KD, 2006, PEDIATRICS, V118, P1583, DOI 10.1542/peds.2006-0590; Sagarin MJ, 2002, PEDIATR EMERG CARE, V18, P417, DOI 10.1097/00006565-200212000-00004; Sarkar S, 2006, J PERINATOL, V26, P286, DOI 10.1038/sj.jp.7211499; Silva YPE, 2007, ARCH DIS CHILD-FETAL, V92, P293, DOI 10.1136/adc.2006.105262; VanLooy JW, 2008, ANN PHARMACOTHER, V42, P947, DOI 10.1345/aph.1K665; Welzing L, 2009, ACTA PAEDIATR, V98, P1416, DOI [10.1111/j.1651-2227.2009.01364.x, 10.1111/j.0803-5253.2009.01364.x]; Wheeler B, 2012, J PAEDIATR CHILD H, V48, P997, DOI 10.1111/j.1440-1754.2012.02589.x	32	10	10	0	5	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0735-1631	1098-8785		AM J PERINAT	Am. J. Perinatol.	JUL	2015	32	9					821	824		10.1055/s-0034-1543987			4	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	CN6UY	WOS:000358571000003	25607227				2020-06-30	J	Tearney, CC; Barter, LS; Pypendop, BH				Tearney, Caitlin C.; Barter, Linda S.; Pypendop, Bruno H.			Cardiovascular effects of equipotent doses of isoflurane alone and isoflurane plus fentanyl in New Zealand White rabbits (Oryctolagus cuniculus)	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							MINIMUM ALVEOLAR CONCENTRATION; ANESTHESIA; CATS; DOGS; HALOTHANE; HORSES	OBJECTIVE To determine effects of equipotent concentrations of fentanyl and isoflurane, compared with isoflurane alone, on cardiovascular variables in New Zealand White rabbits (Oryctolagus cuniculus). ANIMALS 6 adult female New Zealand White rabbits. PROCEDURES Rabbits were anesthetized with isoflurane, and lungs were mechanically ventilated. The minimum alveolar concentration (MAC) of isoflurane alone (baseline) and with fentanyl administered IV to achieve 3 targeted plasma concentrations was determined for each rabbit by means of an electrical stimulus. Cardiovascular variables were measured in a separate experiment at 1.3X isoflurane MAC and equipotent doses of isoflurane plus fentanyl at the same 3 targeted plasma concentrations. Blood samples were collected for measurement of blood gas variables and plasma fentanyl concentrations. Treatment effects were evaluated by repeated-measures ANOVA followed by 2-tailed paired t tests with sequentially rejective Bonferroni correction. RESULTS Mean +/- SD MAC of isoflurane was 1.95 +/- 0.27%. Mean measured plasma fentanyl concentrations of 4.97, 8.93, and 17.19 ng/mL reduced isoflurane MAC by 17%, 37%, and 56%, respectively. Mean measured plasma fentanyl concentrations during cardiovascular measurements were 5.49, 10.26, and 18.40 ng/mL. Compared with baseline measurements, heart rate was significantly lower at all 3 plasma fentanyl concentrations, mean arterial blood pressure and systemic vascular resistance were significantly higher at mean fentanyl concentrations of 10.26 and 18.40 ng/mL, and cardiac output was significantly higher at 18.40 ng of fentanyl/mL. CONCLUSIONS AND CLINICAL RELEVANCE Administration of fentanyl in isoflurane-anesthetized rabbits resulted in improved mean arterial blood pressure and cardiac output, compared with isoflurane alone. This balanced anesthesia technique may prove useful in the management of clinical cases in this species.	[Tearney, Caitlin C.; Barter, Linda S.; Pypendop, Bruno H.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA	Barter, LS (reprint author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.	lsbarter@ucdavis.edu		Pypendop, Bruno/0000-0002-0894-0991	University of California-Davis Center for Companion Animal HealthUniversity of California System	Supported by the University of California-Davis Center for Companion Animal Health.	AVMA, 2012, US PET OWN DEM SOURC; Barter LS, 2015, AM J VET RES, V76, P111, DOI 10.2460/ajvr.76.2.111; Barter LS, 2013, AM J VET RES, V74, P1274, DOI 10.2460/ajvr.74.10.1274; Brodbelt DC, 2008, VET ANAESTH ANALG, V35, P365, DOI 10.1111/j.1467-2995.2008.00397.x; Chittock DR, 1998, PRINCIPLES PRACTICE, P317; Darovic GO, 2002, HEMODYNAMIC MONITORI, P191; FLECKNELL PA, 1989, LAB ANIM, V23, P147, DOI 10.1258/002367789780863655; Gosliga JM, 2015, AM J VET RES, V76, P116, DOI 10.2460/ajvr.76.2.116; Haskins S, 2005, COMPARATIVE MED, V55, P156; Hedenqvist P, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-21; ILKIW JE, 1994, CAN J VET RES, V58, P248; Ilkiw JE, 1997, AM J VET RES, V58, P1274; Imai A, 1999, AM J VET RES, V60, P1189; LIEBENBERG SP, 1980, LAB ANIM, V14, P297, DOI 10.1258/002367780781071012; Monteiro ER, 2010, AM J VET RES, V71, P1133, DOI 10.2460/ajvr.71.10.1133; Pascoe PJ, 1997, AM J VET RES, V58, P1267; Pitsikoulis C, 2008, RESP PHYSIOL NEUROBI, V164, P373, DOI 10.1016/j.resp.2008.08.010; Pypendop BH, 2004, AM J VET RES, V65, P20, DOI 10.2460/ajvr.2004.65.20; Raisis AL, 2005, VET ANAESTH ANALG, V32, P331, DOI 10.1111/j.1467-2995.2005.00192.x; REITAN JA, 1978, ANESTH ANALG, V57, P31; Stoelting RK, 2006, PHARM PHYSL ANESTHET, P266; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; WARREN DJ, 1974, J APPL PHYSIOL, V36, P246; Zehnder AM, 2012, AM J VET RES, V73, P1859, DOI 10.2460/ajvr.73.12.1859	24	2	2	0	12	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	JUL	2015	76	7					591	598		10.2460/ajvr.76.7.591			8	Veterinary Sciences	Veterinary Sciences	CN1IP	WOS:000358172600012	26111088				2020-06-30	J	Zecca, E; Manzoni, A; Centurioni, F; Farina, A; Bonizzoni, E; Seiler, D; Perrone, T; Caraceni, A				Zecca, Ernesto; Manzoni, Andrea; Centurioni, Fabio; Farina, Alberto; Bonizzoni, Erminio; Seiler, Dan; Perrone, Tania; Caraceni, Augusto			Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						transdermal fentanyl; bilayer matrix; drug delivery; pain	TRANSDERMAL FENTANYL; CANCER PAIN; BIOEQUIVALENCE; DELIVERY; ANALGESIA; EFFICACY; OPIOIDS; SYSTEM	AimsTransdermal fentanyl is a well established treatment for cancer pain. The aim of the present study is to assess the relative bioavailability of fentanyl from two different transdermal systems by evaluating plasma drug concentrations after single administration of Fentalgon (R) (test), a novel bilayer matrix type patch, and Durogesic SMAT (reference), a monolayer matrix type patch. In the Fentalgon patch the upper 6% fentanyl reservoir layer maintains a stable concentration gradient between the lower 4% donor layer and the skin. The system provides a constant drug delivery over 72 h. MethodsThis was an open label, single centre, randomized, single dose, two period crossover clinical trial, that included 36 healthy male volunteers. The patches were applied to non-irritated and non-irradiated skin on the intraclavicular pectoral area. Blood samples were collected at different time points (from baseline to 120 h post-removal of the devices) and fentanyl concentrations were determined using a validated LC/MS/MS method. Bioequivalence was to be claimed if the 90% confidence interval of AUC(0,t) and C-max ratios (test: reference) were within the acceptance range of 80-125% and 75-133%, respectively. ResultsThe 90% confidence intervals of the AUC(0,t) ratio (116.3% [109.6, 123.4%]) and C-max ratio (114.4% [105.8, 123.8%] were well included in the acceptance range and the C-max ratio also met the narrower bounds of 80-125%. There was no relevant difference in overall safety profiles of the two preparations investigated, which were adequately tolerated, as expected for opioid-naive subjects. ConclusionsThe new bilayer matrix type patch, Fentalgon (R), is bioequivalent to the monolayer matrix type Durogesic SMAT fentanyl patch with respect to the rate and extent of exposure of fentanyl (Eudra/CT no. 2005-000046-36).	[Zecca, Ernesto; Manzoni, Andrea; Centurioni, Fabio; Caraceni, Augusto] IRCCS Ist Nazl Tumori, Palliat Care Pain Therapy & Rehabil Fdn, Milan, Italy; [Farina, Alberto; Perrone, Tania] Italfarmaco SpA, Med Affairs Dept, Milan, Italy; [Bonizzoni, Erminio] Univ Milan, Dept Clin Sci & Community, Sect Med Stat & Biometry, Milan, Italy; [Seiler, Dan] Freelance Consultant Phase & Clin Trials, Hamburg, Germany; [Caraceni, Augusto] NTNU, European Palliat Care Ctr PRC, Dept Canc Res & Mol Med, Trondheim, Norway	Zecca, E (reprint author), IRCCS Ist Nazl Tumori, Palliat Care Pain Therapy & Rehabil Fdn, Milan, Italy.	ernesto.zecca@istitutotumori.mi.it	Zecca, Ernesto/K-2159-2018; Caraceni, Augusto/C-1012-2017	Zecca, Ernesto/0000-0003-1689-0370; Caraceni, Augusto/0000-0002-0375-6204; Farina, Alberto/0000-0003-1896-1179	Italfarmaco S.p.A.; Molteni; Gruenenthal; Prostrakan; Mundipharma; Teva Pharmaceutici	All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author). AF and TP are employed by Italfarmaco S.p.A. DS was employed by the conducting CRO Scope International Life Sciences, during the conduct of the study and later by Helm AG, the sponsor of the study. EZ and FC received a grant from Italfarmaco S.p.A. AF, TP, EZ, FC and EB declare no support from any other organizations for the submitted work, no financial relationships with any other organizations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work. AM declares no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years. AC declares grants received by his institution from Molteni, Gruenenthal, Prostrakan, Mundipharma, Teva Pharmaceutici, board membership participaton for Gruenenthal and Pfizer, and honoraria from Molteni.	Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Chow SC, 1992, DESIGNS ANAL BIOAVAI; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hall EJ, 2004, POSTGRAD MED J, V80, P148, DOI 10.1136/pgmj.2003.015511; HAUSCHKE D, 1990, INT J CLIN PHARM TH, V28, P72; Hollander M., 1973, NONPARAMETRIC STAT M; Hoy SM, 2008, DRUGS, V68, P1711, DOI 10.2165/00003495-200868120-00008; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Kress HG, 2010, EUR J PHARM BIOPHARM, V75, P225, DOI 10.1016/j.ejpb.2010.02.005; Liu J, 2014, INT J CLIN PHARM TH, V52, P175, DOI 10.5414/CP201901; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Oliveira G, 2012, TOXICOL IN VITRO, V26, P645, DOI 10.1016/j.tiv.2012.02.007; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.2307/2333709; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; Walter C, 2009, CLIN PHARMACOKINET, V48, P625, DOI 10.2165/11317200-000000000-00000; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7; YEE LY, 1992, ANN PHARMACOTHER, V26, P1393, DOI 10.1177/106002809202601113	20	5	5	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	JUL	2015	80	1					110	115		10.1111/bcp.12595			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL3AK	WOS:000356820500011	25612845	Green Published, Other Gold			2020-06-30	J	Fanti, L; Gemma, M; Agostoni, M; Rossi, G; Ruggeri, L; Azzolini, ML; Dabizzi, E; Beretta, L; Testoni, PA				Fanti, Lorella; Gemma, Marco; Agostoni, Massimo; Rossi, Gemma; Ruggeri, Laura; Azzolini, Maria Luisa; Dabizzi, Emanuele; Beretta, Luigi; Testoni, Pier Alberto			Target Controlled Infusion for non-anaesthesiologist propofol sedation during gastrointestinal endoscopy: The first double blind randomized controlled trial	DIGESTIVE AND LIVER DISEASE			English	Article						Gastrointestinal endoscopy; Propofol; Sedation; Target Controlled Infusion	OUTPATIENT COLONOSCOPY; MODERATE SEDATION; MONITORED ANESTHESIA; EUROPEAN-SOCIETY; DEEP SEDATION; NURSES; MIDAZOLAM; SAFETY; GASTROENTEROLOGY; AGENTS	Background: Target Controlled Infusion is a sophisticated tool for providing optimal sedation regimen avoiding under or oversedation in gastrointestinal endoscopy. Aims: To compare standard moderate sedation vs. non-anaesthesiologist-administered propofol sedation during gastrointestinal endoscopy. Methods: Randomized controlled trial of 70 consecutive colonoscopies and 70 consecutive esophagogastroduodenoscopies (EGD). Standard group (n = 70), received fentanyl (1 mu g/kg) + midazolam (0.03-0.04 mg/kg) or midazolam only; propofol group (n = 70), received fentanyl (1 mu g/kg) + propofol Target Controlled Infusion (1.2-1.6 mu g/ml) or propofol Target Controlled Infusion only. Discharge time, endoscopist satisfaction and patient satisfaction were recorded in all endoscopies. Results: Colonoscopy: discharge time was significantly shorter in the propofol than the standard group (1.1 +/- 0.3 vs. 5 +/- 10.2 min, respectively; P = 0.03). Endoscopist satisfaction was significantly higher (98.3 +/- 11.4/100 vs. 87.2 +/- 12/100; P = 0.001); patient satisfaction was significantly higher (95 +/- 9.3/100 vs. 85.5 +/- 14.4/100; P = 0.002) in the propofol compared to the standard group. EGD: discharge time was not significantly different in the propofol and standard groups (1.1 +/- 0.7 vs. 3.9 perpendicular to 9.2 min, respectively; P = 0.146). Endoscopist satisfaction was significantly higher (92.7 perpendicular to 14.3/100 vs. 82.8 +/- 21.2/100; P = 0.03); patient satisfaction was significantly higher (93.8 +/- 18.21100 vs. 76.5 +/- 25.21100; P = 0.003). In the propofol group 94.3% of patients vs. 71.4% of patients in standard group asked to receive the same sedation in the future (P = 0.021). Conclusion: Target Controlled Infusion is a promising method for non-anaesthesiologist-administered propofol sedation. (C) 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.	[Fanti, Lorella; Rossi, Gemma; Dabizzi, Emanuele; Testoni, Pier Alberto] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Div Gastroenterol & Gastrointestinal Endoscopy, I-20132 Milan, Italy; [Gemma, Marco; Agostoni, Massimo; Ruggeri, Laura; Azzolini, Maria Luisa; Beretta, Luigi] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Anesthesiol, I-20132 Milan, Italy	Fanti, L (reprint author), Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Div Gastroenterol & Gastrointestinal Endoscopy, Via Olgettina 60, I-20132 Milan, Italy.	fanti.lorella@hsr.it		Gemma, Marco/0000-0002-9543-3831; Ruggeri, Laura/0000-0003-4447-9749; , Massimo/0000-0003-4723-2362; turi, stefano/0000-0001-7365-3510			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Bell GD, 2004, ENDOSCOPY, V36, P23; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Dumonceau JM, 2013, ENDOSCOPY, V45, P496, DOI 10.1055/s-0033-1344142; Dumonceau JM, 2010, EUR J ANAESTH, V27, P1016, DOI 10.1097/EJA.0b013e32834136bf; Fanti L, 2007, DIGEST LIVER DIS, V39, P81, DOI 10.1016/j.dld.2006.09.004; Fanti L, 2004, GASTROINTEST ENDOSC, V60, P361, DOI 10.1016/S0016-5107(04)01713-4; Heuss LT, 2003, GASTROINTEST ENDOSC, V57, P664, DOI 10.1067/mge.2003.191; Hsieh YH, 2009, J CLIN GASTROENTEROL, V43, P753, DOI 10.1097/MCG.0b013e3181862a8c; Hsu WH, 2013, J DIGEST DIS, V14, P147, DOI 10.1111/1751-2980.12020; Kulling D, 2003, ENDOSCOPY, V35, P679; Leslie K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006059.pub2; Levitzky BE, 2012, ENDOSCOPY, V44, P13, DOI 10.1055/s-0031-1291421; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Moerman AT, 2004, J CLIN ANESTH, V16, P237, DOI 10.1016/j.jclinane.2003.08.005; Padmanabhan U, 2009, ANESTH ANALG, V109, P1448, DOI 10.1213/ane.0b013e3181a6ad31; Patel S, 2005, AM J GASTROENTEROL, V100, P2689, DOI 10.1111/j.1572-0241.2005.00320.x; Qadeer MA, 2005, CLIN GASTROENTEROL H, V3, P1049, DOI 10.1016/S1542-3565(05)00742-1; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Riphaus A, 2009, ENDOSCOPY, V41, P787, DOI 10.1055/s-0029-1215035; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Sieg A, 2014, J GASTROEN HEPATOL, V29, P517, DOI 10.1111/jgh.12458; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Tohda G, 2006, ENDOSCOPY, V38, P360, DOI 10.1055/s-2005-921192; Tohda G, 2006, ENDOSCOPY, V38, P684, DOI 10.1055/s-2006-925374; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Walker JA, 2003, AM J GASTROENTEROL, V98, P1744, DOI 10.1016/S0002-9270(03)00496-9; Wang DR, 2013, SCAND J GASTROENTERO, V48, P101, DOI 10.3109/00365521.2012.737360	31	10	11	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1590-8658	1878-3562		DIGEST LIVER DIS	Dig. Liver Dis.	JUL	2015	47	7					566	571		10.1016/j.dld.2015.03.003			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CL0IK	WOS:000356625100008	25840875				2020-06-30	J	Bloomgarden, ZT; Drexler, A; Farley, S				Bloomgarden, Zachary T.; Drexler, Andrew; Farley, Steven			New approaches to wound healing for diabetes	JOURNAL OF DIABETES			English	Editorial Material							GROWTH-FACTOR; FOOT; THERAPIES; ULCERS		[Bloomgarden, Zachary T.] Mt Sinai Sch Med, New York, NY 10029 USA; [Drexler, Andrew] Univ Calif Los Angeles, Schoof Med, Los Angeles, CA 90024 USA; [Farley, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA	Bloomgarden, ZT (reprint author), Mt Sinai Sch Med, New York, NY 10029 USA.	zbloom@gmail.com	Bloomgarden, Zachary/AAF-5163-2020				Bigliardi PL, 2002, J RECEPT SIGNAL TR R, V22, P191, DOI 10.1081/RRS-120014595; Daburkar M, 2014, J PHARM BIOALLIED SC, V6, P205, DOI 10.4103/0975-7406.135248; Dissemond J, 2015, J WOUND CARE, V24, P53, DOI 10.12968/jowc.2015.24.2.53; Dumville JC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009099.pub3; Gupta M, 2015, J DIABETES, V7, P573, DOI 10.1111/1753-0407.12223; Henshaw FR, 2014, J DIABETES COMPLICAT, V28, P850, DOI 10.1016/j.jdiacomp.2014.07.012; Hussan F, 2014, J WOUND CARE, V23, P400, DOI 10.12968/jowc.2014.23.8.400; Jull AB, 2013, COCHRANE DB SYST REV, V2, P2, DOI DOI 10.1002/14651858; Mikaili P, 2014, MED HYPOTHESES, V83, P172, DOI 10.1016/j.mehy.2014.05.002; Mohajeri G, 2014, J RES MED SCI, V19, P520; Richmond NA, 2013, MED CLIN N AM, V97, P883, DOI 10.1016/j.mcna.2013.03.014; Sekhar MS, 2014, MED HYPOTHESES, V82, P86, DOI 10.1016/j.mehy.2013.11.013; Sibbald RG, 2012, ADV SKIN WOUND CARE, V25, P77, DOI 10.1097/01.ASW.0000411408.97930.af; Singla Sanjeev, 2014, J Nat Sci Biol Med, V5, P273, DOI 10.4103/0976-9668.136160; Snyder RJ, 2009, OSTOMY WOUND MANAG, V55, P28; Zhan LX, 2015, J VASC SURG, V61, P939, DOI 10.1016/j.jvs.2014.11.045; Zhao XH, 2014, METABOLISM, V63, P1304, DOI 10.1016/j.metabol.2014.06.005; Zykova SN, 2014, J DIABETES INVEST, V5, P392, DOI 10.1111/jdi.12165	18	1	1	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1753-0393	1753-0407		J DIABETES	J. Diabetes	JUL	2015	7	4					435	436		10.1111/1753-0407.12295			2	Endocrinology & Metabolism	Endocrinology & Metabolism	CJ9ZJ	WOS:000355862700001	25817830				2020-06-30	J	Gupta, M; Poonawala, T; Farooqui, M; Ericson, ME; Gupta, K				Gupta, Mihir; Poonawala, Tasneem; Farooqui, Mariya; Ericson, Marna E.; Gupta, Kalpna			Topical fentanyl stimulates healing of ischemic wounds in diabetic rats	JOURNAL OF DIABETES			English	Article						angiogenesis; fentanyl; lymphangiogenesis; wound; diabetes; pain; fentanyl; opioid	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE; BIOLOGICAL FUNCTION; FOOT ULCERATION; LEG ULCERS; ANGIOGENESIS; RECEPTOR; ACTIVATION; EXPRESSION; PROTECTS	BackgroundTopically applied opioids promote angiogenesis and healing of ischemic wounds in rats. We examined if topical fentanyl stimulates wound healing in diabetic rats by stimulating growth-promoting signaling, angiogenesis, lymphangiogenesis and nerve regeneration. MethodsWe used Zucker diabetic fatty rats that develop obesity and diabetes on a high fat diet due to a mutation in the Leptin receptor. Fentanyl blended with hydrocream was applied topically on ischemic wounds twice daily, and wound closure was analyzed regularly. Wound histology was analyzed by hematoxylin and eosin staining. Angiogenesis, lymphangiogenesis, nerve fibers and phospho-platelet derived growth factor receptor- (PDGFR-) were visualized by CD31-, lymphatic vessel endothelium-1, protein gene product 9.5- and anti-phospho PDGFR--immunoreactivity, respectively. Nitric oxide synthase (NOS) and PDGFR- signaling were analyzed using Western immunoblotting. ResultsFentanyl significantly promoted wound closure as compared to phosphate-buffered saline (PBS). Histology scores were significantly higher in fentanyl-treated wounds, indicative of increased granulation tissue formation, reduced edema and inflammation, and increased matrix deposition. Fentanyl treatment resulted in increased wound angiogenesis, lymphatic vasculature, nerve fibers, nitric oxide, NOS and PDGFR- signaling as compared to PBS. Phospho-PDGFR- co-localized with CD31 co-staining for vasculature. ConclusionsTopically applied fentanyl promotes closure of ischemic wounds in diabetic rats. Increased angiogenesis, lymphangiogenesis, peripheral nerve regeneration, NO and PDGFR- signaling are associated with fentanyl-induced tissue remodeling and wound healing.	[Gupta, Mihir] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Poonawala, Tasneem; Farooqui, Mariya; Gupta, Kalpna] Univ Minnesota, Sch Med, Div Hematol Oncol & Transplantat, Vasc Biol Ctr,Dept Med, Minneapolis, MN 55455 USA; [Ericson, Marna E.] Univ Minnesota, Sch Med, Dept Dermatol, Minneapolis, MN 55455 USA	Gupta, K (reprint author), Univ Minnesota, Vasc Biol Ctr, Med Hematol Oncol & Transplantat, Mayo Mail Code 480 420 Delaware St SE, Minneapolis, MN 55455 USA.	gupta014@umn.edu	ericson, marna e/C-9591-2017	ericson, marna e/0000-0003-1862-4957; Farooqui, Mariya/0000-0002-2136-8694	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 HL68802, UO1 HL117664-01]	The authors are thankful to Niroop S. Ammbashankar for technical help with peripheral nerve analysis, and Susan T. Thompson for preparation of graphics. This work was supported by NIH RO1 HL68802 and UO1 HL117664-01.	Adler AI, 1999, DIABETES CARE, V22, P1029, DOI 10.2337/diacare.22.7.1029; BELLMAN S, 1959, Acta Chir Scand, V116, P99; Bigliardi PL, 2015, BRIT J PHARMACOL, V172, P501, DOI 10.1111/bph.12687; Bigliardi PL, 2009, EXP DERMATOL, V18, P424, DOI 10.1111/j.1600-0625.2009.00844.x; Blecher K, 2012, NANOMED-NANOTECHNOL, V8, P1364, DOI 10.1016/j.nano.2012.02.014; Brice G, 2002, J MED GENET, V39, P478, DOI 10.1136/jmg.39.7.478; Charbaji N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042616; Chen C, 2006, CURR NEUROVASC RES, V3, P171, DOI 10.2174/156720206778018767; Chesnoy S, 2003, PHARMACEUT RES, V20, P345, DOI 10.1023/A:1022635600479; Chong HC, 2014, MOL THER, V22, P1593, DOI 10.1038/mt.2014.102; Connor H, 1999, DIABETIC MED, V16, P799; CUNNINGHAM LD, 1992, J CLIN INVEST, V89, P878, DOI 10.1172/JCI115667; Delaney KMH, 2013, HEMOGLOBIN, V37, P325, DOI 10.3109/03630269.2013.789968; Farley P, 2011, J PHARM PHARMACOL, V63, P747, DOI 10.1111/j.2042-7158.2011.01252.x; FLYNN MD, 1992, DIABETIC MED, V9, P320, DOI 10.1111/j.1464-5491.1992.tb01790.x; Fujioka N, 2011, ANESTH ANALG, V113, P1353, DOI 10.1213/ANE.0b013e318232b35a; Galeano M, 2003, DIABETOLOGIA, V46, P546, DOI 10.1007/s00125-003-1064-1; Galeano M, 2001, SURGERY, V129, P467, DOI 10.1067/msy.2001.112072; Gallagher RE, 2005, CLIN J PAIN, V21, P190, DOI 10.1097/00002508-200503000-00012; Goldsmith JR, 2013, AM J PATHOL, V182, P776, DOI 10.1016/j.ajpath.2012.11.021; Goldsmith JR, 2011, AM J PATHOL, V179, P673, DOI 10.1016/j.ajpath.2011.04.032; GOODMAN L, 1994, J BIOL CHEM, V269, P19250; Gross ER, 2006, AM J PHYSIOL-HEART C, V291, pH827, DOI 10.1152/ajpheart.00003.2006; Gupta K, 2002, CANCER RES, V62, P4491; Gupta M, 2007, ANGIOGENESIS BASIC S, P303; Halabi-Tawil M, 2008, BRIT J DERMATOL, V158, P339, DOI 10.1111/j.1365-2133.2007.08323.x; Han G, 2012, AM J PATHOL, V180, P1465, DOI 10.1016/j.ajpath.2011.12.013; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Hood DC, 2008, J GLAUCOMA, V17, P519, DOI 10.1097/IJG.0b013e3181629a02; Kirchner LM, 2003, WOUND REPAIR REGEN, V11, P127, DOI 10.1046/j.1524-475X.2003.11208.x; Kunz D, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-90; Li R, 2009, ANESTH ANALG, V108, P23, DOI 10.1213/ane.0b013e3181884ba6; Luk K, 2012, J ONCOL, V2012, DOI 10.1155/2012/458385; Maejima D, 2011, MICROCIRCULATION, V18, P474, DOI 10.1111/j.1549-8719.2011.00108.x; Martin A, 2003, MED RES REV, V23, P117, DOI 10.1002/med.10024; MCNEELY MJ, 1995, DIABETES CARE, V18, P216, DOI 10.2337/diacare.18.2.216; Mikaili P, 2014, MED HYPOTHESES, V83, P172, DOI 10.1016/j.mehy.2014.05.002; Minniti CP, 2014, AM J HEMATOL, V89, P1, DOI 10.1002/ajh.23571; Nguyen J, 2014, BRIT J ANAESTH, V113, P4, DOI 10.1093/bja/aeu090; ODEN BO, 1960, ACTA CHIR SCAND, V120, P100; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; Oliver G, 2004, NAT REV IMMUNOL, V4, P35, DOI 10.1038/nri1258; Penkowa M, 2003, J NEUROSCI RES, V73, P481, DOI 10.1002/jnr.10681; Petrova TV, 2004, NAT MED, V10, P974, DOI 10.1038/nm1094; Poonawala T, 2005, WOUND REPAIR REGEN, V13, P165, DOI 10.1111/j.1067-1927.2005.130207.x; Ramsey SD, 1999, DIABETES CARE, V22, P382, DOI 10.2337/diacare.22.3.382; Rees RS, 1999, WOUND REPAIR REGEN, V7, P141, DOI 10.1046/j.1524-475X.1999.00141.x; Scavelli C, 2004, J ANAT, V204, P433, DOI 10.1111/j.0021-8782.2004.00293.x; Schaffer MR, 1997, SURGERY, V121, P513, DOI 10.1016/S0039-6060(97)90105-7; SEHGAL PB, 1990, J INVEST DERMATOL, V94, pS2, DOI 10.1111/1523-1747.ep12874963; SHAFRIR E, 1992, DIABETES METAB REV, V8, P179, DOI 10.1002/dmr.5610080302; Shyng YC, 2001, INT J ORAL MAX SURG, V30, P70, DOI 10.1054/ijom.2000.0004; Singleton PA, 2006, MICROVASC RES, V72, P3, DOI 10.1016/j.mvr.2006.04.004; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; Stein C, 2013, TRENDS PHARMACOL SCI, V34, P303, DOI 10.1016/j.tips.2013.03.006; Stevens MJ, 2000, DIABETES, V49, P1006, DOI 10.2337/diabetes.49.6.1006; Tsang MW, 2003, DIABETES CARE, V26, P1856, DOI 10.2337/diacare.26.6.1856; Vrabec JT, 1998, OTOLARYNG HEAD NECK, V118, P304, DOI 10.1016/S0194-5998(98)70305-5; Weber ML, 2013, BRIT J ANAESTH, V111, P1004, DOI 10.1093/bja/aet221; Wietecha MS, 2013, ADV WOUND CARE, V2, P81, DOI 10.1089/wound.2011.0348; Witte MH, 2001, MICROSC RES TECHNIQ, V55, P122, DOI 10.1002/jemt.1163; Wong GTC, 2010, J CARDIOTHOR VASC AN, V24, P790, DOI 10.1053/j.jvca.2009.09.012; Zagon IS, 2008, ARCH OPHTHALMOL-CHIC, V126, P501, DOI 10.1001/archopht.126.4.501; Zagon IS, 2007, BRAIN RES BULL, V72, P18, DOI 10.1016/j.brainresbull.2006.12.007; Zagon IS, 1998, BRAIN RES, V803, P61, DOI 10.1016/S0006-8993(98)00610-6	65	14	14	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1753-0393	1753-0407		J DIABETES	J. Diabetes	JUL	2015	7	4					573	583		10.1111/1753-0407.12223			11	Endocrinology & Metabolism	Endocrinology & Metabolism	CJ9ZJ	WOS:000355862700018	25266258	Other Gold, Green Accepted			2020-06-30	J	Mounteney, J; Giraudon, I; Denissov, G; Griffiths, P				Mounteney, Jane; Giraudon, Isabelle; Denissov, Gleb; Griffiths, Paul			Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Editorial Material						Fentanyl; Overdose deaths; Europe; Outbreaks; Illicit production; Diversion of medicines	MORTALITY; DEATHS; TRENDS	Fentanyl is a synthetic opioid analgesic historically used as a pain reliever and an anaesthetic. Recent concerns have arisen around the illicit use of fentanyl and its analogues in a number of European countries, linked to their high potency and associated risk of fatal overdose. Evidence has been emerging from Estonia for over a decade of entrenched patterns of fentanyl use, including injection of the drug and hundreds of overdose deaths. More recently, reports indicate that both fentanyl and 3-methylfentanyl (TMF) have been marketed as a replacement for heroin in European countries (e.g. Bulgaria, Slovakia) affected by heroin shortages. In addition, Germany, Finland and the United Kingdom, reported new outbreaks of fentanyl-related deaths. This combination of increasing mortality data alongside law enforcement intelligence suggesting both diversion and illicit production of fentanyls, prompted wider investigation using a targeted multi-source data collection exercise and analysis. This identified that in the European context, fentanyls are 'low use but high risk/harm' substances. Evidence shows that Estonia stands out as having an endemic problem, while the use of fentanyls in other European countries appears to be geographically localised. Developments in illicit supply of fentanyls reflect the complexity of Europe's contemporary drug market: manifesting illicit production and use, the diversion and misuse of medicines, and the online sale of non-controlled new psychoactive substances. Likewise effective and integrated responses will need to address fentanyl production, diversion as well as ensuring the availability of harm reduction measures to users. (C) 2015 Elsevier B.V. All rights reserved.	[Mounteney, Jane; Giraudon, Isabelle; Griffiths, Paul] EMCDDA, Lisbon, Portugal; [Denissov, Gleb] Estonian Causes Death Registry, Tallinn, Estonia	Mounteney, J (reprint author), EMCDDA, Lisbon, Portugal.	jane.mounteney@emcdda.europa.eu					Corkery J., 2014, DRUG RELATED DEATHS; Denissov G., 2014, ALARMING RISE FATAL; EMCDDA, 2012, FENT EUR EMCDDA TREN; EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), 2014, EUR DRUG REP 2014 TR; Estonian National Report to the EMCDDA, 2014, REP DRUG SIT EST 201; European Monitoring Centre for Drugs and Drug Addiction, 2011, EMCDDA TRENDSP STUD; Fischer B, 2014, DRUG ALCOHOL REV, V33, P19, DOI 10.1111/dar.12089; Griffiths P, 2014, ADDICTION, V109, P182, DOI 10.1111/add.12306; Griffiths P, 2012, ADDICTION, V107, P1539, DOI 10.1111/j.1360-0443.2012.03829.x; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Mounteney J, 2009, INT J DRUG POLICY, V20, P161, DOI 10.1016/j.drugpo.2007.09.006; Mounteney J, 2010, SUBST USE MISUSE, V45, P266, DOI 10.3109/10826080903368598; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Talu A, 2010, INT J DRUG POLICY, V21, P56, DOI 10.1016/j.drugpo.2009.02.007; Tammi T, 2011, YHTEISKUNTAPOLITIIKK, V76, P45; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; Uuskula A, 2013, INT J DRUG POLICY, V24, P312, DOI 10.1016/j.drugpo.2012.11.002; Vorobjov S, 2012, J SUBST ABUSE TREAT, V42, P413, DOI 10.1016/j.jsat.2011.09.014; World Health Organization, 2011, ENS BAL NAT POL CONT	26	93	96	2	37	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	JUL	2015	26	7					626	631		10.1016/j.drugpo.2015.04.003			6	Substance Abuse	Substance Abuse	CL5EK	WOS:000356982400004	25976511				2020-06-30	J	Fredheim, OMS; Mahic, M; Skurtveit, S; Borchgrevink, PC				Fredheim, Olav Magnus S.; Mahic, Milada; Skurtveit, Svetlana; Borchgrevink, Petter C.			Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study	PALLIATIVE MEDICINE			English	Article						Fentanyl; nasal; breakthrough pain; pharmacoepidemiology	BREAKTHROUGH PAIN	Background: Breakthrough pain affects 40%-90% of patients with cancer pain. Nasal fentanyl is one of the recommended treatments, particularly if the breakthrough pain is of rapid onset. Aim: To investigate the prevalence of use of nasal fentanyl, to study which strong opioids have been used prior to nasal fentanyl and to examine which opioids are used concomitantly with nasal fentanyl. Design: Longitudinal cohort study based on death cohorts defined according to year of death. Setting/participants: The study is based on data from the complete national Norwegian Prescription Database. The study population included all persons in Norway who died in the years 2010, 2011 and 2012 and who had received nasal fentanyl with reimbursement for palliative treatment. Results: Of those who died from cancer in 2010, 2011 and 2012, 611 persons (2%) received dispensed prescriptions of nasal fentanyl. Two-thirds had received other short-acting strong opioids before nasal fentanyl. One quarter did not receive a long-acting opioid concomitantly with nasal fentanyl, but 68% of these received only one dispensed prescription of nasal fentanyl. Of those who received a long-acting opioid together with nasal fentanyl, transdermal fentanyl was the most common drug (65%). One-third received another short-acting opioid concomitantly with nasal fentanyl. Conclusion: The use of nasal fentanyl was surprisingly low. There is a need for clinical research addressing the use of nasal fentanyl without a long-acting opioid for background pain and the use of nasal fentanyl together with another short-acting opioid.	[Fredheim, Olav Magnus S.; Borchgrevink, Petter C.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Pain & Palliat Res Grp, Fac Med, N-7491 Trondheim, Norway; [Fredheim, Olav Magnus S.; Borchgrevink, Petter C.] St Olavs Univ Hosp, Dept Pain & Complex Disorders, Natl Competence Ctr Complex Symptom Disorders, Trondheim, Norway; [Fredheim, Olav Magnus S.] Akershus Univ Hosp, Div Surg, Ctr Palliat Med, Lorenskog, Norway; [Mahic, Milada; Skurtveit, Svetlana] Norwegian Inst Publ Hlth, Div Epidemiol, Dept Pharmacoepidemiol, Oslo, Norway; [Skurtveit, Svetlana] Univ Oslo, Norwegian Ctr Addict Res, Oslo, Norway	Fredheim, OMS (reprint author), Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Pain & Palliat Res Grp, Fac Med, Postbox 8905, N-7491 Trondheim, Norway.	olav.m.fredheim@ntnu.no		Fredheim, Olav/0000-0002-0931-0027; Skurtveit, Svetlana/0000-0001-7525-9701			[Anonymous], 2013, CANC STAT; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001	7	0	0	1	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163	1477-030X		PALLIATIVE MED	Palliat. Med.	JUL	2015	29	7					661	666		10.1177/0269216315575252			6	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	CJ8PA	WOS:000355764100008	25762579				2020-06-30	J	Davies, A; Kleeberg, UR; Jarosz, J; Mercadante, S; Poulain, P; O'Brien, T; Schneid, H; Kress, H				Davies, Andrew; Kleeberg, Ulrich R.; Jarosz, Jerzy; Mercadante, Sebastiano; Poulain, Philippe; O'Brien, Tony; Schneid, Helene; Kress, Hans G.			Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain	SUPPORTIVE CARE IN CANCER			English	Article						Breakthrough pain; Chronic pain; Fentanyl buccal tablet; Opioid analgesic; Pain management; Cancer patients	PREVALENCE; TOLERABILITY; ASSOCIATION; EFFICACY; CITRATE; IMPACT; SPRAY	This open-label study evaluated the effects of fentanyl buccal tablet (FBT) on functioning and mood in cancer patients with breakthrough cancer pain (BTcP). Opioid-tolerant patients in seven European countries with up to four BTcP episodes/day received FBT doses (100-800 mu g) identified during open-label titration to treat up to eight BTcP episodes during an open-label treatment period. In countries where FBT was not commercially available, patients could enter an open-label continuation phase. Functionality and satisfaction assessments included change from baseline to the end of the treatment period in the modified Brief Pain Inventory (BPI-7S) seven-item interference subscale, patient's global assessment of satisfaction and ease of use, and Patient's Global Impression of Change (PGIC). Safety was also assessed. Of 330 randomized patients, 218 completed the treatment period and 88 entered the continuation phase. Median background pain intensity was 4.0 (mild) throughout the study. After the treatment period, mean (SD) global modified BPI-7S score improved from 39.7 (15.9) at baseline to 31.6 (16.8) for a mean change of -8.6 (95 % confidence interval CI -10.5, -6.7; P < 0.0001), and 74.5 % of patients reported improvement in overall status (PGIC) compared with 25.5 % who reported no change or worsening (P < 0.001). Treatment-related adverse events (a parts per thousand yen2 patients) during the continuation phase were application site erythema (6.9 %), application site swelling (4.6 %), and vertigo (4.6 %). FBT may improve patient functioning, mood, and overall satisfaction in the management of BTcP. Long-term data did not indicate new safety concerns with FBT doses up to 800 mu g.	[Davies, Andrew] Royal Surrey Cty Hosp NHS Fdn Trust, Guildford GU2 7XX, Surrey, England; [Kleeberg, Ulrich R.] Hamatol Onkol Praxis Hamburg Altona, Hamburg, Germany; [Jarosz, Jerzy] Polish Acad Sci, Mossakowski Med Res Ctr, Warsaw, Poland; [Mercadante, Sebastiano] Casa Cura Alta Specialita, Maddalena Terapia Dolore & Cure Palliat, Palermo, Italy; [Poulain, Philippe] Polyclin Ormeau, Tarbes, France; [O'Brien, Tony] Marymount Hosp, Dept Palliat Med, Cork, Ireland; [O'Brien, Tony] Cork Univ Hosp, Cork, Ireland; [Schneid, Helene] Teva Labs, La Def, France; [Kress, Hans G.] Med Univ AKH, Dept Special Anaesthesia & Pain Therapy, Vienna, Austria	Davies, A (reprint author), Royal Surrey Cty Hosp NHS Fdn Trust, Egerton Rd, Guildford GU2 7XX, Surrey, England.	adavies12@nhs.net			Cephalon, Inc. (Frazer, PA); Teva Pharmaceuticals	This study was sponsored by Cephalon, Inc. (Frazer, PA), now a wholly owned subsidiary of Teva Pharmaceuticals Industries Ltd. Writing support was provided by Bina J. Patel, PharmD, of Peloton Advantage, LLC, funded by Teva Pharmaceuticals. The authors wish to thank Ronghua Yang, PhD, of Teva Pharmaceuticals for assistance with the statistical analysis and acknowledge the 135 investigators for their contributions to the study.	[Anonymous], 1996, INT C HARM TECHN REQ; [Anonymous], 2011, EFF BUCC TABL PACK I; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; FENTORA, 2013, FENT BUCC TABL PACK; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Kleeberg UR, 2015, EUR J PAIN, V19, P528, DOI 10.1002/ejp.577; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; PORTENOY RK, 1992, CANCER-AM CANCER SOC, V70, P1616, DOI 10.1002/1097-0142(19920915)70:6<1616::AID-CNCR2820700630>3.0.CO;2-7; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Webster Lynn R, 2011, J Opioid Manag, V7, P297; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	25	5	5	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	JUL	2015	23	7					2135	2143		10.1007/s00520-014-2590-8			9	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	CJ1PI	WOS:000355255600037	25556611				2020-06-30	J	Marcus, DJ; Zee, M; Hughes, A; Yuill, MB; Hohmann, AG; Mackie, K; Guindon, J; Morgan, DJ				Marcus, David J.; Zee, Michael; Hughes, Alex; Yuill, Matthew B.; Hohmann, Andrea G.; Mackie, Ken; Guindon, Josee; Morgan, Daniel J.			Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase	MOLECULAR PAIN			English	Article						Morphine; Fentanyl; JNK; GPCR; GRK; Cisplatin; Desensitization; Tolerance; Mu opioid receptor; Chemotherapy	INDUCED PERIPHERAL NEUROPATHY; ACTIVATED PROTEIN-KINASES; LOCUS-CERULEUS NEURONS; OPIOID RECEPTORS; SIGNALING PATHWAY; FORMALIN TEST; NITRIC-OXIDE; PAIN; MICE; DESENSITIZATION	Background: Morphine and fentanyl are opioid analgesics in wide clinical use that act through the mu-opioid receptor (MOR). However, one limitation of their long-term effectiveness is the development of tolerance. Receptor desensitization has been proposed as a putative mechanism driving tolerance to G protein-coupled receptor (GPCR) agonists. Recent studies have found that tolerance to morphine is mediated by the c-Jun N-terminal Kinase (JNK) signaling pathway. The goal of the present study was to test the hypotheses that: 1) JNK inhibition will be antinociceptive on its own; 2) JNK inhibition will augment morphine antinociception and; 3) JNK mediates chronic tolerance for the antinociceptive effects of morphine using acute (hotplate and tail-flick), inflammatory (10 mu l of formalin 2.5 %) and chemotherapy (cisplatin 5 mg/kg ip once weekly)-induced neuropathic pain assays. Results: We found that JNK inhibition by SP600125 (3 mg/kg) produces a greater antinociceptive effect than morphine (6 mg/kg) alone in the formalin test. Moreover, co-administration of morphine (6 mg/kg) with SP600125 (3 mg/kg) produced a sub-additive antinociceptive effect in the formalin test. We also show that pre-treatment with SP600125 (3 or 10 mg/kg), attenuates tolerance to the antinociceptive effects of morphine (10 mg/kg), but not fentanyl (0.3 mg/kg), in the tail-flick and hotplate tests. Pre-treatment with SP600125 also attenuates tolerance to the hypothermic effects of both morphine and fentanyl. We also examined the role of JNK in morphine tolerance in a cisplatin-induced model of neuropathic pain. Interestingly, treatment with SP600125 (3 mg/kg) alone attenuated mechanical and cold allodynia in a chemotherapy-induced pain model using cisplatin. Strikingly, SP600125 (3 mg/kg) pre-treatment prolonged the anti-allodynic effect of morphine by several days (5 and 7 days for mechanical and cold, respectively). Conclusions: These results demonstrate that JNK signaling plays a crucial role in mediating antinociception as well as chronic tolerance to the antinociceptive effects of morphine in acute, inflammatory, and neuropathic pain states. Thus, inhibition of JNK signaling pathway, via SP600125, represents an efficacious pharmacological approach to delay tolerance to the antinociceptive effects of chronic morphine in diverse pain models.	[Marcus, David J.; Zee, Michael; Morgan, Daniel J.] Penn State Coll Med, Dept Anesthesiol, Hershey, PA 17033 USA; [Yuill, Matthew B.; Morgan, Daniel J.] Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA; [Marcus, David J.; Zee, Michael; Hughes, Alex; Hohmann, Andrea G.; Mackie, Ken; Guindon, Josee; Morgan, Daniel J.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA; [Marcus, David J.; Zee, Michael; Hughes, Alex; Hohmann, Andrea G.; Mackie, Ken; Guindon, Josee; Morgan, Daniel J.] Indiana Univ, Gill Ctr Biomol Sci, Bloomington, IN 47405 USA; [Guindon, Josee] Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Lubbock, TX 79430 USA	Guindon, J (reprint author), Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.	josee.guindon@ttuhsc.edu; djm68@psu.edu	; Mackie, Ken/E-3715-2013	Morgan, Daniel/0000-0002-9467-4019; Mackie, Ken/0000-0001-8501-6199	NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); Lilly Presidential Life Science Professorship; Indiana University METACyt Initiative (Lilly Foundation); Linda and Jack Gill Center for Biomolecular Science; Pennsylvania Department of Health using CURE Tobacco Settlement Funds; second CURE grant; Pennsylvania Department of Health using Tobacco Settlement Funds;  [DA021644];  [DA037673];  [DA037355];  [DA036385];  [DA011322];  [DA021696]	This work has been supported by NIDA. Data shown in Figs. 1, 2, 5 and 6 (collected by JG) was supported by DA021644 (AGH), DA037673 (AGH) and a Lilly Presidential Life Science Professorship (to AGH). Data shown in Figs. 3 and 4 (collected by DM, MZ and AH) was supported by DA037355 (DJM), DA036385 (DJM), DA011322 (KM), and DA021696 (KM). Additional support was provided by the Indiana University METACyt Initiative (funded in part by a grant from the Lilly Foundation), the Linda and Jack Gill Center for Biomolecular Science, and a grant from the Pennsylvania Department of Health using CURE Tobacco Settlement Funds (DJM). Matthew Yuill was supported by a second CURE grant to Robert Levenson from the Pennsylvania Department of Health using Tobacco Settlement Funds.	BABEY AM, 1994, NEUROPHARMACOLOGY, V33, P1463, DOI 10.1016/0028-3908(94)90050-7; Bailey CP, 2009, EUR J NEUROSCI, V29, P307, DOI 10.1111/j.1460-9568.2008.06573.x; BALDINO F, 1980, BRAIN RES, V196, P199, DOI 10.1016/0006-8993(80)90726-X; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; Chen Y, 2008, J NEUROSCI, V28, P5836, DOI 10.1523/JNEUROSCI.4170-07.2008; Christie M J, 1987, NIDA Res Monogr, V78, P158; Coderre TJ, 1997, BEHAV BRAIN SCI, V20, P404, DOI 10.1017/S0140525X97251484; CODERRE TJ, 1992, J NEUROSCI, V12, P3665; Corbett AD, 2006, BRIT J PHARMACOL, V147, pS153, DOI 10.1038/sj.bjp.0706435; Deng LT, 2015, BIOL PSYCHIAT, V77, P475, DOI 10.1016/j.biopsych.2014.04.009; Doll C, 2011, BRIT J PHARMACOL, V164, P298, DOI 10.1111/j.1476-5381.2011.01382.x; Draper NR, 1998, COMMUN STAT-THEOR M, V27, P2581, DOI 10.1080/03610929808832244; Dubner R, 1999, PAIN, pS45; Guindon J, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-56; Guindon J, 2013, PHARMACOL RES, V67, P94, DOI 10.1016/j.phrs.2012.10.013; Guindon J, 2009, CNS NEUROL DISORD-DR, V8, P403, DOI 10.2174/187152709789824660; Guo RX, 2009, NEUROSCI LETT, V467, P95, DOI 10.1016/j.neulet.2009.10.013; Han HX, 2012, ANESTH ANALG, V115, P1221, DOI 10.1213/ANE.0b013e318266c1ee; Hao J, 2008, NEUROSCIENCE, V152, P1067, DOI 10.1016/j.neuroscience.2007.12.038; Hervera A, 2012, EUR J PHARMACOL, V685, P42, DOI 10.1016/j.ejphar.2012.04.009; Koch T, 2008, PHARMACOL THERAPEUT, V117, P199, DOI 10.1016/j.pharmthera.2007.10.003; Le Bars D, 2001, PHARMACOL REV, V53, P597; Levitt ES, 2012, MOL PHARMACOL, V82, P983, DOI 10.1124/mol.112.081547; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Mao QH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078239; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Mittal N, 2012, NEUROPSYCHOPHARMACOL, V37, P1953, DOI 10.1038/npp.2012.42; NARITA M, 1995, EUR J PHARMACOL, V280, pR1, DOI 10.1016/0014-2999(95)00322-C; Nitsche JF, 2002, J NEUROSCI, V22, P10906; OSBORNE PB, 1995, BRIT J PHARMACOL, V115, P925, DOI 10.1111/j.1476-5381.1995.tb15899.x; Pavao-de-Souza GF, 2012, PHARMACOL BIOCHEM BE, V101, P320, DOI 10.1016/j.pbb.2012.01.018; Puig S, 1996, PAIN, V64, P345, DOI 10.1016/0304-3959(95)00121-2; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; Verdu E, 1999, MUSCLE NERVE, V22, P329, DOI 10.1002/(SICI)1097-4598(199903)22:3<329::AID-MUS5>3.0.CO;2-8; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; Watson GS, 1997, PAIN, V70, P53, DOI 10.1016/S0304-3959(96)03299-X; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	43	23	25	0	10	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1744-8069			MOL PAIN	Mol. Pain	JUN 12	2015	11								34	10.1186/s12990-015-0031-4			15	Neurosciences	Neurosciences & Neurology	CK2RP	WOS:000356059600001	26065412	DOAJ Gold, Green Published			2020-06-30	J	Domino, EF; Hirasawa-Fujita, M; Ni, LS; Guthrie, SK; Zubieta, JK				Domino, Edward F.; Hirasawa-Fujita, Mika; Ni, Lisong; Guthrie, Sally K.; Zubieta, Jon Kar			Regional brain [C-11]carfentanil binding following tobacco smoking	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY			English	Article						[C-11]carfentanil; A118G; OPRM1; PET; Smoking	MU-OPIOID-RECEPTOR; OPRM1 A118G POLYMORPHISM; ASN40ASP VARIANT; NICOTINE; ACTIVATION; ADDICTION; RELEASE; REWARD; MICE; ANTINOCICEPTION	Objective: To determine if overnight tobacco abstinent carriers of the AG or GG (*G) vs. the AA variant of the human mu opioid receptor (OPRM1) Al 18G polymorphism (rs1799971) differ in [C-11]carfentanil binding after tobacco smoking. Methods: Twenty healthy American male smokers who abstained from tobacco overnight were genotyped and completed positron emission tomography (PET) scans with the mu opioicl receptor agonist, [C-11]carfentanil. They smoked cleniconized (clenic) and average nicotine (avnic) cigarettes during the PET scans. Results: Smoking avnic cigarette decreased the binding potential (BPND) of [C-11]carfentanil in the right medial prefrontal cortex (mPfc; 6, 56, 18), left anterior medial prefrontal cortex (amPfc; 2,46,44), right ventral striatum (vStr; 16, 3, 10), left insula (Ins; 42, 10, 12), right hippocampus (Hippo; 18, 6, 14) and left cerebellum (Oil; 10, 88, 34), and increased the BPNT, in left amygdala (Amy; 20.0. 221, left putamen (Put; 22, 10, 6) and left nucleus accumbens (NAcc; 10, 12, 8). In the AA allele carriers, avnic cigarette smoking significantly changed the BPND compared to after denic smoking in most brain areas listed above. However in the ""C; carriers the significant BPND changes were confirmed in only amPfc and vStr. Free mu opioid receptor availability was significantly less in the "G than the AA carriers in the Amy and NAcc. Conclusion: The present study demonstrates that BPNT, changes induced by avnic smoking in OPRM1 'G carriers were blunted compared to the AA carriers. Also "G smokers had less free mu opioicl receptor availability in Amy and NAcc. (C) 2015 Elsevier Inc. All rights reserved.	[Domino, Edward F.; Hirasawa-Fujita, Mika; Ni, Lisong] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Guthrie, Sally K.] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA; [Guthrie, Sally K.; Zubieta, Jon Kar] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA	Domino, EF (reprint author), Univ Michigan, Dept Pharmacol, 1301 MSRBIII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	efdabcde@umich.edu			Smoking Research Foundation; Department of Pharmacology Psychopharmacology Research Fund [C361024]; Education and Research Development Fund [276157]; National Institutes of Health GrantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 DA 016423, RO1 AT 001415]	This work was supported in part by the Smoking Research Foundation, Department of Pharmacology Psychopharmacology Research Fund C361024, Education and Research Development Fund 276157, and by the National Institutes of Health Grants RO1 DA 016423 to EFD, and RO1 AT 001415 to JKZ. We thank the members of the University of Michigan PET Facility as well as the University of Michigan DNA Sequencing Core. The authors also would like thank Drs. Catherine L. Evans, Robert A. Koeppe for their help in the PET imaging, Kathleen B. Welch, the statistician Staff Specialist in the University of Michigan Center for Statistical Consultation and Research, Dr. Vicki L. Ellingrod for replicating the DNA A118G genotyping, and Lisa and Victor Chen for their help in analyzing the data.	Becker A, 2002, N-S ARCH PHARMACOL, V365, P296, DOI 10.1007/s00210-002-0533-2; Berrendero F, 2002, J NEUROSCI, V22, P10935; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Breese CR, 1997, J PHARMACOL EXP THER, V282, P7; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Cortinez LI, 2005, EUR J ANAESTH, V22, P56, DOI 10.1017/S0265021505000128; DAVENPORT KE, 1990, NEUROSCI LETT, V113, P40, DOI 10.1016/0304-3940(90)90491-Q; David SP, 2005, BIOL PSYCHIAT, V58, P488, DOI 10.1016/j.biopsych.2005.04.028; DHATT RK, 1995, J NEUROCHEM, V64, P1878; Domino EF, 2012, PROG NEURO-PSYCHOPH, V38, P236, DOI 10.1016/j.pnpbp.2012.04.003; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Galeote L, 2006, J NEUROCHEM, V97, P416, DOI 10.1111/j.1471-4159.2006.03751.x; Goodman LS, 2006, GOODMAN GILMANS PHAR; Huang P, 2012, BIOCHEM J, V441, P379, DOI 10.1042/BJ20111050; Isola R, 2009, PSYCHOPHARMACOLOGY, V201, P507, DOI 10.1007/s00213-008-1315-4; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Kreek MJ, 2005, PHARMACOL REV, V57, P1, DOI 10.1124/pr.57.1.1; Lerman C, 2004, PHARMACOGENOMICS J, V4, P184, DOI 10.1038/sj.tpj.6500238; LONDON ED, 1988, J NEUROSCI, V8, P3920; Mague SD, 2009, P NATL ACAD SCI USA, V106, P10847, DOI 10.1073/pnas.0901800106; Miyazaki T, 2009, OPEN PAIN J, V2, P71; Miyazaki T, 2010, BRAIN RES, V1313, P185, DOI 10.1016/j.brainres.2009.12.022; Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926; Ramchandani VA, 2011, MOL PSYCHIATR, V16, P809, DOI 10.1038/mp.2010.56; Ray R, 2006, PSYCHOPHARMACOLOGY, V188, P355, DOI 10.1007/s00213-006-0504-2; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Schroeder BE, 2001, NEUROSCIENCE, V105, P535, DOI 10.1016/S0306-4522(01)00221-4; Scott DJ, 2007, NEUROPSYCHOPHARMACOL, V32, P450, DOI 10.1038/sj.npp.1301238; Sola RJ, 2009, J PHARM SCI-US, V98, P1223, DOI 10.1002/jps.21504; Verhagen M, 2012, PHARMACOGENOMICS, V13, P917, DOI [10.2217/PGS.12.76, 10.2217/pgs.12.76]; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Walters CL, 2005, NEURON, V46, P933, DOI 10.1016/j.neuron.2005.05.005; Wand GS, 2011, PSYCHONEUROENDOCRINO, V36, P1453, DOI 10.1016/j.psyneuen.2011.03.019; Wang YJ, 2012, NEUROSCIENCE, V205, P178, DOI 10.1016/j.neuroscience.2011.12.033; Zhang Lan, 2006, Behav Brain Funct, V2, P28, DOI 10.1186/1744-9081-2-28; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200; Zhang Y, 2015, NEUROPSYCHOPHARMACOL	39	12	12	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-5846	1878-4216		PROG NEURO-PSYCHOPH	Prog. Neuro-Psychopharmacol. Biol. Psychiatry	JUN 3	2015	59						100	104		10.1016/j.pnpbp.2015.01.007			5	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CB9WP	WOS:000349984900012	25598501	Green Accepted			2020-06-30	J	Guo, SB; Li, B; Gao, CJ; Tian, Y				Guo, Shanbin; Li, Bo; Gao, Chengjie; Tian, Yue			Epidural Analgesia With Bupivacaine and Fentanyl Versus Ropivacaine and Fentanyl for Pain Relief in Labor A Meta-Analysis	MEDICINE			English	Review							0.125-PERCENT ROPIVACAINE; PLUS FENTANYL; SUFENTANIL; ANESTHESIA; PATIENT; METAANALYSIS; INFUSIONS; 2-MU-G/ML; DELIVERY; MODE	The aim of this study was to compare the efficacy and safety of the combinational use of bupivacaine and fentanyl versus ropivacaine and fentanyl in epidural analgesia for labor.Multiple electronic databases were searched by using appropriate MeSH terms, and keywords for original research papers published before October 2014. Meta-analyses were based on mean differences between the groups as well as odds ratios. Statistical heterogeneity was tested by I-2 index.Fifteen randomized controlled trials, recruiting 2097 parturient mothers overall, were selected for the meta-analyses. Concentrations of the preparations used (weight/volume; mean and standard deviations) were bupivacaine 0.1023%0.0375%, ropivacaine 0.1095%+/- 0.042%, and fentanyl 0.00021%+/- 0.000089%. There were no statistically significant differences between both the combinations in the mean change in Visual Analog Score for pain during labor, incidence of instrumental or cesarean delivery, neonate Apgar score of <7, maternal satisfaction, duration of either first or second stage of labor, oxytocin use for induction, onset of analgesia, and duration of analgesia. Women who received ropivacaine and fentanyl had significantly lower incidence of motor blocks (odds ratio [95% CI]=0.38 [0.30, 0.48] P<0.00001, fixed effect and 0.38 [0.27, 0.54] P<0.0001, random effects I-2 30%) when compared with women who received bupivacaine and fentanyl. Incidence of side effects was similar for both the combinations.Analgesia with ropivacaine in combination with fentanyl at 0.1%:0.0002% ratio for labor pain relief is associated with lower incidence of motor blocks in comparison with analgesia with bupivacaine and fentanyl at similar ratio (0.1%: 0.0002%).	[Guo, Shanbin] China Med Univ, Shengjing Hosp, Dept Pharm, Shenyang 110004, Peoples R China; [Li, Bo; Gao, Chengjie] PLA Jinan Mil Area Command, Jinan Gen Hosp, Dept Anesthesiol, Jinan, Peoples R China; [Tian, Yue] China Med Univ, Shengjing Hosp, Dept Anesthesiol, Shenyang 110004, Peoples R China	Tian, Y (reprint author), China Med Univ, Shengjing Hosp, Dept Anesthesiol, 36 Sanhao St, Shenyang 110004, Peoples R China.	tianyue_sj@sina.com					Asik I, 2002, EUR J ANAESTH, V19, P263; Atienzar MC, 2004, EUR J ANAESTH, V21, P770; Bolukbasi D, 2005, INT J OBSTET ANESTH, V14, P288, DOI 10.1016/j.ijoa.2005.04.007; BREEN TW, 1993, ANESTH ANALG, V77, P919; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; Cambic CR, 2010, BRIT J ANAESTH, V105, pI50, DOI 10.1093/bja/aeq311; Campbell DC, 2000, ANESTH ANALG, V90, P1384, DOI 10.1097/00000539-200006000-00023; Chen SY, 2014, TAIWAN J OBSTET GYNE, V53, P8, DOI 10.1016/j.tjog.2012.01.039; Fernandez-Guisasola J, 2001, ANESTH ANALG, V92, P1261, DOI 10.1097/00000539-200105000-00034; Finegold H, 2000, CAN J ANAESTH, V47, P740, DOI 10.1007/BF03019475; Fischer C, 2000, ANESTHESIOLOGY, V92, P1588, DOI 10.1097/00000542-200006000-00015; Gautier P, 1999, ANESTHESIOLOGY, V90, P772, DOI 10.1097/00000542-199903000-00020; Girard T, 2006, Acta Anaesthesiol Belg, V57, P45; Gomar C, 2000, EUR J ANAESTH, V17, P542, DOI 10.1046/j.1365-2346.2000.00733.x; Halpern SH, 2003, ANESTHESIOLOGY, V98, P1431, DOI 10.1097/00000542-200306000-00020; Halpern SH, 2003, ANESTH ANALG, V96, P1473, DOI 10.1213/01.ANE.0000052383.01056.8F; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hitzeman N, 2012, AM FAM PHYSICIAN, V86, P241; Jung H, 2013, KOREAN J ANESTHESIOL, V65, P379, DOI 10.4097/kjae.2013.65.5.379; Lee BB, 2004, ANESTH ANALG, V98, P1145, DOI 10.1213/01.ANE.0000103264.71747.0F; Leone Stefania, 2008, Acta Biomed, V79, P92; Li B, 2015, J CLIN PHARMACOL, V55, P584, DOI 10.1002/jcph.453; Lv BS, 2014, CURR MED RES OPIN, V5, P1; McClure JH, 1996, BRIT J ANAESTH, V76, P300; Meister GC, 2000, ANESTH ANALG, V90, P632, DOI 10.1097/00000539-200003000-00024; Neha A, 2012, ANESTHESIA UPDATE, V15, P38; Owen MD, 2002, ANESTH ANALG, V94, P179, DOI 10.1097/00000539-200201000-00034; Paddalwar S, 2013, INDIAN J PAIN, V27, P147; Palm S, 2001, ANAESTHESIA, V56, P526, DOI 10.1046/j.1365-2044.2001.02050.x; Pirbudak L, 2002, EUR J ANAESTH, V19, P271, DOI 10.1017/S0265021502000431; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; Smedvig JP, 2001, ACTA ANAESTH SCAND, V45, P595, DOI 10.1034/j.1399-6576.2001.045005595.x; Thornton JG, 2001, LANCET, V358, P2, DOI 10.1016/S0140-6736(00)05295-8; van de Velde M, 2007, ANESTHESIOLOGY, V106, P149, DOI 10.1097/00000542-200701000-00024	37	13	15	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUN	2015	94	23							e880	10.1097/MD.0000000000000880			10	Medicine, General & Internal	General & Internal Medicine	CQ6KF	WOS:000360712500001	26061307	DOAJ Gold, Green Published			2020-06-30	J	Peterson-Layne, C; Sandler, AJ				Peterson-Layne, Cathleen; Sandler, Aaron J.			Neuraxial Anesthesia for Labor and Delivery in a Parturient with Unstable Cervical Spine Fracture	A & A CASE REPORTS			English	Article							CESAREAN DELIVERY	We report the successful anesthetic management of labor and passive second-stage delivery in a parturient requiring cervical spine stabilization with a halo. A 25-year-old, Gravida 1, Para 0 at 37 weeks of gestation, admitted for observation after a recent motor vehicle collision, required induction of labor for preeclampsia. The mode of delivery was dependent on a successful anesthetic technique for a passive second stage of labor. The injury and halo presented concerns for access to her airway and preservation of neurologic status. An epidural placed early in labor allowed for adequate analgesia, as well as sacral extension for a forceps-assisted delivery.	[Peterson-Layne, Cathleen; Sandler, Aaron J.] Duke Univ Hosp, Dept Anesthesiol, Durham, NC 27710 USA	Peterson-Layne, C (reprint author), Duke Univ Hosp, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	layne003@mc.duke.edu					Barber EL, 2011, OBSTET GYNECOL, V118, P29, DOI 10.1097/AOG.0b013e31821e5f65; Chestnut DH, 2009, CHESTNUTS OBSTET ANE, P498; EASON JR, 1987, ANAESTHESIA, V42, P745, DOI 10.1111/j.1365-2044.1987.tb05320.x; Fernando R, 2009, CHESTNUTS OBSTET ANE, P416; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; Howell C J, 1992, Int J Obstet Anesth, V1, P93, DOI 10.1016/0959-289X(92)90008-R; PAECH MJ, 1991, ANAESTH INTENS CARE, V19, P393, DOI 10.1177/0310057X9101900316; SIMMONS SW, 2007, [No title captured], V3, DOI DOI 10.1002/14651858.CD003401.PUB2; Tsen LC, 2009, CHESTNUTS OBSTET ANE, P542; Villar J, 2007, BRIT MED J, V335, P1025, DOI 10.1136/bmj.39363.706956.55	10	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237			A A CASE REP	A A Case Rep.	JUN 1	2015	4	11					145	147		10.1213/XAA.0000000000000145			3	Anesthesiology	Anesthesiology	CM3HO	WOS:000357572900001	26035219				2020-06-30	J	Okajima, H; Tanaka, O; Ushio, M; Higuchi, Y; Nagai, Y; Iijima, K; Horikawa, Y; Ijichi, K				Okajima, Hanae; Tanaka, Osamu; Ushio, Masahiro; Higuchi, Yasuko; Nagai, Yukiko; Iijima, Katsuhiro; Horikawa, Yoshio; Ijichi, Kazuko			Ultrasound-guided continuous thoracic paravertebral block provides comparable analgesia and fewer episodes of hypotension than continuous epidural block after lung surgery	JOURNAL OF ANESTHESIA			English	Article						Ultrasound guidance; Thoracic paravertebral block; Epidural block; Postoperative analgesia; Lung surgery	INTRAVENOUS FENTANYL INFUSIONS; POSTTHORACOTOMY PAIN; RANDOMIZED-TRIALS; THORACOTOMY; MANAGEMENT; EFFICACY; SITE	Both paravertebral block (PVB) and thoracic epidural block (TEB) are recommended for postoperative pain relief after lung surgery. The addition of fentanyl to the anesthetic solution became popular for TEB because of the stronger effects; however, there have been few comparable trials about the addition of fentanyl to PVB. The purpose of this study was thus to compare postoperative analgesia, side effects, and complications between ultrasound-guided PVB (USG-PVB) and TEB with the addition of fentanyl to ropivacaine after lung surgery. We examined 90 consecutive patients (age 18-75 years) scheduled for video-assisted thoracic surgery (VATS). In both groups, all blocks (four blocks in USG-PVB and one block in TEB) and one catheter insertion were performed preoperatively. Continuous postoperative infusion (0.1 % ropivacaine plus fentanyl at 0.4 mg/day) was undertaken for 36 h in both groups. The recorded data included the verbal rating scale (VRS) for pain, blood pressure, side effects, complications for 2 days, and overall satisfaction score. There was no difference in the frequency of taking supplemental analgesics (twice or more frequently), or in VRS. Hypotension occurred significantly more frequently in TEB (n = 7/33) than in PVB (n = 1/36) (P = 0.02); on the other hand, the incidences of PONV and pruritus, as well as overall satisfaction score, were similar. There were no complications in both groups; however, the catheters migrated intrathoracically in four patients in PVB. USG-PVB achieved similar pain relief and lowered the incidence of hypotension compared with TEB. We conclude that both blocks with the same concentration of ropivacaine and fentanyl can provide adequate postoperative analgesia for VATS.	[Okajima, Hanae; Tanaka, Osamu; Higuchi, Yasuko; Nagai, Yukiko; Iijima, Katsuhiro; Ijichi, Kazuko] Nishi Kobe Med Ctr, Dept Anesthesiol, Nishi Ku, Kobe, Hyogo 6512273, Japan; [Ushio, Masahiro] Kakogawa West City Hosp, Dept Anesthesiol, Kakogawa, Hyogo 6758611, Japan; [Horikawa, Yoshio] Hyogo Brain & Heart Ctr, Dept Anesthesiol, Himeji, Hyogo 6700981, Japan	Okajima, H (reprint author), Nishi Kobe Med Ctr, Dept Anesthesiol, Nishi Ku, 5-7-1 Kojidai, Kobe, Hyogo 6512273, Japan.	hanae1123catseeye@hotmail.com					Bimston DN, 1999, SURGERY, V126, P650, DOI 10.1016/S0039-6060(99)70118-2; Cowie B, 2010, ANESTH ANALG, V110, P1735, DOI 10.1213/ANE.0b013e3181dd58b0; Davies RG, 2006, BRIT J ANAESTH, V96, P418, DOI 10.1093/bja/ael020; George MJ, 2006, ANAESTHESIA, V61, P659, DOI 10.1111/j.1365-2044.2006.04713.x; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff; Kotze A, 2009, BRIT J ANAESTH, V103, P626, DOI 10.1093/bja/aep272; LOPER KA, 1990, ANESTH ANALG, V70, P72; Luyet C, 2009, BRIT J ANAESTH, V102, P534, DOI 10.1093/bja/aep015; Macias A, 2002, ANESTH ANALG, V95, P1344, DOI 10.1097/00000539-200211000-00046; PURCELLJONES G, 1989, ANESTH ANALG, V68, P32; Richardson J, 1996, ANAESTHESIA, V51, P137, DOI 10.1111/j.1365-2044.1996.tb07700.x; Richardson J, 1999, BRIT J ANAESTH, V83, P387; SANDLER AN, 1992, ANESTHESIOLOGY, V77, P626, DOI 10.1097/00000542-199210000-00003	14	21	27	0	7	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	JUN	2015	29	3					373	378		10.1007/s00540-014-1947-y			6	Anesthesiology	Anesthesiology	CL9FJ	WOS:000357281100009	25398399				2020-06-30	J	Pacifici, GM				Pacifici, Gian Maria			Clinical Pharmacology of Fentanyl in Preterm Infants. A Review	PEDIATRICS AND NEONATOLOGY			English	Review						fentanyl; metabolism; neonate; pharmacokinetics; pharmacodynamics	CHEST-WALL RIGIDITY; EXTRACORPOREAL MEMBRANE-OXYGENATION; CONTINUOUS-INFUSION; MECHANICAL VENTILATION; RESPIRATORY DEPRESSION; LIVER-MICROSOMES; MUSCLE RIGIDITY; NEWBORN-INFANTS; CARDIAC-SURGERY; DOSE FENTANYL	Fentanyl is a synthetic opioid that is very important in anesthetic practice because of its relatively short time to peak analgesic effect and the rapid termination of action after small bolus doses. The objective of this survey is to review the clinical pharmacology of fentanyl in pre-term infants. The bibliographic search was performed using PubMed and EMBASE databases as search engines. In addition, the books Neofax: A manual of drugs used in neonatal care and Neonatal formulary were consulted. Fentanyl is N-dealkylated by CYP3A4 into the inactive norfentanyl. Fentanyl may be administered as bolus doses or as a continuous infusion. In neonates, there is a remarkable interindividual variability in the kinetic parameters. In neonates, fentanyl half-life ranges from 317 minutes to 1266 minutes and in adults it is 222 minutes. Respiratory depression occurs when fentanyl doses are >5 mu g/kg. Chest wall rigidity may occur in neonates and occasionally is associated with laryngospasm. Tolerance to fentanyl may develop after prolonged use of this drug. Significant withdrawal symptoms have been reported in infants treated with continuous infusion for 5 days or longer. Fentanyl is an extremely potent analgesic and is the opioid analgesic most frequently used in the neonatal intensive care unit. Copyright (C) 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.	Univ Pisa, Sch Med, Dept Translat Res & New Technol Med & Surg, Pharmacol Sect, I-56100 Pisa, Italy	Pacifici, GM (reprint author), Univ Pisa, Sch Med, Dept Translat Res & New Technol Med & Surg, Pharmacol Sect, I-56100 Pisa, Italy.	pacifici@biomed.unipi.it			Ministry of the University and Scientific and Technologic Research (Rome, Italy)Ministry of Education, Universities and Research (MIUR)	This work has been supported by the Ministry of the University and Scientific and Technologic Research (Rome, Italy). The author thanks Dr Rosa Baviello and Dr Ida Bertolini, of the Medical Library of the University of Pisa (Pisa, Italy), for the prompt retrieving of the literature. Particular thanks to Dr Tessa Piazzini, of the Biomedical Library of the University of Florence (Florence, Italy) who performed the bibliographic search with EMBASE.	Allegaert K, 2006, INT J CLIN PHARM TH, V44, P303; Anand KJS, 2007, J PERINATOL, V27, pS4, DOI 10.1038/sj.jp.7211712; Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; ARNOLD JH, 1991, J PEDIATR-US, V119, P639, DOI 10.1016/S0022-3476(05)82419-9; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Bailey P. L., 1994, ANESTHESIA, P291; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Bergqvist LL, 2009, J PERINATOL, V29, P44, DOI 10.1038/jp.2008.129; Bolisetty S, 1999, INTENS CARE MED, V25, P1337, DOI 10.1007/s001340051074; BOVILL JG, 1980, BRIT J ANAESTH, V52, P795, DOI 10.1093/bja/52.8.795; Buck ML, 2003, CLIN PHARMACOKINET, V42, P403, DOI 10.2165/00003088-200342050-00001; COLLINS C, 1985, ANESTH ANALG, V64, P1078; Das UG, 2001, PEDIATRICS, V108, P1012, DOI 10.1542/peds.108.4.1012; Dewhirst E, 2012, PEDIATR EMERG CARE, V28, P465, DOI 10.1097/PEC.0b013e3182535a2a; ELLENBROEK B, 1985, BRAIN RES, V345, P132, DOI 10.1016/0006-8993(85)90843-1; Encinas E, 2013, PEDIATR DRUGS, V15, P247, DOI 10.1007/s40272-013-0029-1; Eventov-Friedman S, 2010, J PERINATOL, V30, P149, DOI 10.1038/jp.2009.66; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Feierman DE, 1996, ANESTH ANALG, V82, P936, DOI 10.1097/00000539-199605000-00008; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; Gruber EM, 2001, ANESTH ANALG, V92, P882; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; Hamon I, 1996, ACTA PAEDIATR, V85, P361, DOI 10.1111/j.1651-2227.1996.tb14033.x; Hay E, 2011, NEONATAL FORMULARY; HOVAV E, 1987, J PHARMACOL EXP THER, V242, P251; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; Kussman BD, 2005, J CARDIOTHOR VASC AN, V19, P316, DOI 10.1053/j.jvca.2005.03.008; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; Lindemann R, 1998, EUR J PEDIATR, V157, P1012, DOI 10.1007/s004310050988; Mainous R O, 1995, Neonatal Netw, V14, P71; MCQUAY HJ, 1979, BRIT J ANAESTH, V51, P543, DOI 10.1093/bja/51.6.543; Prakash Smita, 2010, J Anaesthesiol Clin Pharmacol, V26, P567; Ranger M, 2007, SEMIN PERINATOL, V31, P283, DOI 10.1053/j.semperi.2007.07.003; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; Santeiro M L, 1997, J Perinatol, V17, P135; Schmidt B, 2010, KLIN PADIATR, V222, P62, DOI 10.1055/s-0029-1225348; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741; STOECKEL H, 1982, BRIT J ANAESTH, V54, P1087, DOI 10.1093/bja/54.10.1087; Sweetman SC, 2005, MARTINDALE COMPLETE, P40; Thummel KE, 2011, GOODMAN GILMANS PHAR, P1931; Tibboel D, 2005, SEMIN FETAL NEONAT M, V10, P195, DOI 10.1016/j.siny.2004.11.002; TRUOG R, 1989, CLIN PERINATOL, V16, P61; Vaughn PR, 1996, J PEDIATR SURG, V31, P1616, DOI 10.1016/S0022-3468(96)90033-0; Wilson AS, 1997, ANESTH ANALG, V84, P315, DOI 10.1097/00000539-199702000-00013; Yaksh T. L., 2011, GOODMAN GILMANS PHAR, P505; Young TE, NEOFAX MANUAL DRUGS	52	14	15	0	4	ELSEVIER TAIWAN	TAIPEI	RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN	1875-9572			PEDIATR NEONATOL	Pediatr. Neonatol.	JUN	2015	56	3					143	148		10.1016/j.pedneo.2014.06.002			6	Pediatrics	Pediatrics	CM0CT	WOS:000357346700002	25176283	DOAJ Gold			2020-06-30	J	Deaton, T; Auten, JD; Darracq, MA				Deaton, Travis; Auten, Jonathan D.; Darracq, Michael A.			Nebulized fentanyl vs intravenous morphine for ED patients with acute abdominal pain: a randomized double-blinded, placebo-controlled clinical trial	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							PEDIATRIC EMERGENCY-DEPARTMENT; INTRANASAL FENTANYL; ANALGESIA; CHILDREN; EFFICACY; DELIVERY; RELIEF	Objectives: Patients with acute abdominal pain commonly present to emergency departments. The safe and effective relief of discomfort is a concern to patients and physicians. Intravenous opioids are the traditional method used to provide pain relief in this setting, but intravenous access is time consuming and not always achievable. Alternative methods of pain control may therefore be necessary for the acute management of painful conditions without adding to the overall physical or psychological discomfort. The purpose of this study was to evaluate the feasibility of nebulized fentanyl (NF) in the alleviation of acute and undifferentiated abdominal pain. We also sought to compare NF with intravenous morphine (IVM) and to assess patient and provider satisfaction with NF. Nebulized fentanyl (2 mu g/kg) was compared to IVM (0.1 mg/kg) at 10, 20, 30, and 40 minutes; and patient and physician satisfaction was recorded. The NF group experienced more rapid pain relief and more sustained and clinically significant pain relief over the 40-minute study interval. There were no adverse effects noted in the NF group. Both patient and physician satisfaction scores were higher in the NF group. Fentanyl citrate at a dose of 2 mu g/kg through a breath-actuated nebulizer appears to be a feasible and safe alternative to IVM (0.1 mg/kg) in the treatment of acute abdominal pain. (C) 2015 Elsevier Inc. All rights reserved.	[Deaton, Travis; Auten, Jonathan D.] Naval Med Ctr San Diego, Dept Emergency Med, San Diego, CA 92134 USA; [Darracq, Michael A.] Univ Calif San Francisco, Dept Emergency Med, Fresno Med Educ Program, Fresno, CA 93701 USA	Darracq, MA (reprint author), Univ Calif San Francisco, Dept Emergency Med, Fresno Med Educ Program, 155 N Fresno St, Fresno, CA 93701 USA.	travis.deaton@gmail.com; jdauten@gmail.com; mike.darracq@gmail.com	Darracq, Michael/I-5328-2019	Auten, Jonathan/0000-0003-2708-899X			Allione A, 2011, INTERN EMERG MED, V6, P69, DOI 10.1007/s11739-010-0463-9; Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1197/aemj.10.3.215; Bhuiya FA, EMERGENCY DEP VISITS; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; CDC, NAT HOSP AMB MED CAR; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Furyk JS, 2009, EMERG MED AUSTRALAS, V21, P203, DOI 10.1111/j.1742-6723.2009.01183.x; Graudins A, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-208; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; Johnston S, 2011, EMERG MED J, V28, P57, DOI 10.1136/emj.2009.078717; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; Motov S.M., 2009, J PAIN RES, V2, P5; NETER J, 1990, APPL LINEAR STAT MOD, P741; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Shervin F, 2014, AM J EMERG MED, V32, P1011, DOI 10.1016/j.ajem.2014.05.051; Steenblik J, 2012, AM J EMERG MED, V30, P1817, DOI 10.1016/j.ajem.2012.02.019; Stephen Robert, 2012, J Opioid Manag, V8, P237, DOI 10.5055/jom.2012.0121; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Todd KH, 1996, ACAD EMERG MED, V3, P142, DOI 10.1111/j.1553-2712.1996.tb03402.x; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616	25	11	12	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JUN	2015	33	6					791	795		10.1016/j.ajem.2015.03.046			5	Emergency Medicine	Emergency Medicine	CL0AS	WOS:000356601400010	25840767				2020-06-30	J	Tamas, K; Istvan, S; Agnes, C; Tamas, P				Tamas, Kullmann; Istvan, Sipocz; Agnes, Csikos; Tamas, Pinter			New option in the management of cancer pain in Hungary: short acting oral opioid therapy	ORVOSI HETILAP			Hungarian	Article						cancer pain; breakthrough pain; morphine; dose titration		Short acting oral morphine has recently been registered again in Hungary. Short acting oral morphine has two essential indications: dose titration at initiation of major analgesic therapy and treatment of breakthrough pain appearing beside round the clock major analgesic therapy. The clinical management of short acting oral morphine is summarised in this article.	[Tamas, Kullmann; Istvan, Sipocz; Tamas, Pinter] Petz Aladar Megyei Oktato Korhaz, Onkoradiol Osztaly, Gyor, Hungary; [Agnes, Csikos] Pecsi Tudomanyegyet, Altalanos Orvostudomanyi Kar, Csaladorvostani Intezet, Hosp Palliat Tanszek, Pecs, Hungary	Tamas, K (reprint author), Vasvari Pal U 2-4, H-9024 Gyor, Hungary.	kullmanndoki@hotmail.com					Biro E, 2013, ORVOSI HETILAP, V154, P455, DOI 10.1556/OH.2013.29569; Csikos A, 2008, J PALLIAT MED, V11, P1083, DOI 10.1089/jpm.2008.0094; Embey-Isztin D., 2009, MANAGEMENT OF PAIN; Heigl P, 2014, ORVOSI HETILAP, V155, P93, DOI 10.1556/OH.2014.29808; Jacquemin D, 2014, MANUEL SOINS PALLIAT; Kasler M., 2011, FUNDAMENTALS ONCOLOG	6	1	1	0	3	AKADEMIAI KIADO RT	BUDAPEST	PRIELLE K U 19, PO BOX 245,, H-1117 BUDAPEST, HUNGARY	0030-6002	1788-6120		ORVOSI HETILAP	Orvosi Hetilap	JUN	2015	156	25					1003	1006		10.1556/650.2015.30171			4	Medicine, General & Internal	General & Internal Medicine	CK3ZB	WOS:000356154400002	26170088	Green Accepted			2020-06-30	J	Atkinson, TJ; Fudin, J; Pham, TC				Atkinson, Timothy J.; Fudin, Jeffrey; Pham, Thien C.			Combined Fentanyl and Methadone Induced Serotonin Syndrome is Called Into Question	PHARMACOTHERAPY			English	Article						serotonin syndrome; methadone; fentanyl; neuroleptic malignant syndrome; NMS	NEUROLEPTIC MALIGNANT SYNDROME		[Atkinson, Timothy J.; Fudin, Jeffrey] VA Tennessee Valley Healthcare Syst, Pain Management, Murfreesboro, TN USA; [Fudin, Jeffrey] Western New England Univ, Coll Pharm, Springfield, MA USA; [Fudin, Jeffrey] Univ Connecticut, Sch Pharm, Pharm Practice, Delmar, NY USA; [Pham, Thien C.] Albany Stratton VAMC, Pain & Palliat Care, Albany, NY USA	Fudin, J (reprint author), Remitigate LLC, 357 Delaware Ave 214, Delmar, NY 12054 USA.	fudinj@gmail.com					ADDONIZIO G, 1987, BIOL PSYCHIAT, V22, P1004, DOI 10.1016/0006-3223(87)90010-2; Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; ALOJADO ES, 1994, ANESTH ANALG, V78, P726; Atkinson T, 2014, PRACT PAIN MANAG, V7, P50; CHANCE WT, 1985, J TRAUMA, V25, P501, DOI 10.1097/00005373-198506000-00005; Darwish M, 2008, ARCH DRUG INF, V1, P50; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Gollapudy S, 2012, J CLIN ANESTH, V24, P251, DOI 10.1016/j.jclinane.2011.04.017; Hillman AD, 2015, PHARMACOTHERAPY, V35, P112, DOI 10.1002/phar.1528; Isbister GK, 2005, CLIN NEUROPHARMACOL, V28, P205, DOI 10.1097/01.wnf.0000177642.89888.85; Kirschner R, 2010, J EMERG MED, V38, P477, DOI 10.1016/j.jemermed.2008.01.003; Koury KM, 2015, PAIN PHYSICIAN, V18, pE27; Medsafe, 2012, PRESCRIBER UPDATE, V33, P31; Ozkardesler S, 2008, J CLIN ANESTH, V20, P143, DOI 10.1016/j.jclinane.2007.06.024; Perry PJ, 2012, ANN CLIN PSYCHIATRY, V24, P155; Rastogi R, 2011, ANESTHESIOLOGY, V115, P1291, DOI 10.1097/ALN.0b013e31823940c0; Samartzis Lampros, 2013, Case Rep Psychiatry, V2013, P617251, DOI 10.1155/2013/617251; Samuelsson A, 2008, BURNS, V34, P617, DOI 10.1016/j.burns.2007.08.003; Tao R, 2003, BRIT J PHARMACOL, V139, P1498, DOI 10.1038/sj.bjp.0705378	19	2	2	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-0008	1875-9114		PHARMACOTHERAPY	Pharmacotherapy	JUN	2015	35	6					E111	E114		10.1002/phar.1601			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL0DZ	WOS:000356610700004	26095009				2020-06-30	J	Christou, C; Oliver, RA; Rawlinson, J; Walsh, WR				Christou, Chris; Oliver, Rema A.; Rawlinson, John; Walsh, William R.			Transdermal fentanyl and its use in ovine surgery	RESEARCH IN VETERINARY SCIENCE			English	Article						Analgesia; Fentanyl; Pre-emptive; Sheep; Ovine	POSTOPERATIVE PAIN; CLINICAL-IMPLICATIONS; PREEMPTIVE ANALGESIA; PHARMACOKINETICS; DELIVERY; HISTORY; SHEEP	Fentanyl delivered via a transdermal patch has the potential to decrease the need for post-operative handling of sheep undergoing surgical procedures. Two studies were performed to test: (1) the ideal timing for the application of pre-emptive analgesic patches and (2) the efficacy of a 2 mu g/kg/h dose, as extrapolated from other species. The first study had sheep divided into two groups. Group 1 had a fentanyl patch applied for 24 h prior to a patch change and group 2 had a fentanyl patch applied 72 h prior to a change. The second study applied the results obtained in the first and tested the efficacy of 2 mu g/kg/h as an effective dose in an orthopaedic surgical environment. Results indicated that the ideal time for pre-emptive fentanyl patch administration is 24-36 h prior to surgery and that 2 mu g/kg/h is an effective minimum therapeutic dose rate for the use of fentanyl as an analgesic in an orthopaedic surgical environment. (C) 2015 Elsevier Ltd. All rights reserved.	[Christou, Chris; Oliver, Rema A.; Rawlinson, John; Walsh, William R.] Univ New S Wales, Prince Wales Clin Sch, Surg & Orthopaed Res Lab, Randwick, NSW 2031, Australia	Christou, C (reprint author), Univ New S Wales, Prince Wales Clin Sch, Surg & Orthopaed Res Lab, Level 1 Clin Sci Bldg Avoca St, Randwick, NSW 2031, Australia.	c.christou@unsw.edu.au		Walsh, William/0000-0002-5023-6148; Christou, Chris/0000-0003-3231-0356			Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; Ahern BJ, 2009, AM J VET RES, V70, P418, DOI 10.2460/ajvr.70.3.418; [Anonymous], 2013, AUSTR COD CAR US AN; Barry S, 2010, VET COMP ORTHOPAED, V23, P385, DOI 10.3415/VCOT-10-01-0017; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hammamond R, 2008, SMALL ANIMAL CLIN PH, P309; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; KNUTSON K, 1987, Journal of Controlled Release, V6, P59, DOI 10.1016/0168-3659(87)90064-2; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; Lane ME, 2013, EUR J PHARM BIOPHARM, V84, P449, DOI 10.1016/j.ejpb.2013.01.018; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Mishra A., 2013, INDIAN J PAIN, V27, P114; Ong CKS, 2005, ANESTH ANALG, V100, P757, DOI 10.1213/01.ANE.0000144428.98767.0E; Orsini JA, 2006, J VET PHARMACOL THER, V29, P539, DOI 10.1111/j.1365-2885.2006.00796.x; Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404; Rollin BE, 1999, PAIN FORUM, V8, P78; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Sehgal N, 2011, PAIN PHYSICIAN, V14, P249; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	20	12	12	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0034-5288	1532-2661		RES VET SCI	Res. Vet. Sci.	JUN	2015	100						252	256		10.1016/j.rvsc.2015.04.006			5	Veterinary Sciences	Veterinary Sciences	CK9KD	WOS:000356558100039	25933932				2020-06-30	J	Khaw, KS; Lee, SWY; Ngan Kee, WD; Law, LW; Lau, TK; Ng, FF; Leung, TY				Khaw, K. S.; Lee, S. W. Y.; Ngan Kee, W. D.; Law, L. W.; Lau, T. K.; Ng, F. F.; Leung, T. Y.			Randomized trial of anaesthetic interventions in external cephalic version for breech presentation	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anesthesia regional; anesthesia; spinal; breech presentation; external cephalic version; obstetrics; remifentanil; analgesia; obstetric; term birth	EPIDURAL-ANESTHESIA; NEURAXIAL BLOCKADE; CESAREAN-SECTION; SUCCESS RATE; ANALGESIA; PREGNANCY; DELIVERY; TERM	Background: Successful external cephalic version (ECV) for breech presenting fetus reduces the need for Caesarean section (CS). We aimed to compare the success rate of ECV with either spinal anaesthesia (SA) or i.v. analgesia using remifentanil. Methods: In a double-phased, stratified randomized blinded controlled study we compared the success rates of ECV, performed under spinal anaesthesia (SA), i.v. analgesia (WA) using remifentanil or no anaesthetic interventions. In phase 1, 189 patients were stratified by parity before randomization to ECV, performed by blinded operators, under SA using either hyperbaric bupivacaine 9 mg with fentany115 mu g, i.v. remifentanil infusion 0.1 mu g kg min(-1), or Control (no anaesthetic intervention). Operators performing ECV were blinded to the treatment allocation. In phase 2, patients in the Control group in whom the initial ECV failed were further randomized to receive either SA (n=9) or IVA (n=9) for a re-attempt. The primary outcome was the incidence of successful ECV. Results: The success rate in Phase 1 was greatest using SA [52/63 (83%)], compared with IVA [40/63 (64%)] and Control [40/63 (64%)], (P=0.027). Median [IQR] pain scores on a visual analogue scale (range 0-100), were 0 [0-0] with SA, 35 [0-60] with IVA and 50 [30-75] in the Control group (P<0.001). Median [IQR] VAS sedation scores were highest with WA [75 (50-80)], followed by SA, [0 (0-50)] and Control [0 (0-0)]. In phase 2, 7/9 (78%) of ECV re-attempts were successful with SA, whereas all re-attempts using IVA failed (P=0.0007). The incidence of fetal bradycardia necessitating emergency CS within 30 min, was similar among groups; 1.6% (1/63) in the SA and WA groups and 3.2% (2/63) in the Control group. Conclusions: SA increased the success rate and reduced pain for both primary and re-attempts of ECV, whereas WA using remifentanil infusion only reduced the pain. There was no significant increase in the incidence of fetal bradycardia or emergency CS, with ECV performed under anaesthetic interventions. Relaxation of the abdominal muscles from SA appears to underlie the improved outcomes for ECV.	[Khaw, K. S.; Lee, S. W. Y.; Ngan Kee, W. D.; Ng, F. F.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; [Law, L. W.; Lau, T. K.; Leung, T. Y.] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Lee, S. W. Y.] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hong Kong, Hong Kong, Peoples R China	Khaw, KS (reprint author), Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China.	kimkhaw@cuhk.edu.hk	Ngan Kee, Warwick/J-8817-2013; Lee, Shara WY/G-1874-2014	Ngan Kee, Warwick/0000-0003-1000-7735; Lee, Shara WY/0000-0001-5257-2076	Research Grants Council of The Hong Kong Special Administrative Region, ChinaHong Kong Research Grants Council [CUHK4405/03M]; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China	The study was substantially supported by a grant from the Research Grants Council of The Hong Kong Special Administrative Region, China (Project no. CUHK4405/03M) and internally funded by the Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China.	Birnbach DJ, 2001, ANESTH ANALG, V93, P410, DOI 10.1097/00000539-200108000-00035; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; CARLAN SJ, 1994, ANESTH ANALG, V79, P525; Chan LYS, 2002, BJOG-INT J OBSTET GY, V109, P627; Cherayil G, 2002, ANESTH ANALG, V94, P1589, DOI 10.1097/00000539-200206000-00041; Cluver C., 2012, COCHRANE DB SYST REV, V1, P184; Fok WY, 2005, ACTA OBSTET GYN SCAN, V84, P748, DOI 10.1111/j.0001-6349.2005.00505.x; Goetzinger KR, 2011, OBSTET GYNECOL, V118, P1137, DOI 10.1097/AOG.0b013e3182324583; Hannah ME, 2000, LANCET, V356, P1375, DOI 10.1016/S0140-6736(00)02840-3; Hehir MP, 2012, AM J OBSTET GYNECOL, V206; HOFMEYR GJ, 1983, BRIT J OBSTET GYNAEC, V90, P392, DOI 10.1111/j.1471-0528.1983.tb08934.x; Hofmeyr GJ, 2000, COCHRANE DB SYST REV; Kee WDN, 2006, CURR OPIN ANESTHESIO, V19, P238, DOI 10.1097/01.aco.0000192816.22989.ba; Khaw KS, 2006, FETAL MATERNAL MED R, V17, P157; Lau TK, 1997, AM J OBSTET GYNECOL, V176, P218, DOI 10.1016/S0002-9378(97)80040-3; Lavoie A, 2010, CAN J ANAESTH, V57, P408, DOI 10.1007/s12630-010-9278-4; Leung TY, 2000, AUST NZ J OBSTET GYN, V40, P253, DOI 10.1111/j.1479-828X.2000.tb03331.x; Leung TY, 2006, ACTA OBSTET GYN SCAN, V85, P182, DOI 10.1080/00016340500408440; Leung TY, 2003, ACTA OBSTET GYN SCAN, V82, P1017, DOI 10.1034/j.1600-0412.2003.00269.x; Leung VKT, 2012, J MATERN-FETAL NEO M, V25, P1774, DOI 10.3109/14767058.2012.663828; Mancuso KM, 2000, OBSTET GYNECOL, V95, P648, DOI 10.1016/S0029-7844(99)00611-0; Neiger R, 1998, AM J OBSTET GYNECOL, V179, P1136, DOI 10.1016/S0002-9378(98)70120-6; O'Brien JA, 2014, ISR J HEALTH POLICY, V3, DOI 10.1186/2045-4015-3-6; Rozenberg P, 2000, BRIT J OBSTET GYNAEC, V107, P406, DOI 10.1111/j.1471-0528.2000.tb13238.x; Schorr SJ, 1997, AM J OBSTET GYNECOL, V177, P1133, DOI 10.1016/S0002-9378(97)70029-2; Suen SSH, 2012, J MATERN-FETAL NEO M, V25, P719, DOI 10.3109/14767058.2011.589931; Sultan P, 2011, INT J OBSTET ANESTH, V20, P299, DOI 10.1016/j.ijoa.2011.07.001; Weiniger CF, 2010, BRIT J ANAESTH, V104, P613, DOI 10.1093/bja/aeq053; Weiniger CF, 2014, ISR J HEALTH POLICY, V3, DOI 10.1186/2045-4015-3-5; Weiniger CF, 2013, CURR OPIN ANESTHESIO, V26, P278, DOI 10.1097/ACO.0b013e328360f64e	30	10	12	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JUN	2015	114	6					944	950		10.1093/bja/aev107			7	Anesthesiology	Anesthesiology	CJ8SB	WOS:000355772700015	25962611	Bronze			2020-06-30	J	Kotrach, HG; Bourbeau, J; Jensen, D				Kotrach, Houssam G.; Bourbeau, Jean; Jensen, Dennis			Does nebulized fentanyl relieve dyspnea during exercise in healthy man?	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						dyspnea; fentanyl; opioid; exercise; chest wall strapping	INTERSTITIAL LUNG-DISEASE; OBSTRUCTIVE PULMONARY-DISEASE; NEUROGENIC PLASMA EXTRAVASATION; EXTERNAL THORACIC RESTRICTION; OPIOID BINDING-SITES; GUINEA-PIG; INHALED MORPHINE; CHOLINERGIC NEUROTRANSMISSION; PHYSIOLOGICAL-MECHANISMS; RESPIRATORY SENSATION	Few therapies exist for the relief of dyspnea in restrictive lung disorders. Accumulating evidence suggests that nebulized opioids selective for the mu-receptor subtype may relieve dyspnea by modulating intrapulmonary opioid receptor activity. Our respective primary and secondary objectives were to test the hypothesis that nebulized fentanyl (a mu-opioid receptor agonist) relieves dyspnea during exercise in the presence of abnormal restrictive ventilatory constraints and to identify the physiological mechanisms of this improvement. In a randomized, double-blind, placebo-controlled crossover study, we examined the effect of 250 mu g nebulized fentanyl, chest wall strapping (CWS), and their interaction on detailed physiological and perceptual responses to constant work rate cycle exercise (85% of maximum incremental work rate) in 14 healthy, fit young men. By design, CWS decreased vital capacity by similar to 20% and mimicked the negative consequences of a mild restrictive lung disorder on exercise endurance time and on dyspnea, breathing pattern, dynamic operating lung volumes, and diaphragmatic electromyographic and respiratory muscle function during exercise. Compared with placebo under both unrestricted control and CWS conditions, nebulized fentanyl had no effect on exercise endurance time, integrated physiological response to exercise, sensory intensity, unpleasantness ratings of exertional dyspnea. Our results do not support a role for intrapulmonary opioids in the neuromodulation of exertional dyspnea in health nor do they provide a physiological rationale for the use of nebulized fentanyl in the management of dyspnea due to mild restrictive lung disorders, specifically those arising from abnormalities of the chest wall and not affiliated with airway inflammation.	[Kotrach, Houssam G.; Jensen, Dennis] McGill Univ, Dept Kinesiol & Phys Educ, Clin Exercise & Resp Physiol Lab, Montreal, PQ, Canada; [Bourbeau, Jean; Jensen, Dennis] McGill Univ, Resp Epidemiol & Clin Res Unit, Montreal Chest Inst, Ctr Hlth, Montreal, PQ, Canada; [Jensen, Dennis] McGill Univ, Res Ctr Phys Act & Hlth, Montreal, PQ, Canada	Jensen, D (reprint author), Dept Kinesiol & Phys Educ, 475 Pine Ave West, Montreal, PQ H2W 1S4, Canada.	dennis.jensen@mcgill.ca			Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada [RGPIN 402598-2011]; Fonds de Recherche du Quebec-SanteFonds de la Recherche en Sante du Quebec; William Dawson Research Scholars Award (McGill University)	Support for this study was provided by Discovery Grant RGPIN 402598-2011 from the Natural Sciences and Engineering Research Council of Canada to D. Jensen. D. Jensen was supported by a Chercheurs-Boursiers Junior 1 salary award from the Fonds de Recherche du Quebec-Sante and by a William Dawson Research Scholars Award (McGill University).	Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Apfelbaum JL, 2004, ANESTH ANALG, V99, P699, DOI 10.1213/01.ANE.0000133143.60584.38; ATS, 2003, AM J RESP CRIT CARE, V167, P211, DOI 10.1164/rccm.167.2.211; Banzett RB, 2011, AM J RESP CRIT CARE, V184, P920, DOI 10.1164/rccm.201101-0005OC; Barnes PJ, 2001, RESP PHYSIOL, V125, P145, DOI 10.1016/S0034-5687(00)00210-3; Baroffio M, 2013, RESP PHYSIOL NEUROBI, V185, P281, DOI 10.1016/j.resp.2012.10.001; BEAUFORD W, 1993, CHEST, V104, P175, DOI 10.1378/chest.104.1.175; Belvisi M. G., 2009, V187, P63, DOI 10.1007/978-3-540-79842-2_4; BELVISI MG, 1992, J APPL PHYSIOL, V72, P1096; BELVISI MG, 1989, J APPL PHYSIOL, V66, P268; Bhargava HN, 1997, PEPTIDES, V18, P1603, DOI 10.1016/S0196-9781(97)00247-7; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Boyden JY, 2015, J AEROSOL MED PULM D, V28, P1, DOI 10.1089/jamp.2014.1136; BUCHAN P, 1992, BRIT J PHARMACOL, V105, P448, DOI 10.1111/j.1476-5381.1992.tb14273.x; Burki NK, 2010, CHEST, V138, P1196, DOI 10.1378/chest.10-0534; Cabot PJ, 1996, EUR J PHARMACOL, V310, P47, DOI 10.1016/0014-2999(96)00363-9; CABOT PJ, 1994, EUR J PHARM-MOLEC PH, V268, P247, DOI 10.1016/0922-4106(94)90195-3; Collard Harold R, 2008, Curr Opin Support Palliat Care, V2, P100, DOI 10.1097/SPC.0b013e3282ff6336; De Vries J, 2006, CURR OPIN PULM MED, V12, P354, DOI 10.1097/01.mcp.0000239553.93443.d8; FULLER RW, 1988, J APPL PHYSIOL, V65, P1125; Hadjiphilippou S, 2014, BMJ SUPPORT PALLIAT, V4, P190, DOI 10.1136/bmjspcare-2013-000565; Hansen JE, 1996, CHEST, V109, P1566, DOI 10.1378/chest.109.6.1566; HARRISEZE AO, 1995, AM J RESP CRIT CARE, V152, P1940, DOI 10.1164/ajrccm.152.6.8520759; Harty HR, 1999, J APPL PHYSIOL, V86, P1142; Holland A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006322.pub2; Holland Anne E, 2010, Chron Respir Dis, V7, P101, DOI 10.1177/1479972309354689; Jankelson D, 1997, EUR RESPIR J, V10, P2270, DOI 10.1183/09031936.97.10102270; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Jensen D, 2009, RESP PHYSIOL NEUROBI, V167, P87, DOI 10.1016/j.resp.2009.01.011; Kallet RH, 2007, RESP CARE, V52, P900; KARLSSON JA, 1990, J PHARMACOL EXP THER, V252, P863; Krajnik M, 2014, CURR OPIN SUPPORT PA, V8, P191, DOI 10.1097/SPC.0000000000000072; Krajnik M, 2010, PHARMACOL REP, V62, P139, DOI 10.1016/S1734-1140(10)70251-6; KUO HP, 1992, AM J PHYSIOL, V263, pL161; Lanken PN, 2008, AM J RESP CRIT CARE, V177, P912, DOI 10.1164/rccm.200605-587ST; Lenth Russ, 2012, JAVA APPLETS POWER S; Leung R, 1996, THORAX, V51, P596, DOI 10.1136/thx.51.6.596; Mahler DA, 2010, CHEST, V137, P674, DOI 10.1378/chest.09-1543; Mannino DM, 2012, INT J TUBERC LUNG D, V16, P1405, DOI 10.5588/ijtld.12.0054; MARCINIUK DD, 1994, CLIN CHEST MED, V15, P287; MARCINIUK DD, 1994, J APPL PHYSIOL, V77, P963; Markovitz G H, 1998, Curr Opin Pulm Med, V4, P272, DOI 10.1097/00063198-199809000-00006; MASOOD AR, 1995, THORAX, V50, P629, DOI 10.1136/thx.50.6.629; MASOOD AR, 1995, CLIN SCI, V88, P447, DOI 10.1042/cs0880447; Mendonca CT, 2014, J APPL PHYSIOL, V116, P570, DOI 10.1152/japplphysiol.00950.2013; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; NEWMAN SP, 1985, CHEST, V88, pS152, DOI 10.1378/chest.88.2.152S; O'Donnell DE, 1998, J APPL PHYSIOL, V84, P2000; O'Donnell DE, 2000, J APPL PHYSIOL, V88, P1859; O'Donnell DE, 2009, RESP PHYSIOL NEUROBI, V167, P116, DOI 10.1016/j.resp.2009.01.010; Ochs M, 2004, AM J RESP CRIT CARE, V169, P120, DOI 10.1164/rccm.200308-1107OC; Oga T, 2000, AM J RESP CRIT CARE, V161, P1897, DOI 10.1164/ajrccm.161.6.9905045; Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST; Patel HJ, 1999, EUR J PHARMACOL, V374, P21, DOI 10.1016/S0014-2999(99)00308-8; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; Puehler W, 2004, NEUROSCIENCE, V129, P473, DOI 10.1016/j.neuroscience.2004.06.086; Ries Andrew L, 2005, COPD, V2, P105; Rocker G, 2012, CAN MED ASSOC J, V184, pE497, DOI 10.1503/cmaj.111758; Rocker Graeme M, 2013, CMAJ Open, V1, pE27, DOI 10.9778/cmajo.20120031; ROGERS DF, 1989, LANCET, V1, P930; Ryerson CJ, 2011, CHEST, V139, P609, DOI 10.1378/chest.10-0608; Ryerson Christopher J, 2010, Curr Opin Support Palliat Care, V4, P69, DOI 10.1097/SPC.0b013e3283392b51; Schaeffer MR, 2014, EXP PHYSIOL, V99, P427, DOI 10.1113/expphysiol.2013.074880; SHANKLEY CE, 1992, AGENTS ACTIONS, V36, P22, DOI 10.1007/BF01991223; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Simon ST, 2012, J PALLIAT MED, V15, P1374, DOI 10.1089/jpm.2012.0249; Soriano JB, 2012, PRIM CARE RESP J, V21, P187, DOI 10.4104/pcrj.2012.00027; Stein C, 2009, HDB EXP PHARM, V495-518, DOI DOI 10.1007/978-3-540-79090-7_; STUBBING DG, 1980, J APPL PHYSIOL, V49, P506; Swigris JJ, 2010, RESP MED, V104, P1350, DOI 10.1016/j.rmed.2010.03.027; Tan WC, 2011, INT J TUBERC LUNG D, V15, P1691, DOI 10.5588/ijtld.11.0211; VANMEERHAEGHE A, 1981, CLIN RES PROC, V17, P15; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; WHIMSTER WF, 1970, THORAX, V25, P141, DOI 10.1136/thx.25.2.141; WILLETTE RN, 1982, EUR J PHARMACOL, V78, P61, DOI 10.1016/0014-2999(82)90372-7; WILLETTE RN, 1982, NEUROPHARMACOLOGY, V21, P1019, DOI 10.1016/0028-3908(82)90116-2; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Young J, 2012, CAN FAM PHYSICIAN, V58, pE401; Zambelli VO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090576; Zebraski SE, 2000, LIFE SCI, V66, P2221, DOI 10.1016/S0024-3205(00)00434-3	81	8	8	0	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587	1522-1601		J APPL PHYSIOL	J. Appl. Physiol.	JUN 1	2015	118	11					1406	1414		10.1152/japplphysiol.01091.2014			9	Physiology; Sport Sciences	Physiology; Sport Sciences	CJ5YE	WOS:000355569200008	26031762	Green Published			2020-06-30	J	Fleet, J; Belan, I; Jones, MJ; Ullah, S; Cyna, AM				Fleet, J.; Belan, I.; Jones, M. J.; Ullah, S.; Cyna, A. M.			A comparison of fentanyl with pethidine for pain relief during childbirth: a randomised controlled trial	BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY			English	Article						Fentanyl; intramuscular; intranasal; labour; pethidine; subcutaneous	VISUAL ANALOG SCALE; OBSTETRIC ANALGESIA; INTRANASAL FENTANYL; LABOR; MEPERIDINE; PHARMACOKINETICS; REMIFENTANIL; TIME	ObjectiveTo compare the efficacy of fentanyl administered via the subcutaneous (s.c.) or intranasal (i.n.) route with intramuscular (i.m.) pethidine in labouring women requesting analgesia. DesignA randomised controlled trial three-armed, parallel-design. SettingA regional hospital and the largest tertiary maternity centre in South Australia. SampleOne hundred and fifty-six healthy parturients birthing at term. MethodsWomen were randomised to receive s.c. fentanyl (n=53), i.n. fentanyl (n=52), or i.m. pethidine (n=51). The outcomes were analysed by intention-to-treat. Main outcome measuresPain scores measured before and 30minutes after opioid administration. ResultsAll groups reported clinically significant reductions in pain scores (mean range 1.2-1.6; P<0.001), with no significant differences between groups. Significantly more women in the fentanyl groups reported satisfaction with using the study drug again, compared with women receiving i.m. pethidine (82.9% i.n.fentanyl, 80.6% s.c.fentanyl, and 44.0% i.m.pethidine; P<0.01). Women in the fentanyl groups experienced less sedation (i.n.fentanyl 7.3%, s.c.fentanyl 2.9%, i.m.pethidine 44%; P0.03), shorter labours by at least 2hours (P<0.05), and fewer difficulties establishing breastfeeding (78.8% i.m.pethidine, 39.4% i.n.fentanyl, and 44.0% s.c.fentanyl; P<0.01). Neonates in the pethidine group were more likely to require nursery admission (P<0.02). ConclusionsFentanyl administered by s.c. and i.n. routes is as efficacious in relieving labour pain as i.m.pethidine, but resulted in greater satisfaction, less sedation, shorter labour, fewer nursery admissions, and fewer difficulties in establishing breastfeeding. Fentanyl appears to be a suitable alternative to pethidine when providing parenteral pain relief to labouring women.	[Fleet, J.; Belan, I.; Jones, M. J.; Ullah, S.] Flinders Univ S Australia, Sch Nursing & Midwifery, Adelaide, SA 5001, Australia; [Ullah, S.] Flinders Univ S Australia, Sch Med, Flinders Ctr Epidemiol & Biostat, Adelaide, SA 5001, Australia; [Cyna, A. M.] Womens & Childrens Hosp, Adelaide, SA, Australia; [Cyna, A. M.] Univ Adelaide, Adelaide, SA, Australia	Fleet, J (reprint author), Univ S Australia, N Terrace, Adelaide, SA 5001, Australia.	julie.fleet@unisa.edu.au	Fleet, Julie-Anne/I-3015-2015; Ullah, Shahid/AAC-3054-2020	Fleet, Julie-Anne/0000-0001-6228-5636; Belan, Ingrid/0000-0002-7007-2961; Ullah, Shahid/0000-0003-0010-2640	Flinders University Student Research Maintenance fund	This study was supported by the Flinders University Student Research Maintenance fund. The funder had no role in the study design, data collection or analysis, decision to publish, or preparation of the article.	Anderson D, 2011, J MIDWIFERY WOM HEAL, V56, P222, DOI 10.1111/j.1542-2011.2011.00061.x; Capper SJ, 2010, EUR J ANAESTH, V27, P241, DOI 10.1097/EJA.0b013e328331a361; Carvalho B, 2013, INT J OBSTET ANESTH, V22, P6, DOI 10.1016/j.ijoa.2012.10.002; CROWELL MK, 1994, J NURSE-MIDWIFERY, V39, P150, DOI 10.1016/0091-2182(94)90097-3; Douma MR, 2010, BRIT J ANAESTH, V104, P209, DOI 10.1093/bja/aep359; Fleet J, 2014, MIDWIFERY, V30, P36, DOI 10.1016/j.midw.2013.01.014; Fleet J, 2011, MIDWIFERY, V27, pE106, DOI 10.1016/j.midw.2009.11.002; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; HODNETT ED, 1987, RES NURS HEALTH, V10, P301, DOI 10.1002/nur.4770100503; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; Kelly AM, 1998, ACAD EMERG MED, V5, P1086, DOI 10.1111/j.1553-2712.1998.tb02667.x; Lehmann KA, 2005, J PAIN SYMPTOM MANAG, V29, pS72, DOI 10.1016/j.jpainsymman.2005.01.005; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Ludington E, 1998, ANESTH ANALG, V87, P723, DOI 10.1097/00000539-199809000-00045; Macintyre PE, 2009, ACUTE PAIN MANAGEMENT, P204, DOI 10.1017/CBO9780511576706.016; MORSELLI PL, 1980, EUR J CLIN PHARMACOL, V18, P25, DOI 10.1007/BF00561475; Muchatuta NA, 2013, ANAESTHESIA, V68, P231, DOI 10.1111/anae.12153; ONeil G, 1997, ANAESTH INTENS CARE, V25, P408, DOI 10.1177/0310057X9702500414; Othman M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009223.pub2; Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5; Radbruch L, 2011, PALLIATIVE MED, V25, P578, DOI 10.1177/0269216310383739; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; Reynolds F, 2002, BJOG-INT J OBSTET GY, V109, P1344, DOI 10.1016/S1470-0328(02)01961-4; Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103; Schwenkglenks M, 2014, PAIN, V155, P1401, DOI 10.1016/j.pain.2014.04.021; Sosa CG, 2004, AM J OBSTET GYNECOL, V191, P1212, DOI 10.1016/j.ajog.2004.03.017; THOMSON AM, 1994, J ADV NURS, V19, P448, DOI 10.1111/j.1365-2648.1994.tb01106.x; Ullman R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007396.pub2; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x	31	16	18	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1470-0328	1471-0528		BJOG-INT J OBSTET GY	BJOG	JUN	2015	122	7					983	992		10.1111/1471-0528.13249			10	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ2QW	WOS:000355330600018	25558983				2020-06-30	J	Chandar, R; Jagadisan, B; Vasudevan, A				Chandar, Rumesh; Jagadisan, Barath; Vasudevan, Arumugam			Propofol-Ketamine and Propofol-Fentanyl Combinations for Nonanesthetist-Administered Sedation	JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION			English	Article						esophagogastroduodenoscopy; fentanyl; ketamine; nonanesthetist-administered propofol sedation; propofol	UPPER GASTROINTESTINAL ENDOSCOPY; PROCEDURAL SEDATION; PEDIATRIC-PATIENTS; ADVERSE EVENTS; CHILDREN; MIDAZOLAM	Objectives: There is a need to compare propofol requirement between propofol-ketamine (PK) and propofol-fentanyl (PF) given as nonanesthetist-administered propofol sedation during pediatric esophagogastroduodenoscopy (EGD). Methods: The study was a parallel-group, randomized, double-blind comparison of the need for additional doses of propofol in the first minute after sedation induction between PK and PF, administered by rotating trainees in pediatrics for sedation during pediatric EGD. A total of 95 children with American Society of Anesthesiologists class I to III between 3 and 12 years undergoing EGD were included and randomized to either of the groups. After midazolam premedication, children received either 0.5 mg/kg ketamine (PK) or 1 mu g/kg of fentanyl (PF) followed by a mandatory 1 mg/kg of propofol. Additional doses of propofol of 0.5 mg/kg each were given to achieve sedation induction (modified Ramsay scale level 6), and further doses were administered during the procedure as required. A total of 92 children (PK, n = 47; PF, n=45) were analyzed. P < 0.05 was considered significant. Results: There was no difference in the propofol dose required for successful scope introduction and also in the need for additional propofol doses and the total additional propofol doses required in the first minute after sedation induction. Propofol injection pain was higher in the PF group (odds ratio 1.78). The adverse events and recovery time were similar. There was no escalation of care, airway intubations, death, or disability. Conclusions: Nonanesthetist-administered propofol sedation is feasible in teaching hospitals. Propofol requirement is similar in both PK and PF combination regimens, but the lower frequency of propofol injection pain may favor the use of PK.	[Chandar, Rumesh; Jagadisan, Barath] Jawaharlal Inst Postgrad Med Educ & Res, Dept Pediat, Pondicherry 605006, India; [Vasudevan, Arumugam] Jawaharlal Inst Postgrad Med Educ & Res, Dept Anesthesiol, Pondicherry 605006, India	Jagadisan, B (reprint author), Jawaharlal Inst Postgrad Med Educ & Res, Dept Pediat, Pondicherry 605006, India.	barathjag@yahoo.com	Vasudevan, Arumugam/E-8975-2011				Abraham NS, 2004, AM J GASTROENTEROL, V99, P1692, DOI 10.1111/j.1572-0241.2004.40157.x; Andropoulos DB, 2012, PEDIAT SEDATION OUTS, P80; [Anonymous], 2008, GASTROINTEST ENDOSC, V68, P1, DOI 10.1016/j.gie.2008.01.028; Barbi E, 2006, ENDOSCOPY, V38, P368, DOI 10.1055/s-2005-921194; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Chiaretti A, 2014, ACTA PAEDIATR, V103, P182, DOI 10.1111/apa.12472; Cravero JP, 2009, ANESTH ANALG, V108, P795, DOI 10.1213/ane.0b013e31818fc334; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; Elitsur Y, 2000, ENDOSCOPY, V32, P788, DOI 10.1055/s-2000-7713; Kaddu R, 2002, GASTROINTEST ENDOSC, V55, P27, DOI 10.1067/mge.2002.120386; Lightdale JR, 2007, J PEDIATR GASTR NUTR, V45, P500, DOI 10.1097/MPG.0b013e3180691168; Mason KP, 2012, BRIT J ANAESTH, V108, P13, DOI 10.1093/bja/aer407; Nafiu OO, 2009, PEDIATR ANESTH, V19, P1048, DOI 10.1111/j.1460-9592.2009.03140.x; Paspatis GA, 2006, J PEDIATR GASTR NUTR, V43, P195, DOI 10.1097/01.mpg.0000228099.04702.39; Rosner B, 2008, AM J EPIDEMIOL, V167, P653, DOI 10.1093/aje/kwm348; Tosun Z, 2007, PEDIATR ANESTH, V17, P983, DOI 10.1111/j.1460-9592.2007.02206.x; van Beek EJAH, 2012, J PEDIATR GASTR NUTR, V54, P171, DOI 10.1097/MPG.0b013e31823a2985	17	11	12	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0277-2116	1536-4801		J PEDIATR GASTR NUTR	J. Pediatr. Gastroenterol. Nutr.	JUN	2015	60	6					762	768		10.1097/MPG.0000000000000722			7	Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics	Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics	CJ1KI	WOS:000355242100012	25996793				2020-06-30	J	Caldwell, CD; Watterberg, KL				Caldwell, C. D.; Watterberg, K. L.			Effect of premedication regimen on infant pain and stress response to endotracheal intubation	JOURNAL OF PERINATOLOGY			English	Article							PROCEDURAL PAIN; PROPOFOL; ATROPINE; MORPHINE	OBJECTIVE: (1) Evaluate the effect of different medications on pain and stress in neonates during nonemergent endotracheal intubation; (2) determine whether gestational age affects medication use; (3) determine whether better sedation results in a decrease in the number of attempts and/or total time for the procedure. STUDY DESIGN: Prospective observational study. Infant responses were measured using a clinical pain scale and blood glucose, a biochemical marker of acute stress. RESULT: A total of 166 infants were included, with adjusted gestational ages 24 to 44 weeks at the time of procedure. Premedication regimens included no medication ('none,' 27%), morphine (19%), morphine+ midazolam (11%), fentanyl (14%), fentanyl+midazolam (19%) and midazolam alone (10%). Fentanyl+midazolam resulted in lower pain scores and less increase in blood glucose (both P<0.0001). No other regimen was different from 'none'. The most immature infants were less likely to receive premedication (P = 0.023), although their pain scores and blood glucose responses were similar to more mature infants. None of the medication regimens reduced the total procedure time (P = 0.55) or the number of attempts (P = 0.145). CONCLUSION: Only fentanyl+midazolam significantly attenuated both the clinical pain score and the increase in blood glucose. Less mature infants had responses similar to those of more mature infants, but were less likely to receive premedication. None of the regimens decreased the time or number of attempts required for successful intubation.	[Caldwell, C. D.; Watterberg, K. L.] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Albuquerque, NM 87131 USA	Caldwell, CD (reprint author), 1 Univ New Mexico, Dept Pediat, Div Neonatol, MSC 10 5590, Albuquerque, NM 87131 USA.	ccaldwell@salud.unm.edu					Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Anand KJS, 1988, BMJ-BRIT MED J, V29, P688; Attardi DM, 2000, ARCH DIS CHILD-FETAL, V83, pF161; Bozza P, 2012, PEDIATR SURG INT, V28, P821, DOI 10.1007/s00383-012-3126-2; Brummelte S, 2012, ANN NEUROL, V71, P385, DOI 10.1002/ana.22267; Carbajal R, 2005, PEDIATRICS, V115, P1494, DOI 10.1542/peds.2004-1425; Carbajal R, 1997, ARCH PEDIATRIE, V4, P623, DOI 10.1016/S0929-693X(97)83360-X; Choong K, 2010, ARCH DIS CHILD-FETAL, V95, pF80, DOI 10.1136/adc.2009.167338; Decaro MH, 2011, EARLY HUM DEV, V87, pS19, DOI 10.1016/j.earlhumdev.2011.01.005; Feltman DM, 2011, J PERINATOL, V31, P38, DOI 10.1038/jp.2010.74; Ghanta S, 2007, PEDIATRICS, V119, pE1248, DOI 10.1542/peds.2006-2708; Kumar P, 2010, PEDIATRICS, V125, P608, DOI 10.1542/peds.2009-2863; Lemyre B, 2009, ARCH DIS CHILD-FETAL, V94, pF439, DOI 10.1136/adc.2008.146068; Lemyre Brigitte, 2004, BMC Pediatr, V4, P20, DOI 10.1186/1471-2431-4-20; LILIEN LD, 1979, J PEDIATR-US, V94, P454, DOI 10.1016/S0022-3476(79)80601-0; McPherson C, 2014, CLIN PERINATOL, V41, P209, DOI 10.1016/j.clp.2013.10.002; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; Papoff P, 2008, PEDIATRICS, V121, P448, DOI 10.1542/peds.2007-3132; Roberts KD, 2006, PEDIATRICS, V118, P1583, DOI 10.1542/peds.2006-0590; Sarkar S, 2006, J PERINATOL, V26, P286, DOI 10.1038/sj.jp.7211499; Silva YPE, 2007, ARCH DIS CHILD-FETAL, V92, P293, DOI 10.1136/adc.2006.105262; Sisto R, 2006, MED BIOL ENG COMPUT, V44, P841, DOI 10.1007/s11517-006-0101-x; Srinivasan G, 1989, J PEDIATR SURG, V21, P718; STEVENS B, 2000, PAIN NEONATES, P101; VanLooy JW, 2008, ANN PHARMACOTHER, V42, P947, DOI 10.1345/aph.1K665; Vinall J, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004666; Zwicker JG, 2014, DEV MED CHILD NEUROL, V56, P514, DOI 10.1111/dmcn.12454	27	8	8	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	JUN	2015	35	6					415	418		10.1038/jp.2014.227			4	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	CJ0DW	WOS:000355145100007	25569679				2020-06-30	J	Jiang, L; Ding, S; Yan, HT; Li, YM; Zhang, LP; Chen, X; Yin, XM; Liu, SB; Tang, XY; Zhang, JB				Jiang, Li; Ding, Sheng; Yan, Hongtao; Li, Yunming; Zhang, Liping; Chen, Xue; Yin, Xiumei; Liu, Shunbi; Tang, Xiuying; Zhang, Jinbao			A Retrospective Comparison of Dexmedetomidine Versus Midazolam for Pediatric Patients with Congenital Heart Disease Requiring Postoperative Sedation	PEDIATRIC CARDIOLOGY			English	Article						Dexmedetomidine; Midazolam; Fentanyl; Pulmonary arterial hypertension; Pediatric	CRITICALLY-ILL CHILDREN; EMERGENCE DELIRIUM SCALE; INTENSIVE-CARE; ANESTHESIA; DISCONTINUATION; HYPERTENSION; MANAGEMENT; ANALGESIA	We hypothesized that postoperative sedation with dexmedetomidine/fentanyl would be effective in infants and neonates with congenital heart disease and pulmonary arterial hypertension (PAH). Children who were < 36 months of age, had congenital heart disease with PAH, and had been treated at our hospital between October 2011 and April 2013 (n = 187) were included in this retrospective study. Either dexmedetomidine/fentanyl (Group Dex) or midazolam/fentanyl (Group Mid) was used for postoperative sedation. The main outcome variables included delirium scores, supplemental sedative/analgesic drugs, ventilator use, and sedation time. Baseline demographics and clinical characteristics were similar between the two groups. The Pediatric Anesthesia Emergence Delirium scale (5.2 +/- A 5.3 vs. 7.1 +/- A 5.2 in the Dex and Mid groups, respectively; P = 0.016) and the incidence of delirium (18.2 vs. 32.0 % in the Dex and Mid groups, respectively; P = 0.039) were significantly lower in the Dex group than in the Mid group. Total sufentanil, midazolam, and propofol doses given during the operation did not differ between the two groups. Group Dex patients required significantly lower doses of adjunctive sedative/analgesic drugs than group Mid patients in the cardiac intensive care unit (CICU; midazolam, P = 0.007; morphine, P < 0.001). In conclusion, we found no differences between dexmedetomidine/fentanyl and midazolam/fentanyl in terms of the duration of sedation, mechanical ventilator use, and CICU stay in children with PAH. However, patients in the Dex group required a lower additional sedative/analgesic drugs and had a lower incidence of delirium than patients in the Mid group.	[Jiang, Li; Ding, Sheng; Zhang, Liping; Chen, Xue; Yin, Xiumei; Liu, Shunbi; Tang, Xiuying] Chengdu Mil Gen Hosp, Dept Cardiovasc Surg, ICU, Chengdu 610083, Sichuan Provinc, Peoples R China; [Yan, Hongtao] Chengdu Mil Gen Hosp, Gen Surg Ctr, Chengdu 610083, Sichuan Provinc, Peoples R China; [Li, Yunming] Chengdu Mil Gen Hosp, Dept Neurosurg, Chengdu 610083, Sichuan Provinc, Peoples R China; [Zhang, Jinbao] Chengdu Mil Gen Hosp, Dept Cardiovasc Surg, Chengdu 610083, Sichuan Provinc, Peoples R China	Zhang, JB (reprint author), Chengdu Mil Gen Hosp, Dept Cardiovasc Surg, Chengdu 610083, Sichuan Provinc, Peoples R China.	zhjbmedsci@163.com		Li, Yunming/0000-0001-6363-4869			Awori M N, 2008, East Afr Med J, V85, P36; Blankespoor RJ, 2012, MINERVA ANESTESIOL, V78, P896; Bong CL, 2009, PEDIATR ANESTH, V19, P593, DOI 10.1111/j.1460-9592.2009.03024.x; Burbano NH, 2012, INTENS CARE MED, V38, P300, DOI 10.1007/s00134-011-2441-8; Fagin A, 2012, J BURN CARE RES, V33, P759, DOI 10.1097/BCR.0b013e318254d48e; Fischer LG, 2003, ANESTH ANALG, V96, P1603, DOI 10.1213/01.ANE.0000062523.67426.0B; Freire AX, 2002, CRIT CARE MED, V30, P2468, DOI 10.1097/00003246-200211000-00011; Friesen RH, 2008, PEDIATR ANESTH, V18, P208, DOI 10.1111/j.1460-9592.2008.02419.x; Gupta P, 2012, PEDIATR CRIT CARE ME, V13, P660, DOI 10.1097/PCC.0b013e318253c7f1; Hosokawa K, 2010, PEDIATR CRIT CARE ME, V11, P39, DOI 10.1097/PCC.0b013e3181b062d7; Janssen NJJF, 2011, INTENS CARE MED, V37, P1331, DOI 10.1007/s00134-011-2244-y; Jenkins I, 2002, PAEDIATR ANAESTH, V12, P837; Koruk S, 2010, CLIN THER, V32, P701, DOI 10.1016/j.clinthera.2010.04.010; Le KN, 2011, INTENS CARE MED, V37, P686, DOI 10.1007/s00134-011-2140-5; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Riker RR, 2005, PHARMACOTHERAPY, V25, p8S, DOI 10.1592/phco.2005.25.5_Part_2.8S; Siddappa R, 2011, PEDIATR ANESTH, V21, P153, DOI 10.1111/j.1460-9592.2010.03502.x; Smania MC, 2008, REV ASSOC MED BRAS, V54, P308, DOI 10.1590/S0104-42302008000400015; Tobias JD, 2004, SOUTH MED J, V97, P451, DOI 10.1097/00007611-200405000-00007; Twite Mark D, 2004, Pediatr Crit Care Med, V5, P521, DOI 10.1097/01.PCC.0000144710.13710.2E; Weber MD, 2008, PEDIATR ANESTH, V18, P87, DOI 10.1111/j.1460-9592.2007.02377.x	23	15	15	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-0643	1432-1971		PEDIATR CARDIOL	Pediatr. Cardiol.	JUN	2015	36	5					993	999		10.1007/s00246-015-1110-z			7	Cardiac & Cardiovascular Systems; Pediatrics	Cardiovascular System & Cardiology; Pediatrics	CI1CC	WOS:000354477000015	25661272				2020-06-30	J	Jensen-Dahm, C; Gasse, C; Astrup, A; Mortensen, PB; Waldemar, G				Jensen-Dahm, Christina; Gasse, Christiane; Astrup, Aske; Mortensen, Preben Bo; Waldemar, Gunhild			Frequent use of opioids in patients with dementia and nursing home residents: A study of the entire elderly population of Denmark	ALZHEIMERS & DEMENTIA			English	Article						Dementia; Opioids; Elderly; Buprenorphine; Fentanyl; Pain	CHRONIC NONMALIGNANT PAIN; CHRONIC NONCANCER PAIN; COGNITIVELY INTACT; PEOPLE; REGISTER; PRESCRIPTION; MANAGEMENT; HEALTH; METAANALYSIS; FRAILTY	Background: Pain is believed to be undertreated in patients with dementia; however, no larger studies have been conducted. The aim was to investigate prevalent use of opioids in elderly with and without dementia in the entire elderly population of Denmark. Method: A register-based cross-sectional study in the entire elderly (>= 65 years) population in 2010 was conducted. Opioid use among elderly with dementia (N = 35,455) was compared with elderly without (N = 870,645), talcing age, sex, comorbidity, and living status into account. Results: Nursing home residents (NHRs) used opioids most frequently (41%), followed by home-living patients with dementia (27.5%) and home-living patients without dementia (16.9%). Buprenorphine and fentanyl (primarily patches) were commonly used among NHRs (18.7%) and home-living patients with dementia (10.7%) but less often by home-living patients without dementia (2.4%). Conclusions: Opioid use in the elderly Danish population was frequent but particularly in patients with dementia and NHR, which may challenge patient safety and needs further investigation. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).	[Jensen-Dahm, Christina; Waldemar, Gunhild] Univ Copenhagen, Rigshosp, DDRC, Dept Neurol, DK-2100 Copenhagen, Denmark; [Gasse, Christiane; Astrup, Aske; Mortensen, Preben Bo] Aarhus Univ, Natl Ctr Register Based Res, Sch Business & Social Sci, Aarhus, Denmark; [Mortensen, Preben Bo] Aarhus Univ, Ctr Integrated Register Based Res, CIRRAU, Aarhus, Denmark; [Mortensen, Preben Bo] IPSYCH, Lundbeck Fdn Initiat Integrat Psychiat Res, Aarhus, Denmark	Jensen-Dahm, C (reprint author), Univ Copenhagen, Rigshosp, DDRC, Dept Neurol, DK-2100 Copenhagen, Denmark.	christina.jensen-dahm@regionh.dk	Mortensen, Preben B/D-2358-2015	Mortensen, Preben B/0000-0002-5230-9865; Gasse, Christiane/0000-0001-6194-1099	Danish Health Foundation [2007B0004]; Danish Ministry of Health [2007-12143-112/59506, 0901110/34501]; Lundbeck FoundationLundbeckfonden [R155-2014-1724]	The Danish Dementia Research Centre is supported by grants from the Danish Health Foundation (j.nr. 2007B0004) and the Danish Ministry of Health (j.nr. 2007-12143-112/59506 and j.nr. 0901110/34501). All researchers were independent of the funders. All authors declare no support from any organization for the submitted work.	Achterberg WP, 2010, PAIN, V148, P70, DOI 10.1016/j.pain.2009.10.008; Andersen TF, 1999, DAN MED BULL, V46, P263; Barber JB, 2009, DRUG SAFETY, V32, P457, DOI 10.2165/00002018-200932060-00003; Bayer A, 2000, BRIT MED J, V321, P992, DOI 10.1136/bmj.321.7267.992; Bell JS, 2011, PAIN, V152, P543, DOI 10.1016/j.pain.2010.11.003; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Berryman C, 2013, PAIN, V154, P1181, DOI 10.1016/j.pain.2013.03.002; Black BS, 2006, ALZ DIS ASSOC DIS, V20, P283, DOI 10.1097/01.wad.0000213854.04861.cc; Blyth FM, 2008, PAIN, V140, P224, DOI 10.1016/j.pain.2008.08.011; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; Closs SJ, 2004, BRIT J GEN PRACT, V54, P919; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Danish National Board of Health: Danish National Board of Health, 1971, DAN NAT BOARD HLTH C; Dosa DM, 2009, J PAIN SYMPTOM MANAG, V38, P515, DOI 10.1016/j.jpainsymman.2008.11.008; FDA, 2007, PUBL HLTH ADV SAF WA; Fredheim OMS, 2010, EUR J PAIN, V14, P289, DOI 10.1016/j.ejpain.2009.05.006; Freynhagen R, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2937; Haasum Y, 2011, DRUG AGING, V28, P283, DOI 10.2165/11587040-000000000-00000; Horgas AL, 1998, NURS RES, V47, P235, DOI 10.1097/00006199-199807000-00009; Husebo BS, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4065; Jensen-Dahm C, 2012, J AM GERIATR SOC, V60, P1274, DOI 10.1111/j.1532-5415.2012.04036.x; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Landi F, 2001, ARCH INTERN MED, V161, P2721, DOI 10.1001/archinte.161.22.2721; Lapane KL, 2012, J AM MED DIR ASSOC, V13, P344, DOI 10.1016/j.jamda.2011.01.007; Lovheim H, 2008, PHARMACOEPIDEM DR S, V17, P912, DOI 10.1002/pds.1600; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Mantyselka P, 2004, AGE AGEING, V33, P496, DOI 10.1093/ageing/afh165; McLachlan AJ, 2011, BRIT J CLIN PHARMACO, V71, P351, DOI 10.1111/j.1365-2125.2010.03847.x; Mellbye A, 2014, EUR J PAIN, V18, P1083, DOI 10.1002/j.1532-2149.2014.00449.x; Monroe TB, 2014, GERIATR GERONTOL INT, V14, P541, DOI 10.1111/ggi.12130; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; NHS - National Institute for Health and Clinical Excellence, 2012, OP PALL CAR SAF EFF; Nuesch E, 2009, COCHRANE DATABASE SY; Papaleontiou M, 2010, J AM GERIATR SOC, V58, P1353, DOI 10.1111/j.1532-5415.2010.02920.x; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Phung TKT, 2007, DEMENT GERIATR COGN, V24, P220, DOI 10.1159/000107084; Phung TKT, 2010, DEMENT GERIATR COGN, V29, P146, DOI 10.1159/000269933; Reynolds KS, 2008, J PAIN SYMPTOM MANAG, V35, P388, DOI 10.1016/j.jpainsymman.2008.01.001; Salem LC, 2012, DEMENT GERIATR COGN, V34, P292, DOI 10.1159/000345485; Scherder E, 2005, BMJ-BRIT MED J, V330, P461, DOI 10.1136/bmj.330.7489.461; Schmader KE, 1998, AGE AGEING, V27, P493, DOI 10.1093/ageing/27.4.493; Schubert I, 2013, DTSCH ARZTEBL INT, V110, P45, DOI 10.3238/arztebl.2013.0045; Statens Serum Institut, 2013, MEDST DK; Takai Y, 2010, PAIN MANAG NURS, V11, P209, DOI 10.1016/j.pmn.2010.08.006; The Ministry of Social Affairs and Integration, 2012, QUAL LIF DEC MAK NUR; Thygesen LC, 2011, SCAND J PUBLIC HEALT, V39, P12, DOI 10.1177/1403494811399956; World Health Organization, 1993, ICD 10 CLASS MENT BE; World Health Organization, 2003, INTR DRUG UT RES	49	47	47	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2015	11	6					691	699		10.1016/j.jalz.2014.06.013			9	Clinical Neurology	Neurosciences & Neurology	CL8NR	WOS:000357231900011	25239738	Other Gold			2020-06-30	J	Park, JH; Lim, BG; Kim, H; Lee, IO; Kong, MH; Kim, NS				Park, Ji Hye; Lim, Byung Gun; Kim, Heezoo; Lee, Il Ok; Kong, Myoung Hoon; Kim, Nan Suk			Comparison of Surgical Pleth Index-guided Analgesia with Conventional Analgesia Practices in Children A Randomized Controlled Trial	ANESTHESIOLOGY			English	Article							EMERGENCE AGITATION; GENERAL-ANESTHESIA; STRESS INDEX; SEVOFLURANE ANESTHESIA; BILATERAL MYRINGOTOMY; PAIN; PROPOFOL; INFUSION; EFFICACY; ENTROPY	Background: To compare surgical pleth index (SPI)-guided analgesia with conventional analgesia by evaluating intraoperative analgesic requirements, postoperative pain, and emergence agitation in children. Methods: This study was designed as a parallel, two-arm, double-blind, randomized controlled trial. Forty-five children undergoing elective adenotonsillectomy were randomly allocated to SPI-guided group (SPI-guided analgesia group, n = 21) or control group (conventional analgesia group, n = 24). Anesthesia was maintained with sevoflurane 2 to 3 vol% in 50% nitrous oxide and oxygen to achieve state entropy between 40 and 60. Intraoperative fentanyl 0.5 g/kg was administered for the first event persisting 3 min and subsequent events persisting 5 min. An event was defined as an SPI over 50 (SPI-guided group) or a blood pressure or heart rate 20% above the baseline (control group). The primary outcome was intraoperative fentanyl requirement. Secondary outcomes included intraoperative sevoflurane consumption, postoperative emergence agitation and pain score, and postoperative rescue analgesic requirements. Results: Intraoperative fentanyl requirement was lower in SPI-guided group than in control group (0.43 0.53 vs. 1.73 +/- 0.59 g/kg; P < 0.001). Intraoperative sevoflurane consumption was similar. The proportion of patients with high emergence agitation scores (4 to 5) was greater in SPI-guided group (61.9 vs. 25.0%; P = 0.01). The postoperative pain score and rescue fentanyl consumption were higher in SPI-guided group (7 [4.5; 9] vs. 3 [2; 6.75]; P = 0.002; 0.50 +/- 0.34 vs. 0.29 +/- 0.30 g/kg; P = 0.04). Conclusions: As currently constructed, SPI does not appear to be valid in children. This may be due to both differences in blood vessel distensibility and baseline increased heart rates in children versus adults.	[Park, Ji Hye; Lim, Byung Gun; Kim, Heezoo; Lee, Il Ok; Kong, Myoung Hoon; Kim, Nan Suk] Korea Univ, Guro Hosp, Dept Anesthesiol & Pain Med, Coll Med, Seoul 152703, South Korea	Lim, BG (reprint author), Korea Univ, Guro Hosp, Dept Anesthesiol & Pain Med, Gurodong Ro 148, Seoul 152703, South Korea.	bglim9205@korea.ac.kr	Lim, Byung Gun/H-4914-2019		Korea University [K1300031]	This work was supported by the Korea University Grant (grant number: K1300031) awarded to Dr. Lim from Korea University (Seoul, Korea).	Ahonen J, 2007, BRIT J ANAESTH, V98, P456, DOI 10.1093/bja/aem035; Aono J, 1999, ACTA ANAESTH SCAND, V43, P542, DOI 10.1034/j.1399-6576.1999.430509.x; Arya VK, 2012, INDIAN J ANAESTH, V56, P454, DOI 10.4103/0019-5049.103960; Bergmann I, 2013, BRIT J ANAESTH, V110, P622, DOI 10.1093/bja/aes426; Chen XZ, 2012, SCI WORLD J, DOI 10.1100/2012/879158; Chen XZ, 2010, ANESTHESIOLOGY, V112, P1175, DOI 10.1097/ALN.0b013e3181d3d641; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Colombo R, 2014, EUR J ANAESTH, V31, P76, DOI 10.1097/01.EJA.0000436116.06728.b3; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Dinenno FA, 2002, CIRCULATION, V106, P1349, DOI 10.1161/01.CIR.0000028819.64790.BE; DORLAS JC, 1985, BRIT J ANAESTH, V57, P524, DOI 10.1093/bja/57.5.524; Ekbom K, 2007, ACTA ANAESTH SCAND, V51, P290, DOI 10.1111/j.1399-6576.2006.01235.x; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Gruenewald M, 2014, BRIT J ANAESTH, V112, P898, DOI 10.1093/bja/aet485; Hamunen K, 2012, BRIT J ANAESTH, V108, P838, DOI 10.1093/bja/aes001; Huiku M, 2007, BRIT J ANAESTH, V98, P447, DOI 10.1093/bja/aem004; Iannuzzi M, 2005, BRIT J ANAESTH, V94, P492, DOI 10.1093/bja/aei075; Inomata S, 2010, BRIT J ANAESTH, V105, P361, DOI 10.1093/bja/aeq168; Jeong WJ, 2012, KOREAN J ANESTHESIOL, V63, P203, DOI 10.4097/kjae.2012.63.3.203; Kallio H, 2008, BRIT J ANAESTH, V101, P383, DOI 10.1093/bja/aen204; Lee CJ, 2010, KOREAN J ANESTHESIOL, V59, P75, DOI 10.4097/kjae.2010.59.2.75; Malviya S, 2006, PEDIATR ANESTH, V16, P554, DOI 10.1111/j.1460-9592.2006.01818.x; Mishra LD, 2006, ACTA ANAESTH SCAND, V50, P124, DOI 10.1111/j.1399-6576.2006.00889.x; Mowafi HA, 2005, ANESTH ANALG, V101, P1506, DOI 10.1213/01.ANE.0000181004.72325.D6; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; Popescu MR, 2013, ROM J MORPHOL EMBRYO, V54, P399; Sarkola T, 2012, ARTERIOSCL THROM VAS, V32, P2516, DOI 10.1161/ATVBAHA.112.252114; Seitsonen ERJ, 2005, ACTA ANAESTH SCAND, V49, P284, DOI 10.1111/j.1399-6576.2005.00654.x; Shalbaf R, 2013, J NEUROSCI METH, V218, P17, DOI 10.1016/j.jneumeth.2013.03.008; Sheykhzade M, 2012, PHARMACOLOGY, V90, P160, DOI 10.1159/000341722; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Struys MMRF, 2007, BRIT J ANAESTH, V99, P359, DOI 10.1093/bja/aem173; SUTTERS KA, 1995, PAIN, V61, P145, DOI 10.1016/0304-3959(94)00166-C; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Wennervirta J, 2008, ACTA ANAESTH SCAND, V52, P1038, DOI 10.1111/j.1399-6576.2008.01687.x; Woods R, 1992, DIGITAL IMAGE PROCES, P173	36	20	20	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUN	2015	122	6					1280	1287		10.1097/ALN.0000000000000650			8	Anesthesiology	Anesthesiology	CU4XJ	WOS:000363534400013	25815454				2020-06-30	J	Tuncali, B; Pekcan, YO; Celebi, A; Zeyneloglu, P				Tuncali, Bahattin; Pekcan, Yonca Ozvardar; Celebi, Arzu; Zeyneloglu, Pinar			Addition of low-dose ketamine to midazolam-fentanyl-propofol-based sedation for colonoscopy: a randomized, double-blind, controlled trial	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Colonoscopy; Ketamine; Safety; Satisfaction; Sedation	MONITORED ANESTHESIA CARE; REMIFENTANIL; ANALGESIA; PREMEDICATION; OPIOIDS	Study Objective: To evaluate the effects of low-dose ketamine on midazolam-fentanyl-propofol-based sedation for outpatient colonoscopy. Design: Prospective, randomized, double-blinded, placebo-controlled trial. Setting: Gastroenterology unit at a practice and clinical research center. Subjects: Ninety-seven healthy American Society of Anesthesiology physical status 1 volunteers. Interventions: Subjects were randomized to receive midazolam (0.02 mg/kg), fentanyl (1 mu g/kg), and ketamine (0.3 mg/kg) and midazolam (0.02 mg/kg), fentanyl (1 mu g/kg), and placebo (0.9% sodium chloride) in group K and group C, respectively. In both groups, incremental doses of propofol were used to maintain a Ramsay sedation score of 3 to 4. Measurements: Values of heart rate, blood pressure, oxygen saturation, and respiratory rate were measured. Procedure times, recovery times, drug doses used, complications associated with the sedation, and physician and patient satisfaction were also recorded. Main Results: In group K, mean amount of propofol used and mean induction time (P < .001), the need for the use of jaw thrust maneuver and mask ventilation, and the incidence of disruptive movements were significantly lower (P < .05) and gastroenterologist satisfaction at the beginning of the procedure was significantly superior (P < .05). Mean systolic blood pressures at 4, 6, 8, and 10 minutes (P < .01); diastolic blood pressures at 4, 6, and 8 minutes (P < .05); respiratory rates at 4, 6, 8, 10, 15, 20, and 25 minutes (P < .01); and oxygen saturation at 6, 8, 10, 15, and 20 minutes (P < .05) were significantly lower in group C. Patient satisfaction scores, recovery times, and discharge times were similar. No patient in either group experienced unpleasant dreams or hallucination in the postanesthesia care unit and on the first postoperative day. Conclusions: Addition of low-dose ketamine to midazolam-fentanyl-propofol-based sedation for outpatient colonoscopy resulted in more rapid and better quality of sedation, less propofol consumption, more stable heinodynamic status, and less adverse effects with similar recovery times in adult patients. (C) 2015 Elsevier Inc. All rights reserved.	[Tuncali, Bahattin; Pekcan, Yonca Ozvardar] Baskent Univ, Zubeyde Hanim Practice & Res Ctr, Dept Anesthesiol, TR-35540 Izmir, Turkey; [Celebi, Arzu] Baskent Univ, Zubeyde Hanim Practice & Res Ctr, Dept Gastroenterol, TR-35540 Izmir, Turkey; [Zeyneloglu, Pinar] Baskent Univ, Fac Med, Dept Anesthesiol, TR-06490 Ankara, Turkey	Tuncali, B (reprint author), Baskent Univ, Zubeyde Hanim Practice & Res Ctr, Dept Anesthesiol, Caher Dudayev Bulvari, TR-35540 Izmir, Turkey.	tuncali.bahattin@gmail.com			Baskent UniversityBaskent University	This study was funded by Baskent University.	Akcaboy ZN, 2006, ACTA ANAESTH SCAND, V50, P736, DOI 10.1111/j.1399-6576.2006.01047.x; Canet J, 2012, ANESTHESIOLOGY, V116, P6, DOI 10.1097/ALN.0b013e31823da398; Chung F, 1995, J CLIN MONITOR, V7, P89; Deng XM, 2001, ANESTH ANALG, V93, P1174, DOI 10.1097/00000539-200111000-00023; Erden IA, 2010, MINERVA ANESTESIOL, V76, P260; Froehlich F, 1997, GASTROINTEST ENDOSC, V45, P1, DOI 10.1016/S0016-5107(97)70295-5; Greilich PE, 2001, ANESTH ANALG, V92, P80; Hirsh I, 2006, DIGEST DIS SCI, V51, P1946, DOI 10.1007/s10620-006-9413-9; Ho WM, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-164; Jun NH, 2011, KOREAN J ANESTHESIOL, V61, P308, DOI 10.4097/kjae.2011.61.4.308; KENTRUP H, 1994, INT J CLIN PHARM TH, V32, P82; Khajavi Mohammadreza, 2013, Anesth Pain Med, V3, P208, DOI 10.5812/aapm.9653; Mandel JE, 2008, ANESTH ANALG, V106, P434, DOI 10.1213/01.ane.0000297300.33441.32; Moerman AT, 2003, EUR J ANAESTH, V20, P461, DOI 10.1097/00003643-200306000-00006; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; REVES JG, 2005, MILLERS ANESTHESIA, P317; ROSING C, 1991, MED KLIN, V86, P190; Rudner R, 2003, GASTROINTEST ENDOSC, V57, P657, DOI 10.1067/mge.2003.207; SCHUTZ SM, 1994, AM J GASTROENTEROL, V89, P1476; Stermer E, 2000, GASTROINTEST ENDOSC, V51, P278, DOI 10.1016/S0016-5107(00)70355-5; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Tang YY, 2010, J MINIM INVAS GYN, V17, P325, DOI 10.1016/j.jmig.2010.01.017; Terruzzi V, 2001, GASTROINTEST ENDOSC, V54, P169, DOI 10.1067/mge.2001.113923; Toklu S, 2009, EUR J ANAESTH, V26, P370, DOI 10.1097/EJA.0b013e328318c666; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Varadarajulu S, 2007, ALIMENT PHARM THER, V25, P987, DOI 10.1111/j.1365-2036.2007.03285.x	26	6	6	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	JUN	2015	27	4					301	306		10.1016/j.jclinane.2015.03.017			6	Anesthesiology	Anesthesiology	CK0LJ	WOS:000355896400005	25801162				2020-06-30	J	Ziesenitz, VC; Konig, SK; Mahlke, NS; Skopp, G; Haefeli, WE; Mikus, G				Ziesenitz, Victoria C.; Koenig, Sonja K.; Mahlke, Nina S.; Skopp, Gisela; Haefeli, Walter E.; Mikus, Gerd			Pharmacokinetic Interaction of Intravenous Fentanyl With Ketoconazole	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						fentanyl; CYP3A inhibition; ketoconazole	DRUG-INTERACTIONS; CYTOCHROME-P450 3A4; HUMAN PLASMA; MIDAZOLAM; METABOLISM; CLEARANCE; INHIBITION; PROBE; IV; PHARMACODYNAMICS	Fentanyl is primarily metabolized by CYP3A, but has also been suggested to act as a weak inhibitor of CYP3A. We investigated the influence of CYP3A inhibition by ketoconazole on the pharmacokinetics of intravenously administered fentanyl and the effect of fentanyl on CYP3A activity. A prospective, open-label, randomized, monocentre, crossover study was conducted in 16 healthy volunteers. They received fentanyl alone (5 microgram per kilogram) or fentanyl plus ketoconazole (200 milligram orally B.I.D. over 2 days). Naloxone (2 x 0.2 milligram i.v.) was given simultaneously with fentanyl to mitigate any opioid effect. Midazolam was administered as a CYP3A probe drug. Fentanyl and its metabolites were quantified by LC/MS/MS in blood and urine samples obtained over 24 hour. Exposure of fentanyl (AUC(0-infinity)) was significantly increased to 133% and systemic clearance was reduced to 78% by ketoconazole, norfentanyl formation was significantly delayed and partial metabolic clearance decreased to 18%. Fentanyl had no influence on midazolam exposure and CYP3A activity whereas ketoconazole decreased CYP3A activity to 13%. Although fentanyl N-dealkylation is substantially inhibited by ketoconazole, exposure of fentanyl itself increased by one third only. Clinically fentanyl dosage adjustments may become necessary when ketoconazole or other strong CYP3A inhibitors are given simultaneously. Fentanyl itself does not influence CYP3A activity.	[Ziesenitz, Victoria C.; Koenig, Sonja K.; Haefeli, Walter E.; Mikus, Gerd] Univ Heidelberg Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, D-69120 Heidelberg, Germany; [Mahlke, Nina S.; Skopp, Gisela] Univ Heidelberg Hosp, Inst Legal & Traff Med, D-69120 Heidelberg, Germany	Mikus, G (reprint author), Univ Heidelberg Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	gerd.mikus@med.uni-heidelberg.de	Ziesenitz, Victoria/J-2945-2019; Mikus, Gerd/D-4152-2013; Haefeli, Walter Emil/AAJ-3024-2020	Ziesenitz, Victoria/0000-0003-2836-4212; Mikus, Gerd/0000-0003-1783-133X; Haefeli, Walter Emil/0000-0003-0672-6876			[Anonymous], 2011, DRUG DEV DRUG INT TA; Feierman DE, 1996, ANESTH ANALG, V82, P936, DOI 10.1097/00000539-199605000-00008; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Fuchs I, 2013, EUR J CLIN PHARMACOL, V69, P507, DOI 10.1007/s00228-012-1388-1; Halama B, 2013, CLIN PHARMACOL THER, V93, P564, DOI 10.1038/clpt.2013.27; Hallberg P, 2006, EUR J CLIN PHARMACOL, V62, P491, DOI 10.1007/s00228-006-0120-4; Han TH, 2007, J CLIN PHARMACOL, V47, P674, DOI 10.1177/0091270007299756; Hase I, 1997, BRIT J ANAESTH, V79, P740; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Horton Robert, 2009, J Pain Symptom Manage, V37, pe2, DOI 10.1016/j.jpainsymman.2009.02.230; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; INCB, 2012, NARC DRUGS EST WORLD; Je YT, 2015, ARCH TOXICOL, V89, P579, DOI 10.1007/s00204-014-1268-9; Katzenmaier S, 2011, CLIN PHARMACOL THER, V90, P666, DOI 10.1038/clpt.2011.164; Katzenmaier S, 2010, EUR J CLIN PHARMACOL, V66, P1137, DOI 10.1007/s00228-010-0878-2; KRONBACH T, 1989, MOL PHARMACOL, V36, P89; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lee JI, 2002, CLIN PHARMACOL THER, V72, P718, DOI 10.1067/mcp.2002.129068; Lepper ER, 2005, CLIN CANCER RES, V11, P7398, DOI 10.1158/1078-0432.CCR-05-0520; Levin TT, 2010, GEN HOSP PSYCHIAT, V32, P648; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mercadante S, 2002, J PAIN SYMPTOM MANAG, V24, P284, DOI 10.1016/S0885-3924(02)00477-3; Oda Y, 1999, BRIT J ANAESTH, V82, P900; Ohno Y, 2007, CLIN PHARMACOKINET, V46, P681, DOI 10.2165/00003088-200746080-00005; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Quintela O, 2004, RAPID COMMUN MASS SP, V18, P2976, DOI 10.1002/rcm.1719; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stoch SA, 2009, J CLIN PHARMACOL, V49, P398, DOI 10.1177/0091270008331133; Takahashi Masahiko, 2004, J Anesth, V18, P1, DOI 10.1007/s00540-003-0214-4; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Tateishi T, 1996, ANESTH ANALG, V82, P167; Tsunoda SM, 1999, CLIN PHARMACOL THER, V66, P461, DOI 10.1016/S0009-9236(99)70009-3; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; WILKINSON GR, 1987, PHARMACOL REV, V39, P1; Zhou SF, 2007, THER DRUG MONIT, V29, P687, DOI 10.1097/FTD.0b013e31815c16f5	41	20	22	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	JUN	2015	55	6					708	717		10.1002/jcph.469			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CK0BO	WOS:000355869100012	25651378				2020-06-30	J	Lozier, MJ; Boyd, M; Stanley, C; Ogilvie, L; King, E; Martin, C; Lewis, L				Lozier, Matthew J.; Boyd, Molly; Stanley, Christina; Ogilvie, Laurie; King, Ewa; Martin, Colleen; Lewis, Lauren			Acetyl Fentanyl, a Novel Fentanyl Analog, Causes 14 Overdose Deaths in Rhode Island, March-May 2013	JOURNAL OF MEDICAL TOXICOLOGY			English	Article									[Lozier, Matthew J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30341 USA; [Lozier, Matthew J.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Air Pollut & Resp Hlth Branch, Atlanta, GA 30341 USA; [Boyd, Molly] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Environm Med Branch, Atlanta, GA USA; [Stanley, Christina] State Rhode Isl Dept Hlth, Off State Med Examiners, Providence, RI 02903 USA; [Ogilvie, Laurie; King, Ewa] State Rhode Isl Dept Hlth, State Hlth Labs, Providence, RI 02903 USA; [Martin, Colleen; Lewis, Lauren] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Hlth Studies Branch, Atlanta, GA 30341 USA	Lozier, MJ (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30341 USA.	mlozier@cdc.gov					AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; BAUM RM, 1985, CHEM ENG NEWS, V63, P7, DOI 10.1021/cen-v063n036.p007; Centers for Disease Control and Prevention NCHS, 2011, UND CAUS DEATH 1999; Conlon LFK, 2014, CANC PAINKILLER MIXE; FERNANDO D, 1991, JAMA-J AM MED ASSOC, V265, P2962, DOI 10.1001/jama.1991.03460220050029; Foerster E H, 1974, J Forensic Sci, V19, P155; Freyer FJ, 2014, PROVIDENCE J; Green TC, 2008, ADDICTION, V103, P979, DOI 10.1111/j.1360-0443.2008.02182.x; Hedegaard H, 2014, MMWR-MORBID MORTAL W, V63, P595; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Jones CM, 2013, DRUG ALCOHOL DEPEN, V132, P95, DOI 10.1016/j.drugalcdep.2013.01.007; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Levi J, 2013, PRESCRIPTION DRUG AB, V2013, P64; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; McDonald T., 2014, NC HLTH OFFICIALS WA; Niedowski E, 2014, RHODE ISLAND TAKES E; Nieves Evelyn, 1991, NY TIMES; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Owens D, 2014, COURANT; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Pennsylvania Department of Drug and Alcohol Programs, 2013, DEP DRUG ALCOHOL PRO; PREBLE E, 1969, INT J ADDICT, V4, P1, DOI 10.3109/10826086909061998; Press A.Md, 2014, HAS 37 DEATHS HEROIN; Rhode Island Department of Health, 2014, AGENCIES LICENSED PR; Rhode Island Department of Health, 2013, HLTH INVESTIGATING N; Rhode Island Department of Health, FATAL DRUG OVERDOSES; Rhode Island Department of Health, HLTH IDENTIFIES NEW; Robin N., 2013, NEW STREET DRUG KILL; Seal KH, 2005, J URBAN HEALTH, V82, P303, DOI 10.1093/jurban/jti053; SOINE WH, 1986, MED RES REV, V6, P41, DOI 10.1002/med.2610060103; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Substance Abuse and Mental Health Services Administration (SAMHSA), 2018, HHS PUBL, VSMA 18-5068; Tobin KE, 2005, ADDICTION, V100, P397, DOI 10.1111/j.1360-0443.2005.00975.x; Tracy M, 2005, DRUG ALCOHOL DEPEN, V79, P181, DOI 10.1016/j.drugalcdep.2005.01.010; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Warner Margaret, 2009, NCHS Data Brief, P1; Wood P, 2014, BALTIMORE SUN; Yokell Michael A, 2011, Med Health R I, V94, P240	43	56	57	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1556-9039	1937-6995		J MED TOXICOL	J. Med. Toxicol.	JUN	2015	11	2			SI		208	217		10.1007/s13181-015-0477-9			10	Toxicology	Toxicology	VF5DA	WOS:000443029000008	25934111	Green Published			2020-06-30	J	Jang, M; Son, WG; Lee, I				Jang, M.; Son, W. -G.; Lee, I.			Fentanyl-induced asystole in two dogs	JOURNAL OF SMALL ANIMAL PRACTICE			English	Article							ANESTHESIA; BRADYCARDIA; GLYCOPYRROLATE; INDUCTION; PROPOFOL	Fentanyl is used in small animals for perioperative analgesia during anaesthesia. Severe bradycardia and asystole were observed on bolus administration of a 3 mu g/kg loading dose of fentanyl in two dogs under isoflurane anaesthesia. Premedication with 10 mu g/kg glycopyrrolate did not prevent asystole in the first case; and although bradycardia was treated with 5 mu g/kg glycopyrrolate administered intravenously in the second case, the heart rate continuously decreased and asystole subsequently developed. Asystole in both cases was quickly corrected by intravenous administration of 004 mg/kg atropine and closed chest compressions. This case report describes asystole induced by fentanyl administration in isoflurane anaesthetised dogs. Atropine was more effective than glycopyrrolate in the treatment of fentanyl-induced asystole.	[Jang, M.; Son, W. -G.; Lee, I.] Seoul Natl Univ, Dept Vet Clin Sci, Coll Vet Med, Seoul 151742, South Korea	Jang, M (reprint author), Seoul Natl Univ, Dept Vet Clin Sci, Coll Vet Med, Seoul 151742, South Korea.				Basic Science Research Promotion program through National Research Foundation (NRF) of Korea - Ministry of Education, Science, and Technology [NRF-2011-0007777, NRF-2012-0002638]; BK21 programMinistry of Education & Human Resources Development (MOEHRD), Republic of Korea; Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University	This research was supported by the Basic Science Research Promotion program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science, and Technology (NRF-2011-0007777, NRF-2012-0002638), and the BK21 program and the Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University.	Adams J. G., 2014, VET ANAESTHESIA, P645; Borer-Weir K, 2014, VET ANAESTHESIA, P101; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; DORRINGTON KL, 1989, ANAESTHESIA, V44, P658, DOI 10.1111/j.1365-2044.1989.tb13588.x; Doxey S, 2004, VET REC, V154, P713, DOI 10.1136/vr.154.23.713; Dyson DH, 1999, CAN VET J, V40, P327; EGAN TD, 1991, ANESTH ANALG, V73, P818; Gurney MA, 2012, J SMALL ANIM PRACT, V53, P377, DOI 10.1111/j.1748-5827.2012.01243.x; Kerr C., 2007, BSAVA MANUAL CANINE, P89; Kinsella SM, 2001, BRIT J ANAESTH, V86, P859, DOI 10.1093/bja/86.6.859; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; MARYNIAK JK, 1987, BRIT J ANAESTH, V59, P390, DOI 10.1093/bja/59.3.390; Mathews LA, 2011, JAVMA-J AM VET MED A, V239, P307, DOI 10.2460/javma.239.3.307; Nordt Sean Patrick, 1997, Journal of Emergency Medicine, V15, P357; Richards D. L. S., 1989, Journal of the Association of Veterinary Anaesthetists of Great Britain and Ireland, V16, P46; STARR NJ, 1986, ANESTHESIOLOGY, V64, P521, DOI 10.1097/00000542-198604000-00023; Steffey EP, 2007, LUMB JONES VET ANEST, P355; Wang J, 1998, BRIT J ANAESTH, V81, P994; WATNEY GCG, 1987, J SMALL ANIM PRACT, V28, P1087, DOI 10.1111/j.1748-5827.1987.tb01333.x	19	1	1	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4510	1748-5827		J SMALL ANIM PRACT	J. Small Anim. Pract.	JUN	2015	56	6					411	413		10.1111/jsap.12312			3	Veterinary Sciences	Veterinary Sciences	CK0CQ	WOS:000355872300010	25599659				2020-06-30	J	Smith, AL; Owen, H; Reynolds, KJ				Smith, Anne-Louise; Owen, Harry; Reynolds, Karen J.			Can short-term heart rate variability be used to monitor fentanyl-midazolam induced changes in ANS preceding respiratory depression?	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Autonomic nervous system (ANS) modulation; Biomedical signal processing; Heart rate variability (HRV); Fentanyl; Midazolam; Airway collapse	OBSTRUCTIVE SLEEP-APNEA; CONFIDENCE-INTERVALS; SINUS ARRHYTHMIA; HEALTHY-VOLUNTEERS; UPPER AIRWAY; ANESTHESIA; INDUCTION; PRESSURE; PROPOFOL; SEDATION	Opioids have an occasional but high-risk side effect of respiratory depression. The detection of critical respiratory depression usually occurs after the event. Earlier detection would be beneficial in preventing increased morbidity and mortality of 0.01 % patients receiving analgesic opioids. Airway patency during inspiration requires vagal modulation. Regulation of the cardiovascular and respiratory centres may be coupled with a central mechanism that is indirectly measurable with heart rate variability (HRV). While opioids tend to increase parasympathetic tone, a decrease in airway stability could be due to a decrease in respiratory parasympathetic activity. Sympathetic arousal generated by apneic events may separately be recognised with short-term HRV. This pilot observational study examined the dynamic sympathovagal changes during fentanyl-midazolam induced respiratory depression on 10 subjects scheduled for minor surgery. A selection of HRV indices, able to work over sub-minute periods on non-stationary signals, were applied including a range of less common indices. Three analyses tested the effects: post-fentanyl, preceding the first central depression, and preceding obstruction of the upper airway. Statistical significance was assessed with overlap of bootstrap percentile confidence intervals for the median. A decrease in total variability, Lomb Total using the Lomb-Scargle method, is a positive finding for short-term HRV use in this study. No significant change before critical respiratory events was observed in traditional, spectral power, respiratory or other indices. One index, PolVar20, indicated a burst of sympathetic activity preceding respiratory depression similar to sleep apnoea arousals that restore airway patency. Before its usefulness in early detection of airway tone can be determined, PolVar20 requires further work: a statistical method for highly skewed distributions, auto adjustment for baseline variability, and detecting a range of sympathetic responses to apnea.	[Smith, Anne-Louise; Reynolds, Karen J.] Flinders Univ S Australia, Med Device Res Inst, Adelaide, SA 5001, Australia; [Smith, Anne-Louise] Flinders Med Ctr, Dept Biomed Engn, Adelaide, SA, Australia; [Owen, Harry] Flinders Univ S Australia, Sch Med, Adelaide, SA 5001, Australia	Smith, AL (reprint author), Flinders Univ S Australia, Med Device Res Inst, GPO Box 2100, Adelaide, SA 5001, Australia.	anne-louise.smith@health.sa.gov.au					A-L Smith, 2011, THESIS FLINDERS U AD; Agelink MW, 2002, CRIT CARE MED, V30, P997, DOI 10.1097/00003246-200205000-00008; ASKANAZI J, 1978, CRIT CARE MED, V6, P143, DOI 10.1097/00003246-197805000-00004; Baguet JP, 2009, J HUM HYPERTENS, V23, P431, DOI 10.1038/jhh.2008.147; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bartels MN, 2000, CHEST, V118, P691, DOI 10.1378/chest.118.3.691; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benumof JL, 2001, J CLIN ANESTH, V13, P144, DOI 10.1016/S0952-8180(01)00232-X; Blues CM, 1998, BRIT J ANAESTH, V81, P333, DOI 10.1093/bja/81.3.333; Bradley TD, 2009, LANCET, V373, P82, DOI 10.1016/S0140-6736(08)61622-0; Camm AJ, 1996, EUR HEART J, V17, P354; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; Chang KL, 2001, ANN BIOMED ENG, V29, P764, DOI 10.1114/1.1397791; Chernick M. R., 2008, BOOTSTRAP METHODS, DOI [10.1002/9780470192573, DOI 10.1002/9780470192573]; Clifford G D, 2002, THESIS OXFORD U OXFO; Cubuk R, 2011, RADIOL MED, V116, P47, DOI 10.1007/s11547-010-0581-5; Cumming G, 2009, STAT MED, V28, P205, DOI 10.1002/sim.3471; de Bruyne MC, 1999, AM J EPIDEMIOL, V150, P1282; Dingli K, 2003, EUR RESPIR J, V22, P943, DOI 10.1183/09031936.03.00098002; DONCHIN Y, 1985, ANESTH ANALG, V64, P811; Duarte Leonardo Teixeira Domingues, 2009, Rev. Bras. Anestesiol., V59, P409, DOI 10.1590/S0034-70942009000400003; ECKBERG DL, 1983, J APPL PHYSIOL, V54, P961; Efron B., 1993, INTRO BOOTSTRAP MONO, V57; Freilich S, 2010, SLEEP MED, V11, P87, DOI 10.1016/j.sleep.2008.12.017; Fukuda K, 2009, MILLERS ANESTHESIA, P769; Furutani M, 2011, PERCEPT MOTOR SKILL, V112, P138, DOI 10.2466/09.13.PMS.112.1.138-150; Furutani Y, 1997, J Cardiol, V29, P171; GALLETLY DC, 1994, BRIT J ANAESTH, V72, P177, DOI 10.1093/bja/72.2.177; Gole Y, 2011, EUR J APPL PHYSIOL, V111, P937, DOI 10.1007/s00421-010-1711-4; Goncalves H, 2008, PHYSIOL MEAS, V29, P1133, DOI 10.1088/0967-3334/29/9/010; Hamilton RM, 2004, INT J CARDIOL, V95, P109, DOI 10.1016/j.ijcard.2003.07.005; Haukoos JS, 2005, ACAD EMERG MED, V12, P360, DOI 10.1197/j.aem.2004.11.018; Iturriaga R, 2010, ADV EXP MED BIOL, V669, P271, DOI 10.1007/978-1-4419-5692-7_55; Keselman HJ, 2002, BRIT J MATH STAT PSY, V55, P27, DOI 10.1348/000711002159680; Ko S, 2003, CAN J ANAESTH, V50, P679, DOI 10.1007/BF03018710; KOMATSU T, 1995, CAN J ANAESTH, V42, P1003, DOI 10.1007/BF03011073; Komatsu T, 1992, J Cardiothorac Vasc Anesth, V6, P444, DOI 10.1016/1053-0770(92)90011-U; KUNA ST, 1986, J APPL PHYSIOL, V60, P1373; Laguna P, 1998, IEEE T BIO-MED ENG, V45, P698, DOI 10.1109/10.678605; LATSON TW, 1992, J CLIN ANESTH, V4, P265, DOI 10.1016/0952-8180(92)90127-M; Lee KC, 2012, BIOL RES NURS, V14, P78, DOI 10.1177/1099800410396704; Lund VE, 1999, ACTA PHYSIOL SCAND, V167, P29; Malhotra A, 2002, LANCET, V360, P237, DOI 10.1016/S0140-6736(02)09464-3; Mathru M, 1996, ANESTHESIOLOGY, V84, P273, DOI 10.1097/00000542-199602000-00004; Michaloudis D, 1998, ANAESTHESIA, V53, P446, DOI 10.1046/j.1365-2044.1998.00323.x; Moody GB, 1993, COMP CARD P LOND UK; Paton JFR, 2000, RESP PHYSIOL, V119, P101, DOI 10.1016/S0034-5687(99)00105-X; Pomfrett CJD, 1999, BRIT J ANAESTH, V82, P659; Ristikankare M, 2009, DIGEST LIVER DIS, V41, P648, DOI 10.1016/j.dld.2009.01.008; Riznyk L, 2005, PHARMACOL REP, V57, P128; Salahuddin L, 2007, 29 ANN INT C IEEE EN; Salahuddin L, 2007, 9 INT C E HLTH NETW; Schachinger H, 2000, BRIT J ANAESTH, V84, P316; Schirdewan A, 2004, J AM COLL CARDIOL, V43, p125A, DOI 10.1016/S0735-1097(04)90527-X; Schubert A, 1997, J CLIN ANESTH, V9, P52, DOI 10.1016/S0952-8180(96)00208-5; Shibata S, 2005, AVIAT SPACE ENVIR MD, V76, P1105; Smith AL, 2013, J CLIN MONIT COMPUT, V27, P569, DOI 10.1007/s10877-013-9471-4; Smith R P, 1998, Sleep Med Rev, V2, P69, DOI 10.1016/S1087-0792(98)90001-6; Sosnowski M, 1994, COMP CARD 1994 BETH; Suppappola S, 1991, P ANN INT C IEEE ENG; Thong T, 2003, 25 ANN INT C IEEE EN; Vettorello M, 2008, ACTA ANAESTH SCAND, V52, P1064, DOI 10.1111/j.1399-6576.2008.01713.x; Voss A, 1996, CARDIOVASC RES, V31, P419; WANG DY, 1993, BRIT J ANAESTH, V71, P354, DOI 10.1093/bja/71.3.354; Wessel N, 2007, INT J BIFURCAT CHAOS, V17, P3325, DOI 10.1142/S0218127407019093; Win NN, 2005, ANESTH ANALG, V101, P97, DOI 10.1213/01.ANE.0000156204.89879.5C; Wolfe R, 2004, J SCI MED SPORT, V7, P138, DOI 10.1016/S1440-2440(04)80003-3; Zickmann B, 1996, J CARDIOTHOR VASC AN, V10, P609, DOI 10.1016/S1053-0770(96)80138-8	68	5	5	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	JUN	2015	29	3					393	405		10.1007/s10877-014-9617-z			13	Anesthesiology	Anesthesiology	CH5US	WOS:000354101400011	25239791				2020-06-30	J	Ball, AJ; Rees, CJ; Corfe, BM; Riley, SA				Ball, Alex J.; Rees, Colin J.; Corfe, Bernard M.; Riley, Stuart A.			Sedation practice and comfort during colonoscopy: lessons learnt from a national screening programme	EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY			English	Article						colonoscopy; discomfort; quality; sedation	GASTROINTESTINAL ENDOSCOPY; COLORECTAL-CANCER; PATIENT COMFORT; QUALITY; NURSE; SCORE; PAIN	Aim Medication may be used to manage discomfort during colonoscopy but practice varies. The relationship between medication use and comfort during colonoscopy was examined in the English Bowel Cancer Screening Programme. Methods Data related to patient comfort and medication use from all 113 316 examinations performed within the English Bowel Cancer Screening Programme between 1 January 2010 and 31 December 2012 were analysed. Comfort was rated on the five-point Modified Gloucester Comfort Scale: 1, no discomfort; 5, severe discomfort. Scores of 4 and 5 were considered to indicate significant discomfort. Correlations between the proportion of examinations associated with significant discomfort and the amounts of medication used by colonoscopists were assessed using Spearman's rho. Logistic regression modelling examined the independent predictors of significant discomfort. Results Patients had a mean age of 65.7 years, and 58% were male. Examinations were performed by 290 endoscopists. In 91% of examinations, there was no significant discomfort reported during examination; however, there was considerable variation between individual colonoscopists (range 76.1-99.2%). Intravenous sedation and opiate analgesia were used during most examinations, but there was wide variation between colonoscopists, with a median (range) usage of 95.1% (4.1-100%) and 97.3% (5.6-100%), respectively. There was no association between the amount of sedation and analgesia used and significant discomfort (rho < 0.2). On multivariate analysis, significant discomfort was found to be more common among female individuals [odds ratio (OR)= 2.0], on incomplete examinations (OR = 6.7), and among patients with diverticulosis (OR = 1.4). Conclusion There was wide variation in medication practice among English screening colonoscopists, but this was unrelated to the occurrence of significant discomfort. Copyright (c) 2015 Wolters Kluwer Health, Inc. All rights reserved.	[Ball, Alex J.; Riley, Stuart A.] Sheffield Teaching Hosp, Dept Gastroenterol, Sheffield S5 7AU, S Yorkshire, England; [Ball, Alex J.; Corfe, Bernard M.] Univ Sheffield, Sch Med, Dept Oncol, Sheffield, S Yorkshire, England; [Riley, Stuart A.] Sheffield Teaching Hosp, South Yorkshire & Bassetlaw Bowel Canc Screening, Sheffield S5 7AU, S Yorkshire, England; [Rees, Colin J.] South Tyneside Gen Hosp, South Tyne Bowel Canc Screening Ctr, South Shields, England; [Rees, Colin J.] Univ Durham, Sch Med Pharm & Hlth, Durham, England	Ball, AJ (reprint author), Sheffield Teaching Hosp, Dept Gastroenterol, Sheffield S5 7AU, S Yorkshire, England.	alex.ball@sth.nhs.uk		Corfe, Bernard/0000-0003-0449-2228			Chilton A, 2011, QUALITY ASSURANCE GU, P6; Darzi A., 2008, HIGH QUALITY CARE AL; Ekkelenkamp VE, 2013, WORLD J GASTROENTERO, V19, P2355, DOI 10.3748/wjg.v19.i15.2355; Fanti L, 2010, WORLD J GASTROENTERO, V16, P2451, DOI 10.3748/wjg.v16.i20.2451; Hoffman MS, 1998, J CLIN GASTROENTEROL, V26, P279, DOI 10.1097/00004836-199806000-00013; Jones RM, 2010, AM J PREV MED, V38, P508, DOI 10.1016/j.amepre.2010.01.021; Korman LY, 2014, GASTROINTEST ENDOSC, V79, P657, DOI 10.1016/j.gie.2013.12.002; Korman LY, 2010, GASTROINTEST ENDOSC, V71, P327, DOI 10.1016/j.gie.2009.08.029; Lee TJW, 2012, GUT, V61, P1050, DOI 10.1136/gutjnl-2011-300651; Maslekar S, 2010, COLORECTAL DIS, V12, P1033, DOI 10.1111/j.1463-1318.2009.01989.x; Munson GW, 2011, GASTROENTEROL NURS, V34, P296, DOI 10.1097/SGA.0b013e3182248777; Paggi S, 2012, GASTROINTEST ENDOSC, V75, P392, DOI 10.1016/j.gie.2011.09.015; Rostom A, 2013, GASTROINTEST ENDOSC, V77, P255, DOI 10.1016/j.gie.2012.10.003; Scholefield JH, 2012, GUT, V61, P1036, DOI 10.1136/gutjnl-2011-300774; Shah SG, 2002, ENDOSCOPY, V34, P435, DOI 10.1055/s-2002-31995; Subramanian S, 2005, J CLIN GASTROENTEROL, V39, P516, DOI 10.1097/01.mcg.0000165667.79530.44; Takahashi Y, 2005, DIS COLON RECTUM, V48, P1295, DOI 10.1007/s10350-004-0940-1; Teague R, 2003, SAFETY SEDATION ENDS; Terruzzi V, 2012, WORLD J GASTRO ENDOS, V4, P137, DOI 10.4253/wjge.v4.i4.137	19	10	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0954-691X	1473-5687		EUR J GASTROEN HEPAT	Eur. J. Gastroenterol. Hepatol.	JUN	2015	27	6					741	746		10.1097/MEG.0000000000000360			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CH0DE	WOS:000353688400020	25874595				2020-06-30	J	Chen, JQ; Wu, Z; Wen, LY; Miao, JZ; Hu, YM; Xue, RP				Chen, Jian-qing; Wu, Zhen; Wen, Lai-you; Miao, Jian-zhong; Hu, Yong-ming; Xue, Ruiping			Preoperative and postoperative analgesic techniques in the treatment of patients undergoing transabdominal hysterectomy: a preliminary randomized trial	BMC ANESTHESIOLOGY			English	Article						Pre-emptive analgesia; Multimodal; Transabdominal hysterectomy; Stress response; Inflammatory cytokines	DOUBLE-BLIND TRIAL; PAIN; KETAMINE	Background: Although pre-emptive analgesia is commonly used for the management of postoperative pain in developed countries, no defined protocol has been carried out and widely practiced, especially in transabdominal hysterectomy. Keeping this in mind the present study aimed to investigate the effects of multimodal pre-emptive analgesia on pain management, stress response and inflammatory factors of patients undergoing transabdominal hysterectomy to find an optimized way of pre-emptive analgesia. Methods: One hundred patients undergoing abdominal hysterectomy were randomly divided into four groups (Trial registration: ChiCTR-IPR-15005848). Group P1 was given intravenous flurbiprofen and epidural fentanyl + ketamine before surgery; Group P2 received intravenous flurbiprofen before surgery and epidural fentanyl + ketamine after surgery; Group P3 was given epidural fentanyl + ketamine before surgery and intravenous flurbiprofen after surgery; Patients in Group C received normal saline treatment. Results: Compared with control group, the first time to request additional analgesics after surgery were significantly later (P<0.05), 24 h dosage of analgesia were significantly less (P<0.05), VAS score at all time periods after surgery were significantly lower (P<0.05) in Group P1, P2, or P3. At 12 h or 24 h after surgery, VAS score in Group P1 was significantly lower than that in group P2 or P3 (P<0.05, P<0.05). No significant adverse effects were found among the groups (P>0.05). At 1 or 2 days after surgery, the levels of cortisol, glucose, and IL-6, TNF-alpha in group P1, P2, and P3 were significantly lower than those in group C (P<0.05); while, the levels in group P2, P3 were significantly lower than those in group P1 (P<0.05). Conclusion: Multimodal pre-emptive analgesia could significantly lower VAS score, inhibit stress response, and reduce inflammatory response in patients undergoing transabdominal hysterectomy, which can be a rational strategy for pain control in future.	[Chen, Jian-qing; Wu, Zhen; Wen, Lai-you; Miao, Jian-zhong; Hu, Yong-ming; Xue, Ruiping] Nantong Univ, Affiliated Jiangyin Hosp, Dept Anesthesiol, 163 Shoushan Rd, Jiangyin, Jiangsu, Peoples R China	Chen, JQ (reprint author), Nantong Univ, Affiliated Jiangyin Hosp, Dept Anesthesiol, 163 Shoushan Rd, Jiangyin, Jiangsu, Peoples R China.	jywly200901@163.com			Wuxi Municipal Bureau of Science and Technology [150]	The study is supported by Wuxi Municipal Bureau of Science and Technology (No. 150).	Du BX, 2014, INT J CLIN EXP MED, V7, P826; Fletcher Mark C, 2012, Dent Clin North Am, V56, P95, DOI 10.1016/j.cden.2011.09.001; Liporaci JLJ, 2012, REV BRAS ANESTESIOL, V62, P502, DOI 10.1016/S0034-7094(12)70148-4; Kehlet H, 2009, CURR OPIN CRIT CARE, V15, P355, DOI 10.1097/MCC.0b013e32832fbbe7; Khalili G, 2013, J CLIN ANESTH, V25, P188, DOI 10.1016/j.jclinane.2012.09.004; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Nesek-Adam V, 2012, SURG LAPARO ENDO PER, V22, P232, DOI 10.1097/SLE.0b013e31824f8ae4; Nordquist D, 2014, PAIN RES TREAT, V2014, DOI 10.1155/2014/902174; Shrestha S K, 2012, Kathmandu Univ Med J (KUMJ), V10, P16; Wang Y, 2012, CHINESE MED J-PEKING, V125, P579, DOI 10.3760/cma.j.issn.0366-6999.2012.04.004; Wilson JA, 2008, PAIN, V135, P108, DOI 10.1016/j.pain.2007.05.011; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0	12	8	8	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	MAY 6	2015	15								70	10.1186/s12871-015-0046-4			7	Anesthesiology	Anesthesiology	DD0IJ	WOS:000369603300001	25943183	DOAJ Gold, Green Published			2020-06-30	J	Borodiciene, J; Gudaityte, J; Macas, A				Borodiciene, Jurgita; Gudaityte, Jurate; Macas, Andrius			Lithotomy versus jack-knife position on haemodynamic parameters assessed by impedance cardiography during anorectal surgery under low dose spinal anaesthesia: a randomized controlled trial	BMC ANESTHESIOLOGY			English	Article						Spinal anaesthesia; Haemodynamic parameters; Cardiac output; Impedance cardiography; Prone position	TOTAL INTRAVENOUS ANESTHESIA; PRONE POSITION; HYPERBARIC BUPIVACAINE; INHALATION	Background: Although the prone position providing better exposure for anorectal surgery is required it can cause a reduction of cardiac output and cardiac index. The goal was to compare haemodynamic changes assessed by impedance cardiography during anorectal surgery under low-dose spinal anaesthesia in lithotomy and jack-knife position. Methods: The prospective randomized controlled study included 104, ASA I-II adult patients admitted for elective minor anorectal surgery, assigned to be performed in lithotomy (groupL, n = 52) or jack-knife position (groupJ, n = 52). After arrival to operating room the standard monitoring, impedance cardiography device was connected to the patient, and the following variables were recorded: cardiac output, cardiac index, systemic vascular resistance, stroke index at times of arrival to operating room, placement for, start and end of surgery and placement to bed. Spinal block was made in the sitting position with 4 mg of 0.5% hyperbaric bupivacaine and 10 mu g of Fentanyl injected over 2 min. Comparison was based on haemodynamic changes between and inside groups over time. Student's t, chi square tests were used for statistical analysis with p < 0.05 regarded as statistically significant. Results: The reduction of cardiac output was statistically significant after placement of the patient into the prone position: from baseline 7.4+/-1.6 to 4.9+/-1.2 after placement for and 4.7+/-1.2 at the start and end of surgery (mean +/-SD l/min). The difference of cardiac output between groups was 2.0 l/min after positioning for and the start of surgery and 1.5 l/min at the end of surgery (p < 0.05). Mean cardiac index reduced from baseline 3.9+/-0.8 to 2.6+/-0.7 and 2.4+/-0.6 (mean+/-SD l/min/m(2)) in groupJ and between groups: by 1.0 l/min/m(2) after placement for, 1.1 at the start and 0.8 at the end of surgery (p < 0.05). Systemic vascular resistance increased from baseline 1080+/-338 to 1483+/-479 after placement for, 1523+/-481 at the start and 1525+/-545 at the end of surgery in groupJ (mean+/-SD dynes/sec/cm(-5), p < 0.05). Conclusions: According to impedance cardiography, jack-knife position after low-dose spinal anaesthesia produces transitory, but statistically significant reduction of cardiac output and cardiac index with increase of systemic vascular resistance, compared to insignificant changes in lithotomy position.	[Borodiciene, Jurgita; Gudaityte, Jurate; Macas, Andrius] Lithuanian Univ Hlth Sci, Dept Anaesthesiol, LT-50009 Kaunas, Lithuania	Borodiciene, J (reprint author), Lithuanian Univ Hlth Sci, Dept Anaesthesiol, Eiveniu Str 2, LT-50009 Kaunas, Lithuania.	jurgita.borodiciene@gmail.com			Foundation of Science; Lithuanian University of Health Sciences; Lithuanian State Foundation of Science and Research	The authors acknowledge prof. Viktoras Saferis, Institute of Biomedical Research, Lithuanian University of Health Sciences for invaluable guidance through statistics. Above all, we should like to thank Asta Juzenaite, Edita Kulikauskaite, Olga Pavlova and other OR staff for support and patience during the study. The study was supported by the grant from Foundation of Science, Lithuanian University of Health Sciences and Lithuanian State Foundation of Science and Research.	BACKOFEN JE, 1985, ANESTH ANALG, V64, P194; Borodiciene J, 2012, ACTA MED LITUANICA, V19, P191; Brown ZE, 2013, ANAESTHESIA, V68, P742, DOI 10.1111/anae.12310; Chamos C, 2013, PERIOPER MED-LONDON, V2, DOI 10.1186/2047-0525-2-19; Conway DH, 2013, EUR J ANAESTH, V30, P501, DOI 10.1097/EJA.0b013e3283603250; Dharmavaram S, 2006, SPINE, V31, P1388, DOI 10.1097/01.brs.0000218485.96713.44; Edgcombe H, 2008, BRIT J ANAESTH, V100, P165, DOI 10.1093/bja/aem380; Fellahi JL, 2014, J CARDIOTHOR VASC AN, V28, P755, DOI 10.1053/j.jvca.2013.12.026; Gudaityte J, 2009, J CLIN ANESTH, V21, P474, DOI 10.1016/j.jclinane.2008.11.014; HATADA T, 1991, AM J SURG, V162, P55, DOI 10.1016/0002-9610(91)90202-O; Mellin-Olsen J, 2010, EUR J ANAESTH, V27, P592, DOI 10.1097/EJA.0b013e32833b1adf; Miyabe M, 1996, SURV ANESTHESIOL, V40, P179; Nakasuji M, 2012, J CLIN ANESTH, V24, P201, DOI 10.1016/j.jclinane.2011.07.014; Ozkose Z, 2001, J NEUROSURG ANESTH, V13, P296, DOI 10.1097/00008506-200110000-00003; Peyton PJ, 2010, ANESTHESIOLOGY, V113, P1220, DOI 10.1097/ALN.0b013e3181ee3130; Salinas Francis V, 2003, Best Pract Res Clin Anaesthesiol, V17, P289, DOI 10.1016/S1521-6896(02)00114-3; Schmittner MD, 2013, INT J COLORECTAL DIS, V28, P873, DOI 10.1007/s00384-012-1619-z; Schmittner MD, 2011, INT J COLORECTAL DIS, V26, P97, DOI 10.1007/s00384-010-1012-8; Sudheer PS, 2006, ANAESTHESIA, V61, P138, DOI 10.1111/j.1365-2044.2005.04464.x; Toyota S, 1998, J CLIN ANESTH, V10, P32, DOI 10.1016/S0952-8180(97)00216-X; Wadsworth R, 1996, ANAESTHESIA, V51, P819, DOI 10.1111/j.1365-2044.1996.tb12608.x; YOKOYAMA M, 1991, ACTA ANAESTH SCAND, V35, P741, DOI 10.1111/j.1399-6576.1991.tb03382.x	22	3	3	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	MAY 6	2015	15								74	10.1186/s12871-015-0055-3			9	Anesthesiology	Anesthesiology	CH9LR	WOS:000354357600001	25943374	DOAJ Gold, Green Published			2020-06-30	J	Chan, SM; Lee, MS; Lu, CH; Cherng, CH; Huang, YS; Yeh, CC; Kuo, CY; Wu, ZF				Chan, Shun-Ming; Lee, Meei-Shyuan; Lu, Chueng-He; Cherng, Chen-Hwan; Huang, Yuan-Shiou; Yeh, Chun-Chang; Kuo, Chan-Yang; Wu, Zhi-Fu			Confounding Factors to Predict the Awakening Effect-Site Concentration of Propofol in Target-Controlled Infusion Based on Propofol and Fentanyl Anesthesia	PLOS ONE			English	Article							MANUALLY CONTROLLED INFUSION; GENERAL-ANESTHESIA; CONSCIOUSNESS; REMIFENTANIL; SUFENTANIL; PHARMACODYNAMICS; PHARMACOKINETICS; SURGERY; AGE; ALFENTANIL	We conducted a large retrospective study to investigate the confounding factors that predict Ce ROC under propofol-based TIVA with TCI. We recorded sex, age, height, weight, Ce LOC, Ce ROC, total propofol and fentanyl consumption dose, and anesthetic time. Simple linear regression models were used to identify potential predictors of Ce ROC, and multiple linear regression models were used to identify the confounding predictors of Ce ROC. We found that Ce ROC correlated with age, sex, Ce LOC, and both total fentanyl and propofol consumption dose. The prediction formula was: Ce ROC = 0.87 - 0.06 x age + 0.18 x Ce LOC + 0.04 (if fentanyl consumption > 150 mu g; if not, ignore this value) + 0.07 x (1 or 2, according to the total propofol consumption dose, 1 for a propofol amount 1000-2000 mg and 2 for a propofol amount > 2000 mg). We simplified the formula further as Ce ROC = 0.87 - 0.06 x age + 0.18 x Ce LOC. In conclusion, Ce ROC can be predicted under TCI with propofol- and fentanyl-based TIVA. The confounding factors that predicted propofol Ce ROC are age, sex, Ce LOC, and total consumption dose of propofol and fentanyl.	[Chan, Shun-Ming; Lu, Chueng-He; Cherng, Chen-Hwan; Huang, Yuan-Shiou; Yeh, Chun-Chang; Kuo, Chan-Yang; Wu, Zhi-Fu] Triserv Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Chan, Shun-Ming; Lu, Chueng-He; Cherng, Chen-Hwan; Huang, Yuan-Shiou; Yeh, Chun-Chang; Kuo, Chan-Yang; Wu, Zhi-Fu] Natl Def Med Ctr, Taipei, Taiwan; [Lee, Meei-Shyuan] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan; [Chan, Shun-Ming; Wu, Zhi-Fu] Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan	Wu, ZF (reprint author), Triserv Gen Hosp, Dept Anesthesiol, Taipei, Taiwan.	aneswu@gmail.com					Aceto P, 2007, NEUROREPORT, V18, P823, DOI 10.1097/WNR.0b013e3280e129f5; [Anonymous], 1979, ASA Newsl, V43, P3; BRODY H, 1992, ACTA NEUROL SCAND, V85, P40, DOI 10.1111/j.1600-0404.1992.tb05037.x; Chan SM, 2009, J MED SCI, V29, P75; Chen JL, 2013, J MED SCI, V33, P205; Chiang MH, 2013, ENDOSCOPY, V45, P907, DOI 10.1055/s-0033-1344645; De Cosmo G, 2005, CURR DRUG TARGETS, V6, P741; De Cosmo G, 2005, NEUROL RES, V27, P433, DOI 10.1179/016164105X21724; Gan TJ, 1999, ANESTHESIOLOGY, V90, P1283, DOI 10.1097/00000542-199905000-00010; Glass PS, 2009, MILLERS ANESTHESIA, P997; Hentgen E, 2002, ANESTH ANALG, V95, P597, DOI 10.1097/00000539-200209000-00019; Horng Huei-Chi, 2007, Acta Anaesthesiol Taiwan, V45, P205; Hoymork SC, 2005, BRIT J ANAESTH, V95, P627, DOI 10.1093/bja/aei245; Iwakiri H, 2005, ANESTH ANALG, V100, P107, DOI 10.1213/01.ANE.0000139358.15909.EA; Jung SM, 2011, ACTA ANAESTH SCAND, V55, P110, DOI 10.1111/j.1399-6576.2010.02327.x; Kreuer S, 2005, EUR J ANAESTH, V22, P123, DOI 10.1017/S0265021505000232; Lentschener C, 2003, ACTA ANAESTH SCAND, V47, P84, DOI 10.1034/j.1399-6576.2003.470115.x; Lin BF, 2012, J NEUROSURG ANESTH, V24, P127, DOI 10.1097/ANA.0b013e31823c4a24; Lu Chueng-He, 2014, Acta Anaesthesiol Taiwan, V52, P6, DOI 10.1016/j.aat.2014.05.004; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; Nunes CS, 2009, J CLIN ANESTH, V21, P3, DOI 10.1016/j.jclinane.2008.06.011; Nunes CS, 2005, J NEUROSURG ANESTH, V17, P110, DOI 10.1097/01.ana.0000163198.02742.9d; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; Schuttler J, 1988, Anaesthesia, V43 Suppl, P2, DOI 10.1111/j.1365-2044.1988.tb09059.x; SHAFER A, 1988, ANESTHESIOLOGY, V69, P348, DOI 10.1097/00000542-198809000-00011; VUYK J, 1992, ANESTHESIOLOGY, V77, P3, DOI 10.1097/00000542-199207000-00002; Vuyk J, 1999, Minerva Anestesiol, V65, P215; Vuyk J, 2001, BRIT J ANAESTH, V86, P183, DOI 10.1093/bja/86.2.183; Wu ZF, 2014, ANESTH ANALG, V119, P1393, DOI 10.1213/ANE.0000000000000435; Yeganeh Naser, 2010, Middle East Journal of Anesthesiology, V20, P785	31	7	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2015	10	5							e0124343	10.1371/journal.pone.0124343			11	Multidisciplinary Sciences	Science & Technology - Other Topics	CH3PP	WOS:000353943000024	25938415	DOAJ Gold, Green Published			2020-06-30	J	Ng, O; Thong, SY; Chia, CS; Teo, MCC				Ng, Oriana; Thong, Sze Ying; Chia, Claramae Shulyn; Teo, Melissa Ching Ching			Revision of loop colostomy under regional anaesthesia and sedation	SINGAPORE MEDICAL JOURNAL			English	Article						abdominal wall surgery; colostomy; ilioinguinal-iliohypogastric; rectus sheath and transversus abdominis plane blocks; ultrasonography-guided regional anaesthesia	SURGICAL ANESTHESIA; HERNIA REPAIR; BLOCK; ROPIVACAINE; SURGERY	Patients presenting for emergency abdominal procedures often have medical issues that cause both general anaesthesia and central neuraxial blockade to pose significant risks. Regional anaesthetic techniques are often used adjunctively for abdominal procedures under general anaesthesia, but there is limited published data on procedures done under peripheral nerve or plexus blocks. We herein report the case of a patient with recent pulmonary embolism and supraventricular tachycardia who required colostomy refashioning. Ultrasonography- guided regional anaesthesia was administered using a combination of ilioinguinal-iliohypogastric, rectus sheath and transversus abdominis plane blocks. This was supplemented with propofol and dexmedetomidine sedation as well as intermittent fentanyl and ketamine boluses to cover for visceral stimulation. We discuss the anatomical rationale for the choice of blocks and compare the anaesthetic conduct with similar cases that were previously reported.	[Ng, Oriana; Thong, Sze Ying] Singapore Gen Hosp, Dept Anaesthesiol, Singapore 169608, Singapore; [Chia, Claramae Shulyn; Teo, Melissa Ching Ching] Natl Canc Ctr Singapore, Div Surg Oncol, Singapore, Singapore	Ng, O (reprint author), Singapore Gen Hosp, Dept Anaesthesiol, Block 2,Level 2,Outram Rd, Singapore 169608, Singapore.	q_sorais@hotmail.com					Abdallah FW, 2012, REGION ANESTH PAIN M, V37, P193, DOI 10.1097/AAP.0b013e3182429531; Beecroft C, 2010, ANAEST INTENS CARE M, V11, P98, DOI 10.1016/j.mpaic.2009.12.003; England RK, 2005, INT J COLORECTAL DIS, V20, P349, DOI 10.1007/s00384-004-0666-5; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; Jensen K, 2013, ANAESTHESIA, V68, P106, DOI 10.1111/anae.12103; Mishra Lipi, 2013, J Anaesthesiol Clin Pharmacol, V29, P540, DOI 10.4103/0970-9185.119140; Pettersson N, 1998, REGION ANESTH PAIN M, V23, P189, DOI 10.1097/00115550-199823020-00013; Phua DSK, 2009, ANAESTH INTENS CARE, V37, P499; Quek K, 2012, ANZCA ASM; Salonen MHA, 2000, REGION ANESTH PAIN M, V25, P47, DOI 10.1016/S1098-7339(00)80010-3; Savas JF, 2004, AM J SURG, V188, P603, DOI 10.1016/j.amjsurg.2004.07.016	11	0	0	1	6	SINGAPORE MEDICAL ASSOC	SINGAPORE	LEVEL 2 ALUMNI MEDICAL CENTRE, 2 COLLEGE RD, SINGAPORE 169850, SINGAPORE	0037-5675			SINGAP MED J	Singap. Med. J.	MAY	2015	56	5					E89	E91		10.11622/smedj.2015081			3	Medicine, General & Internal	General & Internal Medicine	CM4II	WOS:000357647700005	26034327	Bronze, Green Published			2020-06-30	J	Kerr, D; Taylor, D; Evans, B				Kerr, D.; Taylor, D.; Evans, B.			Patient-controlled intranasal fentanyl analgesia: a pilot study to assess practicality and tolerability during childbirth	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Analgesia; Childbirth; Fentanyl; Intranasal; Obstetric; Patient-controlled	RANDOMIZED CONTROLLED-TRIAL; POSTOPERATIVE ANALGESIA; INTRAVENOUS MORPHINE; ORAL MORPHINE; DOUBLE-BLIND; PAIN RELIEF; LABOR PAIN; MANAGEMENT; EXPECTATIONS; EFFICACY	Background: Intranasal administration of fentanyl is a non-invasive method of analgesic delivery which has been shown to be effective. This pilot study aimed to assess the practicality and tolerability of patient-controlled intranasal fentanyl for relieving pain during childbirth. Methods: This prospective, non-randomised, clinical trial recruited women with a singleton pregnancy during November 2009 to October 2011. Exclusion criteria included respiratory disease, gestation <37 weeks and pregnancy complications. The device administered fentanyl 54 mu g per spray, incorporating a 3-min lock-out. Data collected included demographics, dose, additional analgesia, adverse events, pain relief and delivery outcomes. Follow-up data were obtained within 48 h regarding tolerability of the device. Results: The final sample included 32 women: mean age was 28.7 years and gestation 39.8 weeks. Mean fentanyl dose was 734 mu g and duration of use was 3.5 h. Most women (78.2%) reported satisfactory to excellent pain relief using the nasal device. Four neonates (12.5%) required bag-mask ventilation at birth: three had adequate respiration within 5 min and one required short-term observation in the special-care nursery. For all items, there was a trend towards an adverse outcome, including neonatal respiratory support, as the dose of fentanyl increased. On follow-up, 84.4% reported they would use intranasal fentanyl for their next childbirth experience. Conclusions: Patient-controlled intranasal fentanyl provides an acceptable level of analgesia during childbirth. It may, however, increase the risk of neonatal respiratory depression. Future, randomised studies should evaluate the safety and efficacy of patient-controlled intranasal fentanyl compared with existing analgesia options. (C) 2014 Elsevier Ltd. All rights reserved.	[Kerr, D.] Victoria Univ, Coll Hlth & Biomed, St Albans, Vic 3021, Australia; [Taylor, D.; Evans, B.] Western Hlth, Footscray, Vic, Australia	Kerr, D (reprint author), Victoria Univ, Coll Hlth & Biomed, 4th Floor, St Albans, Vic 3021, Australia.	deb.kerr@vu.edu.au		Kerr, Debra/0000-0002-2956-2432	Victoria University; Western Health	This work was funded by internal Victoria University and Western Health funding grants. The authors have no conflicts of interest to declare.	Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Bricker L, 2002, AM J OBSTET GYNECOL, V186, pS94, DOI 10.1067/mob.2002.121549; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; EISELE JH, 1982, ANESTH ANALG, V61, P179; Fenwick J, 2005, MIDWIFERY, V21, P23, DOI 10.1016/j.midw.2004.07.001; Fernando R, 1997, ANAESTHESIA, V52, P517, DOI 10.1111/j.1365-2044.1997.154-az0160.x; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Fleet J, COMMUNICATION; HANNAH P, 1992, BRIT J PSYCHIAT, V160, P777, DOI 10.1192/bjp.160.6.777; Hauck Y, 2007, MIDWIFERY, V23, P235, DOI 10.1016/j.midw.2006.02.002; IBM Corp, 2013, IBM SPSS STAT WIND V; Johnston S, 2011, EMERG MED J, V28, P57, DOI 10.1136/emj.2009.078717; Joly LM, 1997, ANESTH ANALG, V85, P465; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; Leeman L, 2003, AM FAM PHYSICIAN, V68, P1115; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Liu EHC, 2004, BMJ-BRIT MED J, V328, P1410, DOI 10.1136/bmj.38097.590810.7C; McCrea BH, 1999, J ADV NURS, V29, P877, DOI 10.1046/j.1365-2648.1999.00961.x; McLachlan H, 2005, BIRTH-ISS PERINAT C, V32, P272, DOI 10.1111/j.0730-7659.2005.00370.x; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Poole JH, 2003, JOGNN-J OBST GYN NEO, V32, P780, DOI 10.1177/0884217503258498; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; ROSAEG OP, 1992, CAN J ANAESTH, V39, P277, DOI 10.1007/BF03008789; Saito Miwako, 2005, J Anesth, V19, P208, DOI 10.1007/s00540-005-0316-2; Schwagmeier R, 1996, ANAESTHESIST, V45, P231, DOI 10.1007/s001010050257; Sinha A, 2011, INT J OBSTET ANESTH, V20, P110, DOI 10.1016/j.ijoa.2010.10.005; Smith CA, COCHRANE DATABASE SY; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Tsui MHY, 2004, BJOG-INT J OBSTET GY, V111, P648, DOI 10.1111/j.1471-0528.2004.00160.x; Wijma K, 1997, J ANXIETY DISORD, V11, P587, DOI 10.1016/S0887-6185(97)00041-8; Wong CA, 2009, IN J WOMENS HEALTH, V1, P139; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	37	8	9	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	MAY	2015	24	2					117	123		10.1016/j.ijoa.2014.11.006			7	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	CJ1HJ	WOS:000355234400005	25555797				2020-06-30	J	Iizuka, T; Nishimura, R				Iizuka, Tomoya; Nishimura, Ryohei			Context-sensitive half-time of fentanyl in dogs	JOURNAL OF VETERINARY MEDICAL SCIENCE			English	Article						canine; fentanyl; half-time; infusion; pharmacokinetics	INTRAVENOUS ANESTHESIA; PHARMACOKINETICS; MANAGEMENT; CATS; PAIN	Context-sensitive half-times (CSHTs) of fentanyl in dogs were determined using pharmacokinetic models reported by Murphy et al. and Sano et al., and compared with a human model. The CSHT was defined as the time required for a 50% decrease in drug concentration in the central compartment after the termination of infusion. Although CSHTs increased gradually as the infusion time increased, the CSHTs in dogs were shorter than those in humans. The CSHTs at steady-state were 31.3 and 69.2 min in dogs, and 306.5 min in humans. The CSHTs of fentanyl in dogs are apparently shorter than those in humans; therefore, a continuous infusion of fentanyl may be a rational regimen in dogs, even if duration of infusion is extended.	[Iizuka, Tomoya; Nishimura, Ryohei] Univ Tokyo, Lab Vet Surg, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan	Nishimura, R (reprint author), Univ Tokyo, Lab Vet Surg, Grad Sch Agr & Life Sci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	arn@mail.ecc.u-tokyo.ac.jp					Beers R, 2004, CNS DRUGS, V18, P1085, DOI 10.2165/00023210-200418150-00004; BELL J, 1994, BRIT J ANAESTH, V73, P162, DOI 10.1093/bja/73.2.162; Duke T, 2013, CAN VET J, V54, P276; Dyson DH, 2008, VET CLIN N AM-SMALL, V38, P1309, DOI 10.1016/j.cvsm.2008.06.006; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; MCQUAY HJ, 1979, BRIT J ANAESTH, V51, P543, DOI 10.1093/bja/51.6.543; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; SCHWILDEN H, 1983, ANAESTHESIA, V38, P51, DOI 10.1111/j.1365-2044.1983.tb15178.x; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; STOECKEL H, 1982, BRIT J ANAESTH, V54, P1087, DOI 10.1093/bja/54.10.1087	14	2	2	0	3	JAPAN SOC VET SCI	TOKYO	UNIV TOKYO, 1-1-1 YAYOI, BUNKYO-KU, TOKYO, 103, JAPAN	0916-7250	1347-7439		J VET MED SCI	J. Vet. Med. Sci.	MAY	2015	77	5					615	617		10.1292/jvms.14-0549			3	Veterinary Sciences	Veterinary Sciences	CJ3FM	WOS:000355368800018	25649313	Green Published, Bronze			2020-06-30	J	Bista, SR; Hardy, J; Tapuni, A; Fu, JL; Gibbons, K; Good, P; Norris, R; Haywood, A				Bista, Sudeep Raj; Hardy, Janet; Tapuni, Angela; Fu, Jinlin; Gibbons, Kirsten; Good, Phillip; Norris, Ross; Haywood, Alison			Validation of a Fentanyl Transdermal Adhesion Scoring Tool for Use in Clinical Practice	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Transdermal; TDS adhesion; scoring tool; fentanyl; validation; FDA	QUALITY-OF-LIFE; SYSTEM; PHARMACOKINETICS; PATCHES; EFFICACY	Context. The therapeutic efficacy of a transdermal system (TDS) is directly related to the adhesion of TDS, with partial adhesion resulting in lower plasma concentration. Currently there is no TDS adhesion scoring tool available for use in the clinical setting. Objectives. To validate a U.S. Food and Drug Administration (FDA) scoring system for the adhesion of the fentanyl TDS in cancer patients. Methods. A library of images was created from photographs of fentanyl/placebo TDS placed on patients/volunteers. Thirty photographs, reflecting varying degrees of adhesion, were selected for each of series A and B, with 10 photographs common to both series. Each series was shown to 30 health professionals asked to score the photographs using the FDA scoring system. Validity was assessed using Spearman's rank correlation and reliability by Cohen's kappa (k). Photo editing software was used to assign control scores to each photograph. Results. Validity was high for both series (>= 0.954). Inter-reliability (k) ranged from 0.327 to 0.858 (average, 0.547) and 0.433-0.910 (average, 0.620) in series A and B, respectively. The combined agreement across both series was 0.585. Intra-rater agreement (k) of the 10 common images was 0.605. No significant difference was observed between the scoring patterns for those with more than 10 years of working experience. Conclusion. Overall, the TDS adhesion score determined by the participants visually in this study corresponded well to those generated by photo editing software, thus rendering the scoring system highly valid. The FDA scoring system is an adequate tool for assessing fentanyl TDS adhesion in clinical practice. (C) 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.	[Bista, Sudeep Raj; Haywood, Alison] Griffith Univ, Griffith Hlth Inst, Sch Pharm, Southport, Qld 4222, Australia; [Hardy, Janet; Tapuni, Angela; Good, Phillip; Norris, Ross] Mater Hlth Serv, South Brisbane, Qld, Australia; [Hardy, Janet; Tapuni, Angela; Fu, Jinlin; Gibbons, Kirsten; Good, Phillip; Haywood, Alison] Mater Med Res Inst, South Brisbane, Qld, Australia; [Good, Phillip] St Vincents Private Hosp, Brisbane, Qld, Australia	Bista, SR (reprint author), Griffith Univ, Sch Pharm, Gold Coast Campus, Southport, Qld 4222, Australia.	s.bista@griffith.edu.au	Good, Phillip/B-4004-2008; Gibbons, Kristen/J-3429-2014	Good, Phillip/0000-0002-8198-0375; Haywood, Alison/0000-0002-5354-8868; Gibbons, Kristen/0000-0002-5679-0932	Griffith University, Gold Coast, AustraliaGriffith University; Mater Research, South Brisbane, Australia	This study was partially supported by Griffith University, Gold Coast, Australia and Mater Research, South Brisbane, Australia. The authors declare no conflicts of interest.	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Akpinar B, 2012, J NEUROL SCI-TURK, V29, P554; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Barratt DT, 2014, PHARMACOGENET GENOM, V24, P185, DOI 10.1097/FPC.0000000000000032; Fauth C, 2002, DRUG DEV IND PHARM, V28, P1251, DOI 10.1081/DDC-120015358; Fleiss JL, 2004, STAT METHODS RATES P; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Harrison LI, 2002, J CLIN PHARMACOL, V42, P1134, DOI 10.1177/009127002401382740; Larsen RH, 2003, PHARMACOL TOXICOL, V93, P244, DOI 10.1046/j.1600-0773.2003.pto930508.x; Minghetti P, 1999, DRUG DEV IND PHARM, V25, P1, DOI 10.1081/DDC-100102135; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; Streiner DL, 2008, HLTH MEASUREMENT SCA; U.S. Food and Drug Administration, DRAFT GUID IN PRESS; van der Toorn F, 2013, J PEDIATR UROL, V9, P1006, DOI 10.1016/j.jpurol.2013.01.015; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Wester RC, 1987, TRANSDERMAL DELIVERY; Wokovich AM, 2006, EUR J PHARM BIOPHARM, V64, P1, DOI 10.1016/j.ejpb.2006.03.009	20	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAY	2015	49	5					934	938		10.1016/j.jpainsymman.2014.09.017			5	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	CI5VI	WOS:000354827500022	25523888	Bronze, Green Published			2020-06-30	J	Murphy, GS; Szokol, JW; Avram, MJ; Greenberg, SB; Marymont, JH; Shear, T; Parikh, KN; Patel, SS; Gupta, DK				Murphy, Glenn S.; Szokol, Joseph W.; Avram, Michael J.; Greenberg, Steven B.; Marymont, Jesse H.; Shear, Torin; Parikh, Kruti N.; Patel, Shivani S.; Gupta, Dhanesh K.			Intraoperative Methadone for the Prevention of Postoperative Pain A Randomized, Double-blinded Clinical Trial in Cardiac Surgical Patients	ANESTHESIOLOGY			English	Article							CARE-UNIT; CARDIOPULMONARY BYPASS; MEDIAN STERNOTOMY; SURGERY; MORPHINE; ANALGESIA; RECOVERY; INTENSITY; RECEPTOR; PHARMACOKINETICS	Background: The intensity of pain after cardiac surgery is often underestimated, and inadequate pain control may be associated with poorer quality of recovery. The aim of this investigation was to examine the effect of intraoperative methadone on postoperative analgesic requirements, pain scores, patient satisfaction, and clinical recovery. Methods: Patients undergoing cardiac surgery with cardiopulmonary bypass (n = 156) were randomized to receive methadone (0.3 mg/kg) or fentanyl (12 mu g/kg) intraoperatively. Postoperative analgesic requirements were recorded. Patients were assessed for pain at rest and with coughing 15 min and 2, 4, 8, 12, 24, 48, and 72 h after tracheal extubation. Patients were also evaluated for level of sedation, nausea, vomiting, itching, hypoventilation, and hypoxia at these times. Results: Postoperative morphine requirements during the first 24 h were reduced from a median of 10 mg in the fentanyl group to 6 mg in the methadone group (median difference [99% CI], -4 [-8 to -2] mg; P < 0.001). Reductions in pain scores with coughing were observed during the first 24 h after extubation; the level of pain with coughing at 12 h was reduced from a median of 6 in the fentanyl group to 4 in the methadone group (-2 [-3 to -1]; P < 0.001). Improvements in patient-perceived quality of pain management were described in the methadone group. The incidence of opioid-related adverse events was not increased in patients administered methadone. Conclusions: Intraoperative methadone administration resulted in reduced postoperative morphine requirements, improved pain scores, and enhanced patient-perceived quality of pain management.	[Murphy, Glenn S.; Szokol, Joseph W.; Greenberg, Steven B.; Marymont, Jesse H.; Shear, Torin; Parikh, Kruti N.; Patel, Shivani S.] Univ Chicago, Pritzker Sch Med, NorthShore Univ HealthSyst, Dept Anesthesiol, Chicago, IL 60637 USA; [Avram, Michael J.; Gupta, Dhanesh K.] Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA	Murphy, GS (reprint author), NorthShore Univ HealthSyst, Dept Anesthesiol, 2650 Ridge Ave, Evanston, IL 60201 USA.	dgmurphy2@yahoo.com	Avram, Michael/M-7681-2019				Agarwal S, 2013, REGION ANESTH PAIN M, V38, P145, DOI 10.1097/AAP.0b013e318281a348; Benedict PE, 1999, CIRCULATION, V100, P357; BERDE CB, 1991, J PEDIATR-US, V119, P136, DOI 10.1016/S0022-3476(05)81054-6; Bowdle TA, 2004, ANESTH ANALG, V98, P1692, DOI 10.1213/01.ANE.0000114085.20751.20; Chaudhary V, 2012, J CARDIOTHOR VASC AN, V26, P439, DOI 10.1053/j.jvca.2011.10.012; CHUI PT, 1992, ANAESTH INTENS CARE, V20, P46, DOI 10.1177/0310057X9202000109; De Hert SG, 2004, ANESTHESIOLOGY, V101, P9, DOI 10.1097/00000542-200407000-00005; Gelinas Celine, 2007, Intensive Crit Care Nurs, V23, P298, DOI 10.1016/j.iccn.2007.03.002; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Gorman AL, 1997, NEUROSCI LETT, V223, P5; Gottschalk A, 2011, ANESTH ANALG, V112, P218, DOI 10.1213/ANE.0b013e3181d8a095; GOURLAY GK, 1984, ANESTHESIOLOGY, V61, P19, DOI 10.1097/00000542-198461010-00005; GOURLAY GK, 1986, ANESTHESIOLOGY, V64, P322; GOURLAY GK, 1982, ANESTHESIOLOGY, V57, P458, DOI 10.1097/00000542-198212000-00005; Gross ER, 2009, ANESTH ANALG, V109, P1395, DOI 10.1213/ANE.0b013e3181b92201; Hansdottir V, 2006, ANESTHESIOLOGY, V104, P142, DOI 10.1097/00000542-200601000-00020; Inturrisi C E, 2005, Minerva Anestesiol, V71, P435; Kharasch ED, 2011, ANESTH ANALG, V112, P13, DOI 10.1213/ANE.0b013e3181fec9a3; Lahtinen P, 2006, ANESTHESIOLOGY, V105, P794, DOI 10.1097/00000542-200610000-00026; Lay T D, 1996, Prog Cardiovasc Nurs, V11, P17; Liu SS, 2004, ANESTHESIOLOGY, V101, P153, DOI 10.1097/00000542-200407000-00024; Mancini I, 2000, CURR OPIN ONCOL, V12, P308, DOI 10.1097/00001622-200007000-00006; Marmor M, 2004, AM J CARDIOL, V93, P1295, DOI 10.1016/j.amjcard.2004.01.072; Maxam-Moore V A, 1994, Am J Crit Care, V3, P31; McDonald SB, 2005, ANESTH ANALG, V100, P25, DOI 10.1213/01.ANE.0000139652.84897.BD; Meehan D A, 1995, Am J Crit Care, V4, P435; Mercadante S, 2007, J PALLIAT MED, V10, P338, DOI 10.1089/jpm.2006.0140; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V37, P632, DOI 10.1016/j.jpainsymman.2007.12.024; Meyerson J, 2001, ACTA ANAESTH SCAND, V45, P940, DOI 10.1034/j.1399-6576.2001.450804.x; Milgrom LB, 2004, AM J CRIT CARE, V13, P116, DOI 10.4037/ajcc2004.13.2.116; Mueller XM, 2000, CHEST, V118, P391, DOI 10.1378/chest.118.2.391; Murphy GS, 2006, J CARDIOTHOR VASC AN, V20, P493, DOI 10.1053/j.jvca.2005.07.036; Murphy GS, 2009, ANESTH ANALG, V109, P311, DOI 10.1213/ane.0b013e3181a90adc; Murphy GS, 2002, ANESTHESIOLOGY, V96, P600, DOI 10.1097/00000542-200203000-00015; PUNTILLO K, 1994, NURS RES, V43, P31; Richlin D M, 1991, J Clin Anesth, V3, P112, DOI 10.1016/0952-8180(91)90007-A; Roediger L, 2006, EUR J ANAESTH, V23, P539, DOI 10.1017/S0265021506000548; Royse C, 2011, ANESTHESIOLOGY, V114, P232, DOI 10.1097/ALN.0b013e318201d184; Salpeter SR, 2013, J PALLIAT MED, V16, P616, DOI 10.1089/jpm.2012.0612; Sharma A, 2011, ANESTHESIOLOGY, V115, P1153, DOI 10.1097/ALN.0b013e318238fec5; White PF, 2003, ANESTHESIOLOGY, V99, P918, DOI 10.1097/00000542-200310000-00026; Yorke J, 2004, HEART LUNG, V33, P33, DOI 10.1016/j.hrtlng.2003.09.002	42	31	31	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2015	122	5					1112	1122		10.1097/ALN.0000000000000633			11	Anesthesiology	Anesthesiology	CH5PT	WOS:000354088500020	25837528				2020-06-30	J	Wu, SB; Cai, LN; Yang, XH; Fu, HG; Sun, K; Yuan, F; Dong, TL				Wu, Shu-Biao; Cai, Li-Na; Yang, Xian-Hui; Fu, Hong-Guang; Sun, Kai; Yuan, Feng; Dong, Tie-Li			Impact of CYP2D6 Polymorphisms on Postoperative Fentanyl Analgesia in Gastric Cancer Patients	GENETIC TESTING AND MOLECULAR BIOMARKERS			English	Article							HUMAN CYTOCHROME-P450 2D6; GENETIC POLYMORPHISMS; OPRM1 A118G; PAIN; CLASSIFICATION; REQUIREMENTS; METABOLISM; EFFICACY; OPIOIDS; NAUSEA	Background: This study investigated the influence of human cytochrome P450 2D6 (CYP2D6) gene polymorphism in gastric cancer (GC) patients to understand the pharmacogenomic basis for patient response to postoperative fentanyl analgesia. Methods: The prospective study design contained 212 patients recovering from radical gastrectomy. Peripheral blood samples were collected after general anesthesia, and CYP2D6 genotypes were analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. After providing adequate instructions to operate the analgesia pump, patients self-administered fentanyl via patient controlled intravenous analgesia. The cumulative amount of fentanyl self-administered and the associated adverse effects were recorded at 6, 12, 24, and 48 h postoperatively. Results: Five patients, out of the 212 patients recruited to this study, failed to complete the study. The remaining 207 patients were classified into three groups based on their genotypes: W/W group (n=44), M/W group (n=112), and M/M group (n=51). Our results demonstrated that the cumulative amount of fentanyl consumption significantly increased in the M/M group at 6, 12, and 24 h postoperatively, compared with the W/W group (p<0.05). In addition, visual analogue scale (VAS) score in the M/M group was significantly higher than the W/W group in the analepsia period after general anesthesia and at 6 h postoperatively (p<0.05). No significant adverse effects were observed in all the groups (p>0.05). Conclusion: CYP2D6 polymorphism influenced patient response to postoperative fentanyl analgesia in GC patients.	[Wu, Shu-Biao; Yang, Xian-Hui; Fu, Hong-Guang; Sun, Kai; Yuan, Feng; Dong, Tie-Li] Zhengzhou Univ, Affiliated Hosp 2, Dept Anesthesiol, Zhengzhou 450014, Peoples R China; [Cai, Li-Na] Zhengzhou Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Zhengzhou 450014, Peoples R China	Dong, TL (reprint author), Zhengzhou Univ, Affiliated Hosp 2, Dept Anesthesiol, Jingba Rd, Zhengzhou 450014, Peoples R China.	dongtieli_930@126.com	Wu, Shubiao/AAA-5324-2020				Aasvang EK, 2010, PAIN, V150, P237, DOI 10.1016/j.pain.2010.03.025; Ajani JA, 2010, J NATL COMPR CANC NE, V8, P378, DOI 10.6004/jnccn.2010.0030; Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; Bennett MI, 2011, PALLIATIVE MED, V25, P553, DOI 10.1177/0269216310378546; Colson J, 2011, PAIN PHYSICIAN, V14, pE86; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Geier M, 2013, FEBS J, V280, P3094, DOI 10.1111/febs.12270; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Ide S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070694; Ingelman-Sundberg M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/sj.tpj.6500285; Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004; Khafagy HF, 2010, J ANESTH, V24, P531, DOI 10.1007/s00540-010-0949-7; Kim KM, 2013, INT J CLIN PHARM TH, V51, P383, DOI 10.5414/CP201824; Kumar SP, 2011, INDIAN J PALLIAT CAR, V17, P116, DOI 10.4103/0973-1075.84532; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Leppert W, 2011, PHARMACOLOGY, V87, P274, DOI 10.1159/000326085; Liao Q, 2013, MOL MED REP, V7, P901, DOI 10.3892/mmr.2013.1270; Liu JP, 2011, FORSCH KOMPLEMENTMED, V18, P257, DOI 10.1159/000333065; Nischal PM, 2014, NATL MED J INDIA, V27, P56; Samer CF, 2010, BRIT J PHARMACOL, V160, P919, DOI 10.1111/j.1476-5381.2010.00709.x; Scheer N, 2012, MOL PHARMACOL, V81, P63, DOI 10.1124/mol.111.075192; Songun I, 2010, LANCET ONCOL, V11, P439, DOI 10.1016/S1470-2045(10)70070-X; Teh LK, 2012, DRUG METAB PHARMACOK, V27, P55, DOI 10.2133/dmpk.DMPK-11-RV-121; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Wang B, 2009, DRUG METAB REV, V41, P573, DOI 10.1080/03602530903118729; Wolters U, 1996, BRIT J ANAESTH, V77, P217, DOI 10.1093/bja/77.2.217; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Yuan RM, 2011, CLIN CHIM ACTA, V412, P755, DOI 10.1016/j.cca.2010.12.038; Zhang W, 2011, MINERVA ANESTESIOL, V77, P33; Zhou SF, 2009, CLIN PHARMACOKINET, V48, P761, DOI 10.2165/11318070-000000000-00000	30	4	4	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1945-0265	1945-0257		GENET TEST MOL BIOMA	Genet. Test. Mol. Biomark.	MAY 1	2015	19	5					248	252		10.1089/gtmb.2014.0318			5	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	CH9QQ	WOS:000354371400006	25825958				2020-06-30	J	Naito, T; Kawakami, J				Naito, Takafumi; Kawakami, Junichi			Interindividual Variation of Pharmacokinetic Disposition of and Clinical Responses to Opioid Analgesics in Cancer Pain Patients	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						cancer pain; individualized therapy; opioid; analgesics; pharmacokinetics	GENETIC POLYMORPHISMS; DRUG-INTERACTIONS; OXYCODONE; FENTANYL; CYP2D6; MORPHINE; ABCB1; REQUIREMENTS; METABOLISM; EFFICACY	Use of prescription opioids for cancer pain according to the World Health Organization analgesic ladder has been accepted in Japan. Although oxycodone and fentanyl are commonly used as first-line analgesics, a few clinical reports have been published on interindividual variations in their pharmacokinetics and clinical responses in cancer patients. (1) Some factors relating to CYP2D6, CYP3A, ATP-binding cassette sub-family B member 1 (ABCB1), and opioid receptor mu 1 (OPRM1) involve oxycodone pharmacokinetics and sensitivity in humans. The relations between their genetic variations and clinical responses to oxycodone are being revealed in limited groups. In our study, the impact of genetic variants and pharmacokinetics on clinical responses to oxycodone were evaluated in Japanese populations. (2) Opioid switching improves the opioid tolerance related to the balance between analgesia and adverse effects. Some patients have difficulty in obtaining better opioid tolerance in recommended conversion ratios. The activities of CYP3A, ABCB1, and OPRM1 contribute to the interindividual variations in clinical responses to fentanyl in cancer patients. However, the variations in opioid switching remain to be clarified in clinical settings. In our study, genetic factors related to interindividual variations in clinical responses in opioid switching to fentanyl were revealed in Japanese populations. In this symposium review, the possibility of approaches to personalized palliative care using opioids based on genetic variants of CYP2D6, CYP3A5, ABCB1, and OPRM1 is discussed.	[Naito, Takafumi; Kawakami, Junichi] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Naito, T (reprint author), Hamamatsu Univ Sch Med, Dept Hosp Pharm, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	naitou@hama-med.ac.jp					Andreassen TN, 2012, EUR J CLIN PHARMACOL, V68, P55, DOI 10.1007/s00228-011-1093-5; Hassan HE, 2007, J PHARM SCI-US, V96, P2494, DOI 10.1002/jps.20893; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Holtman JR, 2006, PHARMACOL BIOCHEM BE, V83, P100, DOI 10.1016/j.pbb.2005.12.013; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lalovic B, 2004, DRUG METAB DISPOS, V32, P447, DOI 10.1124/dmd.32.4.447; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Mercadante S, 1999, J PAIN SYMPTOM MANAG, V18, P347, DOI 10.1016/S0885-3924(99)00099-8; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Morita T, 2005, J PAIN SYMPTOM MANAG, V30, P96, DOI 10.1016/j.jpainsymman.2004.12.010; Naito T, 2011, J CLIN PHARMACOL, V51, P1529, DOI 10.1177/0091270010388033; Oertel BG, 2008, CLIN PHARMACOL THER, V83, P577, DOI 10.1038/sj.clpt.6100441; Otsuka Kuniko, 2007, J Pain Palliat Care Pharmacother, V21, P37, DOI 10.1300/J354v21n03_06; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Samer CF, 2010, BRIT J PHARMACOL, V160, P919, DOI 10.1111/j.1476-5381.2010.00709.x; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Takeda F., 2001, JPN J CLIN MED, V59, P1663; Yamaguchi T, 2013, JPN J CLIN ONCOL, V43, P896, DOI 10.1093/jjco/hyt099; Zhang W, 2011, EUR J ANAESTH, V28, P245, DOI 10.1097/EJA.0b013e3283438b39; Zwisler ST, 2010, ACTA ANAESTH SCAND, V54, P232, DOI 10.1111/j.1399-6576.2009.02104.x; Zwisler ST, 2010, FUND CLIN PHARMACOL, V24, P517, DOI 10.1111/j.1472-8206.2009.00781.x	22	1	1	0	5	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					709	715		10.1248/yakushi.14-00234-4			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600011	25948306	Bronze			2020-06-30	J	Visoiu, M; Cassara, A; Yang, CI				Visoiu, Mihaela; Cassara, Antonio; Yang, Charles Inshik			Bilateral Paravertebral Blockade (T7-10) Versus Incisional Local Anesthetic Administration for Pediatric Laparoscopic Cholecystectomy: A Prospective, Randomized Clinical Study	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	34th Annual Meeting of the Society-for-Obstetric-Anesthesia-and-Perinatology	MAY 05-09, 2014	Toronto, CANADA	Soc Obstet Anesthesia & Perinatol			ABDOMINIS PLANE BLOCK; PAIN; INFILTRATION; ANALGESIA; SURGERY	BACKGROUND: Single-injection paravertebral nerve blocks (PVBs) provide effective postoperative analgesia after adult laparoscopic cholecystectomy (LC). We sought to compare PVBs with local anesthetic injections at laparoscopic port sites in a pediatric population. METHODS: Eighty-three patients (8-17 years old) scheduled for LC were randomized prospectively to 2 treatment groups: the PVB group received ropivacaine 0.5% injected in the paravertebral space and normal saline injections at laparoscopic instrument sites, and the port infiltration group received normal saline in the paravertebral space and ropivacaine 0.5% at instrument sites. Postoperative analgesia was provided with hydromorphone via patient-controlled analgesia for up to 12 hours, followed by oxycodone and hydromorphone. The total amount of analgesic, serial visual analog scale scores for pain and subject pain control satisfaction, type and characteristics of pain, and complications were recorded for 24 hours. RESULTS: The intraoperative fentanyl requirement (ng/kg/min) was lower in the PVB group than in the port infiltration group (12.81 vs 16.57, P = 0.007). Total postoperative analgesic consumption and mean visual analog scale scores were not different between the groups. Baseline pain recorded before surgery correlated with self-reported postoperative pain scores only in the port infiltration group. The rate of complications was low and similar between groups. There was no difference in incidence of patient-reported incisional, visceral, or gas pain. Shoulder pain, however, was 49% less (95% confidence interval, 0.269-0.893) in the port infiltration group. CONCLUSIONS: PVBs did not reduce postoperative pain associated with pediatric LC but decreased intraoperative fentanyl requirements.	[Visoiu, Mihaela; Cassara, Antonio] Univ Pittsburgh, Childrens Hosp Pittsburgh, Acute Intervent Perioperat Pediat Pain Serv, Dept Anesthesiol,Med Ctr, Pittsburgh, PA 15213 USA; [Yang, Charles Inshik] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Anesthesiol,Pediat Chron Pain Management, Pittsburgh, PA 15213 USA	Visoiu, M (reprint author), Childrens Hosp Pittsburgh, Dept Anesthesiol, Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.	visoium@upmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1TR000005]	The project described was supported by the National Institutes of Health through grant number UL1TR000005.	Agarwal A, 2012, SAUDI J ANAESTH, V6, P344, DOI 10.4103/1658-354X.105860; Berberoglu M, 1998, J LAPAROENDOSC ADV A, V8, P273, DOI 10.1089/lap.1998.8.273; Bisgaard T, 1999, ANESTH ANALG, V89, P1017, DOI 10.1097/00000539-199910000-00036; Bisgaard T, 2001, EUR J SURG, V167, P84; Chen CK, 2013, KOREAN J ANESTHESIOL, V64, P511, DOI 10.4097/kjae.2013.64.6.511; El-Dawlatly AA, 2009, BRIT J ANAESTH, V102, P763, DOI 10.1093/bja/aep067; Fredrickson MJ, 2010, REGION ANESTH PAIN M, V35, P28, DOI 10.1097/AAP.0b013e3181c771bd; Goebel S, 2013, CLIN J PAIN, V29, P392, DOI 10.1097/AJP.0b013e318262e2c8; Groenewald CB, 2012, PEDIATR ANESTH, V22, P661, DOI 10.1111/j.1460-9592.2012.03807.x; Luchetti M, 1996, REGION ANESTH, V21, P465; Marhofer D, 2013, ANESTHESIOLOGY, V118, P1106, DOI 10.1097/ALN.0b013e318289465f; Matsui K, 1994, Masui, V43, P1718; Motamed C, 2000, ANAESTHESIA, V55, P118, DOI 10.1046/j.1365-2044.2000.055002118.x; Naja AZ, 2004, EUR J ANAESTH, V21, P489; Ortiz J, 2012, REGION ANESTH PAIN M, V37, P188, DOI 10.1097/AAP.0b013e318244851b; Petersen PL, 2012, ANESTH ANALG, V115, P527, DOI 10.1213/ANE.0b013e318261f16e; Ra YS, 2010, KOREAN J ANESTHESIOL, V58, P362, DOI 10.4097/kjae.2010.58.4.362; Sullivan MJL, 2006, PAIN, V122, P282, DOI 10.1016/j.pain.2006.02.001; Tsao JCI, 2004, J PEDIATR PSYCHOL, V29, P379, DOI 10.1093/jpepsy/jsh041; Van Damme S, 2004, PAIN, V107, P70, DOI 10.1016/j.pain.2003.09.023; Wills VL, 2000, BRIT J SURG, V87, P273, DOI 10.1046/j.1365-2168.2000.01374.x	21	12	13	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2015	120	5					1106	1113		10.1213/ANE.0000000000000545			8	Anesthesiology	Anesthesiology	CG5OU	WOS:000353342800029	25427288				2020-06-30	J	Bokoch, MP; Behrends, M; Neice, A; Larson, MD				Bokoch, Michael P.; Behrends, Matthias; Neice, Andrew; Larson, Merlin D.			Fentanyl, an agonist at the mu opioid receptor, depresses pupillary unrest	AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL			English	Article						Pupil; Oscillations; Opioids; Midbrain	NOXIOUS-STIMULATION; PERIAQUEDUCTAL GRAY; IN-VITRO; NEURONS; RAT; PUPILLOMETRY; OSCILLATIONS; ANESTHESIA; TRANSMISSION; ACTIVATION	Pupillary unrest is a chaotic fluctuation in pupil size that is observed in darkness with the onset of drowsiness, and in ambient light. The mechanism of pupillary unrest in darkness as well as in ambient light is unknown but studies suggest that it is caused by fluctuating activity in the Edinger-Westphal (E.W.) nucleus. Neurons in the periaqueductal gray with oscillating firing patterns that are inhibitory to the E.W. nucleus have been described in the cat. We theorized that such oscillating neurons produce pupillary unrest in light and would be depressed by agents, such as opioids, known to depress inhibitory pathways in the midbrain. An infrared pupillometer was used to measure the effect of light on pupillary unrest in eight volunteer subjects, and on 20 patients scheduled for knee arthroscopy who received fentanyl as premedication. Pupillary unrest was quantified through spectral analysis of fast Fourier transforms. Sixteen-second measurements of pupil size at 33 Hz were filtered to eliminate blink artifacts and baseline drift Pupillary unrest was augmented by excitation of the E.W. nucleus by light and was depressed by 40 +/- 20% after the administration of the moderate dose of 1 mcg/kg of fentanyl. Recovery from the drug effect was observed. Based upon the data from this study we propose that pupillary unrest in light originates within oscillating inhibitory neurons that intermittently depress the E. W. nucleus. (C) 2015 Elsevier B.V. All rights reserved.	[Bokoch, Michael P.; Behrends, Matthias; Larson, Merlin D.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; [Neice, Andrew] Oregon Hlth & Sci Univ, Dept Anesthesia & Perioperat Med, Portland, OR 97239 USA	Larson, MD (reprint author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA.	larsonm@anesthesia.ucsf.edu	Bokoch, Michael P./J-2637-2019	Bokoch, Michael P./0000-0003-1387-9547	Department of Anesthesiology and Perioperative Care, University of California, San FranciscoUniversity of California System	Financial support was obtained from the Department of Anesthesiology and Perioperative Care, University of California, San Francisco. The authors would like to acknowledge the assistance and advice of Benjamin Ma, M.D., and Chief of the UCSF Sports Medicine Service for his co-operation in allowing this research to be conducted at the UCSF ORTHOPEDIC INSTITUTE in San Francisco. We also thank Neuroptics, Inc (Irvine, California) for loan of the pupillometer that was used in this study.	Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; Buzsaki G., 2006, RHYTHMS BRAIN; Buzsaki G, 2012, ANNU REV NEUROSCI, V35, P203, DOI 10.1146/annurev-neuro-062111-150444; CHIENG B, 1994, BRIT J PHARMACOL, V113, P303, DOI 10.1111/j.1476-5381.1994.tb16209.x; CHRISTIE MJ, 1991, PROG BRAIN RES, V88, P197; Christie MJ, 2000, CLIN EXP PHARMACOL P, V27, P520, DOI 10.1046/j.1440-1681.2000.03291.x; Du R, 2005, NEUROSURGERY, V57, P198, DOI 10.1227/01.NEU.0000163425.79170.CB; DUGGAN AW, 1983, PHARMACOL REV, V35, P219; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Finnegan TF, 2006, J NEUROPHYSIOL, V95, P2032, DOI 10.1152/jn.01004.2005; Fukuda F, 2010, ANESTHESIA; GRUNBERGER J, 1990, EUR ARCH PSY CLIN N, V240, P109, DOI 10.1007/BF02189980; Grunberger J, 2000, WIEN KLIN WOCHENSCHR, V112, P75; HEINRICHER MM, 1987, J NEUROSCI, V7, P271; HEY JA, 1985, N-S ARCH PHARMACOL, V328, P258, DOI 10.1007/BF00515551; Hunter JD, 2000, VISION RES, V40, P567, DOI 10.1016/S0042-6989(99)00200-X; Ichinohe N, 2001, AUTON NEUROSCI-BASIC, V94, P42, DOI 10.1016/S1566-0702(01)00342-3; Kerchner GA, 2002, J NEUROPHYSIOL, V88, P520, DOI 10.1152/jn.2002.88.1.520; Klingner J, 2011, PSYCHOPHYSIOLOGY, V48, P323, DOI 10.1111/j.1469-8986.2010.01069.x; Larson MD, 1997, ANESTHESIOLOGY, V87, P849, DOI 10.1097/00000542-199710000-00019; Larson MD, 1996, ANESTHESIOLOGY, V85, P748, DOI 10.1097/00000542-199610000-00009; Larson MD, 2001, BRIT J CLIN PHARMACO, V51, P27, DOI 10.1046/j.1365-2125.2001.01311.x; LARSON MD, 1993, ANESTH ANALG, V76, P1072; Larson MD, 2008, CLIN NEUROPHYSIOL, V119, P1358, DOI 10.1016/j.clinph.2008.01.106; Loewenfeld I.E., 1999, PUPIL ANATOMY PHYSL; LOWENSTEIN O, 1964, ANN NY ACAD SCI, V117, P142, DOI 10.1111/j.1749-6632.1964.tb48169.x; Ludtke H, 1998, VISION RES, V38, P2889, DOI 10.1016/S0042-6989(98)00081-9; LYNCH TJ, 1990, J OCUL PHARMACOL, V6, P165, DOI 10.1089/jop.1990.6.165; MCLAREN JW, 1992, INVEST OPHTH VIS SCI, V33, P671; MERRITT SL, 1994, NURS RES, V43, P56; Pedersen NP, 2011, J NEUROPHYSIOL, V106, P731, DOI 10.1152/jn.01062.2010; SMITH JD, 1968, SCIENCE, V162, P1302, DOI 10.1126/science.162.3859.1302; STARK L, 1958, SCIENCE, V127, P588, DOI 10.1126/science.127.3298.588; STARK L, 1969, AUTOMATICA, V5, P655, DOI 10.1016/0005-1098(69)90032-6; STARK LAWRENCE, 1963, BOL INST ESTUD MED BIOL MEX, V21, P201; Szabadi E, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00094; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205; TRAVAGLI RA, 1995, J NEUROPHYSIOL, V74, P519, DOI 10.1152/jn.1995.74.2.519; Vaughan CW, 1997, J PHYSIOL-LONDON, V498, P463, DOI 10.1113/jphysiol.1997.sp021872; Vaughan CW, 1997, NATURE, V390, P611, DOI 10.1038/37610; Wang CA, 2012, J NEUROSCI, V32, P3629, DOI 10.1523/JNEUROSCI.5512-11.2012; Warga M, 2009, VISION RES, V49, P295, DOI 10.1016/j.visres.2008.09.019; Yu YX, 2005, AUTON NEUROSCI-BASIC, V117, P17, DOI 10.1016/j.autneu.2004.10.001	44	12	14	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1566-0702	1872-7484		AUTON NEUROSCI-BASIC	Auton. Neurosci-Basic Clin.	MAY	2015	189						68	74		10.1016/j.autneu.2015.01.004			7	Neurosciences	Neurosciences & Neurology	CG6QP	WOS:000353427400011	25737234				2020-06-30	J	Belmont, AP; Nossair, F; Brambilla, D; Friedman, M; Boswinkel, J; Bradford, AB; Kwiatkowski, JL				Belmont, Ami P.; Nossair, Fadi; Brambilla, Donald; Friedman, Marjorie; Boswinkel, Jan; Bradford, Andrea B.; Kwiatkowski, Janet L.			Safety of Deep Sedation in Young Children with Sickle Cell Disease: A Retrospective Cohort Study	JOURNAL OF PEDIATRICS			English	Article							RESEARCH CONSORTIUM; PEDIATRIC SEDATION/ANESTHESIA; ADVERSE EVENTS; OPERATING-ROOM; RISK-FACTORS; TRANSFUSION; ANESTHESIA; MANAGEMENT; PROPOFOL; RATES	Objective To assess the rates and types of complications associated with deep sedation in children with sickle cell disease (SCD) and to explore potential risk factors. Study design This was a retrospective cohort study of children with SCD and a comparison group of children without SCD who underwent magnetic resonance imaging with deep sedation. The rates of general and SCD-associated sedation complications were calculated, and potential associated clinical and laboratory variables were assessed. Results A total of 162 sedation records in 94 subjects with SCD and 324 sedation records in 321 subjects without SCD were assessed (mean age, 4.3 years in both groups). Pentobarbital, fentanyl, and midazolam were used in the majority of sedation episodes without routine presedation transfusion. Sedation-related complication rates did not differ significantly between the SCD and comparison groups. Within 1 month after the sedation procedure, 17 children (10%) experienced a vaso-occlusive pain episode (VOE), and 2 children (1.2%) developed acute chest syndrome. Preprocedure and postprocedure rates of these complications did not differ significantly. Subjects who developed VOE after sedation had a significantly higher VOE rate before sedation, but no other significant clinical or laboratory risk factors were identified. Conclusion Deep sedation in young children with SCD using a standard protocol is safe, with a sedation-related complication rate comparable to that of the general pediatric population. The observed rate of VOE, although not significantly higher than expected, warrants further investigation.	[Belmont, Ami P.; Nossair, Fadi; Friedman, Marjorie; Kwiatkowski, Janet L.] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; [Brambilla, Donald] RTI Int, Rockville, MD USA; [Boswinkel, Jan; Bradford, Andrea B.; Kwiatkowski, Janet L.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Kwiatkowski, JL (reprint author), Childrens Hosp Philadelphia, 3501 Civ Ctr Blvd,Colket Bldg,Room 11024, Philadelphia, PA 19104 USA.	kwiatkowski@email.chop.edu		Brambilla, Donald/0000-0002-7276-4689			Baxter AL, 2007, PEDIATR EMERG CARE, V23, P690, DOI 10.1097/PEC.0b013e3181558d5c; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Cravero JP, 2009, CURR OPIN ANESTHESIO, V22, P509, DOI 10.1097/ACO.0b013e32832dba6e; Cravero JP, 2009, ANESTH ANALG, V108, P795, DOI 10.1213/ane.0b013e31818fc334; Firth PG, 2004, ANESTHESIOLOGY, V101, P766, DOI 10.1097/00000542-200409000-00027; Fu T, 2005, PEDIATR BLOOD CANCER, V45, P43, DOI 10.1002/pbc.20283; Howard J, 2013, LANCET, V381, P930, DOI 10.1016/S0140-6736(12)61726-7; KOSHY M, 1995, BLOOD, V86, P3676, DOI 10.1182/blood.V86.10.3676.bloodjournal86103676; Kwiatkowski JL, 2009, BRIT J HAEMATOL, V146, P300, DOI 10.1111/j.1365-2141.2009.07753.x; Mallory MD, 2009, PEDIATR ANESTH, V19, P601, DOI 10.1111/j.1460-9592.2009.03023.x; Mason KP, 2012, BRIT J ANAESTH, V108, P13, DOI 10.1093/bja/aer407; Ohene-Frempong K, 1998, BLOOD, V91, P288; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; VICHINSKY EP, 1995, NEW ENGL J MED, V333, P206, DOI 10.1056/NEJM199507273330402	14	1	1	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	MAY	2015	166	5					1226	1232		10.1016/j.jpeds.2015.01.054			7	Pediatrics	Pediatrics	CG6DW	WOS:000353387100027	25919732				2020-06-30	J	Pinna, MAC; Bruera, E; Moralo, MJR; Correas, MAS; Vargas, RM				Cuervo Pinna, Miguel Angel; Bruera, Eduardo; Redondo Moralo, Maria Jose; Sanchez Correas, Miguel Angel; Mota Vargas, Rafael			A Randomized Crossover Clinical Trial to Evaluate the Efficacy of Oral Transmucosal Fentanyl Citrate in the Treatment of Dyspnea on Exertion in Patients With Advanced Cancer	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						dyspnea; exertion; oral transmucosal fentanyl citrate; advanced cancer	NEBULIZED FENTANYL; MANAGEMENT; HYDROMORPHONE; INTENSITY	Background: Morphine is the only opioid which has been clearly demonstrated as effective in the treatment of dyspnea. The role of other opioids has not been sufficiently substantiated. Objective: To evaluate the efficacy of oral transmucosal fentanyl citrate (OTFC) in the treatment of dyspnea on exertion in patients with advanced cancer. Design: This is a randomized, double-blind crossover clinical trial to evaluate the efficacy of OTFC in dyspnea on exertion after the completion of a 6-minute walk test (6MWT). All patients were attended in 2011 by the Palliative Care Supportive Team from Badajoz. In visit 1, patients were randomly assigned to 1 of the 2 treatment groups. In visit 2, the patients who had been receiving the investigational product were given placebos and vice versa. Results: Thirteen patients were recruited (26 6MWT), with a mean age of 65 years. Of the patients, 11 (76%)were males and lung cancer was the most frequently represented etiology. The patients were classified into 3e categories: better response in the first period, the same response in both the periods, and better response in the second period. No differences between the treatments were demonstrated (P: 1). There were no differences in changes in oxygen saturation (P: .7541) nor in the distance walked in the different sequences (P: .6550). No significant differences were found in relation to the Edmonton Symptom Assessment System, either before or after the 6MWT (P: .1234). No secondary effects associated with the medication were observed. Conclusion: It could not be demonstrated that the OTFC improved exertion dyspnea in patients with advanced cancer. A placebo effect was observed in all the patients.	[Cuervo Pinna, Miguel Angel; Redondo Moralo, Maria Jose; Sanchez Correas, Miguel Angel; Mota Vargas, Rafael] Reg Programme Palliat Care Extremadura, Palliat Care Team Badajoz, Ave Damian Tellez Lafuente 30-1 B, Badajoz 06010, Spain; [Bruera, Eduardo] FT McGraw Chair Treatment Canc Houston, Dept Palliat Care & Rehabil Med, Houston, TX USA	Pinna, MAC (reprint author), Reg Programme Palliat Care Extremadura, Palliat Care Team Badajoz, Ave Damian Tellez Lafuente 30-1 B, Badajoz 06010, Spain.	miguelangel.cuervop@gmail.com					Ben-Aharon I, 2008, J CLIN ONCOL, V26, P2396, DOI 10.1200/JCO.2007.15.5796; Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; Bruera E, 2005, J PAIN SYMPTOM MANAG, V29, P613, DOI 10.1016/j.jpainsymman.2004.08.016; Bruera E, 2000, J PAIN SYMPTOM MANAG, V19, P357, DOI 10.1016/S0885-3924(00)00126-3; Charles MA, 2008, J PAIN SYMPTOM MANAG, V36, P29, DOI 10.1016/j.jpainsymman.2007.08.016; Clemens KE, 2008, SUPPORT CARE CANCER, V16, P93, DOI 10.1007/s00520-007-0310-3; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Pinna MAC, 2009, AM J HOSP PALLIAT ME, V26, P89, DOI 10.1177/1049909108327588; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007; Johnson MJ, 2013, J PAIN SYMPTOM MANAG, V46, P957, DOI 10.1016/j.jpainsymman.2013.01.011; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Senn SJ, 2002, CROSS OVER TRIALS CL; Simon ST, 2013, J PAIN SYMPTOM MANAG, V45, P561, DOI 10.1016/j.jpainsymman.2012.02.022; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Smith TJ, 2009, J PALLIAT MED, V12, P771, DOI 10.1089/jpm.2009.0113; Viola R, 2008, SUPPORT CARE CANCER, V16, P329, DOI 10.1007/s00520-007-0389-6	20	11	11	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	MAY	2015	32	3					298	304		10.1177/1049909113513063			7	Health Care Sciences & Services	Health Care Sciences & Services	CF8HQ	WOS:000352797300007	24259406				2020-06-30	J	Knapman, A; Santiago, M; Connor, M				Knapman, Alisa; Santiago, Marina; Connor, Mark			A6V polymorphism of the human mu-opioid receptor decreases signalling of morphine and endogenous opioids in vitro	BRITISH JOURNAL OF PHARMACOLOGY			English	Article							FLUORESCENCE-BASED ASSAY; CONCISE GUIDE; GENETIC ASSOCIATION; CANCER PAIN; PHARMACOLOGY; VARIANT; ACTIVATION; PHARMACOGENETICS; DESENSITIZATION; BUPRENORPHINE	Background and PurposePolymorphisms of the opioid receptor (MOPr) may contribute to the variation in responses to opioid drugs in clinical and unregulated situations. The A6V variant of MOPr (MOPr-A6V) is present in up to 20% of individuals in some populations, and may be associated with heightened susceptibility to drug abuse. There are no functional studies examining the acute signalling of MOPr-A6Vin vitro, so we investigated potential functional differences between MOPr and MOPr-A6V at several signalling pathways using structurally distinct opioid ligands. Experimental ApproachCHO and AtT-20 cells stably expressing MOPr and MOPr-A6V were used. AC inhibition and ERK1/2 phosphorylation were assayed in CHO cells; K channel activation was assayed in AtT-20 cells. Key ResultsBuprenorphine did not inhibit AC or stimulate ERK1/2 phosphorylation in CHO cells expressing MOPr-A6V, but buprenorphine activation of K channels in AtT-20 cells was preserved. [D-Ala2, N-MePhe4, Gly-ol]-enkephalin, morphine and -endorphin inhibition of AC was significantly reduced via MOPr-A6V, as was signalling of all opioids to ERK1/2. However, there was little effect of the A6V variant on K channel activation. Conclusions and ImplicationsSignalling to AC and ERK via the mutant MOPr-A6V was decreased for many opioids, including the clinically significant drugs morphine, buprenorphine and fentanyl, as well endogenous opioids. The MOPr-A6V variant is common and this compromised signalling may affect individual responses to opioid therapy, while the possible disruption of the endogenous opioid system may contribute to susceptibility to substance abuse.	[Knapman, Alisa; Santiago, Marina; Connor, Mark] Macquarie Univ, Australian Sch Adv Med, Sydney, NSW 2109, Australia	Connor, M (reprint author), Macquarie Univ, 2 Technol Pl, Sydney, NSW 2109, Australia.	mark.connor@mq.edu.au	Connor, Mark/A-4197-2008	Connor, Mark/0000-0003-2538-2001; J Santiago, Marina/0000-0002-3421-4774; Junqueira Santiago, Marina/0000-0001-9388-8309	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1011979]; Postgraduate Scholarships from Macquarie University; Australian School of Advanced Medicine	This study was supported by the National Health and Medical Research Council of Australia project grant 1011979 to M. C. A. K. and M. S. were recipients of Postgraduate Scholarships from Macquarie University, topped up by the Australian School of Advanced Medicine. We thank Mac Christie and Yan Ping Du for their assistance with the binding assays, and Courtney Breen for providing a protocol and advice on the ERK ELISA.	Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1797, DOI 10.1111/bph.12451; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1607, DOI 10.1111/bph.12447; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Belmer A, 2014, MOL PHARMACOL, V85, P127, DOI 10.1124/mol.113.089086; Berrettini WH, 1997, ADDICT BIOL, V2, P303, DOI 10.1080/13556219772598; Boom M, 2012, CURR PHARM DESIGN, V18, P5994, DOI 10.2174/138161212803582469; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; Compton P, 2003, AM J MED GENET B, V121B, P76, DOI 10.1002/ajmg.b.20057; Connor M, 2004, BRIT J PHARMACOL, V143, P685, DOI 10.1038/sj.bjp.0705938; Cox BM, 2014, BRIT J PHARMACOL, V172, P317; Crist RC, 2014, PHARMACOL BIOCHEM BE, V123, P25, DOI 10.1016/j.pbb.2013.10.018; Crowley JJ, 2003, PSYCHIAT GENET, V13, P169, DOI 10.1097/00041444-200309000-00006; Crystal HA, 2012, ADDICT BIOL, V17, P181, DOI 10.1111/j.1369-1600.2010.00265.x; Diatchenko Luda, 2011, Eur J Pain Suppl, V5, P433; Fortin JP, 2010, MOL PHARMACOL, V78, P837, DOI 10.1124/mol.110.064188; Granier S, 2012, NATURE, V485, P400, DOI 10.1038/nature11111; Gupta A, 2008, J BIOL CHEM, V283, P10735, DOI 10.1074/jbc.M709454200; Gupta A, 2007, J BIOL CHEM, V282, P5116, DOI 10.1074/jbc.M609254200; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Herrick-Davis K, 2013, MOL PHARMACOL, V84, P630, DOI 10.1124/mol.113.087072; Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895; Kapur Suman, 2007, Journal of Integrative Neuroscience, V6, P511, DOI 10.1142/S0219635207001635; Kenakin T, 2010, PHARMACOL REV, V62, P265, DOI 10.1124/pr.108.000992; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Knapman A, 2015, BRIT J PHARMACOL, V172, P349, DOI 10.1111/bph.12644; Knapman A, 2014, BRIT J PHARMACOL, V171, P4273, DOI 10.1111/bph.12785; Knapman A, 2014, J BIOMOL SCREEN, V19, P223, DOI 10.1177/1087057113501391; Knapman A, 2013, J BIOMOL SCREEN, V18, P269, DOI 10.1177/1087057112461376; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lotsch J, 2005, TRENDS MOL MED, V11, P82, DOI 10.1016/j.molmed.2004.12.006; Luttrell LM, 2005, J MOL NEUROSCI, V26, P253, DOI 10.1385/JMN:26:2-3:253; Mague SD, 2010, DRUG ALCOHOL DEPEN, V108, P172, DOI 10.1016/j.drugalcdep.2009.12.016; Malik RU, 2013, J BIOL CHEM, V288, P17167, DOI 10.1074/jbc.M113.464065; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973; Mura E, 2013, J PAIN RES, V6, P331, DOI 10.2147/JPR.S42040; Nguyen VH, 1998, EUR J PHARMACOL, V361, P157, DOI 10.1016/S0014-2999(98)00706-7; Nozaki C, 2007, EUR J PHARMACOL, V560, P160, DOI 10.1016/j.ejphar.2007.01.021; Oertel BG, 2009, J BIOL CHEM, V284, P6530, DOI 10.1074/jbc.M807030200; Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Pineyro G, 2007, CELL SIGNAL, V19, P8, DOI 10.1016/j.cellsig.2006.05.026; Ravindranathan A, 2009, P NATL ACAD SCI USA, V106, P10811, DOI 10.1073/pnas.0904509106; Rommelspacher H, 2001, ALCOHOL, V24, P129, DOI 10.1016/S0741-8329(01)00139-2; Sauer Brian, 1994, Current Opinion in Biotechnology, V5, P521, DOI 10.1016/0958-1669(94)90068-X; Skorpen F, 2008, PALLIATIVE MED, V22, P310, DOI 10.1177/0269216308089302; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; Srinivasan S, 2004, J CLIN INVEST, V114, P1158, DOI 10.1172/JCI200421927; Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008; Virk MS, 2009, J NEUROSCI, V29, P7341, DOI 10.1523/JNEUROSCI.3723-08.2009; Walter C, 2009, PAIN, V146, P270, DOI 10.1016/j.pain.2009.07.013; Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939; Zernikow Boris, 2009, Paediatr Drugs, V11, P129, DOI 10.2165/00148581-200911020-00004; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	55	5	6	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	MAY	2015	172	9					2258	2272		10.1111/bph.13047			15	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CF8LB	WOS:000352809900007	25521224	Green Published, Bronze			2020-06-30	J	Li, B; Wang, HX; Gao, CJ				Li, Bo; Wang, Huixia; Gao, Chengjie			Bupivacaine in Combination With Fentanyl or Sufentanil in Epidural/Intrathecal Analgesia for Labor: A Meta-Analysis	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						epidural; intrathecal; bupivacaine; fentanyl; sufentanil; labor; analgesia	HEART-RATE ABNORMALITIES; CONTROLLED EPIDURAL ANALGESIA; INTRATHECAL FENTANYL; DOUBLE-BLIND; REGIONAL ANALGESIA; CONTROLLED TRIAL; ANESTHESIA; EFFICACY; PLACEBO; PAIN	This study is to compare the effectiveness of combinational use of bupivacaine with fentanyl (BUPI-FEN) and sufentanil (BUPI-SUF) in epidural/intrathecal analgesia for labor. Electronic databases were searched for relevant research papers published between 1985 and 2014. Meta-analyses of mean differences or odds ratios were performed and statistical heterogeneity between the studies tested by I-2 index. Ten studies recruiting a total of 728 women in labor were selected. Concentrations of the anesthetics used as mean +/- sd were bupivacaine 0.115 +/- 0.056%, fentanyl 0.0007 +/- 0.001%, and sufentanil 0.00017 +/- 0.00022%. Duration of analgesia was not significantly different between BUPI-SUF and BUPI-FEN administered mothers (mean difference [95%CI] of -33.55 [-74.94, 7.83] minutes; P=.11) under random effects. The onset of analgesia was also not significantly different between both groups (mean difference [95%CI] of -0.61 [-1.38, 0.16] minutes; P=.12). The number of neonates with Apgar score < 7 was significantly lower in BUPI-FEN group (odd ratio [95%CI] of 0.31 [0.10, 0.95]; P<.05). Pruritus incidence was similar. In conclusion, BUPI-FEN combination exhibits significantly better tolerability at an approximate ratio of 6 FEN:1 SUF, albeit, both fentanyl and sufentanil in combination with bupivacaine provide similar analgesic properties via the epidural or intrathecal routes for labor pain relief.	[Li, Bo; Wang, Huixia; Gao, Chengjie] PLA Jinan Mil Area Command, Jinan Gen Hosp, Dept Anesthesiol, Jinan 250031, Peoples R China	Gao, CJ (reprint author), PLA Jinan Mil Area Command, Jinan Gen Hosp, Dept Anesthesiol, 25 Shifan Rd, Jinan 250031, Peoples R China.	gaochj@hotmail.com					Abrao KC, 2009, OBSTET GYNECOL, V113, P41, DOI 10.1097/AOG.0b013e31818f5eb6; Cambic CR, 2010, BRIT J ANAESTH, V105, pI50, DOI 10.1093/bja/aeq311; Cascio M, 1997, CAN J ANAESTH, V44, P605, DOI 10.1007/BF03015443; Cheng CJC, 2001, CAN J ANAESTH, V48, P570, DOI 10.1007/BF03016834; Cicarelli Domingos Dias, 2007, Rev. Bras. Anestesiol., V57, P272, DOI 10.1590/S0034-70942007000300005; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; Connelly NR, 2000, ANESTH ANALG, V91, P374, DOI 10.1097/00000539-200008000-00026; Dostbil A, 2014, NIGER J CLIN PRACT, V17, P205, DOI 10.4103/1119-3077.127559; Everaert N, 2015, J PERINAT MED, V43, P481, DOI 10.1515/jpm-2014-0077; Gaiser RR, 1998, J CLIN ANESTH, V10, P488, DOI 10.1016/S0952-8180(98)00076-2; Gambling DR, 1998, ANESTHESIOLOGY, V89, P1336, DOI 10.1097/00000542-199812000-00010; Gomar C, 2000, EUR J ANAESTH, V17, P542, DOI 10.1046/j.1365-2346.2000.00733.x; Herman NL, 1998, J CLIN ANESTH, V10, P670, DOI 10.1016/S0952-8180(98)00113-5; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hitzeman N, 2012, AM FAM PHYSICIAN, V86, P241; JORROT JC, 1989, ANN FR ANESTH, V8, P321, DOI 10.1016/S0750-7658(89)80073-5; Jung H, 2013, KOREAN J ANESTHESIOL, V65, P379, DOI 10.4097/kjae.2013.65.5.379; Kalra S, 2010, SAUDI J ANAESTH, V4, P178, DOI 10.4103/1658-354X.71569; Le Guen H, 2001, J CLIN ANESTH, V13, P98, DOI 10.1016/S0952-8180(01)00221-5; Leone Stefania, 2008, Acta Biomed, V79, P92; Lilker S, 2009, J CLIN ANESTH, V21, P108, DOI 10.1016/j.jclinane.2008.06.027; Lo W. K., 1999, SMJ, V40, P639; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; Lowe N K, 1996, J Obstet Gynecol Neonatal Nurs, V25, P82, DOI 10.1111/j.1552-6909.1996.tb02517.x; Maciejewski D, 2012, ANAESTH INTENSIVE TH, V44, P35; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Ngarnprasertwong Pornswan, 2007, Journal of the Medical Association of Thailand, V90, P1368; Nickells JS, 2000, ANAESTHESIA, V55, P17, DOI 10.1046/j.1365-2044.2000.01071.x; Norris MC, 2001, ANESTHESIOLOGY, V95, P913, DOI 10.1097/00000542-200110000-00020; Parpaglioni R, 2009, ACTA ANAESTH SCAND, V53, P1214, DOI 10.1111/j.1399-6576.2009.02033.x; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; Rolfseng OK, 2002, EUR J ANAESTH, V19, P812, DOI 10.1017/S026502150200131X; Rowlands S, 1998, BAILLIERE CLIN OB GY, V12, P347, DOI 10.1016/S0950-3552(98)80071-0; RUSSELL R, 1993, ANAESTHESIA, V48, P856, DOI 10.1111/j.1365-2044.1993.tb07413.x; Sezer OA, 2007, INT J OBSTET ANESTH, V16, P226, DOI 10.1016/j.ijoa.2007.02.007; Simmons SW, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003401.pub3; Thomas JM, 1999, CLIN PHARMACOKINET, V36, P67, DOI 10.2165/00003088-199936010-00005; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66; Van de Velde M, 2001, REGION ANESTH PAIN M, V26, P257, DOI 10.1053/rapm.2001.22258	40	6	9	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	MAY	2015	55	5					584	591		10.1002/jcph.453			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CF5VX	WOS:000352626500014	25535687				2020-06-30	J	Gutierrez-Blanco, E; Victoria-Mora, JM; Ibancovichi-Camarillo, JA; Sauri-Arceo, CH; Bolio-Gonzalez, ME; Acevedo-Arcique, CM; Marin-Cano, G; Steagall, PVM				Gutierrez-Blanco, Eduardo; Victoria-Mora, Jose M.; Ibancovichi-Camarillo, Jose A.; Sauri-Arceo, Carlos H.; Bolio-Gonzalez, Manuel E.; Acevedo-Arcique, Carlos M.; Marin-Cano, Gabriela; Steagall, Paulo V. M.			Postoperative analgesic effects of either a constant rate infusion of fentanyl, lidocaine, ketamine, dexmedetomidine, or the combination lidocaine-ketamine-dexmedetomidine after ovariohysterectomy in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						analgesia; constant rate infusion; dog; pain scales	ISOFLURANE ANESTHESIA; INTRAVENOUS LIDOCAINE; PAIN; PHARMACOKINETICS; SURGERY; PHARMACODYNAMICS; CARDIOPULMONARY; RECOVERY; BEHAVIOR; SCALE	ObjectiveTo evaluate the postoperative analgesic effects of a constant rate infusion (CRI) of either fentanyl (FENT), lidocaine (LIDO), ketamine (KET), dexmedetomidine (DEX), or the combination lidocaine-ketamine-dexmedetomidine (LKD) in dogs. Study designRandomized, prospective, blinded, clinical study. AnimalsFifty-four dogs. MethodsAnesthesia was induced with propofol and maintained with isoflurane. Treatments were intravenous (IV) administration of a bolus at start of anesthesia, followed by an IV CRI until the end of anesthesia, then a CRI at a decreased dose for a further 4hours: CONTROL/BUT (butorphanol 0.4mgkg(-1), infusion rate of saline 0.9% 2mLkg(-1)hour(-1)); FENT (5gkg(-1), 10gkg(-1)hour(-1), then 2.5gkg(-1)hour(-1)); KET (1mgkg(-1), 40gkg(-1)minute(-1), then 10gkg(-1)minute(-1)); LIDO (2mgkg(-1), 100gkg(-1)minute(-1), then 25gkg(-1)minute(-1)); DEX (1gkg(-1), 3gkg(-1)hour(-1), then 1gkg(-1)hour(-1)); or a combination of LKD at the aforementioned doses. Postoperative analgesia was evaluated using the Glasgow composite pain scale, University of Melbourne pain scale, and numerical rating scale. Rescue analgesia was morphine and carprofen. Data were analyzed using Friedman or Kruskal-Wallis test with appropriate post-hoc testing (p<0.05). ResultsAnimals requiring rescue analgesia included CONTROL/BUT (n=8), KET (n=3), DEX (n=2), and LIDO (n=2); significantly higher in CONTROL/BUT than other groups. No dogs in LKD and FENT groups received rescue analgesia. CONTROL/BUT pain scores were significantly higher at 1hour than FENT, DEX and LKD, but not than KET or LIDO. Fentanyl and LKD sedation scores were higher than CONTROL/BUT at 1hour. Conclusions and clinical relevanceLKD and FENT resulted in adequate postoperative analgesia. LIDO, CONTROL/BUT, KET and DEX may not be effective for treatment of postoperative pain in dogs undergoing ovariohysterectomy.	[Gutierrez-Blanco, Eduardo; Sauri-Arceo, Carlos H.; Bolio-Gonzalez, Manuel E.] Yucatan Autonomous Univ, Fac Vet Med, Dept Anim Hlth & Prevent Med, Merida 97000, Yucatan, Mexico; [Victoria-Mora, Jose M.; Marin-Cano, Gabriela] Mexico State Autonomous Univ, Fac Vet Med, Dept Vet Orthoped & Traumatol, Toluca, Mexico; [Ibancovichi-Camarillo, Jose A.; Acevedo-Arcique, Carlos M.] Mexico State Autonomous Univ, Fac Vet Med, Dept Vet Anesthesiol, Toluca, Mexico; [Steagall, Paulo V. M.] Univ Montreal, Fac Vet Med, Dept Clin Sci, St Hyacinthe, PQ J2S 7C6, Canada	Gutierrez-Blanco, E (reprint author), Yucatan Autonomous Univ, Fac Vet Med, Dept Anim Hlth & Prevent Med, Km 15-5 Rd Merida Xmatkuil, Merida 97000, Yucatan, Mexico.	gublan@uady.mx	Steagall, Paulo/W-6043-2019	Steagall, Paulo/0000-0003-4150-6043; Ibancovichi, Jose Antonio/0000-0003-1760-687X	Ministry of Public Education of Mexico PROMEP-SEP	Ministry of Public Education of Mexico PROMEP-SEP for grant support of E Gutierrez-Blanco's PhD program.	Anil SS, 2002, J AM VET MED ASSOC, V220, P313, DOI 10.2460/javma.2002.220.313; Bell RF, 2005, ACTA ANAESTH SCAND, V49, P1405, DOI 10.1111/j.1399-6576.2005.00814.x; Boscan P, 2005, AM J VET RES, V66, P2122, DOI 10.2460/ajvr.2005.66.2122; Columbano N, 2012, VET J, V193, P448, DOI 10.1016/j.tvjl.2011.12.005; Ebert B, 1997, EUR J PHARMACOL, V333, P99, DOI 10.1016/S0014-2999(97)01116-3; Firth AM, 1999, J AM VET MED ASSOC, V214, P651; Gaynor JS, 2009, HDB VET PAIN MANAGEM, P78; Gutierrez-Blanco E, 2013, VET ANAESTH ANALG, V40, P599, DOI 10.1111/vaa.12079; Holton L, 2001, VET REC, V148, P525, DOI 10.1136/vr.148.17.525; Holton LL, 1998, J AM VET MED ASSOC, V212, P61; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Lervik A, 2012, VET ANAESTH ANALG, V39, P414, DOI 10.1111/j.1467-2995.2012.00713.x; Lin GY, 2008, VET ANAESTH ANALG, V35, P141, DOI 10.1111/j.1467-2995.2007.00365.x; MacDougall LM, 2009, VET ANAESTH ANALG, V36, P512, DOI 10.1111/j.1467-2995.2009.00480.x; Marret E, 2008, BRIT J SURG, V95, P1331, DOI 10.1002/bjs.6375; Mathews K, 2014, J SMALL ANIM PRACT, V55, pE10, DOI 10.1111/jsap.12200; McCarthy GC, 2010, DRUGS, V70, P1149, DOI 10.2165/10898560-000000000-00000; Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099; Murrell JC, 2005, VET ANAESTH ANALG, V32, P117, DOI 10.1111/j.1467-2995.2005.00233.x; Ortega M, 2011, CAN VET J, V52, P856; Pascoe PJ, 2006, VET ANAESTH ANALG, V33, P97, DOI 10.1111/j.1467-2995.2005.00236.x; Pozzi A, 2006, JAVMA-J AM VET MED A, V228, P53, DOI 10.2460/javma.228.1.53; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Sarrau S, 2007, J SMALL ANIM PRACT, V48, P670, DOI 10.1111/j.1748-5827.2007.00362.x; Slingsby LS, 2000, RES VET SCI, V69, P147, DOI 10.1053/rvsc.2000.0406; Smith LJ, 2004, VET ANAESTH ANALG, V31, P53, DOI 10.1111/j.1467-2995.2004.00142.x; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; THOMSON AH, 1987, J PHARMACOKINET BIOP, V15, P101, DOI 10.1007/BF01062338; Uilenreef JJ, 2008, VET ANAESTH ANALG, V35, P1, DOI 10.1111/j.1467-2995.2007.00344.x; Valtolina C, 2009, VET ANAESTH ANALG, V36, P369, DOI 10.1111/j.1467-2995.2009.00461.x; van Oostrom H, 2011, VET J, V190, P338, DOI 10.1016/j.tvjl.2010.11.025; Wagner AE, 2002, J AM VET MED ASSOC, V221, P72, DOI 10.2460/javma.2002.221.72; WILCKE JR, 1983, J VET PHARMACOL THER, V6, P49, DOI 10.1111/j.1365-2885.1983.tb00454.x	33	15	17	0	29	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2015	42	3					309	318		10.1111/vaa.12215			10	Veterinary Sciences	Veterinary Sciences	CG1XB	WOS:000353067700013	25039918				2020-06-30	J	Manini, AF; Yiannoulos, G; Bergamaschi, MM; Hernandez, S; Olmedo, R; Barnes, AJ; Winkel, G; Sinha, R; Jutras-Aswad, D; Huestis, MA; Hurd, YL				Manini, Alex F.; Yiannoulos, Georgia; Bergamaschi, Mateus M.; Hernandez, Stephanie; Olmedo, Ruben; Barnes, Allan J.; Winkel, Gary; Sinha, Rajita; Jutras-Aswad, Didier; Huestis, Marilyn A.; Hurd, Yasmin L.			Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans	JOURNAL OF ADDICTION MEDICINE			English	Article						cannabidiol; cannabis; opioid dependence; pharmacokinetics	CANNABINOID RECEPTOR; OPIOID RECEPTORS; NEURAL BASIS; NUCLEUS; PLASMA; CB1; DELTA-9-TETRAHYDROCANNABINOL; SCHIZOPHRENIA; INHIBITION; HYDROLYSIS	Objectives: Cannabidiol (CBD) is hypothesized as a potential treatment for opioid addiction, with safety studies an important first step for medication development. We determined CBD safety and pharmacokinetics when administered concomitantly with a high-potency opioid in healthy subjects. Methods: This double-blind, placebo-controlled cross-over study of CBD, coadministered with intravenous fentanyl, was conducted at the Clinical Research Center in Mount Sinai Hospital, a tertiary care medical center in New York City. Participants were healthy volunteers aged 21 to 65 years with prior opioid exposure, regardless of the route. Blood samples were obtained before and after 400 or 800 mg of CBD pretreatment, followed by a single 0.5 (session 1) or 1.0 mu g/kg (session 2) of intravenous fentanyl dose. The primary outcome was the Systematic Assessment for Treatment Emergent Events (SAFTEE) to assess safety and adverse effects. CBD peak plasma concentrations, time to reach peak plasma concentrations (t(max)), and area under the curve (AUC) were measured. Results: SAFTEE data were similar between groups without respiratory depression or cardiovascular complications during any test session. After low-dose CBD, t(max) occurred at 3 and 1.5 hours in sessions 1 and 2, respectively. After high-dose CBD, tmax occurred at 3 and 4 hours in sessions 1 and 2, respectively. There were no significant differences in plasma CBD or cortisol (AUC P = NS) between sessions. Conclusions: Cannabidiol does not exacerbate adverse effects associated with intravenous fentanyl administration. Coadministration of CBD and opioids was safe and well tolerated. These data provide the foundation for future studies examining CBD as a potential treatment for opioid abuse.	[Manini, Alex F.; Hernandez, Stephanie; Olmedo, Ruben] Icahn Sch Med Mt Sinai, Div Med Toxicol, Dept Emergency Med, New York, NY 10029 USA; [Yiannoulos, Georgia; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Dept Psychiat, Bronx, NY USA; [Yiannoulos, Georgia; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Dept Neurosci, Bronx, NY USA; [Yiannoulos, Georgia; Hurd, Yasmin L.] James J Peters VA Med Ctr, Bronx, NY USA; [Bergamaschi, Mateus M.] Univ Sao Paulo, Dept Clin Toxicol & Food Sci Anal, Sch Pharmaceut Sci Ribeirao Preto, BR-05508 Sao Paulo, Brazil; [Barnes, Allan J.; Huestis, Marilyn A.] NIDA, Chem & Drug Metab, Intramural Res Program, NIH, Baltimore, MD USA; [Winkel, Gary] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Sinha, Rajita] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Jutras-Aswad, Didier] Univ Montreal, Ctr Hosp Univ Montreal, Res Ctr, Montreal, PQ, Canada; [Jutras-Aswad, Didier] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada	Hurd, YL (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.	yasmin.hurd@mssm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA027781]; CTSAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1RR029887]	Supported by a research grant from the National Institutes of Health grant DA027781 (YLH) and CTSA (UL1RR029887).	AGURELL S, 1981, EXPERIENTIA, V37, P1090, DOI 10.1007/BF02085029; Bergamaschi MM, 2013, ANAL BIOANAL CHEM, V405, P4679, DOI 10.1007/s00216-013-6837-x; Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327; Borgwardt SJ, 2008, BIOL PSYCHIAT, V64, P966, DOI 10.1016/j.biopsych.2008.05.011; CONSROE P, 1991, PHARMACOL BIOCHEM BE, V40, P701, DOI 10.1016/0091-3057(91)90386-G; CONSROE P, 1991, PHARMACOL BIOCHEM BE, V40, P517, DOI 10.1016/0091-3057(91)90357-8; Crippa JAD, 2004, NEUROPSYCHOPHARMACOL, V29, P417, DOI 10.1038/sj.npp.1300340; Crippa JAS, 2011, J PSYCHOPHARMACOL, V25, P121, DOI 10.1177/0269881110379283; Dijkstra BAG, 2007, ADDICT BIOL, V12, P176, DOI 10.1111/j.1369-1600.2007.00067.x; Ellgren M, 2007, NEUROPSYCHOPHARMACOL, V32, P607, DOI 10.1038/sj.npp.1301127; Englund A, 2013, J PSYCHOPHARMACOL, V27, P19, DOI 10.1177/0269881112460109; Fatseas M, 2011, BIOL PSYCHIAT, V70, P720, DOI 10.1016/j.biopsych.2011.05.015; Fusar-Poli P, 2009, ARCH GEN PSYCHIAT, V66, P95, DOI 10.1001/archgenpsychiatry.2008.519; GLARE PA, 1991, THER DRUG MONIT, V13, P1, DOI 10.1097/00007691-199101000-00001; Karschner EL, 2010, ANAL BIOANAL CHEM, V397, P603, DOI 10.1007/s00216-010-3599-6; Kathmann M, 2006, N-S ARCH PHARMACOL, V372, P354, DOI 10.1007/s00210-006-0033-x; Katsidoni V, 2013, ADDICT BIOL, V18, P286, DOI 10.1111/j.1369-1600.2012.00483.x; LEVINE J, 1986, PSYCHOPHARMACOL BULL, V22, P343; Leweke FM, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.15; Massi P, 2013, BRIT J CLIN PHARMACO, V75, P303, DOI 10.1111/j.1365-2125.2012.04298.x; Mecha M, 2013, NEUROBIOL DIS, V59, P141, DOI 10.1016/j.nbd.2013.06.016; Mechoulam R, 2007, CHEM BIODIVERS, V4, P1678, DOI 10.1002/cbdv.200790147; Muller-Vahl Kirsten R, 2008, Expert Rev Neurother, V8, P1037, DOI 10.1586/14737175.8.7.1037; Pertwee RG, 2002, EUR J PHARMACOL, V456, P99, DOI 10.1016/S0014-2999(02)02624-9; Qin N, 2008, J NEUROSCI, V28, P6231, DOI 10.1523/JNEUROSCI.0504-08.2008; Reid MJ, 2001, BIOCHEM PHARMACOL, V61, P1357, DOI 10.1016/S0006-2952(01)00616-5; Ren YH, 2009, J NEUROSCI, V29, P14764, DOI 10.1523/JNEUROSCI.4291-09.2009; Rodriguez JJ, 2001, J NEUROSCI, V21, P823; ROSENKRANTZ H, 1981, TOXICOL APPL PHARM, V58, P118, DOI 10.1016/0041-008X(81)90122-8; Schoffelmeer ANM, 2006, NEUROPHARMACOLOGY, V51, P773, DOI 10.1016/j.neuropharm.2006.05.019; Thomas A, 2007, BRIT J PHARMACOL, V150, P613, DOI 10.1038/sj.bjp.0707133; Tomida I, 2006, J GLAUCOMA, V15, P349, DOI 10.1097/01.ijg.0000212260.04488.60; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Zacny J P, 1992, J Subst Abuse, V4, P197, DOI 10.1016/0899-3289(92)90019-T; Zuardi AW, 2009, J PSYCHOPHARMACOL, V23, P979, DOI 10.1177/0269881108096519; Zuardi AW, 2006, J PSYCHOPHARMACOL, V20, P683, DOI 10.1177/0269881106060967; ZUARDI AW, 1993, BRAZ J MED BIOL RES, V26, P213; ZUARDI AW, 1982, PSYCHOPHARMACOLOGY, V76, P245, DOI 10.1007/BF00432554; ZUARDI AW, 1995, J CLIN PSYCHIAT, V56, P485	39	29	29	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1932-0620	1935-3227		J ADDICT MED	J. Addict. Med.	MAY-JUN	2015	9	3					204	210		10.1097/ADM.0000000000000118			7	Substance Abuse	Substance Abuse	DD1VH	WOS:000369710200006	25748562	Green Accepted			2020-06-30	J	Larson, KJ; Wittwer, ED; Nicholson, WT; Weingarten, TN; Price, DL; Sprung, J				Larson, Kelly J.; Wittwer, Erica D.; Nicholson, Wayne T.; Weingarten, Toby N.; Price, Daniel L.; Sprung, Juraj			Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Anesthesia; Myoclonus; Methylene blue; Selective serotonin uptake inhibitor serotonin syndrome uptake inhibitor; Serotonin syndrome	PROLONGED POSTOPERATIVE DISORIENTATION; SEROTONIN TOXICITY; PARATHYROIDECTOMY; INFUSION; ENCEPHALOPATHY; INHIBITION	Serotonin released in the nerve synapses is cleared through reuptake into presynaptic neurons and metabolism with monoamine oxidase (MAO). Therapy with selective serotonin reuptake inhibitors (SSRIs) or MAO inhibitors increases serotonin concentration in the synaptic cleft and may result in serotonin syndrome (SS). Our patient undergoing sentinel lymph node biopsy was on fluoxetine (SSRI) and intraoperatively developed SS after receiving fentanyl (200 mu g) and methylene blue (MAO inhibitor), 7 mg subcutaneously into the scalp. Initial presentation was several episodes of generalized muscle activity, which was later diagnosed as lower extremity myoclonus consistent with SS. Upon awakening, the patient showed no evidence of encephalopathy, and the clonus was less intense. The patient was discharge home the next day. Our case suggests the possibility that even a small dose of methylene blue, when administered simultaneously with other serotoninergic medications, may be associated with serotonin toxicity. (C) 2014 Elsevier Inc. All rights reserved.	[Larson, Kelly J.; Wittwer, Erica D.; Nicholson, Wayne T.; Weingarten, Toby N.; Sprung, Juraj] Mayo Clin, Dept Anesthesiol, Rochester, MN 55905 USA; [Price, Daniel L.] Mayo Clin, Dept Otorhinolaryngol, Rochester, MN 55905 USA	Sprung, J (reprint author), Mayo Clin, Dept Anesthesiol, 200 1st St SW, Rochester, MN 55905 USA.	sprung.juraj@mayo.edu					Bach KK, 2004, ANESTH ANALG, V99, P1573, DOI 10.1213/01.ANE.0000134860.73875.CF; Barras ACH, 2010, J NEUROL NEUROSUR PS, V81, P1412, DOI 10.1136/jnnp.2009.172221; Brosen K, 1998, INT CLIN PSYCHOPHARM, V13, pS45, DOI 10.1097/00004850-199809005-00009; Davis JJ, 2013, J CLIN ANESTH, V25, P52, DOI 10.1016/j.jclinane.2012.05.002; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; Food and Drug Administration, 2011, FDA DRUG SAF COMM SE; Gillman PK, 2011, J PSYCHOPHARMACOL, V25, P429, DOI 10.1177/0269881109359098; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Gury C, 1999, ENCEPHALE, V25, P470; Kartha SS, 2006, OTOLARYNG HEAD NECK, V135, P765, DOI 10.1016/j.otohns.2006.05.026; Khan M A S, 2007, Ann R Coll Surg Engl, V89, pW9, DOI 10.1308/147870807X160434; Khavandi A, 2008, MED J AUSTRALIA, V189, P534, DOI 10.5694/j.1326-5377.2008.tb02168.x; Kirschner R, 2010, J EMERG MED, V38, P477, DOI 10.1016/j.jemermed.2008.01.003; Li XQ, 2004, DRUG METAB DISPOS, V32, P821, DOI 10.1124/dmd.32.8.821; Majithia A, 2006, J LARYNGOL OTOL, V120, P138, DOI 10.1017/S0022215105005098; Margolis JM, 2000, DRUG METAB DISPOS, V28, P1187; Marken Patricia A., 2000, Prim Care Companion J Clin Psychiatry, V2, P205; Martindale SJ, 2003, ANAESTHESIA, V58, P1041, DOI 10.1046/j.1365-2044.2003.03415_23.x; Mathew S, 2006, ANAESTHESIA, V61, P580, DOI 10.1111/j.1365-2044.2006.04619.x; Mihai R, 2007, CAN J ANAESTH, V54, P79, DOI 10.1007/BF03021907; Ng BKW, 2010, PSYCHOSOMATICS, V51, P194, DOI 10.1176/appi.psy.51.3.194; OTTON SV, 1993, CLIN PHARMACOL THER, V53, P401, DOI 10.1038/clpt.1993.43; Patel AS, 2006, HEAD NECK-J SCI SPEC, V28, P567, DOI 10.1002/hed.20416; Pollack G, 2009, LARYNGOSCOPE, V119, P1941, DOI 10.1002/lary.20581; Ring BJ, 2001, J PHARMACOL EXP THER, V297, P1044; Rowley M, 2009, NEUROCRIT CARE, V11, P88, DOI 10.1007/s12028-009-9206-z; Shopes Ellen, 2013, AANA J, V81, P215; Stanford SC, 2010, J PSYCHOPHARMACOL, V24, P1433, DOI 10.1177/0269881109105450; Strandell J, 2004, PHYTOMEDICINE, V11, P98, DOI 10.1078/0944-7113-00379; Sweet G, 2007, J AM COLL SURGEONS, V204, P454, DOI 10.1016/j.jamcollsurg.2006.12.030; Tissot TA, 2003, ANESTHESIOLOGY, V98, P1511, DOI 10.1097/00000542-200306000-00033; Torkamani A., 2014, MEDSCAPE DRUG REFERE	32	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2015	27	3					247	251		10.1016/j.jclinane.2014.11.002			5	Anesthesiology	Anesthesiology	CG5XG	WOS:000353368600012	25499271				2020-06-30	J	Gomez, EB; Aleta, AG; Diaz, EM; Berga, FM; Garcia-Aparicio, L; Lopez, AO				Blazquez Gomez, E.; Garces Aleta, A.; Monclus Diaz, E.; Manen Berga, F.; Garcia-Aparicio, L.; Ontanilla Lopez, A.			Anaesthetic management in a paediatric patient with a difficult airway due to epidermolysis bullosa dystrophica	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION			Spanish	Article						Dystrophic epidermolysis bullosa; Anaesthesia; Airway management		Dystrophic epidermolysis bullosa (DEB) is a rare inherited disorder characterized by blistering after minimal trauma. These blisters tend to form dystrophic scars, leading to limiting and life-threatening sequelae. The anaesthetic management of patients with DEB is a challenge, even for the most experienced anaesthesiologists, but basic principles can help us prepare the plan of care. The main goats are to prevent trauma/infection of skin/mucous, and to establish a secure airway without causing bullae. Patient positioning and the instruments used to monitor vital signs and administering anaesthetic agents can cause new lesions. It is advisable to lubricate the instruments and to avoid adhesive material and shearing forces on the skin. Besides the implications of the comorbidities, there is a potential difficult intubation and difficult vascular access. Acute airway obstruction can occur due to airway instrumentation. We report the case of a patient diagnosed with EBD difficult airway and undergoing correction of syndactylyl and dental extractions. (C) 2014 Sociedad Espanola de Anestesiologia, Reanimacion y Terapeutica del Dolor. Published by Elsevier Espana, S.L.U. All rights reserved.	[Blazquez Gomez, E.; Ontanilla Lopez, A.] Univ Seville, Hosp Univ Virgen Macarena, UGC Anestesiol Reanimac & Terapeut Dolor, Seville, Spain; [Garces Aleta, A.; Monclus Diaz, E.; Manen Berga, F.] Univ Barcelona, Hosp St Joan Deu, Serv Anestesiol, Barcelona, Spain; [Garcia-Aparicio, L.] Univ Barcelona, Hosp St Joan Deu, Serv Cirugia Pediat, Barcelona, Spain	Gomez, EB (reprint author), Univ Seville, Hosp Univ Virgen Macarena, UGC Anestesiol Reanimac & Terapeut Dolor, Seville, Spain.	eva_bg@msn.com	Garcia-Aparicio, Luis/W-1665-2018	Garcia-Aparicio, Luis/0000-0003-0744-562X			Ames WA, 1999, BRIT J ANAESTH, V82, P746; Benavente MA, 2003, PAEDIATR ANAESTH, V13, P274, DOI 10.1046/j.1460-9592.2003.01028_1.x; Crowley Kelly L, 2004, AANA J, V72, P261; Culpepper T L, 2001, AANA J, V69, P114; Garcia I, 2009, REV ESP ANEST REANIM, V56, P569, DOI 10.1016/S0034-9356(09)70460-8; Herod J, 2002, PAEDIATR ANAESTH, V12, P388, DOI 10.1046/j.1460-9592.2002.00768.x; Intong LRA, 2012, CLIN DERMATOL, V30, P70, DOI 10.1016/j.clindermatol.2011.03.012; Iohom G, 2001, EUR J ANAESTH, V18, P745, DOI 10.1046/j.1365-2346.2001.00916.x; Van Den Heuvel I, 2013, MINERVA ANESTESIOL, V79, P727	9	0	0	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0034-9356	2340-3284		REV ESP ANEST REANIM	Rev. Esp. Anestesiol. Reanim.	MAY	2015	62	5					280	284		10.1016/j.redar.2014.08.003			5	Anesthesiology	Anesthesiology	VH0ET	WOS:000449607500007	25497148				2020-06-30	J	Mercadante, S; Vellucci, R; Cuomo, A; Adile, C; Cortegiani, A; Valle, A; Villari, P; Casuccio, A				Mercadante, Sebastiano; Vellucci, Renato; Cuomo, Arturo; Adile, Claudio; Cortegiani, Andrea; Valle, Alessandro; Villari, Patrizia; Casuccio, Alessandra			Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain	SUPPORTIVE CARE IN CANCER			English	Article						Cancer pain; Breakthrough pain; Intranasal fentanyl; Tolerability	PEDIATRIC EMERGENCY-DEPARTMENT; PECTIN NASAL SPRAY; RANDOMIZED CONTROLLED-TRIAL; OPIOID-TOLERANT PATIENTS; OPEN-LABEL; DOUBLE-BLIND; INTRAVENOUS MORPHINE; HEALTHY-SUBJECTS; CROSSOVER TRIAL; BUCCAL TABLET	The aim of the present study was to assess the long-term tolerability and efficacy of intranasal fentanyl (INFS) in opioid-tolerant patients with breakthrough cancer pain (BTP). A 6 months, observational, prospective, cohort study design was employed to follow advanced cancer patients with BTP receiving INFS under routine clinical practice. Eligible adult cancer patients suffering from BTP had been prescribed INFS at effective doses. Data were collected at T0 and at month intervals for six months. The principal outcomes were the evaluation of possible serious adverse effects with prolonged use of INFS, the efficacy of BTP treatment with INFS, the quality of sleep, the rate of INFS discontinuation, and reasons for that. Seventy-five patients were surveyed. Thirty-four patients (45.3 %) had a follow-up at 3 months, and twelve patients (16 %) were followed up at 6 months. The mean opioid doses, expressed as oral morphine equivalents, ranged 111-180 mg/day, while the mean INFS doses were 87-119 mu g. Adverse effects were reported in a minority of patients and were considered to be associated with opioid therapy used for background pain. The quality of sleep significantly improved during the first 3-4 months. Finally, efficacy based on a general impression regarding the efficacy of INFS was good-excellent in most patients and statistically improved in time up to the third month. The long-term use of INFS in advanced cancer patients is effective and safe. No serious adverse effects were found up to six months of assessment. The level of quality of sleep and patients' satisfaction was relatively good, considering the advanced stage of disease.	[Mercadante, Sebastiano; Adile, Claudio; Villari, Patrizia] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; [Vellucci, Renato] Osped, Pain Unit, Florence, Italy; [Cuomo, Arturo] Natl Canc Inst Pascale, Pain Unit, Anesthesia & Intens Care, Naples, Italy; [Cortegiani, Andrea] Univ Palermo, Policlin P Giaccone, Sect Anesthesia Analgesia Intens Care & Emergency, Dept Biopathol Med & Forens Biotechnol DIBIMEF, Palermo, Italy; [Valle, Alessandro] FARO Fdn, Turin, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Sci Hlth Promot & Mother Child Care G DAless, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	cuomo, arturo/AAL-4416-2020; Cortegiani, Andrea/H-4902-2016; casuccio, alessandra/B-1730-2013	Cortegiani, Andrea/0000-0003-1416-9993; casuccio, alessandra/0000-0002-5676-9535; vellucci, renato/0000-0002-5462-7920; Adile, Claudio/0000-0002-0664-3520			Barrett MJ, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-74; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Chung S, 2010, PEDIATR RADIOL, V40, P1236, DOI 10.1007/s00247-009-1521-1; Dietrich E, 2012, ANN PHARMACOTHER, V46, P1382, DOI 10.1345/aph.1R069; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Harlos MS, 2013, J PAIN SYMPTOM MANAG, V46, P265, DOI 10.1016/j.jpainsymman.2012.07.009; Helliwell L, 2010, EMERG MED J, V27, P715, DOI 10.1136/emj.2010.101204; Herd D, 2009, EMERG MED AUSTRALAS, V21, P335, DOI 10.1111/j.1742-6723.2009.01207.x; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Johnston S, 2011, EMERG MED J, V28, P57, DOI 10.1136/emj.2009.078717; Kaessner N, 2012, INT J CLIN PHARM TH, V50, P665, DOI 10.5414/CP201737; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Kongsgaard UE, 2014, SUPPORT CARE CANCER, V22, P1655, DOI 10.1007/s00520-014-2128-0; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Kusre SR, 2011, EMERG MED J, V28, P1077, DOI 10.1136/emermed-2011-200892; Leppert Wojciech, 2010, Cancer Manag Res, V2, P225, DOI 10.2147/CMR.S7926; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Nave R, 2013, DRUG DELIV, V20, P216, DOI 10.3109/10717544.2012.762435; Nave R, 2012, INT J CLIN PHARM TH, V50, P751, DOI 10.5414/CP201729; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Plock N, 2013, INT J CLIN PHARM TH, V51, P495, DOI 10.5414/CP201867; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Smith HS, 2013, J PAIN RES, V6, P189, DOI 10.2147/JPR.S40745; Taylor D, 2014, J PAIN SYMPTOM MANAG, V47, P1001, DOI 10.1016/j.jpainsymman.2013.07.012; Thronas M, 2014, J Opioid Manag, V10, P21, DOI 10.5055/jom.2014.0188; Veldhorst-Janssen NML, 2012, J PALLIAT MED, V15, P631, DOI 10.1089/jpm.2012.0013; Veldhorst-Janssen NML, 2010, CLIN THER, V32, P1427, DOI 10.1016/j.clinthera.2010.07.001; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Vissers DCJ, 2011, VALUE HEALTH, V14, P274, DOI 10.1016/j.jval.2010.09.007; Webster LR, 2013, PAIN MED, V14, P1332, DOI 10.1111/pme.12184; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x	45	13	13	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	MAY	2015	23	5					1349	1354		10.1007/s00520-014-2491-x			6	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	CE9CJ	WOS:000352140900018	25351457	Bronze			2020-06-30	J	Belkouch, A; Zidouh, S; Rafai, M; Chouaib, N; Sirbou, R; Elbouti, A; Bakkali, H; Belyamani, L				Belkouch, Ahmed; Zidouh, Saad; Rafai, Mostafa; Chouaib, Naoufal; Sirbou, Rachid; Elbouti, Anass; Bakkali, Hicham; Belyamani, Lahcen			Does intranasal fentanyl provide efficient analgesia for renal colic in adults?	PAN AFRICAN MEDICAL JOURNAL			English	Article						Emergency department; renal colic; intranasal fentanyl	RANDOMIZED CONTROLLED-TRIAL; ORAL MORPHINE; CHILDREN; CROSSOVER; BURNS; PAIN	Introduction: Intranasal fentanyl provides rapid and powerful analgesia which is particularly interesting in patients without intravenous access. We propose to use it for analgesia in adults presenting renal colics. Methods: A prospective study was conducted from the 2nd January to February 2013 in our emergency department. Patients aged up to 18 years old who presented with renal colic were included in this audit. Patients were excluded if they had loss of consciousness, cognitive impairment, acute or chronic nasal problems. A formal written consent was obtained from patients. The research team was alerted by medical and nursing staff. A member of the research team would check with medical or nursing staff whether administration of Intra nasal (IN) fentanyl was required. It was administered at a pre-calculated dose of 1.5 mg/kg and 50 mg/ml concentration was used. Data was prospectively collected by one of the researchers at various intervals during the patient's presentation and recorded on a pre-formatted data sheet. Pain scores were collected at 5, 15, 30, 45 and 60 minutes following IN fentanyl using a visual analogue scale pain. Observations routinely collected for patients receiving IV opiates and any adverse events were also recorded. Results: 23 eligible patients were enrolled; median age was 51,3years. 47,8% were women and the mean weight was 73 kg. Median dose of IN fentanyl was 106 mu g. Two patients have required morphinic analgesia despite having received adapted dose of IN fentanyl. The initial pain scores before IN fentanyl were high with a median of 82,2 mm (59-100). Five minutes after IN fentanyl administration the median pain score dropped to 48mm(36-63) and achieved the lowest score of 8mm(0-22) at 30 min. Pain scores were significantly lower at 5 min (P < 0.001) and at all subsequent time points (P < 0.001). No side effects were recorded. Conclusion: Intranasal fentanyl seems to be efficient for analgesia in adult patients with renal colic.	[Belkouch, Ahmed; Zidouh, Saad; Rafai, Mostafa; Chouaib, Naoufal; Sirbou, Rachid; Elbouti, Anass; Bakkali, Hicham; Belyamani, Lahcen] Mohamed V Mil Hosp Instruct, Emergency Dept, Fac Med & Pharm, Rabat, Morocco	Belkouch, A (reprint author), Mohamed V Mil Hosp Instruct, Emergency Dept, Fac Med & Pharm, Rabat, Morocco.			Rafai, Mostafa/0000-0002-4465-0465; BELYAMANI, LAHCEN/0000-0003-1464-6649			Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Holdgate Anna, 2003, Emerg Med (Fremantle), V15, P441, DOI 10.1046/j.1442-2026.2003.00499.x; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; Younge P, 1999, EMERGEN MED, V11, P90	10	2	3	0	2	AFRICAN FIELD EPIDEMIOLOGY NETWORK-AFENET	KAMPALA	PO BOX 12874, KAMPALA, 00000, UGANDA	1937-8688			PAN AFR MED J	Pan Afr. Med. J.	APR 24	2015	20								UNSP 407	10.11604/pamj.2015.20.407.6010			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	DM8TL	WOS:000376637300003	26301011	DOAJ Gold, Green Published			2020-06-30	J	Zhu, M; Wang, HY; Zhu, A; Niu, KJ; Wang, GL				Zhu, Min; Wang, Haiyun; Zhu, Ai; Niu, Kaijun; Wang, Guolin			Meta-Analysis of Dexmedetomidine on Emergence Agitation and Recovery Profiles in Children after Sevoflurane Anesthesia: Different Administration and Different Dosage	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIALS; PEDIATRIC-PATIENTS; POSTOPERATIVE ANALGESIA; AMBULATORY SURGERY; REDUCES AGITATION; GREATER INCIDENCE; TONSILLECTOMY; HALOTHANE; DELIRIUM; MIDAZOLAM	The objective of this article is to evaluate the effect of dexmedetomidine on emergence agitation (EA) and recovery profiles in children after sevoflurane anesthesia and its pharmacological mechanisms. Standard bibliographic databases, including MEDLINE, EMBASE, PsycINFP, Springer and ISI Web of Knowledge, were artificially searched to identify all randomized controlled trials (RCTs) comparing the impact of dexmedetomidine with placebo, fentanyl and midazolam on EA and recovery profiles after sevoflurane anesthesia in post-anesthesia care unit (PACU). Two authors assessed the quality of each study independently in accordance with strict inclusion criteria and extracted data. RevMan 5.0 software was applied for performing statistic analysis. The outcomes analyzed included: 1) incidence of EA, 2) emergence time, 3) time to extubation, 4) incidence of post-operation nausea and vomiting, 5) number of patients requiring an analgesic, and 6) time to discharge from PACU. A total of 1364 patients (696 in the dexmedetomidine group and 668 in the placebo, fentanyl and midazolam group) from 20 prospective RCTs were included in the meta-analysis. Compared with placebo, dexmedetomidine decreased the incidence of EA (risk ratio [RR] 0.37; 95% CI 0.30 to 0.46), incidence of nausea and vomiting (RR 0.57; 95% CI 0.38 to 0.85) and number of patients requiring an analgesic (RR 0.43; 95% CI 0.31 to 0.59). However, dexmedetomidine had a significantly delayed effect on the emergence time (weighted mean differences [WMD] 1.16; 95% CI 0.72 to 1.60), time to extubation (WMD 0.61; 95% CI 0.27 to 0.95), and time to discharge from recovery room (WMD 2.67; 95% CI 0.95 to 4.39). Compared with fentanyl (RR 1.39; 95% CI 0.78 to 2.48) and midazolam (RR 1.12; 95% CI 0.54 to 2.35), dexmedetomidine has no significantly difference on the incidence of EA. However, the analgesia effect of dexmedetomidine on postoperation pain has no significantly statistical differences compared with fentanyl (RR 1.12; 95% CI 0.66 to 1.91), which implied that its analgesia effect might play an important role in decreasing the incident of EA. No evidence of publication bias was observed.	[Zhu, Min; Wang, Haiyun; Zhu, Ai; Wang, Guolin] Tianjin Med Univ, Gen Hosp, Tianjin Res Inst Anesthesiol, Dept Anesthesiol, Tianjin 300052, Peoples R China; [Niu, Kaijun] Tianjin Med Univ, Sch Publ Hlth, Dept Epidemiol, Tianjin 300052, Peoples R China	Wang, HY (reprint author), Tianjin Med Univ, Gen Hosp, Tianjin Res Inst Anesthesiol, Dept Anesthesiol, Tianjin 300052, Peoples R China.	wanghy819@hotmail.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China [81071059, 81100984]; Science and Technology Supported Key Project of Tianjin [12ZCZDSY03000]; Scientific Grant from Tianjin Health Bureau [09KZ106]	This work was supported by Natural Science Foundation of China (81071059, 81100984), Science and Technology Supported Key Project of Tianjin (12ZCZDSY03000), Scientific Grant from Tianjin Health Bureau (09KZ106). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akin A, 2012, PEDIATR ANESTH, V22, P871, DOI 10.1111/j.1460-9592.2012.03802.x; Ali Monaz Abdulrahman, 2013, Saudi J Anaesth, V7, P296, DOI 10.4103/1658-354X.115363; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; Asaad OM, 2011, EGYPT J ANAESTH, V27, P233, DOI [10.1016/j.egja.2011.07.006, 10.1016/j.egja.2010.12.005]; Bock M, 2002, BRIT J ANAESTH, V88, P790, DOI 10.1093/bja/88.6.790; Chen JY, 2013, CAN J ANESTH, V60, P385, DOI 10.1007/s12630-013-9886-x; Cohen IT, 2002, PAEDIATR ANAESTH, V12, P604, DOI 10.1046/j.1460-9592.2002.00903.x; Cohen IT, 2003, PAEDIATR ANAESTH, V13, P63, DOI 10.1046/j.1460-9592.2003.00948.x; Cohen IT, 2000, ANESTH ANALG, V94, P1178; Coursin D B, 2001, Curr Opin Crit Care, V7, P221, DOI 10.1097/00075198-200108000-00002; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Cravero JP, 2000, J CLIN ANESTH, V12, P397, DOI 10.1016/S0952-8180(00)00180-X; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dahmani S, 2014, CURR OPIN ANESTHESIO, V27, P309, DOI 10.1097/ACO.0000000000000076; DYCK JB, 1993, ANESTHESIOLOGY, V78, P813, DOI 10.1097/00000542-199305000-00002; El-Rahmawy GF, 2013, EGYPT J ANAESTH, V29, P137, DOI 10.1016/j.egja.2012.10.005; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Goa K L, 1999, Paediatr Drugs, V1, P127, DOI 10.2165/00128072-199901020-00005; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Gupta N, 2013, J NEUROSURG ANESTH, V25, P271, DOI 10.1097/ANA.0b013e31828cb6c0; Hamunen K, 2005, PAIN, V117, P40, DOI 10.1016/j.pain.2005.05.012; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Hatch DJ, 1999, BRIT J ANAESTH, V83, P42; He L, 2013, ANAESTH INTENS CARE, V41, P328, DOI 10.1177/0310057X1304100309; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Ihmsen H, 2012, ANAESTHESIST, V61, P1059, DOI 10.1007/s00101-012-2114-1; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jurgens S, 2003, ANAESTHESIA, V58, P296, DOI 10.1046/j.1365-2044.2003.307226.x; Keaney A, 2004, PEDIATR ANESTH, V14, P866, DOI 10.1111/j.1460-9592.2004.01310.x; Kim NY, 2014, YONSEI MED J, V55, P209, DOI 10.3349/ymj.2014.55.1.209; Koruk S, 2010, J ANESTH, V24, P858, DOI 10.1007/s00540-010-1023-1; Kuratani N, 2008, ANESTHESIOLOGY, V109, P225, DOI 10.1097/ALN.0b013e31817f5c18; Lalicevic S, 2004, CURR THER RES CLIN E, V65, P360, DOI 10.1016/j.curtheres.2004.07.002; Meng QT, 2012, INT J PEDIATR OTORHI, V76, P1036, DOI 10.1016/j.ijporl.2012.03.028; Moir MS, 2000, LARYNGOSCOPE, V110, P1824, DOI 10.1097/00005537-200011000-00011; Mountain Brian W, 2011, AANA J, V79, P219; Ozcengiz D, 2011, J ANESTH, V25, P184, DOI 10.1007/s00540-011-1099-2; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; Pestieau SR, 2011, PEDIATR ANESTH, V21, P1128, DOI 10.1111/j.1460-9592.2011.03615.x; Phan Hanna, 2008, Paediatr Drugs, V10, P49, DOI 10.2165/00148581-200810010-00006; Saadawy I, 2009, ACTA ANAESTH SCAND, V53, P251, DOI 10.1111/j.1399-6576.2008.01818.x; Sato M, 2010, J ANESTH, V24, P675, DOI 10.1007/s00540-010-0976-4; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Sun L, 2014, ACTA ANAESTH SCAND, V58, P642, DOI 10.1111/aas.12292; Tobias JD, 2004, SOUTH MED J, V97, P451, DOI 10.1097/00007611-200405000-00007; Tobias JD, 2002, PAEDIATR ANAESTH, V12, P171, DOI 10.1046/j.1460-9592.2002.00805.x; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; TWERSKY RS, 1993, J CLIN ANESTH, V5, pS57; Uysal HY, 2011, J CLIN ANESTH, V23, P53, DOI 10.1016/j.jclinane.2010.07.001; Viitanen H, 1999, ANESTH ANALG, V89, P75, DOI 10.1097/00000539-199907000-00014; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Voepel-Lewis Terri, 2005, J Perianesth Nurs, V20, P239, DOI 10.1016/j.jopan.2005.05.006; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08; Xu LL, 2012, J ANESTH, V26, P556, DOI 10.1007/s00540-012-1354-1; Zhang CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099718	63	30	37	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0123728	10.1371/journal.pone.0123728			22	Multidisciplinary Sciences	Science & Technology - Other Topics	CF8XK	WOS:000352845100203	25874562	DOAJ Gold, Green Published			2020-06-30	J	Rosseland, LA; Narum, J; Stubhaug, A; Kongsgaard, U; Sorteberg, W; Sorteberg, A				Rosseland, Leiv Arne; Narum, Jon; Stubhaug, Audun; Kongsgaard, Ulf; Sorteberg, Wilhelm; Sorteberg, Angelika			The effect of tracheotomy on drug consumption in patients with acute aneurysmal subarachnoid hemorrhage: an observational study	BMC ANESTHESIOLOGY			English	Article						Tracheotomy; Subarachnoid hemorrhage; Blood pressure; Stroke; Critical care; Midazolam; Fentanyl; Noradrenaline; Dopamine	PERCUTANEOUS DILATATIONAL TRACHEOSTOMY; CRITICALLY-ILL PATIENTS; CARE-UNIT PATIENTS; SURGICAL TRACHEOSTOMY; INTENSIVE-CARE; RANDOMIZED-TRIAL; RISK-FACTORS; FOLLOW-UP; METAANALYSIS; VENTILATION	Background: Patients with aneurysmal subarachnoid hemorrhage (aSAH) are common in intensive care units (ICU). In patients with aSAH, sedation is used as a neuroprotective measure in order to secure adequate cerebral perfusion pressure (CPP). Compared with the use of an endotracheal tube, a tracheotomy has the advantage of securing the airway at a much lower level of distress, and aSAH patients can often be awakened more rapidly. Little is known about the impact of tracheotomy on the consumption of sedative/analgesic and vasoactive drugs and the maintenance of CPP within defined limits in aSAH patients. Methods: We conducted an observational study of aSAH patients who underwent percutaneous tracheotomy. A prospective registry of patient data was supplemented with retrospective retrievals from medical records. Sedative, analgesic and vasoactive drug doses were registered for 3 days prior to and after percutaneous tracheotomy, respectively. Blood pressure, CPP, and the mode of mechanical ventilation were registered 24 h prior to and after tracheotomy. Results: Between January 2001 and June 2009, 902 aSAH patients were admitted to our hospital; 74 (8%) were deeply comatose/dying upon arrival. The ruptured aneurysm was repaired in 828 patients (surgical repair 50%) and percutaneous tracheotomy was performed 182 times in 178 patients (59 men and 119 women). This subpopulation (178 of 828 patients) was significantly older (56 vs. 53 years) and presented with a more severe Hunt & Hess grade (p < 0.001). Percutaneous tracheotomy caused a marked decline in mean daily consumption of the analgesics/sedatives fentanyl, midazolam, and propofol, as well as the vasoactive drugs noradrenaline and dopamine. These declines were statistically and clinically significant. The mean CPP was 76 mmHg (SD 8.6) the day before and 79 mmHg (SD 9.6) 24 h after percutaneous tracheotomy. After percutaneous tracheotomy, mechanical ventilatory support could be reduced to a patient-controlled ventilatory support mode in a significant number of patients (p < 0.001). Conclusions: Percutaneous tracheotomy in aSAH patients is a swift procedure with low risk that is associated with a significant decline in the consumption of sedative/analgesic and vasoactive drugs while clinical surveillance parameters remain stable or improve.	[Rosseland, Leiv Arne; Narum, Jon; Stubhaug, Audun; Kongsgaard, Ulf] Oslo Univ Hosp, Rikshosp, Div Emergencies & Crit Care, Dept Anesthesiol, N-0027 Oslo, Norway; [Rosseland, Leiv Arne; Stubhaug, Audun; Kongsgaard, Ulf] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Sorteberg, Wilhelm; Sorteberg, Angelika] Oslo Univ Hosp, Rikshosp, Dept Neurosurg, N-0027 Oslo, Norway	Rosseland, LA (reprint author), Oslo Univ Hosp, Rikshosp, Div Emergencies & Crit Care, Dept Anesthesiol, N-0027 Oslo, Norway.	l.a.rosseland@medisin.uio.no					Antonelli M, 2005, CRIT CARE MED, V33, P1015, DOI 10.1097/01.CCM.0000163401.77581.86; Audibert G, 1996, ANN FR ANESTH, V15, P338; AWAD IA, 1987, STROKE, V18, P365, DOI 10.1161/01.STR.18.2.365; Delaney A, 2006, CRIT CARE, V10, DOI 10.1186/cc4887; Freeman BD, 2001, CRIT CARE MED, V29, P926, DOI 10.1097/00003246-200105000-00002; Griffiths J, 2005, BMJ-BRIT MED J, V330, P1243, DOI 10.1136/bmj.38467.485671.E0; HAZARD P, 1991, CRIT CARE MED, V19, P1018, DOI 10.1097/00003246-199108000-00008; Holdgaard HO, 1998, ACTA ANAESTH SCAND, V42, P545, DOI 10.1111/j.1399-6576.1998.tb05164.x; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Kleffmann J, 2012, NEUROCRIT CARE, V17, P85, DOI 10.1007/s12028-012-9709-x; Kost Karen M, 2005, Laryngoscope, V115, P1, DOI 10.1097/01.MLG.0000163744.89688.E8; LeRoux PD, 1996, J NEUROSURG, V85, P39, DOI 10.3171/jns.1996.85.1.0039; Lindekleiv H, 2011, NEUROLOGY, V76, P637, DOI 10.1212/WNL.0b013e31820c30d3; Meyer R, 2011, NEUROCRIT CARE, V14, P24, DOI 10.1007/s12028-010-9437-z; Mocco J, 2006, NEUROSURGERY, V59, P529, DOI 10.1227/01.NEU.0000228680.22550.A2; Neuschmelting V, 2009, ACTA NEUROCHIR, V151, P487, DOI 10.1007/s00701-009-0287-4; Nieszkowska A, 2005, CRIT CARE MED, V33, P2527, DOI 10.1097/01.CCM.0000186898.58709.AA; Nieuwkamp DJ, 2011, STROKE, V42, P902, DOI 10.1161/STROKEAHA.110.602722; Palma JA, 2012, CEPHALALGIA, V32, P500, DOI 10.1177/0333102412444011; Rondeau N, 2012, NEUROCRIT CARE, V17, P183, DOI 10.1007/s12028-012-9732-y; Rosseland LA, 2011, ACTA ANAESTH SCAND, V55, P835, DOI 10.1111/j.1399-6576.2011.02458.x; Samuels O, 2011, NEUROCRIT CARE, V14, P334, DOI 10.1007/s12028-011-9505-z; Sandvei MS, 2012, ACTA NEUROL SCAND, V125, P382, DOI 10.1111/j.1600-0404.2011.01578.x; Veelo DP, 2006, CRIT CARE, V10, DOI 10.1186/cc4961; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Young D, 2013, JAMA-J AM MED ASSOC, V309, P2121, DOI 10.1001/jama.2013.5154	26	2	2	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	APR 8	2015	15								47	10.1186/s12871-015-0029-5			8	Anesthesiology	Anesthesiology	CF8WZ	WOS:000352844000001	25883531	DOAJ Gold, Green Published			2020-06-30	J	Nusrat, S; Mahmood, S; Bitar, H; Tierney, WM; Bielefeldt, K; Madhoun, MF				Nusrat, Salman; Mahmood, Sultan; Bitar, Hussein; Tierney, William M.; Bielefeldt, Klaus; Madhoun, Mohammad F.			The Impact of Chronic Opioid Use on Colonoscopy Outcomes	DIGESTIVE DISEASES AND SCIENCES			English	Article						Sedation; Procedural duration; Adverse events; Discomfort; Bowel preparation	GASTROINTESTINAL ENDOSCOPY; UNITED-STATES; SCREENING COLONOSCOPY; POLYETHYLENE-GLYCOL; CHRONIC PAIN; SEDATION; POPULATION; QUALITY; PATIENT; RISK	Background Endoscopic procedures are frequently performed on patients chronically on opioids, raising concerns about the safety and efficacy of conventional sedation. Aims We hypothesized that chronic opioid use is associated with longer procedure times, higher dosages of sedation medications, and an increase in adverse effects. Methods This is a retrospective review from June 2012 to June 2013. Patients on chronic opioids (opioids use >= 12 weeks) were compared to randomly selected patients matched for age, race, and sex. Multivariate regression analysis was performed to identify factors that were independently predictive of longer procedure times. Results Patients on chronic opioids required higher doses of fentanyl (122.0 +/- 45.3 vs. 105.8 +/- 47.2 lg; P < 0.0001) and midazolam (5.3 +/- 5.3 vs. 4.4 +/- 2 mg; P = 0.0037) and were more likely to receive diphenhydramine (42.8 vs. 22.6 %; P < 0.001). The induction period (11.3 +/- 8.8 vs. 7.5 +/- 4.0 min), duration of procedure (39.1 +/- 17.5 vs. 33.4 +/- 14.1 min), and recovery times (38.7 +/- 15.3 vs. 33.8 +/- 12.1 min) were significantly longer for patients on chronic opioids. In the multivariate regression analysis, opioid use was an independent predictor of longer procedure duration (P < 0.05). Hypotensive episodes did not differ between groups (2.8 vs. 2.7 %; P = 0.8). However, patients on chronic opioids experienced more pain (13.4 vs. 5.9 %; P 0.001) and hypertensive episodes (8.1 vs. 2.8 %; P 0.002). Conclusion Patients on chronic opioids represent a highrisk population with longer procedural times and more discomfort, despite higher dosages of sedative agents. Prospective studies are required to define the risks and benefits of more costly alternative sedation strategies for patients on chronic opioids.	[Nusrat, Salman; Mahmood, Sultan; Bitar, Hussein; Tierney, William M.; Madhoun, Mohammad F.] Univ Oklahoma, Hlth Sci Ctr, Dept Internal Med, Sect Digest Dis, Oklahoma City, OK 73104 USA; [Nusrat, Salman; Mahmood, Sultan; Bitar, Hussein; Tierney, William M.; Madhoun, Mohammad F.] Vet Affair Med Ctr, Oklahoma City, OK USA; [Bielefeldt, Klaus] Univ Pittsburgh, Med Ctr, Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA	Nusrat, S (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Internal Med, Sect Digest Dis, 920 Stanton Young Blvd WP 1345, Oklahoma City, OK 73104 USA.	salman-nusrat@ouhsc.edu					Aisenberg J, 2005, AM J GASTROENTEROL, V100, P996, DOI 10.1111/j.1572-0241.2005.50034.x; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Bal BS, 2012, DIGEST DIS SCI, V57, P2527, DOI 10.1007/s10620-012-2188-2; Bernstein C, 2005, GASTROINTEST ENDOSC, V61, P72, DOI 10.1016/S0016-5107(04)02461-7; Blero D, 2012, NAT REV GASTRO HEPAT, V9, P162, DOI 10.1038/nrgastro.2012.3; Bowles CJA, 2004, GUT, V53, P277, DOI 10.1136/gut.2003.016436; Bryson EO, 2011, INT ANESTHESIOL CLIN, V49, P67, DOI 10.1097/AIA.0b013e3181fa13d6; Chung YW, 2007, DIGEST LIVER DIS, V39, P872, DOI 10.1016/j.dld.2007.04.019; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Corley DA, 2013, CLIN GASTROENTEROL H, V11, P172, DOI 10.1016/j.cgh.2012.09.010; Daubresse M, 2013, MED CARE, V51, P870, DOI 10.1097/MLR.0b013e3182a95d86; Davila RE, 2006, GASTROINTEST ENDOSC, V63, P546, DOI 10.1016/j.gie.2006.02.002; Demyttenaere K, 2007, PAIN, V129, P332, DOI 10.1016/j.pain.2007.01.022; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Froehlich F, 2005, GASTROINTEST ENDOSC, V61, P378, DOI 10.1016/S0016-5107(04)02776-2; Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009; Glomsaker TB, 2013, SCAND J GASTROENTERO, V48, P868, DOI 10.3109/00365521.2013.794470; Harewood GC, 2002, AM J GASTROENTEROL, V97, P3186, DOI 10.1111/j.1572-0241.2002.07129.x; Hassan C, 2012, ENDOSCOPY, V44, P456, DOI 10.1055/s-0032-1308936; Hoff G, 2013, NAT REV GASTRO HEPAT, V10, P325, DOI 10.1038/nrgastro.2013.71; Holme O, 2013, ENDOSCOPY, V45, P691, DOI 10.1055/s-0033-1344239; Joseph EK, 2010, J NEUROSCI, V30, P4660, DOI 10.1523/JNEUROSCI.5530-09.2010; Kim WH, 2000, GASTROINTEST ENDOSC, V52, P600, DOI 10.1067/mge.2000.109802; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Lee J, 1999, ULSTER MED J, V68, P68; Leung WD, 2014, DIGEST DIS SCI, V59, P12, DOI 10.1007/s10620-013-2976-3; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Michelini S, 1996, PHARMACOPSYCHIATRY, V29, P127; Minoli G, 2000, GASTROINTEST ENDOSC, V52, P39, DOI 10.1067/mge.2000.106683; Mosher HJ, 2014, J HOSP MED, V9, P82, DOI 10.1002/jhm.2113; Nelson DB, 2002, GASTROINTEST ENDOSC, V55, P307, DOI 10.1067/mge.2002.121883; Pizzi LT, 2012, PHARMACOTHERAPY, V32, P502, DOI 10.1002/j.1875-9114.2012.01101.x; QUINE MA, 1995, GUT, V36, P462, DOI 10.1136/gut.36.3.462; Radaelli F, 2008, AM J GASTROENTEROL, V103, P1122, DOI 10.1111/j.1572-0241.2007.01778.x; Research CoAP Care Research IoMCoAP Medicine Io, 2011, REL PAIN AM BL TRANS; Rockville M., 2009, SUBSTANCE ABUSE MENT; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Seeff LC, 2004, GASTROENTEROLOGY, V127, P1670, DOI 10.1053/j.gastro.2004.09.051; Shah HA, 2007, GASTROENTEROLOGY, V132, P2297, DOI 10.1053/j.gastro.2007.03.032; Sherer EA, 2012, GASTROINTEST ENDOSC, V75, P545, DOI 10.1016/j.gie.2011.09.022; Sinicrope PS, 2012, CANCER EPIDEM BIOMAR, V21, P347, DOI 10.1158/1055-9965.EPI-11-0818; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; SULLIVAN M, 1993, APS J, V2, P141, DOI 10.1016/S1058-9139(05)80078-6; Sullivan MD, 2008, PAIN, V138, P440, DOI 10.1016/j.pain.2008.04.027; Taylor C, 2001, AM J GASTROENTEROL, V96, P710; Terruzzi V, 2001, GASTROINTEST ENDOSC, V54, P169, DOI 10.1067/mge.2001.113923; URE T, 1995, SURG ENDOSC-ULTRAS, V9, P505; Vargo JJ, 2007, J CLIN GASTROENTEROL, V41, P591, DOI 10.1097/01.mcg.0000225634.52780.0e; Verma S, 2012, WORLD J GASTROENTERO, V18, P4350, DOI 10.3748/wjg.v18.i32.4350; Wood JD, 2004, NEUROGASTROENT MOTIL, V16, P17, DOI 10.1111/j.1743-3150.2004.00554.x	50	6	6	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	APR	2015	60	4					1016	1023		10.1007/s10620-015-3639-3			8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CI0YC	WOS:000354464900034	25822037				2020-06-30	J	Ozturk, T; Agdanli, D; Bayturan, O; Cikrikci, C; Keles, GT				Ozturk, T.; Agdanli, D.; Bayturan, O.; Cikrikci, C.; Keles, G. T.			Effects of conventional vs high-dose rocuronium on the QTc interval during anesthesia induction and intubation in patients undergoing coronary artery surgery: a randomized, double-blind, parallel trial	BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH			English	Article						QTc; Rocuronium; Induction; Intubation	TRACHEAL INTUBATION; CORRUGATOR SUPERCILII; PROPOFOL ANESTHESIA; ORBICULARIS OCULI; SPECTRAL ENTROPY; DISEASE; IMPACT	Myocardial ischemia, as well as the induction agents used in anesthesia, may cause corrected QT interval (QTc) prolongation. The objective of this randomized, double-blind trial was to determine the effects of high-vs conventional-dose bolus rocuronium on QTc duration and the incidence of dysrhythmias following anesthesia induction and intubation. Fifty patients about to undergo coronary artery surgery were randomly allocated to receive conventional-dose (0.6 mg/kg, group C, n=25) or high-dose (1.2 mg/kg, group H, n=25) rocuronium after induction with etomidate and fentanyl. QTc, heart rate, and mean arterial pressure were recorded before induction (T0), after induction (T1), after rocuronium (just before laryngoscopy; T2), 2 min after intubation (T3), and 5 min after intubation (T4). The occurrence of dysrhythmias was recorded. In both groups, QTc was significantly longer at T3 than at baseline [475 vs 429 ms in group C (P=0.001), and 459 vs 434 ms in group H (P=0.005)]. The incidence of dysrhythmias in group C (28%) and in group H (24%) was similar. The QTc after high-dose rocuronium was not significantly longer than after conventional-dose rocuronium in patients about to undergo coronary artery surgery who were induced with etomidate and fentanyl. In both groups, compared with baseline, QTc was most prolonged at 2 min after intubation, suggesting that QTc prolongation may be due to the nociceptive stimulus of intubation.	[Ozturk, T.; Agdanli, D.; Cikrikci, C.; Keles, G. T.] Celal Bayar Univ, Sch Med, Dept Anesthesiol & Reanimat, Manisa, Turkey; [Bayturan, O.] Celal Bayar Univ, Sch Med, Dept Cardiol, Manisa, Turkey	Ozturk, T (reprint author), Celal Bayar Univ, Sch Med, Dept Anesthesiol & Reanimat, Manisa, Turkey.	ozturktulun@yahoo.com			Scientific Research Council of Celal Bayar University, Manisa, TurkeyCelal Bayar University	Research supported by the Scientific Research Council of Celal Bayar University, Manisa, Turkey.	Abou-Arab MH, 2007, BRIT J ANAESTH, V98, P604, DOI 10.1093/bja/aem064; Artukoglu F, 2008, ANN CARD ANAESTH, V11, P38, DOI [10.4103/0971-9784.38448, 10.4103/0971-9784.41575]; Babu NG, 2011, INT J PHARM BIOMED R, V2, P182; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Cammu G, 2005, EUR J ANAESTH, V22, P25, DOI 10.1017/S0265021505000062; Cammu G, 2007, ACTA ANAESTH BELG, V58, P7; Claudius C, 2008, ANESTHESIOLOGY, V108, P1117, DOI 10.1097/ALN.0b013e318173f62f; Fuchs-Buder T, 2007, ACTA ANAESTH SCAND, V51, P789, DOI 10.1111/j.1399-6576.2007.01352.x; Hans P, 2006, BRIT J ANAESTH, V97, P842, DOI 10.1093/bja/ael253; Kawaguchi M, 2009, BRIT J ANAESTH, V102, P667, DOI 10.1093/bja/aep040; Lee HJ, 2009, BRIT J ANAESTH, V102, P869, DOI 10.1093/bja/aep064; Lee HJ, 2013, EUR J ANAESTH, V30, P556, DOI 10.1097/EJA.0b013e3283625039; LISCHKE V, 1994, ACTA ANAESTH SCAND, V38, P144, DOI 10.1111/j.1399-6576.1994.tb03856.x; Lysakowski C, 2007, ACTA ANAESTH SCAND, V51, P848, DOI 10.1111/j.1399-6576.2007.01367.x; Mencke T, 2006, ANESTH ANALG, V102, P306, DOI 10.1213/01.ANE.0000181290.37527.CE; Puhringer FK, 2008, ANESTHESIOLOGY, V109, P188, DOI 10.1097/ALN.0b013e31817f5bc7; Schneider G, 2002, J NEUROSURG ANESTH, V14, P7, DOI 10.1097/00008506-200201000-00002; Smith CE, 1999, J CARDIOTHOR VASC AN, V13, P567, DOI 10.1016/S1053-0770(99)90009-5; Staikou C, 2014, BRIT J ANAESTH, V112, P217, DOI 10.1093/bja/aet412; Sze E, 2008, ANN NONINVAS ELECTRO, V13, P327, DOI 10.1111/j.1542-474X.2008.00250.x	20	1	2	0	1	ASSOC BRAS DIVULG CIENTIFICA	SAO PAULO	FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL	0100-879X	1678-4510		BRAZ J MED BIOL RES	Brazilian J. Med. Biol. Res.	APR	2015	48	4					370	376		10.1590/1414-431X20144294			7	Biology; Medicine, Research & Experimental	Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine	CH6ZH	WOS:000354184800013	25714880	DOAJ Gold, Green Published			2020-06-30	J	Srivastava, VK; Agrawal, S; Kadiyala, VN; Ahmed, M; Sharma, S; Kumar, R				Srivastava, Vinit K.; Agrawal, Sanjay; Kadiyala, Venkat N.; Ahmed, Mukadder; Sharma, Sunil; Kumar, Raj			The efficacy of pregabalin for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled double-blind study	JOURNAL OF ANESTHESIA			English	Article						Pregabalin; Catheter-related bladder discomfort; Analgesia	NEUROGENIC DETRUSOR OVERACTIVITY; METAANALYSIS; TOLTERODINE; GABAPENTIN; PAIN	The present study evaluated the efficacy of preoperative pregabalin for prevention of catheter-related bladder discomfort. Prospective, randomized, placebo controlled, double blinded study. Sixty patients of either sex undergoing elective spine surgery and requiring urinary bladder catheterization were randomly assigned to two groups. The patients in Group P (pregabalin group) received 150 mg of pregabalin orally 1 h prior to induction of anesthesia with sips of water and the patients in Group C (control group) received placebo. Anesthesia technique was identical in both the groups. Catheter-related bladder discomfort (CRBD) was evaluated on a 4-point scale (1 = no discomfort, 2 = mild, 3 = moderate, 4 = severe), on arrival (0 h) and again at 1, 2, and 6 h postoperatively. Patients were provided patient-controlled analgesia with fentanyl for postoperative pain relief. The incidence of CRBD was significantly less in the pregabalin group compared with the control group at all time intervals (P < 0.05). The severity of CRBD was reduced in the pregabalin group compared with the control group at all time intervals except 6 h. The postoperative consumption of fentanyl was significantly less in group P, while the sedation score was significantly higher in the group P compared to group C. Pretreatment with pregabalin 150 mg prevents CRBD and also decreases postoperative fentanyl consumption. Clinical Trials.gov identifier: (ref: CTRI/2013/11/004170).	[Srivastava, Vinit K.; Kadiyala, Venkat N.; Ahmed, Mukadder] Apollo Hosp, Dept Anesthesia, Bilaspur 495006, Chhattisgarh, India; [Agrawal, Sanjay] Himalayan Inst Med Sci, Dept Anesthesia, Dehra Dun, Uttarakhand, India; [Sharma, Sunil; Kumar, Raj] Apollo Hosp, Dept Neurosurg, Bilaspur 495006, Chhattisgarh, India	Srivastava, VK (reprint author), Apollo Hosp, Dept Anesthesia, Bilaspur 495006, Chhattisgarh, India.	drvinit75@gmail.com		Agrawal, Sanjay/0000-0002-2806-1943			Agarwal A, 2008, BRIT J ANAESTH, V101, P506, DOI 10.1093/bja/aen217; Agarwal A, 2006, BRIT J ANAESTH, V96, P377, DOI 10.1093/bja/ael003; Bala I, 2012, UROLOGY, V79, P853, DOI 10.1016/j.urology.2011.11.050; Burke SM, 2010, ANESTH ANALG, V110, P1180, DOI 10.1213/ANE.0b013e3181cf949a; Clarke H, 2012, ANESTH ANALG, V115, P428, DOI 10.1213/ANE.0b013e318249d36e; Ergenoglu P, 2012, CURR THER RES CLIN E, V73, P186, DOI 10.1016/j.curtheres.2012.08.001; Henriques T, 2001, SPINE, V26, P293, DOI 10.1097/00007632-200102010-00015; Kavoussi R, 2006, EUR NEUROPSYCHOPHARM, V16, pS128, DOI 10.1016/j.euroneuro.2006.04.005; Loutochin O, 2012, NEUROUROL URODYNAM, V31, P1197, DOI 10.1002/nau.21214; Madhuvrata P, 2012, EUR UROL, V62, P816, DOI 10.1016/j.eururo.2012.02.036; Marencak J, 2011, NEUROUROL URODYNAM, V30, P75, DOI 10.1002/nau.20928; Moharari RS, 2014, PAIN PRACT, V14, P146, DOI 10.1111/papr.12055; Ryu JH, 2013, BRIT J ANAESTH, V111, P932, DOI 10.1093/bja/aet249; Tauzin-Fin P, 2012, ANN FR ANESTH, V31, P605, DOI 10.1016/j.annfar.2012.03.009; Thorpe AJ, 2010, CURR OPIN INVEST DR, V11, P761; White PF, 2009, ANESTH ANALG, V108, P1140, DOI 10.1213/ane.0b013e31818d40ce; Yoshimura N, 2002, J UROLOGY, V168, P1897, DOI 10.1016/S0022-5347(05)64261-9	17	20	21	0	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2015	29	2					212	216		10.1007/s00540-014-1911-x			5	Anesthesiology	Anesthesiology	CF9CL	WOS:000352859100010	25200037				2020-06-30	J	Rutherford, W; Sneyd, R; Weekes, L; Thomas, M; Edwards, S; Pugsley, R; Marshall, S; Bickley, J; Clark, T; Franklin, D; Hughes, A; Connor, D; Mint, G; Montgomery, J; Paddle, J; Rockett, M; Kusre, S; Wilson, T; Teare, T; Boyd, M; Droog, S; Tavener, G; Gill, J; Souter, N; Savva, A; Gardiner, H; Gokhale, O; Debrunner, R; Marginean, C; Fontaine, E; Lawson, T; Mawer, R; Howells, E; Boyd, N; Ward, C; Allen, R; Carr, G; Braggins, S; Robinson-Lynch, C; Collingwood, L; Gould, J; Lau, E; Leung, S; Malak, M; Hills, G; Vanhoutte, J; Stammers, K; Patel, R; Poore, S; Fox, J; Davies, R; Humphries, G; Twohig, C; Yi-Ling, JL; Morjaria, A; Shields, T; Thakral, N; Mahendran, N; Nageswaran, P; Kyle, L; Theverajah, J; Bilak, J; Osbourne, J; Young, M; Sherwood, E; Jerrum, C; Marsh, S; Shephard, E; Tolppa, T; Dare, O; Walker, E; Rui, JLZ; Dbeis, R; Payne, F; Follows, A; Chu, C; Dang, T; Ball, G; Whyman, S; Mohammed, M; Thomas, O				Rutherford, William; Sneyd, Robert; Weekes, Lauren; Thomas, Megan; Edwards, Sean; Pugsley, Rebecca; Marshall, Simon; Bickley, James; Clark, Thomas; Franklin, Danielle; Hughes, Alexandra; Connor, David; Mint, Gary; Montgomery, Jane; Paddle, Jonathan; Rockett, Mark; Kusre, Sandeep; Wilson, Timothy; Teare, Thomas; Boyd, Matthew; Droog, Sarah; Tavener, Geoff; Gill, Juleen; Souter, Nicholas; Savva, Andrew; Gardiner, Harriet; Gokhale, Olivia; Debrunner, Robert; Marginean, Carmen; Fontaine, Elizabeth; Lawson, Tom; Mawer, Rebecca; Howells, Emily; Boyd, Nick; Ward, Claire; Allen, Richard; Carr, Georgie; Braggins, Suzanne; Robinson-Lynch, Callan; Collingwood, Louise; Gould, Jain; Lau, Elizabeth; Leung, Siu; Malak, Marian; Hills, George; Vanhoutte, Jane; Stammers, Kathryn; Patel, Roma; Poore, Sophie; Fox, Jonah; Davies, Rhoclri; Humphries, George; Twohig, Callum; Yi-Ling, June Low; Morjaria, Anisha; Shields, Tim; Thakral, Nikhil; Mahendran, Nilakshini; Nageswaran, Pratheeshaa; Kyle, Laura; Theverajah, Josh; Bilak, Joanna; Osbourne, Jack; Young, Matt; Sherwood, Emily; Jerrum, Christina; Marsh, Sophie; Shephard, Emma; Tolppa, Timo; Dare, Oliver; Walker, Eleanor; Rui, Joyce Luk Zhu; Dbeis, Rachel; Payne, Francesca; Follows, Andrew; Chu, Caren; Dang, Tien; Ball, Geoffrey; Whyman, Sarah; Mohammed, Mazed; Thomas, Oliver		SWARM	Sedation practice in six acute hospitals - a snapshot survey	ANAESTHESIA			English	Article							UPPER GASTROINTESTINAL ENDOSCOPY	The number of UK hospital patients receiving procedural sedation remains unknown. Our trainee research network recorded all procedural sedation given over a 48-h period at six acute hospitals in the South West of England. Three hundred and sixty patients aged between 1 and 96 years old were sedated. Most sedation occurred in endoscopy units (56.4%), operating theatres (30.3%) and cardiology departments (7.2%). Sedation was administered in 82.8% of cases by consultants, and in only 5.6% of cases by nurses. The most frequent sedative combination was midazolam and fentanyl, with median (IQR [range]) doses of 2 (2-3 [1-10]) mg and 50 (50-100 [10-300]) mu g used, respectively. We tested a methodology that could be used in a UK-wide denominator survey to describe sedation practice across the NHS. A national audit collecting serious adverse outcomes of sedation (severe harm or death) could then identify hotspots of sedation risk (clinical areas, patient groups, procedures and sedation techniques) where consistent application of current and improved standards might reduce harm.	[Rutherford, William; Sneyd, Robert; Weekes, Lauren] Derriford Hosp, Plymouth, Devon, England; [Thomas, Megan] Royal Cornwall Hosp, Truro, Cornwall, England; [Edwards, Sean] Royal Devon & Exeter Hosp, Exeter, Devon, England; [Pugsley, Rebecca] Musgrove Pk Hosp, Taunton, Somerset, England; [Marshall, Simon] Torbay Hosp, Torquay, Devon, England; [Bickley, James] North Devon Dist Hosp, Barnstaple, Devon, England; [SWARM] South West Peninsula Deanery, Plymouth, Devon, England	Rutherford, W (reprint author), Derriford Hosp, Plymouth, Devon, England.	william.rutherford@nhs.net	Boyd, Matthew/AAH-7649-2020; Sneyd, John R/B-2957-2012; Dbeis, Rachel/N-3729-2015	Sneyd, John R/0000-0003-3546-9856; Dare, Oliver/0000-0002-2647-0022; Dbeis, Rachel/0000-0002-4950-5339; kyle, laura/0000-0002-2394-3736; Franklin, Danielle/0000-0001-7394-0114			Academy of Medical Royal Colleges, 2014, IMPL ENS SAF SED PRA; [Anonymous], 2003, GUID SAF SED END PRO; DANESHMEND TK, 1991, GUT, V32, P12, DOI 10.1136/gut.32.1.12; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; National confidential enquiry into patient o death, 2004, SCOP OUR PRACT; National Institute for Health and Care Excellence, 2010, SED CHILDR YOUNG PEO; National Patient Safety Agency, 2008, RED RISK OV MAD INJ; QUINE MA, 1995, GUT, V36, P462, DOI 10.1136/gut.36.3.462; *ROYAL COLL RAD, 2003, SAF SED AN AN RAD DE; Royal College of Anaesthetists, 2012, SAF SED AD EM DEP; Royal College of Anaesthetists, 2009, NAT AUD MAJ COMPL CE; The Royal College of Anaesthetists, 2011, MAJ COMPL AIRW MAN U	12	8	8	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	APR	2015	70	4					407	415		10.1111/anae.12940			9	Anesthesiology	Anesthesiology	CE8YL	WOS:000352129900007	25407168				2020-06-30	J	Lyon, RM; Perkins, ZB; Chatterjee, D; Lockey, DJ; Russell, MQ				Lyon, Richard M.; Perkins, Zane B.; Chatterjee, Debamoy; Lockey, David J.; Russell, Malcolm Q.		Kent Surrey Sussex Air Ambulance	Significant modification of traditional rapid sequence induction improves safety and effectiveness of pre-hospital trauma anaesthesia	CRITICAL CARE			English	Article							HEMODYNAMIC-RESPONSE; TRACHEAL INTUBATION; BRAIN-INJURY; HEAD-INJURY; EMERGENCY-DEPARTMENT; AIRWAY MANAGEMENT; NATIONAL AUDIT; KETAMINE; AGENT; HYPERTENSION	Introduction: Rapid Sequence Induction of anaesthesia (RSI) is the recommended method to facilitate emergency tracheal intubation in trauma patients. In emergency situations, a simple and standardised RSI protocol may improve the safety and effectiveness of the procedure. A crucial component of developing a standardised protocol is the selection of induction agents. The aim of this study is to compare the safety and effectiveness of a traditional RSI protocol using etomidate and suxamethonium with a modified RSI protocol using fentanyl, ketamine and rocuronium. Methods: We performed a comparative cohort study of major trauma patients undergoing pre-hospital RSI by a physician-led Helicopter Emergency Medical Service. Group 1 underwent RSI using etomidate and suxamethonium and Group 2 underwent RSI using fentanyl, ketamine and rocuronium. Apart from the induction agents, the RSI protocol was identical in both groups. Outcomes measured included laryngoscopy view, intubation success, haemodynamic response to laryngoscopy and tracheal intubation, and mortality. Results: Compared to Group 1 (n = 116), Group 2 RSI (n = 145) produced significantly better laryngoscopy views (p = 0.013) and resulted in significantly higher first-pass intubation success (95% versus 100%; p = 0.007). A hypertensive response to laryngoscopy and tracheal intubation was less frequent following Group 2 RSI (79% versus 37%; p < 0.0001). A hypotensive response was uncommon in both groups (1% versus 6%; p = 0.05). Only one patient in each group developed true hypotension (SBP < 90 mmHg) on induction. Conclusions: In a comparative, cohort study, pre-hospital RSI using fentanyl, ketamine and rocuronium produced superior intubating conditions and a more favourable haemodynamic response to laryngoscopy and tracheal intubation. An RSI protocol using fixed ratios of these agents delivers effective pre-hospital trauma anaesthesia.	[Lyon, Richard M.; Perkins, Zane B.; Chatterjee, Debamoy; Russell, Malcolm Q.] Kent Surrey & Sussex Air Ambulance Trust, Marden TN12 9QJ, Kent, England; [Lockey, David J.] Univ Bristol, Sch Clin Sci, Bristol BS16 1LE, Avon, England; [Lockey, David J.] Univ Stavanger Norway, North Bristol NHS Trust, Bristol BS16 1LE, Avon, England; [Perkins, Zane B.] Univ London, Ctr Trauma Sci, London E1 2AT, England	Perkins, ZB (reprint author), Kent Surrey & Sussex Air Ambulance Trust, Wheelbarrow Pk Estate,Pattenden Lane, Marden TN12 9QJ, Kent, England.	zane.perkins@nhs.net	Perkins, Zane/AAC-6949-2019	Perkins, Zane/0000-0003-4807-8803; Lyon, Richard/0000-0002-6339-5666			CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohen L, 2015, ANN EMERG MED, V65, P43, DOI 10.1016/j.annemergmed.2014.06.018; Cook TM, 2011, BRIT J ANAESTH, V106, P617, DOI 10.1093/bja/aer058; Filanovsky Y, 2010, CAN J EMERG MED, V12, P154; Goldberg ME, 1998, PHARMACOTHERAPY, V18, P911; Helm M, 2006, BRIT J ANAESTH, V96, P67, DOI 10.1093/bja/aei275; HICKEY S, 1992, ACTA ANAESTH SCAND, V36, P21, DOI 10.1111/j.1399-6576.1992.tb03416.x; Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B; KING BD, 1951, ANESTHESIOLOGY, V12, P556, DOI 10.1097/00000542-195109000-00002; KUISMA M, 1995, EPILEPSIA, V36, P1241, DOI 10.1111/j.1528-1157.1995.tb01069.x; Lockey D, 2014, BRIT J ANAESTH, V113, P220, DOI 10.1093/bja/aeu227; Lockey DJ, 2014, BRIT J ANAESTH, V113, P211, DOI 10.1093/bja/aeu205; Lossius HM, 2011, CRIT CARE, V15, DOI 10.1186/cc9973; MARLOW R, 1991, CAN J ANAESTH, V38, P844, DOI 10.1007/BF03036958; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Morris C, 2009, ANAESTHESIA, V64, P532, DOI 10.1111/j.1365-2044.2008.05835.x; Morris J, 2001, ANAESTHESIA, V56, P1090, DOI 10.1046/j.1365-2044.2001.01962.x; Mort Thomas C, 2007, J Intensive Care Med, V22, P157, DOI 10.1177/0885066607299525; Murray MJ, 1996, J CARDIOTHOR VASC AN, V10, P173, DOI 10.1016/S1053-0770(96)80232-1; Oglesby AJ, 2004, EMERG MED J, V21, P655, DOI 10.1136/emj.2003.009043; Perkins ZB, 2013, INJURY, V44, P618, DOI 10.1016/j.injury.2012.03.019; Perkins ZB, 2013, J TRAUMA ACUTE CARE, V74, P1074, DOI 10.1097/TA.0b013e3182827305; Perry J, 2003, COCHRANE DB SYST REV, V1; PERRY JJ, 2008, [No title captured], V2; Sellmann T, 2012, DTSCH ARZTEBL INT, V109, P849, DOI 10.3238/arztebl.2012.0849; Sikorski RA, 2014, CURR ANESTHESIOLOGY, V4, P225, DOI DOI 10.1007/s40140-014-0066-5; Sivilotti MLA, 1998, ANN EMERG MED, V31, P313, DOI 10.1016/S0196-0644(98)70341-5; STEPT WJ, 1970, ANESTH ANAL CURR RES, V49, P633; The Association of Anaesthetists of Great Britain and Ireland, 2009, PREH AN SAF GUID; Thomassen O, 2010, ACTA ANAESTH SCAND, V54, P1179, DOI 10.1111/j.1399-6576.2010.02302.x; Varon J, 2008, VASC HEALTH RISK MAN, V4, P615, DOI 10.2147/VHRM.S2471; Wallace C, 2014, CONTIN ED ANAESTHESI, V14, P130, DOI DOI 10.1093/BJACEACCP/MKT047); WEISSBLOOM LJ, 1992, CAN J ANAESTH, V39, P780, DOI 10.1007/BF03008288; Woodall N, 2011, ANAESTHESIA, V66, P27, DOI 10.1111/j.1365-2044.2011.06931.x; Zeiler FA, 2014, NEUROCRIT CARE, V21, P163, DOI 10.1007/s12028-013-9950-y	35	38	38	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	APR 1	2015	19								134	10.1186/s13054-015-0872-2			10	Critical Care Medicine	General & Internal Medicine	CF2CE	WOS:000352354100001	25879683	DOAJ Gold, Green Published, Green Accepted			2020-06-30	J	Kleeberg, UR; Davies, A; Jarosz, J; Mercadante, S; Poulain, P; O'Brien, T; Schneid, H; Kress, HG				Kleeberg, U. R.; Davies, A.; Jarosz, J.; Mercadante, S.; Poulain, P.; O'Brien, T.; Schneid, H.; Kress, H. G.			Pan-European, open- label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain	EUROPEAN JOURNAL OF PAIN			English	Article							OPIOID-TREATED PATIENTS; PREVALENCE; ASSOCIATION	BackgroundFentanyl buccal tablet (FBT), a rapid onset opioid used to treat breakthrough cancer pain, must be titrated to an effective dose that provides adequate analgesia and minimizes undesirable events. This open-label, randomized study compared the percentage of patients achieving an effective dose of FBT when starting titration at 100 or 200g. MethodsOpioid-tolerant patients with chronic cancer-related pain who experienced up to four breakthrough pain episodes daily were randomized to a starting dose of 100 or 200g for the titration period. The dose was increased until an effective dose (100, 200, 400, 600 or 800g) providing adequate analgesia with acceptable adverse events was achieved. Patients achieving an effective dose entered a treatment period during which they treated up to eight breakthrough pain episodes with their effective dose. ResultsA total of 442 patients from 135 sites in seven European countries were screened. Non-inferiority was established with the percentage of patients achieving an effective dose starting titration at 200g (81.4%) compared with the 100-g (75.2%) starting dose. The most common effective doses of FBT were 200g (39.6%) and 400g (26.9%). No new safety concerns were identified with use of FBT at doses up to 800g per episode. ConclusionsThis study involving a real clinical practice setting showed a similar percentage of patients safely achieving an effective dose by titration starting with 100 versus 200g of FBT.	[Kleeberg, U. R.] Hamatol Onkol Praxis Hamburg Altona, Hamburg, Germany; [Davies, A.] Royal Surrey Cty Hosp NHS Fdn Trust, Palliat Care, Guildford, Surrey, England; [Jarosz, J.] Polish Acad Sci, Mossakowski Med Res Ctr, Warsaw, Poland; [Mercadante, S.] La Maddalena Canc Ctr Palermo, Palliat Care, Palermo, Italy; [Poulain, P.] Polyclin Ormeau, Unite Soins Palliatifs, Tarbes, France; [O'Brien, T.] Cork Univ Hosp, Marymount Univ Hosp, Dept Palliat Med, Cork, Ireland; [O'Brien, T.] Univ Coll, Cork, Ireland; [Schneid, H.] Teva Pharmaceut Ind Ltd, Maisons Alfort, France; [Kress, H. G.] Med Univ AKH Vienna, Dept Special Anaesthesia & Pain Therapy, Vienna, Austria	Davies, A (reprint author), Royal Surrey Cty Hosp NHS Fdn Trust, Palliat Care, Guildford, Surrey, England.	adavies12@nhs.net			Cephalon, Inc. (Frazer, PA, USA); Teva Pharmaceuticals	This study was sponsored by Cephalon, Inc. (Frazer, PA, USA), now a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd. Writing support was provided by Bina Patel, PharmD, of Peloton Advantage, LLC, funded by Teva Pharmaceuticals.	Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Effentora SPC, 2011, EFFENTORA BUCCAL TAB; Fentora PI, 2013, FENTORA FENTANYL BUC; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; International Conference on Harmonisation Working Group, 1996, INT C HARM TECHN REQ; Kleeberg UR, 2011, PAIN PRACT, V11, P185, DOI 10.1111/j.1533-2500.2010.00414.x; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	19	7	7	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	APR	2015	19	4					528	537		10.1002/ejp.577			10	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	CE8LC	WOS:000352092800012	25181451				2020-06-30	J	Guillory, JE; Hancock, JT; Woodruff, C; Keilman, J				Guillory, Jamie E.; Hancock, Jeffrey T.; Woodruff, Christopher; Keilman, Jeffrey			Text Messaging Reduces Analgesic Requirements During Surgery	PAIN MEDICINE			English	Article						Fentanyl; Psychosocial Factors; Social	VIRTUAL-REALITY; SOCIAL SUPPORT; PREOPERATIVE ANXIETY; SELF-AFFIRMATION; PAIN-CONTROL; SATISFACTION; SCALE	ObjectiveThis study aims to determine whether communicating via short message service text message during surgery procedures leads to decreased intake of fentanyl for patients receiving regional anesthesia below the waist compared with a distraction condition and no intervention. MethodsNinety-eight patients receiving regional anesthesia for minor surgeries were recruited from a hospital in Montreal, QC, between January and March 2012. Patients were randomly assigned to text message with a companion, text message with a stranger, play a distracting mobile phone game, or receive standard perioperative management. Participants who were asked to text message or play a game did so before receiving the anesthetic and continued until the end of the procedure. ResultsThe odds of receiving supplemental analgesia during surgery for patients receiving standard perioperative management were 6.77 (P=0.009; N=13/25) times the odds for patients in the text a stranger condition (N=22/25 of patients), 4.39 times the odds for those in the text a companion condition (P=0.03; N=19/23), and 1.96 times the odds for those in the distraction condition (P=0.25; N=17/25). ConclusionText messaging during surgery provides analgesic-sparing benefits that surpass distraction techniques, suggesting that mobile phones provide new opportunities for social support to improve patient comfort and reduce analgesic requirements during minor surgeries and in other clinical settings.	[Guillory, Jamie E.; Hancock, Jeffrey T.] Cornell Univ, Ithaca, NY USA; [Woodruff, Christopher; Keilman, Jeffrey] McGill Univ, Montreal, PQ, Canada; [Woodruff, Christopher; Keilman, Jeffrey] LaSalle Hosp, La Salle, PQ, Canada	Guillory, JE (reprint author), Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, 530 Parnassus Ave,Suite 366, San Francisco, CA 94143 USA.	jamie.guillory@ucsf.edu			Cornell University	This research was supported by Cornell University.	Binnings E B, 1987, AANA J, V55, P333; Brown JL, 2003, PSYCHOSOM MED, V65, P276, DOI 10.1097/01.PSY.0000030388.62434.46; CUTRONA CE, 1992, COMMUN RES, V19, P154, DOI 10.1177/009365092019002002; Duggan M., 2013, CELL PHONE ACTIVITIE; Guillory J, 2011, 29TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, P745; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; Hoffman HG, 2004, J CLIN PSYCHOL, V60, P189, DOI 10.1002/jclp.10244; Hoffman HG, 2001, CYBERPSYCHOL BEHAV, V4, P527, DOI 10.1089/109493101750527088; KIECOLTGLASER JK, 1987, PSYCHOSOM MED, V49, P13, DOI 10.1097/00006842-198701000-00002; KIECOLTGLASER JK, 1984, PSYCHOSOM MED, V46, P7, DOI 10.1097/00006842-198401000-00003; KIECOLTGLASER JK, 1984, PSYCHOSOM MED, V46, P15, DOI 10.1097/00006842-198401000-00004; Koch ME, 1998, ANESTHESIOLOGY, V89, P300, DOI 10.1097/00000542-199808000-00005; KULIK JA, 1989, HEALTH PSYCHOL, V8, P221, DOI 10.1037/0278-6133.8.2.221; LANGER EJ, 1975, J EXP SOC PSYCHOL, V11, P155, DOI 10.1016/S0022-1031(75)80018-7; LATTA JN, 1994, IEEE COMPUT GRAPH, V14, P23, DOI 10.1109/38.250915; Lazarus R. S., 1984, STRESS APPRAISAL COP, P22; Master SL, 2009, PSYCHOL SCI, V20, P1316, DOI 10.1111/j.1467-9280.2009.02444.x; Moerman N, 1996, ANESTH ANALG, V82, P445, DOI 10.1097/00000539-199603000-00002; Nolen-Hoeksema S, 2002, PSYCHOL AGING, V17, P116, DOI 10.1037//0882-7974.17.1.116; Patel A, 2006, PEDIATR ANESTH, V16, P1019, DOI 10.1111/j.1460-9592.2006.01914.x; Schmeichel BJ, 2009, J PERS SOC PSYCHOL, V96, P770, DOI 10.1037/a0014635; Schneider S M, 2000, Pediatr Nurs, V26, P593; Sherman DK, 2006, ADV EXP SOC PSYCHOL, V38, P183, DOI 10.1016/S0065-2601(06)38004-5; Tausczik YR, 2010, J LANG SOC PSYCHOL, V29, P24, DOI 10.1177/0261927X09351676; Van Lieshout EJ, 2007, CRIT CARE, V11, DOI 10.1186/cc6115; Walther JB, 2005, J LANG SOC PSYCHOL, V24, P36, DOI 10.1177/0261927X04273036; Walther JB, 1996, COMMUN RES, V23, P3, DOI 10.1177/009365096023001001; ZELMAN DC, 1991, PAIN, V46, P105, DOI 10.1016/0304-3959(91)90040-5; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	29	7	7	0	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	APR	2015	16	4					667	672		10.1111/pme.12610			6	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	CF5SP	WOS:000352617600008	25529995	Bronze			2020-06-30	J	Kennedy, DJ; Schneider, B; Smuck, M; Plastaras, CT				Kennedy, David J.; Schneider, Byron; Smuck, Matthew; Plastaras, Christopher T.			The Use of Moderate Sedation for the Secondary Prevention of Adverse Vasovagal Reactions	PAIN MEDICINE			English	Article						Epidural (Injection Space); Sedation; Block; Safety; Facet Joint; Fluoroscopy; Spine	LOW-BACK-PAIN; EPIDURAL STEROID INJECTIONS; CONSCIOUS SEDATION; COMPLICATIONS; POPULATION; PREVALENCE; EFFICACY; SCIATICA; SYNCOPE; EVENTS	BackgroundVasovagal reactions can occur with spine procedures and may result in premature procedure termination or other adverse events. ObjectiveTo evaluate if moderate sedation is an effective means of secondary prevention for vasovagal reactions. MethodsProspectively collected data on 6,364 consecutive spine injections. ResultsOf the 6,364 spine injections, 6,150 spine injections were done without moderate sedation and resulted in 205 vasovagal reactions (3.3% [95% confidence interval {CI} 2.9-3.8%]). One hundred thirty-four spine procedures were performed on patients that had a history of prior vasovagal reaction during a spine procedure. Of these, 90 procedures were performed without moderate sedation, and 21/90 (23.3% [95% CI 15.2-32.1%]) were complicated by a repeat vasovagal reaction. None of 44 repeat injections that utilized moderate sedation experienced a repeat vasovagal reaction (0% [95% CI 0-9.6%]) ((2)=12.17, P<0.00048). The rate of vasovagal reaction in patients with a history of prior reaction undergoing repeat injection without conscious sedation was significantly higher (23.3% [95% CI 15.2-32.1%]) than the rate in patients with no such history (3.0% [95% CI 2.6-3.5%] [(2)=113.4, P<1.78E-26]). ConclusionsA history of vasovagal reaction is a strong predictor of experiencing a vasovagal reaction on subsequent procedures. No vasovagal reactions occurred with the use of moderate sedation, including in the 44 injections in patients that had a history of vasovagal reaction during spine procedures. The overall low rate of vasovagal reactions is low, and greater benefits of moderate sedation were observed when utilized as secondary prevention of repeat vasovagal reactions.	[Kennedy, David J.; Schneider, Byron; Smuck, Matthew] Stanford Univ, Dept Orthopaed, Redwood City, CA 94063 USA; [Plastaras, Christopher T.] Univ Penn, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA	Kennedy, DJ (reprint author), Stanford Univ, Dept Orthopaed, Pavil C,MC 6342, Redwood City, CA 94063 USA.	djkenned@stanford.edu		Kennedy, David/0000-0001-8061-0287			Ahmed Shihab U, 2005, Pain Physician, V8, P181; Arepally A, 2001, CARDIOVASC INTER RAD, V24, P185, DOI 10.1007/s002700002549; Botwin KP, 2001, AM J PHYS MED REHAB, V80, P416, DOI 10.1097/00002060-200106000-00005; Botwin KP, 2000, ARCH PHYS MED REHAB, V81, P1045, DOI 10.1053/apmr.2000.7166; Cassidy JD, 1998, SPINE, V23, P1860, DOI 10.1097/00007632-199809010-00012; Cicala R S, 1989, J Pain Symptom Manage, V4, P64, DOI 10.1016/0885-3924(89)90024-9; Cucuzzella Tony R, 2006, Spine J, V6, P364, DOI 10.1016/j.spinee.2005.09.005; Derby MD, 2001, ED GUIDELINES INTERV; Diehn FE, 2013, PAIN MED, V14, P994, DOI 10.1111/pme.12092; Dreyfuss P, 2009, PM&R, V1, P60, DOI 10.1016/j.pmrj.2008.10.006; Friedly J, 2007, SPINE, V32, P1754, DOI 10.1097/BRS.0b013e3180b9f96e; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hodges SD, 1998, SPINE, V23, P2137, DOI 10.1097/00007632-199810010-00020; Hodges SD, 1998, SPINE, V23, P2141; Huston CW, 2005, ARCH PHYS MED REHAB, V86, P277, DOI 10.1016/j.apmr.2004.02.018; Karaman H, 2011, SPINE, V36, pE819, DOI 10.1097/BRS.0b013e3181f32bae; Kennedy DJ, 2013, PAIN MED, V14, P1854, DOI 10.1111/pme.12241; Kennedy DJ, 2013, JAMA-J AM MED ASSOC, V310, P1736, DOI 10.1001/jama.2013.277957; Kim N, 2007, SPINE, V32, pE748, DOI 10.1097/BRS.0b013e31815b7e9f; Koes BW, 1995, PAIN, V63, P279, DOI 10.1016/0304-3959(95)00124-7; Lauven P, 1990, SCAND J GASTROENTE S, V179, P1; Manchikanti L, 2012, PAIN PHYSICIAN, V15, P131; Moya A, 2009, EUR HEART J, V30, P2631, DOI 10.1093/eurheartj/ehp298; PAPAGEORGIOU AC, 1995, SPINE, V20, P1889, DOI 10.1097/00007632-199509000-00009; Plastaras CT, 2012, PM&R, V4, P473, DOI 10.1016/j.pmrj.2012.02.001; Rozenberg S, 1999, REV RHUM, V66, P79; Schaufele MK, 2011, SPINE J, V11, P1093, DOI 10.1016/j.spinee.2011.07.028; Schneider B, 2014, PM&R, V6, P914, DOI 10.1016/j.pmrj.2014.04.003; Schwamburger Nathan T, 2012, Gen Dent, V60, pe341; Stauber B, 2012, PAIN PHYSICIAN, V15, P147; Thampi SP, 2012, PHYS MED REH CLIN N, V23, P423, DOI 10.1016/j.pmr.2012.02.014; Trentman TL, 2009, PAIN PRACT, V9, P59, DOI 10.1111/j.1533-2500.2008.00242.x; Ankur V, 2013, INT J CARDIOL, V167, P1906, DOI 10.1016/j.ijcard.2012.04.144; WALDMAN SD, 1989, REGION ANESTH, V14, P149; Wieling W, 2004, HEART, V90, P1094, DOI 10.1136/hrt.2003.022996; Zhou Y, 2008, PAIN PHYSICIAN, V11, P43	36	4	4	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	APR	2015	16	4					673	679		10.1111/pme.12632			7	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	CF5SP	WOS:000352617600009	25529469	Bronze			2020-06-30	J	Candiotti, K				Candiotti, Keith			Sum of the Parts	ANESTHESIA AND ANALGESIA			English	Editorial Material									Univ Miami, Miller Sch Med, Dept Anesthesiol, Perioperat Med & Pain Management, Miami, FL 33136 USA	Candiotti, K (reprint author), Univ Miami, Miller Sch Med, Dept Anesthesiol, Perioperat Med & Pain Management, 1611 NW 12th Ave, Miami, FL 33136 USA.	kcandiotti@miami.edu					Manjunath P, 2011, PATIENTS CAN PREDICT; Zhang F, 2015, ANESTH ANALG, V120, P933, DOI 10.1213/ANE.0000000000000563	2	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2015	120	4					717	717		10.1213/ANE.0000000000000644			1	Anesthesiology	Anesthesiology	CE1GF	WOS:000351559400008	25790204				2020-06-30	J	Phipps, JB; Joshi, N; Regal, KA; Li, JF; Sinatra, RS				Phipps, J. Brad; Joshi, Nitin; Regal, Kelly A.; Li, Jinfang; Sinatra, Raymond S.			Pharmacokinetic characteristics of fentanyl iontophoretic trandermal system over a range of applied current	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY			English	Review						fentanyl; iontophoretic transdermal system; patient-controlled analgesia; pharmacokinetic	TRANSDERMAL SYSTEM	Objective: To evaluate the pharmacokinetic (PK) characteristics of a modified fentanyl iontophoretic transdermal system (ITS). Research design and methods: This was a prospective, open-label, single-center, randomized, 3-period, 5-treatment, 6-sequence study. Each subject was randomly assigned to receive three treatments in a sequence consisting of intravenous fentanyl citrate, fentanyl ITS at 170 mu A, and then one of three other fentanyl ITS treatments at 140, 200 or 230 mu A. Main outcome measures: The following PK parameters were determined: C-max, t(max), t(1/2), AUC(23-25) and amount of fentanyl absorbed into systemic circulation (i.e., Dose Absorbed). Results: Fifty-two subjects received at least one fentanyl treatment. Serum exposure (C-max and AUC(23-25)) and Dose Absorbed increased with increasing current. The median tmax ranged from 23.0 to 23.2 h across the 4 ITS groups. Mean t(1/2) values ranged from 11.0 to 13.0 h. The Dose Absorbed from the fentanyl ITS at 170 mu A met bioequivalence criteria when compared to data from an earlier version of the fentanyl ITS. Conclusions: Exposure of fentanyl and the amount of fentanyl absorbed increased with the magnitude of applied current with the ITS. The fentanyl ITS at 170 mu A is bioequivalent to an earlier version of the system.	[Phipps, J. Brad; Joshi, Nitin] Medicines Co, Redwood City, CA 94063 USA; [Regal, Kelly A.; Li, Jinfang] ProPharma Serv, Superior, CO USA; [Sinatra, Raymond S.] West Haven VA Med Ctr, West Haven, CT USA	Phipps, JB (reprint author), Medicines Co, 900 Saginaw Dr,Suite 200, Redwood City, CA 94063 USA.	jbradley.phipps@THEMEDCO.com			Incline Therapeutics, Inc.; Medicines Company	Study funding was provided by Incline Therapeutics, Inc., a wholly owned subsidiary of The Medicines Company (Parsippany, NJ). The analyses and writing of this manuscript were supported financially by The Medicines Company. Brad Phipps and Nitin Joshi are employees of The Medicines Company. Raymond S Sinatra is Acting Director of Pain Medicine at the West Haven VA Medical Center, West Haven CT, and serves as a consultant to The Medicines Company. Kelly Regal and Jinfang Li are employees of ProPharma Services and provided PK and statistical analysis services to Incline Therapeutics.	Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Gupta SK, 1998, J PHARM SCI, V87, P976, DOI 10.1021/js970437d; Gupta SK, 1999, J PHARM SCI, V88, P835, DOI 10.1021/js980258b; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Phipps JB, 2002, MODIFIED RELEASE DRU, P499; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan G, 2009, CURR MED RES OPIN, V25, P363, DOI 10.1185/03007990802594941 ; US Department of Health and Human Services, 2014, GUID IND STAT APPR E; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	15	8	8	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1742-5255	1744-7607		EXPERT OPIN DRUG MET	Expert Opin. Drug Metab. Toxicol.	APR	2015	11	4					481	489		10.1517/17425255.2015.1020296			9	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	CD6WO	WOS:000351231200002	25728546	Bronze			2020-06-30	J	Zhang, F; Tong, JB; Hu, J; Zhang, H; Ouyang, W; Huang, D; Tang, QP; Liao, Q				Zhang, Fan; Tong, Jianbin; Hu, Jie; Zhang, Hao; Ouyang, Wen; Huang, Dong; Tang, Qiuping; Liao, Qin			COMT Gene Haplotypes Are Closely Associated with Postoperative Fentanyl Dose in Patients	ANESTHESIA AND ANALGESIA			English	Article							CATECHOL-O-METHYLTRANSFERASE; CANCER PAIN PATIENTS; MORPHINE REQUIREMENTS; OPIOID USE; POLYMORPHISMS; SENSITIVITY; FIBROMYALGIA; PERCEPTION; OPRM1	BACKGROUND: Fentanyl's analgesic efficacy varies widely among individuals. The single-nucleotide polymorphisms (SNPs) of catechol-O-methyltransferase (COMT) modulate sensitivity to pain. It remains unclear, however, whether COMT genetic variability affects postoperative fentanyl analgesia in patients undergoing radical gastrectomy. METHODS: One hundred fifteen patients, ASA physical status I-III, who were scheduled for radical gastrectomy under general anesthesia, were enrolled in this study. Patient-controlled IV analgesia with fentanyl was administered during the first 48 hours after surgery. Visual analog scale score for patients' pain was maintained at mm. The amount of fentanyl consumed and side effects were recorded for the first 24 and 48 hours postoperatively. The SNPs of COMT (rs6269, rs4633, rs4818, and rs4680) of all patients were screened by DNA sequence analysis of polymerase chain reaction-amplified DNA or polymerase chain reaction-restriction fragment length polymorphism. RESULTS: There were no significant differences in the doses of fentanyl used among patients possessing different SNPs of COMT rs6269, rs4633, rs4818, and rs4680 at 24 (all P>0.207) and 48 (all P>0.148) hours after surgery. COMT gene haplotypes combined by COMT rs6269, rs4633, rs4818, and rs4680, however, significantly affected fentanyl consumption at 24 (P = 0.029) and 48 (P = 0.032) hours after surgery. Among the haplotypes of COMT gene, patients with haplotype ACCG consumed more fentanyl than GCGG and ATCA haplotypes during the first 24 and 48 hours (all P < 0.042) after surgery. No significant differences were found in the incidence of nausea, vomiting, and dizziness among the 4 SNPs of COMT gene (all P>0.079) and their haplotypes (all P>0.482). CONCLUSIONS: COMT gene haplotype constructed by rs6269, rs4633, rs4818, and rs4680 contributes to the individual variation of postoperative analgesia with fentanyl. Patients carrying the COMT gene haplotype ACCG consumed the most drug during the first 24 and 48 hours postoperatively.	[Zhang, Fan; Tong, Jianbin; Hu, Jie; Ouyang, Wen; Huang, Dong; Liao, Qin] Cent S Univ, Dept Anesthesiol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China; [Zhang, Hao] Cent S Univ, Dept Nephropathy, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China; [Tang, Qiuping] Cent S Univ, Dept Psychol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China	Liao, Q (reprint author), Cent S Univ, Dept Anesthesiol, Xiangya Hosp 3, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	xy3yyliaoqin@sina.com					Andersen S, 2009, PHARMACOGENOMICS, V10, P669, DOI 10.2217/PGS.09.13; Blum K, 2007, MED HYPOTHESES, V69, P1054, DOI 10.1016/j.mehy.2006.12.062; [邓婕 Deng Jie], 2011, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V31, P1039; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; Droney J, 2011, CLIN ONCOL-UK, V23, P418, DOI 10.1016/j.clon.2011.04.015; GULDBERG HC, 1975, PHARMACOL REV, V27, P135; Henker RA, 2013, BIOL RES NURS, V15, P309, DOI 10.1177/1099800411436171; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Kolesnikov Y, 2011, ANESTH ANALG, V112, P448, DOI 10.1213/ANE.0b013e318202cc8d; Martinez-Jauand M, 2013, EUR J PAIN, V17, P16, DOI 10.1002/j.1532-2149.2012.00153.x; Nackley AG, 2010, METHODS MOL BIOL, V617, P375, DOI 10.1007/978-1-60327-323-7_28; Rakvag TT, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-64; Rakvag TT, 2005, PAIN, V116, P73, DOI 10.1016/j.pain.2005.03.032; Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023; Ross JR, 2008, CANCER-AM CANCER SOC, V112, P1390, DOI 10.1002/cncr.23292; Shifman S, 2002, AM J HUM GENET, V71, P1296, DOI 10.1086/344514; Vargas-Alarcon G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2316; Xie T, 1999, MOL PHARMACOL, V56, P31; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546	20	20	21	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2015	120	4					933	940		10.1213/ANE.0000000000000563			8	Anesthesiology	Anesthesiology	CE1GF	WOS:000351559400033	25532715				2020-06-30	J	Zach, KJ; Ramakrishna, H; Chandrasekaran, K; Weis, RA				Zach, Kelly J.; Ramakrishna, Harish; Chandrasekaran, Krishnashwamy; Weis, Ricardo A.			Laparoscopic colectomy in an adult with single ventricle physiology: Anesthetic implications and management	ANNALS OF CARDIAC ANAESTHESIA			English	Article						Anesthesia; Blalock-Taussig shunt; Congenital heart disease; Laparoscopic surgery; Single ventricle physiology		Increasing numbers of adult patients with complex congenital heart conditions are presenting for noncardiac surgery later in life. These disorders can present challenges for surgical and anesthesia providers. Specifically, single ventricle lesions offer anatomic and physiologic concerns during the perioperative period. Single ventricle physiology represents a delicate balance between systemic and pulmonary blood flow. Any alterations in blood flow through these systems can produce undesirable hemodynamic changes, especially during the perioperative period. We present a case of an adult patient with a single left ventricle who presented for laparoscopic total colectomy due to inflammatory bowel disease. His abnormal anatomy coupled with the hemodynamic disruptions caused by laparoscopy presented significant anesthetic challenges. We highlight the anesthetic concerns of single ventricle physiology, specifically pertaining to laparoscopic surgery. We provide recommendations for safely managing these patients perioperatively. With detailed preoperative evaluation and close hemodynamic monitoring during the perioperative period, these patients can experience successful surgical and anesthetic outcomes.	[Zach, Kelly J.; Ramakrishna, Harish; Weis, Ricardo A.] Mayo Clin Hosp, Dept Anesthesia, Div Cardiothorac Anethesia, Phoenix, AZ USA; [Chandrasekaran, Krishnashwamy] Mayo Clin Hosp, Dept Cardiol, Phoenix, AZ USA	Zach, KJ (reprint author), 5777 E Mayo Blvd, Phoenix, AZ 85054 USA.	zach.kelly@mayo.edu					Cannesson M, 2009, ANESTHESIOLOGY, V111, P432, DOI 10.1097/ALN.0b013e3181ae51a6; Feinstein JA, 2012, J AM COLL CARDIOL, V59, pS1, DOI 10.1016/j.jacc.2011.09.022; Foster E, 2001, J AM COLL CARDIOL, V37, P1176, DOI 10.1016/S0735-1097(01)01277-3; Gerges FJ, 2006, J CLIN ANESTH, V18, P67, DOI 10.1016/j.jclinane.2005.01.013; Gueugniaud PY, 1998, ANESTH ANALG, V86, P290, DOI 10.1097/00000539-199802000-00012; Gulack BCH, 2013, J LAPAROENDOSC ADV S, V23, P733, DOI 10.1089/lap.2013.0076; Harji DP, 2014, BRIT J SURG, V101, pE126, DOI 10.1002/bjs.9348; Jaquiss RDB, 2009, CURR OPIN CARDIOL, V24, P113, DOI 10.1097/HCO.0b013e328323d85a; JORIS JL, 1993, ANESTH ANALG, V76, P1067; Leyvi G, 2010, J CARDIOTHOR VASC AN, V24, P121, DOI 10.1053/j.jvca.2009.07.018; Mackie AS, 2007, AM J CARDIOL, V99, P839, DOI 10.1016/j.amjcard.2006.10.054; Maxwell BG, 2013, ANESTHESIOLOGY, V119, P762, DOI 10.1097/ALN.0b013e3182a56de3; McClain CD, 2006, ANESTH ANALG, V103, P856, DOI 10.1213/01.ane.0000237294.88298.8e; MCLAUGHLIN JG, 1995, SURG ENDOSC-ULTRAS, V9, P121; Mcrae ME, 2013, AACN ADV CRIT CARE, V24, P264, DOI 10.1097/NCI.0b013e31829744c7; Petit CJ, 2011, CONGENIT HEART DIS, V6, P406, DOI 10.1111/j.1747-0803.2011.00560.x; Struthers AD, 1998, LANCET, V352, P568, DOI 10.1016/S0140-6736(97)11478-7; Torres A, 2002, J PEDIATR SURG, V37, P1399, DOI 10.1053/jpsu.2002.35377; Walter EMBD, 2009, J CARDIAC SURG, V24, P383, DOI 10.1111/j.1540-8191.2008.00759.x; Warnes CA, 2001, J AM COLL CARDIOL, V37, P1170, DOI 10.1016/S0735-1097(01)01272-4; Warnes CA, 2008, CIRCULATION, V118, P2395, DOI 10.1161/CIRCULATIONAHA.108.190811; Williams RG, 2006, J AM COLL CARDIOL, V47, P701, DOI 10.1016/j.jacc.2005.08.074; Yuki K, 2011, J ANESTH, V25, P247, DOI 10.1007/s00540-010-1081-4	23	6	7	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0971-9784	0974-5181		ANN CARD ANAESTH	Ann. Card. Anaesth.	APR-JUN	2015	18	2					252	256		10.4103/0971-9784.154495			5	Anesthesiology	Anesthesiology	V4B3R	WOS:000218777000028	25849703	DOAJ Gold, Green Published			2020-06-30	J	Bird, MF; Vardanyan, RS; Hruby, VJ; Calo, G; Guerrini, R; Salvadori, S; Trapella, C; McDonald, J; Rowbotham, DJ; Lambert, DG				Bird, M. F.; Vardanyan, R. S.; Hruby, V. J.; Calo, G.; Guerrini, R.; Salvadori, S.; Trapella, C.; McDonald, J.; Rowbotham, D. J.; Lambert, D. G.			Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands	BRITISH JOURNAL OF ANAESTHESIA			English	Article						delta receptors; fentanyl; mu receptors; opioid; pharmacology - analgesics opioid	DYNORPHIN A-(1-13) AMIDE; MORPHINE-TOLERANCE; POTENT; DEPENDENCE; AGONIST; DMT; HETERODIMERIZATION; INTERNALIZATION; TRAFFICKING; RADIOLIGAND	Background. Opioid tolerance is a limiting factor in chronic pain. Delta opioid peptide (DOP)(8) receptor antagonism has been shown to reduce tolerance. Here, the common clinical mu opioid peptide (MOP)(R) receptor agonist fentanyl has been linked to the DOP antagonist Dmt-Tic (2',6'-dimethyl-L-tyrosyl-1,2,3,4-tetrahydrisoquinoline-3-carboxylic acid) to create new bivalent compounds. Methods. Binding affinities of bivalents(#9, #10, #11, #12 and #13) were measured in Chinese hamster ovary (CHO) cells expressing recombinant human MOP, DOP, Kappa opioid peptide (KOP)(K) and nociceptin/orphanin FQ opioid peptide (NOP) receptors. Functional studies, measuring GTIly[35S] or B-arrestin recruitment, were performed in membranes or whole cells respectively expressing MOP and DOP. Results.The new bivalents bound to MOP (pKi :#9:7.31; #10:7.58; #11:7.91; #12:7.94; #13:8.03) and DOP (#9:8.03; #10:8.16; #11:8.17; #12:9.67; #13:9.71). In GTRy[S-35] functional assays, compounds #9(pEC(50):6.74; intrinsic activity:0.05) #10(7.13;0.34) and #11(7.52;0.27) showed weak partial agonist activity at MOP. Compounds #12 and #13, with longer linkers, showed no functional activity at MOP. In antagonist assays at MOP, compounds #9 (pK(b):6.87), #10(7.55) #11(7.81) #12(6.91) and #13(7.05) all reversed the effects of fentanyl. At DOP, all compounds showed antagonist affinity (#9:6.85; #10:8.06; #11:8.11; #12:9.42; #13:9.00), reversing the effects of DPDPE ([D-Pen(25)]enkephalin). In p-arrestin assays, compared with fentanyl (with response at maximum concentration (RMC):13.62), all compounds showed reduced ability to activate parrestin (#9 RMC:1.58; #10:2.72; #11:2.40; #12:1.29; #13:1.58). Compared with fentanyl, the intrinsic activity was: #9:0.12; #10:0.20; #11:0.18; #12:0.09 and #13:0.12. Conclusions. The addition of a linker between fentanyl and Dmt-Tic did not alter the ability to bind to MOP and DOP, however a substantial loss in MOPfunctional activity was apparent. This highlights the difficulty in multifunctional opioid development.	[Bird, M. F.; McDonald, J.; Rowbotham, D. J.; Lambert, D. G.] Univ Leicester, Leicester Royal Infirm, Div Anaesthesia Crit Care & Pain Management, Dept Cardiovasc Sci, Leicester LE2 7LX, Leics, England; [Vardanyan, R. S.; Hruby, V. J.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA; [Calo, G.] Univ Ferrara, Dept Med Sci, Pharmacol Sect, I-44100 Ferrara, Italy; [Calo, G.] Italian Inst Neurosci, Ferrara, Italy; [Guerrini, R.; Salvadori, S.; Trapella, C.] Univ Ferrara, Dept Chem & Pharmaceut Sci, I-44100 Ferrara, Italy; [Guerrini, R.; Salvadori, S.; Trapella, C.] Univ Ferrara, LTTA, I-44100 Ferrara, Italy	Lambert, DG (reprint author), Univ Leicester, Leicester Royal Infirm, Div Anaesthesia Crit Care & Pain Management, Dept Cardiovasc Sci, Robert Kilpatrick Clin Sci Bldg, Leicester LE2 7LX, Leics, England.	dgl3@le.ac.uk	Trapella, Claudio/I-2128-2012	Trapella, Claudio/0000-0002-6666-143X; Guerrini, Remo/0000-0002-7619-0918; Lambert, David/0000-0003-4769-8090; SALVADORI, Severo/0000-0002-8224-2358	BJA/ROCA; Italian Ministry of University grant FIRB Future in ricercu [CRBFR109 SBM]	Funding from BJA/ROCA to D.G.L and D.J.R. Funding from Italian Ministry of University grant FIRB 2010 Future in ricercu CRBFR109 SBM to C.T.	ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P295, DOI 10.1177/026921639500900404; Balboni G, 2005, J MED CHEM, V48, P8112, DOI 10.1021/jm058259l; Balboni G, 2002, J MED CHEM, V45, P713, DOI 10.1021/jm010449i; Balboni G, 2011, EUR J MED CHEM, V46, P799, DOI 10.1016/j.ejmech.2010.12.001; Ballesta JJ, 2012, BRIT J PHARMACOL, V166, P309, DOI 10.1111/j.1476-5381.2011.01750.x; Bryant SD, 2003, BIOPOLYMERS, V71, P86, DOI 10.1002/bip.10399; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Colvin LA, 2008, BRIT J ANAESTH, V101, P1, DOI 10.1093/bja/aen120; Daniels DJ, 2005, P NATL ACAD SCI USA, V102, P19208, DOI 10.1073/pnas.0506627102; Dietis N, 2012, BRIT J ANAESTH, V108, P262, DOI 10.1093/bja/aer377; Dietis N, 2009, BRIT J ANAESTH, V103, P38, DOI 10.1093/bja/aep129; Fichna J, 2007, J MED CHEM, V50, P512, DOI 10.1021/jm060998u; GADDUM JH, 1957, PHARMACOL REV, V9, P211; Garzon J, 2005, NEUROPHARMACOLOGY, V48, P853, DOI 10.1016/j.neuropharm.2005.01.004; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Gupta A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000807; Hasbi A, 2007, BIOCHEMISTRY-US, V46, P12997, DOI 10.1021/bi701436w; Hashiba E, 2001, N-S ARCH PHARMACOL, V363, P28, DOI 10.1007/s002100000327; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Ibba M, 2008, N-S ARCH PHARMACOL, V378, P553, DOI 10.1007/s00210-008-0350-3; Liggett SB, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002331; LIPKOWSKI AW, 1987, LIFE SCI, V40, P2283, DOI 10.1016/0024-3205(87)90065-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; McDonald J, 2003, N-S ARCH PHARMACOL, V367, P183, DOI 10.1007/s00210-002-0661-8; Nitsche JF, 2002, J NEUROSCI, V22, P10906; Nobles KN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001707; Ong Edmund W, 2014, Cells, V3, P152, DOI 10.3390/cells3010152; Peng XM, 2006, J MED CHEM, V49, P256, DOI 10.1021/jm050577x; Podolsky AT, 2013, LIFE SCI, V93, P1010, DOI 10.1016/j.lfs.2013.09.016; Rozenfeld R, 2007, FASEB J, V21, P2455, DOI 10.1096/fj.06-7793com; Schiller PW, 2010, LIFE SCI, V86, P598, DOI 10.1016/j.lfs.2009.02.025; SNYDER KR, 1992, J MED CHEM, V35, P4330, DOI 10.1021/jm00101a010; STORY SC, 1992, INT J PEPT PROT RES, V40, P89; Vardanyan R, 2011, BIOORGAN MED CHEM, V19, P6135, DOI 10.1016/j.bmc.2011.08.027; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3; Zuo ZY, 2005, ANESTH ANALG, V101, P728, DOI 10.1213/01.ANE.0000160588.32007.AD	39	5	5	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	APR	2015	114	4					646	656		10.1093/bja/aeu454			11	Anesthesiology	Anesthesiology	CE6SI	WOS:000351968100016	25680364	Bronze, Green Published			2020-06-30	J	Varndell, W; Elliott, D; Fry, M				Varndell, Wayne; Elliott, Doug; Fry, Margaret			Emergency nurses practices in assessing and administering continuous intravenous sedation for critically ill adult patients: A retrospective record review'	INTERNATIONAL EMERGENCY NURSING			English	Article						Sedation assessment; Emergency nurse	MECHANICALLY VENTILATED PATIENTS; CRITICAL-CARE; PROCEDURAL SEDATION; ANALGESIA; SCALE; VALIDATION; PROTOCOL; OUTCOMES; TRIAL; PAIN	Aim: To generate an initial profile of emergency nurses' practices in and factors influencing the assessment and administration of continuous intravenous sedation and analgesia for critically ill mechanically ventilated adult patients. Background: Emergency nurses are relied upon to assess and manage critically ill patients, some of whom require continuous intravenous sedation. Balancing sedation is a highly complex activity. There is however little evidence relating to how emergency nurses manage continuous intravenous analgesia and sedation for the critically ill intubated patients. Design: Descriptive study. Method: A 12-month retrospective medical record review was undertaken from January to December 2009 of patients (>16 years) administered continuous intravenous sedation in ED. Results: Fifty-five patients received ongoing intravenous sedation within the ED during a median length of stay of 3.4 h. Assessment of patient depth/quality of sedation and pain-relief varied and were rarely documented. Adverse events were documented, majority (16%) drug administration related. Thematic analysis identified three themes: 'Maintaining sedation', 'Directionless-directions', and 'Navigating the balance'. Conclusion: Emergency nurses provide continuity of patient care and optimisation of analgesia and sedation for critically ill sedated patients. The safety and effectiveness of continuous intravenous sedation for the critically ill adult patient in ED are dependent on the expertise and decision-making abilities of the nurse. (C) 2014 Elsevier Ltd. All rights reserved.	[Varndell, Wayne] Univ Technol Sydney, Prince Wales Hosp, Emergency Dept, Fac Hlth, Sydney, NSW 2007, Australia; [Elliott, Doug; Fry, Margaret] Univ Technol Sydney, Fac Hlth, Sydney, NSW 2007, Australia	Varndell, W (reprint author), Prince Wales Hosp, Emergency Dept, Sydney, NSW, Australia.	wayne.varndell@sesiahs.health.nsw.gov.au	Varndell, Wayne/AAN-7093-2020; Elliott, Doug/O-5674-2019; Elliott, Doug/F-8086-2017; Fry, Margaret/F-8082-2017	Elliott, Doug/0000-0002-6081-5442; Elliott, Doug/0000-0002-6081-5442; Fry, Margaret/0000-0003-1265-7096; Varndell, Wayne/0000-0002-4752-9679			Aissaoui Y, 2005, ANESTH ANALG, V101, P1470, DOI 10.1213/01.ANE.0000182331.68722.FF; Aitken LM, 2009, J CLIN NURS, V18, P36, DOI 10.1111/j.1365-2702.2008.02318.x; Australia and New Zealand College of Anaesthetists, 2010, GUID SED AN DIAGN IN; Australian and New Zealand College of Anesthetists, 2008, GUID SED AN DIAGN IN; Australian Institute of Health and Welfare, 2008, AUSTR HOSP STAT 2008; Australian Institute of Health and Welfare, 2010, AUSTR HOSP STAT 2009; Australian Institute of Health and Welfare, 2013, AUSTR HOSP STAT 2011; Bahn EL, 2005, EMERG MED CLIN N AM, V23, P503, DOI 10.1016/j.emc.2004.12.013; BAKER T. L., 1994, DOING SOCIAL RES; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bonomo JB, 2008, AM J EMERG MED, V26, P469, DOI 10.1016/j.ajem.2007.05.024; Brattebo G, 2002, BRIT MED J, V324, P1386, DOI 10.1136/bmj.324.7350.1386; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A; Castner J., 2009, J EMERG NURS, V34, P558; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Chao A, 2006, J TRAUMA, V60, P579, DOI 10.1097/01.ta.0000195644.58761.93; College of Emergency Nursing Australasia, 2011, POS STAT MECH VENT; Dellinger AB, 2007, J MIX METHOD RES, V1, P309, DOI 10.1177/1558689807306147; Egerod I, 2002, J CLIN NURS, V11, P831, DOI 10.1046/j.1365-2702.2002.00725.x; Emergency Nurses Association, 2008, PROC SED CONS STAT; Foster A, 2003, SURG ENDOSC, V17, P1766, DOI 10.1007/s00464-002-8701-5; Gearing RE, 2006, J CAN ACAD CHILD ADO, V15, P126; Gelinas C, 2009, J PAIN SYMPTOM MANAG, V37, P58, DOI 10.1016/j.jpainsymman.2007.12.022; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Green SM, 2009, ANN EMERG MED, V53, P436, DOI 10.1016/j.annemergmed.2008.10.029; Hess Dean R, 2004, Respir Care, V49, P1171; Ibrahim EH, 2001, CRIT CARE CLIN, V17, P989, DOI 10.1016/S0749-0704(05)70190-1; Innes G, 1999, J EMERG MED, V17, P145, DOI 10.1016/S0736-4679(98)00135-8; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jacques T, 2006, RESUSCITATION, V69, P175, DOI 10.1016/j.resuscitation.2005.08.015; Joacobsen K., 2011, INTRO HLTH RES METHO; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2007, CRIT CARE MED, V35, P365, DOI 10.1097/01.CCM.0000254334.46406.B3; Kress JP, 2001, SEM RESP CRIT CARE M, V22, P199, DOI 10.1055/s-2001-13833; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Machin D., 2007, MED STAT TEB HLTH SC; Mehra B., 2002, QUALITATIVE REPORT, P7; MIMSOnline, 2013, MIMSONLINE; Miner JR, 2005, ACAD EMERG MED, V12, P124, DOI 10.1197/j.aem.2004.08.054; Nasraway S.J., 2002, CRITICAL CARE MED, V30; Nguyen HB, 2000, ACAD EMERG MED, V7, P1354, DOI 10.1111/j.1553-2712.2000.tb00492.x; O'Connor G, 2009, EUR J EMERG MED, V16, P296, DOI 10.1097/MEJ.0b013e32831090bd; Onwuegbuzie A. J., 2004, QUALITATIVE REPORT, V9, P770; Patanwala AE, 2011, ACAD EMERG MED, V18, P11, DOI 10.1111/j.1553-2712.2010.00954.x; Perry J., 2008, COCHRANE DATABASE SY, V16; Polit DF, 2010, ESSENTIALS NURSING R; QRS International Pty Ltd, 2012, NVIVO; Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Rodrigues Junior Geraldo Rolim, 2004, Sao Paulo Med. J., V122, P8, DOI 10.1590/S1516-31802004000100003; Rose L, 2007, AUSTRALAS EMERG NURS, V10, P26, DOI 10.1016/j.aenj.2006.10.002; Rubin A., 2009, STAT EVIDENCE BASED; Ryan G. W., 2003, FIELD METHOD, V15, P85, DOI DOI 10.1177/1525822X02239569; Samuelson K A M, 2008, Acta Anaesthesiol Scand, V52, P1116, DOI 10.1111/j.1399-6576.2008.01702.x; Schneider Z., 2013, WRITNING PROPOSALS G; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sessler CN, 2008, CHEST, V133, P552, DOI 10.1378/chest.07-2026; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Shenton A. K., 2004, ED INFORM, V22, P63, DOI DOI 10.3233/EFI-2004-22201; STRYDOM H, 2002, [No title captured]; SUN XL, 1994, HEART LUNG, V23, P169; Treggiari MM, 2009, CRIT CARE MED, V37, P2527, DOI 10.1097/CCM.0b013e3181a5689f; van Teijlingen Edwin, 2002, Nurs Stand, V16, P33; Varndell W, 2015, AUSTRALAS EMERG NURS, V18, P59, DOI 10.1016/j.aenj.2014.08.002; Varndell W, 2013, AUSTRALAS EMERG NURS, V16, P64, DOI 10.1016/j.aenj.2013.04.001; Walker Nikki, 2006, Intensive Crit Care Nurs, V22, P338, DOI 10.1016/j.iccn.2006.03.008; Weinert C R, 2001, Am J Crit Care, V10, P156; Wood S, 2011, J EMERG MED, V40, P419, DOI 10.1016/j.jemermed.2010.02.021	68	6	6	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1755-599X	1878-013X		INT EMERG NURS	Int. Emerg. Nurs.	APR	2015	23	2					81	88		10.1016/j.ienj.2014.09.005			8	Nursing	Nursing	CH6HZ	WOS:000354139000008	25449551				2020-06-30	J	Handsaker, S; Dempsey, L; Fabby, C				Handsaker, Scott; Dempsey, Laura; Fabby, Carole			Use of oral formulations of fentanyl for breakthrough cancer pain	International Journal of Palliative Nursing			English	Editorial Material							TRANSMUCOSAL FENTANYL; CITRATE; MANAGEMENT; CROSSOVER; REGIMEN		[Handsaker, Scott] Mid North Coast NSW, NSW Palliat Serv, Silver Chain Grp, Port Macquarie, NSW, Australia; [Dempsey, Laura] Natl Univ Ireland, Sch Nursing & Midwifery, Galway, Ireland; [Fabby, Carole] St Fionnans Community Nursing Unit, Nursing, Achill, County Mayo, Ireland	Dempsey, L (reprint author), Natl Univ Ireland, Sch Nursing & Midwifery, Galway, Ireland.	laura.dempsey@nuigal-way.ie		Dempsey, Laura/0000-0003-2541-8318			Bhatnagar S, 2014, INDIAN J PALLIAT CAR, V20, P182, DOI 10.4103/0973-1075.138386; Bornemann-Cimenti H, 2013, DTSCH ARZTEBL INT, V110, P271, DOI 10.3238/arztebl.2013.0271; Buchanan A, 2014, INT J PALLIAT NURS, V20, P6, DOI 10.12968/ijpn.2014.20.1.6; Darba J, 2014, CLINICOECONOMIC OUTC, V6, P1, DOI 10.2147/CEOR.S52273; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Gordon DB, 2006, ONCOL NURS FORUM, V33, P257, DOI 10.1188/06.ONF.257-264; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Handsaker S, 2013, INT J PALLIAT NURS, V19, P60, DOI 10.12968/ijpn.2013.19.2.60; Kuo Kuan-Ling, 2013, J Pain Palliat Care Pharmacother, V27, P167, DOI 10.3109/15360288.2013.787137; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Novotna S, 2014, CLIN THER, V36, P357, DOI 10.1016/j.clinthera.2014.01.006; Parikh N, 2013, CLIN THER, V35, P236, DOI 10.1016/j.clinthera.2013.02.017; Soden K, 2010, PALLIATIVE MED, V24, P294, DOI 10.1177/0269216309355918; Webster LR, 2013, PAIN MED, V14, P1332, DOI 10.1111/pme.12184	17	0	0	0	0	MARK ALLEN GROUP	LONDON	ST JUDES CHURCH, DULWICH RD, LONDON, SE24 0PB, ENGLAND	1357-6321			INT J PALLIAT NURS	Int. J. Palliat. Nurs.	APR	2015	21	4					168	172		10.12968/ijpn.2015.21.4.168			4	Nursing	Nursing	EE1AQ	WOS:000389313100004	25901588				2020-06-30	J	Przybylowski, K; Tyczka, J; Szczesny, D; Bienert, A; Wiczling, P; Kut, K; Plenzler, E; Kaliszan, R; Grzeskowiak, E				Przybylowski, Krzysztof; Tyczka, Joanna; Szczesny, Damian; Bienert, Agnieszka; Wiczling, Pawel; Kut, Katarzyna; Plenzler, Emilia; Kaliszan, Roman; Grzeskowiak, Edmund			Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery	JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS			English	Article						Propofol; PK/PD; AAI index; Cancer patients; Major lung surgery	TOTAL INTRAVENOUS ANESTHESIA; BISPECTRAL INDEX; POPULATION PHARMACOKINETICS; INFUSION; BLOOD; REMIFENTANIL; MODELS; CHROMATOGRAPHY; MULTICENTER; PERFORMANCE	Despite the growing number of cancer cases and cancer surgeries around the world, the pharmacokinetics (PK) and pharmacodynamics (PD) of anesthetics used in this population are poorly understood. Patients operated due to cancer are usually in severe state and often require chemotherapy. It might affect the PK/PD of drugs used in this population. Therefore, in this study we explored the PK/PD of propofol in cancer patients having a major lung surgery. 23 patients that underwent a propofol-fentanyl total intravenous anesthesia were included in the analysis. A large set of demographic, biochemical and hemodynamic parameters was collected for the purpose of covariate analysis. Nonlinear mixed effect modeling in NONMEM was used to analyze the collected data. A three-compartment model was sufficient to describe PK of propofol. The anesthetic effect (AAI index) was linked to the propofol effect site concentrations through a sigmoidal E (max) model. A slightly higher value of clearance, a lower value of distribution clearance, and a decreased volume of peripheral compartment were observed in our patients, as compared with the literature values reported for healthy volunteers by Schnider et al. and by Eleveld et al. Despite these differences, both models led to a clinically insignificant bias of -8 and -1 % in concentration predictions, as reflected by the median performance error. The C (e50) and propofol biophase concentration at the time of postoperative orientation were low and equaled 1.40 and 1.13 mg/L. The population PK/PD model was proposed for cancer patients undergoing a major lung surgery. The large body of studied covariates did not affect PK/PD of propofol significantly. The modification of propofol dosage in the group of patients under study is not necessary when TCI-guided administration of propofol by means of the Schnider model is used.	[Przybylowski, Krzysztof; Bienert, Agnieszka; Kut, Katarzyna; Plenzler, Emilia; Grzeskowiak, Edmund] Poznan Univ Med Sci, Dept Clin Pharm & Biopharm, Poznan, Poland; [Tyczka, Joanna] Pulm Dis & Thorac Surg Ctr, Dept Intens Care, Poznan, Poland; [Szczesny, Damian; Wiczling, Pawel; Kaliszan, Roman] Med Univ Gdansk, Dept Biopharmaceut & Pharmacokinet, PL-80416 Gdansk, Poland	Wiczling, P (reprint author), Med Univ Gdansk, Dept Biopharmaceut & Pharmacokinet, Al Gen J Hallera 107, PL-80416 Gdansk, Poland.	wiczling@gumed.edu.pl	Wiczling, Pawel/T-3987-2018	Wiczling, Pawel/0000-0002-2878-3161; Bienert, Agnieszka/0000-0001-7272-5738; Grzeskowiak, Edmund/0000-0002-9938-6729			Absalom AR, 2009, BRIT J ANAESTH, V103, P26, DOI 10.1093/bja/aep143; ALBANESE J, 1990, ANESTHESIOLOGY, V73, P214, DOI 10.1097/00000542-199008000-00004; Beal SL, 2001, J PHARMACOKINET PHAR, V28, P481, DOI 10.1023/A:1012299115260; Bergstrand M, 2011, AAPS J, V13, P143, DOI 10.1208/s12248-011-9255-z; Bienert A, 2012, PHARMACOL REP, V64, P782, DOI 10.1016/S1734-1140(12)70874-5; Bienert A, 2011, ARZNEIMITTEL-FORSCH, V61, P545, DOI 10.1055/s-0031-1300552; Bjornsson MA, 2010, J PHARMACOKINET PHAR, V37, P243, DOI 10.1007/s10928-010-9157-1; Bresson J, 2013, ANESTH ANALG, V117, P1257, DOI 10.1213/ANE.0b013e3182a6d2f8; Chan MTV, 1999, ANESTHESIOLOGY, V90, P1571, DOI 10.1097/00000542-199906000-00012; Cillo JE, 1999, ORAL SURG ORAL MED O, V87, P530, DOI 10.1016/S1079-2104(99)70129-0; Dawidowicz AL, 2003, BIOMED CHROMATOGR, V17, P447, DOI 10.1002/bmc.269; Dawidowicz AL, 2000, BIOMED CHROMATOGR, V14, P249, DOI 10.1002/1099-0801(200006)14:4<249::AID-BMC981>3.0.CO;2-H; Diepstraten J, 2012, CLIN PHARMACOKINET, V51, P543, DOI [10.2165/11632940-000000000-00000, 10.1007/BF03261930]; Eleveld DJ, 2014, ANESTH ANALG, V118, P1221, DOI 10.1213/ANE.0000000000000165; Fu F, 2014, BRIT J ANAESTH, V112, P506, DOI 10.1093/bja/aet383; Gao JD, 2012, CHINESE MED J-PEKING, V125, P1389, DOI 10.3760/cma.j.issn.0366-6999.2012.08.005; Glass PS, 2005, MILLERS ANESTHESIA, V1, P439; Hiraoka H, 2004, CLIN PHARMACOL THER, V75, P324, DOI 10.1016/j.clpt.2003.12.004; Kreuer S, 2003, BRIT J ANAESTH, V91, P336, DOI 10.1093/bja/aeg189; LEGUELLEC C, 1995, ANESTH ANALG, V81, P855, DOI 10.1097/00000539-199510000-00034; Masui K, 2010, ANESTH ANALG, V111, P368, DOI 10.1213/ANE.0b013e3181bdcf5b; Mazoit JX, 1999, BRIT J CLIN PHARMACO, V47, P35, DOI 10.1046/j.1365-2125.1999.00860.x; Mi WD, 2003, J CLIN ANESTH, V15, P103, DOI 10.1016/S0952-8180(02)00510-X; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Ozkose Z, 2002, J CLIN ANESTH, V14, P161, DOI 10.1016/S0952-8180(01)00368-3; Parke J, 1999, COMPUT METH PROG BIO, V59, P19, DOI 10.1016/S0169-2607(98)00098-4; Peeters MMM, 2008, CLIN PHARMACOL THER, V83, P443, DOI 10.1038/sj.clpt.6100309; PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8; Savic RM, 2009, AAPS J, V11, P558, DOI 10.1208/s12248-009-9133-0; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; Schuttler J, 2000, ANESTHESIOLOGY, V92, P727, DOI 10.1097/00000542-200003000-00017; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; SHAFER SL, 1993, J CLIN ANESTH, V5, pS14; Slinger MD, 2011, PRINCIPLES PRACTICE, P732; Snyder GL, 2011, BRIT J ANAESTH, V2, P106; Steinbacher D M, 2001, Anesth Prog, V48, P66; van Kralingen S, 2011, CLIN PHARMACOKINET, V50, P739, DOI 10.2165/11592890-000000000-00000; Vereecke HEM, 2005, ANESTHESIOLOGY, V103, P500, DOI 10.1097/00000542-200509000-00012; Vuyk J, 2001, Acta Anaesthesiol Belg, V52, P445; Wiczling P, 2012, PHARMACOL REP, V64, P113, DOI 10.1016/S1734-1140(12)70737-5; Zaba Z, 2007, CNS DRUGS, V21, P165, DOI 10.2165/00023210-200721020-00006	41	10	11	2	16	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1567-567X	1573-8744		J PHARMACOKINET PHAR	J. Pharmacokinet. Pharmacodyn.	APR	2015	42	2					111	122		10.1007/s10928-015-9404-6			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CD6BB	WOS:000351172300002	25628234	Green Published, Other Gold			2020-06-30	J	Adams, J; Frawley, J; Steel, A; Broom, A; Sibbritt, D				Adams, Jon; Frawley, Jane; Steel, Amie; Broom, Alex; Sibbritt, David			Use of pharmacological and non-pharmacological labour pain management techniques and their relationship to maternal and infant birth outcomes: Examination of a nationally representative sample of 1835 pregnant women	MIDWIFERY			English	Article						Childbirth; Infant health; Labour pain; Pain management; Pregnancy outcome	INTRAPARTUM EPIDURAL ANALGESIA; RISK-FACTORS; MASSAGE; HEALTH	Aim: women use various labour pain management techniques during birth. The objective of this study is to investigate women's use of pharmacological and non-pharmacological labour pain management techniques in relation to birth outcomes. Methods: a sub-survey of a nationally representative sample of pregnant women (n=1835) from the Australian Longitudinal Study on Women's Health. Results: our analysis identified women's use of water for labour pain management as decreasing the likelihood of their baby being admitted to special care nursery (OR=0.42, p < 0.004) whereas the use of epidural increased this likelihood (OR= 3.38, p <0001) as well as for instrumental childbirth (OR=7.27, p <0001) Epidural and pethidine use decreased women's likelihood of continuing breast-feeding (ORs=0.68 and 0.59, respectively, both p < 0.01) whereas the use of breathing techniques and massage for pain control increased the likelihood of women continuing breast-feeding (ORs = 1.72 and 1.62, respectively, both p < 0.01), Conclusions: our study illustrates associations between the use of both pharmacological and non pharmacological labour pain management techniques and selected birth outcomes while controlling for confounding variables. There remain significant gaps in the evidence base for the use of non pharmacological labour pain control methods and our findings provide a platform with which to develop a broad clinical research programme around this topic. (C) 2015 Elsevier Lid. All rights reserved.	[Adams, Jon; Frawley, Jane; Steel, Amie] Univ Technol Sydney, Fac Hlth, Ultimo, NSW 2006, Australia; [Steel, Amie] Endeavour Coll Nat Hlth, Brisbane, Qld 4006, Australia; [Broom, Alex] Univ Queensland, Sch Social Sci, St Lucia, Qld 4072, Australia; [Sibbritt, David] Univ Technol Sydney, David Sibbritt Fac Hlth, Ultimo, NSW 2006, Australia	Adams, J (reprint author), Univ Technol Sydney, Fac Hlth, Level 7,Bldg 10,235-253 Jones St, Ultimo, NSW 2006, Australia.	Jon.adams@uts.edu.au; Jane.frawley@uts.edu.au; Amie.steel@uts.edu.au; a.broom@uq.edu.au; david.sibbritt@uts.edu.au	Sibbritt, David W/F-8070-2017; Frawley, Jane/G-4476-2016	Sibbritt, David W/0000-0003-3561-9447; Adams, Jon/0000-0002-9901-5717; Steel, Amie/0000-0001-6643-9444; Frawley, Jane/0000-0001-6037-0140; Broom, Alexander/0000-0003-1258-1140	Australian Department of Health and AgeingAustralian GovernmentDepartment of Health & Ageing; NHMRCNational Health and Medical Research Council of Australia; ARCFondation ARC pour la Recherche sur le CancerAustralian Research Council [DP1094765]	The Australian Longitudinal Study on Women's Health, which was conceived and developed by groups of interdisciplinary researchers at the Universities of Newcastle and University of Queensland, is funded by the Australian Department of Health and Ageing. We thank all participants for their valuable contribution to this project. We also thank the NHMRC for funding Professor Jon Adams via an NHMRC Career Development Fellowship as well as the ARC for funding this project via their Discovery Project Funding (DP1094765) and for funding Associate Professor Alex Broom via an ARC Future Fellowship.	Australian Institute of Family Studies (AIFS), 2008, AUSTR I FAM STUD AIF; Beckmann MM, 2006, COCHRANE DB SYST REV, V1; Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140-6736(02)09454-0; Bouwstra H, 2003, J NUTR, V133, P4243; Brown WJ, 1999, J WOMEN HEALTH GEN-B, V8, P681, DOI 10.1089/jwh.1.1999.8.681; Carpenter L, 2012, J PAEDIATR CHILD H, V48, P419, DOI 10.1111/j.1440-1754.2011.02241.x; Carter MF, 2012, J MATERN-FETAL NEO M, V25, P343, DOI 10.3109/14767058.2011.576723; Diego M, 2009, INT J NEUROSCI, V119, P630, DOI 10.1080/00207450802329605; Gartner LM, 2005, PEDIATRICS, V115, P496, DOI [10.1542/peds.2004-2491, 10.1542/peds.2011-3552]; Handa VL, 2012, OBSTET GYNECOL, V119, P233, DOI 10.1097/AOG.0b013e318240df4f; Henderson JJ, 2003, AUST NZ J OBSTET GYN, V43, P372, DOI 10.1046/j.0004-8666.2003.t01-1-00117.x; Hirayama F, 2012, BJOG-INT J OBSTET GY, V119, P340, DOI 10.1111/j.1471-0528.2011.03210.x; Holmes AV, 2011, J PEDIATR-US, V159, P186, DOI 10.1016/j.jpeds.2011.02.006; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; Lain S, 2008, INT J GYNECOL OBSTET, V102, P253, DOI 10.1016/j.ijgo.2008.04.023; Laws P, 2009, AUSTR MOTHERS BABIES; LEONCAVA N, 2002, [No title captured]; Li Z., 2011, PERINATAL STAT SERIE, V20; Mammas IN, 2009, J MATERN-FETAL NEO M, V22, P365, DOI 10.1080/14767050802556067; Matthiesen AS, 2001, BIRTH-ISS PERINAT C, V28, P13, DOI 10.1046/j.1523-536x.2001.00013.x; NHS. National Health Service, 2012, NHS MAT STAT 2010 11; NISSEN E, 1995, ACTA PAEDIATR, V84, P140, DOI 10.1111/j.1651-2227.1995.tb13596.x; O'Mahony F, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005455.pub2; Oddy W H, 2001, Breastfeed Rev, V9, P11; Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x; Rathfisch G, 2010, J ADV NURS, V66, P2640, DOI 10.1111/j.1365-2648.2010.05428.x; Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103; Torvaldsen S, 2006, INT BREASTFEED J, V1, DOI 10.1186/1746-4358-1-24; Wiklund I, 2009, MIDWIFERY, V25, pE31, DOI 10.1016/j.midw.2007.07.005	29	16	16	0	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0266-6138	1532-3099		MIDWIFERY	Midwifery	APR	2015	31	4					458	463		10.1016/j.midw.2014.12.012			6	Nursing	Nursing	CG7ZJ	WOS:000353526100009	25649472				2020-06-30	J	Yassin, SM; Terblanche, M; Yassin, J; McKenzie, CA				Yassin, Sarah M.; Terblanche, Marius; Yassin, James; McKenzie, Catherine A.			A web-based survey of United Kingdom sedation practice in the intensive care unit	JOURNAL OF CRITICAL CARE			English	Article						Sedation; Midazolam; Propofol; Intensive care; Morphine; Delirium	CRITICALLY-ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; ICU PATIENTS; DELIRIUM; INTERRUPTION; RELIABILITY; VALIDITY; PROTOCOL; ANALGESICS; MIDAZOLAM	Purpose: The purpose of this work was to obtain a detailed perspective of sedation practice. Sedation included sedative and opioid choice, presence of local guidelines, and use of scoring systems. Methods: AWeb-based survey was designed. The aim was to gain sufficient detail of UK sedation while also being succinct enough to complete in 15 minutes. It was composed of relevant demographics, policy, sedative choice, and analgesia. The survey was piloted before launch. The investigators selected the intensive care unit (ICU) pharmacist as the respondent. Results: One hundred fifty-seven ICUs responded. Eighty-nine (59%) reported use of sedation guidelines, 78% undertook sedation holds, and 87% use sedation scores. Only 42% used a daily sedation target. Seventy (43%) assess for delirium; 27 of those use a validated tool. Propofol (89%) use was common, followed by midazolam (49%). Morphine (49%), fentanyl (34%), and alfentanil (34%) were the most frequently used opioids. Conclusion: This survey confirmed expected variation in UK sedation practice. Recognized strategies such as target sedation score and sedation policy are underused. A 43% uptake in delirium screening suggests that larger engagement is required to meet national standards. (C) 2014 Elsevier Inc. All rights reserved.	[Yassin, Sarah M.; McKenzie, Catherine A.] Kings Coll London, Inst Pharmaceut Sci, London SE1 7RT, England; [Terblanche, Marius] Kings Coll London, Sch Med, London SE1 9RT, England; [Yassin, Sarah M.; Terblanche, Marius; McKenzie, Catherine A.] Guys & St Thomas NHS Fdn Trust GSTFT, St Thomas Hosp, London SE1 7EH, England; [Yassin, James] Royal Sussex Cty Hosp, Dept Crit Care, Brighton BN2 5BE, E Sussex, England	McKenzie, CA (reprint author), Guys & St Thomas NHS Fdn Trust, St Thomas Hosp, Westminster Bridge Rd, London SE1 7EH, England.	Catherine.mckenzie@gstt.nhs.uk		Edgeworth, Cathrine/0000-0002-5190-9711; Terblanche, Marius/0000-0002-6148-5721	Guys and St Thomas' Charity; National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' National Health Service Foundation Trust; King's College London	This work was undertaken from a grant awarded from Guys and St Thomas' Charity.; The research was also supported by the National Institute for Health Research Biomedical Research Centre based at Guy's and St Thomas' National Health Service Foundation Trust and King's College London. The views expressed are those of the author (s) and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.	Astra Zeneca UK ltd, 2012, SED AN CRIT ILL SUMM; BAUER TM, 1995, LANCET, V346, P145, DOI 10.1016/S0140-6736(95)91209-6; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; GORDON HL, 1986, BRIT MED J, V293, P818, DOI 10.1136/bmj.293.6550.818-b; Intensive Care Society/ Faculty of Intensive Care Medicine, 2013, COR STAND INT CAR UN; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; Mac Sweeney R, 2010, QJM-INT J MED, V103, P243, DOI 10.1093/qjmed/hcp194; Marshall J, 2008, CRIT CARE MED, V36, P427, DOI 10.1097/01.CCM.0000300275.63811.B3; Martin J, 2007, CRIT CARE, V11, DOI 10.1186/cc6189; McKenzie CA, 2005, CRIT CARE, V9, pR32, DOI 10.1186/cc3010; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872; O'Connor M, 2010, AM J CRIT CARE, V19, P285, DOI 10.4037/ajcc2009541; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Park GR, 2003, OXFORD TXB MED, P1250; Pasin L, 2014, PLOS ONE, V9, DOI 10.1371/annotation/3f0f682b-f8aa-4e9c-9d60-8aac54bb4c22; Patel RP, 2009, CRIT CARE MED, V37, P825, DOI 10.1097/CCM.0b013e31819b8608; Pfizer UK ltd, 2013, SUMM PROD CHAR LYR; Ramaswamy S, 2009, INTENS CARE MED, V35; Reschreiter H, 2008, CRIT CARE, V12, DOI 10.1186/cc7141; Riker RR, 2014, NEUROCRIT CARE; Salluh JIF, 2009, J CRIT CARE, V24, P556, DOI 10.1016/j.jcrc.2009.04.004; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Tanios MA, 2009, J CRIT CARE, V24, P66, DOI 10.1016/j.jcrc.2008.03.037; Wilson KC, 2005, CHEST, V128, P1674, DOI 10.1378/chest.128.3.1674	31	13	13	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	APR	2015	30	2					436	U326	436.e1	10.1016/j.jcrc.2014.11.006			6	Critical Care Medicine	General & Internal Medicine	CB8WV	WOS:000349913800046	25483928				2020-06-30	J	Holzinger, U; Brunner, R; Losert, H; Fuhrmann, V; Herkner, H; Madl, C; Sterz, F; Schneeweiss, B				Holzinger, Ulrike; Brunner, Richard; Losert, Heidrun; Fuhrmann, Valentin; Herkner, Harald; Madl, Christian; Sterz, Fritz; Schneeweiss, Bruno			Resting energy expenditure and substrate oxidation rates correlate to temperature and outcome after cardiac arrest - a prospective observational cohort study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL PATIENTS; CHRONIC-RENAL-FAILURE; OXYGEN-CONSUMPTION; INDIRECT CALORIMETRY; COMATOSE SURVIVORS; METABOLISM; HYPOTHERMIA; INSULIN; MECHANISMS	Introduction: Targeted temperature management improves outcome after cardiopulmonary resuscitation. Reduction of resting energy expenditure might be one mode of action. The aim of this study was to correlate resting energy expenditure and substrate oxidation rates with targeted temperature management at 33 degrees C and outcome in patients after cardiac arrest. Methods: This prospective, observational cohort study was performed at the department of emergency medicine and a medical intensive care unit of a university hospital. Patients after successful cardiopulmonary resuscitation undergoing targeted temperature management at 33 degrees C for 24 hours with subsequent rewarming to 36 degrees C and standardized sedation, analgesic and paralytic medication were included. Indirect calorimetry was performed five times within 48 h after cardiac arrest. Measurements were correlated to outcome with repeated measures ANOVA, linear and logistic regression analysis. Results: In 25 patients resting energy expenditure decreased 20 (18 to 27) % at 33 degrees C compared to 36 degrees C without differences between outcome groups (favourable vs. unfavourable: 25 (21 to 26) vs. 21 (16 to 26); P = 0.5). In contrast to protein oxidation rate (favourable vs. unfavourable: 35 (11 to 68) g/day vs. 39 (7 to 75) g/day, P = 0.8) patients with favourable outcome had a significantly higher fat oxidation rate (139 (104 to 171) g/day vs. 117 (70 to 139) g/day, P < 0.05) and a significantly lower glucose oxidation rate (30 (-34 to 88) g/day vs. 77 (19 to 138) g/day; P < 0.05) as compared to patients with unfavourable neurological outcome. Conclusions: Targeted temperature management at 33 degrees C after cardiac arrest reduces resting energy expenditure by 20% compared to 36 degrees C. Glucose and fat oxidation rates differ significantly between patients with favourable and unfavourable neurological outcome.	[Holzinger, Ulrike; Brunner, Richard; Madl, Christian; Schneeweiss, Bruno] Med Univ Vienna, ICU 13H1, Dept Med 3, Div Gastroenterol & Hepatol, A-1090 Vienna, Austria; [Losert, Heidrun; Herkner, Harald; Sterz, Fritz] Med Univ Vienna, Dept Emergency Med, A-1090 Vienna, Austria; [Fuhrmann, Valentin] Univ Med Ctr Hamburg Eppendorf, Dept Intens Care, D-20246 Hamburg, Germany	Holzinger, U (reprint author), Med Univ Vienna, ICU 13H1, Dept Med 3, Div Gastroenterol & Hepatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	ulrike.holzinger@meduniwien.ac.at					Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bruder N, 1998, CRIT CARE MED, V26, P568, DOI 10.1097/00003246-199803000-00033; BURSZTEIN S, 1977, J APPL PHYSIOL, V42, P117; CHAMBERLAIN D, 1991, RESUSCITATION, V22, P1, DOI 10.1016/0300-9572(91)90061-3; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; HAMER J, 1978, ACTA NEUROCHIR, V44, P151, DOI 10.1007/BF01402057; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzer M, 2010, NEW ENGL J MED, V363, P1256, DOI 10.1056/NEJMct1002402; HOOPARIS R, 1988, AM J PHYSIOL, V255, pR1035; KURPAD AV, 1994, AM J PHYSIOL, V266, pE877; LIVESEY G, 1988, AM J CLIN NUTR, V47, P608; Magistretti Pierre J., 1995, P657; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P210, DOI 10.1164/ajrccm.151.1.7812556; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P10, DOI 10.1164/ajrccm.151.1.7812538; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MARSH WH, 1965, CLIN CHEM, V11, P624; NATALI A, 1990, DIABETES, V39, P490, DOI 10.2337/diabetes.39.4.490; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Poblete B, 1997, BRIT J ANAESTH, V78, P123; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; SCHNEEWEISS B, 1993, GASTROENTEROLOGY, V105, P1515, DOI 10.1016/0016-5085(93)90159-A; SCHNEEWEISS B, 1990, HEPATOLOGY, V11, P387, DOI 10.1002/hep.1840110309; SCHNEEWEISS B, 1992, METABOLISM, V41, P125, DOI 10.1016/0026-0495(92)90138-Z; SCHNEEWEISS B, 1990, AM J CLIN NUTR, V52, P596; Sessler DI, 2009, CRIT CARE MED, V37, pS203, DOI 10.1097/CCM.0b013e3181aa5568; SIMONSON DC, 1990, AM J PHYSIOL, V258, pE399; Terao Y, 2003, CRIT CARE MED, V31, P830, DOI 10.1097/01.CCM.0000054868.93459.E1; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Urabe T, 1996, J NEUROCHEM, V67, P265; Vallerand AL, 1999, AVIAT SPACE ENVIR MD, V70, P42; Vernon DD, 2000, CRIT CARE MED, V28, P1569, DOI 10.1097/00003246-200005000-00051; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; WELLE S, 1988, J CLIN ENDOCR METAB, V66, P593, DOI 10.1210/jcem-66-3-593	39	11	11	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	MAR 29	2015	19								128	10.1186/s13054-015-0856-2			9	Critical Care Medicine	General & Internal Medicine	CG3SD	WOS:000353199000002	25888299	DOAJ Gold, Green Published			2020-06-30	J	Bowman, SL; Soohoo, AL; Shiwarski, DJ; Schulz, S; Pradhan, AA; Puthenveedu, MA				Bowman, Shanna L.; Soohoo, Amanda L.; Shiwarski, Daniel J.; Schulz, Stefan; Pradhan, Amynah A.; Puthenveedu, Manojkumar A.			Cell-Autonomous Regulation of Mu-Opioid Receptor Recycling by Substance P	CELL REPORTS			English	Article							PROTEIN-KINASE-C; LOCUS-CERULEUS NEURONS; COUPLED RECEPTORS; MEMBRANE TRAFFICKING; MORPHINE-TOLERANCE; MICE LACKING; DESENSITIZATION; PHOSPHORYLATION; INTERNALIZATION; ACTIVATION	How neurons coordinate and reprogram multiple neurotransmitter signals is an area of broad interest. Here, we show that substance P (SP), a neuropeptide associated with inflammatory pain, reprograms opioid receptor recycling and signaling. SP, through activation of the neurokinin 1 (NK1R) receptor, increases the post-endocytic recycling of the muopioid receptor (MOR) in trigeminal ganglion (TG) neurons in an agonist-selective manner. SP-mediated protein kinase C (PKC) activation is both required and sufficient for increasing recycling of exogenous and endogenous MOR in TG neurons. The target of this cross-regulation is MOR itself, given that mutation of either of two PKC phosphorylation sites on MOR abolishes the SP-induced increase in recycling and resensitization. Furthermore, SP enhances the resensitization of fentanyl-induced, but not morphine-induced, antinociception in mice. Our results define a physiological pathway that cross-regulates opioid receptor recycling via direct modification of MOR and suggest a mode of homeostatic interaction between the pain and analgesic systems.	[Bowman, Shanna L.; Soohoo, Amanda L.; Shiwarski, Daniel J.; Puthenveedu, Manojkumar A.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Schulz, Stefan] Univ Jena, Jena Univ Hosp, Inst Pharmacol & Toxicol, D-07747 Jena, Germany; [Pradhan, Amynah A.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA	Puthenveedu, MA (reprint author), Carnegie Mellon Univ, Dept Biol Sci, 4400 Fifth Ave, Pittsburgh, PA 15213 USA.	map3@andrew.cmu.edu	Puthenveedu, Manojkumar A/A-3795-2016; Schulz, Stefan/A-6928-2017; Zajac, Amanda/C-5884-2015	Puthenveedu, Manojkumar A/0000-0002-3177-4231; Schulz, Stefan/0000-0002-5997-8885; Shiwarski, Daniel/0000-0001-6978-303X; Zajac, Amanda/0000-0003-0180-0950	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS007433, DA031243, DA024698, DA036086]	We thank Dr. Alison Barth, Joanne Steinmiller, Jen Dry-Henich, Dr. Rebecca Seal, and Adam Goldring for providing help with isolation of TG neurons and for critical comments. We thank Drs. Mark von Zastrow and Rachel Vistein for reagents and technical help. Wethank Drs. John T. Williams and Seksiri Arttamangkul for generously providing the Alexa 594-conjugated dermorphin. We thank Drs. Adam Linstedt, Tina Lee, Joann Trejo, Peter Friedman, Guillermo Romero, Jean-Pierre Vilardaga, Alessandro Bisello, and Aylin Hanyaloglu for comments and suggestions. S.L.B. was supported by an NIH T32 grant NS007433, A.A.P. was supported by NIH DA031243, and M.A.P. was supported by NIH DA024698 and DA036086.	Aicher SA, 2000, J NEUROSCI, V20, P4345; Alvarez VA, 2002, J NEUROSCI, V22, P5769; Anggono V, 2012, CURR OPIN NEUROBIOL, V22, P461, DOI 10.1016/j.conb.2011.12.006; Arttamangkul S, 2000, MOL PHARMACOL, V58, P1570; Arttamangkul S, 2008, MOL PHARMACOL, V74, P972, DOI 10.1124/mol.108.048512; Arttamangkul S, 2012, MOL PHARMACOL, V81, P348, DOI 10.1124/mol.111.076208; Bailey CP, 2004, MOL PHARMACOL, V66, P1592, DOI 10.1124/mol.104.004747; Berg KA, 2007, J PHARMACOL EXP THER, V321, P839, DOI 10.1124/jpet.106.116681; Chen W, 2009, NEUROSCIENCE, V161, P157, DOI 10.1016/j.neuroscience.2009.03.021; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dang VC, 2004, J NEUROSCI, V24, P7699, DOI 10.1523/JNEUROSCI.2499-04.2004; Dang VC, 2011, J NEUROSCI, V31, P7122, DOI 10.1523/JNEUROSCI.5999-10.2011; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; Doll C, 2012, BRIT J PHARMACOL, V167, P1259, DOI 10.1111/j.1476-5381.2012.02080.x; Doll C, 2011, BRIT J PHARMACOL, V164, P298, DOI 10.1111/j.1476-5381.2011.01382.x; Feng B, 2011, MOL PHARMACOL, V79, P768, DOI 10.1124/mol.110.069096; Gadd CA, 2003, J NEUROSCI, V23, P8271, DOI 10.1523/jneurosci.23-23-08271.2003; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; GEORGE EB, 1988, J MEMBRANE BIOL, V105, P55, DOI 10.1007/BF01871106; Hanyaloglu AC, 2007, J BIOL CHEM, V282, P3095, DOI 10.1074/jbc.M605398200; Hunt SP, 2001, NAT REV NEUROSCI, V2, P83, DOI 10.1038/35053509; Illing S, 2014, BRIT J PHARMACOL, V171, P1330, DOI 10.1111/bph.12546; Inoue M, 2000, J PHARMACOL EXP THER, V293, P662; Jean-Alphonse F, 2011, MOL CELL ENDOCRINOL, V331, P205, DOI 10.1016/j.mce.2010.07.010; Just S, 2013, MOL PHARMACOL, V83, P633, DOI 10.1124/mol.112.082875; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Komatsu T, 2009, PEPTIDES, V30, P1689, DOI 10.1016/j.peptides.2009.06.002; Kramer HK, 1999, J NEUROCHEM, V72, P594, DOI 10.1046/j.1471-4159.1999.0720594.x; Lao LJ, 2008, BRAIN RES, V1197, P85, DOI 10.1016/j.brainres.2007.12.040; Lupp A, 2011, REGUL PEPTIDES, V167, P9, DOI 10.1016/j.regpep.2010.09.004; Macdonald SG, 1996, BIOCHEMISTRY-US, V35, P2909, DOI 10.1021/bi952351+; Malin SA, 2007, NAT PROTOC, V2, P152, DOI 10.1038/nprot.2006.461; Mann A, 2015, BRIT J PHARMACOL, V172, P311, DOI 10.1111/bph.12627; Marchese A, 2008, ANNU REV PHARMACOL, V48, P601, DOI 10.1146/annurev.pharmtox.48.113006.094646; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; MOHRLAND JS, 1979, BRAIN RES, V171, P556, DOI 10.1016/0006-8993(79)91062-X; Murtra P, 2000, NATURE, V405, P180, DOI 10.1038/35012069; Nichols ML, 1999, SCIENCE, V286, P1558, DOI 10.1126/science.286.5444.1558; Perl ER, 2007, NAT REV NEUROSCI, V8, P71, DOI 10.1038/nrn2042; Pfeiffer M, 2003, J BIOL CHEM, V278, P51630, DOI 10.1074/jbc.M307095200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pradhan AAA, 2010, J NEUROSCI, V30, P16459, DOI 10.1523/JNEUROSCI.3748-10.2010; Puthenveedu MA, 2010, CELL, V143, P761, DOI 10.1016/j.cell.2010.10.003; Raehal KM, 2011, PHARMACOL REV, V63, P1001, DOI 10.1124/pr.111.004598; Roman-Vendrell C, 2012, J BIOL CHEM, V287, P14782, DOI 10.1074/jbc.M111.319616; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Scita G, 2010, NATURE, V463, P464, DOI 10.1038/nature08910; Soohoo AL, 2013, MOL BIOL CELL, V24, P1725, DOI 10.1091/mbc.E12-07-0550; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Stein C, 2009, CURR OPIN PHARMACOL, V9, P3, DOI 10.1016/j.coph.2008.12.009; Talbot JN, 2005, J PHARMACOL EXP THER, V314, P596, DOI 10.1124/jpet.104.082156; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Vistein R, 2013, P NATL ACAD SCI USA, V110, P15289, DOI 10.1073/pnas.1306340110; von Zastrow M, 2012, NEURON, V76, P22, DOI 10.1016/j.neuron.2012.09.022; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; Yu YJ, 2010, J NEUROSCI, V30, P11703, DOI 10.1523/JNEUROSCI.6282-09.2010; Yu YJ, 2009, J NEUROSCI, V29, P222, DOI 10.1523/JNEUROSCI.4315-08.2009; Yudowski GA, 2006, NAT NEUROSCI, V9, P622, DOI 10.1038/nn1679; Yudowski GA, 2009, MOL BIOL CELL, V20, P2774, DOI 10.1091/mbc.E08-08-0892	62	21	22	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	MAR 24	2015	10	11					1925	1936		10.1016/j.celrep.2015.02.045			12	Cell Biology	Cell Biology	CE4CY	WOS:000351779600013	25801029	DOAJ Gold, Green Accepted			2020-06-30	J	Yu, ZQ; Zhang, CL; Xu, YJ; Chang, MJ; Jin, JJ; Luo, L; Li, XP; Liu, D				Yu, Z-Q.; Zhang, C-L.; Xu, Y-J.; Chang, M-J.; Jin, J-J.; Luo, L.; Li, X-P.; Liu, D.			Chronopharmacology of Analgesic Effect and Tolerance Induced by Six Narcotic Analgesics in Mice	DRUG RESEARCH			English	Article						narcotic analgesics; tolerance; chronopharmacology; 24 h rhythm; time of administration		Narcotic analgesics, especially morphine, exert significantly different effects depending on the time within one day. The objective of this study was to observe whether the dosing time of 6 narcotic analgesics in mice affected their efficacy, pain tolerance and recovery of tolerance. The chronopharmacology of these 6 narcotics was evaluated using a hot-plate model. Maximum possible effect (MPE) of morphine showed a significant 24 h rhythm, which was higher during the dark phase and lower during the light phase (P < 0.05). Conversely, MPEs of fentanyl and bucinnazine groups during the light phase exceeded those during the dark phase (P < 0.05). Pain tolerance developed after drug administration at 9:00 am or 9:00 pm for 5 days, of which bucinnazine produced lower tolerance at 9:00 am. After a 2-day washout period, the mice rapidly recovered from tolerance at 3:00 pm for 5-day morphine dosing at 9:00 pm, and for fentanyl dosing at 9:00 am. Not all narcotic analgesics displayed significant circadian variations, and the dosing time-dependent effects also depended on the types of narcotics. Therefore, the time of administration is crucial in clinical pain treatment. Chronotherapy may be more effective to relieve pain while reducing side effects.	[Yu, Z-Q.; Zhang, C-L.; Xu, Y-J.; Chang, M-J.; Jin, J-J.; Luo, L.; Li, X-P.; Liu, D.] Huazhong Univ Sci & Technol, Dept Pharm, Tongji Hosp, Tongji Med Coll, Jiefang Ave 1095, Wuhan 430074, Peoples R China; [Yu, Z-Q.] China Pharmaceut Univ, Dept Clin Pharm, Coll Pharmacol, Nanjing, Jiangsu, Peoples R China	Liu, D (reprint author), Huazhong Univ Sci & Technol, Dept Pharm, Tongji Hosp, Tongji Med Coll, Jiefang Ave 1095, Wuhan 430074, Peoples R China.	ld2069@outlook.com						0	2	4	0	3	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	2194-9379	2194-9387		DRUG RES	Drug Res.	MAR	2015	65	3					141	146		10.1055/s-0034-1374617			6	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CD0AT	WOS:000350733200005	24782288				2020-06-30	J	Thronaes, M; Popper, L; Eeg, M; Jaatun, E; Kvitberg, M; Kaasa, S				Thronaes, Morten; Popper, Lars; Eeg, Martin; Jaatun, Ellen; Kvitberg, Magnar; Kaasa, Stein			Efficacy and Tolerability of Intranasal Fentanyl Spray in Cancer Patients With Breakthrough Pain	CLINICAL THERAPEUTICS			English	Article						breakthrough pain; cross-over efficacy phase; Instanyl; intranasal fentanyl spray; pain intensity difference	PECTIN NASAL SPRAY; DOUBLE-BLIND; OPEN-LABEL; ORAL MORPHINE; CROSSOVER; PHARMACOKINETICS; PHASE; MANAGEMENT; OPIOIDS	Purpose: The aims of this study were to explore the efficacy of intranasal fentanyl spray* (INFS) 400 jig to evaluate 12-week tolerability of the nasal mucosa and to explore safety data for all dose strengths of INFS in patients with cancer-related breakthrough pain (BTP). Methods: Patients received a test dose of INFS 50 jig, followed by a titration phase. Those patients with doses titrated to 200 or 400 jig entered a randomized, double-blind, cross-over efficacy phase, in which 8 episodes of BIT were randomly treated with INFS 400 jig (6 episodes) and placebo (2 episodes), followed by a tolerability phase. Patients with doses titrated to 50 or 100 jig entered the tolerability phase directly. Primary outcome was measured by pain intensity difference at 10 minutes, analyzed using ANCOVA, and presented as least square mean difference. Examination of the nasal cavity was conducted at inclusion and after 12 weeks of treatment by an otorhinolaryngologist. Findings: Forty-six patients were included. Thirtyeight patients' doses were titrated to an effective dose of INFS; 50 jig (n = 8), 100 jig (n = 9), 200 jig (n = 9), and 400 jig (n = 12); 15 patients entered the efficacy phase and 31 entered the tolerability phase. In the efficacy phase, 88 and 29 episodes of BTP were treated with INFS 400 jig and placebo, respectively. Pain intensity difference at 10 minutes least square mean for INFS 400 jig was 2.5 (95% CI, 1.42-3.49) (P < 0.001) and least square mean difference between INFS 400 jig and placebo was 1.1 (95% CI, 0.41-1.79) (P = 0.002). Runny nose (10%) and change in color of the mucosa (9%) were the most frequent findings of nasal examination, and nausea and dizziness were the most frequent treatment-related adverse events. One serious adverse event (ie, respiratory depression) was considered related to INFS. Implications: INFS 400 jig is effective and nasal tolerability and overall safety profile is acceptable during 12 weeks of use. (C) 2015 Elsevier HS Journals, Inc. All rights reserved.	[Thronaes, Morten; Jaatun, Ellen; Kaasa, Stein] Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, European Palliat Care Res Ctr, Trondheim, Norway; [Thronaes, Morten; Kaasa, Stein] Univ Trondheim Hosp, Canc Clin, St Olavs Hosp, Trondheim, Norway; [Popper, Lars] Takeda Pharma AS, Clin Sci, Roskilde, Denmark; [Eeg, Martin] Takeda Pharma AS, Analyt Sci, Roskilde, Denmark; [Jaatun, Ellen] Univ Trondheim Hosp, St Olavs Hosp, Dept Otorhinolaryngol, Trondheim, Norway; [Kvitberg, Magnar] Drammen Hosp, Dept Oncol, Palliat Unit, Drammen, Norway	Thronaes, M (reprint author), St Olavs Hosp, Kunnskapssenteret 4th Floor, N-7006 Trondheim, Norway.	morten.thrones@ntnu.no		Eeg, Martin Krogager/0000-0003-3824-744X	Takeda Pharmaceutical Company Limited.Takeda Pharmaceutical Company Ltd	This study was funded by Takeda Pharmaceutical Company Limited. Lars Popper and Martin Eeg were employees of Takeda at the time the study was conducted and during the development of the manuscript. The authors have full control of all primary data, and have agreed to allow the Journal to review these data if requested. The authors have indicated that they have no other conflicts of interest regarding the content of this article.	Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Colloca L, 2005, NAT REV NEUROSCI, V6, P545, DOI 10.1038/nrn1705; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies A, 2014, J PAIN SYMPTOM MANAG, V47, P57; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2010, NAT MED, V16, P1284, DOI 10.1038/nm.2249; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2011, CURR PAIN HEADACHE R, V15, P244, DOI 10.1007/s11916-011-0191-5; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; Plock N, 2013, INT J CLIN PHARM TH, V51, P495, DOI 10.5414/CP201867; Portenoy R K, 1989, Oncology (Williston Park), V3, P25; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Taylor D, 2014, J PAIN SYMPTOM MANAG, V47, P1001, DOI 10.1016/j.jpainsymman.2013.07.012; Webster LR, 2013, PAIN MED, V14, P1332, DOI 10.1111/pme.12184; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020	30	8	9	0	4	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	MAR	2015	37	3					585	596		10.1016/j.clinthera.2014.12.010			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CG4JV	WOS:000353252300013	25641199				2020-06-30	J	Cole, JB; Dunbar, JF; McIntire, SA; Regelmann, WE; Slusher, TM				Cole, Jon B.; Dunbar, John F.; McIntire, Sarah A.; Regelmann, Warren E.; Slusher, Tina M.			Butyrfentanyl Overdose Resulting in Diffuse Alveolar Hemorrhage	PEDIATRICS			English	Article							PULMONARY HEMORRHAGE; NALOXONE; REVERSAL; EDEMA; DOGS	Butyrfentanyl is a potent short-acting opioid and a fentanyl analog with uncertain clinical effects. A review of the literature reveals no human case reports of butyrfentanyl overdose. As the use of analog and synthetic drugs continues to increase, clinicians are often faced with tremendous uncertainty when they encounter patients exposed to these synthetic drugs. We describe, to our knowledge, the first case of a butyrfentanyl overdose that resulted in clinically significant hemoptysis, acute lung injury, hypoxic respiratory failure, and diffuse alveolar hemorrhage. Complicating this case was a false-positive urine drug screen for fentanyl. Clinicians who encounter fentanyl exposures should be aware they may in fact be dealing with butyrfentanyl. As little is known of butyrfentanyl and our patient suffered a significant pulmonary hemorrhage, those who encounter butyrfentanyl exposures should monitor for hemorrhagic complications.	[Cole, Jon B.] Hennepin Reg Poison Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; [Slusher, Tina M.] Hennepin Cty Med Ctr, Div Crit Care Med, Dept Pediat, Minneapolis, MN 55415 USA; [Dunbar, John F.] Hennepin Cty Med Ctr, Transit Residency, Minneapolis, MN 55415 USA; [McIntire, Sarah A.] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; [McIntire, Sarah A.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Regelmann, Warren E.] Univ Minnesota, Sch Med, Dept Pediat, Div Pulm Med, Minneapolis, MN 55455 USA	Cole, JB (reprint author), Hennepin Reg Poison Ctr, 701 Pk Ave, Minneapolis, MN 55415 USA.	jon.cole@hcmed.org	Cole, Jon B/J-5788-2019	Cole, Jon B/0000-0002-7714-8826			ALBURGES ME, 1992, J ANAL TOXICOL, V16, P36, DOI 10.1093/jat/16.1.36; [Anonymous], 2011, MMWR-MORBID MORTAL W, V60, P1487; DUBERSTEIN JL, 1971, AM J MED, V51, P704, DOI 10.1016/0002-9343(71)90298-1; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Kuehn BM, 2012, JAMA-J AM MED ASSOC, V307, P242, DOI 10.1001/jama.2011.1998; MILLS CA, 1988, ANESTH ANALG, V67, P730; MILLS CA, 1990, CAN J ANAESTH, V37, P238, DOI 10.1007/BF03005476; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Osler W, 1880, MONTREAL GEN HOSP RE, V1, P291; Porter R, 2011, PEDIATR EMERG CARE, V27, P742, DOI 10.1097/PEC.0b013e318226df00; PROUGH DS, 1984, ANESTHESIOLOGY, V60, P485, DOI 10.1097/00000542-198405000-00018; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Schwartz DR, 1999, CHEST, V115, P1194, DOI 10.1378/chest.115.4.1194	13	30	31	0	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2015	135	3					E740	E743		10.1542/peds.2014-2878			4	Pediatrics	Pediatrics	CF0BD	WOS:000352206600026	25713275				2020-06-30	J	Colak, S; Erdogan, MO; Afacan, MA; Kosargelir, M; Aktas, S; Tayfur, I				Colak, Sahin; Erdogan, Mehmet Ozgur; Afacan, Mustafa Ahmet; Kosargelir, Mehmet; Aktas, Sezin; Tayfur, Ismail			Neuropsychiatric side effects due to a transdermal fentanyl patch: hallucinations	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							CANCER PAIN	Opioid analgesics are used commonly in end-stage cancer patients for pain treatment. Central nervous system adverse effects are rare. A 73-year-old female patient was admitted to the emergency department for auditory and visual hallucinations. The patient had been receiving palliative treatment for liver, cervical, and lumbar bone metastases from an unknown origin. The patient used a transdermal fentanyl patch for palliative pain management and metoclopramide hydrochloride for nausea and vomiting. The patient had suffered weight loss of 10 kg within 5 months, and laboratory findings revealed hypoalbuminemia. The patient was considered to have experienced a fentanyl overdose, and the transdermal fentanyl patch treatment was stopped. The hallucinations improved during follow-up, and the patient was discharged with a dose adjustment. End-stage cancer patients with weight loss and hypoalbuminemia may be more prone to opioid adverse effects, such as hallucinations. The dose of fentanyl must be adjusted for weight loss, and correction of hypoalbuminemia may also lower the incidence of such adverse effects.	[Colak, Sahin; Erdogan, Mehmet Ozgur; Afacan, Mustafa Ahmet; Kosargelir, Mehmet; Aktas, Sezin] Haydarpasa Numune Training & Res Hosp, Emergency Med Clin, Istanbul, Turkey; [Tayfur, Ismail] Namik Kemal Univ, Sch Med, Dept Emergency Med Tekirdag, Istanbul, Turkey	Colak, S (reprint author), Haydarpasa Numune Training & Res Hosp, Emergency Med Clin, Istanbul, Turkey.	drsahincolak@hotmail.com	TAYFUR, Ismail/S-2208-2017; Erdogan, Mehmet Ozgur/N-5852-2017	Erdogan, Mehmet Ozgur/0000-0001-7325-6646; Kandis, Hayati/0000-0001-9151-6050; afacan, mustafa ahmet/0000-0003-1045-0681			Bruera E, 1997, PAIN, V69, P199, DOI 10.1016/S0304-3959(96)03238-1; Ertok I, 2014, ANKARA MED J, V14, P26; Larsen RH, 2003, PHARMACOL TOXICOL, V93, P244, DOI 10.1046/j.1600-0773.2003.pto930508.x; LoVecchio F, 2011, AM J EMERG MED, V29, P131; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Mercadante S, 2007, DRUG AGING, V24, P761, DOI 10.2165/00002512-200724090-00004; Okon TR, 2008, J PAIN SYMPTOM MANAG, V35, P327, DOI 10.1016/j.jpainsymman.2007.04.023; Ozden SY, 1990, J KARTAL TRAIN RES H, V1, P176	8	3	3	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	MAR	2015	33	3							477.e1	10.1016/j.ajem.2014.08.051			2	Emergency Medicine	Emergency Medicine	CE6GP	WOS:000351935100055	25227974				2020-06-30	J	Shackelford, SA; Fowler, M; Schultz, K; Summers, A; Galvagno, SM; Gross, KR; Mabry, RL; Bailey, JA; Kotwal, RS; Butler, FK				Shackelford, Stacy A.; Fowler, Marcie; Schultz, Keith; Summers, Angela; Galvagno, Samuel M.; Gross, Kirby R.; Mabry, Robert L.; Bailey, Jeffrey A.; Kotwal, Russ S.; Butler, Frank K.			Prehospital Pain Medication Use by U.S. Forces in Afghanistan	MILITARY MEDICINE			English	Article							COMBAT CASUALTY CARE; POSTTRAUMATIC-STRESS-DISORDER; KETAMINE; MANAGEMENT; TRAUMA; BATTLEFIELD; EXPERIENCE; OPERATIONS; FENTANYL; EFFICACY	We report the results of a process improvement initiative to examine the current use and safety of prehospital pain medications by U.S. Forces in Afghanistan. Prehospital pain medication data were prospectively collected on 309 casualties evacuated from point of injury (POI) to surgical hospitals from October 2012 to March 2013. Vital signs obtained from POI and flight medics and on arrival to surgical hospitals were compared using one-way analysis of variance test. 119 casualties (39%) received pain medication during POI care and 283 (92%) received pain medication during tactical evacuation (TACEVAC). Morphine and oral transmucosal fentanyl citrate were the most commonly used pain medications during POI care, whereas ketamine and fentanyl predominated during TACEVAC. Ketamine was associated with increase in systolic blood pressure compared to morphine (+7 +/- 17 versus -3 +/- 14 mm Hg, p = 0.04). There was no difference in vital signs on arrival to the hospital between casualties who received no pain medication, morphine, fentanyl, or ketamine during TACEVAC. In this convenience sample, fentanyl and ketamine were as safe as morphine for prehospital use within the dose ranges administered. Future efforts to improve battlefield pain control should focus on improved delivery of pain control at POI and the role of combination therapies.	[Shackelford, Stacy A.] Univ Maryland, Med Ctr, Ctr Sustainment Trauma & Readiness Skills, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Fowler, Marcie; Gross, Kirby R.; Mabry, Robert L.; Bailey, Jeffrey A.; Kotwal, Russ S.; Butler, Frank K.] US Army Inst Surg Res, Joint Trauma Syst, Ft Sam Houston, TX 78234 USA; [Schultz, Keith] 81 Med Operat Squadron, Keesler AFB, MS 39534 USA; [Summers, Angela] 212 Combat Support Hosp, Miesau Ad, Germany; [Galvagno, Samuel M.] Univ Maryland, Med Ctr, Dept Anesthesiol, Baltimore, MD 21201 USA	Shackelford, SA (reprint author), Univ Maryland, Med Ctr, Ctr Sustainment Trauma & Readiness Skills, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.			Galvagno, Samuel/0000-0001-5563-4092			Beecher HK, 1944, J AMER MED ASSOC, V124, P1193, DOI 10.1001/jama.1944.62850170001007; Beekley AC, 2007, SURG CLIN N AM, V87, P157, DOI 10.1016/j.suc.2006.09.008; Bryant RA, 2009, BIOL PSYCHIAT, V65, P438, DOI 10.1016/j.biopsych.2008.10.032; Buckenmaier CC, 2010, MIL MED, V175, P7, DOI 10.7205/MILMED-D-10-00172; Butler FK, 1996, MIL MED, V161, P3; Butler Frank K, 2014, J Spec Oper Med, V14, P13; Butler FK, 2007, MIL MED, V172, P1; Butler FK, 2012, J TRAUMA ACUTE CARE, V73, pS395, DOI 10.1097/TA.0b013e3182754850; Camu Frederic, 2002, Best Pract Res Clin Anaesthesiol, V16, P475, DOI 10.1053/bean.2002.0262; Cevik E, 2013, AM J EMERG MED, V31, P108, DOI 10.1016/j.ajem.2012.06.012; Davey CMT, 2012, J ROY ARMY MED CORPS, V158, P186, DOI 10.1136/jramc-158-03-07; Dickey N., 2012, PREHOSPITAL USE KETA; Filanovsky Y, 2010, CAN J EMERG MED, V12, P154; Green SM, 2000, ACAD EMERG MED, V7, P278, DOI 10.1111/j.1553-2712.2000.tb01076.x; Haas D A, 1992, Anesth Prog, V39, P61; Hocking G, 1996, J R Army Med Corps, V142, P101; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Kotwal RS, 2004, ANN EMERG MED, V44, P121, DOI 10.1016/j.annemergmed.2004.03.025; Kotwal Russ S, 2013, J Spec Oper Med, V13, P82; Kragh JF, 2008, J TRAUMA, V64, pS38, DOI 10.1097/TA.0b013e31816086b1; Malchow RJ, 2008, CRIT CARE MED, V36, pS346, DOI 10.1097/CCM.0b013e31817e2fc9; Malsby RF, 2013, MIL MED, V178, P785, DOI 10.7205/MILMED-D-13-00047; McGhee LL, 2008, J TRAUMA, V64, pS195, DOI 10.1097/TA.0b013e318160ba1d; Naval Operational Medical Lessons Learned, 2011, NAVAL OPERATIONAL ME; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Sheridan RL, 2014, J TRAUMA ACUTE CARE, V76, P828, DOI 10.1097/TA.0b013e3182ab111c; Wedmore IS, 2012, J TRAUMA ACUTE CARE, V73, pS490, DOI 10.1097/TA.0b013e3182754674; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007	30	18	18	0	9	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	MAR	2015	180	3					304	309		10.7205/MILMED-D-14-00257			6	Medicine, General & Internal	General & Internal Medicine	CD3OI	WOS:000350987700016	25735021	Bronze			2020-06-30	J	Drees, R; Johnson, RA; Stepien, RL; Del Rio, AM; Francois, CJ				Drees, Randi; Johnson, Rebecca A.; Stepien, Rebecca L.; Del Rio, Alejandro Munoz; Francois, Christopher J.			EFFECTS OF TWO DIFFERENT ANESTHETIC PROTOCOLS ON CARDIAC FLOW MEASURED BY TWO DIMENSIONAL PHASE CONTRAST MAGNETIC RESONANCE IMAGING	VETERINARY RADIOLOGY & ULTRASOUND			English	Article						aortic; dog; heart; mitral; pulmonic; tricuspid	MINIMUM ALVEOLAR CONCENTRATION; CONTINUOUS RATE INFUSION; CONSTANT RATE INFUSION; ISOFLURANE ANESTHESIA; CLINICAL CARDIOLOGY; LIDOCAINE-KETAMINE; DOGS; DEXMEDETOMIDINE; FENTANYL; MRI	Companion animals are routinely anesthetized or heavily sedated for cardiac MRI studies, however effects of varying anesthetic protocols on cardiac function measurements are incompletely understood. The purpose of this prospective study was to compare effects of two anesthetic protocols (Protocol A: Midazolam, fentanyl; Protocol B: Dexmedetomidine) on quantitative and qualitative blood flow values measured through the aortic, pulmonic, mitral, and tricuspid valves using two-dimensional phase contrast magnetic resonance imaging (2D PC MRI) in healthy dogs. Mean flow per heartbeat values through the pulmonary artery (Qp) and aorta (Qs) were compared to right and left ventricular stroke volumes (RVSV, LVSV) measured using a reference standard of 2D Cine balanced steady-state free precession MRI. Pulmonary to systemic flow ratio (Qp/Qs) was also calculated. Differences in flow and Qp/Qs values generated using 2D PC MRI did not differ between the two anesthetic protocols (P = 1). Mean differences between Qp and RVSV were 3.82 ml/beat (95% limits of agreement: 3.62, -11.26) and 1.9 ml/beat (-7.86, 11.66) for anesthesia protocols A and B, respectively. Mean differences between Qs and LVSV were 1.65 ml/beat (-5.04, 8.34) and 0.03 ml/beat (-4.65, 4.72) for anesthesia protocols A and B, respectively. Mild tricuspid or mitral reflux was seen in 2/10 dogs using 2D PC MRI. No aortic or pulmonic insufficiency was observed. Findings from the current study indicated that these two anesthetic protocols yield similar functional measures of cardiac blood flow using 2D PC MRI in healthy dogs. Future studies in clinically affected patients are needed. (C) 2014 American College of Veterinary Radiology.	[Drees, Randi; Johnson, Rebecca A.] UW Madison, VMTH DSS, Madison, WI 53726 USA; [Stepien, Rebecca L.] UW Madison, DMS, Madison, WI 53726 USA; [Del Rio, Alejandro Munoz] UW Madison, Dept Med Phys, Madison, WI 53726 USA; [Del Rio, Alejandro Munoz; Francois, Christopher J.] UW Madison, Sch Med & Publ Hlth, Dept Radiol, Madison, WI 53726 USA	Drees, R (reprint author), Univ London Royal Vet Coll, Dept Clin Sci & Serv, Brookmans Park AL9 7TA, Herts, England.	rdrees@rvc.ac.uk		Francois, Christopher/0000-0001-5254-1181	Clinical and Translational Science Award (CTSA) programUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [1UL1RR025011]; National Center for Advancing Translational Sciences (NCATS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [9U54TR000021]; Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]	The project was supported by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR) grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021; Dr. Johnson was additionally supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427.	Aguado D, 2011, VET J, V189, P63, DOI 10.1016/j.tvjl.2010.05.029; ATKINSON DJ, 1991, RADIOLOGY, V178, P357, DOI 10.1148/radiology.178.2.1987592; Bellenger NG, 2000, J CARDIOV MAGN RESON, V2, P271, DOI 10.3109/10976640009148691; Bernstein MA, 1998, MAGN RESON MED, V39, P300, DOI 10.1002/mrm.1910390218; Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422; Braz LG, 2008, J INVEST SURG, V21, P360, DOI 10.1080/08941930802440803; Carr JC, 2001, RADIOLOGY, V219, P828, DOI 10.1148/radiology.219.3.r01jn44828; Chai P, 2005, J CARDIOVASC MAGN R, V7, P705, DOI 10.1081/JCMR-200065639; Chetboul V, 2010, VET CLIN N AM-SMALL, V40, P529, DOI 10.1016/j.cvsm.2010.03.007; Chia JM, 2000, J MAGN RESON IMAGING, V12, P678, DOI 10.1002/1522-2586(200011)12:5<678::AID-JMRI4>3.0.CO;2-5; Cokic I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073193; Colletti Patrick M, 2005, Curr Cardiol Rep, V7, P52, DOI 10.1007/s11886-005-0011-9; Constantine G, 2004, LANCET, V363, P2162, DOI 10.1016/S0140-6736(04)16509-4; Cornell CC, 2004, J VET INTERN MED, V18, P311, DOI 10.1892/0891-6640(2004)18&lt;311:ASOMCM&gt;2.0.CO;2; Daniel GB BA, 2006, TXB VET NUCL MED, P275; DUMOULIN CL, 1989, MAGN RESON MED, V9, P139, DOI 10.1002/mrm.1910090117; Ebner LS, 2013, AM J VET RES, V74, P963, DOI 10.2460/ajvr.74.7.963; FOX PR, 1983, VET CLIN N AM-SMALL, V13, P259, DOI 10.1016/S0195-5616(83)50029-6; Francois CJ, 2004, RADIOLOGY, V230, P389, DOI 10.1148/radiol.2302020761; Friedrich MG, 2013, CAN J CARDIOL, V29, P260, DOI 10.1016/j.cjca.2012.07.007; Gilbert SH, 2010, VET J, V183, P124, DOI 10.1016/j.tvjl.2008.11.018; Grimm KA, 2005, AM J VET RES, V66, P1222, DOI 10.2460/ajvr.2005.66.1222; Gallach RG, 2013, J AM ANIM HOSP ASSOC, V49, P398, DOI 10.5326/JAAHA-MS-5925; Heniff MS, 1997, ACAD EMERG MED, V4, P1115, DOI 10.1111/j.1553-2712.1997.tb03692.x; Hockings PD, 2003, TOXICOL MECH METHOD, V13, P39, DOI 10.1080/15376510309822; Holm S., 1979, SCAND J STAT, V17, P571; Hudsmith LE, 2005, J CARDIOVASC MAGN R, V7, P775, DOI 10.1080/10976640500295516; JONES DJ, 1979, ANESTHESIOLOGY, V51, P430, DOI 10.1097/00000542-197911000-00012; Kali A, 2013, RADIOLOGY, V269, P386, DOI 10.1148/radiol.13122397; Keating SCJ, 2013, AM J VET RES, V74, P672, DOI 10.2460/ajvr.74.5.672; Kim JH, 2013, VET J, V198, P450, DOI 10.1016/j.tvjl.2013.08.007; Lin GY, 2008, VET ANAESTH ANALG, V35, P141, DOI 10.1111/j.1467-2995.2007.00365.x; MacDonald KA, 2006, J VET INTERN MED, V20, P627, DOI 10.1892/0891-6640(2006)20[627:TDIAGE]2.0.CO;2; Mai W, 2010, VET RADIOL ULTRASOUN, V51, P428, DOI 10.1111/j.1740-8261.2010.01673.x; Markl M, 2003, MAGN RESON MED, V50, P791, DOI 10.1002/mrm.10582; McDonald K M, 1998, J Card Fail, V4, P203, DOI 10.1016/S1071-9164(98)80007-9; Meyer J, 2013, AM J VET RES, V74, P1223, DOI 10.2460/ajvr.74.9.1223; Pascoe PJ, 2006, VET ANAESTH ANALG, V33, P97, DOI 10.1111/j.1467-2995.2005.00236.x; PELC N J, 1991, Magnetic Resonance Quarterly, V7, P229; R Development Core Team, 2012, R LANG ENV STAT COMP; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Seddighi Reza, 2011, Vet Anaesth Analg, V38, P195, DOI 10.1111/j.1467-2995.2011.00615.x; Serres Francois, 2009, J Vet Cardiol, V11, P23, DOI 10.1016/j.jvc.2009.04.001; Sieslack AK, 2013, AM J VET RES, V74, P990, DOI 10.2460/ajvr.74.7.990; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Stepien RL, 1998, J APPL PHYSIOL, V85, P1368; THOMAS WP, 1984, VET RADIOLOGY, V25, P50, DOI 10.1111/j.1740-8261.1984.tb01910.x; Uilenreef JJ, 2008, VET ANAESTH ANALG, V35, P1, DOI 10.1111/j.1467-2995.2007.00344.x	48	9	9	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8183	1740-8261		VET RADIOL ULTRASOUN	Vet. Radiol. Ultrasound	MAR-APR	2015	56	2					168	175		10.1111/vru.12200			8	Veterinary Sciences	Veterinary Sciences	CD9DQ	WOS:000351398100010	25124271	Green Accepted			2020-06-30	J	Sin, B; Ternas, T; Motov, SM				Sin, Billy; Ternas, Theologia; Motov, Sergey M.			The Use of Subdissociative-dose Ketamine for Acute Pain in the Emergency Department	ACADEMIC EMERGENCY MEDICINE			English	Review							INTRANASAL KETAMINE; NMDA-RECEPTOR; ANALGESIA; MANAGEMENT; SEDATION; INFUSION; CHILDREN; PATIENT	ObjectivesKetamine is a well-known anesthetic with its use trailing back to the 1960s. It has antagonistic effects at the N-methyl-d-aspartate receptor. There is emerging literature to suggest the use of subdissociative-dose ketamine (SDDK) for pain reduction. This evidence-based review evaluates the evidence regarding the use of SDDK for acute pain control in the emergency department (ED). MethodsThe MEDLINE and EMBASE databases were searched. Randomized controlled trials (RCTs) that described or evaluated the use of SDDK for acute pain in the ED were included. Literature was excluded if it was not published in English. Duplicate articles, unpublished reports, abstracts, and review articles were also excluded. Quality assessment and evaluation of literature were evaluated based on the GRADE criteria. The primary outcome of interest in this review was the difference in pain score from baseline to cutoff time as specified in the studies. Secondary outcome measures were the incidence of adverse events and reduction in the amount of adjuvant opioids consumed by patients who received SDDK. ResultsFour RCTs met the inclusion criteria, which enrolled a total of 428 patients. Three adult trials and one pediatric trial were identified. The level of evidence for the individual trials ranged from low to moderate. A significant reduction in pain scores was only found in two of the four trials. One trial found a significant reduction in mean pain scores when ketamine was compared to morphine (p<0.05). Another trial reported a significant decrease in mean distress scores, favoring SDDK over fentanyl (1.0 vs. 2.7, p<0.05). One trial found a significant reduction in the amount of morphine consumed, favoring ketamine over placebo (0.14mg/kg, 95% confidence interval [CI]=0.13 to 0.16mg/kg vs. 0.2mg/kg, 95% CI=0.18 to 0.22mg/kg; p<0.001). An emergence phenomenon was reported in one trial. ConclusionsFour RCTs with methodologic limitations failed to provide convincing evidence to either support or refute the use of SDDK for acute pain control in the ED. (C) 2015 by the Society for Academic Emergency Medicine	[Sin, Billy; Ternas, Theologia] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm, Brooklyn, NY 11201 USA; [Sin, Billy] Brooklyn Hosp Ctr, Div Pharmacotherapy Serv, Dept Pharm, Brooklyn, NY USA; [Motov, Sergey M.] Maimonides Hosp, Dept Emergency Med, Brooklyn, NY 11219 USA; [Motov, Sergey M.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA	Sin, B (reprint author), Long Isl Univ, Arnold & Marie Schwartz Coll Pharm, Brooklyn, NY 11201 USA.	Billy.Sin@liu.edu					Ahern TL, 2013, AM J EMERG MED, V31, P847, DOI 10.1016/j.ajem.2013.02.008; Andolfatto G, 2013, ACAD EMERG MED, V20, P1050, DOI 10.1111/acem.12229; Bennett GJ, 2000, J PAIN SYMPTOM MANAG, V19, pS2; Bredlau AL, 2013, J PEDIATR-US, V163, P194, DOI 10.1016/j.jpeds.2012.12.077; Brozek JL, 2009, ALLERGY, V64, P669, DOI 10.1111/j.1398-9995.2009.01973.x; Chizh BA, 2005, CURR PHARM DESIGN, V11, P2977, DOI 10.2174/1381612054865082; Dupen A, 2007, PAIN MANAG NURS, V8, P113, DOI 10.1016/j.pmn.2007.02.004; Galinski M, 2007, AM J EMERG MED, V25, P385, DOI 10.1016/j.ajem.2006.11.016; Green SM, 2000, ACAD EMERG MED, V7, P278, DOI 10.1111/j.1553-2712.2000.tb01076.x; Green SM, 2011, ANN EMERG MED, V57, P449, DOI 10.1016/j.annemergmed.2010.11.030; Gurnani A, 1996, ANAESTH INTENS CARE, V24, P32, DOI 10.1177/0310057X9602400106; Haas D A, 1992, Anesth Prog, V39, P61; Herring AA, 2013, AM J EMERG MED, V31, P416, DOI 10.1016/j.ajem.2012.08.031; Himmelseher S, 2005, ANESTHESIOLOGY, V102, P211, DOI 10.1097/00000542-200501000-00030; Hocking G, 2003, ANESTH ANALG, V97, P1730, DOI 10.1213/01.ANE.0000086618.28845.9B; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Lester L, 2010, AM J EMERG MED, V28, P820, DOI 10.1016/j.ajem.2009.07.023; Malhotra AK, 1996, NEUROPSYCHOPHARMACOL, V14, P301, DOI 10.1016/0893-133X(95)00137-3; MERCADANTE S, 1995, J PAIN SYMPTOM MANAG, V10, P564, DOI 10.1016/0885-3924(95)00102-5; Messenger DW, 2008, ACAD EMERG MED, V15, P877, DOI 10.1111/j.1553-2712.2008.00219.x; Niesters M, 2014, BRIT J CLIN PHARMACO, V77, P357, DOI 10.1111/bcp.12094; OYE I, 1992, J PHARMACOL EXP THER, V260, P1209; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; Richards JR, 2013, AM J EMERG MED, V31, P390, DOI 10.1016/j.ajem.2012.07.027; Sharieff GQ, 2007, PEDIATR EMERG CARE, V23, P881, DOI 10.1097/pec.0b013e31815c9df6; Talwic QA, 2013, J OPIOID MANAG, V9, P379; Yeaman F, 2014, EMERG MED AUSTRALAS, V26, P237, DOI 10.1111/1742-6723.12173; Yeaman F, 2013, EMERG MED AUSTRALAS, V25, P161, DOI 10.1111/1742-6723.12059	28	18	18	1	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	MAR	2015	22	3			SI		251	257		10.1111/acem.12604			7	Emergency Medicine	Emergency Medicine	CD3MA	WOS:000350981500001	25716117				2020-06-30	J	Li, XZ; Xia, Q; Li, W				Li, Xiuze; Xia, Qing; Li, Wei			Comparison of the effects of dezocine, fentanyl, and placebo on emergence agitation after sevoflurane anesthesia in children	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						dezocine; fentanyl; emergence agitation; sevoflurane; children	PEDIATRIC-PATIENTS; PREVENTION; DELIRIUM; ADENOTONSILLECTOMY; DEXMEDETOMIDINE; REMIFENTANIL; PROPOFOL; SURGERY; PAIN; END	Objectives: The purpose of the study was to compare the efficacy and adverse events of dezocine with that of fentanyl or placebo for the control of emergence agitation. Methods: 114 children scheduled for adenotonsillectomy under sevoflurane anesthesia were allocated randomly into 1 of the 3 groups to receive dezocine 0.1 mg x kg(-1) (group D, n = 38), fentanyl 1 mu gxkg(-1) (group F, n = 38), or saline (group S, n = 38) just before the end of anesthesia. Emergence agitation scores were assessed. Postoperative pain scores, awakening and extubation times, and the incidence of adverse effects were recorded. Results: Emergence agitation scores, the incidence of emergence agitation and severe emergence agitation were significantly lower in groups D and F than in group S (p = 0.021, p = 0.018, and p = 0.028, respectively). The postoperative pain scores were lower in groups D and F as compared to group S (p = 0.01). Awakening and extubation times in groups D and F were longer than that of group S (p = 0.001 and p = 0.000, respectively). The overall incidence of postoperative complications was higher in group F compared to that in groups D and S (p = 0.01). Conclusions: In children undergoing adenotonsillectomy under sevoflurane anesthesia, a single IV injection of dezocine 0.1 mg x kg(-1) and fentanyl 1 mu gxkg(-1) were comparable in decreasing the incidence and severity of emergence agitation. However, the use of dezocine was associated with a lower incidence of postoperative side effects.	[Li, Xiuze; Xia, Qing; Li, Wei] Mianyang Cent Hosp, Dept Anesthesiol, Mianyang 621000, Sichuan, Peoples R China	Li, XZ (reprint author), Mianyang Cent Hosp, Dept Anesthesiol, 12 Changjia Lane, Mianyang 621000, Sichuan, Peoples R China.	lxz123@126.com					Abdulatif M, 2013, ANAESTHESIA, V68, P1045, DOI 10.1111/anae.12380; Aouad MT, 2005, CURR OPIN ANESTHESIO, V18, P614, DOI 10.1097/01.aco.0000188420.84763.35; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Bong CL, 2009, PEDIATR ANESTH, V19, P593, DOI 10.1111/j.1460-9592.2009.03024.x; Choi HR, 2011, KOREAN J ANESTHESIOL, V61, P148, DOI 10.4097/kjae.2011.61.2.148; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; da Silva LM, 2008, J PEDIAT-BRAZIL, V84, P107, DOI [10.2223/JPED.1763, 10.1590/S0021-75572008000200004]; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Dalens BJ, 2006, ANESTH ANALG, V102, P1056, DOI 10.1213/01.ane.0000200282.38041.1f; Dong YX, 2010, ANAESTH INTENS CARE, V38, P718, DOI 10.1177/0310057X1003800416; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Hung WT, 2005, J CLIN ANESTH, V17, P494, DOI 10.1016/j.jclinane.2004.09.014; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; JACOBS AM, 1992, J AM PODIAT MED ASSN, V82, P520, DOI 10.7547/87507315-82-10-520; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Liu RY, 2014, ANESTHESIOLOGY, V120, P714, DOI 10.1097/ALN.0000000000000076; Locatelli BG, 2013, PEDIATR ANESTH, V23, P301, DOI 10.1111/pan.12038; Na HS, 2013, ACTA ANAESTH SCAND, V57, P100, DOI 10.1111/aas.12006; OBRIEN JJ, 1989, DRUGS, V38, P226, DOI 10.2165/00003495-198938020-00005; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; TYLER DC, 1993, PAIN, V52, P301, DOI 10.1016/0304-3959(93)90163-J; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Zhang CM, 2013, CLIN THER, V35, P1622, DOI 10.1016/j.clinthera.2013.08.016	25	5	7	0	21	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	MAR	2015	53	3					241	246		10.5414/CP202184			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CD1OC	WOS:000350843200006	25669611				2020-06-30	J	Wu, AHB; Hamilton, R; Middleberg, R; Kacinko, S; Kearney, T				Wu, Alan H. B.; Hamilton, Rebecca; Middleberg, Robert; Kacinko, Sherri; Kearney, Thomas			Investigation of Postmortem Absorption and Redistribution After the Application of a Fentanyl Patch	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; fentanyl transdermal patch; postmortem redistribution; postmortem absorption; liquid chromatography; mass spectrometry; stratum corneum		Fentanyl deaths have increased with availability of transdermal patches. Interpretation of postmortem fentanyl levels may be complicated by postmortem redistribution and absorption of fentanyl from a patch. We applied an unused 100-g/h fentanyl patch onto the lower abdomen of a decedent with no premortem fentanyl exposure. Ocular fluid, blood, and urine were collected prior to placement, and the decedent was refrigerated for 23h. Prior to the autopsy, urine, subcutaneous tissue under the patch, and samples from the same anatomic sites were obtained. We observed no fentanyl in any postpatch placement samples (LOD: 0.1ng/mL for blood and vitreous fluid, 1.0ng/mL urine, 2.0ng/g for tissues). Although we observed no postmortem absorption of fentanyl, this was only a single case; therefore, we recommend that patches be removed after receipt of a cadaver before initiation of an autopsy, with the location of removed patch documented.	[Wu, Alan H. B.] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Kearney, Thomas] Univ Calif San Francisco, San Francisco, CA 94143 USA	Wu, AHB (reprint author), San Francisco Gen Hosp, Clin Chem Lab, 1001 Potrero Ave,Room 2M27, San Francisco, CA USA.	wualan@labmed2.ucsf.edu					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; [Anonymous], 2010, NATL ESTIMATES DRUG; [Anonymous], 2007, FDA PUBL HLTH ADV IM; [Anonymous], 2012, FDA REM PUBL POT LIF; [Anonymous], 2013, FENTANYL PATCH CAN B; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Ferner RE, 2008, BRIT J CLIN PHARMACO, V66, P430, DOI 10.1111/j.1365-2125.2008.03231.x; Palamalai V, 2013, CLIN BIOCHEM, V46, P598, DOI 10.1016/j.clinbiochem.2013.02.001; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Pelissier-Alicot AL, 2003, J ANAL TOXICOL, V27, P533, DOI 10.1093/jat/27.8.533; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416	11	0	0	1	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	MAR	2015	60	2					532	535		10.1111/1556-4029.12651			4	Medicine, Legal	Legal Medicine	CD0LM	WOS:000350764300043	25676881	Green Published			2020-06-30	J	Ferrari, R; Zanolin, ME; Duse, G; Visentin, M				Ferrari, Renata; Zanolin, Maria E.; Duse, Genni; Visentin, Marco			Effectiveness of Opioid Analgesics in Chronic Noncancer Pain	PAIN PRACTICE			English	Article						opioid analgesics; chronic pain; risk of misuse; effectiveness; quality of life	INVENTORY	BackgroundThere is general agreement about the need to perform a screening test to assess the risk of opioid misuse prior to starting a long-term opioid treatment for chronic noncancer pain. The evidence supporting the effectiveness of opioid long-term treatment is weak, and no predictors of its usefulness have been assessed. ObjectiveThe aim of this study was to assess the effect on pain and quality of life of chronic opioid treatment, and detect the possible predictors of its effectiveness. MethodsThis observational, prospective study was conducted in 2 Italian Pain Relief Units on 77 patients affected by intractable chronic pain. Patients were submitted to psychological tests, investigating the individual pain experience, risk of opioid misuse, mood states, quality of life, and personality characteristics prior to starting treatment and at 2,4, and 6-month follow-up. ResultsBoth maximum and habitual pain, as measured with VAS, underwent a statistically significant reduction at 2, 4, and 6-month follow-up. In multivariate analysis, lower scores in the Pain Medication Questionnaire (PMQ) were predictive of a major reduction in maximum VAS (P=0.005). Both low PMQ and MMPI-cynicism scores were predictive of habitual VAS decrease (P=0.012 and P=0.028, respectively). ConclusionThe results indicate that pain relief significantly improved over a 6-month period of opioid treatment, together with quality of life. The outcome was better in patients with a pretreatment low risk of opioid misuse, low scores in the Cynicism scale of MMPI-2, and no aberrant drug behaviors at follow-up. Therefore, a psychological screening and support is crucial for a good outcome of opioid therapy for chronic noncancer pain patients.	[Ferrari, Renata] San Bortolo Hosp, Div Psychol, I-36100 Vicenza, Italy; [Zanolin, Maria E.] Univ Verona, Unit Epidemiol & Med Stat, I-37100 Verona, Italy; [Duse, Genni] S Antonio Hosp, Pain Management Unit, Padua, Italy; [Visentin, Marco] San Bortolo Hosp, Pain Management & Palliat Care Unit, I-36100 Vicenza, Italy	Ferrari, R (reprint author), San Bortolo Hosp, Div Psychol, Via Rodolfi, I-36100 Vicenza, Italy.	renata.ferrari@ulssvicenza.it					Adams LL, 2004, J PAIN SYMPTOM MANAG, V27, P440, DOI 10.1016/j.jpainsymman.2003.10.009; Ballantyne JC, 2012, J MED TOXICOL, V8, P417, DOI 10.1007/s13181-012-0257-8; Beck A. T., 1996, MANUAL FOR THE BECK; Bertin G, 1992, THE EUROPEAN GROUP F, P183; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Caraceni AT, 2013, MINERVA ANESTESIOL; Chapman CR, 2010, J PAIN, V11, P807, DOI 10.1016/j.jpain.2010.02.019; Chinellato A, 2011, EUR J PAIN, V15, P220, DOI 10.1016/j.ejpain.2010.11.005; Croft P, 2010, CHRONIC PAIN EPIDEMI; Dowling Leah S, 2007, J Opioid Manag, V3, P257; Emshoff R, 2011, PAIN, V152, P2277, DOI 10.1016/j.pain.2011.06.003; Ferrari R, 2000, PAIN MED, V1, P123, DOI 10.1046/j.1526-4637.2000.00020.x; Ghisi M, 2006, BECK DEPRESSION INVE; Hathaway SR, 1989, MMPI 2 MANUAL FOR AD; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; Italian Ministry of Health, 2010, REPORT TO THE PARLIA; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; Manchikanti L, 2011, PAIN PHYSICIAN, V14, pE133; Noble M, 2010, COCH LIB, P214; Pancheri P, 1996, INT ADAPTATION MMPI, P416; PEDRABISSI L, 1996, STAI STATE TRAIT ANX; Spielberger C. D., 1983, STATE TRAIT ANXIETY	23	4	4	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	MAR	2015	15	3					272	278		10.1111/papr.12176			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	CD3MI	WOS:000350982300011	25914912				2020-06-30	J	Tarquinio, KM; Howell, JD; Montgomery, V; Turner, DA; Hsing, DD; Parker, MM; Brown, CA; Walls, RM; Nadkarni, VM; Nishisaki, A				Tarquinio, Keiko M.; Howell, Joy D.; Montgomery, Vicki; Turner, David A.; Hsing, Deyin D.; Parker, Margaret M.; Brown, Calvin A., III; Walls, Ron M.; Nadkarni, Vinay M.; Nishisaki, Akira		Natl Emergency Airway Registry Chi; Pediat Acute Lung Injury Sepsis In	Current Medication Practice and Tracheal Intubation Safety Outcomes From a Prospective Multicenter Observational Cohort Study	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						endotracheal intubation; narcotic; paralytic; pediatrics; premedication; sedative	RAPID-SEQUENCE INTUBATION; NEONATAL ENDOTRACHEAL INTUBATION; INTENSIVE-CARE-UNIT; CONTROLLED-TRIAL; AIRWAY MANAGEMENT; CHILDREN; ATROPINE; PREMEDICATION; PROPOFOL; ANESTHESIA	Objectives: Tracheal intubation in PICUs is often associated with adverse tracheal intubation-associated events. There is a paucity of data regarding medication selection for safe tracheal intubations in PICUs. Our primary objective was to evaluate the association of medication selection on specific tracheal intubation-associated events across PICUs. Design: Prospective observational cohort study. Setting: Nineteen PICUs in North America. Subjects: Critically ill children requiring tracheal intubation. Interventions: None. Measurement and Main Results: Using the National Emergency Airway Registry for Children, tracheal intubation quality improvement data were prospectively collected from July 2010 to March 2013. Patient, provider, and practice characteristics including medications and dosages were collected. Adverse tracheal intubation-associated events were defined a priori. A total of 3,366 primary tracheal intubations were reported. Adverse tracheal intubation-associated events occurred in 593 tracheal intubations (18%). Fentanyl and midazolam were the most commonly used induction medications (64% and 58%, respectively). Neuromuscular blockade was used in 92% of tracheal intubation with the majority using rocuronium (64%) followed by vecuronium (20%). Etomidate and succinylcholine were rarely used (1.6% and 0.7%, respectively). Vagolytics were administered in 37% of tracheal intubations (51% in infants; 28% in > 1 yr old; p < 0.001). Ketamine was used in 27% of tracheal intubations but more often for tracheal intubations in patients with unstable hemodynamics (39% vs 25%; p < 0.001). However, ketamine use was not associated with lower prevalence of new hypotension (ketamine 8% vs no ketamine 14%; p = 0.08). Conclusions: In this large, pediatric multicenter registry, fentanyl, midazolam, and ketamine were the most commonly used induction agents, and the majority of tracheal intubations involved neuromuscular blockade. Ketamine use was not associated with lower prevalence of hypotension.	[Tarquinio, Keiko M.] Brown Univ, Rhode Isl Hosp, Dept Pediat, Hasbro Childrens Hosp,Warren Alpert Med Sch, Providence, RI 02903 USA; [Howell, Joy D.; Hsing, Deyin D.] Weill Cornell Med Coll, Dept Pediat, New York, NY USA; [Montgomery, Vicki] Univ Louisville, Louisville, KY 40292 USA; [Turner, David A.] Duke Univ, Med Ctr, Dept Pediat, Div Pediat Crit Care Med,Duke Childrens Hosp, Durham, NC 27710 USA; [Parker, Margaret M.] SUNY Stony Brook, Sch Med, Dept Pediat, Stony Brook, NY 11794 USA; [Brown, Calvin A., III; Walls, Ron M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA; [Nadkarni, Vinay M.; Nishisaki, Akira] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA	Nishisaki, A (reprint author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA.	nishisaki@email.chop.edu	Cheifetz, Ira/I-8692-2019	Cheifetz, Ira/0000-0002-1174-1571	Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1R03HS021583-01, 1 R18 HS022464-01]; Laerdal Foundation Acute Care Medicine; Agency for Healthcare Research and Quality (AHRQ)United States Department of Health & Human ServicesAgency for Healthcare Research & Quality; AHRQUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R03 HS21583-01]; AHRQUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Supported, in part, by grants 1R03HS021583-01 and 1 R18 HS022464-01 from the Agency for Healthcare Research and Quality.; Drs. Nadkarni and Nishisaki (Principal Investigator) received support from the Endowed Chair, Critical Care Medicine, The Children's Hospital of Philadelphia, and Unrestricted Research fund from Laerdal Foundation Acute Care Medicine. Dr. Nishisaki received support for article research from the Agency for Healthcare Research and Quality (AHRQ). His institution received grant support from AHRQ R03 HS21583-01 (government funded) and from Nihon Kohden America (for evaluation of noninvasive capnography). Dr. Tarquinio is employed by the Lifespan Physicians Group and received support for article research from the AHRQ. Her institution received grant support from the National Institutes of Health (grant submitted, review pending). Dr. Howell received royalties from UpToDateOnline.org (status asthmaticus review article) and received support for article research from the AHRQ. Drs. Montgomery, Turner, Hsing, and Nadkarni received support for article research from the AHRQ. Dr. Parker provided expert testimony for Charles X. Connick, PLLC; and received support for article research from the AHRQ. Dr. Brown III received support for article research from the AHRQ. His institution received grant support (part of AHRQ grant for compliance monitoring). Dr. Walls received support for development of educational presentations from the Airway Management Education Center and received support for article research from the AHRQ. His institution received grant support (part of AHRQ grant for compliance monitoring).	Adams HA, 1997, ANAESTHESIST, V46, P1081, DOI 10.1007/s001010050510; Andrews JI, 1999, ACTA ANAESTH SCAND, V43, P4, DOI 10.1034/j.1399-6576.1999.430102.x; Annila P, 1998, BRIT J ANAESTH, V80, P756, DOI 10.1093/bja/80.6.756; Bovill JG, 2006, SEMIN CARDIOTHORAC V, V10, P43, DOI 10.1177/108925320601000108; Brierley J, 2009, CRIT CARE MED, V37, P666, DOI 10.1097/CCM.0b013e31819323c6; Carroll CL, 2010, PEDIATR CRIT CARE ME, V11, P343, DOI 10.1097/PCC.0b013e3181c51426; Chen J J, 1990, Ma Zui Xue Za Zhi, V28, P163; Cheng CAY, 2002, PAEDIATR ANAESTH, V12, P140, DOI 10.1046/j.1460-9592.2002.00771.x; CORDEIRO AMG, 2004, PEDIATR CRIT CARE ME, V5, P364; Cornfield DN, 2002, PEDIATRICS, V110, P1177, DOI 10.1542/peds.110.6.1177; DAS G, 1989, INT J CLIN PHARM TH, V27, P473; Durrmeyer X, 2013, PEDIATR CRIT CARE ME, V14, pE169, DOI 10.1097/PCC.0b013e3182720616; Easley RB, 2000, CRIT CARE MED, V28, P2058, DOI 10.1097/00003246-200006000-00065; ESENER Z, 1994, TURKISH J PEDIATR, V36, P11; Fastle RK, 2004, PEDIATR EMERG CARE, V20, P651, DOI 10.1097/01.pec.0000142947.35394.81; Felmet K, 2003, PEDIATRICS, V112, P1002, DOI 10.1542/peds.112.4.1002; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Ghanta S, 2007, PEDIATRICS, V119, pE1248, DOI 10.1542/peds.2006-2708; Hanouz JL, 2004, ANESTH ANALG, V99, P1689, DOI 10.1213/01.ANE.0000136466.85913.3C; Jones P, 2013, PEDIATR CRIT CARE ME, V14, pE289, DOI 10.1097/PCC.0b013e31828a8624; Jones P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057478; Kim KS, 2011, J ANESTH, V25, P195, DOI 10.1007/s00540-011-1092-9; Kumar P, 2010, PEDIATRICS, V125, P608, DOI 10.1542/peds.2009-2863; Lemyre B, 2009, ARCH DIS CHILD-FETAL, V94, pF439, DOI 10.1136/adc.2008.146068; Miller Ronald D, 2010, MILLERS ANESTHESIA, V2; Nishisaki A, 2013, CRIT CARE MED, V41, P874, DOI 10.1097/CCM.0b013e3182746736; Nishisaki A, 2012, PEDIATR CRIT CARE ME, V13, pE5, DOI 10.1097/PCC.0b013e3181fe472d; Nishisaki A, 2011, RESUSCITATION, V82, P386, DOI 10.1016/j.resuscitation.2010.11.024; Nishisaki A, 2010, ANESTHESIOLOGY, V113, P214, DOI 10.1097/ALN.0b013e3181e19bf2; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; Papaioannou V, 2008, ACTA ANAESTH BELG, V59, P79; Roberts KD, 2006, PEDIATRICS, V118, P1583, DOI 10.1542/peds.2006-0590; Sagarin MJ, 2002, PEDIATR EMERG CARE, V18, P417, DOI 10.1097/00006565-200212000-00004; Sanders RC, 2013, PEDIATRICS, V131, pE821, DOI 10.1542/peds.2012-2127; Skapik Julia Lynn, 2009, J Patient Saf, V5, P95, DOI 10.1097/PTS.0b013e3181a70c68; Sneyd JR, 2010, BRIT J ANAESTH, V104, P535, DOI 10.1093/bja/aeq060; Sprung J, 1998, ANESTHESIOLOGY, V88, P1202, DOI 10.1097/00000542-199805000-00010; Wheeler B, 2012, J PAEDIATR CHILD H, V48, P997, DOI 10.1111/j.1440-1754.2012.02589.x; Wysowski DK, 2006, ANESTHESIOLOGY, V105, P1047, DOI 10.1097/00000542-200611000-00027; Zelicof-Paul A, 2005, CURR OPIN PEDIATR, V17, P355, DOI 10.1097/01.mop.0000162365.64140.b7	40	29	30	2	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2015	16	3					210	218		10.1097/PCC.0000000000000319			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	CD1AZ	WOS:000350807300005	25581629				2020-06-30	J	Kudchadkar, SR; Shaffner, DH				Kudchadkar, Sapna R.; Shaffner, Donald H.			Pharmacologic Recipes for Tracheal Intubation in the PICU: What's on the Menu?	PEDIATRIC CRITICAL CARE MEDICINE			English	Editorial Material						adverse events; children; intubation; pediatric critical care; sedation	LARYNGOSCOPY; RESPONSES; PRESSURE; CHILDREN		[Kudchadkar, Sapna R.; Shaffner, Donald H.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Dept Pediat,Charlotte R Bloomberg Childrens Ctr, Baltimore, MD 21205 USA	Kudchadkar, SR (reprint author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Dept Pediat,Charlotte R Bloomberg Childrens Ctr, Baltimore, MD 21205 USA.			Kudchadkar, Sapna/0000-0003-3089-0318			Bembea Melania M, 2012, J Pediatr Pharmacol Ther, V17, P236, DOI 10.5863/1551-6776-17.3.236; BURNEY RG, 1975, ANESTH ANALG, V54, P687; Chameides L, 2011, PEDIAT ADV LIFE SUPP; Kudchadkar SR, 2014, CRIT CARE MED, V42, P1592, DOI 10.1097/CCM.0000000000000326; Miller RD, 2010, MILLERS ANESTHESIA; RUSSELL WJ, 1981, BRIT J ANAESTH, V53, P837, DOI 10.1093/bja/53.8.837; Shaffner DH, 2013, PEDIATR CRIT CARE ME, V14, P651, DOI 10.1097/PCC.0b013e31828a8a43; SHRIBMAN AJ, 1987, BRIT J ANAESTH, V59, P295, DOI 10.1093/bja/59.3.295; Tarquinio KM, 2015, PEDIATR CRIT CARE ME, V16, P210, DOI 10.1097/PCC.0000000000000319; Wilcox SR, 2012, CRIT CARE MED, V40, P1808, DOI 10.1097/CCM.0b013e31824e0e67; Yavascaoglu B, 2008, EUR J ANAESTH, V25, P517, DOI 10.1017/S0265021508003529	11	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2015	16	3					290	292		10.1097/PCC.0000000000000348			4	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	CD1AZ	WOS:000350807300015	25738927				2020-06-30	J	Canovas-Martinez, L; Carceller-Ruiz, JJ; Diaz-Parada, P; Illodo-Miramontes, G; Freire-Vila, E; De la Iglesia-Lopez, A; Iglesias, BG; Lopez-Ulloa, B; Dominguez-Suarez, E; Camba-Rodriguez, A				Canovas-Martinez, Luz; Carceller-Ruiz, Jose J.; Diaz-Parada, Pilar; Illodo-Miramontes, Gustavo; Freire-Vila, Enrique; De la Iglesia-Lopez, Aurora; Garcia Iglesias, Belen; Lopez-Ulloa, Beatriz; Dominguez-Suarez, Enrique; Camba-Rodriguez, Alberto			Efficacy and Safety of Sublingual Fentanyl Tablets for the Management of Breakthrough Pain in Patients with Chronic Musculoskeletal Pain with Neuropathic Component: Multicenter Prospective Study	CLINICAL DRUG INVESTIGATION			English	Article							CHRONIC NONCANCER PAIN; SPANISH VERSION; OPIOIDS; QUESTIONNAIRE; PREVALENCE; THERAPY	Background and Objective Despite its prevalence and impact, breakthrough pain (BTP) in chronic non-cancer pain with neuropathic component, has not been well studied and is sometimes unrecognized and often undertreated. We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL). Methods A multicenter, prospective, open-label study was conducted over a 30-day period. Efficacy was evaluated using a visual analogue scale (VAS) and time to onset of action of SLF. The incidence of dependence was assessed by the Leeds Dependence Questionnaire (LDQ). Changes in QoL were evaluated using the Brief Pain Questionnaire (BPI) and the EuroQol (EQ-5D). Adverse events (AE) were recorded throughout. Results 106 patients were enrolled and 105 completed the study. The average pain reduction across the study was -3.30 points [95 % confidence interval (CI) 2.9-3.7; P < 0.0001]. Pain intensity improvement from baseline was statistically significant at first assessment and all subsequent assessments (P < 0.0001). The most common AEs included nausea (33.87 %), constipation (33.06 %), somnolence (19.35 %) and vomiting (6.45 %). No significant differences were observed on LDQ (P = 0.71). QoL as measured by BPI showed statistically significant improvement in all four severity items and all interference items (P < 0.0001) and a significant improvement in the percentage of pain relief reported by patients (P < 0.0001). EQ-5D results showed a trend towards improvement. Mean self-rate health status, as measured by the EQ VAS scale increased significantly (P < 0.0001). Conclusion SLF provides significant reductions in BTP intensity. The results of the BPI and EQ-5D assessments indicate that pain relief is associated with improvement of functioning and enhancement of QoL.	[Canovas-Martinez, Luz] Complexo Hosp Univ Ourense, Dept Anesthesiol, Pain Unit, Orense 32005, Spain; [Carceller-Ruiz, Jose J.; Lopez-Ulloa, Beatriz] Complexo Hosp Univ Santiago de Compostela, Pain Unit, La Coruna, Spain; [Diaz-Parada, Pilar] Complexo Hosp Pontevedra, Pain Unit, Pontevedra, Spain; [Illodo-Miramontes, Gustavo] Hosp Salnes, Dept Anesthesiol, Pain Unit, Pontevedra, Spain; [Freire-Vila, Enrique; De la Iglesia-Lopez, Aurora] Complexo Hosp Univ Juan Canalejo, Pain Unit, La Coruna, Spain; [Garcia Iglesias, Belen] Hosp Da Costa, Pain Unit, Lugo, Spain; [Dominguez-Suarez, Enrique] Hosp Lucus Augusti, Pain Unit, Lugo, Spain; [Camba-Rodriguez, Alberto] Hosp Ferrol, Pain Unit, La Coruna, Spain	Canovas-Martinez, L (reprint author), Complexo Hosp Univ Ourense, Dept Anesthesiol, Pain Unit, C Ramon Puga Noguerol 52-54, Orense 32005, Spain.	maria.de.la.luz.canovas.martinez@sergas.es					Abstral (Sublingual Fentanyl Citrate), SUMM PROD CHAR; Argoff CE, 2007, CLIN J PAIN, V23, P15, DOI 10.1097/01.ajp.0000210945.27052.b3; Badia X, 2003, MED CLIN-BARCELONA, V120, P52, DOI 10.1157/13042265; Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Chaparro LE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004959.pub4; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fishbain DA, 2008, PAIN MED, V9, P444, DOI 10.1111/j.1526-4637.2007.00370.x; Foley KM, 2003, NEW ENGL J MED, V348, P1279, DOI 10.1056/NEJMe030014; Guitart J, 2013, CLIN DRUG INVEST, V33, P675, DOI 10.1007/s40261-013-0111-z; Guy W, 1976, ECDEU ASSESSMENT MAN, P217; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Katz WA, 2008, AM J THER, V15, P256, DOI 10.1097/MJT.0b013e3181671c5a; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; McCarberg B, 2006, AM J MANAG CARE, V12, pS263; McNicol ED, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006146.pub2; Moore RA, 2013, BRIT J ANAESTH, V111, P38, DOI 10.1093/bja/aet126; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Perez C, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-66; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; RAISTRICK D, 1994, ADDICTION, V89, P563, DOI 10.1111/j.1360-0443.1994.tb03332.x; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Webster Lynn R, 2011, J Opioid Manag, V7, P297; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Zeppetella G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub3	32	1	2	0	7	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	MAR	2015	35	3					169	177		10.1007/s40261-015-0268-8			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CC1LX	WOS:000350103300003	25655006				2020-06-30	J	Gardner, MA; Sampsel, S; Jenkins, WW; Owens, JE				Gardner, Michael A.; Sampsel, Sheena; Jenkins, Werner W.; Owens, Janel E.			Analysis of Fentanyl in Urine by DLLME-GC-MS	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							SOLID-PHASE MICROEXTRACTION; LIQUID; CHROMATOGRAPHY	Fentanyl is a synthetic narcotic anesthetic similar to 80-100 times more potent than morphine. Owing to the potential for its abuse, the drug may be included in a forensic toxicology work-up, which requires fast, precise and accurate measurements. Here, the stability of fentanyl was assessed when stored at three different temperatures (-20, 4 and 25 degrees C) in synthetic urine. Stability at those three temperatures was demonstrated over 12 weeks upon analysis by gas chromatography-mass spectrometry with a deuterated internal standard (fentanyl-D-5) utilizing three different extraction techniques: liquid-liquid extraction (LLE), solid-phase extraction and dispersed liquid-liquid micro-extraction (DLLME). The DLLME method was then optimized before use in the analysis of fentanyl in urine samples obtained from autopsy cases at the El Paso County Coroner's Office. Accuracy of the DLLME method was assessed by completing spike and recovery studies at three different fortification levels (10, 100 and 250 ng/mL) with excellent recovery (89.9-102.6%). The excellent comparability between DLLME and LLE is demonstrated (Bland-Altman difference plot with a mean difference of 4.9 ng/mL) and the use of this methodology in the analysis of forensically relevant samples is discussed.	[Gardner, Michael A.; Jenkins, Werner W.; Owens, Janel E.] Univ Colorado, Dept Chem & Biochem, Colorado Springs, CO 80918 USA; [Sampsel, Sheena] Univ Colorado, Beth El Coll Nursing & Hlth Sci, Colorado Springs, CO 80918 USA; [Jenkins, Werner W.] El Paso Cty Coroners Off, Colorado Springs, CO USA	Owens, JE (reprint author), Univ Colorado, Dept Chem & Biochem, 1420 Austin Bluffs Pkwy, Colorado Springs, CO 80918 USA.	jowens2@uccs.edu			Committee on Research and Creative Works from UCCS	Dr Robert C. Bux and Jamie Bowman and Howard Reisner from the El Paso County Coroner's Office are acknowledged for their assistance in identifying relevant case numbers, providing negative control simulated urine and for their assistance to students M.G. and S.S. Undergraduate students Joshua Doverspike and Christopher Radford are acknowledged for their assistance in creating figures for the manuscript. We appreciate the review of the manuscript by Luis Lowe (UCCS) before submission. Faculty start-up funds and a grant from the Committee on Research and Creative Works from UCCS to J.E.O. are gratefully acknowledged.	Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Allen MJ, 2010, CLIN CHEM, V56, P1675, DOI 10.1373/clinchem.2010.150672; [Anonymous], 2005, NONPHARMACEUTICAL FE, P793; Asensio-Ramos M, 2011, J CHROMATOGR A, V1218, P7415, DOI 10.1016/j.chroma.2011.05.096; Barroso M, 2012, BIOANALYSIS, V4, P1805, DOI 10.4155/BIO.12.139; Bassan DM, 2011, ANAL BIOANAL CHEM, V400, P43, DOI 10.1007/s00216-011-4784-y; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boyaci E, 2014, ANAL CHIM ACTA, V809, P69, DOI 10.1016/j.aca.2013.11.056; Dufresne C, 2002, ANAL LETT, V35, P1575, DOI 10.1081/AL-120006732; Ebrahimzadeh H, 2008, ANAL CHIM ACTA, V626, P193, DOI 10.1016/j.aca.2008.07.047; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Gupta PK, 2007, ANAL BIOANAL CHEM, V388, P579, DOI 10.1007/s00216-007-1279-y; Han D, 2012, MICROCHIM ACTA, V176, P1, DOI 10.1007/s00604-011-0678-0; Kim J, 2014, J PHARMACEUT BIOMED, V89, P99, DOI 10.1016/j.jpba.2013.10.041; Kocurova L, 2012, MICROCHEM J, V102, P11, DOI 10.1016/j.microc.2011.12.002; Kohler I, 2013, J PHARMACEUT BIOMED, V73, P82, DOI 10.1016/j.jpba.2012.03.036; Lung DD, 2014, FORENSIC TOXICOL, V32, P118, DOI 10.1007/s11419-013-0216-3; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; McIntyre IM, 2014, INT J LEGAL MED, V128, P65, DOI 10.1007/s00414-013-0897-5; Mrvos R, 2012, J EMERG MED, V42, P549, DOI 10.1016/j.jemermed.2011.05.017; Raikos N, 2009, J SEP SCI, V32, P1018, DOI 10.1002/jssc.200800447; Ramos L, 2012, J CHROMATOGR A, V1221, P84, DOI 10.1016/j.chroma.2011.11.011; Rezaee M, 2006, J CHROMATOGR A, V1116, P1, DOI 10.1016/j.chroma.2006.03.007; Saraji M, 2011, ANAL BIOANAL CHEM, V400, P2149, DOI 10.1007/s00216-011-4874-x; Strano-Rossi S, 2011, J APPL TOXICOL, V31, P649, DOI 10.1002/jat.1613; Strano-Rossi S, 2011, ANAL BIOANAL CHEM, V399, P1623, DOI 10.1007/s00216-010-4471-4; Vardini MT, 2012, J LIQ CHROMATOGR R T, V35, P988, DOI 10.1080/10826076.2011.637277	27	12	14	0	58	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAR	2015	39	2					118	125		10.1093/jat/bku136			8	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	CC3BL	WOS:000350219100006	25492522	Bronze			2020-06-30	J	Funes, FJ; Granados, MD; Morgaz, J; Navarrete, R; Fernandez-Sarmiento, A; Gomez-Villamandos, R; Munoz, P; Quiros, S; Carrillo, JM; Lopez-Villalba, I; Dominguez, JM				Funes, Francisco J.; del Mar Granados, Maria; Morgaz, Juan; Navarrete, Rocio; Fernandez-Sarmiento, Andres; Gomez-Villamandos, Rafael; Munoz, Pilar; Quiros, Setefilla; Carrillo, Jose M.; Lopez-Villalba, Ignacio; Dominguez, Juan M.			Anaesthetic and cardiorespiratory effects of a constant rate infusion of fentanyl in isoflurane-anaesthetized sheep	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anaesthesia; cardiopulmonary; fentanyl; isoflurane; sheep	MINIMUM ALVEOLAR CONCENTRATION; PROPOFOL-FENTANYL; SEVOFLURANE; CARDIOPULMONARY; GOATS; PHARMACOKINETICS; MIDAZOLAM; SURGERY; HORSES; DOGS	ObjectiveTo determine the anaesthetic and cardiorespiratory effects of a constant rate infusion of fentanyl in sheep anaesthetized with isoflurane and undergoing orthopaedic surgery. Study designProspective, randomised, blinded' controlled study. AnimalsTwenty healthy sheep (weight mean 41.1SD 4.5kg). MethodsSheep were sedated with intravenous (IV) dexmedetomidine (4gkg(-1)) and morphine (0.2mgkg(-1)). Anaesthesia was induced with propofol (1mgkg(-1)minute(-1) to effect IV) and maintained with isoflurane in oxygen and a continuous rate infusion (CRI) of fentanyl 10gkg(-1)hour(-1) (group F) or saline (group P) for 100minutes. The anaesthetic induction dose of propofol, isoflurane expiratory fraction (Feiso) required for maintenance and cardiorespiratory measurements were recorded and blood gases analyzed at predetermined intervals. The quality of recovery was assessed. Results were compared between groups using t-tests or Mann-Whitney as relevant. ResultsThe propofol induction dose was 4.7 +/- 2.4mgkg(-1). Feiso was significantly lower (by 22.6%) in group F sheep than group P (p=0). Cardiac index (mean +/- SDmLkg(-1)minute(-1)) was significantly (p=0.012) lower in group F (90 +/- 15) than group P (102 +/- 35). Other measured cardiorespiratory parameters did not differ statistically significantly between groups. Recovery times and recovery quality were statistically similar in both groups. Conclusions and clinical relevanceFentanyl reduced isoflurane requirements without clinically affecting the cardiorespiratory stability or post-operative recovery in anaesthetized sheep undergoing orthopaedic surgery.	[Funes, Francisco J.; del Mar Granados, Maria; Morgaz, Juan; Navarrete, Rocio; Fernandez-Sarmiento, Andres; Gomez-Villamandos, Rafael; Munoz, Pilar; Quiros, Setefilla; Lopez-Villalba, Ignacio; Dominguez, Juan M.] Univ Cordoba, Fac Vet, Dept Anim Med & Surg, Anaesthesia Unit, Cordoba 14014, Spain; [Carrillo, Jose M.] CEU Cardenal Herrera Univ, Fac Vet, Dept Anim Med & Surg, Valencia, Spain	Funes, FJ (reprint author), Univ Cordoba, Fac Vet, Dept Anim Med & Surg, Anaesthesia Unit, Cordoba 14014, Spain.	funescagno@hotmail.com	Quiros-Carmona, Setefilla/V-4942-2017; Navarrete-Calvo, Rocio/K-6716-2016; MORGAZ, JUAN/L-1056-2014; Gomez-Villamandos, Rafael/O-6372-2019; Fernandez-Sarmiento, Jose Andres/B-6760-2011	Quiros-Carmona, Setefilla/0000-0001-9606-2131; Navarrete-Calvo, Rocio/0000-0003-4605-4162; MORGAZ, JUAN/0000-0002-5512-1622; Gomez Villamandos, Rafael Jesus/0000-0003-3624-3306	Garcia Cugat Foundation; Ministry of Education, Culture and Sport of Spanish Government [AP2009-0495]	The authors would like to thank the Garcia Cugat Foundation for supporting this project. One of the authors (F.J. F) was the recipient of a grant from the Ministry of Education, Culture and Sport of Spanish Government (FPU Program: AP2009-0495). The authors do not have any financial interest or other relationship with any commercial company related to this study.	Ahern BJ, 2009, AM J VET RES, V70, P418, DOI 10.2460/ajvr.70.3.418; Ambros B, 2008, AM J VET RES, V69, P1391, DOI 10.2460/ajvr.69.11.1391; Bernards CM, 1996, ANESTHESIOLOGY, V85, P91, DOI 10.1097/00000542-199607000-00013; Criado AB, 2003, VET ANAESTH ANALG, V30, P250, DOI 10.1046/j.1467-2995.2003.00123.x; Dzikiti BT, 2010, VET ANAESTH ANALG, V37, P519, DOI 10.1111/j.1467-2995.2010.00568.x; Dzikiti TB, 2011, VET REC, V168, DOI 10.1136/vr.d999; Gutierrez-Blanco E, 2013, VET ANAESTH ANALG, V40, P599, DOI 10.1111/vaa.12079; Hikasa Y, 2000, SMALL RUMINANT RES, V36, P241, DOI 10.1016/S0921-4488(99)00121-2; Kastner SBR, 2006, J VET PHARMACOL THER, V29, P63, DOI 10.1111/j.1365-2885.2006.00701.x; Kastner SBR, 2005, AM J VET RES, V66, P1496, DOI 10.2460/ajvr.2005.66.1496; Knych HKD, 2009, AM J VET RES, V70, P1193, DOI 10.2460/ajvr.70.10.1193; Kronen PW, 2005, LAB ANIM-UK, V39, P428, DOI 10.1258/002367705774286385; Levionnois O, 2008, LAB ANIM-UK, V42, P505, DOI 10.1258/la.2007.007041; Liehmann L, 2006, VET ANAESTH ANALG, V33, P158, DOI 10.1111/j.1467-2995.2005.00251.x; Meredith James R, 2008, J Emerg Trauma Shock, V1, P88, DOI 10.4103/0974-2700.43189; Mohamadnia AR, 2008, VET REC, V163, P210, DOI 10.1136/vr.163.7.210; Nolan AM, 1991, VET ANAESTH ANALG, V18, P30; Riebold TW, 2007, VET ANAESTH ANALG, P1096; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Schauvliege S, 2006, LAB ANIM-UK, V40, P341, DOI 10.1258/002367706778476406; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; Tranquilli W.J., 2007, LUMB JONES VET ANEST; Upton RN, 2009, BRIT J ANAESTH, V103, P848, DOI 10.1093/bja/aep269; VANWIJNG.I, 1968, LIFE SCI PT 1 PHYSI, V7, P225, DOI 10.1016/0024-3205(68)90195-1; Waterman AE, 1990, J ASS VET ANAESTH, V17, P20	26	12	12	1	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAR	2015	42	2					157	164		10.1111/vaa.12216			8	Veterinary Sciences	Veterinary Sciences	CC1XQ	WOS:000350139100005	25082232				2020-06-30	J	Bista, SR; Haywood, A; Hardy, J; Lobb, M; Tapuni, A; Norris, R				Bista, Sudeep Raj; Haywood, Alison; Hardy, Janet; Lobb, Michael; Tapuni, Angela; Norris, Ross			Protein binding of fentanyl and its metabolite nor-fentanyl in human plasma, albumin and alpha-1 acid glycoprotein	XENOBIOTICA			English	Article						Adsorption; cancer; pain; ultrafiltration	EQUILIBRIUM DIALYSIS; ULTRAFILTRATION; PHARMACOKINETICS; ALFENTANIL; DRUGS	1. Fentanyl is a highly lipophilic opioid commonly used to treat cancer pain. Plasma protein binding (PPB) of fentanyl in human plasma is reported as 80-85%, however it is unclear whether fentanyl binds primarily to albumin (ALB) or alpha-1 acid glycoprotein (AAG) and no studies have been conducted on the metabolite, nor-fentanyl. Fentanyl is also known to bind to plasticware and ultrafiltration (UF) devices which impacts adversely on binding experiments. 2. PPB of fentanyl and nor-fentanyl to ALB and AAG in isotonic phosphate buffer solution and seeded human plasma was quantified. PPB was also performed in plasma samples obtained from cancer patients receiving transdermal fentanyl. The adsorption of fentanyl and norfentanyl to UF devices and plasticware commonly used in PPB studies was also assessed. 3. Fentanyl was shown to bind primarily to ALB as opposed to AAG, with nor-fentanyl exhibiting negligible binding to plasma proteins. Total PPB of fentanyl was 86-89% in seeded human plasma. PPB in 56 cancer patient samples was 95.1 +/- 3.52% for fentanyl and 32.4 +/- 21.9% for nor-fentanyl. 4. UF was shown to be a reliable and convenient method for PPB studies, thereby removing the need for complex testing for adsorption of the drug to plasticware during UF.	[Bista, Sudeep Raj; Haywood, Alison; Norris, Ross] Griffith Univ, Sch Pharm, Griffith Hlth Inst, Gold Coast, Qld, Australia; [Bista, Sudeep Raj; Haywood, Alison; Hardy, Janet; Lobb, Michael; Tapuni, Angela; Norris, Ross] Mater Med Res Inst, Mater Pathol Serv, South Brisbane, Qld, Australia; [Norris, Ross] St Vincents Hosp, SydPath, Sydney, NSW 2010, Australia	Bista, SR (reprint author), Griffith Univ, Sch Pharm, Gold Coast Campus, Nathan, Qld 4222, Australia.	s.bista@griffith.edu.au	Hardy, Janet/F-2501-2012	Haywood, Alison/0000-0002-5354-8868	Griffith Health Institute, Griffith UniversityGriffith University; Mater Medical Research Institute	We thank Griffith Health Institute, Griffith University and Mater Medical Research Institute for partially funding this study. The authors report no declarations of interest.	Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; BOWER S, 1981, J PHARM PHARMACOL, V33, P507, DOI 10.1111/j.2042-7158.1981.tb13849.x; BOWERS WF, 1984, CLIN PHARMACOKINET, V9, P49, DOI 10.2165/00003088-198400091-00007; Brash J L, 1969, J Biomed Mater Res, V3, P175, DOI 10.1002/jbm.820030114; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; KREMER JMH, 1988, PHARMACOL REV, V40, P1; KURZ H, 1977, ARZNEIMITTEL-FORSCH, V27, P1373; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; Miller RS, 1995, BRIT J CLIN PHARMACO, V40, P553; PACIFICI GM, 1992, CLIN PHARMACOKINET, V23, P449, DOI 10.2165/00003088-199223060-00005; Peters Jr T., 1996, ALL ALBUMIN BIOCH GE; ROTHSCHILD MA, 1988, HEPATOLOGY, V8, P385, DOI 10.1002/hep.1840080234; Rowland M, 2011, CLIN PHARMACOKINETIC; Shargel L, 2005, APPL BIOPHARMACEUTIC; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Taylor S, 2006, J PHARMACEUT BIOMED, V41, P299, DOI 10.1016/j.jpba.2005.10.031; Tesseromatis C, 2011, ACUTE PHASE PROTEINS - REGULATION AND FUNCTIONS OF ACUTE PHASE PROTEINS, P247; Thakurta SG, 2011, J MATER SCI-MATER M, V22, P137, DOI 10.1007/s10856-010-4169-3; Wang CG, 2013, J PHARMACEUT BIOMED, V75, P112, DOI 10.1016/j.jpba.2012.11.018; Wiesner G, 1996, ANAESTHESIST, V45, P323, DOI 10.1007/s001010050267; Wilson AS, 1997, ANESTH ANALG, V84, P315, DOI 10.1097/00000539-199702000-00013; Wright JD, 1996, CLIN PHARMACOKINET, V30, P445, DOI 10.2165/00003088-199630060-00003	25	9	10	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0049-8254	1366-5928		XENOBIOTICA	Xenobiotica	MAR	2015	45	3					207	212		10.3109/00498254.2014.971093			6	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	CC6CH	WOS:000350451700003	25314012				2020-06-30	J	Park, SY; Chun, HR; Kim, MG; Lee, SJ; Kim, SH; Ok, SY; Cho, A				Park, Sun Young; Chun, Hea Rim; Kim, Mun Gyu; Lee, Se Jin; Kim, Sang Ho; Ok, Si Young; Cho, Ana			Transient Horner's syndrome following thoracic epidural anesthesia for mastectomy: a prospective observational study	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							MODIFIED RADICAL-MASTECTOMY; NEUROLOGIC COMPLICATIONS; PEDIATRIC-PATIENT; ANALGESIA; LABOR	Transient Horner's syndrome is an uncommon complication of epidural anesthesia, though its exact incidence in thoracic epidural anesthesia is not clear. Therefore, this study prospectively evaluated the incidence of Horner's syndrome after thoracic epidural anesthesia for mastectomy. Patients scheduled for mastectomy, with or without breast reconstruction, were enrolled in this prospective observational study from September 2010 to December 2013. Intraoperative thoracic epidural anesthesia was established using 0.375% or 0.5% ropivacaine 15 mL with thoracic epidural analgesia continued postoperatively with a continuous infusion of 0.15% ropivacaine 2 mL center dot hr(-1) with fentanyl 8 mu g center dot hr(-1). Signs of Horner's syndrome (miosis, ptosis, and hyperemia) were assessed at one and two hours as well as one, two, and three days postoperatively. Thoracic epidural anesthesia was successful in 439 patients, with six (1.4%) of these patients acquiring Horner's syndrome. All signs of Horner's syndrome resolved gradually within 180 min of discontinuing the epidural infusion. In one patient with Horner's syndrome, a radiographic contrast injection confirmed that the drug had spread to the cervical epidural level. The incidence of Horner's syndrome following thoracic epidural anesthesia and continuous thoracic epidural analgesia for mastectomy was 1.4%. The mechanism was consistent with cephalic spread of the epidural local anesthetic. This trial was registered at: Clinicaltrials.gov, number: NCT02130739.	[Park, Sun Young; Chun, Hea Rim; Kim, Mun Gyu; Lee, Se Jin; Kim, Sang Ho; Ok, Si Young; Cho, Ana] Soonchunhyang Univ Seoul Hosp, Dept Anesthesiol & Pain Med, Seoul 140743, South Korea	Park, SY (reprint author), Soonchunhyang Univ Seoul Hosp, Dept Anesthesiol & Pain Med, Seoul 140743, South Korea.	sunnypark97@gmail.com			Soonchunhyang University Research Fund	This work was supported by the Soonchunhyang University Research Fund.	Aronson LA, 2000, PAEDIATR ANAESTH, V10, P89, DOI 10.1046/j.1460-9592.2000.00445.x; Barbara R, 2011, OBSTET GYNECOL SURV, V66, P114, DOI 10.1097/OGX.0b013e31821d6e5c; CLAYTON KC, 1983, ANAESTHESIA, V38, P583, DOI 10.1111/j.1365-2044.1983.tb14074.x; DAHLGREN N, 1995, ACTA ANAESTH SCAND, V39, P872, DOI 10.1111/j.1399-6576.1995.tb04190.x; Day CJE, 1996, REGION ANESTH, V21, P197; Doss NW, 2001, ANESTH ANALG, V92, P1552; Giebler RM, 1997, ANESTHESIOLOGY, V86, P55, DOI 10.1097/00000542-199701000-00009; Martinez-Garcia E, 2008, PEDIATR ANESTH, V18, P1119, DOI 10.1111/j.1460-9592.2008.02625.x; Menendez C, 2000, AM SURGEON, V66, P756; Rabinovich A, 2010, EUR J OBSTET GYN R B, V149, P229, DOI 10.1016/j.ejogrb.2009.11.020; Yeh CC, 1999, WORLD J SURG, V23, P256, DOI 10.1007/PL00013180; YUEN EC, 1995, NEUROLOGY, V45, P1795, DOI 10.1212/WNL.45.10.1795; Zadra N, 2000, PAEDIATR ANAESTH, V10, P573, DOI 10.1046/j.1460-9592.2000.0571e.x	13	5	5	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	MAR	2015	62	3					252	257		10.1007/s12630-014-0284-9			6	Anesthesiology	Anesthesiology	CB8WO	WOS:000349912900003	25560203	Bronze			2020-06-30	J	Carvalho, JCA; Khemka, R; Loke, J; Tsui, BCH				Carvalho, Jose C. A.; Khemka, Rakhi; Loke, Julian; Tsui, Ban C. H.			Low-dose intrathecal local anesthetic does not increase the threshold current for the epidural stimulation test: a prospective observational trial of neuraxial analgesia in labouring women	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							NERVE-STIMULATION; CATHETER PLACEMENT; ELECTRICAL-STIMULATION; CONFIRMATION; GUIDANCE; NEEDLE	The purpose of this study was to investigate the ability of the electrical epidural stimulation test (EST) to determine the position of the epidural catheter during combined spinal-epidural (CSE) anesthesia for labour analgesia. This was a prospective observational trial of attempted EST during neuraxial analgesia in labouring women. Ten women received a double-segment CSE technique and one woman underwent continuous spinal analgesia following inadvertent dural puncture and deliberate placement of the catheter tip in the intrathecal space. In all CSE cases, the spinal injection was performed below the level of the epidural insertion. The motor threshold current (MTC) was determined by EST through the existing epidural/intrathecal catheter immediately following and at five, ten, and 15 mins after intrathecal injection of bupivacaine 1.75 mg and fentanyl 15 mu g. Changes in the MTC were expressed as a percent change compared with baseline. The MTC required to elicit muscle contractions in women with epidurally placed catheters was unaffected by the intrathecal injection of the analgesic mixture (P = 0.731). The MTC increased following an intrathecal injection of the same mixture in a woman who had the catheter placed intrathecally. The intrathecal injection of a low dose of bupivacaine-fentanyl does not affect the MTC if the catheter is placed in the epidural space; however, it does affect the threshold if the catheter is placed intrathecally. We also confirm that the EST can help to determine the position of the epidural catheter prior to injection of the test dose. This trial was registered at ClinicalTrials.gov (NCT00464841).	[Carvalho, Jose C. A.; Khemka, Rakhi] Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada; [Carvalho, Jose C. A.] Univ Toronto, Mt Sinai Hosp, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada; [Loke, Julian] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Loke, Julian] Abbotsford Reg Hosp & Canc Ctr, Abbotsford, BC, Canada; [Tsui, Ban C. H.] Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB T6G 2G3, Canada	Tsui, BCH (reprint author), Univ Alberta, Dept Anesthesiol & Pain Med, 8-120 Clin Sci Bldg, Edmonton, AB T6G 2G3, Canada.	btsui@ualberta.ca			Alberta Heritage Foundation for Medical Research (AHFMR)Alberta Heritage Foundation for Medical Research; Canadian Anesthesia Research Foundation	The authors thank Dr. Gareth Corry for assistance with manuscript preparation. Dr. Tsui is supported by a Clinical Scholar Award from the Alberta Heritage Foundation for Medical Research (AHFMR). Dr. Tsui's research is supported by the Canadian Anesthesia Research Foundation.	Abdallah F, 2014, CAN J ANESTH, V61, P881, DOI 10.1007/s12630-014-0145-6; Casati A, 1998, REGION ANESTH PAIN M, V23, P390, DOI 10.1016/S1098-7339(98)90013-X; COLLIS RE, 1993, LANCET, V341, P767, DOI 10.1016/0140-6736(93)90548-U; de Medicis E, 2005, ANESTH ANALG, V101, P1830, DOI 10.1213/01.ANE.0000184130.73634.BE; ELDOR J, 1992, BRIT J ANAESTH, V68, P634, DOI 10.1093/bja/68.6.634-a; FELSBY S, 1995, ANESTH ANALG, V80, P821, DOI 10.1097/00000539-199504000-00029; Goobie SM, 2003, ANESTH ANALG, V97, P984, DOI 10.1213/01.ANE.0000080609.05942.38; Hayatsu K, 2001, ANESTH ANALG, V93, P1035, DOI 10.1097/00000539-200110000-00048; LYONS G, 1992, ANAESTHESIA, V47, P199, DOI 10.1111/j.1365-2044.1992.tb02117.x; Margarido CB, 2013, CAN J ANESTH, V60, P393, DOI 10.1007/s12630-013-9887-9; McAuliffe NA, 2013, CAN J ANESTH, V60, P976, DOI 10.1007/s12630-013-0002-z; Morley-Forster PK, 2006, CAN J ANAESTH, V53, P375, DOI 10.1007/BF03022502; Prusinkiewicz C, 2005, ACTA ANAESTH SCAND, V49, P579, DOI 10.1111/j.1399-6576.2005.00630.x; Quan D, 1999, UPOJ, V12, P45, DOI DOI 10.1016/B978-0-7506-1183-1.50010-3; Standring S, 2008, GRAYS ANATOMY ANATOM; Sutherland MA, 2009, REGION ANESTH PAIN M, V34, P575, DOI 10.1097/AAP.0b013e3181bfbe1e; Tamai H, 2004, REGION ANESTH PAIN M, V29, P92, DOI 10.1016/j.rapm.2003.11.012; Tsui BCH, 2007, ACTA ANAESTH SCAND, V51, P255, DOI 10.1111/j.1399-6576.2006.1184.x; Tsui BCH, 2006, ANESTH ANALG, V103, P775, DOI 10.1213/01.ANE.0000227123.96546.69; Tsui BCH, 2006, ACTA ANAESTH SCAND, V50, P514, DOI 10.1111/j.1399-6576.2005.00969.x; Tsui BCH, 2005, ACTA ANAESTH SCAND, V49, P1562, DOI 10.1111/j.1399-6576.2005.00736.x; Tsui BCH, 2004, REGION ANESTH PAIN M, V29, P189, DOI 10.1016/j.rapm.2004.02.002; Tsui BCH, 1998, CAN J ANAESTH, V45, P640, DOI 10.1007/BF03012093; Tsui BCH, 2000, CAN J ANAESTH, V47, P471, DOI 10.1007/BF03018980; Tsui BCH, 1999, REGION ANESTH PAIN M, V24, P17, DOI 10.1016/S1098-7339(99)90160-8	25	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	MAR	2015	62	3					265	270		10.1007/s12630-014-0291-x			6	Anesthesiology	Anesthesiology	CB8WO	WOS:000349912900005	25501494	Bronze			2020-06-30	J	Tiwari, AK; Wong, DT; Venkatraghaven, L				Tiwari, Akhilesh Kumar; Wong, David T.; Venkatraghaven, Lashmi			Anesthetic considerations and airway management in a professional singer: case report and brief review	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter									[Tiwari, Akhilesh Kumar; Wong, David T.; Venkatraghaven, Lashmi] Toronto Western Hosp, Dept Anesthesia, Toronto, ON M5T 2S8, Canada	Venkatraghaven, L (reprint author), Toronto Western Hosp, Dept Anesthesia, Toronto, ON M5T 2S8, Canada.	lashmi.venkatraghavan@uhn.on.ca					Malhotra D, 2009, INDIAN J ANAESTH, V53, P442; Mendels EJ, 2012, ARCH OTOLARYNGOL, V138, P257, DOI 10.1001/archoto.2011.1427; Merchant R, 2014, CAN J ANESTH, V61, P46, DOI 10.1007/s12630-013-0074-9; Yamanaka H, 2009, BRIT J ANAESTH, V103, P452, DOI 10.1093/bja/aep169	4	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	MAR	2015	62	3					323	324		10.1007/s12630-014-0259-x			2	Anesthesiology	Anesthesiology	CB8WO	WOS:000349912900014	25351978				2020-06-30	J	Xing, SZ; Zhang, Y				Xing, Shao-Zhi; Zhang, Ying			Efficacy and safety of transdermal fentanyl for the treatment of oral mucositis pain caused by chemoradiotherapy in patients with esophageal squamous cell carcinoma	SUPPORTIVE CARE IN CANCER			English	Article						Esophageal squamous cell carcinoma; Transdermal fentanyl; Chemoradiotherapy; Oral mucositis	LONG-TERM TREATMENT; QUALITY-OF-LIFE; CANCER PAIN; DEFINITIVE CHEMORADIOTHERAPY; MANAGEMENT; MORPHINE; CHEMOTHERAPY; TRIAL; HEAD; RADIOTHERAPY	Oral mucositis is one of the most painful side effects found in esophageal squamous cell carcinoma (ESCC) patients treated with chemoradiotherapy. The transdermal route of administration is worthy of investigation for patients who suffer from dysphagia due to severe oral mucositis. In this phase 2 study, we investigated the efficacy and safety of transdermal fentanyl (TDF) for mucositis pain caused by chemoradiotherapy in ESCC patients. Forty-six ESCC patients who experienced moderate to severe oral mucosal pain during chemoradiotherapy received TDF for pain relief. The assessment of pain was made according to the Numeric Rating Scale (NRS). Efficacy and safety of TDF was collected and conducted in an open-label fashion. The analgesic effect, quality of life, and side effects were evaluated after the administration of transdermal fentanyl using the paired sample Wilcoxon signed rank test. The mucositis-induced pain disappeared in 31 (67.4 %) patients during the treatment with transdermal fentanyl with the median time of onset at day 6.6 (range 3-14). The median Numeric Rating Scale (NRS) score was reduced from 6 (range 3-9) before treatment to 4.5 (range 2-9), 3 (range 2-8), 2.5 (range 1-8), 2 (range 0-6), and 0 (range 0-4) on days 3, 6, 9, 11, and 15, respectively, after treatment (P < 0.001). The patients' quality of life also improved significantly (P < 0.01). The side effects of treatment were mild and disappeared within several days. Transdermal fentanyl is an effective, convenient, and well-tolerated treatment for mucositis pain caused by chemoradiotherapy, which can improve ESCC patients' quality of life.	[Xing, Shao-Zhi] Binzhou Med Coll, Sch Clin Med, Dept Oncol, Binzhou 256603, Peoples R China; [Zhang, Ying] Binzhou Med Coll, Sch Clin Med, Dept Nutr, Binzhou 256603, Peoples R China	Xing, SZ (reprint author), Binzhou Med Coll, Sch Clin Med, Dept Oncol, 661 Yellow River Second St, Binzhou 256603, Peoples R China.	xingshaozhi@yeah.net					AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Baba Y, 2014, WORLD J GASTRO ONCOL, V6, P121, DOI 10.4251/wjgo.v6.i5.121; Blazeby JM, 2014, ANN SURG, V259, pE81, DOI 10.1097/SLA.0b013e3182480871; Cai QQ, 2008, EXPERT OPIN PHARMACO, V9, P3137, DOI [10.1517/14656560802504508, 10.1517/14656560802504508 ]; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Conroy T, 2014, LANCET ONCOL, V15, P305, DOI 10.1016/S1470-2045(14)70028-2; D'Journo XB, 2014, J THORAC DIS, V6, pS253, DOI 10.3978/j.issn.2072-1439.2014.04.16; Demarosi F, 2004, BONE MARROW TRANSPL, V33, P1247, DOI 10.1038/sj.bmt.1704515; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Elting LS, 2007, INT J RADIAT ONCOL, V68, P1110, DOI 10.1016/j.ijrobp.2007.01.053; Gibson RJ, 2013, SUPPORT CARE CANCER, V21, P313, DOI 10.1007/s00520-012-1644-z; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Ishikura S, 2003, J CLIN ONCOL, V21, P2697, DOI 10.1200/JCO.2003.03.055; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Kim JG, 2005, TRANSPL P, V37, P4488, DOI 10.1016/j.transproceed.2005.11.038; Kostler WJ, 2001, CA-CANCER J CLIN, V51, P290, DOI 10.3322/canjclin.51.5.290; Maathuis MHJ, 2011, EUR J GEN PRACT, V17, P229, DOI 10.3109/13814788.2011.602966; Mitra F, 2013, PAIN MED, V14, P75, DOI 10.1111/pme.12011; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Naidu MUR, 2004, NEOPLASIA, V6, P423, DOI 10.1593/neo.04169; National Cancer Institute, 2009, NIH PUBLICATION, V09-7473; Saroja G, 2010, INDIAN J PALLIAT CAR, V16, DOI 10.4103/0973-1075.63138; Saunders DP, 2013, SUPPORT CARE CANCER, V21, P3191, DOI 10.1007/s00520-013-1871-y; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Shaiova L, 2007, J PALLIAT MED, V10, P1063, DOI 10.1089/jpm.2006.0262; Shin Hai-Rim, 2008, J Prev Med Public Health, V41, P84; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Sonis ST, 2009, ORAL ONCOL, V45, P1015, DOI 10.1016/j.oraloncology.2009.08.006; Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; Worthington HV, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000978.pub3; Yazbeck VY, 2013, CANCER J, V19, P231, DOI 10.1097/PPO.0b013e31829453fb	37	9	11	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	MAR	2015	23	3					753	759		10.1007/s00520-014-2419-5			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	CA6JU	WOS:000349020000019	25179692				2020-06-30	J	Bedard, G; Davies, A; McDonald, R; Hawley, P; Buchanan, A; Popovic, M; Wong, E; Chow, E				Bedard, Gillian; Davies, Andrew; McDonald, Rachel; Hawley, Philippa; Buchanan, Alison; Popovic, Marko; Wong, Erin; Chow, Edward			Breakthrough cancer pain: a comparison of surveys with European and Canadian patients	SUPPORTIVE CARE IN CANCER			English	Article						Breakthrough pain; Cancer; Patients' perspectives	MANAGEMENT; ASSOCIATION; FENTANYL	Breakthrough cancer pain is defined as a transient exacerbation of pain that occurs spontaneously or in response to a trigger, despite stable and controlled background pain. Breakthrough pain often causes significant functional impairments for patients and can decrease quality of life. The objective of the study was to determine differences between breakthrough cancer pain incidence and management in Canada and Europe. Data collected from previous studies of breakthrough cancer pain in Canada and Europe was compared. A standard survey with identical inclusion/exclusion criteria was utilized for both patient populations. Both groups of patients had a similar number and duration of breakthrough pain episodes, and similar pain intensity and pain interference with their daily activities. European patients reported better analgesic efficacy and satisfaction with management, and a greater percentage of European patients were prescribed a transmucosal fentanyl formulation (19.1 vs 2.9 %). More European patients (55 %) than Canadian patients (32.5 %) took their rescue medication every time they had a breakthrough pain episode. Breakthrough cancer pain in both Canadian and European patients greatly impacts their daily living, and both groups of patients had similar experiences with breakthrough cancer pain. Currently, this pain is not adequately managed for many patients. The role for new analgesic treatments in management of breakthrough cancer pain needs further study.	[Bedard, Gillian; McDonald, Rachel; Popovic, Marko; Wong, Erin; Chow, Edward] Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Dept Radiat Oncol, Toronto, ON M4N 3M5, Canada; [Davies, Andrew; Buchanan, Alison] Royal Surrey Cty Hosp, Guildford, Surrey, England; [Hawley, Philippa] Univ British Columbia, BC Canc Agcy, Vancouver, BC V5Z 1M9, Canada	Chow, E (reprint author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Dept Radiat Oncol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	Edward.Chow@sunnybrook.ca		Popovic, Marko/0000-0002-0370-5968			Bedard G, 2013, SUPPORT CARE CANCER, V21, P2557, DOI 10.1007/s00520-013-1817-4; Black B, 2011, PAIN MED, V12, P880, DOI 10.1111/j.1526-4637.2011.01113.x; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Ferrell BR, 2002, J PAIN SYMPTOM MANAG, V23, P329, DOI 10.1016/S0885-3924(02)00380-9; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2007, DRUG AGING, V24, P761, DOI 10.2165/00002512-200724090-00004; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L; Webber K, 2011, SUPPORT CARE CANCER, V19, P2041, DOI 10.1007/s00520-010-1062-z; World Health Organisation, 2014, WHOS CANC PAIN LADD	16	10	11	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	MAR	2015	23	3					791	796		10.1007/s00520-014-2426-6			6	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	CA6JU	WOS:000349020000023	25193599				2020-06-30	J	Bihel, F; Humbert, JP; Schneider, S; Bertin, I; Wagner, P; Schmitt, M; Laboureyras, E; Petit-Demouliere, B; Schneider, E; Mollereau, C; Simonnet, G; Simonin, F; Bourguignon, JJ				Bihel, Frederic; Humbert, Jean-Paul; Schneider, Severine; Bertin, Isabelle; Wagner, Patrick; Schmitt, Martine; Laboureyras, Emilie; Petit-Demouliere, Benoit; Schneider, Elodie; Mollereau, Catherine; Simonnet, Guy; Simonin, Frederic; Bourguignon, Jean-Jacques			Development of a Peptidomimetic Antagonist of Neuropeptide FF Receptors for the Prevention of Opioid-Induced Hyperalgesia	ACS CHEMICAL NEUROSCIENCE			English	Article						NPFF; GPCR; GPR147; GPR74; peptidomimetic; unnatural amino acid; ornithine; arginine; bioisoster; opioid-induced hyperalgesia	MORPHINE ANALGESIC TOLERANCE; BLOOD-BRAIN-BARRIER; PHARMACOLOGICAL CHARACTERIZATION; LIBRARY DESIGN; NPFF RECEPTORS; PAIN; PEPTIDES; RATS; INVOLVEMENT; HYPOTHERMIA	Through the development of a new class of unnatural ornithine derivatives as bioisosteres of arginine, we have designed an orally active peptidomimetic antagonist of neuropeptide FF receptors (NPFFR). Systemic low-dose administration of this compound to rats blocked opioid-induced hyperalgesia, without any apparent side-effects. Interestingly, we also observed that this compound potentiated opioid-induced analgesia. This unnatural ornithine derivative provides a novel therapeutic approach for both improving analgesia and reducing hyperalgesia induced by opioids in patients being treated for chronic pain.	[Bihel, Frederic; Schneider, Severine; Wagner, Patrick; Schmitt, Martine; Bourguignon, Jean-Jacques] Univ Strasbourg, CNRS, UMR7200, Fac Pharm, F-67400 Illkirch Graffenstaden, France; [Humbert, Jean-Paul; Bertin, Isabelle; Simonin, Frederic] Univ Strasbourg, CNRS, UMR7242, ESBS, F-67412 Illkirch Graffenstaden, France; [Laboureyras, Emilie; Simonnet, Guy] Univ Bordeaux Segalen, INCIA, CNRS, UMR5287, F-33076 Bordeaux, France; [Petit-Demouliere, Benoit] Univ Strasbourg, Inst Clin Souris, F-67404 Illkirch Graffenstaden, France; [Schneider, Elodie] Phenopro, F-67400 Illkirch Graffenstaden, France; [Mollereau, Catherine] Univ Toulouse, CNRS, UMR5089, IPBS, F-31077 Toulouse, France	Bihel, F (reprint author), Univ Strasbourg, CNRS, UMR7200, Fac Pharm, F-67400 Illkirch Graffenstaden, France.	fbihel@unistra.fr; simonin@unistra.fr	BIHEL, Frederic/B-2895-2008; Schmitt, Martine/B-5878-2016; BIHEL, Frederic/K-7004-2019	BIHEL, Frederic/0000-0002-4122-0929; Schmitt, Martine/0000-0002-8723-9502; BIHEL, Frederic/0000-0002-4122-0929; Mollereau, Catherine/0000-0003-1543-5624; Bertrand, Sandrine S/0000-0002-3020-7980	Agence National de la RechercheFrench National Research Agency (ANR) [ANR-06-Neuro-041-01, ANR-08-EBIO-014-01]; Alsace BioValley (Conectus, Pharmadol)Region Grand-Est; Conseil Regional d'Alsace (Pharmadol)Region Grand-Est; Communaute Urbaine de Strasbourg (Pharmadol); ICFRC (Pharmadol); OSEO (Pharmadol); Direction Generale des Entreprises (Pharmadol); French government	This work was supported by grants from Agence National de la Recherche (ANR-06-Neuro-041-01, ANR-08-EBIO-014-01), Alsace BioValley (Conectus, Pharmadol), Conseil Regional d'Alsace (Pharmadol), Communaute Urbaine de Strasbourg (Pharmadol), ICFRC (Pharmadol), OSEO (Pharmadol), Direction Generale des Entreprises (Pharmadol). This work has been published within the LABEX ANR-10-LABX-0034_Medalis and received financial support from the French government managed by "Agence National de la Recherche" under "Programme d'investissement d'avenir.	Abraham MH, 2004, EUR J MED CHEM, V39, P235, DOI 10.1016/j.ejmech.2003.12.004; ALLARD M, 1989, BRAIN RES, V500, P169, DOI 10.1016/0006-8993(89)90311-9; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Ayachi S, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00158; Becker JAJ, 1999, J BIOL CHEM, V274, P27513, DOI 10.1074/jbc.274.39.27513; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Crofford LJ, 2010, NAT REV RHEUMATOL, V6, P191, DOI 10.1038/nrrheum.2010.24; Elhabazi K, 2012, BRIT J PHARMACOL, V165, P424, DOI 10.1111/j.1476-5381.2011.01563.x; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; Fang Q, 2008, REGUL PEPTIDES, V147, P45, DOI 10.1016/j.regpep.2007.12.007; Findeisen M, 2012, J MED CHEM, V55, P6124, DOI 10.1021/jm300535s; Findeisen M, 2011, CHEMMEDCHEM, V6, P1081, DOI 10.1002/cmdc.201100089; Gealageas R, 2012, BIOORG MED CHEM LETT, V22, P7471, DOI 10.1016/j.bmcl.2012.10.049; Gicquiaux H, 2002, J BIOL CHEM, V277, P6645, DOI 10.1074/jbc.M107224200; Goodnow RA, 2003, COMB CHEM HIGH T SCR, V6, P649; Gratton J. A., 1997, J PHARM PHARMACOL, V49, P1211; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Hitchcock SA, 2008, CURR OPIN CHEM BIOL, V12, P318, DOI 10.1016/j.cbpa.2008.03.019; Kalliomaki ML, 2004, NEUROSCIENCE, V124, P81, DOI 10.1016/j.neuroscience.2003.10.026; Kelder J, 1999, PHARMACEUT RES, V16, P1514, DOI 10.1023/A:1015040217741; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Laguzzi R, 1996, BRAIN RES, V711, P193, DOI 10.1016/0006-8993(95)01382-2; Lameh J, 2010, J PHARMACOL EXP THER, V334, P244, DOI 10.1124/jpet.109.164384; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; Lefrere I, 2002, J BIOL CHEM, V277, P39169, DOI 10.1074/jbc.M205084200; MAJANE EA, 1991, PEPTIDES, V12, P1303, DOI 10.1016/0196-9781(91)90211-7; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Mazarguil H, 2001, PEPTIDES, V22, P1471, DOI 10.1016/S0196-9781(01)00468-5; McNally GP, 1999, NEUROSCI BIOBEHAV R, V23, P1059, DOI 10.1016/S0149-7634(99)00040-8; Mollereau C, 2005, MOL PHARMACOL, V67, P965, DOI 10.1124/mol.104.004614; Mollereau C, 2002, EUR J PHARMACOL, V451, P245, DOI 10.1016/S0014-2999(02)02224-0; Mouledous L, 2010, NEUROPEPTIDES, V44, P453, DOI 10.1016/j.npep.2010.05.003; Murase T, 1996, PEPTIDES, V17, P353, DOI 10.1016/0196-9781(95)02137-X; Obach RS, 1997, J PHARMACOL EXP THER, V283, P46; Ossipov MH, 2003, LIFE SCI, V73, P783, DOI 10.1016/S0024-3205(03)00410-7; PAYZA K, 1993, J PHARMACOL EXP THER, V267, P88; Prokai L, 2006, PEPTIDES, V27, P1015, DOI 10.1016/j.peptides.2005.06.032; ROTH BL, 1987, NEUROPEPTIDES, V10, P37, DOI 10.1016/0143-4179(87)90087-4; ROTHMAN RB, 1992, SYNAPSE, V12, P129, DOI 10.1002/syn.890120206; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Sirnonin F., 2006, P NATL ACAD SCI USA, V103, P466; Ueda H, 2009, FRONT BIOSCI, V14, P5260, DOI 10.2741/3596; Vyas N, 2006, PEPTIDES, V27, P990, DOI 10.1016/j.peptides.2005.07.024; Wang YQ, 2008, PEPTIDES, V29, P1183, DOI 10.1016/j.peptides.2008.02.016; White JM, 2004, ADDICT BEHAV, V29, P1311, DOI 10.1016/j.addbeh.2004.06.007; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757; Zhang LH, 2012, ACS COMB SCI, V14, P108, DOI 10.1021/co200141b	49	17	17	0	23	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	MAR	2015	6	3					438	445		10.1021/cn500219h			8	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	CD9LN	WOS:000351419900012	25588572	Bronze			2020-06-30	J	Graudins, A; Meek, R; Egerton-Warburton, D; Oakley, E; Seith, R				Graudins, Andis; Meek, Robert; Egerton-Warburton, Dianna; Oakley, Ed; Seith, Robert			The PICHFORK (Pain in Children Fentanyl or Ketamine) Trial: A Randomized Controlled Trial Comparing Intranasal Ketamine and Fentanyl for the Relief of Moderate to Severe Pain in Children With Limb Injuries	ANNALS OF EMERGENCY MEDICINE			English	Article							VISUAL ANALOG SCALE; CLINICALLY SIGNIFICANT DIFFERENCE; PEDIATRIC EMERGENCY-DEPARTMENT; ANALGESIA; EFFICACY; RELIABILITY; ADULT; NASAL; SCORE	Study objective: We compare the analgesic effectiveness of intranasal fentanyl and ketamine in children. Methods: This was a double-blind, randomized, controlled trial comparing fentanyl at 1.5 mu g/kg with ketamine at 1 mg/kg in children aged 3 to 13 years and weighing less than 50 kg, with isolated limb injury and pain of more than 6 of 10 at triage. The sample size was 40 in each arm. Subjects were coadministered oral ibuprofen at 10 mg/kg. The primary outcome was median pain rating reduction at 30 minutes. Secondary outcomes were pain rating reduction at 15 and 60 minutes, subjective improvement and satisfaction, University of Michigan Sedation Score, adverse events, and rescue analgesia. Results: Eighty children enrolled, and 73 were available for analysis: 37 fentanyl and 36 ketamine. Median age was. 8 years; 63% were male children; median baseline pain rating was 80 mm. At 30 minutes, median reductions for ketamine and fentanyl were 45 and 40 mm, respectively (difference 5 mm; 95% confidence interval [Cl] 10 to 20 mm). Reduction exceeded 20 mm for ketamine and fentanyl in 82% and 79% of patients, respectively (difference 3%; 95% Cl -22% to 16%). Pain rating reduction was maintained to 60 minutes in both groups. Satisfaction was reported for ketamine and fentanyl by 83% and 72% of patients, respectively (difference 11%; 95% Cl -9% to 30%). Adverse events, mainly mild, were reported for ketamine and fentanyl by 78% and 40% of patients, respectively (difference 38%; 95% Cl -58% to 16%). Three ketamine patients had a moderate degree of sedation by University of Michigan Sedation Score. Conclusion: Intranasal fentanyl and ketamine were associated with similar pain reduction in children with moderate to severe pain from limb injury. Ketamine was associated with more minor adverse events.	[Graudins, Andis; Meek, Robert; Egerton-Warburton, Dianna] Monash Univ, Sch Clin Sci Monash Hlth, Monash Hlth Emergency Med Res Grp, Dept Med,Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Seith, Robert] Monash Hlth, Pediat Emergency Dept, Monash Med Ctr, Clayton, Vic, Australia; [Graudins, Andis; Meek, Robert; Egerton-Warburton, Dianna; Seith, Robert] Monash Hlth, Monash Hlth Emergency Med Program, Clayton, Vic, Australia; [Graudins, Andis; Meek, Robert; Egerton-Warburton, Dianna; Seith, Robert] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Oakley, Ed] Royal Childrens Hosp, Dept Emergency Med, Parkville, Vic 3052, Australia	Graudins, A (reprint author), Monash Univ, Sch Clin Sci Monash Hlth, Monash Hlth Emergency Med Res Grp, Dept Med,Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia.	andis.graudins@monashhealth.org		Egerton-Warburton, Diana/0000-0003-0262-1305; Graudins, Andis/0000-0002-0310-3983	Jack Brockhoff Foundation	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This study was funded by an unrestricted grant from the Jack Brockhoff Foundation.	Afridi SK, 2013, NEUROLOGY, V80, P642, DOI 10.1212/WNL.0b013e3182824e66; Altman DG, 1999, BRIT MED J, V319, P703, DOI 10.1136/bmj.319.7211.703; Andolfatto G, 2013, ACAD EMERG MED, V20, P1050, DOI 10.1111/acem.12229; Bailey B, 2012, PAIN, V153, P839, DOI 10.1016/j.pain.2012.01.006; Bird SB, 2001, ANN EMERG MED, V38, P639, DOI 10.1067/mem.2001.118012; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Carr DB, 2004, PAIN, V108, P17, DOI 10.1016/j.pain.2003.07.001; Christensen K, 2007, ACUTE PAIN, V9, P183; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; de Tovar C, 2010, PAIN RES MANAG, V15, P163, DOI 10.1155/2010/475907; Diaz JH, 1997, PAEDIATR ANAESTH, V7, P273, DOI 10.1046/j.1460-9592.1997.d01-93.x; Graudins A, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-208; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Huge V, 2010, EUR J PAIN, V14, P387, DOI 10.1016/j.ejpain.2009.08.002; Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Middleton PM, 2010, J EMERG PRIMARY HLTH, V14, P439; Nielsen BN, 2014, PEDIATR ANESTH, V24, P170, DOI 10.1111/pan.12268; Powell CV, 2001, ANN EMERG MED, V37, P28; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Reid C, 2011, EMERG MED J, V28, P328, DOI 10.1136/emj.2010.092825; Weber F, 2004, PEDIATR ANESTH, V14, P983, DOI 10.1111/j.1460-9592.2004.01358.x; WEKSLER N, 1993, CAN J ANAESTH, V40, P119, DOI 10.1007/BF03011307; Yeaman F, 2014, EMERG MED AUSTRALAS, V26, P237, DOI 10.1111/1742-6723.12173; Yeaman F, 2013, EMERG MED AUSTRALAS, V25, P161, DOI 10.1111/1742-6723.12059	26	55	56	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	MAR	2015	65	3					248	254		10.1016/j.annemergmed.2014.09.024			7	Emergency Medicine	Emergency Medicine	CC9QN	WOS:000350705800004	25447557				2020-06-30	J	Barbosa, TC; Fernandes, IA; Magalhaes, N; Cavalcanti, IL; Secher, NH; Nobrega, ACL; Vianna, LC				Barbosa, Thales C.; Fernandes, Igor A.; Magalhaes-, Nisval, Jr.; Cavalcanti, Ismar L.; Secher, Niels H.; Nobrega, Antonio C. L.; Vianna, Lauro C.			Oscillatory blood pressure response to the onset of cycling exercise in men: role of group III/IV muscle afferents	EXPERIMENTAL PHYSIOLOGY			English	Article							INITIAL ORTHOSTATIC HYPOTENSION; DYNAMIC EXERCISE; HEART-RATE; CARDIOVASCULAR-RESPONSES; CIRCULATORY RESPONSE; EPIDURAL-ANESTHESIA; RHYTHMIC EXERCISE; STATIC EXERCISE; CENTRAL COMMAND; NERVE ACTIVITY	New Findings What is the central question of this study? Neural feedback from groupIII/IV muscle afferents has a key role in regulation of cardiovascular responses to exercise. Blood pressure oscillates in the first seconds of dynamic exercise, but the contribution of muscle afferent feedback to this pattern is unclear. What is the main finding and its importance? We demonstrate that attenuation of groupIII/IV muscle afferent feedback by spinal fentanyl impairs the pressor response after 10s of moderate leg cycling exercise, but this afferent feedback does not appear to be necessary for induction of the oscillatory pattern of blood pressure at the onset of exercise. We investigated whether attenuation of the central projections of groupIII/IV skeletal muscle afferents via lumbar intrathecal administration of the -opioid receptor agonist fentanyl affects the oscillatory blood pressure (BP) response to the onset of dynamic exercise. Eight healthy, recreationally active men (28 +/- 3years old) performed 40s of cycling at 80W (60r.p.m.) before (control) and after fentanyl administration, while heart rate, stroke volume, cardiac output, systolic, mean and diastolic BP and total vascular conductance were continuously monitored. Sytolic and mean BP responses to cycling included an initial increase (from 0 to 3s), followed by a transient decrease below resting levels (from 3 to 10s) and then a sustained increase (>10s). In the presence of fentanyl, systolic and mean BP responses closely matched those in control conditions in the first 10s, but were blunted thereafter (P<0.05). In contrast, fentanyl did not modify the heart rate, stroke volume, cardiac output, diastolic BP or total vascular conductance responses to 40s of cycling (P>0.05). These findings suggest that during moderate leg cycling exercise the muscle afferents contribute to the BP response after approximate to 10s, but that they do not appear to be implicated in the oscillation of BP at the onset of exercise.	[Barbosa, Thales C.; Fernandes, Igor A.; Nobrega, Antonio C. L.; Vianna, Lauro C.] Univ Fed Fluminense, Dept Physiol & Pharmacol, Rio De Janeiro, Brazil; [Magalhaes-, Nisval, Jr.; Cavalcanti, Ismar L.] Univ Fed Fluminense, Dept Anaesthesiol, Rio De Janeiro, Brazil; [Secher, Niels H.] Univ Copenhagen, Rigshosp, Dept Anaesthesiol, Copenhagen Muscle Res Ctr, DK-1168 Copenhagen, Denmark; [Vianna, Lauro C.] Univ Brasilia, Fac Phys Educ, BR-70910900 Brasilia, DF, Brazil	Vianna, LC (reprint author), Univ Brasilia, Fac Phys Educ, BR-70910900 Brasilia, DF, Brazil.	lcvianna@unb.br	Fernandes, Igor A/G-9589-2012; Nobrega, Antonio Claudio/F-4825-2012; da Nobrega, Antonio Claudio Lucas/O-5107-2019; Vianna, Lauro/A-8188-2008	Fernandes, Igor A/0000-0003-3873-2656; Nobrega, Antonio Claudio/0000-0002-3830-2886; da Nobrega, Antonio Claudio Lucas/0000-0002-3830-2886; Vianna, Lauro/0000-0002-5747-0295; Fernandes, Igor Alexandre/0000-0002-0206-6316	Brazilian National Council of Scientific and Technological Development (CNPq)National Council for Scientific and Technological Development (CNPq); Foundation of Research Support of Rio de Janeiro State (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ); Coordination for the Improvement of Higher Education Personnel (CAPES)CAPES; Brazilian Funding Agency for Studies and Projects (FINEP); programme Science without Borders [PVE 051/2012 - CNPq/CAPES]	This study was supported by grants from the Brazilian National Council of Scientific and Technological Development (CNPq), the Foundation of Research Support of Rio de Janeiro State (FAPERJ), Coordination for the Improvement of Higher Education Personnel (CAPES) and the Brazilian Funding Agency for Studies and Projects (FINEP). N.H.S. was sponsored by the programme Science without Borders (PVE 051/2012 - CNPq/CAPES).	ALMEN T, 1962, ACTA RADIOL, V57, P264, DOI 10.3109/00016926209171754; Amann M, 2011, J PHYSIOL-LONDON, V589, P5299, DOI 10.1113/jphysiol.2011.213769; Amann M, 2011, J PHYSIOL-LONDON, V589, P3855, DOI 10.1113/jphysiol.2011.209353; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Amann M, 2008, J APPL PHYSIOL, V105, P1714, DOI 10.1152/japplphysiol.90456.2008; Bell MPD, 2005, EXP PHYSIOL, V90, P383, DOI 10.1113/expphysiol.2004.029140; Boushel R, 2010, ACTA PHYSIOL, V199, P367, DOI 10.1111/j.1748-1716.2010.02133.x; Caringi D, 1998, AM J PHYSIOL-HEART C, V274, pH139; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; CORCONDILAS A, 1964, J APPL PHYSIOL, V19, P142; Cui J, 2006, J PHYSIOL-LONDON, V576, P625, DOI 10.1113/jphysiol.2006.116640; Drew RC, 2008, J APPL PHYSIOL, V104, P716, DOI 10.1152/japplphysiol.00956.2007; Ettinger SM, 1996, J APPL PHYSIOL, V80, P245; FAGRAEUS L, 1976, J APPL PHYSIOL, V40, P679; FERNANDES A, 1990, J PHYSIOL-LONDON, V420, P281, DOI 10.1113/jphysiol.1990.sp017912; Fisher JP, 2005, EXP PHYSIOL, V90, P773, DOI 10.1113/expphysiol.2005.030577; FRIEDMAN DB, 1993, J PHYSIOL-LONDON, V470, P681, DOI 10.1113/jphysiol.1993.sp019882; Gandevia SC, 2001, PHYSIOL REV, V81, P1725; Gladwell VF, 2002, J PHYSIOL-LONDON, V540, P1095, DOI 10.1113/jphysiol.2001.013486; HOLMGREN A, 1956, Scand J Clin Lab Invest, V8 Suppl 24, P1; Ishii K, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.92; Krogh A, 1913, J PHYSIOL-LONDON, V47, P112; Leal AK, 2013, AM J PHYSIOL-HEART C, V305, pH1246, DOI 10.1152/ajpheart.00116.2013; MEINTJES AF, 1995, CIRC RES, V77, P326, DOI 10.1161/01.RES.77.2.326; MITCHELL JH, 1977, AM J PHYSIOL, V233, pH374; MORILAK DA, 1990, J PHARMACOL EXP THER, V254, P671; NOBREGA ACL, 1995, J APPL PHYSIOL, V79, P1405; NOBREGA ACL, 1993, MED SCI SPORT EXER, V25, P37; NOBREGA ACL, 1994, MED SCI SPORT EXER, V26, P709; NOBREGA ACL, 1990, BRAZ J MED BIOL RES, V23, P1259; Nobrega ACL, 1997, J APPL PHYSIOL, V83, P712; NOBREGA ACL, 1994, EUR J APPL PHYSIOL, V68, P336, DOI 10.1007/BF00571453; O'Leary DS, 1998, AM J PHYSIOL-HEART C, V275, pH220; PUNNEN S, 1984, NEUROPHARMACOLOGY, V23, P939, DOI 10.1016/0028-3908(84)90008-X; SECHER NH, 1988, ACTA PHYSIOL SCAND, V133, P233, DOI 10.1111/j.1748-1716.1988.tb08402.x; SPRANGERS RLH, 1991, J APPL PHYSIOL, V70, P523; STRANGE S, 1993, J PHYSIOL-LONDON, V470, P693, DOI 10.1113/jphysiol.1993.sp019883; Takahashi M, 2004, J APPL PHYSIOL, V97, P2077, DOI 10.1152/japplphysiol.00546.2004; Trinity JD, 2010, AM J PHYSIOL-HEART C, V299, pH1693, DOI 10.1152/ajpheart.00482.2010; Tschakovsky ME, 2011, AM J PHYSIOL-HEART C, V301, pH2102, DOI 10.1152/ajpheart.00571.2011; Tsuchimochi H, 2002, AM J PHYSIOL-HEART C, V283, pH1896, DOI 10.1152/ajpheart.00112.2002; WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566; Wieling W, 1996, J PHYSIOL-LONDON, V494, P601, DOI 10.1113/jphysiol.1996.sp021518; Wieling W, 2007, CLIN SCI, V112, P157, DOI 10.1042/CS20060091; WILLIAMS CA, 1989, CARDIOVASC RES, V23, P191, DOI 10.1093/cvr/23.3.191; Williamson JW, 2010, EXP PHYSIOL, V95, P1043, DOI 10.1113/expphysiol.2009.051870; WILLIAMSON JW, 1995, J APPL PHYSIOL, V78, P1273	48	7	7	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0958-0670	1469-445X		EXP PHYSIOL	Exp. Physiol.	MAR	2015	100	3					302	311		10.1113/expphysiol.2014.083857			10	Physiology	Physiology	CC6ED	WOS:000350456900011	25581883				2020-06-30	J	Torres, LM; Trinidad, JM; Calderon, E; Benitez, D; Perelman, M				Torres, Luis M.; Trinidad, Jose M.; Calderon, Enrique; Benitez, Diego; Perelman, Michael			Fentanyl pectin nasal spray for breakthrough cancer pain	INTERNATIONAL JOURNAL OF PALLIATIVE NURSING			English	Editorial Material							PREVALENCE; PHARMACOKINETICS; RECOMMENDATIONS; MANAGEMENT; EFFICACY; OPIOIDS; RELIEF		[Torres, Luis M.] Puerta Del Mar Univ Hosp, Crit Care & Pain Treatment Dept, Anesthesia, Cadiz, Spain; [Trinidad, Jose M.; Calderon, Enrique; Benitez, Diego] Puerta Del Mar Univ Hosp, Anesthesiol, Cadiz, Spain; [Perelman, Michael] Archimedes Dev Ltd, Nottingham, England	Torres, LM (reprint author), Puerta Del Mar Univ Hosp, Crit Care & Pain Treatment Dept, Anesthesia, Cadiz, Spain.	lm.torres@me.com	Torres, Luis Miguel/O-1720-2015; Torres, Luis M/Q-6983-2019	Torres, Luis Miguel/0000-0002-0194-7875; 			Abernethy Amy P, 2008, Am J Manag Care, V14, pS129; BENNETT D, 2005, [No title captured], V30, P354; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Castile J, 2013, DRUG DEV IND PHARM, V39, P816, DOI 10.3109/03639045.2012.707210; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250; Kress HG, 2010, EUR J PAIN S, V4, P191; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Taylor D, 2014, J PAIN SYMPTOM MANAG, V47, P1001, DOI 10.1016/j.jpainsymman.2013.07.012; Taylor Donald, 2010, J Support Oncol, V8, P184; Torres L.M., 2014, Rev. Soc. Esp. Dolor, V21, P191; Torres LM, 2014, J PALLIAT MED, V17, P1150, DOI 10.1089/jpm.2014.0089; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	24	0	0	0	4	MARK ALLEN GROUP	LONDON	ST JUDES CHURCH, DULWICH RD, LONDON, SE24 0PB, ENGLAND	1357-6321			INT J PALLIAT NURS	Int. J. Palliat. Nurs.	MAR	2015	21	3					114	116		10.12968/ijpn.2015.21.3.114			3	Nursing	Nursing	EE1AO	WOS:000389312900003	25815759				2020-06-30	J	Pecina, M; Love, T; Stohler, CS; Goldman, D; Zubieta, JK				Pecina, Marta; Love, Tiffany; Stohler, Christian S.; Goldman, David; Zubieta, Jon-Kar			Effects of the Mu Opioid Receptor Polymorphism (OPRM1 A118G) on Pain Regulation, Placebo Effects and Associated Personality Trait Measures	NEUROPSYCHOPHARMACOLOGY			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISM; MORPHINE CONSUMPTION; INDIVIDUAL-DIFFERENCES; DOPAMINE TRANSMISSION; AFFECTIVE DIMENSIONS; INDUCED ANALGESIA; REWARD; NEUROTICISM; RESPONSES; BINDING	Mu-opioid receptors (MOPRs) are critically involved in the modulation of pain and analgesia, and represent a candidate mechanism for the development of biomarkers of pain conditions and their responses to treatment. To further understand the human implications of genetic variation within the opioid system in pain and opioid-mediated placebo responses, we investigated the association between the functional single-nucleotide polymorphism (SNP) in the mu-opioid receptor gene (OPRM1), A118G, and psychophysical responses, personality traits, and neurotransmitter systems (dopamine (DA), opioid) related to pain and placebo analgesia. OPRM1 G carriers, compared with AA homozygotes, showed an overall reduction of baseline mu-opioid receptor availability in regions implicated in pain and affective regulation. In response to a sustained painful stimulus, we found no effect of Al I 8G on pain-induced endogenous opioid release. Instead, AA homozygotes showed a blunted DA response in the nucleus accumbens (NAc) in response to the pain challenge. After placebo administration, G carriers showed more pronounced mood disturbances and lower placebo-induced mu-opioid system activation in the anterior insula (aINS), the amygdala (AMY), the NAc, the thalamus (THA), and the brainstem, as well as lower levels of DA D-2/3 activation in the NAc. At a trait level, G carriers reported higher NEO-Neuroticism scores; a personality trait previously associated with increased pain and lower placebo responses, which were negatively correlated with baseline, mu-opioid receptor availability in the aINS and subgenual anterior cingulate cortex (sgACC). Our results demonstrate that the A118G OPRM1 polymorphism contributes to interindividual variations in the function of neurotransmitters responsive to pain (endogenous opioid and dopamine), as well as their regulation through cognitive-emotional influences in the context of therapeutic expectations, the so-called placebo effect. These effects are relevant to human vulnerability to disease processes where these neurotransmitters have a role, such as persistent pain, mood, and substance use disorders, and responses to their treatments.	[Pecina, Marta; Love, Tiffany; Zubieta, Jon-Kar] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Stohler, Christian S.] Columbia Univ, Coll Dent Med, New York, NY USA; [Goldman, David] NIAAA, Neurogenet Lab, Rockville, MD 20852 USA; [Zubieta, Jon-Kar] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI 48109 USA	Zubieta, JK (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu	Love, Tiffany/W-8427-2019; Pecina, Marta/W-7135-2019; Goldman, David/F-9772-2010; STOHLER, CHRISTIAN/AAQ-7539-2020	Love, Tiffany/0000-0001-9299-3190; Goldman, David/0000-0002-1724-5405; 	Phil F. Jenkins Foundation;  [R01 DA 022520];  [R01 DA 27494]	Work was supported by R01 DA 022520, R01 DA 27494 (JKZ), and the Phil F. Jenkins Foundation. The authors declare no conflict of interest.	Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; Benedetti F, 2013, PHYSIOL REV, V93, P1207, DOI 10.1152/physrev.00043.2012; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Canli T, 2004, J PERS, V72, P1105, DOI 10.1111/j.1467-6494.2004.00292.x; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; Costa P.T., 1992, REVISED NEO PERSONAL; COSTA PT, 1980, J PERS SOC PSYCHOL, V38, P668, DOI 10.1037/0022-3514.38.4.668; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Gear RW, 1999, J NEUROSCI, V19, P7175, DOI 10.1523/JNEUROSCI.19-16-07175.1999; Goubert L, 2004, PAIN, V107, P234, DOI 10.1016/j.pain.2003.11.005; Hall KT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048135; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; Hodgkinson CA, 2008, ALCOHOL ALCOHOLISM, V43, P505, DOI 10.1093/alcalc/agn032; Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1; Hsu DT, 2013, MOL PSYCHIATR, V18, P1211, DOI [10.1038/mp.2013.96, 10.1038/mp.2013.139]; JOHNSON SW, 1992, J NEUROSCI, V12, P483; Kelley JM, 2009, PSYCHOSOM MED, V71, P789, DOI 10.1097/PSY.0b013e3181acee12; Kroslak T, 2007, J NEUROCHEM, V103, P77, DOI 10.1111/j.1471-4159.2007.04738.x; Mague SD, 2010, DRUG ALCOHOL DEPEN, V108, P172, DOI 10.1016/j.drugalcdep.2009.12.016; Mague SD, 2009, P NATL ACAD SCI USA, V106, P10847, DOI 10.1073/pnas.0901800106; McNair DM, 1992, EDITS MANUAL PROFILE; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; Narendran R, 2008, SYNAPSE, V62, P851, DOI 10.1002/syn.20566; Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578; Norris CJ, 2007, PSYCHOPHYSIOLOGY, V44, P823, DOI 10.1111/j.1469-8986.2007.00551.x; Oertel BG, 2006, PHARMACOGENET GENOM, V16, P625, DOI 10.1097/01.fpc.0000220566.90466.a2; Oroszi G, 2004, PHARMACOGENOMICS, V5, P1037, DOI 10.1517/14622416.5.8.1037; PANKSEPP J, 1980, BEHAV NEURAL BIOL, V30, P197, DOI 10.1016/S0163-1047(80)91077-8; Pecina M, 2014, MOL PSYCHIATR, V19, P385, DOI 10.1038/mp.2013.124; Pecina M, 2013, MOL PSYCHIATR, V18, P135, DOI 10.1038/mp.2012.16; Pecina M, 2014, SOC COGN AFFECT NEUR, V9, P1013, DOI 10.1093/scan/nst079; Pecina M, 2013, NEUROPSYCHOPHARMACOL, V38, P639, DOI 10.1038/npp.2012.227; Prossin AR, 2010, AM J PSYCHIAT, V167, P925, DOI 10.1176/appi.ajp.2010.09091348; Pruessner JC, 2004, J NEUROSCI, V24, P2825, DOI 10.1523/JNEUROSCI.3422-03.2004; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Shoji Y, 1999, J NEUROSCI, V19, P2347; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Stohler CS, 1999, PAIN, V79, P165, DOI 10.1016/S0304-3959(98)00171-7; Tan EC, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-32; Taylor KS, 2010, PAIN, V151, P582, DOI 10.1016/j.pain.2010.06.032; Wang YJ, 2012, NEUROSCIENCE, V205, P178, DOI 10.1016/j.neuroscience.2011.12.033; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Way BM, 2009, P NATL ACAD SCI USA, V106, P15079, DOI 10.1073/pnas.0812612106; Weerts EM, 2013, INT J NEUROPSYCHOPH, V16, P47, DOI 10.1017/S146114571200017X; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0; Zald DH, 2004, J NEUROSCI, V24, P4105, DOI 10.1523/JNEUROSCI.4643-03.2004; ZHANG X, 1993, IEEE T BIO-MED ENG, V40, P344, DOI 10.1109/10.222327; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	57	63	67	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	MAR	2015	40	4					957	965		10.1038/npp.2014.272			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CB3DS	WOS:000349509000017	25308352	Green Published, Bronze			2020-06-30	J	Kim, NY; Kim, SY; Ju, HM; Kil, HK				Kim, Na Young; Kim, So Yeon; Ju, Hyang Mi; Kil, Hae Keum			Selective Spinal Anesthesia Using 1 mg of Bupivacaine with Opioid in Elderly Patients for Transurethral Resection of Prostate	YONSEI MEDICAL JOURNAL			English	Article						Transurethral resection of prostate; 1 mg bupivacaine; anesthesia; spinal; opioids; aged patients	INTRATHECAL FENTANYL; HYPERPLASIA; SUFENTANIL; TEMPERATURE; ANALGESIA; BLOCKADE; SPREAD; RISK	Purpose: This study was to evaluate the characteristics of selective spinal anesthesia using 1 mg of bupivacaine combined with fentanyl or sufentanil in elderly patients undergoing transurethral resection of prostate. Materials and Methods: Fifty-six patients were randomized into two groups. The Fentanyl group received 0.5% hyperbaric bupivacaine 0.2 mL+fentanyl 20 mu g+5% dextrose 1.4 mL, and the Sufentanil group received 0.5% hyperbaric bupivacaine 0.2 mL+sufentanil 5 mu g+5% dextrose 1.7 mL intrathecally. Intraoperative and postoperative characteristics were evaluated. Patient satisfaction was assessed postoperatively. Results: Twenty-six patients in each group completed the study. The median peak sensory block level was similar between two groups, but sensory regression time was longer in the Sufentanil group than the Fentanyl group (p=0.017). All patients were able to move themselves to the bed without any aid when they arrived at the admission room. Pain scores were lower in the Sufentanil group than the Fentanyl group at postoperative 6, 12, and 18 hours (p=0.001). Compared to the Fentanyl group, the Sufentanil group required less postoperative analgesia (p=0.023) and the time to the first analgesic request was longer (p=0.025). Twenty-four of 26 patients (92.3%) in each group showed "good" satisfaction level. Conclusion: Selective spinal anesthesia using 1 mg of bupivacaine with fentanyl or sufentanil provided appropriate sensory block level with spared motor function for transurethral resection of the prostate in elderly patients. Intrathecal sufentanil was superior to fentanyl in postoperative analgesic quality.	[Kim, Na Young; Kim, So Yeon; Ju, Hyang Mi; Kil, Hae Keum] Severance Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Kim, Na Young; Kim, So Yeon; Kil, Hae Keum] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea	Kil, HK (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med,Severance Hosp, 50-1 Yonsei Ro, Seoul 120752, South Korea.	hkkil@yuhs.ac		Kim, Na Young/0000-0003-3685-2005; Kim, So Yeon/0000-0001-5352-157X	Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, and Republic of Korea [A084120]	This study was partly supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, and Republic of Korea (A084120).	ARRIGHI HM, 1991, UROLOGY, V38, P4, DOI 10.1016/0090-4295(91)80191-9; BEERS RA, 1994, CAN J ANAESTH, V41, P807, DOI 10.1007/BF03011588; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; CARPENTER RL, 1992, ANESTHESIOLOGY, V76, P906, DOI 10.1097/00000542-199206000-00006; Carron M, 2007, ANESTH ANALG, V105, P1515, DOI 10.1213/01.ane.0000286079.45616.8c; CHAMBERLAIN DP, 1986, ANESTHESIOLOGY, V65, P139, DOI 10.1097/00000542-198608000-00002; Chung Bl, 2012, CAMPBELL WALSH UROLO, V1, P33; de Santiago J, 2009, ANESTH ANALG, V109, P1456, DOI 10.1213/ANE.0b013e3181ba792e; Fleisher LA, 1998, ANESTH ANALG, V87, P1271, DOI 10.1097/00000539-199812000-00012; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Hocking G, 2004, BRIT J ANAESTH, V93, P568, DOI 10.1093/bja/aeh204; Hong JY, 2011, J UROLOGY, V185, P1374, DOI 10.1016/j.juro.2010.11.086; Imarengiaye CO, 2003, ANESTHESIOLOGY, V98, P511, DOI 10.1097/00000542-200302000-00033; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; Kim SY, 2009, BRIT J ANAESTH, V103, P750, DOI 10.1093/bja/aep263; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Li MK, 2008, BJU INT, V101, P197, DOI 10.1111/j.1464-410X.2007.07320.x; Malhotra V, 2010, MILLERS ANESTHESIA, P2105; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; RACLE JP, 1988, BRIT J ANAESTH, V60, P508, DOI 10.1093/bja/60.5.508; Reich O, 2008, J UROLOGY, V180, P246, DOI 10.1016/j.juro.2008.03.058; Richardson MG, 1997, ANESTH ANALG, V84, P95, DOI 10.1097/00000539-199701000-00018; ROCCO AG, 1985, ANESTH ANALG, V64, P917; Standl TG, 2001, ANESTHESIOLOGY, V94, P230, DOI 10.1097/00000542-200102000-00011; STIENSTRA R, 1990, REGION ANESTH, V15, P6; Vaghadia H, 1998, CAN J ANAESTH, V45, pR64, DOI 10.1007/BF03019208; Vaghadia H, 2012, ACTA ANAESTH SCAND, V56, P217, DOI 10.1111/j.1399-6576.2011.02599.x; Wassef MR, 2007, ANESTH ANALG, V104, P1594, DOI 10.1213/01.ane.0000261510.37489.00; Zohar E, 2007, ANESTH ANALG, V104, P552, DOI 10.1213/01.ane.0000255329.55037.cd	31	2	3	0	1	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	MAR 1	2015	56	2					535	542		10.3349/ymj.2015.56.2.535			8	Medicine, General & Internal	General & Internal Medicine	CC0FP	WOS:000350011500031	25684006	DOAJ Gold, Green Published			2020-06-30	J	Kim, KS; Ita, K; Simon, L				Kim, Kwang Seok; Ita, Kevin; Simon, Laurent			Modelling of dissolving microneedles for transdermal drug delivery: Theoretical and experimental aspects	EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						Dissolving microneedle array; Elimination; Pitch; Single needle model; Parameter estimation	SKIN PERMEABILITY; STRATUM-CORNEUM; ARRAYS; PENETRATION; THICKNESS; PERMEATION; GEOMETRY; BEHAVIOR; SYSTEM; LAYERS	A mathematical model was developed to predict the amount of drug delivered into the skin via the dissolution of a microneedle (MN). This approach differs markedly from previous research which focused on similar phenomena but failed to include a biological membrane. Dimensionless governing equations were derived to help predict the needle height and fate of the active ingredient in the skin layer after application of the device. Simulation studies with fentanyl revealed that the drug concentration was proportional to its mass fraction in the MN. The effect of the pitch on skin permeation was mildly nonlinear. A larger amount of fentanyl was delivered from microneedle arrays with smaller pitch size. The dissolution process was independent of changes in the elimination rate constant. An optimization algorithm was applied to show how to recover this parameter from needle height - time data. (C) 2014 Elsevier B.V. All rights reserved.	[Kim, Kwang Seok; Simon, Laurent] New Jersey Inst Technol, Otto H York Dept Chem Biol & Pharmaceut Engn, Newark, NJ 07102 USA; [Ita, Kevin] Touro Univ, Coll Pharm, Vallejo, CA 94592 USA	Simon, L (reprint author), New Jersey Inst Technol, Otto H York Dept Chem Biol & Pharmaceut Engn, Newark, NJ 07102 USA.	ksbears@kgs.or.kr; kevin.ita@tu.edu; laurent.simon@njit.edu					Ai-Qallaf B, 2008, CHEM ENG SCI, V63, P2523, DOI 10.1016/j.ces.2008.02.007; Al-Qallaf B, 2009, INT J CHEM REACT ENG, V7; Al-Qallaf B, 2009, J DRUG TARGET, V17, P108, DOI [10.1080/10611860802472370, 10.1080/10611860802472370 ]; Al-Qallaf B, 2009, ANN NY ACAD SCI, V1161, P83, DOI 10.1111/j.1749-6632.2009.04083.x; Cheung Karmen, 2014, J Diabetes Sci Technol, V8, P444, DOI 10.1177/1932296813519720; Davidson A, 2008, CHEM ENG RES DES, V86, P1196, DOI 10.1016/j.cherd.2008.06.002; Dias M, 2007, INT J PHARM, V340, P65, DOI 10.1016/j.ijpharm.2007.03.030; Dokoumetzidis A, 2006, INT J PHARMACEUT, V321, P1, DOI 10.1016/j.ijpharm.2006.07.011; Frum Y, 2007, EUR J PHARM SCI, V30, P280, DOI 10.1016/j.ejps.2006.11.014; Garland MJ, 2012, J CONTROL RELEASE, V159, P52, DOI 10.1016/j.jconrel.2012.01.003; HOLBROOK KA, 1974, J INVEST DERMATOL, V62, P415, DOI 10.1111/1523-1747.ep12701670; Hood RL, 2011, J MED DEVICES, V5, DOI 10.1115/1.4004833; Ito Y, 2006, EUR J PHARM SCI, V29, P82, DOI 10.1016/j.ejps.2006.05.011; Kanr M, 2014, EUR J PHARM BIOPHARM, V86, P284, DOI 10.1016/j.ejpb.2013.10.007; Kim KS, 2011, MATH BIOSCI, V229, P93, DOI 10.1016/j.mbs.2010.11.002; Kim M, 2012, BIOMATERIALS, V33, P668, DOI 10.1016/j.biomaterials.2011.09.074; Kimura C, 2007, EUR J PHARM BIOPHARM, V67, P420, DOI 10.1016/j.ejpb.2007.02.022; Kiptoo PK, 2006, J CONTROL RELEASE, V113, P137, DOI 10.1016/j.jconrel.2006.04.003; Lee JW, 2008, BIOMATERIALS, V29, P2113, DOI 10.1016/j.biomaterials.2007.12.048; Maurya A, 2014, J PHARM SCI-US, V103, P1497, DOI 10.1002/jps.23938; Miyano T, 2005, BIOMED MICRODEVICES, V7, P185, DOI 10.1007/s10544-005-3024-7; Nayak A, 2013, BIOTECHNOL LETT, V35, P1351, DOI 10.1007/s10529-013-1217-3; Olatunji O, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.40377; Olatunji O, 2013, J PHARM SCI-US, V102, P1209, DOI 10.1002/jps.23439; Olatunji O, 2012, J PHARM SCI-US, V101, P164, DOI 10.1002/jps.22736; Park JH, 2008, INT J PHARMACEUT, V359, P94, DOI 10.1016/j.ijpharm.2008.03.032; Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304; Raphael AP, 2013, J CONTROL RELEASE, V166, P87, DOI 10.1016/j.jconrel.2012.12.010; Russell LM, 2008, EUR J PHARM BIOPHARM, V69, P861, DOI 10.1016/j.ejpb.2008.02.002; Shang L, 2014, AAPS PHARMSCITECH, V15, P803, DOI 10.1208/s12249-014-0105-z; Simon L, 2007, MATH BIOSCI, V209, P593, DOI 10.1016/j.mbs.2007.03.009; Simon L, 2006, J MEMBRANE SCI, V278, P124, DOI 10.1016/j.memsci.2005.10.049; Vasquez PA, 2005, 2005 INTERNATIONAL CONFERENCE ON MEMS, NANO AND SMART SYSTEMS, PROCEEDINGS, P383, DOI 10.1109/ICMENS.2005.20; Verbaan FJ, 2008, J CONTROL RELEASE, V128, P80, DOI 10.1016/j.jconrel.2008.02.009; Windisch A., 2013, PHYS EDUC, V48, P221	35	15	16	1	38	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0928-0987	1879-0720		EUR J PHARM SCI	Eur. J. Pharm. Sci.	FEB 20	2015	68						137	143		10.1016/j.ejps.2014.12.008			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CA9VD	WOS:000349272000016	25513710				2020-06-30	J	Silva, RA; Leng, JC; He, LS; Brock-Utne, JG; Drover, DR; Leng, T				Silva, Ruwan A.; Leng, Jody C.; He, Lisa; Brock-Utne, John G.; Drover, David R.; Leng, Theodore			Risk Factors for Respiratory Depression in Patients Undergoing Retrobulbar Block for Vitreoretinal Surgery	Ophthalmic Surgery Lasers & Imaging Retina			English	Article							CATARACT-SURGERY; INTRAOCULAR SURGERY; ALFENTANIL; ANESTHESIA; SEDATION; PROPOFOL; PAIN; PLACEMENT; MIDAZOLAM; FENTANYL	BACKGROUND AND OBJECTIVE: To determine the risk factors for respiratory depression during retrobulbar block administration before vitreoretinal surgery. PATIENTS AND METHODS: Prospective, observational case series of 113 patients undergoing monitored anesthesia care and retrobulbar block before vitreoretinal surgery at a tertiary medical center. RESULTS: Chin lift, jaw thrust, and bag mask ventilation were performed in eight (7.1%), nine (8%), and six (5.3%) patients, respectively. No patients required intubation. Age, sex, body mass index, history of obstructive sleep apnea, American Society of Anesthesiologists physical status level, and baseline oxygen saturation were not predictive of airway intervention. Of the four anesthetic agents utilized (midazolam, fentanyl, alfentanil, and propofol), only propofol and fentanyl were associated with an increased risk for clinically significant apnea. Use of three medications for sedation was associated with a 5.4-fold increase in the relative risk of requiring a respiratory rescue intervention. CONCLUSION: During preoperative sedation for retrobulbar block administration, the use of propofol, fentanyl, or a combination of three anesthetics is associated with a statistically significant increase in the risk for respiratory depression requiring resuscitation.	[Silva, Ruwan A.; He, Lisa; Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94303 USA; [Leng, Jody C.; Brock-Utne, John G.; Drover, David R.] Stanford Univ, Dept Anesthesiol, Sch Med, Stanford, CA 94305 USA	Leng, T (reprint author), Stanford Univ, Sch Med, Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.	tedleng@stanford.edu	Leng, Theodore/AAQ-7459-2020	Leng, Theodore/0000-0002-8461-3562			[Anonymous], 2012, FENT PACK INS; [Anonymous], 2008, ALF PACK INS; Boezaart AP, 1998, J CLIN ANESTH, V10, P204, DOI 10.1016/S0952-8180(98)00008-7; deCordoba JL, 1996, REGION ANESTH, V21, P171; Drug Enforcement Administration, PROP EV SECT; Fang ZT, 2006, J CLIN ANESTH, V18, P114, DOI 10.1016/j.jclinane.2005.08.007; Ferrari L R, 1992, J Clin Anesth, V4, P93, DOI 10.1016/0952-8180(92)90021-R; HAMILTON RC, 1985, ANESTHESIOLOGY, V63, P688, DOI 10.1097/00000542-198512000-00022; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; Huang J J, 2001, AANA J, V69, P111; Inan UU, 2003, J CATARACT REFR SURG, V29, P1137, DOI 10.1016/S0886-3350(02)02053-9; Kiefer RT, 1998, EUR J OPHTHALMOL, V8, P239; KOAY P, 1992, BRIT J OPHTHALMOL, V76, P225, DOI 10.1136/bjo.76.4.225; Lim TH, 2008, OPHTHAL SURG LAS IM, V39, P191, DOI 10.3928/15428877-20080501-09; Maghsoudi Behzad, 2007, Middle East Journal of Anesthesiology, V19, P595; McHardy FE, 2000, CAN J ANAESTH, V47, P211, DOI 10.1007/BF03018914; Roy FH, 2006, ANN OPHTHALMOL, V38, P99, DOI 10.1385/AO:38:2:99; SALMON JF, 1992, BRIT J OPHTHALMOL, V76, P598, DOI 10.1136/bjo.76.10.598; WANG BC, 1989, ANESTHESIOLOGY, V71, P845, DOI 10.1097/00000542-198912000-00006; YEE JB, 1994, ANESTH ANALG, V79, P320; Yee JB, 1996, J CLIN ANESTH, V8, P623, DOI 10.1016/S0952-8180(96)00137-7	21	3	4	0	0	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	2325-8160	2325-8179		OSLI RETINA	Ophthalmic Surg. Lasers Imag. Retin.	FEB	2015	46	2					243	247		10.3928/23258160-20150213-22			5	Ophthalmology; Surgery	Ophthalmology; Surgery	CG5TZ	WOS:000353360100013	25707051				2020-06-30	J	Shimoyama, N; Gomyo, I; Katakami, N; Okada, M; Yukitoshi, N; Ohta, E; Shimoyama, M				Shimoyama, Naohito; Gomyo, Ikuo; Katakami, Nobuyuki; Okada, Masakuni; Yukitoshi, Nobuyuki; Ohta, Eri; Shimoyama, Megumi			Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial	INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY			English	Article						Breakthrough pain; Cancer pain; Sublingual fentanyl tablet; Opioid; Dose titration	CITRATE; MANAGEMENT; PHARMACOKINETICS	Background Breakthrough cancer pain typically has a rapid onset and relatively short duration. Due to this temporal profile, it may not be adequately relieved by oral opioid analgesics. The sublingual fentanyl orally disintegrating tablet is a formulation by which fentanyl can be rapidly absorbed across the oral mucosa producing rapid-onset analgesia, and which may be effective for breakthrough pain treatment. Methods A multicenter, randomized, placebo-controlled, double-blind comparative study was conducted to evaluate the efficacy and safety of the sublingual fentanyl tablet at optimized doses for breakthrough pain treatment in cancer patients treated with strong opioid analgesics at fixed intervals. The optimal dose was determined by open-label dose titration. The efficacy and safety of a 12-week extended treatment were also evaluated. Results Eleven of 42 subjects who received the sublingual fentanyl tablet experienced adverse drug reactions. Common reactions were somnolence, constipation, nausea, and vomiting. No serious adverse reactions occurred. Sublingual fentanyl tablets at optimal doses and placebo were administered to 37 subjects in a double-blinded manner. A significant analgesic effect of the sublingual fentanyl tablet was present compared to placebo at 30 min after administration. The sublingual fentanyl tablet was also effective and safe during extended treatment, in which changes in basal opioid doses as well as sublingual fentanyl tablet doses were made as needed. Conclusion Sublingual fentanyl tablets at doses determined by titration were effective and safe for breakthrough pain treatment in cancer patients treated with strong opioid analgesics at fixed intervals. Extended treatment up to 12 weeks was also effective and safe.	[Shimoyama, Naohito] Jikei Univ, Sch Med, Dept Palliat Med, Minato Ku, Tokyo 1058461, Japan; [Gomyo, Ikuo] Saito Yukoukai Hosp, Dept Palliat Med, Osaka 5670085, Japan; [Katakami, Nobuyuki] Inst Biomed Res & Innovat Hosp, Fdn Biomed Res & Innovat, Div Integrated Oncol, Chuo Ku, Kobe, Hyogo 6500047, Japan; [Okada, Masakuni] Shakaihoken Kobe Cent Hosp, Dept Internal Med, Kita Ku, Kobe, Hyogo 6511145, Japan; [Yukitoshi, Nobuyuki] Kyowa Hakko Kirin Co Ltd, Clin Dev Dept 2, Dev Div, Chiyoda Ku, Tokyo 1008185, Japan; [Ohta, Eri] Kyowa Hakko Kirin Co Ltd, Clin Data Evaluat Dept, Dev Div, Chiyoda Ku, Tokyo 1008185, Japan; [Shimoyama, Megumi] Teikyo Univ, Chiba Med Ctr, Dept Anesthesiol, Ichihara, Chiba 2990111, Japan	Shimoyama, N (reprint author), Jikei Univ, Sch Med, Dept Palliat Med, Minato Ku, 3-25-8 Nishi Shimbashi, Tokyo 1058461, Japan.	nshimoya@jikei.ac.jp			Kyowa Hakko Kirin, Co., Ltd.Kyowa Kirin Ltd	The sponsor of this clinical trial was Kyowa Hakko Kirin, Co., Ltd.	BENNETT D, 2005, [No title captured], V30, P354; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; CHERNY NI, 1993, CANCER-AM CANCER SOC, V72, P3393, DOI 10.1002/1097-0142(19931201)72:11+<3393::AID-CNCR2820721606>3.0.CO;2-O; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; England Ruth, 2011, BMJ Support Palliat Care, V1, P349, DOI 10.1136/bmjspcare-2011-000037; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Potenoy RK, 1990, PAIN, V41, P273; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Simmonds MA, 1999, ONCOLOGY-NY, V13, P1103; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; Todd KH, 1996, ACAD EMERG MED, V3, P142, DOI 10.1111/j.1553-2712.1996.tb03402.x; Yamaguchi T, 2013, JPN J CLIN ONCOL, V43, P896, DOI 10.1093/jjco/hyt099	13	4	4	1	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1341-9625	1437-7772		INT J CLIN ONCOL	Int. J. Clin. Oncol.	FEB	2015	20	1					198	206		10.1007/s10147-014-0697-z			9	Oncology	Oncology	CE8OY	WOS:000352104100029	24839047				2020-06-30	J	Barter, LS; Hawkins, MG; Pypendop, BH				Barter, Linda S.; Hawkins, Michelle G.; Pypendop, Bruno H.			Effects of fentanyl on isoflurane minimum alveolar concentration in New Zealand White rabbits (Oryctolagus cuniculus)	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							STIMULATION; HORSES; CATS	OBJECTIVE To determine effects of increasing plasma fentanyl concentrations on the minimum alveolar concentration (MAC) of isoflurane in rabbits. ANIMALS 6 adult female New Zealand White rabbits (Oryctolagus cuniculus). PROCEDURES Rabbits were anesthetized with isoflurane in oxygen; ventilation was controlled and body temperature maintained between 38.5 degrees and 39.5 degrees C. Fentanyl was administered IV by use of a computer-controlled infusion system to achieve 6 target plasma concentrations. Isoflurane MAC was determined in duplicate by use of the bracketing technique with a supramaximal electrical stimulus. Blood samples were collected for measurement of plasma fentanyl concentration at each MAC determination. The MAC values were analyzed with a repeated-measures ANOVA followed by Holm-Sidak pairwise comparisons. RESULTS Mean +/- SD plasma fentanyl concentrations were 0 +/- 0 ng/mL (baseline), 1.2 +/- 0.1 ng/mL, 2.2 +/- 0.3 ng/mL, 4.4 +/- 0.4 ng/mL, 9.2 +/- 0.4 ng/mL, 17.5 +/- 2.6 ng/mL, and 36.8 +/- 2.4 ng/mL. Corresponding mean values for isoflurane MAC were 1.92 +/- 0.16%, 1.80 +/- 0.16%, 1.60 +/- 0.23%, 1.46 +/- 0.22%, 1.12 +/- 0.19%, 0.89 +/- 0.14%, and 0.70 +/- 0.15%, respectively. Isoflurane MAC for plasma fentanyl concentrations >= 2.2 ng/mL differed significantly from the baseline value. In 3 rabbits, excessive spontaneous movement prevented MAC determination at the highest plasma fentanyl concentration. CONCLUSIONS AND CLINICAL RELEVANCE Fentanyl reduced isoflurane MAC by approximately 60% in New Zealand White rabbits. Further studies will be needed to investigate the cardiorespiratory effects of isoflurane and fentanyl combinations in rabbits; however, fentanyl may prove to be a useful adjunct to inhalation anesthesia in this species.	[Barter, Linda S.; Pypendop, Bruno H.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA; [Hawkins, Michelle G.] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA	Barter, LS (reprint author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.	lsbarter@ucdavis.edu		Pypendop, Bruno/0000-0002-0894-0991	Center for Companion Animal Health, School of Veterinary Medicine, University of California-DavisUniversity of California System	Supported by the Center for Companion Animal Health, School of Veterinary Medicine, University of California-Davis.	Barter LS, 2014, VET ANAESTH ANALG, V41, P393, DOI 10.1111/vaa.12131; Barter LS, 2013, AM J VET RES, V74, P1274, DOI 10.2460/ajvr.74.10.1274; BORKOWSKI GL, 1990, LAB ANIM SCI, V40, P270; Brodbelt DC, 2008, VET ANAESTH ANALG, V35, P365, DOI 10.1111/j.1467-2995.2008.00397.x; Criado AB, 2003, VET ANAESTH ANALG, V30, P250, DOI 10.1046/j.1467-2995.2003.00123.x; Dzikiti TB, 2011, VET REC, V168, DOI 10.1136/vr.d999; FLECKNELL PA, 1989, LAB ANIM, V23, P147, DOI 10.1258/002367789780863655; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; Ilkiw JE, 1997, AM J VET RES, V58, P1274; Imai A, 1999, AM J VET RES, V60, P1189; Knych HKD, 2009, AM J VET RES, V70, P1193, DOI 10.2460/ajvr.70.10.1193; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; LASTER MJ, 1993, ANESTH ANALG, V76, P1310, DOI 10.1213/00000539-199376060-00021; MARINI RP, 1993, LAB ANIM SCI, V43, P338; Pascoe PJ, 1997, AM J VET RES, V58, P1267; Schnellbacher RW, 2013, AM J VET RES, V74, P1377, DOI 10.2460/ajvr.74.11.1377; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; Turner PV, 2006, AM J VET RES, V67, P770, DOI 10.2460/ajvr.67.5.770	18	4	4	0	10	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	FEB	2015	76	2					111	115		10.2460/ajvr.76.2.111			5	Veterinary Sciences	Veterinary Sciences	CE6CJ	WOS:000351923200001	25629907				2020-06-30	J	Ren, J; Ding, XQ; Greer, JJ				Ren, Jun; Ding, Xiuqing; Greer, John J.			5-HT1A Receptor Agonist Befiradol Reduces Fentanyl-induced Respiratory Depression, Analgesia, and Sedation in Rats	ANESTHESIOLOGY			English	Article							INDUCED VENTILATORY DEPRESSION; STEM-SPINAL CORD; 5-HYDROXYTRYPTAMINE (HT)1A RECEPTORS; TAIL-FLICK RESPONSE; IN-VITRO; AMPAKINE CX717; SELECTIVE 5-HT1A-R-AGONIST; INDUCED ANTINOCICEPTION; NEONATAL-RATS; BRAIN	Background: There is an unmet clinical need to develop a pharmacological therapy to counter opioid-induced respiratory depression without interfering with analgesia or behavior. Several studies have demonstrated that 5-HT1A receptor agonists alleviate opioid-induced respiratory depression in rodent models. However, there are conflicting reports regarding their effects on analgesia due in part to varied agonist receptor selectivity and presence of anesthesia. Therefore the authors performed a study in rats with befiradol (F13640 and NLX-112), a highly selective 5-HT1A receptor agonist without anesthesia. Methods: Respiratory neural discharge was measured using in vitro preparations. Plethysmographic recording, nociception testing, and righting reflex were used to examine respiratory ventilation, analgesia, and sedation, respectively. Results: Befiradol (0.2 mg/kg, n = 6) reduced fentanyl-induced respiratory depression (53.7 +/- 5.7% of control minute ventilation 4 min after befiradol vs. saline 18.7 +/- 2.2% of control, n = 9; P < 0.001), duration of analgesia (90.4 +/- 11.6 min vs. saline 130.5 +/- 7.8 min; P = 0.011), duration of sedation (39.8 +/- 4 min vs. saline 58 +/- 4.4 min; P = 0.013); and induced baseline hyperventilation, hyperalgesia, and "behavioral syndrome" in nonsedated rats. Further, the befiradol-induced alleviation of opioid-induced respiratory depression involves sites or mechanisms not functioning in vitro brainstem-spinal cord and medullary slice preparations. Conclusions: The reversal of opioid-induced respiratory depression and sedation by befiradol in adult rats was robust, whereas involved mechanisms are unclear. However, there were adverse concomitant decreases in fentanyl-induced analgesia and altered baseline ventilation, nociception, and behavior.	[Ren, Jun; Ding, Xiuqing; Greer, John J.] Univ Alberta, Dept Physiol, Neurosci & Mental Hlth Inst, Edmonton, AB T6G 2S2, Canada; [Greer, John J.] Alberta Innovates Hlth Sci Fdn, Edmonton, AB, Canada	Greer, JJ (reprint author), Univ Alberta, Dept Physiol, Neurosci & Mental Hlth Inst, 4-142 Katz Bldg, Edmonton, AB T6G 2S2, Canada.	john.greer@ualberta.ca			Canadian Institutes of Health (Edmonton, Alberta, Canada)	Supported by the Canadian Institutes of Health (Edmonton, Alberta, Canada).	ALHAIDER AA, 1993, J PHARMACOL EXP THER, V265, P378; Bardin L, 2005, J PHARMACOL EXP THER, V312, P1034, DOI 10.1124/jpet.104.077669; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; BERGE OG, 1985, NEUROSCI LETT, V54, P71, DOI 10.1016/S0304-3940(85)80120-8; BROCKHAUS J, 1993, J PHYSIOL-LONDON, V462, P421, DOI 10.1113/jphysiol.1993.sp019562; Buritova J, 2009, NEUROPHARMACOLOGY, V56, P350, DOI 10.1016/j.neuropharm.2008.09.004; Colpaert FC, 2002, NEUROPHARMACOLOGY, V43, P945, DOI 10.1016/S0028-3908(02)00119-3; Colpaert FC, 2006, CURR OPIN INVEST DR, V7, P40; Corcoran AE, 2014, J NEUROSCI, V34, P51, DOI 10.1523/JNEUROSCI.0864-13.2014; DEAKIN JFW, 1978, BRIT J PHARMACOL, V64, P201, DOI 10.1111/j.1476-5381.1978.tb17290.x; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497; FUNK GD, 1995, J NEUROSCI, V15, P4046; Funk GD, 2013, RESP PHYSIOL NEUROBI, V186, P236, DOI 10.1016/j.resp.2013.01.011; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; GREER JJ, 1992, J NEUROPHYSIOL, V67, P996; Guenther U, 2010, ANESTH ANALG, V111, P901, DOI 10.1213/ANE.0b013e3181eac011; Guenther U, 2012, ANESTHESIOLOGY, V116, P56, DOI 10.1097/ALN.0b013e31823d08fa; Guenther U, 2009, ANESTH ANALG, V108, P1169, DOI 10.1213/ane.0b013e318198f828; Hodges MR, 2010, J APPL PHYSIOL, V108, P1425; Jarzyna D, 2011, PAIN MANAG NURS, V12, P118, DOI 10.1016/j.pmn.2011.06.008; Johnson SM, 2012, RESP PHYSIOL NEUROBI, V180, P1, DOI 10.1016/j.resp.2011.10.002; Kimura S, 2013, EUR J PHARMACOL, V703, P33, DOI 10.1016/j.ejphar.2013.02.009; Kiss I, 2005, EUR J PHARMACOL, V523, P29, DOI 10.1016/j.ejphar.2005.09.003; LALLEY PM, 1994, J PHYSIOL-LONDON, V476, P117; Levitt ES, 2013, J APPL PHYSIOL, V115, P1626, DOI 10.1152/japplphysiol.00889.2013; Llado-Pelfort L, 2010, BRIT J PHARMACOL, V160, P1929, DOI 10.1111/j.1476-5381.2010.00738.x; Llado-Pelfort L, 2012, PSYCHOPHARMACOLOGY, V221, P261, DOI 10.1007/s00213-011-2569-9; Lotsch J, 2005, CLIN PHARMACOL THER, V78, P278, DOI 10.1016/j.clpt.2005.05.010; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Manzke T, 2010, J CLIN INVEST, V120, P4118, DOI 10.1172/JCI43029; MILLAN MJ, 1990, NEUROPHARMACOLOGY, V29, P315, DOI 10.1016/0028-3908(90)90020-R; MILLAN MJ, 1989, NEUROSCI LETT, V107, P227, DOI 10.1016/0304-3940(89)90822-7; MILLAN MJ, 1991, J PHARMACOL EXP THER, V256, P983; MILLAN MJ, 1991, J PHARMACOL EXP THER, V256, P993; Montandon G, 2011, J NEUROSCI, V31, P1292, DOI 10.1523/JNEUROSCI.4611-10.2011; MONTI JM, 1992, J SLEEP RES, V1, P169, DOI 10.1111/j.1365-2869.1992.tb00033.x; Newman-Tancredi A, 2009, BRIT J PHARMACOL, V156, P338, DOI 10.1111/j.1476-5381.2008.00001.x; Oertel BG, 2007, CLIN PHARMACOL THER, V81, P59, DOI 10.1038/sj.clpt.6100018; Oertel BG, 2010, CLIN PHARMACOL THER, V87, P204, DOI 10.1038/clpt.2009.194; Onimaru H, 1998, PFLUG ARCH EUR J PHY, V435, P485, DOI 10.1007/s004240050543; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Powell KR, 1996, PSYCHOPHARMACOLOGY, V126, P42, DOI 10.1007/BF02246409; Ren J, 2006, J NEUROSCI, V26, P3721, DOI 10.1523/JNEUROSCI.0026-06.2006; Ren J, 2006, AM J RESP CRIT CARE, V174, P1384, DOI 10.1164/rccm.200606-778OC; Ren J, 2013, ANESTHESIOLOGY, V118, P1437, DOI 10.1097/ALN.0b013e318291079c; Ren J, 2012, J APPL PHYSIOL, V113, P1004, DOI 10.1152/japplphysiol.00752.2012; Ren J, 2009, ANESTHESIOLOGY, V110, P1364, DOI 10.1097/ALN.0b013e31819faa2a; Richter DW, 2003, TRENDS MOL MED, V9, P542, DOI 10.1016/j.molmed.2003.10.010; Sahibzada N, 2000, J PHARMACOL EXP THER, V292, P704; Schwarzacher SW, 2002, NEUROSCIENCE, V115, P1247, DOI 10.1016/S0306-4522(02)00540-7; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149; St-John WM, 2009, J APPL PHYSIOL, V107, P679, DOI 10.1152/japplphysiol.91461.2008; Talley EM, 1997, J NEUROSCI, V17, P4473; Thompson CA, 2007, AM J HEALTH-SYST PH, V64, P798, DOI 10.2146/news070035; Toppin VAL, 2007, J APPL PHYSIOL, V103, P220, DOI 10.1152/japplphysiol.00071.2007; TRICKLEBANK MD, 1984, EUR J PHARMACOL, V106, P271, DOI 10.1016/0014-2999(84)90714-3	57	16	18	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	FEB	2015	122	2					424	434		10.1097/ALN.0000000000000490			11	Anesthesiology	Anesthesiology	CE3NZ	WOS:000351734900022	25313880				2020-06-30	J	Agrafiotis, M; Tryfon, S; Siopi, D; Chassapidou, G; Galanou, A; Tsara, V				Agrafiotis, Michalis; Tryfon, Stavros; Siopi, Demetra; Chassapidou, Georgia; Galanou, Artemis; Tsara, Venetia			Successful management of drug-induced hypercapnic acidosis with naloxone and noninvasive positive pressure ventilation	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							CHRONIC PAIN; OVERDOSE	A 74-year-old man was referred to our hospital due to deteriorating level of consciousness and desaturation. His Glasgow Coma Scale was 6, and his pupils were constricted but responded to light. Chest radiograph was negative for significant findings. Arterial blood gas evaluation on supplemental oxygen revealed severe acute on chronic respiratory acidosis: pH 7.15; PCO2, 133 mm Hg; PO2, 64 mm Hg; and HCO3, 31 mmol/L. He regained full consciousness (Glasgow Coma Scale, 15) after receiving a 0.4 mg dose of naloxone, but because of persistent severe respiratory acidosis (pH 7.21; PCO2, 105 mm Hg), he was immediately commenced on noninvasive positive pressure ventilation (NIV) displaying a remarkable improvement in arterial blood gas values within the next few hours. However, in the days that followed, he remained dependent on NIV, and he was finally discharged on a home mechanical ventilation prescription. In cases of drug- induced respiratory depression, NIV should be regarded as an acceptable treatment, as it can provide ventilatory support without the increased risks associated with invasive mechanical ventilation.	[Agrafiotis, Michalis; Tryfon, Stavros; Siopi, Demetra; Chassapidou, Georgia; Galanou, Artemis; Tsara, Venetia] Georgios Papanikolaou Gen Hosp Thessaloniki, Dept Pulm Med, Thessaloniki 57010, Greece	Agrafiotis, M (reprint author), Georgios Papanikolaou Gen Hosp Thessaloniki, Dept Pulm Med, G Papanikolaou Ave, Thessaloniki 57010, Greece.	m.agrafiotis@gmail.com	Tryfon, Stavros/R-8331-2019	Tryfon, Stavros/0000-0001-5102-0480			Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Dahan A, 2013, PAIN PHYSICIAN, V16, pE85; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Girou E, 2000, JAMA-J AM MED ASSOC, V284, P2361, DOI 10.1001/jama.284.18.2361; Gonzva J, 2013, AM J EMERG MED, V31; Lyttle MD, 2012, PEDIATR EMERG CARE, V28, P463, DOI 10.1097/PEC.0b013e31825358b4; Pinheiro MB, 2014, EUR J PHYS REHAB MED, V50, P301; Ridgway ZA, 2007, EMERG MED J, V24, P681, DOI 10.1136/emj.2007.048991; Spiller HA, 1997, J TOXICOL-CLIN TOXIC, V35, P361, DOI 10.3109/15563659709043367	9	0	0	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	FEB	2015	33	2							312.e3	10.1016/j.ajem.2014.08.006			2	Emergency Medicine	Emergency Medicine	CC6AW	WOS:000350447900055	25176564				2020-06-30	J	Shimoyama, N; Gomyo, I; Teramoto, O; Kojima, K; Higuchi, H; Yukitoshi, N; Ohta, E; Shimoyama, M				Shimoyama, Naohito; Gomyo, Ikuo; Teramoto, Osamu; Kojima, Keisuke; Higuchi, Hitomi; Yukitoshi, Nobuyuki; Ohta, Eri; Shimoyama, Megumi			Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						breakthrough pain; cancer pain; sublingual fentanyl tablet; opioid; conversion ratio	TRANSMUCOSAL FENTANYL; CITRATE; PHARMACOKINETICS; MANAGEMENT; TOLERABILITY; TITRATION; REGIMEN	Objective: A randomized, crossover, double-blinded placebo-controlled and non-blinded active drug-controlled, comparative clinical trial was conducted to evaluate the efficacy and safety of sublingual fentanyl tablet. Methods: Subjects were patients treated with strong opioids at fixed intervals for chronic cancer pain and with oral morphine as rescue medication for breakthrough pain. Sublingual fentanyl was administered at doses that were 1/25th (high dose) and 1/50th (low dose) of the dose of rescue morphine and was compared with placebo and oral morphine. The primary endpoint was pain intensity difference at 30 min after administration. (Clinical Trials Government; NCT00684632). Results: Fifty-one patients were enrolled in the investigation. Their mean pain intensity in visual analog scale before rescue medication prior to the investigation was 60.96 (16.44, standard deviation) mm. Compared with placebo, the low and high doses of sublingual fentanyl showed significant analgesic effects (least squares mean difference, 4.54 and 8.49 mm; P = 0.014, P < 0.001, respectively). Adverse reactions were observed in 17.6%, the most common being constipation, nausea and somnolence. The incidence of adverse reactions during the high-dose administration period was higher than that during the low-dose and active control drug administration periods. Conclusions: Patients treated with strong opioid analgesics at fixed intervals for chronic cancer pain and with oral morphine at doses up to 20 mg as rescue medication were investigated. The doses of sublingual fentanyl to treat breakthrough pain were determined from rescue morphine doses by use of conversion ratios. In these patients, administration of sublingual fentanyl at doses determined by a conversion ratio of 1/50 was effective and safe. Further studies are needed to validate the use of this conversion method.	[Shimoyama, Naohito] Jikei Univ, Grad Sch Med, Dept Palliat Med, Tokyo 1058461, Japan; [Gomyo, Ikuo] Saito Yukoukai Hosp, Dept Palliat Med, Ibaraki, Japan; [Teramoto, Osamu] Omigawa Gen Hosp, Dept Surg, Katori, Japan; [Kojima, Keisuke] Kumamoto Univ Hosp, Dept Resp Med, Kumamoto, Japan; [Higuchi, Hitomi] Showa Univ Hosp, Dept Palliat Med, Tokyo, Japan; [Yukitoshi, Nobuyuki] Kyowa Hakko Kirin Co Ltd, Dev Div, Clin Dev Dept 2, Tokyo, Japan; [Ohta, Eri] Kyowa Hakko Kirin Co Ltd, Dev Div, Clin Data Evaluat Dept, Tokyo, Japan; [Shimoyama, Megumi] Teikyo Univ, Chiba Med Ctr, Dept Anesthesiol, Ichihara, Chiba, Japan	Shimoyama, N (reprint author), Jikei Univ, Grad Sch Med, Minato Ku, 3-25-8 Nishi Shimbashi, Tokyo 1058461, Japan.	nshimoya@jikei.ac.jp			Kyowa Hakko Kirin Co., Ltd.Kyowa Kirin Ltd	This Phase III trial was sponsored by Kyowa Hakko Kirin Co., Ltd. and was conducted under the supervision of the Pharmaceuticals and Medical Devices Agency (PMDA, Japan).	Abstral SPC, 2013, DAT OF REV; Actiq SPC, 2012, DAT OF REV; BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; CHERNY NI, 1993, CANCER-AM CANCER SOC, V72, P3393, DOI 10.1002/1097-0142(19931201)72:11+<3393::AID-CNCR2820721606>3.0.CO;2-O; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; England Ruth, 2011, BMJ Support Palliat Care, V1, P349, DOI 10.1136/bmjspcare-2011-000037; Hans GH, 2013, CURR MED RES OPIN, V29, P1523, DOI 10.1185/03007995.2013.837816; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lister N, 2011, J CLIN PHARMACOL, V51, P1195, DOI 10.1177/0091270010379410; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2013, CURR MED RES OPIN, V29, P1527, DOI 10.1185/03007995.2013.826640; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Potenoy RK, 1990, PAIN, V41, P273; Simmonds MA, 1999, ONCOLOGY-NY, V13, P1103; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; Yamaguchi T, 2013, JPN J CLIN ONCOL, V43, P896, DOI 10.1093/jjco/hyt099	19	8	8	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	FEB	2015	45	2					189	196		10.1093/jjco/hyu182			8	Oncology	Oncology	CC3DJ	WOS:000350224800008	25378647	Bronze			2020-06-30	J	Sviggum, HP; Yacoubian, S; Liu, X; Tsen, LC				Sviggum, H. P.; Yacoubian, S.; Liu, X.; Tsen, L. C.			The effect of bupivacaine with fentanyl temperature on initiation and maintenance of labor epidural analgesia: a randomized controlled study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Epidural; Labor analgesia; Bupivacaine; Fentanyl; Temperature; Obstetric	MATERNAL TEMPERATURE; EXTRADURAL ANALGESIA; SPINAL-ANESTHESIA; FEVER; 0.5-PERCENT; INJECTION; DELIVERY; SPEED; BLOCK; WARM	Background: Labor epidural analgesia is highly effective, but can be limited by slow onset and incomplete blockade. The administration of warmed, compared to room temperature, bupivacaine has resulted in more rapid onset epidural anesthesia. We hypothesized that the administration of bupivacaine with fentanyl at 37 degrees C versus 20 degrees C would result in improved initial and ongoing labor epidural analgesia. Methods: In this prospective, randomized, doubled blinded study, 54 nulliparous, laboring women were randomized to receive epidural bupivacaine 0.125% with fentanyl 2 mu g/mL (20 mL initial and 6 mL hourly boluses) at either 37 degrees C or 20 degrees C. Pain verbal rating scores (VRS), sensory level, oral temperature, and side effects were assessed after epidural loading (time 0), at 5, 10, 15, 20, 30, 60 min, and at hourly intervals. The primary outcome was the time to achieve initial satisfactory analgesia (VRS <= 3) Secondary outcomes included ongoing quality of sensory blockade, body temperature and shivering. Results: There were no differences between groups in patient demographics, initial pain scores, cervical dilatation, body temperature or mode of delivery. Epidural bupivacaine at 37 degrees C resulted in shorter mean (+/- SD) analgesic onset time (9.2 +/- 4.7 vs. 16.0 +/- 10.5 min, P = 0.005) and improved analgesia for the first 15 min after initial bolus (P = 0.001-0.03). Although patient temperature increased during the study (P < 0.01), there were no differences between the groups (P = 0.09). Six (24%) and 10 (40%) patients experienced shivering in the 37 degrees C and 20 degrees C groups, respectively (P = 0.23). Conclusions: The administration of epidural 0.125% bupivacaine with fentanyl 2 mu g/mL at 37 degrees C versus 20 degrees C resulted in more rapid onset and improved labor analgesia for the first 15 min. There was no evidence of improved ongoing labor analgesia or differences in side effects between groups. (C) 2014 Elsevier Ltd. All rights reserved.	[Sviggum, H. P.; Yacoubian, S.; Liu, X.; Tsen, L. C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA	Tsen, LC (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	sviggum.hans@mayo.edu; ltsen@zeus.bwh.harvard.edu		Tsen, Lawrence/0000-0002-1964-723X			BEARDSWORTH D, 1989, REGION ANESTH, V14, P199; CAMANN WR, 1991, BRIT J ANAESTH, V67, P565, DOI 10.1093/bja/67.5.565; Cappiello E, 2008, ANESTH ANALG, V107, P1646, DOI 10.1213/ane.0b013e318184ec14; CLARK V, 1994, BRIT J ANAESTH, V72, P221, DOI 10.1093/bja/72.2.221; Cook TM, 2009, BRIT J ANAESTH, V102, P179, DOI 10.1093/bja/aen360; Eisenach JC, 1999, ANESTHESIOLOGY, V91, P299, DOI 10.1097/00000542-199907000-00038; Frolich MA, 2012, ANESTHESIOLOGY, V117, P302, DOI 10.1097/ALN.0b013e31825a30ef; Goetzl L, 2012, CURR OPIN ANESTHESIO, V25, P292, DOI 10.1097/ACO.0b013e3283530d7c; Hess PE, 2001, ANESTH ANALG, V93, P414; Kuczkowski KM, 2008, ANN FR ANESTH, V27, P113, DOI 10.1016/j.annfar.2007.11.002; Leo S, 2010, INT J OBSTET ANESTH, V19, P357, DOI 10.1016/j.ijoa.2010.07.006; LIM ETM, 1992, ANAESTH INTENS CARE, V20, P453, DOI 10.1177/0310057X9202000409; Liu Fu-Chao, 2009, Chang Gung Med J, V32, P643; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Mehta PM, 1987, REGIONAL ANESTHESIA, V12, P135; Najafianaraki A, 2012, SAUDI J ANAESTH, V6, P336, DOI 10.4103/1658-354X.105854; Patel NP, 2012, ANAESTHESIA, V67, P584, DOI 10.1111/j.1365-2044.2011.07045.x; PLOECKINGER B, 1995, GYNECOL OBSTET INVES, V39, P24, DOI 10.1159/000292370; Riley LE, 2011, OBSTET GYNECOL, V117, P588, DOI 10.1097/AOG.0b013e31820b0503; Santagostino G, 1992, Minerva Anestesiol, V58, P433; Segal S, 2010, ANESTH ANALG, V111, P1467, DOI 10.1213/ANE.0b013e3181f713d4; SHEHABI Y, 1990, ANAESTH INTENS CARE, V18, P31, DOI 10.1177/0310057X9001800106; Simmons SW, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003401.pub3; Soens MA, 2007, ANESTHESIOLOGY, V106, pB11; STIENSTRA R, 1988, ANESTH ANALG, V67, P272; STIENSTRA R, 1989, ANESTH ANALG, V69, P593; STIENSTRA R, 1990, REGION ANESTH, V15, P6; Vallejo MC, 2001, CAN J ANAESTH, V48, P1122, DOI 10.1007/BF03020380; Van de Velde M, 2004, Acta Anaesthesiol Belg, V55, P17; Van de Velde M, 2001, REGION ANESTH PAIN M, V26, P257, DOI 10.1053/rapm.2001.22258; WALMSLEY AJ, 1986, BRIT J ANAESTH, V58, P1130, DOI 10.1093/bja/58.10.1130; Wong CA, 2011, ANESTH ANALG, V112, P904, DOI 10.1213/ANE.0b013e31820e7c2f	32	5	5	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	FEB	2015	24	1					15	21		10.1016/j.ijoa.2014.07.001			7	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	CB6GP	WOS:000349725800004	25433572				2020-06-30	